,entities,start_chars,end_chars,text,pmid,label
4079,secondary hyperparathyroidism,28,57,22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.,10027919_0,1
0,22-oxacalcitriol,0,16,22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.,10027919_0,0
4080,renal failure,106,119,22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.,10027919_0,1
4081,renal failure,101,114,"BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.",10027919_1,1
4082,of bone,192,199,"BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.",10027919_1,1
4083,bone disease,237,249,"BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.",10027919_1,1
0,Calcitriol,12,22,"BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.",10027919_1,0
1,parathyroid hormone,58,77,"BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease.",10027919_1,0
4085,secondary hyperparathyroidism,17,46,"In long-standing secondary hyperparathyroidism, OCT (0.03 microg/kg) stabilized serum PTH levels during the first months.",10027919_10,1
16,PTH,86,89,"In long-standing secondary hyperparathyroidism, OCT (0.03 microg/kg) stabilized serum PTH levels during the first months.",10027919_10,0
17,PTH,6,9,"Serum PTH levels rose thereafter, but the rise was less pronounced compared with baseline than the rise seen in Nx control.",10027919_11,0
4086,hyperphosphatemia,64,81,These effects were accompanied by episodes of hypercalcemia and hyperphosphatemia.,10027919_12,1
19,normal renal function,16,37,"In animals with normal renal function, OCT induced a transient decrease in serum PTH levels at a dose of 0.1 microg/kg, which was not sustained with lowering of the doses.",10027919_13,1
20,PTH,81,84,"In animals with normal renal function, OCT induced a transient decrease in serum PTH levels at a dose of 0.1 microg/kg, which was not sustained with lowering of the doses.",10027919_13,0
22,bone formation,34,48,"In Nx dogs, OCT reversed abnormal bone formation, such as woven osteoid and fibrosis, but did not significantly alter the level of bone turnover.",10027919_14,1
4087,osteoid,64,71,"In Nx dogs, OCT reversed abnormal bone formation, such as woven osteoid and fibrosis, but did not significantly alter the level of bone turnover.",10027919_14,1
23,mineralization,26,40,"In addition, OCT improved mineralization lag time, (that is, the rate at which osteoid mineralizes) in both Nx and Sham dogs.",10027919_15,1
4088,osteoid,79,86,"In addition, OCT improved mineralization lag time, (that is, the rate at which osteoid mineralizes) in both Nx and Sham dogs.",10027919_15,1
4089,renal insufficiency,143,162,"CONCLUSIONS: These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency, it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and, therefore, does not increase the risk of adynamic bone disease.",10027919_16,1
4090,secondary hyperparathyroidism,202,231,"CONCLUSIONS: These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency, it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and, therefore, does not increase the risk of adynamic bone disease.",10027919_16,1
4091,bone disease,332,344,"CONCLUSIONS: These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency, it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and, therefore, does not increase the risk of adynamic bone disease.",10027919_16,1
1,vitamin D,6,15,"A new vitamin D analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics.",10027919_2,0
2,22-oxacalcitriol,26,42,"A new vitamin D analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics.",10027919_2,0
4,PTH,67,70,This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or impaired renal function.,10027919_3,0
5,renal function,128,142,This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or impaired renal function.,10027919_3,1
7,supplemental phosphate,21,43,The animals received supplemental phosphate to enhance PTH secretion.,10027919_5,0
8,PTH,55,58,The animals received supplemental phosphate to enhance PTH secretion.,10027919_5,0
4084,renal insufficiency,94,113,"RESULTS: In Nx dogs, OCT significantly decreased serum PTH levels soon after the induction of renal insufficiency.",10027919_9,1
15,PTH,55,58,"RESULTS: In Nx dogs, OCT significantly decreased serum PTH levels soon after the induction of renal insufficiency.",10027919_9,0
2,methylprednisolone,67,85,"Hypotension, bradycardia, and asystole after high-dose intravenous methylprednisolone in a monitored patient.",10074612_0,0
26,high-dose,45,54,"Hypotension, bradycardia, and asystole after high-dose intravenous methylprednisolone in a monitored patient.",10074612_0,0
27,high-dose methylprednisolone,95,123,"We report a case of hypotension, bradycardia, and asystole after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode.",10074612_1,0
4092,cardiac disease,32,47,There was a history of ischemic cardiac disease 9 years earlier.,10074612_2,1
4093,renal failure,94,107,"The patient was admitted with a pulmonary-renal syndrome with hemoptysis, rapidly progressive renal failure, and hypoxemia that required mechanical ventilation in the intensive care unit.",10074612_3,1
30,hypoxemia,113,122,"The patient was admitted with a pulmonary-renal syndrome with hemoptysis, rapidly progressive renal failure, and hypoxemia that required mechanical ventilation in the intensive care unit.",10074612_3,1
29,pulmonary-renal syndrome,32,56,"The patient was admitted with a pulmonary-renal syndrome with hemoptysis, rapidly progressive renal failure, and hypoxemia that required mechanical ventilation in the intensive care unit.",10074612_3,1
34,cardiac rhythm,78,92,"After receiving advanced cardiopulmonary resuscitation, the patient recovered cardiac rhythm.",10074612_4,1
33,cardiopulmonary resuscitation,25,54,"After receiving advanced cardiopulmonary resuscitation, the patient recovered cardiac rhythm.",10074612_4,1
36,ventricular arrhythmia,43,65,The ECG showed a junctional rhythm without ventricular arrhythmia.,10074612_5,1
35,junctional,17,27,The ECG showed a junctional rhythm without ventricular arrhythmia.,10074612_5,1
4094,sudden death,54,66,This study reviews the current proposed mechanisms of sudden death after a high dose of intravenous methylprednisolone (IVMP).,10074612_6,1
3,methylprednisolone,100,118,This study reviews the current proposed mechanisms of sudden death after a high dose of intravenous methylprednisolone (IVMP).,10074612_6,0
38,IVMP,120,124,This study reviews the current proposed mechanisms of sudden death after a high dose of intravenous methylprednisolone (IVMP).,10074612_6,0
37,high dose,75,84,This study reviews the current proposed mechanisms of sudden death after a high dose of intravenous methylprednisolone (IVMP).,10074612_6,0
4095,cardiac disease,30,45,"Rapid infusion and underlying cardiac disease were important risk factors in the case reported here, and the authors discount ventricular arrhythmia as the main mechanism.",10074612_8,1
40,discount ventricular arrhythmia,117,148,"Rapid infusion and underlying cardiac disease were important risk factors in the case reported here, and the authors discount ventricular arrhythmia as the main mechanism.",10074612_8,1
4096,Parkinson's disease,21,40,"Ten patients who had Parkinson's disease with disabling dyskinesia were included in this study to evaluate the role of mental (mental calculation) and motor (flexion/extension of right fingers, flexion/extension of left fingers, flexion/extension of the neck, speaking aloud) tasks on the worsening of peak-dose dyskinesia following administration of an effective single dose of apomorphine.",10091616_1,1
44,right fingers,179,192,"Ten patients who had Parkinson's disease with disabling dyskinesia were included in this study to evaluate the role of mental (mental calculation) and motor (flexion/extension of right fingers, flexion/extension of left fingers, flexion/extension of the neck, speaking aloud) tasks on the worsening of peak-dose dyskinesia following administration of an effective single dose of apomorphine.",10091616_1,1
45,left fingers,215,227,"Ten patients who had Parkinson's disease with disabling dyskinesia were included in this study to evaluate the role of mental (mental calculation) and motor (flexion/extension of right fingers, flexion/extension of left fingers, flexion/extension of the neck, speaking aloud) tasks on the worsening of peak-dose dyskinesia following administration of an effective single dose of apomorphine.",10091616_1,1
46,peak-dose dyskinesia,302,322,"Ten patients who had Parkinson's disease with disabling dyskinesia were included in this study to evaluate the role of mental (mental calculation) and motor (flexion/extension of right fingers, flexion/extension of left fingers, flexion/extension of the neck, speaking aloud) tasks on the worsening of peak-dose dyskinesia following administration of an effective single dose of apomorphine.",10091616_1,1
48,movements of right,151,169,"Compared with the score at rest (1.3+/-0.3), a significant aggravation of the dyskinesia score was observed during speaking aloud (5.2+/-1.1, p<0.05), movements of right (4.5+/-1.0, p<0.05) and left (3.7+/-0.8, p<0.05) fingers, movements of the neck (5.1+/-1.0, p<0.05), and mental calculation (3.1+/-1.0, p<0.05).",10091616_2,1
4098,Parkinson's disease,43,62,Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal.,10091617_0,1
4099,drug withdrawal,103,118,Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal.,10091617_0,1
4097,postural hypotension,19,39,Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal.,10091617_0,1
51,UKPDRG,67,73,OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.,10091617_1,0
4100,Parkinson's Disease,31,50,OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.,10091617_1,1
4101,Parkinson's disease,127,146,OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.,10091617_1,1
4,selegiline,180,190,OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease (PD) randomized to receive 10 mg selegiline per day and L-dopa compared with those taking L-dopa alone.,10091617_1,0
4111,orthostatic hypotension,125,148,CONCLUSION: This study confirms our previous finding that selegiline in combination with L-dopa is associated with selective orthostatic hypotension.,10091617_10,1
12,selegiline,58,68,CONCLUSION: This study confirms our previous finding that selegiline in combination with L-dopa is associated with selective orthostatic hypotension.,10091617_10,0
62,metamphetamine,144,158,The possibilities that these cardiovascular findings might be the result of non-selective inhibition of monoamine oxidase or of amphetamine and metamphetamine are discussed.,10091617_11,0
61,non-selective,76,89,The possibilities that these cardiovascular findings might be the result of non-selective inhibition of monoamine oxidase or of amphetamine and metamphetamine are discussed.,10091617_11,0
13,monoamine oxidase,104,121,The possibilities that these cardiovascular findings might be the result of non-selective inhibition of monoamine oxidase or of amphetamine and metamphetamine are discussed.,10091617_11,0
5,selegiline,37,47,"Recently, we found that therapy with selegiline and L-dopa was associated with selective systolic orthostatic hypotension which was abolished by withdrawal of selegiline.",10091617_2,0
6,selegiline,159,169,"Recently, we found that therapy with selegiline and L-dopa was associated with selective systolic orthostatic hypotension which was abolished by withdrawal of selegiline.",10091617_2,0
4102,orthostatic hypotension,98,121,"Recently, we found that therapy with selegiline and L-dopa was associated with selective systolic orthostatic hypotension which was abolished by withdrawal of selegiline.",10091617_2,1
4103,blood pressure,33,47,This unwanted effect on postural blood pressure was not the result of underlying autonomic failure.,10091617_3,1
4104,autonomic failure,81,98,This unwanted effect on postural blood pressure was not the result of underlying autonomic failure.,10091617_3,1
4105,orthostatic hypotension,274,297,The aims of this study were to confirm our previous findings in a separate cohort of patients and to determine the time course of the cardiovascular consequences of stopping selegiline in the expectation that this might shed light on the mechanisms by which the drug causes orthostatic hypotension.,10091617_4,1
7,selegiline,174,184,The aims of this study were to confirm our previous findings in a separate cohort of patients and to determine the time course of the cardiovascular consequences of stopping selegiline in the expectation that this might shed light on the mechanisms by which the drug causes orthostatic hypotension.,10091617_4,0
56,head-up tilt,54,66,METHODS: The cardiovascular responses to standing and head-up tilt were studied repeatedly in PD patients receiving selegiline and as the drug was withdrawn.,10091617_5,1
8,selegiline,116,126,METHODS: The cardiovascular responses to standing and head-up tilt were studied repeatedly in PD patients receiving selegiline and as the drug was withdrawn.,10091617_5,0
4106,orthostatic hypotension,38,61,"RESULTS: Head-up tilt caused systolic orthostatic hypotension which was marked in six of 20 PD patients on selegiline, one of whom lost consciousness with unrecordable blood pressures.",10091617_6,1
57,Head-up tilt,9,21,"RESULTS: Head-up tilt caused systolic orthostatic hypotension which was marked in six of 20 PD patients on selegiline, one of whom lost consciousness with unrecordable blood pressures.",10091617_6,1
4107,blood pressures,168,183,"RESULTS: Head-up tilt caused systolic orthostatic hypotension which was marked in six of 20 PD patients on selegiline, one of whom lost consciousness with unrecordable blood pressures.",10091617_6,1
9,selegiline,107,117,"RESULTS: Head-up tilt caused systolic orthostatic hypotension which was marked in six of 20 PD patients on selegiline, one of whom lost consciousness with unrecordable blood pressures.",10091617_6,0
4108,orthostatic hypotension,19,42,A lesser degree of orthostatic hypotension occurred with standing.,10091617_7,1
10,selegiline,67,77,Orthostatic hypotension was ameliorated 4 days after withdrawal of selegiline and totally abolished 7 days after discontinuation of the drug.,10091617_8,0
4109,Orthostatic hypotension,0,23,Orthostatic hypotension was ameliorated 4 days after withdrawal of selegiline and totally abolished 7 days after discontinuation of the drug.,10091617_8,1
4110,blood pressures,81,96,Stopping selegiline also significantly reduced the supine systolic and diastolic blood pressures consistent with a previously undescribed supine pressor action.,10091617_9,1
11,selegiline,9,19,Stopping selegiline also significantly reduced the supine systolic and diastolic blood pressures consistent with a previously undescribed supine pressor action.,10091617_9,0
59,pressor action,145,159,Stopping selegiline also significantly reduced the supine systolic and diastolic blood pressures consistent with a previously undescribed supine pressor action.,10091617_9,0
64,chlorhexidine-digluconate,100,125,The results have shown that the degradation product p-choloroaniline is not a significant factor in chlorhexidine-digluconate associated erosive cystitis.,1009330_2,0
65,erosive cystitis,137,153,The results have shown that the degradation product p-choloroaniline is not a significant factor in chlorhexidine-digluconate associated erosive cystitis.,1009330_2,1
14,degradation product,32,51,The results have shown that the degradation product p-choloroaniline is not a significant factor in chlorhexidine-digluconate associated erosive cystitis.,1009330_2,0
66,kanamycin-colistin,21,39,A high percentage of kanamycin-colistin and povidone-iodine irrigations were associated with erosive cystitis and suggested a possible complication with human usage.,1009330_3,0
15,povidone-iodine,44,59,A high percentage of kanamycin-colistin and povidone-iodine irrigations were associated with erosive cystitis and suggested a possible complication with human usage.,1009330_3,0
69,Picloxydine irrigations,0,23,Picloxydine irrigations appeared to have a lower incidence of erosive cystitis but further studies would have to be performed before it could be recommended for use in urological procedures.,1009330_4,0
70,erosive cystitis,62,78,Picloxydine irrigations appeared to have a lower incidence of erosive cystitis but further studies would have to be performed before it could be recommended for use in urological procedures.,1009330_4,1
73,tetrandrine,11,22,Effects of tetrandrine and fangchinoline on experimental thrombosis in mice and human platelet aggregation.,10193204_0,0
74,fangchinoline,27,40,Effects of tetrandrine and fangchinoline on experimental thrombosis in mice and human platelet aggregation.,10193204_0,0
75,experimental thrombosis,44,67,Effects of tetrandrine and fangchinoline on experimental thrombosis in mice and human platelet aggregation.,10193204_0,1
76,human platelet aggregation,80,106,Effects of tetrandrine and fangchinoline on experimental thrombosis in mice and human platelet aggregation.,10193204_0,0
77,Tetrandrine,0,11,Tetrandrine (TET) and fangchinoline (FAN) are two naturally occurring analogues with a bisbenzylisoquinoline structure.,10193204_1,0
16,bisbenzylisoquinoline,87,108,Tetrandrine (TET) and fangchinoline (FAN) are two naturally occurring analogues with a bisbenzylisoquinoline structure.,10193204_1,0
78,fangchinoline,22,35,Tetrandrine (TET) and fangchinoline (FAN) are two naturally occurring analogues with a bisbenzylisoquinoline structure.,10193204_1,0
80,experimental thrombosis,82,105,"The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.",10193204_2,1
81,collagen plus epinephrine,117,142,"The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.",10193204_2,0
82,EP,144,146,"The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.",10193204_2,0
83,blood coagulation,186,203,"The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.",10193204_2,0
17,platelet aggregation,161,181,"The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro.",10193204_2,0
85,i.p.,52,56,"In the in vivo study, the administration (50 mg/kg, i.p.) of TET and FAN in mice showed the inhibition of thrombosis by 55% and 35%, respectively, while acetylsalicylic acid (ASA, 50 mg/kg, i.p.), a positive control, showed only 30% inhibition.",10193204_3,0
4112,ASA,175,178,"In the in vivo study, the administration (50 mg/kg, i.p.) of TET and FAN in mice showed the inhibition of thrombosis by 55% and 35%, respectively, while acetylsalicylic acid (ASA, 50 mg/kg, i.p.), a positive control, showed only 30% inhibition.",10193204_3,1
18,acetylsalicylic acid,153,173,"In the in vivo study, the administration (50 mg/kg, i.p.) of TET and FAN in mice showed the inhibition of thrombosis by 55% and 35%, respectively, while acetylsalicylic acid (ASA, 50 mg/kg, i.p.), a positive control, showed only 30% inhibition.",10193204_3,0
19,human platelet,13,27,"In the vitro human platelet aggregations induced by the agonists used in tests, TET and FAN showed the inhibitions dose dependently.",10193204_4,0
89,APTT,136,140,"In addition, neither TET nor FAN showed any anticoagulation activities in the measurement of the activated partial thromboplastin time (APTT), prothrombin time (PT) and thrombin time (TT) using human-citrated plasma.",10193204_5,0
20,antiplatelet,94,106,These results suggest that antithrombosis of TET and FAN in mice may be mainly related to the antiplatelet aggregation activities.,10193204_6,0
21,N-acetyl-beta-D-glucosaminidase,6,37,"Urine N-acetyl-beta-D-glucosaminidase--a marker of tubular damage?BACKGROUND: Although an indicator of renal tubular dysfunction, an increased urinary N-acetyl-beta-D-glucosaminidase (NAG) activity might reflect increased lysosomal activity in renal tubular cells.",10193809_0,0
95,renal tubular dysfunction,103,128,"Urine N-acetyl-beta-D-glucosaminidase--a marker of tubular damage?BACKGROUND: Although an indicator of renal tubular dysfunction, an increased urinary N-acetyl-beta-D-glucosaminidase (NAG) activity might reflect increased lysosomal activity in renal tubular cells.",10193809_0,1
4113,renal tubular,244,257,"Urine N-acetyl-beta-D-glucosaminidase--a marker of tubular damage?BACKGROUND: Although an indicator of renal tubular dysfunction, an increased urinary N-acetyl-beta-D-glucosaminidase (NAG) activity might reflect increased lysosomal activity in renal tubular cells.",10193809_0,1
22,N-acetyl-beta-D-glucosaminidase,151,182,"Urine N-acetyl-beta-D-glucosaminidase--a marker of tubular damage?BACKGROUND: Although an indicator of renal tubular dysfunction, an increased urinary N-acetyl-beta-D-glucosaminidase (NAG) activity might reflect increased lysosomal activity in renal tubular cells.",10193809_0,0
96,lysosomal,222,231,"Urine N-acetyl-beta-D-glucosaminidase--a marker of tubular damage?BACKGROUND: Although an indicator of renal tubular dysfunction, an increased urinary N-acetyl-beta-D-glucosaminidase (NAG) activity might reflect increased lysosomal activity in renal tubular cells.",10193809_0,0
23,Puromycin aminonucleoside,9,34,METHODS: Puromycin aminonucleoside (PAN) was administered to Sprague Dawley rats to induce proteinuria.,10193809_1,0
24,isoenzyme,118,127,"The morphological appearance of the kidneys was examined on days three, four, six, eight and thirty three and the NAG isoenzyme patterns on days zero, four, eight and thirty three.",10193809_3,0
25,high molecular weight,60,81,Electrophoresis showed a generalised increase in middle and high molecular weight urine proteins from day four onwards.,10193809_5,0
106,Protein droplets,0,16,Protein droplets first appeared prominent in tubular cells on day four.,10193809_6,0
26,isoenzyme,44,53,Peak urine NAG activity and a change in NAG isoenzyme pattern coincided with both the peak proteinuria and the reduction in intracellular protein and NAG droplets (day six onwards).,10193809_7,0
110,intracellular protein,124,145,Peak urine NAG activity and a change in NAG isoenzyme pattern coincided with both the peak proteinuria and the reduction in intracellular protein and NAG droplets (day six onwards).,10193809_7,0
115,renal tubules,64,77,Urine NAG activity is thus a measure of altered function in the renal tubules and not simply an indicator of damage.,10193809_9,1
27,lignocaine,66,76,Cauda equina syndrome after spinal anaesthesia with hyperbaric 5% lignocaine: a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993-1997.Six cases of cauda equina syndrome with varying severity were reported to the Swedish Pharmaceutical Insurance during the period 1993-1997.,10225068_0,0
4116,cauda equina syndrome,197,218,Cauda equina syndrome after spinal anaesthesia with hyperbaric 5% lignocaine: a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993-1997.Six cases of cauda equina syndrome with varying severity were reported to the Swedish Pharmaceutical Insurance during the period 1993-1997.,10225068_0,1
4115,cauda equina syndrome,103,124,Cauda equina syndrome after spinal anaesthesia with hyperbaric 5% lignocaine: a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993-1997.Six cases of cauda equina syndrome with varying severity were reported to the Swedish Pharmaceutical Insurance during the period 1993-1997.,10225068_0,1
4114,Cauda equina syndrome,0,21,Cauda equina syndrome after spinal anaesthesia with hyperbaric 5% lignocaine: a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993-1997.Six cases of cauda equina syndrome with varying severity were reported to the Swedish Pharmaceutical Insurance during the period 1993-1997.,10225068_0,1
117,hyperbaric,52,62,Cauda equina syndrome after spinal anaesthesia with hyperbaric 5% lignocaine: a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993-1997.Six cases of cauda equina syndrome with varying severity were reported to the Swedish Pharmaceutical Insurance during the period 1993-1997.,10225068_0,1
116,spinal anaesthesia,28,46,Cauda equina syndrome after spinal anaesthesia with hyperbaric 5% lignocaine: a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993-1997.Six cases of cauda equina syndrome with varying severity were reported to the Swedish Pharmaceutical Insurance during the period 1993-1997.,10225068_0,1
121,hyperbaric,50,60,All were associated with spinal anaesthesia using hyperbaric 5% lignocaine.,10225068_1,1
120,spinal anaesthesia,25,43,All were associated with spinal anaesthesia using hyperbaric 5% lignocaine.,10225068_1,1
28,lignocaine,64,74,All were associated with spinal anaesthesia using hyperbaric 5% lignocaine.,10225068_1,0
124,inadequate block,93,109,Five cases had single-shot spinal anaesthesia and one had a repeat spinal anaesthetic due to inadequate block.,10225068_2,1
122,single-shot spinal anaesthesia,15,45,Five cases had single-shot spinal anaesthesia and one had a repeat spinal anaesthetic due to inadequate block.,10225068_2,1
123,spinal anaesthetic,67,85,Five cases had single-shot spinal anaesthesia and one had a repeat spinal anaesthetic due to inadequate block.,10225068_2,1
29,lignocaine,26,36,The dose of hyperbaric 5% lignocaine administered ranged from 60 to 120 mg.,10225068_3,0
126,hyperbaric,70,80,Three of the cases were most likely caused by direct neurotoxicity of hyperbaric 5% lignocaine.,10225068_4,1
30,lignocaine,84,94,Three of the cases were most likely caused by direct neurotoxicity of hyperbaric 5% lignocaine.,10225068_4,0
4117,neurotoxicity,53,66,Three of the cases were most likely caused by direct neurotoxicity of hyperbaric 5% lignocaine.,10225068_4,1
128,compressive aetiology,146,167,"In the other 3 cases, direct neurotoxicity was also probable, but unfortunately radiological investigations were not done to definitely exclude a compressive aetiology.",10225068_5,1
4118,neurotoxicity,29,42,"In the other 3 cases, direct neurotoxicity was also probable, but unfortunately radiological investigations were not done to definitely exclude a compressive aetiology.",10225068_5,1
129,neurological deficits,30,51,All cases sustained permanent neurological deficits.,10225068_6,1
31,sirolimus,46,55,Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes.,10328196_0,0
32,rapamycin,66,75,Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes.,10328196_0,0
4119,capillary leak syndrome,107,130,Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes.,10328196_0,1
131,lesional lymphocytes,149,169,Systemic toxicity following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes.,10328196_0,1
36,T-cell activation,94,111,BACKGROUND: Sirolimus (formerly rapamycin) is an immunosuppressive agent that interferes with T-cell activation.,10328196_1,0
34,rapamycin,32,41,BACKGROUND: Sirolimus (formerly rapamycin) is an immunosuppressive agent that interferes with T-cell activation.,10328196_1,0
33,Sirolimus,12,21,BACKGROUND: Sirolimus (formerly rapamycin) is an immunosuppressive agent that interferes with T-cell activation.,10328196_1,0
35,immunosuppressive agent,49,72,BACKGROUND: Sirolimus (formerly rapamycin) is an immunosuppressive agent that interferes with T-cell activation.,10328196_1,0
37,sirolimus,101,110,After 2 individuals with psoriasis developed a capillary leak syndrome following treatment with oral sirolimus lesional skin cells and activated peripheral blood cells were analyzed for induction of apoptosis.,10328196_2,0
4120,capillary leak syndrome,47,70,After 2 individuals with psoriasis developed a capillary leak syndrome following treatment with oral sirolimus lesional skin cells and activated peripheral blood cells were analyzed for induction of apoptosis.,10328196_2,1
38,apoptotic,142,151,OBSERVATIONS: A keratome skin specimen from 1 patient with sirolimus-induced capillary leak syndrome had a 2.3-fold increase in percentage of apoptotic cells (to 48%) compared with an unaffected sirolimus-treated patient with psoriasis (21%).,10328196_3,0
4121,capillary leak syndrome,77,100,OBSERVATIONS: A keratome skin specimen from 1 patient with sirolimus-induced capillary leak syndrome had a 2.3-fold increase in percentage of apoptotic cells (to 48%) compared with an unaffected sirolimus-treated patient with psoriasis (21%).,10328196_3,1
133,keratome,16,24,OBSERVATIONS: A keratome skin specimen from 1 patient with sirolimus-induced capillary leak syndrome had a 2.3-fold increase in percentage of apoptotic cells (to 48%) compared with an unaffected sirolimus-treated patient with psoriasis (21%).,10328196_3,1
39,sirolimus,194,203,"Activated peripheral blood T cells from patients with psoriasis tended to exhibit greater spontaneous or dexamethasone-induced apoptosis than did normal T cells, particularly in the presence of sirolimus.",10328196_4,0
4122,adverse effects,20,35,"CONCLUSIONS: Severe adverse effects of sirolimus include fever, anemia, and capillary leak syndrome.",10328196_5,1
40,sirolimus,39,48,"CONCLUSIONS: Severe adverse effects of sirolimus include fever, anemia, and capillary leak syndrome.",10328196_5,0
4123,capillary leak syndrome,76,99,"CONCLUSIONS: Severe adverse effects of sirolimus include fever, anemia, and capillary leak syndrome.",10328196_5,1
138,T lymphocytes,104,117,"These symptoms may be the result of drug-induced apoptosis of lesional leukocytes, especially activated T lymphocytes, and possibly release of inflammatory mediators.",10328196_6,0
139,inflammatory mediators,143,165,"These symptoms may be the result of drug-induced apoptosis of lesional leukocytes, especially activated T lymphocytes, and possibly release of inflammatory mediators.",10328196_6,0
4124,drug-induced,36,48,"These symptoms may be the result of drug-induced apoptosis of lesional leukocytes, especially activated T lymphocytes, and possibly release of inflammatory mediators.",10328196_6,1
140,capillary leak,51,65,"Because patients with severe psoriasis may develop capillary leak from various systemic therapies, clinical monitoring is advisable for patients with inflammatory diseases who are treated with immune modulators.",10328196_7,1
41,modulators,200,210,"Because patients with severe psoriasis may develop capillary leak from various systemic therapies, clinical monitoring is advisable for patients with inflammatory diseases who are treated with immune modulators.",10328196_7,0
4125,inflammatory diseases,150,171,"Because patients with severe psoriasis may develop capillary leak from various systemic therapies, clinical monitoring is advisable for patients with inflammatory diseases who are treated with immune modulators.",10328196_7,1
42,ACE inhibitors,18,32,Angioedema due to ACE inhibitors: common and inadequately diagnosed.,10342929_0,0
43,angiotensin-converting enzyme,45,74,The estimated incidence of angioedema during angiotensin-converting enzyme (ACE) inhibitor treatment is between 1 and 7 per thousand patients.,10342929_1,0
143,adverse effect,25,39,This potentially serious adverse effect is often preceded by minor manifestations that may serve as a warning.,10342929_2,1
144,parathyroid function,53,73,Effect of lithium maintenance therapy on thyroid and parathyroid function.,10354657_0,1
165,Familial thyroid illness,13,37,CONCLUSIONS: Familial thyroid illness is a risk factor for hypothyroidism and hypercalcemia during lithium therapy.,10354657_14,1
146,family history,84,98,"These were evaluated with respect to the duration of lithium therapy, age, sex, and family history (whether or not the patient had a first-degree relative with thyroid disease).",10354657_2,1
4126,thyroid disease,160,175,"These were evaluated with respect to the duration of lithium therapy, age, sex, and family history (whether or not the patient had a first-degree relative with thyroid disease).",10354657_2,1
148,Affective Disorders,9,28,"SETTING: Affective Disorders Clinic at St. Mary's Hospital, Montreal.",10354657_4,1
150,bipolar disorder,66,82,PATIENTS: One hundred and one patients (28 men and 73 women) with bipolar disorder receiving lithium maintenance therapy ranging from 1 year's to 32 years' duration.,10354657_5,1
151,endocrinological diagnoses,66,92,The control group consisted of 82 patients with no psychiatric or endocrinological diagnoses from the hospital's out-patient clinics.,10354657_6,1
153,thyroid-stimulating hormone,64,91,"OUTCOME MEASURES: Laboratory analyses of calcium, magnesium and thyroid-stimulating hormone levels performed before beginning lithium therapy and at biannual follow-up.",10354657_7,0
154,hypothyroid,80,91,"RESULTS: Hypothyroidism developed in 40 patients, excluding 8 patients who were hypothyroid at baseline.",10354657_8,1
156,thyroid illness,55,70,All patients having first-degree relatives affected by thyroid illness had accelerated onset of hypothyroidism (3.7 years after onset of lithium therapy) compared with patients without a family history (8.6 years after onset of lithium therapy).,10354657_9,1
155,first-degree relatives,20,42,All patients having first-degree relatives affected by thyroid illness had accelerated onset of hypothyroidism (3.7 years after onset of lithium therapy) compared with patients without a family history (8.6 years after onset of lithium therapy).,10354657_9,1
160,family history,187,201,All patients having first-degree relatives affected by thyroid illness had accelerated onset of hypothyroidism (3.7 years after onset of lithium therapy) compared with patients without a family history (8.6 years after onset of lithium therapy).,10354657_9,1
157,onset of,87,95,All patients having first-degree relatives affected by thyroid illness had accelerated onset of hypothyroidism (3.7 years after onset of lithium therapy) compared with patients without a family history (8.6 years after onset of lithium therapy).,10354657_9,1
170,psychiatric symptoms,52,72,Cocaine-induced mood disorder: prevalence rates and psychiatric symptoms in an outpatient cocaine-dependent sample.,10365197_0,1
168,Cocaine-induced mood disorder,0,29,Cocaine-induced mood disorder: prevalence rates and psychiatric symptoms in an outpatient cocaine-dependent sample.,10365197_0,1
171,cocaine-dependent,90,107,Cocaine-induced mood disorder: prevalence rates and psychiatric symptoms in an outpatient cocaine-dependent sample.,10365197_0,1
174,mood disorders,116,130,This paper attempts to examine and compare prevalence rates and symptom patterns of DSM substance-induced and other mood disorders.,10365197_1,1
4127,substance-induced,88,105,This paper attempts to examine and compare prevalence rates and symptom patterns of DSM substance-induced and other mood disorders.,10365197_1,1
175,cocaine-dependent,4,21,"243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.",10365197_2,1
176,cocaine-induced mood disorder,39,68,"243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.",10365197_2,1
178,mood disorders,83,97,"243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.",10365197_2,1
179,no mood disorder,102,118,"243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.",10365197_2,1
180,psychiatric symptoms,148,168,"243 cocaine-dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms.",10365197_2,1
181,CIMD,24,28,The prevalence rate for CIMD was 12% at baseline.,10365197_3,0
183,depressive disorders,93,113,Introduction of the DSM-IV diagnosis of CIMD did not substantially affect rates of the other depressive disorders.,10365197_4,1
185,symptom severity,23,39,Patients with CIMD had symptom severity levels between those of patients with and without a mood disorder.,10365197_5,1
186,mood disorder,92,105,Patients with CIMD had symptom severity levels between those of patients with and without a mood disorder.,10365197_5,1
4128,intracerebral hemorrhage,52,76,Effect of fucoidan treatment on collagenase-induced intracerebral hemorrhage in rats.,10406016_0,1
189,fucoidan,10,18,Effect of fucoidan treatment on collagenase-induced intracerebral hemorrhage in rats.,10406016_0,0
4129,brain damage,57,69,Inflammatory cells are postulated to mediate some of the brain damage following ischemic stroke.,10406016_1,1
190,Inflammatory cells,0,18,Inflammatory cells are postulated to mediate some of the brain damage following ischemic stroke.,10406016_1,1
4130,ischemic stroke,80,95,Inflammatory cells are postulated to mediate some of the brain damage following ischemic stroke.,10406016_1,1
44,anti-inflammatory agents,31,55,Investigation of more specific anti-inflammatory agents and hemodiluting agents are warranted in intracerebral hemorrhage.,10406016_10,0
207,hemodiluting agents,60,79,Investigation of more specific anti-inflammatory agents and hemodiluting agents are warranted in intracerebral hemorrhage.,10406016_10,0
4135,intracerebral hemorrhage,97,121,Investigation of more specific anti-inflammatory agents and hemodiluting agents are warranted in intracerebral hemorrhage.,10406016_10,1
4131,Intracerebral hemorrhage,0,24,Intracerebral hemorrhage is associated with more inflammation than ischemic stroke.,10406016_2,1
4132,ischemic stroke,67,82,Intracerebral hemorrhage is associated with more inflammation than ischemic stroke.,10406016_2,1
4133,brain damage,95,107,"We tested the sulfated polysaccharide fucoidan, which has been reported to reduce inflammatory brain damage, in a rat model of intracerebral hemorrhage induced by injection of bacterial collagenase into the caudate nucleus.",10406016_3,1
192,fucoidan,38,46,"We tested the sulfated polysaccharide fucoidan, which has been reported to reduce inflammatory brain damage, in a rat model of intracerebral hemorrhage induced by injection of bacterial collagenase into the caudate nucleus.",10406016_3,0
193,bacterial collagenase,176,197,"We tested the sulfated polysaccharide fucoidan, which has been reported to reduce inflammatory brain damage, in a rat model of intracerebral hemorrhage induced by injection of bacterial collagenase into the caudate nucleus.",10406016_3,0
4134,intracerebral hemorrhage,127,151,"We tested the sulfated polysaccharide fucoidan, which has been reported to reduce inflammatory brain damage, in a rat model of intracerebral hemorrhage induced by injection of bacterial collagenase into the caudate nucleus.",10406016_3,1
194,caudate nucleus,207,222,"We tested the sulfated polysaccharide fucoidan, which has been reported to reduce inflammatory brain damage, in a rat model of intracerebral hemorrhage induced by injection of bacterial collagenase into the caudate nucleus.",10406016_3,1
195,fucoidan,57,65,Rats were treated with seven day intravenous infusion of fucoidan (30 micrograms h-1) or vehicle.,10406016_4,0
197,Motor behavior,0,14,"Motor behavior, passive avoidance, and skilled forelimb function were tested repeatedly for six weeks.",10406016_6,1
198,passive avoidance,16,33,"Motor behavior, passive avoidance, and skilled forelimb function were tested repeatedly for six weeks.",10406016_6,1
199,forelimb function,47,64,"Motor behavior, passive avoidance, and skilled forelimb function were tested repeatedly for six weeks.",10406016_6,1
200,blood clotting,53,67,"Fucoidan-treated rats exhibited evidence of impaired blood clotting and hemodilution, had larger hematomas, and tended to have less inflammation in the vicinity of the hematoma after three days.",10406016_7,1
202,motor function,52,66,They showed significantly more rapid improvement of motor function in the first week following hemorrhage and better memory retention in the passive avoidance test.,10406016_8,1
203,memory retention,117,133,They showed significantly more rapid improvement of motor function in the first week following hemorrhage and better memory retention in the passive avoidance test.,10406016_8,1
206,neuronal loss,38,51,Acute white matter edema and eventual neuronal loss in the striatum adjacent to the hematoma did not differ between the two groups.,10406016_9,1
205,white matter,6,18,Acute white matter edema and eventual neuronal loss in the striatum adjacent to the hematoma did not differ between the two groups.,10406016_9,1
45,cefotetan,67,76,Severe immune hemolytic anemia associated with prophylactic use of cefotetan in obstetric and gynecologic procedures.,10411803_0,0
4136,hemolytic anemia,14,30,Severe immune hemolytic anemia associated with prophylactic use of cefotetan in obstetric and gynecologic procedures.,10411803_0,1
4137,hemolytic anemia,131,147,"Second- and third-generation cephalosporins, especially cefotetan, are increasingly associated with severe, sometimes fatal immune hemolytic anemia.",10411803_1,1
212,third-generation,12,28,"Second- and third-generation cephalosporins, especially cefotetan, are increasingly associated with severe, sometimes fatal immune hemolytic anemia.",10411803_1,0
211,Second-,0,7,"Second- and third-generation cephalosporins, especially cefotetan, are increasingly associated with severe, sometimes fatal immune hemolytic anemia.",10411803_1,0
46,cefotetan,56,65,"Second- and third-generation cephalosporins, especially cefotetan, are increasingly associated with severe, sometimes fatal immune hemolytic anemia.",10411803_1,0
4138,hemolytic anemias,56,73,We noticed that 10 of our 35 cases of cefotetan-induced hemolytic anemias were in patients who had received cefotetan prophylactically for obstetric and gynecologic procedures.,10411803_2,1
47,cefotetan,108,117,We noticed that 10 of our 35 cases of cefotetan-induced hemolytic anemias were in patients who had received cefotetan prophylactically for obstetric and gynecologic procedures.,10411803_2,0
4139,hemolytic anemia,38,54,Eight of these cases of severe immune hemolytic anemia are described.,10411803_3,1
217,nonsteroidal anti-inflammatory drugs,11,47,Effects of nonsteroidal anti-inflammatory drugs on hemostasis in patients with aneurysmal subarachnoid hemorrhage.,10414674_0,0
4140,aneurysmal subarachnoid hemorrhage,79,113,Effects of nonsteroidal anti-inflammatory drugs on hemostasis in patients with aneurysmal subarachnoid hemorrhage.,10414674_0,1
219,nonsteroidal anti-inflammatory drugs,33,69,Platelet function is impaired by nonsteroidal anti-inflammatory drugs (NSAIDs) with prominent anti-inflammatory properties.,10414674_1,0
230,antithrombin III,112,128,"Coagulation (prothrombin time [PT], activated partial thromboplastin time [APPT], fibrinogen concentration, and antithrombin III [AT III]) was comparable between the two groups.",10414674_10,0
228,APPT,75,79,"Coagulation (prothrombin time [PT], activated partial thromboplastin time [APPT], fibrinogen concentration, and antithrombin III [AT III]) was comparable between the two groups.",10414674_10,0
226,prothrombin time,13,29,"Coagulation (prothrombin time [PT], activated partial thromboplastin time [APPT], fibrinogen concentration, and antithrombin III [AT III]) was comparable between the two groups.",10414674_10,0
231,cerebral artery aneurysms,40,65,"If ketoprofen is used before surgery on cerebral artery aneurysms, it may pose an additional risk factor for hemorrhage.",10414674_12,1
220,intracranial surgery,36,56,Their safety in patients undergoing intracranial surgery is under debate.,10414674_2,1
4141,aneurysmal subarachnoid hemorrhage,14,48,"Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal SAH.",10414674_3,1
49,adenosine diphosphate,52,73,Maximal platelet aggregation induced by 6 microM of adenosine diphosphate decreased after administration of ketoprofen.,10414674_6,0
48,platelet aggregation,8,28,Maximal platelet aggregation induced by 6 microM of adenosine diphosphate decreased after administration of ketoprofen.,10414674_6,0
51,platelet aggregation,144,164,"In contrast, maximal platelet aggregation increased in the acetaminophen group on the third postoperative day as compared with the pretreatment platelet aggregation results (P < .05).",10414674_8,0
50,platelet aggregation,21,41,"In contrast, maximal platelet aggregation increased in the acetaminophen group on the third postoperative day as compared with the pretreatment platelet aggregation results (P < .05).",10414674_8,0
4142,intracranial hematoma,62,83,One patient in the ketoprofen group developed a postoperative intracranial hematoma.,10414674_9,1
235,recurarization,10,24,A case of recurarization in the recovery room is reported.,10457883_1,1
52,atracurium,16,26,Accumulation of atracurium in the intravenous line led to recurarization after flushing the line in the recovery room.,10457883_2,0
238,recurarization,58,72,Accumulation of atracurium in the intravenous line led to recurarization after flushing the line in the recovery room.,10457883_2,1
241,desaturation,33,45,A respiratory arrest with severe desaturation and bradycardia occurred.,10457883_3,1
240,respiratory arrest,2,20,A respiratory arrest with severe desaturation and bradycardia occurred.,10457883_3,1
4143,neuromuscular blockade,66,88,"Circumstances leading to this event and the mechanisms enabling a neuromuscular blockade to occur, following the administration of a small dose of relaxant, are discussed.",10457883_4,1
242,small dose,133,143,"Circumstances leading to this event and the mechanisms enabling a neuromuscular blockade to occur, following the administration of a small dose of relaxant, are discussed.",10457883_4,0
54,propofol,165,173,The haemodynamic effects of propofol in combination with ephedrine in elderly patients (ASA groups 3 and 4).The marked vasodilator and negative inotropic effects of propofol are disadvantages in frail elderly patients.,10520387_0,0
243,haemodynamic,4,16,The haemodynamic effects of propofol in combination with ephedrine in elderly patients (ASA groups 3 and 4).The marked vasodilator and negative inotropic effects of propofol are disadvantages in frail elderly patients.,10520387_0,0
53,propofol,28,36,The haemodynamic effects of propofol in combination with ephedrine in elderly patients (ASA groups 3 and 4).The marked vasodilator and negative inotropic effects of propofol are disadvantages in frail elderly patients.,10520387_0,0
55,propofol,82,90,We investigated the safety and efficacy of adding different doses of ephedrine to propofol in order to obtund the hypotensive response.,10520387_1,0
56,propofol,77,85,"The haemodynamic effects of adding 15, 20 or 25 mg of ephedrine to 200 mg of propofol were compared to control in 40 ASA 3/4 patients over 60 years presenting for genito-urinary surgery.",10520387_2,0
247,haemodynamic,4,16,"The haemodynamic effects of adding 15, 20 or 25 mg of ephedrine to 200 mg of propofol were compared to control in 40 ASA 3/4 patients over 60 years presenting for genito-urinary surgery.",10520387_2,0
4145,genito-urinary,163,177,"The haemodynamic effects of adding 15, 20 or 25 mg of ephedrine to 200 mg of propofol were compared to control in 40 ASA 3/4 patients over 60 years presenting for genito-urinary surgery.",10520387_2,1
4144,ASA,117,120,"The haemodynamic effects of adding 15, 20 or 25 mg of ephedrine to 200 mg of propofol were compared to control in 40 ASA 3/4 patients over 60 years presenting for genito-urinary surgery.",10520387_2,1
57,propofol,29,37,The addition of ephedrine to propofol appears to be an effective method of obtunding the hypotensive response to propofol at all doses used in this study.,10520387_3,0
58,propofol,113,121,The addition of ephedrine to propofol appears to be an effective method of obtunding the hypotensive response to propofol at all doses used in this study.,10520387_3,0
59,propofol,85,93,"However, marked tachycardia associated with the use of ephedrine in combination with propofol occurred in the majority of patients, occasionally reaching high levels in individual patients.",10520387_4,0
4146,myocardial ischemia,45,64,"Due to the risk of this tachycardia inducing myocardial ischemia, we would not recommend the use in elderly patients of any of the ephedrine/propofol/mixtures studied.",10520387_5,1
60,Nitric oxide synthase,0,21,Nitric oxide synthase expression in the course of lead-induced hypertension.,10523326_0,0
4147,lead-induced,50,62,Nitric oxide synthase expression in the course of lead-induced hypertension.,10523326_0,1
251,nitrotyrosine,144,157,"We recently showed elevated reactive oxygen species (ROS), reduced urinary excretion of NO metabolites (NOx), and increased NO sequestration as nitrotyrosine in various tissues in rats with lead-induced hypertension.",10523326_1,0
61,reactive oxygen species,28,51,"We recently showed elevated reactive oxygen species (ROS), reduced urinary excretion of NO metabolites (NOx), and increased NO sequestration as nitrotyrosine in various tissues in rats with lead-induced hypertension.",10523326_1,0
252,lead-induced hypertension,190,215,"We recently showed elevated reactive oxygen species (ROS), reduced urinary excretion of NO metabolites (NOx), and increased NO sequestration as nitrotyrosine in various tissues in rats with lead-induced hypertension.",10523326_1,1
67,stimulatory,111,122,"This is, in part, due to ROS-mediated NO inactivation, lead-associated inhibition of NOS activity, and perhaps stimulatory actions of increased shear stress associated with hypertension.",10523326_10,0
279,shear stress,144,156,"This is, in part, due to ROS-mediated NO inactivation, lead-associated inhibition of NOS activity, and perhaps stimulatory actions of increased shear stress associated with hypertension.",10523326_10,1
62,NO synthase,131,142,"This study was designed to discern whether the reduction in urinary NOx in lead-induced hypertension is, in part, due to depressed NO synthase (NOS) expression.",10523326_2,0
4148,lead-induced,75,87,"This study was designed to discern whether the reduction in urinary NOx in lead-induced hypertension is, in part, due to depressed NO synthase (NOS) expression.",10523326_2,1
254,lead acetate,79,91,"Male Sprague-Dawley rats were randomly assigned to a lead-treated group (given lead acetate, 100 ppm, in drinking water and regular rat chow), a group given lead and vitamin E-fortified chow, or a normal control group given either regular food and water or vitamin E-fortified food for 12 weeks.",10523326_3,0
63,drinking water,105,119,"Male Sprague-Dawley rats were randomly assigned to a lead-treated group (given lead acetate, 100 ppm, in drinking water and regular rat chow), a group given lead and vitamin E-fortified chow, or a normal control group given either regular food and water or vitamin E-fortified food for 12 weeks.",10523326_3,0
64,malondialdehyde,51,66,"Tail blood pressure, urinary NOx excretion, plasma malondialdehyde (MDA), and endothelial and inducible NOS (eNOS and iNOS) isotypes in the aorta and kidney were measured.",10523326_4,0
259,eNOS,109,113,"Tail blood pressure, urinary NOx excretion, plasma malondialdehyde (MDA), and endothelial and inducible NOS (eNOS and iNOS) isotypes in the aorta and kidney were measured.",10523326_4,0
258,MDA,68,71,"Tail blood pressure, urinary NOx excretion, plasma malondialdehyde (MDA), and endothelial and inducible NOS (eNOS and iNOS) isotypes in the aorta and kidney were measured.",10523326_4,0
4149,blood pressure,5,19,"Tail blood pressure, urinary NOx excretion, plasma malondialdehyde (MDA), and endothelial and inducible NOS (eNOS and iNOS) isotypes in the aorta and kidney were measured.",10523326_4,1
65,inducible,94,103,"Tail blood pressure, urinary NOx excretion, plasma malondialdehyde (MDA), and endothelial and inducible NOS (eNOS and iNOS) isotypes in the aorta and kidney were measured.",10523326_4,0
66,isotypes,124,132,"Tail blood pressure, urinary NOx excretion, plasma malondialdehyde (MDA), and endothelial and inducible NOS (eNOS and iNOS) isotypes in the aorta and kidney were measured.",10523326_4,0
263,eNOS,173,177,"The lead-treated group exhibited a rise in blood pressure and plasma MDA concentration, a fall in urinary NOx excretion, and a paradoxical rise in vascular and renal tissue eNOS and iNOS expression.",10523326_5,0
261,MDA,69,72,"The lead-treated group exhibited a rise in blood pressure and plasma MDA concentration, a fall in urinary NOx excretion, and a paradoxical rise in vascular and renal tissue eNOS and iNOS expression.",10523326_5,0
4150,blood pressure,43,57,"The lead-treated group exhibited a rise in blood pressure and plasma MDA concentration, a fall in urinary NOx excretion, and a paradoxical rise in vascular and renal tissue eNOS and iNOS expression.",10523326_5,1
267,eNOS,180,184,"Vitamin E supplementation ameliorated hypertension, lowered plasma MDA concentration, and raised urinary NOx excretion while significantly lowering vascular, but not renal, tissue eNOS and iNOS expression.",10523326_6,0
266,MDA,67,70,"Vitamin E supplementation ameliorated hypertension, lowered plasma MDA concentration, and raised urinary NOx excretion while significantly lowering vascular, but not renal, tissue eNOS and iNOS expression.",10523326_6,0
265,Vitamin E,0,9,"Vitamin E supplementation ameliorated hypertension, lowered plasma MDA concentration, and raised urinary NOx excretion while significantly lowering vascular, but not renal, tissue eNOS and iNOS expression.",10523326_6,0
4151,blood pressure,50,64,"Vitamin E supplementation had no effect on either blood pressure, plasma MDA, or NOS expression in the control group.",10523326_7,1
269,Vitamin E,0,9,"Vitamin E supplementation had no effect on either blood pressure, plasma MDA, or NOS expression in the control group.",10523326_7,0
270,MDA,73,76,"Vitamin E supplementation had no effect on either blood pressure, plasma MDA, or NOS expression in the control group.",10523326_7,0
273,cell-free preparations,84,106,The study also revealed significant inhibition of NOS enzymatic activity by lead in cell-free preparations.,10523326_8,0
274,lead-induced hypertension,15,40,"In conclusion, lead-induced hypertension in this model was associated with a compensatory upregulation of renal and vascular eNOS and iNOS expression.",10523326_9,1
4152,compensatory,77,89,"In conclusion, lead-induced hypertension in this model was associated with a compensatory upregulation of renal and vascular eNOS and iNOS expression.",10523326_9,1
277,eNOS,125,129,"In conclusion, lead-induced hypertension in this model was associated with a compensatory upregulation of renal and vascular eNOS and iNOS expression.",10523326_9,0
68,Glyceryl trinitrate,0,19,Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura.,10524660_0,0
4153,migraine without aura,39,60,Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura.,10524660_0,1
4154,migraine with aura,77,95,Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura.,10524660_0,1
282,nociception,163,174,"Migraine with aura and migraine without aura have the same pain phase, thus indicating that migraine with aura and migraine without aura share a common pathway of nociception.",10524660_1,1
281,pain phase,59,69,"Migraine with aura and migraine without aura have the same pain phase, thus indicating that migraine with aura and migraine without aura share a common pathway of nociception.",10524660_1,1
4155,Migraine with aura,0,18,"Migraine with aura and migraine without aura have the same pain phase, thus indicating that migraine with aura and migraine without aura share a common pathway of nociception.",10524660_1,1
4156,migraine without aura,23,44,"Migraine with aura and migraine without aura have the same pain phase, thus indicating that migraine with aura and migraine without aura share a common pathway of nociception.",10524660_1,1
4157,migraine with aura,92,110,"Migraine with aura and migraine without aura have the same pain phase, thus indicating that migraine with aura and migraine without aura share a common pathway of nociception.",10524660_1,1
4158,migraine without aura,115,136,"Migraine with aura and migraine without aura have the same pain phase, thus indicating that migraine with aura and migraine without aura share a common pathway of nociception.",10524660_1,1
296,pain mechanisms,57,72,The results therefore suggest that NO is involved in the pain mechanisms of migraine with aura.,10524660_10,1
4164,migraine with aura,76,94,The results therefore suggest that NO is involved in the pain mechanisms of migraine with aura.,10524660_10,1
4165,migraine with aura,188,206,"Since cortical spreading depression has been shown to liberate NO in animals, this finding may help our understanding of the coupling between cortical spreading depression and headache in migraine with aura.",10524660_11,1
297,spreading depression,15,35,"Since cortical spreading depression has been shown to liberate NO in animals, this finding may help our understanding of the coupling between cortical spreading depression and headache in migraine with aura.",10524660_11,1
298,spreading depression,151,171,"Since cortical spreading depression has been shown to liberate NO in animals, this finding may help our understanding of the coupling between cortical spreading depression and headache in migraine with aura.",10524660_11,1
283,messenger molecule nitric oxide,60,91,"In recent years, increasing evidence has suggested that the messenger molecule nitric oxide (NO) is involved in pain mechanisms of migraine without aura.",10524660_2,0
4159,migraine without aura,131,152,"In recent years, increasing evidence has suggested that the messenger molecule nitric oxide (NO) is involved in pain mechanisms of migraine without aura.",10524660_2,1
4161,migraine with aura,227,245,"In order to clarify whether the same is true for migraine with aura, in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate (GTN) (0.5 microg/kg/min for 20 min) in 12 sufferers of migraine with aura.",10524660_3,1
4160,migraine with aura,49,67,"In order to clarify whether the same is true for migraine with aura, in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate (GTN) (0.5 microg/kg/min for 20 min) in 12 sufferers of migraine with aura.",10524660_3,1
69,glyceryl trinitrate,151,170,"In order to clarify whether the same is true for migraine with aura, in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate (GTN) (0.5 microg/kg/min for 20 min) in 12 sufferers of migraine with aura.",10524660_3,0
285,GTN,172,175,"In order to clarify whether the same is true for migraine with aura, in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate (GTN) (0.5 microg/kg/min for 20 min) in 12 sufferers of migraine with aura.",10524660_3,0
4162,migraine without aura,70,91,The specific aim was to elucidate whether an aura and/or an attack of migraine without aura could be induced.,10524660_4,1
287,Aura symptoms,0,13,Aura symptoms were not elicited in any subject.,10524660_6,1
289,GTN,90,93,Headache was more severe in migraineurs than in the controls during and immediately after GTN infusion (p=0.037) as well as during the following 11 h (p = 0.008).,10524660_7,0
288,migraineurs,28,39,Headache was more severe in migraineurs than in the controls during and immediately after GTN infusion (p=0.037) as well as during the following 11 h (p = 0.008).,10524660_7,1
291,migraineurs,76,87,"In the controls, the GTN-induced headache gradually disappeared, whereas in migraineurs peak headache intensity occurred at a mean time of 240 min post-infusion.",10524660_8,1
4163,migraine without aura,95,116,At this time the induced headache in 6 of 12 migraineurs fulfilled the diagnostic criteria for migraine without aura of the International Headache Society.,10524660_9,1
293,migraineurs,45,56,At this time the induced headache in 6 of 12 migraineurs fulfilled the diagnostic criteria for migraine without aura of the International Headache Society.,10524660_9,1
70,Gemcitabine,0,11,Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin.,10526274_0,0
72,cisplatin,123,132,Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin.,10526274_0,0
71,vinorelbine,17,28,Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin.,10526274_0,0
4166,nonsmall cell lung carcinoma,32,60,Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin.,10526274_0,1
313,1-year survival,52,67,The median time to progression was 16 weeks and the 1-year survival rate was 33%. Toxicity was mild.,10526274_14,1
314,Grade 3 neurotoxicity,144,165,"Six patients (12%) had World Health Organization Grade 3-4 neutropenia, 2 patients (4%) had Grade 3-4 thrombocytopenia, and 2 patients (4%) had Grade 3 neurotoxicity.",10526274_15,1
4168,Grade 3,49,56,"Six patients (12%) had World Health Organization Grade 3-4 neutropenia, 2 patients (4%) had Grade 3-4 thrombocytopenia, and 2 patients (4%) had Grade 3 neurotoxicity.",10526274_15,1
4169,Grade 3,92,99,"Six patients (12%) had World Health Organization Grade 3-4 neutropenia, 2 patients (4%) had Grade 3-4 thrombocytopenia, and 2 patients (4%) had Grade 3 neurotoxicity.",10526274_15,1
4170,Grade 3,44,51,The median age of those patients developing Grade 3-4 neutropenia was significantly higher than that of the remaining patients (75 years vs. 72 years; P = 0.047).,10526274_17,1
315,VNB,40,43,CONCLUSIONS: The combination of GEM and VNB is moderately active and well tolerated except in patients age >/= 75 years.,10526274_18,0
316,myelosuppression,40,56,This age group had an increased risk of myelosuppression.,10526274_19,1
4167,lung carcinoma,53,67,"BACKGROUND: Although the prevalence of nonsmall cell lung carcinoma (NSCLC) is high among elderly patients, few data are available regarding the efficacy and toxicity of chemotherapy in this group of patients.",10526274_2,1
300,nonsmall,39,47,"BACKGROUND: Although the prevalence of nonsmall cell lung carcinoma (NSCLC) is high among elderly patients, few data are available regarding the efficacy and toxicity of chemotherapy in this group of patients.",10526274_2,1
77,granulocyte-colony stimulating factor,34,71,Therefore the prophylactic use of granulocyte-colony stimulating factor should be considered with this treatment.,10526274_20,0
317,New chemotherapy combinations,0,29,New chemotherapy combinations with higher activity and lower toxicity are needed for elderly patients with advanced NSCLC.,10526274_21,0
73,vinorelbine,55,66,"Recent reports indicate that single agent therapy with vinorelbine (VNB) or gemcitabine (GEM) may obtain a response rate of 20-30% in elderly patients, with acceptable toxicity and improvement in symptoms and quality of life.",10526274_3,0
305,quality of life,209,224,"Recent reports indicate that single agent therapy with vinorelbine (VNB) or gemcitabine (GEM) may obtain a response rate of 20-30% in elderly patients, with acceptable toxicity and improvement in symptoms and quality of life.",10526274_3,1
302,single agent,29,41,"Recent reports indicate that single agent therapy with vinorelbine (VNB) or gemcitabine (GEM) may obtain a response rate of 20-30% in elderly patients, with acceptable toxicity and improvement in symptoms and quality of life.",10526274_3,0
303,VNB,68,71,"Recent reports indicate that single agent therapy with vinorelbine (VNB) or gemcitabine (GEM) may obtain a response rate of 20-30% in elderly patients, with acceptable toxicity and improvement in symptoms and quality of life.",10526274_3,0
74,gemcitabine,76,87,"Recent reports indicate that single agent therapy with vinorelbine (VNB) or gemcitabine (GEM) may obtain a response rate of 20-30% in elderly patients, with acceptable toxicity and improvement in symptoms and quality of life.",10526274_3,0
75,cisplatin,170,179,In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed.,10526274_4,0
306,VNB,77,80,In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed.,10526274_4,0
76,cisplatin,171,180,"METHODS: Forty-nine patients with advanced NSCLC were included, 38 of whom were age >/= 70 years and 11 were age < 70 years but who had some contraindication to receiving cisplatin.",10526274_5,0
308,VNB,27,30,"Treatment was comprised of VNB, 25 mg/m(2), plus GEM, 1000 mg/m(2), both on Days 1, 8, and 15 every 28 days.",10526274_7,0
320,calcium chloride,65,81,Rapid reversal of life-threatening diltiazem-induced tetany with calcium chloride.,10533019_0,0
322,intravenous diltiazem,96,117,We describe a patient who developed tetany with sudden respiratory arrest after the infusion of intravenous diltiazem.,10533019_1,0
321,sudden respiratory arrest,48,73,We describe a patient who developed tetany with sudden respiratory arrest after the infusion of intravenous diltiazem.,10533019_1,1
325,aggressive airway,150,167,"The administration of calcium chloride rapidly resolved the patient's tetany with prompt recovery of respiratory function, averting the need for more aggressive airway management and ventilatory support.",10533019_2,1
324,respiratory function,101,121,"The administration of calcium chloride rapidly resolved the patient's tetany with prompt recovery of respiratory function, averting the need for more aggressive airway management and ventilatory support.",10533019_2,1
323,calcium chloride,22,38,"The administration of calcium chloride rapidly resolved the patient's tetany with prompt recovery of respiratory function, averting the need for more aggressive airway management and ventilatory support.",10533019_2,0
330,calcium chloride,136,152,The emergency physician should be aware that life-threatening tetany may accompany the administration of intravenous diltiazem and that calcium chloride may be a rapid and effective remedy.,10533019_3,0
329,intravenous diltiazem,105,126,The emergency physician should be aware that life-threatening tetany may accompany the administration of intravenous diltiazem and that calcium chloride may be a rapid and effective remedy.,10533019_3,0
328,life-threatening tetany,45,68,The emergency physician should be aware that life-threatening tetany may accompany the administration of intravenous diltiazem and that calcium chloride may be a rapid and effective remedy.,10533019_3,1
4171,heart failure,56,69,"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.",10539815_0,1
78,angiotensin-converting enzyme inhibitor,77,116,"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.",10539815_0,0
79,angiotensin-converting enzyme inhibitor,211,250,"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.",10539815_0,0
334,renal function,360,374,"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.",10539815_0,1
333,CHF,326,329,"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.",10539815_0,0
331,renal function,24,38,"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.",10539815_0,1
4173,congestive heart failure,300,324,"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.",10539815_0,1
4172,left ventricular dysfunction,154,182,"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function.",10539815_0,1
363,renal function,74,88,"Diuretic therapy was likewise associated with a greater risk of decreased renal function in the enalapril group (RR 1.89, 95% CI 1.70-2.08) than in the placebo group (RR 1.35, 95% CI 1.09-1.66).",10539815_10,1
86,RR,113,115,"Diuretic therapy was likewise associated with a greater risk of decreased renal function in the enalapril group (RR 1.89, 95% CI 1.70-2.08) than in the placebo group (RR 1.35, 95% CI 1.09-1.66).",10539815_10,0
87,RR,167,169,"Diuretic therapy was likewise associated with a greater risk of decreased renal function in the enalapril group (RR 1.89, 95% CI 1.70-2.08) than in the placebo group (RR 1.35, 95% CI 1.09-1.66).",10539815_10,0
88,RR,60,62,"Conversely, enalapril had a relative renoprotective effect (RR 1.33, 95% CI 1.13-1.53) compared with placebo (RR 1.96, 95% CI 1.57-2.44) in patients with diabetes.",10539815_11,0
89,RR,110,112,"Conversely, enalapril had a relative renoprotective effect (RR 1.33, 95% CI 1.13-1.53) compared with placebo (RR 1.96, 95% CI 1.57-2.44) in patients with diabetes.",10539815_11,0
90,RR,84,86,"A lower risk of renal impairment was seen in both groups with beta-blocker therapy (RR 0.70, 95% CI 0.57-0.85) and higher baseline ejection fraction (RR 0.93 per 5% increment, 95% CI 0.91-0. 96).",10539815_12,0
91,RR,150,152,"A lower risk of renal impairment was seen in both groups with beta-blocker therapy (RR 0.70, 95% CI 0.57-0.85) and higher baseline ejection fraction (RR 0.93 per 5% increment, 95% CI 0.91-0. 96).",10539815_12,0
367,renal impairment,16,32,"A lower risk of renal impairment was seen in both groups with beta-blocker therapy (RR 0.70, 95% CI 0.57-0.85) and higher baseline ejection fraction (RR 0.93 per 5% increment, 95% CI 0.91-0. 96).",10539815_12,1
369,ejection fraction,131,148,"A lower risk of renal impairment was seen in both groups with beta-blocker therapy (RR 0.70, 95% CI 0.57-0.85) and higher baseline ejection fraction (RR 0.93 per 5% increment, 95% CI 0.91-0. 96).",10539815_12,1
368,beta-blocker,62,74,"A lower risk of renal impairment was seen in both groups with beta-blocker therapy (RR 0.70, 95% CI 0.57-0.85) and higher baseline ejection fraction (RR 0.93 per 5% increment, 95% CI 0.91-0. 96).",10539815_12,0
371,CHF,106,109,CONCLUSIONS: Enalapril use caused a 33% increase in the risk of decreased renal function in patients with CHF.,10539815_13,0
370,renal function,74,88,CONCLUSIONS: Enalapril use caused a 33% increase in the risk of decreased renal function in patients with CHF.,10539815_13,1
373,advanced age,17,29,Diuretic use and advanced age increased this risk.,10539815_14,0
375,renal impairment,50,66,"Diabetes was associated with an increased risk of renal impairment in all patients with CHF, but this risk was reduced in the enalapril group compared with the placebo group.",10539815_15,1
376,CHF,88,91,"Diabetes was associated with an increased risk of renal impairment in all patients with CHF, but this risk was reduced in the enalapril group compared with the placebo group.",10539815_15,0
378,beta-Blocker,0,12,beta-Blocker therapy and higher ejection fraction were renoprotective in all patients regardless of therapy.,10539815_16,0
380,renoprotective,55,69,beta-Blocker therapy and higher ejection fraction were renoprotective in all patients regardless of therapy.,10539815_16,0
379,ejection fraction,32,49,beta-Blocker therapy and higher ejection fraction were renoprotective in all patients regardless of therapy.,10539815_16,1
80,angiotensin-converting enzyme inhibitor,123,162,OBJECTIVE: To quantify specific clinical predictors of reduction in renal function in patients with CHF who are prescribed angiotensin-converting enzyme inhibitor therapy.,10539815_2,0
337,CHF,100,103,OBJECTIVE: To quantify specific clinical predictors of reduction in renal function in patients with CHF who are prescribed angiotensin-converting enzyme inhibitor therapy.,10539815_2,0
336,renal function,68,82,OBJECTIVE: To quantify specific clinical predictors of reduction in renal function in patients with CHF who are prescribed angiotensin-converting enzyme inhibitor therapy.,10539815_2,1
341,CHF,170,173,"METHOD: We analyzed data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF.",10539815_3,0
4174,Left Ventricular Dysfunction,45,73,"METHOD: We analyzed data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF.",10539815_3,1
81,creatinine,56,66,Decreased renal function was defined as a rise in serum creatinine >/=0.5 mg/dL (44 micromol/L) from baseline.,10539815_5,0
342,renal function,10,24,Decreased renal function was defined as a rise in serum creatinine >/=0.5 mg/dL (44 micromol/L) from baseline.,10539815_5,1
4175,blood pressure,171,185,"We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.",10539815_6,1
346,history of hypertension,200,223,"We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.",10539815_6,1
82,creatinine,146,156,"We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.",10539815_6,0
343,renal function,79,93,"We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.",10539815_6,1
344,ejection fraction,118,135,"We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.",10539815_6,1
347,beta-blocker,274,286,"We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.",10539815_6,0
83,antiplatelet,246,258,"We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy.",10539815_6,0
348,renal function,91,105,RESULTS: Patients randomly assigned to enalapril had a 33% greater likelihood of decreased renal function than controls (P =.003).,10539815_7,1
351,older age,67,76,"By multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta-blocker therapy and higher ejection fraction were renoprotective.",10539815_8,1
354,beta-blocker,164,176,"By multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta-blocker therapy and higher ejection fraction were renoprotective.",10539815_8,0
355,ejection fraction,196,213,"By multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta-blocker therapy and higher ejection fraction were renoprotective.",10539815_8,1
353,renal function,140,154,"By multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta-blocker therapy and higher ejection fraction were renoprotective.",10539815_8,1
356,renoprotective,219,233,"By multivariate analysis, in both the placebo and enalapril groups older age, diuretic therapy, and diabetes were associated with decreased renal function, whereas beta-blocker therapy and higher ejection fraction were renoprotective.",10539815_8,0
360,enalapril group,133,148,"Older age was associated with a greater risk of developing decreased renal function in both groups, but significantly more so in the enalapril group (enalapril: risk ratio [RR] 1.42 per 10 years, 95% confidence interval [CI] 1.32-1.52 with enalapril; placebo: RR 1.18, 95% CI 1.12-1.25).",10539815_9,0
359,renal function,69,83,"Older age was associated with a greater risk of developing decreased renal function in both groups, but significantly more so in the enalapril group (enalapril: risk ratio [RR] 1.42 per 10 years, 95% confidence interval [CI] 1.32-1.52 with enalapril; placebo: RR 1.18, 95% CI 1.12-1.25).",10539815_9,1
85,RR,260,262,"Older age was associated with a greater risk of developing decreased renal function in both groups, but significantly more so in the enalapril group (enalapril: risk ratio [RR] 1.42 per 10 years, 95% confidence interval [CI] 1.32-1.52 with enalapril; placebo: RR 1.18, 95% CI 1.12-1.25).",10539815_9,0
84,RR,173,175,"Older age was associated with a greater risk of developing decreased renal function in both groups, but significantly more so in the enalapril group (enalapril: risk ratio [RR] 1.42 per 10 years, 95% confidence interval [CI] 1.32-1.52 with enalapril; placebo: RR 1.18, 95% CI 1.12-1.25).",10539815_9,0
357,Older age,0,9,"Older age was associated with a greater risk of developing decreased renal function in both groups, but significantly more so in the enalapril group (enalapril: risk ratio [RR] 1.42 per 10 years, 95% confidence interval [CI] 1.32-1.52 with enalapril; placebo: RR 1.18, 95% CI 1.12-1.25).",10539815_9,1
92,olanzapine,35,45,Hypomania-like syndrome induced by olanzapine.,10565806_0,0
381,Hypomania-like syndrome,0,23,Hypomania-like syndrome induced by olanzapine.,10565806_0,1
382,specified psychotic disorder,63,91,We report a female patient with a diagnosis of a not otherwise specified psychotic disorder (DSM-IV) who developed hypomania shortly after the introduction of olanzapine treatment.,10565806_1,1
93,olanzapine,159,169,We report a female patient with a diagnosis of a not otherwise specified psychotic disorder (DSM-IV) who developed hypomania shortly after the introduction of olanzapine treatment.,10565806_1,0
4176,hypomania,115,124,We report a female patient with a diagnosis of a not otherwise specified psychotic disorder (DSM-IV) who developed hypomania shortly after the introduction of olanzapine treatment.,10565806_1,1
384,dopamine D4 receptor antagonist,12,43,"A selective dopamine D4 receptor antagonist, NRA0160: a preclinical neuropharmacological profile.",10579464_0,0
385,NRA0160,45,52,"A selective dopamine D4 receptor antagonist, NRA0160: a preclinical neuropharmacological profile.",10579464_0,0
94,( 3,22,25,"NRA0160, 5 - [2- ( 4- ( 3 - fluorobenzylidene) piperidin-1-yl) ethyl] - 4 -(4-fluorophenyl) thiazole-2-carboxamide, has a high affinity for human cloned dopamine D4.2, D4.4 and D4.7 receptors, with Ki values of 0.5, 0.9 and 2.7 nM, respectively.",10579464_1,0
387,fluorobenzylidene,28,45,"NRA0160, 5 - [2- ( 4- ( 3 - fluorobenzylidene) piperidin-1-yl) ethyl] - 4 -(4-fluorophenyl) thiazole-2-carboxamide, has a high affinity for human cloned dopamine D4.2, D4.4 and D4.7 receptors, with Ki values of 0.5, 0.9 and 2.7 nM, respectively.",10579464_1,0
388,thiazole-2-carboxamide,92,114,"NRA0160, 5 - [2- ( 4- ( 3 - fluorobenzylidene) piperidin-1-yl) ethyl] - 4 -(4-fluorophenyl) thiazole-2-carboxamide, has a high affinity for human cloned dopamine D4.2, D4.4 and D4.7 receptors, with Ki values of 0.5, 0.9 and 2.7 nM, respectively.",10579464_1,0
389,D4.4,168,172,"NRA0160, 5 - [2- ( 4- ( 3 - fluorobenzylidene) piperidin-1-yl) ethyl] - 4 -(4-fluorophenyl) thiazole-2-carboxamide, has a high affinity for human cloned dopamine D4.2, D4.4 and D4.7 receptors, with Ki values of 0.5, 0.9 and 2.7 nM, respectively.",10579464_1,0
390,D4.7 receptors,177,191,"NRA0160, 5 - [2- ( 4- ( 3 - fluorobenzylidene) piperidin-1-yl) ethyl] - 4 -(4-fluorophenyl) thiazole-2-carboxamide, has a high affinity for human cloned dopamine D4.2, D4.4 and D4.7 receptors, with Ki values of 0.5, 0.9 and 2.7 nM, respectively.",10579464_1,0
391,NRA0160,0,7,"NRA0160 is over 20,000fold more potent at the dopamine D4.2 receptor compared with the human cloned dopamine D2L receptor.",10579464_2,0
392,dopamine D2L receptor,100,121,"NRA0160 is over 20,000fold more potent at the dopamine D4.2 receptor compared with the human cloned dopamine D2L receptor.",10579464_2,0
396,Ki=180,120,126,"NRA0160 has negligible affinity for the human cloned dopamine D3 receptor (Ki=39 nM), rat serotonin (5-HT)2A receptors (Ki=180 nM) and rat alpha1 adrenoceptor (Ki=237 nM).",10579464_3,0
395,serotonin (5-HT)2A receptors,90,118,"NRA0160 has negligible affinity for the human cloned dopamine D3 receptor (Ki=39 nM), rat serotonin (5-HT)2A receptors (Ki=180 nM) and rat alpha1 adrenoceptor (Ki=237 nM).",10579464_3,0
394,Ki=39 nM,75,83,"NRA0160 has negligible affinity for the human cloned dopamine D3 receptor (Ki=39 nM), rat serotonin (5-HT)2A receptors (Ki=180 nM) and rat alpha1 adrenoceptor (Ki=237 nM).",10579464_3,0
397,alpha1 adrenoceptor,139,158,"NRA0160 has negligible affinity for the human cloned dopamine D3 receptor (Ki=39 nM), rat serotonin (5-HT)2A receptors (Ki=180 nM) and rat alpha1 adrenoceptor (Ki=237 nM).",10579464_3,0
95,dopamine D3 receptor,53,73,"NRA0160 has negligible affinity for the human cloned dopamine D3 receptor (Ki=39 nM), rat serotonin (5-HT)2A receptors (Ki=180 nM) and rat alpha1 adrenoceptor (Ki=237 nM).",10579464_3,0
393,NRA0160,0,7,"NRA0160 has negligible affinity for the human cloned dopamine D3 receptor (Ki=39 nM), rat serotonin (5-HT)2A receptors (Ki=180 nM) and rat alpha1 adrenoceptor (Ki=237 nM).",10579464_3,0
398,NRA0160,0,7,NRA0160 and clozapine antagonized locomotor hyperactivity induced by methamphetamine (MAP) in mice.,10579464_4,0
399,locomotor hyperactivity,34,57,NRA0160 and clozapine antagonized locomotor hyperactivity induced by methamphetamine (MAP) in mice.,10579464_4,1
400,NRA0160,0,7,"NRA0160 and clozapine antagonized MAP-induced stereotyped behavior in mice, although their effects did not exceed 50% inhibition, even at the highest dose given.",10579464_5,0
403,NRA0160,0,7,"NRA0160 and clozapine significantly induced catalepsy in rats, although their effects did not exceed 50% induction even at the highest dose given.",10579464_6,0
96,PPI,84,87,NRA0160 and clozapine significantly reversed the disruption of prepulse inhibition (PPI) in rats produced by apomorphine.,10579464_7,0
405,NRA0160,0,7,NRA0160 and clozapine significantly reversed the disruption of prepulse inhibition (PPI) in rats produced by apomorphine.,10579464_7,0
407,NRA0160,0,7,NRA0160 and clozapine significantly shortened the phencyclidine (PCP)-induced prolonged swimming latency in rats in a water maze task.,10579464_8,0
409,NRA0160,28,35,These findings suggest that NRA0160 may have unique antipsychotic activities without the liability of motor side effects typical of classical antipsychotics.,10579464_9,0
4177,side effects,108,120,These findings suggest that NRA0160 may have unique antipsychotic activities without the liability of motor side effects typical of classical antipsychotics.,10579464_9,1
411,artery calcification,17,37,"Warfarin-induced artery calcification is accelerated by growth and vitamin D.The present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.",10669626_0,1
97,Gla protein,272,283,"Warfarin-induced artery calcification is accelerated by growth and vitamin D.The present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.",10669626_0,0
413,artery calcification,167,187,"Warfarin-induced artery calcification is accelerated by growth and vitamin D.The present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.",10669626_0,1
414,gamma-carboxylation,242,261,"Warfarin-induced artery calcification is accelerated by growth and vitamin D.The present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.",10669626_0,0
415,artery wall,379,390,"Warfarin-induced artery calcification is accelerated by growth and vitamin D.The present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.",10669626_0,1
412,vitamin D,125,134,"Warfarin-induced artery calcification is accelerated by growth and vitamin D.The present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma-carboxylation of matrix Gla protein, a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall.",10669626_0,0
417,artery calcification,83,103,The first series of experiments examined the influence of age and growth status on artery calcification in Warfarin-treated rats.,10669626_1,1
446,High doses,0,10,"High doses of the vitamin K antagonist Warfarin are also known to cause calcification of the artery media, but at treatment times of 2 weeks or longer yet not at 1 week.",10669626_10,0
447,vitamin K,18,27,"High doses of the vitamin K antagonist Warfarin are also known to cause calcification of the artery media, but at treatment times of 2 weeks or longer yet not at 1 week.",10669626_10,0
455,artery calcification,197,217,"There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.",10669626_12,1
454,vitamin D,176,185,"There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.",10669626_12,0
452,vitamin D,106,115,"There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.",10669626_12,0
450,vitamin D,49,58,"There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.",10669626_12,0
451,artery calcification,67,87,"There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium.",10669626_12,1
457,vitamin D,87,96,"Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D, the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a calcification inhibitor.",10669626_13,0
458,vitamin D,131,140,"Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D, the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a calcification inhibitor.",10669626_13,0
98,Gla protein,232,243,"Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D, the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a calcification inhibitor.",10669626_13,0
459,artery calcification,56,76,"High levels of matrix Gla protein are found at sites of artery calcification in rats treated with vitamin D plus Warfarin, and chemical analysis showed that the protein that accumulated was indeed not gamma-carboxylated.",10669626_14,1
460,vitamin D,98,107,"High levels of matrix Gla protein are found at sites of artery calcification in rats treated with vitamin D plus Warfarin, and chemical analysis showed that the protein that accumulated was indeed not gamma-carboxylated.",10669626_14,0
461,gamma-carboxylated,201,219,"High levels of matrix Gla protein are found at sites of artery calcification in rats treated with vitamin D plus Warfarin, and chemical analysis showed that the protein that accumulated was indeed not gamma-carboxylated.",10669626_14,0
99,Gla protein,22,33,"High levels of matrix Gla protein are found at sites of artery calcification in rats treated with vitamin D plus Warfarin, and chemical analysis showed that the protein that accumulated was indeed not gamma-carboxylated.",10669626_14,0
100,gamma-carboxyglutamate,46,68,"These observations indicate that although the gamma-carboxyglutamate residues of matrix Gla protein are apparently required for its function as a calcification inhibitor, they are not required for its accumulation at calcification sites.",10669626_15,0
101,Gla protein,88,99,"These observations indicate that although the gamma-carboxyglutamate residues of matrix Gla protein are apparently required for its function as a calcification inhibitor, they are not required for its accumulation at calcification sites.",10669626_15,0
421,focal calcification,129,148,Treatment for 2 weeks with Warfarin caused massive focal calcification of the artery media in 20-day-old rats and less extensive focal calcification in 42-day-old rats.,10669626_2,1
419,focal calcification,51,70,Treatment for 2 weeks with Warfarin caused massive focal calcification of the artery media in 20-day-old rats and less extensive focal calcification in 42-day-old rats.,10669626_2,1
422,artery calcification,16,36,"In contrast, no artery calcification could be detected in 10-month-old adult rats even after 4 weeks of Warfarin treatment.",10669626_3,1
423,artery calcification,65,85,"To directly examine the importance of growth to Warfarin-induced artery calcification in animals of the same age, 20-day-old rats were fed for 2 weeks either an ad libitum diet or a 6-g/d restricted diet that maintains weight but prevents growth.",10669626_4,1
428,artery calcification,160,180,"Concurrent treatment of both dietary groups with Warfarin produced massive focal calcification of the artery media in the ad libitum-fed rats but no detectable artery calcification in the restricted-diet, growth-inhibited group.",10669626_5,1
426,focal calcification,75,94,"Concurrent treatment of both dietary groups with Warfarin produced massive focal calcification of the artery media in the ad libitum-fed rats but no detectable artery calcification in the restricted-diet, growth-inhibited group.",10669626_5,1
436,artery calcification,383,403,"Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.",10669626_6,1
434,artery calcification,215,235,"Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.",10669626_6,1
431,artery calcification,53,73,"Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum phosphate and susceptibility to artery calcification, with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats.",10669626_6,1
439,artery calcification,76,96,This observation suggests that increased susceptibility to Warfarin-induced artery calcification could be related to higher serum phosphate levels.,10669626_7,1
442,artery calcification,94,114,The second set of experiments examined the possible synergy between vitamin D and Warfarin in artery calcification.,10669626_8,1
441,vitamin D,68,77,The second set of experiments examined the possible synergy between vitamin D and Warfarin in artery calcification.,10669626_8,0
444,vitamin D,14,23,High doses of vitamin D are known to cause calcification of the artery media in as little as 3 to 4 days.,10669626_9,0
443,High doses,0,10,High doses of vitamin D are known to cause calcification of the artery media in as little as 3 to 4 days.,10669626_9,0
4178,drug-induced,156,168,These studies were conducted to examine the differential response to a drug challenge under varied experimental test conditions routinely employed to study drug-induced behavioral and neurophysiological responses in rodents.,10683478_1,1
478,striatal,43,51,"However, apomorphine-induced reductions in striatal dopamine turnover were detected in both novel and home cage environments.",10683478_10,1
466,nonselective dopamine agonist,15,44,"Apomorphine, a nonselective dopamine agonist, was selected due to its biphasic behavioral effects, its ability to induce hypothermia, and to produce distinct changes to dopamine turnover in the rodent brain.",10683478_2,0
102,biphasic,70,78,"Apomorphine, a nonselective dopamine agonist, was selected due to its biphasic behavioral effects, its ability to induce hypothermia, and to produce distinct changes to dopamine turnover in the rodent brain.",10683478_2,0
470,drug-induced hypothermia,95,119,"Moreover, test conditions can impact upon other physiological responses to apomorphine such as drug-induced hypothermia.",10683478_5,1
4179,Drug-induced,0,12,"Drug-induced gross activity counts were increased in the novel exploratory box only, while measures of stereotypic behavior were similar in both.",10683478_7,1
475,HVA:DA,39,45,Dopamine turnover ratios (DOPAC:DA and HVA:DA) were found to be lower in those animals exposed to the exploratory box when compared to their home cage counterparts.,10683478_9,0
103,DOPAC,26,31,Dopamine turnover ratios (DOPAC:DA and HVA:DA) were found to be lower in those animals exposed to the exploratory box when compared to their home cage counterparts.,10683478_9,0
4180,Gerstmann syndrome,22,40,Acetazolamide-induced Gerstmann syndrome.,10692744_0,1
480,acetazolamide,27,40,Acute confusion induced by acetazolamide is a well known adverse drug reaction in patients with renal impairment.,10692744_1,0
4181,adverse drug reaction,57,78,Acute confusion induced by acetazolamide is a well known adverse drug reaction in patients with renal impairment.,10692744_1,1
481,renal impairment,96,112,Acute confusion induced by acetazolamide is a well known adverse drug reaction in patients with renal impairment.,10692744_1,1
4182,Gerstmann syndrome,42,60,"We report a case of acetazolamide-induced Gerstmann syndrome in a patient with normal renal function, to highlight predisposing factors that are frequently overlooked.",10692744_2,1
482,normal renal function,79,100,"We report a case of acetazolamide-induced Gerstmann syndrome in a patient with normal renal function, to highlight predisposing factors that are frequently overlooked.",10692744_2,1
485,antiestrogenic drug,21,40,"Tamoxifen (TAM), the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer, induces changes in normal discoid shape of erythrocytes and hemolytic anemia.",10704919_1,0
4184,hemolytic anemia,162,178,"Tamoxifen (TAM), the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer, induces changes in normal discoid shape of erythrocytes and hemolytic anemia.",10704919_1,1
4183,breast cancer,87,100,"Tamoxifen (TAM), the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer, induces changes in normal discoid shape of erythrocytes and hemolytic anemia.",10704919_1,1
504,peripheral proteins,32,51,"However, TAM induces release of peripheral proteins of membrane-cytoskeleton and cytosol proteins essentially bound to band 3.",10704919_10,0
505,membrane-cytoskeleton,55,76,"However, TAM induces release of peripheral proteins of membrane-cytoskeleton and cytosol proteins essentially bound to band 3.",10704919_10,0
506,cytosol proteins,81,97,"However, TAM induces release of peripheral proteins of membrane-cytoskeleton and cytosol proteins essentially bound to band 3.",10704919_10,0
507,alpha-T,7,14,Either alpha-T or alpha-TAc increases membrane packing and prevents TAM partition into model membranes.,10704919_11,0
508,alpha-TAc,18,27,Either alpha-T or alpha-TAc increases membrane packing and prevents TAM partition into model membranes.,10704919_11,0
511,structural damage,147,164,These effects suggest that the protection from hemolysis by tocopherols is related to a decreased TAM incorporation in condensed membranes and the structural damage of the erythrocyte membrane is consequently avoided.,10704919_12,1
512,erythrocyte membrane,172,192,These effects suggest that the protection from hemolysis by tocopherols is related to a decreased TAM incorporation in condensed membranes and the structural damage of the erythrocyte membrane is consequently avoided.,10704919_12,0
514,red cell membrane,75,92,"Therefore, TAM-induced hemolysis results from a structural perturbation of red cell membrane, leading to changes in the framework of the erythrocyte membrane and its cytoskeleton caused by its high partition in the membrane.",10704919_13,0
515,erythrocyte membrane,137,157,"Therefore, TAM-induced hemolysis results from a structural perturbation of red cell membrane, leading to changes in the framework of the erythrocyte membrane and its cytoskeleton caused by its high partition in the membrane.",10704919_13,0
4186,hemolytic anemia,118,134,"These defects explain the abnormal erythrocyte shape and decreased mechanical stability promoted by TAM, resulting in hemolytic anemia.",10704919_14,1
518,biomembranes,123,135,"Additionally, since membrane leakage is a final stage of cytotoxicity, the disruption of the structural characteristics of biomembranes by TAM may contribute to the multiple mechanisms of its anticancer action.",10704919_15,0
519,anticancer action,192,209,"Additionally, since membrane leakage is a final stage of cytotoxicity, the disruption of the structural characteristics of biomembranes by TAM may contribute to the multiple mechanisms of its anticancer action.",10704919_15,0
4185,hemolytic anemia,135,151,"This work evaluates the effects of TAM on isolated human erythrocytes, attempting to identify the underlying mechanisms on TAM-induced hemolytic anemia and the involvement of biomembranes in its cytostatic action mechanisms.",10704919_2,1
487,biomembranes,175,187,"This work evaluates the effects of TAM on isolated human erythrocytes, attempting to identify the underlying mechanisms on TAM-induced hemolytic anemia and the involvement of biomembranes in its cytostatic action mechanisms.",10704919_2,0
104,cytostatic,195,205,"This work evaluates the effects of TAM on isolated human erythrocytes, attempting to identify the underlying mechanisms on TAM-induced hemolytic anemia and the involvement of biomembranes in its cytostatic action mechanisms.",10704919_2,0
488,total hemolysis,93,108,"The extension of hemolysis is variable with erythrocyte samples, but 12.5 microM TAM induces total hemolysis of all tested suspensions.",10704919_4,1
492,inactivated functional hydroxyl,135,166,The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced hemolysis is not related to oxidative membrane damage.,10704919_6,0
490,alpha-T,84,91,The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced hemolysis is not related to oxidative membrane damage.,10704919_6,0
491,alpha-TAc,123,132,The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced hemolysis is not related to oxidative membrane damage.,10704919_6,0
494,oxidative membrane damage,224,249,The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced hemolysis is not related to oxidative membrane damage.,10704919_6,1
105,alpha-tocopherol,66,82,The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced hemolysis is not related to oxidative membrane damage.,10704919_6,0
106,alpha-tocopherol acetate,97,121,The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced hemolysis is not related to oxidative membrane damage.,10704919_6,0
496,hemoglobin oxidation,64,84,This was further evidenced by absence of oxygen consumption and hemoglobin oxidation both determined in parallel with TAM-induced hemolysis.,10704919_7,0
498,peroxidation,51,63,"Furthermore, it was observed that TAM inhibits the peroxidation of human erythrocytes induced by AAPH, thus ruling out TAM-induced cell oxidative stress.",10704919_8,0
499,AAPH,97,101,"Furthermore, it was observed that TAM inhibits the peroxidation of human erythrocytes induced by AAPH, thus ruling out TAM-induced cell oxidative stress.",10704919_8,0
501,oxidative stress,136,152,"Furthermore, it was observed that TAM inhibits the peroxidation of human erythrocytes induced by AAPH, thus ruling out TAM-induced cell oxidative stress.",10704919_8,1
107,K(+),59,63,"Hemolysis caused by TAM was not preceded by the leakage of K(+) from the cells, also excluding a colloid-osmotic type mechanism of hemolysis, according to the effects on osmotic fragility curves.",10704919_9,0
520,"(Na,K)-ATPase",52,65,"Changes of sodium and ATP affinities of the cardiac (Na,K)-ATPase during and after nitric oxide deficient hypertension.",10706004_0,0
108,nitric oxide,83,95,"Changes of sodium and ATP affinities of the cardiac (Na,K)-ATPase during and after nitric oxide deficient hypertension.",10706004_0,0
539,K(Na),4,9,The K(Na) value for Na+ returned to control value.,10706004_10,0
116,Na+,20,23,The K(Na) value for Na+ returned to control value.,10706004_10,0
543,Na+-binding,151,162,"Inhibition of NO-synthase induced a reversible hypertension accompanied by depressed Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na,K)-ATPase.",10706004_11,0
544,"(Na,K)-ATPase",181,194,"Inhibition of NO-synthase induced a reversible hypertension accompanied by depressed Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na,K)-ATPase.",10706004_11,0
117,NO-synthase,14,25,"Inhibition of NO-synthase induced a reversible hypertension accompanied by depressed Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na,K)-ATPase.",10706004_11,0
4188,blood pressure,18,32,"After recovery of blood pressure to control values, the extrusion of Na+ from cardiac cells was normalized, as revealed by restoration of the (Na,K)-ATPase activity.",10706004_12,1
118,Na+,69,72,"After recovery of blood pressure to control values, the extrusion of Na+ from cardiac cells was normalized, as revealed by restoration of the (Na,K)-ATPase activity.",10706004_12,0
546,"(Na,K)-ATPase",142,155,"After recovery of blood pressure to control values, the extrusion of Na+ from cardiac cells was normalized, as revealed by restoration of the (Na,K)-ATPase activity.",10706004_12,0
112,L-NAME,258,264,"To assess the molecular basis of disturbances in transmembraneous transport of Na+, we studied the response of cardiac (Na,K)-ATPase to NO-deficient hypertension induced in rats by NO-synthase inhibition with 40 mg/kg/day N(G)-nitro-L-arginine methyl ester (L-NAME) for 4 four weeks.",10706004_4,0
109,Na+,79,82,"To assess the molecular basis of disturbances in transmembraneous transport of Na+, we studied the response of cardiac (Na,K)-ATPase to NO-deficient hypertension induced in rats by NO-synthase inhibition with 40 mg/kg/day N(G)-nitro-L-arginine methyl ester (L-NAME) for 4 four weeks.",10706004_4,0
111,N(G)-nitro-L-arginine methyl ester,222,256,"To assess the molecular basis of disturbances in transmembraneous transport of Na+, we studied the response of cardiac (Na,K)-ATPase to NO-deficient hypertension induced in rats by NO-synthase inhibition with 40 mg/kg/day N(G)-nitro-L-arginine methyl ester (L-NAME) for 4 four weeks.",10706004_4,0
110,NO-synthase,181,192,"To assess the molecular basis of disturbances in transmembraneous transport of Na+, we studied the response of cardiac (Na,K)-ATPase to NO-deficient hypertension induced in rats by NO-synthase inhibition with 40 mg/kg/day N(G)-nitro-L-arginine methyl ester (L-NAME) for 4 four weeks.",10706004_4,0
526,"(Na,K)-ATPase",119,132,"To assess the molecular basis of disturbances in transmembraneous transport of Na+, we studied the response of cardiac (Na,K)-ATPase to NO-deficient hypertension induced in rats by NO-synthase inhibition with 40 mg/kg/day N(G)-nitro-L-arginine methyl ester (L-NAME) for 4 four weeks.",10706004_4,0
113,L-NAME,31,37,"After 4-week administration of L-NAME, the systolic blood pressure (SBP) increased by 36%.",10706004_5,0
4187,blood pressure,52,66,"After 4-week administration of L-NAME, the systolic blood pressure (SBP) increased by 36%.",10706004_5,1
531,"(Na,K)-ATPase",20,33,"When activating the (Na,K)-ATPase with its substrate ATP, no changes in Km and Vmax values were observed in NO-deficient rats.",10706004_7,0
532,substrate ATP,43,56,"When activating the (Na,K)-ATPase with its substrate ATP, no changes in Km and Vmax values were observed in NO-deficient rats.",10706004_7,0
533,Vmax,79,83,"When activating the (Na,K)-ATPase with its substrate ATP, no changes in Km and Vmax values were observed in NO-deficient rats.",10706004_7,0
536,K(Na),69,74,"During activation with Na+, the Vmax remained unchanged, however the K(Na) increased by 50%, indicating a profound decrease in the affinity of the Na+-binding site in NO-deficient rats.",10706004_8,0
537,Na+-binding site,147,163,"During activation with Na+, the Vmax remained unchanged, however the K(Na) increased by 50%, indicating a profound decrease in the affinity of the Na+-binding site in NO-deficient rats.",10706004_8,0
114,Na+,23,26,"During activation with Na+, the Vmax remained unchanged, however the K(Na) increased by 50%, indicating a profound decrease in the affinity of the Na+-binding site in NO-deficient rats.",10706004_8,0
535,Vmax,32,36,"During activation with Na+, the Vmax remained unchanged, however the K(Na) increased by 50%, indicating a profound decrease in the affinity of the Na+-binding site in NO-deficient rats.",10706004_8,0
538,"(Na,K)-ATPase",50,63,"After recovery from hypertension, the activity of (Na,K)-ATPase increased, due to higher affinity of the ATP-binding site, as revealed from the lowered Km value for ATP.",10706004_9,0
115,ATP-binding,105,116,"After recovery from hypertension, the activity of (Na,K)-ATPase increased, due to higher affinity of the ATP-binding site, as revealed from the lowered Km value for ATP.",10706004_9,0
119,dopamine D2 receptor,122,142,"It has been shown that bromocriptine-induced tachycardia, which persisted after adrenalectomy, is (i) mediated by central dopamine D2 receptor activation and (ii) reduced by 5-day isoproterenol pretreatment, supporting therefore the hypothesis that this effect is dependent on sympathetic outflow to the heart.",10721819_1,0
566,central tachycardia,49,68,"They suggest that, in normal conscious rats, the central tachycardia of bromocriptine appears to predominate and to mask the bradycardia of this agonist at peripheral dopamine D2 receptors.",10721819_10,1
123,dopamine D2 receptors,167,188,"They suggest that, in normal conscious rats, the central tachycardia of bromocriptine appears to predominate and to mask the bradycardia of this agonist at peripheral dopamine D2 receptors.",10721819_10,0
122,bromocriptine,72,85,"They suggest that, in normal conscious rats, the central tachycardia of bromocriptine appears to predominate and to mask the bradycardia of this agonist at peripheral dopamine D2 receptors.",10721819_10,0
4190,blood pressure,93,107,Isoproterenol pretreatment for 15 days caused cardiac hypertrophy without affecting baseline blood pressure and heart rate.,10721819_3,1
554,heart rate,112,122,Isoproterenol pretreatment for 15 days caused cardiac hypertrophy without affecting baseline blood pressure and heart rate.,10721819_3,1
4189,cardiac hypertrophy,46,65,Isoproterenol pretreatment for 15 days caused cardiac hypertrophy without affecting baseline blood pressure and heart rate.,10721819_3,1
120,bromocriptine,29,42,"In control rats, intravenous bromocriptine (150 microg/kg) induced significant hypotension and tachycardia.",10721819_4,0
121,domperidone,0,11,domperidone (0.5 mg/kg).,10721819_6,0
556,cardiac vagal,8,21,Neither cardiac vagal nor sympathetic tone was altered by isoproterenol pretreatment.,10721819_7,1
557,sympathetic tone,26,42,Neither cardiac vagal nor sympathetic tone was altered by isoproterenol pretreatment.,10721819_7,1
561,EC50,226,230,"In isolated perfused heart preparations from isoproterenol-pretreated rats, the isoproterenol-induced maximal increase in left ventricular systolic pressure was significantly reduced, compared with saline-pretreated rats (the EC50 of the isoproterenol-induced increase in left ventricular systolic pressure was enhanced approximately 22-fold).",10721819_8,0
4191,left ventricular,122,138,"In isolated perfused heart preparations from isoproterenol-pretreated rats, the isoproterenol-induced maximal increase in left ventricular systolic pressure was significantly reduced, compared with saline-pretreated rats (the EC50 of the isoproterenol-induced increase in left ventricular systolic pressure was enhanced approximately 22-fold).",10721819_8,1
4192,left ventricular,272,288,"In isolated perfused heart preparations from isoproterenol-pretreated rats, the isoproterenol-induced maximal increase in left ventricular systolic pressure was significantly reduced, compared with saline-pretreated rats (the EC50 of the isoproterenol-induced increase in left ventricular systolic pressure was enhanced approximately 22-fold).",10721819_8,1
564,cardiac beta-adrenoceptor,184,209,"These results show that 15-day isoproterenol pretreatment not only abolished but reversed bromocriptine-induced tachycardia to bradycardia, an effect that is mainly related to further cardiac beta-adrenoceptor desensitization rather than to impairment of autonomic regulation of the heart.",10721819_9,0
4193,heart failure,72,85,Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure.,10728962_0,1
125,milrinone,48,57,The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension.,10728962_1,0
4194,heart failure,85,98,The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension.,10728962_1,1
124,phosphodiesterase inhibitors,11,39,The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension.,10728962_1,0
126,milrinone,83,92,"In patients with decompensated heart failure with hypotension after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone.",10728962_2,0
127,milrinone,186,195,"In patients with decompensated heart failure with hypotension after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone.",10728962_2,0
568,decompensated heart failure,17,44,"In patients with decompensated heart failure with hypotension after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone.",10728962_2,1
569,low doses,94,103,"In patients with decompensated heart failure with hypotension after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone.",10728962_2,0
4195,blood pressure,128,142,"In patients with decompensated heart failure with hypotension after treatment with milrinone, low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone.",10728962_2,1
572,clonidine's,28,39,A developmental analysis of clonidine's effects on cardiac rate and ultrasound production in infant rats.,10737864_0,0
575,extreme cold exposure,78,99,"Under controlled conditions, infant rats emit ultrasonic vocalizations during extreme cold exposure and after administration of the alpha(2) adrenoceptor agonist, clonidine.",10737864_1,1
576,adrenoceptor agonist,141,161,"Under controlled conditions, infant rats emit ultrasonic vocalizations during extreme cold exposure and after administration of the alpha(2) adrenoceptor agonist, clonidine.",10737864_1,0
578,sympathetic withdrawal,115,137,"Given that sympathetic neural dominance exhibits a similar developmental pattern, and given that clonidine induces sympathetic withdrawal and bradycardia, we hypothesized that clonidine's developmental effects on cardiac rate and ultrasound production would mirror each other.",10737864_3,1
583,cardiac rate,119,131,"Age-related changes in ultrasound production corresponded with changes in cardiovascular variables, including baseline cardiac rate and clonidine-induced bradycardia.",10737864_5,1
587,cardiovascular function,197,220,This experiment is discussed with regard to the hypothesis that ultrasound production is the acoustic by-product of a physiological maneuver that compensates for clonidine's detrimental effects on cardiovascular function.,10737864_6,1
4196,venous thromboembolism,59,81,Recurrent use of newer oral contraceptives and the risk of venous thromboembolism.,10739826_0,1
128,oral contraceptives,23,42,Recurrent use of newer oral contraceptives and the risk of venous thromboembolism.,10739826_0,0
589,OC,126,128,"The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.",10739826_1,0
588,VTE,78,81,"The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.",10739826_1,0
4197,venous thromboembolism,54,76,"The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.",10739826_1,1
129,oral contraceptives,105,124,"The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.",10739826_1,0
590,OC,170,172,"The epidemiological studies that assessed the risk of venous thromboembolism (VTE) associated with newer oral contraceptives (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers.",10739826_1,0
592,VTE,77,80,"Data from a Transnational case-control study were used to assess the risk of VTE for the latter patterns of use, while accounting for duration of use.",10739826_2,0
595,VTE,27,30,"The adjusted rate ratio of VTE for repeat users of third generation OC was 0.6 (95% CI:0.3-1.2) relative to repeat users of second generation pills, whereas it was 1.3 (95% CI:0.7-2.4) for switchers from second to third generation pills relative to switchers from third to second generation pills.",10739826_5,0
596,third generation OC,51,70,"The adjusted rate ratio of VTE for repeat users of third generation OC was 0.6 (95% CI:0.3-1.2) relative to repeat users of second generation pills, whereas it was 1.3 (95% CI:0.7-2.4) for switchers from second to third generation pills relative to switchers from third to second generation pills.",10739826_5,0
597,CI:0.3-1.2,84,94,"The adjusted rate ratio of VTE for repeat users of third generation OC was 0.6 (95% CI:0.3-1.2) relative to repeat users of second generation pills, whereas it was 1.3 (95% CI:0.7-2.4) for switchers from second to third generation pills relative to switchers from third to second generation pills.",10739826_5,0
599,third generation,214,230,"The adjusted rate ratio of VTE for repeat users of third generation OC was 0.6 (95% CI:0.3-1.2) relative to repeat users of second generation pills, whereas it was 1.3 (95% CI:0.7-2.4) for switchers from second to third generation pills relative to switchers from third to second generation pills.",10739826_5,0
130,second generation,124,141,"The adjusted rate ratio of VTE for repeat users of third generation OC was 0.6 (95% CI:0.3-1.2) relative to repeat users of second generation pills, whereas it was 1.3 (95% CI:0.7-2.4) for switchers from second to third generation pills relative to switchers from third to second generation pills.",10739826_5,0
131,second generation,273,290,"The adjusted rate ratio of VTE for repeat users of third generation OC was 0.6 (95% CI:0.3-1.2) relative to repeat users of second generation pills, whereas it was 1.3 (95% CI:0.7-2.4) for switchers from second to third generation pills relative to switchers from third to second generation pills.",10739826_5,0
600,third generation,28,44,We conclude that second and third generation agents are associated with equivalent risks of VTE when the same agent is used repeatedly after interruption periods or when users are switched between the two generations of pills.,10739826_6,0
602,OC,67,69,These analyses suggest that the higher risk observed for the newer OC in other studies may be the result of inadequate comparisons of pill users with different patterns of pill use.,10739826_7,0
4198,hyperalgesia,95,107,Differential effects of systemically administered ketamine and lidocaine on dynamic and static hyperalgesia induced by intradermal capsaicin in humans.,10743446_0,1
4199,hyperalgesia,141,153,We have examined the effect of systemic administration of ketamine and lidocaine on brush-evoked (dynamic) pain and punctate-evoked (static) hyperalgesia induced by capsaicin.,10743446_1,1
4205,hyperalgesia,116,128,The differential effects of ketamine and lidocaine on static and dynamic hyperalgesia suggest that the two types of hyperalgesia are mediated by separate mechanisms and have a distinct pharmacology.,10743446_10,1
4204,hyperalgesia,73,85,The differential effects of ketamine and lidocaine on static and dynamic hyperalgesia suggest that the two types of hyperalgesia are mediated by separate mechanisms and have a distinct pharmacology.,10743446_10,1
610,Capsaicin 100 micrograms,0,24,Capsaicin 100 micrograms was injected intradermally on the volar forearm followed by an i.v.,10743446_3,0
614,kg-1,117,121,"infusion of ketamine (bolus 0.1 mg kg-1 over 10 min followed by infusion of 7 micrograms kg-1 min-1), lidocaine 5 mg kg-1 or saline for 50 min.",10743446_4,0
613,kg-1 min-1,89,99,"infusion of ketamine (bolus 0.1 mg kg-1 over 10 min followed by infusion of 7 micrograms kg-1 min-1), lidocaine 5 mg kg-1 or saline for 50 min.",10743446_4,0
612,kg-1,35,39,"infusion of ketamine (bolus 0.1 mg kg-1 over 10 min followed by infusion of 7 micrograms kg-1 min-1), lidocaine 5 mg kg-1 or saline for 50 min.",10743446_4,0
4201,hyperalgesia,142,154,"The following were measured: spontaneous pain, pain evoked by punctate and brush stimuli (VAS), and areas of brush-evoked and punctate-evoked hyperalgesia.",10743446_6,1
4200,punctate,62,70,"The following were measured: spontaneous pain, pain evoked by punctate and brush stimuli (VAS), and areas of brush-evoked and punctate-evoked hyperalgesia.",10743446_6,1
615,spontaneous pain,29,45,"The following were measured: spontaneous pain, pain evoked by punctate and brush stimuli (VAS), and areas of brush-evoked and punctate-evoked hyperalgesia.",10743446_6,1
4202,hyperalgesia,67,79,Ketamine reduced both the area of brush-evoked and punctate-evoked hyperalgesia significantly and it tended to reduce brush-evoked pain.,10743446_7,1
619,brush-evoked pain,118,135,Ketamine reduced both the area of brush-evoked and punctate-evoked hyperalgesia significantly and it tended to reduce brush-evoked pain.,10743446_7,1
4203,hyperalgesia,46,58,Lidocaine reduced the area of punctate-evoked hyperalgesia significantly.,10743446_8,1
620,spontaneous pain,34,50,It tended to reduce VAS scores of spontaneous pain but had no effect on evoked pain.,10743446_9,1
621,evoked pain,72,83,It tended to reduce VAS scores of spontaneous pain but had no effect on evoked pain.,10743446_9,1
132,cyclosporine,65,77,Treatment of tacrolimus-related adverse effects by conversion to cyclosporine in liver transplant recipients.,10743694_0,0
623,liver transplant,81,97,Treatment of tacrolimus-related adverse effects by conversion to cyclosporine in liver transplant recipients.,10743694_0,1
4206,adverse effects,32,47,Treatment of tacrolimus-related adverse effects by conversion to cyclosporine in liver transplant recipients.,10743694_0,1
626,CyA,113,116,"When tacrolimus side effects persist despite dose reduction, conversion to cyclosporine-based immunosuppression (CyA) is necessary.",10743694_1,0
624,tacrolimus side effects,5,28,"When tacrolimus side effects persist despite dose reduction, conversion to cyclosporine-based immunosuppression (CyA) is necessary.",10743694_1,1
625,cyclosporine-based immunosuppression,75,111,"When tacrolimus side effects persist despite dose reduction, conversion to cyclosporine-based immunosuppression (CyA) is necessary.",10743694_1,0
643,CyA,79,82,"When tacrolimus side effects are unresponsive to dose reduction, conversion to CyA can be accomplished safely, with no increased risk of rejection and excellent long-term outcome.",10743694_10,0
629,primary immunosuppression,51,76,"Of 388 liver recipients who received tacrolimus as primary immunosuppression, 70 required conversion to CyA. We recorded indication for conversion, whether conversion was early or late after transplantation, tacrolimus dose and trough blood level at conversion, and incidence of rejection after conversion.",10743694_3,0
133,tacrolimus,37,47,"Of 388 liver recipients who received tacrolimus as primary immunosuppression, 70 required conversion to CyA. We recorded indication for conversion, whether conversion was early or late after transplantation, tacrolimus dose and trough blood level at conversion, and incidence of rejection after conversion.",10743694_3,0
134,tacrolimus,208,218,"Of 388 liver recipients who received tacrolimus as primary immunosuppression, 70 required conversion to CyA. We recorded indication for conversion, whether conversion was early or late after transplantation, tacrolimus dose and trough blood level at conversion, and incidence of rejection after conversion.",10743694_3,0
4208,insulin-dependent,59,76,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,1
4207,neurotoxicity,38,51,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,1
4209,diabetes mellitus,78,95,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,1
4210,neurotoxicity,217,230,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,1
631,gastrointestinal (GI) toxicity,128,158,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,1
633,post-transplant lmphoproliferate disease,305,345,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,1
135,(1,183,185,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,0
136,(2,353,355,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,0
137,(1,373,375,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,0
632,hepatotoxicity,285,299,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,1
634,PTLD,347,351,"Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1).",10743694_5,0
637,late-conversion,6,21,"Among late-conversion patients, 37 (90.2%) had improvement/resolution; in 4 (9.8%), adverse effects persisted.",10743694_7,1
4211,adverse effects,84,99,"Among late-conversion patients, 37 (90.2%) had improvement/resolution; in 4 (9.8%), adverse effects persisted.",10743694_7,1
640,functioning grafts,42,60,"Sixty-two patients (88.6%) are alive with functioning grafts 686 +/- 362 days (range, 154-1433 days) after conversion.",10743694_9,1
648,aggressive behavior,81,100,"In male animals, repeated apomorphine treatment induced a gradual development of aggressive behavior as evidenced by the increased intensity of aggressiveness and shortened latency before the first attack toward the opponent.",10791295_2,1
4212,juvenile rheumatoid arthritis,25,54,Ocular manifestations of juvenile rheumatoid arthritis.,1079693_0,1
651,Ocular manifestations,0,21,Ocular manifestations of juvenile rheumatoid arthritis.,1079693_0,1
4213,juvenile rheumatoid arthritis,25,54,We followed 210 cases of juvenile rheumatoid arthritis closely for eleven years.,1079693_1,1
661,band keratopathy,13,29,"Cataract and band keratopathy occurred in only 22 and 13% of our group, respectively.",1079693_10,1
4214,chorioretinopathy,89,106,We used chloroquine or hydroxychloroquine in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs.,1079693_11,1
662,posterior subcapsular cataracts,96,127,Systemically administered corticosteroids were used in 75 of 210 cases; a significant number of posterior subcapsular cataracts was found.,1079693_12,1
4215,keratoconjunctivitis sicca,8,34,Typical keratoconjunctivitis sicca developed in three of the uveitis cases.,1079693_13,1
664,band keratopathy,33,49,"Surgical treatment of cataracts, band keratopathy, and glaucoma achieved uniformly discouraging results.",1079693_15,1
652,monoarticular,88,101,Iridocyclitis was seen most frequently in young female patients (0 to 4 years) with the monoarticular or pauciatricular form of the arthritis.,1079693_3,1
653,pauciatricular,105,119,Iridocyclitis was seen most frequently in young female patients (0 to 4 years) with the monoarticular or pauciatricular form of the arthritis.,1079693_3,1
655,active uveitis,80,94,"Although 61% of patients had a noncontributory ocular history on entry, 42% had active uveitis on entry.",1079693_5,1
656,detecting uveitis,30,47,Our approach was effective in detecting uveitis in new cases and exacerbations of uveitis in established cases.,1079693_6,1
660,visual acuity,132,145,"Forty-four percent of patients with uveitis had one or more identifiable signs or symptoms, such as red eye, ocular pain, decreased visual acuity, or photophobia, in order of decreasing frequency.",1079693_7,1
659,ocular pain,109,120,"Forty-four percent of patients with uveitis had one or more identifiable signs or symptoms, such as red eye, ocular pain, decreased visual acuity, or photophobia, in order of decreasing frequency.",1079693_7,1
658,red eye,100,107,"Forty-four percent of patients with uveitis had one or more identifiable signs or symptoms, such as red eye, ocular pain, decreased visual acuity, or photophobia, in order of decreasing frequency.",1079693_7,0
657,signs or,73,81,"Forty-four percent of patients with uveitis had one or more identifiable signs or symptoms, such as red eye, ocular pain, decreased visual acuity, or photophobia, in order of decreasing frequency.",1079693_7,1
4216,Intracranial aneurysms,0,22,Intracranial aneurysms and cocaine abuse: analysis of prognostic indicators.,10807237_0,1
4217,cocaine abuse,27,40,Intracranial aneurysms and cocaine abuse: analysis of prognostic indicators.,10807237_0,1
4218,subarachnoid hemorrhage,26,49,OBJECTIVE: The outcome of subarachnoid hemorrhage associated with cocaine abuse is reportedly poor.,10807237_1,1
4219,cocaine abuse,66,79,OBJECTIVE: The outcome of subarachnoid hemorrhage associated with cocaine abuse is reportedly poor.,10807237_1,1
4225,cocaine-related,113,128,Hunt and Hess grade (P < 0.005) and age (P < 0.007) were significant predictors of outcome for the patients with cocaine-related aneurysms.,10807237_10,1
674,aneurysmal rupture,36,54,CONCLUSION: Cocaine use predisposed aneurysmal rupture at a significantly earlier age and in much smaller aneurysms.,10807237_11,1
4220,cocaine-related,81,96,METHODS: A review of admissions during a 6-year period revealed 14 patients with cocaine-related aneurysms.,10807237_3,1
4222,cocaine abuse,103,116,This group was compared with a control group of 135 patients with ruptured aneurysms and no history of cocaine abuse.,10807237_4,1
4221,ruptured aneurysms,66,84,This group was compared with a control group of 135 patients with ruptured aneurysms and no history of cocaine abuse.,10807237_4,1
668,Hess grade,64,74,"Age at presentation, time of ictus after intoxication, Hunt and Hess grade of subarachnoid hemorrhage, size of the aneurysm, location of the aneurysm, and the Glasgow Outcome Scale score were assessed and compared.",10807237_5,1
4223,subarachnoid hemorrhage,78,101,"Age at presentation, time of ictus after intoxication, Hunt and Hess grade of subarachnoid hemorrhage, size of the aneurysm, location of the aneurysm, and the Glasgow Outcome Scale score were assessed and compared.",10807237_5,1
4224,anterior circulation,66,86,"In patients in the study group, all aneurysms were located in the anterior circulation.",10807237_7,1
4226,blood pressure,36,50,Effect of intravenous nimodipine on blood pressure and outcome after acute stroke.,10835440_0,1
4227,acute stroke,69,81,Effect of intravenous nimodipine on blood pressure and outcome after acute stroke.,10835440_0,1
676,nimodipine,22,32,Effect of intravenous nimodipine on blood pressure and outcome after acute stroke.,10835440_0,0
4228,blood pressure,147,161,BACKGROUND AND PURPOSE: The Intravenous Nimodipine West European Stroke Trial (INWEST) found a correlation between nimodipine-induced reduction in blood pressure (BP) and an unfavorable outcome in acute stroke.,10835440_1,1
4229,acute stroke,197,209,BACKGROUND AND PURPOSE: The Intravenous Nimodipine West European Stroke Trial (INWEST) found a correlation between nimodipine-induced reduction in blood pressure (BP) and an unfavorable outcome in acute stroke.,10835440_1,1
677,Nimodipine,40,50,BACKGROUND AND PURPOSE: The Intravenous Nimodipine West European Stroke Trial (INWEST) found a correlation between nimodipine-induced reduction in blood pressure (BP) and an unfavorable outcome in acute stroke.,10835440_1,0
705,high-dose nimodipine,124,144,"CONCLUSIONS: DBP, but not SBP, reduction was associated with neurological worsening after the intravenous administration of high-dose nimodipine after acute stroke.",10835440_10,0
704,neurological worsening,61,83,"CONCLUSIONS: DBP, but not SBP, reduction was associated with neurological worsening after the intravenous administration of high-dose nimodipine after acute stroke.",10835440_10,1
701,DBP,13,16,"CONCLUSIONS: DBP, but not SBP, reduction was associated with neurological worsening after the intravenous administration of high-dose nimodipine after acute stroke.",10835440_10,0
4231,acute stroke,151,163,"CONCLUSIONS: DBP, but not SBP, reduction was associated with neurological worsening after the intravenous administration of high-dose nimodipine after acute stroke.",10835440_10,1
706,low-dose nimodipine,4,23,"For low-dose nimodipine, the results were not conclusive.",10835440_11,0
707,nimodipine,70,80,These results do not confirm or exclude a neuroprotective property of nimodipine.,10835440_12,0
141,neuroprotective,42,57,These results do not confirm or exclude a neuroprotective property of nimodipine.,10835440_12,0
680,BP,157,159,We sought to confirm this correlation with and without adjustment for prognostic variables and to investigate outcome in subgroups with increasing levels of BP reduction.,10835440_2,0
683,high-dose,187,196,"METHODS: Patients with a clinical diagnosis of ischemic stroke (within 24 hours) were consecutively allocated to receive placebo (n=100), 1 mg/h (low-dose) nimodipine (n=101), or 2 mg/h (high-dose) nimodipine (n=94).",10835440_3,0
138,low-dose,146,154,"METHODS: Patients with a clinical diagnosis of ischemic stroke (within 24 hours) were consecutively allocated to receive placebo (n=100), 1 mg/h (low-dose) nimodipine (n=101), or 2 mg/h (high-dose) nimodipine (n=94).",10835440_3,0
684,nimodipine,198,208,"METHODS: Patients with a clinical diagnosis of ischemic stroke (within 24 hours) were consecutively allocated to receive placebo (n=100), 1 mg/h (low-dose) nimodipine (n=101), or 2 mg/h (high-dose) nimodipine (n=94).",10835440_3,0
4230,ischemic stroke,47,62,"METHODS: Patients with a clinical diagnosis of ischemic stroke (within 24 hours) were consecutively allocated to receive placebo (n=100), 1 mg/h (low-dose) nimodipine (n=101), or 2 mg/h (high-dose) nimodipine (n=94).",10835440_3,1
682,nimodipine,156,166,"METHODS: Patients with a clinical diagnosis of ischemic stroke (within 24 hours) were consecutively allocated to receive placebo (n=100), 1 mg/h (low-dose) nimodipine (n=101), or 2 mg/h (high-dose) nimodipine (n=94).",10835440_3,0
686,high dose,117,126,"RESULTS: Two hundred sixty-five patients were included in this analysis (n=92, 93, and 80 for placebo, low dose, and high dose, respectively).",10835440_5,0
139,low dose,103,111,"RESULTS: Two hundred sixty-five patients were included in this analysis (n=92, 93, and 80 for placebo, low dose, and high dose, respectively).",10835440_5,0
687,Nimodipine,0,10,Nimodipine treatment resulted in a statistically significant reduction in systolic BP (SBP) and diastolic BP (DBP) from baseline compared with placebo during the first few days.,10835440_6,0
695,beta=0.49,149,158,"In multivariate analysis, a significant correlation between DBP reduction and worsening of the neurological score was found for the high-dose group (beta=0.49, P=0. 048).",10835440_7,0
692,DBP,60,63,"In multivariate analysis, a significant correlation between DBP reduction and worsening of the neurological score was found for the high-dose group (beta=0.49, P=0. 048).",10835440_7,0
140,P=0,160,163,"In multivariate analysis, a significant correlation between DBP reduction and worsening of the neurological score was found for the high-dose group (beta=0.49, P=0. 048).",10835440_7,0
4232,visceral pain,105,118,Cyclophosphamide-induced cystitis in freely-moving conscious rats: behavioral approach to a new model of visceral pain.,10840460_0,1
4233,visceral pain,31,44,PURPOSE: To develop a model of visceral pain in rats using a behavioral approach.,10840460_1,1
722,mg./kg,35,41,by the intravesical route and of 5 mg./kg.,10840460_12,0
147,CP,14,16,"i.v. RESULTS: CP dose-relatedly induced marked behavioral modifications in male rats: breathing rate decrease, closing of the eyes and occurrence of specific postures.",10840460_13,0
724,behavioral disorders,41,61,Morphine dose-dependently reversed these behavioral disorders.,10840460_14,1
148,CP,92,94,A dose of 0.5 mg./kg. produced a reduction of almost 50% of the behavioral score induced by CP 200 mg./kg.,10840460_15,0
728,bladder wall,77,89,"At the time of administration of morphine, histological modifications of the bladder wall, such as chorionic and muscle layer edema, were observed.",10840460_17,1
729,muscle layer edema,113,131,"At the time of administration of morphine, histological modifications of the bladder wall, such as chorionic and muscle layer edema, were observed.",10840460_17,1
149,CP,16,18,"In female rats, CP 200 mg./kg.",10840460_18,0
711,antitumoral agent,26,43,"Cyclophosphamide (CP), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein, was used to induce cystitis.",10840460_2,0
713,toxic metabolite,112,128,"Cyclophosphamide (CP), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein, was used to induce cystitis.",10840460_2,0
142,CP,18,20,"Cyclophosphamide (CP), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein, was used to induce cystitis.",10840460_2,0
710,Cyclophosphamide,0,16,"Cyclophosphamide (CP), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein, was used to induce cystitis.",10840460_2,0
150,CP,16,18,"intravesically, CP did not produce any behavioral effects, whereas acrolein at 0.5 mg.",10840460_21,0
151,CP,73,75,intravesically induced behavioral modifications identical to those under CP 200 mg./kg.,10840460_22,0
4234,visceral pain,156,169,"CONCLUSIONS: Overall, these results indicate that this experimental model of CP-induced cystitis may be an interesting new behavioral model of inflammatory visceral pain, allowing a better understanding of these painful syndromes and thus a better therapeutic approach to them.",10840460_26,1
143,CP,23,25,"MATERIALS AND METHODS: CP was administered at doses of 50, 100 and 200 mg./kg.",10840460_3,0
144,(1,95,97,i.v.) on CP-induced behavioral modifications were tested administered alone and after naloxone (1 mg./kg.,10840460_6,0
145,CP,30,32,"In addition, 90 minutes after CP injection, that is, at the time of administration of morphine, the bladder was removed in some rats for histological examination.",10840460_8,0
146,CP,118,120,"Finally, to show that the bladder is essential for the CP-induced behavioral modifications, female rats also received CP at doses of 200 mg./kg.",10840460_9,0
739,maternal tuberculosis,78,99,A 17-day-old infant on isoniazid therapy 13 mg/kg daily from birth because of maternal tuberculosis was admitted after 4 days of clonic fits.,1085609_1,1
740,clonic fits,129,140,A 17-day-old infant on isoniazid therapy 13 mg/kg daily from birth because of maternal tuberculosis was admitted after 4 days of clonic fits.,1085609_1,1
4235,pyridoxine deficiency,101,122,"The fits ceased within 4 hours of administering intramuscular pyridoxine, suggesting an aetiology of pyridoxine deficiency secondary to isoniazid medication.",1085609_3,1
4236,of children,36,47,Ketamine sedation for the reduction of children's fractures in the emergency department.,10901305_0,1
741,emergency department,67,87,Ketamine sedation for the reduction of children's fractures in the emergency department.,10901305_0,1
4240,Blood pressure,0,14,Blood pressure and heart rate remained stable.,10901305_12,1
756,heart rate,19,29,Blood pressure and heart rate remained stable.,10901305_12,1
757,ataxic movements,132,148,"Minor side effects included nausea (thirteen patients), emesis (eight of the thirteen patients with nausea), clumsiness (evident as ataxic movements in ten patients), and dysphoric reaction (one patient).",10901305_13,1
4241,side effects,6,18,"Minor side effects included nausea (thirteen patients), emesis (eight of the thirteen patients with nausea), clumsiness (evident as ataxic movements in ten patients), and dysphoric reaction (one patient).",10901305_13,1
758,dysphoric reaction,171,189,"Minor side effects included nausea (thirteen patients), emesis (eight of the thirteen patients with nausea), clumsiness (evident as ataxic movements in ten patients), and dysphoric reaction (one patient).",10901305_13,1
4242,of children,119,130,"CONCLUSIONS: Ketamine reliably, safely, and quickly provided adequate sedation to effectively facilitate the reduction of children's fractures in the emergency department at our institution.",10901305_15,1
4237,of children,114,125,The purpose of the present study was to examine the safety and efficacy of ketamine for sedation in the treatment of children's fractures in the emergency department.,10901305_2,1
743,emergency department,145,165,The purpose of the present study was to examine the safety and efficacy of ketamine for sedation in the treatment of children's fractures in the emergency department.,10901305_2,1
745,isolated fracture,155,172,"METHODS: One hundred and fourteen children (average age, 5.3 years; range, twelve months to ten years and ten months) who underwent closed reduction of an isolated fracture or dislocation in the emergency department at a level-I trauma center were prospectively evaluated.",10901305_3,1
746,emergency department,195,215,"METHODS: One hundred and fourteen children (average age, 5.3 years; range, twelve months to ten years and ten months) who underwent closed reduction of an isolated fracture or dislocation in the emergency department at a level-I trauma center were prospectively evaluated.",10901305_3,1
4239,body weight,209,220,Ketamine hydrochloride was administered intravenously (at a dose of two milligrams per kilogram of body weight) in ninety-nine of the patients and intramuscularly (at a dose of four milligrams per kilogram of body weight) in the other fifteen.,10901305_4,1
4238,body weight,99,110,Ketamine hydrochloride was administered intravenously (at a dose of two milligrams per kilogram of body weight) in ninety-nine of the patients and intramuscularly (at a dose of four milligrams per kilogram of body weight) in the other fifteen.,10901305_4,1
748,Ketamine hydrochloride,0,22,Ketamine hydrochloride was administered intravenously (at a dose of two milligrams per kilogram of body weight) in ninety-nine of the patients and intramuscularly (at a dose of four milligrams per kilogram of body weight) in the other fifteen.,10901305_4,0
754,fracture reduction,162,180,"The average score according to the Children's Hospital of Eastern Ontario Pain Scale was 6.4 points (range, 5 to 10 points), reflecting minimal or no pain during fracture reduction.",10901305_8,1
753,no pain,147,154,"The average score according to the Children's Hospital of Eastern Ontario Pain Scale was 6.4 points (range, 5 to 10 points), reflecting minimal or no pain during fracture reduction.",10901305_8,1
152,acetylcholine receptor,82,104,Prednisolone-induced muscle dysfunction is caused more by atrophy than by altered acetylcholine receptor expression.,10910842_0,0
763,muscle physiology,41,58,Large doses of glucocorticoids can alter muscle physiology and susceptibility to neuromuscular blocking drugs by mechanisms not clearly understood.,10910842_1,1
764,neuromuscular blocking drugs,81,109,Large doses of glucocorticoids can alter muscle physiology and susceptibility to neuromuscular blocking drugs by mechanisms not clearly understood.,10910842_1,0
797,P10 group,32,41,AChR expression was less in the P10 group than in the S group.,10910842_10,0
796,AChR,0,4,AChR expression was less in the P10 group than in the S group.,10910842_10,0
798,S group,54,61,AChR expression was less in the P10 group than in the S group.,10910842_10,0
800,muscle mass,36,47,"The evoked tensions correlated with muscle mass (r(2) = 0.32, P < 0.001), however, not with expression of AChR. The 50% effective dose of d-tubocurarine did not correlate with muscle mass or AChR expression.",10910842_11,1
163,d-tubocurarine,138,152,"The evoked tensions correlated with muscle mass (r(2) = 0.32, P < 0.001), however, not with expression of AChR. The 50% effective dose of d-tubocurarine did not correlate with muscle mass or AChR expression.",10910842_11,0
802,muscle mass,176,187,"The evoked tensions correlated with muscle mass (r(2) = 0.32, P < 0.001), however, not with expression of AChR. The 50% effective dose of d-tubocurarine did not correlate with muscle mass or AChR expression.",10910842_11,1
804,neuromuscular dysfunction,29,54,"Our results suggest that the neuromuscular dysfunction after prednisolone is dose-dependent, and derives primarily from muscle atrophy and derives less so from changes in AChR expression.",10910842_12,1
4243,muscle atrophy,120,134,"Our results suggest that the neuromuscular dysfunction after prednisolone is dose-dependent, and derives primarily from muscle atrophy and derives less so from changes in AChR expression.",10910842_12,1
808,neuromuscular physiology,76,100,IMPLICATIONS: The mechanisms by which chronic glucocorticoid therapy alters neuromuscular physiology and pharmacology are unclear.,10910842_13,1
4244,muscle atrophy,82,96,We suggest that the observed effects are dose-dependent and derive primarily from muscle atrophy and derive less from changes in acetylcholine receptor expression.,10910842_14,1
164,acetylcholine receptor,129,151,We suggest that the observed effects are dose-dependent and derive primarily from muscle atrophy and derive less from changes in acetylcholine receptor expression.,10910842_14,0
766,muscle function,75,90,"We investigated the effects of moderate and large doses of prednisolone on muscle function and pharmacology, and their relationship to changes in muscle size and acetylcholine receptor (AChR) expression.",10910842_2,1
768,AChR,186,190,"We investigated the effects of moderate and large doses of prednisolone on muscle function and pharmacology, and their relationship to changes in muscle size and acetylcholine receptor (AChR) expression.",10910842_2,0
153,acetylcholine receptor,162,184,"We investigated the effects of moderate and large doses of prednisolone on muscle function and pharmacology, and their relationship to changes in muscle size and acetylcholine receptor (AChR) expression.",10910842_2,0
154,P100,174,178,"With institutional approval, 35 Sprague-Dawley rats were randomly allocated to receive daily subcutaneous doses of 10 mg/kg prednisolone (P10 group), 100 mg/kg prednisolone (P100 group), or an equal volume of saline (S group) for 7 days.",10910842_3,0
155,P100,63,67,A fourth group of rats was pair fed (food restricted) with the P100 rats for 7 days (FR group).,10910842_4,0
773,FR group,85,93,A fourth group of rats was pair fed (food restricted) with the P100 rats for 7 days (FR group).,10910842_4,0
779,muscle mass,202,213,"On Day 8, the nerve-evoked peak twitch tensions, tetanic tensions, and fatigability, and the dose-response curves of d-tubocurarine in the tibialis cranialis muscle were measured in vivo and related to muscle mass or expression of AChRs.",10910842_5,1
776,tetanic tensions,49,65,"On Day 8, the nerve-evoked peak twitch tensions, tetanic tensions, and fatigability, and the dose-response curves of d-tubocurarine in the tibialis cranialis muscle were measured in vivo and related to muscle mass or expression of AChRs.",10910842_5,1
156,d-tubocurarine,117,131,"On Day 8, the nerve-evoked peak twitch tensions, tetanic tensions, and fatigability, and the dose-response curves of d-tubocurarine in the tibialis cranialis muscle were measured in vivo and related to muscle mass or expression of AChRs.",10910842_5,0
780,body weight gain,8,24,"Rate of body weight gain was depressed in the P100, FR, and P10 groups compared with the S group.",10910842_6,1
781,P10,60,63,"Rate of body weight gain was depressed in the P100, FR, and P10 groups compared with the S group.",10910842_6,0
157,P100,46,50,"Rate of body weight gain was depressed in the P100, FR, and P10 groups compared with the S group.",10910842_6,0
784,P10,63,66,Tibialis muscle mass was smaller in the P100 group than in the P10 or S groups.,10910842_7,0
158,P100,40,44,Tibialis muscle mass was smaller in the P100 group than in the P10 or S groups.,10910842_7,0
783,Tibialis muscle mass,0,20,Tibialis muscle mass was smaller in the P100 group than in the P10 or S groups.,10910842_7,1
160,P100,166,170,"The evoked peak twitch and tetanic tensions were less in the P100 group than in the P10 or S groups, however, tension per milligram of muscle mass was greater in the P100 group than in the S group.",10910842_8,0
159,P100,61,65,"The evoked peak twitch and tetanic tensions were less in the P100 group than in the P10 or S groups, however, tension per milligram of muscle mass was greater in the P100 group than in the S group.",10910842_8,0
787,P10,84,87,"The evoked peak twitch and tetanic tensions were less in the P100 group than in the P10 or S groups, however, tension per milligram of muscle mass was greater in the P100 group than in the S group.",10910842_8,0
789,muscle mass,135,146,"The evoked peak twitch and tetanic tensions were less in the P100 group than in the P10 or S groups, however, tension per milligram of muscle mass was greater in the P100 group than in the S group.",10910842_8,1
792,P10,95,98,The 50% effective dose of d-tubocurarine (microg/kg) in the tibialis muscle was smaller in the P10 (33.6 +/- 5.4) than in the S (61.9 +/- 5.0) or the P100 (71.3 +/- 9.6) groups.,10910842_9,0
161,d-tubocurarine,26,40,The 50% effective dose of d-tubocurarine (microg/kg) in the tibialis muscle was smaller in the P10 (33.6 +/- 5.4) than in the S (61.9 +/- 5.0) or the P100 (71.3 +/- 9.6) groups.,10910842_9,0
162,P100,150,154,The 50% effective dose of d-tubocurarine (microg/kg) in the tibialis muscle was smaller in the P10 (33.6 +/- 5.4) than in the S (61.9 +/- 5.0) or the P100 (71.3 +/- 9.6) groups.,10910842_9,0
165,Cyclosporine,0,12,Cyclosporine and tacrolimus-associated thrombotic microangiopathy.,11007689_0,0
4245,thrombotic microangiopathy,39,65,Cyclosporine and tacrolimus-associated thrombotic microangiopathy.,11007689_0,1
4246,thrombotic microangiopathy,19,45,The development of thrombotic microangiopathy (TMA) associated with the use of cyclosporine has been well documented.,11007689_1,1
810,TMA,47,50,The development of thrombotic microangiopathy (TMA) associated with the use of cyclosporine has been well documented.,11007689_1,0
166,cyclosporine,79,91,The development of thrombotic microangiopathy (TMA) associated with the use of cyclosporine has been well documented.,11007689_1,0
179,tacrolimus,47,57,Patients who are switched from cyclosporine to tacrolimus or vice versa should be closely monitored for the signs and symptoms of recurrent TMA.,11007689_10,0
4248,signs and symptoms,108,126,Patients who are switched from cyclosporine to tacrolimus or vice versa should be closely monitored for the signs and symptoms of recurrent TMA.,11007689_10,1
829,TMA,140,143,Patients who are switched from cyclosporine to tacrolimus or vice versa should be closely monitored for the signs and symptoms of recurrent TMA.,11007689_10,0
178,cyclosporine,31,43,Patients who are switched from cyclosporine to tacrolimus or vice versa should be closely monitored for the signs and symptoms of recurrent TMA.,11007689_10,0
814,intravenous immunoglobulin G,157,185,"Treatments have included discontinuation or reduction of cyclosporine dose with or without concurrent plasma exchange, plasma infusion, anticoagulation, and intravenous immunoglobulin G infusion.",11007689_2,0
812,plasma exchange,102,117,"Treatments have included discontinuation or reduction of cyclosporine dose with or without concurrent plasma exchange, plasma infusion, anticoagulation, and intravenous immunoglobulin G infusion.",11007689_2,0
167,cyclosporine,57,69,"Treatments have included discontinuation or reduction of cyclosporine dose with or without concurrent plasma exchange, plasma infusion, anticoagulation, and intravenous immunoglobulin G infusion.",11007689_2,0
818,graft loss,149,159,"However, for recipients of organ transplantation, removing the inciting agent is not without the attendant risk of precipitating acute rejection and graft loss.",11007689_3,1
817,acute rejection,129,144,"However, for recipients of organ transplantation, removing the inciting agent is not without the attendant risk of precipitating acute rejection and graft loss.",11007689_3,1
816,inciting agent,63,77,"However, for recipients of organ transplantation, removing the inciting agent is not without the attendant risk of precipitating acute rejection and graft loss.",11007689_3,0
815,organ transplantation,27,48,"However, for recipients of organ transplantation, removing the inciting agent is not without the attendant risk of precipitating acute rejection and graft loss.",11007689_3,1
168,tacrolimus,42,52,The last decade has seen the emergence of tacrolimus as a potent immunosuppressive agent with mechanisms of action virtually identical to those of cyclosporine.,11007689_4,0
170,cyclosporine,147,159,The last decade has seen the emergence of tacrolimus as a potent immunosuppressive agent with mechanisms of action virtually identical to those of cyclosporine.,11007689_4,0
169,immunosuppressive agent,65,88,The last decade has seen the emergence of tacrolimus as a potent immunosuppressive agent with mechanisms of action virtually identical to those of cyclosporine.,11007689_4,0
171,tacrolimus,26,36,"As a result, switching to tacrolimus has been reported to be a viable therapeutic option in the setting of cyclosporine-induced TMA.",11007689_5,0
819,therapeutic option,70,88,"As a result, switching to tacrolimus has been reported to be a viable therapeutic option in the setting of cyclosporine-induced TMA.",11007689_5,0
820,TMA,128,131,"As a result, switching to tacrolimus has been reported to be a viable therapeutic option in the setting of cyclosporine-induced TMA.",11007689_5,0
822,TMA,99,102,"With the more widespread application of tacrolimus in organ transplantation, tacrolimus-associated TMA has also been recognized.",11007689_6,0
821,organ transplantation,54,75,"With the more widespread application of tacrolimus in organ transplantation, tacrolimus-associated TMA has also been recognized.",11007689_6,1
172,tacrolimus,40,50,"With the more widespread application of tacrolimus in organ transplantation, tacrolimus-associated TMA has also been recognized.",11007689_6,0
173,cyclosporine,105,117,"However, literature regarding the incidence of the recurrence of TMA in patients exposed sequentially to cyclosporine and tacrolimus is limited.",11007689_7,0
823,TMA,65,68,"However, literature regarding the incidence of the recurrence of TMA in patients exposed sequentially to cyclosporine and tacrolimus is limited.",11007689_7,0
174,tacrolimus,122,132,"However, literature regarding the incidence of the recurrence of TMA in patients exposed sequentially to cyclosporine and tacrolimus is limited.",11007689_7,0
825,TMA,97,100,We report a case of a living donor renal transplant recipient who developed cyclosporine-induced TMA that responded to the withdrawal of cyclosporine in conjunction with plasmapheresis and fresh frozen plasma replacement therapy.,11007689_8,0
824,renal transplant,35,51,We report a case of a living donor renal transplant recipient who developed cyclosporine-induced TMA that responded to the withdrawal of cyclosporine in conjunction with plasmapheresis and fresh frozen plasma replacement therapy.,11007689_8,1
175,cyclosporine,137,149,We report a case of a living donor renal transplant recipient who developed cyclosporine-induced TMA that responded to the withdrawal of cyclosporine in conjunction with plasmapheresis and fresh frozen plasma replacement therapy.,11007689_8,0
4247,loss of,122,129,Introduction of tacrolimus as an alternative immunosuppressive agent resulted in the recurrence of TMA and the subsequent loss of the renal allograft.,11007689_9,1
827,TMA,99,102,Introduction of tacrolimus as an alternative immunosuppressive agent resulted in the recurrence of TMA and the subsequent loss of the renal allograft.,11007689_9,0
176,tacrolimus,16,26,Introduction of tacrolimus as an alternative immunosuppressive agent resulted in the recurrence of TMA and the subsequent loss of the renal allograft.,11007689_9,0
177,immunosuppressive agent,45,68,Introduction of tacrolimus as an alternative immunosuppressive agent resulted in the recurrence of TMA and the subsequent loss of the renal allograft.,11007689_9,0
828,renal allograft,134,149,Introduction of tacrolimus as an alternative immunosuppressive agent resulted in the recurrence of TMA and the subsequent loss of the renal allograft.,11007689_9,1
4249,Parkinson's disease,42,61,Apomorphine: an underutilized therapy for Parkinson's disease.,11009181_0,1
830,dopaminergic drug,26,43,Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease.,11009181_1,0
4250,Parkinson's disease,75,94,Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease.,11009181_1,1
4251,Parkinson's disease,114,133,"While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating Parkinson's disease by subcutaneous administration of apomorphine has only recently become the subject of systematic study.",11009181_2,1
180,antiparkinsonian,15,31,"While powerful antiparkinsonian effects had been observed as early as 1951, the potential of treating fluctuating Parkinson's disease by subcutaneous administration of apomorphine has only recently become the subject of systematic study.",11009181_2,0
832,apomorphine injections,96,118,A number of small scale clinical trials have unequivocally shown that intermittent subcutaneous apomorphine injections produce antiparkinsonian benefit close if not identical to that seen with levodopa and that apomorphine rescue injections can reliably revert off-periods even in patients with complex on-off motor swings.,11009181_3,0
181,antiparkinsonian,127,143,A number of small scale clinical trials have unequivocally shown that intermittent subcutaneous apomorphine injections produce antiparkinsonian benefit close if not identical to that seen with levodopa and that apomorphine rescue injections can reliably revert off-periods even in patients with complex on-off motor swings.,11009181_3,0
182,dopamine agonists,209,226,"Continuous subcutaneous apomorphine infusions can reduce daily off-time by more than 50% in this group of patients, which appears to be a stronger effect than that generally seen with add-on therapy with oral dopamine agonists or COMT inhibitors.",11009181_4,0
836,COMT inhibitors,230,245,"Continuous subcutaneous apomorphine infusions can reduce daily off-time by more than 50% in this group of patients, which appears to be a stronger effect than that generally seen with add-on therapy with oral dopamine agonists or COMT inhibitors.",11009181_4,0
843,psychiatric complications,129,154,"The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems, whereas sedation and psychiatric complications play a lesser role.",11009181_7,1
842,cutaneous tolerability,75,97,"The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems, whereas sedation and psychiatric complications play a lesser role.",11009181_7,1
4252,side effects,9,21,"The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems, whereas sedation and psychiatric complications play a lesser role.",11009181_7,1
4253,Parkinson's disease,89,108,"Given the marked degree of efficacy of subcutaneous apomorphine treatment in fluctuating Parkinson's disease, this approach seems to deserve more widespread clinical use.",11009181_8,1
4254,Alzheimer's disease,189,208,"OBJECTIVE: The pharmacological response to drugs that act on the cholinergic system of the iris has been used to predict deficits in central cholinergic functioning due to diseases such as Alzheimer's disease, yet correlations between central and peripheral responses have not been properly studied.",11022397_1,1
187,eye drops,4,13,All eye drops were given in a randomized order.,11022397_10,0
857,word recall,125,136,"In 2 separate sessions, a single dose of scopolamine (0.5 mg, intravenously) or placebo was administered, and the effects on word recall were measured using the Buschke Selective Reminding Test over 2 hours.",11022397_11,1
4255,Buschke,161,168,"In 2 separate sessions, a single dose of scopolamine (0.5 mg, intravenously) or placebo was administered, and the effects on word recall were measured using the Buschke Selective Reminding Test over 2 hours.",11022397_11,1
858,Pupil size,18,28,OUTCOME MEASURES: Pupil size at time points after administration of tropicamide and pilocarpine; scopolamine-induced impairment in word recall.,11022397_12,1
188,tropicamide,68,79,OUTCOME MEASURES: Pupil size at time points after administration of tropicamide and pilocarpine; scopolamine-induced impairment in word recall.,11022397_12,0
189,tropicamide,107,118,RESULTS: There was no significant difference between elderly and young volunteers in pupillary response to tropicamide at any time point (p > 0.05).,11022397_13,0
864,pupil size,82,92,"The elderly group had a significantly greater pilocarpine-induced net decrease in pupil size 85, 125, 165 and 215 minutes after administration, compared with the young group (p < 0.05).",11022397_14,1
190,tropicamide,93,104,CONCLUSION: There is an age-related pupillary response to pilocarpine that is not found with tropicamide.,11022397_16,0
184,(2,110,112,"This study assessed the effect of normal aging on (1) the tropicamide-induced increase in pupil diameter, and (2) the reversal of this effect with pilocarpine.",11022397_2,0
849,pupil diameter,90,104,"This study assessed the effect of normal aging on (1) the tropicamide-induced increase in pupil diameter, and (2) the reversal of this effect with pilocarpine.",11022397_2,1
183,(1,50,52,"This study assessed the effect of normal aging on (1) the tropicamide-induced increase in pupil diameter, and (2) the reversal of this effect with pilocarpine.",11022397_2,0
850,age-dependent changes,53,74,Scopolamine was used as a positive control to detect age-dependent changes in central cholinergic functioning in the elderly.,11022397_3,1
185,tropicamide,14,25,"In 1 session, tropicamide (20 microL, 0.01%) was administered to one eye and placebo to the other.",11022397_8,0
186,tropicamide,20,31,"In another session, tropicamide (20 microL, 0.01%) was administered to both eyes, followed 23 minutes later by the application of pilocarpine (20 microL, 0.1%) to one eye and placebo to the other.",11022397_9,0
870,opioid,39,45,Pain responses in methadone-maintained opioid abusers.,11027904_0,1
872,opioid,36,42,"Providing pain management for known opioid abusers is a challenging clinical task, in part because little is known about their pain experience and analgesic requirements.",11027904_1,0
874,pain tolerance,36,50,This study was designed to describe pain tolerance and analgesic response in a sample of opioid addicts stabilized in methadone-maintenance (MM) treatment (n = 60) in comparison to matched nondependent control subjects (n = 60).,11027904_2,1
875,opioid,89,95,This study was designed to describe pain tolerance and analgesic response in a sample of opioid addicts stabilized in methadone-maintenance (MM) treatment (n = 60) in comparison to matched nondependent control subjects (n = 60).,11027904_2,0
877,cold-pressor,70,82,"By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.",11027904_3,0
191,CP,84,86,"By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.",11027904_3,0
879,opioid,180,186,"By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.",11027904_3,0
192,nonsteroidal anti-inflammatory,212,242,"By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.",11027904_3,0
878,therapeutic doses,152,169,"By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.",11027904_3,0
193,analgesic agents,261,277,"By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents.",11027904_3,0
194,CP,71,73,"Results showed that MM individuals were significantly less tolerant of CP pain than control subjects, replicating previous work.",11027904_4,0
880,opioid,28,34,These data indicate that MM opioid abusers represent a pain-intolerant subset of clinical patients.,11027904_6,1
882,Analgesic effect,0,16,"Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study.",11027905_0,0
902,T30,49,52,A significant difference in MMSE was observed at T30 in patients who received 0.50 mg/kg of ketamine.,11027905_10,0
4260,neuropathic pain,77,93,"Ketamine can improve morphine analgesia in difficult pain syndromes, such as neuropathic pain.",11027905_11,1
4259,pain syndromes,53,67,"Ketamine can improve morphine analgesia in difficult pain syndromes, such as neuropathic pain.",11027905_11,1
4261,adverse effects,35,50,"However, the occurrence of central adverse effects should be taken into account, especially when using higher doses.",11027905_12,1
196,NMDA,70,74,"Animal and clinical studies have suggested that N-methyl-D-aspartate (NMDA) antagonists, such as ketamine, may be effective in improving opioid analgesia in difficult pain syndromes, such as neuropathic pain.",11027905_2,0
4256,pain syndromes,167,181,"Animal and clinical studies have suggested that N-methyl-D-aspartate (NMDA) antagonists, such as ketamine, may be effective in improving opioid analgesia in difficult pain syndromes, such as neuropathic pain.",11027905_2,1
886,opioid,137,143,"Animal and clinical studies have suggested that N-methyl-D-aspartate (NMDA) antagonists, such as ketamine, may be effective in improving opioid analgesia in difficult pain syndromes, such as neuropathic pain.",11027905_2,0
4257,neuropathic pain,191,207,"Animal and clinical studies have suggested that N-methyl-D-aspartate (NMDA) antagonists, such as ketamine, may be effective in improving opioid analgesia in difficult pain syndromes, such as neuropathic pain.",11027905_2,1
195,N-methyl-D-aspartate,48,68,"Animal and clinical studies have suggested that N-methyl-D-aspartate (NMDA) antagonists, such as ketamine, may be effective in improving opioid analgesia in difficult pain syndromes, such as neuropathic pain.",11027905_2,0
896,T120,342,346,"Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180).",11027905_4,0
895,T60,323,326,"Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180).",11027905_4,0
893,T0,279,281,"Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180).",11027905_4,0
892,arterial pressure,215,232,"Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180).",11027905_4,1
891,dry mouth,93,102,"Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180).",11027905_4,1
890,Pain intensity,0,14,"Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180).",11027905_4,1
4258,nausea and vomiting,45,64,"Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180).",11027905_4,1
897,T180,366,370,"Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180).",11027905_4,0
197,saline solution,18,33,"Ketamine, but not saline solution, significantly reduced the pain intensity in almost all the patients at both doses.",11027905_5,0
899,higher doses,55,67,This effect was more relevant in patients treated with higher doses.,11027905_6,0
900,unpleasant sensation,46,66,"Hallucinations occurred in 4 patients, and an unpleasant sensation (""empty head"") was also reported by 2 patients.",11027905_7,1
904,High-dose methylprednisolone,0,28,High-dose methylprednisolone may do more harm for spinal cord injury.,11058428_0,0
4262,spinal cord injury,50,68,High-dose methylprednisolone may do more harm for spinal cord injury.,11058428_0,1
906,high-dose methylprednisolone,67,95,"Because of the National Acute Spinal Cord Injury Studies (NASCIS), high-dose methylprednisolone became the standard of care for the acute spinal cord injury.",11058428_1,0
4264,spinal cord injury,138,156,"Because of the National Acute Spinal Cord Injury Studies (NASCIS), high-dose methylprednisolone became the standard of care for the acute spinal cord injury.",11058428_1,1
4263,Spinal Cord Injury,30,48,"Because of the National Acute Spinal Cord Injury Studies (NASCIS), high-dose methylprednisolone became the standard of care for the acute spinal cord injury.",11058428_1,1
909,high-dose methylprednisolone,100,128,"In the NASCIS, there was no mention regarding the possibility of acute corticosteroid myopathy that high-dose methylprednisolone may cause.",11058428_2,0
908,corticosteroid myopathy,71,94,"In the NASCIS, there was no mention regarding the possibility of acute corticosteroid myopathy that high-dose methylprednisolone may cause.",11058428_2,1
911,clinical condition,139,157,The dosage of methylprednisolone recommended by the NASCIS 3 is the highest dose of steroids ever being used during a 2-day period for any clinical condition.,11058428_3,1
198,methylprednisolone,14,32,The dosage of methylprednisolone recommended by the NASCIS 3 is the highest dose of steroids ever being used during a 2-day period for any clinical condition.,11058428_3,0
4265,spinal cord injury,62,80,We hypothesize that it may cause some damage to the muscle of spinal cord injury patients.,11058428_4,1
912,steroid myopathy,9,25,"Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.",11058428_5,1
913,neurological improvement,53,77,"Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.",11058428_5,1
916,steroid myopathy,162,178,"Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.",11058428_5,1
915,natural motor recovery,130,152,"Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.",11058428_5,1
199,methylprednisolone,211,229,"Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.",11058428_5,0
4266,spinal cord injury,244,262,"Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury.",11058428_5,1
200,methylprednisolone,84,102,"To our knowledge, this is the first discussion considering the possibility that the methylprednisolone recommended by NASCIS may cause acute corticosteroid myopathy.",11058428_6,0
918,corticosteroid myopathy,141,164,"To our knowledge, this is the first discussion considering the possibility that the methylprednisolone recommended by NASCIS may cause acute corticosteroid myopathy.",11058428_6,1
201,rapamycin,14,23,Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience.,11063349_0,0
919,renal transplant,45,61,Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience.,11063349_0,1
202,cyclosporine,103,115,BACKGROUND: The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine (CsA) or tacrolimus (Tac) toxicity.,11063349_1,0
203,tacrolimus,125,135,BACKGROUND: The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine (CsA) or tacrolimus (Tac) toxicity.,11063349_1,0
920,RAPA,64,68,BACKGROUND: The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine (CsA) or tacrolimus (Tac) toxicity.,11063349_1,0
921,Tac,137,140,BACKGROUND: The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine (CsA) or tacrolimus (Tac) toxicity.,11063349_1,0
938,PTLD,69,73,"RAPA was discontinued in four patients, because of pneumonia in two, PTLD in one, and oral aphtous ulcers in one.",11063349_11,0
937,RAPA,0,4,"RAPA was discontinued in four patients, because of pneumonia in two, PTLD in one, and oral aphtous ulcers in one.",11063349_11,0
939,RAPA,0,4,RAPA levels were high (>15 ng/ml) in 7 of 13 (54%) patients.,11063349_12,0
940,RAPA,13,17,CONCLUSIONS: RAPA conversion provides adequate immunosuppression to enable CsA withdrawal.,11063349_13,0
943,over-immunosuppression,83,105,"However, when converting patients to RAPA drug levels should be monitored to avoid over-immunosuppression and adequate antiviral and Pneumocystis carinii pneumonia prophylaxis should be given.",11063349_14,1
942,RAPA,37,41,"However, when converting patients to RAPA drug levels should be monitored to avoid over-immunosuppression and adequate antiviral and Pneumocystis carinii pneumonia prophylaxis should be given.",11063349_14,0
4271,Pneumocystis carinii pneumonia,133,163,"However, when converting patients to RAPA drug levels should be monitored to avoid over-immunosuppression and adequate antiviral and Pneumocystis carinii pneumonia prophylaxis should be given.",11063349_14,1
923,fixed dose rapamycin,61,81,METHODS: Twenty renal transplant recipients were switched to fixed dose rapamycin (RAPA) (5 mg/day) 0 to 204 months posttransplant.,11063349_2,0
924,RAPA,83,87,METHODS: Twenty renal transplant recipients were switched to fixed dose rapamycin (RAPA) (5 mg/day) 0 to 204 months posttransplant.,11063349_2,0
922,renal transplant,16,32,METHODS: Twenty renal transplant recipients were switched to fixed dose rapamycin (RAPA) (5 mg/day) 0 to 204 months posttransplant.,11063349_2,1
4267,lymphoproliferative disorder,149,177,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,1
926,chronic CsA,32,43,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,1
927,Tac nephrotoxicity,47,65,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,1
929,Tac,85,88,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,0
930,PTLD,179,183,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,0
931,hepatotoxicity,207,221,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,1
204,(3,98,100,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,0
205,(2,198,200,"The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1.",11063349_4,0
932,chronic nephrotoxicity,48,70,RESULTS: In the 12 patients switched because of chronic nephrotoxicity there was a significant decrease in serum creatinine [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months].,11063349_6,1
206,creatinine,113,123,RESULTS: In the 12 patients switched because of chronic nephrotoxicity there was a significant decrease in serum creatinine [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months].,11063349_6,0
933,Facial dysmorphism,0,18,Facial dysmorphism improved in two patients.,11063349_7,0
934,No relapse,0,10,No relapse of PTLD was observed.,11063349_8,1
935,PTLD,14,18,No relapse of PTLD was observed.,11063349_8,0
4270,bronchiolitis obliterans,150,174,"Five patients developed pneumonia (two Pneumocystis carinii pneumonia, one infectious mononucleosis with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans.",11063349_9,1
4269,infectious mononucleosis,75,99,"Five patients developed pneumonia (two Pneumocystis carinii pneumonia, one infectious mononucleosis with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans.",11063349_9,1
4268,Pneumocystis carinii pneumonia,39,69,"Five patients developed pneumonia (two Pneumocystis carinii pneumonia, one infectious mononucleosis with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans.",11063349_9,1
936,polyclonal,105,115,"Five patients developed pneumonia (two Pneumocystis carinii pneumonia, one infectious mononucleosis with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans.",11063349_9,1
4272,multifocal,72,82,"Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction.",11077455_0,1
948,visual field,21,33,PURPOSE: Symptomatic visual field constriction thought to be associated with vigabatrin has been reported.,11077455_1,1
207,vigabatrin,77,87,PURPOSE: Symptomatic visual field constriction thought to be associated with vigabatrin has been reported.,11077455_1,0
967,visual field,71,83,Multifocal ERG showed abnormalities that sometimes correlated with the visual field appearance and confirmed that the deficit occurs at the retinal level.,11077455_10,1
4274,Multifocal,0,10,Multifocal ERG showed abnormalities that sometimes correlated with the visual field appearance and confirmed that the deficit occurs at the retinal level.,11077455_10,1
968,visual field,19,31,CONCLUSION: Marked visual field constriction appears to be associated with vigabatrin therapy.,11077455_11,1
209,vigabatrin,75,85,CONCLUSION: Marked visual field constriction appears to be associated with vigabatrin therapy.,11077455_11,0
970,field defects,4,17,The field defects and some electrophysiological abnormalities persist when vigabatrin therapy is withdrawn.,11077455_12,1
210,vigabatrin,75,85,The field defects and some electrophysiological abnormalities persist when vigabatrin therapy is withdrawn.,11077455_12,0
952,visual field loss,129,146,"The current study investigated the visual fields and visual electrophysiology of eight patients with known vigabatrin-attributed visual field loss, three of whom were reported previously.",11077455_2,1
950,visual fields,35,48,"The current study investigated the visual fields and visual electrophysiology of eight patients with known vigabatrin-attributed visual field loss, three of whom were reported previously.",11077455_2,1
208,vigabatrin,45,55,Six of the patients were no longer receiving vigabatrin.,11077455_3,0
953,peripheral fields,25,42,METHODS: The central and peripheral fields were examined with the Humphrey Visual Field Analyzer.,11077455_4,1
4273,multifocal,103,113,"Full visual electrophysiology, including flash electroretinography (ERG), pattern electroretinography, multifocal ERG using the VERIS system, electro-oculography, and flash and pattern visual evoked potentials, was undertaken.",11077455_5,1
959,pattern visual,177,191,"Full visual electrophysiology, including flash electroretinography (ERG), pattern electroretinography, multifocal ERG using the VERIS system, electro-oculography, and flash and pattern visual evoked potentials, was undertaken.",11077455_5,1
960,visual field,38,50,RESULTS: Seven patients showed marked visual field constriction with some sparing of the temporal visual field.,11077455_6,1
961,visual field,98,110,RESULTS: Seven patients showed marked visual field constriction with some sparing of the temporal visual field.,11077455_6,1
211,dobutamine,56,66,Myocardial ischemia due to coronary artery spasm during dobutamine stress echocardiography.,11078231_0,0
4276,coronary artery spasm,27,48,Myocardial ischemia due to coronary artery spasm during dobutamine stress echocardiography.,11078231_0,1
4275,Myocardial ischemia,0,19,Myocardial ischemia due to coronary artery spasm during dobutamine stress echocardiography.,11078231_0,1
4277,myocardial ischemia,83,102,Dobutamine stress echocardiography (DSE) is a useful and safe provocation test for myocardial ischemia.,11078231_1,1
212,Dobutamine,0,10,Dobutamine stress echocardiography (DSE) is a useful and safe provocation test for myocardial ischemia.,11078231_1,0
973,DSE,36,39,Dobutamine stress echocardiography (DSE) is a useful and safe provocation test for myocardial ischemia.,11078231_1,0
215,dobutamine,29,39,These findings indicate that dobutamine can provoke coronary spasm in some patients with coronary spastic angina.,11078231_10,0
987,coronary spastic angina,89,112,These findings indicate that dobutamine can provoke coronary spasm in some patients with coronary spastic angina.,11078231_10,1
986,coronary spasm,52,66,These findings indicate that dobutamine can provoke coronary spasm in some patients with coronary spastic angina.,11078231_10,1
988,DSE,5,8,"When DSE is performed to evaluate coronary artery disease, not only fixed coronary stenosis, but also coronary spasm should be considered as a genesis of asynergy.",11078231_11,0
989,coronary spasm,102,116,"When DSE is performed to evaluate coronary artery disease, not only fixed coronary stenosis, but also coronary spasm should be considered as a genesis of asynergy.",11078231_11,1
4287,coronary artery disease,34,57,"When DSE is performed to evaluate coronary artery disease, not only fixed coronary stenosis, but also coronary spasm should be considered as a genesis of asynergy.",11078231_11,1
4288,coronary stenosis,74,91,"When DSE is performed to evaluate coronary artery disease, not only fixed coronary stenosis, but also coronary spasm should be considered as a genesis of asynergy.",11078231_11,1
4278,coronary artery,71,86,"Until now, the test has been focused only on the organic lesion in the coronary artery, and positive DSE has indicated the presence of significant fixed coronary artery stenosis.",11078231_2,1
4279,coronary artery stenosis,153,177,"Until now, the test has been focused only on the organic lesion in the coronary artery, and positive DSE has indicated the presence of significant fixed coronary artery stenosis.",11078231_2,1
975,organic lesion,49,63,"Until now, the test has been focused only on the organic lesion in the coronary artery, and positive DSE has indicated the presence of significant fixed coronary artery stenosis.",11078231_2,1
976,DSE,101,104,"Until now, the test has been focused only on the organic lesion in the coronary artery, and positive DSE has indicated the presence of significant fixed coronary artery stenosis.",11078231_2,0
4280,myocardial ischemia,51,70,The aim of the present study is to examine whether myocardial ischemia due to coronary spasm is induced by dobutamine.,11078231_3,1
213,dobutamine,107,117,The aim of the present study is to examine whether myocardial ischemia due to coronary spasm is induced by dobutamine.,11078231_3,0
977,coronary spasm,78,92,The aim of the present study is to examine whether myocardial ischemia due to coronary spasm is induced by dobutamine.,11078231_3,1
4281,coronary artery stenosis,91,115,We performed DSE on 51 patients with coronary spastic angina but without significant fixed coronary artery stenosis.,11078231_4,1
978,DSE,13,16,We performed DSE on 51 patients with coronary spastic angina but without significant fixed coronary artery stenosis.,11078231_4,0
979,coronary spastic angina,37,60,We performed DSE on 51 patients with coronary spastic angina but without significant fixed coronary artery stenosis.,11078231_4,1
980,variant angina,85,99,All patients had anginal attacks at rest with ST elevation on the electrocardiogram (variant angina).,11078231_5,1
4282,ST,46,48,All patients had anginal attacks at rest with ST elevation on the electrocardiogram (variant angina).,11078231_5,1
981,Coronary spasm,0,14,"Coronary spasm was induced by intracoronary injection of acetylcholine, and no fixed coronary artery stenosis was documented on angiograms in all patients.",11078231_6,1
4283,coronary artery stenosis,85,109,"Coronary spasm was induced by intracoronary injection of acetylcholine, and no fixed coronary artery stenosis was documented on angiograms in all patients.",11078231_6,1
214,dobutamine,35,45,"DSE was performed with intravenous dobutamine infusion with an incremental doses of 5, 10, 20, 30, and 40 microg/kg/min every 5 minutes.",11078231_7,0
982,DSE,0,3,"DSE was performed with intravenous dobutamine infusion with an incremental doses of 5, 10, 20, 30, and 40 microg/kg/min every 5 minutes.",11078231_7,0
4284,ST,52,54,"Of the 51 patients, 7 patients showed asynergy with ST elevation.",11078231_8,1
4285,chest pain,27,37,"All 7 patients (13.7%) had chest pain during asynergy, and both chest pain and electrocardiographic changes were preceded by asynergy.",11078231_9,1
4286,chest pain,64,74,"All 7 patients (13.7%) had chest pain during asynergy, and both chest pain and electrocardiographic changes were preceded by asynergy.",11078231_9,1
990,intravenous metoprolol,10,32,Effect of intravenous metoprolol or intravenous metoprolol plus glucagon on dobutamine-induced myocardial ischemia.,11079278_0,0
991,intravenous metoprolol,36,58,Effect of intravenous metoprolol or intravenous metoprolol plus glucagon on dobutamine-induced myocardial ischemia.,11079278_0,0
4289,myocardial ischemia,95,114,Effect of intravenous metoprolol or intravenous metoprolol plus glucagon on dobutamine-induced myocardial ischemia.,11079278_0,1
216,dobutamine,58,68,"STUDY OBJECTIVE: To determine the effect of metoprolol on dobutamine stress testing with technetium-99m sestamibi single-photon emission computed tomography imaging and ST-segment monitoring, and to assess the impact of intravenous glucagon on metoprolol's effects.",11079278_1,0
994,metoprolol's,244,256,"STUDY OBJECTIVE: To determine the effect of metoprolol on dobutamine stress testing with technetium-99m sestamibi single-photon emission computed tomography imaging and ST-segment monitoring, and to assess the impact of intravenous glucagon on metoprolol's effects.",11079278_1,0
217,technetium-99m,89,103,"STUDY OBJECTIVE: To determine the effect of metoprolol on dobutamine stress testing with technetium-99m sestamibi single-photon emission computed tomography imaging and ST-segment monitoring, and to assess the impact of intravenous glucagon on metoprolol's effects.",11079278_1,0
1006,metoprolol-glucagon,78,97,No significant differences were found in any parameter between metoprolol and metoprolol-glucagon.,11079278_11,0
4290,myocardial ischemia,94,113,"CONCLUSION: During dobutamine stress testing, metoprolol attenuates or eliminates evidence of myocardial ischemia.",11079278_12,1
220,dobutamine,19,29,"CONCLUSION: During dobutamine stress testing, metoprolol attenuates or eliminates evidence of myocardial ischemia.",11079278_12,0
1008,Glucagon 1 mg,0,13,"Glucagon 1 mg, although somewhat effective, does not correct this effect to the extent that it can be administered clinically.",11079278_13,0
218,dobutamine,33,43,INTERVENTION: Patients underwent dobutamine stress tests per standard protocol.,11079278_5,0
219,dobutamine,7,17,"Before dobutamine was begun, no therapy was given during the first visit, and patients were randomized on subsequent visits to receive metoprolol or metoprolol plus glucagon 1 mg.",11079278_6,0
999,glucagon 1 mg,165,178,"Before dobutamine was begun, no therapy was given during the first visit, and patients were randomized on subsequent visits to receive metoprolol or metoprolol plus glucagon 1 mg.",11079278_6,0
1000,heart rate,56,66,Metoprolol was dosed to achieve a resting predobutamine heart rate below 65 beats/minute or a total intravenous dose of 20 mg.,11079278_7,1
221,GPi,37,40,Evidence of functional somatotopy in GPi from results of pallidotomy.,11099450_0,0
1010,pallidotomy,57,68,Evidence of functional somatotopy in GPi from results of pallidotomy.,11099450_0,1
1012,unilateral pallidotomy,131,153,The objective of this study was to explore the functional anatomy of the globus pallidus internus (GPi) by studying the effects of unilateral pallidotomy on parkinsonian 'off' signs and levodopa-induced dyskinesias (LID).,11099450_1,1
222,GPi,99,102,The objective of this study was to explore the functional anatomy of the globus pallidus internus (GPi) by studying the effects of unilateral pallidotomy on parkinsonian 'off' signs and levodopa-induced dyskinesias (LID).,11099450_1,0
1013,parkinsonian,157,169,The objective of this study was to explore the functional anatomy of the globus pallidus internus (GPi) by studying the effects of unilateral pallidotomy on parkinsonian 'off' signs and levodopa-induced dyskinesias (LID).,11099450_1,1
1011,globus pallidus internus,73,97,The objective of this study was to explore the functional anatomy of the globus pallidus internus (GPi) by studying the effects of unilateral pallidotomy on parkinsonian 'off' signs and levodopa-induced dyskinesias (LID).,11099450_1,1
1017,contralateral limbs,232,251,"We found significant positive correlations between the preoperative levodopa responsiveness of motor signs and the levodopa responsiveness of scores in timed tests (Core Assessment Program for Intracerebral Transplantations) in the contralateral limbs and the improvement in these scores after surgery, whereas there was no correlation with the improvement in LID.",11099450_2,1
1015,motor signs,95,106,"We found significant positive correlations between the preoperative levodopa responsiveness of motor signs and the levodopa responsiveness of scores in timed tests (Core Assessment Program for Intracerebral Transplantations) in the contralateral limbs and the improvement in these scores after surgery, whereas there was no correlation with the improvement in LID.",11099450_2,1
223,GPi,118,121,"We also found a highly significant correlation (P: < 0.0001, r = 0.8) between the volume of the ventral lesion in the GPi and the improvement in LID in the contralateral limbs, whereas there was no correlation between the ventral volume and the improvement in parkinsonian 'off' signs.",11099450_3,0
1018,ventral lesion,96,110,"We also found a highly significant correlation (P: < 0.0001, r = 0.8) between the volume of the ventral lesion in the GPi and the improvement in LID in the contralateral limbs, whereas there was no correlation between the ventral volume and the improvement in parkinsonian 'off' signs.",11099450_3,1
1019,contralateral limbs,156,175,"We also found a highly significant correlation (P: < 0.0001, r = 0.8) between the volume of the ventral lesion in the GPi and the improvement in LID in the contralateral limbs, whereas there was no correlation between the ventral volume and the improvement in parkinsonian 'off' signs.",11099450_3,1
1023,parkinsonian,123,135,The volumes of the total lesion cylinder and the dorsal lesion did not correlate with the outcome of either dyskinesias or parkinsonian 'off' signs.,11099450_4,1
1022,dorsal lesion,49,62,The volumes of the total lesion cylinder and the dorsal lesion did not correlate with the outcome of either dyskinesias or parkinsonian 'off' signs.,11099450_4,1
1026,ventral lesion volume,147,168,The differential predictive value of levodopa responsiveness for the outcome of parkinsonian 'off' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian 'off' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian 'off' signs and dyskinesias.,11099450_5,1
1028,pathophysiological,253,271,The differential predictive value of levodopa responsiveness for the outcome of parkinsonian 'off' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian 'off' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian 'off' signs and dyskinesias.,11099450_5,1
1025,parkinsonian,80,92,The differential predictive value of levodopa responsiveness for the outcome of parkinsonian 'off' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian 'off' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian 'off' signs and dyskinesias.,11099450_5,1
224,GPi,37,40,"Whereas cells in a wider area of the GPi may be implicated in parkinsonism, the ventral GPi seems to be crucial for the manifestation of LID.",11099450_6,0
225,GPi,88,91,"Whereas cells in a wider area of the GPi may be implicated in parkinsonism, the ventral GPi seems to be crucial for the manifestation of LID.",11099450_6,0
1032,pallidotomy,209,220,"We suggest that our observations are additional proof of the functional somatotopy of the systems within the GPi that mediate parkinsonism and dyskinesias, especially along the dorsoventral trajectory used in pallidotomy.",11099450_7,1
1030,somatotopy,72,82,"We suggest that our observations are additional proof of the functional somatotopy of the systems within the GPi that mediate parkinsonism and dyskinesias, especially along the dorsoventral trajectory used in pallidotomy.",11099450_7,0
226,GPi,109,112,"We suggest that our observations are additional proof of the functional somatotopy of the systems within the GPi that mediate parkinsonism and dyskinesias, especially along the dorsoventral trajectory used in pallidotomy.",11099450_7,0
227,GPi,79,82,"The outcome of pallidotomy in which the lesion involves the ventral and dorsal GPi could be the net effect of alteration in the activity of pathways which mediate different symptoms, and hence could be variable.",11099450_8,0
1033,pallidotomy,15,26,"The outcome of pallidotomy in which the lesion involves the ventral and dorsal GPi could be the net effect of alteration in the activity of pathways which mediate different symptoms, and hence could be variable.",11099450_8,1
1036,metastatic nonsmall cell lung carcinoma,115,154,"Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.",11135224_0,1
228,Paclitaxel,0,10,"Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.",11135224_0,0
229,cisplatin,12,21,"Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.",11135224_0,0
1034,gemcitabine combination chemotherapy,27,63,"Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.",11135224_0,0
1037,Cisplatin-based chemotherapy combinations,12,53,BACKGROUND: Cisplatin-based chemotherapy combinations improve quality of life and survival in advanced nonsmall cell lung carcinoma (NSCLC).,11135224_1,0
1039,nonsmall,103,111,BACKGROUND: Cisplatin-based chemotherapy combinations improve quality of life and survival in advanced nonsmall cell lung carcinoma (NSCLC).,11135224_1,1
1038,quality of life,62,77,BACKGROUND: Cisplatin-based chemotherapy combinations improve quality of life and survival in advanced nonsmall cell lung carcinoma (NSCLC).,11135224_1,1
4291,lung carcinoma,117,131,BACKGROUND: Cisplatin-based chemotherapy combinations improve quality of life and survival in advanced nonsmall cell lung carcinoma (NSCLC).,11135224_1,1
4293,Grade 3,26,33,"World Health Organization Grade 3-4 neutropenia and thrombocytopenia occurred in 39.9% and 11.4% of patients, respectively.",11135224_10,1
1056,treatment-related death,14,37,There was one treatment-related death.,11135224_11,1
1057,Nonhematologic,0,14,Nonhematologic toxicities were mild.,11135224_12,1
239,paclitaxel,32,42,"CONCLUSIONS: The combination of paclitaxel, cisplatin, and gemcitabine is well tolerated and shows high activity in metastatic NSCLC.",11135224_14,0
240,cisplatin,44,53,"CONCLUSIONS: The combination of paclitaxel, cisplatin, and gemcitabine is well tolerated and shows high activity in metastatic NSCLC.",11135224_14,0
241,gemcitabine,59,70,"CONCLUSIONS: The combination of paclitaxel, cisplatin, and gemcitabine is well tolerated and shows high activity in metastatic NSCLC.",11135224_14,0
1041,active drugs,21,33,The emergence of new active drugs might translate into more effective regimens for the treatment of this disease.,11135224_2,0
232,gemcitabine,131,142,"METHODS: The objective of this study was to determine the feasibility, response rate, and toxicity of a paclitaxel, cisplatin, and gemcitabine combination to treat metastatic NSCLC.",11135224_3,0
230,paclitaxel,104,114,"METHODS: The objective of this study was to determine the feasibility, response rate, and toxicity of a paclitaxel, cisplatin, and gemcitabine combination to treat metastatic NSCLC.",11135224_3,0
231,cisplatin,116,125,"METHODS: The objective of this study was to determine the feasibility, response rate, and toxicity of a paclitaxel, cisplatin, and gemcitabine combination to treat metastatic NSCLC.",11135224_3,0
233,paclitaxel,175,185,"Thirty-five consecutive chemotherapy-naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of paclitaxel (135 mg/m(2) given intravenously in 3 hours) on Day 1, cisplatin (120 mg/m(2) given intravenously in 6 hours) on Day 1, and gemcitabine (800 mg/m(2) given intravenously in 30 minutes) on Days 1 and 8, every 4 weeks.",11135224_4,0
235,gemcitabine,310,321,"Thirty-five consecutive chemotherapy-naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of paclitaxel (135 mg/m(2) given intravenously in 3 hours) on Day 1, cisplatin (120 mg/m(2) given intravenously in 6 hours) on Day 1, and gemcitabine (800 mg/m(2) given intravenously in 30 minutes) on Days 1 and 8, every 4 weeks.",11135224_4,0
234,cisplatin,241,250,"Thirty-five consecutive chemotherapy-naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0-2 were treated with a combination of paclitaxel (135 mg/m(2) given intravenously in 3 hours) on Day 1, cisplatin (120 mg/m(2) given intravenously in 6 hours) on Day 1, and gemcitabine (800 mg/m(2) given intravenously in 30 minutes) on Days 1 and 8, every 4 weeks.",11135224_4,0
1049,consolidation radiotherapy,55,81,"Although responding patients were scheduled to receive consolidation radiotherapy and 24 patients received preplanned second-line chemotherapy after disease progression, the response and toxicity rates reported refer only to the chemotherapy regimen given.",11135224_5,0
4292,disease progression,149,168,"Although responding patients were scheduled to receive consolidation radiotherapy and 24 patients received preplanned second-line chemotherapy after disease progression, the response and toxicity rates reported refer only to the chemotherapy regimen given.",11135224_5,1
237,cisplatin,112,121,"After 154 courses of therapy, the median dose intensity was 131 mg/m(2) for paclitaxel (97.3%), 117 mg/m(2) for cisplatin (97.3%), and 1378 mg/m(2) for gemcitabine (86.2%).",11135224_9,0
238,gemcitabine,152,163,"After 154 courses of therapy, the median dose intensity was 131 mg/m(2) for paclitaxel (97.3%), 117 mg/m(2) for cisplatin (97.3%), and 1378 mg/m(2) for gemcitabine (86.2%).",11135224_9,0
236,paclitaxel,76,86,"After 154 courses of therapy, the median dose intensity was 131 mg/m(2) for paclitaxel (97.3%), 117 mg/m(2) for cisplatin (97.3%), and 1378 mg/m(2) for gemcitabine (86.2%).",11135224_9,0
4294,urinary incontinence,33,53,Serotonergic antidepressants and urinary incontinence.,11147747_0,1
1061,Serotonergic antidepressants,0,28,Serotonergic antidepressants and urinary incontinence.,11147747_0,0
1062,serotonergic antidepressants,9,37,Many new serotonergic antidepressants have been introduced over the past decade.,11147747_1,0
1063,package inserts,83,98,Although urinary incontinence is listed as one side effect of these drugs in their package inserts there is only one report in the literature.,11147747_2,0
4296,side effect,47,58,Although urinary incontinence is listed as one side effect of these drugs in their package inserts there is only one report in the literature.,11147747_2,1
4295,urinary incontinence,9,29,Although urinary incontinence is listed as one side effect of these drugs in their package inserts there is only one report in the literature.,11147747_2,1
242,venlafaxine,72,83,This concerns 2 male patients who experienced incontinence while taking venlafaxine.,11147747_3,0
4297,side effect,209,220,"In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.",11147747_4,1
243,venlafaxine,224,235,"In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.",11147747_4,0
1064,selective serotonin reuptake inhibitors paroxetine,104,154,"In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.",11147747_4,0
245,beta-blockers,72,85,"In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.",11147747_5,0
244,lithium carbonate,50,67,"In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.",11147747_5,0
1066,5HT4 receptors,108,122,Animal studies suggest that incontinence secondary to serotonergic antidepressants could be mediated by the 5HT4 receptors found on the bladder.,11147747_6,0
1065,serotonergic antidepressants,54,82,Animal studies suggest that incontinence secondary to serotonergic antidepressants could be mediated by the 5HT4 receptors found on the bladder.,11147747_6,0
4298,side effect,72,83,Further research is needed to delineate the frequency of this troubling side effect and how best to treat it.,11147747_7,1
1067,differential sensitivity,32,56,Acute cocaine-induced seizures: differential sensitivity of six inbred mouse strains.,11166519_0,1
1069,clonic running seizure,79,101,"Seizure end points included latency to forelimb or hindlimb clonus, latency to clonic running seizure and latency to jumping bouncing seizure.",11166519_3,1
1071,SJL,69,72,A range of strain specific sensitivities was documented with A/J and SJL mice being most sensitive and C57BL/6J most resistant.,11166519_4,0
1074,SJL,28,31,"EEG recordings were made in SJL, A/J and C57BL/6J mice revealing a close correspondence between electrical activity and behavior.",11166519_6,0
1077,cocaine-induced seizures,97,121,Additional studies of these murine strains may be useful for investigating genetic influences on cocaine-induced seizures.,11166519_8,1
1078,emergency department seizure,37,65,Screening for stimulant use in adult emergency department seizure patients.,11185967_0,1
1079,emergency department seizure,141,169,OBJECTIVE: The objective of this study was to determine the prevalence of positive plasma drug screening for cocaine or amphetamine in adult emergency department seizure patients.,11185967_1,1
1081,cocaine metabolite benzoylecgonine,42,76,Plasma was tested for amphetamine and the cocaine metabolite benzoylecgonine using enzyme-mediated immunoassay methodology.,11185967_3,0
1083,benzoylecgonine,20,35,Plasma samples with benzoylecgonine greater than 150 ng/mL or an amphetamine greater than 500 ng/mL were defined as positive.,11185967_4,0
1084,alcohol-related seizure disorder,52,84,"Patient demographics, history of underlying drug or alcohol-related seizure disorder, estimated time from seizure to sample collection, history or suspicion of cocaine or amphetamine abuse, results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers.",11185967_5,1
4299,amphetamine abuse,171,188,"Patient demographics, history of underlying drug or alcohol-related seizure disorder, estimated time from seizure to sample collection, history or suspicion of cocaine or amphetamine abuse, results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers.",11185967_5,1
1089,benzoylecgonine,106,121,"RESULTS: Fourteen of 248 (5.6%, 95% CI 2.7%-8.5%) plasma samples were positive by immunoassay testing for benzoylecgonine and no samples (0%, 95% CI 0-1.2%) were positive for amphetamine.",11185967_6,0
4300,amphetamine abuse,110,127,Positive test results were more common in patient visits where there was a history or suspicion of cocaine or amphetamine abuse (p < 0.0005).,11185967_7,1
4301,drug abuse,132,142,"As a result, routine plasma screening would yield few cases of stimulant drug in which there was neither a history nor suspicion of drug abuse in this population.",11185967_9,1
246,sodium valproate,16,32,Contribution of sodium valproate to the syndrome of inappropriate secretion of antidiuretic hormone.,11195262_0,0
1091,antidiuretic hormone,79,99,Contribution of sodium valproate to the syndrome of inappropriate secretion of antidiuretic hormone.,11195262_0,0
4302,inappropriate secretion,52,75,Contribution of sodium valproate to the syndrome of inappropriate secretion of antidiuretic hormone.,11195262_0,1
247,sodium valproate,61,77,We report the case of a 62-year-old man who was administered sodium valproate (VPA) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).,11195262_1,0
4303,inappropriate secretion,131,154,We report the case of a 62-year-old man who was administered sodium valproate (VPA) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).,11195262_1,1
4304,SIADH,180,185,We report the case of a 62-year-old man who was administered sodium valproate (VPA) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).,11195262_1,1
1093,antidiuretic hormone,158,178,We report the case of a 62-year-old man who was administered sodium valproate (VPA) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).,11195262_1,0
1092,VPA,79,82,We report the case of a 62-year-old man who was administered sodium valproate (VPA) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).,11195262_1,0
1095,generalized tonic-clonic convulsions,51,87,He had been taking VPA for treatment of idiopathic generalized tonic-clonic convulsions since he was 56 years old.,11195262_2,0
1094,VPA,19,22,He had been taking VPA for treatment of idiopathic generalized tonic-clonic convulsions since he was 56 years old.,11195262_2,0
1097,zonisamide,28,38,"After substituting VPA with zonisamide, the serum sodium level returned to normal.",11195262_3,0
1096,VPA,19,22,"After substituting VPA with zonisamide, the serum sodium level returned to normal.",11195262_3,0
4305,SIADH,28,33,We consider this episode of SIADH to be the result of a combination of factors including a weakness of the central nervous system and the long-term administration of VPA.,11195262_4,1
4306,central nervous system,107,129,We consider this episode of SIADH to be the result of a combination of factors including a weakness of the central nervous system and the long-term administration of VPA.,11195262_4,1
1099,VPA,166,169,We consider this episode of SIADH to be the result of a combination of factors including a weakness of the central nervous system and the long-term administration of VPA.,11195262_4,0
1101,chronic hypertension,124,144,Hypotension following the initiation of tizanidine in a patient treated with an angiotensin converting enzyme inhibitor for chronic hypertension.,11198499_0,1
248,angiotensin converting enzyme inhibitor,80,119,Hypotension following the initiation of tizanidine in a patient treated with an angiotensin converting enzyme inhibitor for chronic hypertension.,11198499_0,0
1100,tizanidine,40,50,Hypotension following the initiation of tizanidine in a patient treated with an angiotensin converting enzyme inhibitor for chronic hypertension.,11198499_0,0
4307,central nervous system,149,171,Centrally acting alpha-2 adrenergic agonists are one of several pharmacologic agents used in the treatment of spasticity related to disorders of the central nervous system.,11198499_1,1
1103,alpha-2 adrenergic agonists,17,44,Centrally acting alpha-2 adrenergic agonists are one of several pharmacologic agents used in the treatment of spasticity related to disorders of the central nervous system.,11198499_1,0
1102,Centrally acting,0,16,Centrally acting alpha-2 adrenergic agonists are one of several pharmacologic agents used in the treatment of spasticity related to disorders of the central nervous system.,11198499_1,0
1105,adverse cardiorespiratory effects,52,85,"In addition to their effects on spasticity, certain adverse cardiorespiratory effects have been reported.",11198499_2,1
249,angiotensin converting enzyme inhibitors,32,72,Adults chronically treated with angiotensin converting enzyme inhibitors may have a limited ability to respond to hypotension when the sympathetic response is simultaneously blocked.,11198499_3,0
1108,tizanidine,195,205,"The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.",11198499_4,0
251,alpha-2,210,217,"The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.",11198499_4,0
250,angiotensin converting enzyme inhibitor,78,117,"The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.",11198499_4,0
1107,control hypertension,122,142,"The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity.",11198499_4,1
252,antihypertensive agents,49,72,The possible interaction of tizanidine and other antihypertensive agents should be kept in mind when prescribing therapy to treat either hypertension or spasticity in such patients.,11198499_5,0
1109,tizanidine,28,38,The possible interaction of tizanidine and other antihypertensive agents should be kept in mind when prescribing therapy to treat either hypertension or spasticity in such patients.,11198499_5,0
1111,pharmacological effects,136,159,Two mouse lines selected for differential sensitivities to beta-carboline-induced seizures are also differentially sensitive to various pharmacological effects of other GABA(A) receptor ligands.,11206082_0,0
1112,GABA(A) receptor ligands,169,193,Two mouse lines selected for differential sensitivities to beta-carboline-induced seizures are also differentially sensitive to various pharmacological effects of other GABA(A) receptor ligands.,11206082_0,0
253,GABA(A) receptor,87,103,"injection of methyl beta-carboline-3-carboxylate (beta-CCM), an inverse agonist of the GABA(A) receptor benzodiazepine site.",11206082_2,0
1115,methyl beta-carboline-3-carboxylate,13,48,"injection of methyl beta-carboline-3-carboxylate (beta-CCM), an inverse agonist of the GABA(A) receptor benzodiazepine site.",11206082_2,0
1116,beta-CCM,50,58,"injection of methyl beta-carboline-3-carboxylate (beta-CCM), an inverse agonist of the GABA(A) receptor benzodiazepine site.",11206082_2,0
254,physiological effects,65,86,Our aim was to characterize both lines' sensitivities to various physiological effects of other ligands of the GABA(A) receptor.,11206082_3,0
255,GABA(A) receptor,111,127,Our aim was to characterize both lines' sensitivities to various physiological effects of other ligands of the GABA(A) receptor.,11206082_3,0
1121,i.p,196,199,"We measured diazepam-induced anxiolysis with the elevated plus-maze test, diazepam-induced sedation by recording the vigilance states, and picrotoxin- and pentylenetetrazol-induced seizures after i.p. injections.",11206082_4,0
1122,.,199,200,"We measured diazepam-induced anxiolysis with the elevated plus-maze test, diazepam-induced sedation by recording the vigilance states, and picrotoxin- and pentylenetetrazol-induced seizures after i.p. injections.",11206082_4,0
257,GABA(A) receptor,256,272,"Results presented here show that the differential sensitivities of BS and BR lines to beta-CCM can be extended to diazepam, picrotoxin, and pentylenetetrazol, suggesting a genetic selection of a general sensitivity and resistance to several ligands of the GABA(A) receptor.",11206082_5,0
1123,beta-CCM,86,94,"Results presented here show that the differential sensitivities of BS and BR lines to beta-CCM can be extended to diazepam, picrotoxin, and pentylenetetrazol, suggesting a genetic selection of a general sensitivity and resistance to several ligands of the GABA(A) receptor.",11206082_5,0
256,picrotoxin,124,134,"Results presented here show that the differential sensitivities of BS and BR lines to beta-CCM can be extended to diazepam, picrotoxin, and pentylenetetrazol, suggesting a genetic selection of a general sensitivity and resistance to several ligands of the GABA(A) receptor.",11206082_5,0
1126,experimental nephropathy,67,91,Association of nitric oxide production and apoptosis in a model of experimental nephropathy.,11208990_0,1
258,nitric oxide,15,27,Association of nitric oxide production and apoptosis in a model of experimental nephropathy.,11208990_0,0
4308,pathological conditions,115,138,BACKGROUND: In recent studies increased amounts of nitric oxide (NO) and apoptosis have been implicated in various pathological conditions in the kidney.,11208990_1,1
259,nitric oxide,51,63,BACKGROUND: In recent studies increased amounts of nitric oxide (NO) and apoptosis have been implicated in various pathological conditions in the kidney.,11208990_1,0
1141,IPRK phenylephrine,7,25,In the IPRK phenylephrine and acetylcholine related responses were significantly impaired in the ADR-nephropathy group.,11208990_10,0
263,apoptotic,48,57,"However, in the ADR-nephropathy group, numerous apoptotic cells were identified in the tubulointerstitial areas.",11208990_12,0
4310,tubulointerstitial,87,105,"However, in the ADR-nephropathy group, numerous apoptotic cells were identified in the tubulointerstitial areas.",11208990_12,1
1142,ED1,76,79,"Double staining revealed numerous interstitial apoptotic cells to stain for ED1, a marker for monocytes/macrophages.",11208990_13,0
1143,monocytes/macrophages,94,115,"Double staining revealed numerous interstitial apoptotic cells to stain for ED1, a marker for monocytes/macrophages.",11208990_13,0
264,apoptotic,47,56,"Double staining revealed numerous interstitial apoptotic cells to stain for ED1, a marker for monocytes/macrophages.",11208990_13,0
4309,nephrotic syndrome,94,112,We have studied the role of NO and its association with apoptosis in an experimental model of nephrotic syndrome induced by a single injection of adriamycin (ADR).,11208990_2,1
1128,adriamycin,146,156,We have studied the role of NO and its association with apoptosis in an experimental model of nephrotic syndrome induced by a single injection of adriamycin (ADR).,11208990_2,0
1133,aminoguanidine,107,121,"These two groups were then divided into: group 1, animals receiving saline; and group 2, animals receiving aminoguanidine (AG) which is a specific inhibitor of inducible-NO synthase.",11208990_5,0
260,group 1,41,48,"These two groups were then divided into: group 1, animals receiving saline; and group 2, animals receiving aminoguanidine (AG) which is a specific inhibitor of inducible-NO synthase.",11208990_5,0
261,group 2,80,87,"These two groups were then divided into: group 1, animals receiving saline; and group 2, animals receiving aminoguanidine (AG) which is a specific inhibitor of inducible-NO synthase.",11208990_5,0
262,synthase,173,181,"These two groups were then divided into: group 1, animals receiving saline; and group 2, animals receiving aminoguanidine (AG) which is a specific inhibitor of inducible-NO synthase.",11208990_5,0
1138,mesangial proliferation,103,126,RESULTS: Histopathological examination of the kidneys of rats treated with ADR revealed focal areas of mesangial proliferation and mild tubulointerstitial inflammation.,11208990_7,1
1139,tubulointerstitial inflammation,136,167,RESULTS: Histopathological examination of the kidneys of rats treated with ADR revealed focal areas of mesangial proliferation and mild tubulointerstitial inflammation.,11208990_7,1
1137,focal areas,88,99,RESULTS: Histopathological examination of the kidneys of rats treated with ADR revealed focal areas of mesangial proliferation and mild tubulointerstitial inflammation.,11208990_7,1
4311,drug-induced,95,107,"Melatonin affects the circadian sleep/wake cycle, but it is not clear whether it may influence drug-induced narcosis.",11226639_1,1
1149,Sodium thiopenthal,0,18,"Sodium thiopenthal was administered intraperitoneally into male rats pre-treated with melatonin (0.05, 0.5, 5 and 50 mg/kg).",11226639_2,0
1152,low doses,15,24,"In particular, low doses reduced the latency to and prolonged the duration of barbiturate narcosis.",11226639_4,0
1153,barbiturate narcosis,78,98,"In particular, low doses reduced the latency to and prolonged the duration of barbiturate narcosis.",11226639_4,1
265,ketamine-,73,82,Melatonin 0.5 and 5 mg/kg influenced the duration but not the latency of ketamine- or diazepam-induced narcosis.,11226639_6,0
1158,pharmacological narcosis,38,62,"Thus, the dual action of melatonin on pharmacological narcosis seems to be specific for the barbiturate mechanism of action.",11226639_7,1
4312,cardiotoxicity,8,22,"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.",11230490_0,1
1159,liposome-encapsulated doxorubicin,59,92,"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.",11230490_0,0
1161,conventional doxorubicin,128,152,"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.",11230490_0,0
4313,breast cancer,223,236,"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.",11230490_0,1
1162,cyclophosphamide,157,173,"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.",11230490_0,0
1160,cyclophosphamide,97,113,"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.",11230490_0,0
1164,Myocet,30,36,"PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).",11230490_1,0
1165,liposome-encapsulated doxorubicin,38,71,"PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).",11230490_1,0
1168,cyclophosphamide,148,164,"PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).",11230490_1,0
4315,breast cancer,298,311,"PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).",11230490_1,1
4314,cardiotoxicity,199,213,"PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC).",11230490_1,1
1172,metastatic disease,95,113,"PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.",11230490_2,1
4316,disease progression,283,302,"PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.",11230490_2,1
1175,cyclophosphamide,241,257,"PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable toxicity.",11230490_2,0
1176,left-ventricular ejection fraction,44,78,"Cardiotoxicity was defined by reductions in left-ventricular ejection fraction, assessed by serial multigated radionuclide angiography scans, or congestive heart failure (CHF).",11230490_3,1
4317,Cardiotoxicity,0,14,"Cardiotoxicity was defined by reductions in left-ventricular ejection fraction, assessed by serial multigated radionuclide angiography scans, or congestive heart failure (CHF).",11230490_3,1
4318,congestive heart failure,145,169,"Cardiotoxicity was defined by reductions in left-ventricular ejection fraction, assessed by serial multigated radionuclide angiography scans, or congestive heart failure (CHF).",11230490_3,1
266,radionuclide,110,122,"Cardiotoxicity was defined by reductions in left-ventricular ejection fraction, assessed by serial multigated radionuclide angiography scans, or congestive heart failure (CHF).",11230490_3,0
1177,CHF,171,174,"Cardiotoxicity was defined by reductions in left-ventricular ejection fraction, assessed by serial multigated radionuclide angiography scans, or congestive heart failure (CHF).",11230490_3,0
1180,CHF,72,75,RESULTS: Six percent of MC patients versus 21% (including five cases of CHF) of AC patients developed cardiotoxicity (P =.0002).,11230490_5,0
4319,cardiotoxicity,102,116,RESULTS: Six percent of MC patients versus 21% (including five cases of CHF) of AC patients developed cardiotoxicity (P =.0002).,11230490_5,1
1182,grade 4,34,41,MC patients also experienced less grade 4 neutropenia.,11230490_7,1
1184,treatment failure,160,177,"Antitumor efficacy of MC versus AC was comparable: objective response rates, 43% versus 43%; median time to progression, 5.1% versus 5.5 months; median time to treatment failure, 4.6 versus 4.4 months; and median survival, 19 versus 16 months.",11230490_8,1
4320,cardiotoxicity,91,105,"CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.",11230490_9,1
1186,Myocet,12,18,"CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.",11230490_9,0
1189,cyclophosphamide,204,220,"CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.",11230490_9,0
1188,grade 4,110,117,"CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.",11230490_9,1
1187,therapeutic index,32,49,"CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC.",11230490_9,0
1193,lidocaine-induced convulsion,32,60,The role of nitrergic system in lidocaine-induced convulsion in the mouse.,11243580_0,0
1195,NO precursor,113,125,"The effects of N-nitro-L-arginine-methyl ester (L-NAME) a nitric oxide (NO) synthase inhibitor and L-arginine, a NO precursor, were investigated on lidocaine-induced convulsions.",11243580_1,0
270,L-arginine,99,109,"The effects of N-nitro-L-arginine-methyl ester (L-NAME) a nitric oxide (NO) synthase inhibitor and L-arginine, a NO precursor, were investigated on lidocaine-induced convulsions.",11243580_1,0
269,synthase inhibitor,76,94,"The effects of N-nitro-L-arginine-methyl ester (L-NAME) a nitric oxide (NO) synthase inhibitor and L-arginine, a NO precursor, were investigated on lidocaine-induced convulsions.",11243580_1,0
268,nitric oxide,58,70,"The effects of N-nitro-L-arginine-methyl ester (L-NAME) a nitric oxide (NO) synthase inhibitor and L-arginine, a NO precursor, were investigated on lidocaine-induced convulsions.",11243580_1,0
267,L-NAME,48,54,"The effects of N-nitro-L-arginine-methyl ester (L-NAME) a nitric oxide (NO) synthase inhibitor and L-arginine, a NO precursor, were investigated on lidocaine-induced convulsions.",11243580_1,0
1194,N-nitro-L-arginine-methyl ester,15,46,"The effects of N-nitro-L-arginine-methyl ester (L-NAME) a nitric oxide (NO) synthase inhibitor and L-arginine, a NO precursor, were investigated on lidocaine-induced convulsions.",11243580_1,0
1196,lidocaine-induced convulsions,148,177,"The effects of N-nitro-L-arginine-methyl ester (L-NAME) a nitric oxide (NO) synthase inhibitor and L-arginine, a NO precursor, were investigated on lidocaine-induced convulsions.",11243580_1,0
1197,physiological saline,54,74,"In the first experiment, four groups of mice received physiological saline (0.9%), L-arginine (300 mg/kg, i.p.), L-NAME (100 mg/kg, i.p.) and diazepam (2 mg/kg), respectively.",11243580_2,0
1200,diazepam (2,142,153,"In the first experiment, four groups of mice received physiological saline (0.9%), L-arginine (300 mg/kg, i.p.), L-NAME (100 mg/kg, i.p.) and diazepam (2 mg/kg), respectively.",11243580_2,0
271,L-arginine,83,93,"In the first experiment, four groups of mice received physiological saline (0.9%), L-arginine (300 mg/kg, i.p.), L-NAME (100 mg/kg, i.p.) and diazepam (2 mg/kg), respectively.",11243580_2,0
272,L-NAME,113,119,"In the first experiment, four groups of mice received physiological saline (0.9%), L-arginine (300 mg/kg, i.p.), L-NAME (100 mg/kg, i.p.) and diazepam (2 mg/kg), respectively.",11243580_2,0
1203,diazepam (2,29,40,"L-NAME (100 mg/kg, i.p.) and diazepam (2 mg/kg) significantly decreased the incidence of lidocaine (50 mg/kg)-induced convulsions.",11243580_5,0
273,L-NAME,0,6,"L-NAME (100 mg/kg, i.p.) and diazepam (2 mg/kg) significantly decreased the incidence of lidocaine (50 mg/kg)-induced convulsions.",11243580_5,0
274,L-arginine,17,27,"In contrast, the L-arginine treatment increased the incidence of lidocaine (80 mg/kg, i.p.)-induced convulsions significantly.",11243580_6,0
1204,lidocaine-induced convulsions,65,94,These results may suggest that NO is a proconvulsant mediator in lidocaine-induced convulsions.,11243580_7,0
1206,cyclophosphamide,56,72,Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors.,11245434_0,0
1207,rHuEPO,106,112,The aim of this study was to examine the impact of anemia prevention by recombinant human erythropoietin (rHuEPO) treatment on the cytotoxicity of cyclophosphamide in solid experimental tumors.,11245434_1,0
275,recombinant human,72,89,The aim of this study was to examine the impact of anemia prevention by recombinant human erythropoietin (rHuEPO) treatment on the cytotoxicity of cyclophosphamide in solid experimental tumors.,11245434_1,0
1208,cyclophosphamide,147,163,The aim of this study was to examine the impact of anemia prevention by recombinant human erythropoietin (rHuEPO) treatment on the cytotoxicity of cyclophosphamide in solid experimental tumors.,11245434_1,0
1209,solid experimental tumors,167,192,The aim of this study was to examine the impact of anemia prevention by recombinant human erythropoietin (rHuEPO) treatment on the cytotoxicity of cyclophosphamide in solid experimental tumors.,11245434_1,1
1225,cyclophosphamide,79,95,"These results suggest that chemotherapy-induced anemia reduces cytotoxicity of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue.",11245434_10,0
1226,rHuEPO,139,145,"These results suggest that chemotherapy-induced anemia reduces cytotoxicity of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue.",11245434_10,0
4321,chemotherapy-induced,27,47,"These results suggest that chemotherapy-induced anemia reduces cytotoxicity of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue.",11245434_10,1
1227,epoetin alpha,157,170,"These results suggest that chemotherapy-induced anemia reduces cytotoxicity of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue.",11245434_10,0
276,carboplatin,42,53,Anemia was induced using a single dose of carboplatin (50 mg/kg i.v.) resulting in a long-lasting reduction (30%) of the hemoglobin concentration.,11245434_2,0
1212,rHuEPO,62,68,"In a second group, the development of anemia was prevented by rHuEPO (1000 IU/kg) administered s.c.",11245434_3,0
277,carboplatin,40,51,three times/week starting 7 days before carboplatin application.,11245434_4,0
278,carboplatin,16,27,"Four days after carboplatin treatment, tumors (DS-sarcoma of the rat) were implanted s.c. onto the hind food dorsum.",11245434_5,0
1214,rHuEPO,24,30,Neither carboplatin nor rHuEPO treatment influenced tumor growth rate per se.,11245434_6,0
279,carboplatin,8,19,Neither carboplatin nor rHuEPO treatment influenced tumor growth rate per se.,11245434_6,0
1215,tumor growth rate,52,69,Neither carboplatin nor rHuEPO treatment influenced tumor growth rate per se.,11245434_6,1
1220,regrowth,140,148,"When tumors were treated with a single dose of cyclophosphamide (60 mg/kg i.p.) 5 days after implantation, a growth delay with a subsequent regrowth of the tumors was observed.",11245434_7,1
1219,growth delay,109,121,"When tumors were treated with a single dose of cyclophosphamide (60 mg/kg i.p.) 5 days after implantation, a growth delay with a subsequent regrowth of the tumors was observed.",11245434_7,1
1217,cyclophosphamide,47,63,"When tumors were treated with a single dose of cyclophosphamide (60 mg/kg i.p.) 5 days after implantation, a growth delay with a subsequent regrowth of the tumors was observed.",11245434_7,0
1221,growth delay,25,37,"In the anemia group, the growth delay was significantly shorter compared with nonanemic controls (13.3 days versus 8.6 days).",11245434_8,1
1224,growth delay,61,73,"In the group where anemia was prevented by rHuEPO treatment, growth delay was comparable with that of nonanemic controls (13.3 days).",11245434_9,1
1223,rHuEPO,43,49,"In the group where anemia was prevented by rHuEPO treatment, growth delay was comparable with that of nonanemic controls (13.3 days).",11245434_9,0
280,antineutrophil cytoplasmic,46,72,Propylthiouracil-induced perinuclear-staining antineutrophil cytoplasmic autoantibody-positive vasculitis in conjunction with pericarditis.,11250767_0,0
4322,Graves' disease,34,49,"RESULTS: A 25-year-old woman with Graves' disease had a febrile illness and evidence of pericarditis, which was confirmed by biopsy.",11250767_4,1
1237,febrile illness,56,71,"RESULTS: A 25-year-old woman with Graves' disease had a febrile illness and evidence of pericarditis, which was confirmed by biopsy.",11250767_4,1
281,antineutrophil cytoplasmic autoantibodies,67,108,Serologic evaluation revealed the presence of perinuclear-staining antineutrophil cytoplasmic autoantibodies (pANCA) against myeloperoxidase (MPO).,11250767_5,0
1238,MPO,142,145,Serologic evaluation revealed the presence of perinuclear-staining antineutrophil cytoplasmic autoantibodies (pANCA) against myeloperoxidase (MPO).,11250767_5,0
282,pANCA,110,115,Serologic evaluation revealed the presence of perinuclear-staining antineutrophil cytoplasmic autoantibodies (pANCA) against myeloperoxidase (MPO).,11250767_5,0
283,myeloperoxidase,125,140,Serologic evaluation revealed the presence of perinuclear-staining antineutrophil cytoplasmic autoantibodies (pANCA) against myeloperoxidase (MPO).,11250767_5,0
284,her,114,117,"Propylthiouracil therapy was withdrawn, and she was treated with a 1-month course of prednisone, which alleviated her symptoms.",11250767_6,0
1243,drug-induced vasculitis,61,84,CONCLUSION: Pericarditis may be the initial manifestation of drug-induced vasculitis attributable to propylthio- uracil therapy.,11250767_8,1
4323,solitary kidney,80,95,Repeated transient anuria following losartan administration in a patient with a solitary kidney.,11256525_0,1
1245,transient anuria,9,25,Repeated transient anuria following losartan administration in a patient with a solitary kidney.,11256525_0,1
285,losartan,36,44,Repeated transient anuria following losartan administration in a patient with a solitary kidney.,11256525_0,0
1246,transient anuria,138,154,We report the case of a 70-year-old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after losartan administration.,11256525_1,1
4325,chronic renal insufficiency,80,107,We report the case of a 70-year-old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after losartan administration.,11256525_1,1
4324,solitary kidney,60,75,We report the case of a 70-year-old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after losartan administration.,11256525_1,1
286,losartan,161,169,We report the case of a 70-year-old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after losartan administration.,11256525_1,0
1256,renovascular disease,150,170,This case report highlights the fact that the angiotensin II receptor antagonist losartan can cause serious unexpected complications in patients with renovascular disease and should be used with extreme caution in this setting.,11256525_10,1
1255,angiotensin II receptor antagonist losartan,46,89,This case report highlights the fact that the angiotensin II receptor antagonist losartan can cause serious unexpected complications in patients with renovascular disease and should be used with extreme caution in this setting.,11256525_10,0
4326,myocardial infarction,26,47,"He was hospitalized for a myocardial infarction with pulmonary edema, treated with high-dose diuretics.",11256525_2,1
1247,high-dose,83,92,"He was hospitalized for a myocardial infarction with pulmonary edema, treated with high-dose diuretics.",11256525_2,0
4327,pulmonary edema,53,68,"He was hospitalized for a myocardial infarction with pulmonary edema, treated with high-dose diuretics.",11256525_2,1
4328,systolic dysfunction,14,34,Due to severe systolic dysfunction losartan was prescribed.,11256525_3,1
287,losartan,35,43,Due to severe systolic dysfunction losartan was prescribed.,11256525_3,0
1248,sudden anuria,64,77,"Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose furosemide and amine infusion.",11256525_4,1
1249,high-dose,112,121,"Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose furosemide and amine infusion.",11256525_4,0
288,losartan,41,49,"Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose furosemide and amine infusion.",11256525_4,0
1250,second dose,72,83,"One week later, by mistake, losartan was prescribed again and after the second dose of 50 mg, the patient developed a second episode of transient anuria lasting 10 hours.",11256525_5,0
289,losartan,28,36,"One week later, by mistake, losartan was prescribed again and after the second dose of 50 mg, the patient developed a second episode of transient anuria lasting 10 hours.",11256525_5,0
1251,his blood pressure,27,45,"During these two episodes, his blood pressure diminished but no severe hypotension was noted.",11256525_6,1
4329,renal artery stenosis,45,66,"Ultimately, an arteriography showed a 70-80% renal artery stenosis.",11256525_7,1
4330,renal artery stenosis,17,38,"In this patient, renal artery stenosis combined with heart failure and diuretic therapy certainly resulted in a strong activation of the renin-angiotensin system (RAS).",11256525_8,1
4331,heart failure,53,66,"In this patient, renal artery stenosis combined with heart failure and diuretic therapy certainly resulted in a strong activation of the renin-angiotensin system (RAS).",11256525_8,1
290,angiotensin II,23,37,"Under such conditions, angiotensin II receptor blockade by losartan probably induced a critical fall in glomerular filtration pressure.",11256525_9,0
291,losartan,59,67,"Under such conditions, angiotensin II receptor blockade by losartan probably induced a critical fall in glomerular filtration pressure.",11256525_9,0
1253,glomerular filtration pressure,104,134,"Under such conditions, angiotensin II receptor blockade by losartan probably induced a critical fall in glomerular filtration pressure.",11256525_9,1
292,Calcineurin-inhibitor,0,21,Calcineurin-inhibitor induced pain syndrome (CIPS): a severe disabling complication after organ transplantation.,11263551_0,0
1257,CIPS,45,49,Calcineurin-inhibitor induced pain syndrome (CIPS): a severe disabling complication after organ transplantation.,11263551_0,0
1258,organ transplantation,90,111,Calcineurin-inhibitor induced pain syndrome (CIPS): a severe disabling complication after organ transplantation.,11263551_0,1
4332,pain syndrome,30,43,Calcineurin-inhibitor induced pain syndrome (CIPS): a severe disabling complication after organ transplantation.,11263551_0,1
1259,Bone pain,0,9,Bone pain after transplantation is a frequent complication that can be caused by several diseases.,11263551_1,1
1261,foot bones,52,62,Bone scans showed an increased tracer uptake of the foot bones.,11263551_4,1
4333,bone marrow,40,51,Magnetic resonance imaging demonstrated bone marrow oedema in the painful bones.,11263551_5,1
4334,reflex sympathetic dystrophy,65,93,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,1
4335,polyneuropathy,95,109,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,1
4336,Morton's neuralgia,111,129,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,1
4337,intermittent claudication,171,196,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,1
4338,foot deformities,210,226,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,1
4339,stress fractures,228,244,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,1
1263,foot pain,49,58,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,1
1264,avascular necrosis,151,169,"Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism.",11263551_6,1
1265,relief of pain,117,131,The reduction of cyclosporine- or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain.,11263551_7,1
293,cyclosporine-,17,30,The reduction of cyclosporine- or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain.,11263551_7,0
294,tacrolimus,34,44,The reduction of cyclosporine- or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain.,11263551_7,0
295,calcium channel blockers,85,109,The reduction of cyclosporine- or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain.,11263551_7,0
1266,CIPS,49,53,"The Calcineurin-inhibitor Induced Pain Syndrome (CIPS) is a rare but severe side effect of cyclosporine or tacrolimus and is accurately diagnosed by its typical presentation, magnetic resonance imaging and bone scans.",11263551_8,0
4341,side effect,76,87,"The Calcineurin-inhibitor Induced Pain Syndrome (CIPS) is a rare but severe side effect of cyclosporine or tacrolimus and is accurately diagnosed by its typical presentation, magnetic resonance imaging and bone scans.",11263551_8,1
4340,Pain Syndrome,34,47,"The Calcineurin-inhibitor Induced Pain Syndrome (CIPS) is a rare but severe side effect of cyclosporine or tacrolimus and is accurately diagnosed by its typical presentation, magnetic resonance imaging and bone scans.",11263551_8,1
296,Calcineurin-inhibitor,4,25,"The Calcineurin-inhibitor Induced Pain Syndrome (CIPS) is a rare but severe side effect of cyclosporine or tacrolimus and is accurately diagnosed by its typical presentation, magnetic resonance imaging and bone scans.",11263551_8,0
297,cyclosporine,91,103,"The Calcineurin-inhibitor Induced Pain Syndrome (CIPS) is a rare but severe side effect of cyclosporine or tacrolimus and is accurately diagnosed by its typical presentation, magnetic resonance imaging and bone scans.",11263551_8,0
298,tacrolimus,107,117,"The Calcineurin-inhibitor Induced Pain Syndrome (CIPS) is a rare but severe side effect of cyclosporine or tacrolimus and is accurately diagnosed by its typical presentation, magnetic resonance imaging and bone scans.",11263551_8,0
1269,life quality,76,88,Incorrect diagnosis of the syndrome will lead to a significant reduction of life quality in patients suffering from CIPS.,11263551_9,1
1270,CIPS,116,120,Incorrect diagnosis of the syndrome will lead to a significant reduction of life quality in patients suffering from CIPS.,11263551_9,0
1271,haemorrhagic myocarditis,6,30,Fatal haemorrhagic myocarditis secondary to cyclophosphamide therapy.,11271907_0,1
1272,secondary to,31,43,Fatal haemorrhagic myocarditis secondary to cyclophosphamide therapy.,11271907_0,1
1273,cyclophosphamide,44,60,Fatal haemorrhagic myocarditis secondary to cyclophosphamide therapy.,11271907_0,0
1275,cyclophosphamide,65,81,Haemorrhagic myocarditis is a rare but important complication of cyclophosphamide therapy.,11271907_1,0
1274,Haemorrhagic myocarditis,0,24,Haemorrhagic myocarditis is a rare but important complication of cyclophosphamide therapy.,11271907_1,1
299,Brain natriuretic peptide,0,25,Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity.,11279304_0,0
4342,cardiotoxicity,66,80,Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity.,11279304_0,1
1278,dose-related,77,89,"Anthracyclines are effective antineoplastic drugs, but they frequently cause dose-related cardiotoxicity.",11279304_1,1
301,antineoplastic drugs,29,49,"Anthracyclines are effective antineoplastic drugs, but they frequently cause dose-related cardiotoxicity.",11279304_1,0
300,Anthracyclines,0,14,"Anthracyclines are effective antineoplastic drugs, but they frequently cause dose-related cardiotoxicity.",11279304_1,0
4343,cardiotoxicity,90,104,"Anthracyclines are effective antineoplastic drugs, but they frequently cause dose-related cardiotoxicity.",11279304_1,1
1287,DNR,84,87,"On the other hand, BNP did not increase in the patients without heart failure given DNR, even at more than 700 mg/m(2).",11279304_10,0
1286,BNP,19,22,"On the other hand, BNP did not increase in the patients without heart failure given DNR, even at more than 700 mg/m(2).",11279304_10,0
4352,heart failure,64,77,"On the other hand, BNP did not increase in the patients without heart failure given DNR, even at more than 700 mg/m(2).",11279304_10,1
310,ANP,20,23,The plasma level of ANP did not always increase in all the patients with clinical and subclinical heart failure.,11279304_11,0
4353,heart failure,98,111,The plasma level of ANP did not always increase in all the patients with clinical and subclinical heart failure.,11279304_11,1
1288,BNP,39,42,These preliminary results suggest that BNP may be useful as an early and sensitive indicator of anthracycline-induced cardiotoxicity.,11279304_12,0
4354,cardiotoxicity,118,132,These preliminary results suggest that BNP may be useful as an early and sensitive indicator of anthracycline-induced cardiotoxicity.,11279304_12,1
4344,cardiotoxicity,4,18,The cardiotoxicity of conventional anthracycline therapy highlights a need to search for methods that are highly sensitive and capable of predicting cardiac dysfunction.,11279304_2,1
1279,cardiac dysfunction,149,168,The cardiotoxicity of conventional anthracycline therapy highlights a need to search for methods that are highly sensitive and capable of predicting cardiac dysfunction.,11279304_2,1
302,anthracycline,35,48,The cardiotoxicity of conventional anthracycline therapy highlights a need to search for methods that are highly sensitive and capable of predicting cardiac dysfunction.,11279304_2,0
4345,cardiotoxicity,159,173,We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced cardiotoxicity in patients with acute leukemia treated with a daunorubicin (DNR)-containing regimen.,11279304_3,1
304,daunorubicin,221,233,We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced cardiotoxicity in patients with acute leukemia treated with a daunorubicin (DNR)-containing regimen.,11279304_3,0
303,brain natriuretic peptide,32,57,We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced cardiotoxicity in patients with acute leukemia treated with a daunorubicin (DNR)-containing regimen.,11279304_3,0
1280,BNP,59,62,We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced cardiotoxicity in patients with acute leukemia treated with a daunorubicin (DNR)-containing regimen.,11279304_3,0
1281,BNP,85,88,We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced cardiotoxicity in patients with acute leukemia treated with a daunorubicin (DNR)-containing regimen.,11279304_3,0
4346,acute leukemia,191,205,We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced cardiotoxicity in patients with acute leukemia treated with a daunorubicin (DNR)-containing regimen.,11279304_3,1
1282,DNR-containing,58,72,Thirteen patients with acute leukemia were treated with a DNR-containing regimen.,11279304_4,0
4347,acute leukemia,23,37,Thirteen patients with acute leukemia were treated with a DNR-containing regimen.,11279304_4,1
305,radionuclide,38,50,Cardiac functions were evaluated with radionuclide angiography before chemotherapies.,11279304_5,0
1283,Cardiac functions,0,17,Cardiac functions were evaluated with radionuclide angiography before chemotherapies.,11279304_5,1
307,ANP,49,52,The plasma levels of atrial natriuretic peptide (ANP) and BNP were measured at the time of radionuclide angiography.,11279304_6,0
308,radionuclide,91,103,The plasma levels of atrial natriuretic peptide (ANP) and BNP were measured at the time of radionuclide angiography.,11279304_6,0
306,atrial natriuretic peptide,21,47,The plasma levels of atrial natriuretic peptide (ANP) and BNP were measured at the time of radionuclide angiography.,11279304_6,0
1284,BNP,58,61,The plasma levels of atrial natriuretic peptide (ANP) and BNP were measured at the time of radionuclide angiography.,11279304_6,0
4348,congestive heart failure,25,49,Three patients developed congestive heart failure after the completion of chemotherapy.,11279304_7,1
4349,heart failure,51,64,Five patients were diagnosed as having subclinical heart failure after the completion of chemotherapy.,11279304_8,1
309,radionuclide,198,210,The plasma levels of BNP in all the patients with clinical and subclinical heart failure increased above the normal limit (40 pg/ml) before the detection of clinical or subclinical heart failure by radionuclide angiography.,11279304_9,0
1285,BNP,21,24,The plasma levels of BNP in all the patients with clinical and subclinical heart failure increased above the normal limit (40 pg/ml) before the detection of clinical or subclinical heart failure by radionuclide angiography.,11279304_9,0
4351,heart failure,181,194,The plasma levels of BNP in all the patients with clinical and subclinical heart failure increased above the normal limit (40 pg/ml) before the detection of clinical or subclinical heart failure by radionuclide angiography.,11279304_9,1
4350,heart failure,75,88,The plasma levels of BNP in all the patients with clinical and subclinical heart failure increased above the normal limit (40 pg/ml) before the detection of clinical or subclinical heart failure by radionuclide angiography.,11279304_9,1
4355,atrial fibrillation,24,43,Effects of verapamil on atrial fibrillation and its electrophysiological determinants in dogs.,11282081_0,1
1293,L-type Ca(2+),132,145,BACKGROUND: Atrial tachycardia-induced remodeling promotes the occurrence and maintenance of atrial fibrillation (AF) and decreases L-type Ca(2+) current.,11282081_1,0
1292,AF,114,116,BACKGROUND: Atrial tachycardia-induced remodeling promotes the occurrence and maintenance of atrial fibrillation (AF) and decreases L-type Ca(2+) current.,11282081_1,0
1291,Atrial tachycardia-induced remodeling,12,49,BACKGROUND: Atrial tachycardia-induced remodeling promotes the occurrence and maintenance of atrial fibrillation (AF) and decreases L-type Ca(2+) current.,11282081_1,1
4356,atrial fibrillation,93,112,BACKGROUND: Atrial tachycardia-induced remodeling promotes the occurrence and maintenance of atrial fibrillation (AF) and decreases L-type Ca(2+) current.,11282081_1,1
1322,autonomic blockade,19,37,"In the presence of autonomic blockade, verapamil failed to promote AF and increased, rather than decreasing, refractoriness.",11282081_10,1
1323,AF,67,69,"In the presence of autonomic blockade, verapamil failed to promote AF and increased, rather than decreasing, refractoriness.",11282081_10,0
1324,atrial conduction,41,58,Neither verapamil nor diltiazem affected atrial conduction in the presence of autonomic blockade.,11282081_11,1
1325,autonomic blockade,78,96,Neither verapamil nor diltiazem affected atrial conduction in the presence of autonomic blockade.,11282081_11,1
1326,Epicardial,0,10,Epicardial mapping suggested that verapamil promoted AF by increasing the number of simultaneous wavefronts reflected by separate zones of reactivation in each cycle.,11282081_12,1
4357,reactivation,139,151,Epicardial mapping suggested that verapamil promoted AF by increasing the number of simultaneous wavefronts reflected by separate zones of reactivation in each cycle.,11282081_12,1
1327,AF,53,55,Epicardial mapping suggested that verapamil promoted AF by increasing the number of simultaneous wavefronts reflected by separate zones of reactivation in each cycle.,11282081_12,0
1331,autonomic tone,119,133,"CONCLUSIONS: Verapamil promotes AF in normal dogs by promoting multiple circuit reentry, an effect dependent on intact autonomic tone and not shared by diltiazem.",11282081_13,1
1330,multiple circuit reentry,63,87,"CONCLUSIONS: Verapamil promotes AF in normal dogs by promoting multiple circuit reentry, an effect dependent on intact autonomic tone and not shared by diltiazem.",11282081_13,1
1328,AF,32,34,"CONCLUSIONS: Verapamil promotes AF in normal dogs by promoting multiple circuit reentry, an effect dependent on intact autonomic tone and not shared by diltiazem.",11282081_13,0
311,L-type,47,53,"There is also a clinical suggestion that acute L-type Ca(2) channel blockade can promote AF, consistent with an AF promoting effect of Ca(2+) channel inhibition.",11282081_2,0
1295,AF,89,91,"There is also a clinical suggestion that acute L-type Ca(2) channel blockade can promote AF, consistent with an AF promoting effect of Ca(2+) channel inhibition.",11282081_2,0
1297,Ca(2+) channel,135,149,"There is also a clinical suggestion that acute L-type Ca(2) channel blockade can promote AF, consistent with an AF promoting effect of Ca(2+) channel inhibition.",11282081_2,0
1296,AF,112,114,"There is also a clinical suggestion that acute L-type Ca(2) channel blockade can promote AF, consistent with an AF promoting effect of Ca(2+) channel inhibition.",11282081_2,0
1299,Ca(2+) channel blockers,65,88,"METHODS: To evaluate the potential mechanisms of AF promotion by Ca(2+) channel blockers, we administered verapamil to morphine-chloralose anesthetized dogs.",11282081_3,0
1300,morphine-chloralose,119,138,"METHODS: To evaluate the potential mechanisms of AF promotion by Ca(2+) channel blockers, we administered verapamil to morphine-chloralose anesthetized dogs.",11282081_3,0
1298,AF,49,51,"METHODS: To evaluate the potential mechanisms of AF promotion by Ca(2+) channel blockers, we administered verapamil to morphine-chloralose anesthetized dogs.",11282081_3,0
1301,autonomic blockade,44,62,Diltiazem was used as a comparison drug and autonomic blockade with atropine and nadolol was applied in some experiments.,11282081_4,1
1302,Epicardial,0,10,Epicardial mapping with 240 epicardial electrodes was used to evaluate activation during AF.,11282081_5,1
1304,AF,89,91,Epicardial mapping with 240 epicardial electrodes was used to evaluate activation during AF.,11282081_5,0
1303,epicardial,28,38,Epicardial mapping with 240 epicardial electrodes was used to evaluate activation during AF.,11282081_5,1
1307,AF,80,82,"RESULTS: Verapamil caused AF promotion in six dogs, increasing mean duration of AF induced by burst pacing, from 8+/-4 s (mean+/-S.E.) to 95+/-39 s (P<0.01 vs. control) at a loading dose of 0.1 mg/kg and 228+/-101 s (P<0.0005 vs. control) at a dose of 0.2 mg/kg.",11282081_6,0
1305,AF,26,28,"RESULTS: Verapamil caused AF promotion in six dogs, increasing mean duration of AF induced by burst pacing, from 8+/-4 s (mean+/-S.E.) to 95+/-39 s (P<0.01 vs. control) at a loading dose of 0.1 mg/kg and 228+/-101 s (P<0.0005 vs. control) at a dose of 0.2 mg/kg.",11282081_6,0
1318,AF,288,290,"In these experiments, verapamil shortened mean effective refractory period (ERP) from 122+/-5 to 114+/-4 ms (P<0.02) at a cycle length of 300 ms, decreased ERP heterogeneity (from 15+/-1 to 10+/-1%, P<0.05), heterogeneously accelerated atrial conduction and decreased the cycle length of AF (94+/-4 to 84+/-3 ms, P<0.005).",11282081_8,0
1317,atrial conduction,236,253,"In these experiments, verapamil shortened mean effective refractory period (ERP) from 122+/-5 to 114+/-4 ms (P<0.02) at a cycle length of 300 ms, decreased ERP heterogeneity (from 15+/-1 to 10+/-1%, P<0.05), heterogeneously accelerated atrial conduction and decreased the cycle length of AF (94+/-4 to 84+/-3 ms, P<0.005).",11282081_8,1
1315,ERP,156,159,"In these experiments, verapamil shortened mean effective refractory period (ERP) from 122+/-5 to 114+/-4 ms (P<0.02) at a cycle length of 300 ms, decreased ERP heterogeneity (from 15+/-1 to 10+/-1%, P<0.05), heterogeneously accelerated atrial conduction and decreased the cycle length of AF (94+/-4 to 84+/-3 ms, P<0.005).",11282081_8,0
1313,ERP,76,79,"In these experiments, verapamil shortened mean effective refractory period (ERP) from 122+/-5 to 114+/-4 ms (P<0.02) at a cycle length of 300 ms, decreased ERP heterogeneity (from 15+/-1 to 10+/-1%, P<0.05), heterogeneously accelerated atrial conduction and decreased the cycle length of AF (94+/-4 to 84+/-3 ms, P<0.005).",11282081_8,0
1321,AF,49,51,"Diltiazem did not affect ERP, AF cycle length or AF duration, but produced conduction acceleration similar to that caused by verapamil (n=5).",11282081_9,0
1319,ERP,25,28,"Diltiazem did not affect ERP, AF cycle length or AF duration, but produced conduction acceleration similar to that caused by verapamil (n=5).",11282081_9,0
1320,AF,30,32,"Diltiazem did not affect ERP, AF cycle length or AF duration, but produced conduction acceleration similar to that caused by verapamil (n=5).",11282081_9,0
4358,tension-type headache,101,122,Calcitonin gene-related peptide levels during nitric oxide-induced headache in patients with chronic tension-type headache.,11284996_0,1
312,Calcitonin gene-related peptide,0,31,Calcitonin gene-related peptide levels during nitric oxide-induced headache in patients with chronic tension-type headache.,11284996_0,0
313,nitric oxide,26,38,It has been proposed that nitric oxide (NO) induced headache in primary headaches may be associated with release of calcitonin gene-related peptide (CGRP).,11284996_1,0
315,CGRP,149,153,It has been proposed that nitric oxide (NO) induced headache in primary headaches may be associated with release of calcitonin gene-related peptide (CGRP).,11284996_1,0
314,calcitonin gene-related peptide,116,147,It has been proposed that nitric oxide (NO) induced headache in primary headaches may be associated with release of calcitonin gene-related peptide (CGRP).,11284996_1,0
1334,GTN,128,131,In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.,11284996_2,0
316,CGRP,62,66,In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.,11284996_2,0
317,glyceryl trinitrate,107,126,In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.,11284996_2,0
4359,tension-type headache,161,182,In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls.,11284996_2,1
1336,GTN,66,69,The subjects were randomly allocated to receive 0.5 microg/kg/min GTN or placebo over 20 min on two headache-free days.,11284996_3,0
1338,GTN,86,89,Both patients and controls developed significantly stronger immediate headache on the GTN day than on the placebo day and the headache was significantly more pronounced in patients than in controls.,11284996_5,0
318,CGRP,51,55,There was no difference between the area under the CGRP curve (AUCCGRP) on GTN vs. placebo day in either patients (P=0.65) or controls (P=0.48).,11284996_6,0
1340,GTN,75,78,There was no difference between the area under the CGRP curve (AUCCGRP) on GTN vs. placebo day in either patients (P=0.65) or controls (P=0.48).,11284996_6,0
1339,AUCCGRP,63,70,There was no difference between the area under the CGRP curve (AUCCGRP) on GTN vs. placebo day in either patients (P=0.65) or controls (P=0.48).,11284996_6,0
1341,AUCCGRP,4,11,The AUCCGRP recorded on the GTN day did not differ between patients and controls (P=0.36).,11284996_7,0
1342,GTN,28,31,The AUCCGRP recorded on the GTN day did not differ between patients and controls (P=0.36).,11284996_7,0
1343,GTN,88,91,"Both in patients and controls, CGRP levels changed significantly over time, on both the GTN and placebo days (P < 0.05).",11284996_8,0
319,CGRP,31,35,"Both in patients and controls, CGRP levels changed significantly over time, on both the GTN and placebo days (P < 0.05).",11284996_8,0
320,CGRP,97,101,The present study indicates that NO-induced immediate headache is not associated with release of CGRP.,11284996_9,0
4360,torsade de pointes,20,38,Fluconazole-induced torsade de pointes.,11302406_0,1
1346,fluconazole,92,103,OBJECTIVE: To present a case of fluconazole-associated torsade de pointes (TDP) and discuss fluconazole's role in causing TDP.,11302406_1,0
1345,TDP,75,78,OBJECTIVE: To present a case of fluconazole-associated torsade de pointes (TDP) and discuss fluconazole's role in causing TDP.,11302406_1,0
4361,torsade de pointes,55,73,OBJECTIVE: To present a case of fluconazole-associated torsade de pointes (TDP) and discuss fluconazole's role in causing TDP.,11302406_1,1
1347,TDP,122,125,OBJECTIVE: To present a case of fluconazole-associated torsade de pointes (TDP) and discuss fluconazole's role in causing TDP.,11302406_1,0
1351,presacral abscess,78,95,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,1
1352,TDP,106,109,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,0
1356,electrolyte abnormalities,283,308,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,1
1353,oral fluconazole,138,154,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,0
4362,coronary artery disease,212,235,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,1
4363,congestive heart failure,253,277,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,1
1358,TDP,384,387,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,0
1357,fluconazole,368,379,"CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP.",11302406_2,0
4364,premature ventricular contractions,91,125,"The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.",11302406_3,1
4365,nonsustained ventricular tachycardia,130,166,"The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.",11302406_3,1
1359,TDP,4,7,"The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.",11302406_3,0
1360,fluconazole,22,33,"The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.",11302406_3,0
1362,drug cessation,195,209,"The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.",11302406_3,1
1364,fluconazole,312,323,"The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP.",11302406_3,0
1366,potassium currents,77,95,The possible mechanism is depression of rapidly activating delayed rectifier potassium currents.,11302406_4,0
1368,TDP,93,96,"In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.",11302406_5,0
1371,fluconazole,257,268,"In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.",11302406_5,0
4366,premature ventricular contractions,136,170,"In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology.",11302406_5,1
1373,low doses,66,75,"CONCLUSIONS: Clinicians should be aware that fluconazole, even at low doses, may cause prolongation of the QT interval, leading to TDP.",11302406_6,0
1372,fluconazole,45,56,"CONCLUSIONS: Clinicians should be aware that fluconazole, even at low doses, may cause prolongation of the QT interval, leading to TDP.",11302406_6,0
1378,ventricular arrhythmias,122,145,Serial electrocardiographic monitoring may be considered when fluconazole is administered in patients who are at risk for ventricular arrhythmias.,11302406_7,1
1377,fluconazole,62,73,Serial electrocardiographic monitoring may be considered when fluconazole is administered in patients who are at risk for ventricular arrhythmias.,11302406_7,0
1379,Nephrotoxicity,0,14,Nephrotoxicity of combined cephalothin-gentamicin regimen.,1130930_0,1
1380,cephalothin-gentamicin,27,49,Nephrotoxicity of combined cephalothin-gentamicin regimen.,1130930_0,0
321,gentamicin sulfate,171,189,"Two patients developed acute tubular necrosis, characterized clinically by acute oliguric renal failure, while they were receiving a combination of cephalothin sodium and gentamicin sulfate therapy.",1130930_1,0
1381,acute tubular necrosis,23,45,"Two patients developed acute tubular necrosis, characterized clinically by acute oliguric renal failure, while they were receiving a combination of cephalothin sodium and gentamicin sulfate therapy.",1130930_1,1
1382,cephalothin sodium,148,166,"Two patients developed acute tubular necrosis, characterized clinically by acute oliguric renal failure, while they were receiving a combination of cephalothin sodium and gentamicin sulfate therapy.",1130930_1,0
4367,renal failure,90,103,"Two patients developed acute tubular necrosis, characterized clinically by acute oliguric renal failure, while they were receiving a combination of cephalothin sodium and gentamicin sulfate therapy.",1130930_1,1
1384,nephrotoxicity,94,108,Patients who are given this drug regimen should be observed very carefully for early signs of nephrotoxicity.,1130930_2,1
1385,High doses,0,10,High doses of this antibiotic combination should be avoided especially in elderly patients.,1130930_3,0
4368,renal insufficiency,14,33,Patients with renal insufficiency should not be given this regimen.,1130930_4,1
1387,nephrotoxicity,108,122,"In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.",11334364_0,1
1388,lung toxicity,143,156,"In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.",11334364_0,1
322,apoptotic,44,53,"In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.",11334364_0,0
323,grape seed,213,223,"In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.",11334364_0,0
4369,cardiotoxicity,181,195,"In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.",11334364_0,1
1390,toxicological effects,137,158,"Grape seed extract, primarily a mixture of proanthocyanidins, has been shown to modulate a wide-range of biological, pharmacological and toxicological effects which are mainly cytoprotective.",11334364_1,0
324,Grape seed extract,0,18,"Grape seed extract, primarily a mixture of proanthocyanidins, has been shown to modulate a wide-range of biological, pharmacological and toxicological effects which are mainly cytoprotective.",11334364_1,0
325,proanthocyanidins,43,60,"Grape seed extract, primarily a mixture of proanthocyanidins, has been shown to modulate a wide-range of biological, pharmacological and toxicological effects which are mainly cytoprotective.",11334364_1,0
1391,cytoprotective,176,190,"Grape seed extract, primarily a mixture of proanthocyanidins, has been shown to modulate a wide-range of biological, pharmacological and toxicological effects which are mainly cytoprotective.",11334364_1,0
1417,serum chemistry,58,73,"Additionally, histopathological alterations mirrored both serum chemistry changes and the pattern of DNA fragmentation.",11334364_10,0
1422,GSPE,167,171,"Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE.",11334364_11,0
1421,DOX,52,55,"Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE.",11334364_11,0
327,apoptotic,64,73,"Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE.",11334364_11,0
1419,AAP,39,42,"Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE.",11334364_11,0
1420,AMI,44,47,"Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE.",11334364_11,0
1423,AAP,6,9,"Since AAP, AMI and DOX undergo biotransformation and are known to produce damaging radicals in vivo, the protection by GSPE may be linked to both inhibition of metabolism and/or detoxification of cytotoxic radicals.",11334364_12,0
1424,AMI,11,14,"Since AAP, AMI and DOX undergo biotransformation and are known to produce damaging radicals in vivo, the protection by GSPE may be linked to both inhibition of metabolism and/or detoxification of cytotoxic radicals.",11334364_12,0
1425,DOX,19,22,"Since AAP, AMI and DOX undergo biotransformation and are known to produce damaging radicals in vivo, the protection by GSPE may be linked to both inhibition of metabolism and/or detoxification of cytotoxic radicals.",11334364_12,0
1427,GSPE,119,123,"Since AAP, AMI and DOX undergo biotransformation and are known to produce damaging radicals in vivo, the protection by GSPE may be linked to both inhibition of metabolism and/or detoxification of cytotoxic radicals.",11334364_12,0
1428,cytotoxic radicals,196,214,"Since AAP, AMI and DOX undergo biotransformation and are known to produce damaging radicals in vivo, the protection by GSPE may be linked to both inhibition of metabolism and/or detoxification of cytotoxic radicals.",11334364_12,0
328,apoptotic,65,74,"Additionally, this may have been the first report on AMI-induced apoptotic death in the lung tissue.",11334364_14,0
1432,GSPE,51,55,"Taken together, these events undoubtedly establish GSPE's abundant bioavailability, and the power to defend multiple target organs from toxic assaults induced by structurally diverse and functionally different entities in vivo.",11334364_15,0
1434,toxic assaults,136,150,"Taken together, these events undoubtedly establish GSPE's abundant bioavailability, and the power to defend multiple target organs from toxic assaults induced by structurally diverse and functionally different entities in vivo.",11334364_15,0
326,grape seed,41,51,"This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.",11334364_2,0
1392,GSPE,78,82,"This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.",11334364_2,0
1394,lung toxicity,164,177,"This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.",11334364_2,1
1393,nephrotoxicity,123,137,"This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.",11334364_2,1
4370,cardiotoxicity,209,223,"This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice.",11334364_2,1
1395,GSPE,71,75,"Experimental design consisted of four groups: control (vehicle alone), GSPE alone, drug alone and GSPE+drug.",11334364_3,0
1396,GSPE+drug,98,107,"Experimental design consisted of four groups: control (vehicle alone), GSPE alone, drug alone and GSPE+drug.",11334364_3,0
1397,GSPE,68,72,"For the cytoprotection study, animals were orally gavaged 100 mg/Kg GSPE for 7-10 days followed by i.p.",11334364_4,0
1399,AAP,42,45,injections of organ specific three drugs (AAP: 500 mg/Kg for 24 h; AMI: 50 mg/Kg/day for four days; DOX: 20 mg/Kg for 48 h).,11334364_5,0
1400,AMI,67,70,injections of organ specific three drugs (AAP: 500 mg/Kg for 24 h; AMI: 50 mg/Kg/day for four days; DOX: 20 mg/Kg for 48 h).,11334364_5,0
1401,DOX,100,103,injections of organ specific three drugs (AAP: 500 mg/Kg for 24 h; AMI: 50 mg/Kg/day for four days; DOX: 20 mg/Kg for 48 h).,11334364_5,0
1404,genomic DNA,106,117,"Parameters of study included analysis of serum chemistry (ALT, BUN and CPK), and orderly fragmentation of genomic DNA (both endonuclease-dependent and independent) in addition to microscopic evaluation of damage and/or protection in corresponding PAS stained tissues.",11334364_6,0
1403,CPK,71,74,"Parameters of study included analysis of serum chemistry (ALT, BUN and CPK), and orderly fragmentation of genomic DNA (both endonuclease-dependent and independent) in addition to microscopic evaluation of damage and/or protection in corresponding PAS stained tissues.",11334364_6,0
1407,GSPE,22,26,"Results indicate that GSPE preexposure prior to AAP, AMI and DOX, provided near complete protection in terms of serum chemistry changes (ALT, BUN and CPK), and significantly reduced DNA fragmentation.",11334364_7,0
1408,AAP,48,51,"Results indicate that GSPE preexposure prior to AAP, AMI and DOX, provided near complete protection in terms of serum chemistry changes (ALT, BUN and CPK), and significantly reduced DNA fragmentation.",11334364_7,0
1409,AMI,53,56,"Results indicate that GSPE preexposure prior to AAP, AMI and DOX, provided near complete protection in terms of serum chemistry changes (ALT, BUN and CPK), and significantly reduced DNA fragmentation.",11334364_7,0
1410,DOX,61,64,"Results indicate that GSPE preexposure prior to AAP, AMI and DOX, provided near complete protection in terms of serum chemistry changes (ALT, BUN and CPK), and significantly reduced DNA fragmentation.",11334364_7,0
1412,CPK,150,153,"Results indicate that GSPE preexposure prior to AAP, AMI and DOX, provided near complete protection in terms of serum chemistry changes (ALT, BUN and CPK), and significantly reduced DNA fragmentation.",11334364_7,0
1414,GSPE,193,197,"Histopathological examination of kidney, heart and lung sections revealed moderate to massive tissue damage with a variety of morphological aberrations by all the three drugs in the absence of GSPE preexposure than in its presence.",11334364_8,0
1415,GSPE+drug,0,9,GSPE+drug exposed tissues exhibited minor residual damage or near total recovery.,11334364_9,0
1435,Cutaneous leucocytoclastic vasculitis,0,37,Cutaneous leucocytoclastic vasculitis associated with oxacillin.,11337188_0,1
4371,renal failure,117,130,"A 67-year-old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.",11337188_1,1
329,his,184,187,"A 67-year-old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.",11337188_1,0
1437,Staphylococcus aureus bacteremia,73,105,"A 67-year-old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia, developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet.",11337188_1,1
1449,leucocytoclastic vasculitis,60,87,Oxacillin should be included among the drugs that can cause leucocytoclastic vasculitis.,11337188_10,1
330,his,32,35,Necrotic blisters were noted on his fingers.,11337188_2,0
1440,leucocytoclastic vasculitis,44,71,Skin biopsies showed findings diagnostic of leucocytoclastic vasculitis.,11337188_3,1
1441,renal function,43,57,The rash disappeared after three weeks and renal function returned to normal.,11337188_5,1
1443,renal involvement,135,152,"Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement.",11337188_6,1
4373,abdominal pain,103,117,"Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement.",11337188_6,1
4372,lower extremities,64,81,"Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement.",11337188_6,1
1442,Leucocytoclastic vasculitis,0,27,"Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement.",11337188_6,1
1446,collagen vascular disease,75,100,"Etiologic factors or associated disorders include infections, medications, collagen vascular disease and neoplasia.",11337188_7,1
1445,associated disorders,21,41,"Etiologic factors or associated disorders include infections, medications, collagen vascular disease and neoplasia.",11337188_7,1
1448,self-limited disorder,16,37,"Usually it is a self-limited disorder, but corticosteroid therapy may be needed in life-threatening cases since early treatment with corticosteroids in severe cases can prevent complications.",11337188_9,1
1453,bipolar depression,178,196,BACKGROUND: Concerns about possible risks of switching to mania associated with antidepressants continue to interfere with the establishment of an optimal treatment paradigm for bipolar depression.,11379838_1,1
1454,bipolar disorder,64,80,METHOD: The response of 44 patients meeting DSM-IV criteria for bipolar disorder to naturalistic treatment was assessed for at least 6 weeks using the Montgomery-Asberg Depression Rating Scale and the Bech-Rafaelson Mania Rating Scale.,11379838_2,1
4374,manic episodes,195,209,"Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.",11379838_3,1
332,selective serotonin reuptake inhibitors,323,362,"Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.",11379838_3,0
331,antidepressant drugs,278,298,"Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.",11379838_3,0
1463,hyperthymia,516,527,"Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age, sex, diagnosis (DSM-IV bipolar I vs. bipolar II), number of previous manic episodes, type of antidepressant therapy used (electroconvulsive therapy vs. antidepressant drugs and, more particularly, selective serotonin reuptake inhibitors [SSRIs]), use and type of mood stabilizers (lithium vs. anticonvulsants), and temperament of the patient, assessed during a normothymic period using the hyperthymia component of the Semi-structured Affective Temperament Interview.",11379838_3,1
4375,hypomania,21,30,"RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.",11379838_4,1
4376,manic episodes,173,187,"RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.",11379838_4,1
4377,hypomanic episodes,217,235,"RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with SSRIs [8/33]); 16% (N = 7) experienced manic episodes, and 11% (N = 5) experienced hypomanic episodes.",11379838_4,1
1466,mood stabilizer,120,135,The incidence of mood switches seemed not to differ between patients receiving an anticonvulsant and those receiving no mood stabilizer.,11379838_6,0
1468,hyperthymia,111,122,"The number of previous manic episodes did not affect the probability of switching, whereas a high score on the hyperthymia component of the Semistructured Affective Temperament Interview was associated with a greater risk of switching (p = .008).",11379838_8,1
4378,manic episodes,23,37,"The number of previous manic episodes did not affect the probability of switching, whereas a high score on the hyperthymia component of the Semistructured Affective Temperament Interview was associated with a greater risk of switching (p = .008).",11379838_8,1
1475,Peritubular capillary basement membrane reduplication,0,53,Peritubular capillary basement membrane reduplication in allografts and native kidney disease: a clinicopathologic study of 278 consecutive renal specimens.,11391224_0,1
4379,kidney disease,79,93,Peritubular capillary basement membrane reduplication in allografts and native kidney disease: a clinicopathologic study of 278 consecutive renal specimens.,11391224_0,1
1480,PTCR,144,148,BACKGROUND: An association has been found between transplant glomerulopathy (TG) and reduplication of peritubular capillary basement membranes (PTCR).,11391224_1,0
4380,glomerulopathy,61,75,BACKGROUND: An association has been found between transplant glomerulopathy (TG) and reduplication of peritubular capillary basement membranes (PTCR).,11391224_1,1
1510,TG,104,106,"PTCR also occurs in certain native kidney diseases, though the association is not as strong as that for TG.",11391224_10,0
1509,PTCR,0,4,"PTCR also occurs in certain native kidney diseases, though the association is not as strong as that for TG.",11391224_10,0
4388,kidney diseases,35,50,"PTCR also occurs in certain native kidney diseases, though the association is not as strong as that for TG.",11391224_10,1
1512,immunologic injury,55,73,"We suggest that repeated endothelial injury, including immunologic injury, may be the cause of this lesion both in allografts and native kidneys.",11391224_11,1
1511,endothelial injury,25,43,"We suggest that repeated endothelial injury, including immunologic injury, may be the cause of this lesion both in allografts and native kidneys.",11391224_11,1
1483,PTCR,131,135,METHODS: We examined 278 consecutive renal specimens (from 135 transplants and 143 native kidneys) for ultrastructural evidence of PTCR.,11391224_3,0
1489,stable grafts,151,164,"In addition to renal allografts with TG, we also examined grafts with acute rejection, recurrent glomerulonephritis, chronic allograft nephropathy and stable grafts (""protocol biopsies"").",11391224_4,1
1487,recurrent glomerulonephritis,87,115,"In addition to renal allografts with TG, we also examined grafts with acute rejection, recurrent glomerulonephritis, chronic allograft nephropathy and stable grafts (""protocol biopsies"").",11391224_4,1
1486,acute rejection,70,85,"In addition to renal allografts with TG, we also examined grafts with acute rejection, recurrent glomerulonephritis, chronic allograft nephropathy and stable grafts (""protocol biopsies"").",11391224_4,1
1485,TG,37,39,"In addition to renal allografts with TG, we also examined grafts with acute rejection, recurrent glomerulonephritis, chronic allograft nephropathy and stable grafts (""protocol biopsies"").",11391224_4,0
1488,chronic allograft nephropathy,117,146,"In addition to renal allografts with TG, we also examined grafts with acute rejection, recurrent glomerulonephritis, chronic allograft nephropathy and stable grafts (""protocol biopsies"").",11391224_4,1
4381,glomerulopathies,49,65,"Native kidney specimens included a wide range of glomerulopathies as well as cases of thrombotic microangiopathy, malignant hypertension, acute interstitial nephritis, and acute tubular necrosis.",11391224_5,1
4382,thrombotic microangiopathy,86,112,"Native kidney specimens included a wide range of glomerulopathies as well as cases of thrombotic microangiopathy, malignant hypertension, acute interstitial nephritis, and acute tubular necrosis.",11391224_5,1
4383,malignant hypertension,114,136,"Native kidney specimens included a wide range of glomerulopathies as well as cases of thrombotic microangiopathy, malignant hypertension, acute interstitial nephritis, and acute tubular necrosis.",11391224_5,1
1491,acute interstitial nephritis,138,166,"Native kidney specimens included a wide range of glomerulopathies as well as cases of thrombotic microangiopathy, malignant hypertension, acute interstitial nephritis, and acute tubular necrosis.",11391224_5,1
1492,acute tubular,172,185,"Native kidney specimens included a wide range of glomerulopathies as well as cases of thrombotic microangiopathy, malignant hypertension, acute interstitial nephritis, and acute tubular necrosis.",11391224_5,1
1493,PTCR,18,22,"RESULTS: We found PTCR in 14 of 15 cases of TG, in 7 transplant biopsy specimens without TG, and in 13 of 143 native kidney biopsy specimens.",11391224_6,0
1494,TG,44,46,"RESULTS: We found PTCR in 14 of 15 cases of TG, in 7 transplant biopsy specimens without TG, and in 13 of 143 native kidney biopsy specimens.",11391224_6,0
1498,Henoch-Schonlein nephritis,96,122,"These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.",11391224_7,1
4384,malignant hypertension,27,49,"These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.",11391224_7,1
1500,cocaine-related acute renal failure,159,194,"These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.",11391224_7,1
1499,crescentic glomerulonephritis,124,153,"These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.",11391224_7,1
4386,lupus nephritis,79,94,"These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.",11391224_7,1
4385,thrombotic microangiopathy,51,77,"These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and cocaine-related acute renal failure.",11391224_7,1
1502,TG,32,34,Mild PTCR in allografts without TG did not predict renal failure or significant proteinuria after follow-up periods of between 3 months and 1 year.,11391224_8,0
1501,PTCR,5,9,Mild PTCR in allografts without TG did not predict renal failure or significant proteinuria after follow-up periods of between 3 months and 1 year.,11391224_8,0
1503,significant proteinuria,68,91,Mild PTCR in allografts without TG did not predict renal failure or significant proteinuria after follow-up periods of between 3 months and 1 year.,11391224_8,1
4387,renal failure,51,64,Mild PTCR in allografts without TG did not predict renal failure or significant proteinuria after follow-up periods of between 3 months and 1 year.,11391224_8,1
1504,PTCR,99,103,"CONCLUSIONS: We conclude that in transplants, there is a strong association between well-developed PTCR and TG, while the significance of mild PTCR and its predictive value in the absence of TG is unclear.",11391224_9,0
1505,TG,108,110,"CONCLUSIONS: We conclude that in transplants, there is a strong association between well-developed PTCR and TG, while the significance of mild PTCR and its predictive value in the absence of TG is unclear.",11391224_9,0
1506,PTCR,143,147,"CONCLUSIONS: We conclude that in transplants, there is a strong association between well-developed PTCR and TG, while the significance of mild PTCR and its predictive value in the absence of TG is unclear.",11391224_9,0
1508,TG,191,193,"CONCLUSIONS: We conclude that in transplants, there is a strong association between well-developed PTCR and TG, while the significance of mild PTCR and its predictive value in the absence of TG is unclear.",11391224_9,0
4389,diabetes insipidus,49,67,The renal pathology in a case of lithium-induced diabetes insipidus.,1141447_0,1
1514,renal pathology,4,19,The renal pathology in a case of lithium-induced diabetes insipidus.,1141447_0,1
4390,diabetes insipidus,26,44,A case of lithium-induced diabetes insipidus is reported.,1141447_1,1
1515,distal nephron,77,91,At necropsy microscopy shoed unique and extensive damage to cells lining the distal nephron.,1141447_2,1
4391,cardiac arrhythmia,17,35,Caffeine-induced cardiac arrhythmia: an unrecognised danger of healthfood products.,11419773_0,1
1518,healthfood products,63,82,Caffeine-induced cardiac arrhythmia: an unrecognised danger of healthfood products.,11419773_0,0
4392,mitral valve prolapse,50,71,"We describe a 25-year-old woman with pre-existing mitral valve prolapse who developed intractable ventricular fibrillation after consuming a ""natural energy"" guarana health drink containing a high concentration of caffeine.",11419773_1,1
4393,ventricular fibrillation,98,122,"We describe a 25-year-old woman with pre-existing mitral valve prolapse who developed intractable ventricular fibrillation after consuming a ""natural energy"" guarana health drink containing a high concentration of caffeine.",11419773_1,1
1523,antisense oligodeoxynucleotide,53,83,Conformationally restricted analogs of BD1008 and an antisense oligodeoxynucleotide targeting sigma1 receptors produce anti-cocaine effects in mice.,11426838_0,0
1524,sigma1 receptors,94,110,Conformationally restricted analogs of BD1008 and an antisense oligodeoxynucleotide targeting sigma1 receptors produce anti-cocaine effects in mice.,11426838_0,0
1525,anti-cocaine,119,131,Conformationally restricted analogs of BD1008 and an antisense oligodeoxynucleotide targeting sigma1 receptors produce anti-cocaine effects in mice.,11426838_0,0
1522,BD1008,39,45,Conformationally restricted analogs of BD1008 and an antisense oligodeoxynucleotide targeting sigma1 receptors produce anti-cocaine effects in mice.,11426838_0,0
333,sigma receptors,35,50,Cocaine's ability to interact with sigma receptors suggests that these proteins mediate some of its behavioral effects.,11426838_1,0
1526,Cocaine's,0,9,Cocaine's ability to interact with sigma receptors suggests that these proteins mediate some of its behavioral effects.,11426838_1,0
339,sigma receptors,58,73,"Together, the data suggests that functional antagonism of sigma receptors is capable of attenuating a number of cocaine-induced behaviors.",11426838_10,0
1527,sigma receptor ligands,23,45,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,0
1530,BD1063,184,190,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,0
1531,"1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine",192,242,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,0
1532,LR132,249,254,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,0
1533,"1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine",256,335,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,0
1529,BD1018,109,115,"Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine).",11426838_2,0
1535,sigma1 receptors,90,106,Competition binding assays demonstrated that all three compounds have high affinities for sigma1 receptors.,11426838_3,0
335,NMDA receptors,134,148,"The three compounds vary in their affinities for sigma2 receptors and exhibit negligible affinities for dopamine, opioid, GABA(A) and NMDA receptors.",11426838_4,0
1537,opioid,114,120,"The three compounds vary in their affinities for sigma2 receptors and exhibit negligible affinities for dopamine, opioid, GABA(A) and NMDA receptors.",11426838_4,0
1536,sigma2 receptors,49,65,"The three compounds vary in their affinities for sigma2 receptors and exhibit negligible affinities for dopamine, opioid, GABA(A) and NMDA receptors.",11426838_4,0
334,GABA(A,122,128,"The three compounds vary in their affinities for sigma2 receptors and exhibit negligible affinities for dopamine, opioid, GABA(A) and NMDA receptors.",11426838_4,0
1541,BD1063,58,64,"In behavioral studies, pre-treatment of mice with BD1018, BD1063, or LR132 significantly attenuated cocaine-induced convulsions and lethality.",11426838_5,0
1542,LR132,69,74,"In behavioral studies, pre-treatment of mice with BD1018, BD1063, or LR132 significantly attenuated cocaine-induced convulsions and lethality.",11426838_5,0
1540,BD1018,50,56,"In behavioral studies, pre-treatment of mice with BD1018, BD1063, or LR132 significantly attenuated cocaine-induced convulsions and lethality.",11426838_5,0
1543,cocaine-induced convulsions,100,127,"In behavioral studies, pre-treatment of mice with BD1018, BD1063, or LR132 significantly attenuated cocaine-induced convulsions and lethality.",11426838_5,0
1545,cocaine-induced lethality,46,71,"Moreover, post-treatment with LR132 prevented cocaine-induced lethality in a significant proportion of animals.",11426838_6,1
4394,post-treatment,10,24,"Moreover, post-treatment with LR132 prevented cocaine-induced lethality in a significant proportion of animals.",11426838_6,1
1544,LR132,30,35,"Moreover, post-treatment with LR132 prevented cocaine-induced lethality in a significant proportion of animals.",11426838_6,0
1546,putative antagonists,46,66,"In contrast to the protection provided by the putative antagonists, the well-characterized sigma receptor agonist di-o-tolylguanidine (DTG) and the novel sigma receptor agonist BD1031 (3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane) each worsened the behavioral toxicity of cocaine.",11426838_7,0
1547,sigma receptor agonist di-o-tolylguanidine,91,133,"In contrast to the protection provided by the putative antagonists, the well-characterized sigma receptor agonist di-o-tolylguanidine (DTG) and the novel sigma receptor agonist BD1031 (3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane) each worsened the behavioral toxicity of cocaine.",11426838_7,0
1548,DTG,135,138,"In contrast to the protection provided by the putative antagonists, the well-characterized sigma receptor agonist di-o-tolylguanidine (DTG) and the novel sigma receptor agonist BD1031 (3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane) each worsened the behavioral toxicity of cocaine.",11426838_7,0
1549,sigma receptor agonist BD1031,154,183,"In contrast to the protection provided by the putative antagonists, the well-characterized sigma receptor agonist di-o-tolylguanidine (DTG) and the novel sigma receptor agonist BD1031 (3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane) each worsened the behavioral toxicity of cocaine.",11426838_7,0
336,stimulatory,138,149,"At doses where alone, they produced no significant effects on locomotion, BD1018, BD1063 and LR132 significantly attenuated the locomotor stimulatory effects of cocaine.",11426838_8,0
1552,LR132,93,98,"At doses where alone, they produced no significant effects on locomotion, BD1018, BD1063 and LR132 significantly attenuated the locomotor stimulatory effects of cocaine.",11426838_8,0
1551,BD1063,82,88,"At doses where alone, they produced no significant effects on locomotion, BD1018, BD1063 and LR132 significantly attenuated the locomotor stimulatory effects of cocaine.",11426838_8,0
1550,BD1018,74,80,"At doses where alone, they produced no significant effects on locomotion, BD1018, BD1063 and LR132 significantly attenuated the locomotor stimulatory effects of cocaine.",11426838_8,0
1554,antisense oligodeoxynucleotide,129,159,"To further validate the hypothesis that the anti-cocaine effects of the novel ligands involved antagonism of sigma receptors, an antisense oligodeoxynucleotide against sigma1 receptors was also shown to significantly attenuate the convulsive and locomotor stimulatory effects of cocaine.",11426838_9,0
1555,sigma1 receptors,168,184,"To further validate the hypothesis that the anti-cocaine effects of the novel ligands involved antagonism of sigma receptors, an antisense oligodeoxynucleotide against sigma1 receptors was also shown to significantly attenuate the convulsive and locomotor stimulatory effects of cocaine.",11426838_9,0
338,stimulatory,256,267,"To further validate the hypothesis that the anti-cocaine effects of the novel ligands involved antagonism of sigma receptors, an antisense oligodeoxynucleotide against sigma1 receptors was also shown to significantly attenuate the convulsive and locomotor stimulatory effects of cocaine.",11426838_9,0
337,sigma receptors,109,124,"To further validate the hypothesis that the anti-cocaine effects of the novel ligands involved antagonism of sigma receptors, an antisense oligodeoxynucleotide against sigma1 receptors was also shown to significantly attenuate the convulsive and locomotor stimulatory effects of cocaine.",11426838_9,0
1553,anti-cocaine,44,56,"To further validate the hypothesis that the anti-cocaine effects of the novel ligands involved antagonism of sigma receptors, an antisense oligodeoxynucleotide against sigma1 receptors was also shown to significantly attenuate the convulsive and locomotor stimulatory effects of cocaine.",11426838_9,0
1557,acute interstitial nephritis,19,47,Ranitidine-induced acute interstitial nephritis in a cadaveric renal allograft.,11431197_0,1
1558,renal allograft,63,78,Ranitidine-induced acute interstitial nephritis in a cadaveric renal allograft.,11431197_0,1
1560,renal transplantation,69,90,Ranitidine frequently is used for preventing peptic ulceration after renal transplantation.,11431197_1,1
1559,peptic ulceration,45,62,Ranitidine frequently is used for preventing peptic ulceration after renal transplantation.,11431197_1,1
1562,acute interstitial nephritis,48,76,This drug occasionally has been associated with acute interstitial nephritis in native kidneys.,11431197_2,1
1563,renal transplantation,34,55,There are no similar reports with renal transplantation.,11431197_3,1
1565,renal allograft,98,113,We report a case of ranitidine-induced acute interstitial nephritis in a recipient of a cadaveric renal allograft presenting with acute allograft dysfunction within 48 hours of exposure to the drug.,11431197_4,1
1564,acute interstitial nephritis,39,67,We report a case of ranitidine-induced acute interstitial nephritis in a recipient of a cadaveric renal allograft presenting with acute allograft dysfunction within 48 hours of exposure to the drug.,11431197_4,1
1566,acute allograft dysfunction,130,157,We report a case of ranitidine-induced acute interstitial nephritis in a recipient of a cadaveric renal allograft presenting with acute allograft dysfunction within 48 hours of exposure to the drug.,11431197_4,1
1569,Allograft function,0,18,Allograft function improved rapidly and returned to baseline after stopping the drug.,11431197_6,1
4395,Cholestatic jaundice,0,20,Cholestatic jaundice associated with the use of metformin.,11467664_0,1
340,metformin hydrochloride,98,121,We report a patient who developed cholestatic jaundice shortly after initiation of treatment with metformin hydrochloride.,11467664_1,0
4396,cholestatic jaundice,34,54,We report a patient who developed cholestatic jaundice shortly after initiation of treatment with metformin hydrochloride.,11467664_1,1
1573,biliary anatomy,22,37,An ERCP showed normal biliary anatomy.,11467664_3,1
1572,ERCP,3,7,An ERCP showed normal biliary anatomy.,11467664_3,0
1577,acute inflammation,116,134,"A percutaneous liver biopsy was obtained showing marked cholestasis, with portal edema, ductular proliferation, and acute inflammation.",11467664_4,1
1575,portal edema,74,86,"A percutaneous liver biopsy was obtained showing marked cholestasis, with portal edema, ductular proliferation, and acute inflammation.",11467664_4,1
1576,ductular proliferation,88,110,"A percutaneous liver biopsy was obtained showing marked cholestasis, with portal edema, ductular proliferation, and acute inflammation.",11467664_4,1
341,Metformin hydrochloride,0,23,"Metformin hydrochloride was discontinued, and the patient's jaundice resolved slowly over a period of several months.",11467664_5,0
1579,hepatotoxicity,144,158,"Given the onset of his jaundice 2 wk after the initiation of metformin, we believe that this case represents an example of metformin-associated hepatotoxicity, the first such case reported.",11467664_6,1
4397,Liver disease,0,13,Liver disease caused by propylthiouracil.,1147734_0,1
4398,chronic active,113,127,"This report presents the clinical, laboratory, and light and electron microscopic observations on a patient with chronic active (aggressive) hepatitis caused by the administration of propylthiouracil.",1147734_1,1
1581,chronic liver disease,86,107,This is an addition to the list of drugs that must be considered in the evaluation of chronic liver disease.,1147734_2,1
1582,levobupivacaine-,53,69,"Systemic toxicity and resuscitation in bupivacaine-, levobupivacaine-, or ropivacaine-infused rats.",11524350_0,0
343,ropivacaine,71,82,"We compared the systemic toxicity of bupivacaine, levobupivacaine, and ropivacaine in anesthetized rats.",11524350_1,0
1584,levobupivacaine,50,65,"We compared the systemic toxicity of bupivacaine, levobupivacaine, and ropivacaine in anesthetized rats.",11524350_1,0
342,bupivacaine,37,48,"We compared the systemic toxicity of bupivacaine, levobupivacaine, and ropivacaine in anesthetized rats.",11524350_1,0
1595,levobupivacaine,24,39,"The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.",11524350_10,0
1596,dysrhythmias,54,66,"The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.",11524350_10,1
350,bupivacaine,173,184,"The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.",11524350_10,0
349,ropivacaine,125,136,"The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine.",11524350_10,0
351,Ropivacaine,59,70,"However, a smaller dose of epinephrine was required in the Ropivacaine group than in the other groups.",11524350_12,0
1598,levobupivacaine,277,292,We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.,11524350_13,0
352,ropivacaine,90,101,We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.,11524350_13,0
4399,cardiac arrest,182,196,We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.,11524350_13,1
354,bupivacaine,262,273,We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.,11524350_13,0
1597,levobupivacaine,42,57,We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.,11524350_13,0
353,bupivacaine,106,117,We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine.,11524350_13,0
344,local anesthetics,77,94,We also compared the ability to resuscitate rats after lethal doses of these local anesthetics.,11524350_2,0
1585,levobupivacaine,13,28,"Bupivacaine, levobupivacaine, or ropivacaine was infused at a rate of 2 mg.",11524350_3,0
345,Bupivacaine,0,11,"Bupivacaine, levobupivacaine, or ropivacaine was infused at a rate of 2 mg.",11524350_3,0
346,ropivacaine,33,44,"Bupivacaine, levobupivacaine, or ropivacaine was infused at a rate of 2 mg.",11524350_3,0
1586,arterial pressure,59,76,"min(-1) while electrocardiogram, electroencephalogram, and arterial pressure were continuously monitored.",11524350_5,1
1589,cardiac compressions,74,94,Epinephrine 0.01 mg/kg was administered at 1-min intervals while external cardiac compressions were applied.,11524350_7,1
1590,systolic arterial pressure,47,73,Resuscitation was considered successful when a systolic arterial pressure > or =100 mm Hg was achieved within 5 min.,11524350_8,1
347,ropivacaine,44,55,The cumulative doses of levobupivacaine and ropivacaine that produced seizures were similar and were larger than those of bupivacaine.,11524350_9,0
348,bupivacaine,122,133,The cumulative doses of levobupivacaine and ropivacaine that produced seizures were similar and were larger than those of bupivacaine.,11524350_9,0
1593,levobupivacaine,24,39,The cumulative doses of levobupivacaine and ropivacaine that produced seizures were similar and were larger than those of bupivacaine.,11524350_9,0
1600,risperidone,61,72,Withdrawal-emergent rabbit syndrome during dose reduction of risperidone.,11532387_0,0
1599,Withdrawal-emergent rabbit syndrome,0,35,Withdrawal-emergent rabbit syndrome during dose reduction of risperidone.,11532387_0,1
1602,extrapyramidal side effect,31,57,Rabbit syndrome (RS) is a rare extrapyramidal side effect caused by prolonged neuroleptic medication.,11532387_1,1
1601,Rabbit syndrome,0,15,Rabbit syndrome (RS) is a rare extrapyramidal side effect caused by prolonged neuroleptic medication.,11532387_1,1
1603,risperidone,50,61,The patient developed RS during dose reduction of risperidone.,11532387_3,0
1604,trihexyphenidyl anticholinergic,42,73,The symptom was treated successfully with trihexyphenidyl anticholinergic therapy.,11532387_4,0
1606,risperidone,127,138,"The underlying mechanism of withdrawal-emergent RS in the present case may have been related to the pharmacological profile of risperidone, a serotonin-dopamine antagonist, suggesting the pathophysiologic influence of the serotonin system in the development of RS.",11532387_5,0
1607,serotonin-dopamine antagonist,142,171,"The underlying mechanism of withdrawal-emergent RS in the present case may have been related to the pharmacological profile of risperidone, a serotonin-dopamine antagonist, suggesting the pathophysiologic influence of the serotonin system in the development of RS.",11532387_5,0
1611,E4031,61,66,"Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog.1.",11569530_0,0
1613,terodiline,95,105,"Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog.1.",11569530_0,0
1614,monophasic,109,119,"Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog.1.",11569530_0,0
355,terfenadine,79,90,"Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog.1.",11569530_0,0
1612,cisapride,68,77,"Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and terodiline on monophasic action potential duration in dog.1.",11569530_0,0
1618,monophasic,118,128,Torsades de pointes (TDP) is a potentially fatal ventricular tachycardia associated with increases in QT interval and monophasic action potential duration (MAPD).,11569530_1,0
4401,ventricular tachycardia,49,72,Torsades de pointes (TDP) is a potentially fatal ventricular tachycardia associated with increases in QT interval and monophasic action potential duration (MAPD).,11569530_1,1
4400,Torsades de pointes,0,19,Torsades de pointes (TDP) is a potentially fatal ventricular tachycardia associated with increases in QT interval and monophasic action potential duration (MAPD).,11569530_1,1
1639,ED50,133,137,"For compounds that have shown TDP in the clinic (terfenadine, terodiline, cisapride) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man (< 10-fold) reflecting their limited safety margins.",11569530_10,0
1638,cisapride,74,83,"For compounds that have shown TDP in the clinic (terfenadine, terodiline, cisapride) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man (< 10-fold) reflecting their limited safety margins.",11569530_10,0
1637,terodiline,62,72,"For compounds that have shown TDP in the clinic (terfenadine, terodiline, cisapride) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man (< 10-fold) reflecting their limited safety margins.",11569530_10,0
1636,TDP,30,33,"For compounds that have shown TDP in the clinic (terfenadine, terodiline, cisapride) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man (< 10-fold) reflecting their limited safety margins.",11569530_10,0
359,terfenadine,49,60,"For compounds that have shown TDP in the clinic (terfenadine, terodiline, cisapride) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man (< 10-fold) reflecting their limited safety margins.",11569530_10,0
1641,TDP,80,83,These data underline the need to maximize the therapeutic ratio with respect to TDP in potential development candidates and the importance of using free drug concentrations in pharmacokinetic/pharmacodynamic studies.,11569530_11,0
356,terfenadine,87,98,TDP is a side-effect that has led to withdrawal of several drugs from the market (e.g. terfenadine and terodiline).,11569530_2,0
1620,terodiline,103,113,TDP is a side-effect that has led to withdrawal of several drugs from the market (e.g. terfenadine and terodiline).,11569530_2,0
1619,TDP,0,3,TDP is a side-effect that has led to withdrawal of several drugs from the market (e.g. terfenadine and terodiline).,11569530_2,0
4402,side-effect,9,20,TDP is a side-effect that has led to withdrawal of several drugs from the market (e.g. terfenadine and terodiline).,11569530_2,1
1621,TDP,36,39,The potential of compounds to cause TDP was evaluated by monitoring their effects on MAPD in dog.,11569530_4,0
1624,TDP,55,58,"Four compounds known to increase QT interval and cause TDP were investigated: terfenadine, terodiline, cisapride and E4031.",11569530_5,0
357,terfenadine,78,89,"Four compounds known to increase QT interval and cause TDP were investigated: terfenadine, terodiline, cisapride and E4031.",11569530_5,0
1627,E4031,117,122,"Four compounds known to increase QT interval and cause TDP were investigated: terfenadine, terodiline, cisapride and E4031.",11569530_5,0
1625,terodiline,91,101,"Four compounds known to increase QT interval and cause TDP were investigated: terfenadine, terodiline, cisapride and E4031.",11569530_5,0
1626,cisapride,103,112,"Four compounds known to increase QT interval and cause TDP were investigated: terfenadine, terodiline, cisapride and E4031.",11569530_5,0
1628,free drug,23,32,"On the basis that only free drug in the systemic circulation will elicit a pharmacological response target, free concentrations in plasma were selected to mimic the free drug exposures in man.",11569530_6,0
1631,ED50,34,38,"These data indicate that the free ED50 in plasma for terfenadine (1.9 nM), terodiline (76 nM), cisapride (11 nM) and E4031 (1.9 nM) closely correlate with the free concentration in man causing QT effects.",11569530_9,0
1632,terodiline,75,85,"These data indicate that the free ED50 in plasma for terfenadine (1.9 nM), terodiline (76 nM), cisapride (11 nM) and E4031 (1.9 nM) closely correlate with the free concentration in man causing QT effects.",11569530_9,0
1633,cisapride,95,104,"These data indicate that the free ED50 in plasma for terfenadine (1.9 nM), terodiline (76 nM), cisapride (11 nM) and E4031 (1.9 nM) closely correlate with the free concentration in man causing QT effects.",11569530_9,0
1634,E4031,117,122,"These data indicate that the free ED50 in plasma for terfenadine (1.9 nM), terodiline (76 nM), cisapride (11 nM) and E4031 (1.9 nM) closely correlate with the free concentration in man causing QT effects.",11569530_9,0
358,terfenadine,53,64,"These data indicate that the free ED50 in plasma for terfenadine (1.9 nM), terodiline (76 nM), cisapride (11 nM) and E4031 (1.9 nM) closely correlate with the free concentration in man causing QT effects.",11569530_9,0
1644,amphotericin B,152,166,Amphotericin B-induced seizures in a patient with AIDS.OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.,11573852_0,0
1647,grand mal seizures,71,89,"CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.",11573852_1,1
1648,amphotericin B,121,135,"CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.",11573852_1,0
1649,petit,142,147,"CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.",11573852_1,0
1659,adverse effect,179,193,"To date, only three cases of seizures associated with amphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.",11573852_10,1
1658,amphotericin B,54,68,"To date, only three cases of seizures associated with amphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.",11573852_10,0
1650,amphotercin,99,110,"Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.",11573852_3,0
4403,cryptococcal meningitis,21,44,"DISCUSSION: AIDS and cryptococcal meningitis, both of which the patient had, can potentially cause seizures.",11573852_4,1
4404,alcohol abuse,29,42,The patient had a history of alcohol abuse; alcohol intake as well as withdrawal can also cause seizures.,11573852_5,1
1651,alcohol intake,44,58,The patient had a history of alcohol abuse; alcohol intake as well as withdrawal can also cause seizures.,11573852_5,1
1653,amphotericin B,41,55,The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.,11573852_8,0
1655,Amphotericin B,13,27,CONCLUSIONS: Amphotericin B seems to be the probable cause of the seizures.,11573852_9,0
360,opioid analgesic,13,29,"Fentanyl, an opioid analgesic, is frequently used in the neonatal intensive care unit setting for these very purposes.",11581460_2,0
1667,chest wall,65,75,"Various reported side effects of fentanyl administration include chest wall rigidity, hypotension, respiratory depression, and bradycardia.",11581460_3,1
4406,respiratory depression,99,121,"Various reported side effects of fentanyl administration include chest wall rigidity, hypotension, respiratory depression, and bradycardia.",11581460_3,1
4405,side effects,17,29,"Various reported side effects of fentanyl administration include chest wall rigidity, hypotension, respiratory depression, and bradycardia.",11581460_3,1
4407,urinary bladder,17,32,"Here, 2 cases of urinary bladder retention leading to renal pelvocalyceal dilatation mimicking hydronephrosis as a result of continuous infusion of fentanyl are reported.",11581460_4,1
362,mycophenolate mofetil,14,35,Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients.,11583940_0,0
361,Sirolimus,0,9,Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients.,11583940_0,0
1669,renal transplant,78,94,Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients.,11583940_0,1
365,tacrolimus,49,59,"Calcineurin inhibitors, such as cyclosporine and tacrolimus, have been available for almost 20 years.",11583940_1,0
363,Calcineurin inhibitors,0,22,"Calcineurin inhibitors, such as cyclosporine and tacrolimus, have been available for almost 20 years.",11583940_1,0
364,cyclosporine,32,44,"Calcineurin inhibitors, such as cyclosporine and tacrolimus, have been available for almost 20 years.",11583940_1,0
1672,chronic nephrotoxicity,137,159,"Although these drugs are highly effective and represent the mainstay of transplant immunosuppression, they are associated with acute and chronic nephrotoxicity.",11583940_2,1
1670,transplant immunosuppression,72,100,"Although these drugs are highly effective and represent the mainstay of transplant immunosuppression, they are associated with acute and chronic nephrotoxicity.",11583940_2,1
1673,Acute nephrotoxicity,0,20,"Acute nephrotoxicity, which occurs in the early period after transplantation, leads to a higher rate of dialysis, and chronic nephrotoxicity may eventually result in graft loss.",11583940_3,1
1674,chronic nephrotoxicity,118,140,"Acute nephrotoxicity, which occurs in the early period after transplantation, leads to a higher rate of dialysis, and chronic nephrotoxicity may eventually result in graft loss.",11583940_3,1
1675,graft loss,166,176,"Acute nephrotoxicity, which occurs in the early period after transplantation, leads to a higher rate of dialysis, and chronic nephrotoxicity may eventually result in graft loss.",11583940_3,1
1676,chronic nephrotoxicity,10,32,Acute and chronic nephrotoxicity is becoming more common as the use of marginal kidneys for transplantation increases.,11583940_4,1
369,rapamycin,86,95,"Two recently available immunosuppressive agents, mycophenolate mofetil and sirolimus (rapamycin), have no nephrotoxicity.",11583940_5,0
368,sirolimus,75,84,"Two recently available immunosuppressive agents, mycophenolate mofetil and sirolimus (rapamycin), have no nephrotoxicity.",11583940_5,0
367,mycophenolate mofetil,49,70,"Two recently available immunosuppressive agents, mycophenolate mofetil and sirolimus (rapamycin), have no nephrotoxicity.",11583940_5,0
366,immunosuppressive agents,23,47,"Two recently available immunosuppressive agents, mycophenolate mofetil and sirolimus (rapamycin), have no nephrotoxicity.",11583940_5,0
1677,nephrotoxicity,106,120,"Two recently available immunosuppressive agents, mycophenolate mofetil and sirolimus (rapamycin), have no nephrotoxicity.",11583940_5,1
1680,renal transplant,118,134,This paper reviews the results of clinical trials that have investigated these new approaches to immunosuppression in renal transplant recipients.,11583940_7,1
1681,Fatal myeloencephalopathy,0,25,Fatal myeloencephalopathy due to accidental intrathecal vincristin administration: a report of two cases.,11587867_0,1
4409,lymphoblastic lymphoma,172,194,We report on two fatal cases of accidental intrathecal vincristine instillation in a 5-year old girl with recurrent acute lymphoblastic leucemia and a 57-year old man with lymphoblastic lymphoma.,11587867_1,1
4408,acute lymphoblastic,116,135,We report on two fatal cases of accidental intrathecal vincristine instillation in a 5-year old girl with recurrent acute lymphoblastic leucemia and a 57-year old man with lymphoblastic lymphoma.,11587867_1,1
1685,motor dysfunction,82,99,"Clinically, the onset was characterized by the signs of opistothonus, sensory and motor dysfunction and ascending paralysis.",11587867_3,1
1684,opistothonus,56,68,"Clinically, the onset was characterized by the signs of opistothonus, sensory and motor dysfunction and ascending paralysis.",11587867_3,1
1688,CD-68,61,66,"Histological and immunohistochemical investigations (HE-LFB, CD-68, Neurofilament) revealed degeneration of myelin and axons as well as pseudocystic transformation in areas exposed to vincristine, accompanied by secondary changes with numerous prominent macrophages.",11587867_4,0
1690,secondary changes,212,229,"Histological and immunohistochemical investigations (HE-LFB, CD-68, Neurofilament) revealed degeneration of myelin and axons as well as pseudocystic transformation in areas exposed to vincristine, accompanied by secondary changes with numerous prominent macrophages.",11587867_4,1
370,Neurofilament,68,81,"Histological and immunohistochemical investigations (HE-LFB, CD-68, Neurofilament) revealed degeneration of myelin and axons as well as pseudocystic transformation in areas exposed to vincristine, accompanied by secondary changes with numerous prominent macrophages.",11587867_4,0
1689,pseudocystic transformation,136,163,"Histological and immunohistochemical investigations (HE-LFB, CD-68, Neurofilament) revealed degeneration of myelin and axons as well as pseudocystic transformation in areas exposed to vincristine, accompanied by secondary changes with numerous prominent macrophages.",11587867_4,1
1687,HE-LFB,53,59,"Histological and immunohistochemical investigations (HE-LFB, CD-68, Neurofilament) revealed degeneration of myelin and axons as well as pseudocystic transformation in areas exposed to vincristine, accompanied by secondary changes with numerous prominent macrophages.",11587867_4,0
4410,clinical course,4,19,The clinical course and histopathological results of the two cases are presented.,11587867_5,1
1695,depressed adolescent,25,45,Palpebral twitching in a depressed adolescent on citalopram.,11642480_0,1
371,citalopram,49,59,Palpebral twitching in a depressed adolescent on citalopram.,11642480_0,0
4411,of children,53,64,Current estimates suggest that between 0.4% and 8.3% of children and adolescents are affected by major depression.,11642480_1,1
372,citalopram,49,59,We report a favorable response to treatment with citalopram by a 15-year-old boy with major depression who exhibited palpebral twitching during his first 2 weeks of treatment.,11642480_2,0
373,his,144,147,We report a favorable response to treatment with citalopram by a 15-year-old boy with major depression who exhibited palpebral twitching during his first 2 weeks of treatment.,11642480_2,0
4412,side effect,21,32,This may have been a side effect of citalopram as it remitted with redistribution of doses.,11642480_3,1
374,citalopram,36,46,This may have been a side effect of citalopram as it remitted with redistribution of doses.,11642480_3,0
375,sulphasalazine,11,25,The 3-week sulphasalazine syndrome strikes again.,11672959_0,0
4413,rheumatoid arthritis,177,197,"A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.",11672959_1,1
376,sulphasalazine,144,158,"A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.",11672959_1,0
1698,lymph node,22,32,"Cervical and inguinal lymph node biopsies showed the features of severe necrotising lymphadenitis, associated with erythrophagocytosis and prominent eosinophilic infiltrates, without viral inclusion bodies, suggestive of an adverse drug reaction.",11672959_2,1
1702,inclusion bodies,189,205,"Cervical and inguinal lymph node biopsies showed the features of severe necrotising lymphadenitis, associated with erythrophagocytosis and prominent eosinophilic infiltrates, without viral inclusion bodies, suggestive of an adverse drug reaction.",11672959_2,0
4414,necrotising lymphadenitis,72,97,"Cervical and inguinal lymph node biopsies showed the features of severe necrotising lymphadenitis, associated with erythrophagocytosis and prominent eosinophilic infiltrates, without viral inclusion bodies, suggestive of an adverse drug reaction.",11672959_2,1
4415,adverse drug reaction,224,245,"Cervical and inguinal lymph node biopsies showed the features of severe necrotising lymphadenitis, associated with erythrophagocytosis and prominent eosinophilic infiltrates, without viral inclusion bodies, suggestive of an adverse drug reaction.",11672959_2,1
1704,multi-organ failure,173,192,"A week later, fulminant drug-induced hepatitis, associated with the presence of anti-nuclear autoantibodies (but not with other markers of autoimmunity), and accompanied by multi-organ failure and sepsis, supervened.",11672959_3,1
4416,drug-induced hepatitis,24,46,"A week later, fulminant drug-induced hepatitis, associated with the presence of anti-nuclear autoantibodies (but not with other markers of autoimmunity), and accompanied by multi-organ failure and sepsis, supervened.",11672959_3,1
377,anti-nuclear autoantibodies,80,107,"A week later, fulminant drug-induced hepatitis, associated with the presence of anti-nuclear autoantibodies (but not with other markers of autoimmunity), and accompanied by multi-organ failure and sepsis, supervened.",11672959_3,0
1705,her drug,61,69,She subsequently died some 5 weeks after the commencement of her drug therapy.,11672959_4,0
1709,focal acute tubulo-interstitial nephritis,112,153,"Post-mortem examination showed evidence of massive hepatocellular necrosis, acute hypersensitivity myocarditis, focal acute tubulo-interstitial nephritis and extensive bone marrow necrosis, with no evidence of malignancy.",11672959_5,1
1708,hypersensitivity myocarditis,82,110,"Post-mortem examination showed evidence of massive hepatocellular necrosis, acute hypersensitivity myocarditis, focal acute tubulo-interstitial nephritis and extensive bone marrow necrosis, with no evidence of malignancy.",11672959_5,1
1707,hepatocellular necrosis,51,74,"Post-mortem examination showed evidence of massive hepatocellular necrosis, acute hypersensitivity myocarditis, focal acute tubulo-interstitial nephritis and extensive bone marrow necrosis, with no evidence of malignancy.",11672959_5,1
1710,bone marrow necrosis,168,188,"Post-mortem examination showed evidence of massive hepatocellular necrosis, acute hypersensitivity myocarditis, focal acute tubulo-interstitial nephritis and extensive bone marrow necrosis, with no evidence of malignancy.",11672959_5,1
378,sulphasalazine,125,139,"It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called ""3-week sulphasalazine syndrome"", a rare, but often fatal, immunoallergic reaction to sulphasalazine.",11672959_6,0
379,sulphasalazine,203,217,"It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called ""3-week sulphasalazine syndrome"", a rare, but often fatal, immunoallergic reaction to sulphasalazine.",11672959_6,0
4417,akathisia,124,133,"Intravenous administration of prochlorperazine by 15-minute infusion versus 2-minute bolus does not affect the incidence of akathisia: a prospective, randomized, controlled trial.",11679859_0,1
4418,akathisia,50,59,STUDY OBJECTIVE: We sought to compare the rate of akathisia after administration of intravenous prochlorperazine as a 2-minute bolus or 15-minute infusion.,11679859_1,1
1714,intravenous prochlorperazine,84,112,STUDY OBJECTIVE: We sought to compare the rate of akathisia after administration of intravenous prochlorperazine as a 2-minute bolus or 15-minute infusion.,11679859_1,0
4423,akathisia,38,47,"In the bolus group, 26.0% (13/50) had akathisia compared with 32.7% (16/49) in the infusion group (Delta=-6.7%; 95% confidence interval [CI] -24.6% to 11.2%).",11679859_11,1
4424,akathisia,48,57,CONCLUSION: A 50% reduction in the incidence of akathisia when prochlorperazine was administered by means of 15-minute intravenous infusion versus a 2-minute intravenous push was not detected.,11679859_14,1
1716,emergency department,75,95,"METHODS: We conducted a prospective, randomized, double-blind study in the emergency department of a central-city teaching hospital.",11679859_2,1
1718,normal saline solution,168,190,Study participants were randomized to receive 10 mg of prochlorperazine administered intravenously by means of 2-minute push (bolus group) or 10 mg diluted in 50 mL of normal saline solution administered by means of intravenous infusion during a 15-minute period (infusion group).,11679859_4,0
4419,akathisia,67,76,The main outcome was the number of study participants experiencing akathisia within 60 minutes of administration.,11679859_5,1
4420,Akathisia,0,9,Akathisia was defined as either a spontaneous report of restlessness or agitation or a change of 2 or more in the patient-reported akathisia rating scale and a change of at least 1 in the investigator-observed akathisia rating scale.,11679859_6,1
4422,akathisia,210,219,Akathisia was defined as either a spontaneous report of restlessness or agitation or a change of 2 or more in the patient-reported akathisia rating scale and a change of at least 1 in the investigator-observed akathisia rating scale.,11679859_6,1
4421,akathisia,131,140,Akathisia was defined as either a spontaneous report of restlessness or agitation or a change of 2 or more in the patient-reported akathisia rating scale and a change of at least 1 in the investigator-observed akathisia rating scale.,11679859_6,1
1723,nimesulide,16,26,Tolerability of nimesulide and paracetamol in patients with NSAID-induced urticaria/angioedema.,11694026_0,0
1724,NSAID-induced urticaria/angioedema,60,94,Tolerability of nimesulide and paracetamol in patients with NSAID-induced urticaria/angioedema.,11694026_0,1
380,paracetamol,31,42,Tolerability of nimesulide and paracetamol in patients with NSAID-induced urticaria/angioedema.,11694026_0,0
1725,nimesulide,44,54,"Previous studies evaluated the tolerance of nimesulide and paracetamol in subjects with cutaneous, respiratory and anaphylactoid reactions induced by nonsteroidal anti-inflammatory drugs (NSAIDs).",11694026_1,0
381,paracetamol,59,70,"Previous studies evaluated the tolerance of nimesulide and paracetamol in subjects with cutaneous, respiratory and anaphylactoid reactions induced by nonsteroidal anti-inflammatory drugs (NSAIDs).",11694026_1,0
4425,anaphylactoid reactions,115,138,"Previous studies evaluated the tolerance of nimesulide and paracetamol in subjects with cutaneous, respiratory and anaphylactoid reactions induced by nonsteroidal anti-inflammatory drugs (NSAIDs).",11694026_1,1
1726,nonsteroidal anti-inflammatory drugs,150,186,"Previous studies evaluated the tolerance of nimesulide and paracetamol in subjects with cutaneous, respiratory and anaphylactoid reactions induced by nonsteroidal anti-inflammatory drugs (NSAIDs).",11694026_1,0
1728,nimesulide,62,72,In this study we investigated tolerability and reliability of nimesulide and paracetamol in a very large number of patients with an exclusive well-documented history of NSAID-induced urticaria/angioedema.,11694026_2,0
382,paracetamol,77,88,In this study we investigated tolerability and reliability of nimesulide and paracetamol in a very large number of patients with an exclusive well-documented history of NSAID-induced urticaria/angioedema.,11694026_2,0
1729,NSAID-induced urticaria/angioedema,169,203,In this study we investigated tolerability and reliability of nimesulide and paracetamol in a very large number of patients with an exclusive well-documented history of NSAID-induced urticaria/angioedema.,11694026_2,1
383,paracetamol,102,113,"Furthermore, we evaluated whether some factors have the potential to increase the risk of reaction to paracetamol and nimesulide.",11694026_3,0
1730,nimesulide,118,128,"Furthermore, we evaluated whether some factors have the potential to increase the risk of reaction to paracetamol and nimesulide.",11694026_3,0
1731,nimesulide,58,68,A single-placebo-controlled oral challenge procedure with nimesulide or paracetamol was applied to 829 patients with a history of NSAID-induced urticaria/angioedema.,11694026_4,0
384,paracetamol,72,83,A single-placebo-controlled oral challenge procedure with nimesulide or paracetamol was applied to 829 patients with a history of NSAID-induced urticaria/angioedema.,11694026_4,0
1733,nimesulide,59,69,A total of 75/829 (9.4%) patients experienced reactions to nimesulide or paracetamol.,11694026_5,0
385,paracetamol,73,84,A total of 75/829 (9.4%) patients experienced reactions to nimesulide or paracetamol.,11694026_5,0
386,paracetamol,131,142,"Of the 715 patients tested with nimesulide 62 (8.6%) showed a positive test, while of 114 subjects submitted to the challenge with paracetamol, 13 (9.6%) did not tolerate this drug.",11694026_6,0
1734,nimesulide,32,42,"Of the 715 patients tested with nimesulide 62 (8.6%) showed a positive test, while of 114 subjects submitted to the challenge with paracetamol, 13 (9.6%) did not tolerate this drug.",11694026_6,0
1735,NSAID-induced urticaria/angioedema,109,143,"Furthermore, 18.28% of patients with a history of chronic urticaria and 11.8% of subjects with an history of NSAID-induced urticaria/angioedema or angioedema alone (with or without chronic urticaria) resulted to be intolerant to alternative drugs.",11694026_7,1
4426,chronic urticaria,50,67,"Furthermore, 18.28% of patients with a history of chronic urticaria and 11.8% of subjects with an history of NSAID-induced urticaria/angioedema or angioedema alone (with or without chronic urticaria) resulted to be intolerant to alternative drugs.",11694026_7,1
4427,chronic urticaria,181,198,"Furthermore, 18.28% of patients with a history of chronic urticaria and 11.8% of subjects with an history of NSAID-induced urticaria/angioedema or angioedema alone (with or without chronic urticaria) resulted to be intolerant to alternative drugs.",11694026_7,1
1738,urticaria/angioedema,116,136,"Taken together, our results confirm the good tolerability of nimesulide and paracetamol in patients who experienced urticaria/angioedema caused by NSAIDs.",11694026_8,1
387,paracetamol,76,87,"Taken together, our results confirm the good tolerability of nimesulide and paracetamol in patients who experienced urticaria/angioedema caused by NSAIDs.",11694026_8,0
1737,nimesulide,61,71,"Taken together, our results confirm the good tolerability of nimesulide and paracetamol in patients who experienced urticaria/angioedema caused by NSAIDs.",11694026_8,0
1739,NSAID-induced angioedema,156,180,"However, the risk of reaction to these alternative study drugs is statistically increased by a history of chronic urticaria and, above all, by a history of NSAID-induced angioedema.",11694026_9,1
4428,chronic urticaria,106,123,"However, the risk of reaction to these alternative study drugs is statistically increased by a history of chronic urticaria and, above all, by a history of NSAID-induced angioedema.",11694026_9,1
1740,gellan ophthalmic timolol,26,51,Comparison of aqueous and gellan ophthalmic timolol with placebo on the 24-hour heart rate response in patients on treatment for glaucoma.,11704023_0,0
1741,heart rate,80,90,Comparison of aqueous and gellan ophthalmic timolol with placebo on the 24-hour heart rate response in patients on treatment for glaucoma.,11704023_0,1
1742,beta-blocker,17,29,PURPOSE: Topical beta-blocker treatment is routine therapy in the management of patients with glaucoma.,11704023_1,0
1770,beta-blocker,70,82,These data quantify the modest bradycardia associated with ophthalmic beta-blocker therapy in a typical patient population on therapy for glaucoma.,11704023_11,0
1744,heart rate,93,103,"Therapy results in systemic absorption, however, the degree of reduction of resting and peak heart rate has not been quantified.",11704023_2,1
1745,timolol solution,74,90,"DESIGN: This trial evaluated the effect of placebo, 0.5% aqueous timolol (timolol solution) and a 0.5% timolol suspension that forms a gel on application to the conjunctiva (timolol gellan) on the 24-hour heart rate in patients currently being treated for glaucoma to quantify the reduction in mean heart rate.",11704023_3,0
1751,gellan,335,341,"METHODS: Forty-three Caucasian patients with primary open-angle glaucoma or ocular hypertension with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), timolol solution (morning and evening in both eyes), or timolol gellan (morning in both eyes with placebo in the evening).",11704023_4,0
4430,ocular hypertension,76,95,"METHODS: Forty-three Caucasian patients with primary open-angle glaucoma or ocular hypertension with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), timolol solution (morning and evening in both eyes), or timolol gellan (morning in both eyes with placebo in the evening).",11704023_4,1
4429,open-angle glaucoma,53,72,"METHODS: Forty-three Caucasian patients with primary open-angle glaucoma or ocular hypertension with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), timolol solution (morning and evening in both eyes), or timolol gellan (morning in both eyes with placebo in the evening).",11704023_4,1
1750,timolol solution,271,287,"METHODS: Forty-three Caucasian patients with primary open-angle glaucoma or ocular hypertension with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), timolol solution (morning and evening in both eyes), or timolol gellan (morning in both eyes with placebo in the evening).",11704023_4,0
1755,gellan,43,49,"RESULTS: Both timolol solution and timolol gellan reduced the mean 24-hour heart rate compared with placebo (P < or = .001), and this reduction was most pronounced during the daytime (-7.5% change in mean heart rate, -5.7 beats/min).",11704023_6,0
1754,timolol solution,14,30,"RESULTS: Both timolol solution and timolol gellan reduced the mean 24-hour heart rate compared with placebo (P < or = .001), and this reduction was most pronounced during the daytime (-7.5% change in mean heart rate, -5.7 beats/min).",11704023_6,0
1760,timolol solution,113,129,"Timolol gellan showed a numerically but not significantly smaller reduction in 24-hour heart rate, compared with timolol solution.",11704023_7,0
1758,gellan,8,14,"Timolol gellan showed a numerically but not significantly smaller reduction in 24-hour heart rate, compared with timolol solution.",11704023_7,0
1764,gellan,167,173,"During the night, the mean 12-hour heart rate on placebo and timolol gellan were both significantly less than on timolol solution; the difference between solution and gellan treatments was statistically significant (P = .01).",11704023_8,0
1763,timolol solution,113,129,"During the night, the mean 12-hour heart rate on placebo and timolol gellan were both significantly less than on timolol solution; the difference between solution and gellan treatments was statistically significant (P = .01).",11704023_8,0
1762,gellan,69,75,"During the night, the mean 12-hour heart rate on placebo and timolol gellan were both significantly less than on timolol solution; the difference between solution and gellan treatments was statistically significant (P = .01).",11704023_8,0
1766,gellan,47,53,CONCLUSIONS: Both timolol solution and timolol gellan decrease the mean 24-hour heart rate compared with placebo.,11704023_9,0
1765,timolol solution,18,34,CONCLUSIONS: Both timolol solution and timolol gellan decrease the mean 24-hour heart rate compared with placebo.,11704023_9,0
4431,hemolytic anemia,44,60,Management strategies for ribavirin-induced hemolytic anemia in the treatment of hepatitis C: clinical and economic implications.,11705128_0,1
4432,hepatitis C,81,92,Management strategies for ribavirin-induced hemolytic anemia in the treatment of hepatitis C: clinical and economic implications.,11705128_0,1
1774,alpha-2b/ribavirin,142,160,OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/ribavirin compared with interferon-alpha monotherapy in the treatment of chronic hepatitis C (CHC).,11705128_1,0
388,interferon-alpha,175,191,OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/ribavirin compared with interferon-alpha monotherapy in the treatment of chronic hepatitis C (CHC).,11705128_1,0
4433,chronic hepatitis C,224,243,OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/ribavirin compared with interferon-alpha monotherapy in the treatment of chronic hepatitis C (CHC).,11705128_1,1
1796,RIHA,135,139,"In comparison, the cost of 48 weeks of combination therapy is  16,459. CONCLUSIONS: The direct cost of treating clinically significant RIHA is 1% ( 170/ 16,459) of drug treatment costs.",11705128_11,0
1798,RIHA,74,78,Questions remain about the optimal dose of ribavirin and the incidence of RIHA in a real-world population.,11705128_12,0
1800,RIHA,84,88,"Despite these uncertainties, this initial evaluation of the direct cost of treating RIHA provides an estimate of the cost and management implications of this clinically important adverse effect.",11705128_13,0
1801,adverse effect,179,193,"Despite these uncertainties, this initial evaluation of the direct cost of treating RIHA provides an estimate of the cost and management implications of this clinically important adverse effect.",11705128_13,1
4434,hemolytic anemia,96,112,Combination therapy is associated with a clinically important adverse effect: ribavirin-induced hemolytic anemia (RIHA).,11705128_2,1
1779,RIHA,114,118,Combination therapy is associated with a clinically important adverse effect: ribavirin-induced hemolytic anemia (RIHA).,11705128_2,0
1778,adverse effect,62,76,Combination therapy is associated with a clinically important adverse effect: ribavirin-induced hemolytic anemia (RIHA).,11705128_2,1
1781,RIHA,91,95,The objective of this study was to evaluate the direct health-care costs and management of RIHA during treatment of CHC in a clinical trial setting.,11705128_3,0
1784,RIHA,115,119,METHODS: A systematic literature review was conducted to synthesize information on the incidence and management of RIHA.,11705128_4,0
1786,RIHA,72,76,Decision-analytic techniques were used to estimate the cost of treating RIHA.,11705128_5,0
1787,RIHA,9,13,"RESULTS: RIHA, defined as a reduction in hemoglobin to less than 100 g/L, occurs in approximately 7% to 9% of patients treated with combination therapy.",11705128_7,0
1789,RIHA,39,43,The standard of care for management of RIHA is reduction or discontinuation of the ribavirin dosage.,11705128_8,0
1790,ribavirin dosage,83,99,The standard of care for management of RIHA is reduction or discontinuation of the ribavirin dosage.,11705128_8,0
1792,RIHA,64,68,We estimated the direct cost of treating clinically significant RIHA to be  170 per patient receiving combination therapy per 48-week treatment course (range  68- 692).,11705128_9,0
1802,plasma lactate,67,81,Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice.,11706060_0,0
389,antiretroviral,9,23,Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice.,11706060_0,0
390,antiretroviral,14,28,Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (LA) in AIDS through mechanisms of mitochondrial dysfunction.,11706060_1,0
1804,mitochondrial,148,161,Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (LA) in AIDS through mechanisms of mitochondrial dysfunction.,11706060_1,1
395,ANF,20,23,"After 10 days, only ANF was elevated, and only in the TG + HAART cohort.",11706060_11,0
1820,TG,54,56,"After 10 days, only ANF was elevated, and only in the TG + HAART cohort.",11706060_11,0
1821,mitochondrial,42,55,Results show that cumulative HAART caused mitochondrial CM with elevated LA in AIDS transgenic mice.,11706060_12,0
1805,mitochondrial,13,26,"To determine mitochondrial events from HAART in vivo, 8-week-old hemizygous transgenic AIDS mice (NL4-3Delta gag/pol; TG) and wild-type FVB/n littermates were treated with the HAART combination of zidovudine, lamivudine, and indinavir or vehicle control for 10 days or 35 days.",11706060_2,0
1807,NL4-3Delta gag/pol,98,116,"To determine mitochondrial events from HAART in vivo, 8-week-old hemizygous transgenic AIDS mice (NL4-3Delta gag/pol; TG) and wild-type FVB/n littermates were treated with the HAART combination of zidovudine, lamivudine, and indinavir or vehicle control for 10 days or 35 days.",11706060_2,0
1808,TG,118,120,"To determine mitochondrial events from HAART in vivo, 8-week-old hemizygous transgenic AIDS mice (NL4-3Delta gag/pol; TG) and wild-type FVB/n littermates were treated with the HAART combination of zidovudine, lamivudine, and indinavir or vehicle control for 10 days or 35 days.",11706060_2,0
1810,molecular markers,97,114,"At termination of the experiments, mice underwent echocardiography, quantitation of abundance of molecular markers of CM (ventricular mRNA encoding atrial natriuretic factor [ANF] and sarcoplasmic calcium ATPase [SERCA2]), and determination of plasma LA.",11706060_3,0
1811,ventricular mRNA,122,138,"At termination of the experiments, mice underwent echocardiography, quantitation of abundance of molecular markers of CM (ventricular mRNA encoding atrial natriuretic factor [ANF] and sarcoplasmic calcium ATPase [SERCA2]), and determination of plasma LA.",11706060_3,0
1812,SERCA2,213,219,"At termination of the experiments, mice underwent echocardiography, quantitation of abundance of molecular markers of CM (ventricular mRNA encoding atrial natriuretic factor [ANF] and sarcoplasmic calcium ATPase [SERCA2]), and determination of plasma LA.",11706060_3,0
391,atrial natriuretic factor,148,173,"At termination of the experiments, mice underwent echocardiography, quantitation of abundance of molecular markers of CM (ventricular mRNA encoding atrial natriuretic factor [ANF] and sarcoplasmic calcium ATPase [SERCA2]), and determination of plasma LA.",11706060_3,0
392,ANF,175,178,"At termination of the experiments, mice underwent echocardiography, quantitation of abundance of molecular markers of CM (ventricular mRNA encoding atrial natriuretic factor [ANF] and sarcoplasmic calcium ATPase [SERCA2]), and determination of plasma LA.",11706060_3,0
393,calcium ATPase,197,211,"At termination of the experiments, mice underwent echocardiography, quantitation of abundance of molecular markers of CM (ventricular mRNA encoding atrial natriuretic factor [ANF] and sarcoplasmic calcium ATPase [SERCA2]), and determination of plasma LA.",11706060_3,0
4435,left ventricular,40,56,"After 35 days in the TG + HAART cohort, left ventricular mass increased 160% by echocardiography.",11706060_5,1
1814,TG,21,23,"After 35 days in the TG + HAART cohort, left ventricular mass increased 160% by echocardiography.",11706060_5,0
1815,ANF mRNA,13,21,"Molecularly, ANF mRNA increased 250% and SERCA2 mRNA decreased 57%.",11706060_6,0
1816,SERCA2,41,47,"Molecularly, ANF mRNA increased 250% and SERCA2 mRNA decreased 57%.",11706060_6,0
394,Molecularly,0,11,"Molecularly, ANF mRNA increased 250% and SERCA2 mRNA decreased 57%.",11706060_6,0
399,Cisplatin,153,162,A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).BACKGROUND: Cisplatin has minimal antitumor activity when used as second- or third-line treatment of metastatic breast carcinoma.,11745184_0,0
4436,breast carcinoma,71,87,A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).BACKGROUND: Cisplatin has minimal antitumor activity when used as second- or third-line treatment of metastatic breast carcinoma.,11745184_0,1
398,amifostine,44,54,A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).BACKGROUND: Cisplatin has minimal antitumor activity when used as second- or third-line treatment of metastatic breast carcinoma.,11745184_0,0
4437,breast carcinoma,253,269,A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).BACKGROUND: Cisplatin has minimal antitumor activity when used as second- or third-line treatment of metastatic breast carcinoma.,11745184_0,1
397,WR-2721,35,42,A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).BACKGROUND: Cisplatin has minimal antitumor activity when used as second- or third-line treatment of metastatic breast carcinoma.,11745184_0,0
396,cisplatin,20,29,A Phase II trial of cisplatin plus WR-2721 (amifostine) for metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).BACKGROUND: Cisplatin has minimal antitumor activity when used as second- or third-line treatment of metastatic breast carcinoma.,11745184_0,0
1828,mg/m2,67,72,Older reports suggest an objective response rate of 8% when 60-120 mg/m2 of cisplatin is administered every 3-4 weeks.,11745184_1,0
400,cisplatin,76,85,Older reports suggest an objective response rate of 8% when 60-120 mg/m2 of cisplatin is administered every 3-4 weeks.,11745184_1,0
4443,disease progression,47,66,Treatment was administered every 3 weeks until disease progression.,11745184_10,1
4444,disease progression,49,68,Most patients (57%) stopped treatment because of disease progression.,11745184_14,1
1845,Neurologic toxicity,0,19,Neurologic toxicity was reported in 52% of patients.,11745184_15,1
416,cisplatin,32,41,CONCLUSIONS: The combination of cisplatin and amifostine in this study resulted in an overall response rate of 16%.,11745184_17,0
417,amifostine,46,56,CONCLUSIONS: The combination of cisplatin and amifostine in this study resulted in an overall response rate of 16%.,11745184_17,0
419,cisplatin,121,130,Neither a tumor-protective effect nor reduced toxicity to normal tissues was observed with the addition of amifostine to cisplatin in this trial.,11745184_18,0
418,amifostine,107,117,Neither a tumor-protective effect nor reduced toxicity to normal tissues was observed with the addition of amifostine to cisplatin in this trial.,11745184_18,0
1831,nephrotoxicity,128,142,"Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.",11745184_2,1
4440,breast carcinoma,216,232,"Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.",11745184_2,1
4439,neurotoxicity,161,174,"Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.",11745184_2,1
4438,ototoxicity,144,155,"Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.",11745184_2,1
401,cisplatin,55,64,"Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.",11745184_2,0
402,cisplatin,111,120,"Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.",11745184_2,0
1830,dose-limiting toxicities,70,94,"Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma.",11745184_2,1
403,WR-2721,0,7,WR-2721 or amifostine initially was developed to protect military personnel in the event of nuclear war.,11745184_3,0
404,amifostine,11,21,WR-2721 or amifostine initially was developed to protect military personnel in the event of nuclear war.,11745184_3,0
1833,nuclear war,92,103,WR-2721 or amifostine initially was developed to protect military personnel in the event of nuclear war.,11745184_3,1
406,alkylating agents,86,103,Amifostine subsequently was shown to protect normal tissues from the toxic effects of alkylating agents and cisplatin without decreasing the antitumor effect of the chemotherapy.,11745184_4,0
407,cisplatin,108,117,Amifostine subsequently was shown to protect normal tissues from the toxic effects of alkylating agents and cisplatin without decreasing the antitumor effect of the chemotherapy.,11745184_4,0
1835,toxic effects,69,82,Amifostine subsequently was shown to protect normal tissues from the toxic effects of alkylating agents and cisplatin without decreasing the antitumor effect of the chemotherapy.,11745184_4,0
405,Amifostine,0,10,Amifostine subsequently was shown to protect normal tissues from the toxic effects of alkylating agents and cisplatin without decreasing the antitumor effect of the chemotherapy.,11745184_4,0
409,amifostine,30,40,"Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and neuropathy were reduced.",11745184_5,0
408,cisplatin,16,25,"Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and neuropathy were reduced.",11745184_5,0
4441,ototoxicity,125,136,"Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and neuropathy were reduced.",11745184_5,1
1836,nephrotoxicity,109,123,"Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and neuropathy were reduced.",11745184_5,1
411,amifostine,63,73,"METHODS: A Phase II study of the combination of cisplatin plus amifostine was conducted in patients with progressive metastatic breast carcinoma who had received one, but not more than one, chemotherapy regimen for metastatic disease.",11745184_6,0
410,cisplatin,48,57,"METHODS: A Phase II study of the combination of cisplatin plus amifostine was conducted in patients with progressive metastatic breast carcinoma who had received one, but not more than one, chemotherapy regimen for metastatic disease.",11745184_6,0
4442,breast carcinoma,128,144,"METHODS: A Phase II study of the combination of cisplatin plus amifostine was conducted in patients with progressive metastatic breast carcinoma who had received one, but not more than one, chemotherapy regimen for metastatic disease.",11745184_6,1
1839,metastatic disease,215,233,"METHODS: A Phase II study of the combination of cisplatin plus amifostine was conducted in patients with progressive metastatic breast carcinoma who had received one, but not more than one, chemotherapy regimen for metastatic disease.",11745184_6,1
412,amifostine,18,28,"Patients received amifostine, 910 mg/m2 intravenously over 15 minutes.",11745184_7,0
1840,mg/m2,34,39,"Patients received amifostine, 910 mg/m2 intravenously over 15 minutes.",11745184_7,0
1841,mg/m2,59,64,"After completion of the amifostine infusion, cisplatin 120 mg/m2 was administered over 30 minutes.",11745184_8,0
413,amifostine,24,34,"After completion of the amifostine infusion, cisplatin 120 mg/m2 was administered over 30 minutes.",11745184_8,0
414,cisplatin,45,54,"After completion of the amifostine infusion, cisplatin 120 mg/m2 was administered over 30 minutes.",11745184_8,0
415,cisplatin,69,78,Intravenous hydration and mannitol was administered before and after cisplatin.,11745184_9,0
420,Oral contraceptives,0,19,Oral contraceptives and the risk of myocardial infarction.,11752354_0,0
4445,myocardial infarction,36,57,Oral contraceptives and the risk of myocardial infarction.,11752354_0,1
421,oral contraceptives,46,65,"BACKGROUND: An association between the use of oral contraceptives and the risk of myocardial infarction has been found in some, but not all, studies.",11752354_1,0
4446,myocardial infarction,82,103,"BACKGROUND: An association between the use of oral contraceptives and the risk of myocardial infarction has been found in some, but not all, studies.",11752354_1,1
423,desogestrel,107,118,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,0
424,second-generation,137,154,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,0
4448,myocardial infarction,508,529,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,1
4447,myocardial infarction,424,445,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,1
425,levonorgestrel,162,176,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,0
1848,third-generation,83,99,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,0
1849,gestodene,122,131,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,0
422,progestagen,59,70,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,0
426,oral contraceptives,178,197,"We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., levonorgestrel) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence.",11752354_2,0
1856,factor V,16,24,"An analysis for factor V Leiden and the G20210A mutation in the prothrombin gene was conducted in 217 patients and 763 controls RESULTS: The odds ratio for myocardial infarction among women who used any type of combined oral contraceptive, as compared with nonusers, was 2.0 (95 percent confidence interval, 1.5 to 2.8).",11752354_4,0
1857,G20210A,40,47,"An analysis for factor V Leiden and the G20210A mutation in the prothrombin gene was conducted in 217 patients and 763 controls RESULTS: The odds ratio for myocardial infarction among women who used any type of combined oral contraceptive, as compared with nonusers, was 2.0 (95 percent confidence interval, 1.5 to 2.8).",11752354_4,0
427,combined oral contraceptive,211,238,"An analysis for factor V Leiden and the G20210A mutation in the prothrombin gene was conducted in 217 patients and 763 controls RESULTS: The odds ratio for myocardial infarction among women who used any type of combined oral contraceptive, as compared with nonusers, was 2.0 (95 percent confidence interval, 1.5 to 2.8).",11752354_4,0
4449,myocardial infarction,156,177,"An analysis for factor V Leiden and the G20210A mutation in the prothrombin gene was conducted in 217 patients and 763 controls RESULTS: The odds ratio for myocardial infarction among women who used any type of combined oral contraceptive, as compared with nonusers, was 2.0 (95 percent confidence interval, 1.5 to 2.8).",11752354_4,1
1862,third-generation oral contraceptives,210,246,"The adjusted odds ratio was 2.5 (95 percent confidence interval, 1.5 to 4.1) among women who used second-generation oral contraceptives and 1.3 (95 percent confidence interval, 0.7 to 2.5) among those who used third-generation oral contraceptives.",11752354_5,0
1861,second-generation oral contraceptives,98,135,"The adjusted odds ratio was 2.5 (95 percent confidence interval, 1.5 to 4.1) among women who used second-generation oral contraceptives and 1.3 (95 percent confidence interval, 0.7 to 2.5) among those who used third-generation oral contraceptives.",11752354_5,0
428,oral contraceptives,21,40,"Among women who used oral contraceptives, the odds ratio was 2.1 (95 percent confidence interval, 1.5 to 3.0) for those without a prothrombotic mutation and 1.9 (95 percent confidence interval, 0.6 to 5.5) for those with a mutation CONCLUSIONS: The risk of myocardial infarction was increased among women who used second-generation oral contraceptives.",11752354_6,0
1866,second-generation oral contraceptives,314,351,"Among women who used oral contraceptives, the odds ratio was 2.1 (95 percent confidence interval, 1.5 to 3.0) for those without a prothrombotic mutation and 1.9 (95 percent confidence interval, 0.6 to 5.5) for those with a mutation CONCLUSIONS: The risk of myocardial infarction was increased among women who used second-generation oral contraceptives.",11752354_6,0
4450,myocardial infarction,257,278,"Among women who used oral contraceptives, the odds ratio was 2.1 (95 percent confidence interval, 1.5 to 3.0) for those without a prothrombotic mutation and 1.9 (95 percent confidence interval, 0.6 to 5.5) for those with a mutation CONCLUSIONS: The risk of myocardial infarction was increased among women who used second-generation oral contraceptives.",11752354_6,1
1868,second-generation oral contraceptives,162,199,The results with respect to the use of third-generation oral contraceptives were inconclusive but suggested that the risk was lower than the risk associated with second-generation oral contraceptives.,11752354_7,0
1867,third-generation oral contraceptives,39,75,The results with respect to the use of third-generation oral contraceptives were inconclusive but suggested that the risk was lower than the risk associated with second-generation oral contraceptives.,11752354_7,0
429,oral contraceptives,67,86,The risk of myocardial infarction was similar among women who used oral contraceptives whether or not they had a prothrombotic mutation.,11752354_8,0
1869,prothrombotic,113,126,The risk of myocardial infarction was similar among women who used oral contraceptives whether or not they had a prothrombotic mutation.,11752354_8,0
4451,myocardial infarction,12,33,The risk of myocardial infarction was similar among women who used oral contraceptives whether or not they had a prothrombotic mutation.,11752354_8,1
1871,American formulation,63,83,Preliminary efficacy assessment of intrathecal injection of an American formulation of adenosine in humans.,11752998_0,0
1873,acute noxious stimulation,299,324,"BACKGROUND: Preclinical studies of intrathecal adenosine suggest it may be effective in the treatment of acute and chronic pain in humans, and preliminary studies in volunteers and patients with a Swedish formulation of adenosine suggests it may be effective in hypersensitivity states but not with acute noxious stimulation.",11752998_1,1
4452,chronic pain,115,127,"BACKGROUND: Preclinical studies of intrathecal adenosine suggest it may be effective in the treatment of acute and chronic pain in humans, and preliminary studies in volunteers and patients with a Swedish formulation of adenosine suggests it may be effective in hypersensitivity states but not with acute noxious stimulation.",11752998_1,1
1875,mechanical hypersensitivity,171,198,"The purpose of this study was to screen for efficacy of a different formulation of adenosine marketed in the US, using both acute noxious stimulation and capsaicin-evoked mechanical hypersensitivity.",11752998_2,1
1874,acute noxious stimulation,124,149,"The purpose of this study was to screen for efficacy of a different formulation of adenosine marketed in the US, using both acute noxious stimulation and capsaicin-evoked mechanical hypersensitivity.",11752998_2,1
4453,mechanical hyperalgesia,127,150,"Cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined.",11752998_4,1
4454,allodynia,155,164,"Cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined.",11752998_4,1
4456,allodynia,142,151,"RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).",11752998_5,1
1883,acute noxious thermal,56,77,"RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).",11752998_5,1
4455,mechanical hyperalgesia,114,137,"RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h. In contrast, residence time of adenosine in cerebrospinal fluid was short (< 4 h).",11752998_5,1
1886,central sensitization,119,140,"CONCLUSIONS: These results show selective inhibition by intrathecal adenosine of hypersensitivity, presumed to reflect central sensitization in humans after peripheral capsaicin injection.",11752998_6,1
4457,neuropathic pain,105,121,The long-lasting effect is consistent with that observed in preliminary reports of patients with chronic neuropathic pain and is not due to prolonged residence of adenosine in cerebrospinal fluid.,11752998_7,1
1890,orthotopic liver transplantation,37,69,End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment.,11773892_0,1
1891,OLTX,71,75,End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment.,11773892_0,0
4459,ESRD,25,29,End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment.,11773892_0,1
4458,End-stage renal disease,0,23,End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment.,11773892_0,1
1893,calcineurin inhibitors cyclosporine,16,51,BACKGROUND: The calcineurin inhibitors cyclosporine and tacrolimus are both known to be nephrotoxic.,11773892_1,0
430,tacrolimus,56,66,BACKGROUND: The calcineurin inhibitors cyclosporine and tacrolimus are both known to be nephrotoxic.,11773892_1,0
4469,hepatorenal syndrome,141,161,"Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.",11773892_10,1
4468,ESRD,40,44,"Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.",11773892_10,1
437,creatinine,84,94,"Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.",11773892_10,0
436,CRF,32,35,"Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.",11773892_10,0
438,creatinine,271,281,"Compared with control patients, CRF and ESRD patients had higher preoperative serum creatinine levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine.",11773892_10,0
439,creatinine,135,145,"Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum creatinine compared with average at 1 year, 3 months, and 4 weeks postoperatively were independent risk factors for the development of CRF or ESRD with odds ratios of 2.6, 2.2, and 1.6, respectively.",11773892_11,0
440,CRF,270,273,"Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum creatinine compared with average at 1 year, 3 months, and 4 weeks postoperatively were independent risk factors for the development of CRF or ESRD with odds ratios of 2.6, 2.2, and 1.6, respectively.",11773892_11,0
4470,ESRD,277,281,"Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum creatinine compared with average at 1 year, 3 months, and 4 weeks postoperatively were independent risk factors for the development of CRF or ESRD with odds ratios of 2.6, 2.2, and 1.6, respectively.",11773892_11,1
4471,ESRD,138,142,"Overall survival from the time of OLTX was not significantly different among groups, but by year 13, the survival of the patients who had ESRD was only 28.2% compared with 54.6% in the control group.",11773892_12,1
1909,OLTX,34,38,"Overall survival from the time of OLTX was not significantly different among groups, but by year 13, the survival of the patients who had ESRD was only 28.2% compared with 54.6% in the control group.",11773892_12,0
4473,ESRD,155,159,Patients developing ESRD had a 6-year survival after onset of ESRD of 27% for the patients receiving hemodialysis versus 71.4% for the patients developing ESRD who subsequently received kidney transplants.,11773892_13,1
4472,ESRD,20,24,Patients developing ESRD had a 6-year survival after onset of ESRD of 27% for the patients receiving hemodialysis versus 71.4% for the patients developing ESRD who subsequently received kidney transplants.,11773892_13,1
1911,onset of ESRD,53,66,Patients developing ESRD had a 6-year survival after onset of ESRD of 27% for the patients receiving hemodialysis versus 71.4% for the patients developing ESRD who subsequently received kidney transplants.,11773892_13,1
4474,ESRD,72,76,CONCLUSIONS: Patients who are more than 10 years post-OLTX have CRF and ESRD at a high rate.,11773892_14,1
441,CRF,64,67,CONCLUSIONS: Patients who are more than 10 years post-OLTX have CRF and ESRD at a high rate.,11773892_14,0
4475,ESRD,19,23,"The development of ESRD decreases survival, particularly in those patients treated with dialysis only.",11773892_15,1
4477,hepatorenal syndrome,109,129,Patients who develop ESRD have a higher preoperative and 1-year serum creatinine and are more likely to have hepatorenal syndrome.,11773892_16,1
442,creatinine,70,80,Patients who develop ESRD have a higher preoperative and 1-year serum creatinine and are more likely to have hepatorenal syndrome.,11773892_16,0
4476,ESRD,21,25,Patients who develop ESRD have a higher preoperative and 1-year serum creatinine and are more likely to have hepatorenal syndrome.,11773892_16,1
4478,ESRD,122,126,"However, an increase of serum creatinine at various times postoperatively is more predictive of the development of CRF or ESRD.",11773892_17,1
444,CRF,115,118,"However, an increase of serum creatinine at various times postoperatively is more predictive of the development of CRF or ESRD.",11773892_17,0
443,creatinine,30,40,"However, an increase of serum creatinine at various times postoperatively is more predictive of the development of CRF or ESRD.",11773892_17,0
1894,orthotopic liver transplantation,13,45,Their use in orthotopic liver transplantation (OLTX) has dramatically improved success rates.,11773892_2,1
4461,ESRD,115,119,"Recently, however, we have had an increase of patients who are presenting after OLTX with end-stage renal disease (ESRD).",11773892_3,1
4460,end-stage renal disease,90,113,"Recently, however, we have had an increase of patients who are presenting after OLTX with end-stage renal disease (ESRD).",11773892_3,1
4463,chronic renal failure,74,95,This retrospective study examines the incidence and treatment of ESRD and chronic renal failure (CRF) in OLTX patients.,11773892_4,1
4462,ESRD,65,69,This retrospective study examines the incidence and treatment of ESRD and chronic renal failure (CRF) in OLTX patients.,11773892_4,1
431,CRF,97,100,This retrospective study examines the incidence and treatment of ESRD and chronic renal failure (CRF) in OLTX patients.,11773892_4,0
4465,ESRD,128,132,"Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.",11773892_7,1
434,creatinine,95,105,"Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.",11773892_7,0
433,CRF,74,77,"Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.",11773892_7,0
432,CRF,54,57,"Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.",11773892_7,0
4464,ESRD,61,65,"Patients were divided into three groups: Controls, no CRF or ESRD, n=748; CRF, sustained serum creatinine >2.5 mg/dl, n=41; and ESRD, n=45.",11773892_7,1
1902,onset of ESRD,146,159,"Groups were compared for preoperative laboratory variables, diagnosis, postoperative variables, survival, type of ESRD therapy, and survival from onset of ESRD.",11773892_8,1
4466,ESRD,114,118,"Groups were compared for preoperative laboratory variables, diagnosis, postoperative variables, survival, type of ESRD therapy, and survival from onset of ESRD.",11773892_8,1
1904,renal dysfunction,57,74,"RESULTS: At 13 years after OLTX, the incidence of severe renal dysfunction was 18.1% (CRF 8.6% and ESRD 9.5%).",11773892_9,1
435,CRF,86,89,"RESULTS: At 13 years after OLTX, the incidence of severe renal dysfunction was 18.1% (CRF 8.6% and ESRD 9.5%).",11773892_9,0
4467,ESRD,99,103,"RESULTS: At 13 years after OLTX, the incidence of severe renal dysfunction was 18.1% (CRF 8.6% and ESRD 9.5%).",11773892_9,1
445,tranexamic acid,80,95,Epileptic seizures following cortical application of fibrin sealants containing tranexamic acid in rats.,11807648_0,0
4479,Epileptic seizures,0,18,Epileptic seizures following cortical application of fibrin sealants containing tranexamic acid in rats.,11807648_0,1
1915,fibrin sealants,53,68,Epileptic seizures following cortical application of fibrin sealants containing tranexamic acid in rats.,11807648_0,0
1916,Fibrin sealants,12,27,BACKGROUND: Fibrin sealants (FS) derived from human plasma are frequently used in neurosurgery.,11807648_1,0
1933,tAMCA,31,36,"Thus, FS containing 47.5 mg/ml tAMCA evoked generalized seizures in all tested rats (n=6) while the lowest concentration of tAMCA (0.5 mg/ml) only evoked brief episodes of jerk-correlated convulsive potentials in 1 of 6 rats.",11807648_10,1
1934,tAMCA,124,129,"Thus, FS containing 47.5 mg/ml tAMCA evoked generalized seizures in all tested rats (n=6) while the lowest concentration of tAMCA (0.5 mg/ml) only evoked brief episodes of jerk-correlated convulsive potentials in 1 of 6 rats.",11807648_10,0
1935,evoked brief episodes,147,168,"Thus, FS containing 47.5 mg/ml tAMCA evoked generalized seizures in all tested rats (n=6) while the lowest concentration of tAMCA (0.5 mg/ml) only evoked brief episodes of jerk-correlated convulsive potentials in 1 of 6 rats.",11807648_10,1
4481,generalized seizures,44,64,"Thus, FS containing 47.5 mg/ml tAMCA evoked generalized seizures in all tested rats (n=6) while the lowest concentration of tAMCA (0.5 mg/ml) only evoked brief episodes of jerk-correlated convulsive potentials in 1 of 6 rats.",11807648_10,1
450,aprotinin,27,36,"In contrast, FS containing aprotinin did not evoke any paroxysmal activity.",11807648_11,0
1938,convulsive action,44,61,INTERPRETATION: Tranexamic acid retains its convulsive action within FS.,11807648_12,0
451,Tranexamic acid,16,31,INTERPRETATION: Tranexamic acid retains its convulsive action within FS.,11807648_12,0
1939,tAMCA,27,32,"Thus, use of FS containing tAMCA for surgery within or close to the CNS may pose a substantial risk to the patient.",11807648_13,1
446,aprotinin,58,67,"In order to increase clot stability, FS typically contain aprotinin, a natural fibrinolysis inhibitor.",11807648_2,0
1917,clot stability,21,35,"In order to increase clot stability, FS typically contain aprotinin, a natural fibrinolysis inhibitor.",11807648_2,0
1918,natural fibrinolysis inhibitor,71,101,"In order to increase clot stability, FS typically contain aprotinin, a natural fibrinolysis inhibitor.",11807648_2,0
1920,tAMCA,69,74,"Recently, synthetic fibrinolysis inhibitors such as tranexamic acid (tAMCA) have been considered as substitutes for aprotinin.",11807648_3,0
448,aprotinin,116,125,"Recently, synthetic fibrinolysis inhibitors such as tranexamic acid (tAMCA) have been considered as substitutes for aprotinin.",11807648_3,0
1919,fibrinolysis inhibitors,20,43,"Recently, synthetic fibrinolysis inhibitors such as tranexamic acid (tAMCA) have been considered as substitutes for aprotinin.",11807648_3,0
447,tranexamic acid,52,67,"Recently, synthetic fibrinolysis inhibitors such as tranexamic acid (tAMCA) have been considered as substitutes for aprotinin.",11807648_3,0
4480,epileptic seizures,39,57,"However, tAMCA has been shown to cause epileptic seizures.",11807648_4,1
1921,tAMCA,9,14,"However, tAMCA has been shown to cause epileptic seizures.",11807648_4,0
1922,tAMCA,27,32,We wanted to study whether tAMCA retains its convulsive action if incorporated into a FS.,11807648_5,0
1923,convulsive action,45,62,We wanted to study whether tAMCA retains its convulsive action if incorporated into a FS.,11807648_5,0
449,aprotinin,22,31,METHOD: FS containing aprotinin or different concentrations of tAMCA (0.5-47.5 mg/ml) were applied to the pial surface of the cortex of anaesthetized rats.,11807648_6,0
1924,tAMCA,63,68,METHOD: FS containing aprotinin or different concentrations of tAMCA (0.5-47.5 mg/ml) were applied to the pial surface of the cortex of anaesthetized rats.,11807648_6,0
1925,pial,106,110,METHOD: FS containing aprotinin or different concentrations of tAMCA (0.5-47.5 mg/ml) were applied to the pial surface of the cortex of anaesthetized rats.,11807648_6,1
1928,tAMCA,24,29,FINDINGS: FS containing tAMCA caused paroxysmal brain activity which was associated with distinct convulsive behaviours.,11807648_8,0
1932,tAMCA,72,77,The degree of these seizures increased with increasing concentration of tAMCA.,11807648_9,0
1941,Delayed-onset heparin-induced thrombocytopenia,0,46,Delayed-onset heparin-induced thrombocytopenia.,11827497_0,1
1942,Heparin-induced thrombocytopenia,12,44,"BACKGROUND: Heparin-induced thrombocytopenia presents 5 to 12 days after heparin exposure, with or without arterial or venous thromboemboli.",11827497_1,1
1943,venous thromboemboli,119,139,"BACKGROUND: Heparin-induced thrombocytopenia presents 5 to 12 days after heparin exposure, with or without arterial or venous thromboemboli.",11827497_1,1
1959,Platelet counts,0,15,Platelet counts were mildly decreased in all but 2 patients on second presentation.,11827497_10,0
1960,therapeutic heparin,37,56,"On readmission, 11 patients received therapeutic heparin, which worsened the patients' clinical condition and, in all 11 cases, decreased the platelet count (mean at readmission, 143 x 10(9) cells/L; mean nadir after heparin re-exposure, 39 x 10(9) cells/L).",11827497_11,0
1965,heparin-induced antibodies,31,57,Results of serologic tests for heparin-induced antibodies were positive in all patients.,11827497_12,0
453,thrombolytic drugs,73,91,"Subsequent treatments included alternative anticoagulants (11 patients), thrombolytic drugs (3 patients), inferior vena cava filters (3 patients) and, eventually, warfarin (11 patients).",11827497_13,0
454,(3,92,94,"Subsequent treatments included alternative anticoagulants (11 patients), thrombolytic drugs (3 patients), inferior vena cava filters (3 patients) and, eventually, warfarin (11 patients).",11827497_13,0
455,(3,133,135,"Subsequent treatments included alternative anticoagulants (11 patients), thrombolytic drugs (3 patients), inferior vena cava filters (3 patients) and, eventually, warfarin (11 patients).",11827497_13,0
1966,alternative anticoagulants,31,57,"Subsequent treatments included alternative anticoagulants (11 patients), thrombolytic drugs (3 patients), inferior vena cava filters (3 patients) and, eventually, warfarin (11 patients).",11827497_13,0
1968,Delayed-onset heparin-induced thrombocytopenia,13,59,CONCLUSIONS: Delayed-onset heparin-induced thrombocytopenia is increasingly being recognized.,11827497_15,1
1970,heparin-induced thrombocytopenia,55,87,"To avoid disastrous outcomes, physicians must consider heparin-induced thrombocytopenia whenever a recently hospitalized patient returns with thromboembolism; therapy with alternative anticoagulants, not heparin, should be initiated.",11827497_16,1
1972,alternative anticoagulants,172,198,"To avoid disastrous outcomes, physicians must consider heparin-induced thrombocytopenia whenever a recently hospitalized patient returns with thromboembolism; therapy with alternative anticoagulants, not heparin, should be initiated.",11827497_16,0
1945,heparin-induced thrombocytopenia,37,69,Delayed recognition and treatment of heparin-induced thrombocytopenia contribute to poor patient outcomes.,11827497_2,1
1949,heparin-induced thrombocytopenia,109,141,OBJECTIVE: To describe and increase awareness of a clinical scenario in which the onset or manifestations of heparin-induced thrombocytopenia are delayed.,11827497_3,1
1948,onset or,82,90,OBJECTIVE: To describe and increase awareness of a clinical scenario in which the onset or manifestations of heparin-induced thrombocytopenia are delayed.,11827497_3,1
1947,clinical scenario,51,68,OBJECTIVE: To describe and increase awareness of a clinical scenario in which the onset or manifestations of heparin-induced thrombocytopenia are delayed.,11827497_3,1
1953,thromboembolic,134,148,PATIENTS: 14 patients seen over a 3-year period in whom heparin-induced thrombocytopenia became apparent on delayed presentation with thromboembolic complications.,11827497_6,1
1952,heparin-induced thrombocytopenia,56,88,PATIENTS: 14 patients seen over a 3-year period in whom heparin-induced thrombocytopenia became apparent on delayed presentation with thromboembolic complications.,11827497_6,1
452,platelet factor 4,107,124,"MEASUREMENTS: Platelet counts, onset of objectively determined thromboembolism, results of heparin-induced platelet factor 4 antibody tests, and outcomes.",11827497_7,0
1956,thromboembolic,192,206,"RESULTS: Patients went home after hospitalizations that had included heparin exposure--in most cases, with no thrombocytopenia recognized--only to return to the hospital (median, day 14) with thromboembolic complications.",11827497_8,1
1957,Thromboemboli,0,13,"Thromboemboli were venous (12 patients, 7 with pulmonary emboli) or arterial (4 patients) or both.",11827497_9,1
1958,pulmonary emboli,47,63,"Thromboemboli were venous (12 patients, 7 with pulmonary emboli) or arterial (4 patients) or both.",11827497_9,1
456,dopamine agonist,59,75,Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children.,11838826_0,0
4482,hyperprolactinemia,33,51,Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children.,11838826_0,1
4483,hyperprolactinemia,123,141,"BACKGROUND: Risperidone, a potent antagonist of both serotonergic (5HT2A) and dopaminergic D2 receptors is associated with hyperprolactinemia in adults and children.",11838826_1,1
1974,5HT2A,67,72,"BACKGROUND: Risperidone, a potent antagonist of both serotonergic (5HT2A) and dopaminergic D2 receptors is associated with hyperprolactinemia in adults and children.",11838826_1,0
1973,Risperidone,12,23,"BACKGROUND: Risperidone, a potent antagonist of both serotonergic (5HT2A) and dopaminergic D2 receptors is associated with hyperprolactinemia in adults and children.",11838826_1,0
457,serotonergic,53,65,"BACKGROUND: Risperidone, a potent antagonist of both serotonergic (5HT2A) and dopaminergic D2 receptors is associated with hyperprolactinemia in adults and children.",11838826_1,0
1975,dopaminergic D2 receptors,78,103,"BACKGROUND: Risperidone, a potent antagonist of both serotonergic (5HT2A) and dopaminergic D2 receptors is associated with hyperprolactinemia in adults and children.",11838826_1,0
464,Cabergoline,13,24,"CONCLUSIONS: Cabergoline may be useful for the treatment of risperidone-induced hyperprolactinemia in youth; however, further research is needed.",11838826_10,0
4489,hyperprolactinemia,80,98,"CONCLUSIONS: Cabergoline may be useful for the treatment of risperidone-induced hyperprolactinemia in youth; however, further research is needed.",11838826_10,1
1980,short stature,163,176,Chronically elevated prolactin levels in children with prolactinomas may be associated with arrested growth and development resulting in either delayed puberty or short stature.,11838826_2,1
4485,delayed puberty,144,159,Chronically elevated prolactin levels in children with prolactinomas may be associated with arrested growth and development resulting in either delayed puberty or short stature.,11838826_2,1
4484,prolactinomas,55,68,Chronically elevated prolactin levels in children with prolactinomas may be associated with arrested growth and development resulting in either delayed puberty or short stature.,11838826_2,1
1981,drug-induced hyperprolactinemia,89,120,These possibilities stress the importance of developing a safe and effective approach to drug-induced hyperprolactinemia in youth.,11838826_3,1
4486,hyperprolactinemia,58,76,We report the successful treatment of risperidone-induced hyperprolactinemia with cabergoline in youth.,11838826_4,1
458,cabergoline,82,93,We report the successful treatment of risperidone-induced hyperprolactinemia with cabergoline in youth.,11838826_4,0
459,cabergoline,124,135,METHODS: We undertook a retrospective case review of four children with risperidone-induced hyperprolactinemia treated with cabergoline.,11838826_5,0
4487,hyperprolactinemia,92,110,METHODS: We undertook a retrospective case review of four children with risperidone-induced hyperprolactinemia treated with cabergoline.,11838826_5,1
460,cabergoline,261,272,"RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week).",11838826_6,0
1984,bipolar disorder,113,129,"RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week).",11838826_6,1
1983,Mental Disorders,79,95,"RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week).",11838826_6,1
461,cabergoline,92,103,"When serum prolactin levels normalized in all four subjects (mean 11.2 +/- 10.9 ng/mL), the cabergoline dose was reduced to 1 mg/week in three of four subjects.",11838826_7,0
462,cabergoline,34,45,"The mean duration of therapy with cabergoline was 523.5 +/- 129.7 days, and the mean duration of therapy with risperidone was 788.5 +/- 162.5 days.",11838826_8,0
1992,risperidone,110,121,"The mean duration of therapy with cabergoline was 523.5 +/- 129.7 days, and the mean duration of therapy with risperidone was 788.5 +/- 162.5 days.",11838826_8,0
463,Cabergoline,0,11,Cabergoline was well tolerated without adverse effects.,11838826_9,0
4488,adverse effects,39,54,Cabergoline was well tolerated without adverse effects.,11838826_9,1
1994,cholestatic hepatitis,6,27,Acute cholestatic hepatitis after exposure to isoflurane.,11847945_0,1
1996,inhalational,85,97,OBJECTIVE: To report a case of acute cholestatic hepatitis following exposure to the inhalational anesthetic isoflurane.,11847945_1,0
1997,anesthetic isoflurane,98,119,OBJECTIVE: To report a case of acute cholestatic hepatitis following exposure to the inhalational anesthetic isoflurane.,11847945_1,0
1995,cholestatic hepatitis,37,58,OBJECTIVE: To report a case of acute cholestatic hepatitis following exposure to the inhalational anesthetic isoflurane.,11847945_1,1
4490,rotator cuff,128,140,CASE SUMMARY: A 70-year-old healthy woman from Iraq developed acute cholestatic hepatitis 3 weeks following repair of the right rotator cuff under general anesthesia.,11847945_2,1
1999,cholestatic hepatitis,68,89,CASE SUMMARY: A 70-year-old healthy woman from Iraq developed acute cholestatic hepatitis 3 weeks following repair of the right rotator cuff under general anesthesia.,11847945_2,1
465,dipyrone,46,54,No other medications were involved except for dipyrone for analgesia.,11847945_4,0
466,alanine aminotransferase,4,28,The alanine aminotransferase was elevated to a peak concentration of 1533 U/L and the serum bilirubin reached a peak of 17.0 mg/dL. There was slow improvement over 4 months.,11847945_5,0
2002,U/L,74,77,The alanine aminotransferase was elevated to a peak concentration of 1533 U/L and the serum bilirubin reached a peak of 17.0 mg/dL. There was slow improvement over 4 months.,11847945_5,0
467,dipyrone,40,48,Accidental reexposure by the patient to dipyrone was uneventful.,11847945_6,0
2005,Accidental reexposure,0,21,Accidental reexposure by the patient to dipyrone was uneventful.,11847945_6,1
2011,cholestatic hepatitis,69,90,"CONCLUSIONS: Isoflurane, a common anesthetic agent, can cause severe cholestatic hepatitis.",11847945_8,1
2010,anesthetic agent,34,50,"CONCLUSIONS: Isoflurane, a common anesthetic agent, can cause severe cholestatic hepatitis.",11847945_8,0
4491,Torsade de pointes,0,18,Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block.,11858397_0,1
4492,left bundle branch block,91,115,Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block.,11858397_0,1
468,metoclopramide,30,44,Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block.,11858397_0,0
4493,torsade de pointes,77,95,There is a growing list of drugs implicated in acquired long QT syndrome and torsade de pointes.,11858397_1,1
469,metoclopramide,39,53,"However, the torsadogenic potential of metoclopramide, a commonly used antiemetic and prokinetic drug, has not been reported in the literature, despite its chemical similarity to procainamide.",11858397_2,0
470,procainamide,179,191,"However, the torsadogenic potential of metoclopramide, a commonly used antiemetic and prokinetic drug, has not been reported in the literature, despite its chemical similarity to procainamide.",11858397_2,0
2013,torsadogenic,13,25,"However, the torsadogenic potential of metoclopramide, a commonly used antiemetic and prokinetic drug, has not been reported in the literature, despite its chemical similarity to procainamide.",11858397_2,1
2014,prokinetic drug,86,101,"However, the torsadogenic potential of metoclopramide, a commonly used antiemetic and prokinetic drug, has not been reported in the literature, despite its chemical similarity to procainamide.",11858397_2,0
471,metoclopramide,162,176,We report on a 92-year-old woman with preexisting complete left bundle branch block who developed torsade de pointes after intravenous and oral administration of metoclopramide.,11858397_3,0
4495,torsade de pointes,98,116,We report on a 92-year-old woman with preexisting complete left bundle branch block who developed torsade de pointes after intravenous and oral administration of metoclopramide.,11858397_3,1
4494,left bundle branch block,59,83,We report on a 92-year-old woman with preexisting complete left bundle branch block who developed torsade de pointes after intravenous and oral administration of metoclopramide.,11858397_3,1
2017,cisapride,52,61,This patient also developed torsade de pointes when cisapride and erythromycin were given simultaneously.,11858397_4,0
4496,torsade de pointes,28,46,This patient also developed torsade de pointes when cisapride and erythromycin were given simultaneously.,11858397_4,1
2019,class IB drugs,106,120,These two episodes were suppressed successfully after discontinuing the offending drugs and administering class IB drugs.,11858397_5,0
2018,offending drugs,72,87,These two episodes were suppressed successfully after discontinuing the offending drugs and administering class IB drugs.,11858397_5,0
472,metoclopramide,37,51,This is the first documentation that metoclopramide provokes torsade de pointes clinically.,11858397_6,0
4497,torsade de pointes,61,79,This is the first documentation that metoclopramide provokes torsade de pointes clinically.,11858397_6,1
4498,torsade de pointes,68,86,Metoclopramide should be used cautiously in patients with a risk of torsade de pointes.,11858397_7,1
473,Metoclopramide,0,14,Metoclopramide should be used cautiously in patients with a risk of torsade de pointes.,11858397_7,0
4499,cell death,49,59,Dopamine D2 receptor signaling controls neuronal cell death induced by muscarinic and glutamatergic drugs.,11860278_0,1
2020,glutamatergic drugs,86,105,Dopamine D2 receptor signaling controls neuronal cell death induced by muscarinic and glutamatergic drugs.,11860278_0,0
475,muscarinic,71,81,Dopamine D2 receptor signaling controls neuronal cell death induced by muscarinic and glutamatergic drugs.,11860278_0,0
474,Dopamine D2 receptor,0,20,Dopamine D2 receptor signaling controls neuronal cell death induced by muscarinic and glutamatergic drugs.,11860278_0,0
4500,epileptic seizures,95,113,"Dopamine (DA), through D1/D2 receptor-mediated signaling, plays a major role in the control of epileptic seizures arising in the limbic system.",11860278_1,1
2021,limbic system,129,142,"Dopamine (DA), through D1/D2 receptor-mediated signaling, plays a major role in the control of epileptic seizures arising in the limbic system.",11860278_1,1
4501,cell death,35,45,Excitotoxicity leading to neuronal cell death in the affected areas is a major consequence of seizures at the cellular level.,11860278_2,1
2022,Excitotoxicity,0,14,Excitotoxicity leading to neuronal cell death in the affected areas is a major consequence of seizures at the cellular level.,11860278_2,1
4502,cell death,111,121,"In this respect, little is known about the role of DA receptors in the occurrence of epilepsy-induced neuronal cell death.",11860278_3,1
2023,DA receptors,51,63,"In this respect, little is known about the role of DA receptors in the occurrence of epilepsy-induced neuronal cell death.",11860278_3,0
476,cholinergic agonist,94,113,Here we analyze the occurrence of seizures and neurotoxicity in D2R -/- mice treated with the cholinergic agonist pilocarpine.,11860278_4,0
2024,D2R,64,67,Here we analyze the occurrence of seizures and neurotoxicity in D2R -/- mice treated with the cholinergic agonist pilocarpine.,11860278_4,0
4503,neurotoxicity,47,60,Here we analyze the occurrence of seizures and neurotoxicity in D2R -/- mice treated with the cholinergic agonist pilocarpine.,11860278_4,1
477,kainic acid,62,73,"We compared these results with those previously obtained with kainic acid (KA), a potent glutamate agonist.",11860278_5,0
478,glutamate agonist,89,106,"We compared these results with those previously obtained with kainic acid (KA), a potent glutamate agonist.",11860278_5,0
4504,neurotoxicity,129,142,"Importantly, D2R -/- mice develop seizures at doses of both drugs that are not epileptogenic for WT littermates and show greater neurotoxicity.",11860278_6,1
2026,epileptogenic,79,92,"Importantly, D2R -/- mice develop seizures at doses of both drugs that are not epileptogenic for WT littermates and show greater neurotoxicity.",11860278_6,1
2025,D2R,13,16,"Importantly, D2R -/- mice develop seizures at doses of both drugs that are not epileptogenic for WT littermates and show greater neurotoxicity.",11860278_6,0
2030,D2R,96,99,"However, pilocarpine-induced seizures result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to KA.",11860278_7,0
2028,neuronal death,66,80,"However, pilocarpine-induced seizures result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to KA.",11860278_7,1
2031,D2R,21,24,"Thus, the absence of D2R lowers the threshold for seizures induced by both glutamate and acetylcholine.",11860278_8,0
4505,neurodegeneration,55,72,"Moreover, the dopaminergic control of epilepsy-induced neurodegeneration seems to be mediated by distinct interactions of D2R signaling with these two neurotransmitters.",11860278_9,1
2032,D2R,122,125,"Moreover, the dopaminergic control of epilepsy-induced neurodegeneration seems to be mediated by distinct interactions of D2R signaling with these two neurotransmitters.",11860278_9,0
479,dopaminergic,14,26,"Moreover, the dopaminergic control of epilepsy-induced neurodegeneration seems to be mediated by distinct interactions of D2R signaling with these two neurotransmitters.",11860278_9,0
480,pregnenolone,87,99,Steroid structure and pharmacological properties determine the anti-amnesic effects of pregnenolone sulphate in the passive avoidance task in rats.,11860495_0,0
2035,anti-amnesic effects,63,83,Steroid structure and pharmacological properties determine the anti-amnesic effects of pregnenolone sulphate in the passive avoidance task in rats.,11860495_0,0
2034,pharmacological properties,22,48,Steroid structure and pharmacological properties determine the anti-amnesic effects of pregnenolone sulphate in the passive avoidance task in rats.,11860495_0,0
481,Pregnenolone,0,12,"Pregnenolone sulphate (PREGS) has generated interest as one of the most potent memory-enhancing neurosteroids to be examined in rodent learning studies, with particular importance in the ageing process.",11860495_1,0
482,neurosteroids,96,109,"Pregnenolone sulphate (PREGS) has generated interest as one of the most potent memory-enhancing neurosteroids to be examined in rodent learning studies, with particular importance in the ageing process.",11860495_1,0
2068,natural PREGS,64,77,"Moreover, enantioselectivity was demonstrated by the ability of natural PREGS to be an order of magnitude more effective than its synthetic enantiomer in reversing scopolamine-induced amnesia.",11860495_10,0
2067,enantioselectivity,10,28,"Moreover, enantioselectivity was demonstrated by the ability of natural PREGS to be an order of magnitude more effective than its synthetic enantiomer in reversing scopolamine-induced amnesia.",11860495_10,0
492,neuroactive steroids,99,119,These results identify a novel neuropharmacological site for the modulation of memory processes by neuroactive steroids.,11860495_11,0
484,GABAergic,129,138,The mechanism by which this endogenous steroid enhances memory formation is hypothesized to involve actions on glutamatergic and GABAergic systems.,11860495_2,0
483,glutamatergic,111,124,The mechanism by which this endogenous steroid enhances memory formation is hypothesized to involve actions on glutamatergic and GABAergic systems.,11860495_2,0
486,N-methyl-d-aspartate receptors,81,111,This hypothesis stems from findings that PREGS is a potent positive modulator of N-methyl-d-aspartate receptors (NMDARs) and a negative modulator of gamma-aminobutyric acid(A) receptors (GABA(A)Rs).,11860495_3,0
487,modulator,136,145,This hypothesis stems from findings that PREGS is a potent positive modulator of N-methyl-d-aspartate receptors (NMDARs) and a negative modulator of gamma-aminobutyric acid(A) receptors (GABA(A)Rs).,11860495_3,0
2040,NMDARs,113,119,This hypothesis stems from findings that PREGS is a potent positive modulator of N-methyl-d-aspartate receptors (NMDARs) and a negative modulator of gamma-aminobutyric acid(A) receptors (GABA(A)Rs).,11860495_3,0
2041,GABA(A)Rs,187,196,This hypothesis stems from findings that PREGS is a potent positive modulator of N-methyl-d-aspartate receptors (NMDARs) and a negative modulator of gamma-aminobutyric acid(A) receptors (GABA(A)Rs).,11860495_3,0
485,modulator,68,77,This hypothesis stems from findings that PREGS is a potent positive modulator of N-methyl-d-aspartate receptors (NMDARs) and a negative modulator of gamma-aminobutyric acid(A) receptors (GABA(A)Rs).,11860495_3,0
488,gamma-aminobutyric,149,167,This hypothesis stems from findings that PREGS is a potent positive modulator of N-methyl-d-aspartate receptors (NMDARs) and a negative modulator of gamma-aminobutyric acid(A) receptors (GABA(A)Rs).,11860495_3,0
2044,NMDAR,63,68,"Moreover, PREGS is able to reverse the amnesic-like effects of NMDAR and GABA(A)R ligands.",11860495_4,0
2042,PREGS,10,15,"Moreover, PREGS is able to reverse the amnesic-like effects of NMDAR and GABA(A)R ligands.",11860495_4,0
2045,GABA(A)R ligands,73,89,"Moreover, PREGS is able to reverse the amnesic-like effects of NMDAR and GABA(A)R ligands.",11860495_4,0
2048,NMDAR,165,170,"To investigate this hypothesis, the present study in rats examined the memory-altering abilities of structural analogs of PREGS, which differ in their modulation of NMDAR and/or GABA(A)R function.",11860495_5,0
2047,PREGS,122,127,"To investigate this hypothesis, the present study in rats examined the memory-altering abilities of structural analogs of PREGS, which differ in their modulation of NMDAR and/or GABA(A)R function.",11860495_5,0
2053,GABA(A)Rs,192,201,"The analogs tested were: 11-ketopregnenolone sulphate (an agent that is inactive at GABA(A)Rs and NMDARs), epipregnanolone ([3beta-hydroxy-5beta-pregnan-20-one] sulphate, an inhibitor of both GABA(A)Rs and NMDARs), and a newly synthesized (-) PREGS enantiomer (which is identical to PREGS in effects on GABA(A)Rs and NMDARs).",11860495_6,0
2055,(-),239,242,"The analogs tested were: 11-ketopregnenolone sulphate (an agent that is inactive at GABA(A)Rs and NMDARs), epipregnanolone ([3beta-hydroxy-5beta-pregnan-20-one] sulphate, an inhibitor of both GABA(A)Rs and NMDARs), and a newly synthesized (-) PREGS enantiomer (which is identical to PREGS in effects on GABA(A)Rs and NMDARs).",11860495_6,0
2056,PREGS,283,288,"The analogs tested were: 11-ketopregnenolone sulphate (an agent that is inactive at GABA(A)Rs and NMDARs), epipregnanolone ([3beta-hydroxy-5beta-pregnan-20-one] sulphate, an inhibitor of both GABA(A)Rs and NMDARs), and a newly synthesized (-) PREGS enantiomer (which is identical to PREGS in effects on GABA(A)Rs and NMDARs).",11860495_6,0
2057,GABA(A)Rs,303,312,"The analogs tested were: 11-ketopregnenolone sulphate (an agent that is inactive at GABA(A)Rs and NMDARs), epipregnanolone ([3beta-hydroxy-5beta-pregnan-20-one] sulphate, an inhibitor of both GABA(A)Rs and NMDARs), and a newly synthesized (-) PREGS enantiomer (which is identical to PREGS in effects on GABA(A)Rs and NMDARs).",11860495_6,0
2058,NMDARs,317,323,"The analogs tested were: 11-ketopregnenolone sulphate (an agent that is inactive at GABA(A)Rs and NMDARs), epipregnanolone ([3beta-hydroxy-5beta-pregnan-20-one] sulphate, an inhibitor of both GABA(A)Rs and NMDARs), and a newly synthesized (-) PREGS enantiomer (which is identical to PREGS in effects on GABA(A)Rs and NMDARs).",11860495_6,0
2052,NMDARs,98,104,"The analogs tested were: 11-ketopregnenolone sulphate (an agent that is inactive at GABA(A)Rs and NMDARs), epipregnanolone ([3beta-hydroxy-5beta-pregnan-20-one] sulphate, an inhibitor of both GABA(A)Rs and NMDARs), and a newly synthesized (-) PREGS enantiomer (which is identical to PREGS in effects on GABA(A)Rs and NMDARs).",11860495_6,0
2051,GABA(A)Rs,84,93,"The analogs tested were: 11-ketopregnenolone sulphate (an agent that is inactive at GABA(A)Rs and NMDARs), epipregnanolone ([3beta-hydroxy-5beta-pregnan-20-one] sulphate, an inhibitor of both GABA(A)Rs and NMDARs), and a newly synthesized (-) PREGS enantiomer (which is identical to PREGS in effects on GABA(A)Rs and NMDARs).",11860495_6,0
2054,NMDARs,206,212,"The analogs tested were: 11-ketopregnenolone sulphate (an agent that is inactive at GABA(A)Rs and NMDARs), epipregnanolone ([3beta-hydroxy-5beta-pregnan-20-one] sulphate, an inhibitor of both GABA(A)Rs and NMDARs), and a newly synthesized (-) PREGS enantiomer (which is identical to PREGS in effects on GABA(A)Rs and NMDARs).",11860495_6,0
2050,11-ketopregnenolone sulphate,25,53,"The analogs tested were: 11-ketopregnenolone sulphate (an agent that is inactive at GABA(A)Rs and NMDARs), epipregnanolone ([3beta-hydroxy-5beta-pregnan-20-one] sulphate, an inhibitor of both GABA(A)Rs and NMDARs), and a newly synthesized (-) PREGS enantiomer (which is identical to PREGS in effects on GABA(A)Rs and NMDARs).",11860495_6,0
489,epipregnanolone,107,122,"The analogs tested were: 11-ketopregnenolone sulphate (an agent that is inactive at GABA(A)Rs and NMDARs), epipregnanolone ([3beta-hydroxy-5beta-pregnan-20-one] sulphate, an inhibitor of both GABA(A)Rs and NMDARs), and a newly synthesized (-) PREGS enantiomer (which is identical to PREGS in effects on GABA(A)Rs and NMDARs).",11860495_6,0
2060,PREGS,32,37,The memory-enhancing effects of PREGS and its analogs were tested in the passive avoidance task using the model of scopolamine-induced amnesia.,11860495_7,0
2063,(-),19,22,Both PREGS and its (-) enantiomer blocked the effects of scopolamine.,11860495_8,0
2062,PREGS,5,10,Both PREGS and its (-) enantiomer blocked the effects of scopolamine.,11860495_8,0
2064,PREGS,30,35,"The results show that, unlike PREGS, 11-ketopregnenolone sulphate and epipregnanolone sulphate failed to block the effect of scopolamine, suggesting that altering the modulation of NMDA receptors diminishes the memory-enhancing effects of PREGS.",11860495_9,0
2065,11-ketopregnenolone sulphate,37,65,"The results show that, unlike PREGS, 11-ketopregnenolone sulphate and epipregnanolone sulphate failed to block the effect of scopolamine, suggesting that altering the modulation of NMDA receptors diminishes the memory-enhancing effects of PREGS.",11860495_9,0
491,NMDA receptors,181,195,"The results show that, unlike PREGS, 11-ketopregnenolone sulphate and epipregnanolone sulphate failed to block the effect of scopolamine, suggesting that altering the modulation of NMDA receptors diminishes the memory-enhancing effects of PREGS.",11860495_9,0
490,epipregnanolone,70,85,"The results show that, unlike PREGS, 11-ketopregnenolone sulphate and epipregnanolone sulphate failed to block the effect of scopolamine, suggesting that altering the modulation of NMDA receptors diminishes the memory-enhancing effects of PREGS.",11860495_9,0
493,poly(ADP-ribose) polymerase,14,41,Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure.,11861791_0,0
4506,heart failure,92,105,Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure.,11861791_0,1
2077,oxidative stress,191,207,Activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress.,11861791_1,1
2074,cell dysfunction,126,142,Activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress.,11861791_1,1
2075,tissue injury,147,160,Activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress.,11861791_1,1
494,poly(ADP-ribose) polymerase,33,60,Activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress.,11861791_1,0
495,PARP,62,66,Activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress.,11861791_1,0
2072,nuclear enzyme,18,32,Activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress.,11861791_1,0
501,PARP,6,10,"Thus, PARP activation contributes to the cardiotoxicity of DOX.",11861791_10,0
4510,cardiotoxicity,41,55,"Thus, PARP activation contributes to the cardiotoxicity of DOX.",11861791_10,1
2100,DOX,59,62,"Thus, PARP activation contributes to the cardiotoxicity of DOX.",11861791_10,0
2104,DOX,121,124,PARP inhibitors may exert protective effects against the development of severe cardiac complications associated with the DOX treatment.,11861791_11,0
502,PARP inhibitors,0,15,PARP inhibitors may exert protective effects against the development of severe cardiac complications associated with the DOX treatment.,11861791_11,0
2101,protective effects,26,44,PARP inhibitors may exert protective effects against the development of severe cardiac complications associated with the DOX treatment.,11861791_11,0
2102,cardiac complications,79,100,PARP inhibitors may exert protective effects against the development of severe cardiac complications associated with the DOX treatment.,11861791_11,1
2080,anthracycline antibiotic,124,148,"Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), a widely used antitumor anthracycline antibiotic.",11861791_2,0
2078,oxidative stress,10,26,"Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), a widely used antitumor anthracycline antibiotic.",11861791_2,1
4507,cardiotoxicity,63,77,"Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), a widely used antitumor anthracycline antibiotic.",11861791_2,1
2079,DOX,94,97,"Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), a widely used antitumor anthracycline antibiotic.",11861791_2,0
496,PARP,45,49,"Thus, we hypothesized that the activation of PARP may contribute to the DOX-induced cardiotoxicity.",11861791_3,0
4508,cardiotoxicity,84,98,"Thus, we hypothesized that the activation of PARP may contribute to the DOX-induced cardiotoxicity.",11861791_3,1
497,PARP,173,177,"Using a dual approach of PARP-1 suppression, by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34, we now demonstrate the role of PARP in the development of cardiac dysfunction induced by DOX.",11861791_4,0
2083,PARP-1,25,31,"Using a dual approach of PARP-1 suppression, by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34, we now demonstrate the role of PARP in the development of cardiac dysfunction induced by DOX.",11861791_4,0
2087,cardiac dysfunction,200,219,"Using a dual approach of PARP-1 suppression, by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34, we now demonstrate the role of PARP in the development of cardiac dysfunction induced by DOX.",11861791_4,1
2088,DOX,231,234,"Using a dual approach of PARP-1 suppression, by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34, we now demonstrate the role of PARP in the development of cardiac dysfunction induced by DOX.",11861791_4,0
2091,DOX,60,63,PARP-1+/+ and PARP-1-/- mice received a single injection of DOX (25 mg/kg i.p).,11861791_5,0
2090,PARP-1-/-,14,23,PARP-1+/+ and PARP-1-/- mice received a single injection of DOX (25 mg/kg i.p).,11861791_5,0
4509,left ventricular,36,52,"Five days after DOX administration, left ventricular performance was significantly depressed in PARP-1+/+ mice, but only to a smaller extent in PARP-1-/- ones.",11861791_6,1
2092,DOX,16,19,"Five days after DOX administration, left ventricular performance was significantly depressed in PARP-1+/+ mice, but only to a smaller extent in PARP-1-/- ones.",11861791_6,0
2095,PJ34,63,67,Similar experiments were conducted in BALB/c mice treated with PJ34 or vehicle.,11861791_7,0
2097,cardiac dysfunction,45,64,Treatment with a PJ34 significantly improved cardiac dysfunction and increased the survival of the animals.,11861791_8,1
2096,PJ34,17,21,Treatment with a PJ34 significantly improved cardiac dysfunction and increased the survival of the animals.,11861791_8,0
498,lactate dehydrogenase,77,98,In addition PJ34 significantly reduced the DOX-induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart.,11861791_9,0
499,creatine kinase,103,118,In addition PJ34 significantly reduced the DOX-induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart.,11861791_9,0
500,metalloproteinase,138,155,In addition PJ34 significantly reduced the DOX-induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart.,11861791_9,0
2098,PJ34,12,16,In addition PJ34 significantly reduced the DOX-induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart.,11861791_9,0
2106,Nephrotoxicity,122,136,"Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients?OBJECTIVE: Nephrotoxicity is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.",11868798_0,1
2107,adverse effect,150,164,"Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients?OBJECTIVE: Nephrotoxicity is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage.",11868798_0,1
4511,side effect,129,140,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,1
4512,neutropenic,357,368,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,1
2110,distal tubular,10,24,Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB. Potassium depletion also potentiates the tubular toxicity of AmB. This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment.,11868798_1,1
2112,hematological disorders,48,71,METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.,11868798_2,1
4513,fungal infection,216,232,METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.,11868798_2,1
2115,oral spironolactone,139,158,METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.,11868798_2,0
2114,AmB,131,134,METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.,11868798_2,0
2113,AmB,118,121,METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection.,11868798_2,0
2116,AmB,40,43,RESULTS: Patients receiving concomitant AmB and spironolactone had significantly higher plasma potassium levels than those receiving AmB alone (P = 0.0027).,11868798_3,0
2117,AmB,133,136,RESULTS: Patients receiving concomitant AmB and spironolactone had significantly higher plasma potassium levels than those receiving AmB alone (P = 0.0027).,11868798_3,0
2118,AmB,25,28,Those patients receiving AmB and spironolactone required significantly less potassium supplementation to maintain their plasma potassium within the normal range (P = 0.022).,11868798_4,0
2122,AmB,81,84,"Moreover, urinary potassium losses were significantly less in patients receiving AmB and spironolactone than those receiving AmB alone (P = 0.040).",11868798_5,0
2123,AmB,125,128,"Moreover, urinary potassium losses were significantly less in patients receiving AmB and spironolactone than those receiving AmB alone (P = 0.040).",11868798_5,0
4514,neutropenic,146,157,CONCLUSION: This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on AmB treatment.,11868798_6,1
503,exo,85,88,Sequential observations of exencephaly and subsequent morphological changes by mouse exo utero development system: analysis of the mechanism of transformation from exencephaly to anencephaly.,11875660_0,0
4515,exencephaly,27,38,Sequential observations of exencephaly and subsequent morphological changes by mouse exo utero development system: analysis of the mechanism of transformation from exencephaly to anencephaly.,11875660_0,1
4516,exencephaly,164,175,Sequential observations of exencephaly and subsequent morphological changes by mouse exo utero development system: analysis of the mechanism of transformation from exencephaly to anencephaly.,11875660_0,1
4517,exencephaly,47,58,"Anencephaly has been suggested to develop from exencephaly; however, there is little direct experimental evidence to support this, and the mechanism of transformation remains unclear.",11875660_1,1
4523,exencephaly,308,319,"These findings suggest that overgrowth of the exencephalic neural tissue causes the altered distribution patterns of vessels, subsequent peripheral circulatory failure and/or hemorrhaging in various parts of the exencephalic head, leading to the multiple modes of tissue reduction during transformation from exencephaly to anencephaly.",11875660_10,1
2149,tissue reduction,264,280,"These findings suggest that overgrowth of the exencephalic neural tissue causes the altered distribution patterns of vessels, subsequent peripheral circulatory failure and/or hemorrhaging in various parts of the exencephalic head, leading to the multiple modes of tissue reduction during transformation from exencephaly to anencephaly.",11875660_10,1
2148,exencephalic head,212,229,"These findings suggest that overgrowth of the exencephalic neural tissue causes the altered distribution patterns of vessels, subsequent peripheral circulatory failure and/or hemorrhaging in various parts of the exencephalic head, leading to the multiple modes of tissue reduction during transformation from exencephaly to anencephaly.",11875660_10,1
2147,neural tissue,59,72,"These findings suggest that overgrowth of the exencephalic neural tissue causes the altered distribution patterns of vessels, subsequent peripheral circulatory failure and/or hemorrhaging in various parts of the exencephalic head, leading to the multiple modes of tissue reduction during transformation from exencephaly to anencephaly.",11875660_10,1
2146,exencephalic,46,58,"These findings suggest that overgrowth of the exencephalic neural tissue causes the altered distribution patterns of vessels, subsequent peripheral circulatory failure and/or hemorrhaging in various parts of the exencephalic head, leading to the multiple modes of tissue reduction during transformation from exencephaly to anencephaly.",11875660_10,1
4522,circulatory failure,148,167,"These findings suggest that overgrowth of the exencephalic neural tissue causes the altered distribution patterns of vessels, subsequent peripheral circulatory failure and/or hemorrhaging in various parts of the exencephalic head, leading to the multiple modes of tissue reduction during transformation from exencephaly to anencephaly.",11875660_10,1
2128,late-gestation,121,135,We examined this theory using the exo utero development system that allows direct and sequential observations of mid- to late-gestation mouse embryos.,11875660_2,1
504,exo,34,37,We examined this theory using the exo utero development system that allows direct and sequential observations of mid- to late-gestation mouse embryos.,11875660_2,0
4518,exencephaly,16,27,"We observed the exencephaly induced by 5-azacytidine at embryonic day 13.5 (E13.5), let the embryos develop exo utero until E18.5, and re-observed the same embryos at E18.5.",11875660_3,1
2129,5-azacytidine,39,52,"We observed the exencephaly induced by 5-azacytidine at embryonic day 13.5 (E13.5), let the embryos develop exo utero until E18.5, and re-observed the same embryos at E18.5.",11875660_3,0
2130,E13.5,76,81,"We observed the exencephaly induced by 5-azacytidine at embryonic day 13.5 (E13.5), let the embryos develop exo utero until E18.5, and re-observed the same embryos at E18.5.",11875660_3,0
505,exo,108,111,"We observed the exencephaly induced by 5-azacytidine at embryonic day 13.5 (E13.5), let the embryos develop exo utero until E18.5, and re-observed the same embryos at E18.5.",11875660_3,0
4519,exencephaly,50,61,We confirmed several cases of transformation from exencephaly to anencephaly.,11875660_4,1
2131,exencephalic,28,40,"However, in many cases, the exencephalic brain tissue was preserved with more or less reduction during this period.",11875660_5,1
4520,exencephaly,58,69,"To analyze the transformation patterns, we classified the exencephaly by size and shape of the exencephalic tissue into several types at E13.5 and E18.5.",11875660_6,1
2133,E13.5,137,142,"To analyze the transformation patterns, we classified the exencephaly by size and shape of the exencephalic tissue into several types at E13.5 and E18.5.",11875660_6,0
2132,exencephalic,95,107,"To analyze the transformation patterns, we classified the exencephaly by size and shape of the exencephalic tissue into several types at E13.5 and E18.5.",11875660_6,1
2134,exencephalic,40,52,"It was found that the transformation of exencephalic tissue was not simply size-dependent, and all cases of anencephaly at E18.5 resulted from embryos with a large amount of exencephalic tissue at E13.5.",11875660_7,1
2136,E13.5,197,202,"It was found that the transformation of exencephalic tissue was not simply size-dependent, and all cases of anencephaly at E18.5 resulted from embryos with a large amount of exencephalic tissue at E13.5.",11875660_7,0
2135,exencephalic,174,186,"It was found that the transformation of exencephalic tissue was not simply size-dependent, and all cases of anencephaly at E18.5 resulted from embryos with a large amount of exencephalic tissue at E13.5.",11875660_7,1
2142,E15.5,181,186,"Microscopic observation showed the configuration of exencephaly at E13.5, frequent hemorrhaging and detachment of the neural plate from surface ectoderm in the exencephalic head at E15.5, and multiple modes of reduction in the exencephalic tissue at E18.5.",11875660_8,0
2141,exencephalic head,160,177,"Microscopic observation showed the configuration of exencephaly at E13.5, frequent hemorrhaging and detachment of the neural plate from surface ectoderm in the exencephalic head at E15.5, and multiple modes of reduction in the exencephalic tissue at E18.5.",11875660_8,1
2143,exencephalic,227,239,"Microscopic observation showed the configuration of exencephaly at E13.5, frequent hemorrhaging and detachment of the neural plate from surface ectoderm in the exencephalic head at E15.5, and multiple modes of reduction in the exencephalic tissue at E18.5.",11875660_8,1
2140,surface ectoderm,136,152,"Microscopic observation showed the configuration of exencephaly at E13.5, frequent hemorrhaging and detachment of the neural plate from surface ectoderm in the exencephalic head at E15.5, and multiple modes of reduction in the exencephalic tissue at E18.5.",11875660_8,1
2138,E13.5,67,72,"Microscopic observation showed the configuration of exencephaly at E13.5, frequent hemorrhaging and detachment of the neural plate from surface ectoderm in the exencephalic head at E15.5, and multiple modes of reduction in the exencephalic tissue at E18.5.",11875660_8,0
4521,exencephaly,52,63,"Microscopic observation showed the configuration of exencephaly at E13.5, frequent hemorrhaging and detachment of the neural plate from surface ectoderm in the exencephalic head at E15.5, and multiple modes of reduction in the exencephalic tissue at E18.5.",11875660_8,1
2145,exencephalic head,102,119,"From observations of the vasculature, altered distribution patterns of vessels were identified in the exencephalic head.",11875660_9,1
2150,substantia nigra,38,54,Erectile dysfunction occurs following substantia nigra lesions in the rat.,11890511_0,1
4524,Erectile dysfunction,0,20,Erectile dysfunction occurs following substantia nigra lesions in the rat.,11890511_0,1
2151,Erectile function,0,17,Erectile function was assessed 6 weeks following uni- and bilateral injections of 6-hydroxydopamine in the substantia nigra nucleus of the brain.,11890511_1,1
2153,6-hydroxydopamine,82,99,Erectile function was assessed 6 weeks following uni- and bilateral injections of 6-hydroxydopamine in the substantia nigra nucleus of the brain.,11890511_1,0
2154,substantia nigra nucleus,107,131,Erectile function was assessed 6 weeks following uni- and bilateral injections of 6-hydroxydopamine in the substantia nigra nucleus of the brain.,11890511_1,1
2157,Intracavernous pressures,0,24,"Intracavernous pressures, following electrical stimulation of the cavernous nerve, decreased in lesioned animals.",11890511_3,1
2158,electrical stimulation,36,58,"Intracavernous pressures, following electrical stimulation of the cavernous nerve, decreased in lesioned animals.",11890511_3,1
2159,cavernous nerve,66,81,"Intracavernous pressures, following electrical stimulation of the cavernous nerve, decreased in lesioned animals.",11890511_3,1
2160,substantia nigra,15,31,Lesions of the substantia nigra were confirmed by histology.,11890511_4,1
2161,substantia nigra,80,96,Concentration of dopamine and its metabolites were decreased in the striatum of substantia nigra lesioned rats.,11890511_5,1
4525,erectile dysfunction,62,82,Lesions of the substantia nigra are therefore associated with erectile dysfunction in rats and may serve as a model to study erectile dysfunction in Parkinson's disease.,11890511_6,1
4526,erectile dysfunction,125,145,Lesions of the substantia nigra are therefore associated with erectile dysfunction in rats and may serve as a model to study erectile dysfunction in Parkinson's disease.,11890511_6,1
4527,Parkinson's disease,149,168,Lesions of the substantia nigra are therefore associated with erectile dysfunction in rats and may serve as a model to study erectile dysfunction in Parkinson's disease.,11890511_6,1
4528,myocardial infarction,55,76,99mTc-glucarate for detection of isoproterenol-induced myocardial infarction in rats.,11897407_0,1
4529,myocardial infarction,88,109,Infarct-avid radiopharmaceuticals are necessary for rapid and timely diagnosis of acute myocardial infarction.,11897407_1,1
2166,artery ligation,52,67,The animal model used to produce infarction implies artery ligation but chemical induction can be easily obtained with isoproterenol.,11897407_2,1
506,glucaric acid,48,61,A new infarct-avid radiopharmaceutical based on glucaric acid was prepared in the hospital radiopharmacy of the INCMNSZ.,11897407_3,0
4530,myocardial infarction,136,157,"99mTc-glucarate was easy to prepare, stable for 96 h and was used to study its biodistribution in rats with isoproterenol-induced acute myocardial infarction.",11897407_4,1
2167,biodistribution,79,94,"99mTc-glucarate was easy to prepare, stable for 96 h and was used to study its biodistribution in rats with isoproterenol-induced acute myocardial infarction.",11897407_4,0
2171,S(h)UV,88,94,Thirty minutes after 99mTc-glucarate administration the standardised heart uptake value S(h)UV was 4.7 in infarcted rat heart which is six times more than in normal rats.,11897407_7,0
2177,cardiac infarction,161,179,"The high image quality suggests that high contrast images can be obtained in humans and the 96 h stability makes it an ideal agent to detect, in patients, early cardiac infarction.",11897407_9,1
2178,morphine-induced catalepsy,25,51,Nicotine potentiation of morphine-induced catalepsy in mice.,11900788_0,1
2182,mecamylamine,54,66,"Intraperitoneal administration of atropine, naloxone, mecamylamine, and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine.",11900788_4,0
507,hexamethonium,72,85,"Intraperitoneal administration of atropine, naloxone, mecamylamine, and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine.",11900788_4,0
508,hexamethonium,47,60,"Intracerebroventricular injection of atropine, hexamethonium, and naloxone also decreased catalepsy induced by morphine plus nicotine.",11900788_5,0
509,hexamethonium,108,121,"Intraperitoneal administration of atropine, but not intraperitoneal or intracerebroventricular injection of hexamethonium, decreased the effect of a single dose of morphine.",11900788_6,0
2186,intracerebroventricular,71,94,"Intraperitoneal administration of atropine, but not intraperitoneal or intracerebroventricular injection of hexamethonium, decreased the effect of a single dose of morphine.",11900788_6,1
2188,opioid,60,66,"It was concluded that morphine catalepsy can be elicited by opioid and cholinergic receptors, and the potentiation of morphine induced by nicotine may also be mediated through cholinergic receptor mechanisms.",11900788_7,0
510,cholinergic receptors,71,92,"It was concluded that morphine catalepsy can be elicited by opioid and cholinergic receptors, and the potentiation of morphine induced by nicotine may also be mediated through cholinergic receptor mechanisms.",11900788_7,0
4531,Parkinson's disease,51,70,Force overflow and levodopa-induced dyskinesias in Parkinson's disease.,11912119_0,1
2191,motor complications,90,109,"We assessed force coordination of the hand in Parkinson's disease and its relationship to motor complications of levodopa therapy, particularly to levodopa-induced dyskinesias (LID).",11912119_1,1
4532,Parkinson's disease,46,65,"We assessed force coordination of the hand in Parkinson's disease and its relationship to motor complications of levodopa therapy, particularly to levodopa-induced dyskinesias (LID).",11912119_1,1
512,dopaminergic,97,109,No correlation was observed between forces and the motor score as well as with the daily dose of dopaminergic medication.,11912119_10,0
2207,motor fluctuations,56,74,Force excess was only observed in patients with LID and motor fluctuations.,11912119_11,1
2210,pathophysiological,62,80,We postulate that both LID and grip force excess share common pathophysiological mechanisms related to motor fluctuations.,11912119_13,1
2211,motor fluctuations,103,121,We postulate that both LID and grip force excess share common pathophysiological mechanisms related to motor fluctuations.,11912119_13,1
4534,Parkinson's disease,60,79,"We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.",11912119_2,1
4535,Parkinson's disease,137,156,"We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.",11912119_2,1
2193,levodopa-induced dyskinesias,107,135,"We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.",11912119_2,1
4533,Parkinson's disease,25,44,"We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without levodopa-induced dyskinesias (Parkinson's disease - LID, n = 10), and age-matched healthy controls.",11912119_2,1
4536,Parkinson's Disease,31,50,"The motor score of the Unified Parkinson's Disease Rating Scale, a dyskinesia score and force in a grip-lift paradigm were assessed ON and OFF levodopa.",11912119_3,1
4537,Parkinson's disease,58,77,A pathological increase of forces was seen in ON-state in Parkinson's disease + LID only.,11912119_4,1
4538,Parkinson's disease,3,22,"In Parkinson's disease + LID, the force involved in pressing down the object before lifting was significantly increased by levodopa (by 61%, P < 0.05).",11912119_5,1
4539,Parkinson's disease,45,64,"In contrast, no excessive force was found in Parkinson's disease - LID.",11912119_7,1
4541,Parkinson's disease,92,111,"Peak grip force in ON-state was 140% (P < 0.05) higher in Parkinson's disease + LID than in Parkinson's disease - LID, while static grip force was increased by 138% (P < 0.01) between groups.",11912119_8,1
4540,Parkinson's disease,58,77,"Peak grip force in ON-state was 140% (P < 0.05) higher in Parkinson's disease + LID than in Parkinson's disease - LID, while static grip force was increased by 138% (P < 0.01) between groups.",11912119_8,1
511,(r,86,88,"Severity of peak-dose dyskinesias was strongly correlated with grip force in ON-state (r = 0.79 with peak force, P < 0.01).",11912119_9,0
2202,peak-dose dyskinesias,12,33,"Severity of peak-dose dyskinesias was strongly correlated with grip force in ON-state (r = 0.79 with peak force, P < 0.01).",11912119_9,1
513,Bupropion,0,9,Bupropion (Zyban) toxicity.,11928786_0,0
2212,Zyban,11,16,Bupropion (Zyban) toxicity.,11928786_0,0
2213,monocyclic antidepressant,15,40,Bupropion is a monocyclic antidepressant structurally related to amphetamine.,11928786_1,0
514,Bupropion,0,9,Bupropion is a monocyclic antidepressant structurally related to amphetamine.,11928786_1,0
2220,Zyban,0,5,Zyban caused significant neurological and cardiovascular toxicity in overdose.,11928786_10,0
2221,toxic effects,14,27,The potential toxic effects should be considered when prescribing it as a smoking cessation aid.,11928786_11,0
2222,smoking cessation,74,91,The potential toxic effects should be considered when prescribing it as a smoking cessation aid.,11928786_11,1
2215,bupropion hydrochloride,42,65,"Zyban, a sustained-release formulation of bupropion hydrochloride, was recently released in Ireland, as a smoking cessation aid.",11928786_2,0
2214,Zyban,0,5,"Zyban, a sustained-release formulation of bupropion hydrochloride, was recently released in Ireland, as a smoking cessation aid.",11928786_2,0
515,sustained-release formulation,9,38,"Zyban, a sustained-release formulation of bupropion hydrochloride, was recently released in Ireland, as a smoking cessation aid.",11928786_2,0
4542,cardiac arrhythmias,30,49,"Two patients developed severe cardiac arrhythmias, including one patient who was resuscitated following a cardiac arrest.",11928786_6,1
4543,cardiac arrest,106,120,"Two patients developed severe cardiac arrhythmias, including one patient who was resuscitated following a cardiac arrest.",11928786_6,1
516,bupropion,165,174,"We report a case of a 31 year old female who required admission to the Intensive Care Unit for ventilation and full supportive therapy, following ingestion of 13.5g bupropion.",11928786_8,0
2219,Recurrent seizures,0,18,Recurrent seizures were treated with diazepam and broad complex tachycardia was successfully treated with adenosine.,11928786_9,1
517,GLEPP1,0,6,GLEPP1 receptor tyrosine phosphatase (Ptpro) in rat PAN nephrosis.,11961407_0,0
519,Ptpro,38,43,GLEPP1 receptor tyrosine phosphatase (Ptpro) in rat PAN nephrosis.,11961407_0,0
518,tyrosine phosphatase,16,36,GLEPP1 receptor tyrosine phosphatase (Ptpro) in rat PAN nephrosis.,11961407_0,0
2244,GLEPP1 protein,11,25,"By day 11, GLEPP1 protein and mRNA had begun to return towards baseline.",11961407_10,0
2246,glomerulosclerotic areas,86,110,"By day 45-126, at a time when glomerular scarring was present, GLEPP1 was absent from glomerulosclerotic areas although the total glomerular content of GLEPP1 was not different from normal.",11961407_11,1
2245,glomerular scarring,30,49,"By day 45-126, at a time when glomerular scarring was present, GLEPP1 was absent from glomerulosclerotic areas although the total glomerular content of GLEPP1 was not different from normal.",11961407_11,1
527,GLEPP1,63,69,"By day 45-126, at a time when glomerular scarring was present, GLEPP1 was absent from glomerulosclerotic areas although the total glomerular content of GLEPP1 was not different from normal.",11961407_11,0
528,GLEPP1,152,158,"By day 45-126, at a time when glomerular scarring was present, GLEPP1 was absent from glomerulosclerotic areas although the total glomerular content of GLEPP1 was not different from normal.",11961407_11,0
2247,podocalyxin,43,54,"We conclude that GLEPP1 expression, unlike podocalyxin, reflects podocyte injury induced by PAN.",11961407_12,0
529,GLEPP1,17,23,"We conclude that GLEPP1 expression, unlike podocalyxin, reflects podocyte injury induced by PAN.",11961407_12,0
530,GLEPP1,0,6,GLEPP1 expression may be a useful marker of podocyte injury.,11961407_13,0
520,Glomerular epithelial protein 1,0,31,Glomerular epithelial protein 1 (GLEPP1) is a podocyte receptor membrane protein tyrosine phosphatase located on the apical cell membrane of visceral glomerular epithelial cell and foot processes.,11961407_2,0
2225,foot processes,181,195,Glomerular epithelial protein 1 (GLEPP1) is a podocyte receptor membrane protein tyrosine phosphatase located on the apical cell membrane of visceral glomerular epithelial cell and foot processes.,11961407_2,1
2224,membrane protein tyrosine phosphatase,64,101,Glomerular epithelial protein 1 (GLEPP1) is a podocyte receptor membrane protein tyrosine phosphatase located on the apical cell membrane of visceral glomerular epithelial cell and foot processes.,11961407_2,0
521,GLEPP1,33,39,Glomerular epithelial protein 1 (GLEPP1) is a podocyte receptor membrane protein tyrosine phosphatase located on the apical cell membrane of visceral glomerular epithelial cell and foot processes.,11961407_2,0
522,cell membrane,124,137,Glomerular epithelial protein 1 (GLEPP1) is a podocyte receptor membrane protein tyrosine phosphatase located on the apical cell membrane of visceral glomerular epithelial cell and foot processes.,11961407_2,0
4544,epithelial cell,161,176,Glomerular epithelial protein 1 (GLEPP1) is a podocyte receptor membrane protein tyrosine phosphatase located on the apical cell membrane of visceral glomerular epithelial cell and foot processes.,11961407_2,1
2227,glomerular injury,58,75,"To better understand the utility of GLEPP1 as a marker of glomerular injury, the amount and distribution of GLEPP1 protein and mRNA were examined by immunohistochemistry, Western blot and RNase protection assay in a model of podocyte injury in the rat.",11961407_4,1
2228,GLEPP1 protein,108,122,"To better understand the utility of GLEPP1 as a marker of glomerular injury, the amount and distribution of GLEPP1 protein and mRNA were examined by immunohistochemistry, Western blot and RNase protection assay in a model of podocyte injury in the rat.",11961407_4,0
523,GLEPP1,36,42,"To better understand the utility of GLEPP1 as a marker of glomerular injury, the amount and distribution of GLEPP1 protein and mRNA were examined by immunohistochemistry, Western blot and RNase protection assay in a model of podocyte injury in the rat.",11961407_4,0
2232,intraperitoneal,58,73,"Puromycin aminonucleoside nephrosis was induced by single intraperitoneal injection of puromycin aminonucleoside (PAN, 20 mg/100g BW).",11961407_5,1
524,Puromycin aminonucleoside,0,25,"Puromycin aminonucleoside nephrosis was induced by single intraperitoneal injection of puromycin aminonucleoside (PAN, 20 mg/100g BW).",11961407_5,0
525,puromycin aminonucleoside,87,112,"Puromycin aminonucleoside nephrosis was induced by single intraperitoneal injection of puromycin aminonucleoside (PAN, 20 mg/100g BW).",11961407_5,0
4545,chronic phase,195,208,"Tissues were analyzed at 0, 5, 7, 11, 21, 45, 80 and 126 days after PAN injection so as to include both the acute phase of proteinuria associated with foot process effacement (days 5-11) and the chronic phase of proteinuria associated with glomerulosclerosis (days 45-126).",11961407_6,1
4546,glomerulosclerosis,240,258,"Tissues were analyzed at 0, 5, 7, 11, 21, 45, 80 and 126 days after PAN injection so as to include both the acute phase of proteinuria associated with foot process effacement (days 5-11) and the chronic phase of proteinuria associated with glomerulosclerosis (days 45-126).",11961407_6,1
2236,foot process effacement,151,174,"Tissues were analyzed at 0, 5, 7, 11, 21, 45, 80 and 126 days after PAN injection so as to include both the acute phase of proteinuria associated with foot process effacement (days 5-11) and the chronic phase of proteinuria associated with glomerulosclerosis (days 45-126).",11961407_6,1
2234,acute phase,108,119,"Tissues were analyzed at 0, 5, 7, 11, 21, 45, 80 and 126 days after PAN injection so as to include both the acute phase of proteinuria associated with foot process effacement (days 5-11) and the chronic phase of proteinuria associated with glomerulosclerosis (days 45-126).",11961407_6,1
2238,GLEPP1 protein,10,24,"At day 5, GLEPP1 protein and mRNA were reduced from the normal range (265.2 +/- 79.6 x 10(6) moles/glomerulus and 100%) to 15% of normal (41.8 +/- 4.8 x 10(6) moles/glomerulus, p < 0.005).",11961407_7,0
526,/- 1,83,87,This occurred in association with an increase in urinary protein content from 1.8 +/- 1 to 99.0 +/- 61 mg/day (p < 0.001).,11961407_8,0
531,MK-801,22,28,Behavioral effects of MK-801 on reserpine-treated mice.,11999899_0,0
534,NMDA,76,80,"The effects of dizocilpine (MK-801), a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, were studied on dopamine-related behaviors induced by reserpine treatments.",11999899_1,0
535,receptor antagonist,82,101,"The effects of dizocilpine (MK-801), a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, were studied on dopamine-related behaviors induced by reserpine treatments.",11999899_1,0
2249,dizocilpine,15,26,"The effects of dizocilpine (MK-801), a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, were studied on dopamine-related behaviors induced by reserpine treatments.",11999899_1,0
532,MK-801,28,34,"The effects of dizocilpine (MK-801), a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, were studied on dopamine-related behaviors induced by reserpine treatments.",11999899_1,0
533,N-methyl-D-aspartate,54,74,"The effects of dizocilpine (MK-801), a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, were studied on dopamine-related behaviors induced by reserpine treatments.",11999899_1,0
2258,vacuous chewing,93,108,"Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and catalepsy, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.",11999899_10,1
542,(1,28,30,"Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and catalepsy, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.",11999899_10,0
543,MK-801,196,202,"Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and catalepsy, whereas MK-801 (0.1 mg/kg) injection 90 min before the test reversed the effects of reserpine.",11999899_10,0
4553,abnormal movements,57,75,"These results show that reserpine produces different and abnormal movements, which are related to dose and schedule employed and can be considered as parkinsonian-like and tardive dsykinesia signs.",11999899_11,1
545,NMDA,39,43,"The glutamatergic blockage produced by NMDA can restore these signs, such as vacuous chewing movements, tongue protrusions, catalepsy and tremor according to the employed model.",11999899_12,0
544,glutamatergic,4,17,"The glutamatergic blockage produced by NMDA can restore these signs, such as vacuous chewing movements, tongue protrusions, catalepsy and tremor according to the employed model.",11999899_12,0
2263,vacuous chewing movements,77,102,"The glutamatergic blockage produced by NMDA can restore these signs, such as vacuous chewing movements, tongue protrusions, catalepsy and tremor according to the employed model.",11999899_12,1
4548,tardive dyskinesia,95,113,"This study focuses on behavioral syndromes that may used as models for Parkinson's disease, or tardive dyskinesia, and its response after glutamatergic blockage.",11999899_2,1
536,glutamatergic,138,151,"This study focuses on behavioral syndromes that may used as models for Parkinson's disease, or tardive dyskinesia, and its response after glutamatergic blockage.",11999899_2,0
2251,behavioral syndromes,22,42,"This study focuses on behavioral syndromes that may used as models for Parkinson's disease, or tardive dyskinesia, and its response after glutamatergic blockage.",11999899_2,1
4547,Parkinson's disease,71,90,"This study focuses on behavioral syndromes that may used as models for Parkinson's disease, or tardive dyskinesia, and its response after glutamatergic blockage.",11999899_2,1
4549,orofacial dyskinesia,89,109,"Reserpine (1 mg/kg), administered once every other day for 4 days, produced increases in orofacial dyskinesia, tongue protrusion and vacuous chewing in mice, which are signs indicative of tardive dyskinesia.",11999899_3,1
4550,tardive dyskinesia,188,206,"Reserpine (1 mg/kg), administered once every other day for 4 days, produced increases in orofacial dyskinesia, tongue protrusion and vacuous chewing in mice, which are signs indicative of tardive dyskinesia.",11999899_3,1
537,(1,10,12,"Reserpine (1 mg/kg), administered once every other day for 4 days, produced increases in orofacial dyskinesia, tongue protrusion and vacuous chewing in mice, which are signs indicative of tardive dyskinesia.",11999899_3,0
4551,Parkinson's disease,76,95,"Reserpine also produced tremor and catalepsy, which are signs suggestive of Parkinson's disease.",11999899_4,1
538,MK-801,0,6,"MK-801 (0.1 mg/kg), administered 30 min before the observation test, prevented the vacuous chewing movements, tongue protrusions and catalepsy induced by reserpine.",11999899_5,0
2254,vacuous chewing movements,83,108,"MK-801 (0.1 mg/kg), administered 30 min before the observation test, prevented the vacuous chewing movements, tongue protrusions and catalepsy induced by reserpine.",11999899_5,1
539,MK-801,9,15,"However, MK-801 injection produced a significant increase of tremor in reserpine-treated mice.",11999899_6,0
4552,oral dyskinesia,145,160,"Reserpine (1 mg/kg), administered 90 min before the test and followed by apomophine injection (0.1 mg/kg) 5 min before the test, did not produce oral dyskinesia in mice.",11999899_7,1
540,(1,10,12,"Reserpine (1 mg/kg), administered 90 min before the test and followed by apomophine injection (0.1 mg/kg) 5 min before the test, did not produce oral dyskinesia in mice.",11999899_7,0
2256,apomophine,73,83,"Reserpine (1 mg/kg), administered 90 min before the test and followed by apomophine injection (0.1 mg/kg) 5 min before the test, did not produce oral dyskinesia in mice.",11999899_7,0
541,MK-801,0,6,MK-801 (0.1 mg/kg) administration attenuated the catalepsy and tremor induced by reserpine.,11999899_9,0
2265,visual disturbances,41,60,"Risperidone-associated, benign transient visual disturbances in schizophrenic patients with a past history of LSD abuse.",12013711_0,1
2267,LSD abuse,110,119,"Risperidone-associated, benign transient visual disturbances in schizophrenic patients with a past history of LSD abuse.",12013711_0,1
2268,LSD abuse,55,64,"Two schizophrenic patients, who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics, were successfully treated with risperidone.",12013711_1,1
2270,risperidone,162,173,"Two schizophrenic patients, who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics, were successfully treated with risperidone.",12013711_1,0
2271,visual disturbances,47,66,"They both reported short episodes of transient visual disturbances, which appeared immediately after starting treatment with risperidone.",12013711_2,1
2272,risperidone,125,136,"They both reported short episodes of transient visual disturbances, which appeared immediately after starting treatment with risperidone.",12013711_2,0
2273,visual disturbances,23,42,"This imagery resembled visual disturbances previously experienced as ""flashbacks"" related to prior LSD consumption.",12013711_3,1
2274,Risperidone,0,11,Risperidone administration was continued and the visual disturbances gradually wore off.,12013711_4,0
2275,visual disturbances,49,68,Risperidone administration was continued and the visual disturbances gradually wore off.,12013711_4,1
2277,visual disturbances,64,83,"During a six-month follow-up period, there was no recurrence of visual disturbances.",12013711_5,1
4554,side effect,77,88,"This phenomenon may be interpreted as a benign, short-term and self-limiting side effect which does not contraindicate the use of risperidone or interfere with treatment.",12013711_6,1
2278,self-limiting,63,76,"This phenomenon may be interpreted as a benign, short-term and self-limiting side effect which does not contraindicate the use of risperidone or interfere with treatment.",12013711_6,1
2279,risperidone,130,141,"This phenomenon may be interpreted as a benign, short-term and self-limiting side effect which does not contraindicate the use of risperidone or interfere with treatment.",12013711_6,0
4555,aplastic anemia,67,82,Antithymocyte globulin in the treatment of D-penicillamine-induced aplastic anemia.,12041669_0,1
546,Antithymocyte globulin,0,22,Antithymocyte globulin in the treatment of D-penicillamine-induced aplastic anemia.,12041669_0,0
548,D-penicillamine,81,96,A patient who received antithymocyte globulin therapy for aplastic anemia due to D-penicillamine therapy is described.,12041669_1,0
547,antithymocyte globulin,23,45,A patient who received antithymocyte globulin therapy for aplastic anemia due to D-penicillamine therapy is described.,12041669_1,0
4556,aplastic anemia,58,73,A patient who received antithymocyte globulin therapy for aplastic anemia due to D-penicillamine therapy is described.,12041669_1,1
2282,blood transfusion,122,139,"Bone marrow recovery and peripheral blood recovery were complete 1 month and 3 months, respectively, after treatment, and blood transfusion or other therapies were not necessary in a follow-up period of more than 2 years.",12041669_2,1
4557,Bone marrow,0,11,"Bone marrow recovery and peripheral blood recovery were complete 1 month and 3 months, respectively, after treatment, and blood transfusion or other therapies were not necessary in a follow-up period of more than 2 years.",12041669_2,1
549,antithymocyte globulin,7,29,Use of antithymocyte globulin may be the optimal treatment of D-penicillamine-induced aplastic anemia.,12041669_3,0
4558,aplastic anemia,86,101,Use of antithymocyte globulin may be the optimal treatment of D-penicillamine-induced aplastic anemia.,12041669_3,1
550,Topiramate,0,10,Topiramate is a recently developed antiepileptic medication that is becoming more widely prescribed because of its efficacy in treating refractory seizures.,12042105_1,0
2285,refractory seizures,136,155,Topiramate is a recently developed antiepileptic medication that is becoming more widely prescribed because of its efficacy in treating refractory seizures.,12042105_1,1
2284,antiepileptic medication,35,59,Topiramate is a recently developed antiepileptic medication that is becoming more widely prescribed because of its efficacy in treating refractory seizures.,12042105_1,0
4559,metabolic acidosis,58,76,Urologists should be aware that this medication can cause metabolic acidosis in patients secondary to inhibition of carbonic anhydrase.,12042105_2,1
551,carbonic anhydrase,116,134,Urologists should be aware that this medication can cause metabolic acidosis in patients secondary to inhibition of carbonic anhydrase.,12042105_2,0
2288,calcium phosphate,165,182,"In addition, a distal tubular acidification defect may result, thus impairing the normal compensatory drop in urine pH. These factors can lead to the development of calcium phosphate nephrolithiasis.",12042105_3,0
4560,compensatory,89,101,"In addition, a distal tubular acidification defect may result, thus impairing the normal compensatory drop in urine pH. These factors can lead to the development of calcium phosphate nephrolithiasis.",12042105_3,1
2287,distal tubular acidification defect,15,50,"In addition, a distal tubular acidification defect may result, thus impairing the normal compensatory drop in urine pH. These factors can lead to the development of calcium phosphate nephrolithiasis.",12042105_3,1
552,Metamizol,0,9,Metamizol potentiates morphine antinociception but not constipation after chronic treatment.,12063090_0,0
553,antinociceptive,24,39,This work evaluates the antinociceptive and constipating effects of the combination of 3.2 mg/kg s.c.,12063090_1,0
561,metamizol,67,76,"These findings show a significant interaction between morphine and metamizol in chronically treated rats, suggesting that this combination could be useful for the treatment of chronic pain.",12063090_10,0
4561,chronic pain,176,188,"These findings show a significant interaction between morphine and metamizol in chronically treated rats, suggesting that this combination could be useful for the treatment of chronic pain.",12063090_10,1
554,metamizol,0,9,metamizol in acutely and chronically treated (once a day for 12 days) rats.,12063090_3,0
555,antinociceptive,17,32,"On the 13th day, antinociceptive effects were assessed using a model of inflammatory nociception, pain-induced functional impairment model, and the charcoal meal test was used to evaluate the intestinal transit.",12063090_4,0
2294,inflammatory nociception,72,96,"On the 13th day, antinociceptive effects were assessed using a model of inflammatory nociception, pain-induced functional impairment model, and the charcoal meal test was used to evaluate the intestinal transit.",12063090_4,1
2295,functional impairment,111,132,"On the 13th day, antinociceptive effects were assessed using a model of inflammatory nociception, pain-induced functional impairment model, and the charcoal meal test was used to evaluate the intestinal transit.",12063090_4,1
2297,intestinal transit,192,210,"On the 13th day, antinociceptive effects were assessed using a model of inflammatory nociception, pain-induced functional impairment model, and the charcoal meal test was used to evaluate the intestinal transit.",12063090_4,1
556,metamizol,45,54,Simultaneous administration of morphine with metamizol resulted in a markedly antinociceptive potentiation and an increasing of the duration of action after a single (298+/-7 vs. 139+/-36 units area (ua); P<0.001) and repeated administration (280+/-17 vs. 131+/-22 ua; P<0.001).,12063090_5,0
557,antinociceptive,78,93,Simultaneous administration of morphine with metamizol resulted in a markedly antinociceptive potentiation and an increasing of the duration of action after a single (298+/-7 vs. 139+/-36 units area (ua); P<0.001) and repeated administration (280+/-17 vs. 131+/-22 ua; P<0.001).,12063090_5,0
558,Antinociceptive,0,15,Antinociceptive effect of morphine was reduced in chronically treated rats (39+/-10 vs. 18+/-5 au) while the combination-induced antinociception was remained similar as an acute treatment (298+/-7 vs. 280+/-17 au).,12063090_6,0
559,antinociceptive,6,21,"Acute antinociceptive effects of the combination were partially prevented by 3.2 mg/kg naloxone s.c. (P<0.05), suggesting the partial involvement of the opioidergic system in the synergism observed.",12063090_7,0
2300,intestinal transit,46,64,"In independent groups, morphine inhibited the intestinal transit in 48+/-4% and 38+/-4% after acute and chronic treatment, respectively, suggesting that tolerance did not develop to the constipating effects.",12063090_8,1
2302,intestinal transit,26,44,"The combination inhibited intestinal transit similar to that produced by morphine regardless of the time of treatment, suggesting that metamizol did not potentiate morphine-induced constipation.",12063090_9,1
560,metamizol,135,144,"The combination inhibited intestinal transit similar to that produced by morphine regardless of the time of treatment, suggesting that metamizol did not potentiate morphine-induced constipation.",12063090_9,0
2303,morphine-induced constipation,164,193,"The combination inhibited intestinal transit similar to that produced by morphine regardless of the time of treatment, suggesting that metamizol did not potentiate morphine-induced constipation.",12063090_9,1
562,Ifosfamide,0,10,Ifosfamide encephalopathy presenting with asterixis.,12084448_0,0
2304,asterixis,42,51,Ifosfamide encephalopathy presenting with asterixis.,12084448_0,1
2305,toxic effects,4,17,CNS toxic effects of the antineoplastic agent ifosfamide (IFX) are frequent and include a variety of neurological symptoms that can limit drug use.,12084448_1,0
2306,antineoplastic agent ifosfamide,25,56,CNS toxic effects of the antineoplastic agent ifosfamide (IFX) are frequent and include a variety of neurological symptoms that can limit drug use.,12084448_1,0
2308,neurological symptoms,101,122,CNS toxic effects of the antineoplastic agent ifosfamide (IFX) are frequent and include a variety of neurological symptoms that can limit drug use.,12084448_1,1
4562,drug use,138,146,CNS toxic effects of the antineoplastic agent ifosfamide (IFX) are frequent and include a variety of neurological symptoms that can limit drug use.,12084448_1,1
563,ifosfamide,146,156,"We report a case of a 51-year-old man who developed severe, disabling negative myoclonus of the upper and lower extremities after the infusion of ifosfamide for plasmacytoma.",12084448_2,0
4563,lower extremities,106,123,"We report a case of a 51-year-old man who developed severe, disabling negative myoclonus of the upper and lower extremities after the infusion of ifosfamide for plasmacytoma.",12084448_2,1
2310,motor symptoms,85,99,"He was awake, revealed no changes of mental status and at rest there were no further motor symptoms.",12084448_3,1
2313,metabolic abnormalities,121,144,Cranial magnetic resonance imaging and extensive laboratory studies failed to reveal structural lesions of the brain and metabolic abnormalities.,12084448_4,1
2312,structural lesions,85,103,Cranial magnetic resonance imaging and extensive laboratory studies failed to reveal structural lesions of the brain and metabolic abnormalities.,12084448_4,1
2314,generalized irregular slowing,43,72,"An electroencephalogram showed continuous, generalized irregular slowing with admixed periodic triphasic waves indicating symptomatic encephalopathy.",12084448_5,1
2315,triphasic waves,95,110,"An electroencephalogram showed continuous, generalized irregular slowing with admixed periodic triphasic waves indicating symptomatic encephalopathy.",12084448_5,1
564,ifosfamide,22,32,The administration of ifosfamide was discontinued and within 12 h the asterixis resolved completely.,12084448_6,0
565,ifosfamide,71,81,"In the patient described, the presence of asterixis during infusion of ifosfamide, normal laboratory findings and imaging studies and the resolution of symptoms following the discontinuation of the drug suggest that negative myoclonus is associated with the use of IFX.",12084448_7,0
566,interleukin 3,19,32,Antagonism between interleukin 3 and erythropoietin in mice with azidothymidine-induced anemia and in bone marrow endothelial cells.,12090760_0,0
2324,IGF-IL-3,85,93,Azidothymidine (AZT)-induced anemia in mice can be reversed by the administration of IGF-IL-3 (fusion protein of insulin-like growth factor II (IGF II) and interleukin 3).,12090760_1,0
571,interleukin 3,156,169,Azidothymidine (AZT)-induced anemia in mice can be reversed by the administration of IGF-IL-3 (fusion protein of insulin-like growth factor II (IGF II) and interleukin 3).,12090760_1,0
570,IGF II,144,150,Azidothymidine (AZT)-induced anemia in mice can be reversed by the administration of IGF-IL-3 (fusion protein of insulin-like growth factor II (IGF II) and interleukin 3).,12090760_1,0
569,insulin-like growth factor II,113,142,Azidothymidine (AZT)-induced anemia in mice can be reversed by the administration of IGF-IL-3 (fusion protein of insulin-like growth factor II (IGF II) and interleukin 3).,12090760_1,0
568,fusion protein,95,109,Azidothymidine (AZT)-induced anemia in mice can be reversed by the administration of IGF-IL-3 (fusion protein of insulin-like growth factor II (IGF II) and interleukin 3).,12090760_1,0
567,Azidothymidine,0,14,Azidothymidine (AZT)-induced anemia in mice can be reversed by the administration of IGF-IL-3 (fusion protein of insulin-like growth factor II (IGF II) and interleukin 3).,12090760_1,0
573,IL-3,24,28,"Although interleukin 3 (IL-3) and erythropoietin (EPO) are known to act synergistically on hematopoietic cell proliferation in vitro, injection of IGF-IL-3 and EPO in AZT-treated mice resulted in a reduction of red cells and an increase of plasma EPO levels as compared to animals treated with IGF-IL-3 or EPO alone.",12090760_2,0
2333,EPO,306,309,"Although interleukin 3 (IL-3) and erythropoietin (EPO) are known to act synergistically on hematopoietic cell proliferation in vitro, injection of IGF-IL-3 and EPO in AZT-treated mice resulted in a reduction of red cells and an increase of plasma EPO levels as compared to animals treated with IGF-IL-3 or EPO alone.",12090760_2,0
572,interleukin 3,9,22,"Although interleukin 3 (IL-3) and erythropoietin (EPO) are known to act synergistically on hematopoietic cell proliferation in vitro, injection of IGF-IL-3 and EPO in AZT-treated mice resulted in a reduction of red cells and an increase of plasma EPO levels as compared to animals treated with IGF-IL-3 or EPO alone.",12090760_2,0
2331,EPO,247,250,"Although interleukin 3 (IL-3) and erythropoietin (EPO) are known to act synergistically on hematopoietic cell proliferation in vitro, injection of IGF-IL-3 and EPO in AZT-treated mice resulted in a reduction of red cells and an increase of plasma EPO levels as compared to animals treated with IGF-IL-3 or EPO alone.",12090760_2,0
2329,EPO,160,163,"Although interleukin 3 (IL-3) and erythropoietin (EPO) are known to act synergistically on hematopoietic cell proliferation in vitro, injection of IGF-IL-3 and EPO in AZT-treated mice resulted in a reduction of red cells and an increase of plasma EPO levels as compared to animals treated with IGF-IL-3 or EPO alone.",12090760_2,0
2328,IGF-IL-3,147,155,"Although interleukin 3 (IL-3) and erythropoietin (EPO) are known to act synergistically on hematopoietic cell proliferation in vitro, injection of IGF-IL-3 and EPO in AZT-treated mice resulted in a reduction of red cells and an increase of plasma EPO levels as compared to animals treated with IGF-IL-3 or EPO alone.",12090760_2,0
2325,EPO,50,53,"Although interleukin 3 (IL-3) and erythropoietin (EPO) are known to act synergistically on hematopoietic cell proliferation in vitro, injection of IGF-IL-3 and EPO in AZT-treated mice resulted in a reduction of red cells and an increase of plasma EPO levels as compared to animals treated with IGF-IL-3 or EPO alone.",12090760_2,0
2332,IGF-IL-3,294,302,"Although interleukin 3 (IL-3) and erythropoietin (EPO) are known to act synergistically on hematopoietic cell proliferation in vitro, injection of IGF-IL-3 and EPO in AZT-treated mice resulted in a reduction of red cells and an increase of plasma EPO levels as compared to animals treated with IGF-IL-3 or EPO alone.",12090760_2,0
2335,EPO,66,69,We tested the hypothesis that the antagonistic effect of IL-3 and EPO on erythroid cells may be mediated by endothelial cells.,12090760_3,0
574,IL-3,57,61,We tested the hypothesis that the antagonistic effect of IL-3 and EPO on erythroid cells may be mediated by endothelial cells.,12090760_3,0
2339,IGF-IL-3,128,136,Bovine liver erythroid cells were cultured on monolayers of human bone marrow endothelial cells previously treated with EPO and IGF-IL-3.,12090760_4,0
2338,EPO,120,123,Bovine liver erythroid cells were cultured on monolayers of human bone marrow endothelial cells previously treated with EPO and IGF-IL-3.,12090760_4,0
2342,IGF-IL-3,132,140,There was a significant reduction of thymidine incorporation into both erythroid and endothelial cells in cultures pre-treated with IGF-IL-3 and EPO.,12090760_5,0
2343,EPO,145,148,There was a significant reduction of thymidine incorporation into both erythroid and endothelial cells in cultures pre-treated with IGF-IL-3 and EPO.,12090760_5,0
2344,EPO,115,118,Endothelial cell culture supernatants separated by ultrafiltration and ultracentrifugation from cells treated with EPO and IL-3 significantly reduced thymidine incorporation into erythroid cells as compared to identical fractions obtained from the media of cells cultured with EPO alone.,12090760_6,0
575,IL-3,123,127,Endothelial cell culture supernatants separated by ultrafiltration and ultracentrifugation from cells treated with EPO and IL-3 significantly reduced thymidine incorporation into erythroid cells as compared to identical fractions obtained from the media of cells cultured with EPO alone.,12090760_6,0
576,IL-3,81,85,These results suggest that endothelial cells treated simultaneously with EPO and IL-3 have a negative effect on erythroid cell production.,12090760_7,0
2346,EPO,73,76,These results suggest that endothelial cells treated simultaneously with EPO and IL-3 have a negative effect on erythroid cell production.,12090760_7,0
577,racemic,57,64,"Ketamine in war/tropical surgery (a final tribute to the racemic mixture).A technique of continuous intravenous anaesthesia with ketamine was used successfully during the Somalia civil war in 1994 and in north Uganda in 1999 for 64 operations in 62 patients, aged from 6 weeks to 70 years, undergoing limb and abdominal surgery including caesarian sections and interventions in neonates.",12091028_0,0
2350,abdominal surgery,310,327,"Ketamine in war/tropical surgery (a final tribute to the racemic mixture).A technique of continuous intravenous anaesthesia with ketamine was used successfully during the Somalia civil war in 1994 and in north Uganda in 1999 for 64 operations in 62 patients, aged from 6 weeks to 70 years, undergoing limb and abdominal surgery including caesarian sections and interventions in neonates.",12091028_0,1
578,glycopyrrolate,35,49,"After premedication with diazepam, glycopyrrolate and local anaesthesia, and induction with standard doses of ketamine, a maintenance dose of 10-20 microg/kg/min of ketamine proved safe and effective.",12091028_2,0
2352,premedication,6,19,"After premedication with diazepam, glycopyrrolate and local anaesthesia, and induction with standard doses of ketamine, a maintenance dose of 10-20 microg/kg/min of ketamine proved safe and effective.",12091028_2,0
2353,local anaesthesia,54,71,"After premedication with diazepam, glycopyrrolate and local anaesthesia, and induction with standard doses of ketamine, a maintenance dose of 10-20 microg/kg/min of ketamine proved safe and effective.",12091028_2,1
2360,anaesthetic blocks,6,24,Local anaesthetic blocks were useful in decreasing the requirement for postoperative analgesia.,12091028_5,0
2361,postoperative analgesia,71,94,Local anaesthetic blocks were useful in decreasing the requirement for postoperative analgesia.,12091028_5,1
2362,antisialogue,3,15,"An antisialogue was usually unnecessary in operations lasting up to 2 h, glycopyrrolate being the best choice for its lowest psychotropic and chronotropic effects, especially in a hot climate.",12091028_6,0
579,glycopyrrolate,73,87,"An antisialogue was usually unnecessary in operations lasting up to 2 h, glycopyrrolate being the best choice for its lowest psychotropic and chronotropic effects, especially in a hot climate.",12091028_6,0
2367,Intravenous ribavirin,0,21,Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children.,12093990_0,0
2368,adenovirus disease,43,61,Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children.,12093990_0,1
2369,immunocompromised children,65,91,Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children.,12093990_0,1
2371,immunocompromised host,79,101,BACKGROUND: Adenovirus is an important cause of morbidity and mortality in the immunocompromised host.,12093990_1,1
2393,immunocompromised children,116,142,OBJECTIVE: We report our experience with intravenous ribavirin therapy for severe adenovirus disease in a series of immunocompromised children and review the literature.,12093990_10,1
2392,adenovirus disease,82,100,OBJECTIVE: We report our experience with intravenous ribavirin therapy for severe adenovirus disease in a series of immunocompromised children and review the literature.,12093990_10,1
2396,adenovirus disease,135,153,DESIGN/METHODS: We retrospectively reviewed the medical records of 5 children treated with intravenous ribavirin for documented severe adenovirus disease.,12093990_11,1
2395,intravenous ribavirin,91,112,DESIGN/METHODS: We retrospectively reviewed the medical records of 5 children treated with intravenous ribavirin for documented severe adenovirus disease.,12093990_11,0
2397,adenovirus hemorrhagic cystitis,23,54,"Two patients developed adenovirus hemorrhagic cystitis after cardiac and bone marrow transplants, respectively.",12093990_12,1
4568,bone marrow,73,84,"Two patients developed adenovirus hemorrhagic cystitis after cardiac and bone marrow transplants, respectively.",12093990_12,1
4569,bone marrow,4,15,The bone marrow transplant patient also received intravenous cidofovir for progressive disseminated disease.,12093990_13,1
2398,disseminated disease,87,107,The bone marrow transplant patient also received intravenous cidofovir for progressive disseminated disease.,12093990_13,1
583,cidofovir,61,70,The bone marrow transplant patient also received intravenous cidofovir for progressive disseminated disease.,12093990_13,0
2399,adenovirus pneumonia,35,55,"An additional 3 children developed adenovirus pneumonia; 2 were neonates, 1 of whom had partial DiGeorge syndrome.",12093990_14,1
4570,DiGeorge syndrome,96,113,"An additional 3 children developed adenovirus pneumonia; 2 were neonates, 1 of whom had partial DiGeorge syndrome.",12093990_14,1
2400,cardiac transplant,46,64,The remaining infant had recently undergone a cardiac transplant.,12093990_15,1
2401,Intravenous ribavirin,0,21,Intravenous ribavirin was administered on a compassionate-use protocol.,12093990_16,0
2404,viral clearance,54,69,RESULTS: Complete clinical recovery followed later by viral clearance was observed in 2 children: the cardiac transplant recipient with adenovirus hemorrhagic cystitis and the immunocompetent neonate with adenovirus pneumonia.,12093990_17,1
2407,adenovirus pneumonia,205,225,RESULTS: Complete clinical recovery followed later by viral clearance was observed in 2 children: the cardiac transplant recipient with adenovirus hemorrhagic cystitis and the immunocompetent neonate with adenovirus pneumonia.,12093990_17,1
2406,adenovirus hemorrhagic cystitis,136,167,RESULTS: Complete clinical recovery followed later by viral clearance was observed in 2 children: the cardiac transplant recipient with adenovirus hemorrhagic cystitis and the immunocompetent neonate with adenovirus pneumonia.,12093990_17,1
2405,cardiac transplant,102,120,RESULTS: Complete clinical recovery followed later by viral clearance was observed in 2 children: the cardiac transplant recipient with adenovirus hemorrhagic cystitis and the immunocompetent neonate with adenovirus pneumonia.,12093990_17,1
2403,clinical recovery,18,35,RESULTS: Complete clinical recovery followed later by viral clearance was observed in 2 children: the cardiac transplant recipient with adenovirus hemorrhagic cystitis and the immunocompetent neonate with adenovirus pneumonia.,12093990_17,1
2408,adenovirus disease,33,51,The remaining 3 children died of adenovirus disease.,12093990_18,1
2372,adenovirus disease,24,42,"The incidence of severe adenovirus disease in pediatrics is increasing in association with growing numbers of immunocompromised children, where case fatality rates as high as 50% to 80% have been reported.",12093990_2,1
584,cidofovir,7,16,Use of cidofovir in 1 child was associated with progressive renal failure and neutropenia.,12093990_20,0
4571,renal failure,60,73,Use of cidofovir in 1 child was associated with progressive renal failure and neutropenia.,12093990_20,1
2410,immunocompromised children,72,98,"DISCUSSION: Our series of patients is representative of the spectrum of immunocompromised children at greatest risk for severe adenovirus disease, namely solid-organ and bone marrow transplant recipients, neonates, and children with immunodeficiency.",12093990_21,1
2411,adenovirus disease,127,145,"DISCUSSION: Our series of patients is representative of the spectrum of immunocompromised children at greatest risk for severe adenovirus disease, namely solid-organ and bone marrow transplant recipients, neonates, and children with immunodeficiency.",12093990_21,1
2412,solid-organ,154,165,"DISCUSSION: Our series of patients is representative of the spectrum of immunocompromised children at greatest risk for severe adenovirus disease, namely solid-organ and bone marrow transplant recipients, neonates, and children with immunodeficiency.",12093990_21,1
4572,bone marrow,170,181,"DISCUSSION: Our series of patients is representative of the spectrum of immunocompromised children at greatest risk for severe adenovirus disease, namely solid-organ and bone marrow transplant recipients, neonates, and children with immunodeficiency.",12093990_21,1
2413,intravenous ribavirin,9,30,"Although intravenous ribavirin was not effective for all children with severe adenovirus disease in this series or in the literature, therapy is unlikely to be of benefit if begun late in the course of the infection.",12093990_22,0
2414,adenovirus disease,78,96,"Although intravenous ribavirin was not effective for all children with severe adenovirus disease in this series or in the literature, therapy is unlikely to be of benefit if begun late in the course of the infection.",12093990_22,1
2416,disseminated adenovirus disease,83,114,"Early identification, eg by polymerase chain reaction of those patients at risk of disseminated adenovirus disease may permit earlier antiviral treatment and better evaluation of therapeutic response.",12093990_23,1
2418,adenovirus disease,43,61,CONCLUSIONS: Two of 5 children with severe adenovirus disease treated with intravenous ribavirin recovered.,12093990_24,1
4573,adenovirus infection,136,156,"The availability of newer rapid diagnostic techniques, such as polymerase chain reaction, may make earlier, more effective treatment of adenovirus infection possible.",12093990_25,1
2420,polymerase chain reaction,63,88,"The availability of newer rapid diagnostic techniques, such as polymerase chain reaction, may make earlier, more effective treatment of adenovirus infection possible.",12093990_25,0
2424,intravenous ribavirin,202,223,"Given the seriousness and increasing prevalence of adenovirus disease in certain hosts, especially children, a large, multicenter clinical trial of potentially useful anti-adenoviral therapies, such as intravenous ribavirin, is clearly required to demonstrate the most effective and least toxic therapy.",12093990_26,0
2423,anti-adenoviral therapies,167,192,"Given the seriousness and increasing prevalence of adenovirus disease in certain hosts, especially children, a large, multicenter clinical trial of potentially useful anti-adenoviral therapies, such as intravenous ribavirin, is clearly required to demonstrate the most effective and least toxic therapy.",12093990_26,0
2421,adenovirus disease,51,69,"Given the seriousness and increasing prevalence of adenovirus disease in certain hosts, especially children, a large, multicenter clinical trial of potentially useful anti-adenoviral therapies, such as intravenous ribavirin, is clearly required to demonstrate the most effective and least toxic therapy.",12093990_26,1
2377,anti-adenovirus therapies,190,215,"There are no approved antiviral agents with proven efficacy for the treatment of severe adenovirus disease, nor are there any prospective randomized, controlled trials of potentially useful anti-adenovirus therapies.",12093990_3,0
580,antiviral agents,22,38,"There are no approved antiviral agents with proven efficacy for the treatment of severe adenovirus disease, nor are there any prospective randomized, controlled trials of potentially useful anti-adenovirus therapies.",12093990_3,0
2375,adenovirus disease,88,106,"There are no approved antiviral agents with proven efficacy for the treatment of severe adenovirus disease, nor are there any prospective randomized, controlled trials of potentially useful anti-adenovirus therapies.",12093990_3,1
2379,adenovirus disease,53,71,Apparent clinical success in the treatment of severe adenovirus disease is limited to a few case reports and small series.,12093990_4,1
581,cidofovir,54,63,Experience is greatest with intravenous ribavirin and cidofovir.,12093990_5,0
2382,intravenous ribavirin,28,49,Experience is greatest with intravenous ribavirin and cidofovir.,12093990_5,0
2383,guanosine analogue,13,31,"Ribavirin, a guanosine analogue, has broad antiviral activity against both RNA and DNA viruses, including documented activity against adenovirus in vitro.",12093990_6,0
2387,C. Intravenous ribavirin,159,183,"Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.",12093990_7,0
2386,treat hepatitis,143,158,"Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.",12093990_7,1
4564,respiratory syncytial virus infection,59,96,"Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.",12093990_7,1
4565,hemorrhagic fever,230,247,"Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses.",12093990_7,1
2390,mild anemia,70,81,The most common adverse effect of intravenous ribavirin is reversible mild anemia.,12093990_8,1
2389,intravenous ribavirin,34,55,The most common adverse effect of intravenous ribavirin is reversible mild anemia.,12093990_8,0
2388,adverse effect,16,30,The most common adverse effect of intravenous ribavirin is reversible mild anemia.,12093990_8,1
4567,adverse effects,72,87,"The use of cidofovir in severe adenovirus infection has been limited by adverse effects, the most significant of which is nephrotoxicity.",12093990_9,1
582,cidofovir,11,20,"The use of cidofovir in severe adenovirus infection has been limited by adverse effects, the most significant of which is nephrotoxicity.",12093990_9,0
2391,nephrotoxicity,122,136,"The use of cidofovir in severe adenovirus infection has been limited by adverse effects, the most significant of which is nephrotoxicity.",12093990_9,1
4566,adenovirus infection,31,51,"The use of cidofovir in severe adenovirus infection has been limited by adverse effects, the most significant of which is nephrotoxicity.",12093990_9,1
2426,asystolic cardiac arrest,8,32,Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous calcium.,12101159_0,1
2427,high dose,78,87,Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous calcium.,12101159_0,0
2428,intravenous calcium,88,107,Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous calcium.,12101159_0,0
585,paracetamol,74,85,"A 51 year old man took a mixed overdose including 1.8-3.6 g of diltiazem, paracetamol, aspirin, isosorbide nitrate, and alcohol.",12101159_1,0
586,activated charcoal,94,112,He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.,12101159_2,0
2431,intravenous fluids,117,135,He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.,12101159_2,0
2430,mild hypotension,56,72,He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids.,12101159_2,1
4574,tonic-clonic seizures,57,78,Eighteen hours after the overdose he had two generalised tonic-clonic seizures.,12101159_3,1
2433,asystolic,108,117,"The patient remained unresponsive with junctional bradycardia, unrecordable blood pressure, and then became asystolic.",12101159_4,1
2432,junctional bradycardia,39,61,"The patient remained unresponsive with junctional bradycardia, unrecordable blood pressure, and then became asystolic.",12101159_4,1
4575,blood pressure,76,90,"The patient remained unresponsive with junctional bradycardia, unrecordable blood pressure, and then became asystolic.",12101159_4,1
2434,high dose,25,34,He was resuscitated with high dose (13.5 g) intravenous calcium and adrenaline (epinephrine).,12101159_5,0
2437,high dose,50,59,"This case suggests there is a role for aggressive high dose intravenous calcium therapy in severe diltiazem overdose, particularly with the onset of asystole.",12101159_7,0
4576,cardiac arrest,42,56,It should be considered early in cases of cardiac arrest after diltiazem overdose.,12101159_8,1
2439,whole bowel,65,76,The case also highlights the problems with delayed toxicity when whole bowel irrigation is not administered.,12101159_9,1
2440,mechanical heart valves,64,87,Low-molecular-weight heparin for the treatment of patients with mechanical heart valves.,12109865_0,1
587,Low-molecular-weight heparin,0,28,Low-molecular-weight heparin for the treatment of patients with mechanical heart valves.,12109865_0,0
2443,noncardiac surgery,151,169,"BACKGROUND: The interruption of oral anticoagulant (OAC) administration is sometimes indicated in patients with mechanical heart valves, mainly before noncardiac surgery, non-surgical interventions, and pregnancy.",12109865_1,1
2442,mechanical heart valves,112,135,"BACKGROUND: The interruption of oral anticoagulant (OAC) administration is sometimes indicated in patients with mechanical heart valves, mainly before noncardiac surgery, non-surgical interventions, and pregnancy.",12109865_1,1
588,oral anticoagulant,32,50,"BACKGROUND: The interruption of oral anticoagulant (OAC) administration is sometimes indicated in patients with mechanical heart valves, mainly before noncardiac surgery, non-surgical interventions, and pregnancy.",12109865_1,0
595,LMWH,66,70,"CONCLUSIONS: In patients with mechanical heart valves, short-term LMWH therapy compares favorably with UH.",12109865_11,0
2462,mechanical heart valves,30,53,"CONCLUSIONS: In patients with mechanical heart valves, short-term LMWH therapy compares favorably with UH.",12109865_11,1
596,LMWH,27,31,Data on mid- and long-term LMWH administration in these patients are sparse.,12109865_12,0
597,LMWH,99,103,Further randomized studies are needed to confirm the safety and precise indications for the use of LMWH in patients with mechanical heart valves.,12109865_13,0
589,Unfractionated heparin,0,22,Unfractionated heparin (UH) is currently the substitute for selected patients.,12109865_2,0
2445,UH,24,26,Unfractionated heparin (UH) is currently the substitute for selected patients.,12109865_2,0
590,Low-molecular-weight heparin,0,28,"Low-molecular-weight heparin (LMWH) offers theoretical advantages over UH, but is not currently considered in clinical guidelines as an alternative to UH in patients with prosthetic valves.",12109865_3,0
2449,prosthetic valves,171,188,"Low-molecular-weight heparin (LMWH) offers theoretical advantages over UH, but is not currently considered in clinical guidelines as an alternative to UH in patients with prosthetic valves.",12109865_3,1
591,LMWH,30,34,"Low-molecular-weight heparin (LMWH) offers theoretical advantages over UH, but is not currently considered in clinical guidelines as an alternative to UH in patients with prosthetic valves.",12109865_3,0
592,LMWH,97,101,HYPOTHESIS: The aim of the present study was to review the data accumulated so far on the use of LMWH in this patient population and to discuss its applicability in common practice.,12109865_4,0
593,LMWH,59,63,"METHODS: For this paper, the current medical literature on LMWH in patients with mechanical heart valves was extensively reviewed.",12109865_5,0
2451,mechanical heart valves,81,104,"METHODS: For this paper, the current medical literature on LMWH in patients with mechanical heart valves was extensively reviewed.",12109865_5,1
2453,thromboembolic,22,36,Data to establish the thromboembolic risk were incomplete.,12109865_8,1
594,(d,253,255,"After excluding case reports, the following groups were constructed: (a) short-term administration, after valve insertion (n = 212); (b) short-term, perioperative (noncardiac)/periprocedural (n = 114); (c) long-term, due to intolerance to OAC (n = 16); (d) long-term, in pregnancy (n = 10).",12109865_9,0
2457,(noncardiac)/periprocedural,163,190,"After excluding case reports, the following groups were constructed: (a) short-term administration, after valve insertion (n = 212); (b) short-term, perioperative (noncardiac)/periprocedural (n = 114); (c) long-term, due to intolerance to OAC (n = 16); (d) long-term, in pregnancy (n = 10).",12109865_9,1
2456,perioperative,149,162,"After excluding case reports, the following groups were constructed: (a) short-term administration, after valve insertion (n = 212); (b) short-term, perioperative (noncardiac)/periprocedural (n = 114); (c) long-term, due to intolerance to OAC (n = 16); (d) long-term, in pregnancy (n = 10).",12109865_9,1
599,metoclopramide,88,102,Cardiac arrest after intravenous metoclopramide - a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest.,12139551_0,0
4578,cardiac arrest,128,142,Cardiac arrest after intravenous metoclopramide - a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest.,12139551_0,1
4577,Cardiac arrest,0,14,Cardiac arrest after intravenous metoclopramide - a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest.,12139551_0,1
598,metoclopramide,33,47,Cardiac arrest after intravenous metoclopramide - a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest.,12139551_0,0
600,metoclopramide,53,67,We describe a patient where intravenous injection of metoclopramide was immediately followed by asystole repeatedly.,12139551_1,0
601,metoclopramide,21,35,The patient received metoclopramide 10 mg i.v.,12139551_2,0
602,metoclopramide,146,160,"five times during 48 h. After interviewing the attending nurses and reviewing the written documentation, it is clear that every administration of metoclopramide was immediately (within s) followed by asystole.",12139551_3,0
2468,chest compressions,43,61,"The patient received atropine 0.5-1 mg and chest compressions, before sinus rhythm again took over.",12139551_5,1
2469,sinus rhythm,70,82,"The patient received atropine 0.5-1 mg and chest compressions, before sinus rhythm again took over.",12139551_5,1
603,metoclopramide,58,72,We interpret this as episodes of cardiac arrest caused by metoclopramide.,12139551_6,0
4579,cardiac arrest,33,47,We interpret this as episodes of cardiac arrest caused by metoclopramide.,12139551_6,1
2470,central venous,28,42,The rapid injection via the central venous route and the concomitant tapering of dopamine infusion might have contributed in precipitating the adverse drug reaction.,12139551_7,1
4580,adverse drug reaction,143,164,The rapid injection via the central venous route and the concomitant tapering of dopamine infusion might have contributed in precipitating the adverse drug reaction.,12139551_7,1
605,nitric oxide,47,59,"Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.",12180796_0,0
2473,tumor growth factor-beta1,110,135,"Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.",12180796_0,0
2472,bFGF,100,104,"Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.",12180796_0,0
604,inducible,29,38,"Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.",12180796_0,0
606,basic fibroblast growth factor,68,98,"Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.",12180796_0,0
607,TGF-beta1,137,146,"Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.",12180796_0,0
608,fenoldopam,180,190,"Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators.",12180796_0,0
2476,tumor growth factor-beta1,216,241,"Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).",12180796_1,0
609,fenoldopam,43,53,"Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).",12180796_1,0
610,inducible,126,135,"Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).",12180796_1,0
611,nitric oxide synthase,144,165,"Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).",12180796_1,0
612,basic fibroblast growth factor,174,204,"Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).",12180796_1,0
2475,bFGF,206,210,"Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).",12180796_1,0
613,TGF-beta1,243,252,"Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1).",12180796_1,0
614,fenoldopam,23,33,Rats were administered fenoldopam for 24 hours by intravenous infusion with or without following repeated daily oral administrations of theophylline.,12180796_2,0
2482,TGF-beta1 antigens,232,250,"Irrespective of theophylline administration, iNOS antigens were remarkably abundant in ED-1-positive cells on day 5 and 8 post-fenoldopam-infusion (DPI); bFGF antigens were remarkably abundant in ED-1-positive cells on 1 and 3 DPI; TGF-beta1 antigens were observed in ED-1-positive cells on and after 5 DPI.",12180796_3,0
2480,bFGF,154,158,"Irrespective of theophylline administration, iNOS antigens were remarkably abundant in ED-1-positive cells on day 5 and 8 post-fenoldopam-infusion (DPI); bFGF antigens were remarkably abundant in ED-1-positive cells on 1 and 3 DPI; TGF-beta1 antigens were observed in ED-1-positive cells on and after 5 DPI.",12180796_3,0
2485,bFGF,87,91,"These results suggest that the peak expression of iNOS antigen was followed by that of bFGF antigen, and bFGF may have a suppressive effect on iNOS expression in these rat arteritis models.",12180796_4,0
2486,bFGF,105,109,"These results suggest that the peak expression of iNOS antigen was followed by that of bFGF antigen, and bFGF may have a suppressive effect on iNOS expression in these rat arteritis models.",12180796_4,0
615,TGF-beta1,19,28,"On the other hand, TGF-beta1 was not considered to have a suppressive effect on iNOS expression in these models.",12180796_5,0
2491,withdrawal seizure-resistant,130,158,The relationship between hippocampal acetylcholine release and cholinergic convulsant sensitivity in withdrawal seizure-prone and withdrawal seizure-resistant selected mouse lines.,12198388_0,1
2490,withdrawal seizure-prone,101,125,The relationship between hippocampal acetylcholine release and cholinergic convulsant sensitivity in withdrawal seizure-prone and withdrawal seizure-resistant selected mouse lines.,12198388_0,1
2489,cholinergic convulsant,63,85,The relationship between hippocampal acetylcholine release and cholinergic convulsant sensitivity in withdrawal seizure-prone and withdrawal seizure-resistant selected mouse lines.,12198388_0,0
4581,hippocampal,25,36,The relationship between hippocampal acetylcholine release and cholinergic convulsant sensitivity in withdrawal seizure-prone and withdrawal seizure-resistant selected mouse lines.,12198388_0,1
616,acetylcholine release,37,58,The relationship between hippocampal acetylcholine release and cholinergic convulsant sensitivity in withdrawal seizure-prone and withdrawal seizure-resistant selected mouse lines.,12198388_0,0
617,cholinergic agents,140,158,"BACKGROUND: The septo-hippocampal cholinergic pathway has been implicated in epileptogenesis, and genetic factors influence the response to cholinergic agents, but limited data are available on cholinergic involvement in alcohol withdrawal severity.",12198388_1,0
2495,alcohol withdrawal severity,221,248,"BACKGROUND: The septo-hippocampal cholinergic pathway has been implicated in epileptogenesis, and genetic factors influence the response to cholinergic agents, but limited data are available on cholinergic involvement in alcohol withdrawal severity.",12198388_1,1
2493,epileptogenesis,77,92,"BACKGROUND: The septo-hippocampal cholinergic pathway has been implicated in epileptogenesis, and genetic factors influence the response to cholinergic agents, but limited data are available on cholinergic involvement in alcohol withdrawal severity.",12198388_1,1
2511,KCl,77,80,"However, the increase in release of ACh produced by the first application of KCl was 2-fold higher in WSP versus WSR mice.",12198388_10,0
623,ACh,36,39,"However, the increase in release of ACh produced by the first application of KCl was 2-fold higher in WSP versus WSR mice.",12198388_10,0
2516,WSP,138,141,"When hippocampal ACh was measured during testing for handling-induced convulsions, extracellular ACh was significantly elevated (192%) in WSP mice, but was nonsignificantly elevated (59%) in WSR mice.",12198388_11,0
624,ACh,97,100,"When hippocampal ACh was measured during testing for handling-induced convulsions, extracellular ACh was significantly elevated (192%) in WSP mice, but was nonsignificantly elevated (59%) in WSR mice.",12198388_11,0
2515,handling-induced convulsions,53,81,"When hippocampal ACh was measured during testing for handling-induced convulsions, extracellular ACh was significantly elevated (192%) in WSP mice, but was nonsignificantly elevated (59%) in WSR mice.",12198388_11,0
2519,cholinergic convulsants,108,131,CONCLUSIONS: These results suggest that differences in cholinergic activity and postsynaptic sensitivity to cholinergic convulsants may be associated with ethanol withdrawal severity and implicate cholinergic mechanisms in alcohol withdrawal.,12198388_12,0
2521,withdrawal severity,163,182,CONCLUSIONS: These results suggest that differences in cholinergic activity and postsynaptic sensitivity to cholinergic convulsants may be associated with ethanol withdrawal severity and implicate cholinergic mechanisms in alcohol withdrawal.,12198388_12,1
4584,postsynaptic,80,92,CONCLUSIONS: These results suggest that differences in cholinergic activity and postsynaptic sensitivity to cholinergic convulsants may be associated with ethanol withdrawal severity and implicate cholinergic mechanisms in alcohol withdrawal.,12198388_12,1
4585,alcohol withdrawal,223,241,CONCLUSIONS: These results suggest that differences in cholinergic activity and postsynaptic sensitivity to cholinergic convulsants may be associated with ethanol withdrawal severity and implicate cholinergic mechanisms in alcohol withdrawal.,12198388_12,1
4586,postsynaptic,106,118,"Specifically, WSP mice may have lower sensitivity to cholinergic convulsants compared with WSR because of postsynaptic receptor desensitization brought on by higher activity of cholinergic neurons.",12198388_13,1
2523,cholinergic convulsants,53,76,"Specifically, WSP mice may have lower sensitivity to cholinergic convulsants compared with WSR because of postsynaptic receptor desensitization brought on by higher activity of cholinergic neurons.",12198388_13,0
2524,WSR,91,94,"Specifically, WSP mice may have lower sensitivity to cholinergic convulsants compared with WSR because of postsynaptic receptor desensitization brought on by higher activity of cholinergic neurons.",12198388_13,0
2522,WSP,14,17,"Specifically, WSP mice may have lower sensitivity to cholinergic convulsants compared with WSR because of postsynaptic receptor desensitization brought on by higher activity of cholinergic neurons.",12198388_13,0
4582,alcohol withdrawal,75,93,"Thus, the relationship between cholinergic activity and responsiveness and alcohol withdrawal was investigated in a genetic animal model of ethanol withdrawal severity.",12198388_2,1
2498,withdrawal severity,148,167,"Thus, the relationship between cholinergic activity and responsiveness and alcohol withdrawal was investigated in a genetic animal model of ethanol withdrawal severity.",12198388_2,1
2500,alcohol-na  ve Withdrawal Seizure-Prone,60,99,METHODS: Cholinergic convulsant sensitivity was examined in alcohol-na  ve Withdrawal Seizure-Prone (WSP) and-Resistant (WSR) mice.,12198388_3,1
2499,Cholinergic convulsant,9,31,METHODS: Cholinergic convulsant sensitivity was examined in alcohol-na  ve Withdrawal Seizure-Prone (WSP) and-Resistant (WSR) mice.,12198388_3,0
618,carbachol,36,45,"Animals were administered nicotine, carbachol, or neostigmine via timed tail vein infusion, and the latencies to onset of tremor and clonus were recorded and converted to threshold dose.",12198388_4,0
4583,CA1,104,107,We also used microdialysis to measure basal and potassium-stimulated acetylcholine (ACh) release in the CA1 region of the hippocampus.,12198388_5,1
2504,microdialysis,13,26,We also used microdialysis to measure basal and potassium-stimulated acetylcholine (ACh) release in the CA1 region of the hippocampus.,12198388_5,1
619,ACh,84,87,We also used microdialysis to measure basal and potassium-stimulated acetylcholine (ACh) release in the CA1 region of the hippocampus.,12198388_5,0
2506,handling-induced convulsions,53,81,Hippocampal ACh also was measured during testing for handling-induced convulsions.,12198388_7,0
620,carbachol,74,83,"RESULTS: Sensitivity to several convulsion endpoints induced by nicotine, carbachol, and neostigmine were significantly greater in WSR versus WSP mice.",12198388_8,0
2508,WSP,142,145,"RESULTS: Sensitivity to several convulsion endpoints induced by nicotine, carbachol, and neostigmine were significantly greater in WSR versus WSP mice.",12198388_8,0
2510,KCl,90,93,"In microdialysis experiments, the lines did not differ in basal release of ACh, and 50 mM KCl increased ACh output in both lines of mice.",12198388_9,0
621,ACh,75,78,"In microdialysis experiments, the lines did not differ in basal release of ACh, and 50 mM KCl increased ACh output in both lines of mice.",12198388_9,0
622,ACh,104,107,"In microdialysis experiments, the lines did not differ in basal release of ACh, and 50 mM KCl increased ACh output in both lines of mice.",12198388_9,0
2509,microdialysis,3,16,"In microdialysis experiments, the lines did not differ in basal release of ACh, and 50 mM KCl increased ACh output in both lines of mice.",12198388_9,1
4587,muscle pain,18,29,Capsaicin-induced muscle pain alters the excitability of the human jaw-stretch reflex.,12202650_0,1
2525,jaw-stretch reflex,67,85,Capsaicin-induced muscle pain alters the excitability of the human jaw-stretch reflex.,12202650_0,1
4590,muscle pain,111,122,"The pathophysiology of painful temporomandibular disorders is not fully understood, but evidence suggests that muscle pain modulates motor function in characteristic ways.",12202650_1,1
4589,temporomandibular disorders,31,58,"The pathophysiology of painful temporomandibular disorders is not fully understood, but evidence suggests that muscle pain modulates motor function in characteristic ways.",12202650_1,1
2526,motor function,133,147,"The pathophysiology of painful temporomandibular disorders is not fully understood, but evidence suggests that muscle pain modulates motor function in characteristic ways.",12202650_1,1
4588,pathophysiology,4,19,"The pathophysiology of painful temporomandibular disorders is not fully understood, but evidence suggests that muscle pain modulates motor function in characteristic ways.",12202650_1,1
2528,jaw-stretch reflex,145,163,This study tested the hypothesis that activation of nociceptive muscle afferent fibers would be linked to an increased excitability of the human jaw-stretch reflex and whether this process would be sensitive to length and velocity of the stretch.,12202650_2,1
4591,masseter muscle,45,60,Capsaicin (10 micro g) was injected into the masseter muscle to induce pain in 11 healthy volunteers.,12202650_3,1
2529,micro g,14,21,Capsaicin (10 micro g) was injected into the masseter muscle to induce pain in 11 healthy volunteers.,12202650_3,0
2537,painful muscle,106,120,"The normalized reflex amplitude was significantly higher during pain, but only at faster stretches in the painful muscle.",12202650_6,1
4592,muscle pain,59,70,Increased sensitivity of the fusimotor system during acute muscle pain could be one likely mechanism to explain the findings.,12202650_7,1
2540,mGluR1,68,74,"The striatum as a target for anti-rigor effects of an antagonist of mGluR1, but not an agonist of group II metabotropic glutamate receptors.",12231232_0,0
2539,anti-rigor effects,29,47,"The striatum as a target for anti-rigor effects of an antagonist of mGluR1, but not an agonist of group II metabotropic glutamate receptors.",12231232_0,0
2541,group II metabotropic glutamate receptors,98,139,"The striatum as a target for anti-rigor effects of an antagonist of mGluR1, but not an agonist of group II metabotropic glutamate receptors.",12231232_0,0
2545,mGluRs,103,109,"The aim of the present study was to find out whether the metabotropic receptor 1 (mGluR1) and group II mGluRs, localized in the striatum, are involved in antiparkinsonian-like effects in rats.",12231232_1,0
2544,group II,94,102,"The aim of the present study was to find out whether the metabotropic receptor 1 (mGluR1) and group II mGluRs, localized in the striatum, are involved in antiparkinsonian-like effects in rats.",12231232_1,0
2543,mGluR1,82,88,"The aim of the present study was to find out whether the metabotropic receptor 1 (mGluR1) and group II mGluRs, localized in the striatum, are involved in antiparkinsonian-like effects in rats.",12231232_1,0
2542,metabotropic receptor 1,57,80,"The aim of the present study was to find out whether the metabotropic receptor 1 (mGluR1) and group II mGluRs, localized in the striatum, are involved in antiparkinsonian-like effects in rats.",12231232_1,0
625,(1,12,14,"Haloperidol (1 mg/kg ip) induced parkinsonian-like muscle rigidity, measured as an increased resistance of a rat's hind foot to passive flexion and extension at the ankle joint.",12231232_2,0
4593,muscle rigidity,51,66,"Haloperidol (1 mg/kg ip) induced parkinsonian-like muscle rigidity, measured as an increased resistance of a rat's hind foot to passive flexion and extension at the ankle joint.",12231232_2,1
2548,ankle joint,165,176,"Haloperidol (1 mg/kg ip) induced parkinsonian-like muscle rigidity, measured as an increased resistance of a rat's hind foot to passive flexion and extension at the ankle joint.",12231232_2,1
2555,group II,216,224,"(RS)-1-aminoindan-1,5-dicarboxylic acid (AIDA; 0.5-15 microg/0.5 microl), a potent and selective mGluR1 antagonist, or (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate (2R,4R-APDC; 7.5-15 microg/0.5 microl), a selective group II agonist, was injected bilaterally into the striatum of haloperidol-treated animals.",12231232_3,0
2553,"(2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate",119,163,"(RS)-1-aminoindan-1,5-dicarboxylic acid (AIDA; 0.5-15 microg/0.5 microl), a potent and selective mGluR1 antagonist, or (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate (2R,4R-APDC; 7.5-15 microg/0.5 microl), a selective group II agonist, was injected bilaterally into the striatum of haloperidol-treated animals.",12231232_3,0
2552,mGluR1,97,103,"(RS)-1-aminoindan-1,5-dicarboxylic acid (AIDA; 0.5-15 microg/0.5 microl), a potent and selective mGluR1 antagonist, or (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate (2R,4R-APDC; 7.5-15 microg/0.5 microl), a selective group II agonist, was injected bilaterally into the striatum of haloperidol-treated animals.",12231232_3,0
2549,"(RS)-1-aminoindan-1,5-dicarboxylic acid",0,39,"(RS)-1-aminoindan-1,5-dicarboxylic acid (AIDA; 0.5-15 microg/0.5 microl), a potent and selective mGluR1 antagonist, or (2R,4R)-4-aminopyrrolidine-2,4-dicarboxylate (2R,4R-APDC; 7.5-15 microg/0.5 microl), a selective group II agonist, was injected bilaterally into the striatum of haloperidol-treated animals.",12231232_3,0
4594,muscle rigidity,77,92,AIDA in doses of 7.5-15 microg/0.5 microl diminished the haloperidol-induced muscle rigidity.,12231232_4,1
4595,muscle rigidity,142,157,"The present results may suggest that the blockade of striatal mGluR1, but not the stimulation of group II mGluRs, may ameliorate parkinsonian muscle rigidity.",12231232_6,1
2559,mGluRs,106,112,"The present results may suggest that the blockade of striatal mGluR1, but not the stimulation of group II mGluRs, may ameliorate parkinsonian muscle rigidity.",12231232_6,0
2558,group II,97,105,"The present results may suggest that the blockade of striatal mGluR1, but not the stimulation of group II mGluRs, may ameliorate parkinsonian muscle rigidity.",12231232_6,0
2557,striatal mGluR1,53,68,"The present results may suggest that the blockade of striatal mGluR1, but not the stimulation of group II mGluRs, may ameliorate parkinsonian muscle rigidity.",12231232_6,0
626,receptor ligands,18,34,Effects of 5-HT1B receptor ligands microinjected into the accumbal shell or core on the cocaine-induced locomotor hyperactivity in rats.,12369736_0,0
2563,cocaine-induced locomotor hyperactivity,88,127,Effects of 5-HT1B receptor ligands microinjected into the accumbal shell or core on the cocaine-induced locomotor hyperactivity in rats.,12369736_0,1
2566,locomotor hyperactivity,171,194,The present study was designed to examine the effect of 5-HT1B receptor ligands microinjected into the subregions of the nucleus accumbens (the shell and the core) on the locomotor hyperactivity induced by cocaine in rats.,12369736_1,1
627,receptor ligands,63,79,The present study was designed to examine the effect of 5-HT1B receptor ligands microinjected into the subregions of the nucleus accumbens (the shell and the core) on the locomotor hyperactivity induced by cocaine in rats.,12369736_1,0
2592,5-HT1B receptors,68,84,"In other words, the present results suggest that the accumbal shell 5-HT1B receptors play a permissive role in the behavioural response to the psychostimulant.",12369736_10,0
2594,psychostimulant,143,158,"In other words, the present results suggest that the accumbal shell 5-HT1B receptors play a permissive role in the behavioural response to the psychostimulant.",12369736_10,0
2571,5-HT1B receptors,155,171,"Male Wistar rats were implanted bilaterally with cannulae into the accumbens shell or core, and then were locally injected with GR 55562 (an antagonist of 5-HT1B receptors) or CP 93129 (an agonist of 5-HT1B receptors).",12369736_2,0
628,CP,176,178,"Male Wistar rats were implanted bilaterally with cannulae into the accumbens shell or core, and then were locally injected with GR 55562 (an antagonist of 5-HT1B receptors) or CP 93129 (an agonist of 5-HT1B receptors).",12369736_2,0
2570,GR,128,130,"Male Wistar rats were implanted bilaterally with cannulae into the accumbens shell or core, and then were locally injected with GR 55562 (an antagonist of 5-HT1B receptors) or CP 93129 (an agonist of 5-HT1B receptors).",12369736_2,0
2572,5-HT1B receptors,200,216,"Male Wistar rats were implanted bilaterally with cannulae into the accumbens shell or core, and then were locally injected with GR 55562 (an antagonist of 5-HT1B receptors) or CP 93129 (an agonist of 5-HT1B receptors).",12369736_2,0
2574,GR,39,41,"Given alone to any accumbal subregion, GR 55562 (0.1-10 microg/side) or CP 93129 (0.1-10 microg/side) did not change basal locomotor activity.",12369736_3,0
629,CP,72,74,"Given alone to any accumbal subregion, GR 55562 (0.1-10 microg/side) or CP 93129 (0.1-10 microg/side) did not change basal locomotor activity.",12369736_3,0
2576,Systemic cocaine,0,16,Systemic cocaine (10 mg/kg) significantly increased the locomotor activity of rats.,12369736_4,0
2578,GR,0,2,"GR 55562 (0.1-10 microg/side), administered intra-accumbens shell prior to cocaine, dose-dependently attenuated the psychostimulant-induced locomotor hyperactivity.",12369736_5,0
2580,psychostimulant-induced locomotor hyperactivity,116,163,"GR 55562 (0.1-10 microg/side), administered intra-accumbens shell prior to cocaine, dose-dependently attenuated the psychostimulant-induced locomotor hyperactivity.",12369736_5,1
2581,GR,71,73,Such attenuation was not found in animals which had been injected with GR 55562 into the accumbens core.,12369736_6,0
630,CP,74,76,"When injected into the accumbens shell (but not the core) before cocaine, CP 93129 (0.1-10 microg/side) enhanced the locomotor response to cocaine; the maximum effect being observed after 10 microg/side of the agonist.",12369736_7,0
631,(1,89,91,The later enhancement was attenuated after intra-accumbens shell treatment with GR 55562 (1 microg/side).,12369736_8,0
2586,GR,80,82,The later enhancement was attenuated after intra-accumbens shell treatment with GR 55562 (1 microg/side).,12369736_8,0
634,CP,278,280,"Our findings indicate that cocaine induced hyperlocomotion is modified by 5-HT1B receptor ligands microinjected into the accumbens shell, but not core, this modification consisting in inhibitory and facilitatory effects of the 5-HT1B receptor antagonist (GR 55562) and agonist (CP 93129), respectively.",12369736_9,0
633,receptor antagonist,234,253,"Our findings indicate that cocaine induced hyperlocomotion is modified by 5-HT1B receptor ligands microinjected into the accumbens shell, but not core, this modification consisting in inhibitory and facilitatory effects of the 5-HT1B receptor antagonist (GR 55562) and agonist (CP 93129), respectively.",12369736_9,0
632,receptor ligands,81,97,"Our findings indicate that cocaine induced hyperlocomotion is modified by 5-HT1B receptor ligands microinjected into the accumbens shell, but not core, this modification consisting in inhibitory and facilitatory effects of the 5-HT1B receptor antagonist (GR 55562) and agonist (CP 93129), respectively.",12369736_9,0
2590,GR,255,257,"Our findings indicate that cocaine induced hyperlocomotion is modified by 5-HT1B receptor ligands microinjected into the accumbens shell, but not core, this modification consisting in inhibitory and facilitatory effects of the 5-HT1B receptor antagonist (GR 55562) and agonist (CP 93129), respectively.",12369736_9,0
4596,chest pain,16,26,Cocaine related chest pain: are we seeing the tip of an iceberg?The recreational use of cocaine is on the increase.,12443032_0,1
2595,cocaine use,89,100,The emergency nurse ought to be familiar with some of the cardiovascular consequences of cocaine use.,12443032_1,1
4598,chest pain,142,152,"In particular, the tendency of cocaine to produce chest pain ought to be in the mind of the emergency nurse when faced with a young victim of chest pain who is otherwise at low risk.",12443032_2,1
4597,chest pain,50,60,"In particular, the tendency of cocaine to produce chest pain ought to be in the mind of the emergency nurse when faced with a young victim of chest pain who is otherwise at low risk.",12443032_2,1
2597,cocaine use,39,50,The mechanism of chest pain related to cocaine use is discussed and treatment dilemmas are discussed.,12443032_3,1
4599,chest pain,17,27,The mechanism of chest pain related to cocaine use is discussed and treatment dilemmas are discussed.,12443032_3,1
4600,renal cell carcinoma,55,75,A phase II study of thalidomide in advanced metastatic renal cell carcinoma.,12448656_0,1
4601,renal cell cancer,102,119,"OBJECTIVES: To evaluate the toxicity and activity of thalidomide in patients with advanced metastatic renal cell cancer and to measure changes of one angiogenic factor, vascular endothelial growth factor (VEGF)165, with therapy.",12448656_1,1
636,vascular endothelial growth factor,169,203,"OBJECTIVES: To evaluate the toxicity and activity of thalidomide in patients with advanced metastatic renal cell cancer and to measure changes of one angiogenic factor, vascular endothelial growth factor (VEGF)165, with therapy.",12448656_1,0
635,angiogenic factor,150,167,"OBJECTIVES: To evaluate the toxicity and activity of thalidomide in patients with advanced metastatic renal cell cancer and to measure changes of one angiogenic factor, vascular endothelial growth factor (VEGF)165, with therapy.",12448656_1,0
2602,(VEGF)165,204,213,"OBJECTIVES: To evaluate the toxicity and activity of thalidomide in patients with advanced metastatic renal cell cancer and to measure changes of one angiogenic factor, vascular endothelial growth factor (VEGF)165, with therapy.",12448656_1,0
2611,lower doses,101,112,"Administration of doses over 800 mg/day was difficult to achieve in this patient population, however lower doses were practical.",12448656_10,0
4603,renal cell carcinoma,59,79,"The dose-response relationship, if any, of thalidomide for renal cell carcinoma is unclear.",12448656_11,1
637,IL-2,62,66,Fifty-nine per cent of patients had had previous therapy with IL-2 and 52% were performance status 2 or 3.,12448656_4,0
2604,VEGF165,16,23,Systemic plasma VEGF165 levels were measured by dual monoclonal ELISA in 8 patients.,12448656_5,0
2605,monoclonal ELISA,53,69,Systemic plasma VEGF165 levels were measured by dual monoclonal ELISA in 8 patients.,12448656_5,0
2608,minor response,158,172,"RESULTS: 24 patients were evaluable for response with one partial response of 11 months duration of a patient with hepatic and pulmonary metastases (4%), one minor response, and 2 patients stable for over 6 months.",12448656_6,1
2607,pulmonary metastases,127,147,"RESULTS: 24 patients were evaluable for response with one partial response of 11 months duration of a patient with hepatic and pulmonary metastases (4%), one minor response, and 2 patients stable for over 6 months.",12448656_6,1
2606,partial response,58,74,"RESULTS: 24 patients were evaluable for response with one partial response of 11 months duration of a patient with hepatic and pulmonary metastases (4%), one minor response, and 2 patients stable for over 6 months.",12448656_6,1
2609,VEGF165,16,23,Systemic plasma VEGF165 levels did not change with therapy.,12448656_8,0
638,low level,48,57,CONCLUSION: These results are consistent with a low level of activity of thalidomide in renal cell carcinoma.,12448656_9,0
4602,renal cell carcinoma,88,108,CONCLUSION: These results are consistent with a low level of activity of thalidomide in renal cell carcinoma.,12448656_9,1
2616,gynecological surgery,237,258,Can lidocaine reduce succinylcholine induced postoperative myalgia?This study was undertaken to determine the effect of lidocaine pretreatment on reduction of succinylcholine-induced myalgia in patients undergoing general anesthesia for gynecological surgery.,12452237_0,1
4609,muscle fasciculation,83,103,A correlation was not found between the incidence of myalgia and the occurrence of muscle fasciculation.,12452237_10,1
2631,heart rate,57,67,The changes in systolic and diastolic blood pressure and heart rate were not significant among the three groups.,12452237_11,1
4610,blood pressure,38,52,The changes in systolic and diastolic blood pressure and heart rate were not significant among the three groups.,12452237_11,1
2633,postoperative myalgia,123,144,"In conclusion, where succinylcholine is used, lidocaine is proven to be the useful pretreatment agent for the reduction of postoperative myalgia.",12452237_12,1
640,normal saline,172,185,"Group PS, the control group, received normal saline and succinylcholine 1.5 mg x kg(-1); Group LS, lidocaine 1.5 mg x kg(-1) and succinylcholine 1.5 mg x kg(-1); Group PR, normal saline and rocuronium 0.6 mg x kg(-1).",12452237_2,0
641,rocuronium,190,200,"Group PS, the control group, received normal saline and succinylcholine 1.5 mg x kg(-1); Group LS, lidocaine 1.5 mg x kg(-1) and succinylcholine 1.5 mg x kg(-1); Group PR, normal saline and rocuronium 0.6 mg x kg(-1).",12452237_2,0
2620,Group PR,162,170,"Group PS, the control group, received normal saline and succinylcholine 1.5 mg x kg(-1); Group LS, lidocaine 1.5 mg x kg(-1) and succinylcholine 1.5 mg x kg(-1); Group PR, normal saline and rocuronium 0.6 mg x kg(-1).",12452237_2,0
639,normal saline,38,51,"Group PS, the control group, received normal saline and succinylcholine 1.5 mg x kg(-1); Group LS, lidocaine 1.5 mg x kg(-1) and succinylcholine 1.5 mg x kg(-1); Group PR, normal saline and rocuronium 0.6 mg x kg(-1).",12452237_2,0
2621,premedication,42,55,"Morphine 0.1 mg x kg(-1) iv was given for premedication and all patients were monitored with a noninvasive blood pressure monitor, ECG and pulse oximetry.",12452237_3,0
4604,blood pressure,107,121,"Morphine 0.1 mg x kg(-1) iv was given for premedication and all patients were monitored with a noninvasive blood pressure monitor, ECG and pulse oximetry.",12452237_3,1
2623,Group PS,84,92,"Anesthesia was induced with 5 mg.kg(-1) thiopental iv. followed by succinylcholine (Group PS, LS) or rocuronium (Group PR) for tracheal intubation.",12452237_4,0
2624,Group PR,113,121,"Anesthesia was induced with 5 mg.kg(-1) thiopental iv. followed by succinylcholine (Group PS, LS) or rocuronium (Group PR) for tracheal intubation.",12452237_4,0
642,rocuronium,101,111,"Anesthesia was induced with 5 mg.kg(-1) thiopental iv. followed by succinylcholine (Group PS, LS) or rocuronium (Group PR) for tracheal intubation.",12452237_4,0
2625,tracheal intubation,127,146,"Anesthesia was induced with 5 mg.kg(-1) thiopental iv. followed by succinylcholine (Group PS, LS) or rocuronium (Group PR) for tracheal intubation.",12452237_4,1
2626,drug administered,172,189,"Following administration of these agents, the presence, and degree of fasciculation were assessed visually on a four point scale by one investigator who was blinded to the drug administered.",12452237_5,0
2627,heart rate,23,33,The blood pressure and heart rate of each patient were monitored on nine occasions.,12452237_6,1
4605,blood pressure,4,18,The blood pressure and heart rate of each patient were monitored on nine occasions.,12452237_6,1
4606,intraoperative,169,183,"Twenty-four hours later, any myalgia experienced was assessed according to a structured questionaire and graded by a four point scale by one investigator blinded to the intraoperative management.",12452237_7,1
4607,muscle fasciculation,26,46,The results indicate that muscle fasciculation was not found in Group PR while the patients in Group LS had a lower incidence of muscle fasciculation than those in Group PS (p < 0.001).,12452237_8,1
4608,muscle fasciculation,129,149,The results indicate that muscle fasciculation was not found in Group PR while the patients in Group LS had a lower incidence of muscle fasciculation than those in Group PS (p < 0.001).,12452237_8,1
2629,Group PS,164,172,The results indicate that muscle fasciculation was not found in Group PR while the patients in Group LS had a lower incidence of muscle fasciculation than those in Group PS (p < 0.001).,12452237_8,0
2628,Group PR,64,72,The results indicate that muscle fasciculation was not found in Group PR while the patients in Group LS had a lower incidence of muscle fasciculation than those in Group PS (p < 0.001).,12452237_8,0
2630,Group PS,48,56,"At 24 h, the incidence of myalgia was higher in Group PS than in Group LS and PR (p < 0.05).",12452237_9,0
2635,ergotamine/caffeine,77,96,Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine.,12464714_0,0
2634,rizatriptan,52,63,Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine.,12464714_0,0
643,receptor agonist,39,55,Rizatriptan is a selective 5-HT(1B/1D) receptor agonist with rapid oral absorption and early onset of action in the acute treatment of migraine.,12464714_1,0
2636,Rizatriptan,0,11,Rizatriptan is a selective 5-HT(1B/1D) receptor agonist with rapid oral absorption and early onset of action in the acute treatment of migraine.,12464714_1,0
2666,rizatriptan,85,96,"More patients were (completely, very or somewhat) satisfied 2 h after treatment with rizatriptan (69.8%) than at 2 h after treatment with ergotamine/caffeine (38.6%, p < or = 0.001).",12464714_10,0
2667,ergotamine/caffeine,138,157,"More patients were (completely, very or somewhat) satisfied 2 h after treatment with rizatriptan (69.8%) than at 2 h after treatment with ergotamine/caffeine (38.6%, p < or = 0.001).",12464714_10,0
2669,rizatriptan,33,44,Recurrence rates were 31.4% with rizatriptan and 15.3% with ergotamine/caffeine.,12464714_11,0
2670,ergotamine/caffeine,60,79,Recurrence rates were 31.4% with rizatriptan and 15.3% with ergotamine/caffeine.,12464714_11,0
2674,ergotamine/caffeine,88,107,"The most common adverse events (incidence > or = 5% in one group) after rizatriptan and ergotamine/caffeine, respectively, were dizziness (6.7 and 5.3%), nausea (4.2 and 8.5%) and somnolence (5.5 and 2.3%).",12464714_13,0
2673,rizatriptan,72,83,"The most common adverse events (incidence > or = 5% in one group) after rizatriptan and ergotamine/caffeine, respectively, were dizziness (6.7 and 5.3%), nausea (4.2 and 8.5%) and somnolence (5.5 and 2.3%).",12464714_13,0
2672,adverse events,16,30,"The most common adverse events (incidence > or = 5% in one group) after rizatriptan and ergotamine/caffeine, respectively, were dizziness (6.7 and 5.3%), nausea (4.2 and 8.5%) and somnolence (5.5 and 2.3%).",12464714_13,1
2641,rizatriptan,87,98,This randomized double- blind crossover outpatient study assessed the preference for 1 rizatriptan 10 mg tablet to 2 ergotamine 1 mg/caffeine 100 mg tablets in 439 patients treating a single migraine attack with each therapy.,12464714_2,0
2642,mg/caffeine,130,141,This randomized double- blind crossover outpatient study assessed the preference for 1 rizatriptan 10 mg tablet to 2 ergotamine 1 mg/caffeine 100 mg tablets in 439 patients treating a single migraine attack with each therapy.,12464714_2,0
2644,ergotamine/caffeine,94,113,"Of patients expressing a preference (89.1%), more than twice as many preferred rizatriptan to ergotamine/caffeine (69.9 vs. 30.1%, p < or = 0.001).",12464714_3,0
2643,rizatriptan,79,90,"Of patients expressing a preference (89.1%), more than twice as many preferred rizatriptan to ergotamine/caffeine (69.9 vs. 30.1%, p < or = 0.001).",12464714_3,0
2646,ergotamine/caffeine,158,177,"Faster relief of headache was the most important reason for preference, cited by 67.3% of patients preferring rizatriptan and 54.2% of patients who preferred ergotamine/caffeine.",12464714_4,0
2645,rizatriptan,110,121,"Faster relief of headache was the most important reason for preference, cited by 67.3% of patients preferring rizatriptan and 54.2% of patients who preferred ergotamine/caffeine.",12464714_4,0
2648,rizatriptan,71,82,The co-primary endpoint of being pain free at 2 h was also in favor of rizatriptan.,12464714_5,0
2647,pain free,33,42,The co-primary endpoint of being pain free at 2 h was also in favor of rizatriptan.,12464714_5,1
2652,rizatriptan,140,151,"Forty-nine percent of patients were pain free 2 h after rizatriptan, compared with 24.3% treated with ergotamine/caffeine (p < or = 0.001), rizatriptan being superior within 1 h of treatment.",12464714_6,0
2651,ergotamine/caffeine,102,121,"Forty-nine percent of patients were pain free 2 h after rizatriptan, compared with 24.3% treated with ergotamine/caffeine (p < or = 0.001), rizatriptan being superior within 1 h of treatment.",12464714_6,0
2650,rizatriptan,56,67,"Forty-nine percent of patients were pain free 2 h after rizatriptan, compared with 24.3% treated with ergotamine/caffeine (p < or = 0.001), rizatriptan being superior within 1 h of treatment.",12464714_6,0
2649,pain free,36,45,"Forty-nine percent of patients were pain free 2 h after rizatriptan, compared with 24.3% treated with ergotamine/caffeine (p < or = 0.001), rizatriptan being superior within 1 h of treatment.",12464714_6,1
2655,rizatriptan,106,117,"Headache relief at 2 h was 75.9% for rizatriptan and 47.3% for ergotamine/caffeine (p < or = 0.001), with rizatriptan being superior to ergotamine/caffeine within 30 min of dosing.",12464714_7,0
2654,ergotamine/caffeine,63,82,"Headache relief at 2 h was 75.9% for rizatriptan and 47.3% for ergotamine/caffeine (p < or = 0.001), with rizatriptan being superior to ergotamine/caffeine within 30 min of dosing.",12464714_7,0
2656,ergotamine/caffeine,136,155,"Headache relief at 2 h was 75.9% for rizatriptan and 47.3% for ergotamine/caffeine (p < or = 0.001), with rizatriptan being superior to ergotamine/caffeine within 30 min of dosing.",12464714_7,0
2653,rizatriptan,37,48,"Headache relief at 2 h was 75.9% for rizatriptan and 47.3% for ergotamine/caffeine (p < or = 0.001), with rizatriptan being superior to ergotamine/caffeine within 30 min of dosing.",12464714_7,0
2660,ergotamine/caffeine,164,183,"Almost 36% of patients taking rizatriptan were pain free at 2 h and had no recurrence or need for additional medication within 24 h, compared to 20% of patients on ergotamine/caffeine (p < or = 0.001).",12464714_8,0
2657,rizatriptan,30,41,"Almost 36% of patients taking rizatriptan were pain free at 2 h and had no recurrence or need for additional medication within 24 h, compared to 20% of patients on ergotamine/caffeine (p < or = 0.001).",12464714_8,0
2658,pain free,47,56,"Almost 36% of patients taking rizatriptan were pain free at 2 h and had no recurrence or need for additional medication within 24 h, compared to 20% of patients on ergotamine/caffeine (p < or = 0.001).",12464714_8,1
2659,no recurrence,72,85,"Almost 36% of patients taking rizatriptan were pain free at 2 h and had no recurrence or need for additional medication within 24 h, compared to 20% of patients on ergotamine/caffeine (p < or = 0.001).",12464714_8,1
2663,"nausea, vomiting",92,108,"Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).",12464714_9,1
2661,Rizatriptan,0,11,"Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).",12464714_9,0
2662,ergotamine/caffeine,33,52,"Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).",12464714_9,0
2664,normal function,159,174,"Rizatriptan was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0.001).",12464714_9,1
644,sodium channel,8,22,"Reduced sodium channel density, altered voltage dependence of inactivation, and increased susceptibility to seizures in mice lacking sodium channel beta 2-subunits.",12481039_0,0
645,sodium channel,133,147,"Reduced sodium channel density, altered voltage dependence of inactivation, and increased susceptibility to seizures in mice lacking sodium channel beta 2-subunits.",12481039_0,0
646,Sodium channel,0,14,"Sodium channel beta-subunits modulate channel gating, assembly, and cell surface expression in heterologous cell systems.",12481039_1,0
647,cell surface,68,80,"Sodium channel beta-subunits modulate channel gating, assembly, and cell surface expression in heterologous cell systems.",12481039_1,0
648,beta2(-/-),13,23,"We generated beta2(-/-) mice to investigate the role of beta2 in control of sodium channel density, localization, and function in neurons in vivo.",12481039_2,0
649,beta2,56,61,"We generated beta2(-/-) mice to investigate the role of beta2 in control of sodium channel density, localization, and function in neurons in vivo.",12481039_2,0
650,sodium channel,76,90,"We generated beta2(-/-) mice to investigate the role of beta2 in control of sodium channel density, localization, and function in neurons in vivo.",12481039_2,0
2677,STX,33,36,Measurements of [(3)H]saxitoxin (STX) binding showed a significant reduction in the level of plasma membrane sodium channels in beta2(-/-) neurons.,12481039_3,0
2678,plasma membrane sodium channels,93,124,Measurements of [(3)H]saxitoxin (STX) binding showed a significant reduction in the level of plasma membrane sodium channels in beta2(-/-) neurons.,12481039_3,0
651,beta2(-/-),128,138,Measurements of [(3)H]saxitoxin (STX) binding showed a significant reduction in the level of plasma membrane sodium channels in beta2(-/-) neurons.,12481039_3,0
2676,[(3)H]saxitoxin,16,31,Measurements of [(3)H]saxitoxin (STX) binding showed a significant reduction in the level of plasma membrane sodium channels in beta2(-/-) neurons.,12481039_3,0
4611,hippocampal,170,181,The loss of beta2 resulted in negative shifts in the voltage dependence of inactivation as well as significant decreases in sodium current density in acutely dissociated hippocampal neurons.,12481039_4,1
2680,plasma membrane sodium channels,203,234,"The integral of the compound action potential in optic nerve was significantly reduced, and the threshold for action potential generation was increased, indicating a reduction in the level of functional plasma membrane sodium channels.",12481039_5,0
4612,optic nerve,49,60,"The integral of the compound action potential in optic nerve was significantly reduced, and the threshold for action potential generation was increased, indicating a reduction in the level of functional plasma membrane sodium channels.",12481039_5,1
4613,optic nerve,74,85,"In contrast, the conduction velocity, the number and size of axons in the optic nerve, and the specific localization of Na(v)1.6 channels in the nodes of Ranvier were unchanged.",12481039_6,1
2681,conduction velocity,17,36,"In contrast, the conduction velocity, the number and size of axons in the optic nerve, and the specific localization of Na(v)1.6 channels in the nodes of Ranvier were unchanged.",12481039_6,1
2682,Na(v)1.6 channels,120,137,"In contrast, the conduction velocity, the number and size of axons in the optic nerve, and the specific localization of Na(v)1.6 channels in the nodes of Ranvier were unchanged.",12481039_6,0
2683,Ranvier,154,161,"In contrast, the conduction velocity, the number and size of axons in the optic nerve, and the specific localization of Na(v)1.6 channels in the nodes of Ranvier were unchanged.",12481039_6,0
652,beta2(-/-),0,10,"beta2(-/-) mice displayed increased susceptibility to seizures, as indicated by reduced latency and threshold for pilocarpine-induced seizures, but seemed normal in other neurological tests.",12481039_7,0
2686,beta2-subunits,27,41,Our observations show that beta2-subunits play an important role in the regulation of sodium channel density and function in neurons in vivo and are required for normal action potential generation and control of excitability.,12481039_8,0
653,sodium channel,86,100,Our observations show that beta2-subunits play an important role in the regulation of sodium channel density and function in neurons in vivo and are required for normal action potential generation and control of excitability.,12481039_8,0
2688,recurrent glioblastomas,83,106,Severe ocular and orbital toxicity after intracarotid injection of carboplatin for recurrent glioblastomas.,12483326_0,1
654,carboplatin,67,78,Severe ocular and orbital toxicity after intracarotid injection of carboplatin for recurrent glioblastomas.,12483326_0,0
2689,malignant tumor,30,45,BACKGROUND: Glioblastoma is a malignant tumor that occurs in the cerebrum during adulthood.,12483326_1,1
2703,intraocular pressure elevation,13,43,"Although the intraocular pressure elevation caused by secondary acute angle-closure glaucoma decreased and ocular pain diminished, inexorable papilledema and exudative retinal detachment continued for 3 weeks.",12483326_10,1
2704,acute angle-closure,64,83,"Although the intraocular pressure elevation caused by secondary acute angle-closure glaucoma decreased and ocular pain diminished, inexorable papilledema and exudative retinal detachment continued for 3 weeks.",12483326_10,1
2705,ocular pain,107,118,"Although the intraocular pressure elevation caused by secondary acute angle-closure glaucoma decreased and ocular pain diminished, inexorable papilledema and exudative retinal detachment continued for 3 weeks.",12483326_10,1
2706,exudative retinal detachment,158,186,"Although the intraocular pressure elevation caused by secondary acute angle-closure glaucoma decreased and ocular pain diminished, inexorable papilledema and exudative retinal detachment continued for 3 weeks.",12483326_10,1
660,his,100,103,"Finally, 6 weeks later, diffuse chorioretinal atrophy with optic atrophy occurred and the vision in his left eye was lost.",12483326_11,0
4615,optic atrophy,59,72,"Finally, 6 weeks later, diffuse chorioretinal atrophy with optic atrophy occurred and the vision in his left eye was lost.",12483326_11,1
2707,diffuse chorioretinal atrophy,24,53,"Finally, 6 weeks later, diffuse chorioretinal atrophy with optic atrophy occurred and the vision in his left eye was lost.",12483326_11,1
2708,left eye,104,112,"Finally, 6 weeks later, diffuse chorioretinal atrophy with optic atrophy occurred and the vision in his left eye was lost.",12483326_11,1
2709,intracarotid,28,40,"CONCLUSION: When performing intracarotid injection of carboplatin, we must be aware of its potentially blinding ocular toxicity.",12483326_12,0
661,carboplatin,54,65,"CONCLUSION: When performing intracarotid injection of carboplatin, we must be aware of its potentially blinding ocular toxicity.",12483326_12,0
4616,ocular toxicity,112,127,"CONCLUSION: When performing intracarotid injection of carboplatin, we must be aware of its potentially blinding ocular toxicity.",12483326_12,1
4617,side effects,111,123,It is recommended that further studies and investigations are undertaken in the effort to minimize such severe side effects.,12483326_13,1
2692,life expectancy,100,115,"With current treatment regimens including combined surgery, radiation and chemotherapy, the average life expectancy of the patients is limited to approximately 1 year.",12483326_2,1
2695,carcinostatics,79,93,"Therefore, patients with glioblastoma sometimes have intracarotid injection of carcinostatics added to the treatment regimen.",12483326_3,0
2694,intracarotid,53,65,"Therefore, patients with glioblastoma sometimes have intracarotid injection of carcinostatics added to the treatment regimen.",12483326_3,0
2693,glioblastoma sometimes,25,47,"Therefore, patients with glioblastoma sometimes have intracarotid injection of carcinostatics added to the treatment regimen.",12483326_3,1
655,carboplatin,11,22,"Generally, carboplatin is said to have milder side effects than cisplatin, whose ocular and orbital toxicity are well known.",12483326_4,0
4614,side effects,46,58,"Generally, carboplatin is said to have milder side effects than cisplatin, whose ocular and orbital toxicity are well known.",12483326_4,1
656,cisplatin,64,73,"Generally, carboplatin is said to have milder side effects than cisplatin, whose ocular and orbital toxicity are well known.",12483326_4,0
657,carboplatin,101,112,"However, we experienced a case of severe ocular and orbital toxicity after intracarotid injection of carboplatin, which is infrequently reported.",12483326_5,0
2699,recurrent glioblastomas,78,101,CASE: A 58-year-old man received an intracarotid injection of carboplatin for recurrent glioblastomas in his left temporal lobe.,12483326_6,1
658,carboplatin,62,73,CASE: A 58-year-old man received an intracarotid injection of carboplatin for recurrent glioblastomas in his left temporal lobe.,12483326_6,0
2700,his left temporal lobe,105,127,CASE: A 58-year-old man received an intracarotid injection of carboplatin for recurrent glioblastomas in his left temporal lobe.,12483326_6,1
2701,visual disturbance,26,44,He complained of pain and visual disturbance in the ipsilateral eye 30 h after the injection.,12483326_7,1
659,carboplatin,47,58,Various ocular symptoms and findings caused by carboplatin toxicity were seen.,12483326_8,0
2702,ocular symptoms,8,23,Various ocular symptoms and findings caused by carboplatin toxicity were seen.,12483326_8,1
4618,Visual hallucinations,0,21,Visual hallucinations associated with zonisamide.,12523465_0,1
2711,zonisamide,38,48,Visual hallucinations associated with zonisamide.,12523465_0,0
662,antiepileptic drug,31,49,Zonisamide is a broad-spectrum antiepileptic drug used to treat various types of seizures.,12523465_1,0
2712,Zonisamide,0,10,Zonisamide is a broad-spectrum antiepileptic drug used to treat various types of seizures.,12523465_1,0
2715,zonisamide,195,205,"Although visual hallucinations have not been reported as an adverse effect of this agent, we describe three patients who experienced complex visual hallucinations and altered mental status after zonisamide treatment was begun or its dosage increased.",12523465_2,0
2713,adverse effect,60,74,"Although visual hallucinations have not been reported as an adverse effect of this agent, we describe three patients who experienced complex visual hallucinations and altered mental status after zonisamide treatment was begun or its dosage increased.",12523465_2,1
2714,mental status,175,188,"Although visual hallucinations have not been reported as an adverse effect of this agent, we describe three patients who experienced complex visual hallucinations and altered mental status after zonisamide treatment was begun or its dosage increased.",12523465_2,1
4620,visual hallucinations,141,162,"Although visual hallucinations have not been reported as an adverse effect of this agent, we describe three patients who experienced complex visual hallucinations and altered mental status after zonisamide treatment was begun or its dosage increased.",12523465_2,1
4619,visual hallucinations,9,30,"Although visual hallucinations have not been reported as an adverse effect of this agent, we describe three patients who experienced complex visual hallucinations and altered mental status after zonisamide treatment was begun or its dosage increased.",12523465_2,1
4621,visual hallucinations,19,40,"During monitoring, visual hallucinations did not correlate with EEG readings, nor did video recording capture any of the described events.",12523465_4,1
4622,visual hallucinations,37,58,None of the patients had experienced visual hallucinations before this event.,12523465_5,1
2716,zonisamide,86,96,The only recent change in their treatment was the introduction or increased dosage of zonisamide.,12523465_6,0
2717,adverse effect,56,70,Further observations and reports will help clarify this adverse effect.,12523465_8,1
2718,zonisamide,86,96,"Until then, clinicians need to be aware of this possible complication associated with zonisamide.",12523465_9,0
2719,novo absence seizures,32,53,Anti-epileptic drugs-induced de novo absence seizures.,12536034_0,1
663,vigabatrin,107,117,The authors present three patients with de novo absence epilepsy after administration of carbamazepine and vigabatrin.,12536034_1,0
2720,novo absence epilepsy,43,64,The authors present three patients with de novo absence epilepsy after administration of carbamazepine and vigabatrin.,12536034_1,1
2721,carbamazepine,89,102,The authors present three patients with de novo absence epilepsy after administration of carbamazepine and vigabatrin.,12536034_1,0
664,novo,67,71,"Despite the underlying diseases, the prognosis for drug-induced de novo absence seizure is good because it subsides rapidly after discontinuing the use of the offending drugs.",12536034_2,0
4624,absence seizure,72,87,"Despite the underlying diseases, the prognosis for drug-induced de novo absence seizure is good because it subsides rapidly after discontinuing the use of the offending drugs.",12536034_2,1
4623,drug-induced,51,63,"Despite the underlying diseases, the prognosis for drug-induced de novo absence seizure is good because it subsides rapidly after discontinuing the use of the offending drugs.",12536034_2,1
2722,offending drugs,159,174,"Despite the underlying diseases, the prognosis for drug-induced de novo absence seizure is good because it subsides rapidly after discontinuing the use of the offending drugs.",12536034_2,0
665,gamma-aminobutyric,4,22,The gamma-aminobutyric acid-transmitted thalamocortical circuitry accounts for a major part of the underlying neurophysiology of the absence epilepsy.,12536034_3,0
4625,absence epilepsy,133,149,The gamma-aminobutyric acid-transmitted thalamocortical circuitry accounts for a major part of the underlying neurophysiology of the absence epilepsy.,12536034_3,1
666,novo,24,28,"Because drug-induced de novo absence seizure is rare, pro-absence drugs can only be considered a promoting factor.",12536034_4,0
4627,absence seizure,29,44,"Because drug-induced de novo absence seizure is rare, pro-absence drugs can only be considered a promoting factor.",12536034_4,1
4626,drug-induced,8,20,"Because drug-induced de novo absence seizure is rare, pro-absence drugs can only be considered a promoting factor.",12536034_4,1
667,novo,131,135,The underlying epileptogenecity of the patients or the synergistic effects of the accompanying drugs is required to trigger the de novo absence seizure.,12536034_5,0
4628,drug-induced,19,31,The possibility of drug-induced aggravation should be considered whenever an unexpected increase in seizure frequency and/or new seizure types appear following a change in drug treatment.,12536034_6,1
2725,drug-induced absence seizures,155,184,"By understanding the underlying mechanism of absence epilepsy, we can avoid the inappropriate use of anticonvulsants in children with epilepsy and prevent drug-induced absence seizures.",12536034_7,1
4629,absence epilepsy,45,61,"By understanding the underlying mechanism of absence epilepsy, we can avoid the inappropriate use of anticonvulsants in children with epilepsy and prevent drug-induced absence seizures.",12536034_7,1
2726,carbimazole,50,61,Acute liver failure with concurrent bupropion and carbimazole therapy.,12549952_0,0
668,bupropion,36,45,Acute liver failure with concurrent bupropion and carbimazole therapy.,12549952_0,0
4630,Acute liver failure,0,19,Acute liver failure with concurrent bupropion and carbimazole therapy.,12549952_0,1
4631,liver failure,37,50,OBJECTIVE: To report a case of fatal liver failure possibly associated with concurrent use of bupropion and carbimazole.,12549952_1,1
2728,carbimazole,108,119,OBJECTIVE: To report a case of fatal liver failure possibly associated with concurrent use of bupropion and carbimazole.,12549952_1,0
669,bupropion,94,103,OBJECTIVE: To report a case of fatal liver failure possibly associated with concurrent use of bupropion and carbimazole.,12549952_1,0
4636,acute liver,62,73,CONCLUSIONS: Clinicians should be aware of the possibility of acute liver insult induced by bupropion given concurrently with other hepatotoxic drugs.,12549952_10,1
676,bupropion,92,101,CONCLUSIONS: Clinicians should be aware of the possibility of acute liver insult induced by bupropion given concurrently with other hepatotoxic drugs.,12549952_10,0
2738,hepatotoxic drugs,132,149,CONCLUSIONS: Clinicians should be aware of the possibility of acute liver insult induced by bupropion given concurrently with other hepatotoxic drugs.,12549952_10,0
670,propranolol,112,123,CASE SUMMARY: A 41-year-old Chinese man with a history of hyperthyroidism had been treated with carbimazole and propranolol for the past 5 years.,12549952_2,0
2729,carbimazole,96,107,CASE SUMMARY: A 41-year-old Chinese man with a history of hyperthyroidism had been treated with carbimazole and propranolol for the past 5 years.,12549952_2,0
2730,smoking cessation,55,72,He received a 10-day course of bupropion as an aid for smoking cessation 10 weeks prior to presentation.,12549952_3,1
671,bupropion,31,40,He received a 10-day course of bupropion as an aid for smoking cessation 10 weeks prior to presentation.,12549952_3,0
4632,acute liver failure,13,32,He developed acute liver failure with rapid deterioration of renal function.,12549952_4,1
2731,renal function,61,75,He developed acute liver failure with rapid deterioration of renal function.,12549952_4,1
4633,drug-induced acute liver injury,44,75,Liver biopsy showed evidence of nonspecific drug-induced acute liver injury.,12549952_5,1
672,His,0,3,His condition was further complicated by sepsis and coagulopathy.,12549952_6,0
4634,coagulopathy,52,64,His condition was further complicated by sepsis and coagulopathy.,12549952_6,1
2733,onset of,33,41,Death resulted 19 days after the onset of symptoms.,12549952_7,1
2734,hepatotoxicity,38,52,"The likelihood that bupropion induced hepatotoxicity in our patient was possible, based on the Naranjo probability scale.",12549952_8,1
673,bupropion,20,29,"The likelihood that bupropion induced hepatotoxicity in our patient was possible, based on the Naranjo probability scale.",12549952_8,0
2736,hepatotoxicity,53,67,"DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole.",12549952_9,1
2737,carbimazole,244,255,"DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole.",12549952_9,0
4635,acute liver failure,155,174,"DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole.",12549952_9,1
675,bupropion,198,207,"DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole.",12549952_9,0
674,bupropion,79,88,"DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole.",12549952_9,0
2739,Pyeloureteral filling defects,0,29,Pyeloureteral filling defects associated with systemic anticoagulation: a case report.,1255900_0,1
2741,systemic anticoagulation,46,70,Pyeloureteral filling defects associated with systemic anticoagulation: a case report.,1255900_0,0
2743,pyeloureteritis cystica,16,39,The etiology of pyeloureteritis cystica has long been attributed to chronic infection and inflammation.,1255900_1,1
4637,chronic infection,68,85,The etiology of pyeloureteritis cystica has long been attributed to chronic infection and inflammation.,1255900_1,1
4638,acute onset,47,58,A case is presented that is unique in that the acute onset and the rapid resolution of pyeloureteral filling defects in this patient were documented by radiography.,1255900_2,1
2744,pyeloureteral filling defects,87,116,A case is presented that is unique in that the acute onset and the rapid resolution of pyeloureteral filling defects in this patient were documented by radiography.,1255900_2,1
2746,pelvic thrombophlebitis,83,106,The disease occurred subsequent to the initiation of heparin therapy for suspected pelvic thrombophlebitis and cleared rapidly subsequent to its discontinuation.,1255900_4,1
2748,submucosal hemorrhage,126,147,The rate of resolution of the radiographic findings may be helpful in distinguishing between true pyeloureteritis cystica and submucosal hemorrhage.,1255900_5,1
2747,true pyeloureteritis cystica,93,121,The rate of resolution of the radiographic findings may be helpful in distinguishing between true pyeloureteritis cystica and submucosal hemorrhage.,1255900_5,1
2750,contrast medium,33,48,BACKGROUND: The use of iodinated contrast medium can result in nephropathy.,12571256_1,0
2768,iodixanol,21,30,"No patient receiving iodixanol had an increase of 1.0 mg per deciliter or more, but 10 patients in the iohexol group (15 percent) did.",12571256_10,0
691,iohexol,103,110,"No patient receiving iodixanol had an increase of 1.0 mg per deciliter or more, but 10 patients in the iohexol group (15 percent) did.",12571256_10,0
693,iohexol,150,157,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,0
692,creatinine,23,33,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,0
2769,iodixanol,101,110,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,0
694,iohexol,226,233,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,0
2770,iodixanol,187,196,"The mean change in the creatinine concentration from day 0 to day 7 was 0.07 mg per deciliter in the iodixanol group and 0.24 mg per deciliter in the iohexol group (P=0.003; value in the iodixanol group minus the value in the iohexol group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]).",12571256_11,0
2774,nonionic contrast medium,154,178,"CONCLUSIONS: Nephropathy induced by contrast medium may be less likely to develop in high-risk patients when iodixanol is used rather than a low-osmolar, nonionic contrast medium.",12571256_12,0
2772,iodixanol,109,118,"CONCLUSIONS: Nephropathy induced by contrast medium may be less likely to develop in high-risk patients when iodixanol is used rather than a low-osmolar, nonionic contrast medium.",12571256_12,0
2773,low-osmolar,141,152,"CONCLUSIONS: Nephropathy induced by contrast medium may be less likely to develop in high-risk patients when iodixanol is used rather than a low-osmolar, nonionic contrast medium.",12571256_12,0
2771,contrast medium,36,51,"CONCLUSIONS: Nephropathy induced by contrast medium may be less likely to develop in high-risk patients when iodixanol is used rather than a low-osmolar, nonionic contrast medium.",12571256_12,0
2759,monomeric contrast medium,219,244,"METHODS: We conducted a randomized, double-blind, prospective, multicenter study comparing the nephrotoxic effects of an iso-osmolar, dimeric, nonionic contrast medium, iodixanol, with those of a low-osmolar, nonionic, monomeric contrast medium, iohexol.",12571256_3,0
2758,low-osmolar,196,207,"METHODS: We conducted a randomized, double-blind, prospective, multicenter study comparing the nephrotoxic effects of an iso-osmolar, dimeric, nonionic contrast medium, iodixanol, with those of a low-osmolar, nonionic, monomeric contrast medium, iohexol.",12571256_3,0
2757,iodixanol,169,178,"METHODS: We conducted a randomized, double-blind, prospective, multicenter study comparing the nephrotoxic effects of an iso-osmolar, dimeric, nonionic contrast medium, iodixanol, with those of a low-osmolar, nonionic, monomeric contrast medium, iohexol.",12571256_3,0
2756,nonionic contrast medium,143,167,"METHODS: We conducted a randomized, double-blind, prospective, multicenter study comparing the nephrotoxic effects of an iso-osmolar, dimeric, nonionic contrast medium, iodixanol, with those of a low-osmolar, nonionic, monomeric contrast medium, iohexol.",12571256_3,0
2755,"iso-osmolar, dimeric",121,141,"METHODS: We conducted a randomized, double-blind, prospective, multicenter study comparing the nephrotoxic effects of an iso-osmolar, dimeric, nonionic contrast medium, iodixanol, with those of a low-osmolar, nonionic, monomeric contrast medium, iohexol.",12571256_3,0
677,iohexol,246,253,"METHODS: We conducted a randomized, double-blind, prospective, multicenter study comparing the nephrotoxic effects of an iso-osmolar, dimeric, nonionic contrast medium, iodixanol, with those of a low-osmolar, nonionic, monomeric contrast medium, iohexol.",12571256_3,0
678,creatinine,57,67,The study involved 129 patients with diabetes with serum creatinine concentrations of 1.5 to 3.5 mg per deciliter who underwent coronary or aortofemoral angiography.,12571256_4,0
679,end point,12,21,The primary end point was the peak increase from base line in the creatinine concentration during the three days after angiography.,12571256_5,0
680,creatinine,66,76,The primary end point was the peak increase from base line in the creatinine concentration during the three days after angiography.,12571256_5,0
682,creatinine,41,51,"Other end points were an increase in the creatinine concentration of 0.5 mg per deciliter or more, an increase of 1.0 mg per deciliter or more, and a change in the creatinine concentration from day 0 to day 7.",12571256_6,0
681,end points,6,16,"Other end points were an increase in the creatinine concentration of 0.5 mg per deciliter or more, an increase of 1.0 mg per deciliter or more, and a change in the creatinine concentration from day 0 to day 7.",12571256_6,0
683,creatinine,164,174,"Other end points were an increase in the creatinine concentration of 0.5 mg per deciliter or more, an increase of 1.0 mg per deciliter or more, and a change in the creatinine concentration from day 0 to day 7.",12571256_6,0
2762,iodixanol,92,101,RESULTS: The creatinine concentration increased significantly less in patients who received iodixanol.,12571256_7,0
684,creatinine,13,23,RESULTS: The creatinine concentration increased significantly less in patients who received iodixanol.,12571256_7,0
685,creatinine,47,57,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,0
686,iohexol,140,147,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,0
687,iohexol,216,223,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,0
2765,iodixanol,182,191,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,0
2764,iodixanol,91,100,"From day 0 to day 3, the mean peak increase in creatinine was 0.13 mg per deciliter in the iodixanol group and 0.55 mg per deciliter in the iohexol group (P=0.001; the increase with iodixanol minus the increase with iohexol, -0.42 mg per deciliter [95 percent confidence interval, -0.73 to -0.22]).",12571256_8,0
2766,iodixanol,30,39,"Two of the 64 patients in the iodixanol group (3 percent) had an increase in the creatinine concentration of 0.5 mg per deciliter or more, as compared with 17 of the 65 patients in the iohexol group (26 percent) (P=0.002; odds ratio for such an increase in the iodixanol group, 0.09 [95 percent confidence interval, 0.02 to 0.41]).",12571256_9,0
2767,iodixanol,261,270,"Two of the 64 patients in the iodixanol group (3 percent) had an increase in the creatinine concentration of 0.5 mg per deciliter or more, as compared with 17 of the 65 patients in the iohexol group (26 percent) (P=0.002; odds ratio for such an increase in the iodixanol group, 0.09 [95 percent confidence interval, 0.02 to 0.41]).",12571256_9,0
690,iohexol,185,192,"Two of the 64 patients in the iodixanol group (3 percent) had an increase in the creatinine concentration of 0.5 mg per deciliter or more, as compared with 17 of the 65 patients in the iohexol group (26 percent) (P=0.002; odds ratio for such an increase in the iodixanol group, 0.09 [95 percent confidence interval, 0.02 to 0.41]).",12571256_9,0
689,creatinine,81,91,"Two of the 64 patients in the iodixanol group (3 percent) had an increase in the creatinine concentration of 0.5 mg per deciliter or more, as compared with 17 of the 65 patients in the iohexol group (26 percent) (P=0.002; odds ratio for such an increase in the iodixanol group, 0.09 [95 percent confidence interval, 0.02 to 0.41]).",12571256_9,0
688,(3,46,48,"Two of the 64 patients in the iodixanol group (3 percent) had an increase in the creatinine concentration of 0.5 mg per deciliter or more, as compared with 17 of the 65 patients in the iohexol group (26 percent) (P=0.002; odds ratio for such an increase in the iodixanol group, 0.09 [95 percent confidence interval, 0.02 to 0.41]).",12571256_9,0
4639,renal injury,49,61,Prenatal dexamethasone programs hypertension and renal injury in the rat.,12574103_0,1
2775,pulmonary development,79,100,Dexamethasone is frequently administered to the developing fetus to accelerate pulmonary development.,12574103_1,1
4641,renal injury,132,144,The purpose of the present study was to determine if prenatal dexamethasone programmed a progressive increase in blood pressure and renal injury in rats.,12574103_2,1
4640,blood pressure,113,127,The purpose of the present study was to determine if prenatal dexamethasone programmed a progressive increase in blood pressure and renal injury in rats.,12574103_2,1
4642,body weight,106,117,"Pregnant rats were given either vehicle or 2 daily intraperitoneal injections of dexamethasone (0.2 mg/kg body weight) on gestational days 11 and 12, 13 and 14, 15 and 16, 17 and 18, or 19 and 20.",12574103_3,1
2777,intraperitoneal,51,66,"Pregnant rats were given either vehicle or 2 daily intraperitoneal injections of dexamethasone (0.2 mg/kg body weight) on gestational days 11 and 12, 13 and 14, 15 and 16, 17 and 18, or 19 and 20.",12574103_3,0
4643,blood pressures,117,132,"Male rats that received prenatal dexamethasone on days 15 and 16, 17 and 18, and 13 and 14 of gestation had elevated blood pressures at 6 months of age; the latter group did not have a reduction in glomerular number.",12574103_6,1
4644,glomerulosclerosis,86,104,Adult rats given dexamethasone on days 15 and 16 of gestation had more glomeruli with glomerulosclerosis than control rats.,12574103_7,1
4645,glomerulosclerosis,98,116,"This study shows that prenatal dexamethasone in rats results in a reduction in glomerular number, glomerulosclerosis, and hypertension when administered at specific points during gestation.",12574103_8,1
697,sirolimus,104,113,"Kidney function and morphology after short-term combination therapy with cyclosporine A, tacrolimus and sirolimus in the rat.",12584269_0,0
696,tacrolimus,89,99,"Kidney function and morphology after short-term combination therapy with cyclosporine A, tacrolimus and sirolimus in the rat.",12584269_0,0
2784,Kidney function,0,15,"Kidney function and morphology after short-term combination therapy with cyclosporine A, tacrolimus and sirolimus in the rat.",12584269_0,1
695,cyclosporine A,73,87,"Kidney function and morphology after short-term combination therapy with cyclosporine A, tacrolimus and sirolimus in the rat.",12584269_0,0
2786,clinical organ transplantation,69,99,BACKGROUND: Sirolimus (SRL) may supplement calcineurin inhibitors in clinical organ transplantation.,12584269_1,1
699,calcineurin inhibitors,43,65,BACKGROUND: Sirolimus (SRL) may supplement calcineurin inhibitors in clinical organ transplantation.,12584269_1,0
698,Sirolimus,12,21,BACKGROUND: Sirolimus (SRL) may supplement calcineurin inhibitors in clinical organ transplantation.,12584269_1,0
2785,SRL,23,26,BACKGROUND: Sirolimus (SRL) may supplement calcineurin inhibitors in clinical organ transplantation.,12584269_1,0
2817,CsA,80,83,The semi-quantitative scoring was significantly worst in the group treated with CsA plus SRL (P<0.001 compared with controls) and the analysis of the total grade of fibrosis also showed the highest proportion in the same group and was significantly different from controls (P<0.02).,12584269_11,1
2818,SRL,89,92,The semi-quantitative scoring was significantly worst in the group treated with CsA plus SRL (P<0.001 compared with controls) and the analysis of the total grade of fibrosis also showed the highest proportion in the same group and was significantly different from controls (P<0.02).,12584269_11,0
2819,SRL,15,18,The FK506 plus SRL combination showed only a marginally higher degree of fibrosis as compared with controls (P=0.05).,12584269_12,0
708,FK506,4,9,The FK506 plus SRL combination showed only a marginally higher degree of fibrosis as compared with controls (P=0.05).,12584269_12,0
709,FK506,98,103,"CONCLUSION: This rat study demonstrated a synergistic nephrotoxic effect of CsA plus SRL, whereas FK506 plus SRL was better tolerated.",12584269_13,0
2821,CsA,76,79,"CONCLUSION: This rat study demonstrated a synergistic nephrotoxic effect of CsA plus SRL, whereas FK506 plus SRL was better tolerated.",12584269_13,1
2822,SRL,85,88,"CONCLUSION: This rat study demonstrated a synergistic nephrotoxic effect of CsA plus SRL, whereas FK506 plus SRL was better tolerated.",12584269_13,0
2823,SRL,109,112,"CONCLUSION: This rat study demonstrated a synergistic nephrotoxic effect of CsA plus SRL, whereas FK506 plus SRL was better tolerated.",12584269_13,0
2787,SRL,27,30,"These are nephrotoxic, but SRL seems to act differently displaying only minor nephrotoxic effects, although this question is still open.",12584269_2,0
700,calcineurin inhibitor,65,86,In a number of treatment protocols where SRL was combined with a calcineurin inhibitor indications of a synergistic nephrotoxic effect were described.,12584269_3,0
2789,SRL,41,44,In a number of treatment protocols where SRL was combined with a calcineurin inhibitor indications of a synergistic nephrotoxic effect were described.,12584269_3,0
701,cyclosporine A,161,175,"The aim of this study was to examine further the renal function, including morphological analysis of the kidneys of male Sprague-Dawley rats treated with either cyclosporine A (CsA), tacrolimus (FK506) or SRL as monotherapies or in different combinations.",12584269_4,0
702,tacrolimus,183,193,"The aim of this study was to examine further the renal function, including morphological analysis of the kidneys of male Sprague-Dawley rats treated with either cyclosporine A (CsA), tacrolimus (FK506) or SRL as monotherapies or in different combinations.",12584269_4,0
703,FK506,195,200,"The aim of this study was to examine further the renal function, including morphological analysis of the kidneys of male Sprague-Dawley rats treated with either cyclosporine A (CsA), tacrolimus (FK506) or SRL as monotherapies or in different combinations.",12584269_4,0
2794,monotherapies,212,225,"The aim of this study was to examine further the renal function, including morphological analysis of the kidneys of male Sprague-Dawley rats treated with either cyclosporine A (CsA), tacrolimus (FK506) or SRL as monotherapies or in different combinations.",12584269_4,0
2793,SRL,205,208,"The aim of this study was to examine further the renal function, including morphological analysis of the kidneys of male Sprague-Dawley rats treated with either cyclosporine A (CsA), tacrolimus (FK506) or SRL as monotherapies or in different combinations.",12584269_4,0
2792,CsA,177,180,"The aim of this study was to examine further the renal function, including morphological analysis of the kidneys of male Sprague-Dawley rats treated with either cyclosporine A (CsA), tacrolimus (FK506) or SRL as monotherapies or in different combinations.",12584269_4,0
2790,renal function,49,63,"The aim of this study was to examine further the renal function, including morphological analysis of the kidneys of male Sprague-Dawley rats treated with either cyclosporine A (CsA), tacrolimus (FK506) or SRL as monotherapies or in different combinations.",12584269_4,1
2796,SRL,105,108,"METHODS: For a period of 2 weeks, CsA 15 mg/kg/day (given orally), FK506 3.0 mg/kg/day (given orally) or SRL 0.4 mg/kg/day (given intraperitoneally) was administered once a day as these doses have earlier been found to achieve a significant immunosuppressive effect in Sprague-Dawley rats.",12584269_5,0
704,FK506,67,72,"METHODS: For a period of 2 weeks, CsA 15 mg/kg/day (given orally), FK506 3.0 mg/kg/day (given orally) or SRL 0.4 mg/kg/day (given intraperitoneally) was administered once a day as these doses have earlier been found to achieve a significant immunosuppressive effect in Sprague-Dawley rats.",12584269_5,0
2795,CsA,34,37,"METHODS: For a period of 2 weeks, CsA 15 mg/kg/day (given orally), FK506 3.0 mg/kg/day (given orally) or SRL 0.4 mg/kg/day (given intraperitoneally) was administered once a day as these doses have earlier been found to achieve a significant immunosuppressive effect in Sprague-Dawley rats.",12584269_5,1
2802,Cr(EDTA,113,120,"In the 'conscious catheterized rat' model, the glomerular filtration rate (GFR) was measured as the clearance of Cr(EDTA).",12584269_6,0
2801,GFR,75,78,"In the 'conscious catheterized rat' model, the glomerular filtration rate (GFR) was measured as the clearance of Cr(EDTA).",12584269_6,0
2807,Sirius Red,287,297,"The morphological analysis of the kidneys included a semi-quantitative scoring system analysing the degree of striped fibrosis, subcapsular fibrosis and the number of basophilic tubules, plus an additional stereological analysis of the total grade of fibrosis in the cortex stained with Sirius Red.",12584269_7,0
2804,subcapsular fibrosis,128,148,"The morphological analysis of the kidneys included a semi-quantitative scoring system analysing the degree of striped fibrosis, subcapsular fibrosis and the number of basophilic tubules, plus an additional stereological analysis of the total grade of fibrosis in the cortex stained with Sirius Red.",12584269_7,1
705,FK506,14,19,"RESULTS: CsA, FK506 and SRL all significantly decreased the GFR.",12584269_8,0
2809,SRL,24,27,"RESULTS: CsA, FK506 and SRL all significantly decreased the GFR.",12584269_8,0
2808,CsA,9,12,"RESULTS: CsA, FK506 and SRL all significantly decreased the GFR.",12584269_8,1
2810,GFR,60,63,"RESULTS: CsA, FK506 and SRL all significantly decreased the GFR.",12584269_8,0
2812,SRL,76,79,"A further deterioration was seen when CsA was combined with either FK506 or SRL, whereas the GFR remained unchanged in the group treated with FK506 plus SRL when compared with treatment with any of the single substances.",12584269_9,0
2813,GFR,93,96,"A further deterioration was seen when CsA was combined with either FK506 or SRL, whereas the GFR remained unchanged in the group treated with FK506 plus SRL when compared with treatment with any of the single substances.",12584269_9,0
2814,SRL,153,156,"A further deterioration was seen when CsA was combined with either FK506 or SRL, whereas the GFR remained unchanged in the group treated with FK506 plus SRL when compared with treatment with any of the single substances.",12584269_9,0
707,FK506,142,147,"A further deterioration was seen when CsA was combined with either FK506 or SRL, whereas the GFR remained unchanged in the group treated with FK506 plus SRL when compared with treatment with any of the single substances.",12584269_9,0
706,FK506,67,72,"A further deterioration was seen when CsA was combined with either FK506 or SRL, whereas the GFR remained unchanged in the group treated with FK506 plus SRL when compared with treatment with any of the single substances.",12584269_9,0
2811,CsA,38,41,"A further deterioration was seen when CsA was combined with either FK506 or SRL, whereas the GFR remained unchanged in the group treated with FK506 plus SRL when compared with treatment with any of the single substances.",12584269_9,1
2826,doxorubicin-induced cardiomyopathy,81,115,"Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings.",12589964_0,1
710,troponin I,22,32,"Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings.",12589964_0,0
2825,myocardial damage,60,77,"Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin-induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings.",12589964_0,1
2828,cTnI,33,37,BACKGROUND: Cardiac troponins I (cTnI) and T (cTnT) have been shown to be highly sensitive and specific markers of myocardial cell injury.,12589964_1,0
2829,T (cTnT,43,50,BACKGROUND: Cardiac troponins I (cTnI) and T (cTnT) have been shown to be highly sensitive and specific markers of myocardial cell injury.,12589964_1,0
2830,myocardial cell injury,115,137,BACKGROUND: Cardiac troponins I (cTnI) and T (cTnT) have been shown to be highly sensitive and specific markers of myocardial cell injury.,12589964_1,1
711,troponins,20,29,BACKGROUND: Cardiac troponins I (cTnI) and T (cTnT) have been shown to be highly sensitive and specific markers of myocardial cell injury.,12589964_1,0
2856,DOX,54,57,Histological evaluation of hearts from all rats given DOX revealed significant slight degrees of perivascular and interstitial fibrosis.,12589964_11,0
2857,perivascular,97,109,Histological evaluation of hearts from all rats given DOX revealed significant slight degrees of perivascular and interstitial fibrosis.,12589964_11,1
2858,interstitial fibrosis,114,135,Histological evaluation of hearts from all rats given DOX revealed significant slight degrees of perivascular and interstitial fibrosis.,12589964_11,1
2860,perivascular,60,72,Only five of the controls exhibited evidence of very slight perivascular fibrosis.,12589964_13,1
2862,DOX,40,43,A significant rise in cTnT was found in DOX rats after cumulative doses of 7.5 and 12 mg/kg in comparison with baseline (p<0.05).,12589964_14,0
2861,cTnT,22,26,A significant rise in cTnT was found in DOX rats after cumulative doses of 7.5 and 12 mg/kg in comparison with baseline (p<0.05).,12589964_14,0
2864,DOX,93,96,cTnT found in rats after 12 mg/kg were significantly greater than that found after 7.5 mg/kg DOX.,12589964_15,0
2863,cTnT,0,4,cTnT found in rats after 12 mg/kg were significantly greater than that found after 7.5 mg/kg DOX.,12589964_15,0
2866,cTnT,25,29,"Maximal cTnI (pg/ml) and cTnT levels were significantly increased in DOX rats compared with controls (p=0.006, 0.007).",12589964_16,0
2867,DOX,69,72,"Maximal cTnI (pg/ml) and cTnT levels were significantly increased in DOX rats compared with controls (p=0.006, 0.007).",12589964_16,0
2868,cTnI,0,4,"cTnI (ng/ml), CK-MB mass and CK remained unchanged in DOX rats compared with controls.",12589964_17,0
2871,DOX,54,57,"cTnI (ng/ml), CK-MB mass and CK remained unchanged in DOX rats compared with controls.",12589964_17,0
2870,CK,29,31,"cTnI (ng/ml), CK-MB mass and CK remained unchanged in DOX rats compared with controls.",12589964_17,0
2869,CK-MB,14,19,"cTnI (ng/ml), CK-MB mass and CK remained unchanged in DOX rats compared with controls.",12589964_17,0
2872,cTnT,68,72,Analysis of data revealed a significant correlation between maximal cTnT and ED and ES LV diameters/BW (r=0.81 and 0.65; p<0.0001).,12589964_19,0
4646,cardiac disorders,239,256,"We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin (DOX)-induced cardiomyopathy, and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model.",12589964_2,1
2831,cTnI,40,44,"We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin (DOX)-induced cardiomyopathy, and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model.",12589964_2,0
2832,cTnT,49,53,"We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin (DOX)-induced cardiomyopathy, and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model.",12589964_2,0
2833,myocardial damage,75,92,"We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin (DOX)-induced cardiomyopathy, and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model.",12589964_2,1
2834,cTnI,201,205,"We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin (DOX)-induced cardiomyopathy, and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model.",12589964_2,0
2873,cTnT,56,60,"A significant relationship was observed between maximal cTnT and the extent of myocardial morphological changes, and between LV diameters/BW and histological findings.",12589964_20,0
2880,histological changes,170,190,"CONCLUSIONS: Among markers of ischemic injury after DOX in rats, cTnT showed the greatest ability to detect myocardial damage assessed by echocardiographic detection and histological changes.",12589964_21,1
2878,myocardial damage,108,125,"CONCLUSIONS: Among markers of ischemic injury after DOX in rats, cTnT showed the greatest ability to detect myocardial damage assessed by echocardiographic detection and histological changes.",12589964_21,1
2875,ischemic injury,30,45,"CONCLUSIONS: Among markers of ischemic injury after DOX in rats, cTnT showed the greatest ability to detect myocardial damage assessed by echocardiographic detection and histological changes.",12589964_21,1
2877,cTnT,65,69,"CONCLUSIONS: Among markers of ischemic injury after DOX in rats, cTnT showed the greatest ability to detect myocardial damage assessed by echocardiographic detection and histological changes.",12589964_21,0
2876,DOX,52,55,"CONCLUSIONS: Among markers of ischemic injury after DOX in rats, cTnT showed the greatest ability to detect myocardial damage assessed by echocardiographic detection and histological changes.",12589964_21,0
713,cardioprotective,398,414,"Although there was a discrepancy between the amount of cTnI and cTnT after DOX, probably due to heterogeneity in cross-reactivities of mAbs to various cTnI and cTnT forms, it is likely that cTnT in rats after DOX indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced cardiotoxicity and possibly for cardioprotective experiments.",12589964_22,0
712,mAbs,135,139,"Although there was a discrepancy between the amount of cTnI and cTnT after DOX, probably due to heterogeneity in cross-reactivities of mAbs to various cTnI and cTnT forms, it is likely that cTnT in rats after DOX indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced cardiotoxicity and possibly for cardioprotective experiments.",12589964_22,0
4647,cardiotoxicity,366,380,"Although there was a discrepancy between the amount of cTnI and cTnT after DOX, probably due to heterogeneity in cross-reactivities of mAbs to various cTnI and cTnT forms, it is likely that cTnT in rats after DOX indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced cardiotoxicity and possibly for cardioprotective experiments.",12589964_22,1
2890,cTnT,290,294,"Although there was a discrepancy between the amount of cTnI and cTnT after DOX, probably due to heterogeneity in cross-reactivities of mAbs to various cTnI and cTnT forms, it is likely that cTnT in rats after DOX indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced cardiotoxicity and possibly for cardioprotective experiments.",12589964_22,0
2889,cell damage,223,234,"Although there was a discrepancy between the amount of cTnI and cTnT after DOX, probably due to heterogeneity in cross-reactivities of mAbs to various cTnI and cTnT forms, it is likely that cTnT in rats after DOX indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced cardiotoxicity and possibly for cardioprotective experiments.",12589964_22,1
2888,DOX,209,212,"Although there was a discrepancy between the amount of cTnI and cTnT after DOX, probably due to heterogeneity in cross-reactivities of mAbs to various cTnI and cTnT forms, it is likely that cTnT in rats after DOX indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced cardiotoxicity and possibly for cardioprotective experiments.",12589964_22,0
2887,cTnT,190,194,"Although there was a discrepancy between the amount of cTnI and cTnT after DOX, probably due to heterogeneity in cross-reactivities of mAbs to various cTnI and cTnT forms, it is likely that cTnT in rats after DOX indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced cardiotoxicity and possibly for cardioprotective experiments.",12589964_22,0
2886,cTnT forms,160,170,"Although there was a discrepancy between the amount of cTnI and cTnT after DOX, probably due to heterogeneity in cross-reactivities of mAbs to various cTnI and cTnT forms, it is likely that cTnT in rats after DOX indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced cardiotoxicity and possibly for cardioprotective experiments.",12589964_22,0
2884,cross-reactivities,113,131,"Although there was a discrepancy between the amount of cTnI and cTnT after DOX, probably due to heterogeneity in cross-reactivities of mAbs to various cTnI and cTnT forms, it is likely that cTnT in rats after DOX indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced cardiotoxicity and possibly for cardioprotective experiments.",12589964_22,0
2885,cTnI,151,155,"Although there was a discrepancy between the amount of cTnI and cTnT after DOX, probably due to heterogeneity in cross-reactivities of mAbs to various cTnI and cTnT forms, it is likely that cTnT in rats after DOX indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced cardiotoxicity and possibly for cardioprotective experiments.",12589964_22,0
2882,cTnT,64,68,"Although there was a discrepancy between the amount of cTnI and cTnT after DOX, probably due to heterogeneity in cross-reactivities of mAbs to various cTnI and cTnT forms, it is likely that cTnT in rats after DOX indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced cardiotoxicity and possibly for cardioprotective experiments.",12589964_22,0
2881,cTnI,55,59,"Although there was a discrepancy between the amount of cTnI and cTnT after DOX, probably due to heterogeneity in cross-reactivities of mAbs to various cTnI and cTnT forms, it is likely that cTnT in rats after DOX indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced cardiotoxicity and possibly for cardioprotective experiments.",12589964_22,0
2883,DOX,75,78,"Although there was a discrepancy between the amount of cTnI and cTnT after DOX, probably due to heterogeneity in cross-reactivities of mAbs to various cTnI and cTnT forms, it is likely that cTnT in rats after DOX indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced cardiotoxicity and possibly for cardioprotective experiments.",12589964_22,0
2838,DOX,54,57,"METHODS: Thirty-five Wistar rats were given 1.5 mg/kg DOX, i.v., weekly for up to 8 weeks for a total cumulative dose of 12 mg/kg BW.",12589964_3,0
2845,CK,116,118,"cTnI was measured with Access(R) (ng/ml) and a research immunoassay (pg/ml), and compared with cTnT, CK-MB mass and CK.",12589964_5,0
2844,CK-MB,101,106,"cTnI was measured with Access(R) (ng/ml) and a research immunoassay (pg/ml), and compared with cTnT, CK-MB mass and CK.",12589964_5,0
2843,cTnT,95,99,"cTnI was measured with Access(R) (ng/ml) and a research immunoassay (pg/ml), and compared with cTnT, CK-MB mass and CK.",12589964_5,0
2841,Access(R),23,32,"cTnI was measured with Access(R) (ng/ml) and a research immunoassay (pg/ml), and compared with cTnT, CK-MB mass and CK.",12589964_5,0
2840,cTnI,0,4,"cTnI was measured with Access(R) (ng/ml) and a research immunoassay (pg/ml), and compared with cTnT, CK-MB mass and CK.",12589964_5,0
2848,DOX,160,163,"By using transthoracic echocardiography, anterior and posterior wall thickness, LV diameters and LV fractional shortening (FS) were measured in all rats before DOX or saline, and at weeks 6 and 9 after treatment in all surviving rats.",12589964_6,0
2847,posterior wall thickness,54,78,"By using transthoracic echocardiography, anterior and posterior wall thickness, LV diameters and LV fractional shortening (FS) were measured in all rats before DOX or saline, and at weeks 6 and 9 after treatment in all surviving rats.",12589964_6,1
2850,DOX,68,71,Histology was performed in DOX-rats at 6 and 9 weeks after the last DOX dose and in all controls.,12589964_7,0
2851,DOX,25,28,RESULTS: Eighteen of the DOX rats died prematurely of general toxicity during the 9-week period.,12589964_8,0
2855,DOX,131,134,"End-diastolic (ED) and end-systolic (ES) LV diameters/BW significantly increased, whereas LV FS was decreased after 9 weeks in the DOX group (p<0.001).",12589964_9,0
2891,hypoxemia,19,28,Octreotide-induced hypoxemia and pulmonary hypertension in premature neonates.,12596116_0,1
2892,premature neonates,59,77,Octreotide-induced hypoxemia and pulmonary hypertension in premature neonates.,12596116_0,1
4648,pulmonary hypertension,33,55,Octreotide-induced hypoxemia and pulmonary hypertension in premature neonates.,12596116_0,1
4649,enterocutaneous fistula,57,80,The authors report 2 cases of premature neonates who had enterocutaneous fistula complicating necrotizing enterocolitis.,12596116_1,1
4650,necrotizing enterocolitis,94,119,The authors report 2 cases of premature neonates who had enterocutaneous fistula complicating necrotizing enterocolitis.,12596116_1,1
2893,premature neonates,30,48,The authors report 2 cases of premature neonates who had enterocutaneous fistula complicating necrotizing enterocolitis.,12596116_1,1
4651,Pulmonary hypertension,0,22,"Pulmonary hypertension developed after administration of a somatostatin analogue, octreotide, to enhance resolution of the fistula.",12596116_2,1
714,somatostatin,59,71,"Pulmonary hypertension developed after administration of a somatostatin analogue, octreotide, to enhance resolution of the fistula.",12596116_2,0
715,octreotide,82,92,"Pulmonary hypertension developed after administration of a somatostatin analogue, octreotide, to enhance resolution of the fistula.",12596116_2,0
2894,premature neonates,119,137,The authors discuss the mechanism of the occurrence of this complication and recommend caution of its use in high-risk premature neonates.,12596116_3,1
4652,vestibulotoxicity,60,77,Protective effect of edaravone against streptomycin-induced vestibulotoxicity in the guinea pig.,12600698_0,1
716,edaravone,21,30,Protective effect of edaravone against streptomycin-induced vestibulotoxicity in the guinea pig.,12600698_0,0
2895,Protective effect,0,17,Protective effect of edaravone against streptomycin-induced vestibulotoxicity in the guinea pig.,12600698_0,0
4653,vestibulotoxicity,60,77,This study investigated alleviation of streptomycin-induced vestibulotoxicity by edaravone in guinea pigs.,12600698_1,1
717,edaravone,81,90,This study investigated alleviation of streptomycin-induced vestibulotoxicity by edaravone in guinea pigs.,12600698_1,0
718,Edaravone,0,9,"Edaravone, a free radical scavenger, has potent free radical quenching action and is used in clinical practice to treat cerebral infarction.",12600698_2,0
4654,cerebral infarction,120,139,"Edaravone, a free radical scavenger, has potent free radical quenching action and is used in clinical practice to treat cerebral infarction.",12600698_2,1
719,free radical scavenger,13,35,"Edaravone, a free radical scavenger, has potent free radical quenching action and is used in clinical practice to treat cerebral infarction.",12600698_2,0
720,free radical,48,60,"Edaravone, a free radical scavenger, has potent free radical quenching action and is used in clinical practice to treat cerebral infarction.",12600698_2,0
721,edaravone,77,86,"Streptomycin was administered to the inner ear by osmotic pump for 24 h, and edaravone (n=8) or saline (n=6) was intraperitoneally injected once a day for 7 days.",12600698_3,0
2899,inner ear,37,46,"Streptomycin was administered to the inner ear by osmotic pump for 24 h, and edaravone (n=8) or saline (n=6) was intraperitoneally injected once a day for 7 days.",12600698_3,1
2902,vestibulo-ocular reflex,23,46,We observed horizontal vestibulo-ocular reflex as a marker of postoperative vestibular function.,12600698_4,1
2903,vestibular function,76,95,We observed horizontal vestibulo-ocular reflex as a marker of postoperative vestibular function.,12600698_4,1
722,edaravone,89,98,Animals injected with saline showed statistically smaller gains than those injected with edaravone.,12600698_5,0
723,edaravone,27,36,These results suggest that edaravone suppresses streptomycin-induced vestibulotoxicity.,12600698_6,0
4655,vestibulotoxicity,69,86,These results suggest that edaravone suppresses streptomycin-induced vestibulotoxicity.,12600698_6,1
4656,venous thromboembolism,12,34,The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study.,12615818_0,1
2904,cyproterone acetate,55,74,The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study.,12615818_0,0
724,ethinyl estradiol,95,112,The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study.,12615818_0,0
4657,polycystic ovary syndrome,181,206,BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).,12615818_1,1
2907,Cyproterone acetate,12,31,BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).,12615818_1,0
2908,CPA/EE,65,71,BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).,12615818_1,0
725,ethinyl estradiol,46,63,BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS).,12615818_1,0
726,combined oral contraceptives,135,163,Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).,12615818_2,0
2912,CPA/EE,101,107,Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).,12615818_2,0
2913,COCs,165,169,Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).,12615818_2,0
2910,VTE,80,83,Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).,12615818_2,0
4658,venous thromboembolism,56,78,Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined oral contraceptives (COCs).,12615818_2,1
2917,PCOS,197,201,"METHODS: Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of VTE associated with CPA/EE.",12615818_4,1
2924,COCs,78,82,RESULTS: The age-adjusted incidence rate ratio for CPA/EE versus conventional COCs was 2.20 [95% confidence interval (CI) 1.35-3.58].,12615818_5,0
2923,CPA/EE,51,57,RESULTS: The age-adjusted incidence rate ratio for CPA/EE versus conventional COCs was 2.20 [95% confidence interval (CI) 1.35-3.58].,12615818_5,0
2926,oral contraception,54,72,"Using as the reference group women who were not using oral contraception, had no recent pregnancy or menopausal symptoms, the case-control analysis gave an adjusted odds ratio (OR(adj)) of 7.44 (95% CI 3.67-15.08) for CPA/EE use compared with an OR(adj) of 2.58 (95% CI 1.60-4.18) for use of conventional COCs.",12615818_6,0
2930,OR(adj,177,183,"Using as the reference group women who were not using oral contraception, had no recent pregnancy or menopausal symptoms, the case-control analysis gave an adjusted odds ratio (OR(adj)) of 7.44 (95% CI 3.67-15.08) for CPA/EE use compared with an OR(adj) of 2.58 (95% CI 1.60-4.18) for use of conventional COCs.",12615818_6,0
2932,OR(adj,246,252,"Using as the reference group women who were not using oral contraception, had no recent pregnancy or menopausal symptoms, the case-control analysis gave an adjusted odds ratio (OR(adj)) of 7.44 (95% CI 3.67-15.08) for CPA/EE use compared with an OR(adj) of 2.58 (95% CI 1.60-4.18) for use of conventional COCs.",12615818_6,0
2927,menopausal symptoms,101,120,"Using as the reference group women who were not using oral contraception, had no recent pregnancy or menopausal symptoms, the case-control analysis gave an adjusted odds ratio (OR(adj)) of 7.44 (95% CI 3.67-15.08) for CPA/EE use compared with an OR(adj) of 2.58 (95% CI 1.60-4.18) for use of conventional COCs.",12615818_6,1
2937,PCOS,126,130,"CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of CPA/EE in women with acne, hirsutism or PCOS although residual confounding by indication cannot be excluded.",12615818_7,1
2938,nephrotoxicity,54,68,The effect of treatment with gum Arabic on gentamicin nephrotoxicity in rats: a preliminary study.,12617329_0,1
727,gum Arabic,29,39,The effect of treatment with gum Arabic on gentamicin nephrotoxicity in rats: a preliminary study.,12617329_0,0
728,gum Arabic,69,79,In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by gentamicin (GM) nephrotoxicity.,12617329_1,0
4659,acute renal failure,83,102,In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by gentamicin (GM) nephrotoxicity.,12617329_1,1
2939,nephrotoxicity,130,144,In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by gentamicin (GM) nephrotoxicity.,12617329_1,1
2943,gum Arabic powder,150,167,"Rats were treated with the vehicle (2 mL/kg of distilled water and 5% w/v cellulose, 10 days), gum Arabic (2 mL/kg of a 10% w/v aqueous suspension of gum Arabic powder, orally for 10 days), or gum Arabic concomitantly with GM (80mg/kg/day intramuscularly, during the last six days of the treatment period).",12617329_2,0
729,gum Arabic,193,203,"Rats were treated with the vehicle (2 mL/kg of distilled water and 5% w/v cellulose, 10 days), gum Arabic (2 mL/kg of a 10% w/v aqueous suspension of gum Arabic powder, orally for 10 days), or gum Arabic concomitantly with GM (80mg/kg/day intramuscularly, during the last six days of the treatment period).",12617329_2,0
2941,distilled water,47,62,"Rats were treated with the vehicle (2 mL/kg of distilled water and 5% w/v cellulose, 10 days), gum Arabic (2 mL/kg of a 10% w/v aqueous suspension of gum Arabic powder, orally for 10 days), or gum Arabic concomitantly with GM (80mg/kg/day intramuscularly, during the last six days of the treatment period).",12617329_2,0
2940,(2 mL/kg,35,43,"Rats were treated with the vehicle (2 mL/kg of distilled water and 5% w/v cellulose, 10 days), gum Arabic (2 mL/kg of a 10% w/v aqueous suspension of gum Arabic powder, orally for 10 days), or gum Arabic concomitantly with GM (80mg/kg/day intramuscularly, during the last six days of the treatment period).",12617329_2,0
2942,gum Arabic (2 mL/kg,95,114,"Rats were treated with the vehicle (2 mL/kg of distilled water and 5% w/v cellulose, 10 days), gum Arabic (2 mL/kg of a 10% w/v aqueous suspension of gum Arabic powder, orally for 10 days), or gum Arabic concomitantly with GM (80mg/kg/day intramuscularly, during the last six days of the treatment period).",12617329_2,0
730,creatinine,63,73,"Nephrotoxicity was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione (GSH) in the kidney cortex, and by light microscopic examination of kidney sections.",12617329_3,0
4660,kidney cortex,134,147,"Nephrotoxicity was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione (GSH) in the kidney cortex, and by light microscopic examination of kidney sections.",12617329_3,1
2944,Nephrotoxicity,0,14,"Nephrotoxicity was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione (GSH) in the kidney cortex, and by light microscopic examination of kidney sections.",12617329_3,1
731,reduced glutathione,101,120,"Nephrotoxicity was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione (GSH) in the kidney cortex, and by light microscopic examination of kidney sections.",12617329_3,0
2945,GSH,122,125,"Nephrotoxicity was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione (GSH) in the kidney cortex, and by light microscopic examination of kidney sections.",12617329_3,0
732,gum Arabic,54,64,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,0
2946,GSH,264,267,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,0
734,gum Arabic,432,442,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,0
2949,tubular necrosis,348,364,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,1
733,creatinine,96,106,"The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose.",12617329_4,0
735,gum Arabic,26,36,It could be inferred that gum Arabic treatment has induced a modest amelioration of some of the histological and biochemical indices of GM nephrotoxicity.,12617329_5,0
2951,nephrotoxicity,139,153,It could be inferred that gum Arabic treatment has induced a modest amelioration of some of the histological and biochemical indices of GM nephrotoxicity.,12617329_5,1
4661,chronic renal failure,99,120,"Further work is warranted on the effect of the treatments on renal functional aspects in models of chronic renal failure, and on the mechanism(s) involved.",12617329_6,1
736,docetaxel,70,79,Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.,12627929_0,0
4662,venous thromboembolism,23,45,Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.,12627929_0,1
2953,androgen-independent prostate cancer,124,160,Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.,12627929_0,1
4663,venous thromboembolism,46,68,STUDY OBJECTIVE: To evaluate the frequency of venous thromboembolism (VTE) in patients with advanced androgen-independent prostate cancer who were treated with docetaxel alone or in combination with thalidomide.,12627929_1,1
2955,androgen-independent prostate cancer,101,137,STUDY OBJECTIVE: To evaluate the frequency of venous thromboembolism (VTE) in patients with advanced androgen-independent prostate cancer who were treated with docetaxel alone or in combination with thalidomide.,12627929_1,1
737,docetaxel,160,169,STUDY OBJECTIVE: To evaluate the frequency of venous thromboembolism (VTE) in patients with advanced androgen-independent prostate cancer who were treated with docetaxel alone or in combination with thalidomide.,12627929_1,0
2958,androgen-independent prostate cancer,55,91,"PATIENTS: Seventy men, aged 50-80 years, with advanced androgen-independent prostate cancer.",12627929_4,1
2959,continuous oral thalidomide,150,177,"INTERVENTION: Each patient received either intravenous docetaxel 30 mg/m2/week for 3 consecutive weeks, followed by 1 week off, or the combination of continuous oral thalidomide 200 mg every evening plus the same docetaxel regimen.",12627929_5,0
739,docetaxel,213,222,"INTERVENTION: Each patient received either intravenous docetaxel 30 mg/m2/week for 3 consecutive weeks, followed by 1 week off, or the combination of continuous oral thalidomide 200 mg every evening plus the same docetaxel regimen.",12627929_5,0
738,docetaxel,55,64,"INTERVENTION: Each patient received either intravenous docetaxel 30 mg/m2/week for 3 consecutive weeks, followed by 1 week off, or the combination of continuous oral thalidomide 200 mg every evening plus the same docetaxel regimen.",12627929_5,0
4664,disease progression,81,100,This 4-week cycle was repeated until there was evidence of excessive toxicity or disease progression.,12627929_6,1
740,docetaxel,64,73,"MEASUREMENTS AND MAIN RESULTS: None of 23 patients who received docetaxel alone developed VTE, whereas 9 of 47 patients (19%) who received docetaxel plus thalidomide developed VTE (p=0.025).",12627929_7,0
741,docetaxel,139,148,"MEASUREMENTS AND MAIN RESULTS: None of 23 patients who received docetaxel alone developed VTE, whereas 9 of 47 patients (19%) who received docetaxel plus thalidomide developed VTE (p=0.025).",12627929_7,0
2960,VTE,90,93,"MEASUREMENTS AND MAIN RESULTS: None of 23 patients who received docetaxel alone developed VTE, whereas 9 of 47 patients (19%) who received docetaxel plus thalidomide developed VTE (p=0.025).",12627929_7,0
2961,VTE,176,179,"MEASUREMENTS AND MAIN RESULTS: None of 23 patients who received docetaxel alone developed VTE, whereas 9 of 47 patients (19%) who received docetaxel plus thalidomide developed VTE (p=0.025).",12627929_7,0
4665,prostate cancer,73,88,CONCLUSION: The addition of thalidomide to docetaxel in the treatment of prostate cancer significantly increases the frequency of VTE.,12627929_8,1
2962,VTE,130,133,CONCLUSION: The addition of thalidomide to docetaxel in the treatment of prostate cancer significantly increases the frequency of VTE.,12627929_8,0
742,docetaxel,43,52,CONCLUSION: The addition of thalidomide to docetaxel in the treatment of prostate cancer significantly increases the frequency of VTE.,12627929_8,0
2963,chemotherapeutic regimens,85,110,Clinicians should be aware of this potential complication when adding thalidomide to chemotherapeutic regimens.,12627929_9,0
2964,cholestatic hepatitis,20,41,Ticlopidine-induced cholestatic hepatitis.,12639165_0,1
2965,cholestatic hepatitis,52,73,"OBJECTIVE: To report 2 cases of ticlopidine-induced cholestatic hepatitis, investigate its mechanism, and compare the observed main characteristics with those of the published cases.",12639165_1,1
2986,immune mediated,87,102,CONCLUSIONS: Cholestatic hepatitis is a rare adverse effect of ticlopidine that may be immune mediated.,12639165_10,0
748,ticlopidine,63,74,CONCLUSIONS: Cholestatic hepatitis is a rare adverse effect of ticlopidine that may be immune mediated.,12639165_10,0
2984,Cholestatic hepatitis,13,34,CONCLUSIONS: Cholestatic hepatitis is a rare adverse effect of ticlopidine that may be immune mediated.,12639165_10,1
2985,adverse effect,45,59,CONCLUSIONS: Cholestatic hepatitis is a rare adverse effect of ticlopidine that may be immune mediated.,12639165_10,1
2987,liver function,53,67,Patients receiving the drug should be monitored with liver function tests along with complete blood cell counts.,12639165_11,1
2988,blood cell,94,104,Patients receiving the drug should be monitored with liver function tests along with complete blood cell counts.,12639165_11,0
749,ticlopidine,68,79,This complication will be observed even less often in the future as ticlopidine is being replaced by the newer antiplatelet agent clopidogrel.,12639165_12,0
2989,antiplatelet agent clopidogrel,111,141,This complication will be observed even less often in the future as ticlopidine is being replaced by the newer antiplatelet agent clopidogrel.,12639165_12,0
2968,percutaneous coronary angioplasty,109,142,"CASE SUMMARIES: Two patients developed prolonged cholestatic hepatitis after receiving ticlopidine following percutaneous coronary angioplasty, with complete remission during the follow-up period.",12639165_2,1
743,ticlopidine,87,98,"CASE SUMMARIES: Two patients developed prolonged cholestatic hepatitis after receiving ticlopidine following percutaneous coronary angioplasty, with complete remission during the follow-up period.",12639165_2,0
2969,complete remission,149,167,"CASE SUMMARIES: Two patients developed prolonged cholestatic hepatitis after receiving ticlopidine following percutaneous coronary angioplasty, with complete remission during the follow-up period.",12639165_2,1
2967,cholestatic hepatitis,49,70,"CASE SUMMARIES: Two patients developed prolonged cholestatic hepatitis after receiving ticlopidine following percutaneous coronary angioplasty, with complete remission during the follow-up period.",12639165_2,1
744,ticlopidine,51,62,"T-cell stimulation by therapeutic concentration of ticlopidine was demonstrated in vitro in the patients, but not in healthy controls.",12639165_3,0
2971,therapeutic concentration,22,47,"T-cell stimulation by therapeutic concentration of ticlopidine was demonstrated in vitro in the patients, but not in healthy controls.",12639165_3,0
2970,T-cell,0,6,"T-cell stimulation by therapeutic concentration of ticlopidine was demonstrated in vitro in the patients, but not in healthy controls.",12639165_3,0
2973,Cholestatic hepatitis,12,33,DISCUSSION: Cholestatic hepatitis is a rare complication of the antiplatelet agent ticlopidine; several cases have been reported but few in the English literature.,12639165_4,1
2974,antiplatelet agent ticlopidine,64,94,DISCUSSION: Cholestatic hepatitis is a rare complication of the antiplatelet agent ticlopidine; several cases have been reported but few in the English literature.,12639165_4,0
2976,cholestatic hepatitis,127,148,"Our patients developed jaundice following treatment with ticlopidine and showed the clinical and laboratory characteristics of cholestatic hepatitis, which resolved after discontinuation of the drug.",12639165_5,1
745,ticlopidine,57,68,"Our patients developed jaundice following treatment with ticlopidine and showed the clinical and laboratory characteristics of cholestatic hepatitis, which resolved after discontinuation of the drug.",12639165_5,0
2977,prolonged course,76,92,"Hepatitis may develop weeks after discontinuation of the drug and may run a prolonged course, but complete remission was observed in all reported cases.",12639165_6,1
2978,complete remission,98,116,"Hepatitis may develop weeks after discontinuation of the drug and may run a prolonged course, but complete remission was observed in all reported cases.",12639165_6,1
746,ticlopidine,106,117,An objective causality assessment revealed that the adverse drug event was probably related to the use of ticlopidine.,12639165_7,0
4666,adverse drug event,52,70,An objective causality assessment revealed that the adverse drug event was probably related to the use of ticlopidine.,12639165_7,1
2982,hepatotoxicity,48,62,"Immune mechanisms may be involved in the drug's hepatotoxicity, as suggested by the T-cell stimulation study reported here.",12639165_9,1
747,drug's,41,47,"Immune mechanisms may be involved in the drug's hepatotoxicity, as suggested by the T-cell stimulation study reported here.",12639165_9,0
2981,Immune mechanisms,0,17,"Immune mechanisms may be involved in the drug's hepatotoxicity, as suggested by the T-cell stimulation study reported here.",12639165_9,0
2983,T-cell,84,90,"Immune mechanisms may be involved in the drug's hepatotoxicity, as suggested by the T-cell stimulation study reported here.",12639165_9,0
4667,nephrotic syndrome,116,134,Epithelial sodium channel (ENaC) subunit mRNA and protein expression in rats with puromycin aminonucleoside-induced nephrotic syndrome.,12653683_0,1
750,Epithelial sodium channel,0,25,Epithelial sodium channel (ENaC) subunit mRNA and protein expression in rats with puromycin aminonucleoside-induced nephrotic syndrome.,12653683_0,0
751,ENaC,27,31,Epithelial sodium channel (ENaC) subunit mRNA and protein expression in rats with puromycin aminonucleoside-induced nephrotic syndrome.,12653683_0,0
752,puromycin,82,91,Epithelial sodium channel (ENaC) subunit mRNA and protein expression in rats with puromycin aminonucleoside-induced nephrotic syndrome.,12653683_0,0
2991,early phase,85,96,"In experimental nephrotic syndrome, urinary sodium excretion is decreased during the early phase of the disease.",12653683_1,1
4668,nephrotic syndrome,16,34,"In experimental nephrotic syndrome, urinary sodium excretion is decreased during the early phase of the disease.",12653683_1,1
3015,gammaENaC,55,64,"Conversely, down-regulation of alphaENaC, betaENaC and gammaENaC mRNA expression on day 3 occurred in the presence of high aldosterone concentrations, and was followed by a return of sodium excretion to control values.",12653683_10,0
3014,betaENaC,42,50,"Conversely, down-regulation of alphaENaC, betaENaC and gammaENaC mRNA expression on day 3 occurred in the presence of high aldosterone concentrations, and was followed by a return of sodium excretion to control values.",12653683_10,0
3013,alphaENaC,31,40,"Conversely, down-regulation of alphaENaC, betaENaC and gammaENaC mRNA expression on day 3 occurred in the presence of high aldosterone concentrations, and was followed by a return of sodium excretion to control values.",12653683_10,0
3023,gammaENaC,39,48,"The amounts of alphaENaC, betaENaC and gammaENaC proteins were not increased during PAN-induced sodium retention.",12653683_11,0
3021,alphaENaC,15,24,"The amounts of alphaENaC, betaENaC and gammaENaC proteins were not increased during PAN-induced sodium retention.",12653683_11,0
3022,betaENaC,26,34,"The amounts of alphaENaC, betaENaC and gammaENaC proteins were not increased during PAN-induced sodium retention.",12653683_11,0
4671,nephrotic syndrome,137,155,"In conclusion, ENaC mRNA expression, especially alphaENaC, is increased in the very early phase of the experimental model of PAN-induced nephrotic syndrome in rats, but appears to escape from the regulation by aldosterone after day 3.",12653683_12,1
3027,early phase,84,95,"In conclusion, ENaC mRNA expression, especially alphaENaC, is increased in the very early phase of the experimental model of PAN-induced nephrotic syndrome in rats, but appears to escape from the regulation by aldosterone after day 3.",12653683_12,1
3025,ENaC mRNA,15,24,"In conclusion, ENaC mRNA expression, especially alphaENaC, is increased in the very early phase of the experimental model of PAN-induced nephrotic syndrome in rats, but appears to escape from the regulation by aldosterone after day 3.",12653683_12,0
3026,alphaENaC,48,57,"In conclusion, ENaC mRNA expression, especially alphaENaC, is increased in the very early phase of the experimental model of PAN-induced nephrotic syndrome in rats, but appears to escape from the regulation by aldosterone after day 3.",12653683_12,0
2992,molecular mechanism(s),4,26,The molecular mechanism(s) leading to salt retention has not been completely elucidated.,12653683_2,0
4669,collecting duct,33,48,The rate-limiting constituent of collecting duct sodium transport is the epithelial sodium channel (ENaC).,12653683_3,1
753,epithelial sodium channel,73,98,The rate-limiting constituent of collecting duct sodium transport is the epithelial sodium channel (ENaC).,12653683_3,0
754,ENaC,100,104,The rate-limiting constituent of collecting duct sodium transport is the epithelial sodium channel (ENaC).,12653683_3,0
755,ENaC,29,33,We examined the abundance of ENaC subunit mRNAs and proteins in puromycin aminonucleoside (PAN)-induced nephrotic syndrome.,12653683_4,0
756,puromycin aminonucleoside,64,89,We examined the abundance of ENaC subunit mRNAs and proteins in puromycin aminonucleoside (PAN)-induced nephrotic syndrome.,12653683_4,0
4670,nephrotic syndrome,104,122,We examined the abundance of ENaC subunit mRNAs and proteins in puromycin aminonucleoside (PAN)-induced nephrotic syndrome.,12653683_4,1
2997,plasma aldosterone,46,64,"The time courses of urinary sodium excretion, plasma aldosterone concentration and proteinuria were studied in male Sprague-Dawley rats treated with a single dose of either PAN or vehicle.",12653683_5,0
2999,single dose,151,162,"The time courses of urinary sodium excretion, plasma aldosterone concentration and proteinuria were studied in male Sprague-Dawley rats treated with a single dose of either PAN or vehicle.",12653683_5,0
3000,alphaENaC,24,33,"The relative amounts of alphaENaC, betaENaC and gammaENaC mRNAs were determined in kidneys from these rats by real-time quantitative TaqMan PCR, and the amounts of proteins by Western blot.",12653683_6,0
3001,betaENaC,35,43,"The relative amounts of alphaENaC, betaENaC and gammaENaC mRNAs were determined in kidneys from these rats by real-time quantitative TaqMan PCR, and the amounts of proteins by Western blot.",12653683_6,0
3002,gammaENaC,48,57,"The relative amounts of alphaENaC, betaENaC and gammaENaC mRNAs were determined in kidneys from these rats by real-time quantitative TaqMan PCR, and the amounts of proteins by Western blot.",12653683_6,0
3003,TaqMan PCR,133,143,"The relative amounts of alphaENaC, betaENaC and gammaENaC mRNAs were determined in kidneys from these rats by real-time quantitative TaqMan PCR, and the amounts of proteins by Western blot.",12653683_6,0
3008,alphaENaC,31,40,A significant up-regulation of alphaENaC and betaENaC mRNA abundance on days 1 and 2 preceded sodium retention on days 2 and 3.,12653683_9,0
3009,betaENaC,45,53,A significant up-regulation of alphaENaC and betaENaC mRNA abundance on days 1 and 2 preceded sodium retention on days 2 and 3.,12653683_9,0
3030,nucleus accumbens,89,106,Sub-chronic low dose gamma-vinyl GABA (vigabatrin) inhibits cocaine-induced increases in nucleus accumbens dopamine.,12684739_0,1
757,low dose,12,20,Sub-chronic low dose gamma-vinyl GABA (vigabatrin) inhibits cocaine-induced increases in nucleus accumbens dopamine.,12684739_0,0
758,vigabatrin,39,49,Sub-chronic low dose gamma-vinyl GABA (vigabatrin) inhibits cocaine-induced increases in nucleus accumbens dopamine.,12684739_0,0
3031,GVG,29,32,RATIONALE: gamma-Vinyl GABA (GVG) irreversibly inhibits GABA-transaminase.,12684739_1,0
759,GABA-transaminase,56,73,RATIONALE: gamma-Vinyl GABA (GVG) irreversibly inhibits GABA-transaminase.,12684739_1,0
760,non-receptor,5,17,This non-receptor mediated inhibition requires de novo synthesis for restoration of functional GABA catabolism.,12684739_2,0
761,novo,50,54,This non-receptor mediated inhibition requires de novo synthesis for restoration of functional GABA catabolism.,12684739_2,0
3033,field defects,104,117,"OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).",12684739_3,1
4672,substance abuse,55,70,"OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).",12684739_3,1
3037,low dose GVG,209,221,"OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA).",12684739_3,0
3043,sub-chronic exposure,93,113,"METHODS: Using in vivo microdialysis, we compared acute exposure (450 mg/kg) to an identical sub-chronic exposure (150 mg/kg per day for 3 days), followed by 1- or 3-day washout.",12684739_4,1
3042,acute exposure,50,64,"METHODS: Using in vivo microdialysis, we compared acute exposure (450 mg/kg) to an identical sub-chronic exposure (150 mg/kg per day for 3 days), followed by 1- or 3-day washout.",12684739_4,1
3041,microdialysis,23,36,"METHODS: Using in vivo microdialysis, we compared acute exposure (450 mg/kg) to an identical sub-chronic exposure (150 mg/kg per day for 3 days), followed by 1- or 3-day washout.",12684739_4,1
762,low dose,25,33,"Finally, we examined the low dose of 150 mg/kg (50 mg/kg per day) using a similar washout period.",12684739_5,0
3046,GVG,21,24,"RESULTS: Sub-chronic GVG exposure inhibited the effect of cocaine for 3 days, which exceeded in magnitude and duration the identical acute dose.",12684739_6,0
3045,Sub-chronic,9,20,"RESULTS: Sub-chronic GVG exposure inhibited the effect of cocaine for 3 days, which exceeded in magnitude and duration the identical acute dose.",12684739_6,1
3048,cocaine-induced,80,95,"CONCLUSIONS: Sub-chronic low dose GVG potentiates and extends the inhibition of cocaine-induced increases in dopamine, effectively reducing cumulative exposures and the risk for VFDS.",12684739_7,1
3047,low dose GVG,25,37,"CONCLUSIONS: Sub-chronic low dose GVG potentiates and extends the inhibition of cocaine-induced increases in dopamine, effectively reducing cumulative exposures and the risk for VFDS.",12684739_7,0
4673,dystonia,31,39,Levodopa-induced oromandibular dystonia in progressive supranuclear palsy.,12691807_0,1
4674,progressive supranuclear palsy,43,73,Levodopa-induced oromandibular dystonia in progressive supranuclear palsy.,12691807_0,1
4676,multiple system atrophy,75,98,Levodopa-induced dyskinesias have been reported in Parkinson's disease and multiple system atrophy.,12691807_1,1
4675,Parkinson's disease,51,70,Levodopa-induced dyskinesias have been reported in Parkinson's disease and multiple system atrophy.,12691807_1,1
3053,PSP,76,79,Cranial dystonias are rare in patients with progressive supranuclear palsy (PSP).,12691807_2,0
4678,progressive supranuclear palsy,44,74,Cranial dystonias are rare in patients with progressive supranuclear palsy (PSP).,12691807_2,1
4677,dystonias,8,17,Cranial dystonias are rare in patients with progressive supranuclear palsy (PSP).,12691807_2,1
3055,PSP,108,111,"In this report we describe an unusual case of reversible levodopa-induced Oromandibular dystonia (OMD) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP, and discuss the possible underlying pathophysiology.",12691807_3,0
4681,pathophysiology,256,271,"In this report we describe an unusual case of reversible levodopa-induced Oromandibular dystonia (OMD) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP, and discuss the possible underlying pathophysiology.",12691807_3,1
4680,drug related,168,180,"In this report we describe an unusual case of reversible levodopa-induced Oromandibular dystonia (OMD) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP, and discuss the possible underlying pathophysiology.",12691807_3,1
4679,dystonia,88,96,"In this report we describe an unusual case of reversible levodopa-induced Oromandibular dystonia (OMD) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP, and discuss the possible underlying pathophysiology.",12691807_3,1
3056,PSP,215,218,"In this report we describe an unusual case of reversible levodopa-induced Oromandibular dystonia (OMD) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP, and discuss the possible underlying pathophysiology.",12691807_3,0
3059,organ transplant,86,102,MR imaging with quantitative diffusion mapping of tacrolimus-induced neurotoxicity in organ transplant patients.,12695819_0,1
4682,neurotoxicity,69,82,MR imaging with quantitative diffusion mapping of tacrolimus-induced neurotoxicity in organ transplant patients.,12695819_0,1
763,tacrolimus,180,190,Our objective was to investigate brain MR imaging findings and the utility of diffusion-weighted (DW) imaging in organ transplant patients who developed neurologic symptoms during tacrolimus therapy.,12695819_1,0
3062,organ transplant,113,129,Our objective was to investigate brain MR imaging findings and the utility of diffusion-weighted (DW) imaging in organ transplant patients who developed neurologic symptoms during tacrolimus therapy.,12695819_1,1
4683,neurologic symptoms,153,172,Our objective was to investigate brain MR imaging findings and the utility of diffusion-weighted (DW) imaging in organ transplant patients who developed neurologic symptoms during tacrolimus therapy.,12695819_1,1
3065,neurologic complications,136,160,"Brain MR studies, including DW imaging, were prospectively performed in 14 organ transplant patients receiving tacrolimus who developed neurologic complications.",12695819_2,1
764,tacrolimus,111,121,"Brain MR studies, including DW imaging, were prospectively performed in 14 organ transplant patients receiving tacrolimus who developed neurologic complications.",12695819_2,0
3064,organ transplant,75,91,"Brain MR studies, including DW imaging, were prospectively performed in 14 organ transplant patients receiving tacrolimus who developed neurologic complications.",12695819_2,1
3067,Apparent diffusion coefficient,0,30,Apparent diffusion coefficient (ADC) values on the initial MR study were correlated with reversibility of the lesions.,12695819_4,0
3069,white matter abnormalities,34,60,"Of the 14 patients, 5 (35.7%) had white matter abnormalities, 1 (7.1%) had putaminal hemorrhage, and 8 (57.1%) had normal findings on initial MR images.",12695819_5,1
4684,putaminal hemorrhage,75,95,"Of the 14 patients, 5 (35.7%) had white matter abnormalities, 1 (7.1%) had putaminal hemorrhage, and 8 (57.1%) had normal findings on initial MR images.",12695819_5,1
3070,white matter abnormalities,26,52,"Among the 5 patients with white matter abnormalities, 4 patients (80.0%) showed higher than normal ADC values on initial MR images, and all showed complete resolution on follow-up images.",12695819_6,1
3073,cortical laminar necrosis,105,130,The remaining 1 patient (20.0%) showed lower than normal ADC value and showed incomplete resolution with cortical laminar necrosis.,12695819_7,1
4685,neurotoxicity,105,118,Diffusion-weighted imaging may be useful in predicting the outcomes of the lesions of tacrolimus-induced neurotoxicity.,12695819_8,1
765,L-arginine,0,10,L-arginine transport in humans with cortisol-induced hypertension.,12707296_0,0
3077,cortisol-induced hypertension,60,89,A deficient L-arginine-nitric oxide system is implicated in cortisol-induced hypertension.,12707296_1,1
4686,blood pressure,9,23,Systolic blood pressure was elevated by an average of 7 mm Hg.,12707296_10,1
769,L-arginine,8,18,"Neither L-arginine transport into mononuclear cells (placebo vs active, 26.3+/-3.6 vs 29.0+/-2.1 pmol/10 000 cells per 5 minutes, respectively, at an l-arginine concentration of 300 micromol/L) nor L-arginine extraction in the forearm (at 80 minutes, placebo vs active, 1 868 904+/-434 962 vs 2 013 910+/-770 619 disintegrations per minute) was affected by cortisol treatment; ie, that L-arginine uptake is not affected by short-term cortisol treatment.",12707296_11,0
770,l-arginine,150,160,"Neither L-arginine transport into mononuclear cells (placebo vs active, 26.3+/-3.6 vs 29.0+/-2.1 pmol/10 000 cells per 5 minutes, respectively, at an l-arginine concentration of 300 micromol/L) nor L-arginine extraction in the forearm (at 80 minutes, placebo vs active, 1 868 904+/-434 962 vs 2 013 910+/-770 619 disintegrations per minute) was affected by cortisol treatment; ie, that L-arginine uptake is not affected by short-term cortisol treatment.",12707296_11,0
771,L-arginine,198,208,"Neither L-arginine transport into mononuclear cells (placebo vs active, 26.3+/-3.6 vs 29.0+/-2.1 pmol/10 000 cells per 5 minutes, respectively, at an l-arginine concentration of 300 micromol/L) nor L-arginine extraction in the forearm (at 80 minutes, placebo vs active, 1 868 904+/-434 962 vs 2 013 910+/-770 619 disintegrations per minute) was affected by cortisol treatment; ie, that L-arginine uptake is not affected by short-term cortisol treatment.",12707296_11,0
772,L-arginine,386,396,"Neither L-arginine transport into mononuclear cells (placebo vs active, 26.3+/-3.6 vs 29.0+/-2.1 pmol/10 000 cells per 5 minutes, respectively, at an l-arginine concentration of 300 micromol/L) nor L-arginine extraction in the forearm (at 80 minutes, placebo vs active, 1 868 904+/-434 962 vs 2 013 910+/-770 619 disintegrations per minute) was affected by cortisol treatment; ie, that L-arginine uptake is not affected by short-term cortisol treatment.",12707296_11,0
773,l-arginine,107,117,We conclude that cortisol-induced increases in blood pressure are not associated with abnormalities in the l-arginine transport system.,12707296_12,0
4687,blood pressure,47,61,We conclude that cortisol-induced increases in blood pressure are not associated with abnormalities in the l-arginine transport system.,12707296_12,1
766,L-arginine,40,50,We investigate whether abnormalities in L-arginine uptake contribute to this deficiency.,12707296_2,0
3078,Hydrocortisone acetate,0,22,Hydrocortisone acetate (50 mg) was given orally every 6 hours for 24 hours after a 5-day fixed-salt diet (150 mmol/d).,12707296_4,0
767,L-arginine,0,10,"L-arginine uptake was assessed in mononuclear cells incubated with L-arginine (1 to 300 micromol/L), incorporating 100 nmol/L [3H]-l-arginine for a period of 5 minutes at 37 degrees C. Forearm [3H]-L-arginine extraction was calculated after infusion of [3H]-L-arginine into the brachial artery at a rate of 100 nCi/min for 80 minutes.",12707296_7,0
3086,brachial artery,278,293,"L-arginine uptake was assessed in mononuclear cells incubated with L-arginine (1 to 300 micromol/L), incorporating 100 nmol/L [3H]-l-arginine for a period of 5 minutes at 37 degrees C. Forearm [3H]-L-arginine extraction was calculated after infusion of [3H]-L-arginine into the brachial artery at a rate of 100 nCi/min for 80 minutes.",12707296_7,1
3085,[3H]-L-arginine,253,268,"L-arginine uptake was assessed in mononuclear cells incubated with L-arginine (1 to 300 micromol/L), incorporating 100 nmol/L [3H]-l-arginine for a period of 5 minutes at 37 degrees C. Forearm [3H]-L-arginine extraction was calculated after infusion of [3H]-L-arginine into the brachial artery at a rate of 100 nCi/min for 80 minutes.",12707296_7,0
3084,[3H]-L-arginine,193,208,"L-arginine uptake was assessed in mononuclear cells incubated with L-arginine (1 to 300 micromol/L), incorporating 100 nmol/L [3H]-l-arginine for a period of 5 minutes at 37 degrees C. Forearm [3H]-L-arginine extraction was calculated after infusion of [3H]-L-arginine into the brachial artery at a rate of 100 nCi/min for 80 minutes.",12707296_7,0
3082,L-arginine (1,67,80,"L-arginine uptake was assessed in mononuclear cells incubated with L-arginine (1 to 300 micromol/L), incorporating 100 nmol/L [3H]-l-arginine for a period of 5 minutes at 37 degrees C. Forearm [3H]-L-arginine extraction was calculated after infusion of [3H]-L-arginine into the brachial artery at a rate of 100 nCi/min for 80 minutes.",12707296_7,0
3083,[3H]-l-arginine,126,141,"L-arginine uptake was assessed in mononuclear cells incubated with L-arginine (1 to 300 micromol/L), incorporating 100 nmol/L [3H]-l-arginine for a period of 5 minutes at 37 degrees C. Forearm [3H]-L-arginine extraction was calculated after infusion of [3H]-L-arginine into the brachial artery at a rate of 100 nCi/min for 80 minutes.",12707296_7,0
768,L-arginine,64,74,Deep forearm venous samples were collected for determination of L-arginine extraction.,12707296_8,0
3089,active phase,68,80,"Plasma cortisol concentrations were significantly raised during the active phase (323+/-43 to 1082+/-245 mmol/L, P<0.05).",12707296_9,0
4688,intracerebral hemorrhage,64,88,Amount of bleeding and hematoma size in the collagenase-induced intracerebral hemorrhage rat model.,12716030_0,1
4689,intracerebral hemorrhage,23,47,The aggravated risk on intracerebral hemorrhage (ICH) with drugs used for stroke patients should be estimated carefully.,12716030_1,1
3108,low-dose collagenase,128,148,"Data suggest that this sensitive hemoglobin assay is useful for ICH detection, and that a model with a small ICH induced with a low-dose collagenase should be used for evaluation of drugs that may affect ICH.",12716030_6,0
3111,Dexatrim,13,21,Case report: Dexatrim (Phenylpropanolamine) as a cause of myocardial infarction.,12734532_0,0
3112,cause of myocardial infarction,49,79,Case report: Dexatrim (Phenylpropanolamine) as a cause of myocardial infarction.,12734532_0,1
3113,sympathetic amine,31,48,Phenylpropanolamine (PPA) is a sympathetic amine used in over-the-counter cold remedies and weight-control preparations worldwide.,12734532_1,0
4690,PPA,21,24,Phenylpropanolamine (PPA) is a sympathetic amine used in over-the-counter cold remedies and weight-control preparations worldwide.,12734532_1,1
774,cold remedies,74,87,Phenylpropanolamine (PPA) is a sympathetic amine used in over-the-counter cold remedies and weight-control preparations worldwide.,12734532_1,0
3116,hypertensive episodes,33,54,Its use has been associated with hypertensive episodes and hemorrhagic strokes in younger women.,12734532_2,1
4691,hemorrhagic strokes,59,78,Its use has been associated with hypertensive episodes and hemorrhagic strokes in younger women.,12734532_2,1
3117,myocardial injury,50,67,"Several reports have linked the abuse of PPA with myocardial injury, especially when overdose is involved.",12734532_3,1
4692,PPA,41,44,"Several reports have linked the abuse of PPA with myocardial injury, especially when overdose is involved.",12734532_3,1
3118,Dexatrim,33,41,We report here the first case of Dexatrim (PPA)-induced myocardial injury in a young woman who was using it at recommended doses for weight control.,12734532_4,0
3119,myocardial injury,56,73,We report here the first case of Dexatrim (PPA)-induced myocardial injury in a young woman who was using it at recommended doses for weight control.,12734532_4,1
3121,myocardial injury,56,73,"In addition, we review the 7 other cases of PPA related myocardial injury that have been reported so far.",12734532_5,1
4693,PPA,44,47,"In addition, we review the 7 other cases of PPA related myocardial injury that have been reported so far.",12734532_5,1
3122,cardiac risk,57,69,"Physicians and patients should be alert to the potential cardiac risk associated with the use of PPA, even at doses generally considered to be safe.",12734532_6,1
4694,PPA,97,100,"Physicians and patients should be alert to the potential cardiac risk associated with the use of PPA, even at doses generally considered to be safe.",12734532_6,1
4695,systemic lupus erythematosus,63,91,Differential diagnosis of high serum creatine kinase levels in systemic lupus erythematosus.,12739036_0,1
775,creatine kinase,37,52,Differential diagnosis of high serum creatine kinase levels in systemic lupus erythematosus.,12739036_0,0
3142,drug-induced side effects,87,112,Discriminating between primary SLE-induced affection of the musculoskeletal system and drug-induced side effects is important for appropriate treatment of SLE patients.,12739036_11,1
4696,systemic lupus erythematosus,40,68,"Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide.",12739036_2,1
3128,cyclophosphamide,155,171,"Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide.",12739036_2,0
3127,renal involvement,80,97,"Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide.",12739036_2,1
3129,CQ,37,39,Additional therapy with chloroquine (CQ) was started because of arthralgia.,12739036_3,0
776,creatine kinase,37,52,"At the same time, slightly increased creatine kinase (CK) levels were noted.",12739036_4,0
3130,CK,54,56,"At the same time, slightly increased creatine kinase (CK) levels were noted.",12739036_4,0
3132,progressive muscular weakness,54,83,"The CK increase persisted, however, and she developed progressive muscular weakness and muscular atrophy.",12739036_6,1
3131,CK,4,6,"The CK increase persisted, however, and she developed progressive muscular weakness and muscular atrophy.",12739036_6,0
4697,muscular atrophy,88,104,"The CK increase persisted, however, and she developed progressive muscular weakness and muscular atrophy.",12739036_6,1
3134,CK,44,46,"Routine controls revealed markedly elevated CK levels of 1,700 U/l.",12739036_7,0
4698,toxic myopathy,92,106,"Thus, muscle biopsy of the deltoid muscle was performed in order to exclude polymyositis or toxic myopathy.",12739036_9,1
777,bupropion,64,73,Seizure associated with sleep deprivation and sustained-release bupropion.,12745515_0,0
4699,sleep deprivation,24,41,Seizure associated with sleep deprivation and sustained-release bupropion.,12745515_0,1
778,bupropion,83,92,This case report describes a generalized seizure associated with sustained-release bupropion use and sleep deprivation.,12745515_1,0
4700,generalized seizure,29,48,This case report describes a generalized seizure associated with sustained-release bupropion use and sleep deprivation.,12745515_1,1
4701,sleep deprivation,101,118,This case report describes a generalized seizure associated with sustained-release bupropion use and sleep deprivation.,12745515_1,1
780,bupropion,171,180,"The subject, a 31-year-old female smoker, was participating in a clinical trial evaluating an investigational medication for smoking cessation that used sustained-release bupropion as an active control.",12745515_2,0
779,investigational,94,109,"The subject, a 31-year-old female smoker, was participating in a clinical trial evaluating an investigational medication for smoking cessation that used sustained-release bupropion as an active control.",12745515_2,0
3147,smoking cessation,125,142,"The subject, a 31-year-old female smoker, was participating in a clinical trial evaluating an investigational medication for smoking cessation that used sustained-release bupropion as an active control.",12745515_2,1
4702,tonic clonic seizure,70,90,"After 5 weeks of bupropion use, the subject experienced a generalized tonic clonic seizure after staying up nearly all night packing and moving to a new residence.",12745515_3,1
781,bupropion,17,26,"After 5 weeks of bupropion use, the subject experienced a generalized tonic clonic seizure after staying up nearly all night packing and moving to a new residence.",12745515_3,0
4703,sleep deprivation,16,33,We suggest that sleep deprivation may add to the risk of bupropion-associated seizures.,12745515_5,1
3151,hippocampal injury,34,52,Estradiol reduces seizure-induced hippocampal injury in ovariectomized female but not in male rats.,12757899_0,1
782,kainic,73,79,Estrogens protect ovariectomized rats from hippocampal injury induced by kainic acid-induced status epilepticus (SE).,12757899_1,0
3153,hippocampal injury,43,61,Estrogens protect ovariectomized rats from hippocampal injury induced by kainic acid-induced status epilepticus (SE).,12757899_1,1
4704,status epilepticus,93,111,Estrogens protect ovariectomized rats from hippocampal injury induced by kainic acid-induced status epilepticus (SE).,12757899_1,1
3154,17beta-estradiol,27,43,We compared the effects of 17beta-estradiol in adult male and ovariectomized female rats subjected to lithium-pilocarpine-induced SE.,12757899_2,0
3155,17beta-estradiol (2,41,60,Rats received subcutaneous injections of 17beta-estradiol (2 microg/rat) or oil once daily for four consecutive days.,12757899_3,0
4705,CA1 hippocampal,37,52,The extent of silver-stained CA3 and CA1 hippocampal neurons was evaluated 2 days after SE.,12757899_5,1
3156,17beta-Estradiol,0,16,17beta-Estradiol did not alter the onset of first clonus in ovariectomized rats but accelerated it in males.,12757899_6,0
4706,CA1,57,60,17beta-Estradiol reduced the argyrophilic neurons in the CA1 and CA3-C sectors of ovariectomized rats.,12757899_7,1
3159,17beta-Estradiol,0,16,17beta-Estradiol reduced the argyrophilic neurons in the CA1 and CA3-C sectors of ovariectomized rats.,12757899_7,0
3166,inflammatory origin,64,83,Postoperative myalgia after succinylcholine: no evidence for an inflammatory origin.,12760988_0,1
3165,Postoperative myalgia,0,21,Postoperative myalgia after succinylcholine: no evidence for an inflammatory origin.,12760988_0,1
4707,side effect,9,20,A common side effect associated with succinylcholine is postoperative myalgia.,12760988_1,1
3167,postoperative myalgia,56,77,A common side effect associated with succinylcholine is postoperative myalgia.,12760988_1,1
3174,postoperative myalgia,59,80,"Furthermore, there was no significant relationship between postoperative myalgia and time course of interleukin-6 concentrations, a marker of inflammation.",12760988_11,1
787,interleukin-6,100,113,"Furthermore, there was no significant relationship between postoperative myalgia and time course of interleukin-6 concentrations, a marker of inflammation.",12760988_11,0
3177,postoperative myalgia,60,81,Pretreatment with dexamethasone is not justified to prevent postoperative myalgia after succinylcholine.,12760988_12,1
3168,inflammatory reaction,56,77,We designed the present study to investigate whether an inflammatory reaction contributes to this myalgia.,12760988_3,1
783,interleukin-6,13,26,"In addition, interleukin-6 (IL-6) as an early marker of inflammation was assessed in a subgroup of 10 patients pretreated with saline.",12760988_7,0
784,IL-6,28,32,"In addition, interleukin-6 (IL-6) as an early marker of inflammation was assessed in a subgroup of 10 patients pretreated with saline.",12760988_7,0
785,IL-6,24,28,"We found an increase of IL-6 for only three patients, but only one patient reported myalgia; no relationship between myalgia and the increase of IL-6 was found.",12760988_8,0
786,IL-6,145,149,"We found an increase of IL-6 for only three patients, but only one patient reported myalgia; no relationship between myalgia and the increase of IL-6 was found.",12760988_8,0
3171,inflammatory origin,43,62,"In conclusion, there is no evidence for an inflammatory origin of succinylcholine-associated myalgia.",12760988_9,1
3178,Pseudoacromegaly,0,16,Pseudoacromegaly induced by the long-term use of minoxidil.,12789195_0,1
3179,endocrine disorder,17,35,Acromegaly is an endocrine disorder caused by chronic excessive growth hormone secretion from the anterior pituitary gland.,12789195_1,1
3181,anterior pituitary gland,98,122,Acromegaly is an endocrine disorder caused by chronic excessive growth hormone secretion from the anterior pituitary gland.,12789195_1,1
3180,chronic excessive growth hormone,46,78,Acromegaly is an endocrine disorder caused by chronic excessive growth hormone secretion from the anterior pituitary gland.,12789195_1,1
4708,of bone,50,57,"Significant disfiguring changes occur as a result of bone, cartilage, and soft tissue hypertrophy, including the thickening of the skin, coarsening of facial features, and cutis verticis gyrata.",12789195_2,1
3182,soft tissue hypertrophy,74,97,"Significant disfiguring changes occur as a result of bone, cartilage, and soft tissue hypertrophy, including the thickening of the skin, coarsening of facial features, and cutis verticis gyrata.",12789195_2,1
3185,Pseudoacromegaly,0,16,"Pseudoacromegaly, on the other hand, is the presence of similar acromegaloid features in the absence of elevated growth hormone or insulin-like growth factor levels.",12789195_3,1
788,growth hormone,113,127,"Pseudoacromegaly, on the other hand, is the presence of similar acromegaloid features in the absence of elevated growth hormone or insulin-like growth factor levels.",12789195_3,0
789,insulin-like growth factor,131,157,"Pseudoacromegaly, on the other hand, is the presence of similar acromegaloid features in the absence of elevated growth hormone or insulin-like growth factor levels.",12789195_3,0
3188,high dose,109,118,We present a patient with pseudoacromegaly that resulted from the long-term use of minoxidil at an unusually high dose.,12789195_4,0
3187,pseudoacromegaly,26,42,We present a patient with pseudoacromegaly that resulted from the long-term use of minoxidil at an unusually high dose.,12789195_4,1
3190,pseudoacromegaly,33,49,This is the first case report of pseudoacromegaly as a side effect of minoxidil use.,12789195_5,1
4709,side effect,55,66,This is the first case report of pseudoacromegaly as a side effect of minoxidil use.,12789195_5,1
4710,prostate cancer,45,60,Combined androgen blockade-induced anemia in prostate cancer patients without bone involvement.,12820454_0,1
4711,prostate cancer,100,115,BACKGROUND: To determine the onset and extent of combined androgen blockade (CAB)-induced anemia in prostate cancer patients without bone involvement.,12820454_1,1
3214,clinical stage,199,213,"The development of severe CAB-induced anemia in prostate cancer patients did not correlate with T baseline values (T < 3 ng/ml versus T > or = 3 ng/ml), with age (< 76 yrs versus > or = 76 yrs), and clinical stage (stage C versus stage D1).",12820454_12,1
4712,prostate cancer,48,63,"The development of severe CAB-induced anemia in prostate cancer patients did not correlate with T baseline values (T < 3 ng/ml versus T > or = 3 ng/ml), with age (< 76 yrs versus > or = 76 yrs), and clinical stage (stage C versus stage D1).",12820454_12,1
3219,rHuEPO-beta,143,154,Severe and clinically evident anemia was easily corrected by subcutaneous injections (3 times/week for 1 month) of recombinant erythropoietin (rHuEPO-beta).,12820454_13,0
794,(3,85,87,Severe and clinically evident anemia was easily corrected by subcutaneous injections (3 times/week for 1 month) of recombinant erythropoietin (rHuEPO-beta).,12820454_13,0
3218,recombinant erythropoietin,115,141,Severe and clinically evident anemia was easily corrected by subcutaneous injections (3 times/week for 1 month) of recombinant erythropoietin (rHuEPO-beta).,12820454_13,0
3220,rHuEPO-beta,34,45,CONCLUSION: Our data suggest that rHuEPO-beta correctable CAB-induced anemia occurs in 14.3% of prostate cancer patients after 6 months of therapy.,12820454_14,0
4713,prostate cancer,96,111,CONCLUSION: Our data suggest that rHuEPO-beta correctable CAB-induced anemia occurs in 14.3% of prostate cancer patients after 6 months of therapy.,12820454_14,1
3191,biopsy-proven prostatic adenocarcinoma,46,84,PATIENTS AND METHODS: Forty-two patients with biopsy-proven prostatic adenocarcinoma [26 with stage C (T3N0M0) and 16 with stage D1 (T3N1M0)] were included in this study.,12820454_2,1
3194,LHRH-A,47,53,"All patients received CAB [leuprolide acetate (LHRH-A) 3.75 mg, intramuscularly, every 28 days plus 250 mg flutamide, tid, per Os] and were evaluated for anemia by physical examination and laboratory tests at baseline and 4 subsequent intervals (1, 2, 3 and 6 months post-CAB).",12820454_3,0
791,flutamide,107,116,"All patients received CAB [leuprolide acetate (LHRH-A) 3.75 mg, intramuscularly, every 28 days plus 250 mg flutamide, tid, per Os] and were evaluated for anemia by physical examination and laboratory tests at baseline and 4 subsequent intervals (1, 2, 3 and 6 months post-CAB).",12820454_3,0
790,leuprolide acetate,27,45,"All patients received CAB [leuprolide acetate (LHRH-A) 3.75 mg, intramuscularly, every 28 days plus 250 mg flutamide, tid, per Os] and were evaluated for anemia by physical examination and laboratory tests at baseline and 4 subsequent intervals (1, 2, 3 and 6 months post-CAB).",12820454_3,0
792,(1,245,247,"All patients received CAB [leuprolide acetate (LHRH-A) 3.75 mg, intramuscularly, every 28 days plus 250 mg flutamide, tid, per Os] and were evaluated for anemia by physical examination and laboratory tests at baseline and 4 subsequent intervals (1, 2, 3 and 6 months post-CAB).",12820454_3,0
793,D2,20,22,"Patients with stage D2-3 disease, abnormal hemoglobin level or renal and liver function tests that were higher than the upper limits were excluded from the study.",12820454_5,0
3197,hemoglobin level,43,59,"Patients with stage D2-3 disease, abnormal hemoglobin level or renal and liver function tests that were higher than the upper limits were excluded from the study.",12820454_5,1
3198,liver function,73,87,"Patients with stage D2-3 disease, abnormal hemoglobin level or renal and liver function tests that were higher than the upper limits were excluded from the study.",12820454_5,1
3202,clinically evident,11,29,Severe and clinically evident anemia of Hb < 11 g/dl with clinical symptoms was detected in 6 patients (14.3%).,12820454_8,1
3203,clinical symptoms,58,75,Severe and clinically evident anemia of Hb < 11 g/dl with clinical symptoms was detected in 6 patients (14.3%).,12820454_8,1
3205,normochromic,28,40,This CAB-induced anemia was normochromic and normocytic.,12820454_9,1
3206,normocytic,45,55,This CAB-induced anemia was normochromic and normocytic.,12820454_9,1
3222,P450s,50,55,Effect of lindane on hepatic and brain cytochrome P450s and influence of P450 modulation in lindane induced neurotoxicity.,12842176_0,0
795,P450,73,77,Effect of lindane on hepatic and brain cytochrome P450s and influence of P450 modulation in lindane induced neurotoxicity.,12842176_0,0
4714,neurotoxicity,108,121,Effect of lindane on hepatic and brain cytochrome P450s and influence of P450 modulation in lindane induced neurotoxicity.,12842176_0,1
796,P450,147,151,"Oral administration of lindane (2.5, 5, 10 and 15 mg/kg, body weight) for 5 days was found to produce a dose-dependent increase in the activity of P450 dependent 7-ethoxyresorufin-O-deethylase (EROD), 7-pentoxyresorufin-O-dealkylase (PROD) and N-nitrosodimethylamine demethylase (NDMA-d) in rat brain and liver.",12842176_1,0
3226,NDMA-d,280,286,"Oral administration of lindane (2.5, 5, 10 and 15 mg/kg, body weight) for 5 days was found to produce a dose-dependent increase in the activity of P450 dependent 7-ethoxyresorufin-O-deethylase (EROD), 7-pentoxyresorufin-O-dealkylase (PROD) and N-nitrosodimethylamine demethylase (NDMA-d) in rat brain and liver.",12842176_1,0
797,EROD,194,198,"Oral administration of lindane (2.5, 5, 10 and 15 mg/kg, body weight) for 5 days was found to produce a dose-dependent increase in the activity of P450 dependent 7-ethoxyresorufin-O-deethylase (EROD), 7-pentoxyresorufin-O-dealkylase (PROD) and N-nitrosodimethylamine demethylase (NDMA-d) in rat brain and liver.",12842176_1,0
798,N-nitrosodimethylamine demethylase,244,278,"Oral administration of lindane (2.5, 5, 10 and 15 mg/kg, body weight) for 5 days was found to produce a dose-dependent increase in the activity of P450 dependent 7-ethoxyresorufin-O-deethylase (EROD), 7-pentoxyresorufin-O-dealkylase (PROD) and N-nitrosodimethylamine demethylase (NDMA-d) in rat brain and liver.",12842176_1,0
3225,", 7-pentoxyresorufin-O-dealkylase",199,232,"Oral administration of lindane (2.5, 5, 10 and 15 mg/kg, body weight) for 5 days was found to produce a dose-dependent increase in the activity of P450 dependent 7-ethoxyresorufin-O-deethylase (EROD), 7-pentoxyresorufin-O-dealkylase (PROD) and N-nitrosodimethylamine demethylase (NDMA-d) in rat brain and liver.",12842176_1,0
4715,body weight,57,68,"Oral administration of lindane (2.5, 5, 10 and 15 mg/kg, body weight) for 5 days was found to produce a dose-dependent increase in the activity of P450 dependent 7-ethoxyresorufin-O-deethylase (EROD), 7-pentoxyresorufin-O-dealkylase (PROD) and N-nitrosodimethylamine demethylase (NDMA-d) in rat brain and liver.",12842176_1,1
799,low dose,119,127,A significant increase in the hepatic and brain P450 monooxygenases was also observed when the duration of exposure of low dose (2.5 mg/kg) of lindane was increased from 5 days to 15 or 21 days.,12842176_2,0
3227,P450 monooxygenases,48,67,A significant increase in the hepatic and brain P450 monooxygenases was also observed when the duration of exposure of low dose (2.5 mg/kg) of lindane was increased from 5 days to 15 or 21 days.,12842176_2,0
3228,P450 monooxygenases,80,99,"As observed with different doses, the magnitude of induction in the activity of P450 monooxygenases was several fold higher in liver microsomes when compared with the brain.",12842176_3,0
3230,2E1 isoenzymes,154,168,"Western blotting studies have indicated that the increase in the P450 enzymes could be due to the increase in the expression of P450 1A1/1A2, 2B1/2B2 and 2E1 isoenzymes.",12842176_4,0
800,P450 enzymes,65,77,"Western blotting studies have indicated that the increase in the P450 enzymes could be due to the increase in the expression of P450 1A1/1A2, 2B1/2B2 and 2E1 isoenzymes.",12842176_4,0
801,P450,128,132,"Western blotting studies have indicated that the increase in the P450 enzymes could be due to the increase in the expression of P450 1A1/1A2, 2B1/2B2 and 2E1 isoenzymes.",12842176_4,0
3231,organic inhibitors,23,41,"In vitro studies using organic inhibitors specific for individual P450 isoenzymes and antibody inhibition experiments have further demonstrated that the increase in the activity of PROD, EROD and NDMA-d are due to the increase in the levels of P450 2B1/2B2, 1A1/1A2 and 2E1 isoenzymes, respectively.",12842176_5,0
3232,P450 isoenzymes,66,81,"In vitro studies using organic inhibitors specific for individual P450 isoenzymes and antibody inhibition experiments have further demonstrated that the increase in the activity of PROD, EROD and NDMA-d are due to the increase in the levels of P450 2B1/2B2, 1A1/1A2 and 2E1 isoenzymes, respectively.",12842176_5,0
3234,NDMA-d,196,202,"In vitro studies using organic inhibitors specific for individual P450 isoenzymes and antibody inhibition experiments have further demonstrated that the increase in the activity of PROD, EROD and NDMA-d are due to the increase in the levels of P450 2B1/2B2, 1A1/1A2 and 2E1 isoenzymes, respectively.",12842176_5,0
3235,2E1 isoenzymes,270,284,"In vitro studies using organic inhibitors specific for individual P450 isoenzymes and antibody inhibition experiments have further demonstrated that the increase in the activity of PROD, EROD and NDMA-d are due to the increase in the levels of P450 2B1/2B2, 1A1/1A2 and 2E1 isoenzymes, respectively.",12842176_5,0
803,P450,244,248,"In vitro studies using organic inhibitors specific for individual P450 isoenzymes and antibody inhibition experiments have further demonstrated that the increase in the activity of PROD, EROD and NDMA-d are due to the increase in the levels of P450 2B1/2B2, 1A1/1A2 and 2E1 isoenzymes, respectively.",12842176_5,0
802,EROD,187,191,"In vitro studies using organic inhibitors specific for individual P450 isoenzymes and antibody inhibition experiments have further demonstrated that the increase in the activity of PROD, EROD and NDMA-d are due to the increase in the levels of P450 2B1/2B2, 1A1/1A2 and 2E1 isoenzymes, respectively.",12842176_5,0
804,P450,258,262,"Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.",12842176_6,0
3240,P450 2E1,297,305,"Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.",12842176_6,0
3237,3-methylcholanthrene,64,84,"Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.",12842176_6,0
3238,P4501A1/1A2,105,116,"Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions.",12842176_6,0
3241,cobalt chloride,71,86,"Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.",12842176_7,0
3242,ethanol inducible P450 isoenzymes,224,257,"Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.",12842176_7,0
4716,neurobehavioral,278,293,"Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity.",12842176_7,1
3244,cyproterone acetate,78,97,Absolute and attributable risk of venous thromboembolism in women on combined cyproterone acetate and ethinylestradiol.,12851669_0,0
4717,venous thromboembolism,34,56,Absolute and attributable risk of venous thromboembolism in women on combined cyproterone acetate and ethinylestradiol.,12851669_0,1
805,ethinylestradiol,102,118,Absolute and attributable risk of venous thromboembolism in women on combined cyproterone acetate and ethinylestradiol.,12851669_0,0
3248,COCs,194,198,"OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).",12851669_1,0
3247,CPA/EE,136,142,"OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).",12851669_1,0
3245,VTE,73,76,"OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).",12851669_1,0
806,ethinylestradiol,118,134,"OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).",12851669_1,0
3246,cyproterone acetate,93,112,"OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).",12851669_1,0
807,combined oral contraceptives,164,192,"OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).",12851669_1,0
4718,venous thromboembolism,49,71,"OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism (VTE) among women on cyproterone acetate plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs).",12851669_1,1
3249,NRP,56,59,"METHODS: From the Danish National Register of Patients (NRP), 1996 to 1998, the records of 1.1 million Danish women, ages 15 to 44 years, were searched for evidence of VTE.",12851669_2,0
3251,VTE,168,171,"METHODS: From the Danish National Register of Patients (NRP), 1996 to 1998, the records of 1.1 million Danish women, ages 15 to 44 years, were searched for evidence of VTE.",12851669_2,0
3254,VTE,78,81,"RESULTS: During the time frame of the study, 330 women were found to have had VTE while on COCs.",12851669_5,0
3255,COCs,91,95,"RESULTS: During the time frame of the study, 330 women were found to have had VTE while on COCs.",12851669_5,0
3256,levonorgestrel-containing COCs,27,57,"Of these women, 67 were on levonorgestrel-containing COCs.",12851669_6,0
808,acetylsalicylic acid,51,71,Comparison of developmental toxicology of aspirin (acetylsalicylic acid) in rats using selected dosing paradigms.,12852481_0,0
3267,organogenesis,198,211,BACKGROUND: Analysis of the literature for nonsteroidal anti-inflammatory drugs (NSAIDs) suggests that a low incidence of developmental anomalies occurs in rats given NSAIDs on specific days during organogenesis.,12852481_1,1
3266,developmental anomalies,122,145,BACKGROUND: Analysis of the literature for nonsteroidal anti-inflammatory drugs (NSAIDs) suggests that a low incidence of developmental anomalies occurs in rats given NSAIDs on specific days during organogenesis.,12852481_1,1
3265,nonsteroidal anti-inflammatory drugs,43,79,BACKGROUND: Analysis of the literature for nonsteroidal anti-inflammatory drugs (NSAIDs) suggests that a low incidence of developmental anomalies occurs in rats given NSAIDs on specific days during organogenesis.,12852481_1,0
3285,DH,13,15,"In contrast, DH and MD were noted in the multiple dose study design only in the high-dose group, and VSD was noted across all dose groups.",12852481_11,0
3289,developmental anomalies,39,62,CONCLUSIONS: High concordance in major developmental anomalies between Wistar and SD rats were noted with the exception of VSD in the SD rats and hydrocephalus in the Wistar rats.,12852481_12,1
4727,ASA,47,50,Variations and malformations were similar when ASA was administered as a single dose or during the period of organogenesis (GDs 6 to 17).,12852481_13,1
4728,ASA,211,214,"It was also evident that, by titrating the dose to achieve a maximum tolerated dose, malformations that normally occur at low incidence, as reported from previous single dose studies, could also be induced with ASA given at multiple doses.",12852481_14,1
3268,developmental anomalies,96,119,"Aspirin (acetylsalicylic acid [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, induces developmental anomalies when administered to Wistar rats on gestational day (GD) 9, 10, or 11 (Kimmel CA, Wilson JG, Schumacher HJ.",12852481_2,1
3271,Kimmel CA,191,200,"Aspirin (acetylsalicylic acid [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, induces developmental anomalies when administered to Wistar rats on gestational day (GD) 9, 10, or 11 (Kimmel CA, Wilson JG, Schumacher HJ.",12852481_2,1
4719,ASA,31,34,"Aspirin (acetylsalicylic acid [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, induces developmental anomalies when administered to Wistar rats on gestational day (GD) 9, 10, or 11 (Kimmel CA, Wilson JG, Schumacher HJ.",12852481_2,1
809,acetylsalicylic acid,9,29,"Aspirin (acetylsalicylic acid [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, induces developmental anomalies when administered to Wistar rats on gestational day (GD) 9, 10, or 11 (Kimmel CA, Wilson JG, Schumacher HJ.",12852481_2,0
810,cyclooxygenase 1,54,70,"Aspirin (acetylsalicylic acid [ASA]), an irreversible cyclooxygenase 1 and 2 inhibitor, induces developmental anomalies when administered to Wistar rats on gestational day (GD) 9, 10, or 11 (Kimmel CA, Wilson JG, Schumacher HJ.",12852481_2,0
4720,ASA,23,26,There are no published ASA studies using the multiple dosing paradigm of GDs 6 to 17.,12852481_4,1
4722,ASA,383,386,"Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.",12852481_5,1
4721,ASA,108,111,"Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.",12852481_5,1
3274,organogenesis,230,243,"Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.",12852481_5,1
3275,incidence malformations,354,377,"Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used.",12852481_5,1
4723,ASA,9,12,"METHODS: ASA was administered as a single dose on GD 9 (0, 250, 500, or 625 mg/kg), 10 (0, 500, 625, or 750 mg/kg), or 11 (0, 500, 750, or 1000 mg/kg) and from GD 6 to GD 17 (0, 50, 125, or 250 mg/kg a day) in the multiple dose study to SD rats.",12852481_6,1
3278,midline defects,102,117,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,1
3281,low-incidence,307,320,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,1
811,et,197,199,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,0
4726,ASA,281,284,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,1
4725,diaphragmatic hernia,136,156,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,1
4724,ventricular septal defects,64,90,"RESULTS: The literature evaluation suggested that NSAIDs induce ventricular septal defects (VSDs) and midline defects (MDs) in rats and diaphragmatic hernia (DH), MDs, and VSDs in rabbits (Cook JC et al., 2003); hence, the present study focused on these malformations, even though ASA induces several other low-incidence malformations.",12852481_8,1
3283,DH,24,26,"In single dose studies, DH, MD, and VSD were induced on GDs 9 and 10.",12852481_9,0
812,flumazenil,46,56,Reversal of central benzodiazepine effects by flumazenil after intravenous conscious sedation with diazepam and opioids: report of a double-blind multicenter study.,1286498_0,0
813,opioids,112,119,Reversal of central benzodiazepine effects by flumazenil after intravenous conscious sedation with diazepam and opioids: report of a double-blind multicenter study.,1286498_0,0
3297,central benzodiazepine,12,34,Reversal of central benzodiazepine effects by flumazenil after intravenous conscious sedation with diazepam and opioids: report of a double-blind multicenter study.,1286498_0,0
814,Flumazenil,4,14,"The Flumazenil in Intravenous Conscious Sedation with Diazepam Multicenter Study Group II.The efficacy and safety of a new benzodiazepine antagonist, flumazenil, were assessed in a double-blind multicenter study.",1286498_1,0
815,flumazenil,150,160,"The Flumazenil in Intravenous Conscious Sedation with Diazepam Multicenter Study Group II.The efficacy and safety of a new benzodiazepine antagonist, flumazenil, were assessed in a double-blind multicenter study.",1286498_1,0
820,Flumazenil,0,10,Flumazenil was found to promptly reverse sedation induced by diazepam in the presence of opioids.,1286498_10,0
821,opioids,89,96,Flumazenil was found to promptly reverse sedation induced by diazepam in the presence of opioids.,1286498_10,0
816,Flumazenil,0,10,"Flumazenil (mean dose, 0.76 mg) or placebo (mean dose, 8.9 ml) was administered intravenously to 130 and 67 patients, respectively, who had been given diazepam in conjunction with an opioid (fentanyl, meperidine, or morphine) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures.",1286498_2,0
3303,opioid,183,189,"Flumazenil (mean dose, 0.76 mg) or placebo (mean dose, 8.9 ml) was administered intravenously to 130 and 67 patients, respectively, who had been given diazepam in conjunction with an opioid (fentanyl, meperidine, or morphine) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures.",1286498_2,0
817,flumazenil,70,80,The group assessable for efficacy comprised 122 patients treated with flumazenil and 64 patients given placebo.,1286498_3,0
4729,loss of,109,116,Ninety-five percent of patients in each group who attained a score of 5 at the 5-minute assessment showed no loss of alertness throughout the 180-minute assessment period.,1286498_5,1
4730,adverse effects,47,62,"Flumazenil was well tolerated, with no serious adverse effects reported.",1286498_7,1
818,Flumazenil,0,10,"Flumazenil was well tolerated, with no serious adverse effects reported.",1286498_7,0
3310,drug-related adverse experiences,117,149,"Thirty-nine (30%) of flumazenil-treated patients, compared with 17 (25%) of placebo-treated patients had one or more drug-related adverse experiences.",1286498_8,1
4731,adverse effects,16,31,The most common adverse effects were nausea and vomiting in the flumazenil group and nausea and injection-site pain in the placebo group.,1286498_9,1
819,flumazenil,64,74,The most common adverse effects were nausea and vomiting in the flumazenil group and nausea and injection-site pain in the placebo group.,1286498_9,0
4732,nausea and vomiting,37,56,The most common adverse effects were nausea and vomiting in the flumazenil group and nausea and injection-site pain in the placebo group.,1286498_9,1
3325,poor clinical outcome,81,102,"Associated factors were co-treatment with other centrally antimuscarinic agents, poor clinical outcome, older age, and longer hospitalization (by 17.5 days, increasing cost); sex, diagnosis or medical co-morbidity, and daily clozapine dose, which fell with age, were unrelated.",12905102_5,1
3327,medical co-morbidity,193,213,"Associated factors were co-treatment with other centrally antimuscarinic agents, poor clinical outcome, older age, and longer hospitalization (by 17.5 days, increasing cost); sex, diagnosis or medical co-morbidity, and daily clozapine dose, which fell with age, were unrelated.",12905102_5,1
3328,daily clozapine,219,234,"Associated factors were co-treatment with other centrally antimuscarinic agents, poor clinical outcome, older age, and longer hospitalization (by 17.5 days, increasing cost); sex, diagnosis or medical co-morbidity, and daily clozapine dose, which fell with age, were unrelated.",12905102_5,0
822,antimuscarinic agents,58,79,"Associated factors were co-treatment with other centrally antimuscarinic agents, poor clinical outcome, older age, and longer hospitalization (by 17.5 days, increasing cost); sex, diagnosis or medical co-morbidity, and daily clozapine dose, which fell with age, were unrelated.",12905102_5,0
3331,inferior clinical outcome,137,162,"Delirium was inconsistently recognized clinically in milder cases and was associated with increased length-of-stay and higher costs, and inferior clinical outcome.",12905102_7,1
3330,length-of-stay,100,114,"Delirium was inconsistently recognized clinically in milder cases and was associated with increased length-of-stay and higher costs, and inferior clinical outcome.",12905102_7,1
3333,MPEP,26,30,"Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats.",12907309_0,0
3335,dopaminergic neurotoxicity,90,116,"Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats.",12907309_0,1
3332,Neuroprotective action,0,22,"Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats.",12907309_0,0
3334,mGluR5 antagonist,44,61,"Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats.",12907309_0,0
825,toxic action,99,111,The aim of this study was to examine the role of metabotropic glutamate receptor 5 (mGluR5) in the toxic action of methamphetamine on dopaminergic neurones in rats.,12907309_1,0
826,dopaminergic,134,146,The aim of this study was to examine the role of metabotropic glutamate receptor 5 (mGluR5) in the toxic action of methamphetamine on dopaminergic neurones in rats.,12907309_1,0
824,mGluR5,84,90,The aim of this study was to examine the role of metabotropic glutamate receptor 5 (mGluR5) in the toxic action of methamphetamine on dopaminergic neurones in rats.,12907309_1,0
823,metabotropic glutamate receptor 5,49,82,The aim of this study was to examine the role of metabotropic glutamate receptor 5 (mGluR5) in the toxic action of methamphetamine on dopaminergic neurones in rats.,12907309_1,0
3339,MPEP,70,74,"A selective antagonist of mGluR5, 2-methyl-6-(phenylethynyl)pyridine (MPEP; 5 mg/kg ip), when administered five times immediately before each methamphetamine injection reversed the above-mentioned methamphetamine effects.",12907309_3,0
3338,selective antagonist,2,22,"A selective antagonist of mGluR5, 2-methyl-6-(phenylethynyl)pyridine (MPEP; 5 mg/kg ip), when administered five times immediately before each methamphetamine injection reversed the above-mentioned methamphetamine effects.",12907309_3,0
827,mGluR5,26,32,"A selective antagonist of mGluR5, 2-methyl-6-(phenylethynyl)pyridine (MPEP; 5 mg/kg ip), when administered five times immediately before each methamphetamine injection reversed the above-mentioned methamphetamine effects.",12907309_3,0
3340,MPEP,9,13,"A single MPEP (5 mg/kg ip) injection reduced the basal extracellular dopamine level in the striatum, as well as dopamine release stimulated either by methamphetamine (10 mg/kg sc) or by intrastriatally administered veratridine (100 microM).",12907309_4,0
3342,veratridine,215,226,"A single MPEP (5 mg/kg ip) injection reduced the basal extracellular dopamine level in the striatum, as well as dopamine release stimulated either by methamphetamine (10 mg/kg sc) or by intrastriatally administered veratridine (100 microM).",12907309_4,0
4733,body temperature,109,125,"Moreover, it transiently diminished the methamphetamine (10 mg/kg sc)-induced hyperthermia and reduced basal body temperature.",12907309_5,1
3344,MPEP,0,4,"MPEP administered into the striatum at high concentrations (500 microM) increased extracellular dopamine levels, while lower concentrations (50-100 microM) were devoid of any effect.",12907309_6,0
829,dopaminergic,82,94,The results of this study suggest that the blockade of mGluR5 by MPEP may protect dopaminergic neurones against methamphetamine-induced toxicity.,12907309_7,0
828,mGluR5,55,61,The results of this study suggest that the blockade of mGluR5 by MPEP may protect dopaminergic neurones against methamphetamine-induced toxicity.,12907309_7,0
3345,MPEP,65,69,The results of this study suggest that the blockade of mGluR5 by MPEP may protect dopaminergic neurones against methamphetamine-induced toxicity.,12907309_7,0
3348,MPEP,28,32,"Neuroprotection rendered by MPEP may be associated with the reduction of the methamphetamine-induced dopamine efflux in the striatum due to the blockade of extrastriatal mGluR5, and with a decrease in hyperthermia.",12907309_8,0
830,mGluR5,170,176,"Neuroprotection rendered by MPEP may be associated with the reduction of the methamphetamine-induced dopamine efflux in the striatum due to the blockade of extrastriatal mGluR5, and with a decrease in hyperthermia.",12907309_8,0
3349,elderly man,60,71,Methylphenidate-induced obsessive-compulsive symptoms in an elderly man.,12907924_0,1
4734,Alzheimer's disease,65,84,An 82-year-old man with treatment-resistant depression and early Alzheimer's disease was started on methylphenidate.,12907924_1,1
3350,treatment-resistant depression,24,54,An 82-year-old man with treatment-resistant depression and early Alzheimer's disease was started on methylphenidate.,12907924_1,1
3351,obsessive-compulsive behavior,12,41,Significant obsessive-compulsive behavior ensued but diminished over several weeks when methylphenidate was replaced by fluvoxamine.,12907924_2,1
3352,fluvoxamine,120,131,Significant obsessive-compulsive behavior ensued but diminished over several weeks when methylphenidate was replaced by fluvoxamine.,12907924_2,0
3353,psychiatric history,25,44,"The patient had no prior psychiatric history, but he had a sister with obsessive-compulsive disorder.",12907924_3,1
3354,obsessive-compulsive disorder,71,100,"The patient had no prior psychiatric history, but he had a sister with obsessive-compulsive disorder.",12907924_3,1
3356,pathological behavior,59,80,It appears that methylphenidate precipitated the patient's pathological behavior.,12907924_4,1
3357,acute interstitial nephritis,22,50,Ciprofloxacin-induced acute interstitial nephritis and autoimmune hemolytic anemia.,12911170_0,1
4735,autoimmune hemolytic anemia,55,82,Ciprofloxacin-induced acute interstitial nephritis and autoimmune hemolytic anemia.,12911170_0,1
4738,hemolytic anemia,97,113,Ciprofloxacin has been associated with several side effects including interstitial nephritis and hemolytic anemia.,12911170_1,1
4737,interstitial nephritis,70,92,Ciprofloxacin has been associated with several side effects including interstitial nephritis and hemolytic anemia.,12911170_1,1
4736,side effects,47,59,Ciprofloxacin has been associated with several side effects including interstitial nephritis and hemolytic anemia.,12911170_1,1
4739,side effects,24,36,The combination of both side effects is extremely rare.,12911170_2,1
4741,autoimmune hemolytic anemia,87,114,"In this report, we describe a case of ciprofloxacin-induced interstitial nephritis and autoimmune hemolytic anemia.",12911170_3,1
4740,interstitial nephritis,60,82,"In this report, we describe a case of ciprofloxacin-induced interstitial nephritis and autoimmune hemolytic anemia.",12911170_3,1
4742,Hemolytic anemia,0,16,Hemolytic anemia improved after stopping the drug and initiation of steroid therapy.,12911170_4,1
3360,acute interstitial nephritis,15,43,"Unfortunately, acute interstitial nephritis was irreversible and the patient developed end-stage renal disease.",12911170_5,1
4743,end-stage renal disease,87,110,"Unfortunately, acute interstitial nephritis was irreversible and the patient developed end-stage renal disease.",12911170_5,1
3362,cocaine kindled-seizures,52,76,Protective efficacy of neuroactive steroids against cocaine kindled-seizures in mice.,12921865_0,1
3361,Protective efficacy,0,19,Protective efficacy of neuroactive steroids against cocaine kindled-seizures in mice.,12921865_0,0
831,neuroactive steroids,23,43,Protective efficacy of neuroactive steroids against cocaine kindled-seizures in mice.,12921865_0,0
3363,psychiatric disorders,108,129,Neuroactive steroids demonstrate pharmacological actions that have relevance for a host of neurological and psychiatric disorders.,12921865_1,1
832,Neuroactive steroids,0,20,Neuroactive steroids demonstrate pharmacological actions that have relevance for a host of neurological and psychiatric disorders.,12921865_1,0
4744,drug dependence,98,113,They offer protection against seizures in a range of models and seem to inhibit certain stages of drug dependence in preclinical assessments.,12921865_2,1
834,gamma-aminobutyric acid,125,148,The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the gamma-aminobutyric acid (GABA(A)) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration (seizure kindling).,12921865_3,0
835,GABA(A)) receptor,150,167,The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the gamma-aminobutyric acid (GABA(A)) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration (seizure kindling).,12921865_3,0
836,convulsant effects,211,229,The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the gamma-aminobutyric acid (GABA(A)) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration (seizure kindling).,12921865_3,0
833,neuroactive steroid,76,95,The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the gamma-aminobutyric acid (GABA(A)) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration (seizure kindling).,12921865_3,0
838,pregnanolone,57,69,"Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice.",12921865_4,0
837,Allopregnanolone,0,16,"Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice.",12921865_4,0
3366,ganaxolone,112,122,"Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice.",12921865_4,0
839,allopregnanolone,150,166,"Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice.",12921865_4,0
3367,synthetic derivative,126,146,"Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice.",12921865_4,0
3370,cocaine-kindled seizures,345,369,"Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice.",12921865_4,1
3372,Kindled seizures,0,16,Kindled seizures were induced by daily administration of 60 mg/kg cocaine for 5 days.,12921865_5,1
3374,ganaxolone,122,132,"All of these positive GABA(A) modulators suppressed the expression of kindled seizures, whereas only allopregnanolone and ganaxolone inhibited the development of kindling.",12921865_6,0
840,allopregnanolone,101,117,"All of these positive GABA(A) modulators suppressed the expression of kindled seizures, whereas only allopregnanolone and ganaxolone inhibited the development of kindling.",12921865_6,0
3373,GABA(A) modulators,22,40,"All of these positive GABA(A) modulators suppressed the expression of kindled seizures, whereas only allopregnanolone and ganaxolone inhibited the development of kindling.",12921865_6,0
3375,ganaxolone,43,53,"Allopregnanolone and pregnanolone, but not ganaxolone, also reduced cumulative lethality associated with kindling.",12921865_7,0
841,Allopregnanolone,0,16,"Allopregnanolone and pregnanolone, but not ganaxolone, also reduced cumulative lethality associated with kindling.",12921865_7,0
842,pregnanolone,21,33,"Allopregnanolone and pregnanolone, but not ganaxolone, also reduced cumulative lethality associated with kindling.",12921865_7,0
844,convulsant,68,78,These findings demonstrate that some neuroactive steroids attenuate convulsant and sensitizing properties of cocaine and add to a growing literature on their potential use in the modulation of effects of drugs of abuse.,12921865_8,0
843,neuroactive steroids,37,57,These findings demonstrate that some neuroactive steroids attenuate convulsant and sensitizing properties of cocaine and add to a growing literature on their potential use in the modulation of effects of drugs of abuse.,12921865_8,0
845,radiocontrast,46,59,Potential deleterious effect of furosemide in radiocontrast nephropathy.,1300436_0,0
3379,intravenous fluids,84,102,The purpose of the study was to determine the efficacy of furosemide in addition to intravenous fluids in the prevention of radiocontrast nephropathy.,1300436_1,0
846,radiocontrast,124,137,The purpose of the study was to determine the efficacy of furosemide in addition to intravenous fluids in the prevention of radiocontrast nephropathy.,1300436_1,0
4745,renal insufficiency,90,109,"18 patients, referred to a radiocontrast study, considered at risk because of preexisting renal insufficiency, were enrolled in a prospective, randomized, controlled trial, performed at the secondary care center of a 1,100-bed private university hospital.",1300436_2,1
847,radiocontrast,27,40,"18 patients, referred to a radiocontrast study, considered at risk because of preexisting renal insufficiency, were enrolled in a prospective, randomized, controlled trial, performed at the secondary care center of a 1,100-bed private university hospital.",1300436_2,0
848,contrast material,129,146,"In addition to fluids, the treatment group received furosemide (mean dose 110 mg) intravenously 30 min prior to the injection of contrast material.",1300436_3,0
849,contrast material,87,104,"Radiological studies were mostly angiographies performed with both ionic and non-ionic contrast material, at an average dose of 245 ml.",1300436_5,0
850,creatinine,125,135,"Renal function significantly deteriorated in the group pretreated with furosemide (p < 0.005 by ANOVA), with a rise in serum creatinine from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).",1300436_6,0
3386,Renal function,0,14,"Renal function significantly deteriorated in the group pretreated with furosemide (p < 0.005 by ANOVA), with a rise in serum creatinine from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l).",1300436_6,1
4746,Renal failure,0,13,Renal failure was associated with weight loss in the furosemide-treated group.,1300436_7,1
3393,weight loss,34,45,Renal failure was associated with weight loss in the furosemide-treated group.,1300436_7,1
851,radiocontrast,51,64,Furosemide may be deleterious in the prevention of radiocontrast nephropathy.,1300436_8,0
3395,blood coagulation,26,43,Progestational agents and blood coagulation.,133615_0,0
852,Progestational agents,0,21,Progestational agents and blood coagulation.,133615_0,0
856,blood group,38,49,All four patients were of the A or AB blood group.,133615_11,0
3403,thromboembolic,72,86,Previous studies suggested the possiblility of increased propensity for thromboembolic episodes in patients possessing the A antigen.,133615_12,1
3404,A antigen,123,132,Previous studies suggested the possiblility of increased propensity for thromboembolic episodes in patients possessing the A antigen.,133615_12,0
857,oral contraceptive,109,127,It appears from these data that hematologic work-ups may be useful in women who are about to start long-term oral contraceptive therapy.,133615_13,0
3396,Thromboembolic,0,14,Thromboembolic and other complications of oral contraceptive therapy in relationship to pretreatment levels of blood coagulation factors: summary report of a ten-year study.,133615_2,1
853,oral contraceptive,42,60,Thromboembolic and other complications of oral contraceptive therapy in relationship to pretreatment levels of blood coagulation factors: summary report of a ten-year study.,133615_2,0
854,blood coagulation factors,111,136,Thromboembolic and other complications of oral contraceptive therapy in relationship to pretreatment levels of blood coagulation factors: summary report of a ten-year study.,133615_2,0
855,oral contraceptives,119,138,"During a ten-year period, 348 women were studied for a total of 5,877 patient months in four separate studies relating oral contraceptives to changes in hematologic parameters.",133615_3,0
3399,blood coagulation,48,65,"Significant increases in certain factors of the blood coagulation and fibrinolysin systems (factors I,II,VII,VIII,IX, and X and plasminogen) were observed in the treated groups.",133615_4,0
3401,"factors I,II",92,104,"Significant increases in certain factors of the blood coagulation and fibrinolysin systems (factors I,II,VII,VIII,IX, and X and plasminogen) were observed in the treated groups.",133615_4,0
4747,hypercoagulability,64,82,"All four had an abnormal blood coagulation profile, suggesting ""hypercoagulability"" before initiation of therapy.",133615_6,1
3402,blood coagulation,25,42,"All four had an abnormal blood coagulation profile, suggesting ""hypercoagulability"" before initiation of therapy.",133615_6,1
4748,myocardial infarction,34,55,"One of these patients developed a myocardial infarction before receiving any medication, shortly after the base-line values were obtained.",133615_8,1
4749,Orthostatic hypotension,0,23,Orthostatic hypotension occurs following alpha 2-adrenoceptor blockade in chronic prazosin-pretreated conscious spontaneously hypertensive rats.1.,1355091_0,1
3406,chronic prazosin-pretreated conscious spontaneously,74,125,Orthostatic hypotension occurs following alpha 2-adrenoceptor blockade in chronic prazosin-pretreated conscious spontaneously hypertensive rats.1.,1355091_0,1
3407,chronic prazosin,43,59,Studies were performed to evaluate whether chronic prazosin treatment alters the alpha 2-adrenoceptor function for orthostatic control of arterial blood pressure in conscious spontaneously hypertensive rats (SHR).,1355091_1,0
4750,blood pressure,147,161,Studies were performed to evaluate whether chronic prazosin treatment alters the alpha 2-adrenoceptor function for orthostatic control of arterial blood pressure in conscious spontaneously hypertensive rats (SHR).,1355091_1,1
3436,alpha 1-agonist cirazoline,48,74,"4. The pressor responses and bradycardia to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist Abbott-53693 (1 and 3 micrograms kg-1 i.v.), and noradrenaline (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic prazosin pretreatment.",1355091_10,0
3437,kg-1,97,101,"4. The pressor responses and bradycardia to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist Abbott-53693 (1 and 3 micrograms kg-1 i.v.), and noradrenaline (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic prazosin pretreatment.",1355091_10,0
3438,alpha 2-agonist Abbott-53693 (1,113,144,"4. The pressor responses and bradycardia to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist Abbott-53693 (1 and 3 micrograms kg-1 i.v.), and noradrenaline (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic prazosin pretreatment.",1355091_10,0
3439,kg-1,162,166,"4. The pressor responses and bradycardia to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist Abbott-53693 (1 and 3 micrograms kg-1 i.v.), and noradrenaline (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic prazosin pretreatment.",1355091_10,0
3440,kg-1,216,220,"4. The pressor responses and bradycardia to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist Abbott-53693 (1 and 3 micrograms kg-1 i.v.), and noradrenaline (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic prazosin pretreatment.",1355091_10,0
3441,chronic prazosin,277,293,"4. The pressor responses and bradycardia to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist Abbott-53693 (1 and 3 micrograms kg-1 i.v.), and noradrenaline (0.1 and 1.0 micrograms kg-1 i.v.) were determined in conscious SHR with and without chronic prazosin pretreatment.",1355091_10,0
3444,cirazoline,44,54,Both the pressor and bradycardia effects of cirazoline were abolished in chronic prazosin treated SHR (n = 4) as compared to the untreated SHR (n = 4).,1355091_11,0
3447,Abbott-53693,42,54,"On the other hand, the pressor effects of Abbott-53693 were similar in both groups of SHR, but the accompanying bradycardia was greater in SHR with chronic prazosin treatment than without such treatment.",1355091_12,0
3450,chronic prazosin,148,164,"On the other hand, the pressor effects of Abbott-53693 were similar in both groups of SHR, but the accompanying bradycardia was greater in SHR with chronic prazosin treatment than without such treatment.",1355091_12,0
3453,chronic prazosin,123,139,"Furthermore, the bradycardia that accompanied the noradrenaline-induced pressor effect in SHR was similar with and without chronic prazosin treatment despite a 47-71% reduction of the pressor effect in chronic alpha 1-receptor blocked SHR.(ABSTRACT TRUNCATED AT 400 WORDS)",1355091_13,0
3454,chronic alpha 1-receptor,202,226,"Furthermore, the bradycardia that accompanied the noradrenaline-induced pressor effect in SHR was similar with and without chronic prazosin treatment despite a 47-71% reduction of the pressor effect in chronic alpha 1-receptor blocked SHR.(ABSTRACT TRUNCATED AT 400 WORDS)",1355091_13,0
3414,rauwolscine (3,151,165,2. Conscious SHR (male 300-350 g) were subjected to 90 degrees head-up tilts for 60 s following acute administration of prazosin (0.1 mg kg-1 i.p.) or rauwolscine (3 mg kg-1 i.v.).,1355091_2,0
3415,kg-1,169,173,2. Conscious SHR (male 300-350 g) were subjected to 90 degrees head-up tilts for 60 s following acute administration of prazosin (0.1 mg kg-1 i.p.) or rauwolscine (3 mg kg-1 i.v.).,1355091_2,0
3412,acute administration of prazosin,96,128,2. Conscious SHR (male 300-350 g) were subjected to 90 degrees head-up tilts for 60 s following acute administration of prazosin (0.1 mg kg-1 i.p.) or rauwolscine (3 mg kg-1 i.v.).,1355091_2,0
4751,Orthostatic hypotension,0,23,Orthostatic hypotension was determined by the average decrease (%) in mean arterial pressure (MAP femoral) over the 60-s tilt period.,1355091_3,1
3416,mean arterial pressure,70,92,Orthostatic hypotension was determined by the average decrease (%) in mean arterial pressure (MAP femoral) over the 60-s tilt period.,1355091_3,1
3418,rauwolscine,97,108,The basal MAP of conscious SHR was reduced to a similar extent by prazosin (-23%(-)-26% MAP) and rauwolscine (-16%(-)-33% MAP).,1355091_4,0
3422,rauwolscine,142,153,"However, the head-up tilt induced orthostatic hypotension in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6).",1355091_5,0
4752,orthostatic hypotension,34,57,"However, the head-up tilt induced orthostatic hypotension in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6).",1355091_5,1
3419,head-up tilt,13,25,"However, the head-up tilt induced orthostatic hypotension in the SHR treated with prazosin (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6).",1355091_5,1
3427,chronic prazosin,27,43,MAP in conscious SHR after chronic prazosin treatment was 14% lower than in the untreated SHR (n = 8).,1355091_7,0
3429,Head-up,0,7,Head-up tilts in these rats did not produce orthostatic hypotension when performed either prior to or after acute dosing of prazosin (0.1 mg kg-1 i.p.).,1355091_8,1
4753,orthostatic hypotension,44,67,Head-up tilts in these rats did not produce orthostatic hypotension when performed either prior to or after acute dosing of prazosin (0.1 mg kg-1 i.p.).,1355091_8,1
3431,rauwolscine (3,30,44,"Conversely, administration of rauwolscine (3 mg kg-1 i.v.) in chronic prazosin treated SHR decreased the basal MAP by 12-31% (n = 4), and subsequent tilts induced further drops of MAP by 19-23% in these rats.",1355091_9,0
3432,kg-1,48,52,"Conversely, administration of rauwolscine (3 mg kg-1 i.v.) in chronic prazosin treated SHR decreased the basal MAP by 12-31% (n = 4), and subsequent tilts induced further drops of MAP by 19-23% in these rats.",1355091_9,0
3433,chronic prazosin,62,78,"Conversely, administration of rauwolscine (3 mg kg-1 i.v.) in chronic prazosin treated SHR decreased the basal MAP by 12-31% (n = 4), and subsequent tilts induced further drops of MAP by 19-23% in these rats.",1355091_9,0
858,modulators,18,28,Effect of humoral modulators of morphine-induced increase in locomotor activity of mice.,137340_0,0
859,modulators,22,32,The effect of humoral modulators on the morphine-induced increase in locomotor activity of mice was studied.,137340_1,0
3460,morphine-HC1,47,59,The subcutaneous administration of 10 mg/kg of morphine-HC1 produced a marked increase in locomotor activity in mice.,137340_2,0
3462,morphine-induced hyperactivity,4,34,The morphine-induced hyperactivity was potentiated by scopolamine and attenuated by physostigmine.,137340_3,1
860,methscopolamine,18,33,"In contrast, both methscopolamine and neostigmine, which do not penetrate the blood-brain barrier, had no effect on the hyperactivity produced by morphine.",137340_4,0
862,tyrosine hydroxylase,90,110,"Pretreatment of mice with alpha-methyltyrosine (20 mg/kg i.p., one hour), an inhibitor of tyrosine hydroxylase, significantly decreased the activity-increasing effects of morphine.",137340_5,0
3465,i.p.,57,61,"Pretreatment of mice with alpha-methyltyrosine (20 mg/kg i.p., one hour), an inhibitor of tyrosine hydroxylase, significantly decreased the activity-increasing effects of morphine.",137340_5,0
861,alpha-methyltyrosine,26,46,"Pretreatment of mice with alpha-methyltyrosine (20 mg/kg i.p., one hour), an inhibitor of tyrosine hydroxylase, significantly decreased the activity-increasing effects of morphine.",137340_5,0
3470,serotonin depletor,90,108,"On the other hand, pretreatment with p-chlorophenylalamine (3 X 320 mg/kg i.p., 24 hr), a serotonin depletor, caused no significant change in the hyperactivity.",137340_6,0
3468,p-chlorophenylalamine (3,37,61,"On the other hand, pretreatment with p-chlorophenylalamine (3 X 320 mg/kg i.p., 24 hr), a serotonin depletor, caused no significant change in the hyperactivity.",137340_6,0
3476,high protein,30,42,Effects of uninephrectomy and high protein feeding on lithium-induced chronic renal failure in rats.,1378968_0,1
4754,chronic renal failure,70,91,Effects of uninephrectomy and high protein feeding on lithium-induced chronic renal failure in rats.,1378968_0,1
3475,uninephrectomy,11,25,Effects of uninephrectomy and high protein feeding on lithium-induced chronic renal failure in rats.,1378968_0,0
4755,renal failure,208,221,"Rats with lithium-induced nephropathy were subjected to high protein (HP) feeding, uninephrectomy (NX) or a combination of these, in an attempt to induce glomerular hyperfiltration and further progression of renal failure.",1378968_1,1
3479,high protein,56,68,"Rats with lithium-induced nephropathy were subjected to high protein (HP) feeding, uninephrectomy (NX) or a combination of these, in an attempt to induce glomerular hyperfiltration and further progression of renal failure.",1378968_1,0
3482,glomerular hyperfiltration,154,180,"Rats with lithium-induced nephropathy were subjected to high protein (HP) feeding, uninephrectomy (NX) or a combination of these, in an attempt to induce glomerular hyperfiltration and further progression of renal failure.",1378968_1,1
3480,uninephrectomy,83,97,"Rats with lithium-induced nephropathy were subjected to high protein (HP) feeding, uninephrectomy (NX) or a combination of these, in an attempt to induce glomerular hyperfiltration and further progression of renal failure.",1378968_1,1
3504,GFR,64,67,"The results indicate that Li-induced nephropathy, even when the GFR is only modestly reduced, is associated with proteinuria and arterial systolic hypertension.",1378968_10,0
4760,systolic hypertension,138,159,"The results indicate that Li-induced nephropathy, even when the GFR is only modestly reduced, is associated with proteinuria and arterial systolic hypertension.",1378968_10,1
3506,GFR,54,57,"In this model of chronic renal failure the decline in GFR is not accompanied by a corresponding fall in effective renal plasma flow, which may be the functional expression of the formation of nonfiltrating atubular glomeruli.",1378968_11,0
3509,atubular glomeruli,206,224,"In this model of chronic renal failure the decline in GFR is not accompanied by a corresponding fall in effective renal plasma flow, which may be the functional expression of the formation of nonfiltrating atubular glomeruli.",1378968_11,1
3508,nonfiltrating,192,205,"In this model of chronic renal failure the decline in GFR is not accompanied by a corresponding fall in effective renal plasma flow, which may be the functional expression of the formation of nonfiltrating atubular glomeruli.",1378968_11,0
4761,chronic renal failure,17,38,"In this model of chronic renal failure the decline in GFR is not accompanied by a corresponding fall in effective renal plasma flow, which may be the functional expression of the formation of nonfiltrating atubular glomeruli.",1378968_11,1
3512,distal delivery,93,108,"The fractional reabsorption of tubular fluid by the proximal tubules is reduced, leaving the distal delivery unchanged.(ABSTRACT TRUNCATED AT 250 WORDS)",1378968_12,1
3487,NX,145,147,"Newborn female Wistar rats were fed a lithium-containing diet (50 mmol/kg) for 8 weeks and then randomized to normal diet, HP diet (40 vs. 19%), NX or HP+NX for another 8 weeks.",1378968_2,0
3491,GFR,128,131,"When comparing all lithium treated versus non-lithium-treated groups, lithium caused a reduction in glomerular filtration rate (GFR) without significant changes in effective renal plasma flow (as determined by a marker secreted into the proximal tubules) or lithium clearance.",1378968_4,0
4757,glomerulosclerosis,72,90,Lithium also caused proteinuria and systolic hypertension in absence of glomerulosclerosis.,1378968_6,1
4756,systolic hypertension,36,57,Lithium also caused proteinuria and systolic hypertension in absence of glomerulosclerosis.,1378968_6,1
863,creatinine,109,119,HP failed to accentuante progression of renal failure and in fact tended to increase GFR and decrease plasma creatinine levels in lithium pretreated rats.,1378968_7,0
4758,renal failure,40,53,HP failed to accentuante progression of renal failure and in fact tended to increase GFR and decrease plasma creatinine levels in lithium pretreated rats.,1378968_7,1
3495,accentuante,13,24,HP failed to accentuante progression of renal failure and in fact tended to increase GFR and decrease plasma creatinine levels in lithium pretreated rats.,1378968_7,0
3496,GFR,85,88,HP failed to accentuante progression of renal failure and in fact tended to increase GFR and decrease plasma creatinine levels in lithium pretreated rats.,1378968_7,0
3499,additive deterioration,13,35,"NX caused an additive deterioration in GFR which, however, was ameliorated by HP.",1378968_8,1
3498,NX,0,2,"NX caused an additive deterioration in GFR which, however, was ameliorated by HP.",1378968_8,0
3500,GFR,39,42,"NX caused an additive deterioration in GFR which, however, was ameliorated by HP.",1378968_8,0
3501,NX+HP,0,5,NX+HP caused a further rise in blood pressure in Li-pretreated rats.,1378968_9,0
4759,blood pressure,31,45,NX+HP caused a further rise in blood pressure in Li-pretreated rats.,1378968_9,1
4762,Hemolytic-uremic syndrome,0,25,Hemolytic-uremic syndrome associated with ingestion of quinine.,1415380_0,1
4763,Hemolytic-uremic syndrome,0,25,"Hemolytic-uremic syndrome following quinine ingestion is a newly described phenomenon, with just two previous descriptions of 4 cases in the literature.",1415380_1,1
864,dipyridamole,72,84,"Treatment has included use of plasma exchange, prednisone, aspirin, and dipyridamole.",1415380_4,0
3514,renal function,46,60,The patients have all regained some degree of renal function.,1415380_5,1
3515,spontaneous resolution,60,82,"However, it is unclear whether pharmacological treatment or spontaneous resolution is responsible for the improvement.",1415380_6,1
4764,hemolytic-uremic syndrome,19,44,Quinine-associated hemolytic-uremic syndrome probably occurs more often than is recognized.,1415380_7,1
866,cyclosporin,107,118,Treatment of Crohn's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin.,1420741_0,0
3516,immunosuppressive properties,67,95,Treatment of Crohn's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin.,1420741_0,0
865,fusidic acid,34,46,Treatment of Crohn's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin.,1420741_0,0
4765,Crohn's disease,13,28,Treatment of Crohn's disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin.,1420741_0,1
867,Fusidic acid,0,12,Fusidic acid is an antibiotic with T-cell specific immunosuppressive effects similar to those of cyclosporin.,1420741_1,0
3517,T-cell,35,41,Fusidic acid is an antibiotic with T-cell specific immunosuppressive effects similar to those of cyclosporin.,1420741_1,0
868,cyclosporin,97,108,Fusidic acid is an antibiotic with T-cell specific immunosuppressive effects similar to those of cyclosporin.,1420741_1,0
3518,immunosuppressive effects,51,76,Fusidic acid is an antibiotic with T-cell specific immunosuppressive effects similar to those of cyclosporin.,1420741_1,0
872,fusidic acid,45,57,The results of this pilot study suggest that fusidic acid may be of benefit in selected chronic active Crohn's disease patients in whom conventional treatment is ineffective.,1420741_10,0
3527,chronic active Crohn's disease,88,118,The results of this pilot study suggest that fusidic acid may be of benefit in selected chronic active Crohn's disease patients in whom conventional treatment is ineffective.,1420741_10,1
873,fusidic acid,67,79,"Because there seems to exist a scientific rationale for the use of fusidic acid at the cytokine level in inflammatory bowel disease, we suggest that the role of this treatment should be further investigated.",1420741_11,0
4770,inflammatory bowel disease,105,131,"Because there seems to exist a scientific rationale for the use of fusidic acid at the cytokine level in inflammatory bowel disease, we suggest that the role of this treatment should be further investigated.",1420741_11,1
869,fusidic acid,161,173,"Because of the need for the development of new treatments for Crohn's disease, a pilot study was undertaken to estimate the pharmacodynamics and tolerability of fusidic acid treatment in chronic active, therapy-resistant patients.",1420741_2,0
4766,Crohn's disease,62,77,"Because of the need for the development of new treatments for Crohn's disease, a pilot study was undertaken to estimate the pharmacodynamics and tolerability of fusidic acid treatment in chronic active, therapy-resistant patients.",1420741_2,1
4767,chronic active,187,201,"Because of the need for the development of new treatments for Crohn's disease, a pilot study was undertaken to estimate the pharmacodynamics and tolerability of fusidic acid treatment in chronic active, therapy-resistant patients.",1420741_2,1
4768,Crohn's disease,6,21,Eight Crohn's disease patients were included.,1420741_3,1
870,Fusidic acid,0,12,Fusidic acid was administered orally in a dose of 500 mg t.d.s. and the treatment was planned to last 8 weeks.,1420741_4,0
871,fusidic acid,41,53,Five of 8 patients (63%) improved during fusidic acid treatment: 3 at two weeks and 2 after four weeks.,1420741_6,0
4769,side effects,31,43,"There were no serious clinical side effects, but dose reduction was required in two patients because of nausea.",1420741_7,1
3524,alkaline phosphatases,30,51,"Biochemically, an increase in alkaline phosphatases was noted in 5 of 8 cases (63%), and the greatest increases were seen in those who had elevated levels prior to treatment.",1420741_8,0
874,propranolol,34,45,Amnestic syndrome associated with propranolol toxicity: a case report.,1423339_0,0
4771,Amnestic syndrome,0,17,Amnestic syndrome associated with propranolol toxicity: a case report.,1423339_0,1
875,propranolol,78,89,An elderly woman developed an Alzheimer-like subacute dementia as a result of propranolol toxicity.,1423339_1,0
3530,Alzheimer-like subacute dementia,30,62,An elderly woman developed an Alzheimer-like subacute dementia as a result of propranolol toxicity.,1423339_1,1
4772,drug toxicity,45,58,There is evidence that cerebral reactions to drug toxicity can exhibit patterns that suggest highly selective involvement of functional subdivisions of the brain.,1423339_3,1
876,beta-blockers,53,66,Changes in depressive status associated with topical beta-blockers.,1428568_0,0
877,beta-blockers,79,92,Depression and sexual dysfunction have been related to side effects of topical beta-blockers.,1428568_1,0
4773,sexual dysfunction,15,33,Depression and sexual dysfunction have been related to side effects of topical beta-blockers.,1428568_1,1
4774,side effects,55,67,Depression and sexual dysfunction have been related to side effects of topical beta-blockers.,1428568_1,1
3534,non selective beta-blocker,80,106,We performed a preliminary study in order to determine any difference between a non selective beta-blocker (timolol) and a selective beta-blocker (betaxolol) regarding CNS side effects.,1428568_2,0
3535,beta-blocker,133,145,We performed a preliminary study in order to determine any difference between a non selective beta-blocker (timolol) and a selective beta-blocker (betaxolol) regarding CNS side effects.,1428568_2,0
4775,side effects,172,184,We performed a preliminary study in order to determine any difference between a non selective beta-blocker (timolol) and a selective beta-blocker (betaxolol) regarding CNS side effects.,1428568_2,1
878,betaxolol,147,156,We performed a preliminary study in order to determine any difference between a non selective beta-blocker (timolol) and a selective beta-blocker (betaxolol) regarding CNS side effects.,1428568_2,0
3536,glaucomatous,6,18,"Eight glaucomatous patients chronically treated with timolol 0.5%/12h, suffering from depression diagnosed through DMS-III-R criteria, were included in the study.",1428568_3,1
3539,follow up,21,30,"During the six-month follow up, depression was quantified through the Beck and Zung-Conde scales every two months.",1428568_4,1
879,betaxolol,27,36,These results suggest that betaxolol could be less of a depression-inducer than timolol in predisposed patients.,1428568_6,0
880,excitatory amino acid antagonist,113,145,"Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist.",1436384_0,0
3546,LY274614,100,108,"Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist.",1436384_0,0
3545,striatal,60,68,"Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist.",1436384_0,1
4776,neurotoxicity,39,52,"Protection against amphetamine-induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist.",1436384_0,1
884,glutamate receptor,178,196,"LY274614, 3SR,4aRS,6SR,8aRS-6-[phosphonomethyl]decahydr oisoquinoline-3- carboxylic acid, has been described as a potent antagonist of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor.",1436384_1,0
883,NMDA,161,165,"LY274614, 3SR,4aRS,6SR,8aRS-6-[phosphonomethyl]decahydr oisoquinoline-3- carboxylic acid, has been described as a potent antagonist of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor.",1436384_1,0
881,carboxylic acid,73,88,"LY274614, 3SR,4aRS,6SR,8aRS-6-[phosphonomethyl]decahydr oisoquinoline-3- carboxylic acid, has been described as a potent antagonist of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor.",1436384_1,0
882,N-methyl-D-aspartate,139,159,"LY274614, 3SR,4aRS,6SR,8aRS-6-[phosphonomethyl]decahydr oisoquinoline-3- carboxylic acid, has been described as a potent antagonist of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor.",1436384_1,0
3551,iprindole,96,105,"A single 18.4 mg/kg (i.p.) dose of (+/-)-amphetamine hemisulfate, given to rats pretreated with iprindole, resulted in persistent depletion of dopamine in the striatum 1 week later.",1436384_3,0
3550,(+/-)-amphetamine hemisulfate,35,64,"A single 18.4 mg/kg (i.p.) dose of (+/-)-amphetamine hemisulfate, given to rats pretreated with iprindole, resulted in persistent depletion of dopamine in the striatum 1 week later.",1436384_3,0
3552,dizocilpine,72,83,"This prolonged depletion of dopamine in the striatum was antagonized by dizocilpine (MK-801, a non-competitive antagonist of NMDA receptors) or by LY274614 (a competitive antagonist of NMDA receptors).",1436384_4,0
3554,LY274614,147,155,"This prolonged depletion of dopamine in the striatum was antagonized by dizocilpine (MK-801, a non-competitive antagonist of NMDA receptors) or by LY274614 (a competitive antagonist of NMDA receptors).",1436384_4,0
887,NMDA receptors,185,199,"This prolonged depletion of dopamine in the striatum was antagonized by dizocilpine (MK-801, a non-competitive antagonist of NMDA receptors) or by LY274614 (a competitive antagonist of NMDA receptors).",1436384_4,0
3553,non-competitive,95,110,"This prolonged depletion of dopamine in the striatum was antagonized by dizocilpine (MK-801, a non-competitive antagonist of NMDA receptors) or by LY274614 (a competitive antagonist of NMDA receptors).",1436384_4,0
886,NMDA receptors,125,139,"This prolonged depletion of dopamine in the striatum was antagonized by dizocilpine (MK-801, a non-competitive antagonist of NMDA receptors) or by LY274614 (a competitive antagonist of NMDA receptors).",1436384_4,0
885,MK-801,85,91,"This prolonged depletion of dopamine in the striatum was antagonized by dizocilpine (MK-801, a non-competitive antagonist of NMDA receptors) or by LY274614 (a competitive antagonist of NMDA receptors).",1436384_4,0
3558,mgkg,77,81,"The protective effect of LY274614 was dose-dependent, being maximum at 10-40 mgkg (i.p.).",1436384_5,0
3556,LY274614,25,33,"The protective effect of LY274614 was dose-dependent, being maximum at 10-40 mgkg (i.p.).",1436384_5,0
3555,protective effect,4,21,"The protective effect of LY274614 was dose-dependent, being maximum at 10-40 mgkg (i.p.).",1436384_5,0
888,at 10,68,73,"The protective effect of LY274614 was dose-dependent, being maximum at 10-40 mgkg (i.p.).",1436384_5,0
3560,LY274614,19,27,"A 10 mg/kg dose of LY274614 was effective in antagonizing the depletion of dopamine in the striatum, when given as long as 8 hr prior to amphetamine but not when given 24 hr prior to amphetamine.",1436384_6,0
3561,LY274614,64,72,Depletion of dopamine in the striatum was also antagonized when LY274614 was given after the injection of amphetamine; LY274614 protected when given up to 4 hr after but not when given 8 or 24 hr after amphetamine.,1436384_7,0
3562,LY274614,119,127,Depletion of dopamine in the striatum was also antagonized when LY274614 was given after the injection of amphetamine; LY274614 protected when given up to 4 hr after but not when given 8 or 24 hr after amphetamine.,1436384_7,0
3563,LY274614,163,171,"The prolonged depletion of dopamine in the striatum in mice, given multiple injections of methamphetamine, was also antagonized dose-dependently and completely by LY274614.",1436384_8,0
889,NMDA receptors,144,158,The data strengthen the evidence that the neurotoxic effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long-lasting in vivo effects in rats.,1436384_9,0
3564,nigrostriatal,104,117,The data strengthen the evidence that the neurotoxic effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long-lasting in vivo effects in rats.,1436384_9,0
3565,LY274614,168,176,The data strengthen the evidence that the neurotoxic effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long-lasting in vivo effects in rats.,1436384_9,0
3566,NMDA receptor antagonist,183,207,The data strengthen the evidence that the neurotoxic effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long-lasting in vivo effects in rats.,1436384_9,0
4777,hemolytic anemia,25,41,Cefotetan-induced immune hemolytic anemia.,1445986_0,1
4778,hemolytic anemia,7,23,Immune hemolytic anemia due to a drug-adsorption mechanism has been described primarily in patients receiving penicillins and first-generation cephalosporins.,1445986_1,1
3567,first-generation cephalosporins,126,157,Immune hemolytic anemia due to a drug-adsorption mechanism has been described primarily in patients receiving penicillins and first-generation cephalosporins.,1445986_1,0
890,cefotetan,71,80,We describe a patient who developed anemia while receiving intravenous cefotetan.,1445986_2,0
3568,Cefotetan-dependent antibodies,0,30,Cefotetan-dependent antibodies were detected in the patient's serum and in an eluate prepared from his red blood cells.,1445986_3,0
891,cefotetan,70,79,"The eluate also reacted weakly with red blood cells in the absence of cefotetan, suggesting the concomitant formation of warm-reactive autoantibodies.",1445986_4,0
3572,drug-induced hemolytic anemia,121,150,"These observations, in conjunction with clinical and laboratory evidence of extravascular hemolysis, are consistent with drug-induced hemolytic anemia, possibly involving both drug-adsorption and autoantibody formation mechanisms.",1445986_5,1
4779,extravascular hemolysis,76,99,"These observations, in conjunction with clinical and laboratory evidence of extravascular hemolysis, are consistent with drug-induced hemolytic anemia, possibly involving both drug-adsorption and autoantibody formation mechanisms.",1445986_5,1
3573,hemolytic reactions,57,76,This case emphasizes the need for increased awareness of hemolytic reactions to all cephalosporins.,1445986_6,1
3574,Ketoconazole-induced neurologic sequelae,0,40,Ketoconazole-induced neurologic sequelae.,14513889_0,1
892,his,157,160,"A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.",14513889_1,0
3575,legs paralysis,54,68,"A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.",14513889_1,1
3576,ketoconazole,122,134,"A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life.",14513889_1,0
3578,clinical picture,149,165,"All complaints faded away within 24 h. Few days later, the patient used another 200 mg ketoconazole tablet, and within an hour experienced a similar clinical picture, which resolved again spontaneously within hours.",14513889_2,1
3577,ketoconazole,87,99,"All complaints faded away within 24 h. Few days later, the patient used another 200 mg ketoconazole tablet, and within an hour experienced a similar clinical picture, which resolved again spontaneously within hours.",14513889_2,0
4780,adverse drug reactions,54,76,"This case illustrates the need for close vigilance in adverse drug reactions, particularly in the elderly.",14513889_4,1
3583,symptom onset,92,105,Development of levodopa-induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and/or duration of symptoms.,14568327_0,1
4781,Parkinson's disease,92,111,Levodopa-induced dyskinesias (LIDs) present a major problem for the long-term management of Parkinson's disease (PD) patients.,14568327_1,1
3589,symptom severity,150,166,"Using macaque monkeys with different types of MPTP-induced parkinsonism, the current study evaluated the degree to which rate of symptom progression, symptom severity, and response to and duration of levodopa therapy may be involved in the development of LIDs.",14568327_3,1
3588,symptom progression,129,148,"Using macaque monkeys with different types of MPTP-induced parkinsonism, the current study evaluated the degree to which rate of symptom progression, symptom severity, and response to and duration of levodopa therapy may be involved in the development of LIDs.",14568327_3,1
4782,MPTP-induced parkinsonism,46,71,"Using macaque monkeys with different types of MPTP-induced parkinsonism, the current study evaluated the degree to which rate of symptom progression, symptom severity, and response to and duration of levodopa therapy may be involved in the development of LIDs.",14568327_3,1
3591,symptom onset,53,66,"Monkeys with acute (short-term) MPTP exposure, rapid symptom onset and short symptom duration prior to initiation of levodopa therapy developed dyskinesia between 11 and 24 days of daily levodopa administration.",14568327_4,1
3590,MPTP,32,36,"Monkeys with acute (short-term) MPTP exposure, rapid symptom onset and short symptom duration prior to initiation of levodopa therapy developed dyskinesia between 11 and 24 days of daily levodopa administration.",14568327_4,0
3599,chronic levodopa,239,255,"In contrast, monkeys with long-term MPTP exposure, slow symptom progression and/or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs (e.g., dyskinesia developed no sooner than 146 days of chronic levodopa administration).",14568327_5,0
3596,long symptom duration,83,104,"In contrast, monkeys with long-term MPTP exposure, slow symptom progression and/or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs (e.g., dyskinesia developed no sooner than 146 days of chronic levodopa administration).",14568327_5,1
3595,symptom progression,56,75,"In contrast, monkeys with long-term MPTP exposure, slow symptom progression and/or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs (e.g., dyskinesia developed no sooner than 146 days of chronic levodopa administration).",14568327_5,1
3594,MPTP,36,40,"In contrast, monkeys with long-term MPTP exposure, slow symptom progression and/or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs (e.g., dyskinesia developed no sooner than 146 days of chronic levodopa administration).",14568327_5,0
4783,pathophysiology,235,250,These data suggest distinct differences in the propensity to develop LIDs in monkeys with different rates of symptom progression or symptom durations prior to levodopa and demonstrate the value of these models for further studying the pathophysiology of LIDs.,14568327_7,1
3600,symptom progression,109,128,These data suggest distinct differences in the propensity to develop LIDs in monkeys with different rates of symptom progression or symptom durations prior to levodopa and demonstrate the value of these models for further studying the pathophysiology of LIDs.,14568327_7,1
893,low dose,77,85,A diet promoting sugar dependency causes behavioral cross-sensitization to a low dose of amphetamine.,14596845_0,0
3603,drug dependency,170,185,Previous research in this laboratory has shown that a diet of intermittent excessive sugar consumption produces a state with neurochemical and behavioral similarities to drug dependency.,14596845_1,1
894,low dose,130,138,The present study examined whether female rats on various regimens of sugar access would show behavioral cross-sensitization to a low dose of amphetamine.,14596845_2,0
3605,cross-sensitization,105,124,The present study examined whether female rats on various regimens of sugar access would show behavioral cross-sensitization to a low dose of amphetamine.,14596845_2,1
3607,12-h deprivation,107,123,"After a 30-min baseline measure of locomotor activity (day 0), animals were maintained on a cyclic diet of 12-h deprivation followed by 12-h access to 10% sucrose solution and chow pellets (12 h access starting 4 h after onset of the dark period) for 21 days.",14596845_3,1
3608,sucrose solution,155,171,"After a 30-min baseline measure of locomotor activity (day 0), animals were maintained on a cyclic diet of 12-h deprivation followed by 12-h access to 10% sucrose solution and chow pellets (12 h access starting 4 h after onset of the dark period) for 21 days.",14596845_3,0
895,low dose,72,80,Nine days later locomotor activity was measured in response to a single low dose of amphetamine (0.5 mg/kg).,14596845_6,0
3613,cyclic sucrose,33,47,"The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection).",14596845_7,0
3618,sugar solution,87,101,"These results suggest that a diet comprised of alternating deprivation and access to a sugar solution and chow produces bingeing on sugar that leads to a long lasting state of increased sensitivity to amphetamine, possibly due to a lasting alteration in the dopamine system.",14596845_8,0
896,mesna,26,31,Use of dexamethasone with mesna for the prevention of ifosfamide-induced hemorrhagic cystitis.,14633084_0,0
897,ifosfamide,78,88,AIM: Hemorrhagic cystitis (HC) is a limiting side-effect of chemotherapy with ifosfamide (IFS).,14633084_1,0
4784,side-effect,45,56,AIM: Hemorrhagic cystitis (HC) is a limiting side-effect of chemotherapy with ifosfamide (IFS).,14633084_1,1
3622,Hemorrhagic cystitis,5,25,AIM: Hemorrhagic cystitis (HC) is a limiting side-effect of chemotherapy with ifosfamide (IFS).,14633084_1,1
907,mesna,78,83,"However, the replacement of last two doses of mesna with saline or all of the mesna doses with dexamethasone did not prevent HC.",14633084_10,0
906,mesna,46,51,"However, the replacement of last two doses of mesna with saline or all of the mesna doses with dexamethasone did not prevent HC.",14633084_10,0
898,mesna,90,95,"In the study presented here, we investigated the use of dexamethasone in combination with mesna for the prevention of IFS-induced HC.",14633084_2,0
899,mesna,84,89,METHODS: Male Wistar rats (150-200 g; 6 rats per group) were treated with saline or mesna 5 min (i.p.) before and 2 and 6 h after (v.o.) administration of IFS.,14633084_3,0
901,mesna,99,104,"One, two or three doses of mesna were replaced with dexamethasone alone or with dexamethasone plus mesna.",14633084_4,0
900,mesna,27,32,"One, two or three doses of mesna were replaced with dexamethasone alone or with dexamethasone plus mesna.",14633084_4,0
902,mesna,67,72,"RESULTS: The replacement of the last dose or the last two doses of mesna with dexamethasone reduced the increase in bladder wet weight induced by IFS by 84.79% and 89.13%, respectively.",14633084_6,0
904,mesna,110,115,"Moreover, the addition of dexamethasone to the last two doses of mesna was more efficient than three doses of mesna alone when evaluated microscopically.",14633084_8,0
903,mesna,65,70,"Moreover, the addition of dexamethasone to the last two doses of mesna was more efficient than three doses of mesna alone when evaluated microscopically.",14633084_8,0
905,mesna,46,51,CONCLUSION: Dexamethasone in combination with mesna was efficient in blocking IFS-induced HC.,14633084_9,0
908,trans-retinoic,5,19,All- trans-retinoic acid-induced erythema nodosum in patients with acute promyelocytic leukemia.,14648024_0,0
4785,acute promyelocytic leukemia,67,95,All- trans-retinoic acid-induced erythema nodosum in patients with acute promyelocytic leukemia.,14648024_0,1
3636,ATRA,59,63,Erythema nodosum associated with all- trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is very rare.,14648024_1,1
4786,acute promyelocytic leukemia,69,97,Erythema nodosum associated with all- trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is very rare.,14648024_1,1
909,trans-retinoic acid,38,57,Erythema nodosum associated with all- trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is very rare.,14648024_1,0
3637,APL,99,102,Erythema nodosum associated with all- trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is very rare.,14648024_1,0
3634,Erythema nodosum,0,16,Erythema nodosum associated with all- trans-retinoic acid (ATRA) for acute promyelocytic leukemia (APL) is very rare.,14648024_1,1
3639,erythema nodosum,57,73,We describe four patients with classic APL who developed erythema nodosum during ATRA therapy.,14648024_2,1
3642,D11,89,92,"Fever and subsequent multiple painful erythematous nodules over extremities developed on D11, D16, D17, and D19, respectively, after ATRA therapy.",14648024_3,0
3644,D17,99,102,"Fever and subsequent multiple painful erythematous nodules over extremities developed on D11, D16, D17, and D19, respectively, after ATRA therapy.",14648024_3,0
3643,D16,94,97,"Fever and subsequent multiple painful erythematous nodules over extremities developed on D11, D16, D17, and D19, respectively, after ATRA therapy.",14648024_3,0
3641,erythematous nodules,38,58,"Fever and subsequent multiple painful erythematous nodules over extremities developed on D11, D16, D17, and D19, respectively, after ATRA therapy.",14648024_3,1
3645,D19,108,111,"Fever and subsequent multiple painful erythematous nodules over extremities developed on D11, D16, D17, and D19, respectively, after ATRA therapy.",14648024_3,0
3648,erythema nodosum,60,76,The skin biopsy taken from each patient was consistent with erythema nodosum.,14648024_4,1
3649,short course,22,34,All patients received short course of steroids.,14648024_5,1
3650,skin lesions,31,43,Fever subsided rapidly and the skin lesions regressed completely.,14648024_6,1
3653,ATRA,63,67,All patients achieved complete remission without withdrawal of ATRA.,14648024_7,0
3652,complete remission,22,40,All patients achieved complete remission without withdrawal of ATRA.,14648024_7,1
3654,ATRA,0,4,ATRA seemed to be the most possible etiology of erythema nodosum in our patients.,14648024_8,1
3655,erythema nodosum,48,64,ATRA seemed to be the most possible etiology of erythema nodosum in our patients.,14648024_8,1
3656,ATRA-induced erythema nodosum,47,76,Short-term use of steroid is very effective in ATRA-induced erythema nodosum.,14648024_9,1
3657,amphotericin B,45,59,Reversible dilated cardiomyopathy related to amphotericin B therapy.,14657095_0,0
4787,dilated cardiomyopathy,11,33,Reversible dilated cardiomyopathy related to amphotericin B therapy.,14657095_0,1
4788,dilated cardiomyopathy,36,58,We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis.,14657095_1,1
3658,amphotericin B,128,142,We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis.,14657095_1,0
4789,congestive heart failure,72,96,We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis.,14657095_1,1
4790,heart failure,40,53,His echocardiographic abnormalities and heart failure resolved after posaconazole was substituted for AmB. It is important to recognize the rare and potentially reversible toxicity of AmB.,14657095_2,1
3661,posaconazole,69,81,His echocardiographic abnormalities and heart failure resolved after posaconazole was substituted for AmB. It is important to recognize the rare and potentially reversible toxicity of AmB.,14657095_2,0
910,His,0,3,His echocardiographic abnormalities and heart failure resolved after posaconazole was substituted for AmB. It is important to recognize the rare and potentially reversible toxicity of AmB.,14657095_2,0
3664,NO-induced migraine,0,19,NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release.,14659530_0,1
912,CGRP,87,91,NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release.,14659530_0,0
3665,platelet serotonin release,137,163,NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release.,14659530_0,0
911,calcitonin gene-related peptide,54,85,NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release.,14659530_0,0
3669,genuine migraine,228,244,"The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin.",14659530_1,1
914,CGRP,103,107,"The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin.",14659530_1,0
913,calcitonin gene-related peptide,70,101,"The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin.",14659530_1,0
3666,platelet serotonin,127,145,"The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin.",14659530_1,0
3667,5-hydroxytriptamine,147,166,"The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin.",14659530_1,0
3668,5-HT,168,172,"The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin.",14659530_1,0
3677,migraine attack,171,186,Platelet serotonin content decreased significantly (P<0.01) after nitroglycerin in subjects with no migraine attack but no consistent change was observed in patients with migraine attack.,14659530_10,1
918,CGRP,36,40,"In conclusion, the fact that plasma CGRP concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between CGRP and migraine.",14659530_11,0
4792,migraine headache,100,117,"In conclusion, the fact that plasma CGRP concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between CGRP and migraine.",14659530_11,1
919,CGRP,157,161,"In conclusion, the fact that plasma CGRP concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between CGRP and migraine.",14659530_11,0
920,CGRP,129,133,"In contrast, serotonin release from platelets does not provoke migraine, it may even counteract the headache and the concomitant CGRP release in this model.",14659530_12,0
3678,serotonin release,13,30,"In contrast, serotonin release from platelets does not provoke migraine, it may even counteract the headache and the concomitant CGRP release in this model.",14659530_12,0
3671,antecubital vein,29,45,"Blood was collected from the antecubital vein four times: 60 min before and after the nitroglycerin application, and 60 and 120 min after the beginning of the migraine attack (mean 344 and 404 min; 12 subjects).",14659530_4,1
3672,migraine attack,159,174,"Blood was collected from the antecubital vein four times: 60 min before and after the nitroglycerin application, and 60 and 120 min after the beginning of the migraine attack (mean 344 and 404 min; 12 subjects).",14659530_4,1
3673,migraine attack,29,44,In those subjects who had no migraine attack (11 subjects) a similar time schedule was used.,14659530_5,1
915,CGRP,7,11,Plasma CGRP concentration increased significantly (P<0.01) during the migraine attack and returned to baseline after the cessation of the migraine.,14659530_6,0
4791,migraine headache,81,98,"In addition, both change and peak, showed significant positive correlations with migraine headache intensity (P<0.001).",14659530_7,1
916,CGRP,16,20,"However, plasma CGRP concentrations failed to change during immediate headache and in the subjects with no migraine attack.",14659530_8,0
3675,5-HT,63,67,Basal CGRP concentration was significantly higher and platelet 5-HT content tended to be lower in subjects who experienced a migraine attack.,14659530_9,0
917,CGRP,6,10,Basal CGRP concentration was significantly higher and platelet 5-HT content tended to be lower in subjects who experienced a migraine attack.,14659530_9,0
3681,intractable hemorrhagic cystitis,20,52,We report a case of intractable hemorrhagic cystitis due to cyclophosphamide therapy for Wegener's granulomatosis.,1468485_1,1
4793,Wegener's granulomatosis,89,113,We report a case of intractable hemorrhagic cystitis due to cyclophosphamide therapy for Wegener's granulomatosis.,1468485_1,1
3682,cyclophosphamide,60,76,We report a case of intractable hemorrhagic cystitis due to cyclophosphamide therapy for Wegener's granulomatosis.,1468485_1,0
3684,physiological saline,58,78,"Conservative treatment, including bladder irrigation with physiological saline and instillation of prostaglandin F2 alpha, failed to totally control hemorrhage.",1468485_2,0
921,prostaglandin F2 alpha,99,121,"Conservative treatment, including bladder irrigation with physiological saline and instillation of prostaglandin F2 alpha, failed to totally control hemorrhage.",1468485_2,0
4794,side effect,3,14,No side effect was noted during the course of therapy.,1468485_5,1
3688,Acute psychosis,0,15,Acute psychosis due to treatment with phenytoin in a nonepileptic patient.,14698717_0,1
4795,nonepileptic,53,65,Acute psychosis due to treatment with phenytoin in a nonepileptic patient.,14698717_0,1
922,antiepileptic drug,40,58,The development of psychosis related to antiepileptic drug treatment is usually attributed to the interaction between the epileptic brain substratum and the antiepileptic drugs.,14698717_1,0
923,antiepileptic drugs,157,176,The development of psychosis related to antiepileptic drug treatment is usually attributed to the interaction between the epileptic brain substratum and the antiepileptic drugs.,14698717_1,0
4796,nonepileptic,14,26,The case of a nonepileptic patient who developed psychosis following phenytoin treatment for trigeminal neuralgia is described.,14698717_2,1
4797,trigeminal neuralgia,93,113,The case of a nonepileptic patient who developed psychosis following phenytoin treatment for trigeminal neuralgia is described.,14698717_2,1
3690,psychotic symptoms,28,46,"This case suggests that the psychotic symptoms that occur following phenytoin treatment in some epileptic patients may be the direct result of medication, unrelated to seizures.",14698717_3,1
924,convulsants,15,26,Effect of some convulsants on the protective activity of loreclezole and its combinations with valproate or clonazepam in amygdala-kindled rats.,14704468_0,0
925,clonazepam,108,118,Effect of some convulsants on the protective activity of loreclezole and its combinations with valproate or clonazepam in amygdala-kindled rats.,14704468_0,0
3694,valproate,95,104,Effect of some convulsants on the protective activity of loreclezole and its combinations with valproate or clonazepam in amygdala-kindled rats.,14704468_0,0
3693,loreclezole,57,68,Effect of some convulsants on the protective activity of loreclezole and its combinations with valproate or clonazepam in amygdala-kindled rats.,14704468_0,0
3696,Loreclezole,0,11,"Loreclezole (5 mg/kg) exerted a significant protective action in amygdala-kindled rats, reducing both seizure and afterdischarge durations.",14704468_1,0
3697,protective action,44,61,"Loreclezole (5 mg/kg) exerted a significant protective action in amygdala-kindled rats, reducing both seizure and afterdischarge durations.",14704468_1,0
3700,valproate,49,58,"The combinations of loreclezole (2.5 mg/kg) with valproate, clonazepam, or carbamazepine (applied at their subprotective doses) also exhibited antiseizure effect in this test.",14704468_2,0
926,clonazepam,60,70,"The combinations of loreclezole (2.5 mg/kg) with valproate, clonazepam, or carbamazepine (applied at their subprotective doses) also exhibited antiseizure effect in this test.",14704468_2,0
3699,loreclezole,20,31,"The combinations of loreclezole (2.5 mg/kg) with valproate, clonazepam, or carbamazepine (applied at their subprotective doses) also exhibited antiseizure effect in this test.",14704468_2,0
3701,carbamazepine,75,88,"The combinations of loreclezole (2.5 mg/kg) with valproate, clonazepam, or carbamazepine (applied at their subprotective doses) also exhibited antiseizure effect in this test.",14704468_2,0
3703,antiseizure,143,154,"The combinations of loreclezole (2.5 mg/kg) with valproate, clonazepam, or carbamazepine (applied at their subprotective doses) also exhibited antiseizure effect in this test.",14704468_2,0
929,L-type calcium channels,100,123,"Among several chemoconvulsants, bicuculline, N-methyl-D-aspartic acid and BAY k-8644 (the opener of L-type calcium channels) reversed the protective activity of loreclezole alone and its combination with valproate.",14704468_4,0
928,N-methyl-D-aspartic acid,45,69,"Among several chemoconvulsants, bicuculline, N-methyl-D-aspartic acid and BAY k-8644 (the opener of L-type calcium channels) reversed the protective activity of loreclezole alone and its combination with valproate.",14704468_4,0
927,bicuculline,32,43,"Among several chemoconvulsants, bicuculline, N-methyl-D-aspartic acid and BAY k-8644 (the opener of L-type calcium channels) reversed the protective activity of loreclezole alone and its combination with valproate.",14704468_4,0
3707,valproate,204,213,"Among several chemoconvulsants, bicuculline, N-methyl-D-aspartic acid and BAY k-8644 (the opener of L-type calcium channels) reversed the protective activity of loreclezole alone and its combination with valproate.",14704468_4,0
3706,loreclezole,161,172,"Among several chemoconvulsants, bicuculline, N-methyl-D-aspartic acid and BAY k-8644 (the opener of L-type calcium channels) reversed the protective activity of loreclezole alone and its combination with valproate.",14704468_4,0
931,anticonvulsive,75,89,"On the other hand, bicuculline, aminophylline and BAY k-8644 inhibited the anticonvulsive action of loreclezole combined with clonazepam.",14704468_5,0
930,bicuculline,19,30,"On the other hand, bicuculline, aminophylline and BAY k-8644 inhibited the anticonvulsive action of loreclezole combined with clonazepam.",14704468_5,0
3708,loreclezole,100,111,"On the other hand, bicuculline, aminophylline and BAY k-8644 inhibited the anticonvulsive action of loreclezole combined with clonazepam.",14704468_5,0
932,clonazepam,126,136,"On the other hand, bicuculline, aminophylline and BAY k-8644 inhibited the anticonvulsive action of loreclezole combined with clonazepam.",14704468_5,0
3709,protective activity,44,63,The results support the hypothesis that the protective activity of loreclezole and its combinations with other antiepileptics may involve potentiation of GABAergic neurotransmission and blockade of L-type of calcium channels.,14704468_6,0
3710,loreclezole,67,78,The results support the hypothesis that the protective activity of loreclezole and its combinations with other antiepileptics may involve potentiation of GABAergic neurotransmission and blockade of L-type of calcium channels.,14704468_6,0
934,L-type,198,204,The results support the hypothesis that the protective activity of loreclezole and its combinations with other antiepileptics may involve potentiation of GABAergic neurotransmission and blockade of L-type of calcium channels.,14704468_6,0
933,GABAergic,154,163,The results support the hypothesis that the protective activity of loreclezole and its combinations with other antiepileptics may involve potentiation of GABAergic neurotransmission and blockade of L-type of calcium channels.,14704468_6,0
935,calcium channels,208,224,The results support the hypothesis that the protective activity of loreclezole and its combinations with other antiepileptics may involve potentiation of GABAergic neurotransmission and blockade of L-type of calcium channels.,14704468_6,0
4798,respiratory chain,26,43,Mitochondrial DNA and its respiratory chain products are defective in doxorubicin nephrosis.,14736955_0,1
936,Mitochondrial DNA,0,17,Mitochondrial DNA and its respiratory chain products are defective in doxorubicin nephrosis.,14736955_0,0
3711,doxorubicin nephrosis,70,91,Mitochondrial DNA and its respiratory chain products are defective in doxorubicin nephrosis.,14736955_0,1
3714,late-onset tubular lesions,102,128,BACKGROUND: Doxorubicin induces a self-perpetuating nephropathy characterized by early glomerular and late-onset tubular lesions in rats.,14736955_1,1
3713,early glomerular,81,97,BACKGROUND: Doxorubicin induces a self-perpetuating nephropathy characterized by early glomerular and late-onset tubular lesions in rats.,14736955_1,1
3712,self-perpetuating nephropathy,34,63,BACKGROUND: Doxorubicin induces a self-perpetuating nephropathy characterized by early glomerular and late-onset tubular lesions in rats.,14736955_1,1
3725,tubular lesions,39,54,"In 'short-term' rats, there were fewer tubular lesions, but similar numbers of glomerular lesions activity.",14736955_10,1
3726,glomerular lesions,79,97,"In 'short-term' rats, there were fewer tubular lesions, but similar numbers of glomerular lesions activity.",14736955_10,1
3727,tubular injury,34,48,"Among all animals, glomerular and tubular injury were inversely correlated with mtDNA levels, mtDNA-encoded respiratory chain activities and with the expression of the mtDNA-encoded respiratory chain subunit COX-I. Injury was positively correlated with superoxide production and the activities of nucleus-encoded mitochondrial or cytoplasmic enzymes.",14736955_11,1
3729,mitochondrial,313,326,"Among all animals, glomerular and tubular injury were inversely correlated with mtDNA levels, mtDNA-encoded respiratory chain activities and with the expression of the mtDNA-encoded respiratory chain subunit COX-I. Injury was positively correlated with superoxide production and the activities of nucleus-encoded mitochondrial or cytoplasmic enzymes.",14736955_11,0
4800,respiratory chain,108,125,"Among all animals, glomerular and tubular injury were inversely correlated with mtDNA levels, mtDNA-encoded respiratory chain activities and with the expression of the mtDNA-encoded respiratory chain subunit COX-I. Injury was positively correlated with superoxide production and the activities of nucleus-encoded mitochondrial or cytoplasmic enzymes.",14736955_11,1
4801,respiratory chain,182,199,"Among all animals, glomerular and tubular injury were inversely correlated with mtDNA levels, mtDNA-encoded respiratory chain activities and with the expression of the mtDNA-encoded respiratory chain subunit COX-I. Injury was positively correlated with superoxide production and the activities of nucleus-encoded mitochondrial or cytoplasmic enzymes.",14736955_11,1
943,mtDNA,80,85,"Among all animals, glomerular and tubular injury were inversely correlated with mtDNA levels, mtDNA-encoded respiratory chain activities and with the expression of the mtDNA-encoded respiratory chain subunit COX-I. Injury was positively correlated with superoxide production and the activities of nucleus-encoded mitochondrial or cytoplasmic enzymes.",14736955_11,0
944,mtDNA,47,52,Kidneys from the 'long-term' group showed more mtDNA deletions than in 'short-term' animals and these were not observed in the other groups.,14736955_12,0
4802,respiratory chain,143,160,CONCLUSIONS: These results suggest an important role for quantitative and qualitative mtDNA alterations through the reduction of mtDNA-encoded respiratory chain function and induction of superoxide in doxorubicin-induced renal lesions.,14736955_13,1
945,mtDNA,86,91,CONCLUSIONS: These results suggest an important role for quantitative and qualitative mtDNA alterations through the reduction of mtDNA-encoded respiratory chain function and induction of superoxide in doxorubicin-induced renal lesions.,14736955_13,0
3731,renal lesions,221,234,CONCLUSIONS: These results suggest an important role for quantitative and qualitative mtDNA alterations through the reduction of mtDNA-encoded respiratory chain function and induction of superoxide in doxorubicin-induced renal lesions.,14736955_13,1
3716,onset of,66,74,We investigated the potential role of mitochondrial injury in the onset of these lesions.,14736955_2,1
3715,mitochondrial,38,51,We investigated the potential role of mitochondrial injury in the onset of these lesions.,14736955_2,0
3717,intravenous doxorubicin (1,32,58,METHODS: Rats were treated with intravenous doxorubicin (1 mg kg(-1) week(-1)) for 7 weeks and were sacrificed either 1 week ('short-term') or 30 weeks ('long-term') following the last dose.,14736955_3,0
3720,tubular injury,15,29,Glomerular and tubular injury was monitored and correlated to the activity or expression of respiratory chain components.,14736955_6,1
4799,respiratory chain,92,109,Glomerular and tubular injury was monitored and correlated to the activity or expression of respiratory chain components.,14736955_6,1
939,mtDNA,131,136,"Finally, we quantified both nuclear and mitochondrial DNA (mtDNA) as well as superoxide production and the 4834 base pair 'common' mtDNA deletion.",14736955_7,0
938,mtDNA,59,64,"Finally, we quantified both nuclear and mitochondrial DNA (mtDNA) as well as superoxide production and the 4834 base pair 'common' mtDNA deletion.",14736955_7,0
937,mitochondrial DNA,40,57,"Finally, we quantified both nuclear and mitochondrial DNA (mtDNA) as well as superoxide production and the 4834 base pair 'common' mtDNA deletion.",14736955_7,0
3722,tubular lesions,62,77,"RESULTS: The 'long-term' group had significant glomerular and tubular lesions, depressed activities of mtDNA-encoded NADH dehydrogenase and cytochrome-c oxidase (COX) and increased citrate synthase activity.",14736955_8,1
941,citrate synthase,181,197,"RESULTS: The 'long-term' group had significant glomerular and tubular lesions, depressed activities of mtDNA-encoded NADH dehydrogenase and cytochrome-c oxidase (COX) and increased citrate synthase activity.",14736955_8,0
940,NADH dehydrogenase,117,135,"RESULTS: The 'long-term' group had significant glomerular and tubular lesions, depressed activities of mtDNA-encoded NADH dehydrogenase and cytochrome-c oxidase (COX) and increased citrate synthase activity.",14736955_8,0
3723,cytochrome-c oxidase,140,160,"RESULTS: The 'long-term' group had significant glomerular and tubular lesions, depressed activities of mtDNA-encoded NADH dehydrogenase and cytochrome-c oxidase (COX) and increased citrate synthase activity.",14736955_8,0
942,mtDNA,75,80,"In addition, expression of the mtDNA-encoded COX subunit I was reduced and mtDNA levels were decreased.",14736955_9,0
3724,COX subunit I,45,58,"In addition, expression of the mtDNA-encoded COX subunit I was reduced and mtDNA levels were decreased.",14736955_9,0
4803,sexual dysfunction,87,105,"A randomized, placebo-controlled, crossover study of ephedrine for SSRI-induced female sexual dysfunction.",14742097_0,1
946,beta-adrenergic agonist,78,101,"The objective of this study was to determine whether ephedrine, an alpha- and beta-adrenergic agonist previously shown to enhance genital blood flow in women, has beneficial effects in reversing antidepressant-induced sexual dysfunction.",14742097_1,0
4804,sexual dysfunction,218,236,"The objective of this study was to determine whether ephedrine, an alpha- and beta-adrenergic agonist previously shown to enhance genital blood flow in women, has beneficial effects in reversing antidepressant-induced sexual dysfunction.",14742097_1,1
3745,sexual satisfaction,274,293,"Nineteen sexually dysfunctional women receiving either fluoxetine, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.",14742097_2,1
3736,Nineteen sexually dysfunctional,0,31,"Nineteen sexually dysfunctional women receiving either fluoxetine, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.",14742097_2,1
3737,paroxetine,82,92,"Nineteen sexually dysfunctional women receiving either fluoxetine, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.",14742097_2,0
3744,sexual desire,238,251,"Nineteen sexually dysfunctional women receiving either fluoxetine, sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction.",14742097_2,1
3746,sexual desire,69,82,"Although there were significant improvements relative to baseline in sexual desire and orgasm intensity/pleasure on 50 mg ephedrine 1-hr prior to sexual activity, significant improvements in these measures, as well as in sexual arousal and orgasmic ability also were noted with placebo.",14742097_3,1
3749,orgasmic,240,248,"Although there were significant improvements relative to baseline in sexual desire and orgasm intensity/pleasure on 50 mg ephedrine 1-hr prior to sexual activity, significant improvements in these measures, as well as in sexual arousal and orgasmic ability also were noted with placebo.",14742097_3,1
4805,breast cancer,42,55,Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition?,14745746_0,1
4806,breast cancer,54,67,This pilot study examines whether hormone therapy for breast cancer affects cognition.,14745746_2,1
3755,ATAC,90,94,"Patients participating in a randomised trial of anastrozole, tamoxifen alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures.",14745746_3,0
947,anastrozole,48,59,"Patients participating in a randomised trial of anastrozole, tamoxifen alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures.",14745746_3,0
4807,breast cancer,132,145,"Patients participating in a randomised trial of anastrozole, tamoxifen alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures.",14745746_3,1
3758,verbal memory,127,140,"Compared with the control group, the patients were impaired on a processing speed task (p=0.032) and on a measure of immediate verbal memory (p=0.026) after controlling for the use of hormone replacement therapy in both groups.",14745746_4,1
3760,psychological morbidity,94,117,Patient group performance was not significantly related to length of treatment or measures of psychological morbidity.,14745746_5,1
3759,length of,59,68,Patient group performance was not significantly related to length of treatment or measures of psychological morbidity.,14745746_5,1
4808,breast cancer,135,148,The results showed specific impairments in processing speed and verbal memory in women receiving hormonal therapy for the treatment of breast cancer.,14745746_6,1
3764,Verbal memory,0,13,"Verbal memory may be especially sensitive to changes in oestrogen levels, a finding commonly reported in studies of hormone replacement therapy in healthy women.",14745746_7,1
3766,hormone therapies,32,49,In view of the increased use of hormone therapies in an adjuvant and preventative setting their impact on cognitive functioning should be investigated more thoroughly.,14745746_8,0
3769,bitter lemon,199,211,"Although the United States Food and Drug Administration banned its use for nocturnal leg cramps due to lack of safety and efficacy, quinine is widely available in beverages including tonic water and bitter lemon.",14765563_1,0
3768,tonic water,183,194,"Although the United States Food and Drug Administration banned its use for nocturnal leg cramps due to lack of safety and efficacy, quinine is widely available in beverages including tonic water and bitter lemon.",14765563_1,0
4809,nocturnal leg cramps,75,95,"Although the United States Food and Drug Administration banned its use for nocturnal leg cramps due to lack of safety and efficacy, quinine is widely available in beverages including tonic water and bitter lemon.",14765563_1,1
3771,neurological complications,80,106,"Numerous anecdotal reports suggest that products containing quinine may produce neurological complications, including confusion, altered mental status, seizures, and coma, particularly in older women.",14765563_2,1
3772,mental status,137,150,"Numerous anecdotal reports suggest that products containing quinine may produce neurological complications, including confusion, altered mental status, seizures, and coma, particularly in older women.",14765563_2,1
3773,quinine-containing beverages,51,79,Psychologists need to inquire about consumption of quinine-containing beverages as part of an evaluation process.,14765563_3,0
948,p300,14,18,Expression of p300 protects cardiac myocytes from apoptosis in vivo.,14975762_0,0
3776,myocardial cell,95,110,Doxorubicin is an anti-tumor agent that represses cardiac-specific gene expression and induces myocardial cell apoptosis.,14975762_1,1
950,cardiac-specific,50,66,Doxorubicin is an anti-tumor agent that represses cardiac-specific gene expression and induces myocardial cell apoptosis.,14975762_1,0
949,anti-tumor agent,18,34,Doxorubicin is an anti-tumor agent that represses cardiac-specific gene expression and induces myocardial cell apoptosis.,14975762_1,0
951,p300,29,33,"Doxorubicin depletes cardiac p300, a transcriptional coactivator that is required for the maintenance of the differentiated phenotype of cardiac myocytes.",14975762_2,0
3777,transcriptional coactivator,37,64,"Doxorubicin depletes cardiac p300, a transcriptional coactivator that is required for the maintenance of the differentiated phenotype of cardiac myocytes.",14975762_2,0
952,p300,21,25,"However, the role of p300 in protection against doxorubicin-induced apoptosis is unknown.",14975762_3,0
953,p300,31,35,Transgenic mice overexpressing p300 in the heart and wild-type mice were subjected to doxorubicin treatment.,14975762_4,0
3780,overexpressing,16,30,Transgenic mice overexpressing p300 in the heart and wild-type mice were subjected to doxorubicin treatment.,14975762_4,0
3783,left ventricular function,103,128,"Compared with wild-type mice, transgenic mice exhibited higher survival rate as well as more preserved left ventricular function and cardiac expression of alpha-sarcomeric actin.",14975762_5,1
3784,alpha-sarcomeric actin,155,177,"Compared with wild-type mice, transgenic mice exhibited higher survival rate as well as more preserved left ventricular function and cardiac expression of alpha-sarcomeric actin.",14975762_5,0
956,bcl-2,111,116,"Expression of p300 increased the cardiac level of bcl-2 and mdm-2, but not that of p53 or other members of the bcl-2 family.",14975762_7,0
3786,mdm-2,60,65,"Expression of p300 increased the cardiac level of bcl-2 and mdm-2, but not that of p53 or other members of the bcl-2 family.",14975762_7,0
3787,p53,83,86,"Expression of p300 increased the cardiac level of bcl-2 and mdm-2, but not that of p53 or other members of the bcl-2 family.",14975762_7,0
954,p300,14,18,"Expression of p300 increased the cardiac level of bcl-2 and mdm-2, but not that of p53 or other members of the bcl-2 family.",14975762_7,0
955,bcl-2,50,55,"Expression of p300 increased the cardiac level of bcl-2 and mdm-2, but not that of p53 or other members of the bcl-2 family.",14975762_7,0
4810,heart failure,148,161,These findings demonstrate that overexpression of p300 protects cardiac myocytes from doxorubicin-induced apoptosis and reduces the extent of acute heart failure in adult mice in vivo.,14975762_8,1
957,p300,50,54,These findings demonstrate that overexpression of p300 protects cardiac myocytes from doxorubicin-induced apoptosis and reduces the extent of acute heart failure in adult mice in vivo.,14975762_8,0
4811,Ebstein's anomaly,100,117,Transient platypnea-orthodeoxia-like syndrome induced by propafenone overdose in a young woman with Ebstein's anomaly.,14976857_0,1
3788,Transient platypnea-orthodeoxia-like syndrome,0,45,Transient platypnea-orthodeoxia-like syndrome induced by propafenone overdose in a young woman with Ebstein's anomaly.,14976857_0,1
958,propafenone,57,68,Transient platypnea-orthodeoxia-like syndrome induced by propafenone overdose in a young woman with Ebstein's anomaly.,14976857_0,0
4814,interatrial,188,199,"In this report we describe the case of a 37-year-old white woman with Ebstein's anomaly, who developed a rare syndrome called platypnea-orthodeoxia, characterized by massive right-to-left interatrial shunting with transient profound hypoxia and cyanosis.",14976857_1,1
4812,Ebstein's anomaly,70,87,"In this report we describe the case of a 37-year-old white woman with Ebstein's anomaly, who developed a rare syndrome called platypnea-orthodeoxia, characterized by massive right-to-left interatrial shunting with transient profound hypoxia and cyanosis.",14976857_1,1
3789,transient profound hypoxia,214,240,"In this report we describe the case of a 37-year-old white woman with Ebstein's anomaly, who developed a rare syndrome called platypnea-orthodeoxia, characterized by massive right-to-left interatrial shunting with transient profound hypoxia and cyanosis.",14976857_1,1
4813,platypnea-orthodeoxia,126,147,"In this report we describe the case of a 37-year-old white woman with Ebstein's anomaly, who developed a rare syndrome called platypnea-orthodeoxia, characterized by massive right-to-left interatrial shunting with transient profound hypoxia and cyanosis.",14976857_1,1
959,propafenone,146,157,"This shunt of blood via a patent foramen ovale occurred in the presence of a normal pulmonary artery pressure, and was probably precipitated by a propafenone overdose.",14976857_2,0
3790,pulmonary artery pressure,84,109,"This shunt of blood via a patent foramen ovale occurred in the presence of a normal pulmonary artery pressure, and was probably precipitated by a propafenone overdose.",14976857_2,1
4815,patent foramen ovale,26,46,"This shunt of blood via a patent foramen ovale occurred in the presence of a normal pulmonary artery pressure, and was probably precipitated by a propafenone overdose.",14976857_2,1
3791,biventricular dysfunction,17,42,"This drug caused biventricular dysfunction, due to its negative inotropic effect, and hypotension, due to its peripheral vasodilatory effect.",14976857_3,1
4816,right atrial,46,58,These effects gave rise to an increase in the right atrial pressure and a decrease in the left one with a consequent stretching of the foramen ovale and the creation of massive right-to-left shunting.,14976857_4,1
3793,massive right-to-left shunting,169,199,These effects gave rise to an increase in the right atrial pressure and a decrease in the left one with a consequent stretching of the foramen ovale and the creation of massive right-to-left shunting.,14976857_4,1
4817,foramen ovale,135,148,These effects gave rise to an increase in the right atrial pressure and a decrease in the left one with a consequent stretching of the foramen ovale and the creation of massive right-to-left shunting.,14976857_4,1
4818,interatrial,17,28,In our case this interatrial shunt was very accurately detected at bubble contrast echocardiography.,14976857_5,1
4819,cholestatic jaundice,20,40,Methimazole-induced cholestatic jaundice.,14982270_0,1
961,antithyroid agent,58,75,Methimazole is a widely used and generally well-tolerated antithyroid agent.,14982270_1,0
960,Methimazole,0,11,Methimazole is a widely used and generally well-tolerated antithyroid agent.,14982270_1,0
963,propranolol,104,115,A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.,14982270_2,0
962,methimazole,76,87,A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism.,14982270_2,0
3795,emergency department,17,37,"When seen at the emergency department 2 weeks later, she still had severe icterus, pruritus, and hyperbilirubinemia, formed mainly of the conjugated fraction.",14982270_4,1
964,propranolol,51,62,"Methimazole-induced cholestasis was diagnosed, and propranolol therapy was resumed.",14982270_5,0
965,methimazole,112,123,"Over the following 9 days, the symptoms improved and plasma bilirubin levels were normal after 12 weeks without methimazole.",14982270_6,0
4820,cholestatic jaundice,95,115,"In rare cases within the first few weeks of therapy, this drug can cause severe and reversible cholestatic jaundice.",14982270_7,1
3798,adverse effect,48,62,"Physicians and patients should be aware of this adverse effect so that, upon occurrence, they can discontinue methimazole therapy and avoid unnecessary invasive procedures.",14982270_8,1
966,methimazole,110,121,"Physicians and patients should be aware of this adverse effect so that, upon occurrence, they can discontinue methimazole therapy and avoid unnecessary invasive procedures.",14982270_8,0
3802,intracranial blood flow,60,83,Noxious chemical stimulation of rat facial mucosa increases intracranial blood flow through a trigemino-parasympathetic reflex--an experimental model for vascular dysfunctions in cluster headache.,15009014_0,1
3803,trigemino-parasympathetic reflex,94,126,Noxious chemical stimulation of rat facial mucosa increases intracranial blood flow through a trigemino-parasympathetic reflex--an experimental model for vascular dysfunctions in cluster headache.,15009014_0,1
4821,cluster headache,179,195,Noxious chemical stimulation of rat facial mucosa increases intracranial blood flow through a trigemino-parasympathetic reflex--an experimental model for vascular dysfunctions in cluster headache.,15009014_0,1
3804,vascular dysfunctions,154,175,Noxious chemical stimulation of rat facial mucosa increases intracranial blood flow through a trigemino-parasympathetic reflex--an experimental model for vascular dysfunctions in cluster headache.,15009014_0,1
3801,facial mucosa,36,49,Noxious chemical stimulation of rat facial mucosa increases intracranial blood flow through a trigemino-parasympathetic reflex--an experimental model for vascular dysfunctions in cluster headache.,15009014_0,1
4824,intracranial vascular,89,110,Cluster headache is characterized by typical autonomic dysfunctions including facial and intracranial vascular disturbances.,15009014_1,1
4823,autonomic dysfunctions,45,67,Cluster headache is characterized by typical autonomic dysfunctions including facial and intracranial vascular disturbances.,15009014_1,1
4822,Cluster headache,0,16,Cluster headache is characterized by typical autonomic dysfunctions including facial and intracranial vascular disturbances.,15009014_1,1
4825,cluster headache,58,74,Similar mechanisms may be involved in the pathogenesis of cluster headache.,15009014_10,1
3808,facial mucosa,151,164,An experimental model was developed in the rat to measure changes in lacrimation and intracranial blood flow following noxious chemical stimulation of facial mucosa.,15009014_3,1
3811,parietal cortex,79,94,Blood flow was monitored in arteries of the exposed cranial dura mater and the parietal cortex using laser Doppler flowmetry.,15009014_4,1
3813,cortical blood flow,85,104,Capsaicin (0.01-1 mm) applied to oral or nasal mucosa induced increases in dural and cortical blood flow and provoked lacrimation.,15009014_5,1
3812,nasal mucosa,41,53,Capsaicin (0.01-1 mm) applied to oral or nasal mucosa induced increases in dural and cortical blood flow and provoked lacrimation.,15009014_5,1
967,hexamethonium chloride,63,85,These responses were blocked by systemic pre-administration of hexamethonium chloride (20 mg/kg).,15009014_6,0
3817,"Arg3,4",129,135,"The evoked increases in dural blood flow were also abolished by topical pre-administration of atropine (1 mm) and [Lys1, Pro2,5, Arg3,4, Tyr6]-VIP (0.1 mm), a vasoactive intestinal polypeptide (VIP) antagonist, onto the exposed dura mater.",15009014_7,0
3816,"Pro2,5",121,127,"The evoked increases in dural blood flow were also abolished by topical pre-administration of atropine (1 mm) and [Lys1, Pro2,5, Arg3,4, Tyr6]-VIP (0.1 mm), a vasoactive intestinal polypeptide (VIP) antagonist, onto the exposed dura mater.",15009014_7,0
3815,Lys1,115,119,"The evoked increases in dural blood flow were also abolished by topical pre-administration of atropine (1 mm) and [Lys1, Pro2,5, Arg3,4, Tyr6]-VIP (0.1 mm), a vasoactive intestinal polypeptide (VIP) antagonist, onto the exposed dura mater.",15009014_7,0
969,vasoactive intestinal polypeptide,159,192,"The evoked increases in dural blood flow were also abolished by topical pre-administration of atropine (1 mm) and [Lys1, Pro2,5, Arg3,4, Tyr6]-VIP (0.1 mm), a vasoactive intestinal polypeptide (VIP) antagonist, onto the exposed dura mater.",15009014_7,0
968,(1,103,105,"The evoked increases in dural blood flow were also abolished by topical pre-administration of atropine (1 mm) and [Lys1, Pro2,5, Arg3,4, Tyr6]-VIP (0.1 mm), a vasoactive intestinal polypeptide (VIP) antagonist, onto the exposed dura mater.",15009014_7,0
3820,facial mucosa,40,53,We conclude that noxious stimulation of facial mucosa increases intracranial blood flow and lacrimation via a trigemino-parasympathetic reflex.,15009014_8,1
3821,intracranial blood flow,64,87,We conclude that noxious stimulation of facial mucosa increases intracranial blood flow and lacrimation via a trigemino-parasympathetic reflex.,15009014_8,1
3822,trigemino-parasympathetic reflex,110,142,We conclude that noxious stimulation of facial mucosa increases intracranial blood flow and lacrimation via a trigemino-parasympathetic reflex.,15009014_8,1
3824,Organophosphate-induced convulsions,0,35,Organophosphate-induced convulsions and prevention of neuropathological damages.,15036754_0,0
3825,neuropathological damages,54,79,Organophosphate-induced convulsions and prevention of neuropathological damages.,15036754_0,1
972,DFP,68,71,"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs).",15036754_1,0
3826,acetylcholinesterases,115,136,"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs).",15036754_1,0
3827,butyrylcholinesterases,149,171,"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs).",15036754_1,0
3828,BChEs,173,178,"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs).",15036754_1,0
970,organophosphorus,5,21,"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs).",15036754_1,0
971,diisopropylfluorophosphate,40,66,"Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs).",15036754_1,0
984,DFP,155,158,"In conclusion, CPA, diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of DFP in rat.",15036754_10,0
3843,2PAM,33,37,"In conclusion, CPA, diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of DFP in rat.",15036754_10,0
973,ACh,148,151,"The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates acetylcholine (ACh) levels.",15036754_2,0
4826,central nervous system,88,110,"The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates acetylcholine (ACh) levels.",15036754_2,1
3829,protective action,4,21,The protective action of subcutaneously (SC) administered antidotes or their combinations in DFP (2.0 mg/kg BW) intoxication was studied in 9-10-weeks-old Han-Wistar male rats.,15036754_3,0
974,DFP,93,96,The protective action of subcutaneously (SC) administered antidotes or their combinations in DFP (2.0 mg/kg BW) intoxication was studied in 9-10-weeks-old Han-Wistar male rats.,15036754_3,0
3837,cholinolytic drug atropine sulfate,317,351,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,0
3835,dizocilpine,228,239,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,0
3836,(+,248,250,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,0
978,DFP,423,426,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,0
3832,pralidoxime-2-chloride,35,57,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,0
3833,2PAM,59,63,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,0
976,NMDA-receptor,203,216,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,0
3831,AChE reactivator,18,34,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,0
977,hydrogen maleate,257,273,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,0
975,receptor agonist,137,153,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,0
3834,anticonvulsant diazepam,82,105,"The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP.",15036754_4,0
979,atropine sulfate,26,42,"The control rats received atropine sulfate, but also saline and olive oil instead of other antidotes and DFP, respectively.",15036754_5,0
980,olive oil,64,73,"The control rats received atropine sulfate, but also saline and olive oil instead of other antidotes and DFP, respectively.",15036754_5,0
981,DFP,105,108,"The control rats received atropine sulfate, but also saline and olive oil instead of other antidotes and DFP, respectively.",15036754_5,0
982,DFP,58,61,All rats were terminated either 24 h or 3 weeks after the DFP injection.,15036754_6,0
3838,DFP-atropine,22,34,The rats treated with DFP-atropine showed severe typical OP-induced toxicity signs.,15036754_7,0
3841,DFP-atropine,55,67,"When CPA, diazepam or 2PAM was given immediately after DFP-atropine, these treatments prevented, delayed or shortened the occurrence of serious signs of poisoning.",15036754_8,0
3840,2PAM,22,26,"When CPA, diazepam or 2PAM was given immediately after DFP-atropine, these treatments prevented, delayed or shortened the occurrence of serious signs of poisoning.",15036754_8,0
3842,Atropine-MK801,0,14,Atropine-MK801 did not offer any additional protection against DFP toxicity.,15036754_9,0
983,DFP,63,66,Atropine-MK801 did not offer any additional protection against DFP toxicity.,15036754_9,0
4828,large B-cell,66,78,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,1
4833,atrial fibrillation,324,343,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,1
4832,muscular dystrophy,293,311,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,1
3845,diffuse B-cell gastric lymphoma,207,238,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,1
4831,myotonic dystrophy,243,261,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,1
4827,Atrial fibrillation,0,19,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,1
4829,myotonic dystrophy,114,132,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,1
4830,Steinert's,134,144,"Atrial fibrillation following chemotherapy for stage IIIE diffuse large B-cell gastric lymphoma in a patient with myotonic dystrophy (Steinert's disease).The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of doxorubicin-based chemotherapy in the same patient.",15042318_0,1
4835,cardiac arrhythmias,29,48,Atrial fibrillation or other cardiac arrhythmias are unusual complications in patients treated with chemotherapy.,15042318_1,1
4834,Atrial fibrillation,0,19,Atrial fibrillation or other cardiac arrhythmias are unusual complications in patients treated with chemotherapy.,15042318_1,1
4836,cardiac toxicity,4,20,The cardiac toxicity intrinsically associated with the aggressive chemotherapy employed could function as a triggering factor for the arrhythmia in the predisposed myocardium of this patient.,15042318_2,1
3848,immune reaction,17,32,Hypersensitivity immune reaction as a mechanism for dilevalol-associated hepatitis.,1504402_0,1
4837,liver injury,162,174,OBJECTIVE: To assess lymphocyte reactivity to dilevalol and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of dilevalol-induced liver injury.,1504402_1,1
3852,dilevalol antigens,97,115,OBJECTIVE: To assess lymphocyte reactivity to dilevalol and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of dilevalol-induced liver injury.,1504402_1,0
985,dilevalol,46,55,OBJECTIVE: To assess lymphocyte reactivity to dilevalol and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of dilevalol-induced liver injury.,1504402_1,0
4838,liver injury,76,88,PATIENT: A 58-year-old woman with a clinical diagnosis of dilevalol-induced liver injury.,1504402_2,1
986,dilevalol,118,127,METHODS: Peripheral blood mononuclear cells collected from the patient were cultured in the presence of a solution of dilevalol and also with sera collected from a volunteer before and after dilevalol intake.,1504402_3,0
987,dilevalol,191,200,METHODS: Peripheral blood mononuclear cells collected from the patient were cultured in the presence of a solution of dilevalol and also with sera collected from a volunteer before and after dilevalol intake.,1504402_3,0
3857,dilevalol solutions,119,138,RESULTS: No lymphocyte proliferation was observed either in the patient or in the healthy volunteer in the presence of dilevalol solutions.,1504402_5,0
4839,proliferative,14,27,A significant proliferative response to serum collected after dilevalol intake was observed in the case of the patient compared with the proliferative response to the serum collected before the drug intake.,1504402_6,1
4840,proliferative,137,150,A significant proliferative response to serum collected after dilevalol intake was observed in the case of the patient compared with the proliferative response to the serum collected before the drug intake.,1504402_6,1
988,dilevalol,62,71,A significant proliferative response to serum collected after dilevalol intake was observed in the case of the patient compared with the proliferative response to the serum collected before the drug intake.,1504402_6,0
4841,liver injury,216,228,"CONCLUSIONS: The methodology used allowed the detection of lymphocyte sensitization to sera containing ex vivo-prepared dilevalol antigens, suggesting the involvement of an immunologic mechanism in dilevalol-induced liver injury.",1504402_8,1
989,ENaC,51,55,Increased expression and apical targeting of renal ENaC subunits in puromycin aminonucleoside-induced nephrotic syndrome in rats.,15075188_0,0
4842,nephrotic syndrome,102,120,Increased expression and apical targeting of renal ENaC subunits in puromycin aminonucleoside-induced nephrotic syndrome in rats.,15075188_0,1
990,puromycin,68,77,Increased expression and apical targeting of renal ENaC subunits in puromycin aminonucleoside-induced nephrotic syndrome in rats.,15075188_0,0
4843,Nephrotic syndrome,0,18,Nephrotic syndrome is often accompanied by sodium retention and generalized edema.,15075188_1,1
3864,generalized edema,64,81,Nephrotic syndrome is often accompanied by sodium retention and generalized edema.,15075188_1,1
3889,type 3,60,66,"In contrast, the protein abundances of Na(+)/H(+) exchanger type 3 (NHE3), Na(+)-K(+)-2Cl(-) cotransporter (BSC-1), and thiazide-sensitive Na(+)-Cl(-) cotransporter (TSC) were decreased.",15075188_10,0
3890,NHE3,68,72,"In contrast, the protein abundances of Na(+)/H(+) exchanger type 3 (NHE3), Na(+)-K(+)-2Cl(-) cotransporter (BSC-1), and thiazide-sensitive Na(+)-Cl(-) cotransporter (TSC) were decreased.",15075188_10,0
1000,cotransporter,151,164,"In contrast, the protein abundances of Na(+)/H(+) exchanger type 3 (NHE3), Na(+)-K(+)-2Cl(-) cotransporter (BSC-1), and thiazide-sensitive Na(+)-Cl(-) cotransporter (TSC) were decreased.",15075188_10,0
999,thiazide-sensitive,120,138,"In contrast, the protein abundances of Na(+)/H(+) exchanger type 3 (NHE3), Na(+)-K(+)-2Cl(-) cotransporter (BSC-1), and thiazide-sensitive Na(+)-Cl(-) cotransporter (TSC) were decreased.",15075188_10,0
998,BSC-1,108,113,"In contrast, the protein abundances of Na(+)/H(+) exchanger type 3 (NHE3), Na(+)-K(+)-2Cl(-) cotransporter (BSC-1), and thiazide-sensitive Na(+)-Cl(-) cotransporter (TSC) were decreased.",15075188_10,0
997,cotransporter,93,106,"In contrast, the protein abundances of Na(+)/H(+) exchanger type 3 (NHE3), Na(+)-K(+)-2Cl(-) cotransporter (BSC-1), and thiazide-sensitive Na(+)-Cl(-) cotransporter (TSC) were decreased.",15075188_10,0
3893,ISOM,99,103,"Moreover, the abundance of the alpha(1)-subunit of the Na-K-ATPase was decreased in the cortex and ISOM, but it remained unchanged in the IM.",15075188_11,0
3892,Na-K-ATPase,55,66,"Moreover, the abundance of the alpha(1)-subunit of the Na-K-ATPase was decreased in the cortex and ISOM, but it remained unchanged in the IM.",15075188_11,0
1002,IM,138,140,"Moreover, the abundance of the alpha(1)-subunit of the Na-K-ATPase was decreased in the cortex and ISOM, but it remained unchanged in the IM.",15075188_11,0
1001,alpha(1)-subunit,31,47,"Moreover, the abundance of the alpha(1)-subunit of the Na-K-ATPase was decreased in the cortex and ISOM, but it remained unchanged in the IM.",15075188_11,0
1003,ENaC,56,60,"In conclusion, the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2, connecting tubule, and collecting duct are likely to play a role in the sodium retention associated with PAN-induced nephrotic syndrome.",15075188_12,0
3896,connecting tubule,124,141,"In conclusion, the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2, connecting tubule, and collecting duct are likely to play a role in the sodium retention associated with PAN-induced nephrotic syndrome.",15075188_12,1
4847,nephrotic syndrome,241,259,"In conclusion, the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2, connecting tubule, and collecting duct are likely to play a role in the sodium retention associated with PAN-induced nephrotic syndrome.",15075188_12,1
4846,collecting duct,147,162,"In conclusion, the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2, connecting tubule, and collecting duct are likely to play a role in the sodium retention associated with PAN-induced nephrotic syndrome.",15075188_12,1
3895,DCT2,118,122,"In conclusion, the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2, connecting tubule, and collecting duct are likely to play a role in the sodium retention associated with PAN-induced nephrotic syndrome.",15075188_12,0
3897,sodium retention,196,212,"In conclusion, the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2, connecting tubule, and collecting duct are likely to play a role in the sodium retention associated with PAN-induced nephrotic syndrome.",15075188_12,1
1004,BSC-1,33,38,"The decreased abundance of NHE3, BSC-1, TSC, and Na-K-ATPase may play a compensatory role to promote sodium excretion.",15075188_13,0
3899,NHE3,27,31,"The decreased abundance of NHE3, BSC-1, TSC, and Na-K-ATPase may play a compensatory role to promote sodium excretion.",15075188_13,0
4848,compensatory,72,84,"The decreased abundance of NHE3, BSC-1, TSC, and Na-K-ATPase may play a compensatory role to promote sodium excretion.",15075188_13,1
3901,Na-K-ATPase,49,60,"The decreased abundance of NHE3, BSC-1, TSC, and Na-K-ATPase may play a compensatory role to promote sodium excretion.",15075188_13,0
991,ENaC,44,48,We hypothesized that epithelial Na channel (ENaC) subunit dysregulation may be responsible for the increased sodium retention.,15075188_3,0
4844,dysregulation,58,71,We hypothesized that epithelial Na channel (ENaC) subunit dysregulation may be responsible for the increased sodium retention.,15075188_3,1
3866,epithelial Na channel,21,42,We hypothesized that epithelial Na channel (ENaC) subunit dysregulation may be responsible for the increased sodium retention.,15075188_3,0
992,puromycin aminonucleoside,47,72,"An experimental group of rats was treated with puromycin aminonucleoside (PAN; 180 mg/kg iv), whereas the control group received only vehicle.",15075188_4,0
3868,significant proteinuria,36,59,"After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.",15075188_5,1
3869,hypoalbuminemia,61,76,"After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites.",15075188_5,1
3871,beta-ENaC,40,49,The protein abundance of alpha-ENaC and beta-ENaC was increased in the inner stripe of the outer medulla (ISOM) and in the inner medulla (IM) but was not altered in the cortex.,15075188_6,0
993,IM,138,140,The protein abundance of alpha-ENaC and beta-ENaC was increased in the inner stripe of the outer medulla (ISOM) and in the inner medulla (IM) but was not altered in the cortex.,15075188_6,0
3874,ISOM,106,110,The protein abundance of alpha-ENaC and beta-ENaC was increased in the inner stripe of the outer medulla (ISOM) and in the inner medulla (IM) but was not altered in the cortex.,15075188_6,0
3870,alpha-ENaC,25,35,The protein abundance of alpha-ENaC and beta-ENaC was increased in the inner stripe of the outer medulla (ISOM) and in the inner medulla (IM) but was not altered in the cortex.,15075188_6,0
994,IM,60,62,"gamma-ENaC abundance was increased in the cortex, ISOM, and IM.",15075188_7,0
3877,ISOM,50,54,"gamma-ENaC abundance was increased in the cortex, ISOM, and IM.",15075188_7,0
3876,gamma-ENaC,0,10,"gamma-ENaC abundance was increased in the cortex, ISOM, and IM.",15075188_7,0
995,plasma membrane,179,194,"Immunoperoxidase brightfield- and laser-scanning confocal fluorescence microscopy demonstrated increased targeting of alpha-ENaC, beta-ENaC, and gamma-ENaC subunits to the apical plasma membrane in the distal convoluted tubule (DCT2), connecting tubule, and cortical and medullary collecting duct segments.",15075188_8,0
3878,Immunoperoxidase,0,16,"Immunoperoxidase brightfield- and laser-scanning confocal fluorescence microscopy demonstrated increased targeting of alpha-ENaC, beta-ENaC, and gamma-ENaC subunits to the apical plasma membrane in the distal convoluted tubule (DCT2), connecting tubule, and cortical and medullary collecting duct segments.",15075188_8,0
3884,and medullary collecting duct,267,296,"Immunoperoxidase brightfield- and laser-scanning confocal fluorescence microscopy demonstrated increased targeting of alpha-ENaC, beta-ENaC, and gamma-ENaC subunits to the apical plasma membrane in the distal convoluted tubule (DCT2), connecting tubule, and cortical and medullary collecting duct segments.",15075188_8,1
3883,connecting tubule,235,252,"Immunoperoxidase brightfield- and laser-scanning confocal fluorescence microscopy demonstrated increased targeting of alpha-ENaC, beta-ENaC, and gamma-ENaC subunits to the apical plasma membrane in the distal convoluted tubule (DCT2), connecting tubule, and cortical and medullary collecting duct segments.",15075188_8,1
3882,DCT2,228,232,"Immunoperoxidase brightfield- and laser-scanning confocal fluorescence microscopy demonstrated increased targeting of alpha-ENaC, beta-ENaC, and gamma-ENaC subunits to the apical plasma membrane in the distal convoluted tubule (DCT2), connecting tubule, and cortical and medullary collecting duct segments.",15075188_8,0
3881,gamma-ENaC subunits,145,164,"Immunoperoxidase brightfield- and laser-scanning confocal fluorescence microscopy demonstrated increased targeting of alpha-ENaC, beta-ENaC, and gamma-ENaC subunits to the apical plasma membrane in the distal convoluted tubule (DCT2), connecting tubule, and cortical and medullary collecting duct segments.",15075188_8,0
3880,beta-ENaC,130,139,"Immunoperoxidase brightfield- and laser-scanning confocal fluorescence microscopy demonstrated increased targeting of alpha-ENaC, beta-ENaC, and gamma-ENaC subunits to the apical plasma membrane in the distal convoluted tubule (DCT2), connecting tubule, and cortical and medullary collecting duct segments.",15075188_8,0
3879,alpha-ENaC,118,128,"Immunoperoxidase brightfield- and laser-scanning confocal fluorescence microscopy demonstrated increased targeting of alpha-ENaC, beta-ENaC, and gamma-ENaC subunits to the apical plasma membrane in the distal convoluted tubule (DCT2), connecting tubule, and cortical and medullary collecting duct segments.",15075188_8,0
3886,alpha-ENaC,68,78,"Immunoelectron microscopy further revealed an increased labeling of alpha-ENaC in the apical plasma membrane of cortical collecting duct principal cells of PAN-treated rats, indicating enhanced apical targeting of alpha-ENaC subunits.",15075188_9,0
4845,collecting duct,121,136,"Immunoelectron microscopy further revealed an increased labeling of alpha-ENaC in the apical plasma membrane of cortical collecting duct principal cells of PAN-treated rats, indicating enhanced apical targeting of alpha-ENaC subunits.",15075188_9,1
996,plasma membrane,93,108,"Immunoelectron microscopy further revealed an increased labeling of alpha-ENaC in the apical plasma membrane of cortical collecting duct principal cells of PAN-treated rats, indicating enhanced apical targeting of alpha-ENaC subunits.",15075188_9,0
3887,alpha-ENaC subunits,214,233,"Immunoelectron microscopy further revealed an increased labeling of alpha-ENaC in the apical plasma membrane of cortical collecting duct principal cells of PAN-treated rats, indicating enhanced apical targeting of alpha-ENaC subunits.",15075188_9,0
3903,pyridoxine-dependent behavioral disorder,2,42,A pyridoxine-dependent behavioral disorder unmasked by isoniazid.,150790_0,1
3904,sleeping difficulties,85,106,"A 3-year-old girl had behavioral deterioration, with hyperkinesis, irritability, and sleeping difficulties after the therapeutic administration of isoniazid.",150790_1,1
4849,hyperkinesis,53,65,"A 3-year-old girl had behavioral deterioration, with hyperkinesis, irritability, and sleeping difficulties after the therapeutic administration of isoniazid.",150790_1,1
1005,pyridoxine hydrochloride,45,69,The administration of pharmacologic doses of pyridoxine hydrochloride led to a disappearance of symptoms.,150790_2,0
1006,niacinamide,29,40,"A placebo had no effect, but niacinamide was as effective as pyridoxine.",150790_4,0
3909,return of,54,63,Periodic withdrawal of pyridoxine was associated with return of the hyperkinesis.,150790_5,1
4850,hyperkinesis,68,80,Periodic withdrawal of pyridoxine was associated with return of the hyperkinesis.,150790_5,1
1007,kynurenine,43,53,Metabolic studies suggested a block in the kynurenine pathway of tryptophan metabolism.,150790_7,0
1008,her,106,109,The patient has been followed for six years and has required pharmacologic doses of pyridoxine to control her behavior.,150790_8,0
3912,pallidotomy?A,40,53,Pallidal stimulation: an alternative to pallidotomy?A resurgence of interest in the surgical treatment of Parkinson's disease (PD) came with the rediscovery of posteroventral pallidotomy by Laitinen in 1985.,15096016_0,1
3911,Pallidal,0,8,Pallidal stimulation: an alternative to pallidotomy?A resurgence of interest in the surgical treatment of Parkinson's disease (PD) came with the rediscovery of posteroventral pallidotomy by Laitinen in 1985.,15096016_0,1
4851,Parkinson's disease,106,125,Pallidal stimulation: an alternative to pallidotomy?A resurgence of interest in the surgical treatment of Parkinson's disease (PD) came with the rediscovery of posteroventral pallidotomy by Laitinen in 1985.,15096016_0,1
3914,posteroventral pallidotomy,160,186,Pallidal stimulation: an alternative to pallidotomy?A resurgence of interest in the surgical treatment of Parkinson's disease (PD) came with the rediscovery of posteroventral pallidotomy by Laitinen in 1985.,15096016_0,1
4852,drug-resistant,47,61,"Laitinen's procedure improved most symptoms in drug-resistant PD, which engendered wide interest in the neurosurgical community.",15096016_1,1
3919,nucleus ventralis intermedius,107,136,"Another lesioning procedure, ventrolateral thalamotomy, has become a powerful alternative to stimulate the nucleus ventralis intermedius, producing high long-term success rates and low morbidity rates.",15096016_2,1
3918,thalamotomy,43,54,"Another lesioning procedure, ventrolateral thalamotomy, has become a powerful alternative to stimulate the nucleus ventralis intermedius, producing high long-term success rates and low morbidity rates.",15096016_2,1
3921,Pallidal,0,8,Pallidal stimulation has not met with the same success.,15096016_3,1
4853,bradykinesia,144,156,"According to the literature pallidotomy improves the ""on"" symptoms of PD, such as dyskinesias, as well as the ""off"" symptoms, such as rigidity, bradykinesia, and on-off fluctuations.",15096016_4,1
3924,Pallidal,0,8,"Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving levodopa-induced dyskinesias.",15096016_5,1
4854,bradykinesia,30,42,"Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving levodopa-induced dyskinesias.",15096016_5,1
4856,lower limbs,130,141,"Stimulation often produces an improvement in the hyper- or dyskinetic upper limbs, but increases the ""freezing"" phenomenon in the lower limbs at the same time.",15096016_6,1
4855,dyskinetic,59,69,"Stimulation often produces an improvement in the hyper- or dyskinetic upper limbs, but increases the ""freezing"" phenomenon in the lower limbs at the same time.",15096016_6,1
3928,pallidotomy,259,270,"Considering the small increase in the patient's independence, the high costs of bilateral implants, and the difficulty most patients experience in handling the devices, the question arises as to whether bilateral pallidal stimulation is a real alternative to pallidotomy.",15096016_7,1
3927,pallidal,213,221,"Considering the small increase in the patient's independence, the high costs of bilateral implants, and the difficulty most patients experience in handling the devices, the question arises as to whether bilateral pallidal stimulation is a real alternative to pallidotomy.",15096016_7,1
4857,temporal lobe epilepsy,63,85,Recurrent excitation in the dentate gyrus of a murine model of temporal lobe epilepsy.,15120741_0,1
3929,dentate gyrus,28,41,Recurrent excitation in the dentate gyrus of a murine model of temporal lobe epilepsy.,15120741_0,1
1009,CD1,173,176,"Similar to rats, systemic pilocarpine injection causes status epilepticus (SE) and the eventual development of spontaneous seizures and mossy fiber sprouting in C57BL/6 and CD1 mice, but the physiological correlates of these events have not been identified in mice.",15120741_1,0
3933,C57BL/6,161,168,"Similar to rats, systemic pilocarpine injection causes status epilepticus (SE) and the eventual development of spontaneous seizures and mossy fiber sprouting in C57BL/6 and CD1 mice, but the physiological correlates of these events have not been identified in mice.",15120741_1,0
3931,spontaneous seizures,111,131,"Similar to rats, systemic pilocarpine injection causes status epilepticus (SE) and the eventual development of spontaneous seizures and mossy fiber sprouting in C57BL/6 and CD1 mice, but the physiological correlates of these events have not been identified in mice.",15120741_1,1
3932,mossy fiber,136,147,"Similar to rats, systemic pilocarpine injection causes status epilepticus (SE) and the eventual development of spontaneous seizures and mossy fiber sprouting in C57BL/6 and CD1 mice, but the physiological correlates of these events have not been identified in mice.",15120741_1,1
4858,status epilepticus,55,73,"Similar to rats, systemic pilocarpine injection causes status epilepticus (SE) and the eventual development of spontaneous seizures and mossy fiber sprouting in C57BL/6 and CD1 mice, but the physiological correlates of these events have not been identified in mice.",15120741_1,1
3935,dentate gyrus,45,58,Population responses in granule cells of the dentate gyrus were examined in transverse slices of the ventral hippocampus from pilocarpine-treated and untreated mice.,15120741_2,1
3936,ventral hippocampus,101,120,Population responses in granule cells of the dentate gyrus were examined in transverse slices of the ventral hippocampus from pilocarpine-treated and untreated mice.,15120741_2,1
1010,bicuculline,41,52,"In Mg(2+)-free bathing medium containing bicuculline, conditions designed to increase excitability in the slices, electrical stimulation of the hilus resulted in a single population spike in granule cells from control mice and pilocarpine-treated mice that did not experience SE.",15120741_3,0
3944,ionotropic glutamate receptor antagonists,196,237,"In SE survivors, similar stimulation resulted in a population spike followed, at a variable latency, by negative DC shifts and repetitive afterdischarges of 3-60 s duration, which were blocked by ionotropic glutamate receptor antagonists.",15120741_4,0
4859,temporal lobe epilepsy,208,230,"These data support the hypothesis that SE-induced mossy fiber sprouting and synaptic reorganization are relevant characteristics of seizure development in these murine strains, resembling rat models of human temporal lobe epilepsy.",15120741_6,1
3948,SE-induced mossy fiber,39,61,"These data support the hypothesis that SE-induced mossy fiber sprouting and synaptic reorganization are relevant characteristics of seizure development in these murine strains, resembling rat models of human temporal lobe epilepsy.",15120741_6,1
4861,Wegener's granulomatosis,26,50,Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide.,15130900_0,1
3950,cyclophosphamide,74,90,Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide.,15130900_0,0
4860,Urinary bladder cancer,0,22,Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide.,15130900_0,1
3951,cyclophosphamide,86,102,"OBJECTIVE: To assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with Wegener's granulomatosis.",15130900_1,0
4863,Wegener's granulomatosis,121,145,"OBJECTIVE: To assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with Wegener's granulomatosis.",15130900_1,1
4862,bladder cancer,50,64,"OBJECTIVE: To assess and characterise the risk of bladder cancer, and its relation to cyclophosphamide, in patients with Wegener's granulomatosis.",15130900_1,1
3962,cyclophosphamide,70,86,"CONCLUSION: The results indicate a dose-response relationship between cyclophosphamide and the risk of bladder cancer, high cumulative risks in the entire cohort, and also the possibility of risk factors operating even before Wegener's granulomatosis.",15130900_10,0
4877,Wegener's granulomatosis,226,250,"CONCLUSION: The results indicate a dose-response relationship between cyclophosphamide and the risk of bladder cancer, high cumulative risks in the entire cohort, and also the possibility of risk factors operating even before Wegener's granulomatosis.",15130900_10,1
4876,bladder cancer,103,117,"CONCLUSION: The results indicate a dose-response relationship between cyclophosphamide and the risk of bladder cancer, high cumulative risks in the entire cohort, and also the possibility of risk factors operating even before Wegener's granulomatosis.",15130900_10,1
4864,Wegener's granulomatosis,103,127,"METHODS: In the population based, nationwide Swedish Inpatient Register a cohort of 1065 patients with Wegener's granulomatosis, 1969-95, was identified.",15130900_2,1
4865,bladder cancer,93,107,"Through linkage with the Swedish Cancer Register, all subjects in this cohort diagnosed with bladder cancer were identified.",15130900_3,1
3955,cyclophosphamide,105,121,"Nested within the cohort, a matched case-control study was performed to estimate the association between cyclophosphamide and bladder cancer using odds ratios (ORs) as relative risk.",15130900_4,0
4866,bladder cancer,126,140,"Nested within the cohort, a matched case-control study was performed to estimate the association between cyclophosphamide and bladder cancer using odds ratios (ORs) as relative risk.",15130900_4,1
4870,Wegener's granulomatosis,171,195,"In the cohort the cumulative risk of bladder cancer after Wegener's granulomatosis, and the relative prevalence of a history of bladder cancer at the time of diagnosis of Wegener's granulomatosis, were also estimated.",15130900_5,1
4868,Wegener's granulomatosis,58,82,"In the cohort the cumulative risk of bladder cancer after Wegener's granulomatosis, and the relative prevalence of a history of bladder cancer at the time of diagnosis of Wegener's granulomatosis, were also estimated.",15130900_5,1
4867,bladder cancer,37,51,"In the cohort the cumulative risk of bladder cancer after Wegener's granulomatosis, and the relative prevalence of a history of bladder cancer at the time of diagnosis of Wegener's granulomatosis, were also estimated.",15130900_5,1
4869,bladder cancer,128,142,"In the cohort the cumulative risk of bladder cancer after Wegener's granulomatosis, and the relative prevalence of a history of bladder cancer at the time of diagnosis of Wegener's granulomatosis, were also estimated.",15130900_5,1
3959,cyclophosphamide,40,56,"RESULTS: The median cumulative doses of cyclophosphamide among cases (n = 11) and controls (n = 25) were 113 g and 25 g, respectively.",15130900_6,0
4871,bladder cancer,12,26,"The risk of bladder cancer doubled for every 10 g increment in cyclophosphamide (OR = 2.0, 95% confidence interval (CI) 0.8 to 4.9).",15130900_7,1
3960,cyclophosphamide,63,79,"The risk of bladder cancer doubled for every 10 g increment in cyclophosphamide (OR = 2.0, 95% confidence interval (CI) 0.8 to 4.9).",15130900_7,0
4875,Wegener's granulomatosis,229,253,"The absolute risk for bladder cancer in the cohort reached 10% 16 years after diagnosis of Wegener's granulomatosis, and a history of bladder cancer was (non-significantly) twice as common as expected at the time of diagnosis of Wegener's granulomatosis.",15130900_9,1
4872,bladder cancer,22,36,"The absolute risk for bladder cancer in the cohort reached 10% 16 years after diagnosis of Wegener's granulomatosis, and a history of bladder cancer was (non-significantly) twice as common as expected at the time of diagnosis of Wegener's granulomatosis.",15130900_9,1
4873,Wegener's granulomatosis,91,115,"The absolute risk for bladder cancer in the cohort reached 10% 16 years after diagnosis of Wegener's granulomatosis, and a history of bladder cancer was (non-significantly) twice as common as expected at the time of diagnosis of Wegener's granulomatosis.",15130900_9,1
4874,bladder cancer,134,148,"The absolute risk for bladder cancer in the cohort reached 10% 16 years after diagnosis of Wegener's granulomatosis, and a history of bladder cancer was (non-significantly) twice as common as expected at the time of diagnosis of Wegener's granulomatosis.",15130900_9,1
1011,alpha2-adrenergic,39,56,Differential modulation by estrogen of alpha2-adrenergic and I1-imidazoline receptor-mediated hypotension in female rats.,15145918_0,0
3965,mixed alpha2-/I1-receptor agonist,95,128,We have recently shown that estrogen negatively modulates the hypotensive effect of clonidine (mixed alpha2-/I1-receptor agonist) in female rats and implicates the cardiovascular autonomic control in this interaction.,15145918_1,0
3998,estrogen downregulates,28,50,These findings suggest that estrogen downregulates alpha2- but not I1-receptor-mediated hypotension and highlight a role for the cardiac autonomic control in alpha-methyldopa-estrogen interaction.,15145918_10,0
1023,alpha2-,51,58,These findings suggest that estrogen downregulates alpha2- but not I1-receptor-mediated hypotension and highlight a role for the cardiac autonomic control in alpha-methyldopa-estrogen interaction.,15145918_10,0
3967,I1-receptors,104,116,The present study investigated whether this effect of estrogen involves interaction with alpha2- and/or I1-receptors.,15145918_2,0
1012,alpha2-,89,96,The present study investigated whether this effect of estrogen involves interaction with alpha2- and/or I1-receptors.,15145918_2,0
1013,rilmenidine,56,67,"Changes evoked by a single intraperitoneal injection of rilmenidine (600 microg/kg) or alpha-methyldopa (100 mg/kg), selective I1- and alpha2-receptor agonists, respectively, in blood pressure, hemodynamic variability, and locomotor activity were assessed in radiotelemetered sham-operated and ovariectomized (Ovx) Sprague-Dawley female rats with or without 12-wk estrogen replacement.",15145918_3,0
1014,alpha-methyldopa,87,103,"Changes evoked by a single intraperitoneal injection of rilmenidine (600 microg/kg) or alpha-methyldopa (100 mg/kg), selective I1- and alpha2-receptor agonists, respectively, in blood pressure, hemodynamic variability, and locomotor activity were assessed in radiotelemetered sham-operated and ovariectomized (Ovx) Sprague-Dawley female rats with or without 12-wk estrogen replacement.",15145918_3,0
4878,blood pressure,178,192,"Changes evoked by a single intraperitoneal injection of rilmenidine (600 microg/kg) or alpha-methyldopa (100 mg/kg), selective I1- and alpha2-receptor agonists, respectively, in blood pressure, hemodynamic variability, and locomotor activity were assessed in radiotelemetered sham-operated and ovariectomized (Ovx) Sprague-Dawley female rats with or without 12-wk estrogen replacement.",15145918_3,1
3969,I1-,127,130,"Changes evoked by a single intraperitoneal injection of rilmenidine (600 microg/kg) or alpha-methyldopa (100 mg/kg), selective I1- and alpha2-receptor agonists, respectively, in blood pressure, hemodynamic variability, and locomotor activity were assessed in radiotelemetered sham-operated and ovariectomized (Ovx) Sprague-Dawley female rats with or without 12-wk estrogen replacement.",15145918_3,0
1015,alpha2-receptor,135,150,"Changes evoked by a single intraperitoneal injection of rilmenidine (600 microg/kg) or alpha-methyldopa (100 mg/kg), selective I1- and alpha2-receptor agonists, respectively, in blood pressure, hemodynamic variability, and locomotor activity were assessed in radiotelemetered sham-operated and ovariectomized (Ovx) Sprague-Dawley female rats with or without 12-wk estrogen replacement.",15145918_3,0
3982,heart rate,316,326,Three time domain indexes of hemodynamic variability were employed: the standard deviation of mean arterial pressure as a measure of blood pressure variability and the standard deviation of beat-to-beat intervals (SDRR) and the root mean square of successive differences in R-wave-to-R-wave intervals as measures of heart rate variability.,15145918_4,1
3977,mean arterial pressure,94,116,Three time domain indexes of hemodynamic variability were employed: the standard deviation of mean arterial pressure as a measure of blood pressure variability and the standard deviation of beat-to-beat intervals (SDRR) and the root mean square of successive differences in R-wave-to-R-wave intervals as measures of heart rate variability.,15145918_4,1
4879,blood pressure,133,147,Three time domain indexes of hemodynamic variability were employed: the standard deviation of mean arterial pressure as a measure of blood pressure variability and the standard deviation of beat-to-beat intervals (SDRR) and the root mean square of successive differences in R-wave-to-R-wave intervals as measures of heart rate variability.,15145918_4,1
1017,alpha-methyldopa,38,54,"In sham-operated rats, rilmenidine or alpha-methyldopa elicited similar hypotension that lasted at least 5 h and was associated with reductions in standard deviation of mean arterial pressure.",15145918_5,0
3986,mean arterial pressure,169,191,"In sham-operated rats, rilmenidine or alpha-methyldopa elicited similar hypotension that lasted at least 5 h and was associated with reductions in standard deviation of mean arterial pressure.",15145918_5,1
1016,rilmenidine,23,34,"In sham-operated rats, rilmenidine or alpha-methyldopa elicited similar hypotension that lasted at least 5 h and was associated with reductions in standard deviation of mean arterial pressure.",15145918_5,0
1018,alpha-methyldopa,25,41,SDRR was reduced only by alpha-methyldopa.,15145918_6,0
1020,rilmenidine,101,112,"Ovx significantly enhanced the hypotensive response to alpha-methyldopa, in contrast to no effect on rilmenidine hypotension.",15145918_7,0
1019,alpha-methyldopa,55,71,"Ovx significantly enhanced the hypotensive response to alpha-methyldopa, in contrast to no effect on rilmenidine hypotension.",15145918_7,0
3988,Ovx,0,3,"Ovx significantly enhanced the hypotensive response to alpha-methyldopa, in contrast to no effect on rilmenidine hypotension.",15145918_7,0
1021,alpha-methyldopa,13,29,The enhanced alpha-methyldopa hypotension in Ovx rats was paralleled with further reduction in SDRR and a reduced locomotor activity.,15145918_8,0
3990,Ovx,45,48,The enhanced alpha-methyldopa hypotension in Ovx rats was paralleled with further reduction in SDRR and a reduced locomotor activity.,15145918_8,0
3991,SDRR,95,99,The enhanced alpha-methyldopa hypotension in Ovx rats was paralleled with further reduction in SDRR and a reduced locomotor activity.,15145918_8,0
3994,17beta-estradiol,22,38,"Estrogen replacement (17beta-estradiol subcutaneous pellet, 14.2 microg/day, 12 wk) of Ovx rats restored the hemodynamic and locomotor effects of alpha-methyldopa to sham-operated levels.",15145918_9,0
3993,Estrogen replacement,0,20,"Estrogen replacement (17beta-estradiol subcutaneous pellet, 14.2 microg/day, 12 wk) of Ovx rats restored the hemodynamic and locomotor effects of alpha-methyldopa to sham-operated levels.",15145918_9,0
1022,alpha-methyldopa,146,162,"Estrogen replacement (17beta-estradiol subcutaneous pellet, 14.2 microg/day, 12 wk) of Ovx rats restored the hemodynamic and locomotor effects of alpha-methyldopa to sham-operated levels.",15145918_9,0
4881,diastolic dysfunction,48,69,Severe reversible left ventricular systolic and diastolic dysfunction due to accidental iatrogenic epinephrine overdose.,15188772_0,1
4880,left ventricular,18,34,Severe reversible left ventricular systolic and diastolic dysfunction due to accidental iatrogenic epinephrine overdose.,15188772_0,1
4002,clinical phenomenon,125,144,Catecholamine-induced cardiomyopathy due to chronic excess of endogenous catecholamines has been recognized for decades as a clinical phenomenon.,15188772_1,1
4003,myocardial dysfunction,24,46,"In contrast, reports of myocardial dysfunction due to acute iatrogenic overdose are rare.",15188772_2,1
4004,acute iatrogenic overdose,54,79,"In contrast, reports of myocardial dysfunction due to acute iatrogenic overdose are rare.",15188772_2,1
4005,hemodynamic compromise,154,176,"A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis.",15188772_3,1
4006,myocardial necrosis,309,328,"A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis.",15188772_3,1
4883,left ventricular,206,222,"A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis.",15188772_3,1
4882,myocardial stunning,101,120,"A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis.",15188772_3,1
1024,biochemical markers,286,305,"A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis.",15188772_3,0
4884,diastolic dysfunction,236,257,"A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis.",15188772_3,1
4007,medical errors,49,63,Our case illustrates the serious consequences of medical errors that can be avoided through improved medication labeling and staff supervision.,15188772_4,1
4885,myocardial infarction,74,95,Cardioprotective effect of tincture of Crataegus on isoproterenol-induced myocardial infarction in rats.,15233872_0,1
1025,Cardioprotective,0,16,Cardioprotective effect of tincture of Crataegus on isoproterenol-induced myocardial infarction in rats.,15233872_0,0
1026,TCR,23,26,"Tincture of Crataegus (TCR), an alcoholic extract of the berries of hawthorn (Crataegus oxycantha), is used in herbal and homeopathic medicine.",15233872_1,0
4009,alcoholic extract,32,49,"Tincture of Crataegus (TCR), an alcoholic extract of the berries of hawthorn (Crataegus oxycantha), is used in herbal and homeopathic medicine.",15233872_1,0
4010,protective effect,46,63,The present study was done to investigate the protective effect of TCR on experimentally induced myocardial infarction in rats.,15233872_2,0
1027,TCR,67,70,The present study was done to investigate the protective effect of TCR on experimentally induced myocardial infarction in rats.,15233872_2,0
4886,myocardial infarction,97,118,The present study was done to investigate the protective effect of TCR on experimentally induced myocardial infarction in rats.,15233872_2,1
4011,lipid peroxidation,113,131,"Pretreatment of TCR, at a dose of 0.5 mL/100 g bodyweight per day, orally for 30 days, prevented the increase in lipid peroxidation and activity of marker enzymes observed in isoproterenol-induced rats (85 mg kg(-1) s. c. for 2 days at an interval of 24 h).",15233872_3,0
4887,bodyweight,47,57,"Pretreatment of TCR, at a dose of 0.5 mL/100 g bodyweight per day, orally for 30 days, prevented the increase in lipid peroxidation and activity of marker enzymes observed in isoproterenol-induced rats (85 mg kg(-1) s. c. for 2 days at an interval of 24 h).",15233872_3,1
1028,TCR,16,19,"Pretreatment of TCR, at a dose of 0.5 mL/100 g bodyweight per day, orally for 30 days, prevented the increase in lipid peroxidation and activity of marker enzymes observed in isoproterenol-induced rats (85 mg kg(-1) s. c. for 2 days at an interval of 24 h).",15233872_3,0
4012,antioxidant enzymes,52,71,TCR prevented the isoproterenol-induced decrease in antioxidant enzymes in the heart and increased the rate of ADP-stimulated oxygen uptake and respiratory coupling ratio.,15233872_4,0
1029,TCR,0,3,TCR prevented the isoproterenol-induced decrease in antioxidant enzymes in the heart and increased the rate of ADP-stimulated oxygen uptake and respiratory coupling ratio.,15233872_4,0
1030,TCR,0,3,TCR protected against pathological changes induced by isoproterenol in rat heart.,15233872_5,0
1031,TCR,40,43,The results show that pretreatment with TCR may be useful in preventing the damage induced by isoproterenol in rat heart.,15233872_6,0
4888,thrombotic,136,146,Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis.,15266215_0,1
1032,nonsteroidal antiinflammatory agents,69,105,Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis.,15266215_0,0
4016,(COX)-2-specific,109,125,There have been concerns that the risk of cardiovascular thrombotic events may be higher with cyclooxygenase (COX)-2-specific inhibitors than nonselective nonsteroidal antiinflammatory drugs (NSAIDs).,15266215_1,0
4018,antiinflammatory drugs,168,190,There have been concerns that the risk of cardiovascular thrombotic events may be higher with cyclooxygenase (COX)-2-specific inhibitors than nonselective nonsteroidal antiinflammatory drugs (NSAIDs).,15266215_1,0
4889,thrombotic,57,67,There have been concerns that the risk of cardiovascular thrombotic events may be higher with cyclooxygenase (COX)-2-specific inhibitors than nonselective nonsteroidal antiinflammatory drugs (NSAIDs).,15266215_1,1
4020,COX-2-specific inhibitor,61,85,"We evaluated cardiovascular event data for valdecoxib, a new COX-2-specific inhibitor in approximately 8000 patients with osteoarthritis and rheumatoid arthritis treated with this agent in randomized clinical trials.",15266215_2,0
4890,rheumatoid arthritis,141,161,"We evaluated cardiovascular event data for valdecoxib, a new COX-2-specific inhibitor in approximately 8000 patients with osteoarthritis and rheumatoid arthritis treated with this agent in randomized clinical trials.",15266215_2,1
4891,thrombotic,32,42,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,1
1033,diclofenac,209,219,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,0
4892,peripheral vascular,80,99,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,1
4893,thrombotic,113,123,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,1
4894,rheumatoid arthritis,332,352,"The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration.",15266215_3,1
1034,low-dose,89,97,The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) aspirin (n = 1051) and nonusers of aspirin (n = 6883).,15266215_4,0
4895,thrombotic,42,52,"Crude and exposure-adjusted incidences of thrombotic events were similar for valdecoxib, NSAIDs, and placebo.",15266215_5,1
4896,thrombotic,20,30,The risk of serious thrombotic events was also similar for each valdecoxib dose.,15266215_6,1
4897,Thrombotic,0,10,"Thrombotic risk was consistently higher for users of aspirin users than nonusers of aspirin (placebo, 1.4% vs. 0%; valdecoxib, 1.7% vs. 0.2%; NSAIDs, 1.9% vs. 0.5%).",15266215_7,1
4026,supratherapeutic,80,96,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.,15266215_9,0
4027,valdecoxib doses,117,133,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.,15266215_9,0
4899,rheumatoid arthritis,267,287,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.,15266215_9,1
4898,thrombotic,184,194,Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials.,15266215_9,1
4900,hypertrophic cardiomyopathy,42,69,Hypersensitivity myocarditis complicating hypertrophic cardiomyopathy heart.,15266362_0,1
4030,Hypersensitivity myocarditis,0,28,Hypersensitivity myocarditis complicating hypertrophic cardiomyopathy heart.,15266362_0,1
4901,hypertrophic cardiomyopathy,77,104,The present report describes a case of eosinophilic myocarditis complicating hypertrophic cardiomyopathy.,15266362_1,1
4031,eosinophilic myocarditis,39,63,The present report describes a case of eosinophilic myocarditis complicating hypertrophic cardiomyopathy.,15266362_1,1
4902,hypertrophic cardiomyopathy,46,73,"The 47-year-old female patient, known to have hypertrophic cardiomyopathy, was admitted with biventricular failure and managed aggressively with dobutamine infusion and other drugs while being assessed for heart transplantation.",15266362_2,1
4034,heart transplantation,206,227,"The 47-year-old female patient, known to have hypertrophic cardiomyopathy, was admitted with biventricular failure and managed aggressively with dobutamine infusion and other drugs while being assessed for heart transplantation.",15266362_2,1
1035,dobutamine,145,155,"The 47-year-old female patient, known to have hypertrophic cardiomyopathy, was admitted with biventricular failure and managed aggressively with dobutamine infusion and other drugs while being assessed for heart transplantation.",15266362_2,0
4033,biventricular failure,93,114,"The 47-year-old female patient, known to have hypertrophic cardiomyopathy, was admitted with biventricular failure and managed aggressively with dobutamine infusion and other drugs while being assessed for heart transplantation.",15266362_2,1
4904,mitral regurgitation,118,138,"On transthoracic echocardiogram, she had moderate left ventricular dysfunction with regional variability and moderate mitral regurgitation.",15266362_3,1
4903,left ventricular dysfunction,50,78,"On transthoracic echocardiogram, she had moderate left ventricular dysfunction with regional variability and moderate mitral regurgitation.",15266362_3,1
4905,apical hypertrophic cardiomyopathy,45,79,The recipient's heart showed the features of apical hypertrophic cardiomyopathy and myocarditis with abundant eosinophils.,15266362_4,1
4036,eosinophilic myocarditis,24,48,Myocarditis is rare and eosinophilic myocarditis is rarer.,15266362_5,1
1036,dobutamine,81,91,It is likely that the hypersensitivity (eosinophilic) myocarditis was related to dobutamine infusion therapy.,15266362_6,0
4038,Eosinophilic myocarditis,0,24,Eosinophilic myocarditis has been reported with an incidence of 2.4% to 7.2% in explanted hearts and may be related to multidrug therapy.,15266362_7,1
1037,multidrug,119,128,Eosinophilic myocarditis has been reported with an incidence of 2.4% to 7.2% in explanted hearts and may be related to multidrug therapy.,15266362_7,0
1038,lignocaine,55,65,Treatment of tinnitus by intratympanic instillation of lignocaine (lidocaine) 2 per cent through ventilation tubes.,1527456_0,0
4906,intratympanic,25,38,Treatment of tinnitus by intratympanic instillation of lignocaine (lidocaine) 2 per cent through ventilation tubes.,1527456_0,1
4907,subjective tinnitus,11,30,Idiopathic subjective tinnitus (IST) is one of the most obscure otological pathologies.,1527456_1,1
4908,otological,64,74,Idiopathic subjective tinnitus (IST) is one of the most obscure otological pathologies.,1527456_1,1
4909,intratympanic,51,64,"This paper presents the results of treating IST by intratympanic instillation of lignocaine (lidocaine) 2 per cent through a grommet, for five weekly courses.",1527456_2,1
1039,lignocaine,81,91,"This paper presents the results of treating IST by intratympanic instillation of lignocaine (lidocaine) 2 per cent through a grommet, for five weekly courses.",1527456_2,0
4043,intractable tinnitus,34,54,"Fifty-two patients suffering from intractable tinnitus entered this therapeutic trial, but only nine finished all five courses.",1527456_3,1
4045,decompensated tinnitus,95,117,"In one patient, the tinnitus was almost completely abolished, but in all the nine patients the decompensated tinnitus changed to a compensated one.",1527456_4,1
4910,side effects,36,48,"Patients should be warned about the side effects of vertigo and vomiting, which subsides gradually with every new instillation, and that the tinnitus may not disappear but will be alleviated, enabling them to cope more easily with the disease and lead a more normal life.",1527456_6,1
4046,normal life,259,270,"Patients should be warned about the side effects of vertigo and vomiting, which subsides gradually with every new instillation, and that the tinnitus may not disappear but will be alleviated, enabling them to cope more easily with the disease and lead a more normal life.",1527456_6,1
4047,beta4 nicotinic acetylcholine receptor,15,53,The alpha3 and beta4 nicotinic acetylcholine receptor subunits are necessary for nicotine-induced seizures and hypolocomotion in mice.,15275829_0,0
1040,alpha3,4,10,The alpha3 and beta4 nicotinic acetylcholine receptor subunits are necessary for nicotine-induced seizures and hypolocomotion in mice.,15275829_0,0
1041,nicotinic acetylcholine receptors,23,56,"Binding of nicotine to nicotinic acetylcholine receptors (nAChRs) elicits a series of dose-dependent behaviors that go from altered exploration, sedation, and tremors, to seizures and death.",15275829_1,0
1042,ion channels,22,34,nAChRs are pentameric ion channels usually composed of alpha and beta subunits.,15275829_2,0
1043,beta subunits,65,78,nAChRs are pentameric ion channels usually composed of alpha and beta subunits.,15275829_2,0
1044,alpha3,29,35,"A gene cluster comprises the alpha3, alpha5 and beta4 subunits, which coassemble to form functional receptors.",15275829_3,0
4052,functional receptors,89,109,"A gene cluster comprises the alpha3, alpha5 and beta4 subunits, which coassemble to form functional receptors.",15275829_3,0
1046,beta4,48,53,"A gene cluster comprises the alpha3, alpha5 and beta4 subunits, which coassemble to form functional receptors.",15275829_3,0
1045,alpha5,37,43,"A gene cluster comprises the alpha3, alpha5 and beta4 subunits, which coassemble to form functional receptors.",15275829_3,0
1049,beta4,117,122,We examined the role of the beta4 subunits in nicotine-induced seizures and hypolocomotion in beta4 homozygous null (beta4 -/-) and alpha3 heterozygous (+/-) mice.,15275829_4,0
4055,(+/-,152,156,We examined the role of the beta4 subunits in nicotine-induced seizures and hypolocomotion in beta4 homozygous null (beta4 -/-) and alpha3 heterozygous (+/-) mice.,15275829_4,0
1050,alpha3,132,138,We examined the role of the beta4 subunits in nicotine-induced seizures and hypolocomotion in beta4 homozygous null (beta4 -/-) and alpha3 heterozygous (+/-) mice.,15275829_4,0
1048,beta4,94,99,We examined the role of the beta4 subunits in nicotine-induced seizures and hypolocomotion in beta4 homozygous null (beta4 -/-) and alpha3 heterozygous (+/-) mice.,15275829_4,0
1047,beta4,28,33,We examined the role of the beta4 subunits in nicotine-induced seizures and hypolocomotion in beta4 homozygous null (beta4 -/-) and alpha3 heterozygous (+/-) mice.,15275829_4,0
1051,beta4,0,5,"beta4 -/- mice were less sensitive to the effects of nicotine both at low doses, measured as decreased exploration in an open field, and at high doses, measured as sensitivity to nicotine-induced seizures.",15275829_5,0
4056,low doses,70,79,"beta4 -/- mice were less sensitive to the effects of nicotine both at low doses, measured as decreased exploration in an open field, and at high doses, measured as sensitivity to nicotine-induced seizures.",15275829_5,0
4058,high doses,140,150,"beta4 -/- mice were less sensitive to the effects of nicotine both at low doses, measured as decreased exploration in an open field, and at high doses, measured as sensitivity to nicotine-induced seizures.",15275829_5,0
1054,beta4,269,274,"Using in situ hybridization probes for the alpha3 and alpha5 subunits, we showed that alpha5 mRNA levels are unchanged, whereas alpha3 mRNA levels are selectively decreased in the mitral cell layer of the olfactory bulb, and the inferior and the superior colliculus of beta4 -/- brains.",15275829_6,0
1053,alpha5,54,60,"Using in situ hybridization probes for the alpha3 and alpha5 subunits, we showed that alpha5 mRNA levels are unchanged, whereas alpha3 mRNA levels are selectively decreased in the mitral cell layer of the olfactory bulb, and the inferior and the superior colliculus of beta4 -/- brains.",15275829_6,0
1052,alpha3,43,49,"Using in situ hybridization probes for the alpha3 and alpha5 subunits, we showed that alpha5 mRNA levels are unchanged, whereas alpha3 mRNA levels are selectively decreased in the mitral cell layer of the olfactory bulb, and the inferior and the superior colliculus of beta4 -/- brains.",15275829_6,0
4060,alpha5 mRNA,86,97,"Using in situ hybridization probes for the alpha3 and alpha5 subunits, we showed that alpha5 mRNA levels are unchanged, whereas alpha3 mRNA levels are selectively decreased in the mitral cell layer of the olfactory bulb, and the inferior and the superior colliculus of beta4 -/- brains.",15275829_6,0
4061,alpha3 mRNA,128,139,"Using in situ hybridization probes for the alpha3 and alpha5 subunits, we showed that alpha5 mRNA levels are unchanged, whereas alpha3 mRNA levels are selectively decreased in the mitral cell layer of the olfactory bulb, and the inferior and the superior colliculus of beta4 -/- brains.",15275829_6,0
4062,mitral cell layer,180,197,"Using in situ hybridization probes for the alpha3 and alpha5 subunits, we showed that alpha5 mRNA levels are unchanged, whereas alpha3 mRNA levels are selectively decreased in the mitral cell layer of the olfactory bulb, and the inferior and the superior colliculus of beta4 -/- brains.",15275829_6,1
4063,olfactory bulb,205,219,"Using in situ hybridization probes for the alpha3 and alpha5 subunits, we showed that alpha5 mRNA levels are unchanged, whereas alpha3 mRNA levels are selectively decreased in the mitral cell layer of the olfactory bulb, and the inferior and the superior colliculus of beta4 -/- brains.",15275829_6,1
4064,superior colliculus,246,265,"Using in situ hybridization probes for the alpha3 and alpha5 subunits, we showed that alpha5 mRNA levels are unchanged, whereas alpha3 mRNA levels are selectively decreased in the mitral cell layer of the olfactory bulb, and the inferior and the superior colliculus of beta4 -/- brains.",15275829_6,1
4065,/-,8,10,alpha3 +/- mice were partially resistant to nicotine-induced seizures when compared to wild-type littermates.,15275829_7,0
1055,alpha3,0,6,alpha3 +/- mice were partially resistant to nicotine-induced seizures when compared to wild-type littermates.,15275829_7,0
1056,alpha5,20,26,mRNA levels for the alpha5 and the beta4 subunits were unchanged in alpha3 +/- brains.,15275829_8,0
1058,alpha3,68,74,mRNA levels for the alpha5 and the beta4 subunits were unchanged in alpha3 +/- brains.,15275829_8,0
1057,beta4,35,40,mRNA levels for the alpha5 and the beta4 subunits were unchanged in alpha3 +/- brains.,15275829_8,0
4067,/-,76,78,mRNA levels for the alpha5 and the beta4 subunits were unchanged in alpha3 +/- brains.,15275829_8,0
1060,alpha3,55,61,"Together, these results suggest that the beta4 and the alpha3 subunits are mediators of nicotine-induced seizures and hypolocomotion.",15275829_9,0
1059,beta4,41,46,"Together, these results suggest that the beta4 and the alpha3 subunits are mediators of nicotine-induced seizures and hypolocomotion.",15275829_9,0
4074,intracranial bleeding,42,63,"The proportion of patients with major and intracranial bleeding increased from 20.2% and 1.9%, respectively, in the first time period, to 33.3% and 7.8%, respectively, in the second.",15276120_2,1
1061,sevoflurane,15,26,The effects of sevoflurane on lidocaine-induced convulsions.,15278670_0,0
4077,lidocaine-induced convulsions,30,59,The effects of sevoflurane on lidocaine-induced convulsions.,15278670_0,0
1062,sevoflurane,17,28,The influence of sevoflurane on lidocaine-induced convulsions was studied in cats.,15278670_1,0
4078,lidocaine-induced convulsions,32,61,The influence of sevoflurane on lidocaine-induced convulsions was studied in cats.,15278670_1,0
1063,sevoflurane,201,212,"The convulsive threshold (mean +/- SD) was 41.4 +/- 6.5 mg. l(-1) with lidocaine infusion (6 mg.kg(-1).min(-1)), increasing significantly to 66.6 +/- 10.9 mg. l(-1) when the end-tidal concentration of sevoflurane was 0.8%.",15278670_2,0
1065,sevoflurane,114,125,"However, the threshold (61.6 +/- 8.7 mg. l(-1)) during 1.6% sevoflurane was not significant from that during 0.8% sevoflurane, indicating a celling effect.",15278670_3,0
1064,sevoflurane,60,71,"However, the threshold (61.6 +/- 8.7 mg. l(-1)) during 1.6% sevoflurane was not significant from that during 0.8% sevoflurane, indicating a celling effect.",15278670_3,0
1066,sevoflurane,72,83,There was no significant difference in the convulsive threshold between sevoflurane and enflurane.,15278670_4,0
4912,blood pressure,127,141,"The rise in blood pressure became less marked when higher concentrations of sevoflurane or enflurane were administered and the blood pressure at convulsions decreased significantly in 1.6% sevoflurane, and in 0.8% and 1.6% enflurane.",15278670_5,1
4911,blood pressure,12,26,"The rise in blood pressure became less marked when higher concentrations of sevoflurane or enflurane were administered and the blood pressure at convulsions decreased significantly in 1.6% sevoflurane, and in 0.8% and 1.6% enflurane.",15278670_5,1
1068,sevoflurane,189,200,"The rise in blood pressure became less marked when higher concentrations of sevoflurane or enflurane were administered and the blood pressure at convulsions decreased significantly in 1.6% sevoflurane, and in 0.8% and 1.6% enflurane.",15278670_5,0
1067,sevoflurane,76,87,"The rise in blood pressure became less marked when higher concentrations of sevoflurane or enflurane were administered and the blood pressure at convulsions decreased significantly in 1.6% sevoflurane, and in 0.8% and 1.6% enflurane.",15278670_5,0
4913,blood pressure,104,118,"However, there was no significant difference in the lidocaine concentrations measured when the systolic blood pressure became 70 mmHg.",15278670_6,1
1069,calcium-dependent potassium channels,31,67,"Apamin, a selective blocker of calcium-dependent potassium channels, was administered intracerebroventricularly in rats anesthetized with 0.8% sevoflurane to investigate the mechanism of the anticonvulsive effects.",15278670_7,0
1070,sevoflurane,143,154,"Apamin, a selective blocker of calcium-dependent potassium channels, was administered intracerebroventricularly in rats anesthetized with 0.8% sevoflurane to investigate the mechanism of the anticonvulsive effects.",15278670_7,0
4083,Apamin,0,6,"Apamin, a selective blocker of calcium-dependent potassium channels, was administered intracerebroventricularly in rats anesthetized with 0.8% sevoflurane to investigate the mechanism of the anticonvulsive effects.",15278670_7,0
4085,Apamin,0,6,Apamin (10 ng) had a tendency to decrease the convulsive threshold (21.6 +/- 2.2 to 19.9 +/- 2.5 mg. l(-1)) but this was not statistically significant.,15278670_8,0
1071,sevoflurane,21,32,It is suggested that sevoflurane reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory depression.,15278670_9,0
4089,circulatory depression,114,136,It is suggested that sevoflurane reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory depression.,15278670_9,1
4914,Cardiac toxicity,0,16,Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer.,15325671_0,1
4915,breast cancer,107,120,Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer.,15325671_0,1
4091,Cyclophosphamide,14,30,INTRODUCTION: Cyclophosphamide is an alkylating agent given frequently as a component of many conditioning regimens.,15325671_1,0
1072,alkylating agent,37,53,INTRODUCTION: Cyclophosphamide is an alkylating agent given frequently as a component of many conditioning regimens.,15325671_1,0
4110,CHF,74,77,Routine EKG monitoring during infusional cyclophosphamide did not predict CHF development.,15325671_10,0
4109,infusional cyclophosphamide,30,57,Routine EKG monitoring during infusional cyclophosphamide did not predict CHF development.,15325671_10,0
4093,high doses,3,13,"In high doses, its nonhematological dose-limiting toxicity is cardiomyopathy.",15325671_2,0
4094,nonhematological,19,35,"In high doses, its nonhematological dose-limiting toxicity is cardiomyopathy.",15325671_2,1
4095,dose-limiting,36,49,"In high doses, its nonhematological dose-limiting toxicity is cardiomyopathy.",15325671_2,1
4096,high-dose cyclophosphamide,52,78,"STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer.",15325671_3,0
1074,carboplatin,94,105,"STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer.",15325671_3,0
4916,breast cancer,176,189,"STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer.",15325671_3,1
1073,paclitaxel,26,36,"STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer.",15325671_3,0
4917,breast cancer,75,88,"Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.",15325671_4,1
4918,diabetes mellitus,419,436,"Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.",15325671_4,1
4919,left-sided,471,481,"Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.",15325671_4,1
4101,CHF,264,267,"Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.",15325671_4,0
4098,infusional cyclophosphamide,104,131,"Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.",15325671_4,0
1075,anthracyclines,451,465,"Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.",15325671_4,0
4100,peritransplant congestive heart failure,223,262,"Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation.",15325671_4,1
4103,infusional cyclophosphamide,85,112,RESULTS: Six of 61 women (10%) developed clinically reversible grade 3 CHF following infusional cyclophosphamide with a median percent decline in ejection fraction of 31%.,15325671_5,0
4104,ejection fraction,146,163,RESULTS: Six of 61 women (10%) developed clinically reversible grade 3 CHF following infusional cyclophosphamide with a median percent decline in ejection fraction of 31%.,15325671_5,1
4920,cardiac toxicity,48,64,Incidence of transient cyclophosphamide-related cardiac toxicity (10%) is comparable to previous recorded literature.,15325671_6,1
4106,CHF,48,51,"Older age was significantly correlated with the CHF development; with median ages for the entire group and for patients developing CHF of 45 and 59, respectively.",15325671_7,0
4107,CHF,131,134,"Older age was significantly correlated with the CHF development; with median ages for the entire group and for patients developing CHF of 45 and 59, respectively.",15325671_7,0
4105,Older age,0,9,"Older age was significantly correlated with the CHF development; with median ages for the entire group and for patients developing CHF of 45 and 59, respectively.",15325671_7,1
4111,Tremor side effects,0,19,"Tremor side effects of salbutamol, quantified by a laser pointer technique.",15338796_0,1
1076,salbutamol,23,33,"Tremor side effects of salbutamol, quantified by a laser pointer technique.",15338796_0,0
4113,tremor side effects,20,39,"OBJECTIVE: To study tremor side effects of salbutamol an easily applicable, quick and low-priced method is needed.",15338796_1,1
1077,salbutamol,43,53,"OBJECTIVE: To study tremor side effects of salbutamol an easily applicable, quick and low-priced method is needed.",15338796_1,0
4122,tremor severity,44,59,RESULTS: Salbutamol significantly increased tremor severity in patients in a dose-dependent way.,15338796_12,1
1079,Salbutamol,9,19,RESULTS: Salbutamol significantly increased tremor severity in patients in a dose-dependent way.,15338796_12,0
4124,age-dependency,25,39,Within healthy adults no age-dependency could be found (b = 0.262 mm/year; P = 0.72).,15338796_13,1
4125,tremor severity,53,68,There was no agreement between the questionnaire and tremor severity (r = 0.093; P = 0.53).,15338796_14,1
1080,(r,69,71,There was no agreement between the questionnaire and tremor severity (r = 0.093; P = 0.53).,15338796_14,0
4126,Postural tremor,0,15,Postural tremor showed no significant difference between the first and third session (P = 0.07).,15338796_15,1
4128,tremor severity,67,82,"Support of the arm decreased tremor severity, exhaustion increased tremor severity significantly.",15338796_16,1
4127,tremor severity,29,44,"Support of the arm decreased tremor severity, exhaustion increased tremor severity significantly.",15338796_16,1
4923,of children,92,103,"DISCUSSION: Quantifying tremor by using an inexpensive laser pointer is, with the exception of children (<12 years) a sensitive and reproducible method.",15338796_18,1
4921,obstructive lung disease,64,88,To determine sensitivity we assessed tremor in 44 patients with obstructive lung disease after administration of cumulative doses of salbutamol.,15338796_5,1
1078,salbutamol,133,143,To determine sensitivity we assessed tremor in 44 patients with obstructive lung disease after administration of cumulative doses of salbutamol.,15338796_5,0
4922,rest tremor,68,79,Postural tremor was measured with the arm horizontally outstretched rest tremor with the arm supported by an armrest and finally tremor was measured after holding a 2-kg weight until exhaustion.,15338796_9,1
4119,Postural tremor,0,15,Postural tremor was measured with the arm horizontally outstretched rest tremor with the arm supported by an armrest and finally tremor was measured after holding a 2-kg weight until exhaustion.,15338796_9,1
4924,side effects,30,42,Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers.,1535072_0,1
1082,serotonin reuptake,54,72,Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers.,1535072_0,0
1081,Yohimbine,0,9,Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers.,1535072_0,0
4925,male impotence,135,149,BACKGROUND: Preclinical and clinical studies suggest that yohimbine facilitates sexual behavior and may be helpful in the treatment of male impotence.,1535072_1,1
1083,yohimbine,58,67,BACKGROUND: Preclinical and clinical studies suggest that yohimbine facilitates sexual behavior and may be helpful in the treatment of male impotence.,1535072_1,0
4131,sexual behavior,80,95,BACKGROUND: Preclinical and clinical studies suggest that yohimbine facilitates sexual behavior and may be helpful in the treatment of male impotence.,1535072_1,1
1095,serotonin reuptake,130,148,CONCLUSION: The results of this study indicate that yohimbine may be an effective treatment for the sexual side effects caused by serotonin reuptake blockers.,1535072_10,0
4930,side effects,107,119,CONCLUSION: The results of this study indicate that yohimbine may be an effective treatment for the sexual side effects caused by serotonin reuptake blockers.,1535072_10,1
1094,yohimbine,52,61,CONCLUSION: The results of this study indicate that yohimbine may be an effective treatment for the sexual side effects caused by serotonin reuptake blockers.,1535072_10,0
1096,yohimbine,92,101,Future controlled studies are needed to further investigate the effectiveness and safety of yohimbine for this indication.,1535072_11,0
1084,yohimbine,35,44,A single case report suggests that yohimbine may be used to treat the sexual side effects of clomipramine.,1535072_2,0
4926,side effects,77,89,A single case report suggests that yohimbine may be used to treat the sexual side effects of clomipramine.,1535072_2,1
1085,yohimbine,21,30,This study evaluated yohimbine as a treatment for the sexual side effects caused by serotonin reuptake blockers.,1535072_3,0
1086,serotonin reuptake,84,102,This study evaluated yohimbine as a treatment for the sexual side effects caused by serotonin reuptake blockers.,1535072_3,0
4927,side effects,61,73,This study evaluated yohimbine as a treatment for the sexual side effects caused by serotonin reuptake blockers.,1535072_3,1
4133,affective disorders,94,113,"METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.",1535072_4,1
4132,obsessive compulsive disorder,33,62,"METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.",1535072_4,1
1087,serotonin reuptake,168,186,"METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.",1535072_4,0
1088,yohimbine,207,216,"METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.",1535072_4,0
4928,side effects,134,146,"METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p.r.n.",1535072_4,1
1089,yohimbine,17,26,Various doses of yohimbine were used to determine the ideal dose for each patient.,1535072_6,0
4136,sexual functioning,55,73,RESULTS: Five of the six patients experienced improved sexual functioning after taking yohimbine.,1535072_7,1
1090,yohimbine,87,96,RESULTS: Five of the six patients experienced improved sexual functioning after taking yohimbine.,1535072_7,0
1092,therapeutic effects,65,84,One patient who failed to comply with yohimbine treatment had no therapeutic effects.,1535072_8,0
1091,yohimbine,38,47,One patient who failed to comply with yohimbine treatment had no therapeutic effects.,1535072_8,0
4929,Side effects,0,12,"Side effects of yohimbine included excessive sweating, increased anxiety, and a wound-up feeling in some patients.",1535072_9,1
1093,yohimbine,16,25,"Side effects of yohimbine included excessive sweating, increased anxiety, and a wound-up feeling in some patients.",1535072_9,0
4139,bone marrow transplantation,34,61,Hemorrhagic cystitis complicating bone marrow transplantation.,1545575_0,1
4138,Hemorrhagic cystitis,0,20,Hemorrhagic cystitis complicating bone marrow transplantation.,1545575_0,1
4142,bone marrow transplantation,117,144,Hemorrhagic cystitis is a potentially serious complication of high-dose cyclophosphamide therapy administered before bone marrow transplantation.,1545575_1,1
4141,high-dose cyclophosphamide,62,88,Hemorrhagic cystitis is a potentially serious complication of high-dose cyclophosphamide therapy administered before bone marrow transplantation.,1545575_1,0
4140,Hemorrhagic cystitis,0,20,Hemorrhagic cystitis is a potentially serious complication of high-dose cyclophosphamide therapy administered before bone marrow transplantation.,1545575_1,1
4931,bone marrow,81,92,"As standard practice at our institution, patients who are scheduled to receive a bone marrow transplant are treated prophylactically with forced hydration and bladder irrigation.",1545575_2,1
1097,mesna,122,127,"In an attempt to obviate the inconvenience of bladder irrigation, we conducted a feasibility trial of uroprophylaxis with mesna, which neutralizes the hepatic metabolite of cyclophosphamide that causes hemorrhagic cystitis.",1545575_3,0
4146,cyclophosphamide,173,189,"In an attempt to obviate the inconvenience of bladder irrigation, we conducted a feasibility trial of uroprophylaxis with mesna, which neutralizes the hepatic metabolite of cyclophosphamide that causes hemorrhagic cystitis.",1545575_3,0
4144,uroprophylaxis,102,116,"In an attempt to obviate the inconvenience of bladder irrigation, we conducted a feasibility trial of uroprophylaxis with mesna, which neutralizes the hepatic metabolite of cyclophosphamide that causes hemorrhagic cystitis.",1545575_3,0
4147,hemorrhagic cystitis,202,222,"In an attempt to obviate the inconvenience of bladder irrigation, we conducted a feasibility trial of uroprophylaxis with mesna, which neutralizes the hepatic metabolite of cyclophosphamide that causes hemorrhagic cystitis.",1545575_3,1
4148,hemorrhagic cystitis,68,88,"Of 97 patients who received standard prophylaxis, 4 had symptomatic hemorrhagic cystitis.",1545575_4,1
4150,bone marrow transplantation,98,125,"In contrast, two of four consecutive patients who received mesna uroprophylaxis before allogeneic bone marrow transplantation had severe hemorrhagic cystitis for at least 2 weeks.",1545575_5,1
4151,hemorrhagic cystitis,137,157,"In contrast, two of four consecutive patients who received mesna uroprophylaxis before allogeneic bone marrow transplantation had severe hemorrhagic cystitis for at least 2 weeks.",1545575_5,1
1098,mesna,59,64,"In contrast, two of four consecutive patients who received mesna uroprophylaxis before allogeneic bone marrow transplantation had severe hemorrhagic cystitis for at least 2 weeks.",1545575_5,0
4153,hemorrhagic cystitis,121,141,"Because of this suboptimal result, we resumed the use of bladder irrigation and forced hydration to minimize the risk of hemorrhagic cystitis.",1545575_6,1
4932,adverse effects,11,26,Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation.,15458908_0,1
1099,raloxifene,43,53,Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation.,15458908_0,0
1100,raloxifene,76,86,Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation.,15458908_0,0
4154,adverse events,56,70,OBJECTIVE: To examine the effect of raloxifene on major adverse events that occur with postmenopausal estrogen therapy or tamoxifen.,15458908_1,1
1101,raloxifene,36,46,OBJECTIVE: To examine the effect of raloxifene on major adverse events that occur with postmenopausal estrogen therapy or tamoxifen.,15458908_1,0
1102,Raloxifene,34,44,"METHODS: The Multiple Outcomes of Raloxifene Evaluation, a multicenter, randomized, double-blind trial, enrolled 7,705 postmenopausal women with osteoporosis.",15458908_2,0
1103,raloxifene,32,42,Women were randomly assigned to raloxifene 60 mg/d or 120 mg/d or placebo.,15458908_3,0
4933,venous thromboembolism,18,40,"Outcomes included venous thromboembolism, cataracts, gallbladder disease, and endometrial hyperplasia or cancer.",15458908_4,1
4934,gallbladder disease,53,72,"Outcomes included venous thromboembolism, cataracts, gallbladder disease, and endometrial hyperplasia or cancer.",15458908_4,1
4935,endometrial hyperplasia,78,101,"Outcomes included venous thromboembolism, cataracts, gallbladder disease, and endometrial hyperplasia or cancer.",15458908_4,1
4936,venous thromboembolism,100,122,"RESULTS: During a mean follow-up of 3.3 years, raloxifene was associated with an increased risk for venous thromboembolism (relative risk [RR] 2.1; 95% confidence interval [CI] 1.2-3.8).",15458908_5,1
1104,raloxifene,47,57,"RESULTS: During a mean follow-up of 3.3 years, raloxifene was associated with an increased risk for venous thromboembolism (relative risk [RR] 2.1; 95% confidence interval [CI] 1.2-3.8).",15458908_5,0
1105,RR,139,141,"RESULTS: During a mean follow-up of 3.3 years, raloxifene was associated with an increased risk for venous thromboembolism (relative risk [RR] 2.1; 95% confidence interval [CI] 1.2-3.8).",15458908_5,0
1106,raloxifene,12,22,"Risk in the raloxifene group was higher than in the placebo group for the first 2 years, but decreased to about the same rate as in the placebo group thereafter.",15458908_7,0
1110,RR,144,146,"Raloxifene did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).",15458908_8,0
4939,endometrial cancer,172,190,"Raloxifene did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).",15458908_8,1
4938,endometrial hyperplasia,119,142,"Raloxifene did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).",15458908_8,1
4937,gallbladder disease,73,92,"Raloxifene did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).",15458908_8,1
1109,RR,94,96,"Raloxifene did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).",15458908_8,0
1108,RR,48,50,"Raloxifene did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).",15458908_8,0
1107,Raloxifene,0,10,"Raloxifene did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).",15458908_8,0
1111,RR,192,194,"Raloxifene did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), gallbladder disease (RR 1.0; 95% CI 0.7-1.3), endometrial hyperplasia (RR 1.3; 95% CI 0.4-5.1), or endometrial cancer (RR 0.9; 95% CI 0.3-2.7).",15458908_8,0
4942,endometrial hyperplasia,157,180,"CONCLUSION: Raloxifene was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer.",15458908_9,1
4940,venous thromboembolism,65,87,"CONCLUSION: Raloxifene was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer.",15458908_9,1
4943,endometrial cancer,185,203,"CONCLUSION: Raloxifene was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer.",15458908_9,1
4941,gallbladder disease,136,155,"CONCLUSION: Raloxifene was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer.",15458908_9,1
1112,Raloxifene,12,22,"CONCLUSION: Raloxifene was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer.",15458908_9,0
4163,carbidopa-levodopa,206,224,"While there is no single correct starting dose for levodopa therapy, many individuals can be started on either the 25/100 or controlled-release formula, following the general rule not to attempt to titrate carbidopa-levodopa to the point of ""normality,"" which can lead to toxicity.",1549199_1,0
4164,adjunctive medications,58,80,The physician should also determine the proper use of any adjunctive medications; such combined therapy has become the standard approach to treatment.,1549199_2,0
4166,therapeutic approaches,89,111,"Following the initial period of therapy, emerging difficulties require a reassessment of therapeutic approaches, such as dosage adjustment or introduction of a dopamine agonist.",1549199_3,0
1113,dopamine agonist,160,176,"Following the initial period of therapy, emerging difficulties require a reassessment of therapeutic approaches, such as dosage adjustment or introduction of a dopamine agonist.",1549199_3,0
4944,adverse effects,15,30,"Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.",1549199_4,1
4945,gastrointestinal disorders,40,66,"Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.",1549199_4,1
4946,orthostatic hypotension,68,91,"Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.",1549199_4,1
4947,parasomnias,143,154,"Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.",1549199_4,1
4168,sleep disturbances,121,139,"Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.",1549199_4,1
4169,drug interactions,159,176,"Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment.",1549199_4,1
4948,Parkinson's disease,39,58,"Nonpharmacologic concerns can help the Parkinson's disease patient achieve and maintain optimal functioning, including daily exercise, physical therapy, and involvement with support groups.",1549199_5,1
4174,beta-thalassemic,37,53,Long term audiological evaluation of beta-thalassemic patients.,15515654_0,1
4949,Long term,0,9,Long term audiological evaluation of beta-thalassemic patients.,15515654_0,1
4950,hearing loss,103,115,OBJECTIVE: The objective of this study was to identify the incidence and to monitor the progression of hearing loss in children and young adults with beta-thalassemia major.,15515654_1,1
4951,beta-thalassemia,150,166,OBJECTIVE: The objective of this study was to identify the incidence and to monitor the progression of hearing loss in children and young adults with beta-thalassemia major.,15515654_1,1
4954,hearing impairment,89,107,CONCLUSION: The findings are indicative of DFO's contributing role in the development of hearing impairment.,15515654_11,1
4184,DFO,43,46,CONCLUSION: The findings are indicative of DFO's contributing role in the development of hearing impairment.,15515654_11,0
4955,hearing impairment,185,203,Regular audiologic evaluation is imperative in all thalassemic patients so that early changes may be recognized and treatment may be judiciously adjusted in order to prevent or reverse hearing impairment.,15515654_12,1
4186,thalassemic,51,62,Regular audiologic evaluation is imperative in all thalassemic patients so that early changes may be recognized and treatment may be judiciously adjusted in order to prevent or reverse hearing impairment.,15515654_12,1
1114,desferrioxamine,24,39,"Subjects were receiving desferrioxamine (DFO) chelation treatment with a mean daily dose of 50-60 mg/kg, 5-6 days a week during the first six years of the study, which was then reduced to 40-50 mg/kg for the following eight years.",15515654_4,0
4176,DFO,41,44,"Subjects were receiving desferrioxamine (DFO) chelation treatment with a mean daily dose of 50-60 mg/kg, 5-6 days a week during the first six years of the study, which was then reduced to 40-50 mg/kg for the following eight years.",15515654_4,0
4952,unilateral or bilateral,121,144,"RESULTS: Overall, 21 out of 104 patients (20.2%) presented with high frequency sensorineural hearing loss (SNHL), either unilateral or bilateral.",15515654_6,1
4177,high frequency sensorineural hearing loss,64,105,"RESULTS: Overall, 21 out of 104 patients (20.2%) presented with high frequency sensorineural hearing loss (SNHL), either unilateral or bilateral.",15515654_6,1
4180,DFO,31,34,"No ototoxic factor, other than DFO, was present in any of the patients.",15515654_7,0
4181,normal hearing,89,103,"Patients with SNHL presented with relatively lower serum ferritin levels than those with normal hearing, however, no statistically significant difference was observed.",15515654_8,1
4953,serum ferritin,51,65,"Patients with SNHL presented with relatively lower serum ferritin levels than those with normal hearing, however, no statistically significant difference was observed.",15515654_8,1
4183,DFO,37,40,Subjects with SNHL were submitted to DFO reduction or temporary withdrawal.,15515654_9,0
4182,SNHL,14,18,Subjects with SNHL were submitted to DFO reduction or temporary withdrawal.,15515654_9,0
4956,cardiotoxicity,31,45,"Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis.",15517007_0,1
4958,systemic sclerosis,171,189,"Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis.",15517007_0,1
4957,autoimmune diseases,124,143,"Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis.",15517007_0,1
4959,multiple sclerosis,194,212,"Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis.",15517007_0,1
4187,stem cell transplantation,78,103,"Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis.",15517007_0,1
4188,stem cell transplantation,26,51,Autologous haematopoietic stem cell transplantation is now a feasible and effective treatment for selected patients with severe autoimmune diseases.,15517007_1,1
4960,autoimmune diseases,128,147,Autologous haematopoietic stem cell transplantation is now a feasible and effective treatment for selected patients with severe autoimmune diseases.,15517007_1,1
4189,transplant-related morbidity,35,63,"However, as predicted, significant transplant-related morbidity and mortality have been observed.",15517007_4,1
4961,cardiac toxicity,32,48,The number of deaths related to cardiac toxicity is low.,15517007_6,1
4190,cyclophosphamide,34,50,"However, caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.",15517007_7,0
4191,heart damage,138,150,"However, caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.",15517007_7,1
4962,systemic sclerosis,165,183,"However, caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.",15517007_7,1
1115,anthracyclines,54,68,"However, caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.",15517007_7,0
1116,mitoxantrone,77,89,"However, caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients.",15517007_7,0
4194,Marrow Transplantation autoimmune disease,121,162,"The object of the meeting was to analyse existing data, both published or available, in the European Group for Blood and Marrow Transplantation autoimmune disease database, and to propose a safe approach to such patients.",15517007_9,1
4963,cardiovascular disease,37,59,"Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes?BACKGROUND: Vitamin C acts as a potent antioxidant; however, it can also be a prooxidant and glycate protein under certain circumstances in vitro.",15531665_0,1
1117,prooxidant,166,176,"Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes?BACKGROUND: Vitamin C acts as a potent antioxidant; however, it can also be a prooxidant and glycate protein under certain circumstances in vitro.",15531665_0,0
4199,glycate protein,181,196,"Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes?BACKGROUND: Vitamin C acts as a potent antioxidant; however, it can also be a prooxidant and glycate protein under certain circumstances in vitro.",15531665_0,0
4198,Vitamin C,100,109,"Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes?BACKGROUND: Vitamin C acts as a potent antioxidant; however, it can also be a prooxidant and glycate protein under certain circumstances in vitro.",15531665_0,0
4196,vitamin C,18,27,"Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes?BACKGROUND: Vitamin C acts as a potent antioxidant; however, it can also be a prooxidant and glycate protein under certain circumstances in vitro.",15531665_0,0
4201,vitamin C,63,72,These observations led us to hypothesize that a high intake of vitamin C in diabetic persons might promote atherosclerosis.,15531665_1,0
4964,cardiovascular disease,97,119,OBJECTIVE: The objective was to examine the relation between vitamin C intake and mortality from cardiovascular disease.,15531665_2,1
4202,vitamin C,61,70,OBJECTIVE: The objective was to examine the relation between vitamin C intake and mortality from cardiovascular disease.,15531665_2,0
4966,coronary artery disease,116,139,"DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.",15531665_3,1
4965,cardiovascular disease,82,104,"DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.",15531665_3,1
4203,vitamin C,40,49,"DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline.",15531665_3,0
4204,free of coronary artery disease,90,121,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,1
4206,vitamin E,306,315,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,0
4968,cardiovascular disease,373,395,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,1
4967,cardiovascular disease,190,212,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,1
4208,vitamin C,490,499,"Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements.",15531665_4,0
4969,coronary artery disease,27,50,"Adjusted relative risks of coronary artery disease were 1.0, 0.81, 0.99, 1.26, and 1.91 (P for trend = 0.01) and of stroke were 1.0, 0.52, 1.23, 2.22, and 2.57 (P for trend < 0.01).",15531665_5,1
4209,vitamin C,30,39,"When dietary and supplemental vitamin C were analyzed separately, only supplemental vitamin C showed a positive association with mortality endpoints.",15531665_6,0
4210,vitamin C,84,93,"When dietary and supplemental vitamin C were analyzed separately, only supplemental vitamin C showed a positive association with mortality endpoints.",15531665_6,0
4970,cardiovascular disease,49,71,Vitamin C intake was unrelated to mortality from cardiovascular disease in the nondiabetic subjects at baseline.,15531665_7,1
4211,Vitamin C,0,9,Vitamin C intake was unrelated to mortality from cardiovascular disease in the nondiabetic subjects at baseline.,15531665_7,0
4971,cardiovascular disease,93,115,CONCLUSION: A high vitamin C intake from supplements is associated with an increased risk of cardiovascular disease mortality in postmenopausal women with diabetes.,15531665_8,1
4213,vitamin C,19,28,CONCLUSION: A high vitamin C intake from supplements is associated with an increased risk of cardiovascular disease mortality in postmenopausal women with diabetes.,15531665_8,0
4216,axonal loss,41,52,Optical coherence tomography can measure axonal loss in patients with ethambutol-induced optic neuropathy.,15565293_0,1
4972,optic neuropathy,89,105,Optical coherence tomography can measure axonal loss in patients with ethambutol-induced optic neuropathy.,15565293_0,1
4217,axonal degeneration,54,73,"PURPOSE: To map and identify the pattern, in vivo, of axonal degeneration in ethambutol-induced optic neuropathy using optical coherence tomography (OCT).",15565293_1,1
4973,optic neuropathy,96,112,"PURPOSE: To map and identify the pattern, in vivo, of axonal degeneration in ethambutol-induced optic neuropathy using optical coherence tomography (OCT).",15565293_1,1
4982,loss of,26,33,"There was a combined mean loss of 46% of fibers from the superior, inferior, and nasal quadrants in the (six) eyes of all three subjects (mean average thickness of 55+/-29 microm).",15565293_10,1
4983,loss of,117,124,"In both sets (four) of eyes of the subjects with persistent visual deficits (patients B and C), there was an average loss of 79% of nerve fiber thickness in the temporal quadrant.",15565293_11,1
4240,visual deficits,60,75,"In both sets (four) of eyes of the subjects with persistent visual deficits (patients B and C), there was an average loss of 79% of nerve fiber thickness in the temporal quadrant.",15565293_11,1
4241,nerve fiber thickness,132,153,"In both sets (four) of eyes of the subjects with persistent visual deficits (patients B and C), there was an average loss of 79% of nerve fiber thickness in the temporal quadrant.",15565293_11,1
4242,temporal quadrant,161,178,"In both sets (four) of eyes of the subjects with persistent visual deficits (patients B and C), there was an average loss of 79% of nerve fiber thickness in the temporal quadrant.",15565293_11,1
4244,temporal fibers,122,137,CONCLUSIONS: The OCT results in these patients with EMB-induced optic neuropathy show considerable loss especially of the temporal fibers.,15565293_12,1
4243,EMB-induced optic neuropathy,52,80,CONCLUSIONS: The OCT results in these patients with EMB-induced optic neuropathy show considerable loss especially of the temporal fibers.,15565293_12,1
4248,papillo-macular bundle,143,165,This is consistent with prior histopathological studies that show predominant loss of parvo-cellular axons (or small-caliber axons) within the papillo-macular bundle in toxic or hereditary optic neuropathies.,15565293_13,1
4984,loss of,78,85,This is consistent with prior histopathological studies that show predominant loss of parvo-cellular axons (or small-caliber axons) within the papillo-macular bundle in toxic or hereditary optic neuropathies.,15565293_13,1
4246,parvo-cellular,86,100,This is consistent with prior histopathological studies that show predominant loss of parvo-cellular axons (or small-caliber axons) within the papillo-macular bundle in toxic or hereditary optic neuropathies.,15565293_13,1
4249,hereditary optic neuropathies,178,207,This is consistent with prior histopathological studies that show predominant loss of parvo-cellular axons (or small-caliber axons) within the papillo-macular bundle in toxic or hereditary optic neuropathies.,15565293_13,1
4985,optic neuropathies,59,77,OCT can be a valuable tool in the quantitative analysis of optic neuropathies.,15565293_14,1
4250,EMB-induced optic neuropathy,40,68,"Additionally, in terms of management of EMB-induced optic neuropathy, it is important to properly manage ethambutol dosing in patients with renal impairment and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached.",15565293_15,1
4251,renal impairment,140,156,"Additionally, in terms of management of EMB-induced optic neuropathy, it is important to properly manage ethambutol dosing in patients with renal impairment and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached.",15565293_15,1
1122,ethambutol,105,115,"Additionally, in terms of management of EMB-induced optic neuropathy, it is important to properly manage ethambutol dosing in patients with renal impairment and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached.",15565293_15,0
1119,antimycobacterial agent,17,40,Ethambutol is an antimycobacterial agent often used to treat tuberculosis.,15565293_2,0
1118,Ethambutol,0,10,Ethambutol is an antimycobacterial agent often used to treat tuberculosis.,15565293_2,0
4219,visual acuity,73,86,"A serious complication of ethambutol is an optic neuropathy that impairs visual acuity, contrast sensitivity, and color vision.",15565293_3,1
1120,ethambutol,26,36,"A serious complication of ethambutol is an optic neuropathy that impairs visual acuity, contrast sensitivity, and color vision.",15565293_3,0
4220,contrast sensitivity,88,108,"A serious complication of ethambutol is an optic neuropathy that impairs visual acuity, contrast sensitivity, and color vision.",15565293_3,1
4975,color vision,114,126,"A serious complication of ethambutol is an optic neuropathy that impairs visual acuity, contrast sensitivity, and color vision.",15565293_3,1
4974,optic neuropathy,43,59,"A serious complication of ethambutol is an optic neuropathy that impairs visual acuity, contrast sensitivity, and color vision.",15565293_3,1
4976,toxic optic neuropathy,28,50,"However, early on, when the toxic optic neuropathy is mild and partly reversible, the funduscopic findings are often subtle and easy to miss.",15565293_4,1
4221,funduscopic,86,97,"However, early on, when the toxic optic neuropathy is mild and partly reversible, the funduscopic findings are often subtle and easy to miss.",15565293_4,1
4225,contrast sensitivity,237,257,"METHODS: Three subjects with a history of ethambutol (EMB)-induced optic neuropathy of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.",15565293_5,1
4222,visual deficits,124,139,"METHODS: Three subjects with a history of ethambutol (EMB)-induced optic neuropathy of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.",15565293_5,1
1121,ethambutol,42,52,"METHODS: Three subjects with a history of ethambutol (EMB)-induced optic neuropathy of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.",15565293_5,0
4977,optic neuropathy,67,83,"METHODS: Three subjects with a history of ethambutol (EMB)-induced optic neuropathy of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.",15565293_5,1
4978,color vision,223,235,"METHODS: Three subjects with a history of ethambutol (EMB)-induced optic neuropathy of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.",15565293_5,1
4224,visual acuity,208,221,"METHODS: Three subjects with a history of ethambutol (EMB)-induced optic neuropathy of short-, intermediate-, and long-term visual deficits were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination.",15565293_5,1
4228,retinal nerve fiber layer,109,134,"In addition, OCT (OCT 3000, Humphrey-Zeiss, Dublin, CA) was performed on both eyes of each subject using the retinal nerve fiber layer (RNFL) analysis protocol.",15565293_6,1
4229,RNFL,136,140,"In addition, OCT (OCT 3000, Humphrey-Zeiss, Dublin, CA) was performed on both eyes of each subject using the retinal nerve fiber layer (RNFL) analysis protocol.",15565293_6,0
4979,optic nerve,49,60,OCT interpolates data from 100 points around the optic nerve to effectively map out the RNFL.,15565293_7,1
4230,RNFL,88,92,OCT interpolates data from 100 points around the optic nerve to effectively map out the RNFL.,15565293_7,0
4231,RNFL,61,65,"RESULTS: The results were compared to the calculated average RNFL of normal eyes accumulated from four prior studies using OCT, n=661.",15565293_8,0
4232,normal eyes,69,80,"RESULTS: The results were compared to the calculated average RNFL of normal eyes accumulated from four prior studies using OCT, n=661.",15565293_8,0
4981,optic nerve,347,358,"In all subjects with history of EMB-induced optic neuropathy, there was a mean loss of 72% nerve fiber layer thickness in the temporal quadrant (patient A, with eventual recovery of visual acuity and fields, 58% loss; patient B, with intermediate visual deficits, 68% loss; patient C, with chronic visual deficits, 90% loss), with an average mean optic nerve thickness of 26+/-16 microm.",15565293_9,1
4234,nerve fiber layer,91,108,"In all subjects with history of EMB-induced optic neuropathy, there was a mean loss of 72% nerve fiber layer thickness in the temporal quadrant (patient A, with eventual recovery of visual acuity and fields, 58% loss; patient B, with intermediate visual deficits, 68% loss; patient C, with chronic visual deficits, 90% loss), with an average mean optic nerve thickness of 26+/-16 microm.",15565293_9,1
4235,temporal quadrant,126,143,"In all subjects with history of EMB-induced optic neuropathy, there was a mean loss of 72% nerve fiber layer thickness in the temporal quadrant (patient A, with eventual recovery of visual acuity and fields, 58% loss; patient B, with intermediate visual deficits, 68% loss; patient C, with chronic visual deficits, 90% loss), with an average mean optic nerve thickness of 26+/-16 microm.",15565293_9,1
4980,loss of,79,86,"In all subjects with history of EMB-induced optic neuropathy, there was a mean loss of 72% nerve fiber layer thickness in the temporal quadrant (patient A, with eventual recovery of visual acuity and fields, 58% loss; patient B, with intermediate visual deficits, 68% loss; patient C, with chronic visual deficits, 90% loss), with an average mean optic nerve thickness of 26+/-16 microm.",15565293_9,1
4236,visual acuity,182,195,"In all subjects with history of EMB-induced optic neuropathy, there was a mean loss of 72% nerve fiber layer thickness in the temporal quadrant (patient A, with eventual recovery of visual acuity and fields, 58% loss; patient B, with intermediate visual deficits, 68% loss; patient C, with chronic visual deficits, 90% loss), with an average mean optic nerve thickness of 26+/-16 microm.",15565293_9,1
4237,visual deficits,247,262,"In all subjects with history of EMB-induced optic neuropathy, there was a mean loss of 72% nerve fiber layer thickness in the temporal quadrant (patient A, with eventual recovery of visual acuity and fields, 58% loss; patient B, with intermediate visual deficits, 68% loss; patient C, with chronic visual deficits, 90% loss), with an average mean optic nerve thickness of 26+/-16 microm.",15565293_9,1
4238,chronic visual deficits,290,313,"In all subjects with history of EMB-induced optic neuropathy, there was a mean loss of 72% nerve fiber layer thickness in the temporal quadrant (patient A, with eventual recovery of visual acuity and fields, 58% loss; patient B, with intermediate visual deficits, 68% loss; patient C, with chronic visual deficits, 90% loss), with an average mean optic nerve thickness of 26+/-16 microm.",15565293_9,1
4233,EMB-induced optic neuropathy,32,60,"In all subjects with history of EMB-induced optic neuropathy, there was a mean loss of 72% nerve fiber layer thickness in the temporal quadrant (patient A, with eventual recovery of visual acuity and fields, 58% loss; patient B, with intermediate visual deficits, 68% loss; patient C, with chronic visual deficits, 90% loss), with an average mean optic nerve thickness of 26+/-16 microm.",15565293_9,1
4253,renal damage,106,118,Individual differences in renal ACE activity in healthy rats predict susceptibility to adriamycin-induced renal damage.,15572383_0,1
4256,renal prognosis,130,145,"BACKGROUND: In man, differences in angiotensin-converting enzyme (ACE) levels, related to ACE (I/D) genotype, are associated with renal prognosis.",15572383_1,1
4254,I/D,95,98,"BACKGROUND: In man, differences in angiotensin-converting enzyme (ACE) levels, related to ACE (I/D) genotype, are associated with renal prognosis.",15572383_1,0
1123,angiotensin-converting enzyme,35,64,"BACKGROUND: In man, differences in angiotensin-converting enzyme (ACE) levels, related to ACE (I/D) genotype, are associated with renal prognosis.",15572383_1,0
1124,(r,212,214,"Baseline renal ACE positively correlated with the relative rise in proteinuria after adriamycin (r = 0.62, P<0.01), renal interstitial alpha-smooth muscle actin (r = 0.49, P<0.05), interstitial macrophage influx (r = 0.56, P<0.05), interstitial collagen III (r = 0.53, P<0.05), glomerular alpha-smooth muscle actin (r = 0.74, P<0.01) and glomerular desmin (r = 0.48, P<0.05).",15572383_10,0
1125,(r,258,260,"Baseline renal ACE positively correlated with the relative rise in proteinuria after adriamycin (r = 0.62, P<0.01), renal interstitial alpha-smooth muscle actin (r = 0.49, P<0.05), interstitial macrophage influx (r = 0.56, P<0.05), interstitial collagen III (r = 0.53, P<0.05), glomerular alpha-smooth muscle actin (r = 0.74, P<0.01) and glomerular desmin (r = 0.48, P<0.05).",15572383_10,0
4270,desmin (r,349,358,"Baseline renal ACE positively correlated with the relative rise in proteinuria after adriamycin (r = 0.62, P<0.01), renal interstitial alpha-smooth muscle actin (r = 0.49, P<0.05), interstitial macrophage influx (r = 0.56, P<0.05), interstitial collagen III (r = 0.53, P<0.05), glomerular alpha-smooth muscle actin (r = 0.74, P<0.01) and glomerular desmin (r = 0.48, P<0.05).",15572383_10,0
4267,alpha-smooth muscle actin (r,135,163,"Baseline renal ACE positively correlated with the relative rise in proteinuria after adriamycin (r = 0.62, P<0.01), renal interstitial alpha-smooth muscle actin (r = 0.49, P<0.05), interstitial macrophage influx (r = 0.56, P<0.05), interstitial collagen III (r = 0.53, P<0.05), glomerular alpha-smooth muscle actin (r = 0.74, P<0.01) and glomerular desmin (r = 0.48, P<0.05).",15572383_10,0
4269,alpha-smooth muscle actin (r,289,317,"Baseline renal ACE positively correlated with the relative rise in proteinuria after adriamycin (r = 0.62, P<0.01), renal interstitial alpha-smooth muscle actin (r = 0.49, P<0.05), interstitial macrophage influx (r = 0.56, P<0.05), interstitial collagen III (r = 0.53, P<0.05), glomerular alpha-smooth muscle actin (r = 0.74, P<0.01) and glomerular desmin (r = 0.48, P<0.05).",15572383_10,0
4266,adriamycin (r,85,98,"Baseline renal ACE positively correlated with the relative rise in proteinuria after adriamycin (r = 0.62, P<0.01), renal interstitial alpha-smooth muscle actin (r = 0.49, P<0.05), interstitial macrophage influx (r = 0.56, P<0.05), interstitial collagen III (r = 0.53, P<0.05), glomerular alpha-smooth muscle actin (r = 0.74, P<0.01) and glomerular desmin (r = 0.48, P<0.05).",15572383_10,0
4274,renal damage,100,112,CONCLUSION: Individual differences in renal ACE activity predict the severity of adriamycin-induced renal damage in this outbred rat strain.,15572383_13,1
4275,favourable course,89,106,This supports the assumption that differences in renal ACE activity predispose to a less favourable course of renal damage.,15572383_14,1
4276,renal damage,110,122,This supports the assumption that differences in renal ACE activity predispose to a less favourable course of renal damage.,15572383_14,1
4258,renal damage,86,98,"Therefore, we studied the predictive effect of renal ACE activity for the severity of renal damage induced by a single injection of adriamycin in rats.",15572383_3,1
4259,adriamycin,132,142,"Therefore, we studied the predictive effect of renal ACE activity for the severity of renal damage induced by a single injection of adriamycin in rats.",15572383_3,0
4260,Hip-His-Leu,29,40,METHODS: Renal ACE activity (Hip-His-Leu cleavage by cortical homogenates) was determined by renal biopsy in 27 adult male Wistar rats.,15572383_4,0
4263,adriamycin,53,63,"After 1 week of recovery, proteinuria was induced by adriamycin [1.5 mg/kg intravenously (i.v.) n = 18; controls, saline i.v.",15572383_5,0
4265,renal interstitial damage,74,99,"RESULTS: As anticipated, adriamycin elicited nephrotic range proteinuria, renal interstitial damage and mild focal glomerulosclerosis.",15572383_9,1
4987,focal glomerulosclerosis,109,133,"RESULTS: As anticipated, adriamycin elicited nephrotic range proteinuria, renal interstitial damage and mild focal glomerulosclerosis.",15572383_9,1
4986,nephrotic,45,54,"RESULTS: As anticipated, adriamycin elicited nephrotic range proteinuria, renal interstitial damage and mild focal glomerulosclerosis.",15572383_9,1
4264,adriamycin,25,35,"RESULTS: As anticipated, adriamycin elicited nephrotic range proteinuria, renal interstitial damage and mild focal glomerulosclerosis.",15572383_9,0
4277,glomerular hypertension,49,72,Hypoxia in renal disease with proteinuria and/or glomerular hypertension.,15579441_0,1
4988,renal disease,11,24,Hypoxia in renal disease with proteinuria and/or glomerular hypertension.,15579441_0,1
1126,vascular endothelial growth factor,114,148,"In this study, we developed a new hypoxia-responsive reporter vector using a hypoxia-responsive element of the 5' vascular endothelial growth factor untranslated region and generated a novel hypoxia-sensing transgenic rat.",15579441_2,0
4281,diseased kidney,88,103,We then applied this animal model to the detection of tubulointerstitial hypoxia in the diseased kidney.,15579441_3,1
4280,tubulointerstitial hypoxia,54,80,We then applied this animal model to the detection of tubulointerstitial hypoxia in the diseased kidney.,15579441_3,1
4989,nephrotic syndrome,108,126,"With this model, we were able to identify diffuse cortical hypoxia in the puromycin aminonucleoside-induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model.",15579441_4,1
1127,puromycin,74,83,"With this model, we were able to identify diffuse cortical hypoxia in the puromycin aminonucleoside-induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model.",15579441_4,0
4282,segmental hypoxia,141,158,"With this model, we were able to identify diffuse cortical hypoxia in the puromycin aminonucleoside-induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model.",15579441_4,1
1128,puromycin aminonucleoside,128,153,"Expression of the hypoxia-responsive transgene increased throughout the observation period, reaching 2.2-fold at 2 weeks in the puromycin aminonucleoside model and 2.6-fold at 4 weeks in the remnant kidney model, whereas that of vascular endothelial growth factor showed a mild decrease, reflecting distinct behaviors of the two genes.",15579441_5,0
1129,vascular endothelial growth factor,229,263,"Expression of the hypoxia-responsive transgene increased throughout the observation period, reaching 2.2-fold at 2 weeks in the puromycin aminonucleoside model and 2.6-fold at 4 weeks in the remnant kidney model, whereas that of vascular endothelial growth factor showed a mild decrease, reflecting distinct behaviors of the two genes.",15579441_5,0
4285,tubulointerstitial injury,69,94,The degree of hypoxia showed a positive correlation with microscopic tubulointerstitial injury in both models.,15579441_6,1
4287,dUTP,116,120,"Finally, we identified the localization of proliferating cell nuclear antigen-positive, ED-1-positive, and terminal dUTP nick-end labeled-positive cells in the hypoxic cortical area in the remnant kidney model.",15579441_7,0
4990,hypoxic,160,167,"Finally, we identified the localization of proliferating cell nuclear antigen-positive, ED-1-positive, and terminal dUTP nick-end labeled-positive cells in the hypoxic cortical area in the remnant kidney model.",15579441_7,1
1130,proliferating cell nuclear,43,69,"Finally, we identified the localization of proliferating cell nuclear antigen-positive, ED-1-positive, and terminal dUTP nick-end labeled-positive cells in the hypoxic cortical area in the remnant kidney model.",15579441_7,0
4290,glomerular diseases,103,122,We propose here a possible pathological tie between chronic tubulointerstitial hypoxia and progressive glomerular diseases.,15579441_8,1
4289,tubulointerstitial hypoxia,60,86,We propose here a possible pathological tie between chronic tubulointerstitial hypoxia and progressive glomerular diseases.,15579441_8,1
4292,adverse events,194,208,Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.BACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.,15580403_0,1
4991,chronic hepatitis,125,142,Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.BACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.,15580403_0,1
4992,Hemolytic anemia,157,173,Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C.BACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin.,15580403_0,1
4993,hemolytic anemia,29,45,"Because of ribavirin-related hemolytic anemia, dose reduction is a common event in this therapy.",15580403_1,1
4994,side effects,107,119,CONCLUSIONS: Reduction of ribavirin at hemoglobin level > or =10 g/dl is suitable in terms of efficacy and side effects.,15580403_10,1
4299,anemia-related,176,190,"METHODS: Thirty-seven of 160 patients who had HCV-genotype 1b, had high virus load, and received 24-week combination therapy developed anemia with hemoglobin level <10 g/dl or anemia-related signs during therapy.",15580403_3,1
4298,hemoglobin level,147,163,"METHODS: Thirty-seven of 160 patients who had HCV-genotype 1b, had high virus load, and received 24-week combination therapy developed anemia with hemoglobin level <10 g/dl or anemia-related signs during therapy.",15580403_3,1
4301,group A,108,115,"After reduction of ribavirin, 27 of 37 patients could continue combination therapy for a total of 24 weeks (group A).",15580403_5,0
4303,anemia-related severe side effects,152,186,"However, 10 of 37 patients with reduction of ribavirin could not continue combination therapy because their <8.5 g/dl hemoglobin values decreased to or anemia-related severe side effects occurred (group B).",15580403_6,1
4309,group B,184,191,"We assessed the final efficacy and safety after reduction of ribavirin in groups A and B. RESULTS: A sustained virological response (SVR) was 29.6% (8/27) in group A and 10% (1/10) in group B, respectively.",15580403_7,0
4308,group A,158,165,"We assessed the final efficacy and safety after reduction of ribavirin in groups A and B. RESULTS: A sustained virological response (SVR) was 29.6% (8/27) in group A and 10% (1/10) in group B, respectively.",15580403_7,0
4310,group A,48,55,"A 34.4% (12/27) of SVR + biological response in group A was higher than 10% (1/10) in group B ( P = 0.051), with slight significance.",15580403_8,0
4311,group B,86,93,"A 34.4% (12/27) of SVR + biological response in group A was higher than 10% (1/10) in group B ( P = 0.051), with slight significance.",15580403_8,0
1131,biological response,25,44,"A 34.4% (12/27) of SVR + biological response in group A was higher than 10% (1/10) in group B ( P = 0.051), with slight significance.",15580403_8,0
4312,acute interstitial nephritis,10,38,Recurrent acute interstitial nephritis induced by azithromycin.,15602202_0,1
4314,acute interstitial nephritis,69,97,"A 14-year-old girl is reported with recurrent, azithromycin-induced, acute interstitial nephritis.",15602202_1,1
4315,renal function,121,135,"The second episode was more severe than the first; and although both were treated with intensive corticosteroid therapy, renal function remained impaired.",15602202_2,1
4995,renal injury,140,152,"Although most cases of antibiotic induced acute interstitial nephritis are benign and self-limited, some patients are at risk for permanent renal injury.",15602202_3,1
4316,acute interstitial nephritis,42,70,"Although most cases of antibiotic induced acute interstitial nephritis are benign and self-limited, some patients are at risk for permanent renal injury.",15602202_3,1
4997,heart failure,77,90,Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.,15632880_0,1
4996,renal insufficiency,23,42,Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.,15632880_0,1
4998,heart failure,91,104,BACKGROUND: A previous randomized controlled trial evaluating the use of spironolactone in heart failure patients reported a low risk of hyperkalemia (2%) and renal insufficiency (0%).,15632880_1,1
1132,(2,150,152,BACKGROUND: A previous randomized controlled trial evaluating the use of spironolactone in heart failure patients reported a low risk of hyperkalemia (2%) and renal insufficiency (0%).,15632880_1,0
4999,renal insufficiency,159,178,BACKGROUND: A previous randomized controlled trial evaluating the use of spironolactone in heart failure patients reported a low risk of hyperkalemia (2%) and renal insufficiency (0%).,15632880_1,1
5008,renal insufficiency,53,72,CONCLUSIONS: Spironolactone-induced hyperkalemia and renal insufficiency are more common in our clinical experience than reported previously.,15632880_10,1
1138,beta-blockers,79,92,This difference is explained by patient comorbidities and more frequent use of beta-blockers.,15632880_11,0
4330,comorbidities,40,53,This difference is explained by patient comorbidities and more frequent use of beta-blockers.,15632880_11,1
5000,heart failure,23,36,"Because treatments for heart failure have changed since the benefits of spironolactone were reported, the prevalence of these complications may differ in current clinical practice.",15632880_2,1
5002,heart failure,117,130,We therefore sought to determine the prevalence and clinical associations of hyperkalemia and renal insufficiency in heart failure patients treated with spironolactone.,15632880_3,1
5001,renal insufficiency,94,113,We therefore sought to determine the prevalence and clinical associations of hyperkalemia and renal insufficiency in heart failure patients treated with spironolactone.,15632880_3,1
5003,heart failure,46,59,METHODS: We performed a case control study of heart failure patients treated with spironolactone in our clinical practice.,15632880_4,1
1133,K(+),48,52,"Cases were patients who developed hyperkalemia (K(+) >5.0 mEq/L) or renal insufficiency (Cr >or=2.5 mg/dL), and they were compared to 2 randomly selected controls per case.",15632880_5,0
5004,renal insufficiency,68,87,"Cases were patients who developed hyperkalemia (K(+) >5.0 mEq/L) or renal insufficiency (Cr >or=2.5 mg/dL), and they were compared to 2 randomly selected controls per case.",15632880_5,1
5005,renal failure,119,132,RESULTS: Sixty-seven of 926 patients (7.2%) required discontinuation of spironolactone due to hyperkalemia (n = 33) or renal failure (n = 34).,15632880_7,1
1134,beta-blockers,211,224,"Patients who developed hyperkalemia were older and more likely to have diabetes, had higher baseline serum potassium levels and lower baseline potassium supplement doses, and were more likely to be treated with beta-blockers than controls (n = 134).",15632880_8,0
1135,creatinine,100,110,"Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum creatinine, required higher doses of loop diuretics, and were more likely to be treated with thiazide diuretics than controls.",15632880_9,0
1136,loop diuretics,137,151,"Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum creatinine, required higher doses of loop diuretics, and were more likely to be treated with thiazide diuretics than controls.",15632880_9,0
1137,thiazide diuretics,193,211,"Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum creatinine, required higher doses of loop diuretics, and were more likely to be treated with thiazide diuretics than controls.",15632880_9,0
5006,renal insufficiency,23,42,"Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum creatinine, required higher doses of loop diuretics, and were more likely to be treated with thiazide diuretics than controls.",15632880_9,1
5007,body weight,62,73,"Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum creatinine, required higher doses of loop diuretics, and were more likely to be treated with thiazide diuretics than controls.",15632880_9,1
4331,epithelial cells,17,33,Aging process of epithelial cells of the rat prostate lateral lobe in experimental hyperprolactinemia induced by haloperidol.,15638391_0,1
5009,hyperprolactinemia,83,101,Aging process of epithelial cells of the rat prostate lateral lobe in experimental hyperprolactinemia induced by haloperidol.,15638391_0,1
4332,prostate lateral lobe,45,66,Aging process of epithelial cells of the rat prostate lateral lobe in experimental hyperprolactinemia induced by haloperidol.,15638391_0,1
5010,hyperprolactinemia,53,71,"The aim of the study was to examine the influence of hyperprolactinemia, induced by haloperidol (HAL) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe.",15638391_1,1
5011,age related,105,116,"The aim of the study was to examine the influence of hyperprolactinemia, induced by haloperidol (HAL) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe.",15638391_1,1
4333,HAL,97,100,"The aim of the study was to examine the influence of hyperprolactinemia, induced by haloperidol (HAL) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe.",15638391_1,0
4334,epithelial cells,152,168,"The aim of the study was to examine the influence of hyperprolactinemia, induced by haloperidol (HAL) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe.",15638391_1,1
4335,prostate lateral lobe,176,197,"The aim of the study was to examine the influence of hyperprolactinemia, induced by haloperidol (HAL) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe.",15638391_1,1
4336,sexually mature,27,42,The study was performed on sexually mature male rats.,15638391_2,1
1139,PRL,35,38,Serum concentrations of prolactin (PRL) and testosterone (T) were measured.,15638391_3,0
1140,Nuclear Antigen,58,73,Immunohistochemical reactions for Anti-Proliferating Cell Nuclear Antigen (PCNA) were performed.,15638391_5,0
1141,PCNA,75,79,Immunohistochemical reactions for Anti-Proliferating Cell Nuclear Antigen (PCNA) were performed.,15638391_5,0
1142,PRL,62,65,"In rats of the experimental group, the mean concentration of: PRL was more than twice higher, whereas T concentration was almost twice lower than that in the control group.",15638391_6,0
1143,PCNA,132,136,"Light microscopy visualized the following: hypertrophy and epithelium hyperplasia of the glandular ducts, associated with increased PCNA expression.",15638391_7,0
4342,glandular ducts,89,104,"Light microscopy visualized the following: hypertrophy and epithelium hyperplasia of the glandular ducts, associated with increased PCNA expression.",15638391_7,1
1144,protein synthesis,101,118,"Electron microscopy revealed changes in columnar epithelial cells, concerning organelles, engaged in protein synthesis and secretion.",15638391_8,0
4345,columnar epithelial cells,40,65,"Electron microscopy revealed changes in columnar epithelial cells, concerning organelles, engaged in protein synthesis and secretion.",15638391_8,1
5012,coronary stenosis,100,117,Relation of perfusion defects observed with myocardial contrast echocardiography to the severity of coronary stenosis: correlation with thallium-201 single-photon emission tomography.,1564236_0,1
4349,hyperemic stimulation,233,254,It has been previously shown that myocardial contrast echocardiography is a valuable technique for delineating regions of myocardial underperfusion secondary to coronary occlusion and to critical coronary stenoses in the presence of hyperemic stimulation.,1564236_1,1
5014,coronary stenoses,196,213,It has been previously shown that myocardial contrast echocardiography is a valuable technique for delineating regions of myocardial underperfusion secondary to coronary occlusion and to critical coronary stenoses in the presence of hyperemic stimulation.,1564236_1,1
5013,coronary occlusion,161,179,It has been previously shown that myocardial contrast echocardiography is a valuable technique for delineating regions of myocardial underperfusion secondary to coronary occlusion and to critical coronary stenoses in the presence of hyperemic stimulation.,1564236_1,1
4348,myocardial underperfusion secondary,122,157,It has been previously shown that myocardial contrast echocardiography is a valuable technique for delineating regions of myocardial underperfusion secondary to coronary occlusion and to critical coronary stenoses in the presence of hyperemic stimulation.,1564236_1,1
5018,coronary stenosis,157,174,"Thus, myocardial contrast echocardiography can be used to visualize and quantitate the amount of jeopardized myocardium during moderate to severe degrees of coronary stenosis.",1564236_10,1
4369,anatomic area,49,62,The results obtained show a correlation with the anatomic area at risk similar to that obtained with thallium-201 SPECT.,1564236_11,1
4371,SPECT,114,119,The results obtained show a correlation with the anatomic area at risk similar to that obtained with thallium-201 SPECT.,1564236_11,0
4370,thallium-201,101,113,The results obtained show a correlation with the anatomic area at risk similar to that obtained with thallium-201 SPECT.,1564236_11,0
5015,coronary stenosis,222,239,The aim of this study was to determine whether myocardial contrast echocardiography performed with a stable solution of sonicated albumin could detect regions of myocardial underperfusion resulting from various degrees of coronary stenosis.,1564236_2,1
4352,myocardial underperfusion,162,187,The aim of this study was to determine whether myocardial contrast echocardiography performed with a stable solution of sonicated albumin could detect regions of myocardial underperfusion resulting from various degrees of coronary stenosis.,1564236_2,1
4351,sonicated albumin,120,137,The aim of this study was to determine whether myocardial contrast echocardiography performed with a stable solution of sonicated albumin could detect regions of myocardial underperfusion resulting from various degrees of coronary stenosis.,1564236_2,0
4353,anatomic area,74,87,The perfusion defect produced in 16 open chest dogs was compared with the anatomic area at risk measured by the postmortem dual-perfusion technique and with thallium-201 single-photon emission tomography (SPECT).,1564236_3,1
5016,coronary occlusion,26,44,"During a transient (20-s) coronary occlusion, a perfusion defect was observed with contrast echocardiography in 14 of the 15 dogs in which the occlusion was produced.",1564236_4,1
1145,(r,77,79,The perfusion defect correlated significantly with the anatomic area at risk (r = 0.74; p less than 0.002).,1564236_5,0
4357,anatomic area,55,68,The perfusion defect correlated significantly with the anatomic area at risk (r = 0.74; p less than 0.002).,1564236_5,1
5017,coronary stenosis,72,89,"During dipyridamole-induced hyperemia, 12 of the 16 dogs with a partial coronary stenosis had a visible area of hypoperfusion by contrast echocardiography.",1564236_6,1
4359,hypoperfusion,112,125,"During dipyridamole-induced hyperemia, 12 of the 16 dogs with a partial coronary stenosis had a visible area of hypoperfusion by contrast echocardiography.",1564236_6,1
1146,(r,105,107,The size of the perfusion defect during stenosis correlated significantly with the anatomic area at risk (r = 0.61; p = 0.02).,1564236_8,0
4361,anatomic area,83,96,The size of the perfusion defect during stenosis correlated significantly with the anatomic area at risk (r = 0.61; p = 0.02).,1564236_8,1
1148,(r,277,279,Thallium-201 SPECT demonstrated a perfusion defect in all 14 dogs analyzed during dipyridamole-induced hyperemia; the size of the perfusion defect correlated with the anatomic area at risk (r = 0.58; p less than 0.03) and with the perfusion defect by contrast echocardiography (r = 0.58; p less than 0.03).,1564236_9,0
4363,SPECT,13,18,Thallium-201 SPECT demonstrated a perfusion defect in all 14 dogs analyzed during dipyridamole-induced hyperemia; the size of the perfusion defect correlated with the anatomic area at risk (r = 0.58; p less than 0.03) and with the perfusion defect by contrast echocardiography (r = 0.58; p less than 0.03).,1564236_9,0
4362,Thallium-201,0,12,Thallium-201 SPECT demonstrated a perfusion defect in all 14 dogs analyzed during dipyridamole-induced hyperemia; the size of the perfusion defect correlated with the anatomic area at risk (r = 0.58; p less than 0.03) and with the perfusion defect by contrast echocardiography (r = 0.58; p less than 0.03).,1564236_9,0
1147,(r,189,191,Thallium-201 SPECT demonstrated a perfusion defect in all 14 dogs analyzed during dipyridamole-induced hyperemia; the size of the perfusion defect correlated with the anatomic area at risk (r = 0.58; p less than 0.03) and with the perfusion defect by contrast echocardiography (r = 0.58; p less than 0.03).,1564236_9,0
4372,Acute reserpine,0,15,Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats.,15649445_0,0
5019,orofacial dyskinesia,108,128,Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats.,15649445_0,1
4373,Reserpine-,0,10,Reserpine- and haloperidol-induced orofacial dyskinesia are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress.,15649445_1,0
1149,free radical,152,164,Reserpine- and haloperidol-induced orofacial dyskinesia are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress.,15649445_1,0
4375,oxidative stress,180,196,Reserpine- and haloperidol-induced orofacial dyskinesia are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress.,15649445_1,1
5020,orofacial dyskinesia,35,55,Reserpine- and haloperidol-induced orofacial dyskinesia are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress.,15649445_1,1
5021,tardive dyskinesia,86,104,Reserpine- and haloperidol-induced orofacial dyskinesia are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress.,15649445_1,1
5022,pathophysiology,116,131,Reserpine- and haloperidol-induced orofacial dyskinesia are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress.,15649445_1,1
5023,orofacial dyskinesia,42,62,"In the present study, the authors induced orofacial dyskinesia by acute reserpine and subchronic haloperidol administration to rats.",15649445_2,1
4376,acute reserpine,66,81,"In the present study, the authors induced orofacial dyskinesia by acute reserpine and subchronic haloperidol administration to rats.",15649445_2,0
4378,vacuous chewing,107,122,"Reserpine injection (one dose of 1 mg/kg s.c.) every other day for 3 days caused a significant increase in vacuous chewing, tongue protrusion and duration of facial twitching, compared to the control.",15649445_3,1
4382,vacuous chewing,101,116,"Haloperidol administration (one dose of 12 mg/kg once a week s.c.) for 4 weeks caused an increase in vacuous chewing, tongue protrusion and duration of facial twitching observed in four weekly evaluations.",15649445_4,1
4383,tongue protrusion,118,135,"Haloperidol administration (one dose of 12 mg/kg once a week s.c.) for 4 weeks caused an increase in vacuous chewing, tongue protrusion and duration of facial twitching observed in four weekly evaluations.",15649445_4,1
4386,subcortical parts,49,66,"A decreased glutamate uptake was observed in the subcortical parts of animals treated with reserpine and haloperidol, compared to the control.",15649445_6,1
4387,orofacial diskinesia,103,123,"Importantly, a decrease in glutamate uptake correlates negatively with an increase in the incidence of orofacial diskinesia.",15649445_7,1
1150,N-methyl-D-aspartate receptors,25,55,The activation of spinal N-methyl-D-aspartate receptors may contribute to degeneration of spinal motor neurons induced by neuraxial morphine after a noninjurious interval of spinal cord ischemia.,15673851_0,0
5024,spinal cord ischemia,174,194,The activation of spinal N-methyl-D-aspartate receptors may contribute to degeneration of spinal motor neurons induced by neuraxial morphine after a noninjurious interval of spinal cord ischemia.,15673851_0,1
4394,aortic occlusion,200,216,We investigated the relationship between the degeneration of spinal motor neurons and activation of N-methyl-d-aspartate (NMDA) receptors after neuraxial morphine following a noninjurious interval of aortic occlusion in rats.,15673851_1,1
4391,spinal motor neurons,61,81,We investigated the relationship between the degeneration of spinal motor neurons and activation of N-methyl-d-aspartate (NMDA) receptors after neuraxial morphine following a noninjurious interval of aortic occlusion in rats.,15673851_1,1
1151,N-methyl-d-aspartate,100,120,We investigated the relationship between the degeneration of spinal motor neurons and activation of N-methyl-d-aspartate (NMDA) receptors after neuraxial morphine following a noninjurious interval of aortic occlusion in rats.,15673851_1,0
1152,NMDA,122,126,We investigated the relationship between the degeneration of spinal motor neurons and activation of N-methyl-d-aspartate (NMDA) receptors after neuraxial morphine following a noninjurious interval of aortic occlusion in rats.,15673851_1,0
5031,spinal cord ischemia,60,80,We suggest that opioids may be neurotoxic in the setting of spinal cord ischemia via NMDA receptor activation.,15673851_10,1
1156,opioids,16,23,We suggest that opioids may be neurotoxic in the setting of spinal cord ischemia via NMDA receptor activation.,15673851_10,0
1157,NMDA receptor,85,98,We suggest that opioids may be neurotoxic in the setting of spinal cord ischemia via NMDA receptor activation.,15673851_10,0
4396,balloon catheter,70,86,Spinal cord ischemia was induced by aortic occlusion for 6 min with a balloon catheter.,15673851_2,1
4395,aortic occlusion,36,52,Spinal cord ischemia was induced by aortic occlusion for 6 min with a balloon catheter.,15673851_2,1
5025,Spinal cord ischemia,0,20,Spinal cord ischemia was induced by aortic occlusion for 6 min with a balloon catheter.,15673851_2,1
4399,group M,83,90,"In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.",15673851_3,0
4398,group C,44,51,"In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation.",15673851_3,0
4402,preischemia,37,48,"Microdialysis samples were collected preischemia, before IT injection, and at 2, 4, 8, 24, and 48 h of reperfusion (after IT injection).",15673851_4,1
4401,Microdialysis,0,13,"Microdialysis samples were collected preischemia, before IT injection, and at 2, 4, 8, 24, and 48 h of reperfusion (after IT injection).",15673851_4,1
5026,reperfusion,103,114,"Microdialysis samples were collected preischemia, before IT injection, and at 2, 4, 8, 24, and 48 h of reperfusion (after IT injection).",15673851_4,1
1153,MK-801,41,47,"Second, we investigated the effect of IT MK-801 (30 mug) on the histopathologic changes in the spinal cord after morphine-induced spastic paraparesis.",15673851_5,0
5027,spinal cord,95,106,"Second, we investigated the effect of IT MK-801 (30 mug) on the histopathologic changes in the spinal cord after morphine-induced spastic paraparesis.",15673851_5,1
5028,spastic paraparesis,130,149,"Second, we investigated the effect of IT MK-801 (30 mug) on the histopathologic changes in the spinal cord after morphine-induced spastic paraparesis.",15673851_5,1
4405,CSF,44,47,"After IT morphine, the cerebrospinal fluid (CSF) glutamate concentration was increased in group M relative to both baseline and group C (P < 0.05).",15673851_6,0
4407,group M,90,97,"After IT morphine, the cerebrospinal fluid (CSF) glutamate concentration was increased in group M relative to both baseline and group C (P < 0.05).",15673851_6,0
1154,MK-801,3,9,IT MK-801 significantly reduced the number of dark-stained alpha-motoneurons after morphine-induced spastic paraparesis compared with the saline group.,15673851_8,0
5029,spastic paraparesis,100,119,IT MK-801 significantly reduced the number of dark-stained alpha-motoneurons after morphine-induced spastic paraparesis compared with the saline group.,15673851_8,1
5030,spastic paraparesis,45,64,"These data indicate that IT morphine induces spastic paraparesis with a concomitant increase in CSF glutamate, which is involved in NMDA receptor activation.",15673851_9,1
1155,NMDA receptor,132,145,"These data indicate that IT morphine induces spastic paraparesis with a concomitant increase in CSF glutamate, which is involved in NMDA receptor activation.",15673851_9,0
4410,CSF,96,99,"These data indicate that IT morphine induces spastic paraparesis with a concomitant increase in CSF glutamate, which is involved in NMDA receptor activation.",15673851_9,0
5032,low back pain,6,19,Acute low back pain during intravenous administration of amiodarone: a report of two cases.,15686794_0,1
4414,sinus rhythm,133,145,Amiodarone represents an effective antiarrhythmic drug for cardioversion of recent-onset atrial fibrillation (AF) and maintenance of sinus rhythm.,15686794_1,1
4413,AF,110,112,Amiodarone represents an effective antiarrhythmic drug for cardioversion of recent-onset atrial fibrillation (AF) and maintenance of sinus rhythm.,15686794_1,0
4412,cardioversion,59,72,Amiodarone represents an effective antiarrhythmic drug for cardioversion of recent-onset atrial fibrillation (AF) and maintenance of sinus rhythm.,15686794_1,1
1158,antiarrhythmic drug,35,54,Amiodarone represents an effective antiarrhythmic drug for cardioversion of recent-onset atrial fibrillation (AF) and maintenance of sinus rhythm.,15686794_1,0
5033,atrial fibrillation,89,108,Amiodarone represents an effective antiarrhythmic drug for cardioversion of recent-onset atrial fibrillation (AF) and maintenance of sinus rhythm.,15686794_1,1
4415,intravenous amiodarone,167,189,"We briefly describe two patients suffering from recent-onset atrial fibrillation, who experienced an acute devastating low back pain a few minutes after initiation of intravenous amiodarone loading.",15686794_2,0
5034,atrial fibrillation,61,80,"We briefly describe two patients suffering from recent-onset atrial fibrillation, who experienced an acute devastating low back pain a few minutes after initiation of intravenous amiodarone loading.",15686794_2,1
5035,low back pain,119,132,"We briefly describe two patients suffering from recent-onset atrial fibrillation, who experienced an acute devastating low back pain a few minutes after initiation of intravenous amiodarone loading.",15686794_2,1
5036,side effect,14,25,"Notably, this side effect has not been ever reported in the medical literature.",15686794_3,1
4418,paediatric surgical,50,69,Ceftriaxone-associated biliary pseudolithiasis in paediatric surgical patients.,15737522_0,1
4417,pseudolithiasis,31,46,Ceftriaxone-associated biliary pseudolithiasis in paediatric surgical patients.,15737522_0,1
4419,pseudolithiasis,43,58,It is well known that ceftriaxone leads to pseudolithiasis in some patients.,15737522_1,1
4421,pseudolithiasis,152,167,"Clinical and experimental studies also suggest that situations causing gallbladder dysfunction, such as fasting, may have a role for the development of pseudolithiasis.",15737522_2,1
4420,gallbladder dysfunction,71,94,"Clinical and experimental studies also suggest that situations causing gallbladder dysfunction, such as fasting, may have a role for the development of pseudolithiasis.",15737522_2,1
4422,pseudolithiasis,83,98,"In this study, we prospectively evaluated the incidence and clinical importance of pseudolithiasis in paediatric surgical patients receiving ceftriaxone treatment, who often had to fast in the post-operative period.",15737522_3,1
5037,post-operative,193,207,"In this study, we prospectively evaluated the incidence and clinical importance of pseudolithiasis in paediatric surgical patients receiving ceftriaxone treatment, who often had to fast in the post-operative period.",15737522_3,1
4425,biliary pathology,117,134,"Fifty children who were given ceftriaxone were evaluated by serial abdominal sonograms. Of those, 13 (26%) developed biliary pathology.",15737522_4,1
4426,pseudolithiasis,43,58,"Comparison of the patients with or without pseudolithiasis revealed no significant difference with respect to age, sex, duration of the treatment and starvation variables.",15737522_5,1
4427,pseudolithiasis,34,49,"After cessation of the treatment, pseudolithiasis resolved spontaneously within a short period.",15737522_6,1
4428,pseudolithiasis,17,32,The incidence of pseudolithiasis is not affected by fasting.,15737522_7,1
4429,symptom severity,65,81,"Quantitative drug levels in stimulant psychosis: relationship to symptom severity, catecholamines and hyperkinesia.",15764424_0,1
5038,hyperkinesia,102,114,"Quantitative drug levels in stimulant psychosis: relationship to symptom severity, catecholamines and hyperkinesia.",15764424_0,1
1159,amphetamine-,185,197,"To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.",15764424_1,0
4431,psychotic symptoms,92,110,"To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.",15764424_1,1
4433,cocaine-induced psychosis,201,226,"To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels.",15764424_1,1
5039,hyperkinesia,100,112,Methamphetamine or amphetamine levels were related to several psychopathology scores and the global hyperkinesia rating.,15764424_2,1
4435,HVA,0,3,HVA levels were related to global hyperkinesia but not to psychopathology ratings.,15764424_3,0
5040,hyperkinesia,34,46,HVA levels were related to global hyperkinesia but not to psychopathology ratings.,15764424_3,1
4436,psychotic symptoms,98,116,"Although many other factors such as sensitization may play a role, intensity of stimulant-induced psychotic symptoms and stereotypies appears to be at least in part dose-related.",15764424_4,1
4437,stereotypies,121,133,"Although many other factors such as sensitization may play a role, intensity of stimulant-induced psychotic symptoms and stereotypies appears to be at least in part dose-related.",15764424_4,1
5041,Coronary aneurysm,0,17,Coronary aneurysm after implantation of a paclitaxel-eluting stent.,15804801_0,1
4444,vessel wall,176,187,"Formation of coronary aneurysm is a rare complication of stenting with bare metal stents, but based on experimental studies drug-eluting stents may induce toxic effects on the vessel wall with incomplete stent apposition, aneurysm formation and with the potential of stent thrombosis or vessel rupture.",15804801_1,1
4440,stenting,57,65,"Formation of coronary aneurysm is a rare complication of stenting with bare metal stents, but based on experimental studies drug-eluting stents may induce toxic effects on the vessel wall with incomplete stent apposition, aneurysm formation and with the potential of stent thrombosis or vessel rupture.",15804801_1,1
4448,vessel rupture,287,301,"Formation of coronary aneurysm is a rare complication of stenting with bare metal stents, but based on experimental studies drug-eluting stents may induce toxic effects on the vessel wall with incomplete stent apposition, aneurysm formation and with the potential of stent thrombosis or vessel rupture.",15804801_1,1
5042,coronary aneurysm,13,30,"Formation of coronary aneurysm is a rare complication of stenting with bare metal stents, but based on experimental studies drug-eluting stents may induce toxic effects on the vessel wall with incomplete stent apposition, aneurysm formation and with the potential of stent thrombosis or vessel rupture.",15804801_1,1
4446,aneurysm formation,222,240,"Formation of coronary aneurysm is a rare complication of stenting with bare metal stents, but based on experimental studies drug-eluting stents may induce toxic effects on the vessel wall with incomplete stent apposition, aneurysm formation and with the potential of stent thrombosis or vessel rupture.",15804801_1,1
4447,stent thrombosis,267,283,"Formation of coronary aneurysm is a rare complication of stenting with bare metal stents, but based on experimental studies drug-eluting stents may induce toxic effects on the vessel wall with incomplete stent apposition, aneurysm formation and with the potential of stent thrombosis or vessel rupture.",15804801_1,1
4449,paclitaxel-eluting stent,119,143,We present a 43-year-old man who developed a coronary aneurysm in the right coronary artery 6 months after receiving a paclitaxel-eluting stent.,15804801_2,0
5043,coronary aneurysm,45,62,We present a 43-year-old man who developed a coronary aneurysm in the right coronary artery 6 months after receiving a paclitaxel-eluting stent.,15804801_2,1
5044,coronary artery,76,91,We present a 43-year-old man who developed a coronary aneurysm in the right coronary artery 6 months after receiving a paclitaxel-eluting stent.,15804801_2,1
4453,aneurysm diameter,137,154,Angiography and intracoronary ultrasound demonstrated lack of contact between stent and vessel wall in a 15-mm long segment with maximal aneurysm diameter of 6.0 mm.,15804801_4,1
4452,vessel wall,88,99,Angiography and intracoronary ultrasound demonstrated lack of contact between stent and vessel wall in a 15-mm long segment with maximal aneurysm diameter of 6.0 mm.,15804801_4,1
4455,graft stent,44,55,The patient was successfully treated with a graft stent.,15804801_5,1
1160,amisulpride,29,40,Pheochromocytoma unmasked by amisulpride and tiapride.,15811908_0,0
1161,tiapride,45,53,Pheochromocytoma unmasked by amisulpride and tiapride.,15811908_0,0
1162,amisulpride,83,94,OBJECTIVE: To describe the unmasking of pheochromocytoma in a patient treated with amisulpride and tiapride.,15811908_1,0
1163,tiapride,99,107,OBJECTIVE: To describe the unmasking of pheochromocytoma in a patient treated with amisulpride and tiapride.,15811908_1,0
4460,headache and vomiting,79,100,CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.,15811908_2,1
4459,acute hypertension,48,66,CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.,15811908_2,1
1165,tiapride,157,165,CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.,15811908_2,0
1164,amisulpride,134,145,CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg.,15811908_2,0
1166,nicardipine,85,96,"Both drugs were immediately discontinued, and the patient recovered after subsequent nicardipine and verapamil treatment.",15811908_3,0
4462,adrenal mass,31,43,"Abdominal ultrasound showed an adrenal mass, and postoperative histologic examination confirmed the diagnosis of pheochromocytoma.",15811908_4,1
4465,substituted benzamide,91,112,"DISCUSSION: Drug-induced symptoms of pheochromocytoma are often associated with the use of substituted benzamide drugs, but the underlying mechanism is unknown.",15811908_5,0
5045,Drug-induced,12,24,"DISCUSSION: Drug-induced symptoms of pheochromocytoma are often associated with the use of substituted benzamide drugs, but the underlying mechanism is unknown.",15811908_5,1
1167,amisulpride,120,131,"In our case, use of the Naranjo probability scale indicated a possible relationship between the hypertensive crisis and amisulpride and tiapride therapy.",15811908_6,0
1168,tiapride,136,144,"In our case, use of the Naranjo probability scale indicated a possible relationship between the hypertensive crisis and amisulpride and tiapride therapy.",15811908_6,0
4467,hypertensive crisis,96,115,"In our case, use of the Naranjo probability scale indicated a possible relationship between the hypertensive crisis and amisulpride and tiapride therapy.",15811908_6,1
4468,hypertensive crisis,104,123,"CONCLUSIONS: As of March 24, 2005, this is the first reported case of amisulpride- and tiapride-induced hypertensive crisis in a patient with pheochromocytoma.",15811908_7,1
1169,tiapride,98,106,Physicians and other healthcare professionals should be aware of this potential adverse effect of tiapride and amisulpride.,15811908_8,0
1170,amisulpride,111,122,Physicians and other healthcare professionals should be aware of this potential adverse effect of tiapride and amisulpride.,15811908_8,0
4469,adverse effect,80,94,Physicians and other healthcare professionals should be aware of this potential adverse effect of tiapride and amisulpride.,15811908_8,1
4470,neurological dysfunction,6,30,"Minor neurological dysfunction, cognitive development, and somatic development at the age of 3 to 7 years after dexamethasone treatment in very-low birth-weight infants.",15814210_0,1
4471,cognitive development,32,53,"Minor neurological dysfunction, cognitive development, and somatic development at the age of 3 to 7 years after dexamethasone treatment in very-low birth-weight infants.",15814210_0,1
4472,somatic development,59,78,"Minor neurological dysfunction, cognitive development, and somatic development at the age of 3 to 7 years after dexamethasone treatment in very-low birth-weight infants.",15814210_0,1
4473,very-low birth-weight infants,139,168,"Minor neurological dysfunction, cognitive development, and somatic development at the age of 3 to 7 years after dexamethasone treatment in very-low birth-weight infants.",15814210_0,1
4475,cognitive development,74,95,"The objective of this study was to assess minor neurological dysfunction, cognitive development, and somatic development after dexamethasone therapy in very-low-birthweight infants.",15814210_1,1
4476,somatic development,101,120,"The objective of this study was to assess minor neurological dysfunction, cognitive development, and somatic development after dexamethasone therapy in very-low-birthweight infants.",15814210_1,1
4474,neurological dysfunction,48,72,"The objective of this study was to assess minor neurological dysfunction, cognitive development, and somatic development after dexamethasone therapy in very-low-birthweight infants.",15814210_1,1
4490,social development,52,70,"There were no differences in development of speech, social development, and the Kaufman Assessment Battery for Children.",15814210_10,1
4492,neurological dysfunctions,70,95,"After dexamethasone treatment, children showed a higher rate of minor neurological dysfunctions.",15814210_11,1
4493,Neurological development,0,24,Neurological development was affected even without neurological diagnosis.,15814210_12,1
4494,neurological diagnosis,51,73,Neurological development was affected even without neurological diagnosis.,15814210_12,1
4496,cognitive development,120,141,Further long-term follow-up studies will be necessary to fully evaluate the impact of dexamethasone on neurological and cognitive development.,15814210_13,1
4480,gestational age,89,104,"Exclusion criteria were asphyxia, malformations, major surgical interventions, small for gestational age, intraventricular haemorrhage grades III and IV, periventricular leukomalacia, and severe psychomotor retardation.",15814210_5,1
5047,periventricular leukomalacia,154,182,"Exclusion criteria were asphyxia, malformations, major surgical interventions, small for gestational age, intraventricular haemorrhage grades III and IV, periventricular leukomalacia, and severe psychomotor retardation.",15814210_5,1
5046,intraventricular haemorrhage,106,134,"Exclusion criteria were asphyxia, malformations, major surgical interventions, small for gestational age, intraventricular haemorrhage grades III and IV, periventricular leukomalacia, and severe psychomotor retardation.",15814210_5,1
4481,psychomotor retardation,195,218,"Exclusion criteria were asphyxia, malformations, major surgical interventions, small for gestational age, intraventricular haemorrhage grades III and IV, periventricular leukomalacia, and severe psychomotor retardation.",15814210_5,1
4483,neurological dysfunctions,57,82,Each child was examined by a neuropediatrician for minor neurological dysfunctions and tested by a psychologist for cognitive development with a Kaufman Assessment Battery for Children and a Draw-a-Man Test.,15814210_6,1
4484,cognitive development,116,137,Each child was examined by a neuropediatrician for minor neurological dysfunctions and tested by a psychologist for cognitive development with a Kaufman Assessment Battery for Children and a Draw-a-Man Test.,15814210_6,1
4489,gross motor function,22,42,Fine motor skills and gross motor function were significantly better in the control group (p<0.01).,15814210_8,1
4498,lipid peroxidation,32,50,"Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats.",15858223_0,0
5048,liver toxicity,63,77,"Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats.",15858223_0,1
1171,Valproic acid,0,13,"Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats.",15858223_0,0
1172,biomarkers,51,61,"Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats.",15858223_0,0
1173,valproic acid,83,96,"Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats.",15858223_0,0
4503,15-F(2t)-isoprostane,173,193,"A single dose of valproic acid (VPA), which is a widely used antiepileptic drug, is associated with oxidative stress in rats, as recently demonstrated by elevated levels of 15-F(2t)-isoprostane (15-F(2t)-IsoP).",15858223_1,0
4502,oxidative stress,100,116,"A single dose of valproic acid (VPA), which is a widely used antiepileptic drug, is associated with oxidative stress in rats, as recently demonstrated by elevated levels of 15-F(2t)-isoprostane (15-F(2t)-IsoP).",15858223_1,1
4500,VPA,32,35,"A single dose of valproic acid (VPA), which is a widely used antiepileptic drug, is associated with oxidative stress in rats, as recently demonstrated by elevated levels of 15-F(2t)-isoprostane (15-F(2t)-IsoP).",15858223_1,0
1175,antiepileptic drug,61,79,"A single dose of valproic acid (VPA), which is a widely used antiepileptic drug, is associated with oxidative stress in rats, as recently demonstrated by elevated levels of 15-F(2t)-isoprostane (15-F(2t)-IsoP).",15858223_1,0
1174,valproic acid,17,30,"A single dose of valproic acid (VPA), which is a widely used antiepileptic drug, is associated with oxidative stress in rats, as recently demonstrated by elevated levels of 15-F(2t)-isoprostane (15-F(2t)-IsoP).",15858223_1,0
5051,steatosis,159,168,"Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of necrosis, steatosis, and elevated levels of serum alpha-GST.",15858223_10,1
4525,oxidative stress,63,79,"Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of necrosis, steatosis, and elevated levels of serum alpha-GST.",15858223_10,1
4524,VPA,38,41,"Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of 15-F(2t)-IsoP, which precedes the onset of necrosis, steatosis, and elevated levels of serum alpha-GST.",15858223_10,0
4504,oxidative stress,78,94,"To determine whether there was a temporal relationship between VPA-associated oxidative stress and hepatotoxicity, adult male Sprague-Dawley rats were treated ip with VPA (500 mg/kg) or 0.9% saline (vehicle) once daily for 2, 4, 7, 10, or 14 days.",15858223_2,1
4505,hepatotoxicity,99,113,"To determine whether there was a temporal relationship between VPA-associated oxidative stress and hepatotoxicity, adult male Sprague-Dawley rats were treated ip with VPA (500 mg/kg) or 0.9% saline (vehicle) once daily for 2, 4, 7, 10, or 14 days.",15858223_2,1
4507,VPA,167,170,"To determine whether there was a temporal relationship between VPA-associated oxidative stress and hepatotoxicity, adult male Sprague-Dawley rats were treated ip with VPA (500 mg/kg) or 0.9% saline (vehicle) once daily for 2, 4, 7, 10, or 14 days.",15858223_2,0
1176,thiobarbituric acid reactive substances,119,158,"Oxidative stress was assessed by determining plasma and liver levels of 15-F(2t)-IsoP, lipid hydroperoxides (LPO), and thiobarbituric acid reactive substances (TBARs).",15858223_3,0
1177,TBARs,160,165,"Oxidative stress was assessed by determining plasma and liver levels of 15-F(2t)-IsoP, lipid hydroperoxides (LPO), and thiobarbituric acid reactive substances (TBARs).",15858223_3,0
4510,lipid hydroperoxides,87,107,"Oxidative stress was assessed by determining plasma and liver levels of 15-F(2t)-IsoP, lipid hydroperoxides (LPO), and thiobarbituric acid reactive substances (TBARs).",15858223_3,0
4511,LPO,109,112,"Oxidative stress was assessed by determining plasma and liver levels of 15-F(2t)-IsoP, lipid hydroperoxides (LPO), and thiobarbituric acid reactive substances (TBARs).",15858223_3,0
4508,Oxidative stress,0,16,"Oxidative stress was assessed by determining plasma and liver levels of 15-F(2t)-IsoP, lipid hydroperoxides (LPO), and thiobarbituric acid reactive substances (TBARs).",15858223_3,1
4513,VPA,82,85,Plasma and liver 15-F(2t)-IsoP were elevated and reached a plateau after day 2 of VPA treatment compared to control.,15858223_4,0
1178,TBARs,17,22,"Liver and plasma TBARs were not increased until 14 days (2-fold vs. control, p < 0.05).",15858223_6,0
1179,S-transferase,72,85,Liver toxicity was evaluated based on serum levels of alpha-glutathione S-transferase (alpha-GST) and by histology.,15858223_7,0
4516,alpha-GST,87,96,Liver toxicity was evaluated based on serum levels of alpha-glutathione S-transferase (alpha-GST) and by histology.,15858223_7,0
5049,Liver toxicity,0,14,Liver toxicity was evaluated based on serum levels of alpha-glutathione S-transferase (alpha-GST) and by histology.,15858223_7,1
4518,hepatotoxicity,83,97,"Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule, necrosis, and steatosis throughout the study.",15858223_8,1
4519,liver capsule,158,171,"Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule, necrosis, and steatosis throughout the study.",15858223_8,1
5050,steatosis,187,196,"Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule, necrosis, and steatosis throughout the study.",15858223_8,1
4521,VPA,50,53,"The liver levels of beta-oxidation metabolites of VPA were decreased by day 14, while the levels of 4-ene-VPA and (E)-2,4-diene-VPA were not elevated throughout the study.",15858223_9,0
4523,"(E)-2,4-diene-VPA",114,131,"The liver levels of beta-oxidation metabolites of VPA were decreased by day 14, while the levels of 4-ene-VPA and (E)-2,4-diene-VPA were not elevated throughout the study.",15858223_9,0
4522,4-ene-VPA,100,109,"The liver levels of beta-oxidation metabolites of VPA were decreased by day 14, while the levels of 4-ene-VPA and (E)-2,4-diene-VPA were not elevated throughout the study.",15858223_9,0
4520,beta-oxidation,20,34,"The liver levels of beta-oxidation metabolites of VPA were decreased by day 14, while the levels of 4-ene-VPA and (E)-2,4-diene-VPA were not elevated throughout the study.",15858223_9,0
4528,acute thrombotic microangiopathy,10,42,Causes of acute thrombotic microangiopathy in patients receiving kidney transplantation.,15859940_0,1
4529,kidney transplantation,65,87,Causes of acute thrombotic microangiopathy in patients receiving kidney transplantation.,15859940_0,1
5052,Thrombotic microangiopathy,12,38,OBJECTIVES: Thrombotic microangiopathy is a well-known problem in patients following renal transplantation.,15859940_1,1
4530,renal transplantation,85,106,OBJECTIVES: Thrombotic microangiopathy is a well-known problem in patients following renal transplantation.,15859940_1,1
5061,hemolytic uremic syndrome,150,175,"CONCLUSIONS: In the literature, the most-frequent cause of hemolytic uremic syndrome in patients following renal transplantation is recurrence of the hemolytic uremic syndrome.",15859940_10,1
4537,renal transplantation,107,128,"CONCLUSIONS: In the literature, the most-frequent cause of hemolytic uremic syndrome in patients following renal transplantation is recurrence of the hemolytic uremic syndrome.",15859940_10,1
4536,cause of hemolytic uremic syndrome,50,84,"CONCLUSIONS: In the literature, the most-frequent cause of hemolytic uremic syndrome in patients following renal transplantation is recurrence of the hemolytic uremic syndrome.",15859940_10,1
1185,procoagulant,71,83,"Other causes include drug-related (cyclosporine, tacrolimus) toxicity, procoagulant status, and antibody-mediated rejection.",15859940_11,0
1184,tacrolimus,49,59,"Other causes include drug-related (cyclosporine, tacrolimus) toxicity, procoagulant status, and antibody-mediated rejection.",15859940_11,0
1183,cyclosporine,35,47,"Other causes include drug-related (cyclosporine, tacrolimus) toxicity, procoagulant status, and antibody-mediated rejection.",15859940_11,0
5062,drug-related,21,33,"Other causes include drug-related (cyclosporine, tacrolimus) toxicity, procoagulant status, and antibody-mediated rejection.",15859940_11,1
5063,antibody-mediated,96,113,"Other causes include drug-related (cyclosporine, tacrolimus) toxicity, procoagulant status, and antibody-mediated rejection.",15859940_11,1
4539,cause of thrombotic microangiopathy,32,67,"We found that the most-frequent cause of thrombotic microangiopathy was drug related, secondary mainly to cyclosporine.",15859940_12,1
1186,cyclosporine,106,118,"We found that the most-frequent cause of thrombotic microangiopathy was drug related, secondary mainly to cyclosporine.",15859940_12,0
5064,drug related,72,84,"We found that the most-frequent cause of thrombotic microangiopathy was drug related, secondary mainly to cyclosporine.",15859940_12,1
5065,thrombotic microangiopathy,39,65,"In the current study, the frequency of thrombotic microangiopathy was similar to the percentage reported in the literature (20%).",15859940_13,1
5053,thrombotic microangiopathy,30,56,"In postrenal transplantation, thrombotic microangiopathy is often a reflection of hemolytic uremic syndrome.",15859940_2,1
5054,hemolytic uremic syndrome,82,107,"In postrenal transplantation, thrombotic microangiopathy is often a reflection of hemolytic uremic syndrome.",15859940_2,1
4531,postrenal transplantation,3,28,"In postrenal transplantation, thrombotic microangiopathy is often a reflection of hemolytic uremic syndrome.",15859940_2,1
4532,renal transplantation,82,103,We aimed to determine the causes of thrombotic microangiopathy in a population of renal transplantation recipients and discuss the literature.,15859940_3,1
5055,thrombotic microangiopathy,36,62,We aimed to determine the causes of thrombotic microangiopathy in a population of renal transplantation recipients and discuss the literature.,15859940_3,1
5056,thrombotic microangiopathy,53,79,"MATERIALS AND METHODS: We investigated the causes of thrombotic microangiopathy during a 1-year period, from June 2003 to June 2004, at the King Fahad National Guard Hospital in Riyadh, Saudi Arabia, by reviewing the slides of all transplant biopsies (n=25) performed during this interval.",15859940_4,1
4534,crossmatching,24,37,Pre- and posttransplant crossmatching was done when possible.,15859940_5,0
5057,thrombotic microangiopathy,23,49,RESULTS: Five cases of thrombotic microangiopathy were found.,15859940_6,1
1181,cyclosporine,75,87,"Three cases were related to cyclosporine, and 1 case was secondary to both cyclosporine and tacrolimus.",15859940_8,0
1182,tacrolimus,92,102,"Three cases were related to cyclosporine, and 1 case was secondary to both cyclosporine and tacrolimus.",15859940_8,0
1180,cyclosporine,28,40,"Three cases were related to cyclosporine, and 1 case was secondary to both cyclosporine and tacrolimus.",15859940_8,0
5058,thrombotic microangiopathy,31,57,The fifth case had features of thrombotic microangiopathy related to an antiphospholipid syndrome in a patient with systemic lupus erythematosus.,15859940_9,1
5059,antiphospholipid syndrome,72,97,The fifth case had features of thrombotic microangiopathy related to an antiphospholipid syndrome in a patient with systemic lupus erythematosus.,15859940_9,1
5060,systemic lupus erythematosus,116,144,The fifth case had features of thrombotic microangiopathy related to an antiphospholipid syndrome in a patient with systemic lupus erythematosus.,15859940_9,1
4542,DFU,125,128,Comparison of developmental toxicity of selective and non-selective cyclooxygenase-2 inhibitors in CRL:(WI)WUBR Wistar rats--DFU and piroxicam study.,15863244_0,0
4540,non-selective cyclooxygenase-2 inhibitors,54,95,Comparison of developmental toxicity of selective and non-selective cyclooxygenase-2 inhibitors in CRL:(WI)WUBR Wistar rats--DFU and piroxicam study.,15863244_0,0
4555,compound dose,118,131,Decrease of fetal length was the only signs of the DFU developmental toxicity observed in pups exposed to the highest compound dose.,15863244_10,0
4554,DFU,51,54,Decrease of fetal length was the only signs of the DFU developmental toxicity observed in pups exposed to the highest compound dose.,15863244_10,0
1188,COX-2 inhibitors,140,156,Prenatal exposure to non-selective COX inhibitors increases the risk of VSD and MD when compared to historic control but not with selective COX-2 inhibitors.,15863244_12,0
4557,non-selective COX inhibitors,21,49,Prenatal exposure to non-selective COX inhibitors increases the risk of VSD and MD when compared to historic control but not with selective COX-2 inhibitors.,15863244_12,0
5068,Prenatal exposure,0,17,Prenatal exposure to non-selective COX inhibitors increases the risk of VSD and MD when compared to historic control but not with selective COX-2 inhibitors.,15863244_12,1
4560,non-selective COX-2 inhibitors,31,61,CONCLUSION: Both selective and non-selective COX-2 inhibitors were toxic for rats fetuses when administered in the highest dose.,15863244_13,0
4561,DFU,7,10,"Unlike DFU, piroxicam was also highly toxic to the dams.",15863244_14,0
1189,COX-2 inhibitors,31,47,Prenatal exposure to selective COX-2 inhibitors does not increase the risk of ventricular septal and midline defects in rat when compared to non-selective drugs and historic control.,15863244_15,0
5069,Prenatal exposure,0,17,Prenatal exposure to selective COX-2 inhibitors does not increase the risk of ventricular septal and midline defects in rat when compared to non-selective drugs and historic control.,15863244_15,1
5070,ventricular septal,78,96,Prenatal exposure to selective COX-2 inhibitors does not increase the risk of ventricular septal and midline defects in rat when compared to non-selective drugs and historic control.,15863244_15,1
4562,midline defects,101,116,Prenatal exposure to selective COX-2 inhibitors does not increase the risk of ventricular septal and midline defects in rat when compared to non-selective drugs and historic control.,15863244_15,1
4544,toxic effects,45,58,"Unlike general toxicity data, their prenatal toxic effects were not extensively studied before.",15863244_2,0
1187,COX-2 inhibitors,198,214,"The aim of the experiment was to evaluate the developmental toxicity of the non-selective (piroxicam) and selective (DFU; 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanon) COX-2 inhibitors.",15863244_3,0
4545,non-selective,76,89,"The aim of the experiment was to evaluate the developmental toxicity of the non-selective (piroxicam) and selective (DFU; 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanon) COX-2 inhibitors.",15863244_3,0
4546,DFU,117,120,"The aim of the experiment was to evaluate the developmental toxicity of the non-selective (piroxicam) and selective (DFU; 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanon) COX-2 inhibitors.",15863244_3,0
4547,phenyl-2(5H)-furanon,176,196,"The aim of the experiment was to evaluate the developmental toxicity of the non-selective (piroxicam) and selective (DFU; 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanon) COX-2 inhibitors.",15863244_3,0
4549,DFU,86,89,"Doses were set at 0.3, 3.0 and 30.0mg/kg for piroxicam and 0.2, 2.0 and 20.0mg/kg for DFU.",15863244_5,0
4552,non-selective COX-2 inhibitor,152,181,"The pooled statistical analysis for ventricular septal (VSD) and midline (MD) defects was performed for rat fetuses exposed to piroxicam, selective and non-selective COX-2 inhibitor based on present and historic data.",15863244_8,0
5066,ventricular septal,36,54,"The pooled statistical analysis for ventricular septal (VSD) and midline (MD) defects was performed for rat fetuses exposed to piroxicam, selective and non-selective COX-2 inhibitor based on present and historic data.",15863244_8,1
4553,skeletal variations,90,109,"RESULTS: Maternal toxicity, intrauterine growth retardation, and increase of external and skeletal variations were found in rats treated with the highest dose of piroxicam.",15863244_9,1
5067,intrauterine growth retardation,28,59,"RESULTS: Maternal toxicity, intrauterine growth retardation, and increase of external and skeletal variations were found in rats treated with the highest dose of piroxicam.",15863244_9,1
1193,rubella vaccine,23,38,In-hospital postpartum rubella vaccine administration was documented for 75.6% of nonimmune women.,15867025_10,0
1190,hepatitis B vaccine,108,127,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,0
1191,rubella vaccine,338,353,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,0
4570,hepatitis B immune globulin,173,200,"Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen-positive mothers, rubella immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women.",15867025_3,0
1192,Hepatitis B vaccine,0,19,Hepatitis B vaccine birth dose was administered to 76.2% of all infants.,15867025_5,0
4576,hepatitis B immune globulin,88,115,All infants who were born to hepatitis B surface antigen-positive mothers also received hepatitis B immune globulin.,15867025_6,0
5071,birth weight,78,90,Multivariate logistic regression showed that the month of delivery and infant birth weight were independent predictors of hepatitis B vaccination.,15867025_7,1
4577,rubella nonimmunity,66,85,Women who were born between 1971 and 1975 had the highest rate of rubella nonimmunity (9.5%).,15867025_9,0
4580,masseter muscle rigidity,24,48,Succinylcholine-induced masseter muscle rigidity during bronchoscopic removal of a tracheal foreign body.,15893386_0,1
5072,foreign body,92,104,Succinylcholine-induced masseter muscle rigidity during bronchoscopic removal of a tracheal foreign body.,15893386_0,1
4581,Masseter muscle rigidity,0,24,Masseter muscle rigidity during general anesthesia is considered an early warning sign of a possible episode of malignant hyperthermia.,15893386_1,1
4582,general anesthesia,32,50,Masseter muscle rigidity during general anesthesia is considered an early warning sign of a possible episode of malignant hyperthermia.,15893386_1,1
5073,malignant hyperthermia,112,134,Masseter muscle rigidity during general anesthesia is considered an early warning sign of a possible episode of malignant hyperthermia.,15893386_1,1
4583,masseter muscle rigidity,116,140,The decision whether to continue or discontinue the procedure depends on the urgency of the surgery and severity of masseter muscle rigidity.,15893386_2,1
4584,masseter muscle rigidity,35,59,"Here, we describe a case of severe masseter muscle rigidity (jaw of steel) after succinylcholine (Sch) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body.",15893386_3,1
1195,general anesthetic,125,143,"Here, we describe a case of severe masseter muscle rigidity (jaw of steel) after succinylcholine (Sch) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body.",15893386_3,0
1194,Sch,98,101,"Here, we describe a case of severe masseter muscle rigidity (jaw of steel) after succinylcholine (Sch) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body.",15893386_3,0
5074,foreign body,201,213,"Here, we describe a case of severe masseter muscle rigidity (jaw of steel) after succinylcholine (Sch) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body.",15893386_3,1
1196,propofol,43,51,Anesthesia was continued uneventfully with propofol infusion while all facilities were available to detect and treat malignant hyperthermia.,15893386_4,0
5075,malignant hyperthermia,117,139,Anesthesia was continued uneventfully with propofol infusion while all facilities were available to detect and treat malignant hyperthermia.,15893386_4,1
1198,daunorubicin,98,110,Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.,15897593_0,0
4586,drugs etoposide,78,93,Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.,15897593_0,0
1197,Dexrazoxane,0,11,Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.,15897593_0,0
4591,myelosuppression,186,202,"PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.",15897593_1,1
5076,cardiac toxicity,207,223,"PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.",15897593_1,1
4589,DNA cleavage-enhancing drugs,105,133,"PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.",15897593_1,0
4588,epipodophyllotoxin etoposide,65,93,"PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.",15897593_1,0
4587,anthracyclines daunorubicin,13,40,"PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use.",15897593_1,0
5077,cardiotoxicity,83,97,Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-induced cardiotoxicity.,15897593_2,1
1200,ICRF-187,13,21,Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-induced cardiotoxicity.,15897593_2,0
1199,Dexrazoxane,0,11,Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-induced cardiotoxicity.,15897593_2,0
1203,daunorubicin,270,282,"EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.",15897593_3,0
1201,dexrazoxane,109,120,"EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.",15897593_3,0
1202,etoposide,259,268,"EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.",15897593_3,0
4592,DNA cleavage,160,172,"EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.",15897593_3,0
1204,/- dexrazoxane,301,315,"EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.",15897593_3,0
1205,granulocyte-macrophage,334,356,"EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays.",15897593_3,0
1206,etoposide,49,58,"Likewise, in vivo, B6D2F1 mice were treated with etoposide, daunorubicin, and doxorubicin, with or without dexrazoxane over a wide range of doses: posttreatment, a full hematologic evaluation was done.",15897593_4,0
1207,daunorubicin,60,72,"Likewise, in vivo, B6D2F1 mice were treated with etoposide, daunorubicin, and doxorubicin, with or without dexrazoxane over a wide range of doses: posttreatment, a full hematologic evaluation was done.",15897593_4,0
1208,dexrazoxane,107,118,"Likewise, in vivo, B6D2F1 mice were treated with etoposide, daunorubicin, and doxorubicin, with or without dexrazoxane over a wide range of doses: posttreatment, a full hematologic evaluation was done.",15897593_4,0
5078,posttreatment,147,160,"Likewise, in vivo, B6D2F1 mice were treated with etoposide, daunorubicin, and doxorubicin, with or without dexrazoxane over a wide range of doses: posttreatment, a full hematologic evaluation was done.",15897593_4,1
4599,weight loss,244,255,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,1
4593,Nontoxic doses,9,23,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,0
4598,myelosuppression,226,242,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,1
4595,weight loss,68,79,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,1
1211,etoposide,102,111,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,0
1209,dexrazoxane,27,38,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,0
1212,dexrazoxane,198,209,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,0
1210,daunorubicin,85,97,"RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin.",15897593_5,0
1214,daunorubicin,189,201,"CONCLUSION: Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from doxorubicin clinically, the potent antagonism of daunorubicin activity raises concern; a possible interference with anticancer efficacy certainly would call for renewed attention.",15897593_6,0
1213,dexrazoxane,63,74,"CONCLUSION: Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from doxorubicin clinically, the potent antagonism of daunorubicin activity raises concern; a possible interference with anticancer efficacy certainly would call for renewed attention.",15897593_6,0
1216,dexrazoxane,99,110,Our data also suggest that significant etoposide dose escalation is perhaps possible by the use of dexrazoxane.,15897593_7,0
1215,etoposide,39,48,Our data also suggest that significant etoposide dose escalation is perhaps possible by the use of dexrazoxane.,15897593_7,0
1217,dexrazoxane,60,71,Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity.,15897593_8,0
1218,etoposide,90,99,Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity.,15897593_8,0
5079,brain metastases,33,49,Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity.,15897593_8,1
4604,high doses,76,86,Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity.,15897593_8,0
4605,cytotoxic chemotherapy,103,125,"If successful, this represents an exciting mechanism for pharmacologic regulation of side effects from cytotoxic chemotherapy.",15897593_9,0
5080,side effects,85,97,"If successful, this represents an exciting mechanism for pharmacologic regulation of side effects from cytotoxic chemotherapy.",15897593_9,1
4607,creatine monohydrate,41,61,Lone atrial fibrillation associated with creatine monohydrate supplementation.,15899738_0,0
5081,atrial fibrillation,5,24,Lone atrial fibrillation associated with creatine monohydrate supplementation.,15899738_0,1
5082,Atrial fibrillation,0,19,Atrial fibrillation in young patients without structural heart disease is rare.,15899738_1,1
5083,heart disease,57,70,Atrial fibrillation in young patients without structural heart disease is rare.,15899738_1,1
4624,Exogenous creatine,0,18,Exogenous creatine is used by athletes to theoretically improve exercise performance.,15899738_10,0
4625,animal products,101,116,"Vegetarians may also take creatine to replace what they are not consuming from meat, fish, and other animal products.",15899738_11,0
4629,dietary supplements,151,170,Clinicians must be diligent when interviewing patients about their drug therapy histories and include questions about their use of herbal products and dietary supplements.,15899738_13,0
4628,herbal products,131,146,Clinicians must be diligent when interviewing patients about their drug therapy histories and include questions about their use of herbal products and dietary supplements.,15899738_13,0
5085,adverse effects,39,54,"In addition, it is important to report adverse effects associated with frequently consumed supplements and herbal products to the Food and Drug Administration and in the literature.",15899738_14,1
4631,herbal products,107,122,"In addition, it is important to report adverse effects associated with frequently consumed supplements and herbal products to the Food and Drug Administration and in the literature.",15899738_14,0
4609,alcohol intoxication,60,80,"Thyroid disorders, illicit drug or stimulant use, and acute alcohol intoxication are among these causes.",15899738_3,1
1219,illicit drug,19,31,"Thyroid disorders, illicit drug or stimulant use, and acute alcohol intoxication are among these causes.",15899738_3,0
4608,Thyroid disorders,0,17,"Thyroid disorders, illicit drug or stimulant use, and acute alcohol intoxication are among these causes.",15899738_3,1
5084,atrial fibrillation,90,109,We report the case of a 30-year-old Caucasian man who came to the emergency department in atrial fibrillation with rapid ventricular response.,15899738_4,1
4611,ventricular response,121,141,We report the case of a 30-year-old Caucasian man who came to the emergency department in atrial fibrillation with rapid ventricular response.,15899738_4,1
1220,His,0,3,"His medical history was unremarkable, except for minor fractures of the fingers and foot.",15899738_5,0
4612,minor fractures,49,64,"His medical history was unremarkable, except for minor fractures of the fingers and foot.",15899738_5,1
4613,Thyroid-stimulating hormone,0,27,"Thyroid-stimulating hormone, magnesium, and potassium levels were within normal limits, urine drug screen was negative, and alcohol use was denied.",15899738_6,0
4617,herbal products,54,69,"However, when the patient was questioned about use of herbal products and supplements, the use of creatine monohydrate was revealed.",15899738_7,0
4618,creatine monohydrate,98,118,"However, when the patient was questioned about use of herbal products and supplements, the use of creatine monohydrate was revealed.",15899738_7,0
4621,intravenous amiodarone,139,161,"The patient was admitted to the hospital, anticoagulated with unfractionated heparin, and given intravenous diltiazem for rate control and intravenous amiodarone for rate and rhythm control.",15899738_8,0
1221,unfractionated heparin,62,84,"The patient was admitted to the hospital, anticoagulated with unfractionated heparin, and given intravenous diltiazem for rate control and intravenous amiodarone for rate and rhythm control.",15899738_8,0
4619,intravenous diltiazem,96,117,"The patient was admitted to the hospital, anticoagulated with unfractionated heparin, and given intravenous diltiazem for rate control and intravenous amiodarone for rate and rhythm control.",15899738_8,0
4633,cocaine metabolite benzoylecgonine,24,58,Seizures induced by the cocaine metabolite benzoylecgonine in rats.,1592014_0,0
4634,t1/2,15,19,"The half-life (t1/2) of cocaine is relatively short, but some of the consequences of its use, such as seizures and strokes, can occur hours after exposure.",1592014_1,0
4648,cocaine-induced seizures,114,138,"The finding that cocaine- and BE-induced seizures differ in several respects suggests more than one mechanism for cocaine-induced seizures and emphasizes the importance of a cocaine metabolite, BE.",1592014_10,1
4649,cocaine metabolite,174,192,"The finding that cocaine- and BE-induced seizures differ in several respects suggests more than one mechanism for cocaine-induced seizures and emphasizes the importance of a cocaine metabolite, BE.",1592014_10,0
4635,delayed sequelae,93,109,This led us to hypothesize that a metabolite of cocaine may be responsible for some of those delayed sequelae.,1592014_2,1
4636,benzoylecgonine,63,78,"We evaluated the potential of the major metabolite of cocaine, benzoylecgonine (BE), to cause seizures.",1592014_3,0
4637,equimolar doses,13,28,Two separate equimolar doses (0.2 and 0.4 mumol) of either cocaine or BE were injected ventricularly in unanesthetized juvenile rats.,1592014_4,0
4640,BE-Induced seizures,0,19,BE-Induced seizures occurred more frequently and had significantly longer latencies than those induced by equimolar amounts of cocaine.,1592014_6,1
4642,cocaine-induced seizures,8,32,"Whereas cocaine-induced seizures were best characterized as brief, generalized, and tonic and resulted in death, those induced by BE were prolonged, often multiple and mixed in type, and rarely resulted in death.",1592014_7,1
4644,rhythmic progression,52,72,Electrical recordings from the hippocampus showed a rhythmic progression in EEG frequency and voltage with clinical seizure expression.,1592014_8,1
4645,clinical seizure,107,123,Electrical recordings from the hippocampus showed a rhythmic progression in EEG frequency and voltage with clinical seizure expression.,1592014_8,1
1222,propofol,83,91,Assessment of the onset and persistence of amnesia during procedural sedation with propofol.,15930398_0,0
4650,procedural sedation,58,77,Assessment of the onset and persistence of amnesia during procedural sedation with propofol.,15930398_0,1
4651,procedural sedation,102,121,"OBJECTIVES: To assess patients' ability to repeat and recall words presented to them while undergoing procedural sedation with propofol, and correlate their recall with their level of awareness as measured by bispectral index (BIS) monitoring.",15930398_1,1
1223,propofol,127,135,"OBJECTIVES: To assess patients' ability to repeat and recall words presented to them while undergoing procedural sedation with propofol, and correlate their recall with their level of awareness as measured by bispectral index (BIS) monitoring.",15930398_1,0
4660,preprocedure,18,30,The mean initial (preprocedure) BIS score was 97.1 (+/-2.3; range 92 to 99).,15930398_10,0
4664,procedural sedation,126,145,"Furthermore, patients had no recall of words repeated prior to procedural sedation in BIS ranges associated with recall after procedural sedation, suggestive of retrograde amnesia.",15930398_19,1
5086,retrograde amnesia,161,179,"Furthermore, patients had no recall of words repeated prior to procedural sedation in BIS ranges associated with recall after procedural sedation, suggestive of retrograde amnesia.",15930398_19,1
1224,propofol,124,132,"METHODS: This was a prospective, single-intervention study of consenting adult patients undergoing procedural sedation with propofol between December 28, 2002, and October 31, 2003.",15930398_2,0
4659,procedural sedations,48,68,No serious adverse events were noted during the procedural sedations.,15930398_8,0
4658,serious adverse events,3,25,No serious adverse events were noted during the procedural sedations.,15930398_8,1
1225,serotonergic,97,109,The selective 5-HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat.,15957009_0,0
4665,receptor antagonist Ro4368554,20,49,The selective 5-HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat.,15957009_0,0
4667,memory deficiency,120,137,The selective 5-HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat.,15957009_0,1
4668,serotonin type 6,15,31,Antagonists at serotonin type 6 (5-HT(6)) receptors show activity in models of learning and memory.,15957009_1,0
1226,ACh,118,121,"Although the underlying mechanism(s) are not well understood, these effects may involve an increase in acetylcholine (ACh) levels.",15957009_2,0
4672,acetylcholinesterase inhibitor metrifonate,368,410,"The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.",15957009_3,0
4670,Ro4368554,99,108,"The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.",15957009_3,0
1228,TRP,283,286,"The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.",15957009_3,0
1227,serotonergic-,256,269,"The present study sought to characterize the cognitive-enhancing effects of the 5-HT(6) antagonist Ro4368554 (3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1H-indole) in a rat object recognition task employing a cholinergic (scopolamine pretreatment) and a serotonergic- (tryptophan (TRP) depletion) deficient model, and compared its pattern of action with that of the acetylcholinesterase inhibitor metrifonate.",15957009_3,0
4674,Ro4368554,192,201,"Initial testing in a time-dependent forgetting task employing a 24-h delay between training and testing showed that metrifonate improved object recognition (at 10 and 30 mg/kg, p.o.), whereas Ro4368554 was inactive.",15957009_4,0
1230,at 10,157,162,"Initial testing in a time-dependent forgetting task employing a 24-h delay between training and testing showed that metrifonate improved object recognition (at 10 and 30 mg/kg, p.o.), whereas Ro4368554 was inactive.",15957009_4,0
1229,metrifonate,116,127,"Initial testing in a time-dependent forgetting task employing a 24-h delay between training and testing showed that metrifonate improved object recognition (at 10 and 30 mg/kg, p.o.), whereas Ro4368554 was inactive.",15957009_4,0
1232,TRP,158,161,"Both, Ro4368554 (3 and 10 mg/kg, intraperitoneally (i.p.)) and metrifonate (10 mg/kg, p.o., respectively) reversed memory deficits induced by scopolamine and TRP depletion (10 mg/kg, i.p., and 3 mg/kg, p.o., respectively).",15957009_5,0
5087,memory deficits,115,130,"Both, Ro4368554 (3 and 10 mg/kg, intraperitoneally (i.p.)) and metrifonate (10 mg/kg, p.o., respectively) reversed memory deficits induced by scopolamine and TRP depletion (10 mg/kg, i.p., and 3 mg/kg, p.o., respectively).",15957009_5,1
1231,metrifonate,63,74,"Both, Ro4368554 (3 and 10 mg/kg, intraperitoneally (i.p.)) and metrifonate (10 mg/kg, p.o., respectively) reversed memory deficits induced by scopolamine and TRP depletion (10 mg/kg, i.p., and 3 mg/kg, p.o., respectively).",15957009_5,0
4675,Ro4368554 (3,6,18,"Both, Ro4368554 (3 and 10 mg/kg, intraperitoneally (i.p.)) and metrifonate (10 mg/kg, p.o., respectively) reversed memory deficits induced by scopolamine and TRP depletion (10 mg/kg, i.p., and 3 mg/kg, p.o., respectively).",15957009_5,0
4679,Ro4368554,24,33,"In conclusion, although Ro4368554 did not improve a time-related retention deficit, it reversed a cholinergic and a serotonergic memory deficit, suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and, possibly, other 5-HT(6) receptor antagonists.",15957009_6,0
4681,object memory,216,229,"In conclusion, although Ro4368554 did not improve a time-related retention deficit, it reversed a cholinergic and a serotonergic memory deficit, suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and, possibly, other 5-HT(6) receptor antagonists.",15957009_6,1
4680,time-related retention deficit,52,82,"In conclusion, although Ro4368554 did not improve a time-related retention deficit, it reversed a cholinergic and a serotonergic memory deficit, suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and, possibly, other 5-HT(6) receptor antagonists.",15957009_6,1
1234,receptor antagonists,272,292,"In conclusion, although Ro4368554 did not improve a time-related retention deficit, it reversed a cholinergic and a serotonergic memory deficit, suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and, possibly, other 5-HT(6) receptor antagonists.",15957009_6,0
1233,serotonergic,116,128,"In conclusion, although Ro4368554 did not improve a time-related retention deficit, it reversed a cholinergic and a serotonergic memory deficit, suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and, possibly, other 5-HT(6) receptor antagonists.",15957009_6,0
4682,Ro4368554,233,242,"In conclusion, although Ro4368554 did not improve a time-related retention deficit, it reversed a cholinergic and a serotonergic memory deficit, suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and, possibly, other 5-HT(6) receptor antagonists.",15957009_6,0
5088,side-effects,81,93,"Amiodarone is an effective antiarrhythmic agent whose utility is limited by many side-effects, the most problematic being pneumonitis.",1595783_1,1
4683,antiarrhythmic agent,27,47,"Amiodarone is an effective antiarrhythmic agent whose utility is limited by many side-effects, the most problematic being pneumonitis.",1595783_1,0
5089,hypersensitivity pneumonitis,155,183,The pulmonary toxicity of amiodarone is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell-mediated hypersensitivity pneumonitis.,1595783_2,1
5090,heart failure,62,75,"The diagnosis depends on exclusion of other entities, such as heart failure, infection, and malignancy.",1595783_4,1
4687,GluR5 kainate receptor antagonists,37,71,Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of pain.,15974569_0,0
1235,prodrugs,4,12,Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of pain.,15974569_0,0
1237,glutamate receptors,139,158,"Amino acids 5 and 7, two potent and selective competitive GluR5 KA receptor antagonists, exhibited high GluR5 receptor affinity over other glutamate receptors.",15974569_1,0
4689,GluR5 KA receptor antagonists,58,87,"Amino acids 5 and 7, two potent and selective competitive GluR5 KA receptor antagonists, exhibited high GluR5 receptor affinity over other glutamate receptors.",15974569_1,0
4690,GluR5 receptor,104,118,"Amino acids 5 and 7, two potent and selective competitive GluR5 KA receptor antagonists, exhibited high GluR5 receptor affinity over other glutamate receptors.",15974569_1,0
1236,Amino acids,0,11,"Amino acids 5 and 7, two potent and selective competitive GluR5 KA receptor antagonists, exhibited high GluR5 receptor affinity over other glutamate receptors.",15974569_1,0
4691,ester prodrugs,6,20,"Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.",15974569_2,0
5091,thermal hyperalgesia,135,155,"Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.",15974569_2,1
5092,mechanical hyperalgesia,179,202,"Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia.",15974569_2,1
4707,vagal mechanism,87,102,"However, macrolide antimicrobials have been reported to be associated with hiccups and vagal mechanism could explain the development of this side-effect.",15985056_12,1
1242,macrolide,9,18,"However, macrolide antimicrobials have been reported to be associated with hiccups and vagal mechanism could explain the development of this side-effect.",15985056_12,0
5093,side-effect,141,152,"However, macrolide antimicrobials have been reported to be associated with hiccups and vagal mechanism could explain the development of this side-effect.",15985056_12,1
1238,baclofen,49,57,Discontinuation of azithromycin and therapy with baclofen finally resolved hiccups.,15985056_4,0
4697,Pharmacotherapeutic agents,12,38,DISCUSSION: Pharmacotherapeutic agents have been uncommonly associated with hiccups.,15985056_6,0
4699,general anaesthesia,88,107,"Corticosteroids (dexamethasone and methylprednisolone), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups.",15985056_7,1
1239,methylprednisolone,35,53,"Corticosteroids (dexamethasone and methylprednisolone), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups.",15985056_7,0
4701,drug-induced hiccups,13,33,Few cases of drug-induced hiccups have been reported related to macrolide antimicrobials.,15985056_8,1
1240,macrolide,64,73,Few cases of drug-induced hiccups have been reported related to macrolide antimicrobials.,15985056_8,0
4702,adverse effect,18,32,"Using the Naranjo adverse effect reaction probability scale this event could be classified as possible (score 5 points), mostly because of the close temporal sequence, previous reports on this reaction with other macrolides and the absence of any alternative explanation for hiccups.",15985056_9,1
1241,macrolides,213,223,"Using the Naranjo adverse effect reaction probability scale this event could be classified as possible (score 5 points), mostly because of the close temporal sequence, previous reports on this reaction with other macrolides and the absence of any alternative explanation for hiccups.",15985056_9,0
4709,cocaine overdose,82,98,Evaluation of the anticocaine monoclonal antibody GNC92H2 as an immunotherapy for cocaine overdose.,16005948_0,1
4708,monoclonal antibody GNC92H2,30,57,Evaluation of the anticocaine monoclonal antibody GNC92H2 as an immunotherapy for cocaine overdose.,16005948_0,0
4710,cocaine overdose,79,95,The illicit use of cocaine continues in epidemic proportions and treatment for cocaine overdose remains elusive.,16005948_1,1
4713,toxic effects,136,149,"Current protein-based technology offers a new therapeutic venue by which antibodies bind the drug in the blood stream, inactivating its toxic effects.",16005948_2,0
4711,therapeutic venue,46,63,"Current protein-based technology offers a new therapeutic venue by which antibodies bind the drug in the blood stream, inactivating its toxic effects.",16005948_2,0
4714,anticocaine antibody GNC92H2,33,61,The therapeutic potential of the anticocaine antibody GNC92H2 was examined using a model of cocaine overdose.,16005948_3,0
4718,LD50,120,124,Swiss albino mice prepared with intrajugular catheters were tested in photocell cages after administration of 93 mg/kg (LD50) of cocaine and GNC92H2 infusions ranging from 30 to 190 mg/kg.,16005948_4,0
4719,GNC92H2,141,148,Swiss albino mice prepared with intrajugular catheters were tested in photocell cages after administration of 93 mg/kg (LD50) of cocaine and GNC92H2 infusions ranging from 30 to 190 mg/kg.,16005948_4,0
4720,GNC92H2,0,7,"GNC92H2 was delivered 30 min before, concomitantly or 3 min after cocaine treatment.",16005948_5,0
4722,GNC92H2,78,85,"Significant blockade of cocaine toxicity was observed with the higher dose of GNC92H2 (190 mg/kg), where premorbid behaviors were reduced up to 40%, seizures up to 77% and death by 72%.",16005948_6,0
4723,premorbid behaviors,105,124,"Significant blockade of cocaine toxicity was observed with the higher dose of GNC92H2 (190 mg/kg), where premorbid behaviors were reduced up to 40%, seizures up to 77% and death by 72%.",16005948_6,1
4724,GNC92H2,13,20,"Importantly, GNC92H2 prevented death even post-cocaine injection.",16005948_7,0
4725,post-cocaine,42,54,"Importantly, GNC92H2 prevented death even post-cocaine injection.",16005948_7,1
4728,cocaine overdose,85,101,The results support the important potential of GNC92H2 as a therapeutic tool against cocaine overdose.,16005948_8,1
4726,GNC92H2,47,54,The results support the important potential of GNC92H2 as a therapeutic tool against cocaine overdose.,16005948_8,0
4727,therapeutic tool,60,76,The results support the important potential of GNC92H2 as a therapeutic tool against cocaine overdose.,16005948_8,0
5094,milk-alkali syndrome,40,60,Calcium carbonate toxicity: the updated milk-alkali syndrome; report of 3 cases and review of the literature.,16006300_0,1
1243,Calcium carbonate,0,17,Calcium carbonate toxicity: the updated milk-alkali syndrome; report of 3 cases and review of the literature.,16006300_0,0
5095,milk-alkali syndrome,134,154,OBJECTIVE: To describe 3 patients with calcium carbonate-induced hypercalcemia and gain insights into the cause and management of the milk-alkali syndrome.,16006300_1,1
4740,vitamin D,77,86,"Treatment with hydration, furosemide, and discontinuation of the calcium and vitamin D source is adequate.",16006300_10,0
1249,Pamidronate,0,11,"Pamidronate treatment is associated with considerable risk for hypocalcemia, even in cases of initially severe hypercalcemia.",16006300_11,0
5096,milk-alkali syndrome,187,207,METHODS: We report the clinical and laboratory data in 3 patients who presented with severe hypercalcemia (corrected serum calcium > or = 14 mg/dL) and review the pertinent literature on milk-alkali syndrome.,16006300_2,1
4733,"1,25-dihydroxyvitamin D",145,168,"RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.",16006300_3,0
1244,parathyroid hormone,93,112,"RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.",16006300_3,0
1245,PTH-related peptide,120,139,"RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.",16006300_3,0
4732,PTH,114,117,"RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.",16006300_3,0
5097,acute renal insufficiency,28,53,"RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations.",16006300_3,1
4734,malignant lesion,3,19,No malignant lesion was found.,16006300_4,1
1246,pamidronate,69,80,"The 2 patients with the higher serum calcium concentrations received pamidronate intravenously (60 and 30 mg, respectively), which caused severe hypocalcemia.",16006300_6,0
1247,calcium carbonate,123,140,"Of the 3 patients, 2 were ingesting acceptable doses of elemental calcium (1 g and 2 g daily, respectively) in the form of calcium carbonate.",16006300_7,0
4737,calcium (1,66,76,"Of the 3 patients, 2 were ingesting acceptable doses of elemental calcium (1 g and 2 g daily, respectively) in the form of calcium carbonate.",16006300_7,0
5098,milk-alkali syndrome,121,141,"In addition to our highlighted cases, we review the history, classification, pathophysiologic features, and treatment of milk-alkali syndrome and summarize the cases reported from early 1995 to November 2003.",16006300_8,1
4739,cause of,49,57,CONCLUSION: Milk-alkali syndrome may be a common cause of unexplained hypercalcemia and can be precipitated by small amounts of orally ingested calcium carbonate in susceptible persons.,16006300_9,1
5099,Milk-alkali syndrome,12,32,CONCLUSION: Milk-alkali syndrome may be a common cause of unexplained hypercalcemia and can be precipitated by small amounts of orally ingested calcium carbonate in susceptible persons.,16006300_9,1
1248,calcium carbonate,144,161,CONCLUSION: Milk-alkali syndrome may be a common cause of unexplained hypercalcemia and can be precipitated by small amounts of orally ingested calcium carbonate in susceptible persons.,16006300_9,0
4743,myocardial injury,33,50,Electrocardiographic evidence of myocardial injury in psychiatrically hospitalized cocaine abusers.,1601297_0,1
5101,bundle branch block,153,172,"Eleven of the cocaine abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction, ischemia, and bundle branch block.",1601297_2,1
5100,myocardial infarction,116,137,"Eleven of the cocaine abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction, ischemia, and bundle branch block.",1601297_2,1
4748,myocardial injury,87,104,"Eleven of the cocaine abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction, ischemia, and bundle branch block.",1601297_2,1
5102,leukocytoclastic vasculitis,17,44,Warfarin-induced leukocytoclastic vasculitis.,16047871_0,1
4752,oral coumarin-derived anticoagulants,31,67,Skin reactions associated with oral coumarin-derived anticoagulants are an uncommon occurrence.,16047871_1,0
4750,Skin reactions,0,14,Skin reactions associated with oral coumarin-derived anticoagulants are an uncommon occurrence.,16047871_1,1
4753,cutaneous small vessel vasculitis,48,81,"Leukocytoclastic vasculitis (LV) is primarily a cutaneous small vessel vasculitis, though systemic involvement may be encountered.",16047871_2,1
5103,Leukocytoclastic vasculitis,0,27,"Leukocytoclastic vasculitis (LV) is primarily a cutaneous small vessel vasculitis, though systemic involvement may be encountered.",16047871_2,1
5104,systemic involvement,90,110,"Leukocytoclastic vasculitis (LV) is primarily a cutaneous small vessel vasculitis, though systemic involvement may be encountered.",16047871_2,1
5105,late-onset,26,36,We report 4 patients with late-onset LV probably due to warfarin.,16047871_3,1
4754,skin eruptions,30,44,All 4 patients presented with skin eruptions that developed after receiving warfarin for several years.,16047871_4,1
4756,Cutaneous lesions,80,97,"The results of skin lesion biopsies were available in 3 patients, confirming LV Cutaneous lesions resolved in all patients after warfarin was discontinued.",16047871_5,1
4755,skin lesion,15,26,"The results of skin lesion biopsies were available in 3 patients, confirming LV Cutaneous lesions resolved in all patients after warfarin was discontinued.",16047871_5,1
4757,rechallenge,24,35,"In 2 of the 4 patients, rechallenge with warfarin led to recurrence of the lesions.",16047871_6,0
4758,late-onset adverse reaction,12,39,LV may be a late-onset adverse reaction associated with warfarin therapy.,16047871_7,1
4760,Cocaine-induced brainstem seizures,0,34,Cocaine-induced brainstem seizures and behavior.,1610717_0,1
4761,sensory/motor behaviors,22,45,A variety of abnormal sensory/motor behaviors associated with electrical discharges recorded from the bilateral brainstem were induced in adult WKY rats by mechanical (electrode implants) and DC electrical current stimulations and by acute and chronic administration of cocaine.,1610717_1,1
4763,electrical discharges,62,83,A variety of abnormal sensory/motor behaviors associated with electrical discharges recorded from the bilateral brainstem were induced in adult WKY rats by mechanical (electrode implants) and DC electrical current stimulations and by acute and chronic administration of cocaine.,1610717_1,1
4764,bilateral brainstem,102,121,A variety of abnormal sensory/motor behaviors associated with electrical discharges recorded from the bilateral brainstem were induced in adult WKY rats by mechanical (electrode implants) and DC electrical current stimulations and by acute and chronic administration of cocaine.,1610717_1,1
1251,serotonergic,64,76,Cognitive functions may also be involved since dopaminergic and serotonergic cellular elements at the brainstem level are also implicated.,1610717_10,0
1250,dopaminergic,47,59,Cognitive functions may also be involved since dopaminergic and serotonergic cellular elements at the brainstem level are also implicated.,1610717_10,0
4767,reticular system,62,78,The electrode implant implicated one side or the other of the reticular system of the brainstem but subjects were not incapacitated by the stimulations.,1610717_2,1
4773,retrocollis,37,48,"The abnormal behaviors were yawning, retrocollis, hyperactivity, hypersensitivity, ""beating drum"" behavior, squealing, head bobbing, circling, sniffing, abnormal posturing, and facial twitching.",1610717_5,1
4779,visual stimulation,51,69,"Hypersensitivity to various auditory, tactile, and visual stimulation was present and shifts in the brainstem ambient power spectral frequency occurred in response to tactile stimulation.",1610717_7,1
4781,pathological discharges,67,90,These findings suggest that the brainstem generates and propagates pathological discharges that can be elicited by mechanical and DC electrical perturbation.,1610717_8,1
4786,therapy-induced dyskinesias,43,70,rTMS of supplementary motor area modulates therapy-induced dyskinesias in Parkinson disease.,16116131_0,1
5107,Parkinson disease,74,91,rTMS of supplementary motor area modulates therapy-induced dyskinesias in Parkinson disease.,16116131_0,1
5106,supplementary motor,8,27,rTMS of supplementary motor area modulates therapy-induced dyskinesias in Parkinson disease.,16116131_0,1
5112,dyskinetic,252,262,"Using repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) in a group of patients with advanced Parkinson disease, the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous apomorphine infusion.",16116131_2,1
5111,SMA,201,204,"Using repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) in a group of patients with advanced Parkinson disease, the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous apomorphine infusion.",16116131_2,1
5110,Parkinson disease,135,152,"Using repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) in a group of patients with advanced Parkinson disease, the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous apomorphine infusion.",16116131_2,1
5109,SMA,93,96,"Using repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) in a group of patients with advanced Parkinson disease, the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous apomorphine infusion.",16116131_2,1
5108,supplementary motor,67,86,"Using repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) in a group of patients with advanced Parkinson disease, the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous apomorphine infusion.",16116131_2,1
5113,drug-induced dyskinesias,45,69,"rTMS at 1 Hz was observed to markedly reduce drug-induced dyskinesias, whereas 5-Hz rTMS induced a slight but not significant increase.",16116131_3,1
5114,brain tumors,16,28,Human malignant brain tumors have a poor prognosis in spite of surgery and radiation therapy.,16132524_1,1
4794,poor prognosis,36,50,Human malignant brain tumors have a poor prognosis in spite of surgery and radiation therapy.,16132524_1,1
1252,water channels,98,112,"Cubic phases consist of curved biocontinuous lipid bilayers, separating two congruent networks of water channels.",16132524_2,0
4797,cytotoxic drugs,19,34,"Used as a host for cytotoxic drugs, the gel-like matrix can easily be applied to the walls of a surgical resection cavity.",16132524_3,0
4799,surgical resection cavity,96,121,"Used as a host for cytotoxic drugs, the gel-like matrix can easily be applied to the walls of a surgical resection cavity.",16132524_3,1
1253,paclitaxel,127,137,"For human glioblastoma recurrences, the feasibility, safety, and short-term effects of a surgical intracavitary application of paclitaxel and carboplatin encapsulated by liquid crystalline cubic phases are examined in a pilot study.",16132524_4,0
1254,carboplatin,142,153,"For human glioblastoma recurrences, the feasibility, safety, and short-term effects of a surgical intracavitary application of paclitaxel and carboplatin encapsulated by liquid crystalline cubic phases are examined in a pilot study.",16132524_4,0
4800,glioblastoma recurrences,10,34,"For human glioblastoma recurrences, the feasibility, safety, and short-term effects of a surgical intracavitary application of paclitaxel and carboplatin encapsulated by liquid crystalline cubic phases are examined in a pilot study.",16132524_4,1
4804,glioblastoma multiforme,46,69,A total of 12 patients with a recurrence of a glioblastoma multiforme underwent re-resection and received an intracavitary application of paclitaxel and carboplatin cubic phases in different dosages.,16132524_5,1
4805,re-resection,80,92,A total of 12 patients with a recurrence of a glioblastoma multiforme underwent re-resection and received an intracavitary application of paclitaxel and carboplatin cubic phases in different dosages.,16132524_5,1
1255,paclitaxel,138,148,A total of 12 patients with a recurrence of a glioblastoma multiforme underwent re-resection and received an intracavitary application of paclitaxel and carboplatin cubic phases in different dosages.,16132524_5,0
1256,paclitaxel,45,55,"Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema, while the remaining patients received only a total of 15 mg paclitaxel.",16132524_6,0
1257,paclitaxel,166,176,"Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema, while the remaining patients received only a total of 15 mg paclitaxel.",16132524_6,0
5115,brain edema,93,104,"Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema, while the remaining patients received only a total of 15 mg paclitaxel.",16132524_6,1
5116,brain edema,21,32,"In the latter group, brain edema was markedly reduced and dealt medically.",16132524_7,1
4809,recurrent glioblastoma,30,52,"Intracavitary chemotherapy in recurrent glioblastoma using cubic phases is feasible and safe, yet the clinical benefit remains to be examined in a clinical phase II study.",16132524_8,1
5117,generalized epilepsies,76,98,Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies.,16157917_0,1
1258,Lamotrigine,0,11,Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies.,16157917_0,0
1259,novo,47,51,Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies.,16157917_0,0
5119,myoclonic jerks,140,155,Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).,16157917_1,1
5118,generalized epilepsies,30,52,Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).,16157917_1,1
1260,lamotrigine,72,83,Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).,16157917_1,0
1261,novo,121,125,Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).,16157917_1,0
4811,LTG,85,88,Five patients with idiopathic generalized epilepsies (IGE) treated with lamotrigine (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ).,16157917_1,0
4814,MJ,35,37,"In three patients, LTG exacerbated MJ in a dose-dependent manner with early aggravation during titration.",16157917_2,0
4813,LTG,19,22,"In three patients, LTG exacerbated MJ in a dose-dependent manner with early aggravation during titration.",16157917_2,0
4817,LTG,20,23,MJ disappeared when LTG dose was decreased by 25 to 50%.,16157917_3,0
5120,myoclonic,78,87,"In two patients, LTG exacerbated MJ in a delayed but more severe manner, with myoclonic status that only ceased after LTG withdrawal.",16157917_4,1
4818,LTG,17,20,"In two patients, LTG exacerbated MJ in a delayed but more severe manner, with myoclonic status that only ceased after LTG withdrawal.",16157917_4,0
4819,MJ,33,35,"In two patients, LTG exacerbated MJ in a delayed but more severe manner, with myoclonic status that only ceased after LTG withdrawal.",16157917_4,0
4820,LTG,118,121,"In two patients, LTG exacerbated MJ in a delayed but more severe manner, with myoclonic status that only ceased after LTG withdrawal.",16157917_4,0
4821,urotensin-II,22,34,Behavioral effects of urotensin-II centrally administered in mice.,16160878_0,0
4822,Urotensin-II,0,12,Urotensin-II (U-II) receptors are widely distributed in the central nervous system.,16160878_1,0
4823,U-II,14,18,Urotensin-II (U-II) receptors are widely distributed in the central nervous system.,16160878_1,0
5121,central nervous system,60,82,Urotensin-II (U-II) receptors are widely distributed in the central nervous system.,16160878_1,1
4860,U-II,24,28,These data suggest that U-II may be involved in some aspects of psychiatric disorders.,16160878_10,0
4861,psychiatric disorders,64,85,These data suggest that U-II may be involved in some aspects of psychiatric disorders.,16160878_10,1
4824,Intracerebroventricular,0,23,Intracerebroventricular (i.c.v.) injection of U-II causes hypertension and bradycardia and stimulates prolactin and thyrotropin secretion.,16160878_2,1
4826,U-II,46,50,Intracerebroventricular (i.c.v.) injection of U-II causes hypertension and bradycardia and stimulates prolactin and thyrotropin secretion.,16160878_2,0
4827,U-II,58,62,"However, the behavioral effects of centrally administered U-II have received little attention.",16160878_3,0
4829,U-II,14,18,"injections of U-II on behavioral, metabolic, and endocrine responses in mice.",16160878_5,0
1262,(1,69,71,"Administration of graded doses of U-II (1-10,000 ng/mouse) provoked: (1) a dose-dependent reduction in the number of head dips in the hole-board test; (2) a dose-dependent reduction in the number of entries in the white chamber in the black-and-white compartment test, and in the number of entries in the central platform and open arms in the plus-maze test; and (3) a dose-dependent increase in the duration of immobility in the forced-swimming test and tail suspension test.",16160878_6,0
1264,(3,363,365,"Administration of graded doses of U-II (1-10,000 ng/mouse) provoked: (1) a dose-dependent reduction in the number of head dips in the hole-board test; (2) a dose-dependent reduction in the number of entries in the white chamber in the black-and-white compartment test, and in the number of entries in the central platform and open arms in the plus-maze test; and (3) a dose-dependent increase in the duration of immobility in the forced-swimming test and tail suspension test.",16160878_6,0
4831,graded doses,18,30,"Administration of graded doses of U-II (1-10,000 ng/mouse) provoked: (1) a dose-dependent reduction in the number of head dips in the hole-board test; (2) a dose-dependent reduction in the number of entries in the white chamber in the black-and-white compartment test, and in the number of entries in the central platform and open arms in the plus-maze test; and (3) a dose-dependent increase in the duration of immobility in the forced-swimming test and tail suspension test.",16160878_6,0
4832,U-II (1,34,41,"Administration of graded doses of U-II (1-10,000 ng/mouse) provoked: (1) a dose-dependent reduction in the number of head dips in the hole-board test; (2) a dose-dependent reduction in the number of entries in the white chamber in the black-and-white compartment test, and in the number of entries in the central platform and open arms in the plus-maze test; and (3) a dose-dependent increase in the duration of immobility in the forced-swimming test and tail suspension test.",16160878_6,0
1263,(2,151,153,"Administration of graded doses of U-II (1-10,000 ng/mouse) provoked: (1) a dose-dependent reduction in the number of head dips in the hole-board test; (2) a dose-dependent reduction in the number of entries in the white chamber in the black-and-white compartment test, and in the number of entries in the central platform and open arms in the plus-maze test; and (3) a dose-dependent increase in the duration of immobility in the forced-swimming test and tail suspension test.",16160878_6,0
4846,water intake,118,130,"Intracerebroventricular injection of U-II also caused an increase in: food intake at doses of 100 and 1,000 ng/mouse, water intake at doses of 100-10,000 ng/mouse, and horizontal locomotion activity at a dose of 10,000 ng/mouse.",16160878_7,1
4843,U-II,37,41,"Intracerebroventricular injection of U-II also caused an increase in: food intake at doses of 100 and 1,000 ng/mouse, water intake at doses of 100-10,000 ng/mouse, and horizontal locomotion activity at a dose of 10,000 ng/mouse.",16160878_7,0
4844,food intake,70,81,"Intracerebroventricular injection of U-II also caused an increase in: food intake at doses of 100 and 1,000 ng/mouse, water intake at doses of 100-10,000 ng/mouse, and horizontal locomotion activity at a dose of 10,000 ng/mouse.",16160878_7,1
5122,body temperature,75,91,"Whatever was the dose, the central administration of U-II had no effect on body temperature, nociception, apomorphine-induced penile erection and climbing behavior, and stress-induced plasma corticosterone level.",16160878_8,1
4851,U-II,53,57,"Whatever was the dose, the central administration of U-II had no effect on body temperature, nociception, apomorphine-induced penile erection and climbing behavior, and stress-induced plasma corticosterone level.",16160878_8,0
4852,nociception,93,104,"Whatever was the dose, the central administration of U-II had no effect on body temperature, nociception, apomorphine-induced penile erection and climbing behavior, and stress-induced plasma corticosterone level.",16160878_8,1
4857,U-II,77,81,"Taken together, the present study demonstrates that the central injection of U-II at doses of 1-10,000 ng/mouse induces anxiogenic- and depressant-like effects in mouse.",16160878_9,0
1265,Group 1,3,10,In Group 1 the rats were trained under the influence of pentobarbital to run to the same shelf as in the normal state.,1616457_3,0
1266,Group 2,3,10,In Group 2 the rats were trained to approach different shelves in different drug states.,1616457_4,0
4865,memory dissociation,18,37,It was shown that memory dissociation occurred in both groups.,1616457_5,1
4866,Groups 1,87,95,Differences in the parameters of training under the influence of pentobarbital between Groups 1 and 2 were revealed.,1616457_6,0
1269,tissue-type plasminogen activator,180,213,"The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.BACKGROUND: Markers of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI), tissue-type plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) levels were studied for the evaluation of short-term effects of raloxifene administration in postmenopausal women.",16167916_0,0
4871,TAFI,173,177,"The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.BACKGROUND: Markers of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI), tissue-type plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) levels were studied for the evaluation of short-term effects of raloxifene administration in postmenopausal women.",16167916_0,0
1268,tPA,76,79,"The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.BACKGROUND: Markers of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI), tissue-type plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) levels were studied for the evaluation of short-term effects of raloxifene administration in postmenopausal women.",16167916_0,0
4870,fibrinolysis inhibitor,149,171,"The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.BACKGROUND: Markers of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI), tissue-type plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) levels were studied for the evaluation of short-term effects of raloxifene administration in postmenopausal women.",16167916_0,0
1273,raloxifene,331,341,"The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.BACKGROUND: Markers of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI), tissue-type plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) levels were studied for the evaluation of short-term effects of raloxifene administration in postmenopausal women.",16167916_0,0
1272,PAI-1,260,265,"The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.BACKGROUND: Markers of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI), tissue-type plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) levels were studied for the evaluation of short-term effects of raloxifene administration in postmenopausal women.",16167916_0,0
4869,TAFI,70,74,"The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.BACKGROUND: Markers of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI), tissue-type plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) levels were studied for the evaluation of short-term effects of raloxifene administration in postmenopausal women.",16167916_0,0
1270,tPA,215,218,"The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.BACKGROUND: Markers of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI), tissue-type plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) levels were studied for the evaluation of short-term effects of raloxifene administration in postmenopausal women.",16167916_0,0
1267,raloxifene,26,36,"The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.BACKGROUND: Markers of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI), tissue-type plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) levels were studied for the evaluation of short-term effects of raloxifene administration in postmenopausal women.",16167916_0,0
1271,plasminogen activator inhibitor-1,225,258,"The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.BACKGROUND: Markers of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI), tissue-type plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) levels were studied for the evaluation of short-term effects of raloxifene administration in postmenopausal women.",16167916_0,0
5123,osteopenia,47,57,"METHODS: Thirty-nine postmenopausal women with osteopenia or osteoporosis were included in this prospective, controlled clinical study.",16167916_1,1
1274,raloxifene hydrochloride,29,53,Twenty-five women were given raloxifene hydrochloride (60 mg/day) plus calcium (500 mg/day).,16167916_2,0
1275,tPA,13,16,"Plasma TAFI, tPA, and PAI-1 antigen levels were measured at baseline and after 3 months of treatment by commercially available ELISA kits.",16167916_4,0
4876,PAI-1 antigen,22,35,"Plasma TAFI, tPA, and PAI-1 antigen levels were measured at baseline and after 3 months of treatment by commercially available ELISA kits.",16167916_4,0
4875,TAFI,7,11,"Plasma TAFI, tPA, and PAI-1 antigen levels were measured at baseline and after 3 months of treatment by commercially available ELISA kits.",16167916_4,0
1277,tPA antigen,185,196,"RESULTS: Three months of raloxifene treatment was associated with a significant decrease in the plasma TAFI antigen concentrations (16% change, P < 0.01), and a significant increase in tPA antigen concentrations (25% change, P < 0.05).",16167916_7,0
4878,TAFI,103,107,"RESULTS: Three months of raloxifene treatment was associated with a significant decrease in the plasma TAFI antigen concentrations (16% change, P < 0.01), and a significant increase in tPA antigen concentrations (25% change, P < 0.05).",16167916_7,0
1276,raloxifene,25,35,"RESULTS: Three months of raloxifene treatment was associated with a significant decrease in the plasma TAFI antigen concentrations (16% change, P < 0.01), and a significant increase in tPA antigen concentrations (25% change, P < 0.05).",16167916_7,0
4880,duration of amenorrhea,89,111,A significant correlation was found between baseline TAFI antigen concentrations and the duration of amenorrhea (P < 0.05; r = 0.33).,16167916_8,1
4879,TAFI,53,57,A significant correlation was found between baseline TAFI antigen concentrations and the duration of amenorrhea (P < 0.05; r = 0.33).,16167916_8,0
5124,venous thromboembolism,50,72,"CONCLUSION: We suggest that the increased risk of venous thromboembolism due to raloxifene treatment may be related to increased tPA levels, but not TAFI levels.",16167916_9,1
1279,tPA,129,132,"CONCLUSION: We suggest that the increased risk of venous thromboembolism due to raloxifene treatment may be related to increased tPA levels, but not TAFI levels.",16167916_9,0
1278,raloxifene,80,90,"CONCLUSION: We suggest that the increased risk of venous thromboembolism due to raloxifene treatment may be related to increased tPA levels, but not TAFI levels.",16167916_9,0
4881,TAFI,149,153,"CONCLUSION: We suggest that the increased risk of venous thromboembolism due to raloxifene treatment may be related to increased tPA levels, but not TAFI levels.",16167916_9,0
5125,subarachnoid hemorrhage,68,91,Absence of acute cerebral vasoconstriction after cocaine-associated subarachnoid hemorrhage.,16174948_0,1
4882,acute cerebral vasoconstriction,11,42,Absence of acute cerebral vasoconstriction after cocaine-associated subarachnoid hemorrhage.,16174948_0,1
4886,arterial vasoconstriction,90,115,"INTRODUCTION: Cocaine use has been associated with neurovascular complications, including arterial vasoconstriction and vasculitis.",16174948_1,1
4885,neurovascular complications,51,78,"INTRODUCTION: Cocaine use has been associated with neurovascular complications, including arterial vasoconstriction and vasculitis.",16174948_1,1
4904,distal vasculature,66,84,Qualitative assessments showed two arterial irregularities in the distal vasculature in each group.,16174948_10,1
4903,arterial irregularities,35,58,Qualitative assessments showed two arterial irregularities in the distal vasculature in each group.,16174948_10,1
4907,distal narrowing,119,135,CONCLUSION: No quantitative evidence for narrowing of large cerebral arteries or qualitative angiographic evidence for distal narrowing or vasculitis could be found in patients who underwent angiography after aneurysmal SAH associated with cocaine use.,16174948_11,1
4905,cerebral arteries,60,77,CONCLUSION: No quantitative evidence for narrowing of large cerebral arteries or qualitative angiographic evidence for distal narrowing or vasculitis could be found in patients who underwent angiography after aneurysmal SAH associated with cocaine use.,16174948_11,1
4909,cocaine use,240,251,CONCLUSION: No quantitative evidence for narrowing of large cerebral arteries or qualitative angiographic evidence for distal narrowing or vasculitis could be found in patients who underwent angiography after aneurysmal SAH associated with cocaine use.,16174948_11,1
4887,cerebral arteries,75,92,"However, there are few studies of angiographic effects of cocaine on human cerebral arteries.",16174948_2,1
4888,cocaine use,169,180,Information on these effects could be obtained from angiograms of patients with cocaine-associated subarachnoid hemorrhage (SAH) who underwent angiography shortly after cocaine use.,16174948_3,1
5126,subarachnoid hemorrhage,99,122,Information on these effects could be obtained from angiograms of patients with cocaine-associated subarachnoid hemorrhage (SAH) who underwent angiography shortly after cocaine use.,16174948_3,1
4893,arterial diameter,187,204,Quantitative arterial diameter measurements from angiograms of these patients were compared to measurements from control patients with SAH who were matched for factors known to influence arterial diameter.,16174948_5,1
4894,small artery,27,39,Qualitative comparisons of small artery changes also were made.,16174948_6,1
5127,internal carotid,93,109,"There were no significant differences between groups in the mean diameters of the intradural internal carotid, sphenoidal segment of the middle cerebral, precommunicating segment of the anterior cerebral, or basilar arteries (p greater than 0.05 for all comparisons, unpaired t-tests).",16174948_8,1
4896,middle cerebral,137,152,"There were no significant differences between groups in the mean diameters of the intradural internal carotid, sphenoidal segment of the middle cerebral, precommunicating segment of the anterior cerebral, or basilar arteries (p greater than 0.05 for all comparisons, unpaired t-tests).",16174948_8,1
4897,anterior cerebral,186,203,"There were no significant differences between groups in the mean diameters of the intradural internal carotid, sphenoidal segment of the middle cerebral, precommunicating segment of the anterior cerebral, or basilar arteries (p greater than 0.05 for all comparisons, unpaired t-tests).",16174948_8,1
4898,basilar arteries,208,224,"There were no significant differences between groups in the mean diameters of the intradural internal carotid, sphenoidal segment of the middle cerebral, precommunicating segment of the anterior cerebral, or basilar arteries (p greater than 0.05 for all comparisons, unpaired t-tests).",16174948_8,1
5128,sphenoidal,111,121,"There were no significant differences between groups in the mean diameters of the intradural internal carotid, sphenoidal segment of the middle cerebral, precommunicating segment of the anterior cerebral, or basilar arteries (p greater than 0.05 for all comparisons, unpaired t-tests).",16174948_8,1
4901,middle cerebral,180,195,"There also were no significant differences between groups when expressing diameters as the sum of the precommunicating segment of the anterior cerebral + sphenoidal segment of the middle cerebral + supraclinoid internal carotid artery + basilar artery divided by the diameter of the petrous internal carotid artery (p greater than 0.05, unpaired t-tests).",16174948_9,1
5132,internal carotid artery,291,314,"There also were no significant differences between groups when expressing diameters as the sum of the precommunicating segment of the anterior cerebral + sphenoidal segment of the middle cerebral + supraclinoid internal carotid artery + basilar artery divided by the diameter of the petrous internal carotid artery (p greater than 0.05, unpaired t-tests).",16174948_9,1
5131,basilar artery,237,251,"There also were no significant differences between groups when expressing diameters as the sum of the precommunicating segment of the anterior cerebral + sphenoidal segment of the middle cerebral + supraclinoid internal carotid artery + basilar artery divided by the diameter of the petrous internal carotid artery (p greater than 0.05, unpaired t-tests).",16174948_9,1
5130,internal carotid artery,211,234,"There also were no significant differences between groups when expressing diameters as the sum of the precommunicating segment of the anterior cerebral + sphenoidal segment of the middle cerebral + supraclinoid internal carotid artery + basilar artery divided by the diameter of the petrous internal carotid artery (p greater than 0.05, unpaired t-tests).",16174948_9,1
5129,sphenoidal,154,164,"There also were no significant differences between groups when expressing diameters as the sum of the precommunicating segment of the anterior cerebral + sphenoidal segment of the middle cerebral + supraclinoid internal carotid artery + basilar artery divided by the diameter of the petrous internal carotid artery (p greater than 0.05, unpaired t-tests).",16174948_9,1
4900,anterior cerebral,134,151,"There also were no significant differences between groups when expressing diameters as the sum of the precommunicating segment of the anterior cerebral + sphenoidal segment of the middle cerebral + supraclinoid internal carotid artery + basilar artery divided by the diameter of the petrous internal carotid artery (p greater than 0.05, unpaired t-tests).",16174948_9,1
5133,with hyperammonemia,45,64,It is usually but not necessarily associated with hyperammonemia.,16181582_3,1
4916,psychiatric disorders,73,94,"Aggressive behaviors have been reported in patients who suffer from some psychiatric disorders, and are common in methamphetamine (METH) abusers.",16192988_1,1
4915,Aggressive behaviors,0,20,"Aggressive behaviors have been reported in patients who suffer from some psychiatric disorders, and are common in methamphetamine (METH) abusers.",16192988_1,1
1280,CD-1,115,119,"Herein, we report that multiple (but not single) injections of METH significantly increased aggressiveness in male CD-1 mice.",16192988_2,0
4920,Western blotting,62,78,Analysis of protein expression using antibody microarrays and Western blotting revealed differential changes in MAP kinase-related pathways after multiple and single METH injections.,16192988_4,0
4924,GSK3alpha,72,81,"There were statistically significant (p<0.05) decreases in MEK1, Erk2p, GSK3alpha, 14-3-3e, and MEK7 in the striata of mice after multiple injections of METH.",16192988_5,0
4923,Erk2p,65,70,"There were statistically significant (p<0.05) decreases in MEK1, Erk2p, GSK3alpha, 14-3-3e, and MEK7 in the striata of mice after multiple injections of METH.",16192988_5,0
4922,MEK1,59,63,"There were statistically significant (p<0.05) decreases in MEK1, Erk2p, GSK3alpha, 14-3-3e, and MEK7 in the striata of mice after multiple injections of METH.",16192988_5,0
4925,striata,108,115,"There were statistically significant (p<0.05) decreases in MEK1, Erk2p, GSK3alpha, 14-3-3e, and MEK7 in the striata of mice after multiple injections of METH.",16192988_5,1
1281,MEK7,96,100,"There were statistically significant (p<0.05) decreases in MEK1, Erk2p, GSK3alpha, 14-3-3e, and MEK7 in the striata of mice after multiple injections of METH.",16192988_5,0
4926,MEK1,0,4,"MEK1 was significantly decreased also after a single injection of METH, but to a much lesser degree than after multiple injections of METH.",16192988_6,0
4927,frontal cortex,7,21,"In the frontal cortex, there was a statistically significant decrease in GSK3alpha after multiple (but not single) injections of METH.",16192988_7,1
4929,GSK3alpha,73,82,"In the frontal cortex, there was a statistically significant decrease in GSK3alpha after multiple (but not single) injections of METH.",16192988_7,0
1282,Amisulpride,0,11,Amisulpride related tic-like symptoms in an adolescent schizophrenic.,16225977_0,0
1283,olanzapine,89,99,"Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ziprasidone.",16225977_1,0
4932,risperidone,76,87,"Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ziprasidone.",16225977_1,0
4933,ziprasidone,104,115,"Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ziprasidone.",16225977_1,0
5134,Tic disorders,0,13,"Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ziprasidone.",16225977_1,1
4935,tic-like symptoms,46,63,"However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or clozapine.",16225977_2,1
1284,quetiapine,134,144,"However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or clozapine.",16225977_2,0
4936,eye-blinking,79,91,We present a 15-year-old girl schizophrenic who developed frequent involuntary eye-blinking movements after 5 months of amisulpride treatment (1000 mg per day).,16225977_3,1
1285,amisulpride,120,131,We present a 15-year-old girl schizophrenic who developed frequent involuntary eye-blinking movements after 5 months of amisulpride treatment (1000 mg per day).,16225977_3,0
1286,amisulpride,71,82,The tic-like symptoms resolved completely after we reduced the dose of amisulpride down to 800 mg per day.,16225977_4,0
1287,her,9,12,"However, her psychosis recurred after the dose reduction.",16225977_5,0
1289,quetiapine,54,64,We then placed her on an additional 100 mg per day of quetiapine.,16225977_6,0
1288,her,15,18,We then placed her on an additional 100 mg per day of quetiapine.,16225977_6,0
4938,complete remission,16,34,She has been in complete remission under the combined medications for more than one year and maintains a fair role function.,16225977_7,1
4939,combined medications,45,65,She has been in complete remission under the combined medications for more than one year and maintains a fair role function.,16225977_7,0
5135,side effects,35,47,No more tic-like symptoms or other side effects have been reported.,16225977_8,1
1291,amisulpride,211,222,"Together with previously reported cases, our patient suggests that tic-like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine, clozapine, or amisulpride.",16225977_9,0
1290,quetiapine,185,195,"Together with previously reported cases, our patient suggests that tic-like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine, clozapine, or amisulpride.",16225977_9,0
4941,tic-like symptoms,67,84,"Together with previously reported cases, our patient suggests that tic-like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine, clozapine, or amisulpride.",16225977_9,1
1292,acitretin,24,33,Recurrent dysphonia and acitretin.,16274958_0,0
1293,acitretin,80,89,We report the case of a woman complaining of dysphonia while she was treated by acitretin.,16274958_1,0
5136,drug withdrawal,37,52,Her symptoms totally regressed after drug withdrawal and reappeared when acitretin was reintroduced.,16274958_2,1
1295,acitretin,73,82,Her symptoms totally regressed after drug withdrawal and reappeared when acitretin was reintroduced.,16274958_2,0
1294,Her,0,3,Her symptoms totally regressed after drug withdrawal and reappeared when acitretin was reintroduced.,16274958_2,0
5137,heart block,29,40,Chloroquine related complete heart block with blindness: case report.,1628552_0,1
4945,fatiguability,131,144,"A 27-year old African woman with history of regular chloroquine ingestion presented with progressive deterioration of vision, easy fatiguability, dyspnoea, dizziness progressing to syncopal attacks.",1628552_1,1
5138,syncopal,181,189,"A 27-year old African woman with history of regular chloroquine ingestion presented with progressive deterioration of vision, easy fatiguability, dyspnoea, dizziness progressing to syncopal attacks.",1628552_1,1
5141,right bundle branch block,160,185,"Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.",1628552_2,1
5139,heart failure,114,127,"Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.",1628552_2,1
5140,heart block,143,154,"Ophthalmological assessment revealed features of chloroquine retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern.",1628552_2,1
5142,heart block,4,15,The heart block was treated by pacemaker insertion and the heart failure resolved spontaneously following chloroquine discontinuation.,1628552_3,1
5143,heart failure,59,72,The heart block was treated by pacemaker insertion and the heart failure resolved spontaneously following chloroquine discontinuation.,1628552_3,1
1296,methyl ester,17,29,Nitro-L-arginine methyl ester: a potential protector against gentamicin ototoxicity.,16298782_0,0
5144,ototoxicity,72,83,Nitro-L-arginine methyl ester: a potential protector against gentamicin ototoxicity.,16298782_0,1
1297,nitric oxide,4,16,"The nitric oxide (NO) inhibitor nitro-L-arginine methyl ester (L-NAME) may act as an otoprotectant against high-frequency hearing loss caused by gentamicin, but further studies are needed to confirm this.",16298782_1,0
1299,L-NAME,63,69,"The nitric oxide (NO) inhibitor nitro-L-arginine methyl ester (L-NAME) may act as an otoprotectant against high-frequency hearing loss caused by gentamicin, but further studies are needed to confirm this.",16298782_1,0
1298,methyl ester,49,61,"The nitric oxide (NO) inhibitor nitro-L-arginine methyl ester (L-NAME) may act as an otoprotectant against high-frequency hearing loss caused by gentamicin, but further studies are needed to confirm this.",16298782_1,0
5145,high-frequency hearing loss,107,134,"The nitric oxide (NO) inhibitor nitro-L-arginine methyl ester (L-NAME) may act as an otoprotectant against high-frequency hearing loss caused by gentamicin, but further studies are needed to confirm this.",16298782_1,1
4948,otoprotectant,85,98,"The nitric oxide (NO) inhibitor nitro-L-arginine methyl ester (L-NAME) may act as an otoprotectant against high-frequency hearing loss caused by gentamicin, but further studies are needed to confirm this.",16298782_1,0
4949,Aminoglycoside antibiotics,0,26,Aminoglycoside antibiotics are still widely used by virtue of their efficacy and low cost.,16298782_2,0
5146,ototoxicity,6,17,"Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss.",16298782_3,1
5147,health problem,31,45,"Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss.",16298782_3,1
5148,sensorineural hearing loss,198,224,"Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss.",16298782_3,1
4950,NO inhibitors,139,152,"Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss.",16298782_3,0
5149,middle ear,105,115,"In this experimental study we used 30 Sprague-Dawley rats, 27 of which had gentamicin instilled into the middle ear.",16298782_4,1
4952,otoprotectant L-NAME,4,24,The otoprotectant L-NAME was administered topically to 12/27 animals.,16298782_5,0
5150,hearing loss,53,65,"Its effect was determined in terms of attenuation of hearing loss, measured by shifts in the auditory brainstem response threshold.",16298782_6,1
5151,hearing loss,34,46,"L-NAME reduced gentamicin-induced hearing loss in the high-frequency range, but gave no protection in the middle or low frequencies.",16298782_7,1
1300,L-NAME,0,6,"L-NAME reduced gentamicin-induced hearing loss in the high-frequency range, but gave no protection in the middle or low frequencies.",16298782_7,0
4954,high-frequency range,54,74,"L-NAME reduced gentamicin-induced hearing loss in the high-frequency range, but gave no protection in the middle or low frequencies.",16298782_7,1
4958,polacrilex gum,117,131,BACKGROUND: Nicotine polacrilex lozenges deliver 25% to 27% more nicotine compared with equivalent doses of nicotine polacrilex gum.,16330293_1,0
4957,polacrilex,21,31,BACKGROUND: Nicotine polacrilex lozenges deliver 25% to 27% more nicotine compared with equivalent doses of nicotine polacrilex gum.,16330293_1,0
4966,product use,88,99,"The incidence of adverse events in the 2 groups was similar during the first 2 weeks of product use (evaluation population: 55.3% lozenge, 54.7% gum), as well as during the entire study (safety population: 63.8% and 58.6%, respectively).",16330293_12,0
4965,adverse events,17,31,"The incidence of adverse events in the 2 groups was similar during the first 2 weeks of product use (evaluation population: 55.3% lozenge, 54.7% gum), as well as during the entire study (safety population: 63.8% and 58.6%, respectively).",16330293_12,1
4968,adverse events,109,123,"Stratification of patients by sex, age, extent of concurrent smoking, extent of product use, and severity of adverse events revealed no clinically significant differences between the lozenge and gum.",16330293_13,1
4970,adverse events,16,30,"The most common adverse events were nausea (17.2% and 16.1%; 95% CI, -3.7 to 6.0), hiccups (10.7% and 6.6%; 95% CI, 0.5 to 7.8), and headache (8.7% and 9.9%; 95% Cl, -5.0 to 2.6).",16330293_14,1
4971,Serious adverse events,0,22,Serious adverse events were reported in 11 and 13 patients in the respective groups.,16330293_15,1
4972,disease condition,115,132,Fewer than 6% of patients in either group were considered by the investigator to have a worsening of their overall disease condition during the study.,16330293_16,1
5152,heart disease,84,97,"METHODS: This was a multicenter, randomized, open-label study in adult smokers with heart disease, hypertension not controlled by medication, and/or diabetes mellitus.",16330293_4,1
5153,diabetes mellitus,149,166,"METHODS: This was a multicenter, randomized, open-label study in adult smokers with heart disease, hypertension not controlled by medication, and/or diabetes mellitus.",16330293_4,1
4977,central sensitization,76,97,Pharmacological modulation of pain-related brain activity during normal and central sensitization states in humans.,16330766_0,1
4978,central sensitization,75,96,Abnormal processing of somatosensory inputs in the central nervous system (central sensitization) is the mechanism accounting for the enhanced pain sensitivity in the skin surrounding tissue injury (secondary hyperalgesia).,16330766_1,1
4979,pain sensitivity,143,159,Abnormal processing of somatosensory inputs in the central nervous system (central sensitization) is the mechanism accounting for the enhanced pain sensitivity in the skin surrounding tissue injury (secondary hyperalgesia).,16330766_1,1
4980,skin surrounding,167,183,Abnormal processing of somatosensory inputs in the central nervous system (central sensitization) is the mechanism accounting for the enhanced pain sensitivity in the skin surrounding tissue injury (secondary hyperalgesia).,16330766_1,1
4981,tissue injury,184,197,Abnormal processing of somatosensory inputs in the central nervous system (central sensitization) is the mechanism accounting for the enhanced pain sensitivity in the skin surrounding tissue injury (secondary hyperalgesia).,16330766_1,1
5154,central nervous system,51,73,Abnormal processing of somatosensory inputs in the central nervous system (central sensitization) is the mechanism accounting for the enhanced pain sensitivity in the skin surrounding tissue injury (secondary hyperalgesia).,16330766_1,1
5155,hyperalgesia,209,221,Abnormal processing of somatosensory inputs in the central nervous system (central sensitization) is the mechanism accounting for the enhanced pain sensitivity in the skin surrounding tissue injury (secondary hyperalgesia).,16330766_1,1
5158,neuropathic pain,101,117,Secondary hyperalgesia shares clinical characteristics with neurogenic hyperalgesia in patients with neuropathic pain.,16330766_2,1
5157,hyperalgesia,71,83,Secondary hyperalgesia shares clinical characteristics with neurogenic hyperalgesia in patients with neuropathic pain.,16330766_2,1
5156,hyperalgesia,10,22,Secondary hyperalgesia shares clinical characteristics with neurogenic hyperalgesia in patients with neuropathic pain.,16330766_2,1
4986,central sensitization,146,167,Abnormal brain responses to somatosensory stimuli have been found in patients with hyperalgesia as well as in normal subjects during experimental central sensitization.,16330766_3,1
5159,hyperalgesia,83,95,Abnormal brain responses to somatosensory stimuli have been found in patients with hyperalgesia as well as in normal subjects during experimental central sensitization.,16330766_3,1
5160,neuropathic pain,83,99,"The aim of this study was to assess the effects of gabapentin, a drug effective in neuropathic pain patients, on brain processing of nociceptive information in normal and central sensitization states.",16330766_4,1
4988,drug effective,65,79,"The aim of this study was to assess the effects of gabapentin, a drug effective in neuropathic pain patients, on brain processing of nociceptive information in normal and central sensitization states.",16330766_4,0
4990,central sensitization,171,192,"The aim of this study was to assess the effects of gabapentin, a drug effective in neuropathic pain patients, on brain processing of nociceptive information in normal and central sensitization states.",16330766_4,1
5161,hyperalgesia,233,245,"Using functional magnetic resonance imaging (fMRI) in normal volunteers, we studied the gabapentin-induced modulation of brain activity in response to nociceptive mechanical stimulation of normal skin and capsaicin-induced secondary hyperalgesia.",16330766_5,1
4994,mechanical stimulation,163,185,"Using functional magnetic resonance imaging (fMRI) in normal volunteers, we studied the gabapentin-induced modulation of brain activity in response to nociceptive mechanical stimulation of normal skin and capsaicin-induced secondary hyperalgesia.",16330766_5,1
4998,central sensitization,219,240,"We found that (i) gabapentin reduced the activations in the bilateral operculoinsular cortex, independently of the presence of central sensitization; (ii) gabapentin reduced the activation in the brainstem, only during central sensitization; (iii) gabapentin suppressed stimulus-induced deactivations, only during central sensitization; this effect was more robust than the effect on brain activation.",16330766_7,1
4996,bilateral operculoinsular cortex,60,92,"We found that (i) gabapentin reduced the activations in the bilateral operculoinsular cortex, independently of the presence of central sensitization; (ii) gabapentin reduced the activation in the brainstem, only during central sensitization; (iii) gabapentin suppressed stimulus-induced deactivations, only during central sensitization; this effect was more robust than the effect on brain activation.",16330766_7,1
4997,central sensitization,127,148,"We found that (i) gabapentin reduced the activations in the bilateral operculoinsular cortex, independently of the presence of central sensitization; (ii) gabapentin reduced the activation in the brainstem, only during central sensitization; (iii) gabapentin suppressed stimulus-induced deactivations, only during central sensitization; this effect was more robust than the effect on brain activation.",16330766_7,1
5000,central sensitization,314,335,"We found that (i) gabapentin reduced the activations in the bilateral operculoinsular cortex, independently of the presence of central sensitization; (ii) gabapentin reduced the activation in the brainstem, only during central sensitization; (iii) gabapentin suppressed stimulus-induced deactivations, only during central sensitization; this effect was more robust than the effect on brain activation.",16330766_7,1
5162,drug-induced,13,25,The observed drug-induced effects were not due to changes in the baseline fMRI signal.,16330766_8,1
5005,central sensitization,282,303,"These findings indicate that gabapentin has a measurable antinociceptive effect and a stronger antihyperalgesic effect most evident in the brain areas undergoing deactivation, thus supporting the concept that gabapentin is more effective in modulating nociceptive transmission when central sensitization is present.",16330766_9,1
1301,antinociceptive,57,72,"These findings indicate that gabapentin has a measurable antinociceptive effect and a stronger antihyperalgesic effect most evident in the brain areas undergoing deactivation, thus supporting the concept that gabapentin is more effective in modulating nociceptive transmission when central sensitization is present.",16330766_9,0
5006,mitochondrial,17,30,Investigation of mitochondrial involvement in the experimental model of epilepsy induced by pilocarpine.,16337777_0,0
5009,epileptogenesis,73,88,"Mitochondrial abnormalities have been associated with several aspects of epileptogenesis, such as energy generation, control of cell death, neurotransmitter synthesis, and free radical (FR) production.",16337777_1,1
1302,free radical,172,184,"Mitochondrial abnormalities have been associated with several aspects of epileptogenesis, such as energy generation, control of cell death, neurotransmitter synthesis, and free radical (FR) production.",16337777_1,0
5163,cell death,128,138,"Mitochondrial abnormalities have been associated with several aspects of epileptogenesis, such as energy generation, control of cell death, neurotransmitter synthesis, and free radical (FR) production.",16337777_1,1
5164,oxidative phosphorylation,86,111,Increased production of FRs may cause mtDNA damage leading to decreased activities of oxidative phosphorylation complexes containing mtDNA-encoded subunits.,16337777_2,1
5011,mtDNA-encoded subunits,133,155,Increased production of FRs may cause mtDNA damage leading to decreased activities of oxidative phosphorylation complexes containing mtDNA-encoded subunits.,16337777_2,0
1303,mtDNA,38,43,Increased production of FRs may cause mtDNA damage leading to decreased activities of oxidative phosphorylation complexes containing mtDNA-encoded subunits.,16337777_2,0
5013,CCO,206,209,"In this study, we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase (CCO), complex IV of the respiratory chain, in the chronic phase of the pilocarpine model of temporal lobe epilepsy.",16337777_3,0
5012,cytochrome c oxidase,184,204,"In this study, we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase (CCO), complex IV of the respiratory chain, in the chronic phase of the pilocarpine model of temporal lobe epilepsy.",16337777_3,0
5168,chronic phase,256,269,"In this study, we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase (CCO), complex IV of the respiratory chain, in the chronic phase of the pilocarpine model of temporal lobe epilepsy.",16337777_3,1
5165,status epilepticus,73,91,"In this study, we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase (CCO), complex IV of the respiratory chain, in the chronic phase of the pilocarpine model of temporal lobe epilepsy.",16337777_3,1
1304,mtDNA,140,145,"In this study, we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase (CCO), complex IV of the respiratory chain, in the chronic phase of the pilocarpine model of temporal lobe epilepsy.",16337777_3,0
5169,temporal lobe epilepsy,298,320,"In this study, we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase (CCO), complex IV of the respiratory chain, in the chronic phase of the pilocarpine model of temporal lobe epilepsy.",16337777_3,1
5167,respiratory chain,230,247,"In this study, we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase (CCO), complex IV of the respiratory chain, in the chronic phase of the pilocarpine model of temporal lobe epilepsy.",16337777_3,1
5166,complex IV,212,222,"In this study, we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase (CCO), complex IV of the respiratory chain, in the chronic phase of the pilocarpine model of temporal lobe epilepsy.",16337777_3,1
1305,mtDNA,46,51,DNA analysis revealed low amounts of a 4.8 kb mtDNA deletion but with no differences in frequency or quantity in the control and experimental groups.,16337777_4,0
5016,mtDNA-encoded subunit of CCO,71,99,We did not find abnormalities in the expression and distribution of an mtDNA-encoded subunit of CCO (CCO-I) or a relative decrease in CCO-I when compared with nuclear-encoded subunits (CCO-IV and SDH-fp).,16337777_5,0
5018,CCO-I,134,139,We did not find abnormalities in the expression and distribution of an mtDNA-encoded subunit of CCO (CCO-I) or a relative decrease in CCO-I when compared with nuclear-encoded subunits (CCO-IV and SDH-fp).,16337777_5,0
5017,CCO-I,101,106,We did not find abnormalities in the expression and distribution of an mtDNA-encoded subunit of CCO (CCO-I) or a relative decrease in CCO-I when compared with nuclear-encoded subunits (CCO-IV and SDH-fp).,16337777_5,0
5020,CCO-IV,185,191,We did not find abnormalities in the expression and distribution of an mtDNA-encoded subunit of CCO (CCO-I) or a relative decrease in CCO-I when compared with nuclear-encoded subunits (CCO-IV and SDH-fp).,16337777_5,0
5021,SDH-fp,196,202,We did not find abnormalities in the expression and distribution of an mtDNA-encoded subunit of CCO (CCO-I) or a relative decrease in CCO-I when compared with nuclear-encoded subunits (CCO-IV and SDH-fp).,16337777_5,0
5019,nuclear-encoded subunits,159,183,We did not find abnormalities in the expression and distribution of an mtDNA-encoded subunit of CCO (CCO-I) or a relative decrease in CCO-I when compared with nuclear-encoded subunits (CCO-IV and SDH-fp).,16337777_5,0
5022,No abnormality,0,14,No abnormality in CCO activity was observed through histochemistry.,16337777_6,1
5023,CCO,18,21,No abnormality in CCO activity was observed through histochemistry.,16337777_6,0
5027,CCO-I,231,236,"Although evidences of mitochondrial abnormalities were found in previously published studies, our results do not suggest that the FRs, generated during the acute phase, determined important abnormalities in mtDNA, in expression of CCO-I, and in CCO activity.",16337777_7,0
5028,CCO,245,248,"Although evidences of mitochondrial abnormalities were found in previously published studies, our results do not suggest that the FRs, generated during the acute phase, determined important abnormalities in mtDNA, in expression of CCO-I, and in CCO activity.",16337777_7,0
1306,mtDNA,207,212,"Although evidences of mitochondrial abnormalities were found in previously published studies, our results do not suggest that the FRs, generated during the acute phase, determined important abnormalities in mtDNA, in expression of CCO-I, and in CCO activity.",16337777_7,0
5025,mitochondrial,22,35,"Although evidences of mitochondrial abnormalities were found in previously published studies, our results do not suggest that the FRs, generated during the acute phase, determined important abnormalities in mtDNA, in expression of CCO-I, and in CCO activity.",16337777_7,0
5026,acute phase,156,167,"Although evidences of mitochondrial abnormalities were found in previously published studies, our results do not suggest that the FRs, generated during the acute phase, determined important abnormalities in mtDNA, in expression of CCO-I, and in CCO activity.",16337777_7,1
5030,suprofen,11,19,Effects of suprofen on the isolated perfused rat kidney.,1636026_0,0
5170,acute renal failure,62,81,"Although suprofen has been associated with the development of acute renal failure in greater than 100 subjects, the mechanism of damage remains unclear.",1636026_1,1
5031,suprofen,9,17,"Although suprofen has been associated with the development of acute renal failure in greater than 100 subjects, the mechanism of damage remains unclear.",1636026_1,0
1307,uric acid,198,207,The direct nephrotoxic effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell-free buffer with or without the addition of 5 mg/dL of uric acid.,1636026_2,0
5033,single dose,36,47,The direct nephrotoxic effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell-free buffer with or without the addition of 5 mg/dL of uric acid.,1636026_2,0
5034,suprofen,60,68,The direct nephrotoxic effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell-free buffer with or without the addition of 5 mg/dL of uric acid.,1636026_2,0
5035,cell-free buffer,138,154,The direct nephrotoxic effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell-free buffer with or without the addition of 5 mg/dL of uric acid.,1636026_2,0
5039,suprofen,132,140,"There were no significant differences in renal sodium excretion, oxygen consumption, or urinary flow rates in kidneys perfused with suprofen compared with the drug-free control groups.",1636026_3,0
1308,uric acid,138,147,"In contrast, a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid; no changes were found with suprofen in the absence of uric acid.",1636026_4,0
1309,uric acid,203,212,"In contrast, a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid; no changes were found with suprofen in the absence of uric acid.",1636026_4,0
5041,suprofen,101,109,"In contrast, a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid; no changes were found with suprofen in the absence of uric acid.",1636026_4,0
5042,suprofen,176,184,"In contrast, a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid; no changes were found with suprofen in the absence of uric acid.",1636026_4,0
5043,suprofen,91,99,"A significant decrease in the baseline excretion rate of uric acid was found in rats given suprofen, compared with drug-free controls.",1636026_5,0
1310,uric acid,57,66,"A significant decrease in the baseline excretion rate of uric acid was found in rats given suprofen, compared with drug-free controls.",1636026_5,0
1311,uric acid,37,46,"However, the fractional excretion of uric acid was unchanged between the groups over the experimental period.",1636026_6,0
5045,suprofen,12,20,"In summary, suprofen causes acute declines in renal function, most likely by directly altering the intrarenal distribution of uric acid.",1636026_7,0
5047,renal function,46,60,"In summary, suprofen causes acute declines in renal function, most likely by directly altering the intrarenal distribution of uric acid.",1636026_7,1
1312,uric acid,126,135,"In summary, suprofen causes acute declines in renal function, most likely by directly altering the intrarenal distribution of uric acid.",1636026_7,0
5171,CA1,38,41,Microinjection of ritanserin into the CA1 region of hippocampus improves scopolamine-induced amnesia in adult male rats.,16364460_0,1
1313,ritanserin,18,28,Microinjection of ritanserin into the CA1 region of hippocampus improves scopolamine-induced amnesia in adult male rats.,16364460_0,0
1315,muscarinic cholinergic,60,82,The effect of ritanserin (5-HT2 antagonist) on scopolamine (muscarinic cholinergic antagonist)-induced amnesia in Morris water maze (MWM) was investigated.,16364460_1,0
5051,5-HT2 antagonist,26,42,The effect of ritanserin (5-HT2 antagonist) on scopolamine (muscarinic cholinergic antagonist)-induced amnesia in Morris water maze (MWM) was investigated.,16364460_1,0
1314,ritanserin,14,24,The effect of ritanserin (5-HT2 antagonist) on scopolamine (muscarinic cholinergic antagonist)-induced amnesia in Morris water maze (MWM) was investigated.,16364460_1,0
5172,CA1,68,71,Rats were divided into eight groups and bilaterally cannulated into CA1 region of the hippocampus.,16364460_2,1
5055,saline+DMSO,65,76,"One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.",16364460_3,0
1316,DMSO,59,63,"One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.",16364460_3,0
5058,ritanserin (2,150,163,"One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.",16364460_3,0
5060,scopolamine (2,230,244,"One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.",16364460_3,0
5056,scopolamine (2,79,93,"One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.",16364460_3,0
1317,DMSO,332,336,"One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.",16364460_3,0
5062,before ritanserin injection)+ritanserin,271,310,"One week later, they received repeatedly vehicles (saline, DMSO, saline+DMSO), scopolamine (2 microg/0.5 microl saline/side; 30 min before training), ritanserin (2, 4 and 8 microg/0.5 microl DMSO/side; 20 min before training) and scopolamine (2 microg/0.5 microl; 30 min before ritanserin injection)+ritanserin (4 microg/0.5 microl DMSO) through cannulae each day.",16364460_3,0
5069,saline group,146,158,The results showed a significant increase in escape latencies and traveled distances to find platform in scopolamine-treated group as compared to saline group.,16364460_6,0
1318,ritanserin,25,35,"However, scopolamine and ritanserin co-administration resulted in a significant decrease in escape latencies and traveled distances as compared to the scopolamine-treated rats.",16364460_8,0
1319,ritanserin,41,51,Our findings show that microinjection of ritanserin into the CA1 region of the hippocampus improves the scopolamine-induced amnesia.,16364460_9,0
5173,CA1,61,64,Our findings show that microinjection of ritanserin into the CA1 region of the hippocampus improves the scopolamine-induced amnesia.,16364460_9,1
5174,renovascular hypertension,91,116,Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension.,1639466_0,1
5074,Adverse effect,0,14,Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension.,1639466_0,1
5075,calcium channel blocker nitrendipine,22,58,Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension.,1639466_0,0
5176,renovascular hypertension,274,299,"The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension.",1639466_1,1
5175,blood pressure,139,153,"The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension.",1639466_1,1
5076,calcium channel blocker nitrendipine,42,78,"The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension.",1639466_1,0
1320,angiotensin converting enzyme inhibitor,86,125,"The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension.",1639466_1,0
5180,glomerulosclerosis,13,31,"Furthermore, glomerulosclerosis index was significantly increased in the nitrendipine-treated group compared with the hypertensive controls (0.38 +/- 0.1 versus 0.13 +/- 0.04).",1639466_10,1
5177,renal artery,32,44,"Six weeks after clipping of one renal artery, hypertensive rats (178 +/- 4 mm Hg) were randomly assigned to three groups: untreated hypertensive controls (n = 8), enalapril-treated (n = 8), or nitrendipine-treated (n = 10).",1639466_2,1
5091,nitrendipine,18,30,Enalapril but not nitrendipine reduced blood pressure significantly.,1639466_6,0
5178,blood pressure,39,53,Enalapril but not nitrendipine reduced blood pressure significantly.,1639466_6,1
5179,glomerulosclerosis,55,73,"Renal plasma flow increased, but albumin excretion and glomerulosclerosis did not change after enalapril treatment.",1639466_8,1
1321,/- 2,80,84,"In contrast, in the nitrendipine-treated group albuminuria increased from 12.8 +/- 2 progressively to 163 +/- 55 compared with 19.2 +/- 9 mg/24 hr in the hypertensive controls.",1639466_9,0
5181,torsades de pointes,21,40,Ketoconazole induced torsades de pointes without concomitant use of QT interval-prolonging drug.,16403073_0,1
5109,Ketoconazole,0,12,Ketoconazole induced torsades de pointes without concomitant use of QT interval-prolonging drug.,16403073_0,0
5110,QT,68,70,Ketoconazole induced torsades de pointes without concomitant use of QT interval-prolonging drug.,16403073_0,0
5113,proarrhythmic,32,45,Ketoconazole is not known to be proarrhythmic without concomitant use of QT interval-prolonging drugs.,16403073_1,0
5112,Ketoconazole,0,12,Ketoconazole is not known to be proarrhythmic without concomitant use of QT interval-prolonging drugs.,16403073_1,0
5184,fungal infection,167,183,We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.,16403073_2,1
5183,torsades de pointes,98,117,We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.,16403073_2,1
5117,ketoconazole,137,149,We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.,16403073_2,0
5116,TdP,119,122,We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.,16403073_2,0
5182,coronary artery disease,23,46,We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ketoconazole for treatment of fungal infection.,16403073_2,1
1322,her,43,46,Genetic study did not find any mutation in her genes that encode cardiac IKr channel proteins.,16403073_4,0
5118,IKr channel proteins,73,93,Genetic study did not find any mutation in her genes that encode cardiac IKr channel proteins.,16403073_4,0
5119,IKr,61,64,"We postulate that by virtue of its direct blocking action on IKr, ketoconazole alone may prolong QT interval and induce TdP. This calls for attention when ketoconazole is administered to patients with risk factors for acquired long QT syndrome.",16403073_5,0
5120,ketoconazole,66,78,"We postulate that by virtue of its direct blocking action on IKr, ketoconazole alone may prolong QT interval and induce TdP. This calls for attention when ketoconazole is administered to patients with risk factors for acquired long QT syndrome.",16403073_5,0
5122,ketoconazole,155,167,"We postulate that by virtue of its direct blocking action on IKr, ketoconazole alone may prolong QT interval and induce TdP. This calls for attention when ketoconazole is administered to patients with risk factors for acquired long QT syndrome.",16403073_5,0
5185,Turner Syndrome,41,56,PTU-associated vasculitis in a girl with Turner Syndrome and Graves' disease.,16418614_0,1
5186,Graves' disease,61,76,PTU-associated vasculitis in a girl with Turner Syndrome and Graves' disease.,16418614_0,1
5126,autoimmune processes,123,143,"Palpable purpura is a concerning clinical finding in pediatric patients and can have many causes, including infectious and autoimmune processes.",16418614_1,1
1323,antineutrophil cytoplasmic antibodies,73,110,"A rare cause, drug-induced vasculitis, may result from the production of antineutrophil cytoplasmic antibodies (ANCAs) in response to a medication.",16418614_2,0
5127,drug-induced vasculitis,14,37,"A rare cause, drug-induced vasculitis, may result from the production of antineutrophil cytoplasmic antibodies (ANCAs) in response to a medication.",16418614_2,1
5128,ANCAs,112,117,"A rare cause, drug-induced vasculitis, may result from the production of antineutrophil cytoplasmic antibodies (ANCAs) in response to a medication.",16418614_2,0
5188,Graves' disease,42,57,We report a girl with Turner syndrome and Graves' disease who presented with palpable purpuric lesions.,16418614_3,1
5187,Turner syndrome,22,37,We report a girl with Turner syndrome and Graves' disease who presented with palpable purpuric lesions.,16418614_3,1
5131,clinical resolution,189,208,"The diagnosis of propylthiouracil (PTU)-associated vasculitis was made by observation of consistent clinical features, the detection of elevated ANA and ANCA in the blood, and the observed clinical resolution of symptoms following withdrawal of PTU.",16418614_4,1
5132,PTU,245,248,"The diagnosis of propylthiouracil (PTU)-associated vasculitis was made by observation of consistent clinical features, the detection of elevated ANA and ANCA in the blood, and the observed clinical resolution of symptoms following withdrawal of PTU.",16418614_4,0
1324,ANCA,153,157,"The diagnosis of propylthiouracil (PTU)-associated vasculitis was made by observation of consistent clinical features, the detection of elevated ANA and ANCA in the blood, and the observed clinical resolution of symptoms following withdrawal of PTU.",16418614_4,0
5189,Cerebral vasculitis,0,19,Cerebral vasculitis following oral methylphenidate intake in an adult: a case report.,16428221_0,1
5190,Cerebral vasculitis,0,19,"Cerebral vasculitis associated with amphetamine abuse is well documented, and in rare cases ischaemic stroke has been reported after methylphenidate intake in children.",16428221_2,1
5191,amphetamine abuse,36,53,"Cerebral vasculitis associated with amphetamine abuse is well documented, and in rare cases ischaemic stroke has been reported after methylphenidate intake in children.",16428221_2,1
5192,ischaemic stroke,92,108,"Cerebral vasculitis associated with amphetamine abuse is well documented, and in rare cases ischaemic stroke has been reported after methylphenidate intake in children.",16428221_2,1
5193,ischaemic strokes,128,145,We report the case of a 63-year-old female who was treated with methylphenidate due to hyperactivity and suffered from multiple ischaemic strokes.,16428221_3,1
5194,ischaemic strokes,83,100,We consider drug-induced cerebral vasculitis as the most likely cause of recurrent ischaemic strokes in the absence of any pathological findings during the diagnostic work-up.,16428221_4,1
5139,cause of,64,72,We consider drug-induced cerebral vasculitis as the most likely cause of recurrent ischaemic strokes in the absence of any pathological findings during the diagnostic work-up.,16428221_4,1
5138,drug-induced cerebral vasculitis,12,44,We consider drug-induced cerebral vasculitis as the most likely cause of recurrent ischaemic strokes in the absence of any pathological findings during the diagnostic work-up.,16428221_4,1
5140,neurological symptoms,91,112,We conclude that methylphenidate mediated vasculitis should be considered in patients with neurological symptoms and a history of methylphenidate therapy.,16428221_5,1
5195,side-effect,15,26,"This potential side-effect, though very rare, represents one more reason to be very restrictive in the use of methylphenidate.",16428221_6,1
1325,Daidzein,0,8,Daidzein activates choline acetyltransferase from MC-IXC cells and improves drug-induced amnesia.,16428827_0,0
5143,drug-induced amnesia,76,96,Daidzein activates choline acetyltransferase from MC-IXC cells and improves drug-induced amnesia.,16428827_0,1
1326,choline acetyltransferase,19,44,Daidzein activates choline acetyltransferase from MC-IXC cells and improves drug-induced amnesia.,16428827_0,0
5196,Alzheimer's disease,203,222,"The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease (AD).",16428827_1,1
1328,ACh,154,157,"The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease (AD).",16428827_1,0
1327,choline acetyltransferase,4,29,"The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease (AD).",16428827_1,0
5148,active component,59,75,"Via the sequential isolation of Pueraria thunbergiana, the active component was ultimately identified as daidzein (4',7-dihydroxy-isoflavone).",16428827_3,0
5149,"4',7-dihydroxy-isoflavone",115,140,"Via the sequential isolation of Pueraria thunbergiana, the active component was ultimately identified as daidzein (4',7-dihydroxy-isoflavone).",16428827_3,0
1329,daidzein,105,113,"Via the sequential isolation of Pueraria thunbergiana, the active component was ultimately identified as daidzein (4',7-dihydroxy-isoflavone).",16428827_3,0
1330,daidzein,39,47,"In order to investigate the effects of daidzein from Pueraria thunbergiana on scopolamine-induced impairments of learning and memory, we conducted a series of in vivo tests.",16428827_4,0
1331,daidzein,18,26,"Administration of daidzein (4.5 mg/kg body weight) to mice was shown significantly to reverse scopolamine-induced amnesia, according to the results of a Y-maze test.",16428827_5,0
5197,body weight,38,49,"Administration of daidzein (4.5 mg/kg body weight) to mice was shown significantly to reverse scopolamine-induced amnesia, according to the results of a Y-maze test.",16428827_5,1
1332,daidzein,38,46,"By way of contrast, mice treated with daidzein prior to the scopolamine injections were noticeably protected from this performance impairment (an approximately 12%-21% decrease in alternation behavior).",16428827_7,0
5156,performance impairment,119,141,"By way of contrast, mice treated with daidzein prior to the scopolamine injections were noticeably protected from this performance impairment (an approximately 12%-21% decrease in alternation behavior).",16428827_7,1
1333,daidzein,28,36,"These results indicate that daidzein might play a role in acetylcholine biosynthesis as a ChAT activator, and that it also ameliorates scopolamine-induced amnesia.",16428827_8,0
5158,acetylcholine biosynthesis,58,84,"These results indicate that daidzein might play a role in acetylcholine biosynthesis as a ChAT activator, and that it also ameliorates scopolamine-induced amnesia.",16428827_8,0
1334,tolterodine,89,100,Urinary symptoms and quality of life changes in Thai women with overactive bladder after tolterodine treatment.,16471092_0,0
5160,Urinary symptoms,0,16,Urinary symptoms and quality of life changes in Thai women with overactive bladder after tolterodine treatment.,16471092_0,1
5161,quality of life,21,36,Urinary symptoms and quality of life changes in Thai women with overactive bladder after tolterodine treatment.,16471092_0,1
5198,overactive bladder,64,82,Urinary symptoms and quality of life changes in Thai women with overactive bladder after tolterodine treatment.,16471092_0,1
5199,overactive bladder,89,107,OBJECTIVES: To study the urinary symptoms and quality of life changes in Thai women with overactive bladder (OAB) after tolterodine treatment.,16471092_1,1
1335,tolterodine,120,131,OBJECTIVES: To study the urinary symptoms and quality of life changes in Thai women with overactive bladder (OAB) after tolterodine treatment.,16471092_1,0
5162,urinary symptoms,25,41,OBJECTIVES: To study the urinary symptoms and quality of life changes in Thai women with overactive bladder (OAB) after tolterodine treatment.,16471092_1,1
5163,quality of life,46,61,OBJECTIVES: To study the urinary symptoms and quality of life changes in Thai women with overactive bladder (OAB) after tolterodine treatment.,16471092_1,1
5164,OAB,109,112,OBJECTIVES: To study the urinary symptoms and quality of life changes in Thai women with overactive bladder (OAB) after tolterodine treatment.,16471092_1,0
5173,dry mouth,69,78,Only one case (3.3%) withdrew from the present study due to a severe dry mouth.,16471092_10,1
1338,Tolterodine,12,23,CONCLUSION: Tolterodine was well tolerated and its effects improved the quality of life in Thai women with OAB.,16471092_12,0
1336,Tolterodine,0,11,"Tolterodine 2 mg, twice daily was given.",16471092_3,0
1337,Short form,0,10,Short form 36 (SF36) questionaires (Thai version) were given before and after 8 weeks of treatment.,16471092_5,0
5200,side effect,16,27,The most common side effect was dry month in 5 cases (16.7%) with 2 cases reporting a moderate degree and 1 case with severe degree.,16471092_9,1
1339,Remifentanil,0,12,Remifentanil pretreatment reduces myoclonus after etomidate.,16563323_0,0
1340,etomidate,50,59,Remifentanil pretreatment reduces myoclonus after etomidate.,16563323_0,0
1342,etomidate,197,206,STUDY OBJECTIVE: The aim of the study was to compare the effect of pretreatment with remifentanil 1 microg/kg and the effect of gender on the incidence of myoclonus after anesthesia induction with etomidate.,16563323_1,0
1341,remifentanil,85,97,STUDY OBJECTIVE: The aim of the study was to compare the effect of pretreatment with remifentanil 1 microg/kg and the effect of gender on the incidence of myoclonus after anesthesia induction with etomidate.,16563323_1,0
1347,etomidate,110,119,"In the placebo group, male patients were associated with significantly increased incidence of myoclonus after etomidate administration.",16563323_10,0
1348,remifentanil,30,42,"CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus.",16563323_11,0
1349,etomidate,79,88,"CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus.",16563323_11,0
5201,side effects,107,119,"CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus.",16563323_11,1
1350,etomidate,65,74,Men experience increased incidence of myoclonus than women after etomidate administration.,16563323_12,0
5187,microg/kg,100,109,PATIENTS: Sixty patients were pretreated in a randomized double-blinded fashion with remifentanil 1 microg/kg or placebo.,16563323_4,0
1343,remifentanil,85,97,PATIENTS: Sixty patients were pretreated in a randomized double-blinded fashion with remifentanil 1 microg/kg or placebo.,16563323_4,0
1344,remifentanil,18,30,"Two minutes after remifentanil or placebo injection, etomidate 0.3 mg/kg was given.",16563323_5,0
1345,etomidate,53,62,"Two minutes after remifentanil or placebo injection, etomidate 0.3 mg/kg was given.",16563323_5,0
1346,remifentanil,72,84,MAIN RESULTS: The incidence of myoclonus was significantly lower in the remifentanil group (6.7%) than in the placebo group (70%) (P < 0.001).,16563323_8,0
5193,process-specific central executive impairments,25,71,MDMA polydrug users show process-specific central executive impairments coupled with impaired social and emotional judgement processes.,16574712_0,1
5192,polydrug,5,13,MDMA polydrug users show process-specific central executive impairments coupled with impaired social and emotional judgement processes.,16574712_0,0
5194,working memory deficits,16,39,"In recent years working memory deficits have been reported in users of MDMA (3,4-methylenedioxymethamphetamine, ecstasy).",16574712_1,1
5195,"3,4-methylenedioxymethamphetamine",77,110,"In recent years working memory deficits have been reported in users of MDMA (3,4-methylenedioxymethamphetamine, ecstasy).",16574712_1,0
5202,drug use,93,101,"Fifteen polydrug ecstasy users and 15 polydrug non-ecstasy user controls completed a general drug use questionnaire, the Brixton Spatial Anticipation task (set shifting), Backward Digit Span procedure (memory updating), Inhibition of Return (inhibition), an emotional intelligence scale, the Tromso Social Intelligence Scale and the Dysexecutive Questionnaire (DEX).",16574712_3,1
5202,emotional intelligence,258,280,"Fifteen polydrug ecstasy users and 15 polydrug non-ecstasy user controls completed a general drug use questionnaire, the Brixton Spatial Anticipation task (set shifting), Backward Digit Span procedure (memory updating), Inhibition of Return (inhibition), an emotional intelligence scale, the Tromso Social Intelligence Scale and the Dysexecutive Questionnaire (DEX).",16574712_3,1
5197,polydrug,8,16,"Fifteen polydrug ecstasy users and 15 polydrug non-ecstasy user controls completed a general drug use questionnaire, the Brixton Spatial Anticipation task (set shifting), Backward Digit Span procedure (memory updating), Inhibition of Return (inhibition), an emotional intelligence scale, the Tromso Social Intelligence Scale and the Dysexecutive Questionnaire (DEX).",16574712_3,0
5198,polydrug,38,46,"Fifteen polydrug ecstasy users and 15 polydrug non-ecstasy user controls completed a general drug use questionnaire, the Brixton Spatial Anticipation task (set shifting), Backward Digit Span procedure (memory updating), Inhibition of Return (inhibition), an emotional intelligence scale, the Tromso Social Intelligence Scale and the Dysexecutive Questionnaire (DEX).",16574712_3,0
5205,polydrug,24,32,"Compared with MDMA-free polydrug controls, MDMA polydrug users showed impairments in set shifting and memory updating, and also in social and emotional judgement processes.",16574712_4,0
5206,polydrug,48,56,"Compared with MDMA-free polydrug controls, MDMA polydrug users showed impairments in set shifting and memory updating, and also in social and emotional judgement processes.",16574712_4,0
5203,drug use,73,81,The latter two deficits remained significant after controlling for other drug use.,16574712_5,1
5208,prefrontal cortex,89,106,These data lend further support to the proposal that cognitive processes mediated by the prefrontal cortex may be impaired by recreational ecstasy use.,16574712_6,1
5212,"3,4-methylenedioxymethamphetamine",9,42,"Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function.",16574713_1,0
5213,5-HT,103,107,"Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced 5-HT neurotoxic lesions on functions in which 5-HT is involved, such as cognitive function.",16574713_1,0
5233,5-HTTLPR,25,33,No significant effect of 5-HTTLPR or gender was observed.,16574713_10,0
5235,impaired memory functioning,93,120,"While the use of MDMA in quantities that may be considered ""moderate"" is not associated with impaired memory functioning, heavy use of MDMA use may lead to long lasting memory impairments.",16574713_11,1
5238,memory function,35,50,No effect of 5-HTTLPR or gender on memory function or MDMA use was observed.,16574713_12,1
5237,5-HTTLPR,13,21,No effect of 5-HTTLPR or gender on memory function or MDMA use was observed.,16574713_12,0
5217,5-HT,8,12,Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.,16574713_2,0
5220,5-HTTLPR,224,232,Because 5-HT transporters play a key element in the regulation of synaptic 5-HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5-HT transporter promoter gene region (5-HTTLPR) when studying the effects of MDMA as well as cognitive functioning.,16574713_2,0
5222,cognitive function,86,104,"The aim of the study was to investigate the effects of moderate and heavy MDMA use on cognitive function, as well as the effects of long-term abstention from MDMA, in subjects genotyped for 5-HTTLPR.",16574713_3,1
5223,5-HTTLPR,190,198,"The aim of the study was to investigate the effects of moderate and heavy MDMA use on cognitive function, as well as the effects of long-term abstention from MDMA, in subjects genotyped for 5-HTTLPR.",16574713_3,0
5226,5-HTTLPR,58,66,DNA from peripheral nuclear blood cells was genotyped for 5-HTTLPR using standard polymerase chain reaction methods.,16574713_6,0
5227,polymerase chain reaction,82,107,DNA from peripheral nuclear blood cells was genotyped for 5-HTTLPR using standard polymerase chain reaction methods.,16574713_6,0
5232,memory impairment,28,45,"In contrast, no evidence of memory impairment was observed in moderate MDMA users.",16574713_9,1
5204,myocardial infarction,94,115,Role of mangiferin on biochemical alterations and antioxidant status in isoproterenol-induced myocardial infarction in rats.,16584858_0,1
5239,mangiferin,8,18,Role of mangiferin on biochemical alterations and antioxidant status in isoproterenol-induced myocardial infarction in rats.,16584858_0,0
1351,polyphenol,66,76,"The current study dealt with the protective role of mangiferin, a polyphenol from Mangifera indica Linn. (Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.",16584858_1,0
5241,protective role,33,48,"The current study dealt with the protective role of mangiferin, a polyphenol from Mangifera indica Linn. (Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.",16584858_1,0
5242,mangiferin,52,62,"The current study dealt with the protective role of mangiferin, a polyphenol from Mangifera indica Linn. (Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.",16584858_1,0
5244,antioxidative,201,214,"The current study dealt with the protective role of mangiferin, a polyphenol from Mangifera indica Linn. (Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.",16584858_1,0
5205,myocardial infarction,154,175,"The current study dealt with the protective role of mangiferin, a polyphenol from Mangifera indica Linn. (Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism.",16584858_1,1
5246,ISPH,26,30,"Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.",16584858_2,0
5249,CK-MB,263,268,"Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.",16584858_2,0
5206,body weight,42,53,"Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.",16584858_2,1
1352,lactate dehydrogenase,196,217,"Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.",16584858_2,0
1353,LDH,219,222,"Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.",16584858_2,0
1354,uric acid,281,290,"Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.",16584858_2,0
5247,myocardial damage,108,125,"Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.",16584858_2,1
1355,iron binding,316,328,"Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.",16584858_2,0
5248,creatine phosphokinase isoenzymes,228,261,"Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity.",16584858_2,0
5250,protective role,4,19,The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.,16584858_3,0
5251,mangiferin,23,33,The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.,16584858_3,0
5252,triphenyl tetrazolium chloride,50,80,The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.,16584858_3,0
5253,ischemic myocardium,141,160,The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium.,16584858_3,1
1360,glutathione,237,248,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,0
5258,Vitamin C,212,221,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,0
1359,glutathione reductase,129,150,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,0
5256,non-enzymic antioxidants,163,187,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,0
5255,antioxidant enzymes,17,36,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,0
1356,superoxide dismutase,45,65,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,0
1357,glutathione peroxidase,77,99,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,0
1358,glutathione transferase,101,124,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,0
5257,cerruloplasmin,196,210,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,0
5259,Vitamin E,223,232,"The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats.",16584858_4,0
5207,body weight,45,56,Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.,16584858_5,1
1361,dimethyl sulphoxide,78,97,Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.,16584858_5,0
5261,mangiferin,23,33,Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels.,16584858_5,0
5266,enzymic antioxidants,27,47,Activities of heart tissue enzymic antioxidants and serum non-enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ISPH-induced MI rats.,16584858_6,0
5268,mangiferin,114,124,Activities of heart tissue enzymic antioxidants and serum non-enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ISPH-induced MI rats.,16584858_6,0
5267,non-enzymic antioxidants,58,82,Activities of heart tissue enzymic antioxidants and serum non-enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ISPH-induced MI rats.,16584858_6,0
5270,mangiferin,44,54,"From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against cardiac damage.",16584858_7,0
5272,cardiac damage,191,205,"From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against cardiac damage.",16584858_7,1
5209,heart failure,237,250,"Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.",16586083_0,1
5208,myocardial infarction,189,210,"Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.",16586083_0,1
1362,cyclooxygenase inhibitors,25,50,"Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.",16586083_0,0
1363,cyclooxygenase inhibitors,273,298,"Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.",16586083_0,0
5274,general problem,52,67,"Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors.",16586083_0,1
5277,Adverse cardiovascular effects,0,30,"Adverse cardiovascular effects occurred mainly, but not exclusively, in patients with concomitant risk factors.",16586083_1,1
1364,Cyclooxygenase inhibitors,0,25,"Cyclooxygenase inhibitors cause complex changes in renal, vascular and cardiac prostanoid profiles thereby increasing vascular resistance and fluid retention.",16586083_2,0
1365,prostanoid,79,89,"Cyclooxygenase inhibitors cause complex changes in renal, vascular and cardiac prostanoid profiles thereby increasing vascular resistance and fluid retention.",16586083_2,0
5280,fluid retention,142,157,"Cyclooxygenase inhibitors cause complex changes in renal, vascular and cardiac prostanoid profiles thereby increasing vascular resistance and fluid retention.",16586083_2,1
5279,vascular resistance,118,137,"Cyclooxygenase inhibitors cause complex changes in renal, vascular and cardiac prostanoid profiles thereby increasing vascular resistance and fluid retention.",16586083_2,1
5281,cardiovascular adverse events,17,46,The incidence of cardiovascular adverse events tends to increase with the daily dose and total exposure time.,16586083_3,1
5284,inhibitory potency,185,203,"A comparison of individual selective and unselective cyclooxygenase inhibitors suggests substance-specific differences, which may depend on differences in pharmacokinetic parameters or inhibitory potency and may be contributed by prostaglandin-independent effects.",16586083_4,0
1366,cyclooxygenase inhibitors,53,78,"A comparison of individual selective and unselective cyclooxygenase inhibitors suggests substance-specific differences, which may depend on differences in pharmacokinetic parameters or inhibitory potency and may be contributed by prostaglandin-independent effects.",16586083_4,0
1368,natriuretic peptide,48,67,"Diagnostic markers such as N-terminal pro brain natriuretic peptide (NT-proBNP) or high-sensitive C-reactive protein might help in the early identification of patients at risk, thus avoiding the occurrence of serious cardiovascular toxicity.",16586083_5,0
5287,NT-proBNP,69,78,"Diagnostic markers such as N-terminal pro brain natriuretic peptide (NT-proBNP) or high-sensitive C-reactive protein might help in the early identification of patients at risk, thus avoiding the occurrence of serious cardiovascular toxicity.",16586083_5,0
1369,C-reactive protein,98,116,"Diagnostic markers such as N-terminal pro brain natriuretic peptide (NT-proBNP) or high-sensitive C-reactive protein might help in the early identification of patients at risk, thus avoiding the occurrence of serious cardiovascular toxicity.",16586083_5,0
1367,N-terminal,27,37,"Diagnostic markers such as N-terminal pro brain natriuretic peptide (NT-proBNP) or high-sensitive C-reactive protein might help in the early identification of patients at risk, thus avoiding the occurrence of serious cardiovascular toxicity.",16586083_5,0
5288,age-dependent impairment,27,51,Pilocarpine seizures cause age-dependent impairment in auditory location discrimination.,16596970_0,1
5210,status epilepticus,18,36,Children who have status epilepticus have continuous or rapidly repeating seizures that may be life-threatening and may cause life-long changes in brain and behavior.,16596970_1,1
5217,Status epilepticus,0,18,"Status epilepticus in rat causes an age-dependent, long-term impairment in auditory discrimination.",16596970_10,1
5305,age-dependent,36,49,"Status epilepticus in rat causes an age-dependent, long-term impairment in auditory discrimination.",16596970_10,1
5306,auditory discrimination,75,98,"Status epilepticus in rat causes an age-dependent, long-term impairment in auditory discrimination.",16596970_10,1
5211,status epilepticus,20,38,The extent to which status epilepticus causes deficits in auditory discrimination is unknown.,16596970_2,1
5289,auditory discrimination,58,81,The extent to which status epilepticus causes deficits in auditory discrimination is unknown.,16596970_2,1
5212,status epilepticus,115,133,A naturalistic auditory location discrimination method was used to evaluate this question using an animal model of status epilepticus.,16596970_3,1
1370,convulsant,81,91,"Male Sprague-Dawley rats were injected with saline on postnatal day (P) 20, or a convulsant dose of pilocarpine on P20 or P45.",16596970_4,0
1371,P45,122,125,"Male Sprague-Dawley rats were injected with saline on postnatal day (P) 20, or a convulsant dose of pilocarpine on P20 or P45.",16596970_4,0
5292,P20,115,118,"Male Sprague-Dawley rats were injected with saline on postnatal day (P) 20, or a convulsant dose of pilocarpine on P20 or P45.",16596970_4,0
1372,P45,76,79,"Pilocarpine on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.",16596970_5,0
5213,status epilepticus,34,52,"Pilocarpine on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.",16596970_5,1
5297,spontaneous seizures,169,189,"Pilocarpine on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.",16596970_5,1
5296,cell loss,156,165,"Pilocarpine on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.",16596970_5,1
5295,P20,140,143,"Pilocarpine on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.",16596970_5,0
5294,spontaneous seizures,110,130,"Pilocarpine on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.",16596970_5,1
5214,status epilepticus,54,72,"Pilocarpine on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.",16596970_5,1
5293,CA3 cell loss,92,105,"Pilocarpine on either day induced status epilepticus; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures.",16596970_5,1
5300,saline P20,9,19,Control (saline P20) rats acquired both discriminations immediately.,16596970_7,0
5301,P20,23,26,"In status epilepticus (P20) rats, acquisition of the sound-source location discrimination was moderately impaired.",16596970_8,0
5215,status epilepticus,3,21,"In status epilepticus (P20) rats, acquisition of the sound-source location discrimination was moderately impaired.",16596970_8,1
1373,P45,20,23,Status epilepticus (P45) rats failed to acquire either sound-source location or sound-silence discriminations.,16596970_9,0
5216,Status epilepticus,0,18,Status epilepticus (P45) rats failed to acquire either sound-source location or sound-silence discriminations.,16596970_9,1
1374,Nerve growth factor,0,19,Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder.,16600756_0,0
5218,overactive bladder,76,94,Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder.,16600756_0,1
5308,PGs,17,20,PURPOSE: NGF and PGs in the bladder can be affected by pathological changes in the bladder and these changes can be detected in urine.,16600756_1,0
5319,OAB,17,20,In patients with OAB urinary PGE2 positively correlated with volume at first desire to void and maximum cystometric capacity (p <0.05).,16600756_10,0
1383,PGE2,29,33,In patients with OAB urinary PGE2 positively correlated with volume at first desire to void and maximum cystometric capacity (p <0.05).,16600756_10,0
1384,PGF2alpha,13,22,"Urinary NGF, PGF2alpha and PGI2 did not correlate with urodynamic parameters in patients with OAB.",16600756_11,0
5321,urodynamic,55,65,"Urinary NGF, PGF2alpha and PGI2 did not correlate with urodynamic parameters in patients with OAB.",16600756_11,1
5322,OAB,94,97,"Urinary NGF, PGF2alpha and PGI2 did not correlate with urodynamic parameters in patients with OAB.",16600756_11,0
1385,PGI2,27,31,"Urinary NGF, PGF2alpha and PGI2 did not correlate with urodynamic parameters in patients with OAB.",16600756_11,0
5323,PGs,21,24,CONCLUSIONS: NGF and PGs have important roles in the development of OAB symptoms in female patients.,16600756_12,0
5324,OAB,68,71,CONCLUSIONS: NGF and PGs have important roles in the development of OAB symptoms in female patients.,16600756_12,0
5326,OAB,67,70,Urinary levels of these factors may be used as markers to evaluate OAB symptoms.,16600756_13,0
5310,OAB,61,64,We investigated changes in urinary NGF and PGs in women with OAB.,16600756_2,0
5309,PGs,43,46,We investigated changes in urinary NGF and PGs in women with OAB.,16600756_2,0
5312,bladder symptoms,82,98,MATERIALS AND METHODS: The study groups included 65 women with OAB and 20 without bladder symptoms who served as controls.,16600756_3,1
1376,PGF2alpha,11,20,"NGF, PGE2, PGF2alpha and PGI2 were measured using enzyme-linked immunosorbent assay and compared between the groups.",16600756_6,0
1378,immunosorbent,64,77,"NGF, PGE2, PGF2alpha and PGI2 were measured using enzyme-linked immunosorbent assay and compared between the groups.",16600756_6,0
1377,PGI2,25,29,"NGF, PGE2, PGF2alpha and PGI2 were measured using enzyme-linked immunosorbent assay and compared between the groups.",16600756_6,0
1375,PGE2,5,9,"NGF, PGE2, PGF2alpha and PGI2 were measured using enzyme-linked immunosorbent assay and compared between the groups.",16600756_6,0
1379,PG,50,52,"In addition, correlations between urinary NGF and PG, and urodynamic parameters in patients with OAB were examined.",16600756_7,0
5316,OAB,97,100,"In addition, correlations between urinary NGF and PG, and urodynamic parameters in patients with OAB were examined.",16600756_7,0
5315,urodynamic,58,68,"In addition, correlations between urinary NGF and PG, and urodynamic parameters in patients with OAB were examined.",16600756_7,1
1380,PGE2,22,26,"RESULTS: Urinary NGF, PGE2 and PGF2alpha were significantly increased in patients with OAB compared with controls (p <0.05).",16600756_8,0
1381,PGF2alpha,31,40,"RESULTS: Urinary NGF, PGE2 and PGF2alpha were significantly increased in patients with OAB compared with controls (p <0.05).",16600756_8,0
5317,OAB,87,90,"RESULTS: Urinary NGF, PGE2 and PGF2alpha were significantly increased in patients with OAB compared with controls (p <0.05).",16600756_8,0
5318,OAB,75,78,"However, urinary PGI2 was not different between controls and patients with OAB.",16600756_9,0
1382,PGI2,17,21,"However, urinary PGI2 was not different between controls and patients with OAB.",16600756_9,0
5219,hepatitis C,62,73,Definition and management of anemia in patients infected with hepatitis C virus.,16629641_0,1
5328,end-stage liver disease,104,127,"Chronic infection with hepatitis C virus (HCV) can progress to cirrhosis, hepatocellular carcinoma, and end-stage liver disease.",16629641_1,1
5220,Chronic infection,0,17,"Chronic infection with hepatitis C virus (HCV) can progress to cirrhosis, hepatocellular carcinoma, and end-stage liver disease.",16629641_1,1
5221,hepatitis C,23,34,"Chronic infection with hepatitis C virus (HCV) can progress to cirrhosis, hepatocellular carcinoma, and end-stage liver disease.",16629641_1,1
5222,hepatocellular carcinoma,74,98,"Chronic infection with hepatitis C virus (HCV) can progress to cirrhosis, hepatocellular carcinoma, and end-stage liver disease.",16629641_1,1
5223,hemolytic anemia,156,172,"Although this regimen produces sustained virologic responses (SVRs) in approximately 50% of patients, it can be associated with a potentially dose-limiting hemolytic anemia.",16629641_3,1
5336,comorbid renal,179,193,"Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders.",16629641_4,1
5337,cardiovascular disorders,197,221,"Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders.",16629641_4,1
5339,quality of life,124,139,"In general, anemia can increase the risk of morbidity and mortality, and may have negative effects on cerebral function and quality of life.",16629641_5,1
5338,cerebral function,102,119,"In general, anemia can increase the risk of morbidity and mortality, and may have negative effects on cerebral function and quality of life.",16629641_5,1
1386,Recombinant human,0,17,Recombinant human erythropoietin has been used to manage ribavirin-associated anemia but has other potential disadvantages.,16629641_7,0
5342,Viramidine,0,10,"Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.",16629641_8,0
1387,prodrug,30,37,"Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.",16629641_8,0
5224,hemolytic anemia,147,163,"Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.",16629641_8,1
5225,chronic hepatitis,181,198,"Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C.",16629641_8,1
5346,fetal growth,75,87,Impact of alcohol exposure after pregnancy recognition on ultrasonographic fetal growth measures.,16634859_0,1
5344,pregnancy recognition,33,54,Impact of alcohol exposure after pregnancy recognition on ultrasonographic fetal growth measures.,16634859_0,1
5343,alcohol exposure,10,26,Impact of alcohol exposure after pregnancy recognition on ultrasonographic fetal growth measures.,16634859_0,1
5348,fetal development,119,136,"BACKGROUND: More than 3 decades after Jones and Smith (1973) reported on the devastation caused by alcohol exposure on fetal development, the rates of heavy drinking during pregnancy remain relatively unchanged.",16634859_1,1
5349,heavy drinking,151,165,"BACKGROUND: More than 3 decades after Jones and Smith (1973) reported on the devastation caused by alcohol exposure on fetal development, the rates of heavy drinking during pregnancy remain relatively unchanged.",16634859_1,1
5347,alcohol exposure,99,115,"BACKGROUND: More than 3 decades after Jones and Smith (1973) reported on the devastation caused by alcohol exposure on fetal development, the rates of heavy drinking during pregnancy remain relatively unchanged.",16634859_1,1
5362,drinking early,27,41,"When women reportedly quit drinking early in their pregnancies, fetal growth measures were not significantly different from a non-alcohol-exposed group, regardless of prior drinking patterns.",16634859_10,1
5363,fetal growth,64,76,"When women reportedly quit drinking early in their pregnancies, fetal growth measures were not significantly different from a non-alcohol-exposed group, regardless of prior drinking patterns.",16634859_10,1
5366,body growth,145,156,Any alcohol consumption postpregnancy recognition among the heavy drinkers resulted in reduced cerebellar growth as well as decreased cranial to body growth in comparison with women who either quit drinking or who were nondrinkers.,16634859_11,1
5365,cerebellar growth,95,112,Any alcohol consumption postpregnancy recognition among the heavy drinkers resulted in reduced cerebellar growth as well as decreased cranial to body growth in comparison with women who either quit drinking or who were nondrinkers.,16634859_11,1
5228,alcohol consumption,4,23,Any alcohol consumption postpregnancy recognition among the heavy drinkers resulted in reduced cerebellar growth as well as decreased cranial to body growth in comparison with women who either quit drinking or who were nondrinkers.,16634859_11,1
5229,Amphetamine abuse,0,17,Amphetamine abuse was predictive of larger cranial to body growth ratios.,16634859_12,1
5373,fetal alcohol effects,201,222,"Although the reliance on self-reported drinking is a limitation in this study, these findings support the benefits of early abstinence and the potential for ultrasound examinations in the detection of fetal alcohol effects.",16634859_14,1
5350,fetal alcohol exposure,24,46,Early identification of fetal alcohol exposure and maternal abstinence led to better infant outcomes.,16634859_2,1
5351,alcohol-related fetal growth impairment,58,97,This study examined the utility of biometry for detecting alcohol-related fetal growth impairment.,16634859_3,1
5226,alcohol consumption,21,40,"Because intensity of alcohol consumption is associated with poorer fetal outcomes, separate analyses were conducted for the heavy (average of >or=5 drinks per drinking day) alcohol consumers.",16634859_6,1
5355,fetal outcomes,67,81,"Because intensity of alcohol consumption is associated with poorer fetal outcomes, separate analyses were conducted for the heavy (average of >or=5 drinks per drinking day) alcohol consumers.",16634859_6,1
5359,uncomplicated pregnancies,139,164,"Fetal measures from the heavy-exposed fetuses were also compared with measures from a nondrinking group that was representative of normal, uncomplicated pregnancies from our clinics.",16634859_7,1
5360,gestational age,128,143,Analyses of covariance were used to determine whether there were differences between groups after controlling for influences of gestational age and drug abuse.,16634859_8,1
5227,drug abuse,148,158,Analyses of covariance were used to determine whether there were differences between groups after controlling for influences of gestational age and drug abuse.,16634859_8,1
1388,amsacrine,22,31,Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer.,1664218_0,0
5230,non-small cell lung cancer,64,90,Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer.,1664218_0,1
5375,CI-921,41,47,Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer.,1664218_0,0
5378,"-N,5-dimethyl- 4-acridinecarboxamide",74,110,"CI-921 (NSC 343499; 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide) is a topoisomerase II poison with high experimental antitumour activity.",1664218_1,0
5377,"-N,5-dimethyl-",74,88,"CI-921 (NSC 343499; 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide) is a topoisomerase II poison with high experimental antitumour activity.",1664218_1,0
5376,CI-921,0,6,"CI-921 (NSC 343499; 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide) is a topoisomerase II poison with high experimental antitumour activity.",1664218_1,0
1389,topoisomerase II,117,133,"CI-921 (NSC 343499; 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide) is a topoisomerase II poison with high experimental antitumour activity.",1664218_1,0
5231,non-small cell lung cancer,69,95,"It was administered by 15 min infusion to 16 evaluable patients with non-small cell lung cancer (NSCLC) (7 with no prior treatment, 9 patients in relapse following surgery/radiotherapy) at a dose (648 mg/m2 divided over 3 days, repeated every 3 weeks) determined by phase I trial.",1664218_2,1
5381,mg/m2,201,206,"It was administered by 15 min infusion to 16 evaluable patients with non-small cell lung cancer (NSCLC) (7 with no prior treatment, 9 patients in relapse following surgery/radiotherapy) at a dose (648 mg/m2 divided over 3 days, repeated every 3 weeks) determined by phase I trial.",1664218_2,0
5232,squamous carcinoma,24,42,"The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1).",1664218_4,1
5382,bronchio-alveolar carcinoma,90,117,"The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1).",1664218_4,1
1391,(1,118,120,"The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1).",1664218_4,0
5383,cell undifferentiated carcinoma,132,163,"The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1).",1664218_4,1
1392,(1,164,166,"The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1).",1664218_4,0
1390,(1,64,66,"The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1).",1664218_4,0
5384,Neutropenia grade,0,17,"Neutropenia grade greater than or equal to 3 was seen in 15 patients, infections with recovery in 3, and grand mal seizures in 1 patient.",1664218_5,1
5385,grand mal seizures,105,123,"Neutropenia grade greater than or equal to 3 was seen in 15 patients, infections with recovery in 3, and grand mal seizures in 1 patient.",1664218_5,1
5386,Grade less,0,10,Grade less than or equal to 2 nausea and vomiting occurred in 66% courses and phlebitis in the infusion arm in 37%.,1664218_6,1
5233,nausea and vomiting,30,49,Grade less than or equal to 2 nausea and vomiting occurred in 66% courses and phlebitis in the infusion arm in 37%.,1664218_6,1
5234,squamous cell carcinoma,15,38,1 patient with squamous cell carcinoma achieved a partial response lasting 5 months.,1664218_7,1
5388,partial response,50,66,1 patient with squamous cell carcinoma achieved a partial response lasting 5 months.,1664218_7,1
5390,desipramine HCl,20,35,Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl.,16680561_0,0
5391,cinacalcet HCl,59,73,Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl.,16680561_0,0
5393,cytochrome P450 isoenzyme,83,108,OBJECTIVE: In vitro work has demonstrated that cinacalcet is a strong inhibitor of cytochrome P450 isoenzyme (CYP) 2D6.,16680561_1,0
5392,cinacalcet,47,57,OBJECTIVE: In vitro work has demonstrated that cinacalcet is a strong inhibitor of cytochrome P450 isoenzyme (CYP) 2D6.,16680561_1,0
5394,CYP,110,113,OBJECTIVE: In vitro work has demonstrated that cinacalcet is a strong inhibitor of cytochrome P450 isoenzyme (CYP) 2D6.,16680561_1,0
1395,CYP2D6,77,83,CONCLUSION: This study demonstrates that cinacalcet is a strong inhibitor of CYP2D6.,16680561_10,0
5413,cinacalcet,41,51,CONCLUSION: This study demonstrates that cinacalcet is a strong inhibitor of CYP2D6.,16680561_10,0
1396,CYP2D6,180,186,"These data suggest that during concomitant treatment with cinacalcet, dose adjustment may be necessary for drugs that demonstrate a narrow therapeutic index and are metabolized by CYP2D6.",16680561_11,0
5414,cinacalcet,58,68,"These data suggest that during concomitant treatment with cinacalcet, dose adjustment may be necessary for drugs that demonstrate a narrow therapeutic index and are metabolized by CYP2D6.",16680561_11,0
1393,CYP2D6,70,76,"The purpose of this study was to evaluate the effect of cinacalcet on CYP2D6 activity, using desipramine as a probe substrate, in healthy subjects.",16680561_2,0
5395,cinacalcet,56,66,"The purpose of this study was to evaluate the effect of cinacalcet on CYP2D6 activity, using desipramine as a probe substrate, in healthy subjects.",16680561_2,0
5402,cinacalcet,266,276,"METHODS: Seventeen subjects who were genotyped as CYP2D6 extensive metabolizers were enrolled in this randomized, open-label, crossover study to receive a single oral dose of desipramine (50 mg) on two separate occasions, once alone and once after multiple doses of cinacalcet (90 mg for 7 days).",16680561_3,0
5397,metabolizers,67,79,"METHODS: Seventeen subjects who were genotyped as CYP2D6 extensive metabolizers were enrolled in this randomized, open-label, crossover study to receive a single oral dose of desipramine (50 mg) on two separate occasions, once alone and once after multiple doses of cinacalcet (90 mg for 7 days).",16680561_3,0
1394,CYP2D6,50,56,"METHODS: Seventeen subjects who were genotyped as CYP2D6 extensive metabolizers were enrolled in this randomized, open-label, crossover study to receive a single oral dose of desipramine (50 mg) on two separate occasions, once alone and once after multiple doses of cinacalcet (90 mg for 7 days).",16680561_3,0
5403,predose,28,35,Blood samples were obtained predose and up to 72 h postdose.,16680561_4,0
5404,postdose,51,59,Blood samples were obtained predose and up to 72 h postdose.,16680561_4,1
5406,cinacalcet,119,129,"Relative to desipramine alone, mean AUC and C(max) of desipramine increased 3.6- and 1.8-fold when coadministered with cinacalcet.",16680561_6,0
5407,cinacalcet,81,91,"The t (1/2,z) of desipramine was longer when desipramine was coadministered with cinacalcet (21.0 versus 43.3 hs).",16680561_7,0
5408,t (max,4,10,The t (max) was similar between the regimens.,16680561_8,0
5410,adverse events,24,38,"Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet.",16680561_9,1
5411,cinacalcet,119,129,"Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet.",16680561_9,0
5412,cinacalcet,263,273,"Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and headache) have been reported for patients treated with either desipramine or cinacalcet.",16680561_9,0
5235,optic neuropathy,22,38,Ethambutol-associated optic neuropathy.,16710500_0,1
5236,visual loss,148,159,"INTRODUCTION: Ethambutol is used in the treatment of tuberculosis, which is still prevalent in Southeast Asia, and can be associated with permanent visual loss.",16710500_1,1
1397,Ethambutol,14,24,"INTRODUCTION: Ethambutol is used in the treatment of tuberculosis, which is still prevalent in Southeast Asia, and can be associated with permanent visual loss.",16710500_1,0
5240,visual loss,59,70,CONCLUSIONS: Ethambutol usage is associated with permanent visual loss and should be avoided if possible or used with caution and proper ophthalmological follow-up.,16710500_10,1
1399,Ethambutol,13,23,CONCLUSIONS: Ethambutol usage is associated with permanent visual loss and should be avoided if possible or used with caution and proper ophthalmological follow-up.,16710500_10,0
5432,chiasmopathy,61,73,"The author postulates that in cases of ethambutol associated chiasmopathy, ethambutol may initially affect the optic nerves and subsequently progress to involve the optic chiasm.",16710500_11,1
5434,optic chiasm,165,177,"The author postulates that in cases of ethambutol associated chiasmopathy, ethambutol may initially affect the optic nerves and subsequently progress to involve the optic chiasm.",16710500_11,1
5433,optic nerves,111,123,"The author postulates that in cases of ethambutol associated chiasmopathy, ethambutol may initially affect the optic nerves and subsequently progress to involve the optic chiasm.",16710500_11,1
1400,ethambutol,39,49,"The author postulates that in cases of ethambutol associated chiasmopathy, ethambutol may initially affect the optic nerves and subsequently progress to involve the optic chiasm.",16710500_11,0
1401,ethambutol,75,85,"The author postulates that in cases of ethambutol associated chiasmopathy, ethambutol may initially affect the optic nerves and subsequently progress to involve the optic chiasm.",16710500_11,0
5237,bitemporal hemianopia,39,60,We report 3 cases which presented with bitemporal hemianopia.,16710500_2,1
5418,CLINICAL PICTURE,0,16,CLINICAL PICTURE: Three patients with ethambutol-associated toxic optic neuropathy are described.,16710500_3,1
5238,toxic optic neuropathy,60,82,CLINICAL PICTURE: Three patients with ethambutol-associated toxic optic neuropathy are described.,16710500_3,1
5422,visual field,79,91,"All 3 patients had loss of central visual acuity, colour vision (Ishihara) and visual field.",16710500_4,1
5419,loss of central visual acuity,19,48,"All 3 patients had loss of central visual acuity, colour vision (Ishihara) and visual field.",16710500_4,1
5420,colour vision,50,63,"All 3 patients had loss of central visual acuity, colour vision (Ishihara) and visual field.",16710500_4,1
5239,bitemporal,28,38,"The visual field loss had a bitemporal flavour, suggesting involvement of the optic chiasm.",16710500_5,1
5423,visual field loss,4,21,"The visual field loss had a bitemporal flavour, suggesting involvement of the optic chiasm.",16710500_5,1
5424,optic chiasm,78,90,"The visual field loss had a bitemporal flavour, suggesting involvement of the optic chiasm.",16710500_5,1
1398,ethambutol,28,38,"TREATMENT: Despite stopping ethambutol on diagnosis, visual function continued to deteriorate for a few months.",16710500_6,0
5425,visual function,53,68,"TREATMENT: Despite stopping ethambutol on diagnosis, visual function continued to deteriorate for a few months.",16710500_6,1
5427,colour vision,37,50,"In the third case, visual acuity and colour vision normalised but the optic discs were pale.",16710500_8,1
5426,visual acuity,19,32,"In the third case, visual acuity and colour vision normalised but the optic discs were pale.",16710500_8,1
5429,loss of visual function,43,66,OUTCOME: All 3 patients had some permanent loss of visual function.,16710500_9,1
5241,neuroleptic malignant syndrome,9,39,Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam.,16720068_0,1
5435,paroxetine,78,88,Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam.,16720068_0,0
5436,depressive symptoms,23,42,"A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia, loss of appetite, exhaustion, and agitation.",16720068_1,1
5242,loss of,99,106,"A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia, loss of appetite, exhaustion, and agitation.",16720068_1,1
5438,paroxetine,57,67,Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam.,16720068_2,0
5439,paroxetine,19,29,"On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.",16720068_3,0
5440,psychomotor retardation,85,108,"On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.",16720068_3,1
5243,muscle rigidity,137,152,"On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors.",16720068_3,1
5245,extrapyramidal,118,132,"The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.",16720068_4,1
5244,blood pressure,54,68,"The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms.",16720068_4,1
1402,creatine phosphokinase,40,62,"Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.",16720068_5,0
1404,alanine aminotransferase,115,139,"Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.",16720068_5,0
1403,aspartate aminotransferase,76,102,"Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels.",16720068_5,0
1406,his,57,60,The patient received bromocriptine and diazepam to treat his symptoms.,16720068_6,0
1405,bromocriptine,21,34,The patient received bromocriptine and diazepam to treat his symptoms.,16720068_6,0
5444,CPK,60,63,"7 days later, the fever disappeared and the patient's serum CPK levels were normalized (175 IU/L).",16720068_7,0
5246,neuroleptic malignant syndrome,40,70,"This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.",16720068_8,1
5445,paroxetine,145,155,"This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment.",16720068_8,0
5247,adverse drug reaction,4,25,"The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case, indicating a probable relationship between the patient's NMS-like adverse symptoms and the combined treatment used in this case.",16720068_9,1
5448,adverse symptoms,151,167,"The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case, indicating a probable relationship between the patient's NMS-like adverse symptoms and the combined treatment used in this case.",16720068_9,1
1408,local anesthetics,234,251,Down-regulation of norepinephrine transporter function induced by chronic administration of desipramine linking to the alteration of sensitivity of local-anesthetics-induced convulsions and the counteraction by co-administration with local anesthetics.,16725121_0,0
1407,norepinephrine transporter,19,45,Down-regulation of norepinephrine transporter function induced by chronic administration of desipramine linking to the alteration of sensitivity of local-anesthetics-induced convulsions and the counteraction by co-administration with local anesthetics.,16725121_0,0
5454,local-anesthetics-induced convulsions,148,185,Down-regulation of norepinephrine transporter function induced by chronic administration of desipramine linking to the alteration of sensitivity of local-anesthetics-induced convulsions and the counteraction by co-administration with local anesthetics.,16725121_0,0
1409,norepinephrine transporter,15,41,Alterations of norepinephrine transporter (NET) function by chronic inhibition of NET in relation to sensitization to seizures induce by cocaine and local anesthetics were studied in mice.,16725121_1,0
1410,local anesthetics,149,166,Alterations of norepinephrine transporter (NET) function by chronic inhibition of NET in relation to sensitization to seizures induce by cocaine and local anesthetics were studied in mice.,16725121_1,0
5455,chronic inhibition,60,78,Alterations of norepinephrine transporter (NET) function by chronic inhibition of NET in relation to sensitization to seizures induce by cocaine and local anesthetics were studied in mice.,16725121_1,1
1411,P2,118,120,"Daily administration of desipramine, an inhibitor of the NET, for 5 days decreased [(3)H]norepinephrine uptake in the P2 fractions of hippocampus but not cortex, striatum or amygdalae.",16725121_2,0
5456,[(3)H]norepinephrine,83,103,"Daily administration of desipramine, an inhibitor of the NET, for 5 days decreased [(3)H]norepinephrine uptake in the P2 fractions of hippocampus but not cortex, striatum or amygdalae.",16725121_2,0
1412,bupivacaine,32,43,"Co-administration of lidocaine, bupivacaine or tricaine with desipramine reversed this effect.",16725121_3,0
5457,tricaine,47,55,"Co-administration of lidocaine, bupivacaine or tricaine with desipramine reversed this effect.",16725121_3,0
5458,[(3)H]norepinephrine,37,57,Daily treatment of cocaine increased [(3)H]norepinephrine uptake into the hippocampus.,16725121_4,0
5459,lidocaine-induced convulsions,77,106,Daily administration of desipramine increased the incidence of appearance of lidocaine-induced convulsions and decreased that of cocaine-induced convulsions.,16725121_5,0
5460,cocaine-induced convulsions,129,156,Daily administration of desipramine increased the incidence of appearance of lidocaine-induced convulsions and decreased that of cocaine-induced convulsions.,16725121_5,0
5248,hippocampal,46,57,These results suggest that down-regulation of hippocampal NET induced by chronic administration of desipramine may be relevant to desipramine-induced sensitization of lidocaine convulsions.,16725121_7,1
5464,lidocaine convulsions,167,188,These results suggest that down-regulation of hippocampal NET induced by chronic administration of desipramine may be relevant to desipramine-induced sensitization of lidocaine convulsions.,16725121_7,0
1414,local anesthetics,32,49,Inhibition of Na(+) channels by local anesthetics may regulate desipramine-induced down-regulation of NET function.,16725121_8,0
1413,Na(+),14,19,Inhibition of Na(+) channels by local anesthetics may regulate desipramine-induced down-regulation of NET function.,16725121_8,0
5249,hippocampal,60,71,Repeated administration of cocaine induces up-regulation of hippocampal NET function.,16725121_9,1
1415,carbachol,33,42,Case report: acute unintentional carbachol intoxication.,16740173_0,0
1416,carbachol,33,42,"INTRODUCTION: Intoxications with carbachol, a muscarinic cholinergic receptor agonist are rare.",16740173_1,0
5469,muscarinic cholinergic receptor agonist,46,85,"INTRODUCTION: Intoxications with carbachol, a muscarinic cholinergic receptor agonist are rare.",16740173_1,0
5251,blood pressure,23,37,"On hospital admission, blood pressure of the intubated, bradyarrhythmic patient was 100/65 mmHg.",16740173_10,1
5252,hypersalivation,34,49,"Further signs were hyperhidrosis, hypersalivation, bronchorrhoea, and severe miosis; the electrocardiographic finding was atrio-ventricular dissociation.",16740173_11,1
5253,atrio-ventricular dissociation,122,152,"Further signs were hyperhidrosis, hypersalivation, bronchorrhoea, and severe miosis; the electrocardiographic finding was atrio-ventricular dissociation.",16740173_11,1
5479,bronchorrhoea,51,64,"Further signs were hyperhidrosis, hypersalivation, bronchorrhoea, and severe miosis; the electrocardiographic finding was atrio-ventricular dissociation.",16740173_11,1
5481,High doses,0,10,"High doses of atropine (up to 50 mg per 24 hours), adrenaline and dopamine were necessary.",16740173_12,0
5483,necessitated reintubation,45,70,"However, increased dyspnoea and bronchospasm necessitated reintubation.",16740173_14,1
5484,Respiratory insufficiency,0,25,Respiratory insufficiency was further worsened by Proteus mirabilis infection and severe bronchoconstriction.,16740173_15,1
5485,mirabilis infection,58,77,Respiratory insufficiency was further worsened by Proteus mirabilis infection and severe bronchoconstriction.,16740173_15,1
5486,bronchoconstriction,89,108,Respiratory insufficiency was further worsened by Proteus mirabilis infection and severe bronchoconstriction.,16740173_15,1
5254,heart failure,49,62,"On the next day he died, probably as a result of heart failure.",16740173_17,1
1421,carbachol,72,81,"Serum samples from the first and second days contained 3.6 and 1.9 mg/l carbachol, respectively.",16740173_18,0
1422,carbachol,66,75,"For the first time, an analytical method for the determination of carbachol in plasma and urine has been developed.",16740173_21,0
1423,carbachol,13,22,The analysed carbachol concentration exceeded the supposed serum level resulting from a therapeutic dose by a factor of 130 to 260.,16740173_22,0
5494,therapeutic dose,88,104,The analysed carbachol concentration exceeded the supposed serum level resulting from a therapeutic dose by a factor of 130 to 260.,16740173_22,0
5496,cause of,96,104,"Especially in old patients, intensivists should consider intoxications (with cholinergics) as a cause of acute cardiovascular failure.",16740173_23,1
5497,cardiovascular failure,111,133,"Especially in old patients, intensivists should consider intoxications (with cholinergics) as a cause of acute cardiovascular failure.",16740173_23,1
1424,cholinergics,77,89,"Especially in old patients, intensivists should consider intoxications (with cholinergics) as a cause of acute cardiovascular failure.",16740173_23,0
5495,intensivists,28,40,"Especially in old patients, intensivists should consider intoxications (with cholinergics) as a cause of acute cardiovascular failure.",16740173_23,0
1417,plant extracts,100,114,METHODS: The son of an 84-year-old male discovered a newspaper report stating clinical success with plant extracts in Alzheimer's disease.,16740173_3,0
5250,Alzheimer's disease,118,137,METHODS: The son of an 84-year-old male discovered a newspaper report stating clinical success with plant extracts in Alzheimer's disease.,16740173_3,1
1418,carbachol,106,115,"The mode of action was said to be comparable to that of the synthetic compound 'carbamylcholin'; that is, carbachol.",16740173_4,0
5472,synthetic compound 'carbamylcholin',60,95,"The mode of action was said to be comparable to that of the synthetic compound 'carbamylcholin'; that is, carbachol.",16740173_4,0
1419,carbachol,18,27,"He bought 25 g of carbachol as pure substance in a pharmacy, and the father was administered 400 to 500 mg.",16740173_5,0
5473,pure substance,31,45,"He bought 25 g of carbachol as pure substance in a pharmacy, and the father was administered 400 to 500 mg.",16740173_5,0
1420,Carbachol,0,9,Carbachol concentrations in serum and urine on day 1 and 2 of hospital admission were analysed by HPLC-mass spectrometry.,16740173_6,0
5476,cardiopulmonary resuscitation,8,37,"Initial cardiopulmonary resuscitation and immediate treatment with adrenaline (epinephrine), atropine and furosemide was successful.",16740173_9,1
5499,cognitive dysfunctions,81,103,Pharmacological evidence for the potential of Daucus carota in the management of cognitive dysfunctions.,16755009_0,1
5501,Daucus carota seeds,60,79,"The present study was aimed at investigating the effects of Daucus carota seeds on cognitive functions, total serum cholesterol levels and brain cholinesterase activity in mice.",16755009_1,0
5502,cognitive functions,83,102,"The present study was aimed at investigating the effects of Daucus carota seeds on cognitive functions, total serum cholesterol levels and brain cholinesterase activity in mice.",16755009_1,1
5255,cholesterol levels,116,134,"The present study was aimed at investigating the effects of Daucus carota seeds on cognitive functions, total serum cholesterol levels and brain cholinesterase activity in mice.",16755009_1,1
5524,DCE,68,71,The extent of inhibition of brain cholinesterase activity evoked by DCE at the dose of 400 mg/kg was 22% in young and 19% in aged mice.,16755009_10,0
5527,DCE,141,144,"There was a remarkable reduction in total cholesterol level as well, to the extent of 23% in young and 21% in aged animals with this dose of DCE.",16755009_11,0
5529,cognitive dysfunctions,69,91,"Therefore, DCE may prove to be a useful remedy for the management of cognitive dysfunctions on account of its multifarious beneficial effects such as, memory improving property, cholesterol lowering property and anticholinesterase activity.",16755009_12,1
5528,DCE,11,14,"Therefore, DCE may prove to be a useful remedy for the management of cognitive dysfunctions on account of its multifarious beneficial effects such as, memory improving property, cholesterol lowering property and anticholinesterase activity.",16755009_12,0
5503,ethanolic extract,4,21,"The ethanolic extract of Daucus carota seeds (DCE) was administered orally in three doses (100, 200, 400 mg/kg) for seven successive days to different groups of young and aged mice.",16755009_2,0
5504,Daucus carota seeds,25,44,"The ethanolic extract of Daucus carota seeds (DCE) was administered orally in three doses (100, 200, 400 mg/kg) for seven successive days to different groups of young and aged mice.",16755009_2,0
5505,DCE,46,49,"The ethanolic extract of Daucus carota seeds (DCE) was administered orally in three doses (100, 200, 400 mg/kg) for seven successive days to different groups of young and aged mice.",16755009_2,0
1425,Diazepam-,0,9,"Diazepam-, scopolamine- and ageing-induced amnesia served as the interoceptive behavioral models.",16755009_4,0
1426,scopolamine-,11,23,"Diazepam-, scopolamine- and ageing-induced amnesia served as the interoceptive behavioral models.",16755009_4,0
5508,ageing-induced amnesia,28,50,"Diazepam-, scopolamine- and ageing-induced amnesia served as the interoceptive behavioral models.",16755009_4,1
5509,DCE,0,3,"DCE (200, 400 mg/kg, p.o.) showed significant improvement in memory scores of young and aged mice.",16755009_5,0
5512,DCE,43,46,The extent of memory improvement evoked by DCE was 23% at the dose of 200 mg/kg and 35% at the dose of 400 mg/kg in young mice using elevated plus maze.,16755009_6,0
5518,DCE,13,16,"Furthermore, DCE reversed the amnesia induced by scopolamine (0.4 mg/kg, i.p.) and diazepam (1 mg/kg, i.p.).",16755009_8,0
5520,diazepam (1,83,94,"Furthermore, DCE reversed the amnesia induced by scopolamine (0.4 mg/kg, i.p.) and diazepam (1 mg/kg, i.p.).",16755009_8,0
1427,acetylcholinesterase,77,97,"Daucus carota extract (200, 400 mg/kg, p.o.) reduced significantly the brain acetylcholinesterase activity and cholesterol levels in young and aged mice.",16755009_9,0
5256,cholesterol levels,111,129,"Daucus carota extract (200, 400 mg/kg, p.o.) reduced significantly the brain acetylcholinesterase activity and cholesterol levels in young and aged mice.",16755009_9,1
5522,Daucus carota extract,0,21,"Daucus carota extract (200, 400 mg/kg, p.o.) reduced significantly the brain acetylcholinesterase activity and cholesterol levels in young and aged mice.",16755009_9,0
1428,Valproic acid,0,13,Valproic acid induced encephalopathy--19 new cases in Germany from 1994 to 2003--a side effect associated to VPA-therapy not only in young children.,16787750_0,0
5257,side effect,83,94,Valproic acid induced encephalopathy--19 new cases in Germany from 1994 to 2003--a side effect associated to VPA-therapy not only in young children.,16787750_0,1
1429,Valproic acid,0,13,Valproic acid (VPA) is a broad-spectrum antiepileptic drug and is usually well-tolerated.,16787750_1,0
1430,antiepileptic drug,40,58,Valproic acid (VPA) is a broad-spectrum antiepileptic drug and is usually well-tolerated.,16787750_1,0
5533,VPA,15,18,Valproic acid (VPA) is a broad-spectrum antiepileptic drug and is usually well-tolerated.,16787750_1,0
5534,haemorrhagic pancreatitis,65,90,"Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, VPA-induced hepatotoxicity and VPA-induced encephalopathy.",16787750_2,1
5258,bone marrow,92,103,"Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, VPA-induced hepatotoxicity and VPA-induced encephalopathy.",16787750_2,1
5535,hepatotoxicity,129,143,"Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, VPA-induced hepatotoxicity and VPA-induced encephalopathy.",16787750_2,1
5259,hyperammonemia,162,176,"The typical signs of VPA-induced encephalopathy are impaired consciousness, sometimes marked EEG background slowing, increased seizure frequency, with or without hyperammonemia.",16787750_3,1
5538,background slowing,97,115,"The typical signs of VPA-induced encephalopathy are impaired consciousness, sometimes marked EEG background slowing, increased seizure frequency, with or without hyperammonemia.",16787750_3,1
5540,VPA,47,50,"There is still no proof of causative effect of VPA in patients with encephalopathy, but only of an association with an assumed causal relation.",16787750_4,0
5545,tap water,173,182,"To assess the antioxidant effects of atorvastatin (atorva) on dexamethasone (dex)-induced hypertension, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.",16820346_1,0
5544,atorva,150,156,"To assess the antioxidant effects of atorvastatin (atorva) on dexamethasone (dex)-induced hypertension, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.",16820346_1,0
1431,antioxidant effects,14,33,"To assess the antioxidant effects of atorvastatin (atorva) on dexamethasone (dex)-induced hypertension, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.",16820346_1,0
5542,atorva,51,57,"To assess the antioxidant effects of atorvastatin (atorva) on dexamethasone (dex)-induced hypertension, 60 male Sprague-Dawley rats were treated with atorva 30 mg/kg/day or tap water for 15 days.",16820346_1,0
5260,blood pressure,23,37,"Dex increased systolic blood pressure (SBP) from 109 +/- 1.8 to 135 +/- 0.6 mmHg and plasma superoxide (5711 +/- 284.9 saline, 7931 +/- 392.8 U/ml dex, P < 0.001).",16820346_2,1
5555,atorva,37,43,"In this prevention study, SBP in the atorva + dex group was increased from 115 +/- 0.4 to 124 +/- 1.5 mmHg, but this was significantly lower than in the dex-only group (P' < 0.05).",16820346_3,0
1432,P',169,171,"In this prevention study, SBP in the atorva + dex group was increased from 115 +/- 0.4 to 124 +/- 1.5 mmHg, but this was significantly lower than in the dex-only group (P' < 0.05).",16820346_3,0
5565,atorva,160,166,"Atorva reversed dex-induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).",16820346_4,0
5559,Atorva,0,6,"Atorva reversed dex-induced hypertension (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001).",16820346_4,0
1433,nitrate/nitrite,7,22,"Plasma nitrate/nitrite (NOx) was decreased in dex-treated rats compared to saline-treated rats (11.2 +/- 1.08 microm, 15.3 +/- 1.17 microm, respectively, P < 0.05).",16820346_5,0
5569,Atorva,0,6,Atorva affected neither plasma NOx nor thymus weight.,16820346_6,0
5570,high-dose cytosine arabinoside,32,62,Peripheral neuropathy caused by high-dose cytosine arabinoside treatment in a patient with acute myeloid leukemia.,16826348_0,0
5262,acute myeloid leukemia,91,113,Peripheral neuropathy caused by high-dose cytosine arabinoside treatment in a patient with acute myeloid leukemia.,16826348_0,1
5261,Peripheral neuropathy,0,21,Peripheral neuropathy caused by high-dose cytosine arabinoside treatment in a patient with acute myeloid leukemia.,16826348_0,1
1434,cytosine arabinoside,110,130,"The central nervous system toxicity of high-dose cytosine arabinoside is well recognized, but the toxicity of cytosine arabinoside in the peripheral nervous system has been infrequently reported.",16826348_1,0
5572,high-dose cytosine arabinoside,39,69,"The central nervous system toxicity of high-dose cytosine arabinoside is well recognized, but the toxicity of cytosine arabinoside in the peripheral nervous system has been infrequently reported.",16826348_1,0
5263,nervous system,149,163,"The central nervous system toxicity of high-dose cytosine arabinoside is well recognized, but the toxicity of cytosine arabinoside in the peripheral nervous system has been infrequently reported.",16826348_1,1
5571,central nervous system toxicity,4,35,"The central nervous system toxicity of high-dose cytosine arabinoside is well recognized, but the toxicity of cytosine arabinoside in the peripheral nervous system has been infrequently reported.",16826348_1,1
5264,acute myeloid leukemia,46,68,A 49-year-old Japanese man was diagnosed with acute myeloid leukemia.,16826348_2,1
5574,high-dose cytosine arabinoside,50,80,"After he achieved complete remission, he received high-dose cytosine arabinoside treatment (2 g/m2 twice a day for 5 days; total, 20 g/m2) as consolidation therapy.",16826348_3,0
5573,complete remission,18,36,"After he achieved complete remission, he received high-dose cytosine arabinoside treatment (2 g/m2 twice a day for 5 days; total, 20 g/m2) as consolidation therapy.",16826348_3,1
5575,(2 g/m2,91,98,"After he achieved complete remission, he received high-dose cytosine arabinoside treatment (2 g/m2 twice a day for 5 days; total, 20 g/m2) as consolidation therapy.",16826348_3,0
5576,g/m2,133,137,"After he achieved complete remission, he received high-dose cytosine arabinoside treatment (2 g/m2 twice a day for 5 days; total, 20 g/m2) as consolidation therapy.",16826348_3,0
5578,high-dose cytosine arabinoside,20,50,"The first course of high-dose cytosine arabinoside resulted in no unusual symptoms, but on day 21 of the second course of treatment, the patient complained of numbness in his right foot.",16826348_4,0
5579,his right foot,171,185,"The first course of high-dose cytosine arabinoside resulted in no unusual symptoms, but on day 21 of the second course of treatment, the patient complained of numbness in his right foot.",16826348_4,1
5265,peripheral neuropathy,51,72,Electromyogram and nerve-conduction studies showed peripheral neuropathy in both peroneal nerves.,16826348_5,1
5581,peroneal nerves,81,96,Electromyogram and nerve-conduction studies showed peripheral neuropathy in both peroneal nerves.,16826348_5,1
5266,graft-versus-host disease,164,189,"This neuropathy was gradually resolving; however, after the patient received allogeneic bone marrow transplantation, the symptoms worsened, with the development of graft-versus-host disease, and the symptoms subsequently responded to methylprednisolone.",16826348_6,1
5582,bone marrow transplantation,88,115,"This neuropathy was gradually resolving; however, after the patient received allogeneic bone marrow transplantation, the symptoms worsened, with the development of graft-versus-host disease, and the symptoms subsequently responded to methylprednisolone.",16826348_6,1
1435,methylprednisolone,234,252,"This neuropathy was gradually resolving; however, after the patient received allogeneic bone marrow transplantation, the symptoms worsened, with the development of graft-versus-host disease, and the symptoms subsequently responded to methylprednisolone.",16826348_6,0
5583,high-dose cytosine arabinoside,68,98,"Although the mechanisms of peripheral neuropathy are still unclear, high-dose cytosine arabinoside is a therapy that is potentially toxic to the peripheral nervous system, and auto/alloimmunity may play an important role in these mechanisms.",16826348_7,0
5584,auto/alloimmunity,176,193,"Although the mechanisms of peripheral neuropathy are still unclear, high-dose cytosine arabinoside is a therapy that is potentially toxic to the peripheral nervous system, and auto/alloimmunity may play an important role in these mechanisms.",16826348_7,1
5268,nervous system,156,170,"Although the mechanisms of peripheral neuropathy are still unclear, high-dose cytosine arabinoside is a therapy that is potentially toxic to the peripheral nervous system, and auto/alloimmunity may play an important role in these mechanisms.",16826348_7,1
5267,peripheral neuropathy,27,48,"Although the mechanisms of peripheral neuropathy are still unclear, high-dose cytosine arabinoside is a therapy that is potentially toxic to the peripheral nervous system, and auto/alloimmunity may play an important role in these mechanisms.",16826348_7,1
5269,neurotoxicity,71,84,Effect of alpha-tocopherol and deferoxamine on methamphetamine-induced neurotoxicity.,16844102_0,1
1437,deferoxamine,31,43,Effect of alpha-tocopherol and deferoxamine on methamphetamine-induced neurotoxicity.,16844102_0,0
1436,alpha-tocopherol,10,26,Effect of alpha-tocopherol and deferoxamine on methamphetamine-induced neurotoxicity.,16844102_0,0
5585,dopaminergic neurotoxicity,29,55,Methamphetamine (MA)-induced dopaminergic neurotoxicity is believed to be associated with the increased formation of free radicals.,16844102_1,1
1438,free radicals,117,130,Methamphetamine (MA)-induced dopaminergic neurotoxicity is believed to be associated with the increased formation of free radicals.,16844102_1,0
5588,DFO,121,124,"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.",16844102_2,0
1439,alpha-tocopherol,34,50,"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.",16844102_2,0
1440,reactive oxygen species,78,101,"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.",16844102_2,0
1441,deferoxamine,107,119,"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.",16844102_2,0
5589,iron chelator,130,143,"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.",16844102_2,0
5270,neurotoxicity,163,176,"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.",16844102_2,1
5587,alpha-TC,52,60,"This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity.",16844102_2,0
5591,alpha-TC,24,32,The rat received either alpha-TC (20 mg/kg) intraperitoneally for 3 days and 30 min prior to MA administration or DFO (50 mg/kg) subcutaneously 30 min before MA administration.,16844102_4,0
5592,DFO,114,117,The rat received either alpha-TC (20 mg/kg) intraperitoneally for 3 days and 30 min prior to MA administration or DFO (50 mg/kg) subcutaneously 30 min before MA administration.,16844102_4,0
5594,DFO,158,161,"The concentrations of dopamine (DA), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and DFO pretreatment.",16844102_5,0
5593,alpha-TC,145,153,"The concentrations of dopamine (DA), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and DFO pretreatment.",16844102_5,0
5596,alpha-TC,0,8,alpha-TC and DFO attenuated the MA-induced hyperthermia as well as the alterations in the locomotor activity.,16844102_6,0
5597,DFO,13,16,alpha-TC and DFO attenuated the MA-induced hyperthermia as well as the alterations in the locomotor activity.,16844102_6,0
5600,lipid peroxidation,13,31,The level of lipid peroxidation was higher and the reduced glutathione concentration was lower in the MA-treated rats.,16844102_7,0
1442,reduced glutathione,51,70,The level of lipid peroxidation was higher and the reduced glutathione concentration was lower in the MA-treated rats.,16844102_7,0
5601,alpha-TC,47,55,These changes were significantly attenuated by alpha-TC and DFO.,16844102_8,0
5602,DFO,60,63,These changes were significantly attenuated by alpha-TC and DFO.,16844102_8,0
5606,neuronal damage,62,77,This suggests that alpha-TC and DFO ameliorate the MA-induced neuronal damage by decreasing the level of oxidative stress.,16844102_9,1
5607,oxidative stress,105,121,This suggests that alpha-TC and DFO ameliorate the MA-induced neuronal damage by decreasing the level of oxidative stress.,16844102_9,1
5603,alpha-TC,19,27,This suggests that alpha-TC and DFO ameliorate the MA-induced neuronal damage by decreasing the level of oxidative stress.,16844102_9,0
5608,Cerebral haemorrhage,0,20,Cerebral haemorrhage induced by warfarin - the influence of drug-drug interactions.,16858720_0,1
5610,preventability,49,63,"PURPOSE: To evaluate the frequency, severity and preventability of warfarin-induced cerebral haemorrhages due to warfarin and warfarin-drug interactions in patients living in the county of Osterg  tland, Sweden. METHODS: All patients with a diagnosed cerebral haemorrhage at three hospitals during the period 2000-2002 were identified.",16858720_1,1
5613,diagnosed cerebral haemorrhage,241,271,"PURPOSE: To evaluate the frequency, severity and preventability of warfarin-induced cerebral haemorrhages due to warfarin and warfarin-drug interactions in patients living in the county of Osterg  tland, Sweden. METHODS: All patients with a diagnosed cerebral haemorrhage at three hospitals during the period 2000-2002 were identified.",16858720_1,1
5611,warfarin-induced cerebral haemorrhages,67,105,"PURPOSE: To evaluate the frequency, severity and preventability of warfarin-induced cerebral haemorrhages due to warfarin and warfarin-drug interactions in patients living in the county of Osterg  tland, Sweden. METHODS: All patients with a diagnosed cerebral haemorrhage at three hospitals during the period 2000-2002 were identified.",16858720_1,1
5623,warfarin-related cerebral haemorrhages,28,66,A significant proportion of warfarin-related cerebral haemorrhages might have been prevented if greater caution had been taken when prescribing drugs known to interact with warfarin.,16858720_10,1
5615,cerebral haemorrhage,127,147,Medical records were studied retrospectively to evaluate whether warfarin and warfarin-drug interactions could have caused the cerebral haemorrhage.,16858720_2,1
5617,cerebral haemorrhage,33,53,"RESULTS: Among 593 patients with cerebral haemorrhage, 59 (10%) were assessed as related to warfarin treatment.",16858720_4,1
5618,fatal outcome,32,45,"Of the 59 cases, 26 (44%) had a fatal outcome, compared to 136 (25%) among the non-warfarin patients (p < 0.01).",16858720_6,1
5620,cerebral haemorrhages,30,51,CONCLUSIONS: Warfarin-induced cerebral haemorrhages are a major clinical problem with a high fatality rate.,16858720_8,1
5621,clinical problem,64,80,CONCLUSIONS: Warfarin-induced cerebral haemorrhages are a major clinical problem with a high fatality rate.,16858720_8,1
5624,thioperamide,30,42,"Antipsychotic-like profile of thioperamide, a selective H3-receptor antagonist in mice.",16867021_0,0
5625,H3-receptor antagonist,56,78,"Antipsychotic-like profile of thioperamide, a selective H3-receptor antagonist in mice.",16867021_0,0
1443,histaminergic,63,76,Experimental and clinical evidence points to a role of central histaminergic system in the pathogenesis of schizophrenia.,16867021_1,0
5661,THP,77,80,Climbing behavior induced by apomorphine was reduced in animals treated with THP.,16867021_10,0
5662,RAMH,53,57,"Such an effect was, however, reversed in presence of RAMH.",16867021_11,0
5663,THP,0,3,"THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.",16867021_12,0
5664,haloperidol-induced catalepsy,60,89,"THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice.",16867021_12,1
5667,THP,16,19,Such effects of THP were reversed by RAMH indicating the involvement of histamine H(3)-receptors.,16867021_13,0
5668,RAMH,37,41,Such effects of THP were reversed by RAMH indicating the involvement of histamine H(3)-receptors.,16867021_13,0
1445,histamine H(3)-receptors,72,96,Such effects of THP were reversed by RAMH indicating the involvement of histamine H(3)-receptors.,16867021_13,0
5669,H(3)-receptor antagonists,33,58,Findings suggest a potential for H(3)-receptor antagonists in improving the refractory cases of schizophrenia.,16867021_14,0
5626,histamine H(3)-receptor ligands,54,85,"The present study was designed to study the effect of histamine H(3)-receptor ligands on neuroleptic-induced catalepsy, apomorphine-induced climbing behavior and amphetamine-induced locomotor activities in mice.",16867021_2,0
5627,neuroleptic-induced catalepsy,89,118,"The present study was designed to study the effect of histamine H(3)-receptor ligands on neuroleptic-induced catalepsy, apomorphine-induced climbing behavior and amphetamine-induced locomotor activities in mice.",16867021_2,1
5630,amphetamine (2,92,106,"Catalepsy was induced by haloperidol (2 mg/kg p.o.), while apomorphine (1.5 mg/kg s.c.) and amphetamine (2 mg/kg s.c.) were used for studying climbing behavior and locomotor activities, respectively.",16867021_3,0
1444,(2,37,39,"Catalepsy was induced by haloperidol (2 mg/kg p.o.), while apomorphine (1.5 mg/kg s.c.) and amphetamine (2 mg/kg s.c.) were used for studying climbing behavior and locomotor activities, respectively.",16867021_3,0
5633,RAMH,27,31,"(R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy.",16867021_4,0
5635,thioperamide,55,67,"(R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy.",16867021_4,0
5636,THP,69,72,"(R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy.",16867021_4,0
5632,(R)-alpha-methylhistamine,0,25,"(R)-alpha-methylhistamine (RAMH) (5 microg i.c.v.) and thioperamide (THP) (15 mg/kg i.p.), per se did not cause catalepsy.",16867021_4,0
5638,THP,18,21,"Administration of THP (3.75, 7.5 and 15 mg/kg i.p.) 1 h prior to haloperidol resulted in a dose-dependent increase in the catalepsy times (P < 0.05).",16867021_5,0
5644,THP,73,76,"However, pretreatment with RAMH significantly reversed such an effect of THP (15 mg/kg i.p.).",16867021_6,0
5646,RAMH,0,4,"RAMH per se showed significant reduction in locomotor time, distance traveled and average speed but THP (15 mg/kg i.p.) per se had no effect on these parameters.",16867021_7,0
5649,THP,100,103,"RAMH per se showed significant reduction in locomotor time, distance traveled and average speed but THP (15 mg/kg i.p.) per se had no effect on these parameters.",16867021_7,0
5652,THP,38,41,"On amphetamine-induced hyperactivity, THP (3.75 and 7.5 mg/kg i.p.) reduced locomotor time, distance traveled and average speed (P < 0.05).",16867021_8,0
5657,RAMH,18,22,Pretreatment with RAMH (5 microg i.c.v.) could partially reverse such effects of THP (3.75 mg/kg i.p.).,16867021_9,0
5659,THP,81,84,Pretreatment with RAMH (5 microg i.c.v.) could partially reverse such effects of THP (3.75 mg/kg i.p.).,16867021_9,0
5670,D-1,17,20,Blockade of both D-1 and D-2 dopamine receptors may induce catalepsy in mice.1.,1687392_0,0
1446,dopamine receptors,29,47,Blockade of both D-1 and D-2 dopamine receptors may induce catalepsy in mice.1.,1687392_0,0
1447,dopamine antagonists,25,45,The catalepsy induced by dopamine antagonists has been tested and the possible dopamine subtypes involved in catalepsy was determined.,1687392_1,0
5672,Dopamine antagonist fluphenazine,3,35,"2. Dopamine antagonist fluphenazine, D-1 antagonist SCH 23390 or D-2 antagonist sulpiride induced catalepsy.",1687392_2,0
5673,D-1 antagonist SCH,37,55,"2. Dopamine antagonist fluphenazine, D-1 antagonist SCH 23390 or D-2 antagonist sulpiride induced catalepsy.",1687392_2,0
5674,D-2 antagonist sulpiride,65,89,"2. Dopamine antagonist fluphenazine, D-1 antagonist SCH 23390 or D-2 antagonist sulpiride induced catalepsy.",1687392_2,0
1448,sulpiride,31,40,The effect of fluphenazine and sulpiride was dose-dependent.,1687392_3,0
1449,SCH,15,18,Combination of SCH 23390 with sulpiride did not induce catalepsy potentiation.,1687392_4,0
1450,sulpiride,30,39,Combination of SCH 23390 with sulpiride did not induce catalepsy potentiation.,1687392_4,0
1452,sulpiride,113,122,"3. D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride.",1687392_5,0
1451,SCH,100,103,"3. D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride.",1687392_5,0
5676,D-1 agonist SKF 38393,3,24,"3. D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride.",1687392_5,0
5677,D-2 agonist quinpirole,28,50,"3. D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride.",1687392_5,0
1453,SKF 38393,15,24,Combination of SKF 38393 with quinpirole did not cause potentiated inhibitory effect on catalepsy induced by dopamine antagonists.,1687392_7,0
1454,dopamine antagonists,109,129,Combination of SKF 38393 with quinpirole did not cause potentiated inhibitory effect on catalepsy induced by dopamine antagonists.,1687392_7,0
5678,quinpirole,30,40,Combination of SKF 38393 with quinpirole did not cause potentiated inhibitory effect on catalepsy induced by dopamine antagonists.,1687392_7,0
5680,D-1 receptor,88,100,"The data may indicate that although D-2 receptor blockade is involved in catalepsy, the D-1 receptor may plan a role.",1687392_9,0
5271,Cauda equina syndrome,0,21,Cauda equina syndrome after epidural steroid injection: a case report.,16904497_0,1
5272,radiculopathy,57,70,"OBJECTIVE: Conventional treatment methods of lumbusacral radiculopathy are physical therapy, epidural steroid injections, oral medications, and spinal manipulative therapy.",16904497_1,1
5683,oral medications,122,138,"OBJECTIVE: Conventional treatment methods of lumbusacral radiculopathy are physical therapy, epidural steroid injections, oral medications, and spinal manipulative therapy.",16904497_1,0
5697,her right leg,93,106,The neurologic evaluation revealed loss of sensation in the saddle area and medial aspect of her right leg.,16904497_10,1
5279,loss of,35,42,The neurologic evaluation revealed loss of sensation in the saddle area and medial aspect of her right leg.,16904497_10,1
5696,saddle area,60,71,The neurologic evaluation revealed loss of sensation in the saddle area and medial aspect of her right leg.,16904497_10,1
5700,right leg,54,63,Deep-tendon reflexes were decreased especially in the right leg.,16904497_12,1
5699,Deep-tendon reflexes,0,20,Deep-tendon reflexes were decreased especially in the right leg.,16904497_12,1
5701,gradual return of,10,27,She had a gradual return of motor function and ability of feeling Foley catheter.,16904497_15,1
5702,motor function,28,42,She had a gradual return of motor function and ability of feeling Foley catheter.,16904497_15,1
5705,steroid injections,51,69,CONCLUSION: Complications associated with epidural steroid injections are rare.,16904497_17,0
5706,Clinical examination,0,20,Clinical examination and continued vigilance for neurologic deterioration after epidural steroid injections is important.,16904497_18,1
5707,neurologic deterioration,49,73,Clinical examination and continued vigilance for neurologic deterioration after epidural steroid injections is important.,16904497_18,1
5685,epidural anesthesia,48,67,Cauda equina syndrome is a rare complication of epidural anesthesia.,16904497_2,1
5273,Cauda equina syndrome,0,21,Cauda equina syndrome is a rare complication of epidural anesthesia.,16904497_2,1
5274,cauda equina syndrome,34,55,The following case is a report of cauda equina syndrome possibly caused by epidural injection of triamcinolone and bupivacaine.,16904497_3,1
1455,bupivacaine,115,126,The following case is a report of cauda equina syndrome possibly caused by epidural injection of triamcinolone and bupivacaine.,16904497_3,0
5275,low back,44,52,CLINICAL FEATURES: A 50-year-old woman with low back and right leg pain was scheduled for epidural steroid injection.,16904497_4,1
5688,leg pain,63,71,CLINICAL FEATURES: A 50-year-old woman with low back and right leg pain was scheduled for epidural steroid injection.,16904497_4,1
5689,L4-5,105,109,INTERVENTION AND OUTCOME: An 18-gauge Touhy needle was inserted until loss of resistance occurred at the L4-5 level.,16904497_5,0
5276,loss of,70,77,INTERVENTION AND OUTCOME: An 18-gauge Touhy needle was inserted until loss of resistance occurred at the L4-5 level.,16904497_5,1
5691,epidural space,41,55,Spread of the contrast medium within the epidural space was determined by radiographic imaging.,16904497_6,1
5690,contrast medium,14,29,Spread of the contrast medium within the epidural space was determined by radiographic imaging.,16904497_6,0
1456,bupivacaine,36,47,"After verifying the epidural space, bupivacaine and triamcinolone diacetate were injected.",16904497_7,0
5694,triamcinolone diacetate,52,75,"After verifying the epidural space, bupivacaine and triamcinolone diacetate were injected.",16904497_7,0
5693,epidural space,20,34,"After verifying the epidural space, bupivacaine and triamcinolone diacetate were injected.",16904497_7,1
5277,radicular,46,55,"After the injection, there was a reduction in radicular symptoms.",16904497_8,1
5695,perineal numbness,37,54,"Three hours later, she complained of perineal numbness and lower extremity weakness.",16904497_9,1
5278,lower extremity weakness,59,83,"Three hours later, she complained of perineal numbness and lower extremity weakness.",16904497_9,1
5708,High-dose,0,9,High-dose testosterone is associated with atherosclerosis in postmenopausal women.,16938416_0,0
5714,aortic atherosclerosis,252,274,"METHODS: In a population-based study in 513 naturally postmenopausal women aged 54-67 years, we studied the association between self-reported intramuscularly administered high-dose estrogen-testosterone therapy (estradiol- and testosterone esters) and aortic atherosclerosis.",16938416_2,1
5711,high-dose,171,180,"METHODS: In a population-based study in 513 naturally postmenopausal women aged 54-67 years, we studied the association between self-reported intramuscularly administered high-dose estrogen-testosterone therapy (estradiol- and testosterone esters) and aortic atherosclerosis.",16938416_2,0
5713,testosterone esters,227,246,"METHODS: In a population-based study in 513 naturally postmenopausal women aged 54-67 years, we studied the association between self-reported intramuscularly administered high-dose estrogen-testosterone therapy (estradiol- and testosterone esters) and aortic atherosclerosis.",16938416_2,0
5280,abdominal aorta,92,107,"Aortic atherosclerosis was diagnosed by radiographic detection of calcified deposits in the abdominal aorta, which have been shown to reflect intima atherosclerosis.",16938416_3,1
5715,Aortic atherosclerosis,0,22,"Aortic atherosclerosis was diagnosed by radiographic detection of calcified deposits in the abdominal aorta, which have been shown to reflect intima atherosclerosis.",16938416_3,1
5719,body mass index,266,281,"In almost half of these women severe atherosclerosis of the aorta was present (n=11), while in women without hormone use severe atherosclerosis of the aorta was present in less than 20% (OR 3.1; 95% CI, 1.1-8.5, adjusted for age, years since menopause, smoking, and body mass index).",16938416_6,1
5282,blood pressure,95,109,"The association remained after additional adjustment for diabetes, cholesterol level, systolic blood pressure, or alcohol use.",16938416_7,1
5281,cholesterol level,67,84,"The association remained after additional adjustment for diabetes, cholesterol level, systolic blood pressure, or alcohol use.",16938416_7,1
5720,alcohol use,114,125,"The association remained after additional adjustment for diabetes, cholesterol level, systolic blood pressure, or alcohol use.",16938416_7,1
5721,high-dose,37,46,CONCLUSION: Our results suggest that high-dose testosterone therapy may adversely affect atherosclerosis in postmenopausal women and indicate that androgen replacement in these women may not be harmless.,16938416_9,0
5723,clinical improvement,10,30,Sustained clinical improvement of a patient with decompensated hepatitis B virus-related cirrhosis after treatment with lamivudine monotherapy.,16960342_0,1
5284,hepatocellular carcinoma,68,92,"Hepatitis B virus (HBV) infection, which causes liver cirrhosis and hepatocellular carcinoma, remains a major health problem in Asian countries.",16960342_1,1
5283,liver cirrhosis,48,63,"Hepatitis B virus (HBV) infection, which causes liver cirrhosis and hepatocellular carcinoma, remains a major health problem in Asian countries.",16960342_1,1
5727,HBV,19,22,"Hepatitis B virus (HBV) infection, which causes liver cirrhosis and hepatocellular carcinoma, remains a major health problem in Asian countries.",16960342_1,0
5285,health problem,110,124,"Hepatitis B virus (HBV) infection, which causes liver cirrhosis and hepatocellular carcinoma, remains a major health problem in Asian countries.",16960342_1,1
5737,liver transplantation,189,210,"The administration of lamivudine to patients with HBV-related cirrhosis, like our present case, should be considered as an initial medical therapeutic option, especially in countries where liver transplantation is not reliably available.",16960342_10,1
5728,chronically infected,98,118,"Recent development of vaccine for prevention is reported to be successful in reducing the size of chronically infected carriers, although the standard medical therapies have not been established up to now.",16960342_2,1
1457,reverse transcriptase inhibitor,45,76,"However, the administration of lamivudine, a reverse transcriptase inhibitor, for 23 months dramatically improved her liver severity.",16960342_6,0
5732,her liver severity,114,132,"However, the administration of lamivudine, a reverse transcriptase inhibitor, for 23 months dramatically improved her liver severity.",16960342_6,1
5286,drug resistant,23,37,"During this period, no drug resistant mutant HBV emerged, and the serum HBV-DNA level was continuously suppressed.",16960342_7,1
5733,HBV,45,48,"During this period, no drug resistant mutant HBV emerged, and the serum HBV-DNA level was continuously suppressed.",16960342_7,0
1458,hepatitis B surface antigen,15,42,"Moreover, both hepatitis B surface antigen and e antigen were observed to have disappeared in this patient.",16960342_9,0
1459,e antigen,47,56,"Moreover, both hepatitis B surface antigen and e antigen were observed to have disappeared in this patient.",16960342_9,0
5738,Antiarrhythmic effects,0,22,Antiarrhythmic effects of optical isomers of cibenzoline on canine ventricular arrhythmias.,1700207_0,0
5739,optical isomers,26,41,Antiarrhythmic effects of optical isomers of cibenzoline on canine ventricular arrhythmias.,1700207_0,0
5740,cibenzoline,45,56,Antiarrhythmic effects of optical isomers of cibenzoline on canine ventricular arrhythmias.,1700207_0,0
5741,ventricular arrhythmias,67,90,Antiarrhythmic effects of optical isomers of cibenzoline on canine ventricular arrhythmias.,1700207_0,1
5743,(+)-cibenzoline,26,41,Antiarrhythmic effects of (+)-cibenzoline and (-)-cibenzoline were examined using two canine ventricular arrhythmia models.,1700207_1,0
5742,Antiarrhythmic effects,0,22,Antiarrhythmic effects of (+)-cibenzoline and (-)-cibenzoline were examined using two canine ventricular arrhythmia models.,1700207_1,0
5744,(-)-cibenzoline,46,61,Antiarrhythmic effects of (+)-cibenzoline and (-)-cibenzoline were examined using two canine ventricular arrhythmia models.,1700207_1,0
1460,channel blockers,48,64,"Digitalis arrhythmia, which is suppressed by Na channel blockers, was induced by intermittent intravenous (i.v.) injection of ouabain in pentobarbital-anesthetized dogs.",1700207_2,0
5746,Digitalis arrhythmia,0,20,"Digitalis arrhythmia, which is suppressed by Na channel blockers, was induced by intermittent intravenous (i.v.) injection of ouabain in pentobarbital-anesthetized dogs.",1700207_2,1
1461,ouabain,126,133,"Digitalis arrhythmia, which is suppressed by Na channel blockers, was induced by intermittent intravenous (i.v.) injection of ouabain in pentobarbital-anesthetized dogs.",1700207_2,0
5748,Adrenaline arrhythmia,0,21,"Adrenaline arrhythmia, which is suppressed by Ca channel blockers, was induced by adrenaline infusion in halothane-anesthetized dogs.",1700207_3,1
5749,Ca channel blockers,46,65,"Adrenaline arrhythmia, which is suppressed by Ca channel blockers, was induced by adrenaline infusion in halothane-anesthetized dogs.",1700207_3,0
5751,(+)-cibenzoline,0,15,"(+)-cibenzoline suppressed digitalis- and adrenaline-induced arrhythmias, respectively.",1700207_5,0
5753,(+)-cibenzoline,47,62,"The minimum effective plasma concentrations of (+)-cibenzoline for digitalis- and adrenaline-induced arrhythmias were 1.4 +/- 0.4 and 2.0 +/- 0.6 micrograms/ml, respectively (mean +/- SD, n = 6).",1700207_6,0
5760,adrenaline-induced arrhythmias,137,167,"A lower dose of 1 mg/kg i.v. of (-)-cibenzoline suppressed the digitalis-induced arrhythmia, whereas 5 mg/kg i.v. was needed to suppress adrenaline-induced arrhythmias.",1700207_7,1
5758,(-)-cibenzoline,32,47,"A lower dose of 1 mg/kg i.v. of (-)-cibenzoline suppressed the digitalis-induced arrhythmia, whereas 5 mg/kg i.v. was needed to suppress adrenaline-induced arrhythmias.",1700207_7,0
5757,lower dose,2,12,"A lower dose of 1 mg/kg i.v. of (-)-cibenzoline suppressed the digitalis-induced arrhythmia, whereas 5 mg/kg i.v. was needed to suppress adrenaline-induced arrhythmias.",1700207_7,0
5761,(-)-cibenzoline,47,62,"The minimum effective plasma concentrations of (-)-cibenzoline for digitalis- and adrenaline-induced arrhythmia were 0.06 +/- 0.04 and 0.7 +/- 0.1 micrograms/ml, respectively (mean +/- SD, n = 6).",1700207_8,0
5762,adrenaline-induced arrhythmia,82,111,"The minimum effective plasma concentrations of (-)-cibenzoline for digitalis- and adrenaline-induced arrhythmia were 0.06 +/- 0.04 and 0.7 +/- 0.1 micrograms/ml, respectively (mean +/- SD, n = 6).",1700207_8,1
5767,Na channels,141,152,"The stronger antiarrhythmic effect of (-)-cibenzoline indicates that (-)-isomer may have an effect nearly 5-20 times stronger in suppressing Na channels, but effects of both drugs on Ca channels may be almost equipotent.",1700207_9,0
5768,Ca channels,183,194,"The stronger antiarrhythmic effect of (-)-cibenzoline indicates that (-)-isomer may have an effect nearly 5-20 times stronger in suppressing Na channels, but effects of both drugs on Ca channels may be almost equipotent.",1700207_9,0
5766,(-)-cibenzoline,38,53,"The stronger antiarrhythmic effect of (-)-cibenzoline indicates that (-)-isomer may have an effect nearly 5-20 times stronger in suppressing Na channels, but effects of both drugs on Ca channels may be almost equipotent.",1700207_9,0
1462,(-)-isomer,69,79,"The stronger antiarrhythmic effect of (-)-cibenzoline indicates that (-)-isomer may have an effect nearly 5-20 times stronger in suppressing Na channels, but effects of both drugs on Ca channels may be almost equipotent.",1700207_9,0
5769,cause of,63,71,Passage of mannitol into the brain around gliomas: a potential cause of rebound phenomenon.,17019386_0,1
5770,rebound phenomenon,72,90,Passage of mannitol into the brain around gliomas: a potential cause of rebound phenomenon.,17019386_0,1
5786,aggravating peritumoral edema,187,216,"CONCLUSIONS: The results of our study show that even after a single bolus, mannitol may leak through the altered BBB near gliomas, reversing the initial plasma-to-blood osmotic gradient, aggravating peritumoral edema and promoting rebound of ICP.",17019386_10,1
5784,BBB,113,116,"CONCLUSIONS: The results of our study show that even after a single bolus, mannitol may leak through the altered BBB near gliomas, reversing the initial plasma-to-blood osmotic gradient, aggravating peritumoral edema and promoting rebound of ICP.",17019386_10,0
5294,ICP,242,245,"CONCLUSIONS: The results of our study show that even after a single bolus, mannitol may leak through the altered BBB near gliomas, reversing the initial plasma-to-blood osmotic gradient, aggravating peritumoral edema and promoting rebound of ICP.",17019386_10,1
5287,brain edema,42,53,AIM: Widespread use of mannitol to reduce brain edema and lower elevated ICP in brain tumor patients continues to be afflicted by the so-called rebound phenomenon.,17019386_2,1
5288,ICP,73,76,AIM: Widespread use of mannitol to reduce brain edema and lower elevated ICP in brain tumor patients continues to be afflicted by the so-called rebound phenomenon.,17019386_2,1
5289,brain tumor,80,91,AIM: Widespread use of mannitol to reduce brain edema and lower elevated ICP in brain tumor patients continues to be afflicted by the so-called rebound phenomenon.,17019386_2,1
5771,brain parenchyma,29,45,Leakage of mannitol into the brain parenchyma through an altered BBB and secondary reversal of osmotic gradient is considered the major cause of rebound .,17019386_3,1
5772,BBB,65,68,Leakage of mannitol into the brain parenchyma through an altered BBB and secondary reversal of osmotic gradient is considered the major cause of rebound .,17019386_3,0
5290,brain tumor,130,141,As a contribution to this issue we decided to research the possible passage of mannitol into the brain after administration to 21 brain tumor patients.,17019386_5,1
5291,malignant glioma,90,106,"METHODS: Mannitol (18% solution; 1 g/kg) was administered as a bolus to patients (ten had malignant glioma, seven brain metastases and four meningioma) about 30 minutes before craniotomy.",17019386_6,1
5292,brain metastases,114,130,"METHODS: Mannitol (18% solution; 1 g/kg) was administered as a bolus to patients (ten had malignant glioma, seven brain metastases and four meningioma) about 30 minutes before craniotomy.",17019386_6,1
5776,white matter,56,68,"During resection, a sample of the surrounding edematous white matter was taken at the same time as a 10 ml venous blood sample.",17019386_7,1
1463,et,120,122,"Mannitol concentrations were measured in plasma and white matter by a modified version of the enzyme assay of Blonquist et al. RESULTS: In most glioma patients, mannitol concentrations in white matter were 2 to 6 times higher than in plasma (mean 3.5 times).",17019386_8,0
5293,neoplastic cells,160,176,In meningioma and metastases patients plasma concentrations of mannitol were higher than white matter concentrations except in three cases with infiltration by neoplastic cells.,17019386_9,1
5782,white matter,89,101,In meningioma and metastases patients plasma concentrations of mannitol were higher than white matter concentrations except in three cases with infiltration by neoplastic cells.,17019386_9,0
5295,atrial fibrillation,45,64,Optimising stroke prevention in non-valvular atrial fibrillation.,17020434_0,1
5296,Atrial fibrillation,0,19,Atrial fibrillation is associated with substantial morbidity and mortality.,17020434_1,1
1464,antithrombotic,34,48,"Pooled data from trials comparing antithrombotic treatment with placebo have shown that warfarin reduces the risk of stroke by 62%, and that aspirin alone reduces the risk by 22%.",17020434_2,0
5788,Ximelagatran,0,12,"Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests.",17020434_4,0
5789,vitamin K,81,90,"Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests.",17020434_4,0
5790,embolic events,129,143,"Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests.",17020434_4,1
5791,liver function,197,211,"Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests.",17020434_4,1
1465,direct thrombin inhibitor,22,47,"Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests.",17020434_4,0
5793,Irbesartan,57,67,The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.,17020434_5,0
5794,Vascular Events,86,101,The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.,17020434_5,1
5796,clopidogrel plus,173,189,The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.,17020434_5,0
5797,af embolic events,217,234,The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events.,17020434_5,1
5798,Idraparinux,0,11,"Idraparinux, a Factor Xa inhibitor, is being evaluated in patients with atrial fibrillation.",17020434_6,0
5297,atrial fibrillation,72,91,"Idraparinux, a Factor Xa inhibitor, is being evaluated in patients with atrial fibrillation.",17020434_6,1
1466,Factor Xa inhibitor,15,34,"Idraparinux, a Factor Xa inhibitor, is being evaluated in patients with atrial fibrillation.",17020434_6,0
5299,remodelling,136,147,Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through cardiac remodelling.,17020434_7,1
5298,atrial fibrillation,100,119,Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through cardiac remodelling.,17020434_7,1
1468,angiotensin II,45,59,Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through cardiac remodelling.,17020434_7,0
1467,Angiotensin-converting enzyme inhibitors,0,40,Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through cardiac remodelling.,17020434_7,0
5799,cardioversion,102,115,Preliminary studies suggest that statins could interfere with the risk of recurrence after electrical cardioversion.,17020434_8,0
5300,left atrial,51,62,"Finally, percutaneous methods for the exclusion of left atrial appendage are under investigation in high-risk patients.",17020434_9,1
1469,quetiapine,62,72,Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.,17042884_0,0
5802,bipolar mania,112,125,Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.,17042884_0,1
5301,extrapyramidal,27,41,Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.,17042884_0,1
5804,bipolar mania,109,122,"OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with bipolar mania.",17042884_1,1
1470,quetiapine,81,91,"OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with bipolar mania.",17042884_1,0
5302,extrapyramidal,24,38,"OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with bipolar mania.",17042884_1,1
5303,akathisia,65,74,"OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with bipolar mania.",17042884_1,1
5837,cerebellar tremor,114,131,"Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.",17042884_10,1
5838,adverse effect,150,164,"Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.",17042884_10,1
1476,quetiapine,95,105,"Lithium was associated with a significantly higher incidence (p < 0.05) of tremor (18.4%) than quetiapine (5.6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving lithium therapy.",17042884_10,0
5839,extrapyramidal syndrome,131,154,"Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.",17042884_11,1
1477,quetiapine,180,190,"Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.",17042884_11,0
5308,akathisia,68,77,"Haloperidol induced a significantly higher incidence (p < 0.001) of akathisia (33.3% versus 5.9%), tremor (30.3% versus 7.8%), and extrapyramidal syndrome (35.4% versus 5.9%) than quetiapine.",17042884_11,1
1478,quetiapine,49,59,No significant differences were observed between quetiapine and placebo on SAS and BARS scores.,17042884_12,0
1479,quetiapine,45,55,Anticholinergic use was low and similar with quetiapine or placebo.,17042884_13,0
1480,quetiapine,79,89,"CONCLUSIONS: In bipolar mania, the incidence of EPS, including akathisia, with quetiapine therapy is similar to that with placebo.",17042884_14,0
5309,akathisia,63,72,"CONCLUSIONS: In bipolar mania, the incidence of EPS, including akathisia, with quetiapine therapy is similar to that with placebo.",17042884_14,1
1471,quetiapine,22,32,"Two studies evaluated quetiapine monotherapy (up to 800 mg/day) (n = 209) versus placebo (n = 198), with lithium or haloperidol monotherapy as respective active controls.",17042884_3,0
1473,divalproex,102,112,"Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203).",17042884_4,0
1472,quetiapine,22,32,"Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203).",17042884_4,0
5813,PBO,179,182,"Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203).",17042884_4,0
5812,mood stabilizer,162,177,"Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203).",17042884_4,0
5811,Li/DVP,120,126,"Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203).",17042884_4,0
5809,mood stabilizer,74,89,"Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203).",17042884_4,0
5810,QTP,114,117,"Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203).",17042884_4,0
5305,Akathisia,87,96,"Extrapyramidal symptoms were evaluated using the Simpson-Angus Scale (SAS), the Barnes Akathisia Rating Scale (BARS), adverse event reports and anticholinergic drug usage.",17042884_5,1
5816,adverse event,118,131,"Extrapyramidal symptoms were evaluated using the Simpson-Angus Scale (SAS), the Barnes Akathisia Rating Scale (BARS), adverse event reports and anticholinergic drug usage.",17042884_5,1
5817,anticholinergic drug,144,164,"Extrapyramidal symptoms were evaluated using the Simpson-Angus Scale (SAS), the Barnes Akathisia Rating Scale (BARS), adverse event reports and anticholinergic drug usage.",17042884_5,0
5304,Extrapyramidal,0,14,"Extrapyramidal symptoms were evaluated using the Simpson-Angus Scale (SAS), the Barnes Akathisia Rating Scale (BARS), adverse event reports and anticholinergic drug usage.",17042884_5,1
5818,EPS-related adverse events,26,52,"RESULTS: The incidence of EPS-related adverse events, including akathisia, was no different with quetiapine monotherapy (12.9%) than with placebo (13.1%).",17042884_6,1
5306,akathisia,64,73,"RESULTS: The incidence of EPS-related adverse events, including akathisia, was no different with quetiapine monotherapy (12.9%) than with placebo (13.1%).",17042884_6,1
1474,quetiapine,97,107,"RESULTS: The incidence of EPS-related adverse events, including akathisia, was no different with quetiapine monotherapy (12.9%) than with placebo (13.1%).",17042884_6,0
5823,PBO,92,95,"Similarly, EPS-related adverse events with QTP + Li/DVP (21.4%) were no different than with PBO + Li/DVP (19.2%).",17042884_7,0
5820,EPS-related adverse events,11,37,"Similarly, EPS-related adverse events with QTP + Li/DVP (21.4%) were no different than with PBO + Li/DVP (19.2%).",17042884_7,1
5829,adverse events,187,201,"Adverse events related to EPS occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.",17042884_8,1
5825,Adverse events,0,14,"Adverse events related to EPS occurred in 59.6% of patients treated with haloperidol (n = 99) monotherapy, whereas 26.5% of patients treated with lithium (n = 98) monotherapy experienced adverse events related to EPS.",17042884_8,1
5834,PBO,135,138,"The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).",17042884_9,0
1475,quetiapine,52,62,"The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).",17042884_9,0
5307,akathisia,17,26,"The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).",17042884_9,1
5832,QTP,111,114,"The incidence of akathisia was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/DVP (3.6%) and PBO + Li/DVP (4.9%).",17042884_9,0
1481,Anti-oxidant effects,0,20,Anti-oxidant effects of atorvastatin in dexamethasone-induced hypertension in the rat.1.,17042910_0,0
5844,O2-,156,159,Dexamethasone (Dex)-induced hypertension is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.,17042910_1,0
5842,endothelial dysfunction,61,84,Dexamethasone (Dex)-induced hypertension is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.,17042910_1,1
1482,nitric oxide,101,113,Dexamethasone (Dex)-induced hypertension is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production.,17042910_1,0
1485,/- 2,60,64,"In rats treated with Dex alone, SBP was increased from 109 +/- 2 to 133 +/- 2 mmHg on Days 4 and Day 14, respectively (P < 0.001).",17042910_10,0
5862,Dex,21,24,"In rats treated with Dex alone, SBP was increased from 109 +/- 2 to 133 +/- 2 mmHg on Days 4 and Day 14, respectively (P < 0.001).",17042910_10,0
1486,/- 2,52,56,"In the Ato + Dex group, SBP was increased from 113 +/- 2 to 119 +/- 2 mmHg on Days 4 to 14, respectively (P < 0.001), but was significantly lower than SBP in the group treated with Dex alone (P < 0.05).",17042910_11,0
5869,Dex,181,184,"In the Ato + Dex group, SBP was increased from 113 +/- 2 to 119 +/- 2 mmHg on Days 4 to 14, respectively (P < 0.001), but was significantly lower than SBP in the group treated with Dex alone (P < 0.05).",17042910_11,0
5865,Dex,13,16,"In the Ato + Dex group, SBP was increased from 113 +/- 2 to 119 +/- 2 mmHg on Days 4 to 14, respectively (P < 0.001), but was significantly lower than SBP in the group treated with Dex alone (P < 0.05).",17042910_11,0
5875,Dex,106,109,"Endothelial-dependent relaxation and eNOS mRNA expression were greater in the Dex + Ato group than in the Dex only group (P < 0.05 and P < 0.0001, respectively).",17042910_12,0
5873,Dex,78,81,"Endothelial-dependent relaxation and eNOS mRNA expression were greater in the Dex + Ato group than in the Dex only group (P < 0.05 and P < 0.0001, respectively).",17042910_12,0
5871,eNOS,37,41,"Endothelial-dependent relaxation and eNOS mRNA expression were greater in the Dex + Ato group than in the Dex only group (P < 0.05 and P < 0.0001, respectively).",17042910_12,0
5877,Dex,99,102,Aortic superoxide production was lower in the Dex + Ato group compared with the group treated with Dex alone (P < 0.0001).,17042910_13,0
5876,Dex,46,49,Aortic superoxide production was lower in the Dex + Ato group compared with the group treated with Dex alone (P < 0.0001).,17042910_13,0
5878,endothelial function,28,48,"Treatment with Ato improved endothelial function, reduced superoxide production and reduced SBP in Dex-treated SD rats.",17042910_15,1
5879,SBP,92,95,"Treatment with Ato improved endothelial function, reduced superoxide production and reduced SBP in Dex-treated SD rats.",17042910_15,0
5846,O2-,157,160,Atorvastatin (Ato) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced O2- production in various forms of hypertension.,17042910_2,0
5845,endothelial function,87,107,Atorvastatin (Ato) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced O2- production in various forms of hypertension.,17042910_2,1
5310,blood pressure,204,218,"In the present study, we investigated whether 50 mg/kg per day, p.o., Ato could prevent endothelial NO synthase (eNOS) downregulation and the increase in O2- in Sprague-Dawley (SD) rats, thereby reducing blood pressure.",17042910_3,1
5847,eNOS,113,117,"In the present study, we investigated whether 50 mg/kg per day, p.o., Ato could prevent endothelial NO synthase (eNOS) downregulation and the increase in O2- in Sprague-Dawley (SD) rats, thereby reducing blood pressure.",17042910_3,0
5849,O2-,154,157,"In the present study, we investigated whether 50 mg/kg per day, p.o., Ato could prevent endothelial NO synthase (eNOS) downregulation and the increase in O2- in Sprague-Dawley (SD) rats, thereby reducing blood pressure.",17042910_3,0
1483,NO synthase,100,111,"In the present study, we investigated whether 50 mg/kg per day, p.o., Ato could prevent endothelial NO synthase (eNOS) downregulation and the increase in O2- in Sprague-Dawley (SD) rats, thereby reducing blood pressure.",17042910_3,0
5851,Ato,43,46,2. Male SD rats (n = 30) were treated with Ato (50 mg/kg per day in drinking water) or tap water for 15 days.,17042910_4,0
5852,tap water,87,96,2. Male SD rats (n = 30) were treated with Ato (50 mg/kg per day in drinking water) or tap water for 15 days.,17042910_4,0
1484,drinking water,68,82,2. Male SD rats (n = 30) were treated with Ato (50 mg/kg per day in drinking water) or tap water for 15 days.,17042910_4,0
5311,blood pressure,9,23,Systolic blood pressure (SBP) was measured on alternate days using the tail-cuff method.,17042910_6,1
5856,Endothelial function,0,20,Endothelial function was assessed by acetylcholine-induced vasorelaxation and phenylephrine-induced vasoconstriction in aortic segments.,17042910_7,1
5857,acetylcholine-induced vasorelaxation,37,73,Endothelial function was assessed by acetylcholine-induced vasorelaxation and phenylephrine-induced vasoconstriction in aortic segments.,17042910_7,0
5860,eNOS,9,13,Vascular eNOS mRNA was assessed by semi-quantitative reverse transcription-polymerase chain reaction.,17042910_8,0
5882,myelomeningocoele,112,129,Is phenytoin administration safe in a hypothermic child?A male neonate with a Chiari malformation and a leaking myelomeningocoele underwent ventriculoperitoneal shunt insertion followed by repair of myelomeningocoele.,17049862_0,1
5884,myelomeningocoele,199,216,Is phenytoin administration safe in a hypothermic child?A male neonate with a Chiari malformation and a leaking myelomeningocoele underwent ventriculoperitoneal shunt insertion followed by repair of myelomeningocoele.,17049862_0,1
5883,ventriculoperitoneal shunt,140,166,Is phenytoin administration safe in a hypothermic child?A male neonate with a Chiari malformation and a leaking myelomeningocoele underwent ventriculoperitoneal shunt insertion followed by repair of myelomeningocoele.,17049862_0,1
5881,Chiari,78,84,Is phenytoin administration safe in a hypothermic child?A male neonate with a Chiari malformation and a leaking myelomeningocoele underwent ventriculoperitoneal shunt insertion followed by repair of myelomeningocoele.,17049862_0,1
5885,Intravenous phenytoin,0,21,Intravenous phenytoin was administered during the later part of the surgery for seizure prophylaxis.,17049862_2,0
5886,acute severe bradycardia,58,82,"Following phenytoin administration, the patient developed acute severe bradycardia, refractory to atropine and adrenaline.",17049862_3,1
1487,cardiac depressant,4,22,The cardiac depressant actions of phenytoin and hypothermia can be additive.,17049862_4,0
5312,adverse cardiac event,74,95,Administration of phenytoin in the presence of hypothermia may lead to an adverse cardiac event in children.,17049862_5,1
5313,nonketotic hyperglycinemia,56,82,Valproate-induced chorea and encephalopathy in atypical nonketotic hyperglycinemia.,17074608_0,1
5314,Nonketotic hyperglycinemia,0,26,Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments.,17074608_1,1
1488,glycine cleavage system,91,114,Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments.,17074608_1,0
5315,amino acid metabolism,44,65,Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments.,17074608_1,1
5888,body compartments,174,191,Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments.,17074608_1,1
5890,psychomotor retardation,114,137,"In the classical form it presents as neonatal apnea, intractable seizures, and hypotonia, followed by significant psychomotor retardation.",17074608_2,1
5889,intractable seizures,53,73,"In the classical form it presents as neonatal apnea, intractable seizures, and hypotonia, followed by significant psychomotor retardation.",17074608_2,1
5316,of children,20,31,An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner.,17074608_3,1
5317,nonketotic hyperglycinemia,37,63,An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner.,17074608_3,1
5891,language delay and mental retardation,42,79,"This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.",17074608_4,1
5893,valproate,222,231,"This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.",17074608_4,0
1489,her,140,143,"This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.",17074608_4,0
5892,acute encephalopathy,162,182,"This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.",17074608_4,1
5318,nonketotic hyperglycinemia,103,129,"This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy.",17074608_4,1
5897,paroxetine,59,69,"Reported medications included bumetanide, pravastatin, and paroxetine.",17111419_4,0
1490,bumetanide,30,40,"Reported medications included bumetanide, pravastatin, and paroxetine.",17111419_4,0
5898,acute onset of,32,46,She then very rapidly developed acute onset of severe facial and extremity tetany.,17111419_6,1
5899,extremity tetany,65,81,She then very rapidly developed acute onset of severe facial and extremity tetany.,17111419_6,1
1491,calcium gluconate,37,54,"Empirical treatment with intravenous calcium gluconate was initiated, and muscle contractions slowly subsided over approximately 10 to 15 minutes.",17111419_7,0
5900,muscle contractions,74,93,"Empirical treatment with intravenous calcium gluconate was initiated, and muscle contractions slowly subsided over approximately 10 to 15 minutes.",17111419_7,1
5902,calcium chelation,52,69,The events are consistent with a severe reaction to calcium chelation by sodium citrate anticoagulant resulting in symptomatic systemic hypocalcemia.,17111419_8,0
5904,systemic hypocalcemia,127,148,The events are consistent with a severe reaction to calcium chelation by sodium citrate anticoagulant resulting in symptomatic systemic hypocalcemia.,17111419_8,1
5903,sodium citrate anticoagulant,73,101,The events are consistent with a severe reaction to calcium chelation by sodium citrate anticoagulant resulting in symptomatic systemic hypocalcemia.,17111419_8,0
1492,bumetanide,58,68,"Upon additional retrospective analysis, it was noted that bumetanide is a loop diuretic that may cause significant hypocalcemia.",17111419_9,0
1493,loop diuretic,74,87,"Upon additional retrospective analysis, it was noted that bumetanide is a loop diuretic that may cause significant hypocalcemia.",17111419_9,0
5320,brain edema,78,89,Delayed institution of hypertension during focal cerebral ischemia: effect on brain edema.,1711760_0,1
5319,cerebral ischemia,49,66,Delayed institution of hypertension during focal cerebral ischemia: effect on brain edema.,1711760_0,1
5908,MCAO,108,112,The effect of induced hypertension instituted after a 2-h delay following middle cerebral artery occlusion (MCAO) on brain edema formation and histochemical injury was studied.,1711760_1,0
5323,brain edema,117,128,The effect of induced hypertension instituted after a 2-h delay following middle cerebral artery occlusion (MCAO) on brain edema formation and histochemical injury was studied.,1711760_1,1
5321,induced hypertension,14,34,The effect of induced hypertension instituted after a 2-h delay following middle cerebral artery occlusion (MCAO) on brain edema formation and histochemical injury was studied.,1711760_1,1
5322,middle cerebral artery occlusion,74,106,The effect of induced hypertension instituted after a 2-h delay following middle cerebral artery occlusion (MCAO) on brain edema formation and histochemical injury was studied.,1711760_1,1
5923,ischemic territory,24,42,"In the periphery of the ischemic territory, SG in the cortex was greater (less edema accumulation) in the hypertensive group (1.041 +/- 0.001 vs 1.039 +/- 0.001, P less than 0.05).",1711760_10,1
1494,/- 2,147,151,"The area of histochemical injury (as a percent of the cross-sectional area of the hemisphere) was less in the hypertensive group (33 +/- 3% vs 21 +/- 2%, P less than 0.05).",1711760_11,0
5932,ischemic core,116,129,"The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.",1711760_12,1
5934,histochemical neuronal dysfunction,230,264,"The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.",1711760_12,1
5931,MCAO,79,83,"The data indicate that phenylephrine-induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction.",1711760_12,0
5324,MCA,33,36,"Under isoflurane anesthesia, the MCA of 14 spontaneously hypertensive rats was occluded.",1711760_2,1
5910,mean arterial pressure,34,56,"In the control group (n = 7), the mean arterial pressure (MAP) was not manipulated.",1711760_3,1
5913,MCAO,91,95,"In the hypertensive group (n = 7), the MAP was elevated by 25-30 mm Hg beginning 2 h after MCAO.",1711760_4,1
5914,MCAO,17,21,"Four hours after MCAO, the rats were killed and the brains harvested.",1711760_5,0
5916,MCAO,97,101,The brains were sectioned along coronal planes spanning the distribution of ischemia produced by MCAO.,1711760_6,0
5918,ischemic territory,112,130,Specific gravity (SG) was determined in the subcortex and in two sites in the cortex (core and periphery of the ischemic territory).,1711760_7,1
5919,neuronal injury,14,29,"The extent of neuronal injury was determined by 2,3,5-triphenyltetrazolium staining.",1711760_8,1
5921,ischemic core,7,20,"In the ischemic core, there was no difference in SG in the subcortex and cortex in the two groups.",1711760_9,1
5936,renal dysfunction,37,54,Sirolimus-associated proteinuria and renal dysfunction.,17147461_0,1
5937,antiproliferative actions,51,76,Sirolimus is a novel immunosuppressant with potent antiproliferative actions through its ability to inhibit the raptor-containing mammalian target of rapamycin protein kinase.,17147461_1,0
5938,mammalian target of rapamycin protein kinase,130,174,Sirolimus is a novel immunosuppressant with potent antiproliferative actions through its ability to inhibit the raptor-containing mammalian target of rapamycin protein kinase.,17147461_1,0
1495,Sirolimus,0,9,Sirolimus is a novel immunosuppressant with potent antiproliferative actions through its ability to inhibit the raptor-containing mammalian target of rapamycin protein kinase.,17147461_1,0
5955,renal function,250,264,"Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed.",17147461_10,1
5954,molecular effects,111,128,"Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed.",17147461_10,0
5329,adverse effects,15,30,"Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed.",17147461_10,1
1506,angiotensin II receptor blockers,317,349,"Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed.",17147461_10,0
1505,angiotensin-converting enzyme inhibitors,273,313,"Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed.",17147461_10,0
1504,sirolimus,168,177,"Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed.",17147461_10,0
1503,sirolimus,132,141,"Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed.",17147461_10,0
5956,renal allograft,30,45,Further long-term analysis of renal allograft studies using sirolimus as de novo immunosuppression along with clinical and laboratory studies will refine these issues in the future.,17147461_11,1
1508,novo,76,80,Further long-term analysis of renal allograft studies using sirolimus as de novo immunosuppression along with clinical and laboratory studies will refine these issues in the future.,17147461_11,0
1507,sirolimus,60,69,Further long-term analysis of renal allograft studies using sirolimus as de novo immunosuppression along with clinical and laboratory studies will refine these issues in the future.,17147461_11,0
1496,Sirolimus,0,9,Sirolimus represents a major therapeutic advance in the prevention of acute renal allograft rejection and chronic allograft nephropathy.,17147461_2,0
5941,chronic allograft nephropathy,106,135,Sirolimus represents a major therapeutic advance in the prevention of acute renal allograft rejection and chronic allograft nephropathy.,17147461_2,1
5940,acute renal allograft,70,91,Sirolimus represents a major therapeutic advance in the prevention of acute renal allograft rejection and chronic allograft nephropathy.,17147461_2,1
5939,therapeutic advance,29,48,Sirolimus represents a major therapeutic advance in the prevention of acute renal allograft rejection and chronic allograft nephropathy.,17147461_2,0
5326,renal cancer,87,99,"Its role in the therapy of glomerulonephritis, autoimmunity, cystic renal diseases and renal cancer is under investigation.",17147461_3,1
5325,cystic renal diseases,61,82,"Its role in the therapy of glomerulonephritis, autoimmunity, cystic renal diseases and renal cancer is under investigation.",17147461_3,1
1498,calcineurin inhibitors,82,104,"Because sirolimus does not share the vasomotor renal adverse effects exhibited by calcineurin inhibitors, it has been designated a 'non-nephrotoxic drug'.",17147461_4,0
5327,adverse effects,53,68,"Because sirolimus does not share the vasomotor renal adverse effects exhibited by calcineurin inhibitors, it has been designated a 'non-nephrotoxic drug'.",17147461_4,1
1497,sirolimus,8,17,"Because sirolimus does not share the vasomotor renal adverse effects exhibited by calcineurin inhibitors, it has been designated a 'non-nephrotoxic drug'.",17147461_4,0
1499,sirolimus,66,75,"However, clinical reports suggest that, under some circumstances, sirolimus is associated with proteinuria and acute renal dysfunction.",17147461_5,0
5945,acute renal dysfunction,111,134,"However, clinical reports suggest that, under some circumstances, sirolimus is associated with proteinuria and acute renal dysfunction.",17147461_5,1
5947,chronic renal damage,60,80,A common risk factor appears to be presence of pre-existing chronic renal damage.,17147461_6,1
1500,calcineurin inhibitor,143,164,The mechanisms of sirolimus-associated proteinuria are multifactorial and may be due to an increase in glomerular capillary pressure following calcineurin inhibitor withdrawal.,17147461_7,0
5949,glomerular capillary pressure,103,132,The mechanisms of sirolimus-associated proteinuria are multifactorial and may be due to an increase in glomerular capillary pressure following calcineurin inhibitor withdrawal.,17147461_7,1
1501,sirolimus,32,41,"It has also been suggested that sirolimus directly causes increased glomerular permeability/injury, but evidence for this mechanism is currently inconclusive.",17147461_8,0
5950,glomerular permeability/injury,68,98,"It has also been suggested that sirolimus directly causes increased glomerular permeability/injury, but evidence for this mechanism is currently inconclusive.",17147461_8,1
1502,sirolimus,44,53,The acute renal dysfunction associated with sirolimus (such as in delayed graft function) may be due to suppression of compensatory renal cell proliferation and survival/repair processes.,17147461_9,0
5951,acute renal dysfunction,4,27,The acute renal dysfunction associated with sirolimus (such as in delayed graft function) may be due to suppression of compensatory renal cell proliferation and survival/repair processes.,17147461_9,1
5952,compensatory renal cell,119,142,The acute renal dysfunction associated with sirolimus (such as in delayed graft function) may be due to suppression of compensatory renal cell proliferation and survival/repair processes.,17147461_9,1
5328,delayed graft function,66,88,The acute renal dysfunction associated with sirolimus (such as in delayed graft function) may be due to suppression of compensatory renal cell proliferation and survival/repair processes.,17147461_9,1
1509,sirolimus,32,41,Proteinuria after conversion to sirolimus in renal transplant recipients.,17175308_0,0
5957,renal transplant,45,61,Proteinuria after conversion to sirolimus in renal transplant recipients.,17175308_0,1
1510,Sirolimus,0,9,"Sirolimus (SRL) is a new, potent immunosuppressive agent.",17175308_1,0
5958,SRL,11,14,"Sirolimus (SRL) is a new, potent immunosuppressive agent.",17175308_1,0
1511,immunosuppressive agent,33,56,"Sirolimus (SRL) is a new, potent immunosuppressive agent.",17175308_1,0
5333,nephrotic,69,78,Twenty-eight percent of patients showed increased proteinuria to the nephrotic range.,17175308_11,1
5334,interstitial nephritis,116,138,Biopsies performed in five patients revealed new pathological changes: One membranoproliferative glomerulopathy and interstitial nephritis.,17175308_12,1
5972,membranoproliferative glomerulopathy,75,111,Biopsies performed in five patients revealed new pathological changes: One membranoproliferative glomerulopathy and interstitial nephritis.,17175308_12,1
5335,graft function,40,54,These patients showed persistently good graft function.,17175308_13,1
1513,creatinine,6,16,Serum creatinine values did not change significantly: 1.98 +/-,17175308_14,0
5974,SRL,17,20,0.8 mg/dL before SRL therapy and 2.53 +/- 1.9 mg/dL at last follow-up (P = .14).,17175308_15,0
5336,Kaposi's sarcoma,32,48,Five patients displayed CAN and Kaposi's sarcoma.,17175308_17,1
1514,(3,99,101,Mean urinary protein of patients who returned to dialysis was 1.26 (0.5 to 3.5) g/d before and 4.7 (3 to 12) g/d after conversion (P = .01).,17175308_18,0
1515,creatinine,11,21,"Mean serum creatinine level before conversion was 2.21 mg/dL and thereafter, 4.93 mg/dL (P = .02).",17175308_19,0
1512,sirolimus,65,74,"More recently, proteinuria has been reported as a consequence of sirolimus therapy, although the mechanism has remained unclear.",17175308_2,0
5977,SRL,46,49,Heavy proteinuria was common after the use of SRL as rescue therapy for renal transplantation.,17175308_20,0
5976,Heavy proteinuria,0,17,Heavy proteinuria was common after the use of SRL as rescue therapy for renal transplantation.,17175308_20,1
5979,renal transplantation,72,93,Heavy proteinuria was common after the use of SRL as rescue therapy for renal transplantation.,17175308_20,1
5980,SRL,54,57,The possibility of de novo glomerular pathology under SRL treatment requires further investigation by renal biopsy.,17175308_22,0
1516,novo,22,26,The possibility of de novo glomerular pathology under SRL treatment requires further investigation by renal biopsy.,17175308_22,0
5961,SRL,128,131,"We retrospectively examined the records of 25 renal transplant patients, who developed or displayed increased proteinuria after SRL conversion.",17175308_3,0
5960,renal transplant,46,62,"We retrospectively examined the records of 25 renal transplant patients, who developed or displayed increased proteinuria after SRL conversion.",17175308_3,1
5963,chronic allograft nephropathy,89,118,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,1
5330,Kaposi's sarcoma,153,169,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,1
5331,skin cancers,176,188,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,1
5962,SRL,55,58,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,0
5964,intestinal tumors,194,211,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,1
5965,BK virus nephropathy,241,261,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,1
5332,renal cell,217,227,"The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2).",17175308_4,1
5966,SRL,0,3,SRL was started at a mean of 78 +/- 42 (15 to 163) months after transplantation.,17175308_5,0
5969,SRL,18,21,Mean follow-up on SRL therapy was 20 +/- 12 (6 to 43) months.,17175308_6,0
5971,no proteinuria,39,53,"Before conversion 8 (32%) patients had no proteinuria, whereas afterwards all patients had proteinuria.",17175308_8,1
1517,anabolic androgenic steroid,31,58,Behavioral effects of pubertal anabolic androgenic steroid exposure in male rats with low serotonin.,17194457_0,0
1518,anabolic androgenic steroid,72,99,"The goal of this study was to assess the interactive effects of chronic anabolic androgenic steroid (AAS) exposure and brain serotonin (5-hydroxytryptamine, 5-HT) depletion on behavior of pubertal male rats.",17194457_1,0
5982,5-HT,157,161,"The goal of this study was to assess the interactive effects of chronic anabolic androgenic steroid (AAS) exposure and brain serotonin (5-hydroxytryptamine, 5-HT) depletion on behavior of pubertal male rats.",17194457_1,0
6003,sexual behavior,54,69,"T alone had no effect on locomotion, irritability, or sexual behavior but increased partner preference and aggression.",17194457_10,1
6004,partner preference,84,102,"T alone had no effect on locomotion, irritability, or sexual behavior but increased partner preference and aggression.",17194457_10,1
6005,T+PCPA,38,44,"The most striking effect of combining T+PCPA was a significant increase in attack frequency as well as a significant decrease in the latency to attack, particularly following physical provocation.",17194457_11,0
6006,attack frequency,75,91,"The most striking effect of combining T+PCPA was a significant increase in attack frequency as well as a significant decrease in the latency to attack, particularly following physical provocation.",17194457_11,1
1520,PCPA,83,87,"Serotonin was depleted beginning on postnatal day 26 with parachlorophenylalanine (PCPA 100 mg/kg, every other day); controls received saline.",17194457_2,0
1519,parachlorophenylalanine,58,81,"Serotonin was depleted beginning on postnatal day 26 with parachlorophenylalanine (PCPA 100 mg/kg, every other day); controls received saline.",17194457_2,0
1521,P40,12,15,"At puberty (P40), half the PCPA-treated rats and half the saline-treated rats began treatment with testosterone (T, 5 mg/kg, 5 days/week).",17194457_3,0
5984,partner preference,67,85,"Behavioral measures included locomotion, irritability, copulation, partner preference, and aggression.",17194457_4,1
5986,physical provocation,77,97,"Animals were tested for aggression in their home cage, both with and without physical provocation (mild tail pinch).",17194457_5,0
5991,5-HIAA,69,75,"Brain levels of 5-HT and its metabolite, 5-hydroxyindoleacetic acid (5-HIAA), were determined using HPLC.",17194457_6,0
5990,5-hydroxyindoleacetic acid,41,67,"Brain levels of 5-HT and its metabolite, 5-hydroxyindoleacetic acid (5-HIAA), were determined using HPLC.",17194457_6,0
5989,5-HT,16,20,"Brain levels of 5-HT and its metabolite, 5-hydroxyindoleacetic acid (5-HIAA), were determined using HPLC.",17194457_6,0
5994,5-HIAA,55,61,PCPA significantly and substantially depleted 5-HT and 5-HIAA in all brain regions examined.,17194457_7,0
5993,5-HT,46,50,PCPA significantly and substantially depleted 5-HT and 5-HIAA in all brain regions examined.,17194457_7,0
1522,PCPA,0,4,PCPA significantly and substantially depleted 5-HT and 5-HIAA in all brain regions examined.,17194457_7,0
1523,PCPA,117,121,"Chronic T treatment significantly decreased 5-HT and 5-HIAA in certain brain areas, but to a much lesser extent than PCPA.",17194457_8,0
5997,5-HIAA,53,59,"Chronic T treatment significantly decreased 5-HT and 5-HIAA in certain brain areas, but to a much lesser extent than PCPA.",17194457_8,0
5996,5-HT,44,48,"Chronic T treatment significantly decreased 5-HT and 5-HIAA in certain brain areas, but to a much lesser extent than PCPA.",17194457_8,0
5998,brain areas,71,82,"Chronic T treatment significantly decreased 5-HT and 5-HIAA in certain brain areas, but to a much lesser extent than PCPA.",17194457_8,1
6002,partner preference,139,157,"Chronic exposure to PCPA alone significantly decreased locomotor activity and increased irritability but had no effect on sexual behavior, partner preference, or aggression.",17194457_9,1
6001,sexual behavior,122,137,"Chronic exposure to PCPA alone significantly decreased locomotor activity and increased irritability but had no effect on sexual behavior, partner preference, or aggression.",17194457_9,1
5999,Chronic exposure,0,16,"Chronic exposure to PCPA alone significantly decreased locomotor activity and increased irritability but had no effect on sexual behavior, partner preference, or aggression.",17194457_9,1
1524,PCPA,20,24,"Chronic exposure to PCPA alone significantly decreased locomotor activity and increased irritability but had no effect on sexual behavior, partner preference, or aggression.",17194457_9,0
6010,mesenchymal tumors,83,101,Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report.,1720453_0,1
6016,Mesenchymal Tumor,209,226,The renal function of 74 children with malignant mesenchymal tumors in complete remission and who have received the same ifosfamide chemotherapy protocol (International Society of Pediatric Oncology Malignant Mesenchymal Tumor Study 84 [SIOP MMT 84]) were studied 1 year after the completion of treatment.,1720453_1,1
1525,ifosfamide,121,131,The renal function of 74 children with malignant mesenchymal tumors in complete remission and who have received the same ifosfamide chemotherapy protocol (International Society of Pediatric Oncology Malignant Mesenchymal Tumor Study 84 [SIOP MMT 84]) were studied 1 year after the completion of treatment.,1720453_1,0
6017,SIOP,237,241,The renal function of 74 children with malignant mesenchymal tumors in complete remission and who have received the same ifosfamide chemotherapy protocol (International Society of Pediatric Oncology Malignant Mesenchymal Tumor Study 84 [SIOP MMT 84]) were studied 1 year after the completion of treatment.,1720453_1,0
6015,complete remission,71,89,The renal function of 74 children with malignant mesenchymal tumors in complete remission and who have received the same ifosfamide chemotherapy protocol (International Society of Pediatric Oncology Malignant Mesenchymal Tumor Study 84 [SIOP MMT 84]) were studied 1 year after the completion of treatment.,1720453_1,1
6014,mesenchymal tumors,49,67,The renal function of 74 children with malignant mesenchymal tumors in complete remission and who have received the same ifosfamide chemotherapy protocol (International Society of Pediatric Oncology Malignant Mesenchymal Tumor Study 84 [SIOP MMT 84]) were studied 1 year after the completion of treatment.,1720453_1,1
6013,renal function,4,18,The renal function of 74 children with malignant mesenchymal tumors in complete remission and who have received the same ifosfamide chemotherapy protocol (International Society of Pediatric Oncology Malignant Mesenchymal Tumor Study 84 [SIOP MMT 84]) were studied 1 year after the completion of treatment.,1720453_1,1
6031,vesicoprostatic tumor,154,175,"Severe toxicity was correlated with the higher cumulative dose of 60 g/m2 of ifosfamide, a younger age (less than 2 1/2 years old), and a predominance of vesicoprostatic tumor involvement.",1720453_10,1
6030,younger age,91,102,"Severe toxicity was correlated with the higher cumulative dose of 60 g/m2 of ifosfamide, a younger age (less than 2 1/2 years old), and a predominance of vesicoprostatic tumor involvement.",1720453_10,1
6029,g/m2,69,73,"Severe toxicity was correlated with the higher cumulative dose of 60 g/m2 of ifosfamide, a younger age (less than 2 1/2 years old), and a predominance of vesicoprostatic tumor involvement.",1720453_10,0
1534,ifosfamide,77,87,"Severe toxicity was correlated with the higher cumulative dose of 60 g/m2 of ifosfamide, a younger age (less than 2 1/2 years old), and a predominance of vesicoprostatic tumor involvement.",1720453_10,0
1535,ifosfamide,83,93,This low percentage (5%) of TDFS must be evaluated with respect to the efficacy of ifosfamide in the treatment of mesenchymal tumors in children.,1720453_11,0
6034,mesenchymal tumors,114,132,This low percentage (5%) of TDFS must be evaluated with respect to the efficacy of ifosfamide in the treatment of mesenchymal tumors in children.,1720453_11,1
6033,TDFS,28,32,This low percentage (5%) of TDFS must be evaluated with respect to the efficacy of ifosfamide in the treatment of mesenchymal tumors in children.,1720453_11,0
6032,low percentage,5,19,This low percentage (5%) of TDFS must be evaluated with respect to the efficacy of ifosfamide in the treatment of mesenchymal tumors in children.,1720453_11,0
1527,ifosfamide,77,87,"Total cumulative doses were 36 or 60 g/m2 of ifosfamide (six or 10 cycles of ifosfamide, vincristine, and dactinomycin [IVA]).",1720453_2,0
1528,dactinomycin,106,118,"Total cumulative doses were 36 or 60 g/m2 of ifosfamide (six or 10 cycles of ifosfamide, vincristine, and dactinomycin [IVA]).",1720453_2,0
6018,g/m2,37,41,"Total cumulative doses were 36 or 60 g/m2 of ifosfamide (six or 10 cycles of ifosfamide, vincristine, and dactinomycin [IVA]).",1720453_2,0
1526,ifosfamide,45,55,"Total cumulative doses were 36 or 60 g/m2 of ifosfamide (six or 10 cycles of ifosfamide, vincristine, and dactinomycin [IVA]).",1720453_2,0
1529,cisplatin,26,35,None of them had received cisplatin chemotherapy.,1720453_3,0
5337,primary tumor,16,29,The most common primary tumor site was the head and neck.,1720453_5,1
5338,head and neck,43,56,The most common primary tumor site was the head and neck.,1720453_5,1
6021,osmolarity,130,140,"Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria.",1720453_6,0
1531,beta 2,196,202,"Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria.",1720453_6,0
6019,Renal function,0,14,"Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria.",1720453_6,1
1530,creatinine,142,152,"Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria.",1720453_6,0
6025,renal abnormalities,81,100,"Fifty-eight patients (78%) had normal renal tests, whereas 16 patients (22%) had renal abnormalities.",1720453_7,1
6027,TDFS,188,192,Two subsets of patients were identified from this latter group: the first included four patients (5% of the total population) who developed major toxicity resulting in Fanconi's syndrome (TDFS); and the second group included five patients with elevated beta 2 microglobulinuria and low phosphate reabsorption.,1720453_8,0
1532,beta 2,253,259,Two subsets of patients were identified from this latter group: the first included four patients (5% of the total population) who developed major toxicity resulting in Fanconi's syndrome (TDFS); and the second group included five patients with elevated beta 2 microglobulinuria and low phosphate reabsorption.,1720453_8,0
6026,Fanconi's syndrome,168,186,Two subsets of patients were identified from this latter group: the first included four patients (5% of the total population) who developed major toxicity resulting in Fanconi's syndrome (TDFS); and the second group included five patients with elevated beta 2 microglobulinuria and low phosphate reabsorption.,1720453_8,1
1533,beta 2,42,48,The remaining seven patients had isolated beta 2 microglobulinuria.,1720453_9,0
6036,UMB24,11,16,"Effects of UMB24 and (+/-)-SM 21, putative sigma2-preferring antagonists, on behavioral toxic and stimulant effects of cocaine in mice.",17241657_0,0
6037,(+/-)-SM,21,29,"Effects of UMB24 and (+/-)-SM 21, putative sigma2-preferring antagonists, on behavioral toxic and stimulant effects of cocaine in mice.",17241657_0,0
6038,sigma2-preferring,43,60,"Effects of UMB24 and (+/-)-SM 21, putative sigma2-preferring antagonists, on behavioral toxic and stimulant effects of cocaine in mice.",17241657_0,0
6040,sigma1 receptors,53,69,"Earlier studies have demonstrated that antagonism of sigma1 receptors attenuates the convulsive, lethal, locomotor stimulatory and rewarding actions of cocaine in mice.",17241657_1,0
1536,stimulatory,115,126,"Earlier studies have demonstrated that antagonism of sigma1 receptors attenuates the convulsive, lethal, locomotor stimulatory and rewarding actions of cocaine in mice.",17241657_1,0
6041,sigma2 receptors,33,49,"In contrast, the contribution of sigma2 receptors is unclear because experimental tools to selectively target this subtype are unavailable.",17241657_2,0
6043,UMB24,48,53,"To begin addressing this need, we characterized UMB24 (1-(2-phenethyl)-4-(2-pyridyl)-piperazine) and (+/-)-SM 21 (3alpha-tropanyl-2-(4-chorophenoxy)butyrate) in receptor binding and behavioral studies.",17241657_3,0
6044,(+/-)-SM,101,109,"To begin addressing this need, we characterized UMB24 (1-(2-phenethyl)-4-(2-pyridyl)-piperazine) and (+/-)-SM 21 (3alpha-tropanyl-2-(4-chorophenoxy)butyrate) in receptor binding and behavioral studies.",17241657_3,0
6045,3alpha-tropanyl-2-(4-chorophenoxy)butyrate,114,156,"To begin addressing this need, we characterized UMB24 (1-(2-phenethyl)-4-(2-pyridyl)-piperazine) and (+/-)-SM 21 (3alpha-tropanyl-2-(4-chorophenoxy)butyrate) in receptor binding and behavioral studies.",17241657_3,0
6048,Receptor binding,0,16,Receptor binding studies confirmed that UMB24 and (+/-)-SM 21 display preferential affinity for sigma2 over sigma1 receptors.,17241657_4,0
6049,UMB24,40,45,Receptor binding studies confirmed that UMB24 and (+/-)-SM 21 display preferential affinity for sigma2 over sigma1 receptors.,17241657_4,0
6050,(+/-)-SM,50,58,Receptor binding studies confirmed that UMB24 and (+/-)-SM 21 display preferential affinity for sigma2 over sigma1 receptors.,17241657_4,0
6051,sigma2,96,102,Receptor binding studies confirmed that UMB24 and (+/-)-SM 21 display preferential affinity for sigma2 over sigma1 receptors.,17241657_4,0
6052,sigma1 receptors,108,124,Receptor binding studies confirmed that UMB24 and (+/-)-SM 21 display preferential affinity for sigma2 over sigma1 receptors.,17241657_4,0
6055,UMB24,63,68,"In behavioral studies, pretreatment of Swiss Webster mice with UMB24 or (+/-)-SM 21 significantly attenuated cocaine-induced convulsions and locomotor activity, but not lethality.",17241657_5,0
6057,cocaine-induced convulsions,109,136,"In behavioral studies, pretreatment of Swiss Webster mice with UMB24 or (+/-)-SM 21 significantly attenuated cocaine-induced convulsions and locomotor activity, but not lethality.",17241657_5,0
6056,(+/-)-SM,72,80,"In behavioral studies, pretreatment of Swiss Webster mice with UMB24 or (+/-)-SM 21 significantly attenuated cocaine-induced convulsions and locomotor activity, but not lethality.",17241657_5,0
6058,(+/-)-SM,25,33,"When administered alone, (+/-)-SM 21 produced no significant effects compared to control injections of saline, but UMB24 had locomotor depressant actions.",17241657_6,0
6059,UMB24,115,120,"When administered alone, (+/-)-SM 21 produced no significant effects compared to control injections of saline, but UMB24 had locomotor depressant actions.",17241657_6,0
6060,sigma2 receptor antagonists,32,59,"Together, the data suggest that sigma2 receptor antagonists have the potential to attenuate some of the behavioral effects of cocaine, and further development of more selective, high affinity ligands are warranted.",17241657_7,0
6061,Progressive myopathy,0,20,Progressive myopathy with up-regulation of MHC-I associated with statin therapy.,17241784_0,1
1537,MHC-I,43,48,Progressive myopathy with up-regulation of MHC-I associated with statin therapy.,17241784_0,0
6062,necrotizing myopathy,20,40,Statins can cause a necrotizing myopathy and hyperCKaemia which is reversible on cessation of the drug.,17241784_1,1
6063,hyperCKaemia,45,57,Statins can cause a necrotizing myopathy and hyperCKaemia which is reversible on cessation of the drug.,17241784_1,1
6064,muscle pathology,20,36,We investigated the muscle pathology in 8 such cases.,17241784_3,1
6066,inflammatory infiltrate,44,67,All had myofibre necrosis but only 3 had an inflammatory infiltrate.,17241784_4,1
6065,myofibre necrosis,8,25,All had myofibre necrosis but only 3 had an inflammatory infiltrate.,17241784_4,1
5339,multifocal,34,44,In all cases there was diffuse or multifocal up-regulation of MHC-I expression even in non-necrotic fibres.,17241784_5,1
1538,MHC-I,62,67,In all cases there was diffuse or multifocal up-regulation of MHC-I expression even in non-necrotic fibres.,17241784_5,0
6068,case spontaneously,108,126,"Progressive improvement occurred in 7 cases after commencement of prednisolone and methotrexate, and in one case spontaneously.",17241784_6,1
6069,immune-mediated myopathy,56,80,These observations suggest that statins may initiate an immune-mediated myopathy that persists after withdrawal of the drug and responds to immunosuppressive therapy.,17241784_7,1
1539,MHC-I,162,167,The mechanism of this myopathy is uncertain but may involve the induction by statins of an endoplasmic reticulum stress response with associated up-regulation of MHC-I expression and antigen presentation by muscle fibres.,17241784_8,0
5345,temporal lobe epilepsy,106,128,This approach provides a framework for identifying potentially novel homologous candidate genes for human temporal lobe epilepsy.,17242861_11,1
5340,temporal lobe epilepsy,68,90,"QTLs for susceptibility to pilocarpine-induced seizures, a model of temporal lobe epilepsy, have not been reported, and CSS have not previously been used to localize seizure susceptibility genes.",17242861_3,1
5341,B6,34,36,We report QTLs identified using a B6 (host) x A/J (donor) CSS panel to localize genes involved in susceptibility to pilocarpine-induced seizures.,17242861_4,1
5342,B6,49,51,"Three hundred fifty-five adult male CSS mice, 58 B6, and 39 A/J were tested for susceptibility to pilocarpine-induced seizures.",17242861_5,1
5343,B6,0,2,B6 mice were resistant to seizures and slower to reach stages compared to A/J mice.,17242861_7,1
5344,B6,104,106,"The CSS for Chromosomes 10 and 18 progressed to the most severe stages, diverging dramatically from the B6 phenotype.",17242861_8,1
6081,CSS10,56,61,Latencies to stages were also significantly shorter for CSS10 and CSS18 mice.,17242861_9,0
6082,CSS18,66,71,Latencies to stages were also significantly shorter for CSS10 and CSS18 mice.,17242861_9,0
5346,detrusor function,49,66,"In cyclophosphamide-induced cystitis in the rat, detrusor function is impaired and the expression and effects of muscarinic receptors altered.",17244258_1,1
1540,muscarinic receptors,113,133,"In cyclophosphamide-induced cystitis in the rat, detrusor function is impaired and the expression and effects of muscarinic receptors altered.",17244258_1,0
1550,carbachol,22,31,"While contractions to carbachol and ATP were the same in inflamed and in control strips when related to a reference potassium response, isoprenaline-induced relaxations were smaller in inflamed strips.",17244258_10,0
1551,muscarinic receptors,109,129,"While postjunctional beta-adrenoceptor-mediated relaxations are reduced, effects by prejunctional inhibitory muscarinic receptors may be increased.",17244258_12,0
6108,postjunctional,6,20,"While postjunctional beta-adrenoceptor-mediated relaxations are reduced, effects by prejunctional inhibitory muscarinic receptors may be increased.",17244258_12,1
1541,muscarinic,183,193,"Responses of urinary strip preparations from control and cyclophosphamide-pretreated rats to electrical field stimulation and to agonists were assessed in the absence and presence of muscarinic, adrenergic and purinergic receptor antagonists.",17244258_3,0
1542,purinergic receptor antagonists,210,241,"Responses of urinary strip preparations from control and cyclophosphamide-pretreated rats to electrical field stimulation and to agonists were assessed in the absence and presence of muscarinic, adrenergic and purinergic receptor antagonists.",17244258_3,0
6088,electrical field,93,109,"Responses of urinary strip preparations from control and cyclophosphamide-pretreated rats to electrical field stimulation and to agonists were assessed in the absence and presence of muscarinic, adrenergic and purinergic receptor antagonists.",17244258_3,1
1543,(1,143,145,"Generally, atropine reduced contractions, but in contrast to controls, it also reduced responses to low electrical field stimulation intensity (1-5 Hz) in inflamed preparations.",17244258_4,0
6090,beta-methylene adenosine-5'-triphosphate,55,95,"In both types, purinoceptor desensitization with alpha,beta-methylene adenosine-5'-triphosphate (alpha,beta-meATP) caused further reductions at low frequencies (<10 Hz).",17244258_5,0
6091,beta-meATP,103,113,"In both types, purinoceptor desensitization with alpha,beta-methylene adenosine-5'-triphosphate (alpha,beta-meATP) caused further reductions at low frequencies (<10 Hz).",17244258_5,0
6092,muscarinic receptor antagonists,4,35,"The muscarinic receptor antagonists atropine, 4-diphenylacetoxy-N-methylpiperidine (4-DAMP) ('M(1)/M(3)/M(5)-selective'), methoctramine ('M(2)-selective') and pirenzepine ('M(1)-selective') antagonized the tonic component of the electrical field stimulation-evoked contractile response more potently than the phasic component.",17244258_6,0
6095,methoctramine,122,135,"The muscarinic receptor antagonists atropine, 4-diphenylacetoxy-N-methylpiperidine (4-DAMP) ('M(1)/M(3)/M(5)-selective'), methoctramine ('M(2)-selective') and pirenzepine ('M(1)-selective') antagonized the tonic component of the electrical field stimulation-evoked contractile response more potently than the phasic component.",17244258_6,0
1544,pirenzepine,159,170,"The muscarinic receptor antagonists atropine, 4-diphenylacetoxy-N-methylpiperidine (4-DAMP) ('M(1)/M(3)/M(5)-selective'), methoctramine ('M(2)-selective') and pirenzepine ('M(1)-selective') antagonized the tonic component of the electrical field stimulation-evoked contractile response more potently than the phasic component.",17244258_6,0
1545,phasic,309,315,"The muscarinic receptor antagonists atropine, 4-diphenylacetoxy-N-methylpiperidine (4-DAMP) ('M(1)/M(3)/M(5)-selective'), methoctramine ('M(2)-selective') and pirenzepine ('M(1)-selective') antagonized the tonic component of the electrical field stimulation-evoked contractile response more potently than the phasic component.",17244258_6,0
6093,4-diphenylacetoxy-N-methylpiperidine,46,82,"The muscarinic receptor antagonists atropine, 4-diphenylacetoxy-N-methylpiperidine (4-DAMP) ('M(1)/M(3)/M(5)-selective'), methoctramine ('M(2)-selective') and pirenzepine ('M(1)-selective') antagonized the tonic component of the electrical field stimulation-evoked contractile response more potently than the phasic component.",17244258_6,0
1546,pirenzepine,89,100,4-DAMP inhibited the tonic contractions in controls more potently than methoctramine and pirenzepine.,17244258_7,0
6101,methoctramine,71,84,4-DAMP inhibited the tonic contractions in controls more potently than methoctramine and pirenzepine.,17244258_7,0
6100,tonic contractions,21,39,4-DAMP inhibited the tonic contractions in controls more potently than methoctramine and pirenzepine.,17244258_7,1
1547,muscarinic receptor,30,49,"In inflamed preparations, the muscarinic receptor antagonism on the phasic component of the electrical field stimulation-evoked contraction was decreased and the pirenzepine and 4-DAMP antagonism on the tonic component was much less efficient than in controls.",17244258_8,0
1548,phasic,68,74,"In inflamed preparations, the muscarinic receptor antagonism on the phasic component of the electrical field stimulation-evoked contraction was decreased and the pirenzepine and 4-DAMP antagonism on the tonic component was much less efficient than in controls.",17244258_8,0
1549,pirenzepine,162,173,"In inflamed preparations, the muscarinic receptor antagonism on the phasic component of the electrical field stimulation-evoked contraction was decreased and the pirenzepine and 4-DAMP antagonism on the tonic component was much less efficient than in controls.",17244258_8,0
6104,4-DAMP,178,184,"In inflamed preparations, the muscarinic receptor antagonism on the phasic component of the electrical field stimulation-evoked contraction was decreased and the pirenzepine and 4-DAMP antagonism on the tonic component was much less efficient than in controls.",17244258_8,0
6106,methoctramine,25,38,"In contrast to controls, methoctramine increased -- instead of decreased -- the tonic responses at high frequencies.",17244258_9,0
1552,hyperpolarization-activated,29,56,Direct inhibition of cardiac hyperpolarization-activated cyclic nucleotide-gated pacemaker channels by clonidine.,17261653_0,0
1553,pacemaker channels,81,99,Direct inhibition of cardiac hyperpolarization-activated cyclic nucleotide-gated pacemaker channels by clonidine.,17261653_0,0
6111,cardiac sympathetic tone,26,50,"BACKGROUND: Inhibition of cardiac sympathetic tone represents an important strategy for treatment of cardiovascular disease, including arrhythmia, coronary heart disease, and chronic heart failure.",17261653_1,1
5349,heart failure,183,196,"BACKGROUND: Inhibition of cardiac sympathetic tone represents an important strategy for treatment of cardiovascular disease, including arrhythmia, coronary heart disease, and chronic heart failure.",17261653_1,1
5347,cardiovascular disease,101,123,"BACKGROUND: Inhibition of cardiac sympathetic tone represents an important strategy for treatment of cardiovascular disease, including arrhythmia, coronary heart disease, and chronic heart failure.",17261653_1,1
5348,coronary heart disease,147,169,"BACKGROUND: Inhibition of cardiac sympathetic tone represents an important strategy for treatment of cardiovascular disease, including arrhythmia, coronary heart disease, and chronic heart failure.",17261653_1,1
6115,drug clonidine,118,132,"Activation of presynaptic alpha2-adrenoceptors is the most widely accepted mechanism of action of the antisympathetic drug clonidine; however, other target proteins have been postulated to contribute to the in vivo actions of clonidine.",17261653_2,0
6116,target proteins,149,164,"Activation of presynaptic alpha2-adrenoceptors is the most widely accepted mechanism of action of the antisympathetic drug clonidine; however, other target proteins have been postulated to contribute to the in vivo actions of clonidine.",17261653_2,0
6113,alpha2-adrenoceptors,26,46,"Activation of presynaptic alpha2-adrenoceptors is the most widely accepted mechanism of action of the antisympathetic drug clonidine; however, other target proteins have been postulated to contribute to the in vivo actions of clonidine.",17261653_2,0
6112,presynaptic,14,25,"Activation of presynaptic alpha2-adrenoceptors is the most widely accepted mechanism of action of the antisympathetic drug clonidine; however, other target proteins have been postulated to contribute to the in vivo actions of clonidine.",17261653_2,1
6114,antisympathetic,102,117,"Activation of presynaptic alpha2-adrenoceptors is the most widely accepted mechanism of action of the antisympathetic drug clonidine; however, other target proteins have been postulated to contribute to the in vivo actions of clonidine.",17261653_2,0
6119,alpha2-adrenoceptors,94,114,"METHODS AND RESULTS: To test whether clonidine elicits pharmacological effects independent of alpha2-adrenoceptors, we have generated mice with a targeted deletion of all 3 alpha2-adrenoceptor subtypes (alpha2ABC-/-).",17261653_3,0
6121,alpha2-adrenoceptor subtypes,173,201,"METHODS AND RESULTS: To test whether clonidine elicits pharmacological effects independent of alpha2-adrenoceptors, we have generated mice with a targeted deletion of all 3 alpha2-adrenoceptor subtypes (alpha2ABC-/-).",17261653_3,0
1554,hypnotic effects,68,84,"Alpha2ABC-/- mice were completely unresponsive to the analgesic and hypnotic effects of clonidine; however, clonidine significantly lowered heart rate in alpha2ABC-/- mice by up to 150 bpm.",17261653_4,0
6127,right atria,89,100,A similar bradycardic effect of clonidine was observed in isolated spontaneously beating right atria from alpha2ABC-knockout and wild-type mice.,17261653_6,1
5350,sinoatrial,68,78,Clonidine inhibited the native pacemaker current (I(f)) in isolated sinoatrial node pacemaker cells and the I(f)-generating hyperpolarization-activated cyclic nucleotide-gated (HCN) 2 and HCN4 channels in transfected HEK293 cells.,17261653_7,1
1557,HCN4,188,192,Clonidine inhibited the native pacemaker current (I(f)) in isolated sinoatrial node pacemaker cells and the I(f)-generating hyperpolarization-activated cyclic nucleotide-gated (HCN) 2 and HCN4 channels in transfected HEK293 cells.,17261653_7,0
1556,HCN,177,180,Clonidine inhibited the native pacemaker current (I(f)) in isolated sinoatrial node pacemaker cells and the I(f)-generating hyperpolarization-activated cyclic nucleotide-gated (HCN) 2 and HCN4 channels in transfected HEK293 cells.,17261653_7,0
1555,hyperpolarization-activated,124,151,Clonidine inhibited the native pacemaker current (I(f)) in isolated sinoatrial node pacemaker cells and the I(f)-generating hyperpolarization-activated cyclic nucleotide-gated (HCN) 2 and HCN4 channels in transfected HEK293 cells.,17261653_7,0
5351,sinoatrial,140,150,"As a consequence of blocking I(f), clonidine reduced the slope of the diastolic depolarization and the frequency of pacemaker potentials in sinoatrial node cells from wild-type and alpha2ABC-knockout mice.",17261653_8,1
6131,diastolic depolarization,70,94,"As a consequence of blocking I(f), clonidine reduced the slope of the diastolic depolarization and the frequency of pacemaker potentials in sinoatrial node cells from wild-type and alpha2ABC-knockout mice.",17261653_8,1
6133,clonidine-like drugs,155,175,"CONCLUSIONS: Direct inhibition of cardiac HCN pacemaker channels contributes to the bradycardic effects of clonidine gene-targeted mice in vivo, and thus, clonidine-like drugs represent novel structures for future HCN channel inhibitors.",17261653_9,0
6134,HCN channel inhibitors,214,236,"CONCLUSIONS: Direct inhibition of cardiac HCN pacemaker channels contributes to the bradycardic effects of clonidine gene-targeted mice in vivo, and thus, clonidine-like drugs represent novel structures for future HCN channel inhibitors.",17261653_9,0
1558,HCN pacemaker channels,42,64,"CONCLUSIONS: Direct inhibition of cardiac HCN pacemaker channels contributes to the bradycardic effects of clonidine gene-targeted mice in vivo, and thus, clonidine-like drugs represent novel structures for future HCN channel inhibitors.",17261653_9,0
1559,sevoflurane,57,68,Cardiac arrest in a child with cerebral palsy undergoing sevoflurane induction of anesthesia after preoperative clonidine.,17263743_0,0
5353,cerebral palsy,31,45,Cardiac arrest in a child with cerebral palsy undergoing sevoflurane induction of anesthesia after preoperative clonidine.,17263743_0,1
5352,Cardiac arrest,0,14,Cardiac arrest in a child with cerebral palsy undergoing sevoflurane induction of anesthesia after preoperative clonidine.,17263743_0,1
6135,heart rate,84,94,Clonidine is a frequently administered alpha2-adrenergic agonist which can decrease heart rate and blood pressure.,17263743_1,1
1560,alpha2-adrenergic,39,56,Clonidine is a frequently administered alpha2-adrenergic agonist which can decrease heart rate and blood pressure.,17263743_1,0
5354,blood pressure,99,113,Clonidine is a frequently administered alpha2-adrenergic agonist which can decrease heart rate and blood pressure.,17263743_1,1
5356,seizure disorder,64,80,"We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.",17263743_2,1
5355,cerebral palsy,45,59,"We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.",17263743_2,1
1561,baclofen,153,161,"We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump.",17263743_2,0
6136,cardiac resuscitation,92,113,"During induction of anesthesia, the patient developed bradycardia and hypotension requiring cardiac resuscitation.",17263743_4,1
5357,cardiac arrest,54,68,There are no previous reports of clonidine-associated cardiac arrest in a child undergoing induction of anesthesia.,17263743_5,1
6138,small intestine,87,102,Angiotensin-converting enzyme (ACE) inhibitor-associated angioedema of the stomach and small intestine: a case report.,17285209_0,1
1562,Angiotensin-converting enzyme,0,29,Angiotensin-converting enzyme (ACE) inhibitor-associated angioedema of the stomach and small intestine: a case report.,17285209_0,0
6141,amlodipine/benazapril 10/5 mg,139,168,"This is a case report on a 45-year old African-American female with newly diagnosed hypertension, who was started on a combination pill of amlodipine/benazapril 10/5 mg.",17285209_1,0
1567,angiotensin receptor blocker,59,87,"The recognition of angiotensin-converting enzyme (ACE) and angiotensin receptor blocker (ARB) intestinal angioedema constitutes a challenge to primary care physicians, internists, emergency room personal and surgeons.",17285209_10,0
1566,angiotensin-converting enzyme,19,48,"The recognition of angiotensin-converting enzyme (ACE) and angiotensin receptor blocker (ARB) intestinal angioedema constitutes a challenge to primary care physicians, internists, emergency room personal and surgeons.",17285209_10,0
5359,nausea and vomiting,81,100,"The very next day, she presented at the emergency room (ER) with abdominal pain, nausea and vomiting.",17285209_2,1
5358,abdominal pain,65,79,"The very next day, she presented at the emergency room (ER) with abdominal pain, nausea and vomiting.",17285209_2,1
6149,pelvic cavity,134,147,"CT scan of the abdomen revealed markedly thickened antrum of the stomach, duodenum and jejunum, along with fluid in the abdominal and pelvic cavity.",17285209_7,1
1563,Angiotensin-converting enzyme inhibitor,0,39,"Angiotensin-converting enzyme inhibitor (ACEI)-induced angioedema was suspected, and anti-hypertensive medications were discontinued.",17285209_8,0
1564,anti-hypertensive,85,102,"Angiotensin-converting enzyme inhibitor (ACEI)-induced angioedema was suspected, and anti-hypertensive medications were discontinued.",17285209_8,0
6150,small bowel thickening,120,142,"Her symptoms improved within the next 24 hours, and repeat CT after 72 hours revealed marked improvement in stomach and small bowel thickening and resolution of ascites.",17285209_9,1
1565,Her,0,3,"Her symptoms improved within the next 24 hours, and repeat CT after 72 hours revealed marked improvement in stomach and small bowel thickening and resolution of ascites.",17285209_9,0
1568,clavulanic acid,62,77,Granulomatous hepatitis due to combination of amoxicillin and clavulanic acid.,1728522_0,0
6152,Granulomatous hepatitis,0,23,Granulomatous hepatitis due to combination of amoxicillin and clavulanic acid.,1728522_0,1
6153,histologic multiple granulomas,88,118,We report the case of a patient with amoxicillin-clavulanic acid-induced hepatitis with histologic multiple granulomas.,1728522_1,1
6154,cholestatic syndrome,119,139,"This type of lesion broadens the spectrum of liver injury due to this drug combination, mainly represented by a benign cholestatic syndrome.",1728522_2,1
5360,liver injury,45,57,"This type of lesion broadens the spectrum of liver injury due to this drug combination, mainly represented by a benign cholestatic syndrome.",1728522_2,1
1569,drug combination,70,86,"This type of lesion broadens the spectrum of liver injury due to this drug combination, mainly represented by a benign cholestatic syndrome.",1728522_2,0
6155,immunoallergic,56,70,The association of granulomas and eosinophilia favor an immunoallergic mechanism.,1728522_3,0
6156,penicillin derivatives,3,25,"As penicillin derivatives and amoxicillin alone are known to induce such types of lesions, the amoxicillin component, with or without a potentiating effect of clavulanic acid, might have a major role.",1728522_4,0
1570,clavulanic acid,159,174,"As penicillin derivatives and amoxicillin alone are known to induce such types of lesions, the amoxicillin component, with or without a potentiating effect of clavulanic acid, might have a major role.",1728522_4,0
6157,amoxicillin component,95,116,"As penicillin derivatives and amoxicillin alone are known to induce such types of lesions, the amoxicillin component, with or without a potentiating effect of clavulanic acid, might have a major role.",1728522_4,0
6159,cardiac dysfunction,22,41,Carbamazepine-induced cardiac dysfunction.,1728915_0,1
6160,clinical syndromes,33,51,Characterization of two distinct clinical syndromes.,1728915_1,1
6162,carbamazepine,72,85,"A patient with sinus bradycardia and atrioventricular block, induced by carbamazepine, prompted an extensive literature review of all previously reported cases.",1728915_2,0
5361,atrioventricular block,37,59,"A patient with sinus bradycardia and atrioventricular block, induced by carbamazepine, prompted an extensive literature review of all previously reported cases.",1728915_2,1
6161,sinus bradycardia,15,32,"A patient with sinus bradycardia and atrioventricular block, induced by carbamazepine, prompted an extensive literature review of all previously reported cases.",1728915_2,1
6164,cardiac dysfunction,81,100,"From the analysis of these cases, two distinct forms of carbamazepine-associated cardiac dysfunction emerged.",1728915_3,1
6165,carbamazepine,75,88,One patient group developed sinus tachycardias in the setting of a massive carbamazepine overdose.,1728915_4,0
5362,sinus tachycardias,28,46,One patient group developed sinus tachycardias in the setting of a massive carbamazepine overdose.,1728915_4,1
5363,bradyarrhythmias,106,122,"The second group consisted almost exclusively of elderly women who developed potentially life-threatening bradyarrhythmias or atrioventricular conduction delay, associated with either therapeutic or modestly elevated carbamazepine serum levels.",1728915_5,1
6167,carbamazepine,217,230,"The second group consisted almost exclusively of elderly women who developed potentially life-threatening bradyarrhythmias or atrioventricular conduction delay, associated with either therapeutic or modestly elevated carbamazepine serum levels.",1728915_5,0
5364,conduction delay,143,159,"The second group consisted almost exclusively of elderly women who developed potentially life-threatening bradyarrhythmias or atrioventricular conduction delay, associated with either therapeutic or modestly elevated carbamazepine serum levels.",1728915_5,1
6168,carbamazepine,8,21,"Because carbamazepine is widely used in the treatment of many neurologic and psychiatric conditions, the recognition of the latter syndrome has important implications for the use of this drug in elderly patients.",1728915_6,0
6169,psychiatric conditions,77,99,"Because carbamazepine is widely used in the treatment of many neurologic and psychiatric conditions, the recognition of the latter syndrome has important implications for the use of this drug in elderly patients.",1728915_6,1
1571,Dobutamine,0,10,Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer.,1732369_0,0
6171,myocardial function,72,91,Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer.,1732369_0,1
6173,of childhood cancer,148,167,Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer.,1732369_0,1
6174,anticancer chemotherapeutic agent,28,61,Doxorubicin is an effective anticancer chemotherapeutic agent known to cause acute and chronic cardiomyopathy.,1732369_1,0
6175,chronic cardiomyopathy,87,109,Doxorubicin is an effective anticancer chemotherapeutic agent known to cause acute and chronic cardiomyopathy.,1732369_1,1
6177,cardiac damage,65,79,"To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin, a cohort study was performed using dobutamine infusion to differentiate asymptomatic long-term survivors of childhood cancer treated with doxorubicin from healthy control subjects.",1732369_2,1
6179,of childhood cancer,205,224,"To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin, a cohort study was performed using dobutamine infusion to differentiate asymptomatic long-term survivors of childhood cancer treated with doxorubicin from healthy control subjects.",1732369_2,1
1572,dobutamine,135,145,"To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin, a cohort study was performed using dobutamine infusion to differentiate asymptomatic long-term survivors of childhood cancer treated with doxorubicin from healthy control subjects.",1732369_2,0
6183,mg/m2,169,174,Echocardiographic data from the experimental group of 21 patients (mean age 16 +/- 5 years) treated from 1.6 to 14.3 years (median 5.3) before this study with 27 to 532 mg/m2 of doxorubicin (mean 196) were compared with echocardiographic data from 12 normal age-matched control subjects.,1732369_3,0
6182,/- 5,80,84,Echocardiographic data from the experimental group of 21 patients (mean age 16 +/- 5 years) treated from 1.6 to 14.3 years (median 5.3) before this study with 27 to 532 mg/m2 of doxorubicin (mean 196) were compared with echocardiographic data from 12 normal age-matched control subjects.,1732369_3,0
1573,dobutamine,7,17,"Graded dobutamine infusions of 0.5, 2.5, 5 and 10 micrograms/kg per min were administered.",1732369_4,0
6187,adverse symptoms,120,136,Dobutamine infusion at 10 micrograms/kg per min was discontinued after six studies secondary to a 50% incidence rate of adverse symptoms.,1732369_6,1
1575,at 10,20,25,Dobutamine infusion at 10 micrograms/kg per min was discontinued after six studies secondary to a 50% incidence rate of adverse symptoms.,1732369_6,0
1574,Dobutamine,0,10,Dobutamine infusion at 10 micrograms/kg per min was discontinued after six studies secondary to a 50% incidence rate of adverse symptoms.,1732369_6,0
6189,end-systolic left ventricular,80,109,"The most important findings were that compared with values in control subjects, end-systolic left ventricular posterior wall dimension and percent of left ventricular posterior wall thickening in doxorubicin-treated patients were decreased at baseline study and these findings were more clearly delineated with dobutamine stimulation.",1732369_7,1
1576,dobutamine,311,321,"The most important findings were that compared with values in control subjects, end-systolic left ventricular posterior wall dimension and percent of left ventricular posterior wall thickening in doxorubicin-treated patients were decreased at baseline study and these findings were more clearly delineated with dobutamine stimulation.",1732369_7,0
5365,left ventricular,150,166,"The most important findings were that compared with values in control subjects, end-systolic left ventricular posterior wall dimension and percent of left ventricular posterior wall thickening in doxorubicin-treated patients were decreased at baseline study and these findings were more clearly delineated with dobutamine stimulation.",1732369_7,1
1577,dobutamine,86,96,End-systolic left ventricular posterior wall dimension at the 5-micrograms/kg per min dobutamine infusion for the doxorubicin-treated group was 14.1 +/- 2.4 mm versus 19.3 +/- 2.6 mm for control subjects (p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS),1732369_9,0
1578,adrenergic neuron,30,47,Detection of abnormal cardiac adrenergic neuron activity in adriamycin-induced cardiomyopathy with iodine-125-metaiodobenzylguanidine.,1732442_0,0
1580,MIBG,38,42,"Radiolabeled metaiodobenzylguanidine (MIBG), an analog of norepinephrine (NE), serves as an index of adrenergic neuron integrity and function.",1732442_1,0
1581,adrenergic neuron,101,118,"Radiolabeled metaiodobenzylguanidine (MIBG), an analog of norepinephrine (NE), serves as an index of adrenergic neuron integrity and function.",1732442_1,0
1579,metaiodobenzylguanidine,13,36,"Radiolabeled metaiodobenzylguanidine (MIBG), an analog of norepinephrine (NE), serves as an index of adrenergic neuron integrity and function.",1732442_1,0
1589,vacuolar,130,138,The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment (scattered or focal vacuolar degeneration) indicates that MIBG scintigraphy may be a useful method for detection of adriamycin-induced cardiomyopathy.,1732442_10,0
1588,adrenergic neuron,35,52,The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment (scattered or focal vacuolar degeneration) indicates that MIBG scintigraphy may be a useful method for detection of adriamycin-induced cardiomyopathy.,1732442_10,0
6208,myocardial impairment,88,109,The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment (scattered or focal vacuolar degeneration) indicates that MIBG scintigraphy may be a useful method for detection of adriamycin-induced cardiomyopathy.,1732442_10,1
1590,MIBG,168,172,The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment (scattered or focal vacuolar degeneration) indicates that MIBG scintigraphy may be a useful method for detection of adriamycin-induced cardiomyopathy.,1732442_10,0
1582,adrenergic neuron,103,120,"Using a rat model of adriamycin-induced cardiomyopathy, we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose-dependently in adriamycin cardiomyopathy.",1732442_2,0
6200,adriamycin,180,190,"Using a rat model of adriamycin-induced cardiomyopathy, we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose-dependently in adriamycin cardiomyopathy.",1732442_2,0
6202,adriamycin,100,110,"The degree of vacuolar degeneration of myocardial cells was analyzed in relation to the duration of adriamycin treatment (2 mg/kg, once a week).",1732442_3,0
1584,(2,121,123,"The degree of vacuolar degeneration of myocardial cells was analyzed in relation to the duration of adriamycin treatment (2 mg/kg, once a week).",1732442_3,0
1583,vacuolar,14,22,"The degree of vacuolar degeneration of myocardial cells was analyzed in relation to the duration of adriamycin treatment (2 mg/kg, once a week).",1732442_3,0
6203,focal degeneration,220,238,"There were no abnormalities or only isolated degeneration in the 1- or 2-wk treatment groups, isolated or scattered degeneration in half of the 3-wk group, frequent scattered degeneration in the 4-wk group, scattered or focal degeneration in the 5-wk group, and extensive degeneration in the 8-wk group.",1732442_4,1
6204,[125I]MIBG 4 hr,27,42,Myocardial accumulation of [125I]MIBG 4 hr after intravenous injection did not differ between the controls and the groups treated 3 wk or less.,1732442_5,0
5367,left ventricular,153,169,"However, the 4-wk group had a slightly lower accumulation in the right ventricular wall (82% of the control) and significantly lower accumulation in the left ventricular wall (about 66% of the control: p less than 0.05).",1732442_6,1
5366,right ventricular,65,82,"However, the 4-wk group had a slightly lower accumulation in the right ventricular wall (82% of the control) and significantly lower accumulation in the left ventricular wall (about 66% of the control: p less than 0.05).",1732442_6,1
5368,left ventricular,54,70,"In the 5-wk group, MIBG accumulation in the right and left ventricular wall was 35% and 27% of that in controls, respectively (p less than 0.001).",1732442_7,1
1585,MIBG,19,23,"In the 5-wk group, MIBG accumulation in the right and left ventricular wall was 35% and 27% of that in controls, respectively (p less than 0.001).",1732442_7,0
5369,left ventricular,54,70,"In the 8-wk group, MIBG accumulation in the right and left ventricular wall was 18% and 14% of that in controls, respectively (p less than 0.001).",1732442_8,1
1586,MIBG,19,23,"In the 8-wk group, MIBG accumulation in the right and left ventricular wall was 18% and 14% of that in controls, respectively (p less than 0.001).",1732442_8,0
6206,adriamycin,58,68,"Thus, MIBG accumulation in the myocardium decreased in an adriamycin dose-dependent manner.",1732442_9,0
1587,MIBG,6,10,"Thus, MIBG accumulation in the myocardium decreased in an adriamycin dose-dependent manner.",1732442_9,0
6210,otoacoustic,116,127,Influence of smoking on developing cochlea. Does smoking during pregnancy affect the amplitudes of transient evoked otoacoustic emissions in newborns?OBJECTIVE: Maternal tobacco smoking has negative effects on fetal growth.,17343925_0,1
6213,fetal growth,210,222,Influence of smoking on developing cochlea. Does smoking during pregnancy affect the amplitudes of transient evoked otoacoustic emissions in newborns?OBJECTIVE: Maternal tobacco smoking has negative effects on fetal growth.,17343925_0,1
6212,tobacco smoking,170,185,Influence of smoking on developing cochlea. Does smoking during pregnancy affect the amplitudes of transient evoked otoacoustic emissions in newborns?OBJECTIVE: Maternal tobacco smoking has negative effects on fetal growth.,17343925_0,1
5370,hearing loss,145,157,"The influence of smoking during pregnancy on the developing cochlea has not been estimated, although smoking has been positively associated with hearing loss in adults.",17343925_1,1
6225,tobacco smoking,34,49,"CONCLUSION: In utero, exposure to tobacco smoking seems to have a small impact on outer hair cells.",17343925_10,0
6226,outer hair cells,82,98,"CONCLUSION: In utero, exposure to tobacco smoking seems to have a small impact on outer hair cells.",17343925_10,1
6228,'s hearing acuity,111,128,Further studies are needed in order to establish a potential negative effect of maternal smoking on the neonate's hearing acuity.,17343925_12,1
6217,healthy neonates,131,147,The objective of this study was to determine the effects of maternal smoking on transient evoked otoacoustic emissions (TEOAEs) of healthy neonates.,17343925_2,1
6216,TEOAEs,120,126,The objective of this study was to determine the effects of maternal smoking on transient evoked otoacoustic emissions (TEOAEs) of healthy neonates.,17343925_2,0
5371,hearing impairment,69,87,METHODS: This study was undertaken as part of neonatal screening for hearing impairment and involved both ears of 200 newborns.,17343925_3,1
5372,heroin dependence,70,87,Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen.,17344330_0,1
5373,opioid use,74,84,BACKGROUND: Methadone is prescribed to heroin addicts to decrease illicit opioid use.,17344330_1,1
6240,QTc,41,44,No association between buprenorphine and QTc was found.,17344330_10,0
1593,buprenorphine,23,36,No association between buprenorphine and QTc was found.,17344330_10,0
1594,buprenorphine,34,47,None of the subjects treated with buprenorphine had QTc interval >0.440 s((1/2)).,17344330_12,0
6242,methadone dose,15,29,A 50 mg higher methadone dose was associated with a 1.2 (95% CI 1.1 to 1.4) times higher odds for syncope.,17344330_13,0
5374,torsade de pointes,60,78,Prolongation of the QT interval in the ECG of patients with torsade de pointes (TdP) has been reported in methadone users.,17344330_2,1
6232,TdP,177,180,"As heroin addicts sometimes faint while using illicit drugs, doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of TdP in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of methadone.",17344330_3,0
1591,illicit drugs,46,59,"As heroin addicts sometimes faint while using illicit drugs, doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of TdP in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of methadone.",17344330_3,0
1592,buprenorphine,154,167,"METHODS: In this cross-sectional study interview, ECGs and blood samples were collected in a population of adult heroin addicts treated with methadone or buprenorphine on a daily basis.",17344330_4,0
5375,Drug Addiction,23,37,"Of the patients at the Drug Addiction Service in the municipal of Copenhagen, 450 (approximately 52%) were included.",17344330_5,1
6234,opioid,24,30,"The association between opioid dose and QT, and methadone dose and reporting of syncope was assessed using multivariate linear regression and logistic regression, respectively.",17344330_8,0
6235,QT,40,42,"The association between opioid dose and QT, and methadone dose and reporting of syncope was assessed using multivariate linear regression and logistic regression, respectively.",17344330_8,0
6236,methadone dose,48,62,"The association between opioid dose and QT, and methadone dose and reporting of syncope was assessed using multivariate linear regression and logistic regression, respectively.",17344330_8,0
6238,Methadone dose,9,23,RESULTS: Methadone dose was associated with longer QT interval of 0.140 ms/mg (p = 0.002).,17344330_9,0
5376,compartment syndrome,34,54,Simvastatin-induced bilateral leg compartment syndrome and myonecrosis associated with hypothyroidism.,17344566_0,1
5377,compartment syndrome,93,113,A 54-year-old hypothyroid male taking thyroxine and simvastatin presented with bilateral leg compartment syndrome and myonecrosis.,17344566_1,1
6247,hypothyroid,14,25,A 54-year-old hypothyroid male taking thyroxine and simvastatin presented with bilateral leg compartment syndrome and myonecrosis.,17344566_1,1
6248,fasciotomies,7,19,Urgent fasciotomies were performed and the patient made an uneventful recovery with the withdrawal of simvastatin.,17344566_2,1
6249,arteriopathic,131,144,It is likely that this complication will be seen more often with the increased worldwide use of this drug and its approval for all arteriopathic patients.,17344566_3,1
5378,Neuroleptic malignant syndrome,0,30,Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment.,17366349_0,1
6250,ziprasidone,42,53,Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment.,17366349_0,0
5380,movement disorders,95,113,Neuroleptic malignant syndrome (NMS) is the rarest and most serious of the neuroleptic-induced movement disorders.,17366349_1,1
5379,Neuroleptic malignant syndrome,0,30,Neuroleptic malignant syndrome (NMS) is the rarest and most serious of the neuroleptic-induced movement disorders.,17366349_1,1
6252,ziprasidone,86,97,We describe a case of neuroleptic malignant syndrome (NMS) associated with the use of ziprasidone.,17366349_2,0
5381,neuroleptic malignant syndrome,22,52,We describe a case of neuroleptic malignant syndrome (NMS) associated with the use of ziprasidone.,17366349_2,1
1595,antipsychotic drugs,85,104,"Although conventional neuroleptics are more frequently associated with NMS, atypical antipsychotic drugs like ziprasidone may also be a cause.",17366349_3,0
6254,ziprasidone,110,121,"Although conventional neuroleptics are more frequently associated with NMS, atypical antipsychotic drugs like ziprasidone may also be a cause.",17366349_3,0
6255,ziprasidone,179,190,The patient is a 24-year-old male with a history of schizophrenia who developed signs and symptoms of NMS after 2 days of treatment with an 80-mg/day dose of orally administrated ziprasidone.,17366349_4,0
5382,signs and symptoms,80,98,The patient is a 24-year-old male with a history of schizophrenia who developed signs and symptoms of NMS after 2 days of treatment with an 80-mg/day dose of orally administrated ziprasidone.,17366349_4,1
6256,ziprasidone,63,74,This case is the earliest (second day of treatment) NMS due to ziprasidone reported in the literature.,17366349_5,0
6257,behavioral abnormalities,22,46,Neuroinflammation and behavioral abnormalities after neonatal terbutaline treatment in rats: implications for autism.,17400887_0,1
6258,terbutaline,62,73,Neuroinflammation and behavioral abnormalities after neonatal terbutaline treatment in rats: implications for autism.,17400887_0,0
5383,Neuroinflammation,0,17,Neuroinflammation and behavioral abnormalities after neonatal terbutaline treatment in rats: implications for autism.,17400887_0,1
6259,neurodevelopmental disorder,12,39,Autism is a neurodevelopmental disorder presenting before 3 years of age with deficits in communication and social skills and repetitive behaviors.,17400887_1,1
6261,repetitive behaviors,126,146,Autism is a neurodevelopmental disorder presenting before 3 years of age with deficits in communication and social skills and repetitive behaviors.,17400887_1,1
6260,social skills,108,121,Autism is a neurodevelopmental disorder presenting before 3 years of age with deficits in communication and social skills and repetitive behaviors.,17400887_1,1
6296,autism spectrum disorders,103,128,This study provides a useful animal model for understanding the neuropathological processes underlying autism spectrum disorders.,17400887_10,1
6295,neuropathological processes,64,91,This study provides a useful animal model for understanding the neuropathological processes underlying autism spectrum disorders.,17400887_10,1
5384,preterm labor,57,70,"Terbutaline, a beta2-adrenoceptor agonist used to arrest preterm labor, has been associated with increased concordance for autism in dizygotic twins.",17400887_3,1
6268,dizygotic twins,133,148,"Terbutaline, a beta2-adrenoceptor agonist used to arrest preterm labor, has been associated with increased concordance for autism in dizygotic twins.",17400887_3,1
6265,Terbutaline,0,11,"Terbutaline, a beta2-adrenoceptor agonist used to arrest preterm labor, has been associated with increased concordance for autism in dizygotic twins.",17400887_3,0
6266,beta2-adrenoceptor,15,33,"Terbutaline, a beta2-adrenoceptor agonist used to arrest preterm labor, has been associated with increased concordance for autism in dizygotic twins.",17400887_3,0
6270,terbutaline,26,37,We studied the effects of terbutaline on microglial activation in different brain regions and behavioral outcomes in developing rats.,17400887_4,0
6272,terbutaline,24,35,Newborn rats were given terbutaline (10 mg/kg) daily on postnatal days (PN) 2 to 5 or PN 11 to 14 and examined 24 h after the last dose and at PN 30.,17400887_5,0
6273,PN,72,74,Newborn rats were given terbutaline (10 mg/kg) daily on postnatal days (PN) 2 to 5 or PN 11 to 14 and examined 24 h after the last dose and at PN 30.,17400887_5,0
6274,PN,86,88,Newborn rats were given terbutaline (10 mg/kg) daily on postnatal days (PN) 2 to 5 or PN 11 to 14 and examined 24 h after the last dose and at PN 30.,17400887_5,0
6276,PN,143,145,Newborn rats were given terbutaline (10 mg/kg) daily on postnatal days (PN) 2 to 5 or PN 11 to 14 and examined 24 h after the last dose and at PN 30.,17400887_5,0
6279,PN,138,140,"Immunohistochemical studies showed that administration of terbutaline on PN 2 to 5 produced a robust increase in microglial activation on PN 30 in the cerebral cortex, as well as in cerebellar and cerebrocortical white matter.",17400887_6,0
6278,PN,73,75,"Immunohistochemical studies showed that administration of terbutaline on PN 2 to 5 produced a robust increase in microglial activation on PN 30 in the cerebral cortex, as well as in cerebellar and cerebrocortical white matter.",17400887_6,0
6280,cerebral cortex,151,166,"Immunohistochemical studies showed that administration of terbutaline on PN 2 to 5 produced a robust increase in microglial activation on PN 30 in the cerebral cortex, as well as in cerebellar and cerebrocortical white matter.",17400887_6,1
6281,cerebrocortical white matter,197,225,"Immunohistochemical studies showed that administration of terbutaline on PN 2 to 5 produced a robust increase in microglial activation on PN 30 in the cerebral cortex, as well as in cerebellar and cerebrocortical white matter.",17400887_6,1
6277,terbutaline,58,69,"Immunohistochemical studies showed that administration of terbutaline on PN 2 to 5 produced a robust increase in microglial activation on PN 30 in the cerebral cortex, as well as in cerebellar and cerebrocortical white matter.",17400887_6,0
6282,terbutaline,48,59,None of these effects occurred in animals given terbutaline on PN 11 to 14.,17400887_7,0
6283,PN,63,65,None of these effects occurred in animals given terbutaline on PN 11 to 14.,17400887_7,0
6285,terbutaline,42,53,"In behavioral tests, animals treated with terbutaline on PN 2 to 5 showed consistent patterns of hyper-reactivity to novelty and aversive stimuli when assessed in a novel open field, as well as in the acoustic startle response test.",17400887_8,0
6286,PN,57,59,"In behavioral tests, animals treated with terbutaline on PN 2 to 5 showed consistent patterns of hyper-reactivity to novelty and aversive stimuli when assessed in a novel open field, as well as in the acoustic startle response test.",17400887_8,0
5385,hyper-reactivity,97,113,"In behavioral tests, animals treated with terbutaline on PN 2 to 5 showed consistent patterns of hyper-reactivity to novelty and aversive stimuli when assessed in a novel open field, as well as in the acoustic startle response test.",17400887_8,1
6290,beta2-adrenoceptor,27,45,"Our findings indicate that beta2-adrenoceptor overstimulation during an early critical period results in microglial activation associated with innate neuroinflammatory pathways and behavioral abnormalities, similar to those described in autism.",17400887_9,0
6294,behavioral abnormalities,181,205,"Our findings indicate that beta2-adrenoceptor overstimulation during an early critical period results in microglial activation associated with innate neuroinflammatory pathways and behavioral abnormalities, similar to those described in autism.",17400887_9,1
5386,neuroinflammatory,150,167,"Our findings indicate that beta2-adrenoceptor overstimulation during an early critical period results in microglial activation associated with innate neuroinflammatory pathways and behavioral abnormalities, similar to those described in autism.",17400887_9,1
6298,TR(-),69,74,Upregulation of brain expression of P-glycoprotein in MRP2-deficient TR(-) rats resembles seizure-induced up-regulation of this drug efflux transporter in normal rats.,17437408_0,0
1596,P-glycoprotein,36,50,Upregulation of brain expression of P-glycoprotein in MRP2-deficient TR(-) rats resembles seizure-induced up-regulation of this drug efflux transporter in normal rats.,17437408_0,0
1597,MRP2,45,49,PURPOSE: The multidrug resistance protein 2 (MRP2) is a drug efflux transporter that is expressed predominantly at the apical domain of hepatocytes but seems also to be expressed at the apical membrane of brain capillary endothelial cells that form the blood-brain barrier (BBB).,17437408_1,0
6302,multidrug resistance protein 2,13,43,PURPOSE: The multidrug resistance protein 2 (MRP2) is a drug efflux transporter that is expressed predominantly at the apical domain of hepatocytes but seems also to be expressed at the apical membrane of brain capillary endothelial cells that form the blood-brain barrier (BBB).,17437408_1,0
6309,BBB,274,277,PURPOSE: The multidrug resistance protein 2 (MRP2) is a drug efflux transporter that is expressed predominantly at the apical domain of hepatocytes but seems also to be expressed at the apical membrane of brain capillary endothelial cells that form the blood-brain barrier (BBB).,17437408_1,0
6303,drug efflux transporter,56,79,PURPOSE: The multidrug resistance protein 2 (MRP2) is a drug efflux transporter that is expressed predominantly at the apical domain of hepatocytes but seems also to be expressed at the apical membrane of brain capillary endothelial cells that form the blood-brain barrier (BBB).,17437408_1,0
6340,Pgp,31,34,A comparable overexpression of Pgp in the BBB was obtained after pilocarpine-induced seizures in wild-type Wistar rats.,17437408_10,0
6341,BBB,42,45,A comparable overexpression of Pgp in the BBB was obtained after pilocarpine-induced seizures in wild-type Wistar rats.,17437408_10,0
1606,MRP2,202,206,Experiments with systemic administration of the Pgp substrate phenobarbital and the selective Pgp inhibitor tariquidar in TR(-) rats substantiated that Pgp is functional and compensates for the lack of MRP2 in the BBB.,17437408_11,0
6346,Pgp inhibitor tariquidar,94,118,Experiments with systemic administration of the Pgp substrate phenobarbital and the selective Pgp inhibitor tariquidar in TR(-) rats substantiated that Pgp is functional and compensates for the lack of MRP2 in the BBB.,17437408_11,0
6349,BBB,214,217,Experiments with systemic administration of the Pgp substrate phenobarbital and the selective Pgp inhibitor tariquidar in TR(-) rats substantiated that Pgp is functional and compensates for the lack of MRP2 in the BBB.,17437408_11,0
6348,Pgp,152,155,Experiments with systemic administration of the Pgp substrate phenobarbital and the selective Pgp inhibitor tariquidar in TR(-) rats substantiated that Pgp is functional and compensates for the lack of MRP2 in the BBB.,17437408_11,0
6347,TR(-),122,127,Experiments with systemic administration of the Pgp substrate phenobarbital and the selective Pgp inhibitor tariquidar in TR(-) rats substantiated that Pgp is functional and compensates for the lack of MRP2 in the BBB.,17437408_11,0
6345,Pgp substrate phenobarbital,48,75,Experiments with systemic administration of the Pgp substrate phenobarbital and the selective Pgp inhibitor tariquidar in TR(-) rats substantiated that Pgp is functional and compensates for the lack of MRP2 in the BBB.,17437408_11,0
6352,BBB,124,127,CONCLUSIONS: The data on TR(-) rats indicate that Pgp plays an important role in the compensation of MRP2 deficiency in the BBB.,17437408_12,0
6350,TR(-),25,30,CONCLUSIONS: The data on TR(-) rats indicate that Pgp plays an important role in the compensation of MRP2 deficiency in the BBB.,17437408_12,0
1607,MRP2,101,105,CONCLUSIONS: The data on TR(-) rats indicate that Pgp plays an important role in the compensation of MRP2 deficiency in the BBB.,17437408_12,0
6351,Pgp,50,53,CONCLUSIONS: The data on TR(-) rats indicate that Pgp plays an important role in the compensation of MRP2 deficiency in the BBB.,17437408_12,0
1608,MRP2,160,164,"Because such a compensatory mechanism most likely occurs to reduce injury to the brain from cytotoxic compounds, the present data substantiate the concept that MRP2 performs a protective role in the BBB.",17437408_13,0
5388,compensatory,15,27,"Because such a compensatory mechanism most likely occurs to reduce injury to the brain from cytotoxic compounds, the present data substantiate the concept that MRP2 performs a protective role in the BBB.",17437408_13,1
6353,cytotoxic compounds,92,111,"Because such a compensatory mechanism most likely occurs to reduce injury to the brain from cytotoxic compounds, the present data substantiate the concept that MRP2 performs a protective role in the BBB.",17437408_13,0
6355,BBB,199,202,"Because such a compensatory mechanism most likely occurs to reduce injury to the brain from cytotoxic compounds, the present data substantiate the concept that MRP2 performs a protective role in the BBB.",17437408_13,0
6358,Pgp,113,116,"Furthermore, our data suggest that TR(-) rats are an interesting tool to study consequences of overexpression of Pgp in the BBB on access of drugs in the brain, without the need of inducing seizures or other Pgp-enhancing events for this purpose.",17437408_14,0
6359,BBB,124,127,"Furthermore, our data suggest that TR(-) rats are an interesting tool to study consequences of overexpression of Pgp in the BBB on access of drugs in the brain, without the need of inducing seizures or other Pgp-enhancing events for this purpose.",17437408_14,0
6356,TR(-),35,40,"Furthermore, our data suggest that TR(-) rats are an interesting tool to study consequences of overexpression of Pgp in the BBB on access of drugs in the brain, without the need of inducing seizures or other Pgp-enhancing events for this purpose.",17437408_14,0
1599,MRP2,136,140,"MRP2 is absent in the transport-deficient (TR(-)) Wistar rat mutant, so that this rat strain was very helpful in defining substrates of MRP2 by comparing tissue concentrations or functional activities of compounds in MRP2-deficient rats with those in transport-competent Wistar rats.",17437408_2,0
6310,TR(-),43,48,"MRP2 is absent in the transport-deficient (TR(-)) Wistar rat mutant, so that this rat strain was very helpful in defining substrates of MRP2 by comparing tissue concentrations or functional activities of compounds in MRP2-deficient rats with those in transport-competent Wistar rats.",17437408_2,0
1598,MRP2,0,4,"MRP2 is absent in the transport-deficient (TR(-)) Wistar rat mutant, so that this rat strain was very helpful in defining substrates of MRP2 by comparing tissue concentrations or functional activities of compounds in MRP2-deficient rats with those in transport-competent Wistar rats.",17437408_2,0
1602,MRP2,158,162,"By using this strategy to study the involvement of MRP2 in brain access of antiepileptic drugs (AEDs), we recently reported that phenytoin is a substrate for MRP2 in the BBB.",17437408_3,0
1601,antiepileptic drugs,75,94,"By using this strategy to study the involvement of MRP2 in brain access of antiepileptic drugs (AEDs), we recently reported that phenytoin is a substrate for MRP2 in the BBB.",17437408_3,0
1600,MRP2,51,55,"By using this strategy to study the involvement of MRP2 in brain access of antiepileptic drugs (AEDs), we recently reported that phenytoin is a substrate for MRP2 in the BBB.",17437408_3,0
6315,AEDs,96,100,"By using this strategy to study the involvement of MRP2 in brain access of antiepileptic drugs (AEDs), we recently reported that phenytoin is a substrate for MRP2 in the BBB.",17437408_3,0
6316,BBB,170,173,"By using this strategy to study the involvement of MRP2 in brain access of antiepileptic drugs (AEDs), we recently reported that phenytoin is a substrate for MRP2 in the BBB.",17437408_3,0
5387,compensatory,85,97,"However, one drawback of such studies in genetically deficient rats is the fact that compensatory changes with upregulation of other transporters can occur.",17437408_4,1
6319,Pgp,66,69,"This prompted us to study the brain expression of P-glycoprotein (Pgp), a major drug efflux transporter in many tissues, including the BBB, in TR(-) rats compared with nonmutant (wild-type) Wistar rats.",17437408_5,0
1603,P-glycoprotein,50,64,"This prompted us to study the brain expression of P-glycoprotein (Pgp), a major drug efflux transporter in many tissues, including the BBB, in TR(-) rats compared with nonmutant (wild-type) Wistar rats.",17437408_5,0
6321,TR(-),143,148,"This prompted us to study the brain expression of P-glycoprotein (Pgp), a major drug efflux transporter in many tissues, including the BBB, in TR(-) rats compared with nonmutant (wild-type) Wistar rats.",17437408_5,0
6320,BBB,135,138,"This prompted us to study the brain expression of P-glycoprotein (Pgp), a major drug efflux transporter in many tissues, including the BBB, in TR(-) rats compared with nonmutant (wild-type) Wistar rats.",17437408_5,0
1604,MRP2,27,31,"METHODS: The expression of MRP2 and Pgp in brain and liver sections of TR(-) rats and normal Wistar rats was determined with immunohistochemistry, by using a novel, highly selective monoclonal MRP2 antibody and the monoclonal Pgp antibody C219, respectively.",17437408_6,0
6324,Pgp,36,39,"METHODS: The expression of MRP2 and Pgp in brain and liver sections of TR(-) rats and normal Wistar rats was determined with immunohistochemistry, by using a novel, highly selective monoclonal MRP2 antibody and the monoclonal Pgp antibody C219, respectively.",17437408_6,0
6329,Pgp antibody C219,226,243,"METHODS: The expression of MRP2 and Pgp in brain and liver sections of TR(-) rats and normal Wistar rats was determined with immunohistochemistry, by using a novel, highly selective monoclonal MRP2 antibody and the monoclonal Pgp antibody C219, respectively.",17437408_6,0
6326,TR(-),71,76,"METHODS: The expression of MRP2 and Pgp in brain and liver sections of TR(-) rats and normal Wistar rats was determined with immunohistochemistry, by using a novel, highly selective monoclonal MRP2 antibody and the monoclonal Pgp antibody C219, respectively.",17437408_6,0
6328,monoclonal MRP2 antibody,182,206,"METHODS: The expression of MRP2 and Pgp in brain and liver sections of TR(-) rats and normal Wistar rats was determined with immunohistochemistry, by using a novel, highly selective monoclonal MRP2 antibody and the monoclonal Pgp antibody C219, respectively.",17437408_6,0
6332,TR(-),189,194,"RESULTS: Immunofluorescence staining with the MRP2 antibody was found to label a high number of microvessels throughout the brain in normal Wistar rats, whereas such labeling was absent in TR(-) rats.",17437408_7,0
1605,MRP2,46,50,"RESULTS: Immunofluorescence staining with the MRP2 antibody was found to label a high number of microvessels throughout the brain in normal Wistar rats, whereas such labeling was absent in TR(-) rats.",17437408_7,0
6334,Pgp,52,55,TR(-) rats exhibited a significant up-regulation of Pgp in brain capillary endothelial cells compared with wild-type controls.,17437408_8,0
6333,TR(-),0,5,TR(-) rats exhibited a significant up-regulation of Pgp in brain capillary endothelial cells compared with wild-type controls.,17437408_8,0
6337,Pgp,32,35,No such obvious upregulation of Pgp was observed in liver sections.,17437408_9,0
1609,xanthine oxidase,8,24,Role of xanthine oxidase in dexamethasone-induced hypertension in rats.1.,17439425_0,0
6363,GC-HT,37,42,Glucocorticoid-induced hypertension (GC-HT) in the rat is associated with nitric oxide-redox imbalance.,17439425_1,0
6382,GC-HT,184,189,"This, together with our previous findings that allopurinol failed to prevent adrenocorticotrophic hormone induced hypertension, suggests that XO activity is not a major determinant of GC-HT in the rat.",17439425_10,0
1613,adrenocorticotrophic hormone,77,105,"This, together with our previous findings that allopurinol failed to prevent adrenocorticotrophic hormone induced hypertension, suggests that XO activity is not a major determinant of GC-HT in the rat.",17439425_10,0
5394,induced hypertension,106,126,"This, together with our previous findings that allopurinol failed to prevent adrenocorticotrophic hormone induced hypertension, suggests that XO activity is not a major determinant of GC-HT in the rat.",17439425_10,1
5395,XO,142,144,"This, together with our previous findings that allopurinol failed to prevent adrenocorticotrophic hormone induced hypertension, suggests that XO activity is not a major determinant of GC-HT in the rat.",17439425_10,1
6365,dexamethasone-induced hypertension,118,152,"2. We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced hypertension (dex-HT).",17439425_2,1
6366,dex-HT,154,160,"2. We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced hypertension (dex-HT).",17439425_2,0
1610,xanthine oxidase,26,42,"2. We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced hypertension (dex-HT).",17439425_2,0
1611,reactive oxygen species,90,113,"2. We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced hypertension (dex-HT).",17439425_2,0
5389,XO,44,46,"2. We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced hypertension (dex-HT).",17439425_2,1
6368,dex,108,111,"3. Thirty male Sprague-Dawley rats were divided randomly into four treatment groups: saline, dexamethasone (dex), allopurinol plus saline, and allopurinol plus dex.",17439425_3,0
6369,allopurinol plus,114,130,"3. Thirty male Sprague-Dawley rats were divided randomly into four treatment groups: saline, dexamethasone (dex), allopurinol plus saline, and allopurinol plus dex.",17439425_3,0
6370,allopurinol plus,143,159,"3. Thirty male Sprague-Dawley rats were divided randomly into four treatment groups: saline, dexamethasone (dex), allopurinol plus saline, and allopurinol plus dex.",17439425_3,0
5390,blood pressures,12,27,4. Systolic blood pressures (SBP) and bodyweights were recorded each alternate day.,17439425_4,1
5391,bodyweights,38,49,4. Systolic blood pressures (SBP) and bodyweights were recorded each alternate day.,17439425_4,1
5392,XO,89,91,"Thymus weight was used as a marker of glucocorticoid activity, and serum urate to assess XO inhibition.",17439425_5,1
6375,SBP,14,17,"Dex increased SBP (110 +/- 2-126 +/- 3 mmHg; P < 0.001) and decreased thymus (P < 0.001) and bodyweights (P"" < 0.01).",17439425_7,0
5393,bodyweights,93,104,"Dex increased SBP (110 +/- 2-126 +/- 3 mmHg; P < 0.001) and decreased thymus (P < 0.001) and bodyweights (P"" < 0.01).",17439425_7,1
6374,Dex,0,3,"Dex increased SBP (110 +/- 2-126 +/- 3 mmHg; P < 0.001) and decreased thymus (P < 0.001) and bodyweights (P"" < 0.01).",17439425_7,0
1612,/- 2,24,28,"Dex increased SBP (110 +/- 2-126 +/- 3 mmHg; P < 0.001) and decreased thymus (P < 0.001) and bodyweights (P"" < 0.01).",17439425_7,0
6377,/- 5,43,47,Allopurinol decreased serum urate from 76 +/- 5 to 30 +/- 3 micromol/L (P < 0.001) in saline and from 84 +/- 13 to 28 +/- 2 micromol/L in dex-treated (P < 0.01) groups.,17439425_8,0
6381,dex-HT,31,37,6. Allopurinol did not prevent dex-HT.,17439425_9,0
5396,Side effects,0,12,Side effects of postoperative administration of methylprednisolone and gentamicin into the posterior sub-Tenon's space.,17466854_0,1
1614,methylprednisolone,48,66,Side effects of postoperative administration of methylprednisolone and gentamicin into the posterior sub-Tenon's space.,17466854_0,0
1615,methylprednisolone,98,116,PURPOSE: To assess the incidence of postoperative emetic side effects after the administration of methylprednisolone and gentamicin into the posterior sub-Tenon's space at the end of routine cataract surgery.,17466854_1,0
6384,emetic side effects,50,69,PURPOSE: To assess the incidence of postoperative emetic side effects after the administration of methylprednisolone and gentamicin into the posterior sub-Tenon's space at the end of routine cataract surgery.,17466854_1,1
6385,posterior sub-Tenon's space,141,168,PURPOSE: To assess the incidence of postoperative emetic side effects after the administration of methylprednisolone and gentamicin into the posterior sub-Tenon's space at the end of routine cataract surgery.,17466854_1,1
6386,cataract surgery,191,207,PURPOSE: To assess the incidence of postoperative emetic side effects after the administration of methylprednisolone and gentamicin into the posterior sub-Tenon's space at the end of routine cataract surgery.,17466854_1,1
6388,Gwardamangia,30,42,"SETTING: St. Luke's Hospital, Gwardamangia, Malta.",17466854_2,1
6393,local infiltration,145,163,METHODS: A double-blind double-armed prospective study comprised 40 patients who had uneventful sutureless phacoemulsification under sub-Tenon's local infiltration of 3 mL of plain lignocaine.,17466854_3,1
1616,lignocaine,181,191,METHODS: A double-blind double-armed prospective study comprised 40 patients who had uneventful sutureless phacoemulsification under sub-Tenon's local infiltration of 3 mL of plain lignocaine.,17466854_3,0
6394,Group A,29,36,"At the end of the procedure, Group A (n = 20) had 20 mg/0.5 mL of methylprednisolone and 10 mg/0.5 mL of gentamicin injected into the posterior sub-Tenon's space and Group B (n = 20) had the same combination injected into the anterior sub-Tenon's space.",17466854_4,0
6398,Group B,166,173,"At the end of the procedure, Group A (n = 20) had 20 mg/0.5 mL of methylprednisolone and 10 mg/0.5 mL of gentamicin injected into the posterior sub-Tenon's space and Group B (n = 20) had the same combination injected into the anterior sub-Tenon's space.",17466854_4,0
6399,anterior sub-Tenon's space,226,252,"At the end of the procedure, Group A (n = 20) had 20 mg/0.5 mL of methylprednisolone and 10 mg/0.5 mL of gentamicin injected into the posterior sub-Tenon's space and Group B (n = 20) had the same combination injected into the anterior sub-Tenon's space.",17466854_4,1
1617,methylprednisolone,66,84,"At the end of the procedure, Group A (n = 20) had 20 mg/0.5 mL of methylprednisolone and 10 mg/0.5 mL of gentamicin injected into the posterior sub-Tenon's space and Group B (n = 20) had the same combination injected into the anterior sub-Tenon's space.",17466854_4,0
6395,mg/0.5,53,59,"At the end of the procedure, Group A (n = 20) had 20 mg/0.5 mL of methylprednisolone and 10 mg/0.5 mL of gentamicin injected into the posterior sub-Tenon's space and Group B (n = 20) had the same combination injected into the anterior sub-Tenon's space.",17466854_4,0
6397,posterior sub-Tenon's space,134,161,"At the end of the procedure, Group A (n = 20) had 20 mg/0.5 mL of methylprednisolone and 10 mg/0.5 mL of gentamicin injected into the posterior sub-Tenon's space and Group B (n = 20) had the same combination injected into the anterior sub-Tenon's space.",17466854_4,1
6396,mg/0.5,92,98,"At the end of the procedure, Group A (n = 20) had 20 mg/0.5 mL of methylprednisolone and 10 mg/0.5 mL of gentamicin injected into the posterior sub-Tenon's space and Group B (n = 20) had the same combination injected into the anterior sub-Tenon's space.",17466854_4,0
6400,"nausea, vomiting",60,76,"Postoperatively, all patients were assessed for symptoms of nausea, vomiting, and headache.",17466854_5,1
6402,Group A,26,33,"RESULTS: Sixty percent in Group A developed postoperative emetic symptoms, headache, or both; 1 patient in Group B developed symptoms.",17466854_7,0
6403,emetic symptoms,58,73,"RESULTS: Sixty percent in Group A developed postoperative emetic symptoms, headache, or both; 1 patient in Group B developed symptoms.",17466854_7,1
5397,side effects,139,151,"CONCLUSIONS: The administration of methylprednisolone and gentamicin in the posterior sub-Tenon's space was related to a high incidence of side effects including nausea, vomiting, and headache.",17466854_8,1
6405,posterior sub-Tenon's space,76,103,"CONCLUSIONS: The administration of methylprednisolone and gentamicin in the posterior sub-Tenon's space was related to a high incidence of side effects including nausea, vomiting, and headache.",17466854_8,1
6406,"nausea, vomiting",162,178,"CONCLUSIONS: The administration of methylprednisolone and gentamicin in the posterior sub-Tenon's space was related to a high incidence of side effects including nausea, vomiting, and headache.",17466854_8,1
1618,methylprednisolone,35,53,"CONCLUSIONS: The administration of methylprednisolone and gentamicin in the posterior sub-Tenon's space was related to a high incidence of side effects including nausea, vomiting, and headache.",17466854_8,0
5398,adverse effects,4,19,All adverse effects were self-limiting.,17466854_9,1
6407,self-limiting,25,38,All adverse effects were self-limiting.,17466854_9,1
6409,substantia nigra,76,92,Peripheral iron dextran induced degeneration of dopaminergic neurons in rat substantia nigra.,17490790_0,1
6408,iron dextran,11,23,Peripheral iron dextran induced degeneration of dopaminergic neurons in rat substantia nigra.,17490790_0,0
1619,dopaminergic,48,60,Peripheral iron dextran induced degeneration of dopaminergic neurons in rat substantia nigra.,17490790_0,0
6410,Iron accumulation,0,17,Iron accumulation is considered to be involved in the pathogenesis of Parkinson's disease.,17490790_1,1
5399,Parkinson's disease,70,89,Iron accumulation is considered to be involved in the pathogenesis of Parkinson's disease.,17490790_1,1
1620,dopaminergic,69,81,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,0
1621,tyrosine hydroxylase,178,198,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,0
1622,dopaminergic,346,358,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,0
5400,iron overload,51,64,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,1
6415,iron dextran,407,419,"To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals.",17490790_2,0
6418,TH-immunoreactive,127,144,The findings showed that peripheral iron dextran overload increased the iron staining positive cells and reduced the number of TH-immunoreactive neurons in the SN.,17490790_3,0
6416,iron dextran,36,48,The findings showed that peripheral iron dextran overload increased the iron staining positive cells and reduced the number of TH-immunoreactive neurons in the SN.,17490790_3,0
6419,dopamine release,13,29,"As a result, dopamine release and content, as well as its metabolites contents were decreased in caudate putamen.",17490790_4,0
6420,caudate putamen,97,112,"As a result, dopamine release and content, as well as its metabolites contents were decreased in caudate putamen.",17490790_4,1
6421,chronic overload group,41,63,Even more dramatic changes were found in chronic overload group.,17490790_5,1
6422,iron dextran,38,50,"These results suggest that peripheral iron dextran can increase the iron level in the SN, where excessive iron causes the degeneration of dopaminergic neurons.",17490790_6,0
1623,dopaminergic,138,150,"These results suggest that peripheral iron dextran can increase the iron level in the SN, where excessive iron causes the degeneration of dopaminergic neurons.",17490790_6,0
1624,dopaminergic,53,65,The chronic iron overload may be more destructive to dopaminergic neurons than the acute iron overload.,17490790_7,0
5402,iron overload,89,102,The chronic iron overload may be more destructive to dopaminergic neurons than the acute iron overload.,17490790_7,1
5401,iron overload,12,25,The chronic iron overload may be more destructive to dopaminergic neurons than the acute iron overload.,17490790_7,1
1625,dopaminergic,48,60,Attenuated disruption of prepulse inhibition by dopaminergic stimulation after maternal deprivation and adolescent corticosterone treatment in rats.,17490864_0,0
6427,overt disease,178,191,"The development of schizophrenia may include an early neurodevelopmental stress component which increases vulnerability to later stressful life events, in combination leading to overt disease.",17490864_1,1
6425,neurodevelopmental stress,54,79,"The development of schizophrenia may include an early neurodevelopmental stress component which increases vulnerability to later stressful life events, in combination leading to overt disease.",17490864_1,1
6426,stressful life,129,143,"The development of schizophrenia may include an early neurodevelopmental stress component which increases vulnerability to later stressful life events, in combination leading to overt disease.",17490864_1,1
6429,chronic periadolescent,127,149,"We investigated the effect of an early stress, in the form of maternal deprivation, combined with a later stress, simulated by chronic periadolescent corticosterone treatment, on behaviour in rats.",17490864_2,0
6428,early stress,33,45,"We investigated the effect of an early stress, in the form of maternal deprivation, combined with a later stress, simulated by chronic periadolescent corticosterone treatment, on behaviour in rats.",17490864_2,1
1626,PPI,75,78,"Acute treatment with apomorphine caused disruption of prepulse inhibition (PPI) in controls and in rats that had undergone either maternal deprivation or corticosterone treatment, but was surprisingly absent in rats that had undergone the combined early and late stress.",17490864_3,0
6432,late stress,258,269,"Acute treatment with apomorphine caused disruption of prepulse inhibition (PPI) in controls and in rats that had undergone either maternal deprivation or corticosterone treatment, but was surprisingly absent in rats that had undergone the combined early and late stress.",17490864_3,1
1627,PPI,46,49,"Amphetamine treatment significantly disrupted PPI in both non-deprived groups, but was absent in both maternally deprived groups.",17490864_4,0
1629,PPI,82,85,"The serotonin-1A receptor agonist, 8-OH-DPAT, induced a significant disruption of PPI in all groups.",17490864_5,0
1628,receptor agonist,17,33,"The serotonin-1A receptor agonist, 8-OH-DPAT, induced a significant disruption of PPI in all groups.",17490864_5,0
1630,dopaminergic,171,183,"These results show an inhibitory interaction of early stress, caused by maternal deprivation, combined with 'adolescent' stress, simulated by corticosterone treatment, on dopaminergic regulation of PPI.",17490864_7,0
1631,PPI,198,201,"These results show an inhibitory interaction of early stress, caused by maternal deprivation, combined with 'adolescent' stress, simulated by corticosterone treatment, on dopaminergic regulation of PPI.",17490864_7,0
6434,early stress,48,60,"These results show an inhibitory interaction of early stress, caused by maternal deprivation, combined with 'adolescent' stress, simulated by corticosterone treatment, on dopaminergic regulation of PPI.",17490864_7,1
1632,dopamine receptor,90,107,"The altered effects of apomorphine and amphetamine could indicate differential changes in dopamine receptor signalling leading to functional desensitisation, or altered modulation of sensory gating in the nucleus accumbens by limbic structures such as the hippocampus.",17490864_8,0
6438,limbic structures,226,243,"The altered effects of apomorphine and amphetamine could indicate differential changes in dopamine receptor signalling leading to functional desensitisation, or altered modulation of sensory gating in the nucleus accumbens by limbic structures such as the hippocampus.",17490864_8,1
5403,myocardial ischemia,98,117,Assessment of a new non-invasive index of cardiac performance for detection of dobutamine-induced myocardial ischemia.,17491223_0,1
5404,myocardial ischemia,91,110,BACKGROUND: Electrocardiography has a very low sensitivity in detecting dobutamine-induced myocardial ischemia.,17491223_1,1
6444,Tc99m-Sestamibi,244,259,"OBJECTIVES: To assess the added diagnostic value of a new cardiac performance index (dP/dtejc) measurement, based on brachial artery flow changes, as compared to standard 12-lead ECG, for detecting dobutamine-induced myocardial ischemia, using Tc99m-Sestamibi single-photon emission computed tomography as the gold standard of comparison to assess the presence or absence of ischemia.",17491223_2,0
6442,brachial artery,117,132,"OBJECTIVES: To assess the added diagnostic value of a new cardiac performance index (dP/dtejc) measurement, based on brachial artery flow changes, as compared to standard 12-lead ECG, for detecting dobutamine-induced myocardial ischemia, using Tc99m-Sestamibi single-photon emission computed tomography as the gold standard of comparison to assess the presence or absence of ischemia.",17491223_2,1
5405,myocardial ischemia,217,236,"OBJECTIVES: To assess the added diagnostic value of a new cardiac performance index (dP/dtejc) measurement, based on brachial artery flow changes, as compared to standard 12-lead ECG, for detecting dobutamine-induced myocardial ischemia, using Tc99m-Sestamibi single-photon emission computed tomography as the gold standard of comparison to assess the presence or absence of ischemia.",17491223_2,1
6445,brachial artery,37,52,Simultaneous measurements of ECG and brachial artery dP/dtejc were performed at each dobutamine level.,17491223_4,1
1633,dobutamine,85,95,Simultaneous measurements of ECG and brachial artery dP/dtejc were performed at each dobutamine level.,17491223_4,0
6447,SPECT,85,90,In 19 of the 40 patients perfusion defects compatible with ischemia were detected on SPECT.,17491223_5,0
1634,dobutamine,44,54,The increase in dP/dtejc during infusion of dobutamine in this group was severely impaired as compared to the non-ischemic group.,17491223_6,0
6449,severely impaired,73,90,The increase in dP/dtejc during infusion of dobutamine in this group was severely impaired as compared to the non-ischemic group.,17491223_6,1
5406,myocardial ischemia,208,227,"CONCLUSIONS: If ECG alone is used for specificity, the combination with dP/dtejc improved the sensitivity of the test and could be a cost-savings alternative to cardiac imaging or perfusion studies to detect myocardial ischemia, especially in patients unable to exercise.",17491223_9,1
5407,myocardial infarction,16,37,Cocaine-induced myocardial infarction: clinical observations and pathogenetic considerations.,1749407_0,1
5408,myocardial infarction,122,143,Clinical and experimental data published to date suggest several possible mechanisms by which cocaine may result in acute myocardial infarction.,1749407_1,1
6457,myocardial oxygen demand,132,156,"In individuals with preexisting, high-grade coronary arterial narrowing, acute myocardial infarction may result from an increase in myocardial oxygen demand associated with cocaine-induced increase in rate-pressure product.",1749407_2,1
5409,myocardial infarction,79,100,"In individuals with preexisting, high-grade coronary arterial narrowing, acute myocardial infarction may result from an increase in myocardial oxygen demand associated with cocaine-induced increase in rate-pressure product.",1749407_2,1
6456,high-grade coronary arterial narrowing,33,71,"In individuals with preexisting, high-grade coronary arterial narrowing, acute myocardial infarction may result from an increase in myocardial oxygen demand associated with cocaine-induced increase in rate-pressure product.",1749407_2,1
6461,atherosclerotic obstruction,40,67,"In other individuals with no underlying atherosclerotic obstruction, coronary occlusion may be due to spasm, thrombus, or both.",1749407_3,1
5410,coronary occlusion,69,87,"In other individuals with no underlying atherosclerotic obstruction, coronary occlusion may be due to spasm, thrombus, or both.",1749407_3,1
6464,epicardial,99,109,"Although certain clinical and experimental findings support the hypothesis that spasm involves the epicardial, medium-size vessels, other data suggest intramural vasoconstriction.",1749407_5,1
6465,Diffuse intramural,0,18,"Diffuse intramural vasoconstriction is not consistent with reports of segmental, discrete infarction.",1749407_6,1
6467,discrete infarction,81,100,"Diffuse intramural vasoconstriction is not consistent with reports of segmental, discrete infarction.",1749407_6,1
5411,umbilical artery,85,101,The finding of cocaine-induced vasoconstriction in segments of (noninnervated) human umbilical artery suggests that the presence or absence of intact innervation is not sufficient to explain the discrepant data involving the possibility of alpha-mediated effects.,1749407_8,1
5412,thrombotic,40,50,"Finally, the contribution of a primary, thrombotic effect of cocaine has not been excluded.",1749407_9,1
5413,chronic hepatitis C,54,73,An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha-2b and ribavirin treatment.,17511042_0,1
6470,delusional parasitosis,26,48,An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha-2b and ribavirin treatment.,17511042_0,1
1635,interferon alpha-2b,99,118,An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha-2b and ribavirin treatment.,17511042_0,0
5414,chronic hepatitis C,20,39,"During treatment of chronic hepatitis C patients with interferon and ribavirin, a lot of side effects are described.",17511042_1,1
5415,side effects,89,101,"During treatment of chronic hepatitis C patients with interferon and ribavirin, a lot of side effects are described.",17511042_1,1
6472,psychogenic parasitosis,42,65,"To the best of our knowledge, no cases of psychogenic parasitosis occurring during interferon therapy have been described in the literature.",17511042_4,1
6474,delusional parasitosis,47,69,We present a 49-year-old woman who developed a delusional parasitosis during treatment with pegylated interferon alpha-2b weekly and ribavirin.,17511042_5,1
1636,interferon alpha-2b,102,121,We present a 49-year-old woman who developed a delusional parasitosis during treatment with pegylated interferon alpha-2b weekly and ribavirin.,17511042_5,0
1637,her,62,65,She complained of seeing parasites and the larvae of fleas in her stools.,17511042_6,0
1638,interferon alpha-2b,56,75,All the complaints disappeared after stopping pegylated interferon alpha-2b and reappeared after restarting it.,17511042_8,0
6476,viral response,29,43,She had a complete sustained viral response.,17511042_9,1
6478,striatal,22,30,Proteomic analysis of striatal proteins in the rat model of L-DOPA-induced dyskinesia.,17532790_0,1
5416,Parkinson's disease,79,98,L-DOPA-induced dyskinesia (LID) is among the motor complications that arise in Parkinson's disease (PD) patients after a prolonged treatment with L-DOPA.,17532790_1,1
6480,motor complications,45,64,L-DOPA-induced dyskinesia (LID) is among the motor complications that arise in Parkinson's disease (PD) patients after a prolonged treatment with L-DOPA.,17532790_1,1
6482,striatal,84,92,"In the present study, we investigated the changes occurring at the protein level in striatal samples obtained from the unilaterally 6-hydroxydopamine-lesion rat model of PD treated with saline, L-DOPA or bromocriptine using two-dimensional difference gel electrophoresis and mass spectrometry (MS).",17532790_3,1
1639,bromocriptine,204,217,"In the present study, we investigated the changes occurring at the protein level in striatal samples obtained from the unilaterally 6-hydroxydopamine-lesion rat model of PD treated with saline, L-DOPA or bromocriptine using two-dimensional difference gel electrophoresis and mass spectrometry (MS).",17532790_3,0
6488,HPLC,260,264,"Among the 2000 spots compared for statistical difference, 67 spots were significantly changed in abundance and identified using matrix-assisted laser desorption/ionization time-of-flight MS, atmospheric pressure matrix-assisted laser desorption/ionization and HPLC coupled tandem MS (LC/MS/MS).",17532790_5,0
6492,proteasome alpha-2,175,193,"Out of these 67 proteins, LID significantly changed the expression level of five proteins: alphabeta-crystalin, gamma-enolase, guanidoacetate methyltransferase, vinculin, and proteasome alpha-2 subunit.",17532790_6,0
6490,alphabeta-crystalin,91,110,"Out of these 67 proteins, LID significantly changed the expression level of five proteins: alphabeta-crystalin, gamma-enolase, guanidoacetate methyltransferase, vinculin, and proteasome alpha-2 subunit.",17532790_6,0
6491,vinculin,161,169,"Out of these 67 proteins, LID significantly changed the expression level of five proteins: alphabeta-crystalin, gamma-enolase, guanidoacetate methyltransferase, vinculin, and proteasome alpha-2 subunit.",17532790_6,0
1640,gamma-enolase,112,125,"Out of these 67 proteins, LID significantly changed the expression level of five proteins: alphabeta-crystalin, gamma-enolase, guanidoacetate methyltransferase, vinculin, and proteasome alpha-2 subunit.",17532790_6,0
1641,guanidoacetate methyltransferase,127,159,"Out of these 67 proteins, LID significantly changed the expression level of five proteins: alphabeta-crystalin, gamma-enolase, guanidoacetate methyltransferase, vinculin, and proteasome alpha-2 subunit.",17532790_6,0
6494,western immunoblotting,33,55,Complementary techniques such as western immunoblotting and immunohistochemistry were performed to investigate the validity of the data obtained using the proteomic approach.,17532790_7,0
5417,chronic kidney disease,144,166,Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease.,17562951_0,1
6499,contrast-induced nephropathy,98,126,Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease.,17562951_0,1
6504,contrast medium iodixanol,146,171,BACKGROUND: No direct comparisons exist of the renal tolerability of the low-osmolality contrast medium iopamidol with that of the iso-osmolality contrast medium iodixanol in high-risk patients.,17562951_1,0
6503,iso-osmolality,131,145,BACKGROUND: No direct comparisons exist of the renal tolerability of the low-osmolality contrast medium iopamidol with that of the iso-osmolality contrast medium iodixanol in high-risk patients.,17562951_1,0
6502,contrast medium iopamidol,88,113,BACKGROUND: No direct comparisons exist of the renal tolerability of the low-osmolality contrast medium iopamidol with that of the iso-osmolality contrast medium iodixanol in high-risk patients.,17562951_1,0
6501,low-osmolality,73,87,BACKGROUND: No direct comparisons exist of the renal tolerability of the low-osmolality contrast medium iopamidol with that of the iso-osmolality contrast medium iodixanol in high-risk patients.,17562951_1,0
6533,intraarterial,128,141,"CONCLUSIONS: The rate of contrast-induced nephropathy, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or iodixanol to high-risk patients, with or without diabetes mellitus.",17562951_10,1
1648,end points,75,85,"CONCLUSIONS: The rate of contrast-induced nephropathy, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or iodixanol to high-risk patients, with or without diabetes mellitus.",17562951_10,0
5420,diabetes mellitus,222,239,"CONCLUSIONS: The rate of contrast-induced nephropathy, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or iodixanol to high-risk patients, with or without diabetes mellitus.",17562951_10,1
1649,iopamidol,160,169,"CONCLUSIONS: The rate of contrast-induced nephropathy, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or iodixanol to high-risk patients, with or without diabetes mellitus.",17562951_10,0
6534,iodixanol,173,182,"CONCLUSIONS: The rate of contrast-induced nephropathy, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or iodixanol to high-risk patients, with or without diabetes mellitus.",17562951_10,0
5418,chronic kidney disease,137,159,"METHODS AND RESULTS: The present study is a multicenter, randomized, double-blind comparison of iopamidol and iodixanol in patients with chronic kidney disease (estimated glomerular filtration rate, 20 to 59 mL/min) who underwent cardiac angiography or percutaneous coronary interventions.",17562951_2,1
1642,iopamidol,96,105,"METHODS AND RESULTS: The present study is a multicenter, randomized, double-blind comparison of iopamidol and iodixanol in patients with chronic kidney disease (estimated glomerular filtration rate, 20 to 59 mL/min) who underwent cardiac angiography or percutaneous coronary interventions.",17562951_2,0
6507,iodixanol,110,119,"METHODS AND RESULTS: The present study is a multicenter, randomized, double-blind comparison of iopamidol and iodixanol in patients with chronic kidney disease (estimated glomerular filtration rate, 20 to 59 mL/min) who underwent cardiac angiography or percutaneous coronary interventions.",17562951_2,0
6509,cardiac angiography,230,249,"METHODS AND RESULTS: The present study is a multicenter, randomized, double-blind comparison of iopamidol and iodixanol in patients with chronic kidney disease (estimated glomerular filtration rate, 20 to 59 mL/min) who underwent cardiac angiography or percutaneous coronary interventions.",17562951_2,1
6510,percutaneous coronary interventions,253,288,"METHODS AND RESULTS: The present study is a multicenter, randomized, double-blind comparison of iopamidol and iodixanol in patients with chronic kidney disease (estimated glomerular filtration rate, 20 to 59 mL/min) who underwent cardiac angiography or percutaneous coronary interventions.",17562951_2,1
6511,SCr,18,21,Serum creatinine (SCr) levels and estimated glomerular filtration rate were assessed at baseline and 2 to 5 days after receiving medications.,17562951_3,0
1643,creatinine,6,16,Serum creatinine (SCr) levels and estimated glomerular filtration rate were assessed at baseline and 2 to 5 days after receiving medications.,17562951_3,0
6514,postdose,26,34,The primary outcome was a postdose SCr increase > or = 0.5 mg/dL (44.2 micromol/L) over baseline.,17562951_4,1
6522,SCr,160,163,"Secondary outcomes were a postdose SCr increase > or = 25%, a postdose estimated glomerular filtration rate decrease of > or = 25%, and the mean peak change in SCr.",17562951_5,0
6518,SCr,35,38,"Secondary outcomes were a postdose SCr increase > or = 25%, a postdose estimated glomerular filtration rate decrease of > or = 25%, and the mean peak change in SCr.",17562951_5,0
6523,contrast volume,17,32,"In 414 patients, contrast volume, presence of diabetes mellitus, use of N-acetylcysteine, mean baseline SCr, and estimated glomerular filtration rate were comparable in the 2 groups.",17562951_6,0
5419,diabetes mellitus,46,63,"In 414 patients, contrast volume, presence of diabetes mellitus, use of N-acetylcysteine, mean baseline SCr, and estimated glomerular filtration rate were comparable in the 2 groups.",17562951_6,1
1644,N-acetylcysteine,72,88,"In 414 patients, contrast volume, presence of diabetes mellitus, use of N-acetylcysteine, mean baseline SCr, and estimated glomerular filtration rate were comparable in the 2 groups.",17562951_6,0
6526,iodixanol,120,129,"SCr increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after iopamidol and 6.7% (14 of 210 patients) after iodixanol (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44).",17562951_7,0
6525,SCr,0,3,"SCr increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after iopamidol and 6.7% (14 of 210 patients) after iodixanol (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44).",17562951_7,0
1645,iopamidol,74,83,"SCr increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after iopamidol and 6.7% (14 of 210 patients) after iodixanol (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44).",17562951_7,0
6527,SCr,157,160,"SCr increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after iopamidol and 6.7% (14 of 210 patients) after iodixanol (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44).",17562951_7,0
6530,SCr,165,168,"In patients with diabetes, SCr increases > or = 0.5 mg/dL were 5.1% (4 of 78 patients) with iopamidol and 13.0% (12 of 92 patients) with iodixanol (P=0.11), whereas SCr increases > or = 25% were 10.3% and 15.2%, respectively (P=0.37).",17562951_8,0
6529,iodixanol,137,146,"In patients with diabetes, SCr increases > or = 0.5 mg/dL were 5.1% (4 of 78 patients) with iopamidol and 13.0% (12 of 92 patients) with iodixanol (P=0.11), whereas SCr increases > or = 25% were 10.3% and 15.2%, respectively (P=0.37).",17562951_8,0
1646,iopamidol,92,101,"In patients with diabetes, SCr increases > or = 0.5 mg/dL were 5.1% (4 of 78 patients) with iopamidol and 13.0% (12 of 92 patients) with iodixanol (P=0.11), whereas SCr increases > or = 25% were 10.3% and 15.2%, respectively (P=0.37).",17562951_8,0
6528,SCr,27,30,"In patients with diabetes, SCr increases > or = 0.5 mg/dL were 5.1% (4 of 78 patients) with iopamidol and 13.0% (12 of 92 patients) with iodixanol (P=0.11), whereas SCr increases > or = 25% were 10.3% and 15.2%, respectively (P=0.37).",17562951_8,0
1647,iopamidol,53,62,"Mean post-SCr increases were significantly less with iopamidol (all patients: 0.07 versus 0.12 mg/dL, 6.2 versus 10.6 micromol/L, P=0.03; patients with diabetes: 0.07 versus 0.16 mg/dL, 6.2 versus 14.1 micromol/L, P=0.01).",17562951_9,0
6536,Hepatonecrosis,0,14,Hepatonecrosis and cholangitis related to long-term phenobarbital therapy: an autopsy report of two patients.,17574447_0,1
6538,chronic liver disease,193,214,"Phenobarbital (PB) has a reputation for safety, and it is commonly believed that PB-related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic liver disease.",17574447_1,1
6539,long history of,44,59,"Here we report of two adult patients with a long history of epilepsy treated with PB who died suddenly: one as consequence of cardiac arrest, the other of acute bronchopneumonia.",17574447_2,1
5421,cardiac arrest,126,140,"Here we report of two adult patients with a long history of epilepsy treated with PB who died suddenly: one as consequence of cardiac arrest, the other of acute bronchopneumonia.",17574447_2,1
6541,acute bronchopneumonia,155,177,"Here we report of two adult patients with a long history of epilepsy treated with PB who died suddenly: one as consequence of cardiac arrest, the other of acute bronchopneumonia.",17574447_2,1
6544,mixed eosinophil,106,122,"At autopsy, analysis of liver parenchyma revealed rich portal inflammatory infiltrate, which consisted of mixed eosinophil and monocyte cells, associated with several foci of necrosis surrounded by a hard ring of non-specific granulomatous tissue.",17574447_3,0
1650,non-specific,213,225,"At autopsy, analysis of liver parenchyma revealed rich portal inflammatory infiltrate, which consisted of mixed eosinophil and monocyte cells, associated with several foci of necrosis surrounded by a hard ring of non-specific granulomatous tissue.",17574447_3,0
6542,liver parenchyma,24,40,"At autopsy, analysis of liver parenchyma revealed rich portal inflammatory infiltrate, which consisted of mixed eosinophil and monocyte cells, associated with several foci of necrosis surrounded by a hard ring of non-specific granulomatous tissue.",17574447_3,1
6549,hepatic biliary ducts,48,69,Inflammatory reactions of internal and external hepatic biliary ducts were also seen.,17574447_4,1
6548,Inflammatory reactions,0,22,Inflammatory reactions of internal and external hepatic biliary ducts were also seen.,17574447_4,1
6551,chronic liver damage,55,75,"Our findings illustrate that PB may be associated with chronic liver damage, which may lead to more serious and deleterious consequences.",17574447_5,1
6553,chronic hepatic enzyme dysfunction,118,152,"For this reason, each clinician should recognize this entity in the differential diagnosis of PB-related asymptomatic chronic hepatic enzyme dysfunction.",17574447_6,1
6554,maltolyl p-coumarate,18,38,"A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.",17600377_0,0
1651,neuroprotective effects,80,103,"A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.",17600377_0,0
6555,cognitive deficits,51,69,"A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models.",17600377_0,1
6560,esterification,146,160,"To develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid.",17600377_1,0
6559,maltolyl p-coumarate,118,138,"To develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid.",17600377_1,0
6561,maltol,164,170,"To develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid.",17600377_1,0
6557,cognitive function,57,75,"To develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid.",17600377_1,1
6562,p-coumaric acid,175,190,"To develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid.",17600377_1,0
6558,neuroprotection,80,95,"To develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid.",17600377_1,1
6565,amyloid beta peptide(1-,135,158,"In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats.",17600377_2,0
6563,maltolyl p-coumarate,46,66,"In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats.",17600377_2,0
5422,cognitive decline,81,98,"In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats.",17600377_2,1
6569,amyloid beta peptide(1-,181,204,Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats.,17600377_3,0
6567,cognitive deficits,44,62,Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats.,17600377_3,1
6566,Maltolyl p-coumarate,0,20,Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats.,17600377_3,0
1652,neuroprotective effects,21,44,We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells.,17600377_4,0
6570,maltolyl p-coumarate,48,68,We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells.,17600377_4,0
6571,maltolyl p-coumarate,27,47,"Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2.",17600377_5,0
6572,amyloid beta peptide(1-42,67,92,"Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2.",17600377_5,0
6573,H2O2,108,112,"Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2.",17600377_5,0
1654,caspase 3,143,152,"We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation.",17600377_6,0
1653,reactive oxygen species,92,115,"We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation.",17600377_6,0
6574,maltolyl p-coumarate,14,34,"We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation.",17600377_6,0
6575,apoptotic cell death,59,79,"We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation.",17600377_6,1
6576,cytochrome c,117,129,"We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation.",17600377_6,0
5423,Alzheimer's disease,142,161,"Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function.",17600377_7,1
6578,maltolyl p-coumarate,76,96,"Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function.",17600377_7,0
6579,neuronal death,199,213,"Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function.",17600377_7,1
6580,cognitive function,241,259,"Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread neuronal death and progressive decline of cognitive function.",17600377_7,1
1655,lipopolysaccharide,91,109,Attenuation of methamphetamine-induced nigrostriatal dopaminergic neurotoxicity in mice by lipopolysaccharide pretreatment.,17608141_0,0
6581,nigrostriatal dopaminergic neurotoxicity,39,79,Attenuation of methamphetamine-induced nigrostriatal dopaminergic neurotoxicity in mice by lipopolysaccharide pretreatment.,17608141_0,1
1656,dopaminergic,85,97,Immunological activation has been proposed to play a role in methamphetamine-induced dopaminergic terminal damage.,17608141_1,0
5424,neurotoxicity,179,192,"In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine neurotoxicity.",17608141_2,1
6584,inflammatory factor,83,102,"In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine neurotoxicity.",17608141_2,0
1657,lipopolysaccharide,40,58,"In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine neurotoxicity.",17608141_2,0
1658,Lipopolysaccharide,0,18,Lipopolysaccharide pretreatment did not affect the basal body temperature or methamphetamine-elicited hyperthermia three days later.,17608141_3,0
5425,body temperature,57,73,Lipopolysaccharide pretreatment did not affect the basal body temperature or methamphetamine-elicited hyperthermia three days later.,17608141_3,1
6588,striatal,77,85,"Such systemic lipopolysaccharide treatment mitigated methamphetamine-induced striatal dopamine and 3,4-dihydroxyphenylacetic acid depletions in a dose-dependent manner.",17608141_4,1
1659,lipopolysaccharide,14,32,"Such systemic lipopolysaccharide treatment mitigated methamphetamine-induced striatal dopamine and 3,4-dihydroxyphenylacetic acid depletions in a dose-dependent manner.",17608141_4,0
1660,(1,24,26,"As the most potent dose (1 mg/kg) of lipopolysaccharide was administered two weeks, one day before or after the methamphetamine dosing regimen, methamphetamine-induced striatal dopamine and 3,4-dihydroxyphenylacetic acid depletions remained unaltered.",17608141_5,0
1661,lipopolysaccharide,37,55,"As the most potent dose (1 mg/kg) of lipopolysaccharide was administered two weeks, one day before or after the methamphetamine dosing regimen, methamphetamine-induced striatal dopamine and 3,4-dihydroxyphenylacetic acid depletions remained unaltered.",17608141_5,0
6594,protective effect,204,221,"Moreover, systemic lipopolysaccharide pretreatment (1 mg/kg) attenuated local methamphetamine infusion-produced dopamine and 3,4-dihydroxyphenylacetic acid depletions in the striatum, indicating that the protective effect of lipopolysaccharide is less likely due to interrupted peripheral distribution or metabolism of methamphetamine.",17608141_6,0
1664,lipopolysaccharide,225,243,"Moreover, systemic lipopolysaccharide pretreatment (1 mg/kg) attenuated local methamphetamine infusion-produced dopamine and 3,4-dihydroxyphenylacetic acid depletions in the striatum, indicating that the protective effect of lipopolysaccharide is less likely due to interrupted peripheral distribution or metabolism of methamphetamine.",17608141_6,0
1663,(1,51,53,"Moreover, systemic lipopolysaccharide pretreatment (1 mg/kg) attenuated local methamphetamine infusion-produced dopamine and 3,4-dihydroxyphenylacetic acid depletions in the striatum, indicating that the protective effect of lipopolysaccharide is less likely due to interrupted peripheral distribution or metabolism of methamphetamine.",17608141_6,0
1662,lipopolysaccharide,19,37,"Moreover, systemic lipopolysaccharide pretreatment (1 mg/kg) attenuated local methamphetamine infusion-produced dopamine and 3,4-dihydroxyphenylacetic acid depletions in the striatum, indicating that the protective effect of lipopolysaccharide is less likely due to interrupted peripheral distribution or metabolism of methamphetamine.",17608141_6,0
5426,neurotoxicity,169,182,We concluded a critical time window for systemic lipopolysaccharide pretreatment in exerting effective protection against methamphetamine-induced nigrostriatal dopamine neurotoxicity.,17608141_7,1
1665,lipopolysaccharide,49,67,We concluded a critical time window for systemic lipopolysaccharide pretreatment in exerting effective protection against methamphetamine-induced nigrostriatal dopamine neurotoxicity.,17608141_7,0
6597,Acute myocarditis,0,17,Acute myocarditis associated with clozapine.,17612891_0,1
6599,acute myocarditis,21,38,"OBJECTIVE: A case of acute myocarditis associated with the commencement of clozapine is described, highlighting the onset, course and possible contributing factors.",17612891_1,1
6602,sudden onset of,59,74,RESULTS: A 20-year-old male with schizophrenia developed a sudden onset of myocarditis after commencement of clozapine.,17612891_3,1
5428,acute renal failure,26,45,"Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.",17615423_0,1
1666,atazanavir,107,117,"Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.",17615423_0,0
5427,rhabdomyolysis,7,21,"Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir.",17615423_0,1
5429,rhabdomyolysis,113,127,"OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and atazanavir resulting in rhabdomyolysis and acute renal failure.",17615423_1,1
5430,acute renal failure,132,151,"OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and atazanavir resulting in rhabdomyolysis and acute renal failure.",17615423_1,1
1667,atazanavir,89,99,"OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and atazanavir resulting in rhabdomyolysis and acute renal failure.",17615423_1,0
1676,rosuvastatin,105,117,"In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors.",17615423_11,0
1677,CYP3A4 inhibitors,308,325,"In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors.",17615423_11,0
1675,CYP3A4 inhibitors,56,73,"In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors.",17615423_11,0
1668,human immunodeficiency virus,52,80,"BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days.",17615423_2,0
5432,coronary artery disease,103,126,"BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days.",17615423_2,1
6609,generalized pain,162,178,"BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days.",17615423_2,1
5431,atrial fibrillation,82,101,"BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days.",17615423_2,1
1669,atazanavir,188,198,"The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously).",17615423_3,0
1670,creatinine,99,109,"Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL creatinine, 1579 U/L aspartate aminotransferase, and 738 U/L alanine aminotransferase.",17615423_4,0
6614,U/L alanine aminotransferase,156,184,"Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL creatinine, 1579 U/L aspartate aminotransferase, and 738 U/L alanine aminotransferase.",17615423_4,0
6613,U/L aspartate aminotransferase,116,146,"Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL creatinine, 1579 U/L aspartate aminotransferase, and 738 U/L alanine aminotransferase.",17615423_4,0
6611,U/L creatine kinase,38,57,"Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL creatinine, 1579 U/L aspartate aminotransferase, and 738 U/L alanine aminotransferase.",17615423_4,0
6615,patient's human immunodeficiency virus,33,71,"Simvastatin, amiodarone, and the patient's human immunodeficiency virus medications were all temporarily discontinued and the patient was given forced alkaline diuresis and started on dialysis.",17615423_5,0
1671,creatinine,74,84,Nine days later the patient's creatine kinase had dropped to 1695 U/L and creatinine was 3.3 mg/dL. The patient was discharged and continued outpatient dialysis for 1 month until his renal function recovered.,17615423_6,0
6619,his renal function,179,197,Nine days later the patient's creatine kinase had dropped to 1695 U/L and creatinine was 3.3 mg/dL. The patient was discharged and continued outpatient dialysis for 1 month until his renal function recovered.,17615423_6,1
6617,patient's creatine kinase,20,45,Nine days later the patient's creatine kinase had dropped to 1695 U/L and creatinine was 3.3 mg/dL. The patient was discharged and continued outpatient dialysis for 1 month until his renal function recovered.,17615423_6,0
5433,rhabdomyolysis,24,38,DISCUSSION: The risk of rhabdomyolysis is increased in the presence of concomitant drugs that inhibit simvastatin metabolism.,17615423_7,1
1672,CYP3A4,30,36,Simvastatin is metabolized by CYP3A4.,17615423_8,0
1673,atazanavir,15,25,Amiodarone and atazanavir are recognized CYP3A4 inhibitors.,17615423_9,0
1674,CYP3A4 inhibitors,41,58,Amiodarone and atazanavir are recognized CYP3A4 inhibitors.,17615423_9,0
1678,levofloxacin,33,45,Interaction between warfarin and levofloxacin: case series.,17639754_0,0
6624,clinical conditions,78,97,Warfarin is the most widely used oral anticoagulant and is indicated for many clinical conditions.,17639754_1,1
1679,oral anticoagulant,33,51,Warfarin is the most widely used oral anticoagulant and is indicated for many clinical conditions.,17639754_1,0
1680,Levofloxacin,0,12,"Levofloxacin, a fluoroquinolone, is one of the most commonly prescribed antibiotics in clinical practice and is effective against Gram-positive, Gram-negative, and atypical bacteria.",17639754_2,0
1681,fluoroquinolone,16,31,"Levofloxacin, a fluoroquinolone, is one of the most commonly prescribed antibiotics in clinical practice and is effective against Gram-positive, Gram-negative, and atypical bacteria.",17639754_2,0
1682,levofloxacin,109,121,"While small prospective studies have not revealed any significant drug-drug interaction between warfarin and levofloxacin, several case reports have indicated that levofloxacin may significantly potentiate the anticoagulation effect of warfarin.",17639754_3,0
1683,levofloxacin,164,176,"While small prospective studies have not revealed any significant drug-drug interaction between warfarin and levofloxacin, several case reports have indicated that levofloxacin may significantly potentiate the anticoagulation effect of warfarin.",17639754_3,0
1684,levofloxacin,121,133,We report 3 cases of serious bleeding complications that appear to be the result of the interaction between warfarin and levofloxacin.,17639754_4,0
1685,levofloxacin,90,102,Physicians should be aware of this potential interaction and use caution when prescribing levofloxacin to patients taking warfarin.,17639754_5,0
6630,stroke-like presentation,33,57,Delayed leukoencephalopathy with stroke-like presentation in chemotherapy recipients.,17682013_0,1
5434,leukoencephalopathy,8,27,Delayed leukoencephalopathy with stroke-like presentation in chemotherapy recipients.,17682013_0,1
5435,leukoencephalopathy,24,43,"BACKGROUND: A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy, most commonly in recipients of intrathecal methotrexate for childhood leukaemia.",17682013_1,1
6631,childhood leukaemia,193,212,"BACKGROUND: A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy, most commonly in recipients of intrathecal methotrexate for childhood leukaemia.",17682013_1,1
5436,cerebrovascular accident,54,78,"BACKGROUND: A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy, most commonly in recipients of intrathecal methotrexate for childhood leukaemia.",17682013_1,1
6650,white matter abnormalities,94,120,"However, fluid attenuated inversion recovery (FLAIR) sequences frequently revealed persistent white matter abnormalities.",17682013_10,1
5442,leukoencephalopathy,58,77,CONCLUSIONS: Several pathophysiological models of delayed leukoencephalopathy after exposure to intrathecal or systemic chemotherapy have been proposed.,17682013_11,1
6657,metabolic derangement,145,166,DWI findings in this cohort are indicative of cytotoxic oedema within cerebral white matter and lend support to an at least partially reversible metabolic derangement as the basis for this syndrome.,17682013_12,1
6656,white matter,79,91,DWI findings in this cohort are indicative of cytotoxic oedema within cerebral white matter and lend support to an at least partially reversible metabolic derangement as the basis for this syndrome.,17682013_12,1
6655,cytotoxic oedema,46,62,DWI findings in this cohort are indicative of cytotoxic oedema within cerebral white matter and lend support to an at least partially reversible metabolic derangement as the basis for this syndrome.,17682013_12,1
6632,published neuroimaging,9,31,Recently published neuroimaging data suggest a common pathophysiology associated with a variety of chemotherapy agents and modes of administration.,17682013_2,1
1686,chemotherapy agents,99,118,Recently published neuroimaging data suggest a common pathophysiology associated with a variety of chemotherapy agents and modes of administration.,17682013_2,0
5437,pathophysiology,54,69,Recently published neuroimaging data suggest a common pathophysiology associated with a variety of chemotherapy agents and modes of administration.,17682013_2,1
6637,stroke-like episodes,107,127,METHODS: We reviewed the medical literature for single reports and case series of patients presenting with stroke-like episodes while receiving systemic or intrathecal chemotherapy.,17682013_3,1
5438,cerebrovascular accidents,14,39,Patients with cerebrovascular accidents were excluded.,17682013_5,1
5439,leukoencephalopathy,43,62,"RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.",17682013_6,1
6640,5-fluorouracil,126,140,"RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.",17682013_6,0
6641,derivative carmofur,149,168,"RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.",17682013_6,0
1687,capecitabine,174,186,"RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine.",17682013_6,0
6645,white matter,118,130,"Diffusion weighted imaging (DWI) of all patients revealed well demarcated hyperintense lesions within the subcortical white matter of the cerebral hemispheres and the corpus callosum, corresponding to areas of decreased proton diffusion on apparent diffusion coefficient (ADC) maps (available in 21/27 patients).",17682013_7,1
5440,cerebral hemispheres,138,158,"Diffusion weighted imaging (DWI) of all patients revealed well demarcated hyperintense lesions within the subcortical white matter of the cerebral hemispheres and the corpus callosum, corresponding to areas of decreased proton diffusion on apparent diffusion coefficient (ADC) maps (available in 21/27 patients).",17682013_7,1
5441,corpus callosum,167,182,"Diffusion weighted imaging (DWI) of all patients revealed well demarcated hyperintense lesions within the subcortical white matter of the cerebral hemispheres and the corpus callosum, corresponding to areas of decreased proton diffusion on apparent diffusion coefficient (ADC) maps (available in 21/27 patients).",17682013_7,1
6648,vascular territories,42,62,Lesions exceeded the confines of adjacent vascular territories.,17682013_8,1
5444,pulmonary hypertension,46,68,Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat.,17702969_0,1
5443,Prenatal exposure,0,17,Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat.,17702969_0,1
6658,selective serotonin reuptake inhibitor antidepressant,27,80,RATIONALE: Fluoxetine is a selective serotonin reuptake inhibitor antidepressant widely used by pregnant women.,17702969_1,0
5451,pulmonary hypertension,76,98,"CONCLUSIONS: In contrast to the adult, fluoxetine exposure in utero induces pulmonary hypertension in the fetal rat as a result of a developmentally regulated increase in pulmonary vascular smooth muscle proliferation.",17702969_11,1
6661,pulmonary hypertension syndrome of the newborn,104,150,Epidemiological data suggest that fluoxetine exposure prenatally increases the prevalence of persistent pulmonary hypertension syndrome of the newborn.,17702969_2,1
5445,pulmonary hypertension,108,130,"The mechanism responsible for this effect is unclear and paradoxical, considering the current evidence of a pulmonary hypertension protective fluoxetine effect in adult rodents.",17702969_3,1
6663,cesarean section,57,73,MEASUREMENTS AND MAIN RESULTS: Fetuses were delivered by cesarean section.,17702969_6,1
5446,pulmonary hypertension,65,87,"As compared with controls, fluoxetine exposure resulted in fetal pulmonary hypertension as evidenced by an increase in the weight ratio of the right ventricle to the left ventricle plus septum (P = 0.02) and by an increase in pulmonary arterial medial thickness (P < 0.01).",17702969_7,1
5449,pulmonary arterial,226,244,"As compared with controls, fluoxetine exposure resulted in fetal pulmonary hypertension as evidenced by an increase in the weight ratio of the right ventricle to the left ventricle plus septum (P = 0.02) and by an increase in pulmonary arterial medial thickness (P < 0.01).",17702969_7,1
5448,left ventricle,166,180,"As compared with controls, fluoxetine exposure resulted in fetal pulmonary hypertension as evidenced by an increase in the weight ratio of the right ventricle to the left ventricle plus septum (P = 0.02) and by an increase in pulmonary arterial medial thickness (P < 0.01).",17702969_7,1
5447,right ventricle,143,158,"As compared with controls, fluoxetine exposure resulted in fetal pulmonary hypertension as evidenced by an increase in the weight ratio of the right ventricle to the left ventricle plus septum (P = 0.02) and by an increase in pulmonary arterial medial thickness (P < 0.01).",17702969_7,1
1688,/- 1,101,105,"Postnatal mortality was increased among experimental animals, and arterial oxygen saturation was 96 +/- 1% in 1-day-old control animals and significantly lower (P < 0.01) in fluoxetine-exposed pups (79 +/- 2%).",17702969_8,0
1689,/- 2,203,207,"Postnatal mortality was increased among experimental animals, and arterial oxygen saturation was 96 +/- 1% in 1-day-old control animals and significantly lower (P < 0.01) in fluoxetine-exposed pups (79 +/- 2%).",17702969_8,0
5450,pulmonary arterial,29,47,"In vitro, fluoxetine induced pulmonary arterial muscle contraction in fetal, but not adult, animals (P < 0.01) and reduced serotonin-induced contraction at both ages (P < 0.01).",17702969_9,1
5452,peripheral neuropathy,39,60,Disulfiram-induced transient optic and peripheral neuropathy: a case report.,17786501_0,1
5454,alcohol dependence,93,111,AIM: To report a case of optic and peripheral neuropathy after chronic use of disulfiram for alcohol dependence management.,17786501_1,1
5453,peripheral neuropathy,35,56,AIM: To report a case of optic and peripheral neuropathy after chronic use of disulfiram for alcohol dependence management.,17786501_1,1
6674,chronic use,63,74,AIM: To report a case of optic and peripheral neuropathy after chronic use of disulfiram for alcohol dependence management.,17786501_1,1
5457,adverse effects,88,103,CONCLUSION: Physicians initiating long-term disulfiram therapy should be aware of these adverse effects.,17786501_10,1
5458,adverse effects,72,87,Patients should be reassured with respect to the reversibility of these adverse effects.,17786501_12,1
6676,loss of vision,51,65,RESULTS: A 57-year-old male presented with gradual loss of vision in both eyes with intermittent headaches for 2 months.,17786501_3,1
1690,His,0,3,"His vision was 6/15 and 2/60 in the right and left eyes, respectively.",17786501_5,0
6677,left eyes,46,55,"His vision was 6/15 and 2/60 in the right and left eyes, respectively.",17786501_5,1
5455,optic nerve,40,51,Fundoscopy revealed bilaterally swollen optic nerve heads.,17786501_6,1
6678,Fundoscopy,0,10,Fundoscopy revealed bilaterally swollen optic nerve heads.,17786501_6,1
6680,central-caecal scotomata,41,65,Visual field testing confirmed bilateral central-caecal scotomata.,17786501_7,1
5456,alcohol dependence,34,52,He had been taking disulfiram for alcohol dependence for the preceding 3 years.,17786501_8,1
1691,antiretroviral,160,174,Mutations associated with lamivudine-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.,17854040_0,0
5459,co-infection,129,141,Mutations associated with lamivudine-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.,17854040_0,1
6684,hepatitis B,66,77,Mutations associated with lamivudine-resistance in therapy-na  ve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.,17854040_0,1
5460,co-infection,193,205,This was an exploratory study to investigate lamivudine-resistant hepatitis B virus (HBV) strains in selected lamivudine-na  ve HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients.,17854040_1,1
1692,human immunodeficiency virus,158,186,This was an exploratory study to investigate lamivudine-resistant hepatitis B virus (HBV) strains in selected lamivudine-na  ve HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients.,17854040_1,0
6691,HBV,128,131,This was an exploratory study to investigate lamivudine-resistant hepatitis B virus (HBV) strains in selected lamivudine-na  ve HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients.,17854040_1,0
6690,HBV,85,88,This was an exploratory study to investigate lamivudine-resistant hepatitis B virus (HBV) strains in selected lamivudine-na  ve HBV carriers with and without human immunodeficiency virus (HIV) co-infection in South African patients.,17854040_1,0
6729,ARV,187,190,"It remains to be seen whether such pre-existing antiviral mutations could result in widespread emergence of HBV resistant strains when lamivudine-containing highly active antiretroviral (ARV) treatment (HAART) regimens become widely applied in South Africa, as this is likely to have potential implications in the management of HBV-HIV co-infected patients.",17854040_10,0
6727,HBV,108,111,"It remains to be seen whether such pre-existing antiviral mutations could result in widespread emergence of HBV resistant strains when lamivudine-containing highly active antiretroviral (ARV) treatment (HAART) regimens become widely applied in South Africa, as this is likely to have potential implications in the management of HBV-HIV co-infected patients.",17854040_10,0
1695,antiretroviral,171,185,"It remains to be seen whether such pre-existing antiviral mutations could result in widespread emergence of HBV resistant strains when lamivudine-containing highly active antiretroviral (ARV) treatment (HAART) regimens become widely applied in South Africa, as this is likely to have potential implications in the management of HBV-HIV co-infected patients.",17854040_10,0
5461,co-infection,72,84,Thirty-five lamivudine-na  ve HBV infected patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 HBV-HIV co-infected patients.,17854040_2,1
6700,HBV,89,92,The latter group was further sub-divided into 13 occult HBV (HBsAg-negative) and 7 overt HBV (HBsAg- positive) patients.,17854040_3,0
6704,anti-HIV,31,39,"HBsAg, anti-HBs, anti-HBc, and anti-HIV 1/2 were determined as part of routine diagnosis using Axsym assays (Abbott Laboratories, North Chicago, IL).",17854040_4,0
6702,anti-HBs,7,15,"HBsAg, anti-HBs, anti-HBc, and anti-HIV 1/2 were determined as part of routine diagnosis using Axsym assays (Abbott Laboratories, North Chicago, IL).",17854040_4,0
1693,HBsAg,0,5,"HBsAg, anti-HBs, anti-HBc, and anti-HIV 1/2 were determined as part of routine diagnosis using Axsym assays (Abbott Laboratories, North Chicago, IL).",17854040_4,0
6703,anti-HBc,17,25,"HBsAg, anti-HBs, anti-HBc, and anti-HIV 1/2 were determined as part of routine diagnosis using Axsym assays (Abbott Laboratories, North Chicago, IL).",17854040_4,0
6708,HBV reverse transcriptase,38,63,"Serum samples were PCR amplified with HBV reverse transcriptase (RT) primers, followed by direct sequencing across the tyrosine-methionine-aspartate-aspartate (YMDD) motif of the major catalytic region in the C domain of the HBV RT enzyme.",17854040_5,0
6709,tyrosine-methionine-aspartate-aspartate (YMDD) motif,119,171,"Serum samples were PCR amplified with HBV reverse transcriptase (RT) primers, followed by direct sequencing across the tyrosine-methionine-aspartate-aspartate (YMDD) motif of the major catalytic region in the C domain of the HBV RT enzyme.",17854040_5,0
6711,C domain,209,217,"Serum samples were PCR amplified with HBV reverse transcriptase (RT) primers, followed by direct sequencing across the tyrosine-methionine-aspartate-aspartate (YMDD) motif of the major catalytic region in the C domain of the HBV RT enzyme.",17854040_5,0
6712,HBV,225,228,"Serum samples were PCR amplified with HBV reverse transcriptase (RT) primers, followed by direct sequencing across the tyrosine-methionine-aspartate-aspartate (YMDD) motif of the major catalytic region in the C domain of the HBV RT enzyme.",17854040_5,0
6713,HBV,0,3,"HBV viral load was performed with Amplicor HBV Monitor test v2.0 (Roche Diagnostics, Penzberg, Germany).",17854040_6,0
1694,Roche,66,71,"HBV viral load was performed with Amplicor HBV Monitor test v2.0 (Roche Diagnostics, Penzberg, Germany).",17854040_6,0
6715,Amplicor HBV Monitor test v2.0,34,64,"HBV viral load was performed with Amplicor HBV Monitor test v2.0 (Roche Diagnostics, Penzberg, Germany).",17854040_6,0
6714,viral load,4,14,"HBV viral load was performed with Amplicor HBV Monitor test v2.0 (Roche Diagnostics, Penzberg, Germany).",17854040_6,1
6716,HBV,0,3,HBV lamivudine-resistant strains were detected in 3 of 15 mono-infected chronic hepatitis B patients and 10 of 20 HBV-HIV co-infected patients.,17854040_7,0
6717,mono-infected,58,71,HBV lamivudine-resistant strains were detected in 3 of 15 mono-infected chronic hepatitis B patients and 10 of 20 HBV-HIV co-infected patients.,17854040_7,1
5462,chronic hepatitis B,72,91,HBV lamivudine-resistant strains were detected in 3 of 15 mono-infected chronic hepatitis B patients and 10 of 20 HBV-HIV co-infected patients.,17854040_7,1
6720,HBV,67,70,"To the best of our knowledge, this constitutes the first report of HBV lamivudine-resistant strains in therapy-na  ve HBV-HIV co-infected patients.",17854040_8,0
6723,HBV,4,7,"The HBV viral loads for mono-infected and co-infected patients ranged from 3.32 x 10(2) to 3.82 x 10(7) and <200 to 4.40 x 10(3) copies/ml, respectively.",17854040_9,0
6733,Rabbit syndrome,0,15,"Rabbit syndrome, antidepressant use, and cerebral perfusion SPECT scan findings.",1786266_0,1
6736,extrapyramidal side effect,26,52,The rabbit syndrome is an extrapyramidal side effect associated with chronic neuroleptic therapy.,1786266_1,1
5463,basal ganglia,59,72,"Repeated cerebral perfusion SPECT scans revealed decreased basal ganglia perfusion while the movement disorder was present, and a return to normal perfusion when the rabbit syndrome resolved.",1786266_3,1
6741,rabbit syndrome,166,181,"Repeated cerebral perfusion SPECT scans revealed decreased basal ganglia perfusion while the movement disorder was present, and a return to normal perfusion when the rabbit syndrome resolved.",1786266_3,1
6740,movement disorder,93,110,"Repeated cerebral perfusion SPECT scans revealed decreased basal ganglia perfusion while the movement disorder was present, and a return to normal perfusion when the rabbit syndrome resolved.",1786266_3,1
1697,HIV protease inhibitor,79,101,Estrogen prevents cholesteryl ester accumulation in macrophages induced by the HIV protease inhibitor ritonavir.,17879945_0,0
1696,cholesteryl ester,18,35,Estrogen prevents cholesteryl ester accumulation in macrophages induced by the HIV protease inhibitor ritonavir.,17879945_0,0
6742,live long lives,29,44,Individuals with HIV can now live long lives with drug therapy that often includes protease inhibitors such as ritonavir.,17879945_1,1
1698,protease inhibitors,83,102,Individuals with HIV can now live long lives with drug therapy that often includes protease inhibitors such as ritonavir.,17879945_1,0
1705,scavenger receptor,42,60,"Ritonavir increased the expression of the scavenger receptor, CD36 mRNA, responsible for the uptake of LDL.",17879945_10,0
6753,CD36 mRNA,62,71,"Ritonavir increased the expression of the scavenger receptor, CD36 mRNA, responsible for the uptake of LDL.",17879945_10,0
1706,transcription factor,97,117,"Additionally, ritonavir treatment selectively increased the relative levels of PPARgamma mRNA, a transcription factor responsible for the regulation of CD36 mRNA expression.",17879945_11,0
6755,CD36 mRNA,152,161,"Additionally, ritonavir treatment selectively increased the relative levels of PPARgamma mRNA, a transcription factor responsible for the regulation of CD36 mRNA expression.",17879945_11,0
6754,PPARgamma mRNA,79,93,"Additionally, ritonavir treatment selectively increased the relative levels of PPARgamma mRNA, a transcription factor responsible for the regulation of CD36 mRNA expression.",17879945_11,0
1707,E2,15,17,"Treatment with E2, however, failed to prevent these increases at the mRNA level.",17879945_12,0
1708,E2,0,2,"E2 did, however, significantly suppress CD36 protein levels as measured by fluorescent immunocytochemistry.",17879945_13,0
1709,CD36 protein,40,52,"E2 did, however, significantly suppress CD36 protein levels as measured by fluorescent immunocytochemistry.",17879945_13,0
1713,cholesteryl ester,147,164,This data suggests that E2 modifies the expression of CD36 at the level of protein expression in monocyte-derived macrophages resulting in reduced cholesteryl ester accumulation following ritonavir treatment.,17879945_14,0
1710,E2,24,26,This data suggests that E2 modifies the expression of CD36 at the level of protein expression in monocyte-derived macrophages resulting in reduced cholesteryl ester accumulation following ritonavir treatment.,17879945_14,0
1711,CD36,54,58,This data suggests that E2 modifies the expression of CD36 at the level of protein expression in monocyte-derived macrophages resulting in reduced cholesteryl ester accumulation following ritonavir treatment.,17879945_14,0
1712,monocyte-derived,97,113,This data suggests that E2 modifies the expression of CD36 at the level of protein expression in monocyte-derived macrophages resulting in reduced cholesteryl ester accumulation following ritonavir treatment.,17879945_14,0
5464,side effects,51,63,"Many patients, however, develop negative long-term side effects such as premature atherosclerosis.",17879945_2,1
6744,premature atherosclerosis,72,97,"Many patients, however, develop negative long-term side effects such as premature atherosclerosis.",17879945_2,1
6745,atherosclerotic lesion,67,89,We have previously demonstrated that ritonavir treatment increases atherosclerotic lesion formation in male mice to a greater extent than in female mice.,17879945_3,1
1699,cholesteryl ester,89,106,"Furthermore, peripheral blood monocytes isolated from ritonavir-treated females had less cholesteryl ester accumulation.",17879945_4,0
1700,HIV protease inhibitor,160,182,"In the present study, we have investigated the molecular mechanisms by which female hormones influence cholesterol metabolism in macrophages in response to the HIV protease inhibitor ritonavir.",17879945_5,0
6748,cholesterol metabolism,103,125,"In the present study, we have investigated the molecular mechanisms by which female hormones influence cholesterol metabolism in macrophages in response to the HIV protease inhibitor ritonavir.",17879945_5,1
6749,THP-1,47,52,"We have utilized the human monocyte cell line, THP-1 as a model to address this question.",17879945_6,0
6751,17beta-estradiol,133,149,"Briefly, cells were differentiated for 72 h with 100 nM PMA to obtain a macrophage-like phenotype in the presence or absence of 1 nM 17beta-estradiol (E2), 100 nM progesterone or vehicle (0.01% ethanol).",17879945_7,0
1701,E2,151,153,"Briefly, cells were differentiated for 72 h with 100 nM PMA to obtain a macrophage-like phenotype in the presence or absence of 1 nM 17beta-estradiol (E2), 100 nM progesterone or vehicle (0.01% ethanol).",17879945_7,0
6750,PMA,56,59,"Briefly, cells were differentiated for 72 h with 100 nM PMA to obtain a macrophage-like phenotype in the presence or absence of 1 nM 17beta-estradiol (E2), 100 nM progesterone or vehicle (0.01% ethanol).",17879945_7,0
1702,Cell extracts,103,116,"Cells were then treated with 30 ng/ml ritonavir or vehicle in the presence of aggregated LDL for 24 h. Cell extracts were harvested, and lipid or total RNA was isolated.",17879945_8,0
1703,E2,0,2,E2 decreased the accumulation of cholesteryl esters in macrophages following ritonavir treatment.,17879945_9,0
1704,cholesteryl esters,33,51,E2 decreased the accumulation of cholesteryl esters in macrophages following ritonavir treatment.,17879945_9,0
6757,Acute hepatitis attack,0,22,Acute hepatitis attack after exposure to telithromycin.,17919553_0,1
6758,telithromycin,41,54,Acute hepatitis attack after exposure to telithromycin.,17919553_0,0
6759,Antibiotic-associated hepatotoxicity,14,50,INTRODUCTION: Antibiotic-associated hepatotoxicity is rare.,17919553_1,1
6784,hepatic dysfunction,69,88,It has been associated with infrequent and usually reversible severe hepatic dysfunction.,17919553_10,1
6788,drug-induced toxic hepatitis,187,215,"Based on a score of 8 on the Naranjo adverse drug reaction probability scale, telithromycin was the probable cause of acute hepatitis in this patient, and pathological findings suggested drug-induced toxic hepatitis.",17919553_11,1
6787,acute hepatitis,118,133,"Based on a score of 8 on the Naranjo adverse drug reaction probability scale, telithromycin was the probable cause of acute hepatitis in this patient, and pathological findings suggested drug-induced toxic hepatitis.",17919553_11,1
6785,telithromycin,78,91,"Based on a score of 8 on the Naranjo adverse drug reaction probability scale, telithromycin was the probable cause of acute hepatitis in this patient, and pathological findings suggested drug-induced toxic hepatitis.",17919553_11,0
5467,adverse drug reaction,37,58,"Based on a score of 8 on the Naranjo adverse drug reaction probability scale, telithromycin was the probable cause of acute hepatitis in this patient, and pathological findings suggested drug-induced toxic hepatitis.",17919553_11,1
6790,telithromycin,143,156,Recurrence of hepatitis attack might have been avoided if the initial incident had been communicated to the attending physician who prescribed telithromycin the second time.,17919553_12,0
6789,hepatitis attack,14,30,Recurrence of hepatitis attack might have been avoided if the initial incident had been communicated to the attending physician who prescribed telithromycin the second time.,17919553_12,1
6791,acute hepatitis,37,52,CONCLUSION: Here we report a case of acute hepatitis probably associated with the administration of telithromycin.,17919553_13,1
6793,telithromycin,100,113,CONCLUSION: Here we report a case of acute hepatitis probably associated with the administration of telithromycin.,17919553_13,0
5465,adverse drug reactions,98,120,"With widespread use of antimicrobial agents, however, hepatic injury occurs frequently, and among adverse drug reactions, idiosyncratic reactions are the most serious.",17919553_2,1
6760,hepatic injury,54,68,"With widespread use of antimicrobial agents, however, hepatic injury occurs frequently, and among adverse drug reactions, idiosyncratic reactions are the most serious.",17919553_2,1
6761,idiosyncratic reactions,122,145,"With widespread use of antimicrobial agents, however, hepatic injury occurs frequently, and among adverse drug reactions, idiosyncratic reactions are the most serious.",17919553_2,1
1714,antimicrobial agents,23,43,"With widespread use of antimicrobial agents, however, hepatic injury occurs frequently, and among adverse drug reactions, idiosyncratic reactions are the most serious.",17919553_2,0
6764,telithromycin,23,36,He had been prescribed telithromycin 400 mg/d PO to treat an upper respiratory tract infection 7 days prior.,17919553_4,0
5466,upper respiratory tract infection,61,94,He had been prescribed telithromycin 400 mg/d PO to treat an upper respiratory tract infection 7 days prior.,17919553_4,1
6770,alkaline phosphatase,155,175,"Admission laboratory tests were as follows: alanine aminotransferase, 67 U/L (reference range, 10-37 U/L); aspartate aminotransferase, 98 U/L (10-40 U/L); alkaline phosphatase, 513 U/L (0-270 U/L); gamma-glutamyltransferase, 32 U/L (7-49 U/L); amylase, 46 U/L (0-220 U/L); total bilirubin, 20.1 mg/dL (0.2-1.0 mg/dL); direct bilirubin, 14.8 mg/dL (0-0.3 mg/dL); and albumin, 4.7 mg/dL (3.5-5.4 mg/dL).",17919553_5,0
1715,alanine aminotransferase,44,68,"Admission laboratory tests were as follows: alanine aminotransferase, 67 U/L (reference range, 10-37 U/L); aspartate aminotransferase, 98 U/L (10-40 U/L); alkaline phosphatase, 513 U/L (0-270 U/L); gamma-glutamyltransferase, 32 U/L (7-49 U/L); amylase, 46 U/L (0-220 U/L); total bilirubin, 20.1 mg/dL (0.2-1.0 mg/dL); direct bilirubin, 14.8 mg/dL (0-0.3 mg/dL); and albumin, 4.7 mg/dL (3.5-5.4 mg/dL).",17919553_5,0
1716,aspartate aminotransferase,107,133,"Admission laboratory tests were as follows: alanine aminotransferase, 67 U/L (reference range, 10-37 U/L); aspartate aminotransferase, 98 U/L (10-40 U/L); alkaline phosphatase, 513 U/L (0-270 U/L); gamma-glutamyltransferase, 32 U/L (7-49 U/L); amylase, 46 U/L (0-220 U/L); total bilirubin, 20.1 mg/dL (0.2-1.0 mg/dL); direct bilirubin, 14.8 mg/dL (0-0.3 mg/dL); and albumin, 4.7 mg/dL (3.5-5.4 mg/dL).",17919553_5,0
1717,gamma-glutamyltransferase,198,223,"Admission laboratory tests were as follows: alanine aminotransferase, 67 U/L (reference range, 10-37 U/L); aspartate aminotransferase, 98 U/L (10-40 U/L); alkaline phosphatase, 513 U/L (0-270 U/L); gamma-glutamyltransferase, 32 U/L (7-49 U/L); amylase, 46 U/L (0-220 U/L); total bilirubin, 20.1 mg/dL (0.2-1.0 mg/dL); direct bilirubin, 14.8 mg/dL (0-0.3 mg/dL); and albumin, 4.7 mg/dL (3.5-5.4 mg/dL).",17919553_5,0
6777,No toxin,0,8,"No toxin, alcohol, or other drugs were reported.",17919553_6,0
6780,telithromycin,104,117,"The patient had suffered a previous episode of ""acute hepatitis of unknown origin,"" that occurred after telithromycin usage.",17919553_7,0
6779,unknown origin,67,81,"The patient had suffered a previous episode of ""acute hepatitis of unknown origin,"" that occurred after telithromycin usage.",17919553_7,1
6778,acute hepatitis,48,63,"The patient had suffered a previous episode of ""acute hepatitis of unknown origin,"" that occurred after telithromycin usage.",17919553_7,1
6782,ketolide antibacterials,46,69,DISCUSSION: Telithromycin is the first of the ketolide antibacterials to receive US Food and Drug Administration approval for clinical use.,17919553_9,0
6781,Telithromycin,12,25,DISCUSSION: Telithromycin is the first of the ketolide antibacterials to receive US Food and Drug Administration approval for clinical use.,17919553_9,0
1718,fluocinolone acetonide,59,81,Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants.,17923537_0,0
5468,Intraocular,0,11,Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants.,17923537_0,1
1719,fluocinolone acetonide,131,153,OBJECTIVE: To report the incidence and management of elevated intraocular pressure (IOP) in patients with uveitis treated with the fluocinolone acetonide (FA) intravitreal implant.,17923537_1,0
5469,intraocular,62,73,OBJECTIVE: To report the incidence and management of elevated intraocular pressure (IOP) in patients with uveitis treated with the fluocinolone acetonide (FA) intravitreal implant.,17923537_1,1
6805,IOP-lowering,81,93,"Topical IOP-lowering medication was administered in 74.8% of implanted eyes, and IOP-lowering surgeries, most of which were trabeculectomies (76.2%), were performed on 36.6% of implanted eyes.",17923537_4,0
6803,IOP-lowering medication,8,31,"Topical IOP-lowering medication was administered in 74.8% of implanted eyes, and IOP-lowering surgeries, most of which were trabeculectomies (76.2%), were performed on 36.6% of implanted eyes.",17923537_4,0
5470,Intraocular,0,11,Intraocular pressure-lowering surgeries were considered a success (postoperative IOP of 6-21 mm Hg with or without additional IOP-lowering medication) in 85.1% of eyes at 1 year.,17923537_5,1
5471,hypotony,12,20,The rate of hypotony (IOP </= 5 mm Hg) following IOP-lowering surgery (42.5%) was not different from that of implanted eyes not subjected to surgery (35.4%) (P = .09).,17923537_6,1
6813,Elevated IOP,12,24,CONCLUSION: Elevated IOP is a significant complication with the FA intravitreal implant but may be controlled with medication and surgery.,17923537_7,0
6814,intravitreal implant,67,87,CONCLUSION: Elevated IOP is a significant complication with the FA intravitreal implant but may be controlled with medication and surgery.,17923537_7,0
6815,subcutaneous heparin,41,61,A study on the effect of the duration of subcutaneous heparin injection on bruising and pain.,17931375_0,0
6827,Pain intensity,0,14,Pain intensity and pain period were statistically significantly lower for the 30-second injection than for the 10-second injection.,17931375_12,1
6829,10-second injection,111,130,Pain intensity and pain period were statistically significantly lower for the 30-second injection than for the 10-second injection.,17931375_12,0
6819,subcutaneous heparin,66,86,METHOD: The sample for the study consisted of 50 patients to whom subcutaneous heparin was administered.,17931375_4,0
6820,right abdominal site,44,64,Heparin was injected over 10 seconds on the right abdominal site and 30 seconds on the left abdominal site.,17931375_5,1
6822,pain intensity,50,64,The visual analog scale (VAS) was used to measure pain intensity and a stop-watch was used to time the pain period.,17931375_8,1
1720,Fas ligand,11,21,Myocardial Fas ligand expression increases susceptibility to AZT-induced cardiomyopathy.,17943461_0,0
5472,Dilated cardiomyopathy,12,34,"BACKGROUND: Dilated cardiomyopathy (DCM) and myocarditis occur in many HIV-infected individuals, resulting in symptomatic heart failure in up to 5% of patients.",17943461_1,1
5473,heart failure,122,135,"BACKGROUND: Dilated cardiomyopathy (DCM) and myocarditis occur in many HIV-infected individuals, resulting in symptomatic heart failure in up to 5% of patients.",17943461_1,1
6834,DCM,36,39,"BACKGROUND: Dilated cardiomyopathy (DCM) and myocarditis occur in many HIV-infected individuals, resulting in symptomatic heart failure in up to 5% of patients.",17943461_1,0
6835,skeletal myopathies,188,207,"Highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome (AIDS), but has resulted in an increase in cardiac and skeletal myopathies.",17943461_2,1
5474,acquired immunodeficiency syndrome,98,132,"Highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome (AIDS), but has resulted in an increase in cardiac and skeletal myopathies.",17943461_2,1
1721,antiretroviral,14,28,"Highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome (AIDS), but has resulted in an increase in cardiac and skeletal myopathies.",17943461_2,0
1722,cytoskeletal,177,189,"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).",17943461_3,0
1723,Fas ligand,261,271,"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).",17943461_3,0
6839,NTg,320,323,"METHODS AND RESULTS: In order to investigate whether the HAART component zidovudine (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0.07, 0.2, and 0.7 mg/ml).",17943461_3,0
6841,cardiac function,15,31,"After 6 weeks, cardiac function was assessed by echocardiography and morphology was assessed by histopathologic and immunohistochemical methods.",17943461_4,1
6844,NTg,0,3,NTg and untreated FasL Tg mice showed little or no change in cardiac structure or function.,17943461_5,0
6845,FasL Tg,18,25,NTg and untreated FasL Tg mice showed little or no change in cardiac structure or function.,17943461_5,0
6848,FasL Tg,25,32,"In contrast, AZT-treated FasL Tg mice developed cardiac dilation and depressed cardiac function in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles.",17943461_6,0
6850,depressed cardiac function,69,95,"In contrast, AZT-treated FasL Tg mice developed cardiac dilation and depressed cardiac function in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles.",17943461_6,1
6849,cardiac dilation,48,64,"In contrast, AZT-treated FasL Tg mice developed cardiac dilation and depressed cardiac function in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles.",17943461_6,1
1724,caspase 3,123,132,"These changes were associated with an increased sarcolemmal expression of Fas and FasL, as well as increased activation of caspase 3, translocation of calpain 1 to the sarcolemma and sarcomere, and increased numbers of cells undergoing apoptosis.",17943461_7,0
1725,calpain,151,158,"These changes were associated with an increased sarcolemmal expression of Fas and FasL, as well as increased activation of caspase 3, translocation of calpain 1 to the sarcolemma and sarcomere, and increased numbers of cells undergoing apoptosis.",17943461_7,0
6852,FasL,82,86,"These changes were associated with an increased sarcolemmal expression of Fas and FasL, as well as increased activation of caspase 3, translocation of calpain 1 to the sarcolemma and sarcomere, and increased numbers of cells undergoing apoptosis.",17943461_7,0
6854,dystrophin,38,48,"These were associated with changes in dystrophin and cardiac troponin I localization, as well as loss of sarcolemmal integrity.",17943461_8,0
5475,loss of,97,104,"These were associated with changes in dystrophin and cardiac troponin I localization, as well as loss of sarcolemmal integrity.",17943461_8,1
1726,troponin I,61,71,"These were associated with changes in dystrophin and cardiac troponin I localization, as well as loss of sarcolemmal integrity.",17943461_8,0
1727,Fas ligand,31,41,"CONCLUSIONS: The expression of Fas ligand in the myocardium, as identified in HIV-positive patients, might increase the susceptibility to HAART-induced cardiomyopathy due to activation of apoptotic pathways, resulting in cardiac dilation and dysfunction.",17943461_9,0
6856,cardiac dilation,221,237,"CONCLUSIONS: The expression of Fas ligand in the myocardium, as identified in HIV-positive patients, might increase the susceptibility to HAART-induced cardiomyopathy due to activation of apoptotic pathways, resulting in cardiac dilation and dysfunction.",17943461_9,1
1728,apoptotic,188,197,"CONCLUSIONS: The expression of Fas ligand in the myocardium, as identified in HIV-positive patients, might increase the susceptibility to HAART-induced cardiomyopathy due to activation of apoptotic pathways, resulting in cardiac dilation and dysfunction.",17943461_9,0
1730,diclofenac,322,332,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,0
6858,etoricoxib,33,43,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,0
6859,etoricoxib,93,103,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,0
6863,etoricoxib,307,317,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,0
5477,rheumatoid arthritis,350,370,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,1
5476,rheumatoid arthritis,47,67,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,1
1729,diclofenac sodium,107,124,"Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis (RA).",17965424_0,0
1731,diclofenac,151,161,PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).,17965424_1,0
6864,etoricoxib,114,124,PATIENTS AND METHODS: A total of 4086 patients (mean age 60.8 years) diagnosed with RA were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054).,17965424_1,0
1737,diclofenac,126,136,CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg.,17965424_10,0
6882,AEs,108,111,CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg.,17965424_10,0
6880,Etoricoxib 90 mg,13,29,CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg.,17965424_10,0
6884,etoricoxib,127,137,"Discontinuations from renovascular AEs, although less common than discontinuations from GI AEs, were significantly higher with etoricoxib.",17965424_11,0
6883,AEs,91,94,"Discontinuations from renovascular AEs, although less common than discontinuations from GI AEs, were significantly higher with etoricoxib.",17965424_11,0
6866,low-dose aspirin,35,51,Use of gastroprotective agents and low-dose aspirin was allowed.,17965424_2,0
6865,gastroprotective agents,7,30,Use of gastroprotective agents and low-dose aspirin was allowed.,17965424_2,0
1732,end point,25,34,The prespecified primary end point consisted of the cumulative rate of patient discontinuations due to clinical and laboratory GI adverse experiences (AEs).,17965424_3,0
6869,AEs,151,154,The prespecified primary end point consisted of the cumulative rate of patient discontinuations due to clinical and laboratory GI adverse experiences (AEs).,17965424_3,0
6868,adverse experiences,130,149,The prespecified primary end point consisted of the cumulative rate of patient discontinuations due to clinical and laboratory GI adverse experiences (AEs).,17965424_3,1
5478,thrombotic,56,66,"General safety was also assessed, including adjudicated thrombotic cardiovascular event data.",17965424_4,1
6871,PGADS,78,83,Efficacy was evaluated using the Patient Global Assessment of Disease Status (PGADS; 0-4 point scale).,17965424_5,0
1733,diclofenac,123,133,"RESULTS: Mean (SD; maximum) duration of treatment was 19.3 (10.3; 32.9) and 19.1 (10.4; 33.1) months in the etoricoxib and diclofenac groups, respectively.",17965424_6,0
6872,etoricoxib,108,118,"RESULTS: Mean (SD; maximum) duration of treatment was 19.3 (10.3; 32.9) and 19.1 (10.4; 33.1) months in the etoricoxib and diclofenac groups, respectively.",17965424_6,0
6874,etoricoxib,79,89,"The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<or=0.001)).",17965424_7,0
6873,AEs,46,49,"The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<or=0.001)).",17965424_7,0
1734,diclofenac,95,105,"The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac (5.2 vs 8.5 events per 100 patient-years, respectively; hazard ratio 0.62 (95% CI: 0.47, 0.81; p<or=0.001)).",17965424_7,0
6877,etoricoxib,113,123,The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).,17965424_8,0
6875,hypertension-related,38,58,The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).,17965424_8,1
1735,diclofenac,167,177,The incidence of discontinuations for hypertension-related and oedema-related AEs were significantly higher with etoricoxib (2.5% and 1.1% respectively) compared with diclofenac (1.5% and 0.4% respectively; p<0.001 for hypertension and p<0.01 for oedema).,17965424_8,0
1736,diclofenac,15,25,"Etoricoxib and diclofenac treatment resulted in similar efficacy (PGADS mean changes from baseline -0.62 vs -0.58, respectively).",17965424_9,0
6879,PGADS,66,71,"Etoricoxib and diclofenac treatment resulted in similar efficacy (PGADS mean changes from baseline -0.62 vs -0.58, respectively).",17965424_9,0
6878,Etoricoxib,0,10,"Etoricoxib and diclofenac treatment resulted in similar efficacy (PGADS mean changes from baseline -0.62 vs -0.58, respectively).",17965424_9,0
6886,norfloxacin,42,53,Anxiogenic potential of ciprofloxacin and norfloxacin in rats.,17975693_0,0
6888,norfloxacin,92,103,"INTRODUCTION: The possible anxiogenic effects of fluoroquinolones, namely ciprofloxacin and norfloxacin, were investigated in adult Charles Foster albino rats of either sex, weighing 150-200 g. METHODS: The drugs were given orally, in doses of 50 mg/kg for five consecutive days and the experiments were performed on the fifth day.",17975693_1,0
1738,fluoroquinolones,49,65,"INTRODUCTION: The possible anxiogenic effects of fluoroquinolones, namely ciprofloxacin and norfloxacin, were investigated in adult Charles Foster albino rats of either sex, weighing 150-200 g. METHODS: The drugs were given orally, in doses of 50 mg/kg for five consecutive days and the experiments were performed on the fifth day.",17975693_1,0
6898,norfloxacin,125,136,CONCLUSION: The present experimental findings substantiate the clinically observed anxiogenic potential of ciprofloxacin and norfloxacin.,17975693_5,0
1739,paracetamol,79,90,Acute liver failure in two patients with regular alcohol consumption ingesting paracetamol at therapeutic dosage.,18004067_0,0
6899,therapeutic dosage,94,112,Acute liver failure in two patients with regular alcohol consumption ingesting paracetamol at therapeutic dosage.,18004067_0,0
5479,Acute liver failure,0,19,Acute liver failure in two patients with regular alcohol consumption ingesting paracetamol at therapeutic dosage.,18004067_0,1
5480,alcohol consumption,49,68,Acute liver failure in two patients with regular alcohol consumption ingesting paracetamol at therapeutic dosage.,18004067_0,1
6900,hepatotoxicity,63,77,BACKGROUND: The possible role of alcohol in the development of hepatotoxicity associated with therapeutic doses of paracetamol (acetaminophen) is currently debated.,18004067_1,1
1740,paracetamol,115,126,BACKGROUND: The possible role of alcohol in the development of hepatotoxicity associated with therapeutic doses of paracetamol (acetaminophen) is currently debated.,18004067_1,0
6901,therapeutic doses,94,111,BACKGROUND: The possible role of alcohol in the development of hepatotoxicity associated with therapeutic doses of paracetamol (acetaminophen) is currently debated.,18004067_1,0
5481,liver failure,92,105,CASE REPORT: We describe 2 patients who were regular consumers of alcohol and who developed liver failure within 3-5 days after hospitalization and stopping alcohol consumption while being treated with 4 g paracetamol/day.,18004067_2,1
5482,alcohol consumption,157,176,CASE REPORT: We describe 2 patients who were regular consumers of alcohol and who developed liver failure within 3-5 days after hospitalization and stopping alcohol consumption while being treated with 4 g paracetamol/day.,18004067_2,1
1741,paracetamol,2,13,A paracetamol serum level obtained in one of these patients was not in the toxic range.,18004067_3,0
6906,therapeutic doses,85,102,Possible risk factors for the development of hepatotoxicity in patients treated with therapeutic doses of paracetamol are discussed.,18004067_4,0
6905,hepatotoxicity,45,59,Possible risk factors for the development of hepatotoxicity in patients treated with therapeutic doses of paracetamol are discussed.,18004067_4,1
1742,paracetamol,106,117,Possible risk factors for the development of hepatotoxicity in patients treated with therapeutic doses of paracetamol are discussed.,18004067_4,0
6908,therapeutic doses,111,128,"CONCLUSION: In patients with risk factors, e.g. regular consumption of alcohol, liver failure is possible when therapeutic doses are ingested.",18004067_5,0
5483,liver failure,80,93,"CONCLUSION: In patients with risk factors, e.g. regular consumption of alcohol, liver failure is possible when therapeutic doses are ingested.",18004067_5,1
6909,liver function,95,109,We propose that the paracetamol dose should not exceed 2 g/day in such patients and that their liver function should be monitored closely while being treated with paracetamol.,18004067_6,1
1743,paracetamol,20,31,We propose that the paracetamol dose should not exceed 2 g/day in such patients and that their liver function should be monitored closely while being treated with paracetamol.,18004067_6,0
1744,paracetamol,163,174,We propose that the paracetamol dose should not exceed 2 g/day in such patients and that their liver function should be monitored closely while being treated with paracetamol.,18004067_6,0
1746,remifentanil,71,83,Reduction of pain during induction with target-controlled propofol and remifentanil.,18006530_0,0
1745,propofol,58,66,Reduction of pain during induction with target-controlled propofol and remifentanil.,18006530_0,0
1747,propofol,33,41,BACKGROUND: Pain on injection of propofol is unpleasant.,18006530_1,0
1759,remifentanil,70,82,"CONCLUSIONS: During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).",18006530_11,0
1760,remifentanil,208,220,"CONCLUSIONS: During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).",18006530_11,0
6931,TCI,50,53,"CONCLUSIONS: During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).",18006530_11,0
1758,propofol,57,65,"CONCLUSIONS: During induction of anaesthesia with TCI of propofol and remifentanil, a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml(-1).",18006530_11,0
1748,remifentanil,75,87,We hypothesized that propofol infusion pain might be prevented by infusing remifentanil before starting the propofol infusion in a clinical setting where target-controlled infusions (TCI) of both drugs were used.,18006530_2,0
1749,propofol,108,116,We hypothesized that propofol infusion pain might be prevented by infusing remifentanil before starting the propofol infusion in a clinical setting where target-controlled infusions (TCI) of both drugs were used.,18006530_2,0
6913,TCI,183,186,We hypothesized that propofol infusion pain might be prevented by infusing remifentanil before starting the propofol infusion in a clinical setting where target-controlled infusions (TCI) of both drugs were used.,18006530_2,0
1750,remifentanil,131,143,"A prospective, randomized, double-blind, placebo-controlled trial was performed to determine the effect-site concentration (Ce) of remifentanil to prevent the pain without producing complications.",18006530_3,0
6918,R2,166,168,"METHODS: A total of 128 patients undergoing general surgery were randomly allocated to receive normal saline (control) or remifentanil to a target Ce of 2 ng ml(-1) (R2), 4 ng ml(-1) (R4), or 6 ng ml(-1) (R6) administered via TCI.",18006530_4,0
6917,general surgery,44,59,"METHODS: A total of 128 patients undergoing general surgery were randomly allocated to receive normal saline (control) or remifentanil to a target Ce of 2 ng ml(-1) (R2), 4 ng ml(-1) (R4), or 6 ng ml(-1) (R6) administered via TCI.",18006530_4,1
6920,TCI,226,229,"METHODS: A total of 128 patients undergoing general surgery were randomly allocated to receive normal saline (control) or remifentanil to a target Ce of 2 ng ml(-1) (R2), 4 ng ml(-1) (R4), or 6 ng ml(-1) (R6) administered via TCI.",18006530_4,0
6919,R6,205,207,"METHODS: A total of 128 patients undergoing general surgery were randomly allocated to receive normal saline (control) or remifentanil to a target Ce of 2 ng ml(-1) (R2), 4 ng ml(-1) (R4), or 6 ng ml(-1) (R6) administered via TCI.",18006530_4,0
1753,R4,184,186,"METHODS: A total of 128 patients undergoing general surgery were randomly allocated to receive normal saline (control) or remifentanil to a target Ce of 2 ng ml(-1) (R2), 4 ng ml(-1) (R4), or 6 ng ml(-1) (R6) administered via TCI.",18006530_4,0
1752,remifentanil,122,134,"METHODS: A total of 128 patients undergoing general surgery were randomly allocated to receive normal saline (control) or remifentanil to a target Ce of 2 ng ml(-1) (R2), 4 ng ml(-1) (R4), or 6 ng ml(-1) (R6) administered via TCI.",18006530_4,0
1751,normal saline,95,108,"METHODS: A total of 128 patients undergoing general surgery were randomly allocated to receive normal saline (control) or remifentanil to a target Ce of 2 ng ml(-1) (R2), 4 ng ml(-1) (R4), or 6 ng ml(-1) (R6) administered via TCI.",18006530_4,0
1754,propofol,50,58,"After the target Ce was achieved, the infusion of propofol was started.",18006530_5,0
1756,propofol,102,110,"Remifentanil-related complications were assessed during the remifentanil infusion, and pain caused by propofol was evaluated using a four-point scale during the propofol infusion.",18006530_6,0
1755,remifentanil,60,72,"Remifentanil-related complications were assessed during the remifentanil infusion, and pain caused by propofol was evaluated using a four-point scale during the propofol infusion.",18006530_6,0
1757,propofol,161,169,"Remifentanil-related complications were assessed during the remifentanil infusion, and pain caused by propofol was evaluated using a four-point scale during the propofol infusion.",18006530_6,0
6922,Groups R4,58,67,"RESULTS: The incidence of pain was significantly lower in Groups R4 and R6 than in the control and R2 groups (12/32 and 6/31 vs 26/31 and 25/32, respectively, P<0.001).",18006530_7,0
6923,R6,72,74,"RESULTS: The incidence of pain was significantly lower in Groups R4 and R6 than in the control and R2 groups (12/32 and 6/31 vs 26/31 and 25/32, respectively, P<0.001).",18006530_7,0
6924,R2,99,101,"RESULTS: The incidence of pain was significantly lower in Groups R4 and R6 than in the control and R2 groups (12/32 and 6/31 vs 26/31 and 25/32, respectively, P<0.001).",18006530_7,0
6925,Groups R4,24,33,Pain was less severe in Groups R4 and R6 than in the control and R2 groups (P<0.001).,18006530_8,0
6926,R6,38,40,Pain was less severe in Groups R4 and R6 than in the control and R2 groups (P<0.001).,18006530_8,0
6927,R2,65,67,Pain was less severe in Groups R4 and R6 than in the control and R2 groups (P<0.001).,18006530_8,0
6929,R6,86,88,"However, both incidence and severity of pain were not different between Groups R4 and R6.",18006530_9,0
6933,cognitive function,96,114,"Associations between use of benzodiazepines or related drugs and health, physical abilities and cognitive function: a non-randomised clinical study in the elderly.",18020536_0,1
6932,physical abilities,73,91,"Associations between use of benzodiazepines or related drugs and health, physical abilities and cognitive function: a non-randomised clinical study in the elderly.",18020536_0,1
6937,cognitive function,136,154,"OBJECTIVE: To describe associations between the use of benzodiazepines or related drugs (BZDs/RDs) and health, functional abilities and cognitive function in the elderly.",18020536_1,1
6952,zopiclone,61,70,"The residual serum concentrations of oxazepam, temazepam and zopiclone were analysed.",18020536_10,0
6958,cognitive function,93,111,"After adjustment for these variables as confounders, use of BZDs/RDs was not associated with cognitive function as measured by the MMSE.",18020536_14,1
6961,depressive symptoms,181,200,"However, use of BZDs/RDs was associated with dizziness, inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay.",18020536_15,1
6962,hospital stay,234,247,"However, use of BZDs/RDs was associated with dizziness, inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay.",18020536_15,1
6966,BZD/RD,64,70,CONCLUSIONS: Long-term use and concomitant use of more than one BZD/RD were common in elderly patients hospitalised because of acute illnesses.,18020536_18,0
6967,acute illnesses,127,142,CONCLUSIONS: Long-term use and concomitant use of more than one BZD/RD were common in elderly patients hospitalised because of acute illnesses.,18020536_18,1
5484,adverse effects,124,139,Long-term use was associated with daytime and night-time symptoms indicative of poorer health and potentially caused by the adverse effects of these drugs.,18020536_19,1
6970,poorer health,80,93,Long-term use was associated with daytime and night-time symptoms indicative of poorer health and potentially caused by the adverse effects of these drugs.,18020536_19,1
6942,Cognitive ability,0,17,Cognitive ability was assessed by the Mini-Mental State Examination (MMSE).,18020536_6,1
6948,cognitive function,31,49,"Health, physical abilities and cognitive function were compared between BZD/RD users and non-users, and adjustments were made for confounding variables.",18020536_9,1
5485,vocal fold palsy,6,22,Acute vocal fold palsy after acute disulfiram intoxication.,18023325_0,1
6971,acute disulfiram intoxication,29,58,Acute vocal fold palsy after acute disulfiram intoxication.,18023325_0,1
6972,Acute peripheral neuropathy,0,27,Acute peripheral neuropathy caused by a disulfiram overdose is very rare and there is no report of it leading to vocal fold palsy.,18023325_1,1
5486,vocal fold palsy,113,129,Acute peripheral neuropathy caused by a disulfiram overdose is very rare and there is no report of it leading to vocal fold palsy.,18023325_1,1
6986,Laryngoscopy,0,12,Laryngoscopy revealed asymmetric vocal fold movements during phonation.,18023325_10,1
5489,vocal fold,33,43,Laryngoscopy revealed asymmetric vocal fold movements during phonation.,18023325_10,1
6987,Her vocal change,0,16,Her vocal change and weakness began to improve spontaneously about 3 weeks after transfer.,18023325_11,1
6988,acute palsy,19,30,This was a case of acute palsy of the recurrent laryngeal nerve and superimposed severe acute sensorimotor axonal polyneuropathy caused by high-dose disulfiram intoxication.,18023325_12,1
6989,high-dose,139,148,This was a case of acute palsy of the recurrent laryngeal nerve and superimposed severe acute sensorimotor axonal polyneuropathy caused by high-dose disulfiram intoxication.,18023325_12,0
5492,polyneuropathy,114,128,This was a case of acute palsy of the recurrent laryngeal nerve and superimposed severe acute sensorimotor axonal polyneuropathy caused by high-dose disulfiram intoxication.,18023325_12,1
5491,severe acute,81,93,This was a case of acute palsy of the recurrent laryngeal nerve and superimposed severe acute sensorimotor axonal polyneuropathy caused by high-dose disulfiram intoxication.,18023325_12,1
5490,laryngeal nerve,48,63,This was a case of acute palsy of the recurrent laryngeal nerve and superimposed severe acute sensorimotor axonal polyneuropathy caused by high-dose disulfiram intoxication.,18023325_12,1
5487,quadriparesis,65,78,"A 49-year-old woman was transferred to our department because of quadriparesis, lancinating pain, sensory loss, and paresthesia of the distal limbs.",18023325_2,1
6973,lancinating pain,80,96,"A 49-year-old woman was transferred to our department because of quadriparesis, lancinating pain, sensory loss, and paresthesia of the distal limbs.",18023325_2,1
6974,sensory loss,98,110,"A 49-year-old woman was transferred to our department because of quadriparesis, lancinating pain, sensory loss, and paresthesia of the distal limbs.",18023325_2,1
6975,high dose,45,54,"One month previously, she had taken a single high dose of disulfiram (130 tablets of ALCOHOL STOP TAB, Shin-Poong Pharm.",18023325_3,0
6977,Ansan,5,10,"Co., Ansan, Korea) in a suicide attempt.",18023325_4,0
6978,suicide attempt,24,39,"Co., Ansan, Korea) in a suicide attempt.",18023325_4,1
6980,sensory dysfunction,58,77,She noticed hoarseness and distally accentuated motor and sensory dysfunction after she had recovered from this state.,18023325_7,1
5488,polyneuropathy,72,86,A nerve conduction study was consistent with severe sensorimotor axonal polyneuropathy.,18023325_8,1
6985,ample denervation,58,75,Laryngeal electromyography (thyroarytenoid muscle) showed ample denervation potentials.,18023325_9,1
1761,levetiracetam,26,39,Encephalopathy induced by levetiracetam added to valproate.,18081909_0,0
6990,valproate,49,58,Encephalopathy induced by levetiracetam added to valproate.,18081909_0,0
1762,levetiracetam,48,61,BACKGROUND: We report on the manifestation of a levetiracetam (LEV)-induced encephalopathy.,18081909_1,0
5493,generalized seizures,68,88,FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).,18081909_2,1
6991,idiopathic epilepsy,43,62,FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).,18081909_2,1
6992,valproate,129,138,FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).,18081909_2,0
6993,VPA,140,143,FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate (VPA) (2000 mg).,18081909_2,0
5494,generalized tonic-clonic seizures,13,46,Frequency of generalized tonic-clonic seizures increased from one per 6 months to two per month.,18081909_3,1
6997,working memory,79,93,"Neuropsychological testing showed impaired word fluency, psychomotor speed and working memory.",18081909_4,1
6996,psychomotor speed,57,74,"Neuropsychological testing showed impaired word fluency, psychomotor speed and working memory.",18081909_4,1
6995,word fluency,43,55,"Neuropsychological testing showed impaired word fluency, psychomotor speed and working memory.",18081909_4,1
7001,bilateral generalized high-amplitude discharges,106,153,The interictal electroencephalogram (EEG) showed a generalized slowing to 5 per second theta rhythms with bilateral generalized high-amplitude discharges.,18081909_5,1
6999,generalized slowing,51,70,The interictal electroencephalogram (EEG) showed a generalized slowing to 5 per second theta rhythms with bilateral generalized high-amplitude discharges.,18081909_5,1
6998,interictal electroencephalogram,4,35,The interictal electroencephalogram (EEG) showed a generalized slowing to 5 per second theta rhythms with bilateral generalized high-amplitude discharges.,18081909_5,1
7000,theta rhythms,87,100,The interictal electroencephalogram (EEG) showed a generalized slowing to 5 per second theta rhythms with bilateral generalized high-amplitude discharges.,18081909_5,1
7002,neuropsychological findings,51,78,"OUTCOME: Following discontinuation of LEV, EEG and neuropsychological findings improved and seizure frequency decreased.",18081909_6,1
1763,beta-adrenergic receptors,33,58,Norepinephrine signaling through beta-adrenergic receptors is critical for expression of cocaine-induced anxiety.,18083142_0,0
7004,cocaine-induced anxiety,89,112,Norepinephrine signaling through beta-adrenergic receptors is critical for expression of cocaine-induced anxiety.,18083142_0,1
7005,psychostimulant,39,54,BACKGROUND: Cocaine is a widely abused psychostimulant that has both rewarding and aversive properties.,18083142_1,0
7007,cocaine's,32,41,"While the mechanisms underlying cocaine's rewarding effects have been studied extensively, less attention has been paid to the unpleasant behavioral states induced by cocaine, such as anxiety.",18083142_2,0
7012,cocaine-induced anxiety,229,252,"METHODS: In this study, we evaluated the performance of dopamine beta-hydroxylase knockout (Dbh -/-) mice, which lack norepinephrine (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-induced anxiety.",18083142_3,1
7011,noradrenergic,202,215,"METHODS: In this study, we evaluated the performance of dopamine beta-hydroxylase knockout (Dbh -/-) mice, which lack norepinephrine (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-induced anxiety.",18083142_3,0
7010,EPM,166,169,"METHODS: In this study, we evaluated the performance of dopamine beta-hydroxylase knockout (Dbh -/-) mice, which lack norepinephrine (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-induced anxiety.",18083142_3,0
1764,dopamine beta-hydroxylase,56,81,"METHODS: In this study, we evaluated the performance of dopamine beta-hydroxylase knockout (Dbh -/-) mice, which lack norepinephrine (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-induced anxiety.",18083142_3,0
7015,EPM,56,59,The Dbh -/- mice had normal baseline performance in the EPM but were completely resistant to the anxiogenic effects of cocaine.,18083142_5,0
7017,Cocaine-induced anxiety,0,23,"Cocaine-induced anxiety was also attenuated in Dbh +/- mice following administration of disulfiram, a dopamine beta-hydroxylase (DBH) inhibitor.",18083142_6,1
1765,dopamine beta-hydroxylase,102,127,"Cocaine-induced anxiety was also attenuated in Dbh +/- mice following administration of disulfiram, a dopamine beta-hydroxylase (DBH) inhibitor.",18083142_6,0
7018,DBH,129,132,"Cocaine-induced anxiety was also attenuated in Dbh +/- mice following administration of disulfiram, a dopamine beta-hydroxylase (DBH) inhibitor.",18083142_6,0
1766,adrenergic antagonists,30,52,"In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced anxiety-like behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist prazosin and the alpha(2) antagonist yohimbine had no effect.",18083142_7,0
7025,alpha(2) antagonist yohimbine,271,300,"In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced anxiety-like behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist prazosin and the alpha(2) antagonist yohimbine had no effect.",18083142_7,0
7024,alpha(1) antagonist prazosin,234,262,"In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced anxiety-like behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist prazosin and the alpha(2) antagonist yohimbine had no effect.",18083142_7,0
7020,beta-adrenergic receptor antagonist propranolol,90,137,"In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced anxiety-like behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist prazosin and the alpha(2) antagonist yohimbine had no effect.",18083142_7,0
1767,beta-adrenergic receptors,69,94,CONCLUSIONS: These results indicate that noradrenergic signaling via beta-adrenergic receptors is required for cocaine-induced anxiety in mice.,18083142_8,0
7026,noradrenergic,41,54,CONCLUSIONS: These results indicate that noradrenergic signaling via beta-adrenergic receptors is required for cocaine-induced anxiety in mice.,18083142_8,0
7027,cocaine-induced anxiety,111,134,CONCLUSIONS: These results indicate that noradrenergic signaling via beta-adrenergic receptors is required for cocaine-induced anxiety in mice.,18083142_8,1
7029,non-cardiac surgery,43,62,Dexmedetomidine and cardiac protection for non-cardiac surgery: a meta-analysis of randomised controlled trials.,18086064_0,1
1768,Dexmedetomidine,0,15,Dexmedetomidine and cardiac protection for non-cardiac surgery: a meta-analysis of randomised controlled trials.,18086064_0,0
7035,non-cardiac surgery,97,116,We conducted a systematic review of the effects of dexmedetomidine on cardiac outcomes following non-cardiac surgery.,18086064_1,1
1769,dexmedetomidine,51,66,We conducted a systematic review of the effects of dexmedetomidine on cardiac outcomes following non-cardiac surgery.,18086064_1,0
7037,cardiac morbidity,103,120,"We included prospective, randomised peri-operative studies of dexmedetomidine that reported mortality, cardiac morbidity or adverse drug events.",18086064_2,1
5495,adverse drug events,124,143,"We included prospective, randomised peri-operative studies of dexmedetomidine that reported mortality, cardiac morbidity or adverse drug events.",18086064_2,1
1770,dexmedetomidine,62,77,"We included prospective, randomised peri-operative studies of dexmedetomidine that reported mortality, cardiac morbidity or adverse drug events.",18086064_2,0
7038,PubMed,2,8,A PubMed Central and EMBASE search was conducted up to July 2007.,18086064_3,0
7039,EMBASE,21,27,A PubMed Central and EMBASE search was conducted up to July 2007.,18086064_3,0
5496,myocardial infarction,148,169,"Dexmedetomidine was associated with a trend towards improved cardiac outcomes; all-cause mortality (OR 0.27, 95% CI 0.01-7.13, p = 0.44), non-fatal myocardial infarction (OR 0.26, 95% CI 0.04-1.60, p = 0.14), and myocardial ischaemia (OR 0.65, 95% CI 0.26-1.63, p = 0.36).",18086064_6,1
1771,Dexmedetomidine,0,15,"Dexmedetomidine was associated with a trend towards improved cardiac outcomes; all-cause mortality (OR 0.27, 95% CI 0.01-7.13, p = 0.44), non-fatal myocardial infarction (OR 0.26, 95% CI 0.04-1.60, p = 0.14), and myocardial ischaemia (OR 0.65, 95% CI 0.26-1.63, p = 0.36).",18086064_6,0
7042,myocardial ischaemia,213,233,"Dexmedetomidine was associated with a trend towards improved cardiac outcomes; all-cause mortality (OR 0.27, 95% CI 0.01-7.13, p = 0.44), non-fatal myocardial infarction (OR 0.26, 95% CI 0.04-1.60, p = 0.14), and myocardial ischaemia (OR 0.65, 95% CI 0.26-1.63, p = 0.36).",18086064_6,1
7043,Peri-operative hypotension,0,26,"Peri-operative hypotension (26%, OR 3.80, 95% CI 1.91-7.54, p = 0.0001) and bradycardia (17%, OR 5.45, 95% CI 2.98-9.95, p < 0.00001) were significantly increased.",18086064_7,1
1772,dexmedetomidine,41,56,A randomised placebo-controlled trial of dexmedetomidine is warranted.,18086064_9,0
5497,Myocardial infarction,0,21,Myocardial infarction in pregnancy associated with clomiphene citrate for ovulation induction: a case report.,18161408_0,1
1773,clomiphene citrate,51,69,Myocardial infarction in pregnancy associated with clomiphene citrate for ovulation induction: a case report.,18161408_0,0
1774,Clomiphene citrate,12,30,BACKGROUND: Clomiphene citrate (CC) is commonly prescribed for ovulation induction.,18161408_1,0
5504,myocardial infarction,105,126,CONCLUSION: This appears to be the first reported case documenting a possible association between CC and myocardial infarction.,18161408_10,1
7056,prophylactic measures,54,75,"Given this life-threatening complication, appropriate prophylactic measures should be used in high-risk woman undergoing ovarian stimulation.",18161408_12,0
7057,ovarian stimulation,121,140,"Given this life-threatening complication, appropriate prophylactic measures should be used in high-risk woman undergoing ovarian stimulation.",18161408_12,1
5498,side effects,36,48,"It is considered safe, with minimal side effects.",18161408_2,1
7047,clot lysis,67,77,"Spontaneous coronary thrombosis or thromboembolism with subsequent clot lysis has been suggested as one of the most common causes of myocardial infarction (MI) during pregnancy, with a subsequently normal coronary angiogram.",18161408_4,1
5499,coronary thrombosis,12,31,"Spontaneous coronary thrombosis or thromboembolism with subsequent clot lysis has been suggested as one of the most common causes of myocardial infarction (MI) during pregnancy, with a subsequently normal coronary angiogram.",18161408_4,1
5500,myocardial infarction,133,154,"Spontaneous coronary thrombosis or thromboembolism with subsequent clot lysis has been suggested as one of the most common causes of myocardial infarction (MI) during pregnancy, with a subsequently normal coronary angiogram.",18161408_4,1
7049,5-week gestation,33,49,CASE: A 33-year-old woman with a 5-week gestation had recently received CC for ovulation induction and presented with chest pain.,18161408_5,1
5501,chest pain,118,128,CASE: A 33-year-old woman with a 5-week gestation had recently received CC for ovulation induction and presented with chest pain.,18161408_5,1
5502,anterior wall myocardial infarction,42,77,An electrocardiogram showed a lateral and anterior wall myocardial infarction.,18161408_6,1
1775,troponin I,38,48,Cardiac enzymes showed a peak rise in troponin I to 9.10 ng/mL. An initial exercise stress test was normal.,18161408_7,0
5503,radiation injury,58,74,"At the time of admission, the patient was at high risk of radiation injury to the fetus, so a coronary angiogram was postponed until the second trimester.",18161408_8,1
7054,coronary vessels,17,33,It showed normal coronary vessels.,18161408_9,1
1777,ribonucleic acid,42,58,"Hypothalamic prolactin receptor messenger ribonucleic acid levels, prolactin signaling, and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on estradiol.",18162529_0,0
1776,prolactin receptor,13,31,"Hypothalamic prolactin receptor messenger ribonucleic acid levels, prolactin signaling, and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on estradiol.",18162529_0,0
7060,pulsatile luteinizing hormone,125,154,"Hypothalamic prolactin receptor messenger ribonucleic acid levels, prolactin signaling, and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on estradiol.",18162529_0,0
5505,Hyperprolactinemia,0,18,Hyperprolactinemia can reduce fertility and libido.,18162529_1,1
1790,SOCS-3,36,42,Estradiol enhanced these effects on SOCS-3 and CIS.,18162529_10,0
1791,SOCS-3,45,51,"Interestingly, estradiol also induced PRL-R, SOCS-3, and CIS mRNA levels independently.",18162529_11,0
7076,PRL-R,38,43,"Interestingly, estradiol also induced PRL-R, SOCS-3, and CIS mRNA levels independently.",18162529_11,0
5510,hyperprolactinemia,66,84,These data show that GnRH pulse frequency is inhibited by chronic hyperprolactinemia in a steroid-dependent manner.,18162529_12,1
5511,steroid-dependent,90,107,These data show that GnRH pulse frequency is inhibited by chronic hyperprolactinemia in a steroid-dependent manner.,18162529_12,1
1792,GnRH,21,25,These data show that GnRH pulse frequency is inhibited by chronic hyperprolactinemia in a steroid-dependent manner.,18162529_12,0
7080,PRL-R,91,96,They also provide evidence for estradiol-dependent and brain region-specific regulation of PRL-R expression and signaling responses by prolactin.,18162529_13,0
5506,hyperprolactinemia,32,50,We first tested whether chronic hyperprolactinemia inhibited two neuroendocrine parameters necessary for female fertility: pulsatile LH secretion and the estrogen-induced LH surge.,18162529_3,1
5507,pulsatile,123,132,We first tested whether chronic hyperprolactinemia inhibited two neuroendocrine parameters necessary for female fertility: pulsatile LH secretion and the estrogen-induced LH surge.,18162529_3,1
1778,female fertility,105,121,We first tested whether chronic hyperprolactinemia inhibited two neuroendocrine parameters necessary for female fertility: pulsatile LH secretion and the estrogen-induced LH surge.,18162529_3,0
5508,hyperprolactinemia,8,26,"Chronic hyperprolactinemia induced by the dopamine antagonist sulpiride caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of estradiol.",18162529_4,1
7063,dopamine antagonist sulpiride,42,71,"Chronic hyperprolactinemia induced by the dopamine antagonist sulpiride caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of estradiol.",18162529_4,0
1780,GnRH,90,94,Sulpiride did not affect the magnitude of a steroid-induced LH surge or the percentage of GnRH neurons activated during the surge.,18162529_5,0
1779,Sulpiride,0,9,Sulpiride did not affect the magnitude of a steroid-induced LH surge or the percentage of GnRH neurons activated during the surge.,18162529_5,0
7068,long form,50,59,Estradiol is known to influence expression of the long form of prolactin receptors (PRL-R) and components of prolactin's signaling pathway.,18162529_6,0
7069,PRL-R,84,89,Estradiol is known to influence expression of the long form of prolactin receptors (PRL-R) and components of prolactin's signaling pathway.,18162529_6,0
1781,prolactin receptors,63,82,Estradiol is known to influence expression of the long form of prolactin receptors (PRL-R) and components of prolactin's signaling pathway.,18162529_6,0
1782,STAT5,165,170,"To test the hypothesis that estrogen increases PRL-R expression and sensitivity to prolactin, we next demonstrated that estradiol greatly augments prolactin-induced STAT5 activation.",18162529_7,0
7070,PRL-R,47,52,"To test the hypothesis that estrogen increases PRL-R expression and sensitivity to prolactin, we next demonstrated that estradiol greatly augments prolactin-induced STAT5 activation.",18162529_7,0
7071,PRL-R,20,25,"Lastly, we measured PRL-R and suppressor of cytokine signaling (SOCS-1 and -3 and CIS, which reflect the level of prolactin signaling) mRNAs in response to sulpiride and estradiol.",18162529_8,0
1783,SOCS-1,64,70,"Lastly, we measured PRL-R and suppressor of cytokine signaling (SOCS-1 and -3 and CIS, which reflect the level of prolactin signaling) mRNAs in response to sulpiride and estradiol.",18162529_8,0
1784,-3,75,77,"Lastly, we measured PRL-R and suppressor of cytokine signaling (SOCS-1 and -3 and CIS, which reflect the level of prolactin signaling) mRNAs in response to sulpiride and estradiol.",18162529_8,0
1785,sulpiride,156,165,"Lastly, we measured PRL-R and suppressor of cytokine signaling (SOCS-1 and -3 and CIS, which reflect the level of prolactin signaling) mRNAs in response to sulpiride and estradiol.",18162529_8,0
5509,choroid plexus,124,138,"Sulpiride induced only SOCS-1 in the medial preoptic area, where GnRH neurons are regulated, but in the arcuate nucleus and choroid plexus, PRL-R, SOCS-3, and CIS mRNA levels were also induced.",18162529_9,1
1786,Sulpiride,0,9,"Sulpiride induced only SOCS-1 in the medial preoptic area, where GnRH neurons are regulated, but in the arcuate nucleus and choroid plexus, PRL-R, SOCS-3, and CIS mRNA levels were also induced.",18162529_9,0
1787,SOCS-1,23,29,"Sulpiride induced only SOCS-1 in the medial preoptic area, where GnRH neurons are regulated, but in the arcuate nucleus and choroid plexus, PRL-R, SOCS-3, and CIS mRNA levels were also induced.",18162529_9,0
1788,GnRH,65,69,"Sulpiride induced only SOCS-1 in the medial preoptic area, where GnRH neurons are regulated, but in the arcuate nucleus and choroid plexus, PRL-R, SOCS-3, and CIS mRNA levels were also induced.",18162529_9,0
1789,SOCS-3,147,153,"Sulpiride induced only SOCS-1 in the medial preoptic area, where GnRH neurons are regulated, but in the arcuate nucleus and choroid plexus, PRL-R, SOCS-3, and CIS mRNA levels were also induced.",18162529_9,0
7075,PRL-R,140,145,"Sulpiride induced only SOCS-1 in the medial preoptic area, where GnRH neurons are regulated, but in the arcuate nucleus and choroid plexus, PRL-R, SOCS-3, and CIS mRNA levels were also induced.",18162529_9,0
7074,arcuate nucleus,104,119,"Sulpiride induced only SOCS-1 in the medial preoptic area, where GnRH neurons are regulated, but in the arcuate nucleus and choroid plexus, PRL-R, SOCS-3, and CIS mRNA levels were also induced.",18162529_9,1
5513,Takotsubo cardiomyopathy,73,97,Reverse or inverted left ventricular apical ballooning syndrome (reverse Takotsubo cardiomyopathy) in a young woman in the setting of amphetamine use.,18177388_0,1
5512,left ventricular apical ballooning syndrome,20,63,Reverse or inverted left ventricular apical ballooning syndrome (reverse Takotsubo cardiomyopathy) in a young woman in the setting of amphetamine use.,18177388_0,1
5515,Takotsubo cardiomyopathy,87,111,"Transient left ventricular apical ballooning syndrome was first described in Japan as ""Takotsubo cardiomyopathy."" This syndrome has been identified in many other countries.",18177388_1,1
5514,left ventricular apical ballooning syndrome,10,53,"Transient left ventricular apical ballooning syndrome was first described in Japan as ""Takotsubo cardiomyopathy."" This syndrome has been identified in many other countries.",18177388_1,1
7082,hyperdynamic apex,61,78,"One of the rarest is the reverse type of this syndrome, with hyperdynamic apex and complete akinesia of the base (as opposed to the classic apical ballooning).",18177388_3,1
5516,apical ballooning syndrome,109,135,"In this article, we report an interesting case of a young woman who presented with this rare type of reverse apical ballooning syndrome occurring after amphetamine use.",18177388_4,1
7083,attention-deficit/hyperactivity disorder,14,54,Clonidine for attention-deficit/hyperactivity disorder: II.,18182964_0,1
7084,adverse events,16,30,ECG changes and adverse events analysis.,18182964_1,1
7086,attention-deficit/hyperactivity disorder,115,155,OBJECTIVE: To examine the safety and tolerability of clonidine used alone or with methylphenidate in children with attention-deficit/hyperactivity disorder (ADHD).,18182964_2,1
7090,vital signs,109,120,Groups were compared regarding adverse events and changes from baseline to week 16 in electrocardiograms and vital signs.,18182964_5,1
7089,adverse events,31,45,Groups were compared regarding adverse events and changes from baseline to week 16 in electrocardiograms and vital signs.,18182964_5,1
7093,adverse events,19,33,Moderate or severe adverse events were more common in subjects on clonidine (79.4% versus 49.2%; p =.0006) but not associated with higher rates of early study withdrawal.,18182964_8,1
7097,drug-related mitochondrial,65,91,Renal Fanconi syndrome and myopathy after liver transplantation: drug-related mitochondrial cytopathy?Advances in the field of transplantation provide a better quality of life and allow more favorable conditions for growth and development in children.,18186898_0,1
7096,liver transplantation,42,63,Renal Fanconi syndrome and myopathy after liver transplantation: drug-related mitochondrial cytopathy?Advances in the field of transplantation provide a better quality of life and allow more favorable conditions for growth and development in children.,18186898_0,1
5517,Renal Fanconi syndrome,0,22,Renal Fanconi syndrome and myopathy after liver transplantation: drug-related mitochondrial cytopathy?Advances in the field of transplantation provide a better quality of life and allow more favorable conditions for growth and development in children.,18186898_0,1
7099,therapeutic regimens,35,55,"However, combinations of different therapeutic regimens require consideration of potential adverse reactions.",18186898_1,0
5518,adverse reactions,91,108,"However, combinations of different therapeutic regimens require consideration of potential adverse reactions.",18186898_1,1
7100,orthotopic liver transplantation,37,69,We describe a 15-yr-old girl who had orthotopic liver transplantation because of Wilson's disease.,18186898_2,1
5519,Wilson's disease,81,97,We describe a 15-yr-old girl who had orthotopic liver transplantation because of Wilson's disease.,18186898_2,1
7101,MMF,12,15,"Tacrolimus, MMF, and steroids were given as immunosuppressant.",18186898_3,0
1793,Tacrolimus,0,10,"Tacrolimus, MMF, and steroids were given as immunosuppressant.",18186898_3,0
7102,hepatitis B infection,40,61,Lamivudine was added because of de nova hepatitis B infection during her follow-up.,18186898_4,1
1794,her,69,72,Lamivudine was added because of de nova hepatitis B infection during her follow-up.,18186898_4,0
5522,hypophosphatemia,100,116,"Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis, hypophosphatemia, glycosuria, and aminoaciduria.",18186898_5,1
5521,metabolic acidosis,80,98,"Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis, hypophosphatemia, glycosuria, and aminoaciduria.",18186898_5,1
5520,renal Fanconi syndrome,45,67,"Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis, hypophosphatemia, glycosuria, and aminoaciduria.",18186898_5,1
1796,sirolimus,109,118,"Although tacrolimus was suspected to be the cause of late post-transplant renal acidosis and was replaced by sirolimus, acidosis, and electrolyte imbalance got worse.",18186898_6,0
1795,tacrolimus,9,19,"Although tacrolimus was suspected to be the cause of late post-transplant renal acidosis and was replaced by sirolimus, acidosis, and electrolyte imbalance got worse.",18186898_6,0
5523,muscle weakness,9,24,Proximal muscle weakness has developed during her follow-up.,18186898_7,1
1797,her,46,49,Proximal muscle weakness has developed during her follow-up.,18186898_7,0
5525,mitochondrial disorders,75,98,"Fanconi syndrome, as well as myopathy, is well recognized in patients with mitochondrial disorders and caused by depletion of mtDNA.",18186898_8,1
5524,Fanconi syndrome,0,16,"Fanconi syndrome, as well as myopathy, is well recognized in patients with mitochondrial disorders and caused by depletion of mtDNA.",18186898_8,1
1798,mtDNA,126,131,"Fanconi syndrome, as well as myopathy, is well recognized in patients with mitochondrial disorders and caused by depletion of mtDNA.",18186898_8,0
1799,tacrolimus,134,144,We suggest that our patient's tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by lamivudine.,18186898_9,0
7104,patient's tubular dysfunction,20,49,We suggest that our patient's tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by lamivudine.,18186898_9,1
7105,mitochondrial,86,99,We suggest that our patient's tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by lamivudine.,18186898_9,1
1802,amlodipine,206,216,"Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension.",18201582_0,0
1801,amlodipine,188,198,"Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension.",18201582_0,0
1800,telmisartan,172,183,"Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension.",18201582_0,0
7110,stage II hypertension,251,272,"Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension.",18201582_0,1
1805,amlodipine,176,186,OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.,18201582_1,0
7116,stage II hypertension,238,259,OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.,18201582_1,1
7113,FDC,112,115,OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.,18201582_1,0
7114,T+A,157,160,OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.,18201582_1,0
1803,telmisartan,120,131,OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.,18201582_1,0
1804,amlodipine,140,150,OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension.,18201582_1,0
7147,T+A group,172,181,"Peripheral edema was reported in 8.5% patients (9/106) in the T+A group compared with 13.5% (14/104) in the A group, and cough was reported in 3.8% patients (4/106) in the T+A group and 1.0% (1/104) patients in the A group; these differences did not reach statistical significance.",18201582_10,0
7144,Peripheral edema,0,16,"Peripheral edema was reported in 8.5% patients (9/106) in the T+A group compared with 13.5% (14/104) in the A group, and cough was reported in 3.8% patients (4/106) in the T+A group and 1.0% (1/104) patients in the A group; these differences did not reach statistical significance.",18201582_10,1
7151,T+A,80,83,"CONCLUSIONS: Among these Indian patients with stage II hypertension, the FDC of T+A was found to be significantly more effective, with regard to BP reductions, than A, and both treatments were well tolerated.",18201582_12,0
7150,FDC,73,76,"CONCLUSIONS: Among these Indian patients with stage II hypertension, the FDC of T+A was found to be significantly more effective, with regard to BP reductions, than A, and both treatments were well tolerated.",18201582_12,0
7149,stage II hypertension,46,67,"CONCLUSIONS: Among these Indian patients with stage II hypertension, the FDC of T+A was found to be significantly more effective, with regard to BP reductions, than A, and both treatments were well tolerated.",18201582_12,1
7119,stage II hypertension,174,195,"METHODS: This comparative, Phase III, 12-week, multicenter, prospective, randomized, double-blind study was conducted in Indian patients aged 18 to 65 years with established stage II hypertension.",18201582_2,1
7120,FDC,32,35,Patients were treated with oral FDC of T+A or A QD before breakfast for 12 weeks; blood pressure (BP) and heart rate were measured in the sitting position.,18201582_3,0
7121,T+A,39,42,Patients were treated with oral FDC of T+A or A QD before breakfast for 12 weeks; blood pressure (BP) and heart rate were measured in the sitting position.,18201582_3,0
7123,heart rate,106,116,Patients were treated with oral FDC of T+A or A QD before breakfast for 12 weeks; blood pressure (BP) and heart rate were measured in the sitting position.,18201582_3,1
5526,blood pressure,82,96,Patients were treated with oral FDC of T+A or A QD before breakfast for 12 weeks; blood pressure (BP) and heart rate were measured in the sitting position.,18201582_3,1
1806,end points,17,27,"Primary efficacy end points were reduction in clinical systolic BP (SBP)/ diastolic BP (DBP) from baseline to study end and number of responders (ie, patients who achieved target SBP/ DBP <130/<80 mm Hg) at end of study.",18201582_4,0
7131,treatment-emergent adverse events,29,62,"Tolerability was assessed by treatment-emergent adverse events, identified using physical examination, laboratory analysis, and electrocardiography.",18201582_5,1
7139,T+A,166,169,"At study end, statistically significant percentage reductions from baseline within groups and between groups were observed in SBP (T+A [-27.4%]; A [-16.6%]) and DBP (T+A [-20.1%]; A [-13.3%]) (all, P < 0.05).",18201582_7,0
7138,DBP,161,164,"At study end, statistically significant percentage reductions from baseline within groups and between groups were observed in SBP (T+A [-27.4%]; A [-16.6%]) and DBP (T+A [-20.1%]; A [-13.3%]) (all, P < 0.05).",18201582_7,0
7137,T+A,131,134,"At study end, statistically significant percentage reductions from baseline within groups and between groups were observed in SBP (T+A [-27.4%]; A [-16.6%]) and DBP (T+A [-20.1%]; A [-13.3%]) (all, P < 0.05).",18201582_7,0
7140,T+A group,42,51,Response rates were 87.3% (89/102) in the T+A group and 69.3% (70/101) in the A group (P < 0.05).,18201582_8,0
7142,adverse events,19,33,"The prevalences of adverse events were not significantly different between the 2 treatment groups (T+A, 16.0% [17/106]; A, 15.4% [16/104]).",18201582_9,1
7143,T+A,99,102,"The prevalences of adverse events were not significantly different between the 2 treatment groups (T+A, 16.0% [17/106]; A, 15.4% [16/104]).",18201582_9,0
7155,heparin-induced thrombocytopenia,80,112,Higher optical density of an antigen assay predicts thrombosis in patients with heparin-induced thrombocytopenia.,18208574_0,1
7153,optical density,7,22,Higher optical density of an antigen assay predicts thrombosis in patients with heparin-induced thrombocytopenia.,18208574_0,0
7154,antigen assay,29,42,Higher optical density of an antigen assay predicts thrombosis in patients with heparin-induced thrombocytopenia.,18208574_0,0
5527,thrombotic,11,21,"Similarly, thrombotic risk increased with age and OD values.",18208574_10,1
7157,platelet count,62,76,"PATIENTS AND METHODS: Patients with more than 50% decrease in platelet count or thrombocytopenia (<150 x 10(9)/L) after exposure to heparin, who had a positive two-step antigen assay [optical density (OD) >0.4 and >50 inhibition with high concentration of heparin] were included in the study.",18208574_2,0
7160,isolated-HIT,73,85,RESULTS: Forty of 94 HIT patients had thrombosis at diagnosis; 54/94 had isolated-HIT without thrombosis.,18208574_3,1
5529,mantle cell lymphoma,245,265,"Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.",18217897_0,1
5528,multiple myeloma,227,243,"Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.",18217897_0,1
7173,lymphoplasmacytic lymphoma,270,296,"Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.",18217897_0,1
1807,immunomodulatory,174,190,"Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.",18217897_0,0
7172,B.Thalidomide,154,167,"Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.",18217897_0,0
7170,non-Hodgkin lymphomas,81,102,"Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma.",18217897_0,1
7175,inflammatory cytokines,113,135,"Its activity is believed to be due modulation of the tumour milieu, including downregulation of angiogenesis and inflammatory cytokines.",18217897_1,0
7176,relapsed/refractory indolent lymphomas,51,89,"Between July 2001 and April 2004, 24 patients with relapsed/refractory indolent lymphomas received thalidomide 200 mg daily with escalation by 100 mg daily every 1-2 weeks as tolerated, up to a maximum of 800 mg daily.",18217897_2,1
7178,partial remission,79,96,"Of 24 evaluable patients, two achieved a complete remission and one achieved a partial remission for an overall response rate of 12.5% (95% confidence interval: 2.6-32.4%).",18217897_4,1
7177,complete remission,41,59,"Of 24 evaluable patients, two achieved a complete remission and one achieved a partial remission for an overall response rate of 12.5% (95% confidence interval: 2.6-32.4%).",18217897_4,1
5531,adverse effects,10,25,"Grade 3-4 adverse effects included myelosuppression, fatigue, somnolence/depressed mood, neuropathy and dyspnea.",18217897_6,1
5530,Grade 3,0,7,"Grade 3-4 adverse effects included myelosuppression, fatigue, somnolence/depressed mood, neuropathy and dyspnea.",18217897_6,1
7181,myelosuppression,35,51,"Grade 3-4 adverse effects included myelosuppression, fatigue, somnolence/depressed mood, neuropathy and dyspnea.",18217897_6,1
7182,somnolence/depressed mood,62,87,"Grade 3-4 adverse effects included myelosuppression, fatigue, somnolence/depressed mood, neuropathy and dyspnea.",18217897_6,1
7183,thromboembolic events,38,59,Of concern was the occurrence of four thromboembolic events.,18217897_7,1
7185,single agent,64,76,"Our results failed to demonstrate an important response rate to single agent thalidomide in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent, lenalidomide.",18217897_8,0
7186,second generation immunomodulatory,173,207,"Our results failed to demonstrate an important response rate to single agent thalidomide in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent, lenalidomide.",18217897_8,0
1808,lenalidomide,215,227,"Our results failed to demonstrate an important response rate to single agent thalidomide in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent, lenalidomide.",18217897_8,0
7188,persistent pain,100,115,Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a capsaicin model of persistent pain: comparisons to two models of acute pain.,18221780_0,1
5532,acute pain,146,156,Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a capsaicin model of persistent pain: comparisons to two models of acute pain.,18221780_0,1
7187,antihyperalgesia,59,75,Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a capsaicin model of persistent pain: comparisons to two models of acute pain.,18221780_0,1
1809,NMDA,19,23,Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a capsaicin model of persistent pain: comparisons to two models of acute pain.,18221780_0,0
5533,acute pain,3,13,"In acute pain models, N-methyl-D-aspartate (NMDA) antagonists enhance the antinociceptive effects of morphine to a greater extent in males than females.",18221780_1,1
1812,antinociceptive,74,89,"In acute pain models, N-methyl-D-aspartate (NMDA) antagonists enhance the antinociceptive effects of morphine to a greater extent in males than females.",18221780_1,0
1811,NMDA,44,48,"In acute pain models, N-methyl-D-aspartate (NMDA) antagonists enhance the antinociceptive effects of morphine to a greater extent in males than females.",18221780_1,0
1810,N-methyl-D-aspartate,22,42,"In acute pain models, N-methyl-D-aspartate (NMDA) antagonists enhance the antinociceptive effects of morphine to a greater extent in males than females.",18221780_1,0
7189,persistent pain,68,83,"The purpose of this investigation was to extend these findings to a persistent pain model which could be distinguished from acute pain models on the basis of the nociceptive fibers activated, neurochemical substrates, and duration of the nociceptive stimulus.",18221780_2,1
5534,acute pain,124,134,"The purpose of this investigation was to extend these findings to a persistent pain model which could be distinguished from acute pain models on the basis of the nociceptive fibers activated, neurochemical substrates, and duration of the nociceptive stimulus.",18221780_2,1
5535,hyperalgesia,24,36,"To this end, persistent hyperalgesia was induced by administration of capsaicin in the tail of gonadally intact F344 rats, following which the tail was immersed in a mildly noxious thermal stimulus, and tail-withdrawal latencies measured.",18221780_3,1
7194,F344,112,116,"To this end, persistent hyperalgesia was induced by administration of capsaicin in the tail of gonadally intact F344 rats, following which the tail was immersed in a mildly noxious thermal stimulus, and tail-withdrawal latencies measured.",18221780_3,0
5536,acute pain,44,54,"For comparison, tests were conducted in two acute pain models, the hotplate and warm water tail-withdrawal procedures.",18221780_4,1
7198,non-competitive NMDA,14,34,"In males, the non-competitive NMDA antagonist dextromethorphan enhanced the antihyperalgesic effect of low to moderate doses of morphine in a dose-and time-dependent manner.",18221780_5,0
1813,dextromethorphan,46,62,"In males, the non-competitive NMDA antagonist dextromethorphan enhanced the antihyperalgesic effect of low to moderate doses of morphine in a dose-and time-dependent manner.",18221780_5,0
1814,dextromethorphan,43,59,"Enhancement of morphine antinociception by dextromethorphan was seen in both males and females in the acute pain models, with the magnitude of this effect being greater in males.",18221780_7,0
5537,acute pain,102,112,"Enhancement of morphine antinociception by dextromethorphan was seen in both males and females in the acute pain models, with the magnitude of this effect being greater in males.",18221780_7,1
7204,persistent pain,103,118,These findings demonstrate a sexually-dimorphic interaction between NMDA antagonists and morphine in a persistent pain model that can be distinguished from those observed in acute pain models.,18221780_8,1
5538,acute pain,174,184,These findings demonstrate a sexually-dimorphic interaction between NMDA antagonists and morphine in a persistent pain model that can be distinguished from those observed in acute pain models.,18221780_8,1
1815,NMDA,68,72,These findings demonstrate a sexually-dimorphic interaction between NMDA antagonists and morphine in a persistent pain model that can be distinguished from those observed in acute pain models.,18221780_8,0
1816,APOE epsilon4,45,58,Increased mental slowing associated with the APOE epsilon4 allele after trihexyphenidyl oral anticholinergic challenge in healthy elderly.,18239197_0,0
1817,trihexyphenidyl,72,87,Increased mental slowing associated with the APOE epsilon4 allele after trihexyphenidyl oral anticholinergic challenge in healthy elderly.,18239197_0,0
7205,mental slowing,10,24,Increased mental slowing associated with the APOE epsilon4 allele after trihexyphenidyl oral anticholinergic challenge in healthy elderly.,18239197_0,1
1819,trihexyphenidyl,122,137,OBJECTIVES: The objectives of this study were to examine the relationship between APOE epsilon4 and subjective effects of trihexyphenidyl on measures reflecting sedation and confusion and to investigate the relationship between trihexyphenidyl-induced subjective effects and objective memory performance.,18239197_1,0
1818,APOE epsilon4,82,95,OBJECTIVES: The objectives of this study were to examine the relationship between APOE epsilon4 and subjective effects of trihexyphenidyl on measures reflecting sedation and confusion and to investigate the relationship between trihexyphenidyl-induced subjective effects and objective memory performance.,18239197_1,0
1820,APOE epsilon4,79,92,"METHODS: This study comprised 24 cognitively intact, health elderly adults (12 APOE epsilon4 carriers) at an outpatient geriatric psychiatry research clinic.",18239197_2,0
7211,double blind,23,35,"This was a randomized, double blind, placebo-controlled, three-way, crossover experimental design.",18239197_3,0
1821,trihexyphenidyl,43,58,All participants received 1.0 mg or 2.0 mg trihexyphenidyl or placebo administered in counterbalanced sequences over a period of three consecutive weeks.,18239197_4,0
5539,Buschke,68,75,"Bond and Lader's visual analog scales and alternate versions of the Buschke Selective Reminding Test were administered in a repeated measures design at baseline, 1, 2.5, and 5 hours postdrug administration.",18239197_5,1
7215,oral dose,18,27,RESULTS: A 2.0-mg oral dose of trihexyphenidyl resulted in increased subjective ratings of mental slowness in carriers of the APOE epsilon4 allele only.,18239197_6,0
1823,APOE epsilon4,126,139,RESULTS: A 2.0-mg oral dose of trihexyphenidyl resulted in increased subjective ratings of mental slowness in carriers of the APOE epsilon4 allele only.,18239197_6,0
1822,trihexyphenidyl,31,46,RESULTS: A 2.0-mg oral dose of trihexyphenidyl resulted in increased subjective ratings of mental slowness in carriers of the APOE epsilon4 allele only.,18239197_6,0
7217,mental slowness,91,106,RESULTS: A 2.0-mg oral dose of trihexyphenidyl resulted in increased subjective ratings of mental slowness in carriers of the APOE epsilon4 allele only.,18239197_6,1
1825,APOE epsilon4,235,248,Drug effects as determined by difference scores between 2.0 mg trihexyphenidyl and placebo on ratings of mental slowness significantly correlated with total and delayed recall on the Buschke Selective Reminding Test in carriers of the APOE epsilon4 allele only.,18239197_7,0
1824,trihexyphenidyl,63,78,Drug effects as determined by difference scores between 2.0 mg trihexyphenidyl and placebo on ratings of mental slowness significantly correlated with total and delayed recall on the Buschke Selective Reminding Test in carriers of the APOE epsilon4 allele only.,18239197_7,0
5540,Buschke,183,190,Drug effects as determined by difference scores between 2.0 mg trihexyphenidyl and placebo on ratings of mental slowness significantly correlated with total and delayed recall on the Buschke Selective Reminding Test in carriers of the APOE epsilon4 allele only.,18239197_7,1
7218,Drug effects,0,12,Drug effects as determined by difference scores between 2.0 mg trihexyphenidyl and placebo on ratings of mental slowness significantly correlated with total and delayed recall on the Buschke Selective Reminding Test in carriers of the APOE epsilon4 allele only.,18239197_7,0
7219,mental slowness,105,120,Drug effects as determined by difference scores between 2.0 mg trihexyphenidyl and placebo on ratings of mental slowness significantly correlated with total and delayed recall on the Buschke Selective Reminding Test in carriers of the APOE epsilon4 allele only.,18239197_7,1
7221,subjective sedation,86,105,"However, no significant effects were found with other visual analog scales reflecting subjective sedation and clear-headedness.",18239197_8,1
7223,epsilon4,16,24,CONCLUSION: The epsilon4 allele in healthy elderly was associated with increased subjective mental slowing after trihexyphenidyl anticholinergic challenge.,18239197_9,0
7225,mental slowing,92,106,CONCLUSION: The epsilon4 allele in healthy elderly was associated with increased subjective mental slowing after trihexyphenidyl anticholinergic challenge.,18239197_9,1
7226,trihexyphenidyl anticholinergic,113,144,CONCLUSION: The epsilon4 allele in healthy elderly was associated with increased subjective mental slowing after trihexyphenidyl anticholinergic challenge.,18239197_9,0
7227,cardiac transplant,90,108,Development of proteinuria after switch to sirolimus-based immunosuppression in long-term cardiac transplant patients.,18261172_0,1
7228,renal dysfunction,42,59,Calcineurin-inhibitor therapy can lead to renal dysfunction in heart transplantation patients.,18261172_1,1
7229,heart transplantation,63,84,Calcineurin-inhibitor therapy can lead to renal dysfunction in heart transplantation patients.,18261172_1,1
1826,Calcineurin-inhibitor,0,21,Calcineurin-inhibitor therapy can lead to renal dysfunction in heart transplantation patients.,18261172_1,0
7251,adverse effect,100,114,"Thus, proteinuria may develop in cardiac transplant patients after switch to Srl, which may have an adverse effect on renal function in these patients.",18261172_10,1
7252,renal function,118,132,"Thus, proteinuria may develop in cardiac transplant patients after switch to Srl, which may have an adverse effect on renal function in these patients.",18261172_10,1
7249,cardiac transplant,33,51,"Thus, proteinuria may develop in cardiac transplant patients after switch to Srl, which may have an adverse effect on renal function in these patients.",18261172_10,1
7250,Srl,77,80,"Thus, proteinuria may develop in cardiac transplant patients after switch to Srl, which may have an adverse effect on renal function in these patients.",18261172_10,0
7253,Srl,0,3,Srl should be used with ACEi/ARB therapy and patients monitored for proteinuria and increased renal dysfunction.,18261172_11,0
7255,renal dysfunction,94,111,Srl should be used with ACEi/ARB therapy and patients monitored for proteinuria and increased renal dysfunction.,18261172_11,1
7230,Srl,48,51,"The novel immunosuppressive (IS) drug sirolmus (Srl) lacks nephrotoxic effects; however, proteinuria associated with Srl has been reported following renal transplantation.",18261172_2,0
7233,Srl,117,120,"The novel immunosuppressive (IS) drug sirolmus (Srl) lacks nephrotoxic effects; however, proteinuria associated with Srl has been reported following renal transplantation.",18261172_2,0
7234,renal transplantation,149,170,"The novel immunosuppressive (IS) drug sirolmus (Srl) lacks nephrotoxic effects; however, proteinuria associated with Srl has been reported following renal transplantation.",18261172_2,1
7235,cardiac transplantation,3,26,"In cardiac transplantation, the incidence of proteinuria associated with Srl is unknown.",18261172_3,1
7237,Srl,73,76,"In cardiac transplantation, the incidence of proteinuria associated with Srl is unknown.",18261172_3,0
7238,cardiac transplant,25,43,"In this study, long-term cardiac transplant patients were switched from cyclosporine to Srl-based IS.",18261172_4,1
1827,cyclosporine,72,84,"In this study, long-term cardiac transplant patients were switched from cyclosporine to Srl-based IS.",18261172_4,0
7240,/-,51,53,Concomitant IS consisted of mycophenolate mofetil +/- steroids.,18261172_5,0
1828,mycophenolate mofetil,28,49,Concomitant IS consisted of mycophenolate mofetil +/- steroids.,18261172_5,0
7243,high-grade proteinuria,41,63,"Before the switch, 11.5% of patients had high-grade proteinuria (>1.0 g/day); this increased to 22.9% postswitch (p = 0.006).",18261172_7,1
7245,angiotensin-releasing blocker,18,47,ACE inhibitor and angiotensin-releasing blocker (ARB) therapy reduced proteinuria development.,18261172_8,0
1829,ACE inhibitor,0,13,ACE inhibitor and angiotensin-releasing blocker (ARB) therapy reduced proteinuria development.,18261172_8,0
7248,renal function,163,177,"Patients without proteinuria had increased renal function (median 42.5 vs. 64.1, p = 0.25), whereas patients who developed high-grade proteinuria showed decreased renal function at the end of follow-up (median 39.6 vs. 29.2, p = 0.125).",18261172_9,1
7246,renal function,43,57,"Patients without proteinuria had increased renal function (median 42.5 vs. 64.1, p = 0.25), whereas patients who developed high-grade proteinuria showed decreased renal function at the end of follow-up (median 39.6 vs. 29.2, p = 0.125).",18261172_9,1
7247,high-grade proteinuria,123,145,"Patients without proteinuria had increased renal function (median 42.5 vs. 64.1, p = 0.25), whereas patients who developed high-grade proteinuria showed decreased renal function at the end of follow-up (median 39.6 vs. 29.2, p = 0.125).",18261172_9,1
7256,Ginsenoside Rg1,0,15,Ginsenoside Rg1 restores the impairment of learning induced by chronic morphine administration in rats.,18308784_0,0
7257,chronic morphine,63,79,Ginsenoside Rg1 restores the impairment of learning induced by chronic morphine administration in rats.,18308784_0,1
7258,Rg1,0,3,"Rg1, as a ginsenoside extracted from Panax ginseng, could ameliorate spatial learning impairment.",18308784_1,0
7260,learning impairment,77,96,"Rg1, as a ginsenoside extracted from Panax ginseng, could ameliorate spatial learning impairment.",18308784_1,1
1830,ginsenoside,10,21,"Rg1, as a ginsenoside extracted from Panax ginseng, could ameliorate spatial learning impairment.",18308784_1,0
1833,NMDA receptor,15,28,This effect is NMDA receptor dependent.,18308784_10,0
7261,Rg1,40,43,Previous studies have demonstrated that Rg1 might be a useful agent for the prevention and treatment of the adverse effects of morphine.,18308784_2,0
5541,adverse effects,108,123,Previous studies have demonstrated that Rg1 might be a useful agent for the prevention and treatment of the adverse effects of morphine.,18308784_2,1
7262,Rg1,55,58,The aim of this study was to investigate the effect of Rg1 on learning impairment by chronic morphine administration and the mechanism responsible for this effect.,18308784_3,0
7263,learning impairment,62,81,The aim of this study was to investigate the effect of Rg1 on learning impairment by chronic morphine administration and the mechanism responsible for this effect.,18308784_3,1
7264,Rg1,114,117,"Male rats were subcutaneously injected with morphine (10 mg/kg) twice a day at 12 hour intervals for 10 days, and Rg1 (30 mg/kg) was intraperitoneally injected 2 hours after the second injection of morphine once a day for 10 days.",18308784_4,0
7265,Spatial learning,0,16,Spatial learning capacity was assessed in the Morris water maze.,18308784_5,1
7267,Morphine/Rg1,42,54,The results showed that rats treated with Morphine/Rg1 decreased escape latency and increased the time spent in platform quadrant and entering frequency.,18308784_6,0
7271,Rg1,98,101,"By implantation of electrodes and electrophysiological recording in vivo, the results showed that Rg1 restored the long-term potentiation (LTP) impaired by morphine in both freely moving and anaesthetised rats.",18308784_7,0
7274,LTP,73,76,"The electrophysiological recording in vitro showed that Rg1 restored the LTP in slices from the rats treated with morphine, but not changed LTP in the slices from normal saline- or morphine/Rg1-treated rats; this restoration could be inhibited by N-methyl-D-aspartate (NMDA) receptor antagonist MK801.",18308784_8,0
7273,Rg1,56,59,"The electrophysiological recording in vitro showed that Rg1 restored the LTP in slices from the rats treated with morphine, but not changed LTP in the slices from normal saline- or morphine/Rg1-treated rats; this restoration could be inhibited by N-methyl-D-aspartate (NMDA) receptor antagonist MK801.",18308784_8,0
7275,LTP,140,143,"The electrophysiological recording in vitro showed that Rg1 restored the LTP in slices from the rats treated with morphine, but not changed LTP in the slices from normal saline- or morphine/Rg1-treated rats; this restoration could be inhibited by N-methyl-D-aspartate (NMDA) receptor antagonist MK801.",18308784_8,0
1831,N-methyl-D-aspartate,247,267,"The electrophysiological recording in vitro showed that Rg1 restored the LTP in slices from the rats treated with morphine, but not changed LTP in the slices from normal saline- or morphine/Rg1-treated rats; this restoration could be inhibited by N-methyl-D-aspartate (NMDA) receptor antagonist MK801.",18308784_8,0
1832,NMDA,269,273,"The electrophysiological recording in vitro showed that Rg1 restored the LTP in slices from the rats treated with morphine, but not changed LTP in the slices from normal saline- or morphine/Rg1-treated rats; this restoration could be inhibited by N-methyl-D-aspartate (NMDA) receptor antagonist MK801.",18308784_8,0
7276,receptor antagonist MK801,275,300,"The electrophysiological recording in vitro showed that Rg1 restored the LTP in slices from the rats treated with morphine, but not changed LTP in the slices from normal saline- or morphine/Rg1-treated rats; this restoration could be inhibited by N-methyl-D-aspartate (NMDA) receptor antagonist MK801.",18308784_8,0
7277,Rg1,17,20,We conclude that Rg1 may significantly improve the spatial learning capacity impaired by chonic morphine administration and restore the morphine-inhibited LTP.,18308784_9,0
7278,spatial learning,51,67,We conclude that Rg1 may significantly improve the spatial learning capacity impaired by chonic morphine administration and restore the morphine-inhibited LTP.,18308784_9,1
7279,chonic morphine,89,104,We conclude that Rg1 may significantly improve the spatial learning capacity impaired by chonic morphine administration and restore the morphine-inhibited LTP.,18308784_9,0
7280,morphine-inhibited LTP,136,158,We conclude that Rg1 may significantly improve the spatial learning capacity impaired by chonic morphine administration and restore the morphine-inhibited LTP.,18308784_9,0
7281,N-pyrimidinyl-2-phenoxyacetamides,13,46,Synthesis of N-pyrimidinyl-2-phenoxyacetamides as adenosine A2A receptor antagonists.,18329269_0,0
7282,adenosine A2A receptor antagonists,50,84,Synthesis of N-pyrimidinyl-2-phenoxyacetamides as adenosine A2A receptor antagonists.,18329269_0,0
7283,N-pyrimidinyl-2-phenoxyacetamide adenosine A(2A) antagonists,12,72,A series of N-pyrimidinyl-2-phenoxyacetamide adenosine A(2A) antagonists is described.,18329269_1,0
5542,Parkinson's disease,187,206,"SAR studies led to compound 14 with excellent potency (K(i) = 0.4 nM), selectivity (A(1)/A(2A) > 100), and efficacy (MED 10 mg/kg p.o.) in the rat haloperidol-induced catalepsy model for Parkinson's disease.",18329269_2,1
7285,K(i,55,58,"SAR studies led to compound 14 with excellent potency (K(i) = 0.4 nM), selectivity (A(1)/A(2A) > 100), and efficacy (MED 10 mg/kg p.o.) in the rat haloperidol-induced catalepsy model for Parkinson's disease.",18329269_2,0
7288,D1,31,33,Evidence for an involvement of D1 and D2 dopamine receptors in mediating nicotine-induced hyperactivity in rats.,1833784_0,0
7289,D2 dopamine receptors,38,59,Evidence for an involvement of D1 and D2 dopamine receptors in mediating nicotine-induced hyperactivity in rats.,1833784_0,0
7309,D2 dopamine receptors,155,176,"The effect appears to be mediated by central nicotine receptors, possibly located on dopaminergic neurons, and also requires the activation of both D1 and D2 dopamine receptors.",1833784_10,0
7308,D1,148,150,"The effect appears to be mediated by central nicotine receptors, possibly located on dopaminergic neurons, and also requires the activation of both D1 and D2 dopamine receptors.",1833784_10,0
7307,central nicotine receptors,37,63,"The effect appears to be mediated by central nicotine receptors, possibly located on dopaminergic neurons, and also requires the activation of both D1 and D2 dopamine receptors.",1833784_10,0
1840,dopaminergic,85,97,"The effect appears to be mediated by central nicotine receptors, possibly located on dopaminergic neurons, and also requires the activation of both D1 and D2 dopamine receptors.",1833784_10,0
7293,D1,151,153,"In addition, the role of dopamine receptors in mediating nicotine-induced locomotor stimulation was investigated by examining the effects of selective D1 and D2 dopamine receptor antagonists on activity induced by nicotine.",1833784_3,0
1834,dopamine receptors,25,43,"In addition, the role of dopamine receptors in mediating nicotine-induced locomotor stimulation was investigated by examining the effects of selective D1 and D2 dopamine receptor antagonists on activity induced by nicotine.",1833784_3,0
7294,D2 dopamine receptor antagonists,158,190,"In addition, the role of dopamine receptors in mediating nicotine-induced locomotor stimulation was investigated by examining the effects of selective D1 and D2 dopamine receptor antagonists on activity induced by nicotine.",1833784_3,0
7298,mecamylamine,81,93,"The stimulant action of nicotine was blocked by the central nicotinic antagonist mecamylamine but not by the peripheral nicotinic blocker hexamethonium, indicating that the response is probably mediated by central nicotinic receptors.",1833784_6,0
1838,nicotinic receptors,214,233,"The stimulant action of nicotine was blocked by the central nicotinic antagonist mecamylamine but not by the peripheral nicotinic blocker hexamethonium, indicating that the response is probably mediated by central nicotinic receptors.",1833784_6,0
1837,hexamethonium,138,151,"The stimulant action of nicotine was blocked by the central nicotinic antagonist mecamylamine but not by the peripheral nicotinic blocker hexamethonium, indicating that the response is probably mediated by central nicotinic receptors.",1833784_6,0
1836,nicotinic,120,129,"The stimulant action of nicotine was blocked by the central nicotinic antagonist mecamylamine but not by the peripheral nicotinic blocker hexamethonium, indicating that the response is probably mediated by central nicotinic receptors.",1833784_6,0
1835,nicotinic,60,69,"The stimulant action of nicotine was blocked by the central nicotinic antagonist mecamylamine but not by the peripheral nicotinic blocker hexamethonium, indicating that the response is probably mediated by central nicotinic receptors.",1833784_6,0
7302,D1/D2 antagonist,132,148,"Nicotine-induced hyperactivity was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine.",1833784_7,0
7301,D2 antagonist raclopride,99,123,"Nicotine-induced hyperactivity was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine.",1833784_7,0
7300,selective D1,50,62,"Nicotine-induced hyperactivity was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine.",1833784_7,0
1839,SCH,74,77,"Nicotine-induced hyperactivity was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine.",1833784_7,0
7299,Nicotine-induced hyperactivity,0,30,"Nicotine-induced hyperactivity was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine.",1833784_7,1
7304,D2 agonist PHNO,22,37,"Pretreatment with the D2 agonist PHNO enhanced nicotine-induced hyperactivity, whereas the D1 agonist SKF 38393 had no effect.",1833784_8,0
7306,D1 agonist SKF 38393,91,111,"Pretreatment with the D2 agonist PHNO enhanced nicotine-induced hyperactivity, whereas the D1 agonist SKF 38393 had no effect.",1833784_8,0
5543,retinal vein occlusion,8,30,Central retinal vein occlusion associated with clomiphene-induced ovulation.,18343374_0,1
1841,clomiphene citrate,78,96,OBJECTIVE: To report a case of central retinal vein occlusion associated with clomiphene citrate (CC).,18343374_1,0
5544,retinal vein occlusion,39,61,OBJECTIVE: To report a case of central retinal vein occlusion associated with clomiphene citrate (CC).,18343374_1,1
5548,side effect,114,125,"Extra caution is warranted in treating infertility patients with CC, and patients should be well informed of this side effect before commencement of therapy.",18343374_10,1
7314,blurred vision,73,87,PATIENT(S): A 36-year-old woman referred from the infertility clinic for blurred vision.,18343374_4,1
5545,retinal vein occlusion,33,55,MAIN OUTCOME MEASURE(S): Central retinal vein occlusion after ovulation induction with CC.,18343374_6,1
5546,retinal vein occlusion,57,79,RESULT(S): A 36-year-old Chinese woman developed central retinal vein occlusion after eight courses of CC.,18343374_7,1
7318,visual disturbance,137,155,"A search of the literature on the thromboembolic complications of CC does not include this severe ophthalmic complication, although mild visual disturbance after CC intake is not uncommon.",18343374_8,1
7317,ophthalmic complication,98,121,"A search of the literature on the thromboembolic complications of CC does not include this severe ophthalmic complication, although mild visual disturbance after CC intake is not uncommon.",18343374_8,1
7316,thromboembolic,34,48,"A search of the literature on the thromboembolic complications of CC does not include this severe ophthalmic complication, although mild visual disturbance after CC intake is not uncommon.",18343374_8,1
5547,retinal vein occlusion,58,80,CONCLUSION(S): This is the first reported case of central retinal vein occlusion after treatment with CC.,18343374_9,1
5549,chronic obstructive pulmonary disease,73,110,Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease.,1835291_0,1
7321,ipratropium bromide,33,52,Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease.,1835291_0,0
5550,chronic obstructive pulmonary disease,288,325,"The bronchodilator effects of a single dose of ipratropium bromide aerosol (36 micrograms) and short-acting theophylline tablets (dose titrated to produce serum levels of 10-20 micrograms/mL) were compared in a double-blind, placebo-controlled crossover study in 21 patients with stable, chronic obstructive pulmonary disease.",1835291_1,1
7323,ipratropium bromide aerosol,47,74,"The bronchodilator effects of a single dose of ipratropium bromide aerosol (36 micrograms) and short-acting theophylline tablets (dose titrated to produce serum levels of 10-20 micrograms/mL) were compared in a double-blind, placebo-controlled crossover study in 21 patients with stable, chronic obstructive pulmonary disease.",1835291_1,0
1842,bronchodilator effects,4,26,"The bronchodilator effects of a single dose of ipratropium bromide aerosol (36 micrograms) and short-acting theophylline tablets (dose titrated to produce serum levels of 10-20 micrograms/mL) were compared in a double-blind, placebo-controlled crossover study in 21 patients with stable, chronic obstructive pulmonary disease.",1835291_1,0
7328,FEV1,48,52,"Mean peak forced expiratory volume in 1 second (FEV1) increases over baseline and the proportion of patients attaining at least a 15% increase in the FEV1 (responders) were 31% and 90%, respectively, for ipratropium and 17% and 50%, respectively, for theophylline.",1835291_2,0
1843,ipratropium,204,215,"Mean peak forced expiratory volume in 1 second (FEV1) increases over baseline and the proportion of patients attaining at least a 15% increase in the FEV1 (responders) were 31% and 90%, respectively, for ipratropium and 17% and 50%, respectively, for theophylline.",1835291_2,0
7329,FEV1,150,154,"Mean peak forced expiratory volume in 1 second (FEV1) increases over baseline and the proportion of patients attaining at least a 15% increase in the FEV1 (responders) were 31% and 90%, respectively, for ipratropium and 17% and 50%, respectively, for theophylline.",1835291_2,0
1844,ipratropium,77,88,The average FEV1 increases during the 6-hour observation period were 18% for ipratropium and 8% for theophylline.,1835291_3,0
7330,FEV1,12,16,The average FEV1 increases during the 6-hour observation period were 18% for ipratropium and 8% for theophylline.,1835291_3,0
1845,ipratropium,47,58,The mean duration of action was 3.8 hours with ipratropium and 2.4 hours with theophylline.,1835291_4,0
5551,side effects,6,18,"While side effects were rare, those experienced after theophylline use did involve the cardiovascular and gastrointestinal systems.",1835291_5,1
5552,chronic airflow obstruction,108,135,These results show that ipratropium is a more potent bronchodilator than oral theophylline in patients with chronic airflow obstruction.,1835291_6,1
1846,ipratropium,24,35,These results show that ipratropium is a more potent bronchodilator than oral theophylline in patients with chronic airflow obstruction.,1835291_6,0
7332,oral theophylline,73,90,These results show that ipratropium is a more potent bronchodilator than oral theophylline in patients with chronic airflow obstruction.,1835291_6,0
5553,febrile neutropenia,100,119,Amikacin is an aminoglycoside commonly used to provide empirical double gram-negative treatment for febrile neutropenia and other suspected infections.,18356633_1,1
1847,Amikacin,0,8,Amikacin is an aminoglycoside commonly used to provide empirical double gram-negative treatment for febrile neutropenia and other suspected infections.,18356633_1,0
1848,aminoglycoside,15,29,Amikacin is an aminoglycoside commonly used to provide empirical double gram-negative treatment for febrile neutropenia and other suspected infections.,18356633_1,0
7337,nephrotoxicity,32,46,"To evaluate amikacin-associated nephrotoxicity in an adult hematology/oncology population, a prospective, randomized, open-label trial was conducted at a university-affiliated medical center.",18356633_3,1
1849,aminoglycoside,113,127,Forty patients with a diagnosis consistent with a hematologic/oncologic disorder that required treatment with an aminoglycoside were randomized to either conventional or extended-interval amikacin.,18356633_4,0
1850,amikacin,188,196,Forty patients with a diagnosis consistent with a hematologic/oncologic disorder that required treatment with an aminoglycoside were randomized to either conventional or extended-interval amikacin.,18356633_4,0
7341,hematologic/oncologic disorder,50,80,Forty patients with a diagnosis consistent with a hematologic/oncologic disorder that required treatment with an aminoglycoside were randomized to either conventional or extended-interval amikacin.,18356633_4,1
7343,nephrotoxicity,18,32,The occurrence of nephrotoxicity by means of an increase in serum creatinine and evaluation of efficacy via amikacin serum concentrations with respective pathogens were assessed.,18356633_5,1
1851,creatinine,66,76,The occurrence of nephrotoxicity by means of an increase in serum creatinine and evaluation of efficacy via amikacin serum concentrations with respective pathogens were assessed.,18356633_5,0
1852,amikacin,108,116,The occurrence of nephrotoxicity by means of an increase in serum creatinine and evaluation of efficacy via amikacin serum concentrations with respective pathogens were assessed.,18356633_5,0
7344,nephrotoxicity,18,32,"The occurrence of nephrotoxicity was similar between the conventional and extended-interval groups, at 10% and 5%, respectively (P = 1.00).",18356633_6,1
1853,at 10,100,105,"The occurrence of nephrotoxicity was similar between the conventional and extended-interval groups, at 10% and 5%, respectively (P = 1.00).",18356633_6,0
7346,nephrotoxicity,18,32,"The occurrence of nephrotoxicity was similar between the two dosing regimens, but the distribution of risk factors was variable between the two groups.",18356633_8,1
7349,High dose dexmedetomidine,0,25,High dose dexmedetomidine as the sole sedative for pediatric MRI.OBJECTIVE: This large-scale retrospective review evaluates the sedation profile of dexmedetomidine.,18363626_0,0
1854,dexmedetomidine,148,163,High dose dexmedetomidine as the sole sedative for pediatric MRI.OBJECTIVE: This large-scale retrospective review evaluates the sedation profile of dexmedetomidine.,18363626_0,0
7355,high dose dexmedetomidine,100,125,"AIM: To determine the hemodynamic responses, efficacy and adverse events associated with the use of high dose dexmedetomidine as the sole sedative for magnetic resonance imaging (MRI) studies.",18363626_1,0
7353,adverse events,58,72,"AIM: To determine the hemodynamic responses, efficacy and adverse events associated with the use of high dose dexmedetomidine as the sole sedative for magnetic resonance imaging (MRI) studies.",18363626_1,1
7367,high dose dexmedetomidine,13,38,"While use of high dose dexmedetomidine is associated with decreases in heart rate and blood pressure outside the established 'awake' norms, this deviation is generally within 20% of norms, and is not associated with adverse sequelae.",18363626_10,0
7371,adverse sequelae,216,232,"While use of high dose dexmedetomidine is associated with decreases in heart rate and blood pressure outside the established 'awake' norms, this deviation is generally within 20% of norms, and is not associated with adverse sequelae.",18363626_10,1
7369,heart rate,71,81,"While use of high dose dexmedetomidine is associated with decreases in heart rate and blood pressure outside the established 'awake' norms, this deviation is generally within 20% of norms, and is not associated with adverse sequelae.",18363626_10,1
5555,blood pressure,86,100,"While use of high dose dexmedetomidine is associated with decreases in heart rate and blood pressure outside the established 'awake' norms, this deviation is generally within 20% of norms, and is not associated with adverse sequelae.",18363626_10,1
1862,Dexmedetomidine,0,15,Dexmedetomidine is useful as the sole sedative for pediatric MRI.,18363626_11,0
1855,Dexmedetomidine,12,27,BACKGROUND: Dexmedetomidine has been used at our institution since 2005 to provide sedation for pediatric radiological imaging studies.,18363626_2,0
7357,high dose dexmedetomidine,43,68,"Over time, an effective protocol utilizing high dose dexmedetomidine as the sole sedative agent has evolved.",18363626_3,0
7358,sedative agent,81,95,"Over time, an effective protocol utilizing high dose dexmedetomidine as the sole sedative agent has evolved.",18363626_3,0
1856,dexmedetomidine,66,81,Data were analyzed from all 747 consecutive patients who received dexmedetomidine for MRI sedation from April 2005 to April 2007.,18363626_5,0
1857,dexmedetomidine,52,67,"RESULTS: Since 2005, the 10-min loading dose of our dexmedetomidine protocol increased from 2 to 3 microg.kg(-1), and the infusion rate increased from 1 to 1.5 to 2 microg.kg(-1).h(-1).",18363626_6,0
1859,dexmedetomidine,279,294,"The current sedation protocol progressively increased the rate of successful sedation (able to complete the imaging study) when using dexmedetomidine alone from 91.8% to 97.6% (P = 0.009), reducing the requirement for adjuvant pentobarbital in the event of sedation failure with dexmedetomidine alone and decreased the mean recovery time by 10 min (P < 0.001).",18363626_7,0
1858,dexmedetomidine,134,149,"The current sedation protocol progressively increased the rate of successful sedation (able to complete the imaging study) when using dexmedetomidine alone from 91.8% to 97.6% (P = 0.009), reducing the requirement for adjuvant pentobarbital in the event of sedation failure with dexmedetomidine alone and decreased the mean recovery time by 10 min (P < 0.001).",18363626_7,0
5554,blood pressures,116,131,"Although dexmedetomidine sedation was associated with a 16% incidence of bradycardia, all concomitant mean arterial blood pressures were within 20% of age-adjusted normal range and oxygen saturations were 95% or higher.",18363626_8,1
1860,dexmedetomidine,9,24,"Although dexmedetomidine sedation was associated with a 16% incidence of bradycardia, all concomitant mean arterial blood pressures were within 20% of age-adjusted normal range and oxygen saturations were 95% or higher.",18363626_8,0
7365,high doses,31,41,CONCLUSION: Dexmedetomidine in high doses provides adequate sedation for pediatric MRI studies.,18363626_9,0
1861,Dexmedetomidine,12,27,CONCLUSION: Dexmedetomidine in high doses provides adequate sedation for pediatric MRI studies.,18363626_9,0
7373,inflammatory arthritis,48,70,Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: A case series from a local surveillance of serious adverse events.,18405372_0,1
1863,sulfasalazine,31,44,Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: A case series from a local surveillance of serious adverse events.,18405372_0,0
7372,Hepatotoxicity,0,14,Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: A case series from a local surveillance of serious adverse events.,18405372_0,1
7376,serious adverse events,115,137,Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: A case series from a local surveillance of serious adverse events.,18405372_0,1
5556,adverse drug reactions,46,68,BACKGROUND: Spontaneous reporting systems for adverse drug reactions (ADRs) are handicapped by under-reporting and limited detail on individual cases.,18405372_1,1
5560,skin rash,21,30,"Seven patients had a skin rash, three eosinophilia and one interstitial nephritis.",18405372_10,1
5561,interstitial nephritis,59,81,"Seven patients had a skin rash, three eosinophilia and one interstitial nephritis.",18405372_10,1
7390,Drug-related hepatotoxicity,0,27,Drug-related hepatotoxicity was judged probable or highly probable in 8 patients.,18405372_13,1
7391,hepatotoxicity,32,46,The likely frequency of serious hepatotoxicity with sulfasalazine was estimated at 0.4% of treated patients.,18405372_14,1
1867,sulfasalazine,52,65,The likely frequency of serious hepatotoxicity with sulfasalazine was estimated at 0.4% of treated patients.,18405372_14,0
7392,hepatotoxicity,20,34,CONCLUSION: Serious hepatotoxicity associated with sulfasalazine appears to be under-appreciated and intensive monitoring and vigilance in the first 6 weeks of treatment is especially important.,18405372_15,1
1868,sulfasalazine,51,64,CONCLUSION: Serious hepatotoxicity associated with sulfasalazine appears to be under-appreciated and intensive monitoring and vigilance in the first 6 weeks of treatment is especially important.,18405372_15,0
1864,disease modifying anti-rheumatic drugs,104,142,We report an investigation from a local surveillance for serious adverse drug reactions associated with disease modifying anti-rheumatic drugs that was triggered by the occurrence of liver failure in two of our patients.,18405372_2,0
5557,adverse drug reactions,65,87,We report an investigation from a local surveillance for serious adverse drug reactions associated with disease modifying anti-rheumatic drugs that was triggered by the occurrence of liver failure in two of our patients.,18405372_2,1
5558,liver failure,183,196,We report an investigation from a local surveillance for serious adverse drug reactions associated with disease modifying anti-rheumatic drugs that was triggered by the occurrence of liver failure in two of our patients.,18405372_2,1
7380,hepatotoxicity,19,33,"Patients', who had hepatotoxicity on sulfasalazine and met a definition of a serious ADR, were identified.",18405372_4,1
1865,sulfasalazine,37,50,"Patients', who had hepatotoxicity on sulfasalazine and met a definition of a serious ADR, were identified.",18405372_4,0
7383,hepatotoxicity,24,38,The likely frequency of hepatotoxicity with sulfasalazine was estimated by making a series of conservative assumptions.,18405372_6,1
1866,sulfasalazine,44,57,The likely frequency of hepatotoxicity with sulfasalazine was estimated by making a series of conservative assumptions.,18405372_6,0
7384,liver transplant,76,92,"Eight patients were hospitalised, two in hepatic failure - one died after a liver transplant.",18405372_8,1
5559,hepatic failure,41,56,"Eight patients were hospitalised, two in hepatic failure - one died after a liver transplant.",18405372_8,1
5562,neurotoxicity,24,37,Methamphetamine-induced neurotoxicity and microglial activation are not mediated by fractalkine receptor signaling.,18410508_0,1
1869,fractalkine receptor,84,104,Methamphetamine-induced neurotoxicity and microglial activation are not mediated by fractalkine receptor signaling.,18410508_0,0
5567,neurotoxicity,76,89,We conclude from these studies that CX3CR1 signaling does not modulate METH neurotoxicity or microglial activation.,18410508_10,1
1877,CX3CR1,36,42,We conclude from these studies that CX3CR1 signaling does not modulate METH neurotoxicity or microglial activation.,18410508_10,0
1870,et,8,10,Cardona et al. [Nat. Neurosci.,18410508_2,0
5563,neurodegeneration,130,147,"9 (2006), 917] recently identified the microglial-specific fractalkine receptor (CX3CR1) as an important mediator of MPTP-induced neurodegeneration of DA neurons.",18410508_3,1
1871,fractalkine receptor,59,79,"9 (2006), 917] recently identified the microglial-specific fractalkine receptor (CX3CR1) as an important mediator of MPTP-induced neurodegeneration of DA neurons.",18410508_3,0
1872,CX3CR1,81,87,"9 (2006), 917] recently identified the microglial-specific fractalkine receptor (CX3CR1) as an important mediator of MPTP-induced neurodegeneration of DA neurons.",18410508_3,0
7396,MPTP,42,46,"Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.",18410508_4,0
5564,neurotoxicity,113,126,"Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.",18410508_4,1
5565,neurotoxicity,189,202,"Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.",18410508_4,1
1873,CX3CR1,153,159,"Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation.",18410508_4,0
7402,striatal neurotoxicity,163,185,Mice in which the CX3CR1 gene has been deleted and replaced with a cDNA encoding enhanced green fluorescent protein (eGFP) were treated with METH and examined for striatal neurotoxicity.,18410508_5,1
7401,eGFP,117,121,Mice in which the CX3CR1 gene has been deleted and replaced with a cDNA encoding enhanced green fluorescent protein (eGFP) were treated with METH and examined for striatal neurotoxicity.,18410508_5,0
1874,green fluorescent protein,90,115,Mice in which the CX3CR1 gene has been deleted and replaced with a cDNA encoding enhanced green fluorescent protein (eGFP) were treated with METH and examined for striatal neurotoxicity.,18410508_5,0
1875,CX3CR1,82,88,"METH depleted DA, caused microglial activation, and increased body temperature in CX3CR1 knockout mice to the same extent and over the same time course seen in wild-type controls.",18410508_6,0
5566,body temperature,62,78,"METH depleted DA, caused microglial activation, and increased body temperature in CX3CR1 knockout mice to the same extent and over the same time course seen in wild-type controls.",18410508_6,1
1876,CX3CR1,23,29,The effects of METH in CX3CR1 knockout mice were not gender-dependent and did not extend beyond the striatum.,18410508_7,0
7410,eGFP,30,34,Striatal microglia expressing eGFP constitutively show morphological changes after METH that are characteristic of activation.,18410508_8,0
7411,eGFP-microglia,86,100,This response was restricted to the striatum and contrasted sharply with unresponsive eGFP-microglia in surrounding brain areas that are not damaged by METH.,18410508_9,0
7416,midpontine,43,53,Nicotine-induced nystagmus correlates with midpontine activation.,18417364_0,0
7415,Nicotine-induced nystagmus,0,26,Nicotine-induced nystagmus correlates with midpontine activation.,18417364_0,1
7417,pathomechanism,4,18,The pathomechanism of nicotine-induced nystagmus (NIN) is unknown.,18417364_1,1
7418,nicotine-induced nystagmus,22,48,The pathomechanism of nicotine-induced nystagmus (NIN) is unknown.,18417364_1,1
7420,brain structures,39,55,The aim of this study was to delineate brain structures that are involved in NIN generation.,18417364_2,1
7421,NIN,77,80,The aim of this study was to delineate brain structures that are involved in NIN generation.,18417364_2,0
7424,eye movements,120,133,Eight healthy volunteers inhaled nicotine in darkness during a functional magnetic resonance imaging (fMRI) experiment; eye movements were registered using video-oculography.,18417364_3,1
7429,posterior basis pontis,100,122,NIN correlated with blood oxygen level-dependent (BOLD) activity levels in a midpontine site in the posterior basis pontis.,18417364_4,1
7428,midpontine,77,87,NIN correlated with blood oxygen level-dependent (BOLD) activity levels in a midpontine site in the posterior basis pontis.,18417364_4,0
5568,pontine,82,89,"NIN-induced midpontine activation may correspond to activation of the dorsomedial pontine nuclei and the nucleus reticularis tegmenti pontis, structures known to participate in the generation of multidirectional saccades and smooth pursuit eye movements.",18417364_5,1
5570,smooth pursuit,225,239,"NIN-induced midpontine activation may correspond to activation of the dorsomedial pontine nuclei and the nucleus reticularis tegmenti pontis, structures known to participate in the generation of multidirectional saccades and smooth pursuit eye movements.",18417364_5,1
7434,tegmenti pontis,125,140,"NIN-induced midpontine activation may correspond to activation of the dorsomedial pontine nuclei and the nucleus reticularis tegmenti pontis, structures known to participate in the generation of multidirectional saccades and smooth pursuit eye movements.",18417364_5,1
5569,multidirectional,195,211,"NIN-induced midpontine activation may correspond to activation of the dorsomedial pontine nuclei and the nucleus reticularis tegmenti pontis, structures known to participate in the generation of multidirectional saccades and smooth pursuit eye movements.",18417364_5,1
7432,dorsomedial,70,81,"NIN-induced midpontine activation may correspond to activation of the dorsomedial pontine nuclei and the nucleus reticularis tegmenti pontis, structures known to participate in the generation of multidirectional saccades and smooth pursuit eye movements.",18417364_5,1
7431,midpontine,12,22,"NIN-induced midpontine activation may correspond to activation of the dorsomedial pontine nuclei and the nucleus reticularis tegmenti pontis, structures known to participate in the generation of multidirectional saccades and smooth pursuit eye movements.",18417364_5,0
7433,nucleus reticularis,105,124,"NIN-induced midpontine activation may correspond to activation of the dorsomedial pontine nuclei and the nucleus reticularis tegmenti pontis, structures known to participate in the generation of multidirectional saccades and smooth pursuit eye movements.",18417364_5,1
7436,hippocampal amino acid neurotransmitters,46,86,Acute effects of N-(2-propylpentanoyl)urea on hippocampal amino acid neurotransmitters in pilocarpine-induced seizure in rats.,18439803_0,0
7435,N-(2-propylpentanoyl)urea,17,42,Acute effects of N-(2-propylpentanoyl)urea on hippocampal amino acid neurotransmitters in pilocarpine-induced seizure in rats.,18439803_0,0
1878,aspartate,159,168,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (VPA).",18439803_1,0
1879,valproic acid,261,274,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (VPA).",18439803_1,0
7440,N-(2-propylpentanoyl)urea (VPU,191,221,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (VPA).",18439803_1,0
7439,hippocampal amino acid neurotransmitters,106,146,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (VPA).",18439803_1,0
7442,VPA,276,279,"The present study aimed to investigate the anticonvulsant activity as well as the effects on the level of hippocampal amino acid neurotransmitters (glutamate, aspartate, glycine and GABA) of N-(2-propylpentanoyl)urea (VPU) in comparison to its parent compound, valproic acid (VPA).",18439803_1,0
7445,ED(50,68,73,"VPU was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced seizure whereas the corresponding value for VPA was 322 mg/kg.",18439803_2,0
7444,VPA,25,28,"VPU was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced seizure whereas the corresponding value for VPA was 322 mg/kg.",18439803_2,0
7443,VPU,0,3,"VPU was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced seizure whereas the corresponding value for VPA was 322 mg/kg.",18439803_2,0
7447,VPA,179,182,"VPU was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced seizure whereas the corresponding value for VPA was 322 mg/kg.",18439803_2,0
5571,hippocampal,123,134,In vivo microdialysis demonstrated that an intraperitoneal administration of pilocarpine induced a pronounced increment of hippocampal glutamate and aspartate whereas no significant change was observed on the level of glycine and GABA.,18439803_3,1
1880,aspartate,149,158,In vivo microdialysis demonstrated that an intraperitoneal administration of pilocarpine induced a pronounced increment of hippocampal glutamate and aspartate whereas no significant change was observed on the level of glycine and GABA.,18439803_3,0
7448,microdialysis,8,21,In vivo microdialysis demonstrated that an intraperitoneal administration of pilocarpine induced a pronounced increment of hippocampal glutamate and aspartate whereas no significant change was observed on the level of glycine and GABA.,18439803_3,1
7449,intraperitoneal,43,58,In vivo microdialysis demonstrated that an intraperitoneal administration of pilocarpine induced a pronounced increment of hippocampal glutamate and aspartate whereas no significant change was observed on the level of glycine and GABA.,18439803_3,1
1881,aspartate,156,165,Pretreatment with either VPU (50 and 100 mg/kg) or VPA (300 and 600 mg/kg) completely abolished pilocarpine-evoked increases in extracellular glutamate and aspartate.,18439803_4,0
7451,VPU,25,28,Pretreatment with either VPU (50 and 100 mg/kg) or VPA (300 and 600 mg/kg) completely abolished pilocarpine-evoked increases in extracellular glutamate and aspartate.,18439803_4,0
7452,VPA,51,54,Pretreatment with either VPU (50 and 100 mg/kg) or VPA (300 and 600 mg/kg) completely abolished pilocarpine-evoked increases in extracellular glutamate and aspartate.,18439803_4,0
7453,extracellular glutamate,128,151,Pretreatment with either VPU (50 and 100 mg/kg) or VPA (300 and 600 mg/kg) completely abolished pilocarpine-evoked increases in extracellular glutamate and aspartate.,18439803_4,0
1882,aspartate,153,162,"In addition, a statistically significant reduction was also observed on the level of GABA and glycine but less than a drastic reduction of glutamate and aspartate level.",18439803_5,0
7456,VPU,26,29,Based on the finding that VPU and VPA could protect the animals against pilocarpine-induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.,18439803_6,0
7457,VPA,34,37,Based on the finding that VPU and VPA could protect the animals against pilocarpine-induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.,18439803_6,0
7459,amino acid neurotransmitters,149,177,Based on the finding that VPU and VPA could protect the animals against pilocarpine-induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.,18439803_6,0
1883,aspartate,256,265,Based on the finding that VPU and VPA could protect the animals against pilocarpine-induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate.,18439803_6,0
7461,VPU,38,41,"Therefore, like VPA, the finding that VPU could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced seizure in experimental animals.",18439803_7,0
7460,VPA,16,19,"Therefore, like VPA, the finding that VPU could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced seizure in experimental animals.",18439803_7,0
1884,aspartate,114,123,"Therefore, like VPA, the finding that VPU could drastically reduce pilocarpine-induced increases in glutamate and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced seizure in experimental animals.",18439803_7,0
5572,atrioventricular block,9,31,Complete atrioventricular block secondary to lithium therapy.,18441470_0,1
5573,Sinus node dysfunction,0,22,Sinus node dysfunction has been reported most frequently among the adverse cardiovascular effects of lithium.,18441470_1,1
7466,adverse cardiovascular effects,67,97,Sinus node dysfunction has been reported most frequently among the adverse cardiovascular effects of lithium.,18441470_1,1
5574,syncopal,63,71,"In the present case, complete atrioventricular (AV) block with syncopal attacks developed secondary to lithium therapy, necessitating permanent pacemaker implantation.",18441470_2,1
5575,syncopal,79,87,Serum lithium levels remained under or within the therapeutic range during the syncopal attacks.,18441470_3,1
7471,mild disturbance,73,89,"Lithium should be used with extreme caution, especially in patients with mild disturbance of AV conduction.",18441470_4,1
7472,AV conduction,93,106,"Lithium should be used with extreme caution, especially in patients with mild disturbance of AV conduction.",18441470_4,1
7473,Protective effect,0,17,Protective effect of verapamil on gastric hemorrhagic ulcers in severe atherosclerotic rats.,18442015_0,0
7474,gastric hemorrhagic ulcers,34,60,Protective effect of verapamil on gastric hemorrhagic ulcers in severe atherosclerotic rats.,18442015_0,1
7475,gastric hemorrhage,40,58,Studies concerning with pathogenesis of gastric hemorrhage and mucosal ulceration produced in atherosclerotic rats are lacking.,18442015_1,1
7476,mucosal ulceration,63,81,Studies concerning with pathogenesis of gastric hemorrhage and mucosal ulceration produced in atherosclerotic rats are lacking.,18442015_1,1
7496,gastric hemorrhage,49,67,"Moreover, a positive correlation of histamine to gastric hemorrhage and to ulcer was found in those atherosclerotic rats.",18442015_10,1
7497,hemorrhagic ulcer,5,22,This hemorrhagic ulcer and various ulcerogenic parameters were dose-dependently ameliorated by daily intragastric verapamil.,18442015_11,1
5583,ulcerogenic,35,46,This hemorrhagic ulcer and various ulcerogenic parameters were dose-dependently ameliorated by daily intragastric verapamil.,18442015_11,1
7501,histamine release,120,137,"Atherosclerosis could produce gastric hemorrhagic ulcer via aggravation of gastric acid back-diffusion, LPO generation, histamine release and microvascular permeability that could be ameliorated by verapamil in rats.",18442015_12,0
7500,LPO,104,107,"Atherosclerosis could produce gastric hemorrhagic ulcer via aggravation of gastric acid back-diffusion, LPO generation, histamine release and microvascular permeability that could be ameliorated by verapamil in rats.",18442015_12,0
7499,gastric hemorrhagic ulcer,30,55,"Atherosclerosis could produce gastric hemorrhagic ulcer via aggravation of gastric acid back-diffusion, LPO generation, histamine release and microvascular permeability that could be ameliorated by verapamil in rats.",18442015_12,1
5584,gastric acid,75,87,"Atherosclerosis could produce gastric hemorrhagic ulcer via aggravation of gastric acid back-diffusion, LPO generation, histamine release and microvascular permeability that could be ameliorated by verapamil in rats.",18442015_12,1
5585,microvascular,142,155,"Atherosclerosis could produce gastric hemorrhagic ulcer via aggravation of gastric acid back-diffusion, LPO generation, histamine release and microvascular permeability that could be ameliorated by verapamil in rats.",18442015_12,1
1886,vitamin D2,280,290,"The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.",18442015_2,0
1885,lipid peroxide,106,120,"The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.",18442015_2,0
5577,microvascular,150,163,"The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.",18442015_2,1
7482,gastric hemorrhage,191,209,"The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.",18442015_2,1
7481,LPO,122,125,"The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.",18442015_2,0
7479,mast cell,77,86,"The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.",18442015_2,1
5576,gastric acid,48,60,"The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol.",18442015_2,1
7483,protective effect,18,35,"Additionally, the protective effect of verapamil on this ulcer model was evaluated.",18442015_3,0
1888,vitamin D2,110,120,Male Wistar rats were challenged intragastrically once daily for 9 days with 1.0 ml/kg of corn oil containing vitamin D2 and cholesterol to induce atherosclerosis.,18442015_4,0
1887,corn oil,90,98,Male Wistar rats were challenged intragastrically once daily for 9 days with 1.0 ml/kg of corn oil containing vitamin D2 and cholesterol to induce atherosclerosis.,18442015_4,0
1889,corn oil,22,30,Control rats received corn oil only.,18442015_5,0
1890,normal saline,98,111,"After gastric surgery, rat stomachs were irrigated for 3 h with either simulated gastric juice or normal saline.",18442015_6,0
7487,simulated gastric juice,71,94,"After gastric surgery, rat stomachs were irrigated for 3 h with either simulated gastric juice or normal saline.",18442015_6,0
7486,gastric surgery,6,21,"After gastric surgery, rat stomachs were irrigated for 3 h with either simulated gastric juice or normal saline.",18442015_6,1
5579,microvascular,78,91,"Gastric acid back-diffusion, mucosal LPO generation, histamine concentration, microvascular permeability, luminal hemoglobin content and ulcer areas were determined.",18442015_7,1
5578,Gastric acid,0,12,"Gastric acid back-diffusion, mucosal LPO generation, histamine concentration, microvascular permeability, luminal hemoglobin content and ulcer areas were determined.",18442015_7,1
7488,LPO,37,40,"Gastric acid back-diffusion, mucosal LPO generation, histamine concentration, microvascular permeability, luminal hemoglobin content and ulcer areas were determined.",18442015_7,0
7492,total cholesterol,60,77,"Elevated atherosclerotic parameters, such as serum calcium, total cholesterol and low-density lipoprotein concentration were obtained in atherosclerotic rats.",18442015_8,0
7491,serum calcium,45,58,"Elevated atherosclerotic parameters, such as serum calcium, total cholesterol and low-density lipoprotein concentration were obtained in atherosclerotic rats.",18442015_8,0
1891,low-density lipoprotein,82,105,"Elevated atherosclerotic parameters, such as serum calcium, total cholesterol and low-density lipoprotein concentration were obtained in atherosclerotic rats.",18442015_8,0
5580,gastric ulcers,7,21,"Severe gastric ulcers accompanied with increased ulcerogenic factors, including gastric acid back-diffusion, histamine release, LPO generation and luminal hemoglobin content were also observed in these rats.",18442015_9,1
7494,LPO,128,131,"Severe gastric ulcers accompanied with increased ulcerogenic factors, including gastric acid back-diffusion, histamine release, LPO generation and luminal hemoglobin content were also observed in these rats.",18442015_9,0
5581,ulcerogenic,49,60,"Severe gastric ulcers accompanied with increased ulcerogenic factors, including gastric acid back-diffusion, histamine release, LPO generation and luminal hemoglobin content were also observed in these rats.",18442015_9,1
5582,gastric acid,80,92,"Severe gastric ulcers accompanied with increased ulcerogenic factors, including gastric acid back-diffusion, histamine release, LPO generation and luminal hemoglobin content were also observed in these rats.",18442015_9,1
1893,HBSAG,96,101,Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.,18464113_0,0
1892,surface antigen,79,94,Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.,18464113_0,0
7506,HBV,19,22,Hepatitis B virus (HBV) is one of the major causes of chronic liver disease worldwide.,18464113_1,0
7507,chronic liver disease,54,75,Hepatitis B virus (HBV) is one of the major causes of chronic liver disease worldwide.,18464113_1,1
1894,alanine aminotransferase,69,93,Comparison of the mean ALT values revealed significantly higher mean alanine aminotransferase (ALT) values in the control group than the prophylactic lamivudine group; 154:64 (p < 0.32).,18464113_13,0
7521,prophylactic lamivudine,24,47,Our study suggests that prophylactic lamivudine significantly decreases the incidence of HBV reactivation and overall morbidity in cancer patients during and after immunosuppressive therapy.,18464113_14,0
7523,nucleotide analogue,75,94,Further studies are needed to determine the most appropriate nucleoside or nucleotide analogue for antiviral prophylaxis during CT and the optimal duration of administration after completion of CT.,18464113_15,0
7524,antiviral prophylaxis,99,120,Further studies are needed to determine the most appropriate nucleoside or nucleotide analogue for antiviral prophylaxis during CT and the optimal duration of administration after completion of CT.,18464113_15,0
7510,hepatic complication,62,82,Cancer patients who are chronic carriers of HBV have a higher hepatic complication rate while receiving cytotoxic chemotherapy (CT) and this has mainly been attributed to HBV reactivation.,18464113_2,1
7509,HBV,44,47,Cancer patients who are chronic carriers of HBV have a higher hepatic complication rate while receiving cytotoxic chemotherapy (CT) and this has mainly been attributed to HBV reactivation.,18464113_2,0
5586,hematological malignancies,50,76,"In this study, cancer patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive lamivudine.",18464113_3,1
7513,antiviral agent lamivudine,117,143,"In this study, cancer patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive lamivudine.",18464113_3,0
7515,prophylactic lamivudin group,4,32,The prophylactic lamivudin group consisted of 37 patients who received prophylactic lamivudine treatment.,18464113_6,0
7517,prophylactic lamivudine,86,109,The historical controls consisted of 50 consecutive patients who underwent CT without prophylactic lamivudine.,18464113_7,0
7527,(CYP)-induced cystitis,131,153,Exaggerated expression of inflammatory mediators in vasoactive intestinal polypeptide knockout (VIP-/-) mice with cyclophosphamide (CYP)-induced cystitis.,18483878_0,1
7526,cyclophosphamide,114,130,Exaggerated expression of inflammatory mediators in vasoactive intestinal polypeptide knockout (VIP-/-) mice with cyclophosphamide (CYP)-induced cystitis.,18483878_0,0
7525,inflammatory mediators,26,48,Exaggerated expression of inflammatory mediators in vasoactive intestinal polypeptide knockout (VIP-/-) mice with cyclophosphamide (CYP)-induced cystitis.,18483878_0,0
1895,vasoactive intestinal polypeptide,52,85,Exaggerated expression of inflammatory mediators in vasoactive intestinal polypeptide knockout (VIP-/-) mice with cyclophosphamide (CYP)-induced cystitis.,18483878_0,0
1896,Vasoactive intestinal polypeptide,0,33,Vasoactive intestinal polypeptide (VIP) is an immunomodulatory neuropeptide distributed in micturition pathways.,18483878_1,0
7528,immunomodulatory neuropeptide,46,75,Vasoactive intestinal polypeptide (VIP) is an immunomodulatory neuropeptide distributed in micturition pathways.,18483878_1,0
7566,VIP(-/-),73,81,This shift in balance may contribute to increased bladder dysfunction in VIP(-/-) mice with bladder inflammation and altered neurochemical expression in micturition pathways.,18483878_10,0
7565,bladder dysfunction,50,69,This shift in balance may contribute to increased bladder dysfunction in VIP(-/-) mice with bladder inflammation and altered neurochemical expression in micturition pathways.,18483878_10,1
7530,VIP(-/-),0,8,VIP(-/-) mice exhibit altered bladder function and neurochemical properties in micturition pathways after cyclophosphamide (CYP)-induced cystitis.,18483878_2,0
7531,bladder function,30,46,VIP(-/-) mice exhibit altered bladder function and neurochemical properties in micturition pathways after cyclophosphamide (CYP)-induced cystitis.,18483878_2,1
7533,cyclophosphamide,106,122,VIP(-/-) mice exhibit altered bladder function and neurochemical properties in micturition pathways after cyclophosphamide (CYP)-induced cystitis.,18483878_2,0
7538,inflammatory mediator,109,130,"Given VIP's role as an anti-inflammatory mediator, we hypothesized that VIP(-/-) mice would exhibit enhanced inflammatory mediator expression after cystitis.",18483878_3,0
7537,VIP(-/-),72,80,"Given VIP's role as an anti-inflammatory mediator, we hypothesized that VIP(-/-) mice would exhibit enhanced inflammatory mediator expression after cystitis.",18483878_3,0
7536,anti-inflammatory mediator,23,49,"Given VIP's role as an anti-inflammatory mediator, we hypothesized that VIP(-/-) mice would exhibit enhanced inflammatory mediator expression after cystitis.",18483878_3,0
7535,VIP's,6,11,"Given VIP's role as an anti-inflammatory mediator, we hypothesized that VIP(-/-) mice would exhibit enhanced inflammatory mediator expression after cystitis.",18483878_3,0
5587,urinary bladder,113,128,A mouse inflammatory cytokine and receptor RT2 profiler array was used to determine regulated transcripts in the urinary bladder of wild type (WT) and VIP(-/-) mice with or without CYP-induced cystitis (150 mg/kg; i.p.; 48 h).,18483878_4,1
7550,CYP,169,172,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,0
7544,CYP,53,56,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,0
7552,CYP,211,214,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,0
7551,VIP(-/-),197,205,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,0
7545,VIP(-/-),75,83,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,0
7546,CYP,99,102,"Four binary comparisons were made: WT control versus CYP treatment (48 h), VIP(-/-) control versus CYP treatment (48 h), WT control versus VIP(-/-) control, and WT with CYP treatment (48 h) versus VIP(-/-) with CYP treatment (48 h).",18483878_5,0
1898,(2,87,89,The genes presented represent (1) greater than 1.5-fold change in either direction and (2) the p value is less than 0.05 for the comparison being made.,18483878_6,0
1897,(1,30,32,The genes presented represent (1) greater than 1.5-fold change in either direction and (2) the p value is less than 0.05 for the comparison being made.,18483878_6,0
1899,IL-1beta,82,90,Several regulated genes were validated using enzyme-linked immunoassays including IL-1beta and CXCL1.,18483878_7,0
1900,CXCL1,95,100,Several regulated genes were validated using enzyme-linked immunoassays including IL-1beta and CXCL1.,18483878_7,0
7554,CYP,0,3,"CYP treatment significantly (p < or = 0.001) increased expression of CXCL1 and IL-1beta in the urinary bladder of WT and VIP(-/-) mice, but expression in VIP(-/-) mice with CYP treatment was significantly (p < or = 0.001) greater (4.2- to 13-fold increase) than that observed in WT urinary bladder (3.6- to 5-fold increase).",18483878_8,0
7556,VIP(-/-),121,129,"CYP treatment significantly (p < or = 0.001) increased expression of CXCL1 and IL-1beta in the urinary bladder of WT and VIP(-/-) mice, but expression in VIP(-/-) mice with CYP treatment was significantly (p < or = 0.001) greater (4.2- to 13-fold increase) than that observed in WT urinary bladder (3.6- to 5-fold increase).",18483878_8,0
1901,CXCL1,69,74,"CYP treatment significantly (p < or = 0.001) increased expression of CXCL1 and IL-1beta in the urinary bladder of WT and VIP(-/-) mice, but expression in VIP(-/-) mice with CYP treatment was significantly (p < or = 0.001) greater (4.2- to 13-fold increase) than that observed in WT urinary bladder (3.6- to 5-fold increase).",18483878_8,0
7557,VIP(-/-),154,162,"CYP treatment significantly (p < or = 0.001) increased expression of CXCL1 and IL-1beta in the urinary bladder of WT and VIP(-/-) mice, but expression in VIP(-/-) mice with CYP treatment was significantly (p < or = 0.001) greater (4.2- to 13-fold increase) than that observed in WT urinary bladder (3.6- to 5-fold increase).",18483878_8,0
1902,IL-1beta,79,87,"CYP treatment significantly (p < or = 0.001) increased expression of CXCL1 and IL-1beta in the urinary bladder of WT and VIP(-/-) mice, but expression in VIP(-/-) mice with CYP treatment was significantly (p < or = 0.001) greater (4.2- to 13-fold increase) than that observed in WT urinary bladder (3.6- to 5-fold increase).",18483878_8,0
7558,CYP,173,176,"CYP treatment significantly (p < or = 0.001) increased expression of CXCL1 and IL-1beta in the urinary bladder of WT and VIP(-/-) mice, but expression in VIP(-/-) mice with CYP treatment was significantly (p < or = 0.001) greater (4.2- to 13-fold increase) than that observed in WT urinary bladder (3.6- to 5-fold increase).",18483878_8,0
7559,WT urinary bladder,279,297,"CYP treatment significantly (p < or = 0.001) increased expression of CXCL1 and IL-1beta in the urinary bladder of WT and VIP(-/-) mice, but expression in VIP(-/-) mice with CYP treatment was significantly (p < or = 0.001) greater (4.2- to 13-fold increase) than that observed in WT urinary bladder (3.6- to 5-fold increase).",18483878_8,1
5588,urinary bladder,95,110,"CYP treatment significantly (p < or = 0.001) increased expression of CXCL1 and IL-1beta in the urinary bladder of WT and VIP(-/-) mice, but expression in VIP(-/-) mice with CYP treatment was significantly (p < or = 0.001) greater (4.2- to 13-fold increase) than that observed in WT urinary bladder (3.6- to 5-fold increase).",18483878_8,1
7560,VIP(-/-),25,33,"The data suggest that in VIP(-/-) mice with bladder inflammation, inflammatory mediators are increased above that observed in WT with CYP.",18483878_9,0
7564,CYP,134,137,"The data suggest that in VIP(-/-) mice with bladder inflammation, inflammatory mediators are increased above that observed in WT with CYP.",18483878_9,0
7562,inflammatory mediators,66,88,"The data suggest that in VIP(-/-) mice with bladder inflammation, inflammatory mediators are increased above that observed in WT with CYP.",18483878_9,0
7561,bladder inflammation,44,64,"The data suggest that in VIP(-/-) mice with bladder inflammation, inflammatory mediators are increased above that observed in WT with CYP.",18483878_9,1
1903,Debrisoquine,0,12,Debrisoquine phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of metoprolol and its enantiomers.,1848636_0,0
1904,beta-2,52,58,Debrisoquine phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of metoprolol and its enantiomers.,1848636_0,0
7569,cardioselective beta-blocker,22,50,The metabolism of the cardioselective beta-blocker metoprolol is under genetic control of the debrisoquine/sparteine type.,1848636_1,0
7589,unchanged drug,105,119,Higher metoprolol/alpha-hydroxymetoprolol ratios in PMs were predictive for higher R-/S-isomer ratios of unchanged drug.,1848636_10,0
7588,metoprolol/alpha-hydroxymetoprolol,7,41,Higher metoprolol/alpha-hydroxymetoprolol ratios in PMs were predictive for higher R-/S-isomer ratios of unchanged drug.,1848636_10,0
7592,ng.ml-1,105,112,"There was a difference in metoprolol potency with higher racemic metoprolol IC50 values in PMs (72 +/- 7 ng.ml-1) than EMs (42 +/- 8 ng.ml-1, P less than .001).(ABSTRACT TRUNCATED AT 250 WORDS)",1848636_11,0
7590,IC50,76,80,"There was a difference in metoprolol potency with higher racemic metoprolol IC50 values in PMs (72 +/- 7 ng.ml-1) than EMs (42 +/- 8 ng.ml-1, P less than .001).(ABSTRACT TRUNCATED AT 250 WORDS)",1848636_11,0
1911,racemic,57,64,"There was a difference in metoprolol potency with higher racemic metoprolol IC50 values in PMs (72 +/- 7 ng.ml-1) than EMs (42 +/- 8 ng.ml-1, P less than .001).(ABSTRACT TRUNCATED AT 250 WORDS)",1848636_11,0
7573,beta-1 adrenoceptor antagonistic potency,147,187,"The two metabolic phenotypes, extensive (EM) and poor metabolizers (PM), show different stereoselective metabolism, resulting in apparently higher beta-1 adrenoceptor antagonistic potency of racemic metoprolol in EMs.",1848636_2,0
1905,racemic,191,198,"The two metabolic phenotypes, extensive (EM) and poor metabolizers (PM), show different stereoselective metabolism, resulting in apparently higher beta-1 adrenoceptor antagonistic potency of racemic metoprolol in EMs.",1848636_2,0
7574,beta-2 adrenoceptor,50,69,We investigated if the latter also applies to the beta-2 adrenoceptor antagonism by metoprolol.,1848636_3,0
1907,S-isomer,108,116,"By using pharmacokinetic pharmacodynamic modeling the pharmacodynamics of racemic metoprolol and the active S-isomer, were quantitated in EMs and PMs in terms of IC50 values, representing metoprolol plasma concentrations resulting in half-maximum receptor occupancy.",1848636_5,0
1906,racemic,74,81,"By using pharmacokinetic pharmacodynamic modeling the pharmacodynamics of racemic metoprolol and the active S-isomer, were quantitated in EMs and PMs in terms of IC50 values, representing metoprolol plasma concentrations resulting in half-maximum receptor occupancy.",1848636_5,0
7579,IC50,162,166,"By using pharmacokinetic pharmacodynamic modeling the pharmacodynamics of racemic metoprolol and the active S-isomer, were quantitated in EMs and PMs in terms of IC50 values, representing metoprolol plasma concentrations resulting in half-maximum receptor occupancy.",1848636_5,0
7581,terbutaline,27,38,Six EMs received 0.5 mg of terbutaline s.c. on two different occasions: 1) 1 hr after administration of a placebo and 2) 1 hr after 150 mg of metoprolol p.o.,1848636_6,0
7582,terbutaline dose,74,90,"Five PMs were studied according to the same protocol, except for a higher terbutaline dose (0.75 mg) on day 2.",1848636_7,0
1909,R-,86,88,"Blood samples for the analysis of plasma potassium, terbutaline, metoprolol (racemic, R- and S-isomer), and alpha-hydroxymetoprolol concentrations were taken at regular time intervals, during 8 hr after metoprolol.",1848636_8,0
1910,S-isomer,93,101,"Blood samples for the analysis of plasma potassium, terbutaline, metoprolol (racemic, R- and S-isomer), and alpha-hydroxymetoprolol concentrations were taken at regular time intervals, during 8 hr after metoprolol.",1848636_8,0
7585,alpha-hydroxymetoprolol,108,131,"Blood samples for the analysis of plasma potassium, terbutaline, metoprolol (racemic, R- and S-isomer), and alpha-hydroxymetoprolol concentrations were taken at regular time intervals, during 8 hr after metoprolol.",1848636_8,0
7584,terbutaline,52,63,"Blood samples for the analysis of plasma potassium, terbutaline, metoprolol (racemic, R- and S-isomer), and alpha-hydroxymetoprolol concentrations were taken at regular time intervals, during 8 hr after metoprolol.",1848636_8,0
1908,racemic,77,84,"Blood samples for the analysis of plasma potassium, terbutaline, metoprolol (racemic, R- and S-isomer), and alpha-hydroxymetoprolol concentrations were taken at regular time intervals, during 8 hr after metoprolol.",1848636_8,0
7587,(+,96,98,"In PMs, metoprolol increased the terbutaline area under the plasma concentration vs. time curve (+67%).",1848636_9,0
7586,terbutaline,33,44,"In PMs, metoprolol increased the terbutaline area under the plasma concentration vs. time curve (+67%).",1848636_9,0
1912,everolimus,72,82,Recovery of tacrolimus-associated brachial neuritis after conversion to everolimus in a pediatric renal transplant recipient--case report and review of the literature.,18503483_0,0
5589,brachial neuritis,34,51,Recovery of tacrolimus-associated brachial neuritis after conversion to everolimus in a pediatric renal transplant recipient--case report and review of the literature.,18503483_0,1
7595,pediatric renal transplant,88,114,Recovery of tacrolimus-associated brachial neuritis after conversion to everolimus in a pediatric renal transplant recipient--case report and review of the literature.,18503483_0,1
1913,immunosuppressive agent,34,57,TAC has been shown to be a potent immunosuppressive agent for solid organ transplantation in pediatrics.,18503483_1,0
7598,solid organ transplantation,62,89,TAC has been shown to be a potent immunosuppressive agent for solid organ transplantation in pediatrics.,18503483_1,1
7597,TAC,0,3,TAC has been shown to be a potent immunosuppressive agent for solid organ transplantation in pediatrics.,18503483_1,0
5590,Neurotoxicity,0,13,Neurotoxicity is a potentially serious toxic effect.,18503483_2,1
7599,neurological deficits,63,84,"It is characterized by encephalopathy, headaches, seizures, or neurological deficits.",18503483_3,1
7600,renal transplant,50,66,"Here, we describe an eight-and-a-half-yr-old male renal transplant recipient with right BN.",18503483_4,1
7601,BN,88,90,"Here, we describe an eight-and-a-half-yr-old male renal transplant recipient with right BN.",18503483_4,0
5591,brachial plexus,72,87,MRI demonstrated hyperintense T2 signals in the cervical cord and right brachial plexus roots indicative of both myelitis and right brachial plexitis.,18503483_5,1
1914,T2,30,32,MRI demonstrated hyperintense T2 signals in the cervical cord and right brachial plexus roots indicative of both myelitis and right brachial plexitis.,18503483_5,0
7602,cervical cord,48,61,MRI demonstrated hyperintense T2 signals in the cervical cord and right brachial plexus roots indicative of both myelitis and right brachial plexitis.,18503483_5,1
7603,right brachial plexitis,126,149,MRI demonstrated hyperintense T2 signals in the cervical cord and right brachial plexus roots indicative of both myelitis and right brachial plexitis.,18503483_5,1
1916,methylprednisolone,105,123,"Symptoms persisted for three months despite TAC dose reduction, administration of IVIG and four doses of methylprednisolone pulse therapy.",18503483_6,0
1915,IVIG,82,86,"Symptoms persisted for three months despite TAC dose reduction, administration of IVIG and four doses of methylprednisolone pulse therapy.",18503483_6,0
7604,TAC,44,47,"Symptoms persisted for three months despite TAC dose reduction, administration of IVIG and four doses of methylprednisolone pulse therapy.",18503483_6,0
7605,TAC,61,64,Improvement and eventually full recovery only occurred after TAC was completely discontinued and successfully replaced by everolimus.,18503483_7,0
1917,everolimus,122,132,Improvement and eventually full recovery only occurred after TAC was completely discontinued and successfully replaced by everolimus.,18503483_7,0
1918,vasoactive,39,49,The hemodynamics of oxytocin and other vasoactive agents during neuraxial anesthesia for cesarean delivery: findings in six cases.,18513945_0,0
7607,cesarean delivery,89,106,The hemodynamics of oxytocin and other vasoactive agents during neuraxial anesthesia for cesarean delivery: findings in six cases.,18513945_0,1
7608,uterotonic,28,38,"Oxytocin is a commonly used uterotonic that can cause significant and even fatal hypotension, particularly when given as a bolus.",18513945_1,0
7609,systemic vascular resistance,59,87,The resulting hypotension can be produced by a decrease in systemic vascular resistance or cardiac output through a decrease in venous return.,18513945_2,1
7610,venous return,128,141,The resulting hypotension can be produced by a decrease in systemic vascular resistance or cardiac output through a decrease in venous return.,18513945_2,1
5592,cardiac output,91,105,The resulting hypotension can be produced by a decrease in systemic vascular resistance or cardiac output through a decrease in venous return.,18513945_2,1
7611,Parturients,0,11,"Parturients with normal volume status, heart valves and pulmonary vasculature most often respond to this hypotension with a compensatory increase in heart rate and stroke volume.",18513945_3,0
7614,pulmonary vasculature,56,77,"Parturients with normal volume status, heart valves and pulmonary vasculature most often respond to this hypotension with a compensatory increase in heart rate and stroke volume.",18513945_3,1
7615,heart rate,149,159,"Parturients with normal volume status, heart valves and pulmonary vasculature most often respond to this hypotension with a compensatory increase in heart rate and stroke volume.",18513945_3,1
5593,compensatory,124,136,"Parturients with normal volume status, heart valves and pulmonary vasculature most often respond to this hypotension with a compensatory increase in heart rate and stroke volume.",18513945_3,1
7613,heart valves,39,51,"Parturients with normal volume status, heart valves and pulmonary vasculature most often respond to this hypotension with a compensatory increase in heart rate and stroke volume.",18513945_3,1
7616,cesarean delivery,32,49,Oxytocin-induced hypotension at cesarean delivery may be incorrectly attributed to blood loss.,18513945_4,1
5594,blood loss,83,93,Oxytocin-induced hypotension at cesarean delivery may be incorrectly attributed to blood loss.,18513945_4,1
7618,systemic vascular resistance,126,154,"Pulse power analysis (also called ""pulse contour analysis"") of an arterial pressure wave form allows continuous evaluation of systemic vascular resistance and cardiac output in real time, thereby elucidating the causative factors behind changes in blood pressure.",18513945_5,1
7617,arterial pressure,66,83,"Pulse power analysis (also called ""pulse contour analysis"") of an arterial pressure wave form allows continuous evaluation of systemic vascular resistance and cardiac output in real time, thereby elucidating the causative factors behind changes in blood pressure.",18513945_5,1
5596,blood pressure,248,262,"Pulse power analysis (also called ""pulse contour analysis"") of an arterial pressure wave form allows continuous evaluation of systemic vascular resistance and cardiac output in real time, thereby elucidating the causative factors behind changes in blood pressure.",18513945_5,1
5595,cardiac output,159,173,"Pulse power analysis (also called ""pulse contour analysis"") of an arterial pressure wave form allows continuous evaluation of systemic vascular resistance and cardiac output in real time, thereby elucidating the causative factors behind changes in blood pressure.",18513945_5,1
7620,cesarean delivery,51,68,Pulse power analysis was conducted in six cases of cesarean delivery performed under neuraxial anesthesia.,18513945_6,1
5598,cardiac output,160,174,"Hypotension in response to oxytocin was associated with a decrease in systemic vascular resistance and a compensatory increase in stroke volume, heart rate and cardiac output.",18513945_7,1
7623,systemic vascular resistance,70,98,"Hypotension in response to oxytocin was associated with a decrease in systemic vascular resistance and a compensatory increase in stroke volume, heart rate and cardiac output.",18513945_7,1
5597,compensatory,105,117,"Hypotension in response to oxytocin was associated with a decrease in systemic vascular resistance and a compensatory increase in stroke volume, heart rate and cardiac output.",18513945_7,1
7624,heart rate,145,155,"Hypotension in response to oxytocin was associated with a decrease in systemic vascular resistance and a compensatory increase in stroke volume, heart rate and cardiac output.",18513945_7,1
7625,cesarean delivery,99,116,Pulse power analysis may be helpful in determining the etiology of and treating hypotension during cesarean delivery under neuraxial anesthesia.,18513945_8,1
1920,puromycin aminonucleoside,38,63,Protective effects of antithrombin on puromycin aminonucleoside nephrosis in rats.,18541230_0,0
1919,antithrombin,22,34,Protective effects of antithrombin on puromycin aminonucleoside nephrosis in rats.,18541230_0,0
7627,Protective effects,0,18,Protective effects of antithrombin on puromycin aminonucleoside nephrosis in rats.,18541230_0,0
5599,nephrotic syndrome,186,204,"We investigated the effects of antithrombin, a plasma inhibitor of coagulation factors, in rats with puromycin aminonucleoside-induced nephrosis, which is an experimental model of human nephrotic syndrome.",18541230_1,1
1923,puromycin,101,110,"We investigated the effects of antithrombin, a plasma inhibitor of coagulation factors, in rats with puromycin aminonucleoside-induced nephrosis, which is an experimental model of human nephrotic syndrome.",18541230_1,0
1921,antithrombin,31,43,"We investigated the effects of antithrombin, a plasma inhibitor of coagulation factors, in rats with puromycin aminonucleoside-induced nephrosis, which is an experimental model of human nephrotic syndrome.",18541230_1,0
1922,coagulation factors,67,86,"We investigated the effects of antithrombin, a plasma inhibitor of coagulation factors, in rats with puromycin aminonucleoside-induced nephrosis, which is an experimental model of human nephrotic syndrome.",18541230_1,0
7629,plasma inhibitor,47,63,"We investigated the effects of antithrombin, a plasma inhibitor of coagulation factors, in rats with puromycin aminonucleoside-induced nephrosis, which is an experimental model of human nephrotic syndrome.",18541230_1,0
1924,Antithrombin,0,12,Antithrombin (50 or 500 IU/kg/i.v.) was administered to rats once a day for 10 days immediately after the injection of puromycin aminonucleoside (50 mg/kg/i.v.).,18541230_2,0
1925,puromycin aminonucleoside,119,144,Antithrombin (50 or 500 IU/kg/i.v.) was administered to rats once a day for 10 days immediately after the injection of puromycin aminonucleoside (50 mg/kg/i.v.).,18541230_2,0
1926,antithrombin,15,27,Treatment with antithrombin attenuated the puromycin aminonucleoside-induced hematological abnormalities.,18541230_3,0
1927,puromycin,43,52,Treatment with antithrombin attenuated the puromycin aminonucleoside-induced hematological abnormalities.,18541230_3,0
7633,renal dysfunction,34,51,Puromycin aminonucleoside-induced renal dysfunction and hyperlipidemia were also suppressed.,18541230_4,1
1928,Puromycin,0,9,Puromycin aminonucleoside-induced renal dysfunction and hyperlipidemia were also suppressed.,18541230_4,0
7636,tubuli,90,96,"Histopathological examination revealed severe renal damage such as proteinaceous casts in tubuli and tubular expansion in the kidney of control rats, while an improvement of the damage was seen in antithrombin-treated rats.",18541230_5,1
7635,renal damage,46,58,"Histopathological examination revealed severe renal damage such as proteinaceous casts in tubuli and tubular expansion in the kidney of control rats, while an improvement of the damage was seen in antithrombin-treated rats.",18541230_5,1
7639,renal tubular epithelial cells,103,133,"In addition, antithrombin treatment markedly suppressed puromycin aminonucleoside-induced apoptosis of renal tubular epithelial cells.",18541230_6,1
1930,puromycin,56,65,"In addition, antithrombin treatment markedly suppressed puromycin aminonucleoside-induced apoptosis of renal tubular epithelial cells.",18541230_6,0
1929,antithrombin,13,25,"In addition, antithrombin treatment markedly suppressed puromycin aminonucleoside-induced apoptosis of renal tubular epithelial cells.",18541230_6,0
1931,puromycin,13,22,"Furthermore, puromycin aminonucleoside-induced increases in renal cytokine content were also decreased.",18541230_7,0
1932,puromycin,84,93,These findings suggest that thrombin plays an important role in the pathogenesis of puromycin aminonucleoside-induced nephrotic syndrome.,18541230_8,0
5600,nephrotic syndrome,118,136,These findings suggest that thrombin plays an important role in the pathogenesis of puromycin aminonucleoside-induced nephrotic syndrome.,18541230_8,1
1933,antithrombin,15,27,Treatment with antithrombin may be clinically effective in patients with nephrotic syndrome.,18541230_9,0
5601,nephrotic syndrome,73,91,Treatment with antithrombin may be clinically effective in patients with nephrotic syndrome.,18541230_9,1
1934,sevoflurane,78,89,"Omitting fentanyl reduces nausea and vomiting, without increasing pain, after sevoflurane for day surgery.",18544179_0,0
5602,nausea and vomiting,26,45,"Omitting fentanyl reduces nausea and vomiting, without increasing pain, after sevoflurane for day surgery.",18544179_0,1
5603,postoperative nausea and vomiting,107,140,"BACKGROUND AND OBJECTIVE: Despite advantages of induction and maintenance of anaesthesia with sevoflurane, postoperative nausea and vomiting occurs frequently.",18544179_1,1
1935,sevoflurane,94,105,"BACKGROUND AND OBJECTIVE: Despite advantages of induction and maintenance of anaesthesia with sevoflurane, postoperative nausea and vomiting occurs frequently.",18544179_1,0
5609,respiratory depression,102,124,"Fentanyl did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, hypotension and bradycardia.",18544179_10,1
5608,intraoperative,26,40,"Fentanyl did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, hypotension and bradycardia.",18544179_10,1
5611,postoperative pain,96,114,"CONCLUSION: As fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery.",18544179_11,1
5610,postoperative nausea and vomiting,36,69,"CONCLUSION: As fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery.",18544179_11,1
7647,day surgery,249,260,"CONCLUSION: As fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery.",18544179_11,1
1938,sevoflurane,234,245,"CONCLUSION: As fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery.",18544179_11,0
7646,adverse cardiorespiratory effects,128,161,"CONCLUSION: As fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery.",18544179_11,1
1936,sevoflurane,139,150,METHODS: This double-blind study examined the incidence and severity of postoperative nausea and vomiting and pain in the first 24 h after sevoflurane anaesthesia in 216 adult day surgery patients.,18544179_3,0
5604,postoperative nausea and vomiting,72,105,METHODS: This double-blind study examined the incidence and severity of postoperative nausea and vomiting and pain in the first 24 h after sevoflurane anaesthesia in 216 adult day surgery patients.,18544179_3,1
5605,postoperative nausea and vomiting,70,103,"RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).",18544179_5,1
7642,fentanyl-dexamethasone,233,255,"RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl-dexamethasone, respectively, to 5% (P = 0.013).",18544179_5,0
5606,postoperative nausea and vomiting,72,105,Dexamethasone had no significant effect on the incidence or severity of postoperative nausea and vomiting.,18544179_7,1
1937,opioids,94,101,"Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids, reducing postoperative nausea and vomiting and nausea prior to discharge from 35% and 33% to 22% and 19% (P = 0.049 and P = 0.035), respectively, while nausea in the first 24 h was decreased from 42% to 27% (P = 0.034).",18544179_8,0
5607,postoperative nausea and vomiting,112,145,"Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids, reducing postoperative nausea and vomiting and nausea prior to discharge from 35% and 33% to 22% and 19% (P = 0.049 and P = 0.035), respectively, while nausea in the first 24 h was decreased from 42% to 27% (P = 0.034).",18544179_8,1
7644,Pain severity,0,13,Pain severity and analgesic requirements were unaffected by the omission of fentanyl.,18544179_9,1
5613,Parkinson's disease,40,59,Valvular heart disease in patients with Parkinson's disease treated with pergolide.,18560792_0,1
5612,Valvular heart disease,0,22,Valvular heart disease in patients with Parkinson's disease treated with pergolide.,18560792_0,1
1939,pergolide,73,82,Valvular heart disease in patients with Parkinson's disease treated with pergolide.,18560792_0,0
1943,pergolide,150,159,"The number of affected valves (n=2.4+/-0.7) and the sum of regurgitation grades (n=2.8+/-1.09) were higher (p=0.008 and p=0.006, respectively) in the pergolide group.",18560792_10,0
7656,regurgitation grades,59,79,"The number of affected valves (n=2.4+/-0.7) and the sum of regurgitation grades (n=2.8+/-1.09) were higher (p=0.008 and p=0.006, respectively) in the pergolide group.",18560792_10,1
7657,pergolide cumulative dose,50,75,Severity of regurgitation was not correlated with pergolide cumulative dose.,18560792_11,0
7658,valvular regurgitation,25,47,"A restrictive pattern of valvular regurgitation, suggestive of the role of pergolide, was observed in 12/30 (40%) patients including two with heart failure.",18560792_12,1
5621,heart failure,142,155,"A restrictive pattern of valvular regurgitation, suggestive of the role of pergolide, was observed in 12/30 (40%) patients including two with heart failure.",18560792_12,1
1944,pergolide,75,84,"A restrictive pattern of valvular regurgitation, suggestive of the role of pergolide, was observed in 12/30 (40%) patients including two with heart failure.",18560792_12,0
5623,heart failure,192,205,"Pergolide was discontinued in 10 patients with valvular heart disease, resulting in a lower regurgitation grade (p=0.01) at the second transthoracic echocardiography and the two patients with heart failure returned to nearly normal clinical examination.",18560792_13,1
7659,regurgitation grade,92,111,"Pergolide was discontinued in 10 patients with valvular heart disease, resulting in a lower regurgitation grade (p=0.01) at the second transthoracic echocardiography and the two patients with heart failure returned to nearly normal clinical examination.",18560792_13,1
5622,valvular heart disease,47,69,"Pergolide was discontinued in 10 patients with valvular heart disease, resulting in a lower regurgitation grade (p=0.01) at the second transthoracic echocardiography and the two patients with heart failure returned to nearly normal clinical examination.",18560792_13,1
1945,Pergolide,0,9,"Pergolide was discontinued in 10 patients with valvular heart disease, resulting in a lower regurgitation grade (p=0.01) at the second transthoracic echocardiography and the two patients with heart failure returned to nearly normal clinical examination.",18560792_13,0
1946,pergolide,102,111,This study supports the high frequency of restrictive valve regurgitation in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot dopamine agonists.,18560792_14,0
5624,high frequency,24,38,This study supports the high frequency of restrictive valve regurgitation in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot dopamine agonists.,18560792_14,1
5625,valve regurgitation,54,73,This study supports the high frequency of restrictive valve regurgitation in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot dopamine agonists.,18560792_14,1
7662,non-ergot dopamine agonists,199,226,This study supports the high frequency of restrictive valve regurgitation in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot dopamine agonists.,18560792_14,0
5615,Parkinson's disease,65,84,Valvular heart abnormalities have been reported in patients with Parkinson's disease (PD) treated with pergolide.,18560792_2,1
1940,pergolide,103,112,Valvular heart abnormalities have been reported in patients with Parkinson's disease (PD) treated with pergolide.,18560792_2,0
5614,heart abnormalities,9,28,Valvular heart abnormalities have been reported in patients with Parkinson's disease (PD) treated with pergolide.,18560792_2,1
5616,drug withdrawal,107,122,"However, the incidence and severity of these abnormalities vary from study to study and their course after drug withdrawal has not been systematically assessed.",18560792_3,1
5618,drug withdrawal,118,133,OBJECTIVES: To estimate the frequency and severity of valvular heart abnormality and its possible reversibility after drug withdrawal in a case-control study.,18560792_4,1
5617,heart abnormality,63,80,OBJECTIVES: To estimate the frequency and severity of valvular heart abnormality and its possible reversibility after drug withdrawal in a case-control study.,18560792_4,1
1941,pergolide,57,66,METHODS: All PD patients in the Amiens area treated with pergolide were invited to attend a cardiologic assessment including transthoracic echocardiography.,18560792_5,0
1942,pergolide,75,84,A second echocardiography was performed (median interval: 13 months) after pergolide withdrawal (n=10 patients).,18560792_7,0
5620,mitral regurgitation,83,103,"RESULTS: Compared to controls, aortic regurgitation (OR: 3.1; 95% IC: 1.1-8.8) and mitral regurgitation (OR: 10.7; 95% IC: 2.1-53) were more frequent in PD patients (tricuspid: NS).",18560792_9,1
5619,aortic regurgitation,31,51,"RESULTS: Compared to controls, aortic regurgitation (OR: 3.1; 95% IC: 1.1-8.8) and mitral regurgitation (OR: 10.7; 95% IC: 2.1-53) were more frequent in PD patients (tricuspid: NS).",18560792_9,1
7663,Heparin-induced thrombocytopenia,0,32,Heparin-induced thrombocytopenia after liver transplantation.,18589141_0,1
7664,liver transplantation,39,60,Heparin-induced thrombocytopenia after liver transplantation.,18589141_0,1
1947,low-molecular weight heparin,51,79,BACKGROUND: Unfractionated heparin sodium (UFH) or low-molecular weight heparin (LMWH) is used in anticoagulant protocols at several institutions to prevent thrombosis after liver transplantation.,18589141_1,0
1948,LMWH,81,85,BACKGROUND: Unfractionated heparin sodium (UFH) or low-molecular weight heparin (LMWH) is used in anticoagulant protocols at several institutions to prevent thrombosis after liver transplantation.,18589141_1,0
7667,liver transplantation,174,195,BACKGROUND: Unfractionated heparin sodium (UFH) or low-molecular weight heparin (LMWH) is used in anticoagulant protocols at several institutions to prevent thrombosis after liver transplantation.,18589141_1,1
7666,UFH,43,46,BACKGROUND: Unfractionated heparin sodium (UFH) or low-molecular weight heparin (LMWH) is used in anticoagulant protocols at several institutions to prevent thrombosis after liver transplantation.,18589141_1,0
7665,Unfractionated heparin sodium,12,41,BACKGROUND: Unfractionated heparin sodium (UFH) or low-molecular weight heparin (LMWH) is used in anticoagulant protocols at several institutions to prevent thrombosis after liver transplantation.,18589141_1,0
7683,hepatic artery thrombosis,23,48,"Two patients developed hepatic artery thrombosis on POD 11 and 19, respectively, although they were HIT antibody-negative and their platelet counts were stable.",18589141_10,1
7684,platelet counts,132,147,"Two patients developed hepatic artery thrombosis on POD 11 and 19, respectively, although they were HIT antibody-negative and their platelet counts were stable.",18589141_10,0
1950,platelet aggregation,20,40,The heparin-induced platelet aggregation test was negative in these patients.,18589141_12,0
7689,liver transplantation,56,77,"CONCLUSIONS: In our series, the occurrence of HIT after liver transplantation was uncommon.",18589141_15,1
7670,platelet count,103,117,"Heparin-induced thrombocytopenia (HIT) is an adverse immune-mediated reaction to heparin, resulting in platelet count decreases of more than 50%.",18589141_2,0
7669,adverse immune-mediated reaction,45,77,"Heparin-induced thrombocytopenia (HIT) is an adverse immune-mediated reaction to heparin, resulting in platelet count decreases of more than 50%.",18589141_2,1
7668,Heparin-induced thrombocytopenia,0,32,"Heparin-induced thrombocytopenia (HIT) is an adverse immune-mediated reaction to heparin, resulting in platelet count decreases of more than 50%.",18589141_2,1
7673,liver transplantation,128,149,"The frequencies of HIT after liver transplantation and platelet factor 4/heparin-reactive antibody (HIT antibody) positivity in liver transplantation patients, however, are unknown.",18589141_3,1
7671,liver transplantation,29,50,"The frequencies of HIT after liver transplantation and platelet factor 4/heparin-reactive antibody (HIT antibody) positivity in liver transplantation patients, however, are unknown.",18589141_3,1
7672,platelet factor 4/heparin-reactive,55,89,"The frequencies of HIT after liver transplantation and platelet factor 4/heparin-reactive antibody (HIT antibody) positivity in liver transplantation patients, however, are unknown.",18589141_3,0
7674,liver transplantation,69,90,PATIENTS AND METHODS: The 32 men and 20 women underwent living donor liver transplantation.,18589141_4,1
1949,LMWH,11,15,"We started LMWH (25 IU/kg/h) on postoperative day (POD) 1, switching to UFH (5000 U/d) on POD 2 or 3.",18589141_5,0
7676,UFH,72,75,"We started LMWH (25 IU/kg/h) on postoperative day (POD) 1, switching to UFH (5000 U/d) on POD 2 or 3.",18589141_5,0
7678,UFH,12,15,The dose of UFH was changed according to the activated clotting time level.,18589141_6,0
7679,clotting time,55,68,The dose of UFH was changed according to the activated clotting time level.,18589141_6,0
7680,Platelet count,0,14,Platelet count was measured daily for 3 weeks.,18589141_8,0
5626,heart failure,92,105,Adriamycin-induced autophagic cardiomyocyte death plays a pathogenic role in a rat model of heart failure.,18619688_0,1
7690,adriamycin,63,73,BACKGROUND: The mechanisms underlying heart failure induced by adriamycin are very complicated and still unclear.,18619688_1,0
5627,heart failure,38,51,BACKGROUND: The mechanisms underlying heart failure induced by adriamycin are very complicated and still unclear.,18619688_1,1
5631,heart failure,90,103,CONCLUSION: Autophagic cardiomyocyte death plays an important role in the pathogenesis of heart failure in rats induced by adriamycin.,18619688_10,1
7715,adriamycin,123,133,CONCLUSION: Autophagic cardiomyocyte death plays an important role in the pathogenesis of heart failure in rats induced by adriamycin.,18619688_10,0
5632,heart failure,59,72,Mitochondrial injury may be involved in the progression of heart failure caused by adriamycin via the autophagy pathway.,18619688_11,1
7716,Mitochondrial injury,0,20,Mitochondrial injury may be involved in the progression of heart failure caused by adriamycin via the autophagy pathway.,18619688_11,1
7717,adriamycin,83,93,Mitochondrial injury may be involved in the progression of heart failure caused by adriamycin via the autophagy pathway.,18619688_11,0
5629,heart failure,185,198,"The aim of this study was to investigate whether autophagy was involved in the progression of heart failure induced by adriamycin, so that we can develop a novel treatment strategy for heart failure.",18619688_2,1
5628,heart failure,94,107,"The aim of this study was to investigate whether autophagy was involved in the progression of heart failure induced by adriamycin, so that we can develop a novel treatment strategy for heart failure.",18619688_2,1
7692,adriamycin,119,129,"The aim of this study was to investigate whether autophagy was involved in the progression of heart failure induced by adriamycin, so that we can develop a novel treatment strategy for heart failure.",18619688_2,0
7695,adriamycin,119,129,"METHODS: 3-methyladenine (3MA), a specific inhibitor on autophagy was used in a heart failure model of rats induced by adriamycin.",18619688_3,0
5630,heart failure,80,93,"METHODS: 3-methyladenine (3MA), a specific inhibitor on autophagy was used in a heart failure model of rats induced by adriamycin.",18619688_3,1
7694,3-methyladenine,9,24,"METHODS: 3-methyladenine (3MA), a specific inhibitor on autophagy was used in a heart failure model of rats induced by adriamycin.",18619688_3,0
7701,MPT,101,104,"We then examined the morphology, expression of beclin 1 gene, mitochondrial permeability transition (MPT), and Na+-K+ ATPase activity in vivo.",18619688_5,0
7700,mitochondrial,62,75,"We then examined the morphology, expression of beclin 1 gene, mitochondrial permeability transition (MPT), and Na+-K+ ATPase activity in vivo.",18619688_5,0
7702,Na+-K+ ATPase,111,124,"We then examined the morphology, expression of beclin 1 gene, mitochondrial permeability transition (MPT), and Na+-K+ ATPase activity in vivo.",18619688_5,0
1951,beclin 1,47,55,"We then examined the morphology, expression of beclin 1 gene, mitochondrial permeability transition (MPT), and Na+-K+ ATPase activity in vivo.",18619688_5,0
1952,mitochondrial membrane,33,55,"We also assessed cell viability, mitochondrial membrane potential changes and counted autophagic vacuoles in cultured cardiomyocytes.",18619688_6,0
7703,cell viability,17,31,"We also assessed cell viability, mitochondrial membrane potential changes and counted autophagic vacuoles in cultured cardiomyocytes.",18619688_6,0
7706,RT-PCR,85,91,"In addition, we analyzed the expression of autophagy associated gene, beclin 1 using RT-PCR and Western blotting in an animal model.",18619688_7,0
7707,Western blotting,96,112,"In addition, we analyzed the expression of autophagy associated gene, beclin 1 using RT-PCR and Western blotting in an animal model.",18619688_7,0
1953,beclin 1,70,78,"In addition, we analyzed the expression of autophagy associated gene, beclin 1 using RT-PCR and Western blotting in an animal model.",18619688_7,0
7709,cardiac function,36,52,RESULTS: 3MA significantly improved cardiac function and reduced mitochondrial injury.,18619688_8,1
7710,mitochondrial,65,78,RESULTS: 3MA significantly improved cardiac function and reduced mitochondrial injury.,18619688_8,0
1954,beclin 1,119,127,"Furthermore, adriamycin induced the formation of autophagic vacuoles, and 3MA strongly downregulated the expression of beclin 1 in adriamycin-induced failing heart and inhibited the formation of autophagic vacuoles.",18619688_9,0
7711,adriamycin,13,23,"Furthermore, adriamycin induced the formation of autophagic vacuoles, and 3MA strongly downregulated the expression of beclin 1 in adriamycin-induced failing heart and inhibited the formation of autophagic vacuoles.",18619688_9,0
7721,kinin B1,101,109,Doxorubicin cardiomyopathy-induced inflammation and apoptosis are attenuated by gene deletion of the kinin B1 receptor.,18627295_0,0
7719,Doxorubicin cardiomyopathy-induced inflammation,0,47,Doxorubicin cardiomyopathy-induced inflammation and apoptosis are attenuated by gene deletion of the kinin B1 receptor.,18627295_0,1
1955,anthracycline,20,33,"Clinical use of the anthracycline doxorubicin (DOX) is limited by its cardiotoxic effects, which are attributed to the induction of apoptosis.",18627295_1,0
7722,DOX,47,50,"Clinical use of the anthracycline doxorubicin (DOX) is limited by its cardiotoxic effects, which are attributed to the induction of apoptosis.",18627295_1,0
1956,cardiotoxic,70,81,"Clinical use of the anthracycline doxorubicin (DOX) is limited by its cardiotoxic effects, which are attributed to the induction of apoptosis.",18627295_1,0
7728,B1R(-/-),138,146,"To elucidate the possible role of the kinin B1 receptor (B1R) during the development of DOX cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of DOX-induced cardiomyopathy.",18627295_2,0
7725,DOX,88,91,"To elucidate the possible role of the kinin B1 receptor (B1R) during the development of DOX cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of DOX-induced cardiomyopathy.",18627295_2,0
7724,B1R,57,60,"To elucidate the possible role of the kinin B1 receptor (B1R) during the development of DOX cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of DOX-induced cardiomyopathy.",18627295_2,0
7723,kinin B1,38,46,"To elucidate the possible role of the kinin B1 receptor (B1R) during the development of DOX cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of DOX-induced cardiomyopathy.",18627295_2,0
7729,cardiac inflammation,165,185,"To elucidate the possible role of the kinin B1 receptor (B1R) during the development of DOX cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of DOX-induced cardiomyopathy.",18627295_2,1
7726,B1R,119,122,"To elucidate the possible role of the kinin B1 receptor (B1R) during the development of DOX cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of DOX-induced cardiomyopathy.",18627295_2,0
7731,DOX,0,3,DOX control mice showed cardiac dysfunction measured by pressure-volume loops in vivo.,18627295_3,0
7732,cardiac dysfunction,24,43,DOX control mice showed cardiac dysfunction measured by pressure-volume loops in vivo.,18627295_3,1
7734,activation state,35,51,"This was associated with a reduced activation state of AKT, as well as an increased bax/bcl2 ratio in Western blots, indicating cardiac apoptosis.",18627295_4,0
7736,cardiac apoptosis,128,145,"This was associated with a reduced activation state of AKT, as well as an increased bax/bcl2 ratio in Western blots, indicating cardiac apoptosis.",18627295_4,1
1957,AKT,55,58,"This was associated with a reduced activation state of AKT, as well as an increased bax/bcl2 ratio in Western blots, indicating cardiac apoptosis.",18627295_4,0
7738,cytokine interleukin 6,48,70,"Furthermore, mRNA levels of the proinflammatory cytokine interleukin 6 were increased in the cardiac tissue.",18627295_5,0
7740,DOX B1R(-/-),3,15,"In DOX B1R(-/-) mice, cardiac dysfunction was improved compared to DOX control mice, which was associated with normalization of the bax/bcl-2 ratio and interleukin 6, as well as AKT activation state.",18627295_6,0
1959,AKT,178,181,"In DOX B1R(-/-) mice, cardiac dysfunction was improved compared to DOX control mice, which was associated with normalization of the bax/bcl-2 ratio and interleukin 6, as well as AKT activation state.",18627295_6,0
7741,cardiac dysfunction,22,41,"In DOX B1R(-/-) mice, cardiac dysfunction was improved compared to DOX control mice, which was associated with normalization of the bax/bcl-2 ratio and interleukin 6, as well as AKT activation state.",18627295_6,1
7742,DOX,67,70,"In DOX B1R(-/-) mice, cardiac dysfunction was improved compared to DOX control mice, which was associated with normalization of the bax/bcl-2 ratio and interleukin 6, as well as AKT activation state.",18627295_6,0
7744,bax/bcl-2 ratio,132,147,"In DOX B1R(-/-) mice, cardiac dysfunction was improved compared to DOX control mice, which was associated with normalization of the bax/bcl-2 ratio and interleukin 6, as well as AKT activation state.",18627295_6,0
1958,interleukin 6,152,165,"In DOX B1R(-/-) mice, cardiac dysfunction was improved compared to DOX control mice, which was associated with normalization of the bax/bcl-2 ratio and interleukin 6, as well as AKT activation state.",18627295_6,0
5633,inflammatory response,93,114,These findings suggest that B1R is detrimental in DOX cardiomyopathy in that it mediates the inflammatory response and apoptosis.,18627295_7,1
7746,B1R,28,31,These findings suggest that B1R is detrimental in DOX cardiomyopathy in that it mediates the inflammatory response and apoptosis.,18627295_7,0
7747,DOX,50,53,These findings suggest that B1R is detrimental in DOX cardiomyopathy in that it mediates the inflammatory response and apoptosis.,18627295_7,0
7748,B1R,75,78,These insights might have useful implications for future studies utilizing B1R antagonists for treatment of human DOX cardiomyopathy.,18627295_8,0
7749,DOX,114,117,These insights might have useful implications for future studies utilizing B1R antagonists for treatment of human DOX cardiomyopathy.,18627295_8,0
7750,inhibitors-induced proteinuria,5,35,"mToR inhibitors-induced proteinuria: mechanisms, significance, and management.",18631865_0,1
1960,mToR,0,4,"mToR inhibitors-induced proteinuria: mechanisms, significance, and management.",18631865_0,0
1964,sirolimus,160,169,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy.",18631865_1,0
1963,mToR,131,135,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy.",18631865_1,0
1962,mammalian target of rapamycin,100,129,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy.",18631865_1,0
1961,calcineurin inhibitors,74,96,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy.",18631865_1,0
7751,renal transplant,174,190,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy.",18631865_1,1
7752,chronic allograft nephropathy,207,236,"Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially sirolimus, in renal transplant recipients with chronic allograft nephropathy.",18631865_1,1
7753,poor transplantation outcome,52,80,"Because proteinuria is a major predictive factor of poor transplantation outcome, many studies focused on this adverse event during the past years.",18631865_2,1
7754,adverse event,111,124,"Because proteinuria is a major predictive factor of poor transplantation outcome, many studies focused on this adverse event during the past years.",18631865_2,1
1967,sirolimus,172,181,Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.,18631865_3,0
1966,calcineurin inhibitors,66,88,Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.,18631865_3,0
1965,sirolimus,31,40,Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.,18631865_3,0
1968,sirolimus,244,253,Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.,18631865_3,0
1969,novo,257,261,Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo.,18631865_3,0
5634,focal segmental glomerulosclerosis,20,54,"Podocyte injury and focal segmental glomerulosclerosis have been related to mToR inhibition in some patients, but the pathways underlying these lesions remain hypothetic.",18631865_4,1
1970,mToR,76,80,"Podocyte injury and focal segmental glomerulosclerosis have been related to mToR inhibition in some patients, but the pathways underlying these lesions remain hypothetic.",18631865_4,0
7757,blockade-induced proteinuria,71,99,We discuss herein the possible mechanisms and the significance of mToR blockade-induced proteinuria.,18631865_5,1
1971,mToR,66,70,We discuss herein the possible mechanisms and the significance of mToR blockade-induced proteinuria.,18631865_5,0
5635,epileptiform,57,69,Detailed spectral profile analysis of penicillin-induced epileptiform activity in anesthetized rats.,18657397_0,1
5636,epileptiform,92,104,In the present study we aimed to portray a detailed spectral analysis of penicillin-induced epileptiform activity in comparison with basal brain activity in anesthetized Wistar rats.,18657397_2,1
7768,left lateral ventricle,138,160,"After a short period of basal activity recording, epileptic focus was induced by injecting 400IU/2 microl penicillin-G potassium into the left lateral ventricle while the cortical activity was continuously recorded.",18657397_4,1
7766,epileptic focus,50,65,"After a short period of basal activity recording, epileptic focus was induced by injecting 400IU/2 microl penicillin-G potassium into the left lateral ventricle while the cortical activity was continuously recorded.",18657397_4,1
1972,penicillin-G potassium,106,128,"After a short period of basal activity recording, epileptic focus was induced by injecting 400IU/2 microl penicillin-G potassium into the left lateral ventricle while the cortical activity was continuously recorded.",18657397_4,0
5637,epileptiform,57,69,"Basal activity, latent period and the penicillin-induced epileptiform activity periods were then analyzed using both conventional methods and spectral analysis.",18657397_5,1
1974,(1,173,175,"Spectral analyses were conducted by dividing the whole spectrum into different frequency bands including delta, theta (slow and fast), alpha-sigma, beta (1 and 2) and gamma (1 and 2) bands.",18657397_6,0
7774,alpha-sigma,135,146,"Spectral analyses were conducted by dividing the whole spectrum into different frequency bands including delta, theta (slow and fast), alpha-sigma, beta (1 and 2) and gamma (1 and 2) bands.",18657397_6,0
1973,(1,153,155,"Spectral analyses were conducted by dividing the whole spectrum into different frequency bands including delta, theta (slow and fast), alpha-sigma, beta (1 and 2) and gamma (1 and 2) bands.",18657397_6,0
1975,beta-2,75,81,"Our results show that the most affected frequency bands were delta, theta, beta-2 and gamma-2 bands during the epileptiform activity and there were marked differences in terms of spectral densities between three investigated episodes (basal activity, latent period and epileptiform activity).",18657397_7,0
5638,epileptiform,111,123,"Our results show that the most affected frequency bands were delta, theta, beta-2 and gamma-2 bands during the epileptiform activity and there were marked differences in terms of spectral densities between three investigated episodes (basal activity, latent period and epileptiform activity).",18657397_7,1
5639,epileptiform,269,281,"Our results show that the most affected frequency bands were delta, theta, beta-2 and gamma-2 bands during the epileptiform activity and there were marked differences in terms of spectral densities between three investigated episodes (basal activity, latent period and epileptiform activity).",18657397_7,1
7778,experimental epilepsies,233,256,Our results may help to analyze novel data obtained using similar experimental models and the simple analysis method described here can be used in similar studies to investigate the basic neuronal mechanism of this or other types of experimental epilepsies.,18657397_8,1
5640,side effects,17,29,Neuropsychiatric side effects after the use of mefloquine.,1867351_0,1
5641,side effects,38,50,This study describes neuropsychiatric side effects in patients after treatment with mefloquine.,1867351_1,1
5642,sleep-wake,101,111,"Reactions consisted mainly of seizures, acute psychoses, anxiety neurosis, and major disturbances of sleep-wake rhythm.",1867351_2,1
7779,acute psychoses,40,55,"Reactions consisted mainly of seizures, acute psychoses, anxiety neurosis, and major disturbances of sleep-wake rhythm.",1867351_2,1
7780,anxiety neurosis,57,73,"Reactions consisted mainly of seizures, acute psychoses, anxiety neurosis, and major disturbances of sleep-wake rhythm.",1867351_2,1
5643,Side effects,0,12,Side effects occurred after both therapeutic and prophylactic intake and were graded from moderate to severe.,1867351_3,1
5644,side effects,39,51,"In a risk analysis of neuropsychiatric side effects in Germany, it is estimated that one of 8,000 mefloquine users suffers from such reactions.",1867351_4,1
7783,neuropsychiatric reactions,157,183,"The incidence calculation revealed that one of 215 therapeutic users had reactions, compared with one of 13,000 in the prophylaxis group, making the risk of neuropsychiatric reactions after mefloquine treatment 60 times higher than after prophylaxis.",1867351_5,1
5645,cardiotoxicity,73,87,High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity.,18674790_0,1
7784,High fat,0,8,High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity.,18674790_0,1
7786,Adriamycin,36,46,"Often, chemotherapy by doxorubicin (Adriamycin) is limited due to life threatening cardiotoxicity in patients during and posttherapy.",18674790_1,0
7787,life threatening cardiotoxicity,66,97,"Often, chemotherapy by doxorubicin (Adriamycin) is limited due to life threatening cardiotoxicity in patients during and posttherapy.",18674790_1,1
5646,cardiotoxicity,103,117,"Recently, we have shown that moderate diet restriction remarkably protects against doxorubicin-induced cardiotoxicity.",18674790_2,1
7790,cardioprotection,5,21,"This cardioprotection is accompanied by decreased cardiac oxidative stress and triglycerides and increased cardiac fatty-acid oxidation, ATP synthesis, and upregulated JAK/STAT3 pathway.",18674790_3,1
7792,cardiac fatty-acid oxidation,107,135,"This cardioprotection is accompanied by decreased cardiac oxidative stress and triglycerides and increased cardiac fatty-acid oxidation, ATP synthesis, and upregulated JAK/STAT3 pathway.",18674790_3,0
7791,oxidative stress,58,74,"This cardioprotection is accompanied by decreased cardiac oxidative stress and triglycerides and increased cardiac fatty-acid oxidation, ATP synthesis, and upregulated JAK/STAT3 pathway.",18674790_3,1
5647,cardiotoxicity,208,222,"In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity.",18674790_4,1
5648,cardiotoxicity,104,118,"A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.",18674790_5,1
7800,lipid peroxidation,141,159,"A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.",18674790_5,1
7799,cardiac dysfunction,120,139,"A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity.",18674790_5,1
7802,doxorubicinol,89,102,Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts.,18674790_6,0
7803,toxic metabolite,104,120,Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts.,18674790_6,0
1979,peroxisome proliferators,180,204,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",18674790_7,0
1978,(2,150,152,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",18674790_7,0
1977,uncoupling proteins,121,140,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",18674790_7,0
1976,(1,65,67,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",18674790_7,0
1981,adiponectin,252,263,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",18674790_7,0
1980,(3,231,233,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",18674790_7,0
7810,ATP/ADP ratio,516,529,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",18674790_7,0
7808,mitochondrial,411,424,"Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration.",18674790_7,0
1982,SOCS3,47,52,Decreased cardiac erythropoietin and increased SOCS3 further downregulated the cardioprotective JAK/STAT3 pathway.,18674790_8,0
7811,cardiac erythropoietin,10,32,Decreased cardiac erythropoietin and increased SOCS3 further downregulated the cardioprotective JAK/STAT3 pathway.,18674790_8,0
5649,cardiotoxicity,83,97,"In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.",18674790_9,1
7813,downregulating,115,129,"In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.",18674790_9,0
7814,mitochondrial ATP,138,155,"In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.",18674790_9,0
7815,oxidative stress,179,195,"In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway.",18674790_9,1
1983,dopaminergic,68,80,Prenatal protein deprivation alters dopamine-mediated behaviors and dopaminergic and glutamatergic receptor binding.,18703024_0,0
7818,Prenatal protein deprivation,0,28,Prenatal protein deprivation alters dopamine-mediated behaviors and dopaminergic and glutamatergic receptor binding.,18703024_0,1
7820,glutamatergic receptor binding,85,115,Prenatal protein deprivation alters dopamine-mediated behaviors and dopaminergic and glutamatergic receptor binding.,18703024_0,0
7821,receptor binding,125,141,The goal of these studies was to use an animal model to examine the effects of prenatal protein deprivation on behaviors and receptor binding with relevance to schizophrenia.,18703024_2,0
7826,(3)H-haloperidol binding,37,61,PD female rats also showed increased (3)H-haloperidol binding and decreased dopamine transporter binding in striatum.,18703024_7,0
1984,dopamine transporter,76,96,PD female rats also showed increased (3)H-haloperidol binding and decreased dopamine transporter binding in striatum.,18703024_7,0
7827,receptor binding,52,68,No statistically significant changes in behavior or receptor binding were found in PD males with the exception of increased (3)H-MK-801 binding in cortex.,18703024_8,0
5650,nutritional deficiency,76,98,This animal model may be useful to explore the mechanisms by which prenatal nutritional deficiency enhances risk for schizophrenia in humans and may also have implications for developmental processes leading to differential sensitivity to drugs of abuse.,18703024_9,1
7829,topical papaverine,19,37,Adverse effects of topical papaverine on auditory nerve function.,18726058_0,0
7830,auditory nerve function,41,64,Adverse effects of topical papaverine on auditory nerve function.,18726058_0,1
5651,Adverse effects,0,15,Adverse effects of topical papaverine on auditory nerve function.,18726058_0,1
1985,Papaverine hydrochloride,12,36,BACKGROUND: Papaverine hydrochloride is a direct-acting vasodilator used to manage vasospasm during various neurosurgical operations.,18726058_1,0
7832,neurosurgical operations,108,132,BACKGROUND: Papaverine hydrochloride is a direct-acting vasodilator used to manage vasospasm during various neurosurgical operations.,18726058_1,1
5652,vasospasm,83,92,BACKGROUND: Papaverine hydrochloride is a direct-acting vasodilator used to manage vasospasm during various neurosurgical operations.,18726058_1,1
7831,direct-acting vasodilator,42,67,BACKGROUND: Papaverine hydrochloride is a direct-acting vasodilator used to manage vasospasm during various neurosurgical operations.,18726058_1,0
5656,sensorineural hearing loss,69,95,One patient showed no recovery of later waves and a delayed profound sensorineural hearing loss.,18726058_12,1
7852,pre-papaverine,47,61,The average recovery time of BAEP waveforms to pre-papaverine baseline values was 39 min.,18726058_13,0
7851,BAEP,29,33,The average recovery time of BAEP waveforms to pre-papaverine baseline values was 39 min.,18726058_13,0
7856,transient disturbance,98,119,CONCLUSIONS: Topical papaverine for the treatment of vasospasm was associated with the onset of a transient disturbance in neurophysiological function of the ascending auditory brainstem pathway.,18726058_14,1
7858,auditory brainstem pathway,168,194,CONCLUSIONS: Topical papaverine for the treatment of vasospasm was associated with the onset of a transient disturbance in neurophysiological function of the ascending auditory brainstem pathway.,18726058_14,1
7857,neurophysiological function,123,150,CONCLUSIONS: Topical papaverine for the treatment of vasospasm was associated with the onset of a transient disturbance in neurophysiological function of the ascending auditory brainstem pathway.,18726058_14,1
5657,vasospasm,53,62,CONCLUSIONS: Topical papaverine for the treatment of vasospasm was associated with the onset of a transient disturbance in neurophysiological function of the ascending auditory brainstem pathway.,18726058_14,1
7853,Topical papaverine,13,31,CONCLUSIONS: Topical papaverine for the treatment of vasospasm was associated with the onset of a transient disturbance in neurophysiological function of the ascending auditory brainstem pathway.,18726058_14,0
5658,eighth nerve,129,141,The complete disappearance of BAEP waveforms with a consistent temporal delay suggests a possible adverse effect on the proximal eighth nerve.,18726058_15,1
7860,temporal delay,63,77,The complete disappearance of BAEP waveforms with a consistent temporal delay suggests a possible adverse effect on the proximal eighth nerve.,18726058_15,1
7861,adverse effect,98,112,The complete disappearance of BAEP waveforms with a consistent temporal delay suggests a possible adverse effect on the proximal eighth nerve.,18726058_15,1
5659,cranial nerve,35,48,Recommendations to avoid potential cranial nerve deficits from papaverine are provided.,18726058_16,1
7833,cranial nerve dysfunction,10,35,Transient cranial nerve dysfunction has been described in a few cases with topical papaverine.,18726058_2,1
7834,topical papaverine,75,93,Transient cranial nerve dysfunction has been described in a few cases with topical papaverine.,18726058_2,0
7836,auditory nerve,106,120,This study supports previous reports and provides neurophysiological evidence of an adverse effect on the auditory nerve.,18726058_3,1
7835,adverse effect,84,98,This study supports previous reports and provides neurophysiological evidence of an adverse effect on the auditory nerve.,18726058_3,1
5654,vasospasm,165,174,METHODS: We conducted a retrospective review of 70 consecutive microvascular decompression operations and studied those patients who received topical papaverine for vasospasm.,18726058_4,1
5653,microvascular,63,76,METHODS: We conducted a retrospective review of 70 consecutive microvascular decompression operations and studied those patients who received topical papaverine for vasospasm.,18726058_4,1
7838,topical papaverine,142,160,METHODS: We conducted a retrospective review of 70 consecutive microvascular decompression operations and studied those patients who received topical papaverine for vasospasm.,18726058_4,0
7840,therapeutic action,40,58,Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients.,18726058_5,0
5655,vasospasm,69,78,Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients.,18726058_5,1
7839,Topical papaverine,0,18,Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients.,18726058_5,0
7842,operative events,49,65,The timing of papaverine application and ongoing operative events was reviewed relative to changes in neurophysiological recordings.,18726058_6,1
7844,nerve function,85,99,Brainstem auditory evoked potentials (BAEPs) were routinely used to monitor cochlear nerve function during these operations.,18726058_7,1
7846,BAEP,75,79,FINDINGS: A temporal relationship was found between topical papaverine and BAEP changes leading to complete waveform loss.,18726058_8,0
7845,topical papaverine,52,70,FINDINGS: A temporal relationship was found between topical papaverine and BAEP changes leading to complete waveform loss.,18726058_8,0
7847,waveform loss,108,121,FINDINGS: A temporal relationship was found between topical papaverine and BAEP changes leading to complete waveform loss.,18726058_8,1
7849,onset of,54,62,The average temporal delay between papaverine and the onset of an adverse BAEP change was 5 min.,18726058_9,1
7862,liver transplantation,60,81,Simvastatin-ezetimibe-induced hepatic failure necessitating liver transplantation.,18752389_0,1
5660,hepatic failure,30,45,Simvastatin-ezetimibe-induced hepatic failure necessitating liver transplantation.,18752389_0,1
7865,coenzyme A reductase inhibitor,109,139,Abstract Serum aminotransferase elevations are a commonly known adverse effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) therapy.,18752389_1,0
7864,adverse effect,64,78,Abstract Serum aminotransferase elevations are a commonly known adverse effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) therapy.,18752389_1,1
1989,hydroxy acid,185,197,"Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent hepatotoxicity.",18752389_10,0
7883,UGT,95,98,"Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent hepatotoxicity.",18752389_10,0
7884,glucuronidation,154,169,"Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent hepatotoxicity.",18752389_10,0
7885,hepatotoxicity,258,272,"Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent hepatotoxicity.",18752389_10,1
1988,Ezetimibe,0,9,"Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent hepatotoxicity.",18752389_10,0
7881,glucuronidation,30,45,"Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent hepatotoxicity.",18752389_10,0
7882,uridine diphosphate glucoronosyltransferases,49,93,"Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent hepatotoxicity.",18752389_10,0
7887,liver transplantation,112,133,"To our knowledge, this is the first case report of simvastatin-ezetimibe-induced liver failure that resulted in liver transplantation.",18752389_11,1
5662,liver failure,81,94,"To our knowledge, this is the first case report of simvastatin-ezetimibe-induced liver failure that resulted in liver transplantation.",18752389_11,1
1990,ezetimibe,124,133,We postulate that the mechanism of the simvastatinezetimibe-induced hepatotoxicity is the increased simvastatin exposure by ezetimibe inhibition of UGT enzymes.,18752389_12,0
7889,UGT,148,151,We postulate that the mechanism of the simvastatinezetimibe-induced hepatotoxicity is the increased simvastatin exposure by ezetimibe inhibition of UGT enzymes.,18752389_12,0
7888,hepatotoxicity,68,82,We postulate that the mechanism of the simvastatinezetimibe-induced hepatotoxicity is the increased simvastatin exposure by ezetimibe inhibition of UGT enzymes.,18752389_12,1
7891,simvastatin-ezetimibe,60,81,Clinicians should be aware of potential hepatotoxicity with simvastatin-ezetimibe especially in elderly patients and should carefully monitor serum aminotransferase levels when starting therapy and titrating the dosage.,18752389_13,0
7890,hepatotoxicity,40,54,Clinicians should be aware of potential hepatotoxicity with simvastatin-ezetimibe especially in elderly patients and should carefully monitor serum aminotransferase levels when starting therapy and titrating the dosage.,18752389_13,1
1986,ezetimibe,64,73,"However, hepatotoxic events have not been widely published with ezetimibe or the combination agent simvastatin-ezetimibe.",18752389_2,0
7866,combination agent simvastatin-ezetimibe,81,120,"However, hepatotoxic events have not been widely published with ezetimibe or the combination agent simvastatin-ezetimibe.",18752389_2,0
5661,fulminant hepatic failure,55,80,We describe a 70-year-old Hispanic woman who developed fulminant hepatic failure necessitating liver transplantation 10 weeks after conversion from simvastatin 40 mg/day to simvastatin 10 mg-ezetimibe 40 mg/day.,18752389_3,1
7867,liver transplantation,95,116,We describe a 70-year-old Hispanic woman who developed fulminant hepatic failure necessitating liver transplantation 10 weeks after conversion from simvastatin 40 mg/day to simvastatin 10 mg-ezetimibe 40 mg/day.,18752389_3,1
7870,hepatotoxicity,119,133,The patient's lipid panel had been maintained with simvastatin for 18 months before the conversion without evidence of hepatotoxicity.,18752389_4,1
7871,serum aminotransferase,73,95,A routine laboratory work-up 10 weeks after conversion revealed elevated serum aminotransferase levels.,18752389_5,0
7874,hepatotoxicity,125,139,"Simvastatinezetimibe and escitalopram (which she was taking for depression) were discontinued, and other potential causes of hepatotoxicity were excluded.",18752389_6,1
7873,escitalopram,25,37,"Simvastatinezetimibe and escitalopram (which she was taking for depression) were discontinued, and other potential causes of hepatotoxicity were excluded.",18752389_6,0
7872,Simvastatinezetimibe,0,20,"Simvastatinezetimibe and escitalopram (which she was taking for depression) were discontinued, and other potential causes of hepatotoxicity were excluded.",18752389_6,0
7876,moderate-to-severe drug toxicity,111,143,"A repeat work-up revealed further elevations in aminotransferase levels, and liver biopsy revealed evidence of moderate-to-severe drug toxicity.",18752389_7,1
7878,postoperative course,55,75,She underwent liver transplantation with an uneventful postoperative course.,18752389_8,1
7877,liver transplantation,14,35,She underwent liver transplantation with an uneventful postoperative course.,18752389_8,1
7879,Her aminotransferase,0,20,"Her aminotransferase levels returned to normal by postoperative day 23, and her 2-year follow-up showed no adverse events.",18752389_9,0
7880,adverse events,107,121,"Her aminotransferase levels returned to normal by postoperative day 23, and her 2-year follow-up showed no adverse events.",18752389_9,1
1987,her,76,79,"Her aminotransferase levels returned to normal by postoperative day 23, and her 2-year follow-up showed no adverse events.",18752389_9,0
5664,focal segmental glomerulosclerosis,117,151,Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.,18754075_0,1
5663,acute renal failure,24,43,Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.,18754075_0,1
7894,bisphosphonate,55,69,Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.,18754075_0,0
7893,Massive proteinuria,0,19,Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.,18754075_0,1
5665,nephrotic syndrome,32,50,A 61-year-old Japanese man with nephrotic syndrome due to focal segmental glomerulosclerosis was initially responding well to steroid therapy.,18754075_1,1
5666,focal segmental glomerulosclerosis,58,92,A 61-year-old Japanese man with nephrotic syndrome due to focal segmental glomerulosclerosis was initially responding well to steroid therapy.,18754075_1,1
7897,alendronate sodium,109,127,"The amount of daily urinary protein decreased from 15.6 to 2.8 g. Within 14 days of the oral bisphosphonate (alendronate sodium) administration, the amount of daily urinary protein increased rapidly up to 12.8 g with acute renal failure.",18754075_2,0
7896,bisphosphonate,93,107,"The amount of daily urinary protein decreased from 15.6 to 2.8 g. Within 14 days of the oral bisphosphonate (alendronate sodium) administration, the amount of daily urinary protein increased rapidly up to 12.8 g with acute renal failure.",18754075_2,0
5667,acute renal failure,217,236,"The amount of daily urinary protein decreased from 15.6 to 2.8 g. Within 14 days of the oral bisphosphonate (alendronate sodium) administration, the amount of daily urinary protein increased rapidly up to 12.8 g with acute renal failure.",18754075_2,1
7898,oral alendronate,24,40,"After discontinuing the oral alendronate, the patient underwent six cycles of hemodialysis and four cycles of LDL apheresis.",18754075_3,0
1991,creatinine,25,35,"Urinary volume and serum creatinine levels recovered to the normal range, with urinary protein disappearing completely within 40 days.",18754075_4,0
5668,acute renal failure,112,131,"This report demonstrates that not only intravenous, but also oral bisphosphonates can aggravate proteinuria and acute renal failure.",18754075_5,1
1992,bisphosphonates,66,81,"This report demonstrates that not only intravenous, but also oral bisphosphonates can aggravate proteinuria and acute renal failure.",18754075_5,0
5669,nephrotic syndrome,68,86,Serum- and glucocorticoid-inducible kinase 1 in doxorubicin-induced nephrotic syndrome.,18768591_0,1
1993,kinase 1,36,44,Serum- and glucocorticoid-inducible kinase 1 in doxorubicin-induced nephrotic syndrome.,18768591_0,0
7902,Serum-,0,6,Serum- and glucocorticoid-inducible kinase 1 in doxorubicin-induced nephrotic syndrome.,18768591_0,0
7904,volume retention,84,100,Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis.,18768591_1,1
1994,epithelial sodium channel,41,66,Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis.,18768591_1,0
7905,renal fibrosis,105,119,Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis.,18768591_1,1
1995,ENaC,126,130,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess.,18768591_2,0
7908,SGK1,69,73,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess.,18768591_2,0
7907,glucocorticoid-inducible kinase,37,68,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess.,18768591_2,0
7909,renal fibrosis,146,160,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess.,18768591_2,1
7906,aldosterone-sensitive serum-,4,32,The aldosterone-sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess.,18768591_2,0
5670,nephrotic syndrome,106,124,The present study was performed to elucidate the role of SGK1 in the volume retention and fibrosis during nephrotic syndrome.,18768591_3,1
7911,volume retention,69,85,The present study was performed to elucidate the role of SGK1 in the volume retention and fibrosis during nephrotic syndrome.,18768591_3,1
7910,SGK1,57,61,The present study was performed to elucidate the role of SGK1 in the volume retention and fibrosis during nephrotic syndrome.,18768591_3,0
7912,wt,40,42,"To this end, doxorubicin (15 mug/g body wt) was injected intravenously into gene-targeted mice lacking SGK1 (sgk1(-/-)) and their wild-type littermates (sgk1(+/+)).",18768591_4,1
7913,SGK1,103,107,"To this end, doxorubicin (15 mug/g body wt) was injected intravenously into gene-targeted mice lacking SGK1 (sgk1(-/-)) and their wild-type littermates (sgk1(+/+)).",18768591_4,0
7915,heavy proteinuria,34,51,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.",18768591_5,1
7918,hypoalbuminemia,194,209,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.",18768591_5,1
5671,nephrotic syndrome,146,164,"Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes.",18768591_5,1
5672,nephrotic,39,48,Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice.,18768591_6,1
7919,Plasma aldosterone,0,18,Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice.,18768591_6,0
7920,SGK1,102,106,Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice.,18768591_6,0
7927,body weight gain,197,213,Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs. +4.1 +/- 0.8 g).,18768591_7,1
7923,/- 5,82,86,Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs. +4.1 +/- 0.8 g).,18768591_7,0
7924,sgk1(-/-),110,119,Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs. +4.1 +/- 0.8 g).,18768591_7,0
7933,sgk1(-/-),101,110,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs. 40 days in sgk1(+/+) mice).",18768591_8,0
7934,sgk1(-/-),190,199,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs. 40 days in sgk1(+/+) mice).",18768591_8,0
5673,nephrotic syndrome,21,39,"During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs. 40 days in sgk1(+/+) mice).",18768591_8,1
5674,nephrotic syndrome,146,164,"In conclusion, gene-targeted mice lacking SGK1 showed blunted volume retention, yet were not protected against renal fibrosis during experimental nephrotic syndrome.",18768591_9,1
7937,renal fibrosis,111,125,"In conclusion, gene-targeted mice lacking SGK1 showed blunted volume retention, yet were not protected against renal fibrosis during experimental nephrotic syndrome.",18768591_9,1
7936,volume retention,62,78,"In conclusion, gene-targeted mice lacking SGK1 showed blunted volume retention, yet were not protected against renal fibrosis during experimental nephrotic syndrome.",18768591_9,1
7935,SGK1,42,46,"In conclusion, gene-targeted mice lacking SGK1 showed blunted volume retention, yet were not protected against renal fibrosis during experimental nephrotic syndrome.",18768591_9,0
7940,fatal outcome,97,110,Severe thrombocytopenia and haemolytic anaemia associated with ciprofloxacin: a case report with fatal outcome.,18791946_0,1
5675,haemolytic anaemia,28,46,Severe thrombocytopenia and haemolytic anaemia associated with ciprofloxacin: a case report with fatal outcome.,18791946_0,1
7942,fatal outcome,49,62,Haematological adverse reactions associated with fatal outcome are rare during treatment with ciprofloxacin.,18791946_1,1
5676,adverse reactions,15,32,Haematological adverse reactions associated with fatal outcome are rare during treatment with ciprofloxacin.,18791946_1,1
7953,life-threatening thrombocytopenia,58,91,"This case report shows that ciprofloxacin may precipitate life-threatening thrombocytopenia and haemolytic anaemia, even in the early phases of treatment and without apparent previous exposures.",18791946_10,1
7954,early phases,128,140,"This case report shows that ciprofloxacin may precipitate life-threatening thrombocytopenia and haemolytic anaemia, even in the early phases of treatment and without apparent previous exposures.",18791946_10,1
5681,haemolytic anaemia,96,114,"This case report shows that ciprofloxacin may precipitate life-threatening thrombocytopenia and haemolytic anaemia, even in the early phases of treatment and without apparent previous exposures.",18791946_10,1
7943,oral ciprofloxacin,100,118,A 30-year old Caucasian man reported with abdominal pain and jaundice after 3-day administration of oral ciprofloxacin for a suspect of urinary tract infection.,18791946_2,0
5678,urinary tract infection,136,159,A 30-year old Caucasian man reported with abdominal pain and jaundice after 3-day administration of oral ciprofloxacin for a suspect of urinary tract infection.,18791946_2,1
5677,abdominal pain,42,56,A 30-year old Caucasian man reported with abdominal pain and jaundice after 3-day administration of oral ciprofloxacin for a suspect of urinary tract infection.,18791946_2,1
5679,lower limbs,72,83,The patient progressively developed petechiae and purpura on thorax and lower limbs.,18791946_4,1
7946,petechial haemorrhages,54,76,An accurate autopsy revealed most organs with diffuse petechial haemorrhages.,18791946_6,1
7947,of bone marrow,9,23,No signs of bone marrow depression were found.,18791946_7,1
5680,microangiopathies,23,40,No thrombi or signs of microangiopathies were observed in arterial vessels.,18791946_8,1
7949,arterial vessels,58,74,No thrombi or signs of microangiopathies were observed in arterial vessels.,18791946_8,1
7948,No thrombi,0,10,No thrombi or signs of microangiopathies were observed in arterial vessels.,18791946_8,1
7951,bacterial growth,42,58,Blood and urine cultures did not show any bacterial growth.,18791946_9,0
7955,myocardial injury,81,98,Isoproterenol induces primary loss of dystrophin in rat hearts: correlation with myocardial injury.,18808529_0,1
7958,coronary hypotension,122,142,"The mechanism of isoproterenol-induced myocardial damage is unknown, but a mismatch of oxygen supply vs. demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed.",18808529_1,1
7956,myocardial damage,39,56,"The mechanism of isoproterenol-induced myocardial damage is unknown, but a mismatch of oxygen supply vs. demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed.",18808529_1,1
7959,myocardial hyperactivity,147,171,"The mechanism of isoproterenol-induced myocardial damage is unknown, but a mismatch of oxygen supply vs. demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed.",18808529_1,1
1999,integrins,322,331,"Taking into account that the sarcolemmal integrity is stabilized by the dystrophin-glycoprotein complex (DGC) that connects actin and laminin in contractile machinery and extracellular matrix and by integrins, this study tests the hypothesis that isoproterenol affects sarcolemmal stability through changes in the DGC and integrins.",18808529_3,0
7963,connects actin,115,129,"Taking into account that the sarcolemmal integrity is stabilized by the dystrophin-glycoprotein complex (DGC) that connects actin and laminin in contractile machinery and extracellular matrix and by integrins, this study tests the hypothesis that isoproterenol affects sarcolemmal stability through changes in the DGC and integrins.",18808529_3,0
7961,dystrophin-glycoprotein complex,72,103,"Taking into account that the sarcolemmal integrity is stabilized by the dystrophin-glycoprotein complex (DGC) that connects actin and laminin in contractile machinery and extracellular matrix and by integrins, this study tests the hypothesis that isoproterenol affects sarcolemmal stability through changes in the DGC and integrins.",18808529_3,0
1997,extracellular matrix,171,191,"Taking into account that the sarcolemmal integrity is stabilized by the dystrophin-glycoprotein complex (DGC) that connects actin and laminin in contractile machinery and extracellular matrix and by integrins, this study tests the hypothesis that isoproterenol affects sarcolemmal stability through changes in the DGC and integrins.",18808529_3,0
7962,DGC,105,108,"Taking into account that the sarcolemmal integrity is stabilized by the dystrophin-glycoprotein complex (DGC) that connects actin and laminin in contractile machinery and extracellular matrix and by integrins, this study tests the hypothesis that isoproterenol affects sarcolemmal stability through changes in the DGC and integrins.",18808529_3,0
7965,DGC,314,317,"Taking into account that the sarcolemmal integrity is stabilized by the dystrophin-glycoprotein complex (DGC) that connects actin and laminin in contractile machinery and extracellular matrix and by integrins, this study tests the hypothesis that isoproterenol affects sarcolemmal stability through changes in the DGC and integrins.",18808529_3,0
1996,laminin,134,141,"Taking into account that the sarcolemmal integrity is stabilized by the dystrophin-glycoprotein complex (DGC) that connects actin and laminin in contractile machinery and extracellular matrix and by integrins, this study tests the hypothesis that isoproterenol affects sarcolemmal stability through changes in the DGC and integrins.",18808529_3,0
1998,integrins,199,208,"Taking into account that the sarcolemmal integrity is stabilized by the dystrophin-glycoprotein complex (DGC) that connects actin and laminin in contractile machinery and extracellular matrix and by integrins, this study tests the hypothesis that isoproterenol affects sarcolemmal stability through changes in the DGC and integrins.",18808529_3,0
2000,integrin,46,54,We found different sensitivity of the DGC and integrin to isoproterenol subcutaneous administration.,18808529_4,0
7966,DGC,38,41,We found different sensitivity of the DGC and integrin to isoproterenol subcutaneous administration.,18808529_4,0
7968,dystrophin,41,51,Immunofluorescent staining revealed that dystrophin is the most sensitive among the structures connecting the actin in the cardiomyocyte cytoskeleton and the extracellular matrix.,18808529_5,0
2001,extracellular matrix,158,178,Immunofluorescent staining revealed that dystrophin is the most sensitive among the structures connecting the actin in the cardiomyocyte cytoskeleton and the extracellular matrix.,18808529_5,0
2003,beta-dystroglycan,62,79,"Subsequently, after lysis of myofilaments, gamma-sarcoglycan, beta-dystroglycan, beta1-integrin, and laminin alpha-2 expressions were reduced followed by their breakdown, as epiphenomena of the myocytolytic process.",18808529_7,0
2002,gamma-sarcoglycan,43,60,"Subsequently, after lysis of myofilaments, gamma-sarcoglycan, beta-dystroglycan, beta1-integrin, and laminin alpha-2 expressions were reduced followed by their breakdown, as epiphenomena of the myocytolytic process.",18808529_7,0
2004,beta1-integrin,81,95,"Subsequently, after lysis of myofilaments, gamma-sarcoglycan, beta-dystroglycan, beta1-integrin, and laminin alpha-2 expressions were reduced followed by their breakdown, as epiphenomena of the myocytolytic process.",18808529_7,0
7971,laminin alpha-2,101,116,"Subsequently, after lysis of myofilaments, gamma-sarcoglycan, beta-dystroglycan, beta1-integrin, and laminin alpha-2 expressions were reduced followed by their breakdown, as epiphenomena of the myocytolytic process.",18808529_7,0
7973,DGC,157,160,"In conclusion, administration of isoproterenol to rats results in primary loss of dystrophin, the most sensitive among the structural proteins that form the DGC that connects the extracellular matrix and the cytoskeleton in cardiomyocyte.",18808529_8,0
2006,extracellular matrix,179,199,"In conclusion, administration of isoproterenol to rats results in primary loss of dystrophin, the most sensitive among the structural proteins that form the DGC that connects the extracellular matrix and the cytoskeleton in cardiomyocyte.",18808529_8,0
2005,structural proteins,123,142,"In conclusion, administration of isoproterenol to rats results in primary loss of dystrophin, the most sensitive among the structural proteins that form the DGC that connects the extracellular matrix and the cytoskeleton in cardiomyocyte.",18808529_8,0
7975,ischaemic injury,26,42,"These changes, related to ischaemic injury, explain the severe alterations in the structural integrity of the sarcolemma of cardiomyocytes and hence severe and irreversible injury induced by isoproterenol.",18808529_9,1
2007,Alpha-lipoic acid,0,17,Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy.,18809400_0,0
7978,experimental chemotherapy neuropathy,69,105,Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy.,18809400_0,1
7977,mitochondrial,27,40,Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy.,18809400_0,0
5682,neurotoxicity,52,65,Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy.,18809400_0,1
2010,neuroprotective effects,196,219,"The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity, if mitochondrial damage plays a critical role in toxic neurodegenerative cascade, and if neuroprotective effects of alpha-lipoic acid depend on mitochondria protection.",18809400_1,0
2009,neuroprotective,47,62,"The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity, if mitochondrial damage plays a critical role in toxic neurodegenerative cascade, and if neuroprotective effects of alpha-lipoic acid depend on mitochondria protection.",18809400_1,0
2008,alpha-lipoic acid,26,43,"The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity, if mitochondrial damage plays a critical role in toxic neurodegenerative cascade, and if neuroprotective effects of alpha-lipoic acid depend on mitochondria protection.",18809400_1,0
7979,mitochondrial,110,123,"The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity, if mitochondrial damage plays a critical role in toxic neurodegenerative cascade, and if neuroprotective effects of alpha-lipoic acid depend on mitochondria protection.",18809400_1,0
5684,neurodegenerative,162,179,"The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity, if mitochondrial damage plays a critical role in toxic neurodegenerative cascade, and if neuroprotective effects of alpha-lipoic acid depend on mitochondria protection.",18809400_1,1
2011,alpha-lipoic acid,223,240,"The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity, if mitochondrial damage plays a critical role in toxic neurodegenerative cascade, and if neuroprotective effects of alpha-lipoic acid depend on mitochondria protection.",18809400_1,0
5683,neurotoxicity,92,105,"The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity, if mitochondrial damage plays a critical role in toxic neurodegenerative cascade, and if neuroprotective effects of alpha-lipoic acid depend on mitochondria protection.",18809400_1,1
7984,chemotherapeutic drugs,254,276,"We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to paclitaxel and cisplatin, two widely used and highly effective chemotherapeutic drugs.",18809400_2,0
5685,peripheral neuropathy,50,71,"We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to paclitaxel and cisplatin, two widely used and highly effective chemotherapeutic drugs.",18809400_2,1
2013,cisplatin,206,215,"We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to paclitaxel and cisplatin, two widely used and highly effective chemotherapeutic drugs.",18809400_2,0
2012,paclitaxel,191,201,"We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to paclitaxel and cisplatin, two widely used and highly effective chemotherapeutic drugs.",18809400_2,0
7981,dorsal root ganglion,145,165,"We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to paclitaxel and cisplatin, two widely used and highly effective chemotherapeutic drugs.",18809400_2,1
7987,toxic agents,194,206,This approach allowed investigating the efficacy of alpha-lipoic acid in preventing axonal damage and apoptosis and the function and ultrastructural morphology of mitochondria after exposure to toxic agents and alpha-lipoic acid.,18809400_3,0
7985,axonal damage,84,97,This approach allowed investigating the efficacy of alpha-lipoic acid in preventing axonal damage and apoptosis and the function and ultrastructural morphology of mitochondria after exposure to toxic agents and alpha-lipoic acid.,18809400_3,1
2014,alpha-lipoic acid,52,69,This approach allowed investigating the efficacy of alpha-lipoic acid in preventing axonal damage and apoptosis and the function and ultrastructural morphology of mitochondria after exposure to toxic agents and alpha-lipoic acid.,18809400_3,0
2015,alpha-lipoic acid,211,228,This approach allowed investigating the efficacy of alpha-lipoic acid in preventing axonal damage and apoptosis and the function and ultrastructural morphology of mitochondria after exposure to toxic agents and alpha-lipoic acid.,18809400_3,0
5686,loss of,101,108,Our results demonstrate that both cisplatin and paclitaxel cause early mitochondrial impairment with loss of membrane potential and induction of autophagic vacuoles in neurons.,18809400_4,1
2016,cisplatin,34,43,Our results demonstrate that both cisplatin and paclitaxel cause early mitochondrial impairment with loss of membrane potential and induction of autophagic vacuoles in neurons.,18809400_4,0
2017,paclitaxel,48,58,Our results demonstrate that both cisplatin and paclitaxel cause early mitochondrial impairment with loss of membrane potential and induction of autophagic vacuoles in neurons.,18809400_4,0
7988,mitochondrial,71,84,Our results demonstrate that both cisplatin and paclitaxel cause early mitochondrial impairment with loss of membrane potential and induction of autophagic vacuoles in neurons.,18809400_4,0
2018,Alpha-lipoic acid,0,17,"Alpha-lipoic acid exerts neuroprotective effects against chemotherapy induced neurotoxicity in sensory neurons: it rescues the mitochondrial toxicity and induces the expression of frataxin, an essential mitochondrial protein with anti-oxidant and chaperone properties.",18809400_5,0
2019,neuroprotective effects,25,48,"Alpha-lipoic acid exerts neuroprotective effects against chemotherapy induced neurotoxicity in sensory neurons: it rescues the mitochondrial toxicity and induces the expression of frataxin, an essential mitochondrial protein with anti-oxidant and chaperone properties.",18809400_5,0
2020,mitochondrial protein,203,224,"Alpha-lipoic acid exerts neuroprotective effects against chemotherapy induced neurotoxicity in sensory neurons: it rescues the mitochondrial toxicity and induces the expression of frataxin, an essential mitochondrial protein with anti-oxidant and chaperone properties.",18809400_5,0
2021,anti-oxidant,230,242,"Alpha-lipoic acid exerts neuroprotective effects against chemotherapy induced neurotoxicity in sensory neurons: it rescues the mitochondrial toxicity and induces the expression of frataxin, an essential mitochondrial protein with anti-oxidant and chaperone properties.",18809400_5,0
7990,mitochondrial,127,140,"Alpha-lipoic acid exerts neuroprotective effects against chemotherapy induced neurotoxicity in sensory neurons: it rescues the mitochondrial toxicity and induces the expression of frataxin, an essential mitochondrial protein with anti-oxidant and chaperone properties.",18809400_5,0
5687,neurotoxicity,78,91,"Alpha-lipoic acid exerts neuroprotective effects against chemotherapy induced neurotoxicity in sensory neurons: it rescues the mitochondrial toxicity and induces the expression of frataxin, an essential mitochondrial protein with anti-oxidant and chaperone properties.",18809400_5,1
7991,frataxin,180,188,"Alpha-lipoic acid exerts neuroprotective effects against chemotherapy induced neurotoxicity in sensory neurons: it rescues the mitochondrial toxicity and induces the expression of frataxin, an essential mitochondrial protein with anti-oxidant and chaperone properties.",18809400_5,0
5688,neurotoxicity,103,116,In conclusion mitochondrial toxicity is an early common event both in paclitaxel and cisplatin induced neurotoxicity.,18809400_6,1
2022,paclitaxel,70,80,In conclusion mitochondrial toxicity is an early common event both in paclitaxel and cisplatin induced neurotoxicity.,18809400_6,0
2023,cisplatin,85,94,In conclusion mitochondrial toxicity is an early common event both in paclitaxel and cisplatin induced neurotoxicity.,18809400_6,0
7992,mitochondrial,14,27,In conclusion mitochondrial toxicity is an early common event both in paclitaxel and cisplatin induced neurotoxicity.,18809400_6,0
2024,Alpha-lipoic acid,0,17,"Alpha-lipoic acid protects sensory neurons through its anti-oxidant and mitochondrial regulatory functions, possibly inducing the expression of frataxin.",18809400_7,0
2025,anti-oxidant,55,67,"Alpha-lipoic acid protects sensory neurons through its anti-oxidant and mitochondrial regulatory functions, possibly inducing the expression of frataxin.",18809400_7,0
7994,mitochondrial,72,85,"Alpha-lipoic acid protects sensory neurons through its anti-oxidant and mitochondrial regulatory functions, possibly inducing the expression of frataxin.",18809400_7,0
7995,frataxin,144,152,"Alpha-lipoic acid protects sensory neurons through its anti-oxidant and mitochondrial regulatory functions, possibly inducing the expression of frataxin.",18809400_7,0
5689,peripheral nerve,82,98,These findings suggest that alpha-lipoic acid might reduce the risk of developing peripheral nerve toxicity in patients undergoing chemotherapy and encourage further confirmatory clinical trials.,18809400_8,1
2026,alpha-lipoic acid,28,45,These findings suggest that alpha-lipoic acid might reduce the risk of developing peripheral nerve toxicity in patients undergoing chemotherapy and encourage further confirmatory clinical trials.,18809400_8,0
2027,methemoglobin,204,217,Toxicity in rhesus monkeys following administration of the 8-aminoquinoline 8-[(4-amino-l-methylbutyl)amino]- 5-(l-hexyloxy)-6-methoxy-4-methylquinoline (WR242511).INTRODUCTION: Many substances that form methemoglobin (MHb) effectively counter cyanide (CN) toxicity.,18821488_0,0
7997,8-aminoquinoline,59,75,Toxicity in rhesus monkeys following administration of the 8-aminoquinoline 8-[(4-amino-l-methylbutyl)amino]- 5-(l-hexyloxy)-6-methoxy-4-methylquinoline (WR242511).INTRODUCTION: Many substances that form methemoglobin (MHb) effectively counter cyanide (CN) toxicity.,18821488_0,0
7998,MHb,219,222,Toxicity in rhesus monkeys following administration of the 8-aminoquinoline 8-[(4-amino-l-methylbutyl)amino]- 5-(l-hexyloxy)-6-methoxy-4-methylquinoline (WR242511).INTRODUCTION: Many substances that form methemoglobin (MHb) effectively counter cyanide (CN) toxicity.,18821488_0,0
7999,CN,253,255,Toxicity in rhesus monkeys following administration of the 8-aminoquinoline 8-[(4-amino-l-methylbutyl)amino]- 5-(l-hexyloxy)-6-methoxy-4-methylquinoline (WR242511).INTRODUCTION: Many substances that form methemoglobin (MHb) effectively counter cyanide (CN) toxicity.,18821488_0,0
8002,MHb,123,126,"Although MHb formers are generally applied as treatments for CN poisoning, it has been proposed that a stable, long-acting MHb former could serve as a CN pretreatment.",18821488_1,0
8003,CN,151,153,"Although MHb formers are generally applied as treatments for CN poisoning, it has been proposed that a stable, long-acting MHb former could serve as a CN pretreatment.",18821488_1,0
8000,MHb,9,12,"Although MHb formers are generally applied as treatments for CN poisoning, it has been proposed that a stable, long-acting MHb former could serve as a CN pretreatment.",18821488_1,0
8001,CN,61,63,"Although MHb formers are generally applied as treatments for CN poisoning, it has been proposed that a stable, long-acting MHb former could serve as a CN pretreatment.",18821488_1,1
8023,WR242511,21,29,It is concluded that WR242511 should not be pursued as a pretreatment for CN poisoning unless the anti-CN characteristics of this compound can be successfully dissociated from those producing undesirable toxicity.,18821488_10,0
8024,CN,74,76,It is concluded that WR242511 should not be pursued as a pretreatment for CN poisoning unless the anti-CN characteristics of this compound can be successfully dissociated from those producing undesirable toxicity.,18821488_10,0
8009,CN,187,189,"Using this rationale, the 8-aminoquinoline WR242511, a potent long-lasting MHb former in rodents and beagle dogs, was studied in the rhesus monkey for advanced development as a potential CN pretreatment.",18821488_2,0
8006,MHb,75,78,"Using this rationale, the 8-aminoquinoline WR242511, a potent long-lasting MHb former in rodents and beagle dogs, was studied in the rhesus monkey for advanced development as a potential CN pretreatment.",18821488_2,0
8005,8-aminoquinoline WR242511,26,51,"Using this rationale, the 8-aminoquinoline WR242511, a potent long-lasting MHb former in rodents and beagle dogs, was studied in the rhesus monkey for advanced development as a potential CN pretreatment.",18821488_2,0
8012,WR242511,169,177,"METHODS: In this study, WR242511 was administered intravenously (IV) in 2 female and 4 male rhesus monkeys in doses of 3.5 and/or 7.0 mg/kg; a single male also received WR242511 orally (PO) at 7.0 mg/kg.",18821488_3,0
8010,WR242511,24,32,"METHODS: In this study, WR242511 was administered intravenously (IV) in 2 female and 4 male rhesus monkeys in doses of 3.5 and/or 7.0 mg/kg; a single male also received WR242511 orally (PO) at 7.0 mg/kg.",18821488_3,0
8014,MHb,18,21,Health status and MHb levels were monitored following exposure.,18821488_4,0
8015,WR242511,31,39,"RESULTS: The selected doses of WR242511, which produced significant methemoglobinemia in beagle dogs in earlier studies conducted elsewhere, produced very little MHb (mean < 2.0%) in the rhesus monkey.",18821488_5,0
5690,methemoglobinemia,68,85,"RESULTS: The selected doses of WR242511, which produced significant methemoglobinemia in beagle dogs in earlier studies conducted elsewhere, produced very little MHb (mean < 2.0%) in the rhesus monkey.",18821488_5,1
8020,WR242511,90,98,"Furthermore, transient hemoglobinuria was noted approximately 60 minutes postinjection of WR242511 (3.5 or 7.0 mg/kg), and 2 lethalities occurred (one IV and one PO) following the 7.0 mg/kg dose.",18821488_6,0
5691,drug-induced,59,71,CONCLUSIONS: These data demonstrate direct and/or indirect drug-induced toxicity.,18821488_9,1
8026,liver tumors,41,53,Etiologic factors in the pathogenesis of liver tumors associated with oral contraceptives.,188339_0,1
2028,oral contraceptives,70,89,Etiologic factors in the pathogenesis of liver tumors associated with oral contraceptives.,188339_0,0
8029,oral contraceptive steroids,96,123,"Within the last several years, previously rare liver tumors have been seen in young women using oral contraceptive steroids.",188339_1,0
8028,liver tumors,47,59,"Within the last several years, previously rare liver tumors have been seen in young women using oral contraceptive steroids.",188339_1,1
8031,Irvine,99,105,"The Registry for Liver Tumors Associated with Oral Contraceptives at the University of California, Irvine, has clearly identified 27 cases.",188339_2,0
2029,Oral Contraceptives,46,65,"The Registry for Liver Tumors Associated with Oral Contraceptives at the University of California, Irvine, has clearly identified 27 cases.",188339_2,0
8033,histopathologic diagnosis,36,61,"Common to these 71 cases has been a histopathologic diagnosis of focal nodular hyperplasia, adenoma, hamartoma, and hepatoma.",188339_4,1
5692,focal nodular hyperplasia,65,90,"Common to these 71 cases has been a histopathologic diagnosis of focal nodular hyperplasia, adenoma, hamartoma, and hepatoma.",188339_4,1
8035,oral contraceptive steroids,83,110,Significant statistical etiologic factors include prolonged uninterrupted usage of oral contraceptive steroids.,188339_5,0
8036,liver rupture,17,30,Eight deaths and liver rupture in 18 patients attest to the seriousness of this new potentially lethal adverse phenomenon.,188339_6,1
8037,adverse phenomenon,103,121,Eight deaths and liver rupture in 18 patients attest to the seriousness of this new potentially lethal adverse phenomenon.,188339_6,1
5693,Parkinson's disease,81,100,Repetitive transcranial magnetic stimulation for levodopa-induced dyskinesias in Parkinson's disease.,18951540_0,1
8046,peak dose dyskinesias,175,196,"In a placebo-controlled, single-blinded, crossover study, we assessed the effect of ""real"" repetitive transcranial magnetic stimulation (rTMS) versus ""sham"" rTMS (placebo) on peak dose dyskinesias in patients with Parkinson's disease (PD).",18951540_1,1
5694,Parkinson's disease,214,233,"In a placebo-controlled, single-blinded, crossover study, we assessed the effect of ""real"" repetitive transcranial magnetic stimulation (rTMS) versus ""sham"" rTMS (placebo) on peak dose dyskinesias in patients with Parkinson's disease (PD).",18951540_1,1
8047,prominent dyskinesias,25,46,"Ten patients with PD and prominent dyskinesias had rTMS (1,800 pulses; 1 Hz rate) delivered over the motor cortex for 4 consecutive days twice, once real stimuli and once sham stimulation were used; evaluations were done at the baseline and 1 day after the end of each of the treatment series.",18951540_2,1
8049,motor cortex,101,113,"Ten patients with PD and prominent dyskinesias had rTMS (1,800 pulses; 1 Hz rate) delivered over the motor cortex for 4 consecutive days twice, once real stimuli and once sham stimulation were used; evaluations were done at the baseline and 1 day after the end of each of the treatment series.",18951540_2,1
8051,clinician-assessed dyskinesia,89,118,Direct comparison between sham and real rTMS effects showed no significant difference in clinician-assessed dyskinesia severity.,18951540_3,1
5695,dystonia,24,32,The major effect was on dystonia subscore.,18951540_5,1
8054,subjective dyskinesia,76,97,"Similarly, in patient diaries, although both treatments caused reduction in subjective dyskinesia scores during the days of intervention, the effect was sustained for 3 days after the intervention for the real rTMS only.",18951540_6,1
5697,adverse effects,39,54,"Following rTMS, no side effects and no adverse effects on motor function and PD symptoms were noted.",18951540_7,1
5696,side effects,19,31,"Following rTMS, no side effects and no adverse effects on motor function and PD symptoms were noted.",18951540_7,1
8057,motor function,58,72,"Following rTMS, no side effects and no adverse effects on motor function and PD symptoms were noted.",18951540_7,1
8058,low-frequency,116,129,The results suggest the existence of residual beneficial clinical aftereffects of consecutive daily applications of low-frequency rTMS on dyskinesias in PD.,18951540_8,1
2030,therapeutic uses,51,67,The effects may be further exploited for potential therapeutic uses.,18951540_9,0
2031,Ifosfamide,0,10,Ifosfamide continuous infusion without mesna.,1899352_0,0
2032,mesna,39,44,Ifosfamide continuous infusion without mesna.,1899352_0,0
2040,Mesna,132,137,"The frequency and predictability of hematuria are not precise, and at least daily monitoring by urine Hematest is essential, adding Mesna to the infusate in patients with persistent hematuria.",1899352_10,0
8070,infusate,145,153,"The frequency and predictability of hematuria are not precise, and at least daily monitoring by urine Hematest is essential, adding Mesna to the infusate in patients with persistent hematuria.",1899352_10,0
8071,persistent hematuria,171,191,"The frequency and predictability of hematuria are not precise, and at least daily monitoring by urine Hematest is essential, adding Mesna to the infusate in patients with persistent hematuria.",1899352_10,1
2041,ifosfamide,37,47,The protracted infusion schedule for ifosfamide permits convenient outpatient administration without Mesna and reduces the drug cost of clinical usage of this agent by up to  890 per cycle.,1899352_11,0
2042,Mesna,101,106,The protracted infusion schedule for ifosfamide permits convenient outpatient administration without Mesna and reduces the drug cost of clinical usage of this agent by up to  890 per cycle.,1899352_11,0
2033,ifosfamide,39,49,Twenty patients received 27 courses of ifosfamide administered as a 24-hour continuous infusion for 14 days without Mesna.,1899352_2,0
2034,Mesna,116,121,Twenty patients received 27 courses of ifosfamide administered as a 24-hour continuous infusion for 14 days without Mesna.,1899352_2,0
2035,ifosfamide,78,88,The goal of the study was to deliver a dose rate and total cumulative dose of ifosfamide that would be comparable to standard bolus or short-term infusions administered with Mesna.,1899352_3,0
2036,Mesna,174,179,The goal of the study was to deliver a dose rate and total cumulative dose of ifosfamide that would be comparable to standard bolus or short-term infusions administered with Mesna.,1899352_3,0
8060,mg/m2/d,67,74,"Dose escalations proceeded from 200 to 300, 400, 450, 500, and 550 mg/m2/d.",1899352_4,0
8061,mg/m2/d,77,84,"Four patients developed transient microscopic hematuria at 400, 450, and 500 mg/m2/d.",1899352_5,0
8062,macroscopic hematuria,27,48,There were no instances of macroscopic hematuria.,1899352_6,1
5698,Grade 2,96,103,"At 550 mg/m2/d, three patients experienced nonurologic toxicity; confusion (1), nausea (1), and Grade 2 leukopenia (1).",1899352_7,1
8064,nonurologic,43,54,"At 550 mg/m2/d, three patients experienced nonurologic toxicity; confusion (1), nausea (1), and Grade 2 leukopenia (1).",1899352_7,1
2039,(1,115,117,"At 550 mg/m2/d, three patients experienced nonurologic toxicity; confusion (1), nausea (1), and Grade 2 leukopenia (1).",1899352_7,0
2038,(1,87,89,"At 550 mg/m2/d, three patients experienced nonurologic toxicity; confusion (1), nausea (1), and Grade 2 leukopenia (1).",1899352_7,0
2037,(1,75,77,"At 550 mg/m2/d, three patients experienced nonurologic toxicity; confusion (1), nausea (1), and Grade 2 leukopenia (1).",1899352_7,0
8066,mg/m2/d,28,35,"The recommended dose of 500 mg/m2/d delivers a total dose of 7 g/m2 per cycle, which is comparable to that delivered in clinical practice for bolus or short-term infusion.",1899352_8,0
8067,g/m2,63,67,"The recommended dose of 500 mg/m2/d delivers a total dose of 7 g/m2 per cycle, which is comparable to that delivered in clinical practice for bolus or short-term infusion.",1899352_8,0
8077,emergency department,79,99,Intracavernous epinephrine: a minimally invasive treatment for priapism in the emergency department.,18996674_0,1
8081,cocaine use,156,167,"A 45-year-old man, an admitted frequent cocaine user, presented to the Emergency Department (ED) on two separate occasions with a history of priapism after cocaine use.",18996674_2,1
8082,management options,4,22,"The management options in the ED, as exemplified by four individual case reports, in particular the use of a minimally invasive method of intracorporal epinephrine instillation, are discussed.",18996674_3,0
5699,ventricular tachycardia,10,33,A case of ventricular tachycardia related to caffeine pretreatment.,18997632_0,1
8087,Intravenous caffeine,0,20,Intravenous caffeine is commonly used to improve seizure duration and quality in such patients and is generally well tolerated aside from occasional reports of relatively benign ventricular ectopy.,18997632_2,0
5700,ventricular ectopy,178,196,Intravenous caffeine is commonly used to improve seizure duration and quality in such patients and is generally well tolerated aside from occasional reports of relatively benign ventricular ectopy.,18997632_2,1
5701,cardiac disease,50,65,We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after caffeine administration.,18997632_3,1
5702,ventricular tachycardia,133,156,We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after caffeine administration.,18997632_3,1
8089,bigeminy,104,112,We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after caffeine administration.,18997632_3,0
8091,intravenous caffeine,9,29,"Although intravenous caffeine is generally well tolerated, the clinician should be aware of the potential for unpredictable and serious ventricular arrhythmias.",18997632_4,0
8092,ventricular arrhythmias,136,159,"Although intravenous caffeine is generally well tolerated, the clinician should be aware of the potential for unpredictable and serious ventricular arrhythmias.",18997632_4,1
8095,rheumatologic disorders,74,97,Prophylactic use of lamivudine with chronic immunosuppressive therapy for rheumatologic disorders.,19037603_0,1
8096,prophylactic administration,93,120,The objective of this study was to report our experience concerning the effectiveness of the prophylactic administration of lamivudine in hepatitis B virus surface antigen (HBs Ag) positive patients with rheumatologic disease.,19037603_1,0
8097,rheumatologic disease,204,225,The objective of this study was to report our experience concerning the effectiveness of the prophylactic administration of lamivudine in hepatitis B virus surface antigen (HBs Ag) positive patients with rheumatologic disease.,19037603_1,1
8111,HBV,30,33,"In three additional patients, HBV DNA levels were increased during follow-up.",19037603_10,0
8113,HBV,55,58,None of the patients had significant clinical sings of HBV activation.,19037603_11,0
8098,rheumatologic diseases,65,87,"From June 2004 to October 2006, 11 HBs Ag positive patients with rheumatologic diseases, who were on both immunosuppressive and prophylactic lamivudine therapies, were retrospectively assessed.",19037603_2,1
8102,HBV,41,44,"Liver function tests, hepatitis B virus (HBV) serologic markers, and HBV DNA levels of the patients during follow-up were obtained from hospital file records.",19037603_3,0
8103,HBV,69,72,"Liver function tests, hepatitis B virus (HBV) serologic markers, and HBV DNA levels of the patients during follow-up were obtained from hospital file records.",19037603_3,0
8100,Liver function,0,14,"Liver function tests, hepatitis B virus (HBV) serologic markers, and HBV DNA levels of the patients during follow-up were obtained from hospital file records.",19037603_3,1
8107,liver function,10,24,"Baseline, liver function tests were elevated in two patients (fourth patient: ALT:122 IU/l, AST:111 IU/l, tenth patient:ALT:294 IU/l, AST:274 IU/l, with minimal changes in the liver biopsy in both).",19037603_6,1
8109,liver function,109,123,Shortly after treatment their tests normalized and during follow-up period none of the patients had abnormal liver function tests.,19037603_7,1
8110,HBV,17,20,In four patients HBV DNA levels were higher than normal at baseline.,19037603_8,0
2043,green tea,10,19,Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats.,19058010_0,0
8116,vitamin E,24,33,Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats.,19058010_0,0
5703,myocardial infarction,71,92,Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats.,19058010_0,1
8122,membrane bound ATPases,191,213,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.",19058010_1,0
5705,myocardial infarction,245,266,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.",19058010_1,1
2044,green tea,67,76,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.",19058010_1,0
2045,endogenous antioxidants,163,186,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.",19058010_1,0
8121,lipid peroxidation,143,161,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.",19058010_1,0
8120,serum marker enzymes,121,141,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.",19058010_1,0
8119,heart weight,94,106,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.",19058010_1,1
5704,body weight,108,119,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.",19058010_1,1
8118,vitamin E,81,90,"The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced myocardial infarction in rats.",19058010_1,0
5706,body weight,266,277,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.",19058010_2,1
2046,ATPase,200,206,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.",19058010_2,0
2047,endogenous antioxidants,279,302,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.",19058010_2,0
2048,ATPase,328,334,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.",19058010_2,0
8127,lipid peroxidation,172,190,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.",19058010_2,0
8124,ISO,37,40,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.",19058010_2,0
8128,K+ ATPase,309,318,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.",19058010_2,0
8125,heart weight,136,148,"Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and Ca+2 ATPase level whereas there was a significant (P<0.05) decrease in body weight, endogenous antioxidants, Na+/ K+ ATPase and Mg+2 ATPase levels.",19058010_2,1
8129,vitamin E,54,63,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,0
8131,heart weight,211,223,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,1
5707,body weight,313,324,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,1
8134,ISO,400,403,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,0
2054,green tea,422,431,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,0
2053,ATPase,374,380,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,0
2049,green tea,18,27,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,0
2052,ATPase,358,364,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,0
2051,endogenous antioxidants,326,349,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,0
2050,ATPase,272,278,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,0
8135,vitamin E,435,444,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,0
8133,lipid peroxidation,247,265,"Administration of green tea (100 mg/kg/day, p.o.) and vitamin E (100 mg/kg/day, p.o.) together for 30 consecutive days and challenged with ISO on the day 29th and 30th, showed a significant (P<0.05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups.",19058010_3,0
5708,myocardial infarction,104,125,These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.,19058010_4,1
8137,vitamin E,75,84,These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.,19058010_4,0
2055,green tea,61,70,These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.,19058010_4,0
8136,protective effect,40,57,These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats.,19058010_4,0
8140,gastrointestinal haemorrhage,27,55,Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.,19058474_0,1
8139,Fatal haemopericardium,0,22,Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.,19058474_0,1
8141,cranberry juice,87,102,Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.,19058474_0,0
8142,internal haemorrhage,26,46,We report a case of fatal internal haemorrhage in an elderly man who consumed only cranberry juice for two weeks while maintaining his usual dosage of warfarin.,19058474_1,1
8144,cranberry juice,83,98,We report a case of fatal internal haemorrhage in an elderly man who consumed only cranberry juice for two weeks while maintaining his usual dosage of warfarin.,19058474_1,0
2056,his,131,134,We report a case of fatal internal haemorrhage in an elderly man who consumed only cranberry juice for two weeks while maintaining his usual dosage of warfarin.,19058474_1,0
8145,fruit juices,87,99,"We propose that naturally occurring compounds such as flavonoids, which are present in fruit juices, may increase the potency of warfarin by competing for the enzymes that normally inactivate warfarin.",19058474_2,0
8146,fruit juices,59,71,"While traditionally regarded as foodstuffs, consumption of fruit juices should be considered when patients develop adverse drug reactions.",19058474_3,0
5709,adverse drug reactions,115,137,"While traditionally regarded as foodstuffs, consumption of fruit juices should be considered when patients develop adverse drug reactions.",19058474_3,1
2057,bupropion,55,64,Effect of increasing intraperitoneal infusion rates on bupropion hydrochloride-induced seizures in mice.,19105845_0,0
2062,bupropion,128,137,"CONCLUSION: In conclusion, the demonstration of an inverse relationship between infusion time of a fixed and convulsive dose of bupropion and the risk of convulsions in a prospective study is novel.",19105845_10,0
8167,convulsive dose,109,124,"CONCLUSION: In conclusion, the demonstration of an inverse relationship between infusion time of a fixed and convulsive dose of bupropion and the risk of convulsions in a prospective study is novel.",19105845_10,0
2059,bupropion,70,79,"This is important, since different controlled release formulations of bupropion release the active drug at different rates.",19105845_2,0
2058,controlled release formulations,35,66,"This is important, since different controlled release formulations of bupropion release the active drug at different rates.",19105845_2,0
8149,active drug,92,103,"This is important, since different controlled release formulations of bupropion release the active drug at different rates.",19105845_2,0
8152,convulsive dose,118,133,"METHODS: We investigated the effect of varying the intraperitoneal infusion rates of bupropion HCl 120 mg/kg, a known convulsive dose 50 (CD50), on the incidence and severity of bupropion-induced convulsions in the Swiss albino mice.",19105845_3,0
2060,CD50,138,142,"METHODS: We investigated the effect of varying the intraperitoneal infusion rates of bupropion HCl 120 mg/kg, a known convulsive dose 50 (CD50), on the incidence and severity of bupropion-induced convulsions in the Swiss albino mice.",19105845_3,0
8150,intraperitoneal,51,66,"METHODS: We investigated the effect of varying the intraperitoneal infusion rates of bupropion HCl 120 mg/kg, a known convulsive dose 50 (CD50), on the incidence and severity of bupropion-induced convulsions in the Swiss albino mice.",19105845_3,1
8151,bupropion HCl,85,98,"METHODS: We investigated the effect of varying the intraperitoneal infusion rates of bupropion HCl 120 mg/kg, a known convulsive dose 50 (CD50), on the incidence and severity of bupropion-induced convulsions in the Swiss albino mice.",19105845_3,0
8153,bupropion-induced convulsions,178,207,"METHODS: We investigated the effect of varying the intraperitoneal infusion rates of bupropion HCl 120 mg/kg, a known convulsive dose 50 (CD50), on the incidence and severity of bupropion-induced convulsions in the Swiss albino mice.",19105845_3,0
8155,bupropion HCl,104,117,"A total of 69 mice, approximately 7 weeks of age, and weighing 21.0 to 29.1 g were randomly assigned to bupropion HCl 120 mg/kg treatment by intraperitoneal (IP) administration in 7 groups (9 to 10 animals per group).",19105845_4,0
8157,Bupropion HCl,0,13,"Bupropion HCl was infused through a surgically implanted IP dosing catheter with infusions in each group of 0 min, 15 min, 30 min, 60 min, 90 min, 120 min, and 240 min.",19105845_5,0
8158,surgically implanted,36,56,"Bupropion HCl was infused through a surgically implanted IP dosing catheter with infusions in each group of 0 min, 15 min, 30 min, 60 min, 90 min, 120 min, and 240 min.",19105845_5,1
8160,bupropion HCl,54,67,RESULTS: The results showed that IP administration of bupropion HCl 120 mg/kg by bolus injection induced convulsions in 6 out of 10 mice (60% of convulsing mice) in group 1.,19105845_7,0
2061,group 1,165,172,RESULTS: The results showed that IP administration of bupropion HCl 120 mg/kg by bolus injection induced convulsions in 6 out of 10 mice (60% of convulsing mice) in group 1.,19105845_7,0
8164,bupropion HCl,145,158,Logistic regression analysis revealed that infusion time was significant (p = 0.0004; odds ratio = 0.974) and increasing the IP infusion time of bupropion HCl 120 mg/kg was associated with a 91% reduced odds of convulsions at infusion times of 15 to 90 min compared to bolus injection.,19105845_8,0
2063,everolimus,43,53,Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.,19135948_0,0
5711,sinusoidal obstruction syndrome,108,139,Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.,19135948_0,1
5712,microangiopathy,144,159,Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.,19135948_0,1
2064,tacrolimus,58,68,Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.,19135948_0,0
5710,Graft-versus-host disease,0,25,Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.,19135948_0,1
5713,graft-versus-host disease,83,108,A calcineurin inhibitor combined with methotrexate is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).,19135948_1,1
8172,hematopoietic stem cell transplantation,133,172,A calcineurin inhibitor combined with methotrexate is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).,19135948_1,1
2065,calcineurin inhibitor,2,23,A calcineurin inhibitor combined with methotrexate is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).,19135948_1,0
2066,Everolimus,0,10,"Everolimus, a derivative of sirolimus, seems to mediate antileukemia effects.",19135948_2,0
2067,sirolimus,28,37,"Everolimus, a derivative of sirolimus, seems to mediate antileukemia effects.",19135948_2,0
2069,tacrolimus,45,55,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,0
5715,acute myeloid leukemia,148,170,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,1
5714,myelodysplastic syndrome,106,130,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,1
2068,everolimus,30,40,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,0
8175,AML,172,175,"We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors.",19135948_3,0
8178,grade IV mucositis,55,73,"All patients engrafted, and only 1 patient experienced grade IV mucositis.",19135948_4,1
5716,microangiopathy,27,42,"Transplantation-associated microangiopathy (TMA) occurred in 7 patients (29%), with 2 cases of acute renal failure.",19135948_6,1
8179,TMA,44,47,"Transplantation-associated microangiopathy (TMA) occurred in 7 patients (29%), with 2 cases of acute renal failure.",19135948_6,0
5717,acute renal failure,95,114,"Transplantation-associated microangiopathy (TMA) occurred in 7 patients (29%), with 2 cases of acute renal failure.",19135948_6,1
5718,sinusoidal obstruction syndrome,86,117,"The study was terminated prematurely because an additional 6 patients (25%) developed sinusoidal obstruction syndrome (SOS), which was fatal in 2 cases.",19135948_7,1
8183,TMA,113,116,"Although this new combination appears to be effective as a prophylactic regimen for acute GVHD, the incidence of TMA and SOS is considerably higher than seen with other regimens.",19135948_9,0
8185,air conduction,27,41,Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas.,19139001_0,1
8187,colorectal adenomas,150,169,Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas.,19139001_0,1
2070,difluoromethylornithine,86,109,Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas.,19139001_0,0
2071,difluoromethylornithine,108,131,A phase III clinical trial assessed the recurrence of adenomatous polyps after treatment for 36 months with difluoromethylornithine (DFMO) plus sulindac or matched placebos.,19139001_1,0
5719,adenomatous polyps,54,72,A phase III clinical trial assessed the recurrence of adenomatous polyps after treatment for 36 months with difluoromethylornithine (DFMO) plus sulindac or matched placebos.,19139001_1,1
8188,DFMO,133,137,A phase III clinical trial assessed the recurrence of adenomatous polyps after treatment for 36 months with difluoromethylornithine (DFMO) plus sulindac or matched placebos.,19139001_1,0
5722,ototoxicity,35,46,"The estimated attributable risk of ototoxicity from exposure to the drug is 8.4% (95% confidence interval, -2.0% to 18.8%; P = 0.12).",19139001_10,1
8204,DFMO,72,76,There is a <2 dB difference in mean threshold for patients treated with DFMO plus sulindac compared with those treated with placebo.,19139001_11,0
8191,serial air conduction,122,143,"Temporary hearing loss is a known toxicity of treatment with DFMO, thus a comprehensive approach was developed to analyze serial air conduction audiograms.",19139001_2,1
5720,hearing loss,10,22,"Temporary hearing loss is a known toxicity of treatment with DFMO, thus a comprehensive approach was developed to analyze serial air conduction audiograms.",19139001_2,1
8190,DFMO,61,65,"Temporary hearing loss is a known toxicity of treatment with DFMO, thus a comprehensive approach was developed to analyze serial air conduction audiograms.",19139001_2,0
8192,air conduction,121,135,The generalized estimating equation method estimated the mean difference between treatment arms with regard to change in air conduction pure tone thresholds while accounting for within-subject correlation due to repeated measurements at frequencies.,19139001_3,1
8193,DFMO,96,100,"Based on 290 subjects, there was an average difference of 0.50 dB between subjects treated with DFMO plus sulindac compared with those treated with placebo (95% confidence interval, -0.64 to 1.63 dB; P = 0.39), adjusted for baseline values, age, and frequencies.",19139001_4,0
8197,DFMO,35,39,There were 14 of 151 (9.3%) in the DFMO plus sulindac group and 4 of 139 (2.9%) in the placebo group who experienced at least 15 dB hearing reduction from baseline in 2 or more consecutive frequencies across the entire range tested (P = 0.02).,19139001_7,0
8199,hearing reduction,132,149,There were 14 of 151 (9.3%) in the DFMO plus sulindac group and 4 of 139 (2.9%) in the placebo group who experienced at least 15 dB hearing reduction from baseline in 2 or more consecutive frequencies across the entire range tested (P = 0.02).,19139001_7,1
5721,hearing loss,137,149,There was no significant difference in the proportion of subjects in the DFMO plus sulindac group who experienced clinically significant hearing loss compared with the placebo group.,19139001_9,1
8201,DFMO,73,77,There was no significant difference in the proportion of subjects in the DFMO plus sulindac group who experienced clinically significant hearing loss compared with the placebo group.,19139001_9,0
8207,F344,91,95,Irreversible damage to the medullary interstitium in experimental analgesic nephropathy in F344 rats.,1919871_0,0
5723,papillary necrosis,6,24,Renal papillary necrosis (RPN) and a decreased urinary concentrating ability developed during continuous long-term treatment with aspirin and paracetamol in female Fischer 344 rats.,1919871_1,1
2072,paracetamol,142,153,Renal papillary necrosis (RPN) and a decreased urinary concentrating ability developed during continuous long-term treatment with aspirin and paracetamol in female Fischer 344 rats.,1919871_1,0
8208,RPN,26,29,Renal papillary necrosis (RPN) and a decreased urinary concentrating ability developed during continuous long-term treatment with aspirin and paracetamol in female Fischer 344 rats.,1919871_1,0
8213,inner medullary structural damage,127,160,The recovery of urinary concentrating ability was related to the length of analgesic treatment and the extent of the resulting inner medullary structural damage.,1919871_4,1
8217,type 1,146,152,This study shows that prolonged analgesic treatment in Fischer 344 rats causes progressive and irreversible damage to the interstitial matrix and type 1 interstitial cells leading to RPN.,1919871_6,0
8219,RPN,183,186,This study shows that prolonged analgesic treatment in Fischer 344 rats causes progressive and irreversible damage to the interstitial matrix and type 1 interstitial cells leading to RPN.,1919871_6,0
8221,structural damage,90,107,The associated urinary concentrating defect is reversible only during the early stages of structural damage to the inner medulla.,1919871_7,1
2073,sulphasalazine,117,131,Proteinase 3-antineutrophil cytoplasmic antibody-(PR3-ANCA) positive necrotizing glomerulonephritis after restarting sulphasalazine treatment.,19203554_0,0
8223,Proteinase 3-antineutrophil,0,27,Proteinase 3-antineutrophil cytoplasmic antibody-(PR3-ANCA) positive necrotizing glomerulonephritis after restarting sulphasalazine treatment.,19203554_0,0
8224,necrotizing glomerulonephritis,69,99,Proteinase 3-antineutrophil cytoplasmic antibody-(PR3-ANCA) positive necrotizing glomerulonephritis after restarting sulphasalazine treatment.,19203554_0,1
2074,sulphasalazine,141,155,"A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.",19203554_1,0
5724,ulcerative colitis,25,43,"A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.",19203554_1,1
8225,red eyes,54,62,"A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.",19203554_1,1
8226,urinary abnormalities,99,120,"A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.",19203554_1,1
5725,pleural effusion,64,80,"A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment.",19203554_1,1
8229,necrotizing glomerulonephritis,55,85,Light microscopy of a kidney biopsy revealed segmental necrotizing glomerulonephritis without deposition of immunoglobulin or complement.,19203554_2,1
8230,Proteinase 3-antineutrophil,0,27,"Proteinase 3-antineutrophil cytoplasmic antibody (PR3-ANCA) titer was elevated at 183 ELISA units (EU) in sera (normal range less than 10 EU), myeloperoxidase-ANCA was negative.",19203554_3,0
8231,PR3-ANCA,50,58,"Proteinase 3-antineutrophil cytoplasmic antibody (PR3-ANCA) titer was elevated at 183 ELISA units (EU) in sera (normal range less than 10 EU), myeloperoxidase-ANCA was negative.",19203554_3,0
8233,myeloperoxidase-ANCA,143,163,"Proteinase 3-antineutrophil cytoplasmic antibody (PR3-ANCA) titer was elevated at 183 ELISA units (EU) in sera (normal range less than 10 EU), myeloperoxidase-ANCA was negative.",19203554_3,0
8234,PR3-ANCA,0,8,"PR3-ANCA titer was 250 and 1,070 EU in pleural effusions on right and left side, respectively.",19203554_4,0
8235,left side,70,79,"PR3-ANCA titer was 250 and 1,070 EU in pleural effusions on right and left side, respectively.",19203554_4,1
5726,pleural effusions,39,56,"PR3-ANCA titer was 250 and 1,070 EU in pleural effusions on right and left side, respectively.",19203554_4,1
8237,PR3-ANCA,207,215,"Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.",19203554_5,0
2076,C-reactive protein,113,131,"Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.",19203554_5,0
2075,sulphasalazine,22,36,"Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.",19203554_5,0
5727,chest pain,92,102,"Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.",19203554_5,1
5728,pleural effusions,150,167,"Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.",19203554_5,1
5729,pleural effusion,296,312,"Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.",19203554_5,1
8236,red eyes,82,90,"Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained.",19203554_5,0
5730,pleural effusion,37,53,"One month after steroid therapy, the pleural effusion disappeared, and PR3-ANCA titer normalized 3 months later.",19203554_6,1
8239,PR3-ANCA,71,79,"One month after steroid therapy, the pleural effusion disappeared, and PR3-ANCA titer normalized 3 months later.",19203554_6,0
8240,necrotizing glomerulonephritis,68,98,This case suggests that sulphasalazine can induce PR3-ANCA-positive necrotizing glomerulonephritis.,19203554_7,1
2077,sulphasalazine,24,38,This case suggests that sulphasalazine can induce PR3-ANCA-positive necrotizing glomerulonephritis.,19203554_7,0
8241,Testosterone-dependent hypertension,0,35,Testosterone-dependent hypertension and upregulation of intrarenal angiotensinogen in Dahl salt-sensitive rats.,19211690_0,1
5731,Blood pressure,0,14,Blood pressure (BP) is more salt sensitive in men than in premenopausal women.,19211690_1,1
8245,salt sensitive,28,42,Blood pressure (BP) is more salt sensitive in men than in premenopausal women.,19211690_1,1
5733,renal injury,60,72,"Testosterone replacement in castrated DS rats increased BP, renal injury, and upregulation of renal angiotensinogen associated with HS diet.",19211690_10,1
2078,angiotensinogen,100,115,"Testosterone replacement in castrated DS rats increased BP, renal injury, and upregulation of renal angiotensinogen associated with HS diet.",19211690_10,0
8261,BP,56,58,"Testosterone replacement in castrated DS rats increased BP, renal injury, and upregulation of renal angiotensinogen associated with HS diet.",19211690_10,0
5734,renal injury,64,76,Testosterone contributes to the development of hypertension and renal injury in male DS rats on HS diet possibly through upregulation of the intrarenal renin-angiotensin system.,19211690_11,1
8247,BP,64,66,"In Dahl salt-sensitive rats (DS), high-salt (HS) diet increases BP more in males than females.",19211690_2,0
8250,ANG II,181,187,"In contrast to the systemic renin-angiotensin system, which is suppressed in response to HS in male DS, intrarenal angiotensinogen expression is increased, and intrarenal levels of ANG II are not suppressed.",19211690_3,0
5732,renal injury,194,206,"In this study, the hypothesis was tested that there is a sexual dimorphism in HS-induced upregulation of intrarenal angiotensinogen mediated by testosterone that also causes increases in BP and renal injury.",19211690_4,1
8254,low-salt,5,13,"On a low-salt (LS) diet, male DS had higher levels of intrarenal angiotensinogen mRNA than females.",19211690_5,0
8256,angiotensinogen mRNA,42,62,"HS diet for 4 wk increased renal cortical angiotensinogen mRNA and protein only in male DS, which was prevented by castration.",19211690_6,0
8257,BP,16,18,Radiotelemetric BP was similar between males and castrated rats on LS diet.,19211690_8,0
8260,glomerular sclerosis,89,109,"HS diet for 4 wk caused a progressive increase in BP, protein and albumin excretion, and glomerular sclerosis in male DS rats, which were attenuated by castration.",19211690_9,1
8259,BP,50,52,"HS diet for 4 wk caused a progressive increase in BP, protein and albumin excretion, and glomerular sclerosis in male DS rats, which were attenuated by castration.",19211690_9,0
8267,subthalamotomy,41,55,Comparison of unilateral pallidotomy and subthalamotomy findings in advanced idiopathic Parkinson's disease.,19234905_0,1
5735,idiopathic Parkinson's disease,77,107,Comparison of unilateral pallidotomy and subthalamotomy findings in advanced idiopathic Parkinson's disease.,19234905_0,1
8266,unilateral pallidotomy,14,36,Comparison of unilateral pallidotomy and subthalamotomy findings in advanced idiopathic Parkinson's disease.,19234905_0,1
8270,subthalamotomy,118,132,"A prospective, randomized, double-blind pilot study to compare the results of stereotactic unilateral pallidotomy and subthalamotomy in advanced idiopathic Parkinson's disease (PD) refractory to medical treatment was designed.",19234905_1,1
5736,idiopathic Parkinson's disease,145,175,"A prospective, randomized, double-blind pilot study to compare the results of stereotactic unilateral pallidotomy and subthalamotomy in advanced idiopathic Parkinson's disease (PD) refractory to medical treatment was designed.",19234905_1,1
8269,stereotactic unilateral pallidotomy,78,113,"A prospective, randomized, double-blind pilot study to compare the results of stereotactic unilateral pallidotomy and subthalamotomy in advanced idiopathic Parkinson's disease (PD) refractory to medical treatment was designed.",19234905_1,1
8295,left hemiballistic movements,127,155,Complications were observed in two patients: one had a left homonymous hemianopsia after pallidotomy and another one developed left hemiballistic movements 3 days after subthalamotomy which partly improved within 1 month with Valproate 1000 mg/day.,19234905_10,1
8294,pallidotomy,89,100,Complications were observed in two patients: one had a left homonymous hemianopsia after pallidotomy and another one developed left hemiballistic movements 3 days after subthalamotomy which partly improved within 1 month with Valproate 1000 mg/day.,19234905_10,1
8296,subthalamotomy,169,183,Complications were observed in two patients: one had a left homonymous hemianopsia after pallidotomy and another one developed left hemiballistic movements 3 days after subthalamotomy which partly improved within 1 month with Valproate 1000 mg/day.,19234905_10,1
8297,Valproate,226,235,Complications were observed in two patients: one had a left homonymous hemianopsia after pallidotomy and another one developed left hemiballistic movements 3 days after subthalamotomy which partly improved within 1 month with Valproate 1000 mg/day.,19234905_10,0
5738,homonymous hemianopsia,60,82,Complications were observed in two patients: one had a left homonymous hemianopsia after pallidotomy and another one developed left hemiballistic movements 3 days after subthalamotomy which partly improved within 1 month with Valproate 1000 mg/day.,19234905_10,1
2080,GPi,74,77,The findings of this study suggest that lesions of the unilateral STN and GPi are equally effective treatment for patients with advanced PD refractory to medical treatment.,19234905_11,0
8276,motor fluctuations,178,196,"Ten consecutive patients (mean age, 58.4 +/- 6.8 years; 7 men, 3 women) with similar characteristics at the duration of disease (mean disease time, 8.4 +/- 3.5 years), disabling motor fluctuations (Hoehn _ Yahr stage 3-5 in off-drug phases) and levodopa-induced dyskinesias were selected.",19234905_2,1
8277,Yahr stage,206,216,"Ten consecutive patients (mean age, 58.4 +/- 6.8 years; 7 men, 3 women) with similar characteristics at the duration of disease (mean disease time, 8.4 +/- 3.5 years), disabling motor fluctuations (Hoehn _ Yahr stage 3-5 in off-drug phases) and levodopa-induced dyskinesias were selected.",19234905_2,1
8273,duration of disease,108,127,"Ten consecutive patients (mean age, 58.4 +/- 6.8 years; 7 men, 3 women) with similar characteristics at the duration of disease (mean disease time, 8.4 +/- 3.5 years), disabling motor fluctuations (Hoehn _ Yahr stage 3-5 in off-drug phases) and levodopa-induced dyskinesias were selected.",19234905_2,1
8280,globus pallidus interna,37,60,Six patients were operated on in the globus pallidus interna (GPi) and four in the subthalamic nucleus (STN).,19234905_4,1
2079,GPi,62,65,Six patients were operated on in the globus pallidus interna (GPi) and four in the subthalamic nucleus (STN).,19234905_4,0
8281,subthalamic nucleus,83,102,Six patients were operated on in the globus pallidus interna (GPi) and four in the subthalamic nucleus (STN).,19234905_4,1
8287,off'-drug,183,192,"Clinical evaluation included the use of the Unified Parkinson's Disease Rating Scale (UPDRS), Hoehn_Yahr score and Schwab England activities of daily living (ADL) score in 'on'- and 'off'-drug conditions before surgery and 6 months after surgery.",19234905_5,0
5737,Parkinson's Disease,52,71,"Clinical evaluation included the use of the Unified Parkinson's Disease Rating Scale (UPDRS), Hoehn_Yahr score and Schwab England activities of daily living (ADL) score in 'on'- and 'off'-drug conditions before surgery and 6 months after surgery.",19234905_5,1
8288,motor signs,88,99,There was statistically significant improvement in all contralateral major parkinsonian motor signs in all patients followed for 6 months.,19234905_6,1
8291,Yahr,26,30,"Changes in UPDRS, Hoehn _ Yahr and Schwab England ADL scores were similar in both groups.",19234905_8,0
8293,Cognitive functions,0,19,Cognitive functions were unchanged in both groups.,19234905_9,1
8303,pain sensitivity,40,56,Pain memory is thought to affect future pain sensitivity and thus contribute to clinical pain conditions.,19269743_1,1
8304,clinical pain conditions,80,104,Pain memory is thought to affect future pain sensitivity and thus contribute to clinical pain conditions.,19269743_1,1
8302,Pain memory,0,11,Pain memory is thought to affect future pain sensitivity and thus contribute to clinical pain conditions.,19269743_1,1
8314,R(2)=0.79,130,139,Correlation with rating recall after one week was best when first-time ratings were requested as late as one day after injection (R(2)=0.79) indicating that both rating retrievals utilized similar memory traces.,19269743_10,0
8306,experimental pain,80,97,Systematic investigations of the human capacity to remember sensory features of experimental pain are sparse.,19269743_2,1
8307,pain memory,30,41,"In order to address long-term pain memory, nine healthy male volunteers received intradermal injections of three doses of capsaicin (0.05, 1 and 20 microg, separated by 15 min breaks), each given three times in a balanced design across three sessions at one week intervals.",19269743_3,1
5739,burning pain,11,23,The strong burning pain decayed exponentially within a few minutes.,19269743_7,1
8317,bortezomib/dexamethasone,84,108,DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.,19274460_0,0
8316,intravenous cyclophosphamide,35,63,DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.,19274460_0,0
8319,newly diagnosed myeloma,150,173,DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma.,19274460_0,1
8324,stem cell transplantation,163,188,A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM).,19274460_1,1
5740,multiple myeloma,231,247,A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM).,19274460_1,1
8322,cyclophosphamide,67,83,A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM).,19274460_1,0
8323,bortezomib,104,114,A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM).,19274460_1,0
8329,cyclophosphamide,187,203,"Thirty patients were treated with three 21-day cycles of bortezomib 1.3 mg/m(2) on days 1, 4, 8, and 11 plus dexamethasone 40 mg on the day of bortezomib injection and the day after plus cyclophosphamide at 900, 1,200, or 1,500 mg/m(2) on day 1.",19274460_2,0
8328,bortezomib,143,153,"Thirty patients were treated with three 21-day cycles of bortezomib 1.3 mg/m(2) on days 1, 4, 8, and 11 plus dexamethasone 40 mg on the day of bortezomib injection and the day after plus cyclophosphamide at 900, 1,200, or 1,500 mg/m(2) on day 1.",19274460_2,0
8326,bortezomib,57,67,"Thirty patients were treated with three 21-day cycles of bortezomib 1.3 mg/m(2) on days 1, 4, 8, and 11 plus dexamethasone 40 mg on the day of bortezomib injection and the day after plus cyclophosphamide at 900, 1,200, or 1,500 mg/m(2) on day 1.",19274460_2,0
8331,cyclophosphamide,30,46,The maximum tolerated dose of cyclophosphamide was defined as 900 mg/m(2).,19274460_3,0
8332,partial response,56,72,"At this dose level, 92% of patients achieved at least a partial response.",19274460_4,1
8335,progressive disease,23,42,No patient experienced progressive disease.,19274460_6,1
8336,adverse events,18,32,The most frequent adverse events were hematological and gastrointestinal toxicities as well as neuropathy.,19274460_7,1
8337,gastrointestinal toxicities,56,83,The most frequent adverse events were hematological and gastrointestinal toxicities as well as neuropathy.,19274460_7,1
8339,cyclophosphamide,56,72,The results suggest that bortezomib in combination with cyclophosphamide at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation.,19274460_8,0
8338,bortezomib,25,35,The results suggest that bortezomib in combination with cyclophosphamide at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation.,19274460_8,0
8341,opioid,122,128,The hemodynamic effects of captopril and other angiotensin-converting enzyme inhibitors may be mediated by the endogenous opioid system.,1928887_1,0
2081,angiotensin-converting enzyme inhibitors,47,87,The hemodynamic effects of captopril and other angiotensin-converting enzyme inhibitors may be mediated by the endogenous opioid system.,1928887_1,0
2082,opioid antagonist,4,21,The opioid antagonist naloxone has been shown to block or reverse the hypotensive actions of captopril.,1928887_2,0
8344,oversulfated chondroitin sulfate,80,112,Identification of a simple and sensitive microplate method for the detection of oversulfated chondroitin sulfate in heparin products.,19289093_0,0
8345,heparin products,116,132,Identification of a simple and sensitive microplate method for the detection of oversulfated chondroitin sulfate in heparin products.,19289093_0,0
5741,critically ill,62,76,Heparin is a commonly implemented anticoagulant used to treat critically ill patients.,19289093_1,1
8347,oversulfated chondroitin sulfate,96,128,"Recently, a number of commercial lots of heparin products were found to be contaminated with an oversulfated chondroitin sulfate (OSCS) derivative that could elicit a hypotensive response in pigs following a single high-dose infusion.",19289093_2,0
8350,high-dose,215,224,"Recently, a number of commercial lots of heparin products were found to be contaminated with an oversulfated chondroitin sulfate (OSCS) derivative that could elicit a hypotensive response in pigs following a single high-dose infusion.",19289093_2,0
8346,heparin products,41,57,"Recently, a number of commercial lots of heparin products were found to be contaminated with an oversulfated chondroitin sulfate (OSCS) derivative that could elicit a hypotensive response in pigs following a single high-dose infusion.",19289093_2,0
8355,EIA,149,152,"We also demonstrated that OSCS can be identified in heparin products using a simple, inexpensive, commercially available heparin enzyme immunoassay (EIA) kit that has a limit of detection of approximately 0.1%, well below the NOEL.",19289093_5,1
8354,heparin enzyme,121,135,"We also demonstrated that OSCS can be identified in heparin products using a simple, inexpensive, commercially available heparin enzyme immunoassay (EIA) kit that has a limit of detection of approximately 0.1%, well below the NOEL.",19289093_5,0
8353,heparin products,52,68,"We also demonstrated that OSCS can be identified in heparin products using a simple, inexpensive, commercially available heparin enzyme immunoassay (EIA) kit that has a limit of detection of approximately 0.1%, well below the NOEL.",19289093_5,0
8357,oversulfated,85,97,This kit may provide a useful method to test heparin products for contamination with oversulfated GAG derivatives.,19289093_6,0
8356,heparin products,45,61,This kit may provide a useful method to test heparin products for contamination with oversulfated GAG derivatives.,19289093_6,0
8359,high-dose co-trimoxazole,42,66,Severe and long lasting cholestasis after high-dose co-trimoxazole treatment for Pneumocystis pneumonia in HIV-infected patients--a report of two cases.,19299179_0,0
8358,long lasting cholestasis,11,35,Severe and long lasting cholestasis after high-dose co-trimoxazole treatment for Pneumocystis pneumonia in HIV-infected patients--a report of two cases.,19299179_0,1
5742,Pneumocystis pneumonia,81,103,Severe and long lasting cholestasis after high-dose co-trimoxazole treatment for Pneumocystis pneumonia in HIV-infected patients--a report of two cases.,19299179_0,1
2083,co-trimoxazole,132,146,"Pneumocystis pneumonia (PCP), a common opportunistic infection in HIV-infected individuals, is generally treated with high doses of co-trimoxazole.",19299179_1,0
5744,opportunistic infection,39,62,"Pneumocystis pneumonia (PCP), a common opportunistic infection in HIV-infected individuals, is generally treated with high doses of co-trimoxazole.",19299179_1,1
5743,Pneumocystis pneumonia,0,22,"Pneumocystis pneumonia (PCP), a common opportunistic infection in HIV-infected individuals, is generally treated with high doses of co-trimoxazole.",19299179_1,1
8360,high doses,118,128,"Pneumocystis pneumonia (PCP), a common opportunistic infection in HIV-infected individuals, is generally treated with high doses of co-trimoxazole.",19299179_1,0
5745,adverse effects,39,54,"However, treatment is often limited by adverse effects.",19299179_2,1
2084,co-trimoxazole,214,228,"Here, we report two cases of severely immunocompromised HIV-infected patients who developed severe intrahepatic cholestasis, and in one patient lesions mimicking liver abscess formation on radiologic exams, during co-trimoxazole treatment for PCP.",19299179_3,0
5746,intrahepatic cholestasis,99,123,"Here, we report two cases of severely immunocompromised HIV-infected patients who developed severe intrahepatic cholestasis, and in one patient lesions mimicking liver abscess formation on radiologic exams, during co-trimoxazole treatment for PCP.",19299179_3,1
5747,liver abscess,162,175,"Here, we report two cases of severely immunocompromised HIV-infected patients who developed severe intrahepatic cholestasis, and in one patient lesions mimicking liver abscess formation on radiologic exams, during co-trimoxazole treatment for PCP.",19299179_3,1
2085,co-trimoxazole,112,126,"Whereas patient 1 showed lesions of up to 1 cm readily detectable on magnetic resonance imaging under prolonged co-trimoxazole treatment, therapy of patient 2 was switched early.",19299179_4,0
5748,apical ballooning syndrome,23,49,5 flourouracil-induced apical ballooning syndrome: a case report.,19300240_0,1
5751,left ventricular,220,236,The apical ballooning syndrome (ABS) is a recently described stress-mediated acute cardiac syndrome characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.,19300240_1,1
8370,midventricle,176,188,The apical ballooning syndrome (ABS) is a recently described stress-mediated acute cardiac syndrome characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.,19300240_1,1
5750,hyperkinesis,194,206,The apical ballooning syndrome (ABS) is a recently described stress-mediated acute cardiac syndrome characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.,19300240_1,1
8368,acute cardiac syndrome,77,99,The apical ballooning syndrome (ABS) is a recently described stress-mediated acute cardiac syndrome characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.,19300240_1,1
8367,stress-mediated,61,76,The apical ballooning syndrome (ABS) is a recently described stress-mediated acute cardiac syndrome characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.,19300240_1,1
5749,apical ballooning syndrome,4,30,The apical ballooning syndrome (ABS) is a recently described stress-mediated acute cardiac syndrome characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.,19300240_1,1
8371,epicardial coronary disease,271,298,The apical ballooning syndrome (ABS) is a recently described stress-mediated acute cardiac syndrome characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.,19300240_1,1
8369,wall-motion abnormalities,127,152,The apical ballooning syndrome (ABS) is a recently described stress-mediated acute cardiac syndrome characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease.,19300240_1,1
8381,apical akinesis,75,90,Echocardiogram revealed a normal ejection fraction and a resolution of the apical akinesis.,19300240_11,1
5757,normal ejection fraction,26,50,Echocardiogram revealed a normal ejection fraction and a resolution of the apical akinesis.,19300240_11,1
8383,cardiac complications,27,48,"Pathogenetic mechanisms of cardiac complications in cancer patients undergoing chemotherapy include coronary vasospasm, endothelial damage and consequent thrombus formation.",19300240_12,1
8385,endothelial damage,120,138,"Pathogenetic mechanisms of cardiac complications in cancer patients undergoing chemotherapy include coronary vasospasm, endothelial damage and consequent thrombus formation.",19300240_12,1
5758,coronary vasospasm,100,118,"Pathogenetic mechanisms of cardiac complications in cancer patients undergoing chemotherapy include coronary vasospasm, endothelial damage and consequent thrombus formation.",19300240_12,1
2087,neuropeptides,89,102,"In our patient, both supraphysiologic levels of plasma catecholamines and stress related neuropeptides caused by cancer diagnosis as well as chemotherapy may have contributed the development of ABS.",19300240_13,0
8386,supraphysiologic,21,37,"In our patient, both supraphysiologic levels of plasma catecholamines and stress related neuropeptides caused by cancer diagnosis as well as chemotherapy may have contributed the development of ABS.",19300240_13,0
8387,plasma catecholamines,48,69,"In our patient, both supraphysiologic levels of plasma catecholamines and stress related neuropeptides caused by cancer diagnosis as well as chemotherapy may have contributed the development of ABS.",19300240_13,0
5752,Cardiotoxicity,0,14,Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents.,19300240_2,1
8372,adverse effect,34,48,Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents.,19300240_2,1
8373,chemotherapeutic agents,52,75,Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents.,19300240_2,0
8375,chemotherapeutic agents,50,73,"However, there are no reports of ABS secondary to chemotherapeutic agents.",19300240_3,0
8376,metastatic cancer,82,99,We describe the case of a woman who developed the syndrome after chemotherapy for metastatic cancer.,19300240_4,1
2086,her,134,137,"A 79-year-old woman presented with typical ischemic chest pain, elevated cardiac enzymes with significant ST-segment abnormalities on her electrocardiogram.",19300240_5,0
8377,ST-segment abnormalities,106,130,"A 79-year-old woman presented with typical ischemic chest pain, elevated cardiac enzymes with significant ST-segment abnormalities on her electrocardiogram.",19300240_5,1
5753,chest pain,52,62,"A 79-year-old woman presented with typical ischemic chest pain, elevated cardiac enzymes with significant ST-segment abnormalities on her electrocardiogram.",19300240_5,1
5754,colorectal cancer,67,84,She underwent recent chemotherapy with fluorouracil for metastatic colorectal cancer.,19300240_6,1
8378,wall-motion abnormality,28,51,Echocardiography revealed a wall-motion abnormality involving the apical and periapical segments which appeared akinetic.,19300240_7,1
5756,akinetic,112,120,Echocardiography revealed a wall-motion abnormality involving the apical and periapical segments which appeared akinetic.,19300240_7,1
5755,periapical,77,87,Echocardiography revealed a wall-motion abnormality involving the apical and periapical segments which appeared akinetic.,19300240_7,1
8380,obstructive coronary lesions,33,61,Coronary angiography revealed no obstructive coronary lesions.,19300240_8,1
8379,Coronary angiography,0,20,Coronary angiography revealed no obstructive coronary lesions.,19300240_8,1
5760,diabetic neuropathy,145,164,Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.,19300402_0,1
8389,streptozotocin,89,103,Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.,19300402_0,0
2088,Bradykinin receptors,0,20,Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.,19300402_0,0
2089,nitric oxide synthase,37,58,Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.,19300402_0,0
5759,hyperalgesia,112,124,Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.,19300402_0,1
8392,L-NIL,164,169,"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.",19300402_1,0
8390,L-NOArg,81,88,"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.",19300402_1,0
8391,inducible NO synthase,141,162,"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.",19300402_1,0
2090,NO synthase,68,79,"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.",19300402_1,0
8394,antihyperalgesic action,270,293,"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.",19300402_1,0
8395,selective antagonists,297,318,"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.",19300402_1,0
2094,bradykinin,373,383,"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.",19300402_1,0
2093,B1,329,331,"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.",19300402_1,0
2092,B2,322,324,"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.",19300402_1,0
2091,NO synthase,233,244,"PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated.",19300402_1,0
8397,pain thresholds,24,39,METHODS: The changes in pain thresholds were determined using mechanical stimuli--the modification of the classic paw withdrawal test described by Randall-Selitto.,19300402_2,1
8399,Randall-Selitto,147,162,METHODS: The changes in pain thresholds were determined using mechanical stimuli--the modification of the classic paw withdrawal test described by Randall-Selitto.,19300402_2,0
2096,NO synthase,126,137,RESULTS: The results of this paper confirm that inhibition of bradykinin receptors and inducible NO synthase but not neuronal NO synthase activity reduces diabetic hyperalgesia.,19300402_3,0
5761,hyperalgesia,164,176,RESULTS: The results of this paper confirm that inhibition of bradykinin receptors and inducible NO synthase but not neuronal NO synthase activity reduces diabetic hyperalgesia.,19300402_3,1
2095,bradykinin receptors,62,82,RESULTS: The results of this paper confirm that inhibition of bradykinin receptors and inducible NO synthase but not neuronal NO synthase activity reduces diabetic hyperalgesia.,19300402_3,0
8400,inducible NO synthase,87,108,RESULTS: The results of this paper confirm that inhibition of bradykinin receptors and inducible NO synthase but not neuronal NO synthase activity reduces diabetic hyperalgesia.,19300402_3,0
8402,L-NOArg,18,25,"Pretreatment with L-NOArg and L-NIL but not 7-NI, significantly increases antihyperalgesic activity both HOE 140 and des Arg10 HOE 140.",19300402_4,0
8403,L-NIL,30,35,"Pretreatment with L-NOArg and L-NIL but not 7-NI, significantly increases antihyperalgesic activity both HOE 140 and des Arg10 HOE 140.",19300402_4,0
8404,7-NI,44,48,"Pretreatment with L-NOArg and L-NIL but not 7-NI, significantly increases antihyperalgesic activity both HOE 140 and des Arg10 HOE 140.",19300402_4,0
2097,NO synthase,75,86,It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as bradykinin are involved in hyperalgesia produced by vincristine.,19300402_5,0
2098,bradykinin,109,119,It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as bradykinin are involved in hyperalgesia produced by vincristine.,19300402_5,0
5762,hyperalgesia,136,148,It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as bradykinin are involved in hyperalgesia produced by vincristine.,19300402_5,1
8406,inducible NO synthase,40,61,It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as bradykinin are involved in hyperalgesia produced by vincristine.,19300402_5,0
8407,L-NOArg,10,17,"Moreover, L-NOArg and 7-NI but not L-NIL intensify antihyperalgesic activity of HOE 140 or des-Arg10HOE 140 in toxic neuropathy.",19300402_6,0
8408,7-NI,22,26,"Moreover, L-NOArg and 7-NI but not L-NIL intensify antihyperalgesic activity of HOE 140 or des-Arg10HOE 140 in toxic neuropathy.",19300402_6,0
8411,des-Arg10HOE,91,103,"Moreover, L-NOArg and 7-NI but not L-NIL intensify antihyperalgesic activity of HOE 140 or des-Arg10HOE 140 in toxic neuropathy.",19300402_6,0
8412,toxic neuropathy,111,127,"Moreover, L-NOArg and 7-NI but not L-NIL intensify antihyperalgesic activity of HOE 140 or des-Arg10HOE 140 in toxic neuropathy.",19300402_6,1
8409,L-NIL,35,40,"Moreover, L-NOArg and 7-NI but not L-NIL intensify antihyperalgesic activity of HOE 140 or des-Arg10HOE 140 in toxic neuropathy.",19300402_6,0
2100,B2,58,60,CONCLUSIONS: Results of these studies suggest that B1 and B2 receptors are engaged in transmission of nociceptive stimuli in both diabetic and toxic neuropathy.,19300402_7,0
2099,B1,51,53,CONCLUSIONS: Results of these studies suggest that B1 and B2 receptors are engaged in transmission of nociceptive stimuli in both diabetic and toxic neuropathy.,19300402_7,0
8414,toxic neuropathy,143,159,CONCLUSIONS: Results of these studies suggest that B1 and B2 receptors are engaged in transmission of nociceptive stimuli in both diabetic and toxic neuropathy.,19300402_7,1
5763,hyperalgesia,26,38,"In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.",19300402_8,1
2101,bradykinin,105,115,"In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.",19300402_8,0
2102,NO synthase,200,211,"In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.",19300402_8,0
8415,inducible NO synthase,40,61,"In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway.",19300402_8,0
2103,bradykinin receptor antagonists,56,87,"Therefore, concomitant administration of small doses of bradykinin receptor antagonists and NO synthase inhibitors can be effective in alleviation of neuropathic pain, even in hospital care.",19300402_9,0
5764,neuropathic pain,150,166,"Therefore, concomitant administration of small doses of bradykinin receptor antagonists and NO synthase inhibitors can be effective in alleviation of neuropathic pain, even in hospital care.",19300402_9,1
2104,NO synthase,92,103,"Therefore, concomitant administration of small doses of bradykinin receptor antagonists and NO synthase inhibitors can be effective in alleviation of neuropathic pain, even in hospital care.",19300402_9,0
8417,small doses,41,52,"Therefore, concomitant administration of small doses of bradykinin receptor antagonists and NO synthase inhibitors can be effective in alleviation of neuropathic pain, even in hospital care.",19300402_9,0
5765,adverse drug reaction,28,49,"Confusion, a rather serious adverse drug reaction with valproic acid: a review of the French Pharmacovigilance database.",19308880_0,1
2105,valproic acid,55,68,"Confusion, a rather serious adverse drug reaction with valproic acid: a review of the French Pharmacovigilance database.",19308880_0,0
5766,adverse drug reaction,30,51,INTRODUCTION: Confusion is an adverse drug reaction frequently observed with valproic acid.,19308880_1,1
2106,valproic acid,77,90,INTRODUCTION: Confusion is an adverse drug reaction frequently observed with valproic acid.,19308880_1,0
5767,adverse drug reaction,78,99,We performed this study in order to describe the main characteristics of this adverse drug reaction.,19308880_3,1
2107,valproic acid,114,127,"METHODS: Using the French Pharmacovigilance database, we selected the cases of confusion reported since 1985 with valproic acid.",19308880_4,0
2108,valproic acid,51,64,RESULTS: 272 cases of confusion were reported with valproic acid: 153 women and 119 men.,19308880_5,0
2109,valproic acid,63,76,Confusion mostly occurred during the two first weeks following valproic acid exposure (39.7%).,19308880_6,0
5768,adverse drug reaction,107,128,"CONCLUSION: This work shows that confusion with valproic acid is a serious, rather frequent but reversible adverse drug reaction.",19308880_9,1
2110,valproic acid,48,61,"CONCLUSION: This work shows that confusion with valproic acid is a serious, rather frequent but reversible adverse drug reaction.",19308880_9,0
5769,intracerebral hemorrhage,100,124,Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of warfarin-associated intracerebral hemorrhage.,19319147_0,1
5770,intracerebral hemorrhage,20,44,Warfarin-associated intracerebral hemorrhage (W-ICH) is a severe type of stroke.,19319147_1,1
5774,PCC,60,63,"In contrast, such extensive lesions were never found in the PCC group.",19319147_11,1
5775,PCC,40,43,We provide experimental data suggesting PCC to be an effective acute treatment for W-ICH in terms of reducing hemorrhagic blood volume.,19319147_12,1
8441,hemorrhagic blood volume,110,134,We provide experimental data suggesting PCC to be an effective acute treatment for W-ICH in terms of reducing hemorrhagic blood volume.,19319147_12,1
8425,human prothrombin complex concentrate,83,120,"Using a mouse model, we tested whether the rapid reversal of anticoagulation using human prothrombin complex concentrate (PCC) can reduce hemorrhagic blood volume.",19319147_3,0
5771,PCC,122,125,"Using a mouse model, we tested whether the rapid reversal of anticoagulation using human prothrombin complex concentrate (PCC) can reduce hemorrhagic blood volume.",19319147_3,1
8427,warfarin (2,33,44,"Male CD-1 mice were treated with warfarin (2 mg/kg over 24 h), resulting in a mean (+/-s.d.) International Normalized Ratio of 3.5+/-0.9.",19319147_4,0
2111,CD-1,5,9,"Male CD-1 mice were treated with warfarin (2 mg/kg over 24 h), resulting in a mean (+/-s.d.) International Normalized Ratio of 3.5+/-0.9.",19319147_4,0
8429,reversed anticoagulation,73,97,"First, we showed that an intravenous administration of human PCC rapidly reversed anticoagulation in mice.",19319147_5,1
5772,PCC,61,64,"First, we showed that an intravenous administration of human PCC rapidly reversed anticoagulation in mice.",19319147_5,1
8431,right striatum,93,107,"Second, a stereotactic injection of collagenase was administered to induce hemorrhage in the right striatum.",19319147_6,1
5773,PCC,65,68,"Forty-five minutes later, the animals were randomly treated with PCC (100 U/kg) or saline i.v. (n=12 per group).",19319147_7,1
8432,hemorrhagic blood volume,46,70,"Twenty-four hours after hemorrhage induction, hemorrhagic blood volume was quantified using a photometric hemoglobin assay.",19319147_8,1
8443,inferior colliculus lesion,11,37,Reversible inferior colliculus lesion in metronidazole-induced encephalopathy: magnetic resonance findings on diffusion-weighted and fluid attenuated inversion recovery imaging.,19346865_0,1
8450,DWI,154,157,"OBJECTIVE: This is to present reversible inferior colliculus lesions in metronidazole-induced encephalopathy, to focus on the diffusion-weighted imaging (DWI) and fluid attenuated inversion recovery (FLAIR) imaging.",19346865_1,0
8472,inferior colliculus lesions,24,51,"CONCLUSIONS: Reversible inferior colliculus lesions could be considered as the characteristic for metronidazole-induced encephalopathy, next to the dentate nucleus involvement.",19346865_10,1
8474,dentate nucleus,148,163,"CONCLUSIONS: Reversible inferior colliculus lesions could be considered as the characteristic for metronidazole-induced encephalopathy, next to the dentate nucleus involvement.",19346865_10,1
8454,DWI,98,101,"Initial brain magnetic resonance imaging (MRI) were obtained after the hospitalization, including DWI (8/8), apparent diffusion coefficient (ADC) map (4/8), FLAIR (7/8), and T2-weighted image (8/8).",19346865_4,0
5776,corpus callosum,159,174,"RESULTS: Initial MRIs showed abnormal high signal intensities on DWI and FLAIR (or T2-weighted image) at the dentate nucleus (8/8), inferior colliculus (6/8), corpus callosum (2/8), pons (2/8), medulla (1/8), and bilateral cerebral white matter (1/8).",19346865_7,1
8462,dentate nucleus,109,124,"RESULTS: Initial MRIs showed abnormal high signal intensities on DWI and FLAIR (or T2-weighted image) at the dentate nucleus (8/8), inferior colliculus (6/8), corpus callosum (2/8), pons (2/8), medulla (1/8), and bilateral cerebral white matter (1/8).",19346865_7,1
8460,DWI,65,68,"RESULTS: Initial MRIs showed abnormal high signal intensities on DWI and FLAIR (or T2-weighted image) at the dentate nucleus (8/8), inferior colliculus (6/8), corpus callosum (2/8), pons (2/8), medulla (1/8), and bilateral cerebral white matter (1/8).",19346865_7,0
8468,DWI,183,186,"High-signal intensity lesions on DWI tended to show low signal intensity on ADC map (3/4), but in one patient, high signal intensity was shown at bilateral dentate nuclei on not only DWI but also ADC map.",19346865_8,0
8470,inferior colliculus,28,47,"All the lesions in dentate, inferior colliculus, pons, and medullas had been resolved completely on follow-up MRIs in 5 patients, but in 1 patient of them, corpus callosal lesion persisted.",19346865_9,1
8471,callosal,163,171,"All the lesions in dentate, inferior colliculus, pons, and medullas had been resolved completely on follow-up MRIs in 5 patients, but in 1 patient of them, corpus callosal lesion persisted.",19346865_9,1
8476,renal transplant,80,96,Clinically significant proteinuria following the administration of sirolimus to renal transplant recipients.,19356053_0,1
2112,sirolimus,67,76,Clinically significant proteinuria following the administration of sirolimus to renal transplant recipients.,19356053_0,0
8477,nephrotoxicity,105,119,"BACKGROUND: Sirolimus is the latest immunosuppressive agent used to prevent rejection, and may have less nephrotoxicity than calcineurin inhibitor (CNI)-based regimens.",19356053_1,1
2113,Sirolimus,12,21,"BACKGROUND: Sirolimus is the latest immunosuppressive agent used to prevent rejection, and may have less nephrotoxicity than calcineurin inhibitor (CNI)-based regimens.",19356053_1,0
2114,immunosuppressive agent,36,59,"BACKGROUND: Sirolimus is the latest immunosuppressive agent used to prevent rejection, and may have less nephrotoxicity than calcineurin inhibitor (CNI)-based regimens.",19356053_1,0
2115,calcineurin inhibitor,125,146,"BACKGROUND: Sirolimus is the latest immunosuppressive agent used to prevent rejection, and may have less nephrotoxicity than calcineurin inhibitor (CNI)-based regimens.",19356053_1,0
8488,nephrotic-range proteinuria,125,152,In 7 of the 28 patients there was a striking temporal association between the initiation of sirolimus and the development of nephrotic-range proteinuria.,19356053_10,1
2123,sirolimus,92,101,In 7 of the 28 patients there was a striking temporal association between the initiation of sirolimus and the development of nephrotic-range proteinuria.,19356053_10,0
2124,sirolimus,42,51,Proteinuria correlated most strongly with sirolimus therapy when compared to other demographic and clinical variables.,19356053_11,0
2125,sirolimus,37,46,"In most patients, discontinuation of sirolimus resulted in a decrease, but not resolution, of proteinuria.",19356053_12,0
8490,pre-existing proteinuria,45,69,CONCLUSIONS: Sirolimus induces or aggravates pre-existing proteinuria in an unpredictable subset of renal allograft recipients.,19356053_13,1
8491,renal allograft,100,115,CONCLUSIONS: Sirolimus induces or aggravates pre-existing proteinuria in an unpredictable subset of renal allograft recipients.,19356053_13,1
2126,Sirolimus,13,22,CONCLUSIONS: Sirolimus induces or aggravates pre-existing proteinuria in an unpredictable subset of renal allograft recipients.,19356053_13,0
2127,sirolimus,52,61,"Proteinuria may improve, but does not resolve, when sirolimus is withdrawn.",19356053_14,0
2116,sirolimus,105,114,To date there has been little documentation of clinically significant proteinuria linked with the use of sirolimus.,19356053_2,0
2117,sirolimus,91,100,We have encountered several patients who developed substantial proteinuria associated with sirolimus use.,19356053_3,0
8480,substantial proteinuria,51,74,We have encountered several patients who developed substantial proteinuria associated with sirolimus use.,19356053_3,1
2119,sirolimus,121,130,"In each patient, the close temporal association between the commencement of sirolimus therapy and proteinuria implicated sirolimus as the most likely etiology of the proteinuria.",19356053_4,0
2118,sirolimus,76,85,"In each patient, the close temporal association between the commencement of sirolimus therapy and proteinuria implicated sirolimus as the most likely etiology of the proteinuria.",19356053_4,0
2120,sirolimus,166,175,METHODS: We analyzed the clinical and laboratory information available for all 119 patients transplanted at the Washington Hospital Center between 1999-2003 for whom sirolimus was a component of their immunosuppressant regimen.,19356053_5,0
2121,creatinine,139,149,"In these patients, the magnitude of proteinuria was assessed on morning urine samples by turbidometric measurement or random urine protein:creatinine ratios, an estimate of grams of proteinuria/day.",19356053_6,0
2122,sirolimus,69,78,"Laboratory results were compared between prior, during and following sirolimus use.",19356053_7,0
8486,post-transplantation,96,116,RESULTS: Twenty-eight patients (24%) developed increased proteinuria from baseline during their post-transplantation course.,19356053_8,1
8487,cause of,30,38,In 21 patients an alternative cause of proteinuria was either obvious or insufficient data was available to be conclusive.,19356053_9,1
2128,essential oil,20,33,Components of lemon essential oil attenuate dementia induced by scopolamine.,19356307_0,0
8493,s-perillyl,44,54,The anti-dementia effects of s-limonene and s-perillyl alcohol were observed using the passive avoidance test (PA) and the open field habituation test (OFH).,19356307_1,0
2129,anti-dementia,4,17,The anti-dementia effects of s-limonene and s-perillyl alcohol were observed using the passive avoidance test (PA) and the open field habituation test (OFH).,19356307_1,0
8492,s-limonene,29,39,The anti-dementia effects of s-limonene and s-perillyl alcohol were observed using the passive avoidance test (PA) and the open field habituation test (OFH).,19356307_1,0
8497,s-perillyl,101,111,"These lemon essential oils showed strong ability to improve memory impaired by scopolamine; however, s-perillyl alcohol relieved the deficit of associative memory in PA only, and did not improve non-associative memory significantly in OFH.",19356307_2,0
8498,non-associative,195,210,"These lemon essential oils showed strong ability to improve memory impaired by scopolamine; however, s-perillyl alcohol relieved the deficit of associative memory in PA only, and did not improve non-associative memory significantly in OFH.",19356307_2,1
2130,essential oils,12,26,"These lemon essential oils showed strong ability to improve memory impaired by scopolamine; however, s-perillyl alcohol relieved the deficit of associative memory in PA only, and did not improve non-associative memory significantly in OFH.",19356307_2,0
8501,vehicle/scopolamine group,123,148,"Analysis of neurotransmitter concentration in some brain regions on the test day showed that dopamine concentration of the vehicle/scopolamine group was significantly lower than that of the vehicle/vehicle group, but this phenomenon was reversed when s-limonene or s-perillyl alcohol were administered before the injection of scopolamine.",19356307_3,0
8503,s-limonene,251,261,"Analysis of neurotransmitter concentration in some brain regions on the test day showed that dopamine concentration of the vehicle/scopolamine group was significantly lower than that of the vehicle/vehicle group, but this phenomenon was reversed when s-limonene or s-perillyl alcohol were administered before the injection of scopolamine.",19356307_3,0
8504,s-perillyl,265,275,"Analysis of neurotransmitter concentration in some brain regions on the test day showed that dopamine concentration of the vehicle/scopolamine group was significantly lower than that of the vehicle/vehicle group, but this phenomenon was reversed when s-limonene or s-perillyl alcohol were administered before the injection of scopolamine.",19356307_3,0
2132,acetylcholinesterase,85,105,"Simultaneously, we found that these two lemon essential oil components could inhibit acetylcholinesterase activity in vitro using the Ellman method.",19356307_4,0
2131,essential oil,46,59,"Simultaneously, we found that these two lemon essential oil components could inhibit acetylcholinesterase activity in vitro using the Ellman method.",19356307_4,0
5777,Long term,0,9,Long term hormone therapy for perimenopausal and postmenopausal women.,19370593_0,1
5778,perimenopausal,30,44,Long term hormone therapy for perimenopausal and postmenopausal women.,19370593_0,1
8507,HT,29,31,"BACKGROUND: Hormone therapy (HT) is widely used for controlling menopausal symptoms and has also been used for the management and prevention of cardiovascular disease, osteoporosis and dementia in older women.",19370593_1,0
8508,menopausal symptoms,64,83,"BACKGROUND: Hormone therapy (HT) is widely used for controlling menopausal symptoms and has also been used for the management and prevention of cardiovascular disease, osteoporosis and dementia in older women.",19370593_1,1
5779,cardiovascular disease,144,166,"BACKGROUND: Hormone therapy (HT) is widely used for controlling menopausal symptoms and has also been used for the management and prevention of cardiovascular disease, osteoporosis and dementia in older women.",19370593_1,1
8523,coronary event,115,129,"In relatively healthy women, combined continuous HT significantly increased the risk of venous thrombo-embolism or coronary event (after one year's use), stroke (after three years), breast cancer and gallbladder disease.",19370593_10,1
5782,venous thrombo-embolism,88,111,"In relatively healthy women, combined continuous HT significantly increased the risk of venous thrombo-embolism or coronary event (after one year's use), stroke (after three years), breast cancer and gallbladder disease.",19370593_10,1
5783,breast cancer,182,195,"In relatively healthy women, combined continuous HT significantly increased the risk of venous thrombo-embolism or coronary event (after one year's use), stroke (after three years), breast cancer and gallbladder disease.",19370593_10,1
5784,gallbladder disease,200,219,"In relatively healthy women, combined continuous HT significantly increased the risk of venous thrombo-embolism or coronary event (after one year's use), stroke (after three years), breast cancer and gallbladder disease.",19370593_10,1
8522,HT,49,51,"In relatively healthy women, combined continuous HT significantly increased the risk of venous thrombo-embolism or coronary event (after one year's use), stroke (after three years), breast cancer and gallbladder disease.",19370593_10,0
5786,gallbladder disease,100,119,"Long-term oestrogen-only HT significantly increased the risk of venous thrombo-embolism, stroke and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer.",19370593_11,1
5785,venous thrombo-embolism,64,87,"Long-term oestrogen-only HT significantly increased the risk of venous thrombo-embolism, stroke and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer.",19370593_11,1
5787,breast cancer,240,253,"Long-term oestrogen-only HT significantly increased the risk of venous thrombo-embolism, stroke and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer.",19370593_11,1
8524,HT,25,27,"Long-term oestrogen-only HT significantly increased the risk of venous thrombo-embolism, stroke and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer.",19370593_11,0
8525,HT,47,49,"The only statistically significant benefits of HT were a decreased incidence of fractures and (for combined HT) colon cancer, with long-term use.",19370593_12,0
8526,HT,108,110,"The only statistically significant benefits of HT were a decreased incidence of fractures and (for combined HT) colon cancer, with long-term use.",19370593_12,0
8527,colon cancer,112,124,"The only statistically significant benefits of HT were a decreased incidence of fractures and (for combined HT) colon cancer, with long-term use.",19370593_12,1
8529,HT,128,130,"Among women aged over 65 who were relatively healthy (i.e. generally fit, without overt disease) and taking continuous combined HT, there was a statistically significant increase in the incidence of dementia.",19370593_13,0
8528,overt disease,82,95,"Among women aged over 65 who were relatively healthy (i.e. generally fit, without overt disease) and taking continuous combined HT, there was a statistically significant increase in the incidence of dementia.",19370593_13,1
8530,HT,78,80,"Among women with cardiovascular disease, long-term use of combined continuous HT significantly increased the risk of venous thrombo-embolism.",19370593_14,0
5788,cardiovascular disease,17,39,"Among women with cardiovascular disease, long-term use of combined continuous HT significantly increased the risk of venous thrombo-embolism.",19370593_14,1
5789,venous thrombo-embolism,117,140,"Among women with cardiovascular disease, long-term use of combined continuous HT significantly increased the risk of venous thrombo-embolism.",19370593_14,1
8531,HT,107,109,"One trial analysed subgroups of 2839 relatively healthy 50 to 59 year old women taking combined continuous HT and 1637 taking oestrogen-only HT, versus similar-sized placebo groups.",19370593_15,0
8532,HT,141,143,"One trial analysed subgroups of 2839 relatively healthy 50 to 59 year old women taking combined continuous HT and 1637 taking oestrogen-only HT, versus similar-sized placebo groups.",19370593_15,0
8534,HT,115,117,"The only significantly increased risk reported was for venous thrombo-embolism in women taking combined continuous HT: their absolute risk remained low, at less than 1/500.",19370593_16,0
5790,venous thrombo-embolism,55,78,"The only significantly increased risk reported was for venous thrombo-embolism in women taking combined continuous HT: their absolute risk remained low, at less than 1/500.",19370593_16,1
5791,chronic disease,72,87,AUTHORS' CONCLUSIONS: HT is not indicated for the routine management of chronic disease.,19370593_18,1
8536,HT,22,24,AUTHORS' CONCLUSIONS: HT is not indicated for the routine management of chronic disease.,19370593_18,0
8537,HT,39,41,"We need more evidence on the safety of HT for menopausal symptom control, though short-term use appears to be relatively safe for healthy younger women.",19370593_19,0
8510,HT,46,48,"OBJECTIVES: To assess the effect of long-term HT on mortality, cardiovascular outcomes, cancer, gallbladder disease, cognition, fractures and quality of life.",19370593_3,0
5780,gallbladder disease,96,115,"OBJECTIVES: To assess the effect of long-term HT on mortality, cardiovascular outcomes, cancer, gallbladder disease, cognition, fractures and quality of life.",19370593_3,1
8512,quality of life,142,157,"OBJECTIVES: To assess the effect of long-term HT on mortality, cardiovascular outcomes, cancer, gallbladder disease, cognition, fractures and quality of life.",19370593_3,1
8513,Menstrual Disorders,103,122,"SEARCH STRATEGY: We searched the following databases to November 2007: Trials Register of the Cochrane Menstrual Disorders and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts.",19370593_4,1
8519,HT,54,56,"SELECTION CRITERIA: Randomised double-blind trials of HT versus placebo, taken for at least one year by perimenopausal or postmenopausal women.",19370593_6,0
5781,perimenopausal,104,118,"SELECTION CRITERIA: Randomised double-blind trials of HT versus placebo, taken for at least one year by perimenopausal or postmenopausal women.",19370593_6,1
8541,perceived pain,26,40,Attentional modulation of perceived pain intensity in capsaicin-induced secondary hyperalgesia.,19387625_0,1
5792,hyperalgesia,82,94,Attentional modulation of perceived pain intensity in capsaicin-induced secondary hyperalgesia.,19387625_0,1
8542,Perceived pain,0,14,Perceived pain intensity is modulated by attention.,19387625_1,1
8543,pain intensity,34,48,"However, it is not known that how pain intensity ratings are affected by attention in capsaicin-induced secondary hyperalgesia.",19387625_2,1
5793,hyperalgesia,114,126,"However, it is not known that how pain intensity ratings are affected by attention in capsaicin-induced secondary hyperalgesia.",19387625_2,1
8544,perceived pain,18,32,Here we show that perceived pain intensity in secondary hyperalgesia is decreased when attention is distracted away from the painful pinprick stimulus with a visual task.,19387625_3,1
5794,hyperalgesia,56,68,Here we show that perceived pain intensity in secondary hyperalgesia is decreased when attention is distracted away from the painful pinprick stimulus with a visual task.,19387625_3,1
5795,hyperalgesia,84,96,"Furthermore, it was found that the magnitude of attentional modulation in secondary hyperalgesia is very similar to that of capsaicin-untreated, control condition.",19387625_4,1
8548,attentional modulation,48,70,"Furthermore, it was found that the magnitude of attentional modulation in secondary hyperalgesia is very similar to that of capsaicin-untreated, control condition.",19387625_4,1
8551,mechanical pain,173,188,"Our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin-induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms.",19387625_5,1
5796,hyperalgesia,133,145,"Our findings, showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin-induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms.",19387625_5,1
8552,salvianolic acid A,27,45,Cardioprotective effect of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.,19445921_0,0
2133,Cardioprotective,0,16,Cardioprotective effect of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.,19445921_0,0
5797,myocardial infarction,71,92,Cardioprotective effect of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.,19445921_0,1
5798,myocardial infarction,121,142,The present study was designed to evaluate the cardioprotective potential of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.,19445921_1,1
8553,salvianolic acid A,77,95,The present study was designed to evaluate the cardioprotective potential of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.,19445921_1,0
2134,cardioprotective,47,63,The present study was designed to evaluate the cardioprotective potential of salvianolic acid A on isoproterenol-induced myocardial infarction in rats.,19445921_1,0
5801,myocardial infarction,155,176,The results of our study suggest that salvianolic acid A possessing antioxidant activity has a significant protective effect against isoproterenol-induced myocardial infarction.,19445921_10,1
2141,antioxidant activity,68,88,The results of our study suggest that salvianolic acid A possessing antioxidant activity has a significant protective effect against isoproterenol-induced myocardial infarction.,19445921_10,0
8575,salvianolic acid A,38,56,The results of our study suggest that salvianolic acid A possessing antioxidant activity has a significant protective effect against isoproterenol-induced myocardial infarction.,19445921_10,0
8576,protective effect,107,124,The results of our study suggest that salvianolic acid A possessing antioxidant activity has a significant protective effect against isoproterenol-induced myocardial infarction.,19445921_10,0
8556,antioxidative,27,40,Cardiac marker enzymes and antioxidative parameters in serum and heart tissues were measured.,19445921_3,0
8555,Cardiac marker enzymes,0,22,Cardiac marker enzymes and antioxidative parameters in serum and heart tissues were measured.,19445921_3,0
8558,mitochondrial respiratory function,10,44,Assay for mitochondrial respiratory function and histopathological examination of heart tissues were performed.,19445921_4,1
2140,glutathione peroxidase,238,260,"Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.",19445921_5,0
2139,superoxide dismutase,203,223,"Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.",19445921_5,0
2138,malondialdehyde,140,155,"Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.",19445921_5,0
2137,creatine kinase,120,135,"Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.",19445921_5,0
2136,aspartate transaminase,96,118,"Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.",19445921_5,0
2135,lactate dehydrogenase,73,94,"Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart.",19445921_5,0
5799,left ventricular,35,51,"These rats also showed declines in left ventricular systolic pressure, maximum and minimum rate of developed left ventricular pressure, and elevation of left ventricular end-diastolic pressure and ST-segment.",19445921_6,1
5800,left ventricular,109,125,"These rats also showed declines in left ventricular systolic pressure, maximum and minimum rate of developed left ventricular pressure, and elevation of left ventricular end-diastolic pressure and ST-segment.",19445921_6,1
8562,left ventricular end-diastolic,153,183,"These rats also showed declines in left ventricular systolic pressure, maximum and minimum rate of developed left ventricular pressure, and elevation of left ventricular end-diastolic pressure and ST-segment.",19445921_6,1
8564,mitochondrial,13,26,"In addition, mitochondrial respiratory dysfunction characterized by decreased respiratory control ratio and ADP/O was observed in isoproterenol-treated rats.",19445921_7,0
8568,cardiac dysfunction,107,126,Administration of salvianolic acid A for a period of 8 days significantly attenuated isoproterenol-induced cardiac dysfunction and myocardial injury and improved mitochondrial respiratory function.,19445921_8,1
8569,myocardial injury,131,148,Administration of salvianolic acid A for a period of 8 days significantly attenuated isoproterenol-induced cardiac dysfunction and myocardial injury and improved mitochondrial respiratory function.,19445921_8,1
8567,salvianolic acid A,18,36,Administration of salvianolic acid A for a period of 8 days significantly attenuated isoproterenol-induced cardiac dysfunction and myocardial injury and improved mitochondrial respiratory function.,19445921_8,0
8570,mitochondrial respiratory function,162,196,Administration of salvianolic acid A for a period of 8 days significantly attenuated isoproterenol-induced cardiac dysfunction and myocardial injury and improved mitochondrial respiratory function.,19445921_8,1
8573,myocardial damage,72,89,The protective role of salvianolic acid A against isoproterenol-induced myocardial damage was further confirmed by histopathological examination.,19445921_9,1
8572,salvianolic acid,23,39,The protective role of salvianolic acid A against isoproterenol-induced myocardial damage was further confirmed by histopathological examination.,19445921_9,0
8571,protective role,4,19,The protective role of salvianolic acid A against isoproterenol-induced myocardial damage was further confirmed by histopathological examination.,19445921_9,0
5802,neurotoxicity,73,86,Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel.,19473225_0,1
2142,paclitaxel,90,100,Long-term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel.,19473225_0,0
8578,amino acid glutamine,150,170,"Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.",19473225_1,0
5803,peripheral neuropathy,6,27,"Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.",19473225_1,1
2143,paclitaxel,89,99,"Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.",19473225_1,0
5804,neurotoxicity,202,215,"Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity.",19473225_1,1
5805,peripheral neuropathy,100,121,"This pilot trial aimed to evaluate the role of glutamate supplementation for preventing PAC-induced peripheral neuropathy in a randomized, placebo-controlled, double-blinded clinical and electro-diagnostic study.",19473225_2,1
5806,ovarian cancer,12,26,"Forty-three ovarian cancer patients were available for analysis following six cycles of the same PAC-containing regimen: 23 had been supplemented by glutamate all along the treatment period, at a daily dose of three times 500 mg (group G), and 20 had received a placebo (group P).",19473225_3,1
8585,group P,271,278,"Forty-three ovarian cancer patients were available for analysis following six cycles of the same PAC-containing regimen: 23 had been supplemented by glutamate all along the treatment period, at a daily dose of three times 500 mg (group G), and 20 had received a placebo (group P).",19473225_3,0
8584,group G,230,237,"Forty-three ovarian cancer patients were available for analysis following six cycles of the same PAC-containing regimen: 23 had been supplemented by glutamate all along the treatment period, at a daily dose of three times 500 mg (group G), and 20 had received a placebo (group P).",19473225_3,0
8588,signs or,56,64,"There was no significant difference in the frequency of signs or symptoms between the two groups although neurotoxicity symptoms presented mostly with lower scores of severity in group G. However, this difference reached statistical significance only with regard to reported pain sensation (P = 0.011).",19473225_5,1
5808,pain sensation,275,289,"There was no significant difference in the frequency of signs or symptoms between the two groups although neurotoxicity symptoms presented mostly with lower scores of severity in group G. However, this difference reached statistical significance only with regard to reported pain sensation (P = 0.011).",19473225_5,1
5807,neurotoxicity,106,119,"There was no significant difference in the frequency of signs or symptoms between the two groups although neurotoxicity symptoms presented mostly with lower scores of severity in group G. However, this difference reached statistical significance only with regard to reported pain sensation (P = 0.011).",19473225_5,1
5809,neurotoxicity,130,143,This pilot study leads to the conclusion that glutamate supplementation at the chosen regimen fails to protect against peripheral neurotoxicity of PAC.,19473225_7,1
2144,alpha-2b,218,226,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,0
8593,ocular myasthenia,15,32,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,1
5811,chronic hepatitis C,245,264,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,1
8594,sudden diplopia,140,155,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,1
5810,chronic hepatitis,89,106,Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC).,19581773_0,1
8597,right upper lid,49,64,Ophthalmologic examinations showed ptosis on the right upper lid and restricted right eye movement without any other neurological signs.,19581773_1,1
8598,right eye movement,80,98,Ophthalmologic examinations showed ptosis on the right upper lid and restricted right eye movement without any other neurological signs.,19581773_1,1
8599,neurological signs,117,135,Ophthalmologic examinations showed ptosis on the right upper lid and restricted right eye movement without any other neurological signs.,19581773_1,1
8602,no abnormality,70,84,A brain imaging study and repetitive nerve stimulation test indicated no abnormality.,19581773_2,1
8603,thyroid function,124,140,"The acetylcholine receptor antibody titer and response to acetylcholinesterase inhibitors were negative, and the results of thyroid function tests were normal.",19581773_3,1
2146,acetylcholinesterase inhibitors,58,89,"The acetylcholine receptor antibody titer and response to acetylcholinesterase inhibitors were negative, and the results of thyroid function tests were normal.",19581773_3,0
2145,acetylcholine receptor,4,26,"The acetylcholine receptor antibody titer and response to acetylcholinesterase inhibitors were negative, and the results of thyroid function tests were normal.",19581773_3,0
8605,ophthalmological symptoms,14,39,The patient's ophthalmological symptoms improved rapidly 3 weeks after discontinuation of pegylated IFN alpha-2b and ribavirin.,19581773_4,1
2147,alpha-2b,104,112,The patient's ophthalmological symptoms improved rapidly 3 weeks after discontinuation of pegylated IFN alpha-2b and ribavirin.,19581773_4,0
8606,ocular myasthenia,4,21,"The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.",19581773_5,1
2148,alpha-2b,75,83,"The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.",19581773_5,0
8610,eye complications,192,209,"The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy.",19581773_5,1
5812,memory deficits,13,28,Learning and memory deficits in ecstasy users and their neural correlates during a face-learning task.,19631624_0,1
8638,right medial frontal gyrus,74,100,"In both ecstasy and cannabis groups brain activation was decreased in the right medial frontal gyrus, left parahippocampal gyrus, left dorsal cingulate gyrus, and left caudate.",19631624_10,1
8639,left parahippocampal gyrus,102,128,"In both ecstasy and cannabis groups brain activation was decreased in the right medial frontal gyrus, left parahippocampal gyrus, left dorsal cingulate gyrus, and left caudate.",19631624_10,1
8640,left caudate,163,175,"In both ecstasy and cannabis groups brain activation was decreased in the right medial frontal gyrus, left parahippocampal gyrus, left dorsal cingulate gyrus, and left caudate.",19631624_10,1
5816,cingulate,142,151,"In both ecstasy and cannabis groups brain activation was decreased in the right medial frontal gyrus, left parahippocampal gyrus, left dorsal cingulate gyrus, and left caudate.",19631624_10,1
8643,isocortical,70,81,These ecstasy-specific effects may be related to the vulnerability of isocortical and allocortical regions to the neurotoxic effects of ecstasy.,19631624_12,1
8644,allocortical,86,98,These ecstasy-specific effects may be related to the vulnerability of isocortical and allocortical regions to the neurotoxic effects of ecstasy.,19631624_12,1
8617,cortical regions,134,150,"In addition, working memory processing in ecstasy users has been shown to be associated with neural alterations in hippocampal and/or cortical regions as measured by functional magnetic resonance imaging (fMRI).",19631624_2,1
8613,working memory,13,27,"In addition, working memory processing in ecstasy users has been shown to be associated with neural alterations in hippocampal and/or cortical regions as measured by functional magnetic resonance imaging (fMRI).",19631624_2,1
5813,hippocampal,115,126,"In addition, working memory processing in ecstasy users has been shown to be associated with neural alterations in hippocampal and/or cortical regions as measured by functional magnetic resonance imaging (fMRI).",19631624_2,1
8616,neural alterations,93,111,"In addition, working memory processing in ecstasy users has been shown to be associated with neural alterations in hippocampal and/or cortical regions as measured by functional magnetic resonance imaging (fMRI).",19631624_2,1
5814,drug use,182,190,"Using functional imaging and a face-learning task, we investigated neural correlates of encoding and recalling face-name associations in 20 recreational drug users whose predominant drug use was ecstasy and 20 controls.",19631624_3,1
8624,parahippocampal,33,48,Deficits in learning and memory: parahippocampal hyperactivity and frontocortical hypoactivity in cannabis users.,19631624_5,1
5815,frontocortical,67,81,Deficits in learning and memory: parahippocampal hyperactivity and frontocortical hypoactivity in cannabis users.,19631624_5,1
8628,frontal regions,120,135,"A conjunction analysis of the encode and recall phases of the task revealed ecstasy-specific hyperactivity in bilateral frontal regions, left temporal, right parietal, bilateral temporal, and bilateral occipital brain regions.",19631624_8,1
8630,right parietal,152,166,"A conjunction analysis of the encode and recall phases of the task revealed ecstasy-specific hyperactivity in bilateral frontal regions, left temporal, right parietal, bilateral temporal, and bilateral occipital brain regions.",19631624_8,1
8631,bilateral temporal,168,186,"A conjunction analysis of the encode and recall phases of the task revealed ecstasy-specific hyperactivity in bilateral frontal regions, left temporal, right parietal, bilateral temporal, and bilateral occipital brain regions.",19631624_8,1
8629,left temporal,137,150,"A conjunction analysis of the encode and recall phases of the task revealed ecstasy-specific hyperactivity in bilateral frontal regions, left temporal, right parietal, bilateral temporal, and bilateral occipital brain regions.",19631624_8,1
8634,right dorsal anterior,49,70,Ecstasy-specific hypoactivity was evident in the right dorsal anterior cingulated cortex (ACC) and left posterior cingulated cortex.,19631624_9,1
8635,left posterior cingulated cortex,99,131,Ecstasy-specific hypoactivity was evident in the right dorsal anterior cingulated cortex (ACC) and left posterior cingulated cortex.,19631624_9,1
2149,tenofovir,45,54,Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.,19642243_0,0
5817,Acute renal failure,0,19,Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.,19642243_0,1
2150,tenofovir disoproxil fumarate,104,133,Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen.,19642243_1,0
5818,Renal failure,0,13,Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen.,19642243_1,1
2151,antiretroviral,148,162,Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen.,19642243_1,0
5821,renal tubule,132,144,Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule.,19642243_2,1
5820,renal insufficiency,73,92,Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule.,19642243_2,1
5819,Fanconi syndrome,52,68,Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule.,19642243_2,1
2152,Tenofovir,0,9,Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule.,19642243_2,0
8645,nephrotoxicity,11,25,Vancomycin nephrotoxicity is infrequent but may result from coadministration with a nephrotoxic agent.,19642243_3,1
2153,tenofovir,32,41,Clinicians should be aware that tenofovir may raise the risk of renal failure during prolonged administration of vancomycin.,19642243_4,0
5822,renal failure,64,77,Clinicians should be aware that tenofovir may raise the risk of renal failure during prolonged administration of vancomycin.,19642243_4,1
8647,hydrogen cyanamide,31,49,Disulfiram-like syndrome after hydrogen cyanamide professional skin exposure: two case reports in France.,19657887_0,0
2154,plant growth regulator,24,46,Hydrogen cyanamide is a plant growth regulator used in agriculture to induce bud break in fruit trees.,19657887_1,0
8649,Hydrogen cyanamide,0,18,Hydrogen cyanamide is a plant growth regulator used in agriculture to induce bud break in fruit trees.,19657887_1,0
5823,alcohol consumption,46,65,These cases confirm the necessity of avoiding alcohol consumption as recommended in the instructions for use of Dormex and of preventing cutaneous contact during use.,19657887_10,1
8660,Dormex,112,118,These cases confirm the necessity of avoiding alcohol consumption as recommended in the instructions for use of Dormex and of preventing cutaneous contact during use.,19657887_10,0
8651,alcohol use,162,173,Contact with the skin can result in percutaneous absorption of the substance that inhibits aldehyde dehydrogenase and can induce acetaldehyde syndrome in case of alcohol use.,19657887_2,1
8650,percutaneous absorption,36,59,Contact with the skin can result in percutaneous absorption of the substance that inhibits aldehyde dehydrogenase and can induce acetaldehyde syndrome in case of alcohol use.,19657887_2,1
2155,aldehyde dehydrogenase,91,113,Contact with the skin can result in percutaneous absorption of the substance that inhibits aldehyde dehydrogenase and can induce acetaldehyde syndrome in case of alcohol use.,19657887_2,0
8653,hydrogen cyanamide,117,135,The purpose of this report is to describe two cases of a disulfiram-like syndrome following occupational exposure to hydrogen cyanamide.,19657887_3,0
8655,hydrogen cyanamide,74,92,"The first case involved a 59-year-old man who used Dormex, which contains hydrogen cyanamide, without protection after consuming a large amount of alcohol during a meal.",19657887_4,0
8657,Dormex,82,88,The second case occurred in a 55-year-old farmer following cutaneous contact with Dormex.,19657887_7,0
8659,arterial hypotension,97,117,"Five hours after exposure, he developed disulfiram-like syndrome with flushing, tachycardia, and arterial hypotension after consuming three glasses of wine.",19657887_8,1
8661,Recurrent dysosmia,0,18,Recurrent dysosmia induced by pyrazinamide.,19674115_0,1
8662,pyrazinamide,30,42,Recurrent dysosmia induced by pyrazinamide.,19674115_0,0
5825,hyperuricemia,64,77,"Pyrazinamide can have adverse effects such as hepatic toxicity, hyperuricemia or digestive disorders.",19674115_1,1
8664,digestive disorders,81,100,"Pyrazinamide can have adverse effects such as hepatic toxicity, hyperuricemia or digestive disorders.",19674115_1,1
8663,Pyrazinamide,0,12,"Pyrazinamide can have adverse effects such as hepatic toxicity, hyperuricemia or digestive disorders.",19674115_1,0
5824,adverse effects,22,37,"Pyrazinamide can have adverse effects such as hepatic toxicity, hyperuricemia or digestive disorders.",19674115_1,1
8666,pyrazinamide,78,90,"In rare cases, alterations in taste and smell function have been reported for pyrazinamide when combined with other drugs.",19674115_2,0
8667,olfactory disorder,31,49,"We report a case of reversible olfactory disorder related to pyrazinamide in a woman, with a positive rechallenge.",19674115_3,1
8669,rechallenge,102,113,"We report a case of reversible olfactory disorder related to pyrazinamide in a woman, with a positive rechallenge.",19674115_3,0
8668,pyrazinamide,61,73,"We report a case of reversible olfactory disorder related to pyrazinamide in a woman, with a positive rechallenge.",19674115_3,0
8671,pyrazinamide,38,50,Dysosmia disappeared completely after pyrazinamide withdrawal and recurred after its rechallenge.,19674115_5,0
8672,rechallenge,85,96,Dysosmia disappeared completely after pyrazinamide withdrawal and recurred after its rechallenge.,19674115_5,0
5826,tardive dystonia,18,34,Sulpiride-induced tardive dystonia.,1967484_0,1
2156,Sulpiride,0,9,Sulpiride is a selective D2-receptor antagonist with antipsychotic and antidepressant properties.,1967484_1,0
8673,D2-receptor antagonist,25,47,Sulpiride is a selective D2-receptor antagonist with antipsychotic and antidepressant properties.,1967484_1,0
5827,tardive dyskinesia,88,106,"Although initially thought to be free of extrapyramidal side effects, sulpiride-induced tardive dyskinesia and parkinsonism have been reported occasionally.",1967484_2,1
8674,free of extrapyramidal side effects,33,68,"Although initially thought to be free of extrapyramidal side effects, sulpiride-induced tardive dyskinesia and parkinsonism have been reported occasionally.",1967484_2,1
2157,sulpiride,104,113,We studied a 37-year-old man who developed persistent segmental dystonia within 2 months after starting sulpiride therapy.,1967484_3,0
5828,dystonia,64,72,We studied a 37-year-old man who developed persistent segmental dystonia within 2 months after starting sulpiride therapy.,1967484_3,1
5829,tardive dystonia,60,76,We could not find any previous reports of sulpiride-induced tardive dystonia.,1967484_4,1
8675,mPGES-1,13,20,Mice lacking mPGES-1 are resistant to lithium-induced polyuria.,19692487_0,0
2161,cotransporter,55,68,"Similarly, the total protein abundance of the Na-K-2Cl cotransporter (NKCC2) in the medulla but not in the cortex of the +/+ mice was significantly reduced by lithium treatment.",19692487_10,0
2162,NKCC2,70,75,"Similarly, the total protein abundance of the Na-K-2Cl cotransporter (NKCC2) in the medulla but not in the cortex of the +/+ mice was significantly reduced by lithium treatment.",19692487_10,0
5830,renal medullary,34,49,"In contrast, the dowregulation of renal medullary NKCC2 expression was significantly attenuated in the -/- mice.",19692487_11,1
2163,NKCC2,50,55,"In contrast, the dowregulation of renal medullary NKCC2 expression was significantly attenuated in the -/- mice.",19692487_11,0
2164,PGE(2,33,38,We conclude that mPGES-1-derived PGE(2) mediates lithium-induced polyuria likely via inhibition of AQP2 and NKCC2 expression.,19692487_12,0
2165,NKCC2,108,113,We conclude that mPGES-1-derived PGE(2) mediates lithium-induced polyuria likely via inhibition of AQP2 and NKCC2 expression.,19692487_12,0
8699,AQP2,99,103,We conclude that mPGES-1-derived PGE(2) mediates lithium-induced polyuria likely via inhibition of AQP2 and NKCC2 expression.,19692487_12,0
2158,PG,64,66,"However, the involvement of a specific, terminal prostaglandin (PG) isomerase has not been evaluated.",19692487_2,0
2159,prostaglandin E synthase-1,100,126,The present study was undertaken to assess lithium-induced polyuria in mice deficient in microsomal prostaglandin E synthase-1 (mPGES-1).,19692487_3,0
8680,mPGES-1,128,135,The present study was undertaken to assess lithium-induced polyuria in mice deficient in microsomal prostaglandin E synthase-1 (mPGES-1).,19692487_3,0
8681,LiCl,25,29,A 2-wk administration of LiCl (4 mmol.kg(-1).day(-1) ip) in mPGES-1 +/+ mice led to a marked polyuria with hyposmotic urine.,19692487_4,0
8682,mPGES-1,60,67,A 2-wk administration of LiCl (4 mmol.kg(-1).day(-1) ip) in mPGES-1 +/+ mice led to a marked polyuria with hyposmotic urine.,19692487_4,0
8683,hyposmotic,107,117,A 2-wk administration of LiCl (4 mmol.kg(-1).day(-1) ip) in mPGES-1 +/+ mice led to a marked polyuria with hyposmotic urine.,19692487_4,1
8684,mPGES-1,40,47,This was associated with elevated renal mPGES-1 protein expression and increased urine PGE(2) excretion.,19692487_5,0
8686,urine PGE(2,81,92,This was associated with elevated renal mPGES-1 protein expression and increased urine PGE(2) excretion.,19692487_5,0
8687,mPGES-1,13,20,"In contrast, mPGES-1 -/- mice were largely resistant to lithium-induced polyuria and a urine concentrating defect, accompanied by nearly complete blockade of high urine PGE(2) and cAMP output.",19692487_6,0
2160,aquaporin-2,114,125,"Immunoblotting, immunohistochemistry, and quantitative (q) RT-PCR consistently detected a significant decrease in aquaporin-2 (AQP2) protein expression in both the renal cortex and medulla of lithium-treated +/+ mice.",19692487_7,0
8691,RT-PCR,59,65,"Immunoblotting, immunohistochemistry, and quantitative (q) RT-PCR consistently detected a significant decrease in aquaporin-2 (AQP2) protein expression in both the renal cortex and medulla of lithium-treated +/+ mice.",19692487_7,0
8693,renal cortex,164,176,"Immunoblotting, immunohistochemistry, and quantitative (q) RT-PCR consistently detected a significant decrease in aquaporin-2 (AQP2) protein expression in both the renal cortex and medulla of lithium-treated +/+ mice.",19692487_7,1
8692,AQP2,127,131,"Immunoblotting, immunohistochemistry, and quantitative (q) RT-PCR consistently detected a significant decrease in aquaporin-2 (AQP2) protein expression in both the renal cortex and medulla of lithium-treated +/+ mice.",19692487_7,0
8696,AQP2,48,52,qRT-PCR detected similar patterns of changes in AQP2 mRNA in the medulla but not in the cortex.,19692487_9,0
8695,qRT-PCR,0,7,qRT-PCR detected similar patterns of changes in AQP2 mRNA in the medulla but not in the cortex.,19692487_9,0
8700,renal blood flow,16,32,Preservation of renal blood flow during hypotension induced with fenoldopam in dogs.,1969772_0,1
2166,fenoldopam,65,75,Preservation of renal blood flow during hypotension induced with fenoldopam in dogs.,1969772_0,0
8701,pharmacological actions,71,94,The introduction of drugs that could induce hypotension with different pharmacological actions would be advantageous because side effects unique to a specific drug could be minimized by selecting appropriate therapy.,1969772_1,0
5831,side effects,125,137,The introduction of drugs that could induce hypotension with different pharmacological actions would be advantageous because side effects unique to a specific drug could be minimized by selecting appropriate therapy.,1969772_1,1
8702,dopamine-1,9,19,"Specific dopamine-1, (DA1) and dopamine-2 (DA2) receptor agonists are now under clinical investigation.",1969772_2,0
2167,receptor agonists,48,65,"Specific dopamine-1, (DA1) and dopamine-2 (DA2) receptor agonists are now under clinical investigation.",1969772_2,0
8703,DA1,22,25,"Specific dopamine-1, (DA1) and dopamine-2 (DA2) receptor agonists are now under clinical investigation.",1969772_2,0
8705,DA1 receptor agonist,34,54,Fenoldopam mesylate is a specific DA1 receptor agonist that lowers blood pressure by vasodilatation.,1969772_3,0
8706,vasodilatation,85,99,Fenoldopam mesylate is a specific DA1 receptor agonist that lowers blood pressure by vasodilatation.,1969772_3,1
5832,blood pressure,67,81,Fenoldopam mesylate is a specific DA1 receptor agonist that lowers blood pressure by vasodilatation.,1969772_3,1
8704,Fenoldopam mesylate,0,19,Fenoldopam mesylate is a specific DA1 receptor agonist that lowers blood pressure by vasodilatation.,1969772_3,0
8707,blood flow,80,90,The hypothesis that fenoldopam could be used to induce hypotension and preserve blood flow to the kidney was tested.,1969772_4,1
2168,fenoldopam,20,30,The hypothesis that fenoldopam could be used to induce hypotension and preserve blood flow to the kidney was tested.,1969772_4,0
8711,general anaesthesia,293,312,"Systemic aortic blood pressure and renal blood flow were measured continuously with a carotid arterial catheter and an electromagnetic flow probe respectively, in order to compare the cardiovascular and renal vascular effects of fenoldopam and sodium nitroprusside in ten dogs under halothane general anaesthesia.",1969772_5,1
8709,carotid arterial catheter,86,111,"Systemic aortic blood pressure and renal blood flow were measured continuously with a carotid arterial catheter and an electromagnetic flow probe respectively, in order to compare the cardiovascular and renal vascular effects of fenoldopam and sodium nitroprusside in ten dogs under halothane general anaesthesia.",1969772_5,1
2170,sodium nitroprusside,244,264,"Systemic aortic blood pressure and renal blood flow were measured continuously with a carotid arterial catheter and an electromagnetic flow probe respectively, in order to compare the cardiovascular and renal vascular effects of fenoldopam and sodium nitroprusside in ten dogs under halothane general anaesthesia.",1969772_5,0
5833,blood pressure,16,30,"Systemic aortic blood pressure and renal blood flow were measured continuously with a carotid arterial catheter and an electromagnetic flow probe respectively, in order to compare the cardiovascular and renal vascular effects of fenoldopam and sodium nitroprusside in ten dogs under halothane general anaesthesia.",1969772_5,1
2169,fenoldopam,229,239,"Systemic aortic blood pressure and renal blood flow were measured continuously with a carotid arterial catheter and an electromagnetic flow probe respectively, in order to compare the cardiovascular and renal vascular effects of fenoldopam and sodium nitroprusside in ten dogs under halothane general anaesthesia.",1969772_5,0
2172,sodium nitroprusside,171,191,Mean arterial pressure was decreased 30 +/- 8 per cent from control with infusion of fenoldopam (3.4 +/- 2.0 micrograms.kg-1.min-1) and 34 +/- 4 per cent with infusion of sodium nitroprusside (5.9 micrograms.kg-1.min-1) (NS).,1969772_6,0
8712,Mean arterial pressure,0,22,Mean arterial pressure was decreased 30 +/- 8 per cent from control with infusion of fenoldopam (3.4 +/- 2.0 micrograms.kg-1.min-1) and 34 +/- 4 per cent with infusion of sodium nitroprusside (5.9 micrograms.kg-1.min-1) (NS).,1969772_6,1
2171,fenoldopam,85,95,Mean arterial pressure was decreased 30 +/- 8 per cent from control with infusion of fenoldopam (3.4 +/- 2.0 micrograms.kg-1.min-1) and 34 +/- 4 per cent with infusion of sodium nitroprusside (5.9 micrograms.kg-1.min-1) (NS).,1969772_6,0
8719,RBF,18,21,Renal blood flow (RBF) increased during fenoldopam-induced hypotension 11 +/- 7 per cent and decreased 21 +/- 8 per cent during sodium nitroprusside-induced hypotension (P less than 0.01).,1969772_7,0
8720,/-,75,77,Renal blood flow (RBF) increased during fenoldopam-induced hypotension 11 +/- 7 per cent and decreased 21 +/- 8 per cent during sodium nitroprusside-induced hypotension (P less than 0.01).,1969772_7,0
2173,Sodium nitroprusside,0,20,Sodium nitroprusside is a non-selective arteriolar and venous vasodilator that can produce redistribution of blood flow away from the kidney during induced hypotension.,1969772_8,0
2174,Fenoldopam,0,10,Fenoldopam is a selective dopamine-1 (DA1) receptor agonist that causes vasodilatation to the kidney and other organs with DA1 receptors and preserves blood flow to the kidney during induced hypotension.,1969772_9,0
2175,receptor agonist,43,59,Fenoldopam is a selective dopamine-1 (DA1) receptor agonist that causes vasodilatation to the kidney and other organs with DA1 receptors and preserves blood flow to the kidney during induced hypotension.,1969772_9,0
8724,dopamine-1,26,36,Fenoldopam is a selective dopamine-1 (DA1) receptor agonist that causes vasodilatation to the kidney and other organs with DA1 receptors and preserves blood flow to the kidney during induced hypotension.,1969772_9,0
8725,DA1,38,41,Fenoldopam is a selective dopamine-1 (DA1) receptor agonist that causes vasodilatation to the kidney and other organs with DA1 receptors and preserves blood flow to the kidney during induced hypotension.,1969772_9,0
8726,vasodilatation,72,86,Fenoldopam is a selective dopamine-1 (DA1) receptor agonist that causes vasodilatation to the kidney and other organs with DA1 receptors and preserves blood flow to the kidney during induced hypotension.,1969772_9,1
8727,DA1 receptors,123,136,Fenoldopam is a selective dopamine-1 (DA1) receptor agonist that causes vasodilatation to the kidney and other organs with DA1 receptors and preserves blood flow to the kidney during induced hypotension.,1969772_9,0
8730,case presentation,39,56,Seizures associated with levofloxacin: case presentation and literature review.,19707748_0,1
2176,levofloxacin,25,37,Seizures associated with levofloxacin: case presentation and literature review.,19707748_0,0
8734,1A2,219,222,"PURPOSE: We present a case of a patient who developed seizures shortly after initiating treatment with levofloxacin and to discuss the potential drug-drug interactions related to the inhibition of cytochrome P450 (CYP) 1A2 in this case, as well as in other cases, of levofloxacin-induced seizures.",19707748_1,0
2178,cytochrome P450,197,212,"PURPOSE: We present a case of a patient who developed seizures shortly after initiating treatment with levofloxacin and to discuss the potential drug-drug interactions related to the inhibition of cytochrome P450 (CYP) 1A2 in this case, as well as in other cases, of levofloxacin-induced seizures.",19707748_1,0
2177,levofloxacin,103,115,"PURPOSE: We present a case of a patient who developed seizures shortly after initiating treatment with levofloxacin and to discuss the potential drug-drug interactions related to the inhibition of cytochrome P450 (CYP) 1A2 in this case, as well as in other cases, of levofloxacin-induced seizures.",19707748_1,0
8733,CYP,214,217,"PURPOSE: We present a case of a patient who developed seizures shortly after initiating treatment with levofloxacin and to discuss the potential drug-drug interactions related to the inhibition of cytochrome P450 (CYP) 1A2 in this case, as well as in other cases, of levofloxacin-induced seizures.",19707748_1,0
2179,levofloxacin,52,64,The main search terms utilized were case report and levofloxacin.,19707748_3,0
2181,levofloxacin,62,74,Drug-drug interactions related to the inhibition of CYP1A2 by levofloxacin are likely involved in the clinical outcome of these cases.,19707748_6,0
2180,CYP1A2,52,58,Drug-drug interactions related to the inhibition of CYP1A2 by levofloxacin are likely involved in the clinical outcome of these cases.,19707748_6,0
2183,CYP1A2,167,173,CONCLUSIONS: Clinicians are exhorted to pay close attention when initiating levofloxacin therapy in patients taking medications with epileptogenic properties that are CYP1A2 substrates.,19707748_7,0
2182,levofloxacin,76,88,CONCLUSIONS: Clinicians are exhorted to pay close attention when initiating levofloxacin therapy in patients taking medications with epileptogenic properties that are CYP1A2 substrates.,19707748_7,0
8741,epileptogenic,133,146,CONCLUSIONS: Clinicians are exhorted to pay close attention when initiating levofloxacin therapy in patients taking medications with epileptogenic properties that are CYP1A2 substrates.,19707748_7,1
8742,Dextran-etodolac,0,16,"Dextran-etodolac conjugates: synthesis, in vitro and in vivo evaluation.",19719056_0,0
8746,antiinflammatory drug,46,67,"Etodolac (E), is a non-narcotic analgesic and antiinflammatory drug.",19719056_1,0
8744,Etodolac (E,0,11,"Etodolac (E), is a non-narcotic analgesic and antiinflammatory drug.",19719056_1,0
8745,non-narcotic analgesic,19,41,"Etodolac (E), is a non-narcotic analgesic and antiinflammatory drug.",19719056_1,0
8759,Acute analgesic,0,15,"Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model (mice) and carrageenan-induced rat paw edema model, respectively.",19719056_10,0
2184,antiinflammatory,20,36,"Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model (mice) and carrageenan-induced rat paw edema model, respectively.",19719056_10,0
2185,acetic acid,71,82,"Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model (mice) and carrageenan-induced rat paw edema model, respectively.",19719056_10,0
8761,ED1-ED4,32,39,"In comparison to control, E and ED1-ED4 showed highly significant analgesic and antiinflammatory activities (p <0.001).",19719056_11,0
2186,antiinflammatory,80,96,"In comparison to control, E and ED1-ED4 showed highly significant analgesic and antiinflammatory activities (p <0.001).",19719056_11,0
8762,ED1-ED4,49,56,Biological evaluation suggested that conjugates (ED1-ED4) retained comparable analgesic and antiinflammatory activities with remarkably reduced ulcerogenicity as compared to their parent drug--etodolac.,19719056_12,0
8763,ulcerogenicity,144,158,Biological evaluation suggested that conjugates (ED1-ED4) retained comparable analgesic and antiinflammatory activities with remarkably reduced ulcerogenicity as compared to their parent drug--etodolac.,19719056_12,1
8764,drug--etodolac,187,201,Biological evaluation suggested that conjugates (ED1-ED4) retained comparable analgesic and antiinflammatory activities with remarkably reduced ulcerogenicity as compared to their parent drug--etodolac.,19719056_12,0
2187,antiinflammatory,92,108,Biological evaluation suggested that conjugates (ED1-ED4) retained comparable analgesic and antiinflammatory activities with remarkably reduced ulcerogenicity as compared to their parent drug--etodolac.,19719056_12,0
8748,etodolac-dextran,80,96,A biodegradable polymer dextran has been utilized as a carrier for synthesis of etodolac-dextran conjugates (ED) to improve its aqueous solubility and reduce gastrointestinal side effects.,19719056_2,0
8747,polymer dextran,16,31,A biodegradable polymer dextran has been utilized as a carrier for synthesis of etodolac-dextran conjugates (ED) to improve its aqueous solubility and reduce gastrointestinal side effects.,19719056_2,0
5834,side effects,175,187,A biodegradable polymer dextran has been utilized as a carrier for synthesis of etodolac-dextran conjugates (ED) to improve its aqueous solubility and reduce gastrointestinal side effects.,19719056_2,1
8750,N-acylimidazole derivative of etodolac,26,64,"An activated moiety, i.e. N-acylimidazole derivative of etodolac (EAI), was condensed with the polysaccharide polymer dextran of different molecular weights (40000, 60000, 110000 and 200000).",19719056_3,0
8749,activated moiety,3,19,"An activated moiety, i.e. N-acylimidazole derivative of etodolac (EAI), was condensed with the polysaccharide polymer dextran of different molecular weights (40000, 60000, 110000 and 200000).",19719056_3,0
8752,polysaccharide polymer dextran,95,125,"An activated moiety, i.e. N-acylimidazole derivative of etodolac (EAI), was condensed with the polysaccharide polymer dextran of different molecular weights (40000, 60000, 110000 and 200000).",19719056_3,0
8753,molecular weights,139,156,"An activated moiety, i.e. N-acylimidazole derivative of etodolac (EAI), was condensed with the polysaccharide polymer dextran of different molecular weights (40000, 60000, 110000 and 200000).",19719056_3,0
8751,EAI,66,69,"An activated moiety, i.e. N-acylimidazole derivative of etodolac (EAI), was condensed with the polysaccharide polymer dextran of different molecular weights (40000, 60000, 110000 and 200000).",19719056_3,0
8754,ester bonding,40,53,IR spectral data confirmed formation of ester bonding in the conjugates.,19719056_4,0
8755,molecular weights,4,21,The molecular weights were determined by measuring viscosity using the Mark-Howink-Sakurada equation.,19719056_6,0
8757,aqueous buffer,79,93,"At pH 9, a higher rate of etodolac release from ED was observed as compared to aqueous buffer of pH 7.4 and 80% human plasma (pH 7.4), following first-order kinetics.",19719056_8,0
8771,[Ca(2+)](i,83,93,Confocal microscopy was used to measure intracellular free-calcium concentrations ([Ca(2+)](i)) in isolated myocytes.,19721134_2,0
5835,ventricular tachycardia,114,137,"The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs.",19721134_3,1
8773,delayed onset of,55,71,"The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs.",19721134_3,1
8777,[Ca(2+)](i,0,10,[Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.,19721134_4,0
2188,aconitine,32,41,[Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.,19721134_4,0
2189,ouabain,45,52,[Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine.,19721134_4,0
8778,mAChR,50,55,"Moreover, M(3)-muscarinic acetylcholine receptor (mAChR) antagonist 4-DAMP (4-diphenylacetoxy-N-methylpiperidine-methiodide) partially abolished the beneficial effects of pilocarpine.",19721134_5,0
8779,4-DAMP,68,74,"Moreover, M(3)-muscarinic acetylcholine receptor (mAChR) antagonist 4-DAMP (4-diphenylacetoxy-N-methylpiperidine-methiodide) partially abolished the beneficial effects of pilocarpine.",19721134_5,0
2190,acetylcholine receptor,26,48,"Moreover, M(3)-muscarinic acetylcholine receptor (mAChR) antagonist 4-DAMP (4-diphenylacetoxy-N-methylpiperidine-methiodide) partially abolished the beneficial effects of pilocarpine.",19721134_5,0
2191,aconitine,119,128,These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR. The mechanism may be related to the improvement of Ca(2+) handling.,19721134_6,0
2192,ouabain,132,139,These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR. The mechanism may be related to the improvement of Ca(2+) handling.,19721134_6,0
2193,Ca(2+),231,237,These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR. The mechanism may be related to the improvement of Ca(2+) handling.,19721134_6,0
5836,side effects,37,49,Comparative cognitive and subjective side effects of immediate-release oxycodone in healthy middle-aged and older adults.,19729346_0,1
2194,oxycodone,71,80,Comparative cognitive and subjective side effects of immediate-release oxycodone in healthy middle-aged and older adults.,19729346_0,0
2195,oxycodone,116,125,"This study measured the objective and subjective neurocognitive effects of a single 10-mg dose of immediate-release oxycodone in healthy, older (> 65 years), and middle-aged (35 to 55 years) adults who were not suffering from chronic or significant daily pain.",19729346_1,0
8785,daily pain,249,259,"This study measured the objective and subjective neurocognitive effects of a single 10-mg dose of immediate-release oxycodone in healthy, older (> 65 years), and middle-aged (35 to 55 years) adults who were not suffering from chronic or significant daily pain.",19729346_1,1
2196,oxycodone,112,121,"Seventy-one participants completed 2 separate study days and were blind to medication condition (placebo, 10-mg oxycodone).",19729346_2,0
8786,postdose,64,72,"Plasma oxycodone concentration peaked between 60 and 90 minutes postdose (P < .01) and pupil size, an indication of physiological effects of the medication, peaked at approximately 90 to 120 minutes postdose (P < .01).",19729346_3,1
2198,physiological effects,116,137,"Plasma oxycodone concentration peaked between 60 and 90 minutes postdose (P < .01) and pupil size, an indication of physiological effects of the medication, peaked at approximately 90 to 120 minutes postdose (P < .01).",19729346_3,0
2197,oxycodone,7,16,"Plasma oxycodone concentration peaked between 60 and 90 minutes postdose (P < .01) and pupil size, an indication of physiological effects of the medication, peaked at approximately 90 to 120 minutes postdose (P < .01).",19729346_3,0
8787,pupil size,87,97,"Plasma oxycodone concentration peaked between 60 and 90 minutes postdose (P < .01) and pupil size, an indication of physiological effects of the medication, peaked at approximately 90 to 120 minutes postdose (P < .01).",19729346_3,0
8788,postdose,199,207,"Plasma oxycodone concentration peaked between 60 and 90 minutes postdose (P < .01) and pupil size, an indication of physiological effects of the medication, peaked at approximately 90 to 120 minutes postdose (P < .01).",19729346_3,1
8791,postdose,114,122,"Significant declines in simple and sustained attention, working memory, and verbal memory were observed at 1 hour postdose compared to baseline for both age groups with a trend toward return to baseline by 5 hours postdose.",19729346_4,1
8792,postdose,214,222,"Significant declines in simple and sustained attention, working memory, and verbal memory were observed at 1 hour postdose compared to baseline for both age groups with a trend toward return to baseline by 5 hours postdose.",19729346_4,1
8790,verbal memory,76,89,"Significant declines in simple and sustained attention, working memory, and verbal memory were observed at 1 hour postdose compared to baseline for both age groups with a trend toward return to baseline by 5 hours postdose.",19729346_4,1
8789,working memory,56,70,"Significant declines in simple and sustained attention, working memory, and verbal memory were observed at 1 hour postdose compared to baseline for both age groups with a trend toward return to baseline by 5 hours postdose.",19729346_4,1
2199,oxycodone,183,192,"This study suggests that for healthy older adults who are not suffering from chronic pain, neurocognitive and pharmacodynamic changes in response to a 10-mg dose of immediate-release oxycodone are similar to those observed for middle-aged adults.",19729346_6,0
5837,chronic pain,77,89,"This study suggests that for healthy older adults who are not suffering from chronic pain, neurocognitive and pharmacodynamic changes in response to a 10-mg dose of immediate-release oxycodone are similar to those observed for middle-aged adults.",19729346_6,1
8795,neurocognitive,91,105,"This study suggests that for healthy older adults who are not suffering from chronic pain, neurocognitive and pharmacodynamic changes in response to a 10-mg dose of immediate-release oxycodone are similar to those observed for middle-aged adults.",19729346_6,1
2200,oxycodone,116,125,"PERSPECTIVE: Study findings indicate that the metabolism, neurocognitive effects, and physical side effects of oral oxycodone are similar for healthy middle-aged and older adults.",19729346_7,0
8798,neurocognitive effects,58,80,"PERSPECTIVE: Study findings indicate that the metabolism, neurocognitive effects, and physical side effects of oral oxycodone are similar for healthy middle-aged and older adults.",19729346_7,1
5838,side effects,95,107,"PERSPECTIVE: Study findings indicate that the metabolism, neurocognitive effects, and physical side effects of oral oxycodone are similar for healthy middle-aged and older adults.",19729346_7,1
2201,opioids,56,63,"Therefore, clinicians should not avoid prescribing oral opioids to older adults based on the belief that older adults are at higher risk for side effects than younger adults.",19729346_8,0
5839,side effects,141,153,"Therefore, clinicians should not avoid prescribing oral opioids to older adults based on the belief that older adults are at higher risk for side effects than younger adults.",19729346_8,1
8804,SSR103800,36,45,The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice.,19759529_0,0
8803,glycine transporter-1 inhibitor,4,35,The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice.,19759529_0,0
8830,SSR103800,55,64,"Together these findings show that the GlyT1 inhibitor, SSR103800, produces antipsychotic-like effects, which differ from those observed with compounds primarily targeting the dopaminergic system, and has a reduced side-effect potential as compared with these latter drugs.",19759529_10,0
2215,dopaminergic,175,187,"Together these findings show that the GlyT1 inhibitor, SSR103800, produces antipsychotic-like effects, which differ from those observed with compounds primarily targeting the dopaminergic system, and has a reduced side-effect potential as compared with these latter drugs.",19759529_10,0
5840,side-effect,214,225,"Together these findings show that the GlyT1 inhibitor, SSR103800, produces antipsychotic-like effects, which differ from those observed with compounds primarily targeting the dopaminergic system, and has a reduced side-effect potential as compared with these latter drugs.",19759529_10,1
8829,GlyT1,38,43,"Together these findings show that the GlyT1 inhibitor, SSR103800, produces antipsychotic-like effects, which differ from those observed with compounds primarily targeting the dopaminergic system, and has a reduced side-effect potential as compared with these latter drugs.",19759529_10,0
2205,NMDA receptor,218,231,"However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce schizophrenic-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor.",19759529_2,0
2202,N-methyl-D-aspartate,59,79,"However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce schizophrenic-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor.",19759529_2,0
2204,glutamatergic,189,202,"However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce schizophrenic-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor.",19759529_2,0
2203,NMDA,81,85,"However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce schizophrenic-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor.",19759529_2,0
8808,schizophrenic-like symptoms,104,131,"However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce schizophrenic-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor.",19759529_2,1
8809,dysfunctioning,167,181,"However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce schizophrenic-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor.",19759529_2,1
2206,glutamatergic,159,172,"As a result, there is a growing interest in the development of pharmacological agents with potential antipsychotic properties that enhance the activity of the glutamatergic system via a modulation of the NMDA receptor.",19759529_3,0
2207,NMDA receptor,204,217,"As a result, there is a growing interest in the development of pharmacological agents with potential antipsychotic properties that enhance the activity of the glutamatergic system via a modulation of the NMDA receptor.",19759529_3,0
8810,pharmacological agents,63,85,"As a result, there is a growing interest in the development of pharmacological agents with potential antipsychotic properties that enhance the activity of the glutamatergic system via a modulation of the NMDA receptor.",19759529_3,0
8813,SSR103800,64,73,"Among them are glycine transporter-1 (GlyT1) inhibitors such as SSR103800, which indirectly enhance NMDA receptor function by increasing the glycine (a co-agonist for the NMDA receptor) levels in the synapse.",19759529_4,0
8812,GlyT1,38,43,"Among them are glycine transporter-1 (GlyT1) inhibitors such as SSR103800, which indirectly enhance NMDA receptor function by increasing the glycine (a co-agonist for the NMDA receptor) levels in the synapse.",19759529_4,0
8811,glycine transporter-1,15,36,"Among them are glycine transporter-1 (GlyT1) inhibitors such as SSR103800, which indirectly enhance NMDA receptor function by increasing the glycine (a co-agonist for the NMDA receptor) levels in the synapse.",19759529_4,0
8814,co-agonist,152,162,"Among them are glycine transporter-1 (GlyT1) inhibitors such as SSR103800, which indirectly enhance NMDA receptor function by increasing the glycine (a co-agonist for the NMDA receptor) levels in the synapse.",19759529_4,0
2208,NMDA receptor,100,113,"Among them are glycine transporter-1 (GlyT1) inhibitors such as SSR103800, which indirectly enhance NMDA receptor function by increasing the glycine (a co-agonist for the NMDA receptor) levels in the synapse.",19759529_4,0
2209,NMDA receptor,171,184,"Among them are glycine transporter-1 (GlyT1) inhibitors such as SSR103800, which indirectly enhance NMDA receptor function by increasing the glycine (a co-agonist for the NMDA receptor) levels in the synapse.",19759529_4,0
2210,MK-801,197,203,"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).",19759529_5,0
8816,SSR103800,81,90,"This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)).",19759529_5,0
8822,non-competitive NMDA receptor antagonist,86,126,"Results showed that SSR103800 (10-30 mg/kg p.o.) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.",19759529_6,0
8821,SSR103800,20,29,"Results showed that SSR103800 (10-30 mg/kg p.o.) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.",19759529_6,0
2211,MK-801,128,134,"Results showed that SSR103800 (10-30 mg/kg p.o.) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.",19759529_6,0
8823,NMDA Nr1(neo-/-,187,202,"Results showed that SSR103800 (10-30 mg/kg p.o.) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice.",19759529_6,0
8824,SSR103800,13,22,"In contrast, SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in dopamine transporter (DAT(-/-)) knockout mice (10-30 mg/kg p.o.).",19759529_7,0
2212,dopamine transporter,102,122,"In contrast, SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in dopamine transporter (DAT(-/-)) knockout mice (10-30 mg/kg p.o.).",19759529_7,0
8825,DAT(-/-),124,132,"In contrast, SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in dopamine transporter (DAT(-/-)) knockout mice (10-30 mg/kg p.o.).",19759529_7,0
2213,olanzapine,56,66,"Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of hyperactivity.",19759529_8,0
2214,aripiprazole,82,94,"Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of hyperactivity.",19759529_8,0
8827,SSR103800,30,39,"However, unlike these latter, SSR103800 did not produce catalepsy (retention on the bar test) up to 30 mg/kg p.o.",19759529_9,0
5841,neurobehavioral,54,69,Effect of Hibiscus rosa sinensis on reserpine-induced neurobehavioral and biochemical alterations in rats.,19761039_0,1
8832,methanolic extract,10,28,Effect of methanolic extract of Hibiscus rosa sinensis (100-300 mg/kg) was studied on reserpine-induced orofacial dyskinesia and neurochemical alterations.,19761039_1,0
5842,orofacial dyskinesia,104,124,Effect of methanolic extract of Hibiscus rosa sinensis (100-300 mg/kg) was studied on reserpine-induced orofacial dyskinesia and neurochemical alterations.,19761039_1,1
8835,intraperitoneal reserpine (1,27,55,"The rats were treated with intraperitoneal reserpine (1 mg/kg, ip) for 3 days every other day.",19761039_2,0
8838,vacuous chewing,47,62,"Reserpine treated rats significantly developed vacuous chewing movements and tongue protrusions however, coadministration of Hibiscus rosa sinensis roots extract (100, 200 and 300 mg/kg, per orally) attenuated the effects.",19761039_4,1
8843,oxidative stress,223,239,"Biochemical analysis of brain revealed that the reserpine treatment significantly increased lipid peroxidation and decreased levels of superoxide dismutase (SOD), catalase (CAT) and glutathione reductase (GSH), an index of oxidative stress process.",19761039_5,1
8841,lipid peroxidation,92,110,"Biochemical analysis of brain revealed that the reserpine treatment significantly increased lipid peroxidation and decreased levels of superoxide dismutase (SOD), catalase (CAT) and glutathione reductase (GSH), an index of oxidative stress process.",19761039_5,0
8842,GSH,205,208,"Biochemical analysis of brain revealed that the reserpine treatment significantly increased lipid peroxidation and decreased levels of superoxide dismutase (SOD), catalase (CAT) and glutathione reductase (GSH), an index of oxidative stress process.",19761039_5,0
2217,glutathione reductase,182,203,"Biochemical analysis of brain revealed that the reserpine treatment significantly increased lipid peroxidation and decreased levels of superoxide dismutase (SOD), catalase (CAT) and glutathione reductase (GSH), an index of oxidative stress process.",19761039_5,0
2216,superoxide dismutase,135,155,"Biochemical analysis of brain revealed that the reserpine treatment significantly increased lipid peroxidation and decreased levels of superoxide dismutase (SOD), catalase (CAT) and glutathione reductase (GSH), an index of oxidative stress process.",19761039_5,0
8844,lipid peroxidation,54,72,"Coadministration of extract significantly reduced the lipid peroxidation and reversed the decrease in brain SOD, CAT and GSH levels.",19761039_6,0
8845,GSH,121,124,"Coadministration of extract significantly reduced the lipid peroxidation and reversed the decrease in brain SOD, CAT and GSH levels.",19761039_6,0
8848,oxidative stress,144,160,The results of the present study suggested that Hibiscus rosa sinensis had a protective role against reserpine-induced orofacial dyskinesia and oxidative stress.,19761039_7,1
5843,orofacial dyskinesia,119,139,The results of the present study suggested that Hibiscus rosa sinensis had a protective role against reserpine-induced orofacial dyskinesia and oxidative stress.,19761039_7,1
8849,Pyrrolidine dithiocarbamate,0,27,Pyrrolidine dithiocarbamate protects the piriform cortex in the pilocarpine status epilepticus model.,19767176_0,0
5844,status epilepticus,76,94,Pyrrolidine dithiocarbamate protects the piriform cortex in the pilocarpine status epilepticus model.,19767176_0,1
8852,PDTC,29,33,Pyrrolidine dithiocarbamate (PDTC) has a dual mechanism of action as an antioxidant and an inhibitor of the transcription factor kappa-beta.,19767176_1,0
8851,Pyrrolidine dithiocarbamate,0,27,Pyrrolidine dithiocarbamate (PDTC) has a dual mechanism of action as an antioxidant and an inhibitor of the transcription factor kappa-beta.,19767176_1,0
2218,transcription factor,108,128,Pyrrolidine dithiocarbamate (PDTC) has a dual mechanism of action as an antioxidant and an inhibitor of the transcription factor kappa-beta.,19767176_1,0
2223,reactive oxygen species,49,72,These data might indicate that the generation of reactive oxygen species and activation of NF-kappaB plays a more central role in seizure-associated neuronal damage in the temporal cortex as compared to the hippocampal hilus.,19767176_10,0
2224,NF-kappaB,91,100,These data might indicate that the generation of reactive oxygen species and activation of NF-kappaB plays a more central role in seizure-associated neuronal damage in the temporal cortex as compared to the hippocampal hilus.,19767176_10,0
5850,hippocampal,207,218,These data might indicate that the generation of reactive oxygen species and activation of NF-kappaB plays a more central role in seizure-associated neuronal damage in the temporal cortex as compared to the hippocampal hilus.,19767176_10,1
8875,temporal cortex,172,187,These data might indicate that the generation of reactive oxygen species and activation of NF-kappaB plays a more central role in seizure-associated neuronal damage in the temporal cortex as compared to the hippocampal hilus.,19767176_10,1
8874,seizure-associated neuronal damage,130,164,These data might indicate that the generation of reactive oxygen species and activation of NF-kappaB plays a more central role in seizure-associated neuronal damage in the temporal cortex as compared to the hippocampal hilus.,19767176_10,1
8876,PDTC,100,104,"However, future investigations are necessary to exactly analyze the biochemical mechanisms by which PDTC exerted its beneficial effects in the piriform cortex.",19767176_11,0
2219,reactive oxygen species,20,43,"Both, production of reactive oxygen species as well as activation of NF-kappaB have been implicated in severe neuronal damage in different sub-regions of the hippocampus as well as in the surrounding cortices.",19767176_2,0
8853,neuronal damage,110,125,"Both, production of reactive oxygen species as well as activation of NF-kappaB have been implicated in severe neuronal damage in different sub-regions of the hippocampus as well as in the surrounding cortices.",19767176_2,1
2220,NF-kappaB,69,78,"Both, production of reactive oxygen species as well as activation of NF-kappaB have been implicated in severe neuronal damage in different sub-regions of the hippocampus as well as in the surrounding cortices.",19767176_2,0
8856,status epilepticus-associated cell loss,22,61,The effect of PDTC on status epilepticus-associated cell loss in the hippocampus and piriform cortex was evaluated in the rat fractionated pilocarpine model.,19767176_3,1
5845,status epilepticus,51,69,Treatment with 150 mg/kg PDTC before and following status epilepticus significantly increased the mortality rate to 100%.,19767176_4,1
5846,status epilepticus,95,113,Administration of 50 mg/kg PDTC (low-dose) did not exert major effects on the development of a status epilepticus or the mortality rate.,19767176_5,1
2221,low-dose,33,41,Administration of 50 mg/kg PDTC (low-dose) did not exert major effects on the development of a status epilepticus or the mortality rate.,19767176_5,0
8864,neuronal damage,62,77,"In vehicle-treated rats, status epilepticus caused pronounced neuronal damage in the piriform cortex comprising both pyramidal cells and interneurons.",19767176_6,1
8866,pyramidal cells,117,132,"In vehicle-treated rats, status epilepticus caused pronounced neuronal damage in the piriform cortex comprising both pyramidal cells and interneurons.",19767176_6,1
5847,status epilepticus,25,43,"In vehicle-treated rats, status epilepticus caused pronounced neuronal damage in the piriform cortex comprising both pyramidal cells and interneurons.",19767176_6,1
8868,Low-dose PDTC,0,13,Low-dose PDTC treatment almost completely protected from lesions in the piriform cortex.,19767176_7,0
5848,hippocampal,50,61,A significant decrease in neuronal density of the hippocampal hilar formation was identified in vehicle- and PDTC-treated rats following status epilepticus.,19767176_8,1
5849,status epilepticus,137,155,A significant decrease in neuronal density of the hippocampal hilar formation was identified in vehicle- and PDTC-treated rats following status epilepticus.,19767176_8,1
8871,hilar formation,62,77,A significant decrease in neuronal density of the hippocampal hilar formation was identified in vehicle- and PDTC-treated rats following status epilepticus.,19767176_8,1
8872,PDTC,55,59,"In conclusion, the NF-kappaB inhibitor and antioxidant PDTC protected the piriform cortex, whereas it did not affect hilar neuronal loss.",19767176_9,0
2222,NF-kappaB inhibitor,19,38,"In conclusion, the NF-kappaB inhibitor and antioxidant PDTC protected the piriform cortex, whereas it did not affect hilar neuronal loss.",19767176_9,0
8873,neuronal loss,123,136,"In conclusion, the NF-kappaB inhibitor and antioxidant PDTC protected the piriform cortex, whereas it did not affect hilar neuronal loss.",19767176_9,1
8878,Anaesthetists' nightmare,0,24,Anaesthetists' nightmare: masseter spasm after induction in an undiagnosed case of myotonia congenita.,19803309_0,0
5851,masseter spasm,26,40,Anaesthetists' nightmare: masseter spasm after induction in an undiagnosed case of myotonia congenita.,19803309_0,1
5852,myotonia congenita,83,101,Anaesthetists' nightmare: masseter spasm after induction in an undiagnosed case of myotonia congenita.,19803309_0,1
2225,suxamethonium,189,202,"We report an undiagnosed case of myotonia congenita in a 24-year-old previously healthy primigravida, who developed life threatening masseter spasm following a standard dose of intravenous suxamethonium for induction of anaesthesia.",19803309_1,0
5853,myotonia congenita,33,51,"We report an undiagnosed case of myotonia congenita in a 24-year-old previously healthy primigravida, who developed life threatening masseter spasm following a standard dose of intravenous suxamethonium for induction of anaesthesia.",19803309_1,1
8879,life threatening masseter spasm,116,147,"We report an undiagnosed case of myotonia congenita in a 24-year-old previously healthy primigravida, who developed life threatening masseter spasm following a standard dose of intravenous suxamethonium for induction of anaesthesia.",19803309_1,1
5855,cardiac toxicity,27,43,Twin preterm neonates with cardiac toxicity related to lopinavir/ritonavir therapy.,19820426_0,1
8881,lopinavir/ritonavir,55,74,Twin preterm neonates with cardiac toxicity related to lopinavir/ritonavir therapy.,19820426_0,0
5854,preterm,5,12,Twin preterm neonates with cardiac toxicity related to lopinavir/ritonavir therapy.,19820426_0,1
8882,twin neonates,10,23,We report twin neonates who were born prematurely at 32 weeks of gestation to a mother with human immunodeficiency virus infection.,19820426_1,1
2226,human immunodeficiency virus,92,120,We report twin neonates who were born prematurely at 32 weeks of gestation to a mother with human immunodeficiency virus infection.,19820426_1,0
8884,protease-inhibitor agent,125,149,"One of the twins developed complete heart block and dilated cardiomyopathy related to lopinavir/ritonavir therapy, a boosted protease-inhibitor agent, while the other twin developed mild bradycardia.",19820426_2,0
8883,lopinavir/ritonavir,86,105,"One of the twins developed complete heart block and dilated cardiomyopathy related to lopinavir/ritonavir therapy, a boosted protease-inhibitor agent, while the other twin developed mild bradycardia.",19820426_2,0
5856,heart block,36,47,"One of the twins developed complete heart block and dilated cardiomyopathy related to lopinavir/ritonavir therapy, a boosted protease-inhibitor agent, while the other twin developed mild bradycardia.",19820426_2,1
5857,dilated cardiomyopathy,52,74,"One of the twins developed complete heart block and dilated cardiomyopathy related to lopinavir/ritonavir therapy, a boosted protease-inhibitor agent, while the other twin developed mild bradycardia.",19820426_2,1
8885,mild bradycardia,182,198,"One of the twins developed complete heart block and dilated cardiomyopathy related to lopinavir/ritonavir therapy, a boosted protease-inhibitor agent, while the other twin developed mild bradycardia.",19820426_2,1
8886,lopinavir/ritonavir,35,54,We recommend caution in the use of lopinavir/ritonavir in the immediate neonatal period.,19820426_3,0
8888,hemodiafiltration,80,97,When drugs disappear from the patient: elimination of intravenous medication by hemodiafiltration.,19843802_0,0
8889,heart transplantation,25,46,"Twenty-three hours after heart transplantation, life-threatening acute right heart failure was diagnosed in a patient requiring continuous venovenous hemodiafiltration (CVVHDF).",19843802_1,1
5858,heart failure,77,90,"Twenty-three hours after heart transplantation, life-threatening acute right heart failure was diagnosed in a patient requiring continuous venovenous hemodiafiltration (CVVHDF).",19843802_1,1
2227,muscle relaxants,51,67,"Increasing doses of catecholamines, sedatives, and muscle relaxants administered through a central venous catheter were ineffective.",19843802_2,0
8891,central venous,91,105,"Increasing doses of catecholamines, sedatives, and muscle relaxants administered through a central venous catheter were ineffective.",19843802_2,1
8892,hypertensive crisis,84,103,"However, a bolus of epinephrine injected through an alternative catheter provoked a hypertensive crisis.",19843802_3,1
8893,central venous,28,42,"Thus, interference with the central venous infusion by the dialysis catheter was suspected.",19843802_4,1
8895,catecholamine doses,65,84,"The catheters were changed, and hemodynamics stabilized at lower catecholamine doses.",19843802_5,0
8896,IV drugs,20,28,"When the effects of IV drugs are inadequate in patients receiving CVVHDF, interference with adjacent catheters resulting in elimination of the drug by CVVHDF should be suspected.",19843802_6,0
8905,osmolality,121,131,"Patients were admitted to the hospital for measurement of lithium level, creatinine clearance, urine volume, and maximum osmolality.",1987816_3,0
2228,creatinine,73,83,"Patients were admitted to the hospital for measurement of lithium level, creatinine clearance, urine volume, and maximum osmolality.",1987816_3,0
8907,osmolality,101,111,"The dosing schedule, duration of lithium treatment, and daily dose of lithium did not affect maximum osmolality or creatinine clearance.",1987816_5,0
2229,creatinine,115,125,"The dosing schedule, duration of lithium treatment, and daily dose of lithium did not affect maximum osmolality or creatinine clearance.",1987816_5,0
8911,extrarenal,48,58,Lithium-induced polyuria seems to be related to extrarenal as well as to renal effects.,1987816_7,1
8910,Lithium-induced polyuria,0,24,Lithium-induced polyuria seems to be related to extrarenal as well as to renal effects.,1987816_7,1
5860,Birth Defects,82,95,Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study.,19884587_0,1
8913,Antibacterial medication,0,24,Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study.,19884587_0,0
5859,birth defects,58,71,Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study.,19884587_0,1
5861,birth defects,86,99,OBJECTIVE: To estimate the association between antibacterial medications and selected birth defects.,19884587_1,1
8914,antibacterial medications,47,72,OBJECTIVE: To estimate the association between antibacterial medications and selected birth defects.,19884587_1,0
5876,birth defects,62,75,"Sulfonamides and nitrofurantoins were associated with several birth defects, indicating a need for additional scrutiny.",19884587_10,1
5862,birth defects,157,170,"DESIGN, SETTING, AND PARTICIPANTS: Population-based, multisite, case-control study of women who had pregnancies affected by 1 of more than 30 eligible major birth defects identified via birth defect surveillance programs in 10 states (n = 13 155) and control women randomly selected from the same geographical regions (n = 4941).",19884587_2,1
5863,birth defect,186,198,"DESIGN, SETTING, AND PARTICIPANTS: Population-based, multisite, case-control study of women who had pregnancies affected by 1 of more than 30 eligible major birth defects identified via birth defect surveillance programs in 10 states (n = 13 155) and control women randomly selected from the same geographical regions (n = 4941).",19884587_2,1
2230,(1,55,57,MAIN EXPOSURE: Reported maternal use of antibacterials (1 month before pregnancy through the end of the first trimester).,19884587_3,0
5864,birth defects,105,118,MAIN OUTCOME MEASURE: Odds ratios (ORs) measuring the association between antibacterial use and selected birth defects adjusted for potential confounders.,19884587_4,1
5865,hypoplastic left heart syndrome,112,143,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,1
5866,coarctation of the aorta,174,198,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,1
5867,choanal atresia,229,244,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,1
5868,diaphragmatic hernia,337,357,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,1
8928,transverse limb deficiency,276,302,"Sulfonamides were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4).",19884587_6,1
5869,anophthalmia,37,49,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,1
5870,microphthalmos,53,67,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,1
5871,hypoplastic left heart syndrome,99,130,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,1
5872,atrial septal defects,161,182,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,1
5873,cleft lip,217,226,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,1
5874,cleft palate,232,244,"Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9).",19884587_7,1
8937,cephalosporins (1,112,129,"Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), cephalosporins (1 defect), and quinolones (1 defect).",19884587_8,0
2231,antibacterial agents,6,26,"Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), cephalosporins (1 defect), and quinolones (1 defect).",19884587_8,0
2232,(2,75,77,"Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), cephalosporins (1 defect), and quinolones (1 defect).",19884587_8,0
8938,quinolones (1,143,156,"Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), cephalosporins (1 defect), and quinolones (1 defect).",19884587_8,0
8936,penicillins (1,88,102,"Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), cephalosporins (1 defect), and quinolones (1 defect).",19884587_8,0
5875,birth defects,147,160,"CONCLUSIONS: Reassuringly, penicillins, erythromycins, and cephalosporins, although used commonly by pregnant women, were not associated with many birth defects.",19884587_9,1
8939,pregnant women,101,115,"CONCLUSIONS: Reassuringly, penicillins, erythromycins, and cephalosporins, although used commonly by pregnant women, were not associated with many birth defects.",19884587_9,1
8943,G145R,47,52,Differential impact of immune escape mutations G145R and P120T on the replication of lamivudine-resistant hepatitis B virus e antigen-positive and -negative strains.,19889778_0,0
2233,P120,57,61,Differential impact of immune escape mutations G145R and P120T on the replication of lamivudine-resistant hepatitis B virus e antigen-positive and -negative strains.,19889778_0,0
8952,sP120T,120,126,"We therefore systematically analyzed the functional impact of the most prevalent immune escape variants, the sG145R and sP120T mutants, on the viral replication efficacy and antiviral drug susceptibility of common treatment-associated mutants with resistance to lamivudine (LAM) and/or HBeAg negativity.",19889778_3,0
8951,sG145R,109,115,"We therefore systematically analyzed the functional impact of the most prevalent immune escape variants, the sG145R and sP120T mutants, on the viral replication efficacy and antiviral drug susceptibility of common treatment-associated mutants with resistance to lamivudine (LAM) and/or HBeAg negativity.",19889778_3,0
8953,viral replication,143,160,"We therefore systematically analyzed the functional impact of the most prevalent immune escape variants, the sG145R and sP120T mutants, on the viral replication efficacy and antiviral drug susceptibility of common treatment-associated mutants with resistance to lamivudine (LAM) and/or HBeAg negativity.",19889778_3,0
2235,HBeAg,286,291,"We therefore systematically analyzed the functional impact of the most prevalent immune escape variants, the sG145R and sP120T mutants, on the viral replication efficacy and antiviral drug susceptibility of common treatment-associated mutants with resistance to lamivudine (LAM) and/or HBeAg negativity.",19889778_3,0
2234,antiviral drug,174,188,"We therefore systematically analyzed the functional impact of the most prevalent immune escape variants, the sG145R and sP120T mutants, on the viral replication efficacy and antiviral drug susceptibility of common treatment-associated mutants with resistance to lamivudine (LAM) and/or HBeAg negativity.",19889778_3,0
5877,treatment-associated,214,234,"We therefore systematically analyzed the functional impact of the most prevalent immune escape variants, the sG145R and sP120T mutants, on the viral replication efficacy and antiviral drug susceptibility of common treatment-associated mutants with resistance to lamivudine (LAM) and/or HBeAg negativity.",19889778_3,1
8956,sP120T,49,55,Replication-competent HBV strains with sG145R or sP120T and LAM resistance (rtM204I or rtL180M/rtM204V) were generated on an HBeAg-positive and an HBeAg-negative background with precore (PC) and basal core promoter (BCP) mutants.,19889778_4,0
8957,rtM204I,76,83,Replication-competent HBV strains with sG145R or sP120T and LAM resistance (rtM204I or rtL180M/rtM204V) were generated on an HBeAg-positive and an HBeAg-negative background with precore (PC) and basal core promoter (BCP) mutants.,19889778_4,0
8955,sG145R,39,45,Replication-competent HBV strains with sG145R or sP120T and LAM resistance (rtM204I or rtL180M/rtM204V) were generated on an HBeAg-positive and an HBeAg-negative background with precore (PC) and basal core promoter (BCP) mutants.,19889778_4,0
8958,rtL180M/rtM204V,87,102,Replication-competent HBV strains with sG145R or sP120T and LAM resistance (rtM204I or rtL180M/rtM204V) were generated on an HBeAg-positive and an HBeAg-negative background with precore (PC) and basal core promoter (BCP) mutants.,19889778_4,0
8961,precore,178,185,Replication-competent HBV strains with sG145R or sP120T and LAM resistance (rtM204I or rtL180M/rtM204V) were generated on an HBeAg-positive and an HBeAg-negative background with precore (PC) and basal core promoter (BCP) mutants.,19889778_4,0
8963,BCP,216,219,Replication-competent HBV strains with sG145R or sP120T and LAM resistance (rtM204I or rtL180M/rtM204V) were generated on an HBeAg-positive and an HBeAg-negative background with precore (PC) and basal core promoter (BCP) mutants.,19889778_4,0
8966,HBV,122,125,"The sG145R mutation strongly reduced HBsAg levels and was able to fully restore the impaired replication of LAM-resistant HBV mutants to the levels of wild-type HBV, and PC or BCP mutations further enhanced viral replication.",19889778_5,0
2236,HBsAg,37,42,"The sG145R mutation strongly reduced HBsAg levels and was able to fully restore the impaired replication of LAM-resistant HBV mutants to the levels of wild-type HBV, and PC or BCP mutations further enhanced viral replication.",19889778_5,0
8968,viral replication,207,224,"The sG145R mutation strongly reduced HBsAg levels and was able to fully restore the impaired replication of LAM-resistant HBV mutants to the levels of wild-type HBV, and PC or BCP mutations further enhanced viral replication.",19889778_5,0
8964,sG145R,4,10,"The sG145R mutation strongly reduced HBsAg levels and was able to fully restore the impaired replication of LAM-resistant HBV mutants to the levels of wild-type HBV, and PC or BCP mutations further enhanced viral replication.",19889778_5,0
8969,sP120T,13,19,"Although the sP120T substitution also impaired HBsAg secretion, it did not enhance the replication of LAM-resistant clones.",19889778_6,0
2237,HBsAg,47,52,"Although the sP120T substitution also impaired HBsAg secretion, it did not enhance the replication of LAM-resistant clones.",19889778_6,0
2238,HBeAg,39,44,"However, the concomitant occurrence of HBeAg negativity (PC/BCP), sP120T, and LAM resistance resulted in the restoration of replication to levels of wild-type HBV.",19889778_7,0
8971,PC/BCP,57,63,"However, the concomitant occurrence of HBeAg negativity (PC/BCP), sP120T, and LAM resistance resulted in the restoration of replication to levels of wild-type HBV.",19889778_7,0
8972,sP120T,66,72,"However, the concomitant occurrence of HBeAg negativity (PC/BCP), sP120T, and LAM resistance resulted in the restoration of replication to levels of wild-type HBV.",19889778_7,0
8977,viral replication,154,171,"In all clones with combined immune escape and LAM resistance mutations, the nucleotide analogues adefovir and tenofovir remained effective in suppressing viral replication in vitro.",19889778_8,1
8975,nucleotide analogues,76,96,"In all clones with combined immune escape and LAM resistance mutations, the nucleotide analogues adefovir and tenofovir remained effective in suppressing viral replication in vitro.",19889778_8,0
2239,tenofovir,110,119,"In all clones with combined immune escape and LAM resistance mutations, the nucleotide analogues adefovir and tenofovir remained effective in suppressing viral replication in vitro.",19889778_8,0
8976,adefovir,97,105,"In all clones with combined immune escape and LAM resistance mutations, the nucleotide analogues adefovir and tenofovir remained effective in suppressing viral replication in vitro.",19889778_8,0
8980,drug susceptibility,95,114,"These findings reveal the differential impact of immune escape variants on the replication and drug susceptibility of complex HBV mutants, supporting the need of close surveillance and treatment adjustment in response to the selection of distinct mutational patterns.",19889778_9,1
5879,acute renal failure,36,55,Dynamic response of blood vessel in acute renal failure.,19893084_0,1
5878,blood vessel,20,32,Dynamic response of blood vessel in acute renal failure.,19893084_0,1
5880,acute renal failure,40,59,"In this study we postulated that during acute renal failure induced by gentamicin the transient or dynamic response of blood vessels could be affected, and that antioxidants can prevent the changes in dynamic responses of blood vessels.",19893084_1,1
2240,end points,75,85,"The new approach to ex vivo blood vessel experiments in which not only the end points of vessels response within the time interval is considered, but also dynamics of this response, was used in this paper.",19893084_2,0
5881,blood vessel,28,40,"The new approach to ex vivo blood vessel experiments in which not only the end points of vessels response within the time interval is considered, but also dynamics of this response, was used in this paper.",19893084_2,1
8988,blood vessels,58,71,Our results confirm the alteration in dynamic response of blood vessels during the change of pressure in gentamicin-treated animals.,19893084_3,1
2241,creatinine,139,149,The beneficial effects of vitamin C administration to gentamicin-treated animals are also confirmed through: lower level of blood urea and creatinine and higher level of potassium.,19893084_4,0
8990,vitamin C,26,35,The beneficial effects of vitamin C administration to gentamicin-treated animals are also confirmed through: lower level of blood urea and creatinine and higher level of potassium.,19893084_4,0
8992,blood vessels,43,56,The pressure dynamic responses of isolated blood vessels show a faster pressure change in gentamicin-treated animals (8.07 +/- 1.7 s vs. 5.64 +/- 0.18 s).,19893084_5,1
8996,Vitamin C,0,9,Vitamin C administration induced slowdown of pressure change back to the control values.,19893084_6,0
9001,vitamin C,262,271,"The pressure dynamic properties, quantitatively defined by comparative pressure dynamic and total pressure dynamic, confirm the alteration in dynamic response of blood vessels during the change of pressure in gentamicin-treated animals and beneficial effects of vitamin C administration.",19893084_7,0
9002,myocardial hypertrophy,11,33,Reversible myocardial hypertrophy induced by tacrolimus in a pediatric heart transplant recipient: case report.,19917396_0,1
9003,pediatric heart transplant,61,87,Reversible myocardial hypertrophy induced by tacrolimus in a pediatric heart transplant recipient: case report.,19917396_0,1
2242,tacrolimus,45,55,Reversible myocardial hypertrophy induced by tacrolimus in a pediatric heart transplant recipient: case report.,19917396_0,0
2243,Tacrolimus,0,10,Tacrolimus is a potent immunosuppressant that is frequently used in organ transplantation.,19917396_1,0
9005,organ transplantation,68,89,Tacrolimus is a potent immunosuppressant that is frequently used in organ transplantation.,19917396_1,1
5882,adverse effects,9,24,"However, adverse effects include cardiac toxicity.",19917396_2,1
5883,cardiac toxicity,33,49,"However, adverse effects include cardiac toxicity.",19917396_2,1
2244,tacrolimus,63,73,Herein we describe transient myocardial hypertrophy induced by tacrolimus after heart transplantation.,19917396_3,0
9007,heart transplantation,80,101,Herein we describe transient myocardial hypertrophy induced by tacrolimus after heart transplantation.,19917396_3,1
9006,transient myocardial hypertrophy,19,51,Herein we describe transient myocardial hypertrophy induced by tacrolimus after heart transplantation.,19917396_3,1
2245,brain natriuretic peptide,89,114,The hypertrophy caused no clinical symptoms but was noted because of elevation of plasma brain natriuretic peptide concentration and confirmed at echocardiography.,19917396_4,0
9008,clinical symptoms,26,43,The hypertrophy caused no clinical symptoms but was noted because of elevation of plasma brain natriuretic peptide concentration and confirmed at echocardiography.,19917396_4,1
9012,humoral rejection,165,182,"Initially, allograft rejection was feared; however, myocardial biopsy samples revealed only interstitial edema and mild myocardial hypertrophy; neither cellular nor humoral rejection was detected.",19917396_5,1
9010,interstitial edema,92,110,"Initially, allograft rejection was feared; however, myocardial biopsy samples revealed only interstitial edema and mild myocardial hypertrophy; neither cellular nor humoral rejection was detected.",19917396_5,1
9011,mild myocardial hypertrophy,115,142,"Initially, allograft rejection was feared; however, myocardial biopsy samples revealed only interstitial edema and mild myocardial hypertrophy; neither cellular nor humoral rejection was detected.",19917396_5,1
2246,tacrolimus,10,20,"The blood tacrolimus concentration was higher than usual at that time; thus, tacrolimus dosage was reduced.",19917396_6,0
2247,tacrolimus,77,87,"The blood tacrolimus concentration was higher than usual at that time; thus, tacrolimus dosage was reduced.",19917396_6,0
2248,tacrolimus,85,95,"Myocardial hypertrophy completely resolved upon reducing the target concentration of tacrolimus and did not recur, as confirmed at echocardiography and myocardial biopsy.",19917396_7,0
9013,Myocardial hypertrophy,0,22,"Myocardial hypertrophy completely resolved upon reducing the target concentration of tacrolimus and did not recur, as confirmed at echocardiography and myocardial biopsy.",19917396_7,1
9015,myocardial hypertrophy,53,75,"Thus, we conclude that tacrolimus induces reversible myocardial hypertrophy.",19917396_8,1
2249,tacrolimus,23,33,"Thus, we conclude that tacrolimus induces reversible myocardial hypertrophy.",19917396_8,0
2250,tacrolimus,22,32,"In patients receiving tacrolimus therapy, blood concentration should be carefully controlled and extreme attention paid to cardiac involvement.",19917396_9,0
9017,Nimodipine,0,10,Nimodipine prevents memory impairment caused by nitroglycerin-induced hypotension in adult mice.,19923525_0,0
9018,memory impairment,20,37,Nimodipine prevents memory impairment caused by nitroglycerin-induced hypotension in adult mice.,19923525_0,1
5884,cognitive dysfunction,115,136,BACKGROUND: Hypotension and a resultant decrease in cerebral blood flow have been implicated in the development of cognitive dysfunction.,19923525_1,1
9020,cerebral blood flow,52,71,BACKGROUND: Hypotension and a resultant decrease in cerebral blood flow have been implicated in the development of cognitive dysfunction.,19923525_1,1
5885,blood pressure,138,152,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,1
9054,NIMO,104,108,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,0
9053,NTG,98,101,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,0
9052,NTG,82,85,"In a separate group of mice not subjected to behavioral studies, the same dose of NTG (n = 3) and NTG + NIMO (n = 3) caused mean arterial blood pressure to decrease from 85.9 +/- 3.8 mm Hg sem to 31.6 +/- 0.8 mm Hg sem and from 86.2 +/- 3.7 mm Hg sem to 32.6 +/- 0.2 mm Hg sem, respectively.",19923525_11,0
5886,blood pressure,14,28,Mean arterial blood pressure in mice treated with NIMO alone decreased from 88.1 +/- 3.8 mm Hg to 80.0 +/- 2.9 mm Hg.,19923525_12,1
9063,NIMO,50,54,Mean arterial blood pressure in mice treated with NIMO alone decreased from 88.1 +/- 3.8 mm Hg to 80.0 +/- 2.9 mm Hg.,19923525_12,0
9078,NIMO,160,164,"PbtO(2) decreased from 51.7 +/- 4.5 mm Hg sem to 33.8 +/- 5.2 mm Hg sem in the NTG group and from 38.6 +/- 6.1 mm Hg sem to 25.4 +/- 2.0 mm Hg sem in the NTG + NIMO groups, respectively.",19923525_14,0
9080,NTG,57,60,"CONCLUSION: In a PA retention paradigm, the injection of NTG immediately after learning produced a significant impairment of long-term associative memory in mice, whereas delayed induced hypotension had no effect.",19923525_16,0
9079,PA retention,17,29,"CONCLUSION: In a PA retention paradigm, the injection of NTG immediately after learning produced a significant impairment of long-term associative memory in mice, whereas delayed induced hypotension had no effect.",19923525_16,1
9082,NTG,78,81,NIMO attenuated the disruption in consolidation of long-term memory caused by NTG but did not improve latency in the absence of hypotension.,19923525_17,0
9081,NIMO,0,4,NIMO attenuated the disruption in consolidation of long-term memory caused by NTG but did not improve latency in the absence of hypotension.,19923525_17,0
9084,calcium homeostasis,78,97,"The observed effect of NIMO may have been attributable to the preservation of calcium homeostasis during hypotension, because there were no differences in the PbtO(2) indices among groups.",19923525_18,1
9083,NIMO,23,27,"The observed effect of NIMO may have been attributable to the preservation of calcium homeostasis during hypotension, because there were no differences in the PbtO(2) indices among groups.",19923525_18,0
9021,nimodipine,30,40,We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory.,19923525_2,0
9024,associative memory,142,160,We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory.,19923525_2,1
9022,NIMO,42,46,We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory.,19923525_2,0
9026,memory retention,64,80,METHODS: The passive avoidance (PA) paradigm was used to assess memory retention.,19923525_3,1
9025,passive avoidance,13,30,METHODS: The passive avoidance (PA) paradigm was used to assess memory retention.,19923525_3,1
9036,NIMO,173,177,"Ninety-six Swiss-Webster mice (30-35 g, 6-8 wk), were randomized into 6 groups 1) saline (control), 2) NTG immediately after learning, 3) NTG 3 h after learning, 4) NTG and NIMO, 5) vehicle, and 6) NIMO alone.",19923525_6,0
9032,groups 1,72,80,"Ninety-six Swiss-Webster mice (30-35 g, 6-8 wk), were randomized into 6 groups 1) saline (control), 2) NTG immediately after learning, 3) NTG 3 h after learning, 4) NTG and NIMO, 5) vehicle, and 6) NIMO alone.",19923525_6,0
9037,NIMO,198,202,"Ninety-six Swiss-Webster mice (30-35 g, 6-8 wk), were randomized into 6 groups 1) saline (control), 2) NTG immediately after learning, 3) NTG 3 h after learning, 4) NTG and NIMO, 5) vehicle, and 6) NIMO alone.",19923525_6,0
9039,cerebral blood flow,83,102,The extent of hypotension and changes in brain tissue oxygenation (PbtO(2)) and in cerebral blood flow were studied in a separate group of animals.,19923525_7,1
9045,NTG,143,146,"Mice subjected to hypotensive episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, NTG + NIMO, or delayed NTG (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively).",19923525_9,0
9046,NIMO,149,153,"Mice subjected to hypotensive episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, NTG + NIMO, or delayed NTG (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively).",19923525_9,0
9047,NTG,166,169,"Mice subjected to hypotensive episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, NTG + NIMO, or delayed NTG (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively).",19923525_9,0
9044,/- 156,91,97,"Mice subjected to hypotensive episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, NTG + NIMO, or delayed NTG (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively).",19923525_9,0
9042,hypotensive episodes,18,38,"Mice subjected to hypotensive episodes showed a significant decrease in latency time (178 +/- 156 s) compared with those injected with saline, NTG + NIMO, or delayed NTG (580 +/- 81 s, 557 +/- 67 s, and 493 +/- 146 s, respectively).",19923525_9,1
5887,Hemolytic anemia,0,16,Hemolytic anemia associated with the use of omeprazole.,1992636_0,1
9088,parietal cell,103,116,Omeprazole is the first drug designed to block the final step in the acid secretory process within the parietal cell.,1992636_1,1
9089,peptic ulcer disease,64,84,"It has been shown to be extremely effective in the treatment of peptic ulcer disease, reflux esophagitis, and the Zollinger-Ellison syndrome.",1992636_2,1
5888,reflux esophagitis,86,104,"It has been shown to be extremely effective in the treatment of peptic ulcer disease, reflux esophagitis, and the Zollinger-Ellison syndrome.",1992636_2,1
5889,Zollinger-Ellison syndrome,114,140,"It has been shown to be extremely effective in the treatment of peptic ulcer disease, reflux esophagitis, and the Zollinger-Ellison syndrome.",1992636_2,1
5891,hemolytic anemia,94,110,We report the first case of a serious short-term adverse reaction with the use of omeprazole: hemolytic anemia.,1992636_4,1
5890,adverse reaction,49,65,We report the first case of a serious short-term adverse reaction with the use of omeprazole: hemolytic anemia.,1992636_4,1
5892,shortness of breath,46,65,"The patient developed weakness, lethargy, and shortness of breath 2 days after starting therapy with omeprazole.",1992636_5,1
2251,her,43,46,"Two weeks after the initiation of therapy, her hematocrit had decreased from 44.1% to 20.4%, and she had a positive direct Coombs antiglobulin test and an elevated indirect bilirubin.",1992636_6,0
9092,her hemoglobin,39,53,"After she discontinued the omeprazole, her hemoglobin and hematocrit gradually returned to normal.",1992636_7,0
9093,patient's hemolytic anemia,45,71,"The mechanism by which omeprazole caused the patient's hemolytic anemia is uncertain, but physicians should be alerted to this possible adverse effect.",1992636_8,1
9094,adverse effect,136,150,"The mechanism by which omeprazole caused the patient's hemolytic anemia is uncertain, but physicians should be alerted to this possible adverse effect.",1992636_8,1
2252,Metabotropic glutamate,0,22,Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson's disease.,19940105_0,0
9096,motor symptoms,52,66,Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson's disease.,19940105_0,1
9095,subtype,34,41,Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson's disease.,19940105_0,0
5893,Parkinson's disease,87,106,Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson's disease.,19940105_0,1
2253,Metabotropic glutamate,0,22,Metabotropic glutamate (mGlu) receptors modulate synaptic transmission in the central nervous system and represent promising therapeutic targets for symptomatic treatment of Parkinson's disease (PD).,19940105_1,0
9098,mGlu),24,29,Metabotropic glutamate (mGlu) receptors modulate synaptic transmission in the central nervous system and represent promising therapeutic targets for symptomatic treatment of Parkinson's disease (PD).,19940105_1,0
5895,Parkinson's disease,174,193,Metabotropic glutamate (mGlu) receptors modulate synaptic transmission in the central nervous system and represent promising therapeutic targets for symptomatic treatment of Parkinson's disease (PD).,19940105_1,1
5894,central nervous system,78,100,Metabotropic glutamate (mGlu) receptors modulate synaptic transmission in the central nervous system and represent promising therapeutic targets for symptomatic treatment of Parkinson's disease (PD).,19940105_1,1
9100,therapeutic targets,125,144,Metabotropic glutamate (mGlu) receptors modulate synaptic transmission in the central nervous system and represent promising therapeutic targets for symptomatic treatment of Parkinson's disease (PD).,19940105_1,0
9128,Selective ligands,0,17,Selective ligands of mGlu7 receptor subtypes may thus be considered as promising compounds for the development of antiparkinsonian therapeutic strategies.,19940105_10,0
9103,motor function,128,142,"Among the eight mGlu receptor subtypes, mGlu7 receptor is prominently expressed in the basal ganglia, but its role in restoring motor function in animal models of PD is not known.",19940105_2,1
5896,basal ganglia,87,100,"Among the eight mGlu receptor subtypes, mGlu7 receptor is prominently expressed in the basal ganglia, but its role in restoring motor function in animal models of PD is not known.",19940105_2,1
9101,mGlu receptor subtypes,16,38,"Among the eight mGlu receptor subtypes, mGlu7 receptor is prominently expressed in the basal ganglia, but its role in restoring motor function in animal models of PD is not known.",19940105_2,0
9102,mGlu7 receptor,40,54,"Among the eight mGlu receptor subtypes, mGlu7 receptor is prominently expressed in the basal ganglia, but its role in restoring motor function in animal models of PD is not known.",19940105_2,0
9108,mGlu7 receptors,121,136,"The effects of N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride (AMN082), the first selective allosteric activator of mGlu7 receptors, were thus tested in different rodent models of PD.",19940105_3,0
9106,AMN082,68,74,"The effects of N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride (AMN082), the first selective allosteric activator of mGlu7 receptors, were thus tested in different rodent models of PD.",19940105_3,0
2254,dihydrochloride,51,66,"The effects of N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride (AMN082), the first selective allosteric activator of mGlu7 receptors, were thus tested in different rodent models of PD.",19940105_3,0
9107,allosteric activator,97,117,"The effects of N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride (AMN082), the first selective allosteric activator of mGlu7 receptors, were thus tested in different rodent models of PD.",19940105_3,0
9110,AMN082,88,94,"Here, we show that oral (5 mg/kg) or intrastriatal administration (0.1 and 0.5 nmol) of AMN082 reverses haloperidol-induced catalepsy in rats.",19940105_4,0
9111,haloperidol-induced catalepsy,104,133,"Here, we show that oral (5 mg/kg) or intrastriatal administration (0.1 and 0.5 nmol) of AMN082 reverses haloperidol-induced catalepsy in rats.",19940105_4,1
9113,6-hydroxydopamine,77,94,AMN082 (2.5 and 5 mg/kg) reduces apomorphine-induced rotations in unilateral 6-hydroxydopamine (6-OHDA)-lesioned rats.,19940105_5,0
9112,AMN082,0,6,AMN082 (2.5 and 5 mg/kg) reduces apomorphine-induced rotations in unilateral 6-hydroxydopamine (6-OHDA)-lesioned rats.,19940105_5,0
9114,AMN082,97,103,"In a more complex task commonly used to evaluate major akinetic symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats.",19940105_6,0
5897,akinetic,55,63,"In a more complex task commonly used to evaluate major akinetic symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats.",19940105_6,1
9116,AMN082,13,19,"In addition, AMN082 reduces the duration of haloperidol-induced catalepsy in a mGlu7 receptor-dependent manner in wild-type but not mGlu7 receptor knockout mice.",19940105_7,0
9117,haloperidol-induced catalepsy,44,73,"In addition, AMN082 reduces the duration of haloperidol-induced catalepsy in a mGlu7 receptor-dependent manner in wild-type but not mGlu7 receptor knockout mice.",19940105_7,1
9118,mGlu7,79,84,"In addition, AMN082 reduces the duration of haloperidol-induced catalepsy in a mGlu7 receptor-dependent manner in wild-type but not mGlu7 receptor knockout mice.",19940105_7,0
9121,mGlu7 receptor,132,146,"In addition, AMN082 reduces the duration of haloperidol-induced catalepsy in a mGlu7 receptor-dependent manner in wild-type but not mGlu7 receptor knockout mice.",19940105_7,0
9124,AMN082,16,22,Higher doses of AMN082 (10 and 20 mg/kg p.o.) have no effect on the same models of PD.,19940105_8,0
9123,Higher doses,0,12,Higher doses of AMN082 (10 and 20 mg/kg p.o.) have no effect on the same models of PD.,19940105_8,0
9126,motor dysfunction,74,91,Overall these findings suggest that mGlu7 receptor activation can reverse motor dysfunction associated with reduced dopamine activity.,19940105_9,1
9125,mGlu7 receptor,36,50,Overall these findings suggest that mGlu7 receptor activation can reverse motor dysfunction associated with reduced dopamine activity.,19940105_9,0
5899,coronary artery spasm,53,74,Sorafenib-induced acute myocardial infarction due to coronary artery spasm.,19944333_0,1
5898,myocardial infarction,24,45,Sorafenib-induced acute myocardial infarction due to coronary artery spasm.,19944333_0,1
5901,chest pain,84,94,A 65-year-old man with advanced renal cell carcinoma was admitted due to continuing chest pain at rest.,19944333_1,1
5900,renal cell carcinoma,32,52,A 65-year-old man with advanced renal cell carcinoma was admitted due to continuing chest pain at rest.,19944333_1,1
9139,cellular proliferation,83,105,Sorafenib is a multikinase inhibitor that targets signaling pathways necessary for cellular proliferation and survival.,19944333_10,1
9138,multikinase inhibitor,15,36,Sorafenib is a multikinase inhibitor that targets signaling pathways necessary for cellular proliferation and survival.,19944333_10,0
9137,Sorafenib,0,9,Sorafenib is a multikinase inhibitor that targets signaling pathways necessary for cellular proliferation and survival.,19944333_10,0
5906,coronary artery spasm,85,106,"On the other hand, the Rho/ROCK pathway has an important role in the pathogenesis of coronary artery spasm.",19944333_11,1
9143,sorafenib,65,74,Our report may show an adverse effect on the Rho/ROCK pathway by sorafenib use.,19944333_12,0
9141,adverse effect,23,37,Our report may show an adverse effect on the Rho/ROCK pathway by sorafenib use.,19944333_12,1
2255,his,17,20,"Two weeks before his admission, sorafenib had been started.",19944333_2,0
9131,sorafenib,32,41,"Two weeks before his admission, sorafenib had been started.",19944333_2,0
5902,non-ST-elevation myocardial infarction,22,60,He was diagnosed with non-ST-elevation myocardial infarction by laboratory data and electrocardiogram.,19944333_3,1
9132,subendocardial infarction,54,79,Enhanced heart magnetic resonance imaging also showed subendocardial infarction.,19944333_4,1
9133,coronary arteries,34,51,"However, there was no stenosis in coronary arteries on angiography.",19944333_5,1
5903,Coronary artery spasm,0,21,Coronary artery spasm was induced by a provocative test.,19944333_6,1
2256,his,89,92,"Cessation of sorafenib and administration of Ca-channel blocker and nitrates ameliorated his symptoms, but relapse occurred after resumption of sorafenib.",19944333_7,0
9134,sorafenib,13,22,"Cessation of sorafenib and administration of Ca-channel blocker and nitrates ameliorated his symptoms, but relapse occurred after resumption of sorafenib.",19944333_7,0
9135,Ca-channel blocker,45,63,"Cessation of sorafenib and administration of Ca-channel blocker and nitrates ameliorated his symptoms, but relapse occurred after resumption of sorafenib.",19944333_7,0
9136,sorafenib,144,153,"Cessation of sorafenib and administration of Ca-channel blocker and nitrates ameliorated his symptoms, but relapse occurred after resumption of sorafenib.",19944333_7,0
5904,stable angina,64,77,Addition of oral nicorandil reduced his symptoms and maintained stable angina status.,19944333_8,1
2258,his,36,39,Addition of oral nicorandil reduced his symptoms and maintained stable angina status.,19944333_8,0
2257,nicorandil,17,27,Addition of oral nicorandil reduced his symptoms and maintained stable angina status.,19944333_8,0
5905,coronary artery spasm,46,67,We report the first case of sorafenib-induced coronary artery spasm.,19944333_9,1
2259,bioactive compound,386,404,A novel animal model to evaluate the ability of a drug delivery system to promote the passage through the BBB.The purpose of this investigation was to explore the potentiality of a novel animal model to be used for the in vivo evaluation of the ability of a drug delivery system to promote the passage through the blood-brain barrier (BBB) and/or to improve the brain localization of a bioactive compound.,19944736_0,0
9145,BBB.The,106,113,A novel animal model to evaluate the ability of a drug delivery system to promote the passage through the BBB.The purpose of this investigation was to explore the potentiality of a novel animal model to be used for the in vivo evaluation of the ability of a drug delivery system to promote the passage through the blood-brain barrier (BBB) and/or to improve the brain localization of a bioactive compound.,19944736_0,0
9149,BBB,335,338,A novel animal model to evaluate the ability of a drug delivery system to promote the passage through the BBB.The purpose of this investigation was to explore the potentiality of a novel animal model to be used for the in vivo evaluation of the ability of a drug delivery system to promote the passage through the blood-brain barrier (BBB) and/or to improve the brain localization of a bioactive compound.,19944736_0,0
9151,acid nanoparticles,32,50,"A Tween 80-coated poly-L-lactid acid nanoparticles was used as a model of colloidal drug delivery system, able to trespass the BBB.",19944736_1,0
9152,BBB,127,130,"A Tween 80-coated poly-L-lactid acid nanoparticles was used as a model of colloidal drug delivery system, able to trespass the BBB.",19944736_1,0
2260,Tacrine,0,7,"Tacrine, administered in LiCl pre-treated rats, induces electrocorticographic seizures and delayed hippocampal damage.",19944736_2,0
9153,LiCl,25,29,"Tacrine, administered in LiCl pre-treated rats, induces electrocorticographic seizures and delayed hippocampal damage.",19944736_2,0
9155,electrocorticographic seizures,56,86,"Tacrine, administered in LiCl pre-treated rats, induces electrocorticographic seizures and delayed hippocampal damage.",19944736_2,1
5907,hippocampal,99,110,"Tacrine, administered in LiCl pre-treated rats, induces electrocorticographic seizures and delayed hippocampal damage.",19944736_2,1
9158,nanoparticle suspension,140,163,"The toxic effects of tacrine-loaded poly-L-lactid acid nanoparticles (5mg/kg), a saline solution of tacrine (5mg/kg) and an empty colloidal nanoparticle suspension were compared following i.p.",19944736_3,0
9157,acid nanoparticles,50,68,"The toxic effects of tacrine-loaded poly-L-lactid acid nanoparticles (5mg/kg), a saline solution of tacrine (5mg/kg) and an empty colloidal nanoparticle suspension were compared following i.p.",19944736_3,0
9156,toxic effects,4,17,"The toxic effects of tacrine-loaded poly-L-lactid acid nanoparticles (5mg/kg), a saline solution of tacrine (5mg/kg) and an empty colloidal nanoparticle suspension were compared following i.p.",19944736_3,0
2261,saline solution,81,96,"The toxic effects of tacrine-loaded poly-L-lactid acid nanoparticles (5mg/kg), a saline solution of tacrine (5mg/kg) and an empty colloidal nanoparticle suspension were compared following i.p.",19944736_3,0
2262,tacrine,100,107,"The toxic effects of tacrine-loaded poly-L-lactid acid nanoparticles (5mg/kg), a saline solution of tacrine (5mg/kg) and an empty colloidal nanoparticle suspension were compared following i.p.",19944736_3,0
2263,nanoparticles,44,57,"All the animals treated with tacrine-loaded nanoparticles showed an earlier outcome of CNS adverse symptoms, i.e. epileptic onset, with respect to those animals treated with the free compound (10 min vs. 22 min respectively).",19944736_5,0
9162,free compound,178,191,"All the animals treated with tacrine-loaded nanoparticles showed an earlier outcome of CNS adverse symptoms, i.e. epileptic onset, with respect to those animals treated with the free compound (10 min vs. 22 min respectively).",19944736_5,0
9161,epileptic onset,114,129,"All the animals treated with tacrine-loaded nanoparticles showed an earlier outcome of CNS adverse symptoms, i.e. epileptic onset, with respect to those animals treated with the free compound (10 min vs. 22 min respectively).",19944736_5,1
9160,adverse symptoms,91,107,"All the animals treated with tacrine-loaded nanoparticles showed an earlier outcome of CNS adverse symptoms, i.e. epileptic onset, with respect to those animals treated with the free compound (10 min vs. 22 min respectively).",19944736_5,1
5908,CA1,93,96,"In addition, tacrine-loaded nanoparticles administration induced damage of neuronal cells in CA1 field of the hippocampus in all treated animals, while the saline solution of tacrine only in 60% of animals.",19944736_6,1
2264,nanoparticles,28,41,"In addition, tacrine-loaded nanoparticles administration induced damage of neuronal cells in CA1 field of the hippocampus in all treated animals, while the saline solution of tacrine only in 60% of animals.",19944736_6,0
2265,saline solution,156,171,"In addition, tacrine-loaded nanoparticles administration induced damage of neuronal cells in CA1 field of the hippocampus in all treated animals, while the saline solution of tacrine only in 60% of animals.",19944736_6,0
9163,neuronal cells,75,89,"In addition, tacrine-loaded nanoparticles administration induced damage of neuronal cells in CA1 field of the hippocampus in all treated animals, while the saline solution of tacrine only in 60% of animals.",19944736_6,1
2266,tacrine,175,182,"In addition, tacrine-loaded nanoparticles administration induced damage of neuronal cells in CA1 field of the hippocampus in all treated animals, while the saline solution of tacrine only in 60% of animals.",19944736_6,0
2267,nanoparticles,6,19,Empty nanoparticles provided similar results to control (saline-treated) group of animals.,19944736_7,0
9166,BBB,274,277,"In conclusion, the evaluation of time-to-onset of symptoms and the severity of neurodegenerative processes induced by the tacrine-lithium model of epilepsy in the rat, could be used to evaluate preliminarily the capability of a drug delivery system to trespass (or not) the BBB in vivo.",19944736_8,0
5909,neurodegenerative,79,96,"In conclusion, the evaluation of time-to-onset of symptoms and the severity of neurodegenerative processes induced by the tacrine-lithium model of epilepsy in the rat, could be used to evaluate preliminarily the capability of a drug delivery system to trespass (or not) the BBB in vivo.",19944736_8,1
5910,frontal lobe,40,52,Phenylephrine but not ephedrine reduces frontal lobe oxygenation following anesthesia-induced hypotension.,19957053_0,1
9167,anesthesia-induced hypotension,75,105,Phenylephrine but not ephedrine reduces frontal lobe oxygenation following anesthesia-induced hypotension.,19957053_0,1
9168,anesthesia-induced hypotension,51,81,BACKGROUND: Vasopressor agents are used to correct anesthesia-induced hypotension.,19957053_1,1
2268,Vasopressor agents,12,30,BACKGROUND: Vasopressor agents are used to correct anesthesia-induced hypotension.,19957053_1,0
9170,anesthesia-induced hypotension,103,133,We describe the effect of phenylephrine and ephedrine on frontal lobe oxygenation (S(c)O(2)) following anesthesia-induced hypotension.,19957053_2,1
9169,S(c)O(2,83,90,We describe the effect of phenylephrine and ephedrine on frontal lobe oxygenation (S(c)O(2)) following anesthesia-induced hypotension.,19957053_2,0
5911,frontal lobe,57,69,We describe the effect of phenylephrine and ephedrine on frontal lobe oxygenation (S(c)O(2)) following anesthesia-induced hypotension.,19957053_2,1
2269,propofol,76,84,"METHODS: Following induction of anesthesia by fentanyl (0.15 mg kg(-1)) and propofol (2.0 mg kg(-1)), 13 patients received phenylephrine (0.1 mg iv) and 12 patients received ephedrine (10 mg iv) to restore mean arterial pressure (MAP).",19957053_3,0
9171,mean arterial pressure,206,228,"METHODS: Following induction of anesthesia by fentanyl (0.15 mg kg(-1)) and propofol (2.0 mg kg(-1)), 13 patients received phenylephrine (0.1 mg iv) and 12 patients received ephedrine (10 mg iv) to restore mean arterial pressure (MAP).",19957053_3,1
5913,frontal lobe,67,79,"Heart rate (HR), MAP, stroke volume (SV), cardiac output (CO), and frontal lobe oxygenation (S(c)O(2)) were registered.",19957053_4,1
9173,stroke volume,22,35,"Heart rate (HR), MAP, stroke volume (SV), cardiac output (CO), and frontal lobe oxygenation (S(c)O(2)) were registered.",19957053_4,1
5912,cardiac output,42,56,"Heart rate (HR), MAP, stroke volume (SV), cardiac output (CO), and frontal lobe oxygenation (S(c)O(2)) were registered.",19957053_4,1
9177,S(c)O(2,116,123,"RESULTS: Induction of anesthesia was followed by a decrease in MAP, HR, SV, and CO concomitant with an elevation in S(c)O(2).",19957053_5,0
9181,/-,38,40,"However, a 14% (from 70 +/- 8% to 60 +/- 7%) reduction in S(c)O(2) (P < 0.05) followed with no change in CO (3.7 +/- 1.1 to 3.4 +/- 0.9 l min(-1)).",19957053_7,0
9190,S(c)O(2,171,178,"The administration of ephedrine led to a similar increase in MAP (53 +/- 9 to 79 +/- 8 mmHg; P < 0.001), restored CO (3.2 +/- 1.2 to 5.0 +/- 1.3 l min(-1)), and preserved S(c)O(2).",19957053_8,0
9186,/-,70,72,"The administration of ephedrine led to a similar increase in MAP (53 +/- 9 to 79 +/- 8 mmHg; P < 0.001), restored CO (3.2 +/- 1.2 to 5.0 +/- 1.3 l min(-1)), and preserved S(c)O(2).",19957053_8,0
5914,frontal lobe,151,163,CONCLUSIONS: The utilization of phenylephrine to correct hypotension induced by anesthesia has a negative impact on S(c)O(2) while ephedrine maintains frontal lobe oxygenation potentially related to an increase in CO.,19957053_9,1
9197,cardiac surgical,78,94,High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients.,19996135_0,1
9193,High-dose tranexamic Acid,0,25,High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients.,19996135_0,0
9195,nonischemic,45,56,High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients.,19996135_0,1
9196,clinical seizures,57,74,High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients.,19996135_0,1
5915,convulsive seizures,100,119,"BACKGROUND: In 2 separate centers, we observed a notable increase in the incidence of postoperative convulsive seizures from 1.3% to 3.8% in patients having undergone major cardiac surgical procedures.",19996135_1,1
9220,clinical seizures,171,188,CONCLUSION: Our results suggest that use of high-dose TXA in older patients in conjunction with cardiopulmonary bypass and open-chamber cardiac surgery is associated with clinical seizures in susceptible patients.,19996135_11,1
9218,open-chamber cardiac surgery,123,151,CONCLUSION: Our results suggest that use of high-dose TXA in older patients in conjunction with cardiopulmonary bypass and open-chamber cardiac surgery is associated with clinical seizures in susceptible patients.,19996135_11,1
9217,cardiopulmonary bypass,96,118,CONCLUSION: Our results suggest that use of high-dose TXA in older patients in conjunction with cardiopulmonary bypass and open-chamber cardiac surgery is associated with clinical seizures in susceptible patients.,19996135_11,1
9216,TXA,54,57,CONCLUSION: Our results suggest that use of high-dose TXA in older patients in conjunction with cardiopulmonary bypass and open-chamber cardiac surgery is associated with clinical seizures in susceptible patients.,19996135_11,0
9215,high-dose,44,53,CONCLUSION: Our results suggest that use of high-dose TXA in older patients in conjunction with cardiopulmonary bypass and open-chamber cardiac surgery is associated with clinical seizures in susceptible patients.,19996135_11,0
9199,high-dose tranexamic acid,64,89,These events were temporally coincident with the initial use of high-dose tranexamic acid (TXA) therapy after withdrawal of aprotinin from general clinical usage.,19996135_2,0
2270,aprotinin,124,133,These events were temporally coincident with the initial use of high-dose tranexamic acid (TXA) therapy after withdrawal of aprotinin from general clinical usage.,19996135_2,0
9202,TXA,115,118,The purpose of this review was to perform a retrospective analysis to examine whether there was a relation between TXA usage and seizures after cardiac surgery.,19996135_3,0
9203,cardiac surgery,144,159,The purpose of this review was to perform a retrospective analysis to examine whether there was a relation between TXA usage and seizures after cardiac surgery.,19996135_3,1
9205,perioperative,82,95,METHODS: An in-depth chart review was undertaken in all 24 patients who developed perioperative seizures.,19996135_4,1
5916,brain injury,135,147,"RESULTS: Twenty-one of the 24 patients did not have evidence of new cerebral ischemic injury, but seizures were likely due to ischemic brain injury in 3 patients.",19996135_6,1
9208,cerebral ischemic injury,68,92,"RESULTS: Twenty-one of the 24 patients did not have evidence of new cerebral ischemic injury, but seizures were likely due to ischemic brain injury in 3 patients.",19996135_6,1
9209,neurological abnormalities,50,76,All patients with seizures did not have permanent neurological abnormalities.,19996135_7,1
9210,high doses,39,49,"All 24 patients with seizures received high doses of TXA intraoperatively ranging from 61 to 259 mg/kg, had a mean age of 69.9 years, and 21 of 24 had undergone open chamber rather than coronary bypass procedures.",19996135_8,0
9214,cardiopulmonary bypass,39,61,All but one patient were managed using cardiopulmonary bypass.,19996135_9,1
9221,argatroban,30,40,Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of heparin-induced thrombocytopenia with thrombosis.,20003049_0,0
9222,cardiac transplant,46,64,Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of heparin-induced thrombocytopenia with thrombosis.,20003049_0,1
9223,heparin-induced thrombocytopenia,101,133,Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of heparin-induced thrombocytopenia with thrombosis.,20003049_0,1
2271,Direct thrombin inhibitors,12,38,BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB).,20003049_1,0
9225,cardiopulmonary bypass,206,228,BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB).,20003049_1,1
9226,CPB,230,233,BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB).,20003049_1,0
5917,critically ill,39,53,"In the following report, a 65-year-old critically ill patient with a suspected history of HITT was administered argatroban for anticoagulation on bypass during heart transplantation.",20003049_2,1
9228,heart transplantation,160,181,"In the following report, a 65-year-old critically ill patient with a suspected history of HITT was administered argatroban for anticoagulation on bypass during heart transplantation.",20003049_2,1
9227,argatroban,112,122,"In the following report, a 65-year-old critically ill patient with a suspected history of HITT was administered argatroban for anticoagulation on bypass during heart transplantation.",20003049_2,0
9231,cryoprecipitate,124,139,"The patient required massive transfusion support (55 units of red blood cells, 42 units of fresh-frozen plasma, 40 units of cryoprecipitate, 40 units of platelets, and three doses of recombinant Factor VIIa) for severe intraoperative and postoperative bleeding.",20003049_3,0
2272,Factor VIIa,195,206,"The patient required massive transfusion support (55 units of red blood cells, 42 units of fresh-frozen plasma, 40 units of cryoprecipitate, 40 units of platelets, and three doses of recombinant Factor VIIa) for severe intraoperative and postoperative bleeding.",20003049_3,0
5918,intraoperative,219,233,"The patient required massive transfusion support (55 units of red blood cells, 42 units of fresh-frozen plasma, 40 units of cryoprecipitate, 40 units of platelets, and three doses of recombinant Factor VIIa) for severe intraoperative and postoperative bleeding.",20003049_3,1
9232,postoperative bleeding,238,260,"The patient required massive transfusion support (55 units of red blood cells, 42 units of fresh-frozen plasma, 40 units of cryoprecipitate, 40 units of platelets, and three doses of recombinant Factor VIIa) for severe intraoperative and postoperative bleeding.",20003049_3,1
9235,ecarin,143,149,STUDY DESIGN AND METHODS: Plasma samples from before and after CPB were analyzed postoperatively for argatroban concentration using a modified ecarin clotting time (ECT) assay.,20003049_4,0
9233,CPB,63,66,STUDY DESIGN AND METHODS: Plasma samples from before and after CPB were analyzed postoperatively for argatroban concentration using a modified ecarin clotting time (ECT) assay.,20003049_4,0
9234,argatroban,101,111,STUDY DESIGN AND METHODS: Plasma samples from before and after CPB were analyzed postoperatively for argatroban concentration using a modified ecarin clotting time (ECT) assay.,20003049_4,0
9240,hepatic impairment,265,283,"RESULTS: Unexpectedly high concentrations of argatroban were measured in these samples (range, 0-32 microg/mL), and a prolonged plasma argatroban half life (t(1/2)) of 514 minutes was observed (published elimination t(1/2) is 39-51 minutes [< or = 181 minutes with hepatic impairment]).",20003049_5,1
9238,t(1/2,157,162,"RESULTS: Unexpectedly high concentrations of argatroban were measured in these samples (range, 0-32 microg/mL), and a prolonged plasma argatroban half life (t(1/2)) of 514 minutes was observed (published elimination t(1/2) is 39-51 minutes [< or = 181 minutes with hepatic impairment]).",20003049_5,0
9236,argatroban,45,55,"RESULTS: Unexpectedly high concentrations of argatroban were measured in these samples (range, 0-32 microg/mL), and a prolonged plasma argatroban half life (t(1/2)) of 514 minutes was observed (published elimination t(1/2) is 39-51 minutes [< or = 181 minutes with hepatic impairment]).",20003049_5,0
9237,argatroban,135,145,"RESULTS: Unexpectedly high concentrations of argatroban were measured in these samples (range, 0-32 microg/mL), and a prolonged plasma argatroban half life (t(1/2)) of 514 minutes was observed (published elimination t(1/2) is 39-51 minutes [< or = 181 minutes with hepatic impairment]).",20003049_5,0
9241,argatroban,35,45,CONCLUSIONS: Correlation of plasma argatroban concentration versus the patient's coagulation variables and clinical course suggest that prolonged elevated levels of plasma argatroban may have contributed to the patient's extended coagulopathy.,20003049_6,0
5920,coagulopathy,230,242,CONCLUSIONS: Correlation of plasma argatroban concentration versus the patient's coagulation variables and clinical course suggest that prolonged elevated levels of plasma argatroban may have contributed to the patient's extended coagulopathy.,20003049_6,1
5919,clinical course,107,122,CONCLUSIONS: Correlation of plasma argatroban concentration versus the patient's coagulation variables and clinical course suggest that prolonged elevated levels of plasma argatroban may have contributed to the patient's extended coagulopathy.,20003049_6,1
9243,argatroban,172,182,CONCLUSIONS: Correlation of plasma argatroban concentration versus the patient's coagulation variables and clinical course suggest that prolonged elevated levels of plasma argatroban may have contributed to the patient's extended coagulopathy.,20003049_6,0
2273,reversal agents,25,40,"Because DTIs do not have reversal agents, surgical teams and transfusion services should remain aware of the possibility of massive transfusion events during anticoagulation with these agents.",20003049_7,0
9245,DTIs,8,12,"Because DTIs do not have reversal agents, surgical teams and transfusion services should remain aware of the possibility of massive transfusion events during anticoagulation with these agents.",20003049_7,0
5921,coagulopathy,103,115,This is the first report to measure plasma argatroban concentration in the context of CPB and extended coagulopathy.,20003049_8,1
9249,CPB,86,89,This is the first report to measure plasma argatroban concentration in the context of CPB and extended coagulopathy.,20003049_8,0
9248,argatroban,43,53,This is the first report to measure plasma argatroban concentration in the context of CPB and extended coagulopathy.,20003049_8,0
2280,azidothymidine,66,80,Sensitivity of erythroid progenitor colonies to erythropoietin in azidothymidine treated immunodeficient mice.,2004015_0,0
9265,3'-azido-3'dideoxythymidine,23,50,The anaemia induced by 3'-azido-3'dideoxythymidine (AZT) is poorly understood.,2004015_1,0
9281,PHZ,105,108,The numbers of BFU-e and the percentage of bone marrow erythroblasts observed were comparable in AZT and PHZ treated mice with similar degrees of anaemia.,2004015_10,0
9280,of bone marrow,40,54,The numbers of BFU-e and the percentage of bone marrow erythroblasts observed were comparable in AZT and PHZ treated mice with similar degrees of anaemia.,2004015_10,1
9279,BFU-e,15,20,The numbers of BFU-e and the percentage of bone marrow erythroblasts observed were comparable in AZT and PHZ treated mice with similar degrees of anaemia.,2004015_10,0
5930,reticulocytosis,9,24,"However, reticulocytosis was inappropriate for the degree of anaemia observed in AZT treated infected mice.",2004015_11,1
9284,BFU-e,67,72,AZT-induced peripheral anaemia in the face of increased numbers of BFU-e and increased levels of plasma EPO suggest a lesion in terminal differentiation.,2004015_12,0
9285,EPO,104,107,AZT-induced peripheral anaemia in the face of increased numbers of BFU-e and increased levels of plasma EPO suggest a lesion in terminal differentiation.,2004015_12,0
9283,peripheral anaemia,12,30,AZT-induced peripheral anaemia in the face of increased numbers of BFU-e and increased levels of plasma EPO suggest a lesion in terminal differentiation.,2004015_12,1
9269,BFU-e,224,229,"We have used a murine model of AIDS, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).",2004015_2,0
9268,erythropoietic precursors,197,222,"We have used a murine model of AIDS, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO).",2004015_2,0
2281,drinking water,71,85,Mice in the early stage of LP-BM5 MuLV disease were given AZT in their drinking water at 1.0 and 2.5 mg/ml.,2004015_3,0
9274,EPO,91,94,"Colony formation by splenic and bone marrow BFUe was stimulated at lower concentrations of EPO in mice receiving AZT for 15 d than for infected, untreated mice.",2004015_6,0
9276,EPO,26,29,The mean plasma levels of EPO observed in AZT treated mice,2004015_8,0
9278,PHZ,88,91,were appropriate for the degree of anaemia observed when compared with phenylhydrazine (PHZ) treated mice.,2004015_9,0
9277,phenylhydrazine,71,86,were appropriate for the degree of anaemia observed when compared with phenylhydrazine (PHZ) treated mice.,2004015_9,0
5931,postoperative delirium,63,85,Sedation depth during spinal anesthesia and the development of postoperative delirium in elderly patients undergoing hip fracture repair.,20042557_0,1
9288,hip fracture repair,117,136,Sedation depth during spinal anesthesia and the development of postoperative delirium in elderly patients undergoing hip fracture repair.,20042557_0,1
5932,intraoperative,41,55,OBJECTIVE: To determine whether limiting intraoperative sedation depth during spinal anesthesia for hip fracture repair in elderly patients can decrease the prevalence of postoperative delirium.,20042557_1,1
9290,hip fracture repair,100,119,OBJECTIVE: To determine whether limiting intraoperative sedation depth during spinal anesthesia for hip fracture repair in elderly patients can decrease the prevalence of postoperative delirium.,20042557_1,1
9289,spinal anesthesia,78,95,OBJECTIVE: To determine whether limiting intraoperative sedation depth during spinal anesthesia for hip fracture repair in elderly patients can decrease the prevalence of postoperative delirium.,20042557_1,1
5933,postoperative delirium,171,193,OBJECTIVE: To determine whether limiting intraoperative sedation depth during spinal anesthesia for hip fracture repair in elderly patients can decrease the prevalence of postoperative delirium.,20042557_1,1
2282,propofol,256,264,"PATIENTS AND METHODS: We performed a double-blind, randomized controlled trial at an academic medical center of elderly patients (>or=65 years) without preoperative delirium or severe dementia who underwent hip fracture repair under spinal anesthesia with propofol sedation.",20042557_2,0
9295,hip fracture repair,207,226,"PATIENTS AND METHODS: We performed a double-blind, randomized controlled trial at an academic medical center of elderly patients (>or=65 years) without preoperative delirium or severe dementia who underwent hip fracture repair under spinal anesthesia with propofol sedation.",20042557_2,1
9296,spinal anesthesia,233,250,"PATIENTS AND METHODS: We performed a double-blind, randomized controlled trial at an academic medical center of elderly patients (>or=65 years) without preoperative delirium or severe dementia who underwent hip fracture repair under spinal anesthesia with propofol sedation.",20042557_2,1
5934,Postoperative delirium,0,22,Postoperative delirium was assessed as defined by Diagnostic and Statistical Manual of Mental Disorders (Third Edition Revised) criteria using the Confusion Assessment Method beginning at any time from the second day after surgery.,20042557_4,1
5935,postoperative delirium,18,40,"The prevalence of postoperative delirium was significantly lower in the light sedation group (11/57 [19%] vs 23/57 [40%] in the deep sedation group; P=.02), indicating that 1 incident of delirium will be prevented for every 4.7 patients treated with light sedation.",20042557_6,1
5936,postoperative delirium,75,97,CONCLUSION: The use of light propofol sedation decreased the prevalence of postoperative delirium by 50% compared with deep sedation.,20042557_8,1
2283,propofol,29,37,CONCLUSION: The use of light propofol sedation decreased the prevalence of postoperative delirium by 50% compared with deep sedation.,20042557_8,0
5937,postoperative delirium,118,140,"Limiting depth of sedation during spinal anesthesia is a simple, safe, and cost-effective intervention for preventing postoperative delirium in elderly patients that could be widely and readily adopted.",20042557_9,1
9305,spinal anesthesia,34,51,"Limiting depth of sedation during spinal anesthesia is a simple, safe, and cost-effective intervention for preventing postoperative delirium in elderly patients that could be widely and readily adopted.",20042557_9,1
5922,cardiac arrhythmias,33,52,Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs.,2004_0,1
2274,psychotropic drugs,75,93,Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs.,2004_0,0
2275,psychotropic drugs,90,108,"Eight patients had cardiac manifestations that were life-threatening in five while taking psychotropic drugs, either phenothiazines or tricyclic antidepressants.",2004_1,0
9251,cardiac manifestations,19,41,"Eight patients had cardiac manifestations that were life-threatening in five while taking psychotropic drugs, either phenothiazines or tricyclic antidepressants.",2004_1,1
2276,tricyclic antidepressants,135,160,"Eight patients had cardiac manifestations that were life-threatening in five while taking psychotropic drugs, either phenothiazines or tricyclic antidepressants.",2004_1,0
9264,cardiac complications,66,87,A prospective clinical trial is suggested to quantify the risk of cardiac complications to patients receiving phenothiazines or tricyclic antidepressant drugs.,2004_10,1
2279,tricyclic antidepressant drugs,128,158,A prospective clinical trial is suggested to quantify the risk of cardiac complications to patients receiving phenothiazines or tricyclic antidepressant drugs.,2004_10,0
9252,Mellaril (thioridazine,53,75,"Although most patients were receiving several drugs, Mellaril (thioridazine) appeared to be responsible for five cases of ventricular tachycardia, one of which was fatal in a 35 year old woman.",2004_2,0
5923,ventricular tachycardia,122,145,"Although most patients were receiving several drugs, Mellaril (thioridazine) appeared to be responsible for five cases of ventricular tachycardia, one of which was fatal in a 35 year old woman.",2004_2,1
5924,Supraventricular tachycardia,0,28,Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine).,2004_3,1
9253,Aventyl,0,7,Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.,2004_4,0
5925,left bundle branch block,65,89,Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman.,2004_4,1
9255,U wave abnormalities,27,47,Electrocardiographic T and U wave abnormalities were present in most patients.,2004_5,1
9261,ventricular pacing,229,247,The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one.,2004_6,1
9259,ventricular pacing,119,137,The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one.,2004_6,1
9258,electric shock,103,117,The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one.,2004_6,1
9256,ventricular arrhythmias,4,27,The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one.,2004_6,1
2277,propranolol,203,214,The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one.,2004_6,0
5926,tachyarrhythmias,4,20,The tachyarrhythmias generally subsided within 48 hours after administration of the drugs was stopped.,2004_7,1
5927,heart disease,92,105,Five of the eight patients were 50 years of age or younger; only one clearly had antecedent heart disease.,2004_8,1
9262,therapeutic doses,111,128,Major cardiac arrhythmias are a potential hazard in patients without heart disease who are receiving customary therapeutic doses of psychotropic drugs.,2004_9,0
5929,heart disease,69,82,Major cardiac arrhythmias are a potential hazard in patients without heart disease who are receiving customary therapeutic doses of psychotropic drugs.,2004_9,1
5928,cardiac arrhythmias,6,25,Major cardiac arrhythmias are a potential hazard in patients without heart disease who are receiving customary therapeutic doses of psychotropic drugs.,2004_9,1
2278,psychotropic drugs,132,150,Major cardiac arrhythmias are a potential hazard in patients without heart disease who are receiving customary therapeutic doses of psychotropic drugs.,2004_9,0
5938,sexual dysfunction,48,66,The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study.,20067456_0,1
2284,bupropion,30,39,The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study.,20067456_0,0
2285,selective serotonin reuptake inhibitor,80,118,The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study.,20067456_0,0
5939,side-effect,205,216,"OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.",20067456_1,1
9309,male sexual dysfunction,98,121,"OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.",20067456_1,1
2286,bupropion,62,71,"OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.",20067456_1,0
2287,selective serotonin reuptake inhibitor,140,178,"OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor (SSRI), as SD is a common side-effect of SSRIs and the most effective treatments have yet to be determined.",20067456_1,0
9322,CGI-SF,19,25,The ASEX score and CGI-SF score were correlated (P= 0.003).,20067456_10,0
9323,CGI-SF,34,40,"In linear regression analyses the CGI-SF score was not affected significantly by the duration of SD, type of SSRI used and age.",20067456_11,0
2293,Bupropion,13,22,CONCLUSIONS: Bupropion is an effective treatment for male SD induced by SSRIs.,20067456_12,0
2294,bupropion,74,83,These results provide empirical support for conducting a further study of bupropion.,20067456_13,0
2288,bupropion,34,43,"The men were randomly assigned to bupropion SR (150 mg twice daily, 117) or placebo (twice daily, 117) for 12 weeks.",20067456_3,0
9312,CGI-SF,77,83,"Efficacy was evaluated using the Clinical Global Impression-Sexual Function (CGI-SF; the primary outcome measure), the International Index of Erectile Function (IIEF), Arizona Sexual Experience Scale (ASEX), and Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) (secondary outcome measures).",20067456_4,0
9315,IIEF,161,165,"Efficacy was evaluated using the Clinical Global Impression-Sexual Function (CGI-SF; the primary outcome measure), the International Index of Erectile Function (IIEF), Arizona Sexual Experience Scale (ASEX), and Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) (secondary outcome measures).",20067456_4,0
9314,Erectile Function,142,159,"Efficacy was evaluated using the Clinical Global Impression-Sexual Function (CGI-SF; the primary outcome measure), the International Index of Erectile Function (IIEF), Arizona Sexual Experience Scale (ASEX), and Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) (secondary outcome measures).",20067456_4,1
9311,Clinical Global Impression-Sexual Function,33,75,"Efficacy was evaluated using the Clinical Global Impression-Sexual Function (CGI-SF; the primary outcome measure), the International Index of Erectile Function (IIEF), Arizona Sexual Experience Scale (ASEX), and Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) (secondary outcome measures).",20067456_4,1
5940,Erectile Dysfunction,212,232,"Efficacy was evaluated using the Clinical Global Impression-Sexual Function (CGI-SF; the primary outcome measure), the International Index of Erectile Function (IIEF), Arizona Sexual Experience Scale (ASEX), and Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) (secondary outcome measures).",20067456_4,1
2289,bupropion,124,133,"RESULTS: After 12 weeks of treatment, the mean (sd) scores for CGI-SF were significantly lower, i.e. better, in patients on bupropion SR, at 2.4 (1.2), than in the placebo group, at 3.9 (1.1) (P= 0.01).",20067456_6,0
9317,CGI-SF,63,69,"RESULTS: After 12 weeks of treatment, the mean (sd) scores for CGI-SF were significantly lower, i.e. better, in patients on bupropion SR, at 2.4 (1.2), than in the placebo group, at 3.9 (1.1) (P= 0.01).",20067456_6,0
2290,bupropion,17,26,"Men who received bupropion had a significant increase in the total IIEF score (54.4% vs 1.2%; P= 0.003), and in the five different domains of the IIEF.",20067456_7,0
9320,IIEF,146,150,"Men who received bupropion had a significant increase in the total IIEF score (54.4% vs 1.2%; P= 0.003), and in the five different domains of the IIEF.",20067456_7,0
9319,IIEF,67,71,"Men who received bupropion had a significant increase in the total IIEF score (54.4% vs 1.2%; P= 0.003), and in the five different domains of the IIEF.",20067456_7,0
2291,bupropion,80,89,"Total ASEX scores were significantly lower, i.e. better, among men who received bupropion than placebo, at 15.5 (4.3) vs 21.5 (4.7) (P= 0.002).",20067456_8,0
2292,bupropion,42,51,The EDITS scores were 67.4 (10.2) for the bupropion and 36.3 (11.7) for the placebo group (P= 0.001).,20067456_9,0
9325,acute phase,114,125,Prevention of seizures and reorganization of hippocampal functions by transplantation of bone marrow cells in the acute phase of experimental epilepsy.,20080419_0,1
9324,of bone marrow,86,100,Prevention of seizures and reorganization of hippocampal functions by transplantation of bone marrow cells in the acute phase of experimental epilepsy.,20080419_0,1
5941,hippocampal,45,56,Prevention of seizures and reorganization of hippocampal functions by transplantation of bone marrow cells in the acute phase of experimental epilepsy.,20080419_0,1
9326,experimental epilepsy,129,150,Prevention of seizures and reorganization of hippocampal functions by transplantation of bone marrow cells in the acute phase of experimental epilepsy.,20080419_0,1
9328,BMCs,91,95,"In this study, we investigated the therapeutic potential of bone marrow mononuclear cells (BMCs) in a model of epilepsy induced by pilocarpine in rats.",20080419_1,0
9327,of bone marrow,57,71,"In this study, we investigated the therapeutic potential of bone marrow mononuclear cells (BMCs) in a model of epilepsy induced by pilocarpine in rats.",20080419_1,1
9329,BMCs,0,4,BMCs obtained from green fluorescent protein (GFP) transgenic mice or rats were transplanted intravenously after induction of status epilepticus (SE).,20080419_2,0
9330,GFP,46,49,BMCs obtained from green fluorescent protein (GFP) transgenic mice or rats were transplanted intravenously after induction of status epilepticus (SE).,20080419_2,0
5942,status epilepticus,126,144,BMCs obtained from green fluorescent protein (GFP) transgenic mice or rats were transplanted intravenously after induction of status epilepticus (SE).,20080419_2,1
2295,green fluorescent protein,19,44,BMCs obtained from green fluorescent protein (GFP) transgenic mice or rats were transplanted intravenously after induction of status epilepticus (SE).,20080419_2,0
9332,Spontaneous recurrent,0,21,Spontaneous recurrent seizures (SRS) were monitored using Racine's seizure severity scale.,20080419_3,1
9337,BMC,209,212,"All of the rats in the saline-treated epileptic control group developed SRS, whereas none of the BMC-treated epileptic animals had seizures in the short term (15 days after transplantation), regardless of the BMC source.",20080419_4,0
9336,short term,147,157,"All of the rats in the saline-treated epileptic control group developed SRS, whereas none of the BMC-treated epileptic animals had seizures in the short term (15 days after transplantation), regardless of the BMC source.",20080419_4,1
5943,chronic phase,19,32,"Over the long-term chronic phase (120 days after transplantation), only 25% of BMC-treated epileptic animals had seizures, but with a lower frequency and duration compared to the epileptic control group.",20080419_5,1
9340,BMCs,73,77,The density of hippocampal neurons in the brains of animals treated with BMCs was markedly preserved.,20080419_6,0
5944,hippocampal,15,26,The density of hippocampal neurons in the brains of animals treated with BMCs was markedly preserved.,20080419_6,1
5945,hippocampal,146,157,"In conclusion, treatment with BMCs can prevent the development of chronic seizures, reduce neuronal loss, and influence the reorganization of the hippocampal neuronal network.",20080419_9,1
9347,neuronal loss,91,104,"In conclusion, treatment with BMCs can prevent the development of chronic seizures, reduce neuronal loss, and influence the reorganization of the hippocampal neuronal network.",20080419_9,1
9346,chronic seizures,66,82,"In conclusion, treatment with BMCs can prevent the development of chronic seizures, reduce neuronal loss, and influence the reorganization of the hippocampal neuronal network.",20080419_9,1
9345,BMCs,30,34,"In conclusion, treatment with BMCs can prevent the development of chronic seizures, reduce neuronal loss, and influence the reorganization of the hippocampal neuronal network.",20080419_9,0
2296,modafinil,23,32,Normalizing effects of modafinil on sleep in chronic cocaine users.,20080983_0,0
2297,modafinil,89,98,OBJECTIVE: The purpose of the present study was to determine the effect of morning-dosed modafinil on sleep and daytime sleepiness in chronic cocaine users.,20080983_1,0
5946,daytime sleepiness,112,130,OBJECTIVE: The purpose of the present study was to determine the effect of morning-dosed modafinil on sleep and daytime sleepiness in chronic cocaine users.,20080983_1,1
2302,Modafinil,0,9,"Modafinil was associated with increased daytime sleep latency, as measured by the Multiple Sleep Latency Test, and a nearly significant decrease in subjective daytime sleepiness.",20080983_10,0
5948,daytime sleepiness,159,177,"Modafinil was associated with increased daytime sleep latency, as measured by the Multiple Sleep Latency Test, and a nearly significant decrease in subjective daytime sleepiness.",20080983_10,1
9369,daytime sleep latency,40,61,"Modafinil was associated with increased daytime sleep latency, as measured by the Multiple Sleep Latency Test, and a nearly significant decrease in subjective daytime sleepiness.",20080983_10,1
9370,Multiple Sleep Latency Test,82,109,"Modafinil was associated with increased daytime sleep latency, as measured by the Multiple Sleep Latency Test, and a nearly significant decrease in subjective daytime sleepiness.",20080983_10,1
9372,sleep architecture,74,92,"CONCLUSIONS: Morning-dosed modafinil promotes nocturnal sleep, normalizes sleep architecture, and decreases daytime sleepiness in abstinent cocaine users.",20080983_11,1
2303,modafinil,27,36,"CONCLUSIONS: Morning-dosed modafinil promotes nocturnal sleep, normalizes sleep architecture, and decreases daytime sleepiness in abstinent cocaine users.",20080983_11,0
9371,nocturnal sleep,46,61,"CONCLUSIONS: Morning-dosed modafinil promotes nocturnal sleep, normalizes sleep architecture, and decreases daytime sleepiness in abstinent cocaine users.",20080983_11,1
5949,daytime sleepiness,108,126,"CONCLUSIONS: Morning-dosed modafinil promotes nocturnal sleep, normalizes sleep architecture, and decreases daytime sleepiness in abstinent cocaine users.",20080983_11,1
5950,cocaine dependence,50,68,These effects may be relevant in the treatment of cocaine dependence.,20080983_12,1
2298,modafinil,80,89,"METHOD: Twenty cocaine-dependent participants were randomly assigned to receive modafinil, 400 mg (N=10), or placebo (N=10) every morning at 7:30 a.m. for 16 days in an inpatient, double-blind randomized trial.",20080983_2,0
9357,polysomnographic,91,107,RESULTS: Progressive abstinence from cocaine was associated with worsening of all measured polysomnographic sleep outcomes.,20080983_6,1
2299,modafinil,23,32,"Compared with placebo, modafinil decreased nighttime sleep latency and increased slow-wave sleep time in cocaine-dependent participants.",20080983_7,0
9358,sleep latency,53,66,"Compared with placebo, modafinil decreased nighttime sleep latency and increased slow-wave sleep time in cocaine-dependent participants.",20080983_7,1
9359,slow-wave sleep time,81,101,"Compared with placebo, modafinil decreased nighttime sleep latency and increased slow-wave sleep time in cocaine-dependent participants.",20080983_7,1
5947,REM sleep,120,129,The effect of modafinil interacted with the abstinence week and was associated with longer total sleep time and shorter REM sleep latency in the third week of abstinence.,20080983_8,1
2300,modafinil,14,23,The effect of modafinil interacted with the abstinence week and was associated with longer total sleep time and shorter REM sleep latency in the third week of abstinence.,20080983_8,0
9360,abstinence week,44,59,The effect of modafinil interacted with the abstinence week and was associated with longer total sleep time and shorter REM sleep latency in the third week of abstinence.,20080983_8,1
9367,cocaine-dependent,164,181,"Comparison of slow-wave sleep time, total sleep time, and sleep latency in cocaine-dependent and healthy participants revealed a normalizing effect of modafinil in cocaine-dependent participants.",20080983_9,1
9365,cocaine-dependent,75,92,"Comparison of slow-wave sleep time, total sleep time, and sleep latency in cocaine-dependent and healthy participants revealed a normalizing effect of modafinil in cocaine-dependent participants.",20080983_9,1
2301,modafinil,151,160,"Comparison of slow-wave sleep time, total sleep time, and sleep latency in cocaine-dependent and healthy participants revealed a normalizing effect of modafinil in cocaine-dependent participants.",20080983_9,0
9364,sleep latency,58,71,"Comparison of slow-wave sleep time, total sleep time, and sleep latency in cocaine-dependent and healthy participants revealed a normalizing effect of modafinil in cocaine-dependent participants.",20080983_9,1
9376,sedatives drugs,87,102,BACKGROUND: TEE is a semi-invasive tool broadly used and its utilization associated to sedatives drugs might to affect the procedure safety.,20084309_1,0
9394,Transient hypotension,0,21,Transient hypotension (SAP<90mmHg) occurred in 1 patient (0.7%).,20084309_10,1
9397,MZ,79,81,"The multivariate analysis showed that severe MR, MP (EF<45%) and high doses of MZ (>5mg) were associated with events (p<0.001).",20084309_11,0
9396,high doses,65,75,"The multivariate analysis showed that severe MR, MP (EF<45%) and high doses of MZ (>5mg) were associated with events (p<0.001).",20084309_11,0
9399,EF,4,6,"The EF was 40%, in the group with MP and 44% in the group with severe MR and it can be a factor associated with clinical events in the last group.",20084309_12,0
9401,clinical events,112,127,"The EF was 40%, in the group with MP and 44% in the group with severe MR and it can be a factor associated with clinical events in the last group.",20084309_12,1
2304,Flumazenil,88,98,OBJECTIVE: to analyze aspects of TEE safety associated to the use of Midazolan (MZ) and Flumazenil (FL) and the influence of the clinical variables on the event rate.,20084309_2,0
9379,Midazolan,69,78,OBJECTIVE: to analyze aspects of TEE safety associated to the use of Midazolan (MZ) and Flumazenil (FL) and the influence of the clinical variables on the event rate.,20084309_2,0
9380,MZ,80,82,OBJECTIVE: to analyze aspects of TEE safety associated to the use of Midazolan (MZ) and Flumazenil (FL) and the influence of the clinical variables on the event rate.,20084309_2,0
9382,MZ,68,70,METHOD: prospective study with 137 patients that underwent TEE with MZ associated to moderate sedation.,20084309_3,0
9385,MZ,90,92,"We analyzed the following events: complications related with the topical anesthesia, with MZ use and with the procedure.",20084309_4,0
5951,mitral regurgitation,151,171,"Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the MZ dose.",20084309_5,1
9388,MZ,185,187,"Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the MZ dose.",20084309_5,0
9389,MZ,18,20,"The mean doses of MZ and FL were 4.3+/-1.9 mg and 0.28+/-0.2 mg, respectively.",20084309_7,0
9391,EF,64,66,"The duration of the examination and the mean ejection fraction (EF) were 16.4+/-6.1 minutes and 60+/-9%, respectively.",20084309_8,0
9390,mean ejection fraction,40,62,"The duration of the examination and the mean ejection fraction (EF) were 16.4+/-6.1 minutes and 60+/-9%, respectively.",20084309_8,1
2305,(2,75,77,Mild hypoxia (SO2<90%) was the most common event (11 patients); 3 patients (2%) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 (5.8%) due to hypoxia caused by MZ use.,20084309_9,0
9392,Mild hypoxia,0,12,Mild hypoxia (SO2<90%) was the most common event (11 patients); 3 patients (2%) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 (5.8%) due to hypoxia caused by MZ use.,20084309_9,1
9393,MZ,200,202,Mild hypoxia (SO2<90%) was the most common event (11 patients); 3 patients (2%) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 (5.8%) due to hypoxia caused by MZ use.,20084309_9,0
5952,airway obstruction,121,139,Mild hypoxia (SO2<90%) was the most common event (11 patients); 3 patients (2%) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 (5.8%) due to hypoxia caused by MZ use.,20084309_9,1
2306,methylergonovine,49,65,Effect of direct intracoronary administration of methylergonovine in patients with and without variant angina.,2008831_0,0
9404,variant angina,95,109,Effect of direct intracoronary administration of methylergonovine in patients with and without variant angina.,2008831_0,1
9406,variant angina,97,111,The effects of intracoronary administration of methylergonovine were studied in 21 patients with variant angina and 22 patients with atypical chest pain and in others without angina pectoris (control group).,2008831_1,1
2307,methylergonovine,47,63,The effects of intracoronary administration of methylergonovine were studied in 21 patients with variant angina and 22 patients with atypical chest pain and in others without angina pectoris (control group).,2008831_1,0
5953,chest pain,142,152,The effects of intracoronary administration of methylergonovine were studied in 21 patients with variant angina and 22 patients with atypical chest pain and in others without angina pectoris (control group).,2008831_1,1
5954,angina pectoris,175,190,The effects of intracoronary administration of methylergonovine were studied in 21 patients with variant angina and 22 patients with atypical chest pain and in others without angina pectoris (control group).,2008831_1,1
2308,Methylergonovine,0,16,Methylergonovine was administered continuously at a rate of 10 micrograms/min up to 50 micrograms.,2008831_2,0
9409,coronary spasm,37,51,"In all patients with variant angina, coronary spasm was provoked at a mean dose of 28 +/- 13 micrograms (mean +/- SD).",2008831_3,1
9408,variant angina,21,35,"In all patients with variant angina, coronary spasm was provoked at a mean dose of 28 +/- 13 micrograms (mean +/- SD).",2008831_3,1
5955,ST,38,40,In the control group neither ischemic ST change nor localized spasm occurred.,2008831_4,1
9413,basal tone,4,14,The basal tone of the right coronary artery was significantly lower than that of the left coronary artery.,2008831_5,1
5956,coronary artery,28,43,The basal tone of the right coronary artery was significantly lower than that of the left coronary artery.,2008831_5,1
5957,coronary artery,90,105,The basal tone of the right coronary artery was significantly lower than that of the left coronary artery.,2008831_5,1
5958,coronary artery,48,63,The percentage of vasoconstriction of the right coronary artery was significantly higher than that of the left coronary artery.,2008831_6,1
5959,coronary artery,111,126,The percentage of vasoconstriction of the right coronary artery was significantly higher than that of the left coronary artery.,2008831_6,1
2309,low dose,105,113,"These results suggest that spasm provocation tests, which use an intracoronary injection of a relatively low dose of methylergonovine, have a high sensitivity in variant angina and the vasoreactivity of the right coronary artery may be greater than that of the other coronary arteries.",2008831_7,0
2310,methylergonovine,117,133,"These results suggest that spasm provocation tests, which use an intracoronary injection of a relatively low dose of methylergonovine, have a high sensitivity in variant angina and the vasoreactivity of the right coronary artery may be greater than that of the other coronary arteries.",2008831_7,0
9415,variant angina,162,176,"These results suggest that spasm provocation tests, which use an intracoronary injection of a relatively low dose of methylergonovine, have a high sensitivity in variant angina and the vasoreactivity of the right coronary artery may be greater than that of the other coronary arteries.",2008831_7,1
9417,coronary arteries,267,284,"These results suggest that spasm provocation tests, which use an intracoronary injection of a relatively low dose of methylergonovine, have a high sensitivity in variant angina and the vasoreactivity of the right coronary artery may be greater than that of the other coronary arteries.",2008831_7,1
9416,vasoreactivity,185,199,"These results suggest that spasm provocation tests, which use an intracoronary injection of a relatively low dose of methylergonovine, have a high sensitivity in variant angina and the vasoreactivity of the right coronary artery may be greater than that of the other coronary arteries.",2008831_7,1
5960,coronary artery,213,228,"These results suggest that spasm provocation tests, which use an intracoronary injection of a relatively low dose of methylergonovine, have a high sensitivity in variant angina and the vasoreactivity of the right coronary artery may be greater than that of the other coronary arteries.",2008831_7,1
5961,Oral manifestations,0,19,"Oral manifestations of ""meth mouth"": a case report.",20098969_0,1
9420,medical risks,108,121,"AIM: The aim of the documentation of this clinical case is to make clinicians aware of ""meth mouth"" and the medical risks associated with this serious condition.",20098969_1,1
9424,violent behavior,211,227,"BACKGROUND: Methamphetamine is a very addictive, powerful stimulant that increases wakefulness and physical activity and can produce other effects such as cardiac dysrhythmias, hypertension, hallucinations, and violent behavior.",20098969_2,1
9423,cardiac dysrhythmias,155,175,"BACKGROUND: Methamphetamine is a very addictive, powerful stimulant that increases wakefulness and physical activity and can produce other effects such as cardiac dysrhythmias, hypertension, hallucinations, and violent behavior.",20098969_2,1
5962,tooth wear,133,143,"Dental patients abusing methamphetamine can present with poor oral hygiene, xerostomia, rampant caries (""meth mouth""), and excessive tooth wear.",20098969_3,1
9427,rampant caries,88,102,"Dental patients abusing methamphetamine can present with poor oral hygiene, xerostomia, rampant caries (""meth mouth""), and excessive tooth wear.",20098969_3,1
9426,poor oral hygiene,57,74,"Dental patients abusing methamphetamine can present with poor oral hygiene, xerostomia, rampant caries (""meth mouth""), and excessive tooth wear.",20098969_3,1
9428,Oral rehabilitation,0,19,Oral rehabilitation of patients using methamphetamine can be challenging.,20098969_4,1
9429,dental pain,63,74,"CASE DESCRIPTION: A 30-year-old Caucasian woman presented with dental pain, bad breath, and self-reported poor esthetics.",20098969_5,1
9430,bad breath,76,86,"CASE DESCRIPTION: A 30-year-old Caucasian woman presented with dental pain, bad breath, and self-reported poor esthetics.",20098969_5,1
9434,intraoral,85,94,"A comprehensive examination including her medical history, panoramic radiograph, and intraoral examination revealed 19 carious lesions, which is not very common for a healthy adult.",20098969_6,1
2311,her,38,41,"A comprehensive examination including her medical history, panoramic radiograph, and intraoral examination revealed 19 carious lesions, which is not very common for a healthy adult.",20098969_6,0
5963,carious lesions,119,134,"A comprehensive examination including her medical history, panoramic radiograph, and intraoral examination revealed 19 carious lesions, which is not very common for a healthy adult.",20098969_6,1
2312,her,13,16,She reported her use of methamphetamine for five years and had not experienced any major carious episodes before she started using the drug.,20098969_7,0
5964,oral manifestations,50,69,CLINICAL SIGNIFICANCE: This clinical case showing oral manifestations of meth mouth was presented to help dental practitioners recognize and manage patients who may be abusing methamphetamines.,20098969_9,1
9439,clinical case,28,41,CLINICAL SIGNIFICANCE: This clinical case showing oral manifestations of meth mouth was presented to help dental practitioners recognize and manage patients who may be abusing methamphetamines.,20098969_9,1
5965,diabetic nephropathy,54,74,The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy.,20103708_0,1
9442,protective role,4,19,The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy.,20103708_0,0
9443,Nrf2,23,27,The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy.,20103708_0,0
5967,renal failure,62,75,"OBJECTIVE: Diabetic nephropathy is one of the major causes of renal failure, which is accompanied by the production of reactive oxygen species (ROS).",20103708_1,1
5966,Diabetic nephropathy,11,31,"OBJECTIVE: Diabetic nephropathy is one of the major causes of renal failure, which is accompanied by the production of reactive oxygen species (ROS).",20103708_1,1
2313,reactive oxygen species,119,142,"OBJECTIVE: Diabetic nephropathy is one of the major causes of renal failure, which is accompanied by the production of reactive oxygen species (ROS).",20103708_1,0
2321,fibronectin,195,206,"Furthermore, activation or overexpression of Nrf2 inhibited the promoter activity of TGF-beta1 in a dose-dependent manner, whereas knockdown of Nrf2 by siRNA enhanced TGF-beta1 transcription and fibronectin production.",20103708_10,0
2320,TGF-beta1,167,176,"Furthermore, activation or overexpression of Nrf2 inhibited the promoter activity of TGF-beta1 in a dose-dependent manner, whereas knockdown of Nrf2 by siRNA enhanced TGF-beta1 transcription and fibronectin production.",20103708_10,0
2318,TGF-beta1,85,94,"Furthermore, activation or overexpression of Nrf2 inhibited the promoter activity of TGF-beta1 in a dose-dependent manner, whereas knockdown of Nrf2 by siRNA enhanced TGF-beta1 transcription and fibronectin production.",20103708_10,0
9469,Nrf2,144,148,"Furthermore, activation or overexpression of Nrf2 inhibited the promoter activity of TGF-beta1 in a dose-dependent manner, whereas knockdown of Nrf2 by siRNA enhanced TGF-beta1 transcription and fibronectin production.",20103708_10,0
9466,Nrf2,45,49,"Furthermore, activation or overexpression of Nrf2 inhibited the promoter activity of TGF-beta1 in a dose-dependent manner, whereas knockdown of Nrf2 by siRNA enhanced TGF-beta1 transcription and fibronectin production.",20103708_10,0
2319,siRNA,152,157,"Furthermore, activation or overexpression of Nrf2 inhibited the promoter activity of TGF-beta1 in a dose-dependent manner, whereas knockdown of Nrf2 by siRNA enhanced TGF-beta1 transcription and fibronectin production.",20103708_10,0
9472,therapeutic activation,119,141,"CONCLUSIONS: This work clearly indicates a protective role of Nrf2 in diabetic nephropathy, suggesting that dietary or therapeutic activation of Nrf2 could be used as a strategy to prevent or slow down the progression of diabetic nephropathy.",20103708_11,0
5976,diabetic nephropathy,221,241,"CONCLUSIONS: This work clearly indicates a protective role of Nrf2 in diabetic nephropathy, suggesting that dietary or therapeutic activation of Nrf2 could be used as a strategy to prevent or slow down the progression of diabetic nephropathy.",20103708_11,1
5975,diabetic nephropathy,70,90,"CONCLUSIONS: This work clearly indicates a protective role of Nrf2 in diabetic nephropathy, suggesting that dietary or therapeutic activation of Nrf2 could be used as a strategy to prevent or slow down the progression of diabetic nephropathy.",20103708_11,1
9470,protective role,43,58,"CONCLUSIONS: This work clearly indicates a protective role of Nrf2 in diabetic nephropathy, suggesting that dietary or therapeutic activation of Nrf2 could be used as a strategy to prevent or slow down the progression of diabetic nephropathy.",20103708_11,0
9471,Nrf2,62,66,"CONCLUSIONS: This work clearly indicates a protective role of Nrf2 in diabetic nephropathy, suggesting that dietary or therapeutic activation of Nrf2 could be used as a strategy to prevent or slow down the progression of diabetic nephropathy.",20103708_11,0
9473,Nrf2,145,149,"CONCLUSIONS: This work clearly indicates a protective role of Nrf2 in diabetic nephropathy, suggesting that dietary or therapeutic activation of Nrf2 could be used as a strategy to prevent or slow down the progression of diabetic nephropathy.",20103708_11,0
9444,Nrf2,0,4,Nrf2 is the primary transcription factor that controls the antioxidant response essential for maintaining cellular redox homeostasis.,20103708_2,0
2314,transcription factor,20,40,Nrf2 is the primary transcription factor that controls the antioxidant response essential for maintaining cellular redox homeostasis.,20103708_2,0
9446,protective role,45,60,"Here, we report our findings demonstrating a protective role of Nrf2 against diabetic nephropathy.",20103708_3,0
9447,Nrf2,64,68,"Here, we report our findings demonstrating a protective role of Nrf2 against diabetic nephropathy.",20103708_3,0
5968,diabetic nephropathy,77,97,"Here, we report our findings demonstrating a protective role of Nrf2 against diabetic nephropathy.",20103708_3,1
9448,protective role,44,59,"RESEARCH DESIGN AND METHODS: We explore the protective role of Nrf2 against diabetic nephropathy using human kidney biopsy tissues from diabetic nephropathy patients, a streptozotocin-induced diabetic nephropathy model in Nrf2(-/-) mice, and cultured human mesangial cells.",20103708_4,0
9449,Nrf2,63,67,"RESEARCH DESIGN AND METHODS: We explore the protective role of Nrf2 against diabetic nephropathy using human kidney biopsy tissues from diabetic nephropathy patients, a streptozotocin-induced diabetic nephropathy model in Nrf2(-/-) mice, and cultured human mesangial cells.",20103708_4,0
5969,diabetic nephropathy,76,96,"RESEARCH DESIGN AND METHODS: We explore the protective role of Nrf2 against diabetic nephropathy using human kidney biopsy tissues from diabetic nephropathy patients, a streptozotocin-induced diabetic nephropathy model in Nrf2(-/-) mice, and cultured human mesangial cells.",20103708_4,1
5970,diabetic nephropathy,136,156,"RESEARCH DESIGN AND METHODS: We explore the protective role of Nrf2 against diabetic nephropathy using human kidney biopsy tissues from diabetic nephropathy patients, a streptozotocin-induced diabetic nephropathy model in Nrf2(-/-) mice, and cultured human mesangial cells.",20103708_4,1
5971,diabetic nephropathy,192,212,"RESEARCH DESIGN AND METHODS: We explore the protective role of Nrf2 against diabetic nephropathy using human kidney biopsy tissues from diabetic nephropathy patients, a streptozotocin-induced diabetic nephropathy model in Nrf2(-/-) mice, and cultured human mesangial cells.",20103708_4,1
5972,diabetic nephropathy,32,52,RESULTS: The glomeruli of human diabetic nephropathy patients were under oxidative stress and had elevated Nrf2 levels.,20103708_5,1
9453,oxidative stress,73,89,RESULTS: The glomeruli of human diabetic nephropathy patients were under oxidative stress and had elevated Nrf2 levels.,20103708_5,1
9454,Nrf2,107,111,RESULTS: The glomeruli of human diabetic nephropathy patients were under oxidative stress and had elevated Nrf2 levels.,20103708_5,0
9456,renal damage,96,108,"In the animal study, Nrf2 was demonstrated to be crucial in ameliorating streptozotocin-induced renal damage.",20103708_6,1
9455,Nrf2,21,25,"In the animal study, Nrf2 was demonstrated to be crucial in ameliorating streptozotocin-induced renal damage.",20103708_6,0
5973,renal injury,115,127,This is evident by Nrf2(-/-) mice having higher ROS production and suffering from greater oxidative DNA damage and renal injury compared with Nrf2(+/+) mice.,20103708_7,1
9457,Nrf2(-/-),19,28,This is evident by Nrf2(-/-) mice having higher ROS production and suffering from greater oxidative DNA damage and renal injury compared with Nrf2(+/+) mice.,20103708_7,0
9458,oxidative DNA damage,90,110,This is evident by Nrf2(-/-) mice having higher ROS production and suffering from greater oxidative DNA damage and renal injury compared with Nrf2(+/+) mice.,20103708_7,1
5974,diabetic nephropathy,106,126,"Mechanistic studies in both in vivo and in vitro systems showed that the Nrf2-mediated protection against diabetic nephropathy is, at least, partially through inhibition of transforming growth factor-beta1 (TGF-beta1) and reduction of extracellular matrix production.",20103708_8,1
2315,transforming growth factor-beta1,173,205,"Mechanistic studies in both in vivo and in vitro systems showed that the Nrf2-mediated protection against diabetic nephropathy is, at least, partially through inhibition of transforming growth factor-beta1 (TGF-beta1) and reduction of extracellular matrix production.",20103708_8,0
2316,TGF-beta1,207,216,"Mechanistic studies in both in vivo and in vitro systems showed that the Nrf2-mediated protection against diabetic nephropathy is, at least, partially through inhibition of transforming growth factor-beta1 (TGF-beta1) and reduction of extracellular matrix production.",20103708_8,0
2317,extracellular matrix,235,255,"Mechanistic studies in both in vivo and in vitro systems showed that the Nrf2-mediated protection against diabetic nephropathy is, at least, partially through inhibition of transforming growth factor-beta1 (TGF-beta1) and reduction of extracellular matrix production.",20103708_8,0
9461,renal mesangial cells,9,30,"In human renal mesangial cells, high glucose induced ROS production and activated expression of Nrf2 and its downstream genes.",20103708_9,1
9463,Nrf2,96,100,"In human renal mesangial cells, high glucose induced ROS production and activated expression of Nrf2 and its downstream genes.",20103708_9,0
9462,high glucose,32,44,"In human renal mesangial cells, high glucose induced ROS production and activated expression of Nrf2 and its downstream genes.",20103708_9,0
9476,antidiabetic drug metformin,4,31,The antidiabetic drug metformin can diminish apoptosis induced by oxidative stress in endothelial cells and prevent vascular dysfunction even in nondiabetic patients.,20164825_1,0
9479,vascular dysfunction,116,136,The antidiabetic drug metformin can diminish apoptosis induced by oxidative stress in endothelial cells and prevent vascular dysfunction even in nondiabetic patients.,20164825_1,1
9493,nephrotoxicity,85,99,"Thus, our study suggests that pleiotropic effects of metformin can lessen gentamicin nephrotoxicity and improve mitochondrial homeostasis.",20164825_10,1
9494,mitochondrial,112,125,"Thus, our study suggests that pleiotropic effects of metformin can lessen gentamicin nephrotoxicity and improve mitochondrial homeostasis.",20164825_10,0
2322,reactive oxygen species,57,80,"Mitochondrial analysis, respiration intensity, levels of reactive oxygen species, permeability transition, and cytochrome c release were assessed 3 and 6 days after gentamicin administration.",20164825_3,0
9481,Mitochondrial,0,13,"Mitochondrial analysis, respiration intensity, levels of reactive oxygen species, permeability transition, and cytochrome c release were assessed 3 and 6 days after gentamicin administration.",20164825_3,0
9484,cytochrome c,111,123,"Mitochondrial analysis, respiration intensity, levels of reactive oxygen species, permeability transition, and cytochrome c release were assessed 3 and 6 days after gentamicin administration.",20164825_3,0
5977,acute renal failure,54,73,Metformin treatment fully blocked gentamicin-mediated acute renal failure.,20164825_4,1
9485,lipid peroxidation,105,123,"This was accompanied by a lower activity of N-acetyl-beta-D-glucosaminidase, together with a decrease of lipid peroxidation and increase of antioxidant systems.",20164825_5,1
2323,N-acetyl-beta-D-glucosaminidase,44,75,"This was accompanied by a lower activity of N-acetyl-beta-D-glucosaminidase, together with a decrease of lipid peroxidation and increase of antioxidant systems.",20164825_5,0
9486,antioxidant systems,140,159,"This was accompanied by a lower activity of N-acetyl-beta-D-glucosaminidase, together with a decrease of lipid peroxidation and increase of antioxidant systems.",20164825_5,0
9487,histological damage,41,60,Metformin also protected the kidney from histological damage 6 days after gentamicin administration.,20164825_6,1
9488,kidney dysfunction,25,43,These in vivo markers of kidney dysfunction and their correction by metformin were complemented by in vitro studies of mitochondrial function.,20164825_7,1
9490,cytochrome c,68,80,"We found that gentamicin treatment depleted respiratory components (cytochrome c, NADH), probably due to the opening of mitochondrial transition pores.",20164825_8,0
2324,NADH,82,86,"We found that gentamicin treatment depleted respiratory components (cytochrome c, NADH), probably due to the opening of mitochondrial transition pores.",20164825_8,0
9491,mitochondrial,120,133,"We found that gentamicin treatment depleted respiratory components (cytochrome c, NADH), probably due to the opening of mitochondrial transition pores.",20164825_8,0
2326,electron transfer,78,95,"These injuries, partly mediated by a rise in reactive oxygen species from the electron transfer chain, were significantly decreased by metformin.",20164825_9,0
2325,reactive oxygen species,45,68,"These injuries, partly mediated by a rise in reactive oxygen species from the electron transfer chain, were significantly decreased by metformin.",20164825_9,0
9495,cardiac angiography,88,107,Risk of nephropathy after consumption of nonionic contrast media by children undergoing cardiac angiography: a prospective study.,20195852_0,1
2327,contrast media,50,64,Risk of nephropathy after consumption of nonionic contrast media by children undergoing cardiac angiography: a prospective study.,20195852_0,0
9498,CIN,75,78,"Despite increasing reports on nonionic contrast media-induced nephropathy (CIN) in hospitalized adult patients during cardiac procedures, the studies in pediatrics are limited, with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography.",20195852_1,0
9497,nonionic contrast media-induced nephropathy,30,73,"Despite increasing reports on nonionic contrast media-induced nephropathy (CIN) in hospitalized adult patients during cardiac procedures, the studies in pediatrics are limited, with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography.",20195852_1,1
9523,CIN,28,31,"Although clinically silent, CIN is not rare in pediatrics.",20195852_10,0
9524,CIN,123,126,"The incidence depends on dosage but not on the type of consumed nonionic CM, nor on the presence of cyanosis, and although CIN usually is reversible, more concern is needed for the prevention of such a complication in children.",20195852_11,0
2329,iohexol,107,114,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.",20195852_2,0
9506,iopromide,93,102,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.",20195852_2,0
9505,CIN,51,54,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.",20195852_2,0
2328,contrast media,72,86,"This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis.",20195852_2,0
9509,group B,99,106,"The 80 patients in the study consecutively received either iopromide (group A, n = 40) or iohexol (group B, n = 40).",20195852_3,0
2330,iohexol,90,97,"The 80 patients in the study consecutively received either iopromide (group A, n = 40) or iohexol (group B, n = 40).",20195852_3,0
9508,group A,70,77,"The 80 patients in the study consecutively received either iopromide (group A, n = 40) or iohexol (group B, n = 40).",20195852_3,0
9507,iopromide,59,68,"The 80 patients in the study consecutively received either iopromide (group A, n = 40) or iohexol (group B, n = 40).",20195852_3,0
2332,creatinine,38,48,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.",20195852_4,0
2331,(Na,13,16,"Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use.",20195852_4,0
9514,CIN,162,165,"Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.",20195852_6,0
9513,End-stage renal damage,102,124,"Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.",20195852_6,1
9512,Loss of kidney function,73,96,"Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.",20195852_6,1
9511,kidney function,56,71,"Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.",20195852_6,1
5978,renal failure,8,21,"Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population.",20195852_6,1
9516,group B,142,149,"Accordingly, among the 15 CIN patients (18.75%), 7.5% of the patients in group A had increased risk and 3.75% had renal injury, whereas 5% of group B had increased risk and 2.5% had renal injury.",20195852_7,0
5980,renal injury,182,194,"Accordingly, among the 15 CIN patients (18.75%), 7.5% of the patients in group A had increased risk and 3.75% had renal injury, whereas 5% of group B had increased risk and 2.5% had renal injury.",20195852_7,1
5979,renal injury,114,126,"Accordingly, among the 15 CIN patients (18.75%), 7.5% of the patients in group A had increased risk and 3.75% had renal injury, whereas 5% of group B had increased risk and 2.5% had renal injury.",20195852_7,1
9517,CIN,35,38,"Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014).",20195852_8,0
9520,cyanotic congenital heart diseases,38,72,"Among the 15 patients with CIN, 6 had cyanotic congenital heart diseases, but the incidence did not differ significantly from that for the noncyanotic patients (p = 0.243).",20195852_9,1
2333,Antituberculosis,0,16,"Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome.",20196116_0,0
5981,acute liver failure,33,52,"Antituberculosis therapy-induced acute liver failure: magnitude, profile, prognosis, and predictors of outcome.",20196116_0,1
5982,acute liver failure,42,61,Antituberculosis therapy (ATT)-associated acute liver failure (ATT-ALF) is the commonest drug-induced ALF in South Asia.,20196116_1,1
2334,Antituberculosis,0,16,Antituberculosis therapy (ATT)-associated acute liver failure (ATT-ALF) is the commonest drug-induced ALF in South Asia.,20196116_1,0
5984,cerebral edema,45,59,"At presentation, advanced encephalopathy and cerebral edema were present in 51 (76%) and 29 (41.4%) patients, respectively.",20196116_10,1
9540,advanced encephalopathy,17,40,"At presentation, advanced encephalopathy and cerebral edema were present in 51 (76%) and 29 (41.4%) patients, respectively.",20196116_10,1
5985,acute renal failure,49,68,"Gastrointestinal bleed, seizures, infection, and acute renal failure were documented in seven (10%), five (7.1%), 26 (37.1%), and seven (10%) patients, respectively.",20196116_11,1
5986,hepatitis E,14,25,"Compared with hepatitis E virus (HEV) and non-A non-E-induced ALF, ATT-ALF patients had nearly similar presentations except for older age and less elevation of liver enzymes.",20196116_12,1
5987,non-A,42,47,"Compared with hepatitis E virus (HEV) and non-A non-E-induced ALF, ATT-ALF patients had nearly similar presentations except for older age and less elevation of liver enzymes.",20196116_12,1
9545,older age,128,137,"Compared with hepatitis E virus (HEV) and non-A non-E-induced ALF, ATT-ALF patients had nearly similar presentations except for older age and less elevation of liver enzymes.",20196116_12,1
9547,ATT-ALF,39,46,"The mortality rate among patients with ATT-ALF was high (67.1%, n = 47), and only 23 (32.9%) patients recovered with medical treatment.",20196116_13,0
9549,serum bilirubin,75,90,"In multivariate analysis, three factors independently predicted mortality: serum bilirubin (>or=10.8 mg/dL), prothrombin time (PT) prolongation (>or=26 seconds), and grade III/IV encephalopathy at presentation.",20196116_14,0
9551,grade III/IV encephalopathy,166,193,"In multivariate analysis, three factors independently predicted mortality: serum bilirubin (>or=10.8 mg/dL), prothrombin time (PT) prolongation (>or=26 seconds), and grade III/IV encephalopathy at presentation.",20196116_14,1
9553,ALF,40,43,CONCLUSION: ATT-ALF constituted 5.7% of ALF at our center and had a high mortality rate.,20196116_15,0
9528,ATT-ALF,23,30,Prospective studies on ATT-ALF are lacking.,20196116_2,0
5983,clinical course,57,72,"The current study prospectively evaluated the magnitude, clinical course, outcome, and prognostic factors in ATT-ALF.",20196116_3,1
9531,ALF,52,55,"From January 1986 to January 2009, 1223 consecutive ALF patients were evaluated: ATT alone was the cause in 70 (5.7%) patients.",20196116_4,0
9533,ATT,22,25,Another 15 (1.2%) had ATT and simultaneous hepatitis virus infection.,20196116_5,1
9534,hepatitis virus infection,43,68,Another 15 (1.2%) had ATT and simultaneous hepatitis virus infection.,20196116_5,1
9538,icterus encephalopathy,45,67,Most had hyperacute presentation; the median icterus encephalopathy interval was 4.5 (0-30) days.,20196116_8,1
9537,hyperacute,9,19,Most had hyperacute presentation; the median icterus encephalopathy interval was 4.5 (0-30) days.,20196116_8,1
9539,ALF,34,37,The median duration of ATT before ALF was 30 (7-350) days.,20196116_9,0
9557,Renal function,0,14,Renal function and hemodynamics during prolonged isoflurane-induced hypotension in humans.,2021202_0,1
9560,glomerular function,48,67,The effect of isoflurane-induced hypotension on glomerular function and renal blood flow was investigated in 20 human subjects.,2021202_1,1
5988,PAH,121,124,"Glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were measured by inulin and para-aminohippurate (PAH) clearance, respectively.",2021202_2,1
2335,para-aminohippurate,100,119,"Glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were measured by inulin and para-aminohippurate (PAH) clearance, respectively.",2021202_2,0
9565,ERPF,66,70,"Glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were measured by inulin and para-aminohippurate (PAH) clearance, respectively.",2021202_2,0
9563,GFR,28,31,"Glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were measured by inulin and para-aminohippurate (PAH) clearance, respectively.",2021202_2,0
2336,nitrous oxide,41,54,"Anesthesia was maintained with fentanyl, nitrous oxide, oxygen, and isoflurane.",2021202_3,0
9568,mean arterial pressure,113,135,Hypotension was induced for 236.9 +/- 15.1 min by increasing the isoflurane inspired concentration to maintain a mean arterial pressure of 59.8 +/- 0.4 mmHg.,2021202_4,1
9571,ERPF,8,12,GFR and ERPF decreased with the induction of anesthesia but not significantly more during hypotension.,2021202_5,0
9570,GFR,0,3,GFR and ERPF decreased with the induction of anesthesia but not significantly more during hypotension.,2021202_5,0
9573,GFR,63,66,"Postoperatively, ERPF returned to preoperative values, whereas GFR was higher than preoperative values.",2021202_6,0
9572,ERPF,17,21,"Postoperatively, ERPF returned to preoperative values, whereas GFR was higher than preoperative values.",2021202_6,0
9574,Renal vascular resistance,0,25,"Renal vascular resistance increased during anesthesia but decreased when hypotension was induced, allowing the maintenance of renal blood flow.",2021202_7,1
9577,renal function,108,122,We conclude that renal compensatory mechanisms are preserved during isoflurane-induced hypotension and that renal function and hemodynamics quickly return to normal when normotension is resumed.,2021202_8,1
5989,compensatory,23,35,We conclude that renal compensatory mechanisms are preserved during isoflurane-induced hypotension and that renal function and hemodynamics quickly return to normal when normotension is resumed.,2021202_8,1
5990,congestive heart failure,122,146,Design and analysis of the HYPREN-trial: safety of enalapril and prazosin in the initial treatment phase of patients with congestive heart failure.,2024540_0,1
2337,angiotensin converting enzyme,26,55,"Since the introduction of angiotensin converting enzyme (ACE) inhibitors into the adjunctive treatment of patients with congestive heart failure, cases of severe hypotension, especially on the first day of treatment, have occasionally been reported.",2024540_1,0
5991,congestive heart failure,120,144,"Since the introduction of angiotensin converting enzyme (ACE) inhibitors into the adjunctive treatment of patients with congestive heart failure, cases of severe hypotension, especially on the first day of treatment, have occasionally been reported.",2024540_1,1
2338,ACE inhibitor,28,41,"To assess the safety of the ACE inhibitor enalapril a multicenter, randomized, prazosin-controlled trial was designed that compared the incidence and severity of symptomatic hypotension on the first day of treatment.",2024540_2,0
9584,prenatally exposed,34,52,Brainstem dysgenesis in an infant prenatally exposed to cocaine.,20304337_0,1
9583,Brainstem dysgenesis,0,20,Brainstem dysgenesis in an infant prenatally exposed to cocaine.,20304337_0,1
5992,cocaine abuse,60,73,Many authors described the effects on the fetus of maternal cocaine abuse during pregnancy.,20304337_1,1
5993,fetal anomalies,89,104,Vasoconstriction appears to be the common mechanism of action leading to a wide range of fetal anomalies.,20304337_2,1
5994,cranial-nerve,37,50,"We report on an infant with multiple cranial-nerve involvement attributable to brainstem dysgenesis, born to a cocaine-addicted mother.",20304337_3,1
9585,brainstem dysgenesis,79,99,"We report on an infant with multiple cranial-nerve involvement attributable to brainstem dysgenesis, born to a cocaine-addicted mother.",20304337_3,1
9587,risperidone,46,57,A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys.,20331935_0,0
9588,bone mineral density,105,125,A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys.,20331935_0,1
2339,selective serotonin reuptake inhibitors,62,101,A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys.,20331935_0,0
5995,hyperprolactinemia,93,111,OBJECTIVE: The aim of the present study was to investigate the effect of risperidone-induced hyperprolactinemia on trabecular bone mineral density (BMD) in children and adolescents.,20331935_1,1
9589,trabecular bone mineral density,115,146,OBJECTIVE: The aim of the present study was to investigate the effect of risperidone-induced hyperprolactinemia on trabecular bone mineral density (BMD) in children and adolescents.,20331935_1,1
2340,selective serotonin reuptake inhibitors,66,105,"Controlling for relevant covariates, we also found treatment with selective serotonin reuptake inhibitors (SSRIs) to be associated with lower trabecular BMD at the radius (P = .03) and BMD z score at the lumbar spine (P < .05).",20331935_10,0
9619,lumbar spine,204,216,"Controlling for relevant covariates, we also found treatment with selective serotonin reuptake inhibitors (SSRIs) to be associated with lower trabecular BMD at the radius (P = .03) and BMD z score at the lumbar spine (P < .05).",20331935_10,1
5998,hyperprolactinemia,116,134,"Of 13 documented fractures, 3 occurred after risperidone and SSRIs were started, and none occurred in patients with hyperprolactinemia.",20331935_12,1
9621,risperidone,45,56,"Of 13 documented fractures, 3 occurred after risperidone and SSRIs were started, and none occurred in patients with hyperprolactinemia.",20331935_12,0
9622,BMD,112,115,CONCLUSIONS: This is the first study to link risperidone-induced hyperprolactinemia and SSRI treatment to lower BMD in children and adolescents.,20331935_13,0
5999,hyperprolactinemia,65,83,CONCLUSIONS: This is the first study to link risperidone-induced hyperprolactinemia and SSRI treatment to lower BMD in children and adolescents.,20331935_13,1
9623,longitudinal course,36,55,Future research should evaluate the longitudinal course of this adverse event to determine its temporal stability and whether a higher fracture rate ensues.,20331935_14,1
9624,adverse event,64,77,Future research should evaluate the longitudinal course of this adverse event to determine its temporal stability and whether a higher fracture rate ensues.,20331935_14,1
9593,risperidone,103,114,"METHOD: Medically healthy 7- to 17-year-old males chronically treated, in a naturalistic setting, with risperidone were recruited for this cross-sectional study through child psychiatry outpatient clinics between November 2005 and June 2007.",20331935_2,0
9605,lumbar spine,126,138,"Volumetric BMD of the ultradistal radius was measured using peripheral quantitative computed tomography, and areal BMD of the lumbar spine was estimated using dual-energy x-ray absorptiometry.",20331935_5,1
5996,Hyperprolactinemia,9,27,RESULTS: Hyperprolactinemia was present in 49% of 83 boys (n = 41) treated with risperidone for a mean of 2.9 years.,20331935_6,1
9607,risperidone,80,91,RESULTS: Hyperprolactinemia was present in 49% of 83 boys (n = 41) treated with risperidone for a mean of 2.9 years.,20331935_6,0
5997,hyperprolactinemia,88,106,Serum testosterone concentration increased with pubertal status but was not affected by hyperprolactinemia.,20331935_7,1
9608,pubertal status,48,63,Serum testosterone concentration increased with pubertal status but was not affected by hyperprolactinemia.,20331935_7,1
9610,BMD,38,41,"As expected, bone mineral content and BMD increased with sexual maturity.",20331935_8,0
9611,sexual maturity,57,72,"As expected, bone mineral content and BMD increased with sexual maturity.",20331935_8,1
9612,sexual development,33,51,"After adjusting for the stage of sexual development and height and BMI z scores, serum prolactin was negatively associated with trabecular volumetric BMD at the ultradistal radius (P < .03).",20331935_9,1
9613,serum prolactin,81,96,"After adjusting for the stage of sexual development and height and BMI z scores, serum prolactin was negatively associated with trabecular volumetric BMD at the ultradistal radius (P < .03).",20331935_9,1
9627,Fear-potentiated startle,0,24,"Fear-potentiated startle, but not light-enhanced startle, is enhanced by anxiogenic drugs.",20394767_0,0
9629,anxiogenic drugs,73,89,"Fear-potentiated startle, but not light-enhanced startle, is enhanced by anxiogenic drugs.",20394767_0,0
2341,non-specific,114,126,"RATIONALE AND OBJECTIVES: The light-enhanced startle paradigm (LES) is suggested to model anxiety, because of the non-specific cue and the long-term effect.",20394767_1,0
9632,conditioned fear,70,86,"In contrast, the fear-potentiated startle (FPS) is suggested to model conditioned fear.",20394767_2,1
9638,alpha(2)-adrenoceptor antagonist yohimbine,52,94,"METHODS: Male Wistar rats received each dose of the alpha(2)-adrenoceptor antagonist yohimbine (0.25-1.0mg/kg), the 5-HT(2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/kg) or the GABA(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS.",20394767_5,0
9639,5-HT(2C,116,123,"METHODS: Male Wistar rats received each dose of the alpha(2)-adrenoceptor antagonist yohimbine (0.25-1.0mg/kg), the 5-HT(2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/kg) or the GABA(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS.",20394767_5,0
9640,receptor agonist m-chlorophenylpiperazine,125,166,"METHODS: Male Wistar rats received each dose of the alpha(2)-adrenoceptor antagonist yohimbine (0.25-1.0mg/kg), the 5-HT(2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/kg) or the GABA(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS.",20394767_5,0
9641,mCPP,168,172,"METHODS: Male Wistar rats received each dose of the alpha(2)-adrenoceptor antagonist yohimbine (0.25-1.0mg/kg), the 5-HT(2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/kg) or the GABA(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS.",20394767_5,0
9642,receptor agonist pentylenetetrazole,211,246,"METHODS: Male Wistar rats received each dose of the alpha(2)-adrenoceptor antagonist yohimbine (0.25-1.0mg/kg), the 5-HT(2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/kg) or the GABA(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS.",20394767_5,0
9643,PTZ,248,251,"METHODS: Male Wistar rats received each dose of the alpha(2)-adrenoceptor antagonist yohimbine (0.25-1.0mg/kg), the 5-HT(2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/kg) or the GABA(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS.",20394767_5,0
2342,yohimbine,83,92,"RESULTS: None of the drugs enhanced LES, whereas mCPP increased percentage FPS and yohimbine increased absolute FPS values.",20394767_6,0
9644,mCPP,49,53,"RESULTS: None of the drugs enhanced LES, whereas mCPP increased percentage FPS and yohimbine increased absolute FPS values.",20394767_6,0
2343,yohimbine,13,22,"Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.",20394767_7,0
9647,PTZ,139,142,"Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.",20394767_7,0
9646,mCPP,78,82,"Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS.",20394767_7,0
2344,tacrolimus,47,57,Rosaceiform dermatitis associated with topical tacrolimus treatment.,20466178_0,0
9651,tacrolimus ointment,104,123,We describe herein 3 patients who developed rosacea-like dermatitis eruptions while using 0.03% or 0.1% tacrolimus ointment for facial dermatitis.,20466178_1,0
9652,facial dermatitis,128,145,We describe herein 3 patients who developed rosacea-like dermatitis eruptions while using 0.03% or 0.1% tacrolimus ointment for facial dermatitis.,20466178_1,1
6000,telangiectasia,29,43,Skin biopsy specimens showed telangiectasia and noncaseating epithelioid granulomatous tissue formation in the papillary to mid dermis.,20466178_2,1
2346,tacrolimus,51,61,"Continuous topical use of immunomodulators such as tacrolimus or pimecrolimus should be regarded as a potential cause of rosaceiform dermatitis, although many cases have not been reported.",20466178_3,0
9655,pimecrolimus,65,77,"Continuous topical use of immunomodulators such as tacrolimus or pimecrolimus should be regarded as a potential cause of rosaceiform dermatitis, although many cases have not been reported.",20466178_3,0
2345,immunomodulators,26,42,"Continuous topical use of immunomodulators such as tacrolimus or pimecrolimus should be regarded as a potential cause of rosaceiform dermatitis, although many cases have not been reported.",20466178_3,0
6001,Central nervous system,0,22,Central nervous system complications during treatment of acute lymphoblastic leukemia in a single pediatric institution.,20470218_0,1
6002,acute lymphoblastic leukemia,57,85,Central nervous system complications during treatment of acute lymphoblastic leukemia in a single pediatric institution.,20470218_0,1
6003,Central nervous system,0,22,Central nervous system (CNS) complications during treatment of childhood acute lymphoblastic leukemia (ALL) remain a challenging clinical problem.,20470218_1,1
9658,of childhood acute lymphoblastic leukemia,60,101,Central nervous system (CNS) complications during treatment of childhood acute lymphoblastic leukemia (ALL) remain a challenging clinical problem.,20470218_1,1
9659,clinical problem,129,145,Central nervous system (CNS) complications during treatment of childhood acute lymphoblastic leukemia (ALL) remain a challenging clinical problem.,20470218_1,1
9660,adverse events,111,125,Outcome improvement with more intensive chemotherapy has significantly increased the incidence and severity of adverse events.,20470218_2,1
9661,neurological complications,37,63,"This study analyzed the incidence of neurological complications during ALL treatment in a single pediatric institution, focusing on clinical, radiological, and electrophysiological findings.",20470218_3,1
6004,leukemic infiltration,32,53,"Exclusion criteria included CNS leukemic infiltration at diagnosis, therapy-related peripheral neuropathy, late-onset encephalopathy, or long-term neurocognitive defects.",20470218_4,1
9664,late-onset encephalopathy,107,132,"Exclusion criteria included CNS leukemic infiltration at diagnosis, therapy-related peripheral neuropathy, late-onset encephalopathy, or long-term neurocognitive defects.",20470218_4,1
9665,neurocognitive defects,147,169,"Exclusion criteria included CNS leukemic infiltration at diagnosis, therapy-related peripheral neuropathy, late-onset encephalopathy, or long-term neurocognitive defects.",20470218_4,1
9663,therapy-related peripheral neuropathy,68,105,"Exclusion criteria included CNS leukemic infiltration at diagnosis, therapy-related peripheral neuropathy, late-onset encephalopathy, or long-term neurocognitive defects.",20470218_4,1
6006,temporal lobe epilepsy,103,125,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,1
6005,leukoencephalopathy syndrome,48,76,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,1
9668,antidiuretic hormone,202,222,"CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose methotrexate toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7).",20470218_6,0
9669,limit permanent damage,125,147,"In conclusion, CNS complications are frequent events during ALL therapy, and require rapid detection and prompt treatment to limit permanent damage.",20470218_7,1
9671,oxidative stress,98,114,"Cocaine causes memory and learning impairments in rats: involvement of nuclear factor kappa B and oxidative stress, and prevention by topiramate.",20477932_0,1
2348,topiramate,134,144,"Cocaine causes memory and learning impairments in rats: involvement of nuclear factor kappa B and oxidative stress, and prevention by topiramate.",20477932_0,0
9670,learning impairments,26,46,"Cocaine causes memory and learning impairments in rats: involvement of nuclear factor kappa B and oxidative stress, and prevention by topiramate.",20477932_0,1
2347,nuclear factor kappa B,71,93,"Cocaine causes memory and learning impairments in rats: involvement of nuclear factor kappa B and oxidative stress, and prevention by topiramate.",20477932_0,0
9672,oxidative stress,87,103,Different mechanisms have been suggested for cocaine toxicity including an increase in oxidative stress but the association between oxidative status in the brain and cocaine induced-behaviour is poorly understood.,20477932_1,1
6007,drug toxicity,129,142,Nuclear factor kappa B (NFkappaB) is a sensor of oxidative stress and participates in memory formation that could be involved in drug toxicity and addiction mechanisms.,20477932_2,1
2350,NFkappaB,24,32,Nuclear factor kappa B (NFkappaB) is a sensor of oxidative stress and participates in memory formation that could be involved in drug toxicity and addiction mechanisms.,20477932_2,0
2349,Nuclear factor kappa B,0,22,Nuclear factor kappa B (NFkappaB) is a sensor of oxidative stress and participates in memory formation that could be involved in drug toxicity and addiction mechanisms.,20477932_2,0
9675,oxidative stress,49,65,Nuclear factor kappa B (NFkappaB) is a sensor of oxidative stress and participates in memory formation that could be involved in drug toxicity and addiction mechanisms.,20477932_2,1
2351,NFkappaB,10,18,"Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats.",20477932_3,0
6008,cocaine addiction,194,211,"Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats.",20477932_3,1
9677,oxidative stress,29,45,"Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats.",20477932_3,1
9678,nNOS,79,83,"Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats.",20477932_3,0
9679,spatial learning,95,111,"Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats.",20477932_3,1
2353,topiramate,148,158,"Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats.",20477932_3,0
2352,neuronal nitric oxide synthase,47,77,"Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats.",20477932_3,0
9682,frontal cortex,39,53,"NFkappaB activity was decreased in the frontal cortex of cocaine treated rats, as well as GSH concentration and glutathione peroxidase activity in the hippocampus, whereas nNOS activity in the hippocampus was increased.",20477932_4,1
9684,nNOS,172,176,"NFkappaB activity was decreased in the frontal cortex of cocaine treated rats, as well as GSH concentration and glutathione peroxidase activity in the hippocampus, whereas nNOS activity in the hippocampus was increased.",20477932_4,0
9683,GSH,90,93,"NFkappaB activity was decreased in the frontal cortex of cocaine treated rats, as well as GSH concentration and glutathione peroxidase activity in the hippocampus, whereas nNOS activity in the hippocampus was increased.",20477932_4,0
2354,NFkappaB,0,8,"NFkappaB activity was decreased in the frontal cortex of cocaine treated rats, as well as GSH concentration and glutathione peroxidase activity in the hippocampus, whereas nNOS activity in the hippocampus was increased.",20477932_4,0
2355,glutathione peroxidase,112,134,"NFkappaB activity was decreased in the frontal cortex of cocaine treated rats, as well as GSH concentration and glutathione peroxidase activity in the hippocampus, whereas nNOS activity in the hippocampus was increased.",20477932_4,0
9685,Memory retrieval,0,16,Memory retrieval of experiences acquired prior to cocaine administration was impaired and negatively correlated with NFkappaB activity in the frontal cortex.,20477932_5,1
2356,NFkappaB,117,125,Memory retrieval of experiences acquired prior to cocaine administration was impaired and negatively correlated with NFkappaB activity in the frontal cortex.,20477932_5,0
9687,frontal cortex,142,156,Memory retrieval of experiences acquired prior to cocaine administration was impaired and negatively correlated with NFkappaB activity in the frontal cortex.,20477932_5,1
2357,glutathione peroxidase,118,140,"In contrast, learning of new tasks was enhanced and correlated with the increase of nNOS activity and the decrease of glutathione peroxidase.",20477932_6,0
9688,nNOS,84,88,"In contrast, learning of new tasks was enhanced and correlated with the increase of nNOS activity and the decrease of glutathione peroxidase.",20477932_6,0
2358,NFkappaB,103,111,These results provide evidence for a possible mechanistic role of oxidative and nitrosative stress and NFkappaB in the alterations induced by cocaine.,20477932_7,0
2359,Topiramate,0,10,"Topiramate prevented all the alterations observed, showing novel neuroprotective properties.",20477932_8,0
2360,neuroprotective,65,80,"Topiramate prevented all the alterations observed, showing novel neuroprotective properties.",20477932_8,0
9690,cisplatin nephrotoxicity,41,65,Coenzyme Q10 treatment ameliorates acute cisplatin nephrotoxicity in mice.,20510337_0,1
9689,Coenzyme Q10,0,12,Coenzyme Q10 treatment ameliorates acute cisplatin nephrotoxicity in mice.,20510337_0,0
6009,acute renal injury,74,92,The nephroprotective effect of coenzyme Q10 was investigated in mice with acute renal injury induced by a single i.p.,20510337_1,1
9691,coenzyme Q10,31,43,The nephroprotective effect of coenzyme Q10 was investigated in mice with acute renal injury induced by a single i.p.,20510337_1,0
2361,cisplatin,13,22,injection of cisplatin (5 mg/kg).,20510337_2,0
9692,Coenzyme Q10,0,12,"Coenzyme Q10 treatment (10 mg/kg/day, i.p.) was applied for 6 consecutive days, starting 1 day before cisplatin administration.",20510337_3,0
2362,cisplatin,102,111,"Coenzyme Q10 treatment (10 mg/kg/day, i.p.) was applied for 6 consecutive days, starting 1 day before cisplatin administration.",20510337_3,0
9693,Coenzyme Q10,0,12,Coenzyme Q10 significantly reduced blood urea nitrogen and serum creatinine levels which were increased by cisplatin.,20510337_4,0
2364,cisplatin,107,116,Coenzyme Q10 significantly reduced blood urea nitrogen and serum creatinine levels which were increased by cisplatin.,20510337_4,0
2363,creatinine,65,75,Coenzyme Q10 significantly reduced blood urea nitrogen and serum creatinine levels which were increased by cisplatin.,20510337_4,0
2367,tumor necrosis factor-alpha,208,235,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,0
9695,Coenzyme Q10,0,12,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,0
9696,antioxidant defense mechanisms,55,85,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,0
9697,lipid peroxidation,160,178,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,0
9698,platinum ion,254,266,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,0
2365,reduced glutathione,87,106,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,0
2368,nitric oxide,237,249,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,0
2369,cisplatin,368,377,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,0
2366,superoxide dismutase,117,137,"Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration.",20510337_5,0
9701,renal tissue,24,36,"Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.",20510337_6,1
2370,cisplatin,56,65,"Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.",20510337_6,0
9702,coenzyme Q10,85,97,"Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.",20510337_6,0
9700,histopathological,6,23,"Also, histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment.",20510337_6,1
2373,caspase-3,176,185,"Immunohistochemical analysis revealed that coenzyme Q10 significantly decreased the cisplatin-induced overexpression of inducible nitric oxide synthase, nuclear factor-kappaB, caspase-3 and p53 in renal tissue.",20510337_7,0
9705,p53,190,193,"Immunohistochemical analysis revealed that coenzyme Q10 significantly decreased the cisplatin-induced overexpression of inducible nitric oxide synthase, nuclear factor-kappaB, caspase-3 and p53 in renal tissue.",20510337_7,0
9703,coenzyme Q10,43,55,"Immunohistochemical analysis revealed that coenzyme Q10 significantly decreased the cisplatin-induced overexpression of inducible nitric oxide synthase, nuclear factor-kappaB, caspase-3 and p53 in renal tissue.",20510337_7,0
2372,nuclear factor-kappaB,153,174,"Immunohistochemical analysis revealed that coenzyme Q10 significantly decreased the cisplatin-induced overexpression of inducible nitric oxide synthase, nuclear factor-kappaB, caspase-3 and p53 in renal tissue.",20510337_7,0
2371,inducible nitric oxide synthase,120,151,"Immunohistochemical analysis revealed that coenzyme Q10 significantly decreased the cisplatin-induced overexpression of inducible nitric oxide synthase, nuclear factor-kappaB, caspase-3 and p53 in renal tissue.",20510337_7,0
9708,therapeutic option,58,76,It was concluded that coenzyme Q10 represents a potential therapeutic option to protect against acute cisplatin nephrotoxicity commonly encountered in clinical practice.,20510337_8,0
9709,cisplatin nephrotoxicity,102,126,It was concluded that coenzyme Q10 represents a potential therapeutic option to protect against acute cisplatin nephrotoxicity commonly encountered in clinical practice.,20510337_8,1
9707,coenzyme Q10,22,34,It was concluded that coenzyme Q10 represents a potential therapeutic option to protect against acute cisplatin nephrotoxicity commonly encountered in clinical practice.,20510337_8,0
9711,bile duct injury,28,44,Reversible cholestasis with bile duct injury following azathioprine therapy.,2051906_0,1
9714,primary polymyositis,28,48,"A 67-year-old patient, with primary polymyositis and without previous evidence of liver disease, developed clinical and biochemical features of severe cholestasis 3 months after initiation of azathioprine therapy.",2051906_2,1
6010,liver disease,82,95,"A 67-year-old patient, with primary polymyositis and without previous evidence of liver disease, developed clinical and biochemical features of severe cholestasis 3 months after initiation of azathioprine therapy.",2051906_2,1
9718,interlobular bile ducts,87,110,Liver biopsy showed cholestasis with both cytological and architectural alterations of interlobular bile ducts.,2051906_3,1
9717,architectural alterations,58,83,Liver biopsy showed cholestasis with both cytological and architectural alterations of interlobular bile ducts.,2051906_3,1
9719,biochemical abnormalities,81,106,Azathioprine withdrawal resulted after 7 weeks in the resolution of clinical and biochemical abnormalities.,2051906_4,1
9722,bile duct injury,140,156,It is believed that this is the first reported case of reversible azathioprine-induced cholestasis associated with histological evidence of bile duct injury.,2051906_5,1
9723,asenapine,23,32,Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia.,20520283_0,0
9724,acute exacerbation,97,115,Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia.,20520283_0,1
9728,bipolar I disorder,152,170,Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features.,20520283_1,1
9725,Asenapine,0,9,Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features.,20520283_1,0
9731,asenapine,122,131,"In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity).",20520283_2,0
9730,acute schizophrenia,50,69,"In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity).",20520283_2,1
9736,asenapine,359,368,"With last observations carried forward (LOCF), mean Positive and Negative Syndrome Scale total score reductions from baseline to endpoint were significantly greater with asenapine at 5 mg BID (-16.2) and haloperidol (-15.4) than placebo (-10.7; both P < 0.05); using mixed model for repeated measures (MMRM), changes at day 42 were significantly greater with asenapine at 5 and 10 mg BID (-21.3 and -19.4, respectively) and haloperidol (-20.0) than placebo (-14.6; all P < 0.05).",20520283_3,0
9734,asenapine,170,179,"With last observations carried forward (LOCF), mean Positive and Negative Syndrome Scale total score reductions from baseline to endpoint were significantly greater with asenapine at 5 mg BID (-16.2) and haloperidol (-15.4) than placebo (-10.7; both P < 0.05); using mixed model for repeated measures (MMRM), changes at day 42 were significantly greater with asenapine at 5 and 10 mg BID (-21.3 and -19.4, respectively) and haloperidol (-20.0) than placebo (-14.6; all P < 0.05).",20520283_3,0
9733,LOCF,40,44,"With last observations carried forward (LOCF), mean Positive and Negative Syndrome Scale total score reductions from baseline to endpoint were significantly greater with asenapine at 5 mg BID (-16.2) and haloperidol (-15.4) than placebo (-10.7; both P < 0.05); using mixed model for repeated measures (MMRM), changes at day 42 were significantly greater with asenapine at 5 and 10 mg BID (-21.3 and -19.4, respectively) and haloperidol (-20.0) than placebo (-14.6; all P < 0.05).",20520283_3,0
9742,LOCF,253,257,"On the Positive and Negative Syndrome Scale positive subscale, all treatments were superior to placebo with LOCF and MMRM; asenapine at 5 mg BID was superior to placebo on the negative subscale with MMRM and on the general psychopathology subscale with LOCF and MMRM.",20520283_4,0
9739,asenapine,123,132,"On the Positive and Negative Syndrome Scale positive subscale, all treatments were superior to placebo with LOCF and MMRM; asenapine at 5 mg BID was superior to placebo on the negative subscale with MMRM and on the general psychopathology subscale with LOCF and MMRM.",20520283_4,0
9737,LOCF,108,112,"On the Positive and Negative Syndrome Scale positive subscale, all treatments were superior to placebo with LOCF and MMRM; asenapine at 5 mg BID was superior to placebo on the negative subscale with MMRM and on the general psychopathology subscale with LOCF and MMRM.",20520283_4,0
9746,asenapine,84,93,"Treatment-related adverse events (AEs) occurred in 44% and 52%, 57%, and 41% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively.",20520283_5,0
9744,Treatment-related adverse events,0,32,"Treatment-related adverse events (AEs) occurred in 44% and 52%, 57%, and 41% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively.",20520283_5,1
9748,asenapine,85,94,"Extrapyramidal symptoms reported as AEs occurred in 15% and 18%, 34%, and 10% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively.",20520283_6,0
6011,Extrapyramidal,0,14,"Extrapyramidal symptoms reported as AEs occurred in 15% and 18%, 34%, and 10% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively.",20520283_6,1
6012,weight change,74,87,"Across all groups, no more than 5% of patients had clinically significant weight change.",20520283_7,1
9751,asenapine,59,68,"Post hoc analyses indicated that efficacy was similar with asenapine and haloperidol; greater contrasts were seen in AEs, especially extrapyramidal symptoms.",20520283_8,0
6013,extrapyramidal,133,147,"Post hoc analyses indicated that efficacy was similar with asenapine and haloperidol; greater contrasts were seen in AEs, especially extrapyramidal symptoms.",20520283_8,1
9754,nelarabine,21,31,"Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.",20528871_0,0
9755,cyclophosphamide,48,64,"Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.",20528871_0,0
6014,T-cell lymphoblastic,99,119,"Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.",20528871_0,1
2374,etoposide,33,42,"Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.",20528871_0,0
9760,CPM,91,94,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.,20528871_1,0
9759,cyclophosphamide,73,89,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.,20528871_1,0
9758,VP,65,67,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.,20528871_1,0
9757,AraG,36,40,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.,20528871_1,0
9756,nelarabine,24,34,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.,20528871_1,0
2375,etoposide,54,63,A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma.,20528871_1,0
6018,musculoskeletal pain,110,130,The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and musculoskeletal pain.,20528871_2,1
6017,motor neuropathy,89,105,The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and musculoskeletal pain.,20528871_2,1
6016,Grade 2,63,70,The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and musculoskeletal pain.,20528871_2,1
6015,side effects,16,28,The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and musculoskeletal pain.,20528871_2,1
9764,AraG,49,53,The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and musculoskeletal pain.,20528871_2,0
9765,AraG,61,65,"Haematological toxicity was greater for the combination than AraG alone, although median time to neutrophil and platelet recovery was consistent with other salvage therapies.",20528871_3,0
9768,complete remission,87,105,All patients had some response to the combined therapy and five of the seven went into complete remission after one or two courses of AraG/VP/CPM.,20528871_4,1
9769,AraG/VP/CPM,134,145,All patients had some response to the combined therapy and five of the seven went into complete remission after one or two courses of AraG/VP/CPM.,20528871_4,0
9770,AraG,45,49,"Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored.",20528871_5,0
9772,cyclophosphamide,101,117,"Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored.",20528871_5,0
2376,etoposide,87,96,"Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide, although neurological toxicity must be closely monitored.",20528871_5,0
6019,neurotoxicity,73,86,Dopamine is not essential for the development of methamphetamine-induced neurotoxicity.,20533999_0,1
2377,dopaminergic,99,111,"It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity.",20533999_1,0
9774,L-dihydroxyphenylalanine,51,75,Here we show that the recently reported ability of L-dihydroxyphenylalanine to reverse the protective effect of alpha-methyl-para-tyrosine on METH-induced DA neurotoxicity is also confounded by drug effects on body temperature.,20533999_3,0
9776,drug effects,194,206,Here we show that the recently reported ability of L-dihydroxyphenylalanine to reverse the protective effect of alpha-methyl-para-tyrosine on METH-induced DA neurotoxicity is also confounded by drug effects on body temperature.,20533999_3,1
2378,alpha-methyl-para-tyrosine,112,138,Here we show that the recently reported ability of L-dihydroxyphenylalanine to reverse the protective effect of alpha-methyl-para-tyrosine on METH-induced DA neurotoxicity is also confounded by drug effects on body temperature.,20533999_3,0
6021,body temperature,210,226,Here we show that the recently reported ability of L-dihydroxyphenylalanine to reverse the protective effect of alpha-methyl-para-tyrosine on METH-induced DA neurotoxicity is also confounded by drug effects on body temperature.,20533999_3,1
6020,neurotoxicity,158,171,Here we show that the recently reported ability of L-dihydroxyphenylalanine to reverse the protective effect of alpha-methyl-para-tyrosine on METH-induced DA neurotoxicity is also confounded by drug effects on body temperature.,20533999_3,1
6022,neurotoxicity,91,104,"Further, we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity, as long as the thermic effects of METH are preserved.",20533999_4,1
2379,dopaminergic,119,131,"In addition, we demonstrate that mice genetically engineered to have unilateral brain DA deficits develop METH-induced dopaminergic deficits that are of comparable magnitude on both sides of the brain.",20533999_5,0
9777,dopaminergic neurotoxicity,104,130,"Taken together, these findings demonstrate that DA is not essential for the development of METH-induced dopaminergic neurotoxicity and suggest that mechanisms independent of DA warrant more intense investigation.",20533999_6,1
9778,adriamycin,10,20,Effect of adriamycin combined with whole body hyperthermia on tumor and normal tissues.,2054792_0,0
9779,whole body hyperthermia,35,58,Effect of adriamycin combined with whole body hyperthermia on tumor and normal tissues.,2054792_0,1
9780,normal tissues,72,86,Effect of adriamycin combined with whole body hyperthermia on tumor and normal tissues.,2054792_0,1
9784,whole body hyperthermia,94,117,Thermal enhancement of Adriamycin-mediated antitumor activity and normal tissue toxicities by whole body hyperthermia were compared using a F344 rat model.,2054792_1,1
9783,normal tissue,66,79,Thermal enhancement of Adriamycin-mediated antitumor activity and normal tissue toxicities by whole body hyperthermia were compared using a F344 rat model.,2054792_1,1
9785,F344,140,144,Thermal enhancement of Adriamycin-mediated antitumor activity and normal tissue toxicities by whole body hyperthermia were compared using a F344 rat model.,2054792_1,0
6023,kidney injury,127,140,"Acute normal tissue toxicities (i.e., leukopenia and thrombocytopenia) and late normal tissue toxicities (i.e., myocardial and kidney injury) were evaluated by functional/physiological assays and by morphological techniques.",2054792_3,1
9788,Acute normal tissue toxicities,0,30,"Acute normal tissue toxicities (i.e., leukopenia and thrombocytopenia) and late normal tissue toxicities (i.e., myocardial and kidney injury) were evaluated by functional/physiological assays and by morphological techniques.",2054792_3,1
9790,Whole body hyperthermia,0,23,Whole body hyperthermia (120 min at 41.5 degrees C) enhanced both Adriamycin-mediated antitumor activity and toxic side effects.,2054792_4,1
6024,side effects,115,127,Whole body hyperthermia (120 min at 41.5 degrees C) enhanced both Adriamycin-mediated antitumor activity and toxic side effects.,2054792_4,1
9795,renal lesions,159,172,"Thermal enhancement ratios estimated for ""acute"" hematological changes were 1.3, whereas those estimated for ""late"" damage (based on morphological cardiac and renal lesions) varied between 2.4 and 4.3.",2054792_6,1
9796,whole body hyperthermia,12,35,"Thus, while whole body hyperthermia enhances Adriamycin-mediated antitumor effect, normal tissue toxicity is also increased, and the potential therapeutic gain of the combined modality treatment is eroded.",2054792_7,1
6025,tachyarrhythmia,26,41,Swallowing-induced atrial tachyarrhythmia triggered by salbutamol: case report and review of the literature.,20552622_0,1
2380,salbutamol,55,65,Swallowing-induced atrial tachyarrhythmia triggered by salbutamol: case report and review of the literature.,20552622_0,0
2383,Salbutamol,12,22,CONCLUSION: Salbutamol is presented here as a possible trigger for SIAT.,20552622_10,0
9806,SIAT,67,71,CONCLUSION: Salbutamol is presented here as a possible trigger for SIAT.,20552622_10,0
9808,beta-blocker,251,263,"Although it is difficult to define causality in a case report, it is logical to think that a beta-agonist like salbutamol (known to induce tachycardia) may be the trigger of adrenergic reflexes originating in the esophagus while swallowing and that a beta-blocker such as atenolol (that blocks the adrenergic activity) may relieve it.",20552622_11,0
2384,beta-agonist,93,105,"Although it is difficult to define causality in a case report, it is logical to think that a beta-agonist like salbutamol (known to induce tachycardia) may be the trigger of adrenergic reflexes originating in the esophagus while swallowing and that a beta-blocker such as atenolol (that blocks the adrenergic activity) may relieve it.",20552622_11,0
2385,salbutamol,111,121,"Although it is difficult to define causality in a case report, it is logical to think that a beta-agonist like salbutamol (known to induce tachycardia) may be the trigger of adrenergic reflexes originating in the esophagus while swallowing and that a beta-blocker such as atenolol (that blocks the adrenergic activity) may relieve it.",20552622_11,0
6026,tachyarrhythmia,41,56,"On electrocardiogram, episodes of atrial tachyarrhythmia were recorded immediately after swallowing; 24-hour Holter monitoring recorded several events.",20552622_2,1
2381,salbutamol,81,91,The patient noticed that before these episodes he had been using an inhalator of salbutamol.,20552622_4,0
2382,beta-agonist,19,31,"After stopping the beta-agonist, and after a week with the atenolol, the arrhythmia disappeared.",20552622_5,0
9800,SIAT,55,59,DISCUSSION: Swallowing-induced atrial tachyarrhythmia (SIAT) is a rare phenomenon.,20552622_6,1
6027,tachyarrhythmia,38,53,DISCUSSION: Swallowing-induced atrial tachyarrhythmia (SIAT) is a rare phenomenon.,20552622_6,1
9801,SIAT,23,27,Fewer than 50 cases of SIAT have been described in the literature.,20552622_7,0
9804,radiofrequency catheter ablation,180,212,"It discusses demographics, clinical characteristics and types of arrhythmia, postulated mechanisms of SIAT, and different treatment possibilities such as medications, surgery, and radiofrequency catheter ablation (RFCA).",20552622_9,1
9805,RFCA,214,218,"It discusses demographics, clinical characteristics and types of arrhythmia, postulated mechanisms of SIAT, and different treatment possibilities such as medications, surgery, and radiofrequency catheter ablation (RFCA).",20552622_9,0
9803,SIAT,102,106,"It discusses demographics, clinical characteristics and types of arrhythmia, postulated mechanisms of SIAT, and different treatment possibilities such as medications, surgery, and radiofrequency catheter ablation (RFCA).",20552622_9,0
9810,urinary bladder function,70,94,The ability of insulin treatment to reverse or prevent the changes in urinary bladder function caused by streptozotocin-induced diabetes mellitus.1.,2055425_0,1
9812,urinary bladder function,57,81,The effects of insulin treatment on in vivo and in vitro urinary bladder function in streptozotocin-diabetic rats were investigated.,2055425_1,1
6028,body weight,58,69,"2. Diabetes of 2 months duration resulted in decreases in body weight and increases in fluid consumption, urine volume, frequency of micturition, and average volume per micturition; effects which were prevented by insulin treatment.",2055425_2,1
9816,nerve stimulation,120,137,"3. Insulin treatment also prevented the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and bethanechol.",2055425_3,1
2386,bethanechol,148,159,"3. Insulin treatment also prevented the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and bethanechol.",2055425_3,0
6029,body weight,60,71,"Diabetes of 4 months duration also resulted in decreases in body weight, and increases in fluid consumption, urine volume, frequency of micturition, and average volume per micturition, effects which were reversed by insulin treatment for the final 2 months of the study.",2055425_5,1
2387,bethanechol,139,150,"Insulin treatment reversed the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and bethanechol.",2055425_7,0
9821,nerve stimulation,111,128,"Insulin treatment reversed the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and bethanechol.",2055425_7,1
9824,urinary bladder function,73,97,The data indicate that the effects of streptozotocin-induced diabetes on urinary bladder function are both prevented and reversed by insulin treatment.,2055425_9,1
9826,inferior colliculus,66,85,Glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus can modulate haloperidol-induced catalepsy.,20558148_0,1
2388,Glutamatergic,0,13,Glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus can modulate haloperidol-induced catalepsy.,20558148_0,0
2389,NMDA receptors,44,58,Glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus can modulate haloperidol-induced catalepsy.,20558148_0,0
9827,haloperidol-induced catalepsy,99,128,Glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus can modulate haloperidol-induced catalepsy.,20558148_0,1
9829,auditory nuclei,129,144,"The inferior colliculus (IC) is primarily involved in the processing of auditory information, but it is distinguished from other auditory nuclei in the brainstem by its connections with structures of the motor system.",20558148_1,1
2390,excitatory amino acid,142,163,"Functional evidence relating the IC to motor behavior derives from experiments showing that activation of the IC by electrical stimulation or excitatory amino acid microinjection causes freezing, escape-like behavior, and immobility.",20558148_2,0
2391,excitatory amino,44,60,The present study examined the influence of excitatory amino acid-mediated mechanisms in the IC on the catalepsy induced by the dopamine receptor blocker haloperidol administered systemically (1 or 0.5 mg/kg) in rats.,20558148_4,0
9834,dopamine receptor blocker,128,153,The present study examined the influence of excitatory amino acid-mediated mechanisms in the IC on the catalepsy induced by the dopamine receptor blocker haloperidol administered systemically (1 or 0.5 mg/kg) in rats.,20558148_4,0
2392,(1,192,194,The present study examined the influence of excitatory amino acid-mediated mechanisms in the IC on the catalepsy induced by the dopamine receptor blocker haloperidol administered systemically (1 or 0.5 mg/kg) in rats.,20558148_4,0
9838,glutamate NMDA receptor antagonists,91,126,"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",20558148_5,0
9840,AP7,166,169,"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",20558148_5,0
9842,NMDA receptor agonist N-methyl-d-aspartate,208,250,"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",20558148_5,0
2393,MK-801,128,134,"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",20558148_5,0
2394,NMDA,252,256,"Haloperidol-induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists, MK-801 (15 or 30 mmol/0.5 microl) and AP7 (10 or 20 nmol/0.5 microl), or of the NMDA receptor agonist N-methyl-d-aspartate (NMDA, 20 or 30 nmol/0.5 microl).",20558148_5,0
2395,MK-801,58,64,"The results showed that intracollicular microinjection of MK-801 and AP7 previous to systemic injections of haloperidol significantly attenuated the catalepsy, as indicated by a reduced latency to step down from a horizontal bar.",20558148_6,0
9846,AP7,69,72,"The results showed that intracollicular microinjection of MK-801 and AP7 previous to systemic injections of haloperidol significantly attenuated the catalepsy, as indicated by a reduced latency to step down from a horizontal bar.",20558148_6,0
2396,NMDA,47,51,"Accordingly, intracollicular microinjection of NMDA increased the latency to step down the bar.",20558148_7,0
9850,haloperidol-induced catalepsy,107,136,These findings suggest that glutamate-mediated mechanisms in the neural circuits at the IC level influence haloperidol-induced catalepsy and participate in the regulation of motor activity.,20558148_8,1
2397,puromycin aminonucleoside,109,134,"Permeability, ultrastructural changes, and distribution of novel proteins in the glomerular barrier in early puromycin aminonucleoside nephrosis.",20588063_0,0
9871,plekhh2,45,52,"Nephrin decreased further, while dendrin and plekhh2 also decreased but a-actinin remained unchanged.",20588063_10,0
9870,dendrin,33,40,"Nephrin decreased further, while dendrin and plekhh2 also decreased but a-actinin remained unchanged.",20588063_10,0
9872,a-actinin,72,81,"Nephrin decreased further, while dendrin and plekhh2 also decreased but a-actinin remained unchanged.",20588063_10,0
9873,protective effect,34,51,ACE inhibition had no significant protective effect.,20588063_11,0
9874,PAN glomeruli,13,26,"CONCLUSIONS: PAN glomeruli already showed significant pathology by day 4, despite relatively mild proteinuria.",20588063_12,1
9875,mild proteinuria,93,109,"CONCLUSIONS: PAN glomeruli already showed significant pathology by day 4, despite relatively mild proteinuria.",20588063_12,1
9877,dendrin,19,26,"The novel proteins dendrin and plekhh2 were both reduced, suggesting roles in PAN, whereas a-actinin was unchanged.",20588063_14,0
9878,plekhh2,31,38,"The novel proteins dendrin and plekhh2 were both reduced, suggesting roles in PAN, whereas a-actinin was unchanged.",20588063_14,0
9879,a-actinin,91,100,"The novel proteins dendrin and plekhh2 were both reduced, suggesting roles in PAN, whereas a-actinin was unchanged.",20588063_14,0
9857,dendrin,199,206,"Using puromycin aminonucleoside nephrosis (PAN) rats, we studied early ultrastructural and permeability changes in relation to the expression of the podocyte-associated molecules nephrin, a-actinin, dendrin, and plekhh2, the last two of which were only recently discovered in podocytes.",20588063_2,0
9856,a-actinin,188,197,"Using puromycin aminonucleoside nephrosis (PAN) rats, we studied early ultrastructural and permeability changes in relation to the expression of the podocyte-associated molecules nephrin, a-actinin, dendrin, and plekhh2, the last two of which were only recently discovered in podocytes.",20588063_2,0
9858,plekhh2,212,219,"Using puromycin aminonucleoside nephrosis (PAN) rats, we studied early ultrastructural and permeability changes in relation to the expression of the podocyte-associated molecules nephrin, a-actinin, dendrin, and plekhh2, the last two of which were only recently discovered in podocytes.",20588063_2,0
2398,puromycin aminonucleoside,6,31,"Using puromycin aminonucleoside nephrosis (PAN) rats, we studied early ultrastructural and permeability changes in relation to the expression of the podocyte-associated molecules nephrin, a-actinin, dendrin, and plekhh2, the last two of which were only recently discovered in podocytes.",20588063_2,0
9864,foot process effacement,31,54,"RESULTS: By day 2, some patchy foot process effacement, but no proteinuria, appeared.",20588063_6,1
9868,foot process effacement,10,33,"By day 4, foot process effacement was complete and proteinuria appeared in parallel with signs of size barrier damage.",20588063_9,1
9885,stereotypies,161,173,"BACKGROUND: Current animal models of obsessive-compulsive disorder (OCD) typically involve acute, drug-induced symptom provocation or a genetic association with stereotypies or anxiety.",20619828_1,1
6030,drug-induced,98,110,"BACKGROUND: Current animal models of obsessive-compulsive disorder (OCD) typically involve acute, drug-induced symptom provocation or a genetic association with stereotypies or anxiety.",20619828_1,1
9882,obsessive-compulsive disorder,37,66,"BACKGROUND: Current animal models of obsessive-compulsive disorder (OCD) typically involve acute, drug-induced symptom provocation or a genetic association with stereotypies or anxiety.",20619828_1,1
9886,tricyclic antidepressant clomipramine,45,82,METHODS: Neonatal rats were treated with the tricyclic antidepressant clomipramine or vehicle between days 9 and 16 twice daily and behaviorally tested in adulthood.,20619828_3,0
9888,behavioral inflexibility,175,199,"RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction.",20619828_4,1
9890,working memory impairment,284,309,"RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction.",20619828_4,1
9889,reversal learning,264,281,"RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction.",20619828_4,1
9891,corticostriatal dysfunction,352,379,"RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction.",20619828_4,1
9892,orbital frontal cortex,128,150,"Dopamine D2 receptors were elevated in the striatum, whereas serotonin 2C, but not serotonin 1A, receptors were elevated in the orbital frontal cortex.",20619828_5,1
2401,serotonin 1A,83,95,"Dopamine D2 receptors were elevated in the striatum, whereas serotonin 2C, but not serotonin 1A, receptors were elevated in the orbital frontal cortex.",20619828_5,0
2400,serotonin 2C,61,73,"Dopamine D2 receptors were elevated in the striatum, whereas serotonin 2C, but not serotonin 1A, receptors were elevated in the orbital frontal cortex.",20619828_5,0
2399,Dopamine D2 receptors,0,21,"Dopamine D2 receptors were elevated in the striatum, whereas serotonin 2C, but not serotonin 1A, receptors were elevated in the orbital frontal cortex.",20619828_5,0
9897,drug exposure,42,55,"This novel model of OCD demonstrates that drug exposure during a sensitive period can program disease-like systems permanently, which could have implications for current and future therapeutic strategies for this and other psychiatric disorders.",20619828_8,1
9900,psychiatric disorders,223,244,"This novel model of OCD demonstrates that drug exposure during a sensitive period can program disease-like systems permanently, which could have implications for current and future therapeutic strategies for this and other psychiatric disorders.",20619828_8,1
9899,therapeutic strategies,181,203,"This novel model of OCD demonstrates that drug exposure during a sensitive period can program disease-like systems permanently, which could have implications for current and future therapeutic strategies for this and other psychiatric disorders.",20619828_8,0
9901,ADAM10,13,19,"Elevation of ADAM10, ADAM17, MMP-2 and MMP-9 expression with media degeneration features CaCl2-induced thoracic aortic aneurysm in a rat model.",20621845_0,0
2403,MMP-2,29,34,"Elevation of ADAM10, ADAM17, MMP-2 and MMP-9 expression with media degeneration features CaCl2-induced thoracic aortic aneurysm in a rat model.",20621845_0,0
2404,MMP-9,39,44,"Elevation of ADAM10, ADAM17, MMP-2 and MMP-9 expression with media degeneration features CaCl2-induced thoracic aortic aneurysm in a rat model.",20621845_0,0
2402,ADAM17,21,27,"Elevation of ADAM10, ADAM17, MMP-2 and MMP-9 expression with media degeneration features CaCl2-induced thoracic aortic aneurysm in a rat model.",20621845_0,0
6031,thoracic aortic aneurysm,103,127,"Elevation of ADAM10, ADAM17, MMP-2 and MMP-9 expression with media degeneration features CaCl2-induced thoracic aortic aneurysm in a rat model.",20621845_0,1
2405,TAA,87,90,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",20621845_1,0
9902,calcium chloride,95,111,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",20621845_1,0
2406,disintegrin,185,196,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",20621845_1,0
9904,TIMPs,293,298,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",20621845_1,0
6032,thoracic aortic aneurysm,61,85,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",20621845_1,1
2410,TAA,303,306,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",20621845_1,0
2409,MMPs,254,258,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",20621845_1,0
2408,matrix metalloproteinases,227,252,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",20621845_1,0
2407,metalloproteinase,201,218,"PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation.",20621845_1,0
2411,normal saline,83,96,METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).,20621845_2,0
6033,Thoracic aorta,9,23,METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).,20621845_2,1
2412,NaCl,98,102,METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline (NaCl).,20621845_2,0
9908,MMP-TIMP,0,8,MMP-TIMP and ADAM mRNAs were semi-quantitatively analyzed and protein expressions were determined by immunohistochemistry.,20621845_4,0
9910,aneurymal,114,123,"RESULTS: Despite similar external diameters among CaCl(2)-treated, non-CaCl(2)-treated and NaCl-treated segments, aneurymal alteration (n=6, 50%), media degeneration with regional disruption, fragmentation of elastic fiber, and increased collagen deposition (n=12, 100%) were demonstrated in CaCl(2)-treated segments.",20621845_5,1
9911,media degeneration,147,165,"RESULTS: Despite similar external diameters among CaCl(2)-treated, non-CaCl(2)-treated and NaCl-treated segments, aneurymal alteration (n=6, 50%), media degeneration with regional disruption, fragmentation of elastic fiber, and increased collagen deposition (n=12, 100%) were demonstrated in CaCl(2)-treated segments.",20621845_5,1
9913,ADAM-10,14,21,"MMP-2, MMP-9, ADAM-10 and ADAM-17 mRNA levels were increased in CaCl(2)-treated segments (all p<0.01), with trends of elevation in CaCl(2)-untreated segments, as compared with NaCl-treated segments.",20621845_6,0
9914,ADAM-17 mRNA,26,38,"MMP-2, MMP-9, ADAM-10 and ADAM-17 mRNA levels were increased in CaCl(2)-treated segments (all p<0.01), with trends of elevation in CaCl(2)-untreated segments, as compared with NaCl-treated segments.",20621845_6,0
2413,MMP-2,0,5,"MMP-2, MMP-9, ADAM-10 and ADAM-17 mRNA levels were increased in CaCl(2)-treated segments (all p<0.01), with trends of elevation in CaCl(2)-untreated segments, as compared with NaCl-treated segments.",20621845_6,0
2414,MMP-9,7,12,"MMP-2, MMP-9, ADAM-10 and ADAM-17 mRNA levels were increased in CaCl(2)-treated segments (all p<0.01), with trends of elevation in CaCl(2)-untreated segments, as compared with NaCl-treated segments.",20621845_6,0
2415,MMP-2,70,75,"Immunohistochemistry displayed significantly increased expressions of MMP-2, MMP-9, ADAM-10 and ADAM-17 (all p<0.01) in intima and media for CaCl(2)-treated segments.",20621845_7,0
9915,ADAM-10,84,91,"Immunohistochemistry displayed significantly increased expressions of MMP-2, MMP-9, ADAM-10 and ADAM-17 (all p<0.01) in intima and media for CaCl(2)-treated segments.",20621845_7,0
2416,MMP-9,77,82,"Immunohistochemistry displayed significantly increased expressions of MMP-2, MMP-9, ADAM-10 and ADAM-17 (all p<0.01) in intima and media for CaCl(2)-treated segments.",20621845_7,0
2417,ADAM-17,96,103,"Immunohistochemistry displayed significantly increased expressions of MMP-2, MMP-9, ADAM-10 and ADAM-17 (all p<0.01) in intima and media for CaCl(2)-treated segments.",20621845_7,0
9916,TIMP mRNA,0,9,TIMP mRNA and tissue levels did not differ obviously among the three aortic segments.,20621845_8,0
2418,TAA,37,40,"CONCLUSION: This study establishes a TAA model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.",20621845_9,0
2419,MMP-2,147,152,"CONCLUSION: This study establishes a TAA model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.",20621845_9,0
2420,MMP-9,154,159,"CONCLUSION: This study establishes a TAA model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.",20621845_9,0
2421,ADAM17,172,178,"CONCLUSION: This study establishes a TAA model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.",20621845_9,0
6034,vascular remodeling,202,221,"CONCLUSION: This study establishes a TAA model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.",20621845_9,1
9920,ADAM10,161,167,"CONCLUSION: This study establishes a TAA model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.",20621845_9,0
9918,periarterial,50,62,"CONCLUSION: This study establishes a TAA model by periarterial CaCl(2) exposure in rats, and demonstrates a significant elevation of expression of MMP-2, MMP-9, ADAM10 and ADAM17 in the pathogenesis of vascular remodeling.",20621845_9,1
2422,Suxamethonium,0,13,Suxamethonium induced prolonged apnea in a patient receiving electroconvulsive therapy.,20633755_0,0
2424,organophosphorus,105,121,Suxamethonium causes prolonged apnea in patients in whom pseudocholinesterase enzyme gets deactivated by organophosphorus (OP) poisons.,20633755_1,0
9922,pseudocholinesterase enzyme,57,84,Suxamethonium causes prolonged apnea in patients in whom pseudocholinesterase enzyme gets deactivated by organophosphorus (OP) poisons.,20633755_1,0
2423,Suxamethonium,0,13,Suxamethonium causes prolonged apnea in patients in whom pseudocholinesterase enzyme gets deactivated by organophosphorus (OP) poisons.,20633755_1,0
9923,severely depressed,41,59,"Here, we present a similar incident in a severely depressed patient who received electroconvulsive therapy (ECT).",20633755_2,1
9927,OP compound,85,96,Prolonged apnea in our case ensued because the information about suicidal attempt by OP compound was concealed from the treating team.,20633755_3,0
9926,suicidal attempt,65,81,Prolonged apnea in our case ensued because the information about suicidal attempt by OP compound was concealed from the treating team.,20633755_3,1
9925,Prolonged apnea,0,15,Prolonged apnea in our case ensued because the information about suicidal attempt by OP compound was concealed from the treating team.,20633755_3,1
6035,congestive heart failure,7,31,Severe congestive heart failure patient on amiodarone presenting with myxedemic coma: a case report.,20635749_0,1
9931,myxedema coma,25,38,This is a case report of myxedema coma secondary to amiodarone-induced hypothyroidism in a patient with severe congestive heart failure (CHF).,20635749_1,1
6036,congestive heart failure,111,135,This is a case report of myxedema coma secondary to amiodarone-induced hypothyroidism in a patient with severe congestive heart failure (CHF).,20635749_1,1
9933,CHF,137,140,This is a case report of myxedema coma secondary to amiodarone-induced hypothyroidism in a patient with severe congestive heart failure (CHF).,20635749_1,0
6037,long term,101,110,To our knowledge and after reviewing the literature there is one case report of myxedema coma during long term amiodarone therapy.,20635749_2,1
9935,myxedema coma,80,93,To our knowledge and after reviewing the literature there is one case report of myxedema coma during long term amiodarone therapy.,20635749_2,1
9937,life threatening,19,35,Myxedema coma is a life threatening condition that carries a mortality reaching as high as 20% with treatment.,20635749_3,1
9936,Myxedema coma,0,13,Myxedema coma is a life threatening condition that carries a mortality reaching as high as 20% with treatment.,20635749_3,1
2425,T4,53,55,The condition is treated with intravenous thyroxine (T4) or intravenous tri-iodo-thyronine (T3).,20635749_4,0
2426,T3,92,94,The condition is treated with intravenous thyroxine (T4) or intravenous tri-iodo-thyronine (T3).,20635749_4,0
9940,thyroid stimulating hormone,138,165,"Patients with CHF on amiodarone may suffer serious morbidity and mortality from hypothyroidism, and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels.",20635749_5,0
9938,CHF,14,17,"Patients with CHF on amiodarone may suffer serious morbidity and mortality from hypothyroidism, and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels.",20635749_5,0
9942,CHF,104,107,This case report carries an important clinical application given the frequent usage of amiodarone among CHF patients.,20635749_6,0
9946,clinical syndrome,124,141,"The myriad clinical presentation of myxedema coma and its serious morbidity and mortality stresses the need to suspect this clinical syndrome among CHF patients presenting with hypotension, weakness or other unexplained symptoms.",20635749_7,1
9944,myxedema coma,36,49,"The myriad clinical presentation of myxedema coma and its serious morbidity and mortality stresses the need to suspect this clinical syndrome among CHF patients presenting with hypotension, weakness or other unexplained symptoms.",20635749_7,1
9943,clinical presentation,11,32,"The myriad clinical presentation of myxedema coma and its serious morbidity and mortality stresses the need to suspect this clinical syndrome among CHF patients presenting with hypotension, weakness or other unexplained symptoms.",20635749_7,1
9947,CHF,148,151,"The myriad clinical presentation of myxedema coma and its serious morbidity and mortality stresses the need to suspect this clinical syndrome among CHF patients presenting with hypotension, weakness or other unexplained symptoms.",20635749_7,0
6038,unexplained symptoms,208,228,"The myriad clinical presentation of myxedema coma and its serious morbidity and mortality stresses the need to suspect this clinical syndrome among CHF patients presenting with hypotension, weakness or other unexplained symptoms.",20635749_7,1
6039,cognitive dysfunction,21,42,Curcumin ameliorates cognitive dysfunction and oxidative damage in phenobarbitone and carbamazepine administered rats.,20667451_0,1
9948,oxidative damage,47,63,Curcumin ameliorates cognitive dysfunction and oxidative damage in phenobarbitone and carbamazepine administered rats.,20667451_0,1
9949,carbamazepine,86,99,Curcumin ameliorates cognitive dysfunction and oxidative damage in phenobarbitone and carbamazepine administered rats.,20667451_0,0
2427,Curcumin,0,8,Curcumin ameliorates cognitive dysfunction and oxidative damage in phenobarbitone and carbamazepine administered rats.,20667451_0,0
6040,cognitive impairment,82,102,"The antiepileptic drugs, phenobarbitone and carbamazepine are well known to cause cognitive impairment on chronic use.",20667451_1,1
9950,carbamazepine,44,57,"The antiepileptic drugs, phenobarbitone and carbamazepine are well known to cause cognitive impairment on chronic use.",20667451_1,0
2428,antiepileptic drugs,4,23,"The antiepileptic drugs, phenobarbitone and carbamazepine are well known to cause cognitive impairment on chronic use.",20667451_1,0
9961,oxidative stress,99,115,Concomitant curcumin administration prevented the cognitive impairment and decreased the increased oxidative stress induced by these antiepileptic drugs.,20667451_10,1
6043,cognitive impairment,50,70,Concomitant curcumin administration prevented the cognitive impairment and decreased the increased oxidative stress induced by these antiepileptic drugs.,20667451_10,1
2439,antiepileptic drugs,133,152,Concomitant curcumin administration prevented the cognitive impairment and decreased the increased oxidative stress induced by these antiepileptic drugs.,20667451_10,0
2438,curcumin,12,20,Concomitant curcumin administration prevented the cognitive impairment and decreased the increased oxidative stress induced by these antiepileptic drugs.,20667451_10,0
9963,carbamazepine,130,143,Curcumin co-administration did not cause any significant alteration in the serum concentrations of both phenobarbitone as well as carbamazepine.,20667451_11,0
2440,Curcumin,0,8,Curcumin co-administration did not cause any significant alteration in the serum concentrations of both phenobarbitone as well as carbamazepine.,20667451_11,0
2441,curcumin,24,32,These results show that curcumin has beneficial effect in mitigating the deterioration of cognitive functions and oxidative damage in rats treated with phenobarbitone and carbamazepine without significantly altering their serum concentrations.,20667451_12,0
9964,cognitive functions,90,109,These results show that curcumin has beneficial effect in mitigating the deterioration of cognitive functions and oxidative damage in rats treated with phenobarbitone and carbamazepine without significantly altering their serum concentrations.,20667451_12,1
9965,oxidative damage,114,130,These results show that curcumin has beneficial effect in mitigating the deterioration of cognitive functions and oxidative damage in rats treated with phenobarbitone and carbamazepine without significantly altering their serum concentrations.,20667451_12,1
9966,carbamazepine,171,184,These results show that curcumin has beneficial effect in mitigating the deterioration of cognitive functions and oxidative damage in rats treated with phenobarbitone and carbamazepine without significantly altering their serum concentrations.,20667451_12,0
2442,curcumin,26,34,The findings suggest that curcumin can be considered as a potential safe and effective adjuvant to phenobarbitone and carbamazepine therapy in preventing cognitive impairment associated with these drugs.,20667451_13,0
9967,carbamazepine,118,131,The findings suggest that curcumin can be considered as a potential safe and effective adjuvant to phenobarbitone and carbamazepine therapy in preventing cognitive impairment associated with these drugs.,20667451_13,0
6044,cognitive impairment,154,174,The findings suggest that curcumin can be considered as a potential safe and effective adjuvant to phenobarbitone and carbamazepine therapy in preventing cognitive impairment associated with these drugs.,20667451_13,1
2430,antiepileptic drugs,122,141,The increase in free radical generation has been implicated as one of the important mechanisms of cognitive impairment by antiepileptic drugs.,20667451_2,0
6041,cognitive impairment,98,118,The increase in free radical generation has been implicated as one of the important mechanisms of cognitive impairment by antiepileptic drugs.,20667451_2,1
2429,free radical,16,28,The increase in free radical generation has been implicated as one of the important mechanisms of cognitive impairment by antiepileptic drugs.,20667451_2,0
2431,Curcumin,0,8,"Curcumin has shown antioxidant, anti-inflammatory and neuro-protective properties.",20667451_3,0
2432,neuro-protective,54,70,"Curcumin has shown antioxidant, anti-inflammatory and neuro-protective properties.",20667451_3,0
6042,cognitive impairment,151,171,"Therefore, the present study was carried out to investigate the effect of chronic curcumin administration on phenobarbitone- and carbamazepine-induced cognitive impairment and oxidative stress in rats.",20667451_4,1
9952,oxidative stress,176,192,"Therefore, the present study was carried out to investigate the effect of chronic curcumin administration on phenobarbitone- and carbamazepine-induced cognitive impairment and oxidative stress in rats.",20667451_4,1
2433,curcumin,82,90,"Therefore, the present study was carried out to investigate the effect of chronic curcumin administration on phenobarbitone- and carbamazepine-induced cognitive impairment and oxidative stress in rats.",20667451_4,0
2434,phenobarbitone-,109,124,"Therefore, the present study was carried out to investigate the effect of chronic curcumin administration on phenobarbitone- and carbamazepine-induced cognitive impairment and oxidative stress in rats.",20667451_4,0
2435,curcumin,32,40,Pharmacokinetic interactions of curcumin with phenobarbitone and carbamazepine were also studied.,20667451_5,0
9953,carbamazepine,65,78,Pharmacokinetic interactions of curcumin with phenobarbitone and carbamazepine were also studied.,20667451_5,0
9954,Vehicle/drugs,0,13,Vehicle/drugs were administered daily for 21days to male Wistar rats.,20667451_6,0
9956,cognitive function,75,93,Passive avoidance paradigm and elevated plus maze test were used to assess cognitive function.,20667451_7,1
9955,Passive avoidance,0,17,Passive avoidance paradigm and elevated plus maze test were used to assess cognitive function.,20667451_7,1
2436,malondialdehyde,80,95,"At the end of study period, serum phenobarbitone and carbamazepine, whole brain malondialdehyde and reduced glutathione levels were estimated.",20667451_8,0
9957,serum phenobarbitone,28,48,"At the end of study period, serum phenobarbitone and carbamazepine, whole brain malondialdehyde and reduced glutathione levels were estimated.",20667451_8,0
2437,reduced glutathione,100,119,"At the end of study period, serum phenobarbitone and carbamazepine, whole brain malondialdehyde and reduced glutathione levels were estimated.",20667451_8,0
9958,carbamazepine,53,66,"At the end of study period, serum phenobarbitone and carbamazepine, whole brain malondialdehyde and reduced glutathione levels were estimated.",20667451_8,0
9959,carbamazepine,41,54,The administration of phenobarbitone and carbamazepine for 21days caused a significant impairment of learning and memory as well as an increased oxidative stress.,20667451_9,0
9960,oxidative stress,145,161,The administration of phenobarbitone and carbamazepine for 21days caused a significant impairment of learning and memory as well as an increased oxidative stress.,20667451_9,1
9971,crocin,53,59,"Effects of active constituents of Crocus sativus L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats.",20683499_0,0
9969,active constituents,11,30,"Effects of active constituents of Crocus sativus L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats.",20683499_0,0
6045,Alzheimer's disease,102,121,"Effects of active constituents of Crocus sativus L., crocin on streptozocin-induced model of sporadic Alzheimer's disease in male rats.",20683499_0,1
9973,crocins,58,65,"BACKGROUND: The involvement of water-soluble carotenoids, crocins, as the main and active components of Crocus sativus L. extract in learning and memory processes has been proposed.",20683499_1,0
9974,active components,83,100,"BACKGROUND: The involvement of water-soluble carotenoids, crocins, as the main and active components of Crocus sativus L. extract in learning and memory processes has been proposed.",20683499_1,0
9972,water-soluble carotenoids,31,56,"BACKGROUND: The involvement of water-soluble carotenoids, crocins, as the main and active components of Crocus sativus L. extract in learning and memory processes has been proposed.",20683499_1,0
6048,neurodegenerative diseases,191,217,"CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.",20683499_10,1
10005,cognitive deficits,108,126,"CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.",20683499_10,1
6049,Alzheimer's disease,226,245,"CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.",20683499_10,1
10004,crocin,70,76,"CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease.",20683499_10,0
6046,Alzheimer's disease,56,75,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.",20683499_2,1
9977,crocins,36,43,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.",20683499_2,0
9978,intracerebroventricular,87,110,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.",20683499_2,1
9979,streptozocin,117,129,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.",20683499_2,0
9980,STZ,131,134,"In the present study, the effect of crocins on sporadic Alzheimer's disease induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated.",20683499_2,0
9982,crocins,94,101,"METHODS: Male adult Wistar rats (n = 90 and 260-290 g) were divided into 1, control; 2 and 3, crocins (15 and 30 mg/kg); 4, STZ; 5 and 6, STZ + crocins (15 and 30 mg/kg) groups.",20683499_3,0
9985,crocins,144,151,"METHODS: Male adult Wistar rats (n = 90 and 260-290 g) were divided into 1, control; 2 and 3, crocins (15 and 30 mg/kg); 4, STZ; 5 and 6, STZ + crocins (15 and 30 mg/kg) groups.",20683499_3,0
2443,(3,75,77,"In Alzheimer's disease groups, rats were injected with STZ-icv bilaterally (3 mg/kg) in first day and 3 days later, a similar STZ-icv application was repeated.",20683499_4,0
6047,Alzheimer's disease,3,22,"In Alzheimer's disease groups, rats were injected with STZ-icv bilaterally (3 mg/kg) in first day and 3 days later, a similar STZ-icv application was repeated.",20683499_4,1
9989,crocin,9,15,"In STZ + crocin animal groups, crocin was applied in doses of 15 and 30 mg/kg, i.p., one day pre-surgery and continued for three weeks.",20683499_5,0
9990,crocin,31,37,"In STZ + crocin animal groups, crocin was applied in doses of 15 and 30 mg/kg, i.p., one day pre-surgery and continued for three weeks.",20683499_5,0
9992,pre-surgery,93,104,"In STZ + crocin animal groups, crocin was applied in doses of 15 and 30 mg/kg, i.p., one day pre-surgery and continued for three weeks.",20683499_5,1
9993,crocin,16,22,Prescription of crocin in each dose was repeated once for two days.,20683499_6,0
9996,spatial cognition,100,117,"However, the learning and memory performance was assessed using passive avoidance paradigm, and for spatial cognition evaluation, Y-maze task was used.",20683499_7,1
9995,passive avoidance,64,81,"However, the learning and memory performance was assessed using passive avoidance paradigm, and for spatial cognition evaluation, Y-maze task was used.",20683499_7,1
9998,crocin,31,37,RESULTS: It was found out that crocin (30 mg/kg)-treated STZ-injected rats show higher correct choices and lower errors in Y-maze than vehicle-treated STZ-injected rats.,20683499_8,0
10001,crocin,13,19,"In addition, crocin in the mentioned dose could significantly attenuated learning and memory impairment in treated STZ-injected group in passive avoidance test.",20683499_9,0
10002,memory impairment,86,103,"In addition, crocin in the mentioned dose could significantly attenuated learning and memory impairment in treated STZ-injected group in passive avoidance test.",20683499_9,1
2444,angiogenesis inhibitors,175,198,Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis.,20698227_0,0
2445,sunitinib,207,216,Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis.,20698227_0,0
10007,sorafenib,221,230,Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis.,20698227_0,0
10008,acute hemolysis,256,271,Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis.,20698227_0,1
2446,interferon alpha,97,113,METHODS: Fourteen patients chronically infected with hepatitis C virus were treated by pegylated interferon alpha 2a and ribavirin.,20698227_2,0
6050,hepatitis C,53,64,METHODS: Fourteen patients chronically infected with hepatitis C virus were treated by pegylated interferon alpha 2a and ribavirin.,20698227_2,1
2447,vascular endothelial growth factor,58,92,"Serum hemoglobin, haptoglobin and angiogenesis markers of vascular endothelial growth factor and angiopoetin-2 were investigated before and after therapy.",20698227_3,0
10010,angiopoetin-2,97,110,"Serum hemoglobin, haptoglobin and angiogenesis markers of vascular endothelial growth factor and angiopoetin-2 were investigated before and after therapy.",20698227_3,0
10009,Serum hemoglobin,0,16,"Serum hemoglobin, haptoglobin and angiogenesis markers of vascular endothelial growth factor and angiopoetin-2 were investigated before and after therapy.",20698227_3,0
6051,hepatitis C,158,169,CONCLUSION: This is the first study in the literature investigating a link between angiogenesis soluble markers and ribavirin induced anemia in patients with hepatitis C and we could not find any relation.,20698227_8,1
10016,cardiac catheterization,82,105,Reduction in injection pain using buffered lidocaine as a local anesthetic before cardiac catheterization.,2070391_0,1
10015,injection pain,13,27,Reduction in injection pain using buffered lidocaine as a local anesthetic before cardiac catheterization.,2070391_0,1
2448,local anesthetic,58,74,Reduction in injection pain using buffered lidocaine as a local anesthetic before cardiac catheterization.,2070391_0,0
10018,buffering solution,34,52,"To determine if the addition of a buffering solution to adjust the pH of lidocaine into the physiologic range would reduce pain during injection, we performed a blinded randomized study in patients undergoing cardiac catheterization.",2070391_2,0
10029,psychotic disorders,103,122,BACKGROUND: Altered serotonergic neural transmission is hypothesized to be a susceptibility factor for psychotic disorders such as schizophrenia.,20705401_1,1
10051,rs6693503,80,89,"In the haplotype-wise analysis, we detected an association between two markers (rs6693503 and rs1805054) and three markers (rs6693503, rs1805054 and rs4912138) in HTR6 and METH-induced psychosis patients, respectively.",20705401_11,0
10052,rs1805054,94,103,"In the haplotype-wise analysis, we detected an association between two markers (rs6693503 and rs1805054) and three markers (rs6693503, rs1805054 and rs4912138) in HTR6 and METH-induced psychosis patients, respectively.",20705401_11,0
10053,rs6693503,124,133,"In the haplotype-wise analysis, we detected an association between two markers (rs6693503 and rs1805054) and three markers (rs6693503, rs1805054 and rs4912138) in HTR6 and METH-induced psychosis patients, respectively.",20705401_11,0
10056,HTR6,163,167,"In the haplotype-wise analysis, we detected an association between two markers (rs6693503 and rs1805054) and three markers (rs6693503, rs1805054 and rs4912138) in HTR6 and METH-induced psychosis patients, respectively.",20705401_11,0
10054,rs1805054,135,144,"In the haplotype-wise analysis, we detected an association between two markers (rs6693503 and rs1805054) and three markers (rs6693503, rs1805054 and rs4912138) in HTR6 and METH-induced psychosis patients, respectively.",20705401_11,0
10055,rs4912138,149,158,"In the haplotype-wise analysis, we detected an association between two markers (rs6693503 and rs1805054) and three markers (rs6693503, rs1805054 and rs4912138) in HTR6 and METH-induced psychosis patients, respectively.",20705401_11,0
6053,pathophysiology,51,66,CONCLUSION: HTR6 may play an important role in the pathophysiology of METH-induced psychosis in the Japanese population.,20705401_12,1
10058,HTR6,12,16,CONCLUSION: HTR6 may play an important role in the pathophysiology of METH-induced psychosis in the Japanese population.,20705401_12,0
10030,serotonin 6,4,15,"The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.",20705401_2,0
2449,olanzapine,128,138,"The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.",20705401_2,0
2450,receptor antagonist,235,254,"The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.",20705401_2,0
10031,second generation antipsychotics,72,104,"The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist.",20705401_2,0
2451,d-amphetamine,58,71,"In addition, the disrupted prepulse inhibition induced by d-amphetamine or phencyclidine was restored by 5-HT6 receptor antagonist in an animal study using rats.",20705401_3,0
2452,receptor antagonist,111,130,"In addition, the disrupted prepulse inhibition induced by d-amphetamine or phencyclidine was restored by 5-HT6 receptor antagonist in an animal study using rats.",20705401_3,0
10034,5-HT6 receptors,132,147,"These animal models were considered to reflect the positive symptoms of schizophrenia, and the above evidence suggests that altered 5-HT6 receptors are involved in the pathophysiology of psychotic disorders.",20705401_4,0
10035,psychotic disorders,187,206,"These animal models were considered to reflect the positive symptoms of schizophrenia, and the above evidence suggests that altered 5-HT6 receptors are involved in the pathophysiology of psychotic disorders.",20705401_4,1
6052,pathophysiology,168,183,"These animal models were considered to reflect the positive symptoms of schizophrenia, and the above evidence suggests that altered 5-HT6 receptors are involved in the pathophysiology of psychotic disorders.",20705401_4,1
10039,rs6693503,33,42,"METHOD: Using five tagging SNPs (rs6693503, rs1805054, rs4912138, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 METH-induced psychosis patients and 337 controls) in the Japanese population.",20705401_7,0
10043,rs9659997,80,89,"METHOD: Using five tagging SNPs (rs6693503, rs1805054, rs4912138, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 METH-induced psychosis patients and 337 controls) in the Japanese population.",20705401_7,0
10042,rs3790757,66,75,"METHOD: Using five tagging SNPs (rs6693503, rs1805054, rs4912138, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 METH-induced psychosis patients and 337 controls) in the Japanese population.",20705401_7,0
10041,rs4912138,55,64,"METHOD: Using five tagging SNPs (rs6693503, rs1805054, rs4912138, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 METH-induced psychosis patients and 337 controls) in the Japanese population.",20705401_7,0
10040,rs1805054,44,53,"METHOD: Using five tagging SNPs (rs6693503, rs1805054, rs4912138, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 METH-induced psychosis patients and 337 controls) in the Japanese population.",20705401_7,0
10047,rs6693503,9,18,RESULTS: rs6693503 was associated with METH-induced psychosis patients in the allele/genotype-wise analysis.,20705401_9,0
2453,L-alpha-glyceryl-phosphorylcholine,10,44,Effect of L-alpha-glyceryl-phosphorylcholine on amnesia caused by scopolamine.,2071257_0,0
10061,L-alpha-GFC,92,103,The present study was carried out to test the effects of L-alpha-glycerylphosphorylcholine (L-alpha-GFC) on memory impairment induced by scopolamine in man.,2071257_1,0
2454,L-alpha-glycerylphosphorylcholine,57,90,The present study was carried out to test the effects of L-alpha-glycerylphosphorylcholine (L-alpha-GFC) on memory impairment induced by scopolamine in man.,2071257_1,0
10062,memory impairment,108,125,The present study was carried out to test the effects of L-alpha-glycerylphosphorylcholine (L-alpha-GFC) on memory impairment induced by scopolamine in man.,2071257_1,1
10065,L-alpha-GFC,51,62,"They were given a ten day pretreatment with either L-alpha-GFC or placebo, p.o., and on the eleventh day either scopolamine or placebo, i.m.",2071257_3,0
2455,capecitabine,10,22,Safety of capecitabine: a review.,20722491_0,0
10067,Fluoropyrimidines,25,42,"IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (5-FU), have been the mainstay of treatment for several solid tumors, including colorectal, breast and head and neck cancers, for > 40 years.",20722491_1,0
10068,5-fluorouracil,58,72,"IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (5-FU), have been the mainstay of treatment for several solid tumors, including colorectal, breast and head and neck cancers, for > 40 years.",20722491_1,0
10069,5-FU,74,78,"IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (5-FU), have been the mainstay of treatment for several solid tumors, including colorectal, breast and head and neck cancers, for > 40 years.",20722491_1,0
10070,solid tumors,129,141,"IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (5-FU), have been the mainstay of treatment for several solid tumors, including colorectal, breast and head and neck cancers, for > 40 years.",20722491_1,1
10071,head and neck cancers,176,197,"IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (5-FU), have been the mainstay of treatment for several solid tumors, including colorectal, breast and head and neck cancers, for > 40 years.",20722491_1,1
2456,capecitabine,84,96,AREAS COVERED IN THIS REVIEW: This article reviews the pharmacology and efficacy of capecitabine with a special emphasis on its safety.,20722491_2,0
2457,capecitabine,82,94,"WHAT THE READER WILL GAIN: The reader will gain better insight into the safety of capecitabine in special populations such as patients with advanced age, renal and kidney disease.",20722491_3,0
10073,advanced age,140,152,"WHAT THE READER WILL GAIN: The reader will gain better insight into the safety of capecitabine in special populations such as patients with advanced age, renal and kidney disease.",20722491_3,1
6054,kidney disease,164,178,"WHAT THE READER WILL GAIN: The reader will gain better insight into the safety of capecitabine in special populations such as patients with advanced age, renal and kidney disease.",20722491_3,1
2458,capecitabine,50,62,We also explore different dosing and schedules of capecitabine administration.,20722491_4,0
2459,Capecitabine,19,31,TAKE HOME MESSAGE: Capecitabine is an oral prodrug of 5-FU and was developed to fulfill the need for a more convenient therapy and provide an improved safety/efficacy profile.,20722491_5,0
2460,prodrug,43,50,TAKE HOME MESSAGE: Capecitabine is an oral prodrug of 5-FU and was developed to fulfill the need for a more convenient therapy and provide an improved safety/efficacy profile.,20722491_5,0
10074,5-FU,54,58,TAKE HOME MESSAGE: Capecitabine is an oral prodrug of 5-FU and was developed to fulfill the need for a more convenient therapy and provide an improved safety/efficacy profile.,20722491_5,0
6055,pancreaticobiliary,113,131,"It has shown promising results alone or in combination with other chemotherapeutic agents in colorectal, breast, pancreaticobiliary, gastric, renal cell and head and neck cancers.",20722491_6,1
6056,renal cell,142,152,"It has shown promising results alone or in combination with other chemotherapeutic agents in colorectal, breast, pancreaticobiliary, gastric, renal cell and head and neck cancers.",20722491_6,1
10075,chemotherapeutic agents,66,89,"It has shown promising results alone or in combination with other chemotherapeutic agents in colorectal, breast, pancreaticobiliary, gastric, renal cell and head and neck cancers.",20722491_6,0
10076,head and neck cancers,157,178,"It has shown promising results alone or in combination with other chemotherapeutic agents in colorectal, breast, pancreaticobiliary, gastric, renal cell and head and neck cancers.",20722491_6,1
10077,toxic effects,27,40,"The most commonly reported toxic effects of capecitabine are diarrhea, nausea, vomiting, stomatitis and hand-foot syndrome.",20722491_7,1
6057,hand-foot syndrome,104,122,"The most commonly reported toxic effects of capecitabine are diarrhea, nausea, vomiting, stomatitis and hand-foot syndrome.",20722491_7,1
2461,capecitabine,44,56,"The most commonly reported toxic effects of capecitabine are diarrhea, nausea, vomiting, stomatitis and hand-foot syndrome.",20722491_7,0
10078,"nausea, vomiting",71,87,"The most commonly reported toxic effects of capecitabine are diarrhea, nausea, vomiting, stomatitis and hand-foot syndrome.",20722491_7,1
10079,advanced age,92,104,"Capecitabine has a well-established safety profile and can be given safely to patients with advanced age, hepatic and renal dysfunctions.",20722491_8,1
10080,renal dysfunctions,118,136,"Capecitabine has a well-established safety profile and can be given safely to patients with advanced age, hepatic and renal dysfunctions.",20722491_8,1
2462,Capecitabine,0,12,"Capecitabine has a well-established safety profile and can be given safely to patients with advanced age, hepatic and renal dysfunctions.",20722491_8,0
10081,S-ketamine,21,31,Neural correlates of S-ketamine induced psychosis during overt continuous verbal fluency.,20727411_0,0
10082,verbal fluency,74,88,Neural correlates of S-ketamine induced psychosis during overt continuous verbal fluency.,20727411_0,1
2463,NMDA,40,44,The glutamatergic N-methyl-D-aspartate (NMDA) receptor has been implicated in the pathophysiology of schizophrenia.,20727411_1,0
10083,glutamatergic N-methyl-D-aspartate,4,38,The glutamatergic N-methyl-D-aspartate (NMDA) receptor has been implicated in the pathophysiology of schizophrenia.,20727411_1,0
6058,pathophysiology,82,97,The glutamatergic N-methyl-D-aspartate (NMDA) receptor has been implicated in the pathophysiology of schizophrenia.,20727411_1,1
6059,pathophysiology,94,109,Our results provide further support for the hypothesis of an NMDA receptor dysfunction in the pathophysiology of schizophrenia.,20727411_11,1
2465,NMDA receptor,61,74,Our results provide further support for the hypothesis of an NMDA receptor dysfunction in the pathophysiology of schizophrenia.,20727411_11,0
10086,non-competitive NMDA receptor antagonist,64,104,"Administered to healthy volunteers, a subanesthetic dose of the non-competitive NMDA receptor antagonist ketamine leads to psychopathological symptoms similar to those observed in schizophrenia.",20727411_2,0
10087,core symptoms,57,70,"In patients with schizophrenia, ketamine exacerbates the core symptoms of illness, supporting the hypothesis of a glutamatergic dysfunction.",20727411_3,1
2464,glutamatergic,114,127,"In patients with schizophrenia, ketamine exacerbates the core symptoms of illness, supporting the hypothesis of a glutamatergic dysfunction.",20727411_3,0
10092,verbal fluency,64,78,"During the scanning period, subjects performed continuous overt verbal fluency tasks (phonological, lexical and semantic).",20727411_5,1
10093,Ketamine-induced psychopathological,0,35,Ketamine-induced psychopathological symptoms were assessed with the Positive and Negative Syndrome Scale (PANSS).,20727411_6,1
10095,verbal fluency,142,156,"Post-hoc t-tests revealed significant differences between placebo and ketamine for the amounts of words generated during lexical and semantic verbal fluency, while the phonological domain remained unaffected.",20727411_8,1
10101,verbal fluency,155,169,"Ketamine led to enhanced cortical activations in supramarginal and frontal brain regions for phonological and lexical verbal fluency, but not for semantic verbal fluency.",20727411_9,1
10100,verbal fluency,118,132,"Ketamine led to enhanced cortical activations in supramarginal and frontal brain regions for phonological and lexical verbal fluency, but not for semantic verbal fluency.",20727411_9,1
10098,supramarginal,49,62,"Ketamine led to enhanced cortical activations in supramarginal and frontal brain regions for phonological and lexical verbal fluency, but not for semantic verbal fluency.",20727411_9,1
6060,acute liver failure,73,92,Long-term prognosis for transplant-free survivors of paracetamol-induced acute liver failure.,20735774_0,1
10104,transplant-free survivors,24,49,Long-term prognosis for transplant-free survivors of paracetamol-induced acute liver failure.,20735774_0,1
6061,acute liver failure,79,98,BACKGROUND: The prognosis for transplant-free survivors of paracetamol-induced acute liver failure remains unknown.,20735774_1,1
10105,transplant-free survivors,30,55,BACKGROUND: The prognosis for transplant-free survivors of paracetamol-induced acute liver failure remains unknown.,20735774_1,1
6075,liver failure,86,99,"Clinical follow-up may be justified by the cause of the liver failure, but not by the liver failure itself.",20735774_10,1
6074,liver failure,56,69,"Clinical follow-up may be justified by the cause of the liver failure, but not by the liver failure itself.",20735774_10,1
6062,acute liver failure,44,63,AIM: To examine whether paracetamol-induced acute liver failure increases long-term mortality.,20735774_2,1
6063,acute liver injury,77,95,"METHODS: We followed up all transplant-free survivors of paracetamol-induced acute liver injury, hospitalized in a Danish national referral centre during 1984-2004.",20735774_3,1
6065,acute liver failure,130,149,We compared age-specific mortality rates from 1 year post-discharge through 2008 between those in whom the liver injury led to an acute liver failure and those in whom it did not.,20735774_4,1
10110,post-discharge,53,67,We compared age-specific mortality rates from 1 year post-discharge through 2008 between those in whom the liver injury led to an acute liver failure and those in whom it did not.,20735774_4,1
6064,liver injury,107,119,We compared age-specific mortality rates from 1 year post-discharge through 2008 between those in whom the liver injury led to an acute liver failure and those in whom it did not.,20735774_4,1
6068,acute liver failure,273,292,"On average, age-specific mortality rates were slightly higher for the 101 patients whose paracetamol-induced liver injury had caused an acute liver failure (adjusted mortality rate ratio = 1.70, 95% CI 1.02-2.85), but the association was age-dependent, and no survivors of acute liver failure died of liver disease, whereas suicides were frequent in both groups.",20735774_6,1
6069,liver disease,301,314,"On average, age-specific mortality rates were slightly higher for the 101 patients whose paracetamol-induced liver injury had caused an acute liver failure (adjusted mortality rate ratio = 1.70, 95% CI 1.02-2.85), but the association was age-dependent, and no survivors of acute liver failure died of liver disease, whereas suicides were frequent in both groups.",20735774_6,1
6066,liver injury,109,121,"On average, age-specific mortality rates were slightly higher for the 101 patients whose paracetamol-induced liver injury had caused an acute liver failure (adjusted mortality rate ratio = 1.70, 95% CI 1.02-2.85), but the association was age-dependent, and no survivors of acute liver failure died of liver disease, whereas suicides were frequent in both groups.",20735774_6,1
10113,age-dependent,238,251,"On average, age-specific mortality rates were slightly higher for the 101 patients whose paracetamol-induced liver injury had caused an acute liver failure (adjusted mortality rate ratio = 1.70, 95% CI 1.02-2.85), but the association was age-dependent, and no survivors of acute liver failure died of liver disease, whereas suicides were frequent in both groups.",20735774_6,1
6067,acute liver failure,136,155,"On average, age-specific mortality rates were slightly higher for the 101 patients whose paracetamol-induced liver injury had caused an acute liver failure (adjusted mortality rate ratio = 1.70, 95% CI 1.02-2.85), but the association was age-dependent, and no survivors of acute liver failure died of liver disease, whereas suicides were frequent in both groups.",20735774_6,1
6070,acute liver failure,54,73,These observations speak against long-term effects of acute liver failure.,20735774_7,1
6071,substance abuse,113,128,"More likely, the elevated mortality rate ratio resulted from incomplete adjustment for the greater prevalence of substance abuse among survivors of acute liver failure.",20735774_8,1
6072,acute liver failure,148,167,"More likely, the elevated mortality rate ratio resulted from incomplete adjustment for the greater prevalence of substance abuse among survivors of acute liver failure.",20735774_8,1
6073,acute liver failure,33,52,CONCLUSIONS: Paracetamol-induced acute liver failure did not affect long-term mortality.,20735774_9,1
6076,Parkinson's disease,46,65,Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap.,20880751_0,1
6077,Parkinson's disease,57,76,Levodopa is the most effective drug for the treatment of Parkinson's disease.,20880751_1,1
10118,dopamine precursor,35,53,"However, the long-term use of this dopamine precursor is complicated by highly disabling fluctuations and dyskinesias.",20880751_2,0
6078,pulsatile,51,60,"Although preclinical and clinical findings suggest pulsatile stimulation of striatal postsynaptic receptors as a key mechanism underlying levodopa-induced dyskinesias, their pathogenesis is still unclear.",20880751_3,1
10120,striatal postsynaptic,76,97,"Although preclinical and clinical findings suggest pulsatile stimulation of striatal postsynaptic receptors as a key mechanism underlying levodopa-induced dyskinesias, their pathogenesis is still unclear.",20880751_3,1
6080,dyskinetic,218,228,"In recent years, evidence from animal models of Parkinson's disease has provided important information to understand the effect of specific receptor and post-receptor molecular mechanisms underlying the development of dyskinetic movements.",20880751_4,1
6079,Parkinson's disease,48,67,"In recent years, evidence from animal models of Parkinson's disease has provided important information to understand the effect of specific receptor and post-receptor molecular mechanisms underlying the development of dyskinetic movements.",20880751_4,1
2466,ionotropic,176,186,"Recent preclinical and clinical data from promising lines of research focus on the differential role of presynaptic versus postsynaptic mechanisms, dopamine receptor subtypes, ionotropic and metabotropic glutamate receptors, and non-dopaminergic neurotransmitter systems in the pathophysiology of levodopa-induced dyskinesias.",20880751_5,0
2467,metabotropic glutamate receptors,191,223,"Recent preclinical and clinical data from promising lines of research focus on the differential role of presynaptic versus postsynaptic mechanisms, dopamine receptor subtypes, ionotropic and metabotropic glutamate receptors, and non-dopaminergic neurotransmitter systems in the pathophysiology of levodopa-induced dyskinesias.",20880751_5,0
10123,presynaptic,104,115,"Recent preclinical and clinical data from promising lines of research focus on the differential role of presynaptic versus postsynaptic mechanisms, dopamine receptor subtypes, ionotropic and metabotropic glutamate receptors, and non-dopaminergic neurotransmitter systems in the pathophysiology of levodopa-induced dyskinesias.",20880751_5,1
10124,dopamine receptor subtypes,148,174,"Recent preclinical and clinical data from promising lines of research focus on the differential role of presynaptic versus postsynaptic mechanisms, dopamine receptor subtypes, ionotropic and metabotropic glutamate receptors, and non-dopaminergic neurotransmitter systems in the pathophysiology of levodopa-induced dyskinesias.",20880751_5,0
10125,non-dopaminergic,229,245,"Recent preclinical and clinical data from promising lines of research focus on the differential role of presynaptic versus postsynaptic mechanisms, dopamine receptor subtypes, ionotropic and metabotropic glutamate receptors, and non-dopaminergic neurotransmitter systems in the pathophysiology of levodopa-induced dyskinesias.",20880751_5,0
6082,pathophysiology,278,293,"Recent preclinical and clinical data from promising lines of research focus on the differential role of presynaptic versus postsynaptic mechanisms, dopamine receptor subtypes, ionotropic and metabotropic glutamate receptors, and non-dopaminergic neurotransmitter systems in the pathophysiology of levodopa-induced dyskinesias.",20880751_5,1
6081,postsynaptic,123,135,"Recent preclinical and clinical data from promising lines of research focus on the differential role of presynaptic versus postsynaptic mechanisms, dopamine receptor subtypes, ionotropic and metabotropic glutamate receptors, and non-dopaminergic neurotransmitter systems in the pathophysiology of levodopa-induced dyskinesias.",20880751_5,1
10128,pallidal neurotensin,11,31,Effects of pallidal neurotensin on haloperidol-induced parkinsonian catalepsy: behavioral and electrophysiological studies.,20882060_0,0
10129,haloperidol-induced parkinsonian catalepsy,35,77,Effects of pallidal neurotensin on haloperidol-induced parkinsonian catalepsy: behavioral and electrophysiological studies.,20882060_0,1
10131,globus pallidus,15,30,OBJECTIVE: The globus pallidus plays a critical role in movement regulation.,20882060_1,1
10134,neurotensin analog,147,165,"Previous studies have indicated that the globus pallidus receives neurotensinergic innervation from the striatum, and systemic administration of a neurotensin analog could produce antiparkinsonian effects.",20882060_2,0
2468,antiparkinsonian,180,196,"Previous studies have indicated that the globus pallidus receives neurotensinergic innervation from the striatum, and systemic administration of a neurotensin analog could produce antiparkinsonian effects.",20882060_2,0
10132,globus pallidus,41,56,"Previous studies have indicated that the globus pallidus receives neurotensinergic innervation from the striatum, and systemic administration of a neurotensin analog could produce antiparkinsonian effects.",20882060_2,1
10138,globus pallidus,53,68,RESULTS: Bilateral infusions of neurotensin into the globus pallidus reversed haloperidol-induced parkinsonian catalepsy in rats.,20882060_5,1
2469,neurotensin,32,43,RESULTS: Bilateral infusions of neurotensin into the globus pallidus reversed haloperidol-induced parkinsonian catalepsy in rats.,20882060_5,0
10142,systemic haloperidol,132,152,Electrophysiological recordings showed that microinjection of neurotensin induced excitation of pallidal neurons in the presence of systemic haloperidol administration.,20882060_6,0
10141,pallidal,96,104,Electrophysiological recordings showed that microinjection of neurotensin induced excitation of pallidal neurons in the presence of systemic haloperidol administration.,20882060_6,1
2470,neurotensin,62,73,Electrophysiological recordings showed that microinjection of neurotensin induced excitation of pallidal neurons in the presence of systemic haloperidol administration.,20882060_6,0
2472,neurotensin,127,138,The neurotensin type-1 receptor antagonist SR48692 blocked both the behavioral and the electrophysiological effects induced by neurotensin.,20882060_7,0
10143,receptor antagonist SR48692,23,50,The neurotensin type-1 receptor antagonist SR48692 blocked both the behavioral and the electrophysiological effects induced by neurotensin.,20882060_7,0
2471,neurotensin,4,15,The neurotensin type-1 receptor antagonist SR48692 blocked both the behavioral and the electrophysiological effects induced by neurotensin.,20882060_7,0
2473,antiparkinsonian,96,112,CONCLUSION: Activation of pallidal neurotensin receptors may be involved in neurotensin-induced antiparkinsonian effects.,20882060_8,0
10144,pallidal neurotensin receptors,26,56,CONCLUSION: Activation of pallidal neurotensin receptors may be involved in neurotensin-induced antiparkinsonian effects.,20882060_8,0
6083,organic mental disorders,17,41,Carmofur-induced organic mental disorders.,2096243_0,1
10145,Organic mental disorder,0,23,Organic mental disorder was observed in a 29-year-old female in the prognostic period after the onset of carmofur-induced leukoencephalopathy.,2096243_1,1
10147,onset of,96,104,Organic mental disorder was observed in a 29-year-old female in the prognostic period after the onset of carmofur-induced leukoencephalopathy.,2096243_1,1
6084,leukoencephalopathy,122,141,Organic mental disorder was observed in a 29-year-old female in the prognostic period after the onset of carmofur-induced leukoencephalopathy.,2096243_1,1
10151,frontal lobe syndrome,210,231,"Symptoms such as euphoria, emotional lability and puerile attitude noted in the patient were diagnosed as organic personality syndrome according to the criteria defined in the DSM-III-R. It is referred to as a frontal lobe syndrome.",2096243_2,1
10149,organic personality syndrome,106,134,"Symptoms such as euphoria, emotional lability and puerile attitude noted in the patient were diagnosed as organic personality syndrome according to the criteria defined in the DSM-III-R. It is referred to as a frontal lobe syndrome.",2096243_2,1
10148,emotional lability,27,45,"Symptoms such as euphoria, emotional lability and puerile attitude noted in the patient were diagnosed as organic personality syndrome according to the criteria defined in the DSM-III-R. It is referred to as a frontal lobe syndrome.",2096243_2,1
6085,periventricular,20,35,Brain CT revealed a periventricular low density area in the frontal white matter and moderate dilatation of the lateral ventricles especially at the bilateral anterior horns.,2096243_3,1
10154,lateral ventricles,112,130,Brain CT revealed a periventricular low density area in the frontal white matter and moderate dilatation of the lateral ventricles especially at the bilateral anterior horns.,2096243_3,1
10153,frontal white matter,60,80,Brain CT revealed a periventricular low density area in the frontal white matter and moderate dilatation of the lateral ventricles especially at the bilateral anterior horns.,2096243_3,1
10155,organic personality syndrome,76,104,"Consequently, carmofur-induced leukoencephalopathy may uncommonly result in organic personality syndrome in the residual state.",2096243_4,1
6086,leukoencephalopathy,31,50,"Consequently, carmofur-induced leukoencephalopathy may uncommonly result in organic personality syndrome in the residual state.",2096243_4,1
10157,structural damage,28,45,It may be attributed to the structural damage to the frontal lobe.,2096243_5,1
6087,frontal lobe,53,65,It may be attributed to the structural damage to the frontal lobe.,2096243_5,1
2474,receptor antagonist,52,71,In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease.,20973483_0,0
6088,Parkinson's disease,92,111,In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease.,20973483_0,1
6089,Parkinson's disease,108,127,The in vivo characterization of a dual adenosine A(2A)/A(1) receptor antagonist in several animal models of Parkinson's disease is described.,20973483_1,1
2475,receptor antagonist,60,79,The in vivo characterization of a dual adenosine A(2A)/A(1) receptor antagonist in several animal models of Parkinson's disease is described.,20973483_1,0
10163,compound 1,36,46,"Discovery and scale-up syntheses of compound 1 are described in detail, highlighting optimization steps that increased the overall yield of 1 from 10.0% to 30.5%.",20973483_2,0
2476,receptor antagonist,34,53,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",20973483_3,0
10167,K(i,90,93,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",20973483_3,0
6090,Parkinson's disease,198,217,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",20973483_3,1
6091,drug-induced,373,385,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",20973483_3,1
10172,6-hydroxydopamine,330,347,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",20973483_3,0
10173,6-OHDA,349,355,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",20973483_3,0
10166,K(i,70,73,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",20973483_3,0
10164,Compound 1,0,10,"Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model.",20973483_3,0
10175,prolonged apnea,54,69,Butyrylcholinesterase gene mutations in patients with prolonged apnea after succinylcholine for electroconvulsive therapy.,21029050_0,1
2477,Butyrylcholinesterase,0,21,Butyrylcholinesterase gene mutations in patients with prolonged apnea after succinylcholine for electroconvulsive therapy.,21029050_0,0
10196,BCHE,106,110,"CONCLUSION: eleven of 13 patients with a prolonged duration of action of succinylcholine had mutations in BCHE, indicating that this is the possible reason for a prolonged period of apnea.",21029050_11,0
2478,K-,144,146,"The duration of action may be prolonged in patients with genetic variants of the butyrylcholinesterase enzyme (BChE), the most common being the K- and the A-variants.",21029050_2,0
10180,BChE,111,115,"The duration of action may be prolonged in patients with genetic variants of the butyrylcholinesterase enzyme (BChE), the most common being the K- and the A-variants.",21029050_2,0
10179,butyrylcholinesterase enzyme,81,109,"The duration of action may be prolonged in patients with genetic variants of the butyrylcholinesterase enzyme (BChE), the most common being the K- and the A-variants.",21029050_2,0
2479,butyrylcholinesterase,84,105,The aim of the study was to assess the clinical significance of genetic variants in butyrylcholinesterase gene (BCHE) in patients with a suspected prolonged duration of action of succinylcholine after ECT.,21029050_3,0
10184,BCHE,112,116,The aim of the study was to assess the clinical significance of genetic variants in butyrylcholinesterase gene (BCHE) in patients with a suspected prolonged duration of action of succinylcholine after ECT.,21029050_3,0
10186,BCHE,40,44,"We determined the BChE activity and the BCHE genotype using molecular genetic methods, the duration of apnea, time to sufficient spontaneous ventilation and whether neuromuscular monitoring was used.",21029050_5,0
10185,BChE,18,22,"We determined the BChE activity and the BCHE genotype using molecular genetic methods, the duration of apnea, time to sufficient spontaneous ventilation and whether neuromuscular monitoring was used.",21029050_5,0
10193,Severe distress,0,15,Severe distress was noted in the recovery phase in two patients.,21029050_9,1
10199,epileptic discharges,62,82,Effects of the hippocampal deep brain stimulation on cortical epileptic discharges in penicillin - induced epilepsy model in rats.,21294084_0,1
6092,hippocampal,15,26,Effects of the hippocampal deep brain stimulation on cortical epileptic discharges in penicillin - induced epilepsy model in rats.,21294084_0,1
10198,brain stimulation,32,49,Effects of the hippocampal deep brain stimulation on cortical epileptic discharges in penicillin - induced epilepsy model in rats.,21294084_0,1
6093,hippocampal,58,69,"AIM: Experimental and clinical studies have revealed that hippocampal DBS can control epileptic activity, but the mechanism of action is obscure and optimal stimulation parameters are not clearly defined.",21294084_1,1
10201,epileptic activity,86,104,"AIM: Experimental and clinical studies have revealed that hippocampal DBS can control epileptic activity, but the mechanism of action is obscure and optimal stimulation parameters are not clearly defined.",21294084_1,1
6099,hippocampal,75,86,These results are important in terms of defining the optimal parameters of hippocampal DBS in patients with epilepsy.,21294084_10,1
10202,high frequency hippocampal,39,65,The aim was to evaluate the effects of high frequency hippocampal stimulation on cortical epileptic activity in penicillin-induced epilepsy model.,21294084_2,1
2480,group-1,3,10,"In group-1 (n=10) hippocampal DBS was off and in the group-2 (n=10) hippocampal DBS was on (185 Hz, 0.5V, 1V, 2V, and 5V for 60 sec) following penicillin G injection intracortically.",21294084_4,0
2481,group-2,53,60,"In group-1 (n=10) hippocampal DBS was off and in the group-2 (n=10) hippocampal DBS was on (185 Hz, 0.5V, 1V, 2V, and 5V for 60 sec) following penicillin G injection intracortically.",21294084_4,0
2482,penicillin G,143,155,"In group-1 (n=10) hippocampal DBS was off and in the group-2 (n=10) hippocampal DBS was on (185 Hz, 0.5V, 1V, 2V, and 5V for 60 sec) following penicillin G injection intracortically.",21294084_4,0
6094,hippocampal,18,29,"In group-1 (n=10) hippocampal DBS was off and in the group-2 (n=10) hippocampal DBS was on (185 Hz, 0.5V, 1V, 2V, and 5V for 60 sec) following penicillin G injection intracortically.",21294084_4,1
6095,hippocampal,68,79,"In group-1 (n=10) hippocampal DBS was off and in the group-2 (n=10) hippocampal DBS was on (185 Hz, 0.5V, 1V, 2V, and 5V for 60 sec) following penicillin G injection intracortically.",21294084_4,1
6096,hippocampal,21,32,In the control group hippocampal DBS was on following 8  l saline injection intracortically.,21294084_5,1
2483,penicillin-G,61,73,"EEG recordings were obtained before and 15 minutes following penicillin-G injection, and at 10th minutes following each stimulus for analysis in terms of frequency, amplitude, and power spectrum.",21294084_6,0
10211,High frequency hippocampal,9,35,RESULTS: High frequency hippocampal DBS suppressed the acute penicillin-induced cortical epileptic activity independent from stimulus intensity.,21294084_7,1
10212,acute penicillin-induced cortical epileptic activity,55,107,RESULTS: High frequency hippocampal DBS suppressed the acute penicillin-induced cortical epileptic activity independent from stimulus intensity.,21294084_7,1
6097,hippocampal,22,33,"In the control group, hippocampal stimulation alone lead only to diffuse slowing of cerebral bioelectrical activity at 5V stimulation.",21294084_8,1
10215,acute cortical epileptic activity,106,139,CONCLUSION: Our results revealed that continuous high frequency stimulation of the hippocampus suppressed acute cortical epileptic activity effectively without causing secondary epileptic discharges.,21294084_9,1
6098,high frequency,49,63,CONCLUSION: Our results revealed that continuous high frequency stimulation of the hippocampus suppressed acute cortical epileptic activity effectively without causing secondary epileptic discharges.,21294084_9,1
10216,epileptic discharges,178,198,CONCLUSION: Our results revealed that continuous high frequency stimulation of the hippocampus suppressed acute cortical epileptic activity effectively without causing secondary epileptic discharges.,21294084_9,1
10221,CCNU,249,253,"CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07).OBJECTIVE: To describe the incidence of haematological, renal, hepatic and gastrointestinal toxicities in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).",21418164_0,0
10217,CCNU,0,4,"CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07).OBJECTIVE: To describe the incidence of haematological, renal, hepatic and gastrointestinal toxicities in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).",21418164_0,0
10220,1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea,203,247,"CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07).OBJECTIVE: To describe the incidence of haematological, renal, hepatic and gastrointestinal toxicities in tumour-bearing dogs receiving 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU).",21418164_0,0
10223,CCNU,63,67,DESIGN: The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated.,21418164_1,0
10224,CCNU,38,42,"RESULTS: Of the 206 dogs treated with CCNU, 185 met the inclusion criteria for at least one class of toxicity.",21418164_2,0
10226,mast cell,58,67,"CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.",21418164_3,1
10225,CCNU,0,4,"CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.",21418164_3,0
10227,brain tumour,76,88,"CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.",21418164_3,1
10228,epitheliotropic lymphoma,114,138,"CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.",21418164_3,1
6100,histiocytic,90,101,"CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma.",21418164_3,1
10229,Gastrointestinal toxicosis,0,26,"Gastrointestinal toxicosis was detected in 37.8% of dogs, the most common sign of which was vomiting (24.3%).",21418164_5,1
2484,alanine transaminase,38,58,"Potential renal toxicity and elevated alanine transaminase (ALT) concentration were reported in 12.2% and 48.8% of dogs, respectively.",21418164_6,0
10230,renal toxicity,10,24,"Potential renal toxicity and elevated alanine transaminase (ALT) concentration were reported in 12.2% and 48.8% of dogs, respectively.",21418164_6,1
6101,hepatic failure,17,32,The incidence of hepatic failure was 1.2%.,21418164_7,1
10232,life threatening,76,92,"CONCLUSIONS: CCNU-associated toxicity in dogs is common, but is usually not life threatening.",21418164_8,1
2485,Perhexiline,0,11,Perhexiline maleate and peripheral neuropathy.,220563_0,0
6102,peripheral neuropathy,24,45,Perhexiline maleate and peripheral neuropathy.,220563_0,1
2486,perhexiline,71,82,"Peripheral neuropathy has been noted as a complication of therapy with perhexiline maleate, a drug widely used in France (and in clinical trials in the United States) for the prophylactic treatment of angina pectoris.",220563_1,0
6103,Peripheral neuropathy,0,21,"Peripheral neuropathy has been noted as a complication of therapy with perhexiline maleate, a drug widely used in France (and in clinical trials in the United States) for the prophylactic treatment of angina pectoris.",220563_1,1
6104,angina pectoris,201,216,"Peripheral neuropathy has been noted as a complication of therapy with perhexiline maleate, a drug widely used in France (and in clinical trials in the United States) for the prophylactic treatment of angina pectoris.",220563_1,1
10234,motor nerve conduction velocity,61,92,"In 24 patients with this complication, the marked slowing of motor nerve conduction velocity and the electromyographic changes imply mainly a demyelinating disorder.",220563_2,1
6105,demyelinating disorder,142,164,"In 24 patients with this complication, the marked slowing of motor nerve conduction velocity and the electromyographic changes imply mainly a demyelinating disorder.",220563_2,1
10236,active denervation,31,49,"In a few cases the presence of active denervation signified a poor prognosis, with only slight improvement.",220563_4,1
10237,poor prognosis,62,76,"In a few cases the presence of active denervation signified a poor prognosis, with only slight improvement.",220563_4,1
6106,vein thrombosis,8,23,Central vein thrombosis and topical dipivalyl epinephrine.,2220369_0,1
10238,topical dipivalyl,28,45,Central vein thrombosis and topical dipivalyl epinephrine.,2220369_0,0
6107,vein thrombosis,64,79,A report is given on an 83-year-old female who acquired central vein thrombosis in her seeing eye one day after having started topical medication with dipivalyl epinephrine for advanced glaucoma discovered in the other eye.,2220369_1,1
10240,dipivalyl,151,160,A report is given on an 83-year-old female who acquired central vein thrombosis in her seeing eye one day after having started topical medication with dipivalyl epinephrine for advanced glaucoma discovered in the other eye.,2220369_1,0
10241,advanced glaucoma,177,194,A report is given on an 83-year-old female who acquired central vein thrombosis in her seeing eye one day after having started topical medication with dipivalyl epinephrine for advanced glaucoma discovered in the other eye.,2220369_1,1
2487,her,83,86,A report is given on an 83-year-old female who acquired central vein thrombosis in her seeing eye one day after having started topical medication with dipivalyl epinephrine for advanced glaucoma discovered in the other eye.,2220369_1,0
10242,adrenergic eye drops,44,64,"From present knowledge about the effects of adrenergic eye drops on ocular blood circulation, it is difficult to suggest an association between the two events, which may be coincidental only.",2220369_2,0
10243,ocular blood circulation,68,92,"From present knowledge about the effects of adrenergic eye drops on ocular blood circulation, it is difficult to suggest an association between the two events, which may be coincidental only.",2220369_2,0
10267,T 1/2 gamma,154,165,"Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours.",2224762_10,0
10265,T beta 1/2,114,124,"Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours.",2224762_10,0
10263,Pirarubicin plasma T 1/2 alpha (+/-,49,84,"Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours.",2224762_10,0
10274,ClT,124,127,"The area under the curve was 537 +/- 149 ng/ml x hours, volume of distribution (Vd) 3504 +/- 644 l/m2, and total clearance (ClT) was 204 + 39.3 l/hour/m2.",2224762_11,0
10275,Adriamycinol,0,12,"Adriamycinol, doxorubicin, adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites.",2224762_12,0
10276,adriamycinone,27,40,"Adriamycinol, doxorubicin, adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites.",2224762_12,0
10277,tetrahydropyranyladriamycinol,46,75,"Adriamycinol, doxorubicin, adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites.",2224762_12,0
10278,Pirarubicin,21,32,Urinary excretion of Pirarubicin in the first 24 hours was less than or equal to 10%.,2224762_13,0
6109,basal cell carcinoma,56,76,"Activity was noted in mesothelioma, leiomyosarcoma, and basal cell carcinoma.",2224762_14,1
10279,starting dose,16,29,The recommended starting dose for Phase II trials is 60 mg/m2 IV bolus every 3 weeks.,2224762_15,0
10280,mg/m2,56,61,The recommended starting dose for Phase II trials is 60 mg/m2 IV bolus every 3 weeks.,2224762_15,0
10247,refractory tumors,145,162,A Phase I study of intravenous (IV) bolus 4'-0-tetrahydropyranyladriamycin (Pirarubicin) was done in 55 patients in good performance status with refractory tumors.,2224762_2,1
10244,intravenous (IV) bolus 4'-0-tetrahydropyranyladriamycin,19,74,A Phase I study of intravenous (IV) bolus 4'-0-tetrahydropyranyladriamycin (Pirarubicin) was done in 55 patients in good performance status with refractory tumors.,2224762_2,0
10245,Pirarubicin,76,87,A Phase I study of intravenous (IV) bolus 4'-0-tetrahydropyranyladriamycin (Pirarubicin) was done in 55 patients in good performance status with refractory tumors.,2224762_2,0
10250,hepatic dysfunction,119,138,"Twenty-six had minimal prior therapy (good risk), 23 had extensive prior therapy (poor risk), and six had renal and/or hepatic dysfunction.",2224762_3,1
10251,mg/m2,44,49,A total of 167 courses at doses of 15 to 70 mg/m2 were evaluable.,2224762_4,0
10254,mg/m2,52,57,"Maximum tolerated dose in good-risk patients was 70 mg/m2, and in poor-risk patients, 60 mg/m2.",2224762_5,0
10256,mg/m2,89,94,"Maximum tolerated dose in good-risk patients was 70 mg/m2, and in poor-risk patients, 60 mg/m2.",2224762_5,0
10257,noncumulative granulocytopenia,45,75,The dose-limiting toxic effect was transient noncumulative granulocytopenia.,2224762_6,1
10258,Granulocyte nadir,0,17,"Granulocyte nadir was on day 14 (range, 4-22).",2224762_7,0
6108,mucositis,101,110,"Less frequent toxic effects included thrombocytopenia, anemia, nausea, mild alopecia, phlebitis, and mucositis.",2224762_8,1
10259,toxic effects,14,27,"Less frequent toxic effects included thrombocytopenia, anemia, nausea, mild alopecia, phlebitis, and mucositis.",2224762_8,1
10260,mild alopecia,71,84,"Less frequent toxic effects included thrombocytopenia, anemia, nausea, mild alopecia, phlebitis, and mucositis.",2224762_8,1
10261,Myelosuppression,0,16,Myelosuppression was more in patients with hepatic dysfunction.,2224762_9,1
10262,hepatic dysfunction,43,62,Myelosuppression was more in patients with hepatic dysfunction.,2224762_9,1
2488,desferrioxamine,64,79,Ocular and auditory toxicity in hemodialyzed patients receiving desferrioxamine.,2234245_0,0
2489,desferrioxamine,70,85,During an 18-month period of study 41 hemodialyzed patients receiving desferrioxamine (10-40 mg/kg BW/3 times weekly) for the first time were monitored for detection of audiovisual toxicity.,2234245_1,0
10285,clinical symptoms,21,38,6 patients presented clinical symptoms of visual or auditory toxicity.,2234245_2,1
10286,ophthalmologic,19,33,"Moreover, detailed ophthalmologic and audiologic studies disclosed abnormalities in 7 more asymptomatic patients.",2234245_3,0
10292,pigmentary retinal,147,165,"Visual toxicity was of retinal origin and was characterized by a tritan-type dyschromatopsy, sometimes associated with a loss of visual acuity and pigmentary retinal deposits.",2234245_4,1
10291,loss of visual acuity,121,142,"Visual toxicity was of retinal origin and was characterized by a tritan-type dyschromatopsy, sometimes associated with a loss of visual acuity and pigmentary retinal deposits.",2234245_4,1
10288,retinal origin,23,37,"Visual toxicity was of retinal origin and was characterized by a tritan-type dyschromatopsy, sometimes associated with a loss of visual acuity and pigmentary retinal deposits.",2234245_4,1
6110,high-frequency,49,63,Auditory toxicity was characterized by a mid- to high-frequency neurosensorial hearing loss and the lesion was of the cochlear type.,2234245_5,1
6111,hearing loss,79,91,Auditory toxicity was characterized by a mid- to high-frequency neurosensorial hearing loss and the lesion was of the cochlear type.,2234245_5,1
10296,partial recovery,176,192,"Desferrioxamine withdrawal resulted in a complete recovery of visual function in 1 patient and partial recovery in 3, and a complete reversal of hearing loss in 3 patients and partial recovery in 3.",2234245_6,1
10295,partial recovery,95,111,"Desferrioxamine withdrawal resulted in a complete recovery of visual function in 1 patient and partial recovery in 3, and a complete reversal of hearing loss in 3 patients and partial recovery in 3.",2234245_6,1
10294,visual function,62,77,"Desferrioxamine withdrawal resulted in a complete recovery of visual function in 1 patient and partial recovery in 3, and a complete reversal of hearing loss in 3 patients and partial recovery in 3.",2234245_6,1
6112,hearing loss,145,157,"Desferrioxamine withdrawal resulted in a complete recovery of visual function in 1 patient and partial recovery in 3, and a complete reversal of hearing loss in 3 patients and partial recovery in 3.",2234245_6,1
2490,Desferrioxamine,0,15,"Desferrioxamine withdrawal resulted in a complete recovery of visual function in 1 patient and partial recovery in 3, and a complete reversal of hearing loss in 3 patients and partial recovery in 3.",2234245_6,0
2491,desferrioxamine,65,80,This toxicity appeared in patients receiving the higher doses of desferrioxamine or coincided with the normalization of ferritin or aluminium serum levels.,2234245_7,0
2492,desferrioxamine,113,128,The data indicate that audiovisual toxicity is not an infrequent complication in hemodialyzed patients receiving desferrioxamine.,2234245_8,0
6113,adverse effects,117,132,Periodical audiovisual monitoring should be performed on hemodialyzed patients receiving the drug in order to detect adverse effects as early as possible.,2234245_9,1
10301,Benzylacyclouridine,0,19,Benzylacyclouridine reverses azidothymidine-induced marrow suppression without impairment of anti-human immunodeficiency virus activity.,2257294_0,0
2494,azidothymidine,96,110,"Increased extracellular concentrations of uridine (Urd) have been reported to reduce, in vitro, azidothymidine (AZT)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman immunodeficiency virus (HIV) activity.",2257294_1,0
2493,uridine,42,49,"Increased extracellular concentrations of uridine (Urd) have been reported to reduce, in vitro, azidothymidine (AZT)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman immunodeficiency virus (HIV) activity.",2257294_1,0
10305,antihuman immunodeficiency virus,211,243,"Increased extracellular concentrations of uridine (Urd) have been reported to reduce, in vitro, azidothymidine (AZT)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman immunodeficiency virus (HIV) activity.",2257294_1,0
2495,granulocyte-macrophage,145,167,"Increased extracellular concentrations of uridine (Urd) have been reported to reduce, in vitro, azidothymidine (AZT)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman immunodeficiency virus (HIV) activity.",2257294_1,0
10310,BAU,115,118,"Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.",2257294_2,0
10306,clinical toxicities,15,34,"Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.",2257294_2,1
10309,benzylacyclouridine,94,113,"Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed.",2257294_2,0
10313,dose-dependent,96,110,"This agent inhibits Urd catabolism and, in vivo, increases the plasma concentration of Urd in a dose-dependent manner, without Urd-related toxicity.",2257294_3,1
10314,Urd-related toxicity,127,147,"This agent inhibits Urd catabolism and, in vivo, increases the plasma concentration of Urd in a dose-dependent manner, without Urd-related toxicity.",2257294_3,1
10315,leukopenic,28,38,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,1
10319,megaloblastosis,367,382,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,1
10316,BAU,158,161,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,0
2496,drinking water,83,97,"In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water (1.5 mg/mL), the continued administration of AZT plus daily BAU (300 mg/kg, orally) partially reversed AZT-induced anemia and leukopenia (P less than .05), increased peripheral reticulocytes (to 4.9%, P less than .01), increased cellularity in the marrow, and improved megaloblastosis.",2257294_4,0
10322,BAU,68,71,"When coadministered with AZT from the onset of drug administration, BAU reduced AZT-induced marrow toxicity.",2257294_5,0
10324,anti-HIV,67,75,"In vitro, at a concentration of 100 mumol/L, BAU possesses minimal anti-HIV activity and has no effect on the ability of AZT to reverse the HIV-induced cytopathic effect in MT4 cells.",2257294_6,0
10323,BAU,45,48,"In vitro, at a concentration of 100 mumol/L, BAU possesses minimal anti-HIV activity and has no effect on the ability of AZT to reverse the HIV-induced cytopathic effect in MT4 cells.",2257294_6,0
10326,Serial epilepsy,0,15,Serial epilepsy caused by levodopa/carbidopa administration in two patients on hemodialysis.,2265898_0,1
10327,levodopa/carbidopa,26,44,Serial epilepsy caused by levodopa/carbidopa administration in two patients on hemodialysis.,2265898_0,0
10328,clinical features,26,43,"Two patients with similar clinical features are presented: both patients had chronic renal failure, on hemodialysis for many years but recently begun on a high-flux dialyzer; both had been receiving a carbidopa/levodopa preparation; and both had the onset of hallucinosis and recurrent seizures, which were refractory to anticonvulsants.",2265898_1,1
6114,chronic renal failure,77,98,"Two patients with similar clinical features are presented: both patients had chronic renal failure, on hemodialysis for many years but recently begun on a high-flux dialyzer; both had been receiving a carbidopa/levodopa preparation; and both had the onset of hallucinosis and recurrent seizures, which were refractory to anticonvulsants.",2265898_1,1
10332,recurrent seizures,276,294,"Two patients with similar clinical features are presented: both patients had chronic renal failure, on hemodialysis for many years but recently begun on a high-flux dialyzer; both had been receiving a carbidopa/levodopa preparation; and both had the onset of hallucinosis and recurrent seizures, which were refractory to anticonvulsants.",2265898_1,1
10331,onset of,250,258,"Two patients with similar clinical features are presented: both patients had chronic renal failure, on hemodialysis for many years but recently begun on a high-flux dialyzer; both had been receiving a carbidopa/levodopa preparation; and both had the onset of hallucinosis and recurrent seizures, which were refractory to anticonvulsants.",2265898_1,1
10330,carbidopa/levodopa,201,219,"Two patients with similar clinical features are presented: both patients had chronic renal failure, on hemodialysis for many years but recently begun on a high-flux dialyzer; both had been receiving a carbidopa/levodopa preparation; and both had the onset of hallucinosis and recurrent seizures, which were refractory to anticonvulsants.",2265898_1,0
10333,vitamin B6,119,129,The first patient died without a diagnosis; the second patient had a dramatic recovery following the administration of vitamin B6.,2265898_2,0
6115,Duchenne,46,54,"Randomized, double-blind trial of mazindol in Duchenne dystrophy.",2266990_0,1
2497,mazindol,34,42,"Randomized, double-blind trial of mazindol in Duchenne dystrophy.",2266990_0,0
2498,growth hormone,23,37,There is evidence that growth hormone may be related to the progression of weakness in Duchenne dystrophy.,2266990_1,0
6116,Duchenne,87,95,There is evidence that growth hormone may be related to the progression of weakness in Duchenne dystrophy.,2266990_1,1
2500,growth hormone,65,79,"We conducted a 12-month controlled trial of mazindol, a putative growth hormone secretion inhibitor, in 83 boys with Duchenne dystrophy.",2266990_2,0
6117,Duchenne,117,125,"We conducted a 12-month controlled trial of mazindol, a putative growth hormone secretion inhibitor, in 83 boys with Duchenne dystrophy.",2266990_2,1
2499,mazindol,44,52,"We conducted a 12-month controlled trial of mazindol, a putative growth hormone secretion inhibitor, in 83 boys with Duchenne dystrophy.",2266990_2,0
10340,mazindol (3,139,150,"Muscle strength, contractures, functional ability and pulmonary function were tested at baseline, and 6 and 12 months after treatment with mazindol (3 mg/d) or placebo.",2266990_3,0
10339,pulmonary function,54,72,"Muscle strength, contractures, functional ability and pulmonary function were tested at baseline, and 6 and 12 months after treatment with mazindol (3 mg/d) or placebo.",2266990_3,1
10337,Muscle strength,0,15,"Muscle strength, contractures, functional ability and pulmonary function were tested at baseline, and 6 and 12 months after treatment with mazindol (3 mg/d) or placebo.",2266990_3,1
2501,Mazindol,0,8,Mazindol did not benefit strength at any point in the study.,2266990_5,0
10344,gastrointestinal symptoms,119,144,"Side effects attributable to mazindol included decreased appetite (36%), dry mouth (10%), behavioral change (22%), and gastrointestinal symptoms (18%); mazindol dosage was reduced in 43% of patients.",2266990_6,1
10342,dry mouth,73,82,"Side effects attributable to mazindol included decreased appetite (36%), dry mouth (10%), behavioral change (22%), and gastrointestinal symptoms (18%); mazindol dosage was reduced in 43% of patients.",2266990_6,0
6118,Side effects,0,12,"Side effects attributable to mazindol included decreased appetite (36%), dry mouth (10%), behavioral change (22%), and gastrointestinal symptoms (18%); mazindol dosage was reduced in 43% of patients.",2266990_6,1
2502,mazindol,29,37,"Side effects attributable to mazindol included decreased appetite (36%), dry mouth (10%), behavioral change (22%), and gastrointestinal symptoms (18%); mazindol dosage was reduced in 43% of patients.",2266990_6,0
2503,mazindol,152,160,"Side effects attributable to mazindol included decreased appetite (36%), dry mouth (10%), behavioral change (22%), and gastrointestinal symptoms (18%); mazindol dosage was reduced in 43% of patients.",2266990_6,0
2506,mazindol,158,166,"The effect of mazindol on GH secretion was estimated indirectly by comparing the postabsorptive IGF-I levels obtained following 3, 6, 9, and 12 months in the mazindol treated to those in the placebo groups.",2266990_7,0
2504,mazindol,14,22,"The effect of mazindol on GH secretion was estimated indirectly by comparing the postabsorptive IGF-I levels obtained following 3, 6, 9, and 12 months in the mazindol treated to those in the placebo groups.",2266990_7,0
2505,IGF-I,96,101,"The effect of mazindol on GH secretion was estimated indirectly by comparing the postabsorptive IGF-I levels obtained following 3, 6, 9, and 12 months in the mazindol treated to those in the placebo groups.",2266990_7,0
6119,postabsorptive,81,95,"The effect of mazindol on GH secretion was estimated indirectly by comparing the postabsorptive IGF-I levels obtained following 3, 6, 9, and 12 months in the mazindol treated to those in the placebo groups.",2266990_7,1
2507,IGF-I,121,126,"Although mazindol-treated patients gained less weight and height than placebo-treated patients, no significant effect on IGF-I levels was observed.",2266990_8,0
10346,less weight,42,53,"Although mazindol-treated patients gained less weight and height than placebo-treated patients, no significant effect on IGF-I levels was observed.",2266990_8,1
6120,Duchenne,55,63,Mazindol doses not slow the progression of weakness in Duchenne dystrophy.,2266990_9,1
2508,Mazindol,0,8,Mazindol doses not slow the progression of weakness in Duchenne dystrophy.,2266990_9,0
10348,memory retrieval,16,32,Facilitation of memory retrieval by pre-test morphine and its state dependency in the step-through type passive avoidance learning test in mice.,2273650_0,1
2509,cycloheximide,36,49,"Amnesia produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial (pre-test), and pre-test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial.",2273650_1,0
2510,cycloheximide,120,133,"Similarly, pre-test scopolamine partially reversed the scopolamine-induced amnesia, but not significantly; and pre-test cycloheximide failed to reverse the cycloheximide-induced amnesia.",2273650_2,0
10358,memory retrieval,47,63,These results suggest that the facilitation of memory retrieval by pre-test morphine might be the direct action of morphine rather than a state dependent effect.,2273650_3,1
10364,nalozone,184,192,"In unanesthetized, spontaneously hypertensive rats the decrease in blood pressure and heart rate produced by intravenous clonidine, 5 to 20 micrograms/kg, was inhibited or reversed by nalozone, 0.2 to 2 mg/kg.",227508_1,0
10362,heart rate,86,96,"In unanesthetized, spontaneously hypertensive rats the decrease in blood pressure and heart rate produced by intravenous clonidine, 5 to 20 micrograms/kg, was inhibited or reversed by nalozone, 0.2 to 2 mg/kg.",227508_1,1
6121,blood pressure,67,81,"In unanesthetized, spontaneously hypertensive rats the decrease in blood pressure and heart rate produced by intravenous clonidine, 5 to 20 micrograms/kg, was inhibited or reversed by nalozone, 0.2 to 2 mg/kg.",227508_1,1
10363,intravenous clonidine,109,130,"In unanesthetized, spontaneously hypertensive rats the decrease in blood pressure and heart rate produced by intravenous clonidine, 5 to 20 micrograms/kg, was inhibited or reversed by nalozone, 0.2 to 2 mg/kg.",227508_1,0
2511,alpha-methyldopa,36,52,The hypotensive effect of 100 mg/kg alpha-methyldopa was also partially reversed by naloxone.,227508_2,0
6122,blood pressure,37,51,Naloxone alone did not affect either blood pressure or heart rate.,227508_3,1
10365,heart rate,55,65,Naloxone alone did not affect either blood pressure or heart rate.,227508_3,1
10369,[3H]-dihydroergocryptine (1,240,267,"In brain membranes from spontaneously hypertensive rats clonidine, 10(-8) to 10(-5) M, did not influence stereoselective binding of [3H]-naloxone (8 nM), and naloxone, 10(-8) to 10(-4) M, did not influence clonidine-suppressible binding of [3H]-dihydroergocryptine (1 nM).",227508_4,0
10368,clonidine-suppressible binding,206,236,"In brain membranes from spontaneously hypertensive rats clonidine, 10(-8) to 10(-5) M, did not influence stereoselective binding of [3H]-naloxone (8 nM), and naloxone, 10(-8) to 10(-4) M, did not influence clonidine-suppressible binding of [3H]-dihydroergocryptine (1 nM).",227508_4,0
10367,[3H]-naloxone,132,145,"In brain membranes from spontaneously hypertensive rats clonidine, 10(-8) to 10(-5) M, did not influence stereoselective binding of [3H]-naloxone (8 nM), and naloxone, 10(-8) to 10(-4) M, did not influence clonidine-suppressible binding of [3H]-dihydroergocryptine (1 nM).",227508_4,0
2512,opiate receptors,140,156,These findings indicate that in spontaneously hypertensive rats the effects of central alpha-adrenoceptor stimulation involve activation of opiate receptors.,227508_5,0
2514,alpha-methyldopa,177,193,"As naloxone and clonidine do not appear to interact with the same receptor site, the observed functional antagonism suggests the release of an endogenous opiate by clonidine or alpha-methyldopa and the possible role of the opiate in the central control of sympathetic tone.",227508_6,0
2513,receptor site,66,79,"As naloxone and clonidine do not appear to interact with the same receptor site, the observed functional antagonism suggests the release of an endogenous opiate by clonidine or alpha-methyldopa and the possible role of the opiate in the central control of sympathetic tone.",227508_6,0
10372,sympathetic tone,256,272,"As naloxone and clonidine do not appear to interact with the same receptor site, the observed functional antagonism suggests the release of an endogenous opiate by clonidine or alpha-methyldopa and the possible role of the opiate in the central control of sympathetic tone.",227508_6,1
10373,halogenated hydroxyquinolines,17,46,Neurotoxicity of halogenated hydroxyquinolines: clinical analysis of cases reported outside Japan.,230316_0,0
6123,Neurotoxicity,0,13,Neurotoxicity of halogenated hydroxyquinolines: clinical analysis of cases reported outside Japan.,230316_0,1
10376,halogenated hydroxyquinolines,74,103,An analysis is presented of 220 cases of possible neurotoxic reactions to halogenated hydroxyquinolines reported from outside Japan.,230316_1,0
6131,side effects,38,50,Older subjects tended to display more side effects.,230316_10,1
10385,myelo-optic neuropathy,30,52,"The full syndrome of subacute myelo-optic neuropathy was more frequent in women, but they tended to have taken greater quantities of the drug.",230316_11,1
10384,full syndrome,4,17,"The full syndrome of subacute myelo-optic neuropathy was more frequent in women, but they tended to have taken greater quantities of the drug.",230316_11,1
10377,neurological disturbance,33,57,In six of the probable cases the neurological disturbance consisted of an acute reversible encephalopathy usually related to the ingestion of a high dose of clioquinol over a short period.,230316_4,1
10378,acute reversible encephalopathy,74,105,In six of the probable cases the neurological disturbance consisted of an acute reversible encephalopathy usually related to the ingestion of a high dose of clioquinol over a short period.,230316_4,1
10379,high dose,144,153,In six of the probable cases the neurological disturbance consisted of an acute reversible encephalopathy usually related to the ingestion of a high dose of clioquinol over a short period.,230316_4,0
6124,optic atrophy,74,87,"The most common manifestation, observed in 15 further cases, was isolated optic atrophy.",230316_5,1
6125,acrodermatitis,98,112,"This was most frequently found in children, many of whom had received clioquinol as treatment for acrodermatitis enteropathica.",230316_6,1
6126,myelopathy,41,51,"In the remaining cases, a combination of myelopathy, visual disturbance, and peripheral neuropathy was the most common manifestation.",230316_7,1
6127,peripheral neuropathy,77,98,"In the remaining cases, a combination of myelopathy, visual disturbance, and peripheral neuropathy was the most common manifestation.",230316_7,1
10380,visual disturbance,53,71,"In the remaining cases, a combination of myelopathy, visual disturbance, and peripheral neuropathy was the most common manifestation.",230316_7,1
6129,peripheral neuropathy,23,44,"Isolated myelopathy or peripheral neuropathy, or these manifestations occurring together, were infrequent.",230316_8,1
6128,myelopathy,9,19,"Isolated myelopathy or peripheral neuropathy, or these manifestations occurring together, were infrequent.",230316_8,1
6130,toxic encephalopathy,40,60,"The onset of all manifestations (except toxic encephalopathy) was usually subacute, with subsequent partial recovery.",230316_9,1
10381,onset of,4,12,"The onset of all manifestations (except toxic encephalopathy) was usually subacute, with subsequent partial recovery.",230316_9,1
10382,partial recovery,100,116,"The onset of all manifestations (except toxic encephalopathy) was usually subacute, with subsequent partial recovery.",230316_9,1
6132,stress incontinence,17,36,Prazosin-induced stress incontinence.,2304736_0,1
2515,antihypertensive drug,64,85,"A case of genuine stress incontinence due to prazosin, a common antihypertensive drug, is presented.",2304736_1,0
6133,stress incontinence,18,37,"A case of genuine stress incontinence due to prazosin, a common antihypertensive drug, is presented.",2304736_1,1
10388,postsynaptic alpha-1 adrenergic receptors,100,141,Prazosin exerts its antihypertensive effects through vasodilatation caused by selective blockade of postsynaptic alpha-1 adrenergic receptors.,2304736_2,0
10387,vasodilatation,53,67,Prazosin exerts its antihypertensive effects through vasodilatation caused by selective blockade of postsynaptic alpha-1 adrenergic receptors.,2304736_2,1
10386,antihypertensive effects,20,44,Prazosin exerts its antihypertensive effects through vasodilatation caused by selective blockade of postsynaptic alpha-1 adrenergic receptors.,2304736_2,0
10392,taking verapamil,137,153,The patient's clinical course is described and correlated with initial urodynamic studies while on prazosin and subsequent studies while taking verapamil.,2304736_4,0
10390,patient's clinical course,4,29,The patient's clinical course is described and correlated with initial urodynamic studies while on prazosin and subsequent studies while taking verapamil.,2304736_4,1
2516,Her,0,3,Her incontinence resolved with the change of medication.,2304736_5,0
10393,urethral pressure,79,96,"The restoration of continence was accompanied by a substantial rise in maximum urethral pressure, maximum urethral closure pressure, and functional urethral length.",2304736_6,1
10394,urethral closure,106,122,"The restoration of continence was accompanied by a substantial rise in maximum urethral pressure, maximum urethral closure pressure, and functional urethral length.",2304736_6,1
6134,stress incontinence,26,45,"Patients who present with stress incontinence while taking prazosin should change their antihypertensive medication before considering surgery, because their incontinence may resolve spontaneously with a change in drug therapy.",2304736_7,1
6135,Myocardial infarction,0,21,Myocardial infarction following sublingual administration of isosorbide dinitrate.,2312209_0,1
2517,isosorbide dinitrate,61,81,Myocardial infarction following sublingual administration of isosorbide dinitrate.,2312209_0,0
6136,myocardial infarction,63,84,A 78-year-old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of isosorbide dinitrate 5 mg sublingually.,2312209_1,1
6137,anterior wall,92,105,A 78-year-old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of isosorbide dinitrate 5 mg sublingually.,2312209_1,1
10396,septal necrosis,26,41,A 78-year-old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of isosorbide dinitrate 5 mg sublingually.,2312209_1,1
10397,sublingually,164,176,A 78-year-old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of isosorbide dinitrate 5 mg sublingually.,2312209_1,1
2518,isosorbide dinitrate,138,158,A 78-year-old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of isosorbide dinitrate 5 mg sublingually.,2312209_1,0
10398,coronary spasm,73,87,"After detailing the course of events, we discuss the role of paradoxical coronary spasm and hypotension-mediated myocardial ischemia occurring downstream to significant coronary arterial stenosis in the pathophysiology of acute coronary insufficiency.",2312209_2,1
10399,coronary arterial stenosis,169,195,"After detailing the course of events, we discuss the role of paradoxical coronary spasm and hypotension-mediated myocardial ischemia occurring downstream to significant coronary arterial stenosis in the pathophysiology of acute coronary insufficiency.",2312209_2,1
6139,pathophysiology,203,218,"After detailing the course of events, we discuss the role of paradoxical coronary spasm and hypotension-mediated myocardial ischemia occurring downstream to significant coronary arterial stenosis in the pathophysiology of acute coronary insufficiency.",2312209_2,1
6138,myocardial ischemia,113,132,"After detailing the course of events, we discuss the role of paradoxical coronary spasm and hypotension-mediated myocardial ischemia occurring downstream to significant coronary arterial stenosis in the pathophysiology of acute coronary insufficiency.",2312209_2,1
6140,acute coronary,222,236,"After detailing the course of events, we discuss the role of paradoxical coronary spasm and hypotension-mediated myocardial ischemia occurring downstream to significant coronary arterial stenosis in the pathophysiology of acute coronary insufficiency.",2312209_2,1
10401,renal function,105,119,Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function.,2320800_0,1
10400,high dose ifosfamide,27,47,Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function.,2320800_0,0
6141,breast cancer,66,79,Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function.,2320800_0,1
10402,g/m2,163,167,"A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.",2320800_1,0
2519,cisplatin,76,85,"A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.",2320800_1,0
2520,ifosfamide,174,184,"A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.",2320800_1,0
6142,breast cancer,37,50,"A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.",2320800_1,1
6143,renal failure,120,133,"A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide.",2320800_1,1
10403,Postrenal failure,0,17,Postrenal failure was excluded by echography.,2320800_2,1
10405,transient hypotension,74,95,"A prerenal component could have contributed to renal failure because of a transient hypotension, due to an increasing ascitis, occurring just before anuria.",2320800_3,1
10406,ascitis,118,125,"A prerenal component could have contributed to renal failure because of a transient hypotension, due to an increasing ascitis, occurring just before anuria.",2320800_3,1
6144,renal failure,47,60,"A prerenal component could have contributed to renal failure because of a transient hypotension, due to an increasing ascitis, occurring just before anuria.",2320800_3,1
10407,renal function,66,80,"However, correction of the hemodynamic parameters did not improve renal function.",2320800_4,1
2521,Ifosfamide,0,10,Ifosfamide is a known nephrotoxic drug with demonstrated tubulopathies.,2320800_5,0
10408,tubulopathies,57,70,Ifosfamide is a known nephrotoxic drug with demonstrated tubulopathies.,2320800_5,1
2523,cisplatin,122,131,"We strongly suspect that this lethal anuria was mainly due to ifosfamide, occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension.",2320800_6,0
2522,ifosfamide,62,72,"We strongly suspect that this lethal anuria was mainly due to ifosfamide, occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension.",2320800_6,0
10409,poor kidney perfusion,154,175,"We strongly suspect that this lethal anuria was mainly due to ifosfamide, occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension.",2320800_6,1
2524,ifosfamide,28,38,We recommend careful use of ifosfamide in patients pretreated with nephrotoxic chemotherapy and inadequate renal perfusion.,2320800_7,0
10411,inadequate renal perfusion,96,122,We recommend careful use of ifosfamide in patients pretreated with nephrotoxic chemotherapy and inadequate renal perfusion.,2320800_7,1
2525,prostaglandin D2,61,77,"Nociceptive effects induced by intrathecal administration of prostaglandin D2, E2, or F2 alpha to conscious mice.",2322844_0,0
2526,E2,79,81,"Nociceptive effects induced by intrathecal administration of prostaglandin D2, E2, or F2 alpha to conscious mice.",2322844_0,0
2527,F2 alpha,86,94,"Nociceptive effects induced by intrathecal administration of prostaglandin D2, E2, or F2 alpha to conscious mice.",2322844_0,0
2528,acetic acid,134,145,The effects of intrathecal administration of prostaglandins on pain responses in conscious mice were evaluated by using hot plate and acetic acid writhing tests.,2322844_1,0
10418,hot plate,120,129,The effects of intrathecal administration of prostaglandins on pain responses in conscious mice were evaluated by using hot plate and acetic acid writhing tests.,2322844_1,0
2529,Prostaglandin D2,0,16,Prostaglandin D2 (0.5-3 ng/mouse) had a hyperalgesic action on the response to a hot plate during a 3-60 min period after injection.,2322844_2,0
6145,hyperalgesic,40,52,Prostaglandin D2 (0.5-3 ng/mouse) had a hyperalgesic action on the response to a hot plate during a 3-60 min period after injection.,2322844_2,1
2532,(3,109,111,"Prostaglandin E2 showed a hyperalgesic effect at doses of 1 pg to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.",2322844_3,0
2531,pg,60,62,"Prostaglandin E2 showed a hyperalgesic effect at doses of 1 pg to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.",2322844_3,0
2530,Prostaglandin E2,0,16,"Prostaglandin E2 showed a hyperalgesic effect at doses of 1 pg to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.",2322844_3,0
6146,hyperalgesic,26,38,"Prostaglandin E2 showed a hyperalgesic effect at doses of 1 pg to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.",2322844_3,1
2533,prostaglandin D2,133,149,"Prostaglandin E2 showed a hyperalgesic effect at doses of 1 pg to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2.",2322844_3,0
2534,acetic acid,33,44,Similar results were obtained by acetic acid writhing tests.,2322844_4,0
6147,hyperalgesic,4,16,"The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.",2322844_5,1
2537,prostanoid,165,175,"The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.",2322844_5,0
2536,substance P,87,98,"The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.",2322844_5,0
2535,prostaglandin D2,27,43,"The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.",2322844_5,0
10421,AH6809,155,161,"The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist.",2322844_5,0
10422,AH6809,65,71,"Conversely, prostaglandin E2-induced hyperalgesia was blocked by AH6809 (greater than or equal to 500 ng) but not by the substance P antagonist.",2322844_6,0
6148,hyperalgesia,37,49,"Conversely, prostaglandin E2-induced hyperalgesia was blocked by AH6809 (greater than or equal to 500 ng) but not by the substance P antagonist.",2322844_6,1
2538,substance P,121,132,"Conversely, prostaglandin E2-induced hyperalgesia was blocked by AH6809 (greater than or equal to 500 ng) but not by the substance P antagonist.",2322844_6,0
2539,Prostaglandin F2 alpha,0,22,Prostaglandin F2 alpha had little effect on pain responses.,2322844_7,0
6150,spinal cord,100,111,"These results demonstrate that both prostaglandin D2 and prostaglandin E2 exert hyperalgesia in the spinal cord, but in different ways.",2322844_8,1
2540,prostaglandin D2,36,52,"These results demonstrate that both prostaglandin D2 and prostaglandin E2 exert hyperalgesia in the spinal cord, but in different ways.",2322844_8,0
6149,hyperalgesia,80,92,"These results demonstrate that both prostaglandin D2 and prostaglandin E2 exert hyperalgesia in the spinal cord, but in different ways.",2322844_8,1
2541,prostaglandin E2,57,73,"These results demonstrate that both prostaglandin D2 and prostaglandin E2 exert hyperalgesia in the spinal cord, but in different ways.",2322844_8,0
6151,localized scleroderma,36,57,D-penicillamine in the treatment of localized scleroderma.,2334179_0,1
2542,D-penicillamine,0,15,D-penicillamine in the treatment of localized scleroderma.,2334179_0,0
6152,Localized scleroderma,0,21,Localized scleroderma has no recognized internal organ involvement but may be disfiguring and disabling when the cutaneous lesions are extensive or affect children.,2334179_1,1
10424,internal organ,40,54,Localized scleroderma has no recognized internal organ involvement but may be disfiguring and disabling when the cutaneous lesions are extensive or affect children.,2334179_1,1
10425,cutaneous lesions,113,130,Localized scleroderma has no recognized internal organ involvement but may be disfiguring and disabling when the cutaneous lesions are extensive or affect children.,2334179_1,1
6153,localized scleroderma,45,66,There is no accepted or proven treatment for localized scleroderma.,2334179_2,1
2543,D-penicillamine,95,110,"Case reports of 11 patients with severe, extensive localized scleroderma who were treated with D-penicillamine are summarized in this article.",2334179_3,0
6154,localized scleroderma,51,72,"Case reports of 11 patients with severe, extensive localized scleroderma who were treated with D-penicillamine are summarized in this article.",2334179_3,1
10427,disease course,55,69,This drug was judged to have a favorable effect on the disease course in 7 (64%) of 11 patients.,2334179_4,1
10430,normal growth,143,156,"Improvement began within 3 to 6 months and consisted of cessation of active cutaneous lesions in all 7 patients, skin softening in 5, and more normal growth of the affected limb in 2 of 3 children.",2334179_5,1
10429,skin softening,113,127,"Improvement began within 3 to 6 months and consisted of cessation of active cutaneous lesions in all 7 patients, skin softening in 5, and more normal growth of the affected limb in 2 of 3 children.",2334179_5,1
10428,active cutaneous lesions,69,93,"Improvement began within 3 to 6 months and consisted of cessation of active cutaneous lesions in all 7 patients, skin softening in 5, and more normal growth of the affected limb in 2 of 3 children.",2334179_5,1
10431,Joint stiffness,0,15,Joint stiffness and contractures also improved.,2334179_6,1
2544,D-penicillamine,12,27,The dose of D-penicillamine associated with a favorable response was as low as 2 to 5 mg/kg per day given over a period ranging from 15 to 53 months.,2334179_7,0
6155,nephrotic syndrome,23,41,D-Penicillamine caused nephrotic syndrome in 1 patient and milder reversible proteinuria in 3 other patients; none developed renal insufficiency.,2334179_8,1
6156,renal insufficiency,125,144,D-Penicillamine caused nephrotic syndrome in 1 patient and milder reversible proteinuria in 3 other patients; none developed renal insufficiency.,2334179_8,1
2545,D-Penicillamine,0,15,D-Penicillamine caused nephrotic syndrome in 1 patient and milder reversible proteinuria in 3 other patients; none developed renal insufficiency.,2334179_8,0
6157,localized scleroderma,76,97,These data suggest that D-penicillamine may be effective in severe cases of localized scleroderma.,2334179_9,1
2546,D-penicillamine,24,39,These data suggest that D-penicillamine may be effective in severe cases of localized scleroderma.,2334179_9,0
10433,regional analgesia,26,44,infusions of morphine and regional analgesia by extradural block.,2334618_1,0
10434,extradural block,48,64,infusions of morphine and regional analgesia by extradural block.,2334618_1,1
10435,respiratory apnoea,31,49,The incidence of postoperative respiratory apnoea was compared between five patients receiving a continuous i.v.,2334618_2,1
10436,upper abdominal surgery,161,184,infusion of morphine (mean 73.6 mg) and five patients receiving a continuous extradural infusion of 0.25% bupivacaine (mean 192 mg) in the 24-h period following upper abdominal surgery.,2334618_3,1
2547,bupivacaine,106,117,infusion of morphine (mean 73.6 mg) and five patients receiving a continuous extradural infusion of 0.25% bupivacaine (mean 192 mg) in the 24-h period following upper abdominal surgery.,2334618_3,0
2548,carbon dioxide,47,61,"Monitoring consisted of airflow detection by a carbon dioxide analyser, chest wall movement detected by pneumatic capsules, and continuous electrocardiograph recorded with a Holter ambulatory monitor.",2334618_4,0
10438,chest wall,72,82,"Monitoring consisted of airflow detection by a carbon dioxide analyser, chest wall movement detected by pneumatic capsules, and continuous electrocardiograph recorded with a Holter ambulatory monitor.",2334618_4,1
10442,central apnoea,40,54,Both obstructive (P less than 0.05) and central apnoea (P less than 0.05) occurred more frequently in patients who had a morphine infusion.,2334618_5,1
6158,tachyarrhythmias,37,53,There was also a higher incidence of tachyarrhythmias (P less than 0.05) and ventricular ectopic beats (P less than 0.05) in the morphine infusion group.,2334618_6,1
6159,ventricular ectopic beats,77,102,There was also a higher incidence of tachyarrhythmias (P less than 0.05) and ventricular ectopic beats (P less than 0.05) in the morphine infusion group.,2334618_6,1
6160,sinus thrombosis,9,25,Cerebral sinus thrombosis as a potential hazard of antifibrinolytic treatment in menorrhagia.,2339463_0,1
2549,antifibrinolytic,51,67,Cerebral sinus thrombosis as a potential hazard of antifibrinolytic treatment in menorrhagia.,2339463_0,0
2550,epsilon-aminocaproic acid,127,152,We describe a 42-year-old woman who developed superior sagittal and left transverse sinus thrombosis associated with prolonged epsilon-aminocaproic acid therapy for menorrhagia.,2339463_1,0
6161,transverse sinus thrombosis,73,100,We describe a 42-year-old woman who developed superior sagittal and left transverse sinus thrombosis associated with prolonged epsilon-aminocaproic acid therapy for menorrhagia.,2339463_1,1
6162,blood loss,99,109,This antifibrinolytic agent has been used in women with menorrhagia to promote clotting and reduce blood loss.,2339463_2,1
2551,antifibrinolytic agent,5,27,This antifibrinolytic agent has been used in women with menorrhagia to promote clotting and reduce blood loss.,2339463_2,0
10444,thromboembolic,27,41,"Although increased risk of thromboembolic disease has been reported during treatment with epsilon-aminocaproic acid, cerebral sinus thrombosis has not been previously described.",2339463_3,1
6163,sinus thrombosis,126,142,"Although increased risk of thromboembolic disease has been reported during treatment with epsilon-aminocaproic acid, cerebral sinus thrombosis has not been previously described.",2339463_3,1
2552,epsilon-aminocaproic acid,90,115,"Although increased risk of thromboembolic disease has been reported during treatment with epsilon-aminocaproic acid, cerebral sinus thrombosis has not been previously described.",2339463_3,0
2553,epsilon-aminocaproic acid,15,40,Careful use of epsilon-aminocaproic acid therapy is recommended.,2339463_4,0
2554,imipenem,22,30,Seizure activity with imipenem therapy: incidence and risk factors.,2343592_0,0
6166,renal disease,113,126,Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.,2343592_1,1
2555,imipenem/cilastatin,179,198,Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.,2343592_1,0
6165,head trauma,82,93,Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.,2343592_1,1
6164,vascular accident,55,72,Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin.,2343592_1,1
10448,anticonvulsant agents,90,111,Neither patient had reported previous seizures or seizure-like activity nor was receiving anticonvulsant agents.,2343592_2,0
10449,therapeutic doses,34,51,All seizures were controlled with therapeutic doses of phenytoin.,2343592_3,0
10451,beta-lactam antibiotics,50,73,Both patients had received maximum doses of other beta-lactam antibiotics without evidence of seizure activity.,2343592_4,0
6168,respiratory failure,89,108,Effects of aminophylline on the threshold for initiating ventricular fibrillation during respiratory failure.,234669_0,1
6167,ventricular fibrillation,57,81,Effects of aminophylline on the threshold for initiating ventricular fibrillation during respiratory failure.,234669_0,1
6170,respiratory failure,70,89,Cardiac arrhythmias have frequently been reported in association with respiratory failure.,234669_1,1
6169,Cardiac arrhythmias,0,19,Cardiac arrhythmias have frequently been reported in association with respiratory failure.,234669_1,1
6171,respiratory failure,106,125,The possible additive role of pharmacologic agents in precipitating cardiac disturbances in patients with respiratory failure has only recently been emphasized.,234669_2,1
10456,precipitating cardiac disturbances,54,88,The possible additive role of pharmacologic agents in precipitating cardiac disturbances in patients with respiratory failure has only recently been emphasized.,234669_2,1
10455,pharmacologic agents,30,50,The possible additive role of pharmacologic agents in precipitating cardiac disturbances in patients with respiratory failure has only recently been emphasized.,234669_2,0
6174,respiratory failure,117,136,The effects of aminophylline on the ventricular fibrillation threshold during normal acid-base conditions and during respiratory failure were studied in anesthetized open chest dogs.,234669_3,1
6172,ventricular fibrillation,36,60,The effects of aminophylline on the ventricular fibrillation threshold during normal acid-base conditions and during respiratory failure were studied in anesthetized open chest dogs.,234669_3,1
6173,acid-base,85,94,The effects of aminophylline on the ventricular fibrillation threshold during normal acid-base conditions and during respiratory failure were studied in anesthetized open chest dogs.,234669_3,1
10459,ventricular myocardium,119,141,The ventricular fibrillation threshold was measured by passing a gated train of 12 constant current pulses through the ventricular myocardium during the vulnerable period of the cardiac cycle.,234669_4,1
6175,ventricular fibrillation,4,28,The ventricular fibrillation threshold was measured by passing a gated train of 12 constant current pulses through the ventricular myocardium during the vulnerable period of the cardiac cycle.,234669_4,1
10461,PO2,165,168,"During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide (CO2) were kept within normal limits.",234669_5,0
6176,ventricular fibrillation,42,66,"During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide (CO2) were kept within normal limits.",234669_5,1
2556,carbon dioxide,174,188,"During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide (CO2) were kept within normal limits.",234669_5,0
10462,PC02,75,79,"When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level.",234669_6,0
6179,ventricular fibrillation,184,208,"When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level.",234669_6,1
6178,hypoventilation,41,56,"When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level.",234669_6,1
6177,respiratory failure,5,24,"When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level.",234669_6,1
6180,respiratory failure,125,144,"These experiments suggest that although many factors may contribute to the increased incidence of ventricular arrhythmias in respiratory failure, pharmacologic agents, particularly aminophylline, may play a significant role.",234669_7,1
10465,ventricular arrhythmias,98,121,"These experiments suggest that although many factors may contribute to the increased incidence of ventricular arrhythmias in respiratory failure, pharmacologic agents, particularly aminophylline, may play a significant role.",234669_7,1
6181,peripheral vascular disease,95,122,Dipyridamole-thallium-201 imaging is often performed in patients unable to exercise because of peripheral vascular disease.,2348231_1,1
10469,methylxanthine derivative,62,87,"Many of these patients are taking pentoxifylline (Trental), a methylxanthine derivative which may improve intermittent claudication.",2348231_2,0
6182,intermittent claudication,106,131,"Many of these patients are taking pentoxifylline (Trental), a methylxanthine derivative which may improve intermittent claudication.",2348231_2,1
10471,methylxanthines,83,98,Whether pentoxifylline inhibits dipyridamole-induced coronary hyperemia like other methylxanthines such as theophylline and should be stopped prior to dipyridamole-thallium-201 imaging is unknown.,2348231_3,0
2557,dipyridamole,48,60,"Therefore, we studied the hyperemic response to dipyridamole in seven open-chest anesthetized dogs after pretreatment with either pentoxifylline (0, 7.5, or 15 mg/kg i.v.) or theophylline (3 mg/kg i.v.).",2348231_4,0
10474,theophylline (3,175,190,"Therefore, we studied the hyperemic response to dipyridamole in seven open-chest anesthetized dogs after pretreatment with either pentoxifylline (0, 7.5, or 15 mg/kg i.v.) or theophylline (3 mg/kg i.v.).",2348231_4,0
2558,Dipyridamole,0,12,Dipyridamole significantly increased coronary blood flow before and after 7.5 or 15 mm/kg i.v.,2348231_6,0
10478,pentoxyifylline,17,32,We conclude that pentoxyifylline does not inhibit dipyridamole-induced coronary hyperemia even at high doses.,2348231_9,0
10479,coronary hyperemia,71,89,We conclude that pentoxyifylline does not inhibit dipyridamole-induced coronary hyperemia even at high doses.,2348231_9,1
10480,high doses,98,108,We conclude that pentoxyifylline does not inhibit dipyridamole-induced coronary hyperemia even at high doses.,2348231_9,0
10481,Cause of,0,8,Cause of death among patients with Parkinson's disease: a rare mortality due to cerebral haemorrhage.,2355241_0,1
10482,cerebral haemorrhage,80,100,Cause of death among patients with Parkinson's disease: a rare mortality due to cerebral haemorrhage.,2355241_0,1
6183,Parkinson's disease,35,54,Cause of death among patients with Parkinson's disease: a rare mortality due to cerebral haemorrhage.,2355241_0,1
6184,Parkinson's disease,113,132,"Causes of death, with special reference to cerebral haemorrhage, among 240 patients with pathologically verified Parkinson's disease were investigated using the Annuals of the Pathological Autopsy Cases in Japan from 1981 to 1985.",2355241_1,1
10483,Causes of death,0,15,"Causes of death, with special reference to cerebral haemorrhage, among 240 patients with pathologically verified Parkinson's disease were investigated using the Annuals of the Pathological Autopsy Cases in Japan from 1981 to 1985.",2355241_1,1
10484,cerebral haemorrhage,43,63,"Causes of death, with special reference to cerebral haemorrhage, among 240 patients with pathologically verified Parkinson's disease were investigated using the Annuals of the Pathological Autopsy Cases in Japan from 1981 to 1985.",2355241_1,1
6185,malignant neoplasms,67,86,"The leading causes of death were pneumonia and bronchitis (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%).",2355241_2,1
6187,cerebral infarction,119,138,"The leading causes of death were pneumonia and bronchitis (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%).",2355241_2,1
6186,heart diseases,96,110,"The leading causes of death were pneumonia and bronchitis (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%).",2355241_2,1
10486,cause of,48,56,"Cerebral haemorrhage was the 11th most frequent cause of death, accounting for only 0.8% of deaths among the patients, whereas it was the 5th most common cause of death among the Japanese general population in 1985.",2355241_3,1
10485,Cerebral haemorrhage,0,20,"Cerebral haemorrhage was the 11th most frequent cause of death, accounting for only 0.8% of deaths among the patients, whereas it was the 5th most common cause of death among the Japanese general population in 1985.",2355241_3,1
10488,cerebral haemorrhage,21,41,The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.,2355241_4,1
10491,parkinsonian brain,217,235,The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.,2355241_4,1
6188,Parkinson's disease,79,98,The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain.,2355241_4,1
10492,cardiorespiratory arrest,44,68,Possible intramuscular midazolam-associated cardiorespiratory arrest and death.,2375138_0,1
2559,Midazolam hydrochloride,0,23,Midazolam hydrochloride is commonly used for dental or endoscopic procedures.,2375138_1,0
10495,cardiovascular depression,123,148,"Although generally consisted safe when given intramuscularly, intravenous administration is known to cause respiratory and cardiovascular depression.",2375138_2,1
10496,cardiorespiratory arrest,50,74,This report describes the first published case of cardiorespiratory arrest and death associated with intramuscular administration of midazolam.,2375138_3,1
6189,Myasthenia gravis,0,17,Myasthenia gravis presenting as weakness after magnesium administration.,2385256_0,1
6190,neuromuscular disease,46,67,We studied a patient with no prior history of neuromuscular disease who became virtually quadriplegic after parenteral magnesium administration for preeclampsia.,2385256_1,1
10499,virtually quadriplegic,79,101,We studied a patient with no prior history of neuromuscular disease who became virtually quadriplegic after parenteral magnesium administration for preeclampsia.,2385256_1,1
10503,postsynaptic neuromuscular blockade,147,182,"While she was weak, 2-Hz repetitive stimulation revealed a decrement without significant facilitation at rapid rates or after exercise, suggesting postsynaptic neuromuscular blockade.",2385256_4,1
2560,her,6,9,"After her strength returned, repetitive stimulation was normal, but single fiber EMG revealed increased jitter and blocking.",2385256_5,0
10506,acetylcholine receptor antibody,4,35,Her acetylcholine receptor antibody level was markedly elevated.,2385256_6,0
6191,myasthenia gravis,92,109,"Although paralysis after magnesium administration has been described in patients with known myasthenia gravis, it has not previously been reported to be the initial or only manifestation of the disease.",2385256_7,1
10508,neuromuscular transmission,135,161,Patients who are unusually sensitive to the neuromuscular effects of magnesium should be suspected of having an underlying disorder of neuromuscular transmission.,2385256_8,1
2561,neuromuscular effects,44,65,Patients who are unusually sensitive to the neuromuscular effects of magnesium should be suspected of having an underlying disorder of neuromuscular transmission.,2385256_8,0
10510,hepatocarcinogenicity,39,60,No enhancement by phenobarbital of the hepatocarcinogenicity of a choline-devoid diet in the rat.,2396046_0,1
10512,hepatocarcinogenicity,115,136,An experiment was performed to test whether inclusion of phenobarbital in a choline-devoid diet would increase the hepatocarcinogenicity of the diet.,2396046_1,1
6195,hepatocellular carcinoma,160,184,"No hepatic preneoplastic nodules or hepatocellular carcinomas developed in rats fed the plain choline-supplemented diet, while one preneoplastic nodule and one hepatocellular carcinoma developed in two rats fed the same diet containing phenobarbital.",2396046_3,1
6194,preneoplastic,131,144,"No hepatic preneoplastic nodules or hepatocellular carcinomas developed in rats fed the plain choline-supplemented diet, while one preneoplastic nodule and one hepatocellular carcinoma developed in two rats fed the same diet containing phenobarbital.",2396046_3,1
6193,hepatocellular carcinomas,36,61,"No hepatic preneoplastic nodules or hepatocellular carcinomas developed in rats fed the plain choline-supplemented diet, while one preneoplastic nodule and one hepatocellular carcinoma developed in two rats fed the same diet containing phenobarbital.",2396046_3,1
6192,preneoplastic,11,24,"No hepatic preneoplastic nodules or hepatocellular carcinomas developed in rats fed the plain choline-supplemented diet, while one preneoplastic nodule and one hepatocellular carcinoma developed in two rats fed the same diet containing phenobarbital.",2396046_3,1
6197,hepatocellular carcinomas,46,71,"The incidence of preneoplastic nodules and of hepatocellular carcinomas was 10% and 37%, respectively, in rats fed the plain choline-devoid diet, and 17% and 30%, in rats fed the phenobarbital-containing choline-devoid diet.",2396046_4,1
6196,preneoplastic,17,30,"The incidence of preneoplastic nodules and of hepatocellular carcinomas was 10% and 37%, respectively, in rats fed the plain choline-devoid diet, and 17% and 30%, in rats fed the phenobarbital-containing choline-devoid diet.",2396046_4,1
10518,hepatocarcinogenicity,42,63,The results evinced no enhancement of the hepatocarcinogenicity of the choline-devoid diet by phenobarbital.,2396046_5,1
10520,neoplastic lesions,9,27,"Sporadic neoplastic lesions were observed in organs other than the liver of some of the animals, irrespective of the diet fed.",2396046_6,1
10521,B3 serotonin,8,20,Midline B3 serotonin nerves in rat medulla are involved in hypotensive effect of methyldopa.,2422478_0,0
6198,spinal cord,233,244,Previous experiments in this laboratory have shown that microinjection of methyldopa onto the ventrolateral cells of the B3 serotonin neurons in the medulla elicits a hypotensive response mediated by a projection descending into the spinal cord.,2422478_1,1
10524,B3 serotonin,121,133,Previous experiments in this laboratory have shown that microinjection of methyldopa onto the ventrolateral cells of the B3 serotonin neurons in the medulla elicits a hypotensive response mediated by a projection descending into the spinal cord.,2422478_1,0
10528,B3 serotonin,90,102,"The present experiments were designed to investigate the role of the midline cells of the B3 serotonin neurons in the medulla, coinciding with the raphe magnus.",2422478_2,0
10537,"5,7-DHT",315,322,"In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.",2422478_3,0
10536,serotonin neurotoxin,269,289,"In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.",2422478_3,0
10533,B3 serotonin,108,120,"In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.",2422478_3,0
10530,spontaneously hypertensive,3,29,"In spontaneously hypertensive, stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly.",2422478_3,1
6199,spinal cord,125,136,"However, intraspinal injection of 5,7-DHT to produce a more selective lesion of only descending serotonin projections in the spinal cord did not affect this hypotension.",2422478_4,1
10539,"5,7-DHT",34,41,"However, intraspinal injection of 5,7-DHT to produce a more selective lesion of only descending serotonin projections in the spinal cord did not affect this hypotension.",2422478_4,0
6200,blood pressure,178,192,"Further, 5,7-DHT lesion of serotonin nerves travelling in the median forebrain bundle, one of the main ascending pathways from the B3 serotonin cells, did not affect the fall in blood pressure associated with a midline B3 serotonin methyldopa injection.",2422478_5,1
10540,"5,7-DHT",9,16,"Further, 5,7-DHT lesion of serotonin nerves travelling in the median forebrain bundle, one of the main ascending pathways from the B3 serotonin cells, did not affect the fall in blood pressure associated with a midline B3 serotonin methyldopa injection.",2422478_5,0
10543,B3 serotonin,131,143,"Further, 5,7-DHT lesion of serotonin nerves travelling in the median forebrain bundle, one of the main ascending pathways from the B3 serotonin cells, did not affect the fall in blood pressure associated with a midline B3 serotonin methyldopa injection.",2422478_5,0
10545,B3 serotonin methyldopa,219,242,"Further, 5,7-DHT lesion of serotonin nerves travelling in the median forebrain bundle, one of the main ascending pathways from the B3 serotonin cells, did not affect the fall in blood pressure associated with a midline B3 serotonin methyldopa injection.",2422478_5,0
2562,B3,57,59,"It is concluded therefore that, unlike the ventrolateral B3 cells which mediate a methyldopa-induced hypotension via descending projections, the midline serotonin B3 cells in the medulla contribute to the hypotensive action of methyldopa, either by way of an ascending projection which does not pass through the median forebrain bundle, or through a projection restricted to the caudal brainstem.",2422478_6,0
10548,serotonin B3,153,165,"It is concluded therefore that, unlike the ventrolateral B3 cells which mediate a methyldopa-induced hypotension via descending projections, the midline serotonin B3 cells in the medulla contribute to the hypotensive action of methyldopa, either by way of an ascending projection which does not pass through the median forebrain bundle, or through a projection restricted to the caudal brainstem.",2422478_6,0
6201,side-effects,19,31,"On two paradoxical side-effects of prednisolone in rats, ribosomal RNA biosyntheses, and a mechanism of action.",2425813_0,1
10555,muscle wastage,22,36,Liver enlargement and muscle wastage occurred in Wistar rats following the subcutaneous administration of prednisolone.,2425813_1,1
10554,Liver enlargement,0,17,Liver enlargement and muscle wastage occurred in Wistar rats following the subcutaneous administration of prednisolone.,2425813_1,1
2563,ribosomal RNA,61,74,In the liver both the content of RNA and the biosynthesis of ribosomal RNA increased while both the RNA content and ribosomal RNA biosynthesis were reduced in the gastrocnemius muscle.,2425813_2,0
2564,ribosomal RNA,116,129,In the liver both the content of RNA and the biosynthesis of ribosomal RNA increased while both the RNA content and ribosomal RNA biosynthesis were reduced in the gastrocnemius muscle.,2425813_2,0
10560,cibenzoline,40,51,Antiarrhythmic plasma concentrations of cibenzoline on canine ventricular arrhythmias.,2435991_0,0
10561,ventricular arrhythmias,62,85,Antiarrhythmic plasma concentrations of cibenzoline on canine ventricular arrhythmias.,2435991_0,1
10562,ventricular arrhythmias,78,101,"Using two-stage coronary ligation-, digitalis-, and adrenaline-induced canine ventricular arrhythmias, antiarrhythmic effects of cibenzoline were examined and the minimum effective plasma concentration for each arrhythmia model was determined.",2435991_1,1
10563,antiarrhythmic effects,103,125,"Using two-stage coronary ligation-, digitalis-, and adrenaline-induced canine ventricular arrhythmias, antiarrhythmic effects of cibenzoline were examined and the minimum effective plasma concentration for each arrhythmia model was determined.",2435991_1,0
10564,cibenzoline,129,140,"Using two-stage coronary ligation-, digitalis-, and adrenaline-induced canine ventricular arrhythmias, antiarrhythmic effects of cibenzoline were examined and the minimum effective plasma concentration for each arrhythmia model was determined.",2435991_1,0
10565,Cibenzoline,0,11,"Cibenzoline suppressed all the arrhythmias, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.), 0.6 +/- 0.2 (by 2 mg/kg i.v.), and 3.5 +/- 1.3 (by 5 mg/kg i.v.) micrograms/ml, respectively (mean +/- SDM, n = 6-7).",2435991_2,0
10567,coronary ligation,148,165,"Cibenzoline suppressed all the arrhythmias, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.), 0.6 +/- 0.2 (by 2 mg/kg i.v.), and 3.5 +/- 1.3 (by 5 mg/kg i.v.) micrograms/ml, respectively (mean +/- SDM, n = 6-7).",2435991_2,1
10566,coronary ligation,124,141,"Cibenzoline suppressed all the arrhythmias, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, digitalis, and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.), 0.6 +/- 0.2 (by 2 mg/kg i.v.), and 3.5 +/- 1.3 (by 5 mg/kg i.v.) micrograms/ml, respectively (mean +/- SDM, n = 6-7).",2435991_2,1
10572,adrenaline-induced arrhythmia,22,51,The concentration for adrenaline-induced arrhythmia was significantly higher than those for the other types of arrhythmias.,2435991_3,1
6202,central nervous system,103,125,"This pharmacological profile is similar to those of mexiletine and tocainide, and all three drugs have central nervous system (CNS) stimulant action.",2435991_4,1
10575,coronary ligation,128,145,"Because cibenzoline had only weak hypotensive and sinus node depressive effects and was found to be orally active when given to coronary ligation arrhythmia dogs, its clinical usefulness is expected.",2435991_5,1
6203,sinus node,50,60,"Because cibenzoline had only weak hypotensive and sinus node depressive effects and was found to be orally active when given to coronary ligation arrhythmia dogs, its clinical usefulness is expected.",2435991_5,1
10574,cibenzoline,8,19,"Because cibenzoline had only weak hypotensive and sinus node depressive effects and was found to be orally active when given to coronary ligation arrhythmia dogs, its clinical usefulness is expected.",2435991_5,0
2565,gamma-hexachlorocyclohexane,24,51,Differential effects of gamma-hexachlorocyclohexane (lindane) on pharmacologically-induced seizures.,2440413_0,0
2566,Gamma-hexachlorocyclohexane,0,27,"Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).",2440413_1,0
2568,gamma-HCH,183,192,"Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).",2440413_1,0
2569,gamma-HCH,274,283,"Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).",2440413_1,0
10579,active ingredient,45,62,"Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).",2440413_1,0
10582,PTZ,156,159,"Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).",2440413_1,0
10581,pentylenetrazol,139,154,"Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).",2440413_1,0
10580,insecticide lindane,70,89,"Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).",2440413_1,0
2567,gamma-HCH,29,38,"Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).",2440413_1,0
2570,et,293,295,"Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al. 1981).",2440413_1,0
2571,gamma-HCH,152,161,"In this study, the severity of response to other seizure-inducing agents was tested in mice 1 and 24 h after intraperitoneal administration of 80 mg/kg gamma-HCH.",2440413_2,0
10583,intraperitoneal,109,124,"In this study, the severity of response to other seizure-inducing agents was tested in mice 1 and 24 h after intraperitoneal administration of 80 mg/kg gamma-HCH.",2440413_2,1
2572,gamma-HCH,37,46,"One hour after the administration of gamma-HCH, the activity of seizure-inducing agents was increased, regardless of their mechanism, while 24 h after gamma-HCH a differential response was observed.",2440413_3,0
2573,gamma-HCH,151,160,"One hour after the administration of gamma-HCH, the activity of seizure-inducing agents was increased, regardless of their mechanism, while 24 h after gamma-HCH a differential response was observed.",2440413_3,0
10584,PTZ,24,27,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,0
10585,PTX,44,47,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,0
10586,3-mercaptopropionic acid,111,135,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,0
10587,MPA,137,140,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,0
10588,BCC,156,159,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,0
10589,"methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (",162,218,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,0
10590,STR,240,243,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,0
2575,bicuculline,143,154,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,0
2574,picrotoxin,32,42,"Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control.",2440413_4,0
2576,gamma-HCH,10,19,"In vitro, gamma-HCH, pentylenetetrazol and picrotoxin were shown to inhibit 3H-TBOB binding in mouse whole brain, with IC50 values of 4.6, 404 and 9.4 microM, respectively.",2440413_5,0
2577,picrotoxin,43,53,"In vitro, gamma-HCH, pentylenetetrazol and picrotoxin were shown to inhibit 3H-TBOB binding in mouse whole brain, with IC50 values of 4.6, 404 and 9.4 microM, respectively.",2440413_5,0
10592,IC50,119,123,"In vitro, gamma-HCH, pentylenetetrazol and picrotoxin were shown to inhibit 3H-TBOB binding in mouse whole brain, with IC50 values of 4.6, 404 and 9.4 microM, respectively.",2440413_5,0
2578,t-butyl,57,64,"MPA, BCC, DMCM, and STR showed no inhibition of 3H-TBOB (t-butyl bicyclo-orthobenzoate) binding at concentrations of 100 micron.",2440413_6,0
10597,3H-TBOB,48,55,"MPA, BCC, DMCM, and STR showed no inhibition of 3H-TBOB (t-butyl bicyclo-orthobenzoate) binding at concentrations of 100 micron.",2440413_6,0
10596,STR,20,23,"MPA, BCC, DMCM, and STR showed no inhibition of 3H-TBOB (t-butyl bicyclo-orthobenzoate) binding at concentrations of 100 micron.",2440413_6,0
10594,BCC,5,8,"MPA, BCC, DMCM, and STR showed no inhibition of 3H-TBOB (t-butyl bicyclo-orthobenzoate) binding at concentrations of 100 micron.",2440413_6,0
10593,MPA,0,3,"MPA, BCC, DMCM, and STR showed no inhibition of 3H-TBOB (t-butyl bicyclo-orthobenzoate) binding at concentrations of 100 micron.",2440413_6,0
10598,PTZ,99,102,"The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and PTX 24 h after gamma-HCH, since the response to only these two seizure-inducing agents is decreased.",2440413_7,0
10599,PTX,107,110,"The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and PTX 24 h after gamma-HCH, since the response to only these two seizure-inducing agents is decreased.",2440413_7,0
2579,gamma-HCH,122,131,"The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and PTX 24 h after gamma-HCH, since the response to only these two seizure-inducing agents is decreased.",2440413_7,0
2580,gamma-HCH,100,109,The in vitro data suggest that the site responsible for the decrease in seizure activity 24 h after gamma-HCH may be the GABA-A receptor-linked chloride channel.,2440413_8,0
2582,chloride channel,144,160,The in vitro data suggest that the site responsible for the decrease in seizure activity 24 h after gamma-HCH may be the GABA-A receptor-linked chloride channel.,2440413_8,0
2581,GABA-A,121,127,The in vitro data suggest that the site responsible for the decrease in seizure activity 24 h after gamma-HCH may be the GABA-A receptor-linked chloride channel.,2440413_8,0
6204,hemorrhagic fever,71,88,Tolerance and antiviral effect of ribavirin in patients with Argentine hemorrhagic fever.,2445283_0,1
6205,hemorrhagic fever,85,102,Tolerance and antiviral effect of ribavirin was studied in 6 patients with Argentine hemorrhagic fever (AHF) of more than 8 days of evolution.,2445283_1,1
10601,antiviral effect,14,30,Tolerance and antiviral effect of ribavirin was studied in 6 patients with Argentine hemorrhagic fever (AHF) of more than 8 days of evolution.,2445283_1,0
10602,AHF,104,107,Tolerance and antiviral effect of ribavirin was studied in 6 patients with Argentine hemorrhagic fever (AHF) of more than 8 days of evolution.,2445283_1,0
10605,adverse effect,33,47,A reversible anemia was the only adverse effect observed.,2445283_4,1
10609,secondary reaction,123,141,"From these results, we conclude that ribavirin has an antiviral effect in advanced cases of AHF, and that anemia, the only secondary reaction observed, can be easily managed.",2445283_5,1
10608,AHF,92,95,"From these results, we conclude that ribavirin has an antiviral effect in advanced cases of AHF, and that anemia, the only secondary reaction observed, can be easily managed.",2445283_5,0
10610,AHF,71,74,The possible beneficial effect of ribavirin during the initial days of AHF is discussed.,2445283_6,0
10614,5-FU,93,97,"Although there have been anecdotal reports of cardiac toxicity associated with fluorouracil (5-FU) therapy, this phenomenon has not been studied in a systematic fashion.",2466960_1,0
6206,cardiac toxicity,46,62,"Although there have been anecdotal reports of cardiac toxicity associated with fluorouracil (5-FU) therapy, this phenomenon has not been studied in a systematic fashion.",2466960_1,1
10638,ST segment deviation,83,103,"We conclude that 5-FU infusion is associated with a significant increase in silent ST segment deviation suggestive of ischemia, particularly among patients with coronary artery disease.",2466960_10,1
10636,5-FU,17,21,"We conclude that 5-FU infusion is associated with a significant increase in silent ST segment deviation suggestive of ischemia, particularly among patients with coronary artery disease.",2466960_10,0
6213,coronary artery disease,161,184,"We conclude that 5-FU infusion is associated with a significant increase in silent ST segment deviation suggestive of ischemia, particularly among patients with coronary artery disease.",2466960_10,1
10617,solid tumors,121,133,We prospectively performed continuous ambulatory ECG monitoring on 25 patients undergoing 5-FU infusion for treatment of solid tumors in order to assess the incidence of ischemic ST changes.,2466960_2,1
10616,5-FU,90,94,We prospectively performed continuous ambulatory ECG monitoring on 25 patients undergoing 5-FU infusion for treatment of solid tumors in order to assess the incidence of ischemic ST changes.,2466960_2,0
6207,ST,179,181,We prospectively performed continuous ambulatory ECG monitoring on 25 patients undergoing 5-FU infusion for treatment of solid tumors in order to assess the incidence of ischemic ST changes.,2466960_2,1
10619,5-FU,50,54,"Patients were monitored for 23 +/- 4 hours before 5-FU infusion, and 98 +/- 9 hours during 5-FU infusion.",2466960_3,0
10621,5-FU,91,95,"Patients were monitored for 23 +/- 4 hours before 5-FU infusion, and 98 +/- 9 hours during 5-FU infusion.",2466960_3,0
10618,/- 4,32,36,"Patients were monitored for 23 +/- 4 hours before 5-FU infusion, and 98 +/- 9 hours during 5-FU infusion.",2466960_3,0
10623,5-FU,64,68,Anginal episodes were rare: only one patient had angina (during 5-FU infusion).,2466960_4,0
10622,Anginal episodes,0,16,Anginal episodes were rare: only one patient had angina (during 5-FU infusion).,2466960_4,1
6210,ST,120,122,"However, asymptomatic ST changes (greater than or equal to 1 mm ST deviation) were common: six of 25 patients (24%) had ST changes before 5-FU infusion v 17 (68%) during 5-FU infusion (P less than .002).",2466960_5,1
6209,ST,64,66,"However, asymptomatic ST changes (greater than or equal to 1 mm ST deviation) were common: six of 25 patients (24%) had ST changes before 5-FU infusion v 17 (68%) during 5-FU infusion (P less than .002).",2466960_5,1
10625,5-FU,170,174,"However, asymptomatic ST changes (greater than or equal to 1 mm ST deviation) were common: six of 25 patients (24%) had ST changes before 5-FU infusion v 17 (68%) during 5-FU infusion (P less than .002).",2466960_5,0
10624,5-FU,138,142,"However, asymptomatic ST changes (greater than or equal to 1 mm ST deviation) were common: six of 25 patients (24%) had ST changes before 5-FU infusion v 17 (68%) during 5-FU infusion (P less than .002).",2466960_5,0
6208,ST,22,24,"However, asymptomatic ST changes (greater than or equal to 1 mm ST deviation) were common: six of 25 patients (24%) had ST changes before 5-FU infusion v 17 (68%) during 5-FU infusion (P less than .002).",2466960_5,1
10626,ischemic episodes,17,34,The incidence of ischemic episodes per patient per hour was 0.05 +/-,2466960_6,1
10634,5-FU,220,224,0.02 prior to 5-FU infusion v 0.13 +/- 0.03 during 5-FU infusion (P less than .001); the duration of ECG changes was 0.6 +/- 0.3 minutes per patient per hour before 5-FU v 1.9 +/- 0.5 minutes per patient per hour during 5-FU (P less than .01).,2466960_7,0
10630,5-FU,51,55,0.02 prior to 5-FU infusion v 0.13 +/- 0.03 during 5-FU infusion (P less than .001); the duration of ECG changes was 0.6 +/- 0.3 minutes per patient per hour before 5-FU v 1.9 +/- 0.5 minutes per patient per hour during 5-FU (P less than .01).,2466960_7,0
10628,5-FU,14,18,0.02 prior to 5-FU infusion v 0.13 +/- 0.03 during 5-FU infusion (P less than .001); the duration of ECG changes was 0.6 +/- 0.3 minutes per patient per hour before 5-FU v 1.9 +/- 0.5 minutes per patient per hour during 5-FU (P less than .01).,2466960_7,0
6211,coronary artery disease,55,78,ECG changes were more common among patients with known coronary artery disease.,2466960_8,1
6212,sudden death,24,36,"There were two cases of sudden death, both of which occurred at the end of the chemotherapy course.",2466960_9,1
10635,chemotherapy course,79,98,"There were two cases of sudden death, both of which occurred at the end of the chemotherapy course.",2466960_9,1
2583,gamma benzene hexachloride,130,156,Is the treatment of scabies hazardous?Treatment for scabies is usually initiated by general practitioners; most consider lindane (gamma benzene hexachloride) the treatment of choice.,2476560_0,0
6215,aplastic anaemia,108,124,Evidence is accumulating that lindane can be toxic to the central nervous system and may be associated with aplastic anaemia.,2476560_2,1
6214,central nervous system,58,80,Evidence is accumulating that lindane can be toxic to the central nervous system and may be associated with aplastic anaemia.,2476560_2,1
2585,biogenic amines,66,81,Mouse strain-dependent effect of amantadine on motility and brain biogenic amines.,2484011_0,0
2584,amantadine,33,43,Mouse strain-dependent effect of amantadine on motility and brain biogenic amines.,2484011_0,0
2586,amantadine hydrochloride,14,38,"The effect of amantadine hydrochloride, injected i.p. in 6 increments of 100 mg/kg each over 30 hr, on mouse motility and whole brain content of selected biogenic amines and major metabolites was studied in 4 strains of mice.",2484011_1,0
2587,biogenic amines,154,169,"The effect of amantadine hydrochloride, injected i.p. in 6 increments of 100 mg/kg each over 30 hr, on mouse motility and whole brain content of selected biogenic amines and major metabolites was studied in 4 strains of mice.",2484011_1,0
10645,i.p.,49,53,"The effect of amantadine hydrochloride, injected i.p. in 6 increments of 100 mg/kg each over 30 hr, on mouse motility and whole brain content of selected biogenic amines and major metabolites was studied in 4 strains of mice.",2484011_1,0
2597,amantadine,49,59,The results suggest a strain-dependent effect of amantadine on motility and indicate a differential response to the acute and multiple dose regimens used.,2484011_10,0
2598,amantadine,122,132,The BALB/C mouse was the most sensitive strain and could serve as the strain of choice for evaluating the side effects of amantadine.,2484011_11,0
6216,side effects,106,118,The BALB/C mouse was the most sensitive strain and could serve as the strain of choice for evaluating the side effects of amantadine.,2484011_11,1
10670,behavioral depression,254,275,The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a behavioral depression caused by amantadine in the BALB/C mice.,2484011_12,1
10667,BALB/C,52,58,The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a behavioral depression caused by amantadine in the BALB/C mice.,2484011_12,0
2599,biogenic amines,33,48,The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a behavioral depression caused by amantadine in the BALB/C mice.,2484011_12,0
2600,monoamine oxidase,152,169,The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a behavioral depression caused by amantadine in the BALB/C mice.,2484011_12,0
2601,amantadine,286,296,The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a behavioral depression caused by amantadine in the BALB/C mice.,2484011_12,0
10649,CDF-I,85,90,"These were the albino Sprague-Dawley ICR and BALB/C, the black C57BL/6 and the brown CDF-I mouse strains.",2484011_2,0
10650,mouse motility,51,65,Amantadine treatment produced a biphasic effect on mouse motility.,2484011_3,1
2588,Amantadine,0,10,Amantadine treatment produced a biphasic effect on mouse motility.,2484011_3,0
2589,biphasic,32,40,Amantadine treatment produced a biphasic effect on mouse motility.,2484011_3,0
2590,amantadine,20,30,The initial dose of amantadine depressed locomotor activity in all mouse strains studied with the BALB/C mice being the most sensitive.,2484011_4,0
10653,BALB/C,123,129,Subsequent amantadine treatments produced enhancement of motility from corresponding control in all mouse strains with the BALB/C mice being the least sensitive.,2484011_5,0
2591,amantadine,11,21,Subsequent amantadine treatments produced enhancement of motility from corresponding control in all mouse strains with the BALB/C mice being the least sensitive.,2484011_5,0
2592,amantadine,172,182,"The locomotor activity was decreased from corresponding controls in all strains studied, except for the ICR mice, during an overnight drug-free period following the fourth amantadine treatment.",2484011_6,0
2593,amantadine,20,30,"Readministration of amantadine, after a drug-free overnight period, increased motility from respective saline control in all strains with exception of the BALB/C mice where suppression of motility occurred.",2484011_7,0
2594,amantadine,15,25,"Treatment with amantadine did not alter whole brain dopamine levels but decreased the amounts of 3,4-dihydroxyphenylacetic acid in the BALB/C mice compared to saline control.",2484011_8,0
10661,"3,4-dihydroxyphenylacetic acid",97,127,"Treatment with amantadine did not alter whole brain dopamine levels but decreased the amounts of 3,4-dihydroxyphenylacetic acid in the BALB/C mice compared to saline control.",2484011_8,0
10662,BALB/C,135,141,"Treatment with amantadine did not alter whole brain dopamine levels but decreased the amounts of 3,4-dihydroxyphenylacetic acid in the BALB/C mice compared to saline control.",2484011_8,0
2595,normetanephrine,18,33,"Conversely, brain normetanephrine concentration was increased from saline control by amantadine in the BALB/C mice.",2484011_9,0
10664,BALB/C,103,109,"Conversely, brain normetanephrine concentration was increased from saline control by amantadine in the BALB/C mice.",2484011_9,0
2596,amantadine,85,95,"Conversely, brain normetanephrine concentration was increased from saline control by amantadine in the BALB/C mice.",2484011_9,0
10672,Chloroacetaldehyde,0,18,Chloroacetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ifosfamide.,2505783_0,0
2602,ifosfamide,97,107,Chloroacetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ifosfamide.,2505783_0,0
10674,cyclophosphamide,77,93,Chloroacetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ifosfamide.,2505783_0,0
10673,urotoxicity,43,54,Chloroacetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ifosfamide.,2505783_0,1
10675,chloroacetaldehyde,40,58,"Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis.",2505783_2,0
10677,CAA,197,200,"Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis.",2505783_2,1
10678,hemorrhagic cystitis,223,243,"Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis.",2505783_2,1
10676,CAA,60,63,"Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis.",2505783_2,1
2603,cytostatics,112,123,"Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis.",2505783_2,0
10679,CAA,26,29,The data demonstrate that CAA after i.v. administration does not contribute to bladder damage.,2505783_3,1
10680,CAA,42,45,"When instilled directly into the bladder, CAA exerts urotoxic effects, it is, however, susceptible to detoxification with mesna.",2505783_4,1
2604,mesna,122,127,"When instilled directly into the bladder, CAA exerts urotoxic effects, it is, however, susceptible to detoxification with mesna.",2505783_4,0
10681,primitive dysfunction,19,40,Source of pain and primitive dysfunction in migraine: an identical site?Twenty common migraine patients received a one sided frontotemporal application of nitroglycerin (10 patients) or placebo ointment (10 patients) in a double blind study.,2515254_0,1
6217,common migraine,79,94,Source of pain and primitive dysfunction in migraine: an identical site?Twenty common migraine patients received a one sided frontotemporal application of nitroglycerin (10 patients) or placebo ointment (10 patients) in a double blind study.,2515254_0,1
6218,frontotemporal,125,139,Source of pain and primitive dysfunction in migraine: an identical site?Twenty common migraine patients received a one sided frontotemporal application of nitroglycerin (10 patients) or placebo ointment (10 patients) in a double blind study.,2515254_0,1
10684,Early onset migraine,0,20,Early onset migraine attacks were induced by nitroglycerin in seven out of 10 patients versus no patient in the placebo group.,2515254_1,1
6219,early onset,52,63,"Subsequently 20 migraine patients, who developed an early onset attack with frontotemporal nitroglycerin, received the drug in a second induction test at other body areas.",2515254_2,1
6220,frontotemporal,76,90,"Subsequently 20 migraine patients, who developed an early onset attack with frontotemporal nitroglycerin, received the drug in a second induction test at other body areas.",2515254_2,1
10685,body areas,160,170,"Subsequently 20 migraine patients, who developed an early onset attack with frontotemporal nitroglycerin, received the drug in a second induction test at other body areas.",2515254_2,1
10686,early onset migraine,3,23,No early onset migraine was observed.,2515254_3,1
6221,frontotemporal,139,153,"Thus the migraine-inducing effect of nitroglycerin seems to depend on direct stimulation of the habitual site of pain, suggesting that the frontotemporal region is of crucial importance in the development of a migraine crisis.",2515254_4,1
10688,migraine crisis,210,225,"Thus the migraine-inducing effect of nitroglycerin seems to depend on direct stimulation of the habitual site of pain, suggesting that the frontotemporal region is of crucial importance in the development of a migraine crisis.",2515254_4,1
10689,migraine attack,44,59,This is not consistent with a CNS origin of migraine attack.,2515254_5,1
6222,CNS origin,30,40,This is not consistent with a CNS origin of migraine attack.,2515254_5,1
10690,carbamazepine,20,33,"Hypersensitivity to carbamazepine presenting with a leukemoid reaction, eosinophilia, erythroderma, and renal failure.",2522601_0,0
6223,leukemoid reaction,52,70,"Hypersensitivity to carbamazepine presenting with a leukemoid reaction, eosinophilia, erythroderma, and renal failure.",2522601_0,1
6224,renal failure,104,117,"Hypersensitivity to carbamazepine presenting with a leukemoid reaction, eosinophilia, erythroderma, and renal failure.",2522601_0,1
10691,carbamazepine,48,61,"We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure.",2522601_1,0
6226,renal failure,164,177,"We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure.",2522601_1,1
6225,leukemoid reaction,112,130,"We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure.",2522601_1,1
10692,generalized erythroderma,77,101,"We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure.",2522601_1,1
10693,carbamazepine,56,69,This is the first report of such an unusual reaction to carbamazepine.,2522601_2,0
6228,side effects,217,229,"Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial.To characterize the nature, time course and dose dependency of zidovudine-related side effects, we undertook a multicenter, prospective, dose-range finding study.",2528969_0,1
2605,Azidothymidine,114,128,"Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial.To characterize the nature, time course and dose dependency of zidovudine-related side effects, we undertook a multicenter, prospective, dose-range finding study.",2528969_0,0
6227,side effects,62,74,"Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial.To characterize the nature, time course and dose dependency of zidovudine-related side effects, we undertook a multicenter, prospective, dose-range finding study.",2528969_0,1
2606,C2,97,99,"Our study group consisted of 74 HIV-positive homosexual men belonging to groups II B, III and IV C2 from the Centers for Disease Control (CDC) classification of HIV disease.",2528969_1,0
6230,Bone marrow,0,11,Bone marrow changes occurred rapidly as demonstrated by megaloblastosis in 95% of 65 specimens at week 18.(ABSTRACT TRUNCATED AT 250 WORDS),2528969_11,1
10714,megaloblastosis,56,71,Bone marrow changes occurred rapidly as demonstrated by megaloblastosis in 95% of 65 specimens at week 18.(ABSTRACT TRUNCATED AT 250 WORDS),2528969_11,1
10705,taking 600,89,99,Subjects were randomly assigned to 4-hourly or 8-hourly regimens within CDC groups while taking 600 and 1200 mg/day.,2528969_3,0
6229,adverse effects,12,27,"Symptomatic adverse effects were present in 96% of subjects, most commonly nausea (64%), fatigue (55%) and headache (49%).",2528969_5,1
10707,red blood cell,2,16,"A red blood cell count decrease, a mean cell volume increase and a granulocyte count decrease developed early in a dose-independent fashion, reverting at least partially during the washout phase.",2528969_9,0
10718,mother-to-infant infection,145,171,"National project on the prevention of mother-to-infant infection by hepatitis B virus in Japan.In Japan, a nationwide prevention program against mother-to-infant infection by hepatitis B virus (HBV) started in 1985.",2533791_0,1
10715,mother-to-infant infection,38,64,"National project on the prevention of mother-to-infant infection by hepatitis B virus in Japan.In Japan, a nationwide prevention program against mother-to-infant infection by hepatitis B virus (HBV) started in 1985.",2533791_0,1
10720,HBV,194,197,"National project on the prevention of mother-to-infant infection by hepatitis B virus in Japan.In Japan, a nationwide prevention program against mother-to-infant infection by hepatitis B virus (HBV) started in 1985.",2533791_0,0
2609,hepatitis B e antigen,156,177,This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers.,2533791_1,0
2610,HBeAg,179,184,This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers.,2533791_1,0
2608,HBsAg,145,150,This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers.,2533791_1,0
2607,hepatitis B surface antigen,116,143,This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) positive mothers.,2533791_1,0
10723,HBIG,78,82,These infants are treated with two injections of hepatitis B immune globulin (HBIG) and at least three injections of plasma derived hepatitis B vaccine.,2533791_2,0
2611,hepatitis B vaccine,132,151,These infants are treated with two injections of hepatitis B immune globulin (HBIG) and at least three injections of plasma derived hepatitis B vaccine.,2533791_2,0
10722,hepatitis B immune globulin,49,76,These infants are treated with two injections of hepatitis B immune globulin (HBIG) and at least three injections of plasma derived hepatitis B vaccine.,2533791_2,0
2612,HBsAg,55,60,"93.4% pregnant women had the chance to be examined for HBsAg, and the positive rate was 1.4 to 1.5%.",2533791_4,0
2614,HBsAg,27,32,The HBeAg positive rate in HBsAg positive was 23 to 26%.,2533791_5,0
2613,HBeAg,4,9,The HBeAg positive rate in HBsAg positive was 23 to 26%.,2533791_5,0
2615,HBsAg,4,9,The HBsAg positive rate in neonates and in infants before two months were 3% and 2% respectively.,2533791_6,0
6231,akathisia,19,28,Fluoxetine-induced akathisia: clinical and theoretical implications.,2549018_0,1
6232,akathisia,116,125,Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.,2549018_1,1
10725,obsessive compulsive disorder,56,85,Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia.,2549018_1,1
6233,akathisia,194,203,"The typical fluoxetine-induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia.",2549018_2,1
6234,akathisia,55,64,"Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.",2549018_3,1
6235,akathisia,126,135,"Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder.",2549018_3,1
6236,Akathisia,0,9,"Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both.",2549018_4,1
6237,side effect,34,45,"Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both.",2549018_4,1
10728,beta-adrenergic antagonist propranolol,111,149,"Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both.",2549018_4,0
2616,dopaminergic,111,123,"The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced ""jitteriness"" may be identical.",2549018_5,0
6240,akathisia,193,202,"The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced ""jitteriness"" may be identical.",2549018_5,1
6239,pathophysiology,155,170,"The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced ""jitteriness"" may be identical.",2549018_5,1
6238,akathisia,44,53,"The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced ""jitteriness"" may be identical.",2549018_5,1
10731,peripheral analgesia,41,61,Involvement of the mu-opiate receptor in peripheral analgesia.,2557556_0,1
10730,mu-opiate receptor,19,37,Involvement of the mu-opiate receptor in peripheral analgesia.,2557556_0,0
10739,[D-Pen2.5]-enkephalin,186,207,"The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.",2557556_1,0
10738,[D-Pen2.5]-enkephalin,186,207,"The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.",2557556_1,0
10741,mechanical nociceptive,317,339,"The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.",2557556_1,1
10734,Tyr-D-Ala-Gly-NMe-Phe-Gly-ol,43,71,"The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.",2557556_1,0
10733,Tyr-D-Ala-Gly-NMe-Phe-Gly-ol,43,71,"The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.",2557556_1,0
10732,Tyr-D-Ala-Gly-NMe-Phe-Gly-ol,43,71,"The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.",2557556_1,0
10737,cyclohexyl]benzeneactemide,147,173,"The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.",2557556_1,0
10740,[D-Ser2]-[Leu]enkephalin-Thr,212,240,"The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.",2557556_1,0
10735,morphiceptin,76,88,"The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.",2557556_1,0
2617,opioid-agonists,252,267,"The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.",2557556_1,0
10736,"trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl",98,145,"The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat.",2557556_1,0
2618,opioid-agonists,52,67,"Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced hyperalgesia.",2557556_2,0
6241,hyperalgesia,141,153,"Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced hyperalgesia.",2557556_2,1
10744,analgesic effect,4,20,The analgesic effect of the mu-agonist morphine was dose-dependently antagonized by naloxone and prevented by co-injection of pertussis toxin.,2557556_3,0
2619,pertussis toxin,126,141,The analgesic effect of the mu-agonist morphine was dose-dependently antagonized by naloxone and prevented by co-injection of pertussis toxin.,2557556_3,0
10745,mu-agonist,28,38,The analgesic effect of the mu-agonist morphine was dose-dependently antagonized by naloxone and prevented by co-injection of pertussis toxin.,2557556_3,0
6242,hyperalgesia,37,49,"Morphine did not, however, alter the hyperalgesia induced by 8-bromo cyclic adenosine monophosphate.",2557556_4,1
2620,adenosine monophosphate,76,99,"Morphine did not, however, alter the hyperalgesia induced by 8-bromo cyclic adenosine monophosphate.",2557556_4,0
10746,analgesic action,21,37,We conclude that the analgesic action of opioids on the peripheral terminals of primary afferents is via a binding site with characteristics of the mu-opioid receptor and that this action is mediated by inhibition of the cyclic adenosine monophosphate second messenger system.,2557556_5,0
10749,binding site,107,119,We conclude that the analgesic action of opioids on the peripheral terminals of primary afferents is via a binding site with characteristics of the mu-opioid receptor and that this action is mediated by inhibition of the cyclic adenosine monophosphate second messenger system.,2557556_5,0
2622,mu-opioid receptor,148,166,We conclude that the analgesic action of opioids on the peripheral terminals of primary afferents is via a binding site with characteristics of the mu-opioid receptor and that this action is mediated by inhibition of the cyclic adenosine monophosphate second messenger system.,2557556_5,0
2621,opioids,41,48,We conclude that the analgesic action of opioids on the peripheral terminals of primary afferents is via a binding site with characteristics of the mu-opioid receptor and that this action is mediated by inhibition of the cyclic adenosine monophosphate second messenger system.,2557556_5,0
2623,adenosine monophosphate,228,251,We conclude that the analgesic action of opioids on the peripheral terminals of primary afferents is via a binding site with characteristics of the mu-opioid receptor and that this action is mediated by inhibition of the cyclic adenosine monophosphate second messenger system.,2557556_5,0
2624,converting enzyme,10,27,Effect of converting enzyme inhibition on the course of adriamycin-induced nephropathy.,2559236_0,0
10755,adriamycin,114,124,The effect of the converting enzyme inhibitor (CEI) enalapril was assessed in Munich-Wistar rats with established adriamycin nephrosis.,2559236_1,0
10753,CEI,47,50,The effect of the converting enzyme inhibitor (CEI) enalapril was assessed in Munich-Wistar rats with established adriamycin nephrosis.,2559236_1,0
10752,converting enzyme inhibitor,18,45,The effect of the converting enzyme inhibitor (CEI) enalapril was assessed in Munich-Wistar rats with established adriamycin nephrosis.,2559236_1,0
10784,glomerular sclerosis,56,76,Reduction in GFR was associated with the development of glomerular sclerosis in both treated and untreated rats.(ABSTRACT TRUNCATED AT 250 WORDS),2559236_10,1
10783,GFR,13,16,Reduction in GFR was associated with the development of glomerular sclerosis in both treated and untreated rats.(ABSTRACT TRUNCATED AT 250 WORDS),2559236_10,0
10757,adriamycin,33,43,"Rats were given a single dose of adriamycin and one month later divided into four groups matched for albuminuria, blood pressure, and plasma albumin concentration.",2559236_2,0
10758,plasma albumin,134,148,"Rats were given a single dose of adriamycin and one month later divided into four groups matched for albuminuria, blood pressure, and plasma albumin concentration.",2559236_2,0
10756,single dose,18,29,"Rats were given a single dose of adriamycin and one month later divided into four groups matched for albuminuria, blood pressure, and plasma albumin concentration.",2559236_2,0
6243,blood pressure,114,128,"Rats were given a single dose of adriamycin and one month later divided into four groups matched for albuminuria, blood pressure, and plasma albumin concentration.",2559236_2,1
10759,Groups 1,0,8,Groups 1 and 3 remained untreated while groups 2 and 4 received enalapril.,2559236_3,0
10760,Groups 1,0,8,Groups 1 and 2 underwent micropuncture studies after 10 days.,2559236_4,0
6244,blood pressure,64,78,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,1
10763,glomerular capillary pressure,148,177,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,1
10767,GFR,293,296,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,0
2627,/- 1,183,187,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,0
2625,/- 2,85,89,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,0
2626,group 2,111,118,"These short-term studies showed that enalapril reduced arterial blood pressure (101 +/- 2 vs. 124 +/- 3 mm Hg, group 2 vs. 1, P less than 0.05) and glomerular capillary pressure (54 +/- 1 vs. 61 +/- 2 mm Hg, P less than 0.05) without reducing albuminuria (617 +/- 50 vs. 570 +/- 47 mg/day) or GFR (1.03 +/- 0.04 vs. 1.04 +/- 0.11 ml/min).",2559236_5,0
10771,adriamycin,122,132,Groups 3 and 4 were studied at four and at six months to assess the effect of enalapril on progression of renal injury in adriamycin nephrosis.,2559236_6,0
10770,Groups 3,0,8,Groups 3 and 4 were studied at four and at six months to assess the effect of enalapril on progression of renal injury in adriamycin nephrosis.,2559236_6,0
6245,renal injury,106,118,Groups 3 and 4 were studied at four and at six months to assess the effect of enalapril on progression of renal injury in adriamycin nephrosis.,2559236_6,1
6246,blood pressure,36,50,Chronic enalapril treatment reduced blood pressure without reducing albuminuria in group 4.,2559236_7,1
10773,group 4,83,90,Chronic enalapril treatment reduced blood pressure without reducing albuminuria in group 4.,2559236_7,0
10776,/-,71,73,"Untreated group 3 rats exhibited a progressive reduction in GFR (0.35 +/- 0.08 ml/min at 4 months, 0.27 +/- 0.07 ml/min at 6 months).",2559236_8,0
10775,GFR,60,63,"Untreated group 3 rats exhibited a progressive reduction in GFR (0.35 +/- 0.08 ml/min at 4 months, 0.27 +/- 0.07 ml/min at 6 months).",2559236_8,0
10778,GFR,61,64,"Enalapril treatment blunted but did not prevent reduction in GFR in group 4 (0.86 +/- 0.15 ml/min at 4 months, 0.69 +/- 0.13 ml/min at 6 months, both P less than 0.05 vs. group 3).",2559236_9,0
10779,group 4,68,75,"Enalapril treatment blunted but did not prevent reduction in GFR in group 4 (0.86 +/- 0.15 ml/min at 4 months, 0.69 +/- 0.13 ml/min at 6 months, both P less than 0.05 vs. group 3).",2559236_9,0
10782,group 3,171,178,"Enalapril treatment blunted but did not prevent reduction in GFR in group 4 (0.86 +/- 0.15 ml/min at 4 months, 0.69 +/- 0.13 ml/min at 6 months, both P less than 0.05 vs. group 3).",2559236_9,0
10785,locus coeruleus,15,30,Involvement of locus coeruleus and noradrenergic neurotransmission in fentanyl-induced muscular rigidity in the rat.,2564649_0,1
10786,noradrenergic,35,48,Involvement of locus coeruleus and noradrenergic neurotransmission in fentanyl-induced muscular rigidity in the rat.,2564649_0,0
6247,muscular rigidity,87,104,Involvement of locus coeruleus and noradrenergic neurotransmission in fentanyl-induced muscular rigidity in the rat.,2564649_0,1
10788,high-dose,78,87,"Whereas muscular rigidity is a well-known side effect that is associated with high-dose fentanyl anesthesia, a paucity of information exists with regard to its underlying mechanism(s).",2564649_1,0
6249,side effect,42,53,"Whereas muscular rigidity is a well-known side effect that is associated with high-dose fentanyl anesthesia, a paucity of information exists with regard to its underlying mechanism(s).",2564649_1,1
6248,muscular rigidity,8,25,"Whereas muscular rigidity is a well-known side effect that is associated with high-dose fentanyl anesthesia, a paucity of information exists with regard to its underlying mechanism(s).",2564649_1,1
10790,locus coeruleus,57,72,"We investigated in this study the possible engagement of locus coeruleus of the pons in this phenomenon, using male Sprague-Dawley rats anesthetized with ketamine.",2564649_2,1
6250,body temperature,37,53,"Under proper control of respiration, body temperature and end-tidal CO2, intravenous administration of fentanyl (50 or 100 micrograms/kg) consistently promoted an increase in electromyographic activity recorded from the gastrocnemius and abdominal rectus muscles.",2564649_3,1
10793,abdominal rectus muscles,238,262,"Under proper control of respiration, body temperature and end-tidal CO2, intravenous administration of fentanyl (50 or 100 micrograms/kg) consistently promoted an increase in electromyographic activity recorded from the gastrocnemius and abdominal rectus muscles.",2564649_3,1
10794,narcotic agent,41,55,"Such an induced muscular rigidity by the narcotic agent was significantly antagonized or even reduced by prior electrolytic lesions of the locus coeruleus or pretreatment with the alpha-adrenoceptor blocker, prazosin.",2564649_4,0
10797,alpha-adrenoceptor blocker,180,206,"Such an induced muscular rigidity by the narcotic agent was significantly antagonized or even reduced by prior electrolytic lesions of the locus coeruleus or pretreatment with the alpha-adrenoceptor blocker, prazosin.",2564649_4,0
6251,muscular rigidity,16,33,"Such an induced muscular rigidity by the narcotic agent was significantly antagonized or even reduced by prior electrolytic lesions of the locus coeruleus or pretreatment with the alpha-adrenoceptor blocker, prazosin.",2564649_4,1
6252,pontine,69,76,"Microinjection of fentanyl (2.5 micrograms/50 nl) directly into this pontine nucleus, on the other hand, elicited discernible electromyographic excitation.",2564649_5,1
10800,noradrenergic,99,112,It is speculated that the induction of muscular rigidity by fentanyl may involve the coerulospinal noradrenergic fibers to the spinal motoneurons.,2564649_6,0
6253,muscular rigidity,39,56,It is speculated that the induction of muscular rigidity by fentanyl may involve the coerulospinal noradrenergic fibers to the spinal motoneurons.,2564649_6,1
6254,muscle rigidity,87,102,"Dexmedetomidine, acting through central alpha-2 adrenoceptors, prevents opiate-induced muscle rigidity in the rat.",2569282_0,1
2628,Dexmedetomidine,0,15,"Dexmedetomidine, acting through central alpha-2 adrenoceptors, prevents opiate-induced muscle rigidity in the rat.",2569282_0,0
10802,alpha-2 adrenoceptors,40,61,"Dexmedetomidine, acting through central alpha-2 adrenoceptors, prevents opiate-induced muscle rigidity in the rat.",2569282_0,0
10803,highly-selective alpha-2 adrenergic agonist dexmedetomidine,4,63,The highly-selective alpha-2 adrenergic agonist dexmedetomidine (D-MED) is capable of inducing muscle flaccidity and anesthesia in rats and dogs.,2569282_1,0
10804,D-MED,65,70,The highly-selective alpha-2 adrenergic agonist dexmedetomidine (D-MED) is capable of inducing muscle flaccidity and anesthesia in rats and dogs.,2569282_1,0
6255,muscle flaccidity,95,112,The highly-selective alpha-2 adrenergic agonist dexmedetomidine (D-MED) is capable of inducing muscle flaccidity and anesthesia in rats and dogs.,2569282_1,1
10824,high-dose D-MED,37,52,The small EMG values obtained in the high-dose D-MED group were comparable with those recorded in earlier studies from control animals not given any opiate.,2569282_10,0
6260,akinetic,42,50,"The high-dose D-MED animals were flaccid, akinetic, and lacked a startle response during the entire experimental period.(ABSTRACT TRUNCATED AT 250 WORDS)",2569282_11,1
6257,side effect,54,65,Intense generalized muscle rigidity is an undesirable side effect of potent opiate agonists.,2569282_2,1
6256,muscle rigidity,20,35,Intense generalized muscle rigidity is an undesirable side effect of potent opiate agonists.,2569282_2,1
10806,opiate-induced rigidity,31,54,"Although the neurochemistry of opiate-induced rigidity has yet to be fully elucidated, recent work suggests a role for a central adrenergic mechanism.",2569282_3,1
10807,D-MED,63,68,"In the present study, the authors determined if treatment with D-MED prevents the muscle rigidity caused by high-dose alfentanil anesthesia in the rat.",2569282_4,0
10808,high-dose alfentanil,108,128,"In the present study, the authors determined if treatment with D-MED prevents the muscle rigidity caused by high-dose alfentanil anesthesia in the rat.",2569282_4,0
6258,muscle rigidity,82,97,"In the present study, the authors determined if treatment with D-MED prevents the muscle rigidity caused by high-dose alfentanil anesthesia in the rat.",2569282_4,1
10814,D-MED,307,312,"Animals (n = 42) were treated intraperitoneally with one of the following six regimens: 1) L-MED (the inactive L-isomer of medetomidine), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.",2569282_5,0
10811,D-MED,159,164,"Animals (n = 42) were treated intraperitoneally with one of the following six regimens: 1) L-MED (the inactive L-isomer of medetomidine), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.",2569282_5,0
10813,D-MED,215,220,"Animals (n = 42) were treated intraperitoneally with one of the following six regimens: 1) L-MED (the inactive L-isomer of medetomidine), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.",2569282_5,0
10815,DG-5128,377,384,"Animals (n = 42) were treated intraperitoneally with one of the following six regimens: 1) L-MED (the inactive L-isomer of medetomidine), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.",2569282_5,0
2633,alpha-2,358,365,"Animals (n = 42) were treated intraperitoneally with one of the following six regimens: 1) L-MED (the inactive L-isomer of medetomidine), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.",2569282_5,0
2632,idazoxan,283,291,"Animals (n = 42) were treated intraperitoneally with one of the following six regimens: 1) L-MED (the inactive L-isomer of medetomidine), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.",2569282_5,0
2631,alpha-2,263,270,"Animals (n = 42) were treated intraperitoneally with one of the following six regimens: 1) L-MED (the inactive L-isomer of medetomidine), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.",2569282_5,0
2630,medetomidine,123,135,"Animals (n = 42) were treated intraperitoneally with one of the following six regimens: 1) L-MED (the inactive L-isomer of medetomidine), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.",2569282_5,0
2629,L-isomer,111,119,"Animals (n = 42) were treated intraperitoneally with one of the following six regimens: 1) L-MED (the inactive L-isomer of medetomidine), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.",2569282_5,0
10810,L-MED,91,96,"Animals (n = 42) were treated intraperitoneally with one of the following six regimens: 1) L-MED (the inactive L-isomer of medetomidine), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline.",2569282_5,0
10819,ALF,44,47,"Each rat was then injected with alfentanil (ALF, 0.5 mg/kg sc).",2569282_7,0
2634,alfentanil,32,42,"Each rat was then injected with alfentanil (ALF, 0.5 mg/kg sc).",2569282_7,0
10821,L-MED,76,81,ALF injection resulted in a marked increase in hindlimb EMG activity in the L-MED treatment group which was indistinguishable from that seen in animals treated with saline.,2569282_8,0
10820,ALF,0,3,ALF injection resulted in a marked increase in hindlimb EMG activity in the L-MED treatment group which was indistinguishable from that seen in animals treated with saline.,2569282_8,0
10822,D-MED,13,18,"In contrast, D-MED prevented alfentanil-induced muscle rigidity in a dose-dependent fashion.",2569282_9,0
6259,muscle rigidity,48,63,"In contrast, D-MED prevented alfentanil-induced muscle rigidity in a dose-dependent fashion.",2569282_9,1
10828,acute hepatitis,46,61,"We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis, 7 months after the onset of administration of clotiazepam, a thienodiazepine derivative.",2572625_1,1
10829,hepatocellular necrosis,77,100,"We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis, 7 months after the onset of administration of clotiazepam, a thienodiazepine derivative.",2572625_1,1
10831,clotiazepam,148,159,"We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis, 7 months after the onset of administration of clotiazepam, a thienodiazepine derivative.",2572625_1,0
10832,thienodiazepine derivative,163,189,"We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis, 7 months after the onset of administration of clotiazepam, a thienodiazepine derivative.",2572625_1,0
10833,Clotiazepam,0,11,Clotiazepam withdrawal was followed by prompt recovery.,2572625_2,0
10834,clotiazepam,69,80,"The administration of several benzodiazepines, chemically related to clotiazepam, did not interfere with recovery and did not induce any relapse of hepatitis.",2572625_3,0
10835,clotiazepam,28,39,This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines.,2572625_4,0
10836,acute hepatitis,51,66,This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines.,2572625_4,1
10837,hepatotoxicity,103,117,This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines.,2572625_4,1
10838,clotiazepam,126,137,This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines.,2572625_4,0
10839,fluvoxamine,48,59,Some central effects of repeated treatment with fluvoxamine.,2576810_0,0
2636,methoxamine,153,164,"We investigated the effect of repeated treatment with fluvoxamine, a selective serotonin uptake inhibitor, on behavioral effects of dopaminomimetics and methoxamine and on the animal behavior in the ""behavioral despair"" test.",2576810_1,0
10840,fluvoxamine,54,65,"We investigated the effect of repeated treatment with fluvoxamine, a selective serotonin uptake inhibitor, on behavioral effects of dopaminomimetics and methoxamine and on the animal behavior in the ""behavioral despair"" test.",2576810_1,0
2635,serotonin uptake inhibitor,79,105,"We investigated the effect of repeated treatment with fluvoxamine, a selective serotonin uptake inhibitor, on behavioral effects of dopaminomimetics and methoxamine and on the animal behavior in the ""behavioral despair"" test.",2576810_1,0
10841,dopaminomimetics,132,148,"We investigated the effect of repeated treatment with fluvoxamine, a selective serotonin uptake inhibitor, on behavioral effects of dopaminomimetics and methoxamine and on the animal behavior in the ""behavioral despair"" test.",2576810_1,0
10844,fluvoxamine,26,37,A repeated treatment with fluvoxamine (twice daily for 14 days) potentiated in mice and in rats (weaker) the amphetamine-induced hyperactivity.,2576810_2,0
10846,fluvoxamine,72,83,The hyperactivity induced by nomifensine in mice remained unaffected by fluvoxamine.,2576810_3,0
2637,nomifensine,29,40,The hyperactivity induced by nomifensine in mice remained unaffected by fluvoxamine.,2576810_3,0
2638,methoxamine,80,91,The stimulation of locomotor activity by intracerebroventricularly administered methoxamine was not affected by repeated treatment with fluvoxamine.,2576810_4,0
10848,fluvoxamine,136,147,The stimulation of locomotor activity by intracerebroventricularly administered methoxamine was not affected by repeated treatment with fluvoxamine.,2576810_4,0
10849,fluvoxamine,18,29,"Given three times fluvoxamine had no effect on the immobilization time in the ""behavioral despair"" test in rats.",2576810_5,0
2639,citalopram,77,87,"The results indicate that fluvoxamine given repeatedly acts differently than citalopram, another selective serotonin uptake inhibitor, and differs also from other antidepressant drugs.",2576810_6,0
10852,fluvoxamine,26,37,"The results indicate that fluvoxamine given repeatedly acts differently than citalopram, another selective serotonin uptake inhibitor, and differs also from other antidepressant drugs.",2576810_6,0
2641,antidepressant drugs,163,183,"The results indicate that fluvoxamine given repeatedly acts differently than citalopram, another selective serotonin uptake inhibitor, and differs also from other antidepressant drugs.",2576810_6,0
2640,serotonin uptake inhibitor,107,133,"The results indicate that fluvoxamine given repeatedly acts differently than citalopram, another selective serotonin uptake inhibitor, and differs also from other antidepressant drugs.",2576810_6,0
10853,5-azacytidine,0,13,5-azacytidine potentiates initiation induced by carcinogens in rat liver.,2578334_0,0
2642,benzo[a]-pyrene,290,305,"To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).",2578334_1,0
2643,N-methyl-N-nitrosourea,319,341,"To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).",2578334_1,0
10858,"1,2-dimethylhydrazine",357,378,"To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).",2578334_1,0
10856,5-azacytidine,134,147,"To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).",2578334_1,0
10854,hypomethylation,44,59,"To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process, 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg).",2578334_1,0
2644,gamma-glutamyltransferase,59,84,The initiated hepatocytes in the liver were assayed as the gamma-glutamyltransferase (gamma-GT) positive foci formed following a 2-week selection regimen consisting of dietary 0.02% 2-acetylaminofluorene coupled with a necrogenic dose of CCl4.,2578334_2,0
10861,2-acetylaminofluorene,182,203,The initiated hepatocytes in the liver were assayed as the gamma-glutamyltransferase (gamma-GT) positive foci formed following a 2-week selection regimen consisting of dietary 0.02% 2-acetylaminofluorene coupled with a necrogenic dose of CCl4.,2578334_2,0
10862,CCl4,238,242,The initiated hepatocytes in the liver were assayed as the gamma-glutamyltransferase (gamma-GT) positive foci formed following a 2-week selection regimen consisting of dietary 0.02% 2-acetylaminofluorene coupled with a necrogenic dose of CCl4.,2578334_2,0
10860,gamma-GT,86,94,The initiated hepatocytes in the liver were assayed as the gamma-glutamyltransferase (gamma-GT) positive foci formed following a 2-week selection regimen consisting of dietary 0.02% 2-acetylaminofluorene coupled with a necrogenic dose of CCl4.,2578334_2,0
10866,cytosine residues,124,141,"Administration of [3H]-5-azadeoxycytidine during the repair synthesis induced by 1,2-DMH further showed that 0.019 mol % of cytosine residues in DNA were substituted by the analogue, indicating that incorporation of 5-AzC occurs during repair synthesis.",2578334_4,0
10864,[3H]-5-azadeoxycytidine,18,41,"Administration of [3H]-5-azadeoxycytidine during the repair synthesis induced by 1,2-DMH further showed that 0.019 mol % of cytosine residues in DNA were substituted by the analogue, indicating that incorporation of 5-AzC occurs during repair synthesis.",2578334_4,0
10869,gamma-GT,149,157,"In the absence of the carcinogen, 5-AzC given after a two thirds partial hepatectomy, when its incorporation should be maximum, failed to induce any gamma-GT positive foci.",2578334_5,0
10868,hepatectomy,73,84,"In the absence of the carcinogen, 5-AzC given after a two thirds partial hepatectomy, when its incorporation should be maximum, failed to induce any gamma-GT positive foci.",2578334_5,1
10870,hypomethylation,25,40,The results suggest that hypomethylation of DNA per se may not be sufficient for initiation.,2578334_6,0
10872,hypomethylation,112,127,"Perhaps two events might be necessary for initiation, the first caused by the carcinogen and a second involving hypomethylation of DNA.",2578334_7,0
10873,Protective effect,0,17,"Protective effect of a specific platelet-activating factor antagonist, BN 52021, on bupivacaine-induced cardiovascular impairments in rats.",2594614_0,0
2645,platelet-activating factor,32,58,"Protective effect of a specific platelet-activating factor antagonist, BN 52021, on bupivacaine-induced cardiovascular impairments in rats.",2594614_0,0
10874,BN,71,73,"Protective effect of a specific platelet-activating factor antagonist, BN 52021, on bupivacaine-induced cardiovascular impairments in rats.",2594614_0,0
6261,blood pressure,127,141,"Administration of the local anaesthetic bupivacaine (1.5 or 2 mg/kg, i.v.) to rats elicited a marked decrease of mean arterial blood pressure (MBP) and heart rate (HR) leading to death (in 67% or 90% of animals respectively).",2594614_1,1
2646,bupivacaine,40,51,"Administration of the local anaesthetic bupivacaine (1.5 or 2 mg/kg, i.v.) to rats elicited a marked decrease of mean arterial blood pressure (MBP) and heart rate (HR) leading to death (in 67% or 90% of animals respectively).",2594614_1,0
10879,BN,82,84,"Intravenous injection of the specific platelet-activating factor (PAF) antagonist BN 52021 (10 mg/kg), 30 min before bupivacaine administration (2 mg/kg i.v.) suppressed both the decrease of MBP and HR.",2594614_2,0
2650,(2,144,146,"Intravenous injection of the specific platelet-activating factor (PAF) antagonist BN 52021 (10 mg/kg), 30 min before bupivacaine administration (2 mg/kg i.v.) suppressed both the decrease of MBP and HR.",2594614_2,0
2647,platelet-activating factor,38,64,"Intravenous injection of the specific platelet-activating factor (PAF) antagonist BN 52021 (10 mg/kg), 30 min before bupivacaine administration (2 mg/kg i.v.) suppressed both the decrease of MBP and HR.",2594614_2,0
2649,bupivacaine,117,128,"Intravenous injection of the specific platelet-activating factor (PAF) antagonist BN 52021 (10 mg/kg), 30 min before bupivacaine administration (2 mg/kg i.v.) suppressed both the decrease of MBP and HR.",2594614_2,0
2648,PAF,66,69,"Intravenous injection of the specific platelet-activating factor (PAF) antagonist BN 52021 (10 mg/kg), 30 min before bupivacaine administration (2 mg/kg i.v.) suppressed both the decrease of MBP and HR.",2594614_2,0
10881,BN,30,32,"In contrast, doses of 1 mg/kg BN 52021 given 30 min before or 10 mg/kg administered 5 min before i.v.",2594614_3,0
2651,bupivacaine,13,24,injection of bupivacaine were ineffective.,2594614_4,0
10885,MBP,123,126,"When BN 52021 (20 mg/kg i.v.) was injected immediately after bupivacaine (2 mg/kg), a partial reversion of the decrease of MBP and HR was observed, whereas the dose of 10 mg/kg was ineffective.",2594614_5,0
10883,bupivacaine (2,61,75,"When BN 52021 (20 mg/kg i.v.) was injected immediately after bupivacaine (2 mg/kg), a partial reversion of the decrease of MBP and HR was observed, whereas the dose of 10 mg/kg was ineffective.",2594614_5,0
10882,BN,5,7,"When BN 52021 (20 mg/kg i.v.) was injected immediately after bupivacaine (2 mg/kg), a partial reversion of the decrease of MBP and HR was observed, whereas the dose of 10 mg/kg was ineffective.",2594614_5,0
10888,BN,107,109,A partial recovery of bupivacaine-induced ECG alterations was observed after pretreatment of the rats with BN 52021.,2594614_6,0
10892,BN,173,175,"Since the administration of BN 52021, at all doses studied, did not alter MBP and HR at the doses used, the bulk of these results clearly demonstrate a protective action of BN 52021, a specific antagonist of PAF, against bupivacaine-induced cardiovascular toxicity.",2594614_7,0
10890,MBP,74,77,"Since the administration of BN 52021, at all doses studied, did not alter MBP and HR at the doses used, the bulk of these results clearly demonstrate a protective action of BN 52021, a specific antagonist of PAF, against bupivacaine-induced cardiovascular toxicity.",2594614_7,0
10889,BN,28,30,"Since the administration of BN 52021, at all doses studied, did not alter MBP and HR at the doses used, the bulk of these results clearly demonstrate a protective action of BN 52021, a specific antagonist of PAF, against bupivacaine-induced cardiovascular toxicity.",2594614_7,0
10891,protective action,152,169,"Since the administration of BN 52021, at all doses studied, did not alter MBP and HR at the doses used, the bulk of these results clearly demonstrate a protective action of BN 52021, a specific antagonist of PAF, against bupivacaine-induced cardiovascular toxicity.",2594614_7,0
2652,PAF,208,211,"Since the administration of BN 52021, at all doses studied, did not alter MBP and HR at the doses used, the bulk of these results clearly demonstrate a protective action of BN 52021, a specific antagonist of PAF, against bupivacaine-induced cardiovascular toxicity.",2594614_7,0
2653,PAF,50,53,"Thus, consistent with its direct effect on heart, PAF appears to be implicated in bupivacaine-induced cardiovascular alterations.",2594614_8,0
10894,flank pain syndrome,30,49,The epidemiology of the acute flank pain syndrome from suprofen.,2598570_0,1
10895,suprofen,55,63,The epidemiology of the acute flank pain syndrome from suprofen.,2598570_0,0
10896,Suprofen,0,8,"Suprofen, a new nonsteroidal anti-inflammatory drug, was marketed in early 1986 as an analgesic agent.",2598570_1,0
10898,analgesic agent,86,101,"Suprofen, a new nonsteroidal anti-inflammatory drug, was marketed in early 1986 as an analgesic agent.",2598570_1,0
10897,nonsteroidal anti-inflammatory drug,16,51,"Suprofen, a new nonsteroidal anti-inflammatory drug, was marketed in early 1986 as an analgesic agent.",2598570_1,0
10899,flank pain syndrome,50,69,"Until physicians began reporting an unusual acute flank pain syndrome to the spontaneous reporting system, 700,000 persons used the drug in the United States. Through August 1986, a total of 163 cases of this syndrome were reported.",2598570_2,1
6262,hay fever,107,116,"Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5).",2598570_4,1
10915,sun exposure,233,245,"Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt.",2598570_5,1
10914,history of gout,164,179,"Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt.",2598570_5,1
10913,young age,31,40,"Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt.",2598570_5,1
6264,kidney stones,147,160,"Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt.",2598570_5,1
6263,renal disease,119,132,"Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt.",2598570_5,1
2654,analgesic agents,66,82,"Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt.",2598570_5,0
10917,acute diffuse crystallization,87,116,These findings are consistent with the postulated mechanism for this unusual syndrome: acute diffuse crystallization of uric acid in renal tubules.,2598570_7,1
10918,renal tubules,133,146,These findings are consistent with the postulated mechanism for this unusual syndrome: acute diffuse crystallization of uric acid in renal tubules.,2598570_7,1
10916,unusual syndrome,69,85,These findings are consistent with the postulated mechanism for this unusual syndrome: acute diffuse crystallization of uric acid in renal tubules.,2598570_7,1
2655,uric acid,120,129,These findings are consistent with the postulated mechanism for this unusual syndrome: acute diffuse crystallization of uric acid in renal tubules.,2598570_7,0
2656,Antihypertensive drugs,0,22,Antihypertensive drugs and depression: a reappraisal.,26094_0,0
2657,methyl dopa,75,86,This was accounted for by a significant number of depressions occurring in methyl dopa treated patients with psychiatric histories.,26094_4,0
2658,diclofenac sodium,41,58,Chronic active hepatitis associated with diclofenac sodium therapy.,2611118_0,0
6265,Chronic active hepatitis,0,24,Chronic active hepatitis associated with diclofenac sodium therapy.,2611118_0,1
10928,Geigy Pharmaceuticals,29,50,"Diclofenac sodium (Voltarol, Geigy Pharmaceuticals) is a non-steroidal anti-inflammatory derivative of phenylacetic acid.",2611118_1,0
10927,Voltarol,19,27,"Diclofenac sodium (Voltarol, Geigy Pharmaceuticals) is a non-steroidal anti-inflammatory derivative of phenylacetic acid.",2611118_1,0
10929,phenylacetic acid,103,120,"Diclofenac sodium (Voltarol, Geigy Pharmaceuticals) is a non-steroidal anti-inflammatory derivative of phenylacetic acid.",2611118_1,0
2659,Diclofenac sodium,0,17,"Diclofenac sodium (Voltarol, Geigy Pharmaceuticals) is a non-steroidal anti-inflammatory derivative of phenylacetic acid.",2611118_1,0
2660,non-steroidal anti-inflammatory,57,88,"Diclofenac sodium (Voltarol, Geigy Pharmaceuticals) is a non-steroidal anti-inflammatory derivative of phenylacetic acid.",2611118_1,0
2661,diclofenac,147,157,"Although generally well-tolerated, asymptomatic abnormalities of liver function have been recorded and, less commonly, severe hepatitis induced by diclofenac.",2611118_2,0
10931,liver function,65,79,"Although generally well-tolerated, asymptomatic abnormalities of liver function have been recorded and, less commonly, severe hepatitis induced by diclofenac.",2611118_2,1
10930,asymptomatic abnormalities,35,61,"Although generally well-tolerated, asymptomatic abnormalities of liver function have been recorded and, less commonly, severe hepatitis induced by diclofenac.",2611118_2,1
2662,diclofenac sodium,87,104,"The patient described developed chronic active hepatitis after six months therapy with diclofenac sodium which progressed despite the withdrawal of the drug, a finding not previously reported.",2611118_3,0
6266,chronic active hepatitis,32,56,"The patient described developed chronic active hepatitis after six months therapy with diclofenac sodium which progressed despite the withdrawal of the drug, a finding not previously reported.",2611118_3,1
10932,ketoconazole,53,65,Arterial hypertension as a complication of prolonged ketoconazole treatment.,2632720_0,0
6267,Arterial hypertension,0,21,Arterial hypertension as a complication of prolonged ketoconazole treatment.,2632720_0,1
10933,ketoconazole,77,89,Two of 14 patients with Cushing's syndrome treated on a long-term basis with ketoconazole developed sustained hypertension.,2632720_1,0
6268,Cushing's syndrome,24,42,Two of 14 patients with Cushing's syndrome treated on a long-term basis with ketoconazole developed sustained hypertension.,2632720_1,1
10935,ketoconazole,89,101,"In both cases normal plasma and urinary free cortisol levels had been achieved following ketoconazole therapy, yet continuous blood pressure monitoring demonstrated hypertension 31 (patient 1) and 52 weeks (patient 2) after treatment.",2632720_2,0
10934,urinary free cortisol,32,53,"In both cases normal plasma and urinary free cortisol levels had been achieved following ketoconazole therapy, yet continuous blood pressure monitoring demonstrated hypertension 31 (patient 1) and 52 weeks (patient 2) after treatment.",2632720_2,0
6269,blood pressure,126,140,"In both cases normal plasma and urinary free cortisol levels had been achieved following ketoconazole therapy, yet continuous blood pressure monitoring demonstrated hypertension 31 (patient 1) and 52 weeks (patient 2) after treatment.",2632720_2,1
2663,deoxycorticosterone,31,50,"In patient 1, plasma levels of deoxycorticosterone and 11-deoxycortisol were elevated.",2632720_3,0
10940,plasma aldosterone,98,116,"In patient 2, in addition to an increase in both deoxycorticosterone and 11-deoxycortisol levels, plasma aldosterone values were raised, with a concomitant suppression of renin levels.",2632720_4,0
2664,deoxycorticosterone,49,68,"In patient 2, in addition to an increase in both deoxycorticosterone and 11-deoxycortisol levels, plasma aldosterone values were raised, with a concomitant suppression of renin levels.",2632720_4,0
10941,high doses,48,58,Our findings show that long-term treatment with high doses of ketoconazole may induce enzyme blockade leading to mineralocorticoid-related hypertension.,2632720_5,0
10942,ketoconazole,62,74,Our findings show that long-term treatment with high doses of ketoconazole may induce enzyme blockade leading to mineralocorticoid-related hypertension.,2632720_5,0
6271,intravascular coagulation,113,138,Effects of an inhibitor of angiotensin converting enzyme (Captopril) on pulmonary and renal insufficiency due to intravascular coagulation in the rat.,2670794_0,1
6270,renal insufficiency,86,105,Effects of an inhibitor of angiotensin converting enzyme (Captopril) on pulmonary and renal insufficiency due to intravascular coagulation in the rat.,2670794_0,1
2665,angiotensin converting enzyme,27,56,Effects of an inhibitor of angiotensin converting enzyme (Captopril) on pulmonary and renal insufficiency due to intravascular coagulation in the rat.,2670794_0,0
2666,tranexamic acid,99,114,Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.,2670794_1,0
2667,AMCA,116,120,Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.,2670794_1,0
6273,renal insufficiency,161,180,Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.,2670794_1,1
6272,intravascular coagulation,13,38,Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man.,2670794_1,1
6274,renal insufficiency,114,133,"Injection of Captopril (1 mg/kg), an inhibitor of angiotensin converting enzyme (ACE), reduced both pulmonary and renal insufficiency in this rat model.",2670794_2,1
10945,Captopril (1,13,25,"Injection of Captopril (1 mg/kg), an inhibitor of angiotensin converting enzyme (ACE), reduced both pulmonary and renal insufficiency in this rat model.",2670794_2,0
2668,angiotensin converting enzyme,50,79,"Injection of Captopril (1 mg/kg), an inhibitor of angiotensin converting enzyme (ACE), reduced both pulmonary and renal insufficiency in this rat model.",2670794_2,0
10947,PaO2,32,36,The lung weights were lower and PaO2 was improved in rats given this enzyme-blocking agent.,2670794_3,0
10948,enzyme-blocking agent,69,90,The lung weights were lower and PaO2 was improved in rats given this enzyme-blocking agent.,2670794_3,0
10949,Renal damage,0,12,Renal damage as reflected by an increase in serum urea and in kidney weight was prevented by Captopril.,2670794_5,1
10951,kidney weight,62,75,Renal damage as reflected by an increase in serum urea and in kidney weight was prevented by Captopril.,2670794_5,1
10950,serum urea,44,54,Renal damage as reflected by an increase in serum urea and in kidney weight was prevented by Captopril.,2670794_5,0
2669,AMCA,108,112,The amount of fibrin in the kidneys was also considerably lower than in animals which received thrombin and AMCA alone.,2670794_6,0
2670,prostacyclin,186,198,It is suggested that the effects of Captopril on the lungs may be attributable to a vasodilatory effect due to a reduction in the circulating level of Angiotension II and an increase in prostacyclin (secondary to an increase in bradykinin).,2670794_7,0
10953,Angiotension II,151,166,It is suggested that the effects of Captopril on the lungs may be attributable to a vasodilatory effect due to a reduction in the circulating level of Angiotension II and an increase in prostacyclin (secondary to an increase in bradykinin).,2670794_7,0
2671,bradykinin,228,238,It is suggested that the effects of Captopril on the lungs may be attributable to a vasodilatory effect due to a reduction in the circulating level of Angiotension II and an increase in prostacyclin (secondary to an increase in bradykinin).,2670794_7,0
10954,glomerular filtration,61,82,"Captopril may, by the same mechanism, reduce the increase in glomerular filtration that is known to occur after an injection of thrombin, thereby diminishing the aggregation of fibrin monomers in the glomeruli, with the result that less fibrin will be deposited and thus less kidney damage will be produced.",2670794_8,1
10956,kidney damage,276,289,"Captopril may, by the same mechanism, reduce the increase in glomerular filtration that is known to occur after an injection of thrombin, thereby diminishing the aggregation of fibrin monomers in the glomeruli, with the result that less fibrin will be deposited and thus less kidney damage will be produced.",2670794_8,1
10955,fibrin monomers,177,192,"Captopril may, by the same mechanism, reduce the increase in glomerular filtration that is known to occur after an injection of thrombin, thereby diminishing the aggregation of fibrin monomers in the glomeruli, with the result that less fibrin will be deposited and thus less kidney damage will be produced.",2670794_8,0
10959,cocaine use,35,46,We describe eight patients in whom cocaine use was related to stroke and review 39 cases from the literature.,2673163_1,1
10962,intranasal,43,53,"Stroke followed cocaine use by inhalation, intranasal, intravenous, and intramuscular routes.",2673163_3,0
6276,arteriovenous malformations,26,53,Intracranial aneurysms or arteriovenous malformations were present in 17 of 32 patients studied angiographically or at autopsy; cerebral vasculitis was present in two patients.,2673163_4,1
6275,Intracranial aneurysms,0,22,Intracranial aneurysms or arteriovenous malformations were present in 17 of 32 patients studied angiographically or at autopsy; cerebral vasculitis was present in two patients.,2673163_4,1
6277,cerebral vasculitis,128,147,Intracranial aneurysms or arteriovenous malformations were present in 17 of 32 patients studied angiographically or at autopsy; cerebral vasculitis was present in two patients.,2673163_4,1
10963,angiographically,96,112,Intracranial aneurysms or arteriovenous malformations were present in 17 of 32 patients studied angiographically or at autopsy; cerebral vasculitis was present in two patients.,2673163_4,1
6278,Cerebral infarction,0,19,"Cerebral infarction occurred in 10 patients (22%), intracerebral hemorrhage in 22 (49%), and subarachnoid hemorrhage in 13 (29%).",2673163_5,1
6279,intracerebral hemorrhage,51,75,"Cerebral infarction occurred in 10 patients (22%), intracerebral hemorrhage in 22 (49%), and subarachnoid hemorrhage in 13 (29%).",2673163_5,1
6280,subarachnoid hemorrhage,93,116,"Cerebral infarction occurred in 10 patients (22%), intracerebral hemorrhage in 22 (49%), and subarachnoid hemorrhage in 13 (29%).",2673163_5,1
6281,intracranial aneurysms,282,304,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,1
2674,(3,164,166,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,0
6284,cerebral infarction,433,452,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,1
2673,(2,100,102,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,0
6282,arteriovenous malformations,309,336,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,1
2672,(1,25,27,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,0
10965,cocaine-associated stroke,104,129,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,1
10970,cocaine-associated stroke,349,374,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,1
10966,young adults,150,162,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,1
10968,cocaine use,240,251,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,1
6283,intracranial hemorrhage,393,416,"These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction.",2673163_6,1
2675,nitroprusside,41,54,A randomized comparison of labetalol and nitroprusside for induced hypotension.,2696505_0,0
6286,blood pressure,116,130,Each patient was subjected to an identical anesthetic protocol and similar drug-induced reductions in mean arterial blood pressure (BP) (50 to 55 mmHg).,2696505_2,1
6285,drug-induced,75,87,Each patient was subjected to an identical anesthetic protocol and similar drug-induced reductions in mean arterial blood pressure (BP) (50 to 55 mmHg).,2696505_2,1
10976,heart rate,88,98,Nitroprusside infusion was associated with a significant (p less than 0.05) increase in heart rate and cardiac output; rebound hypertension was observed in three patients after discontinuation of nitroprusside.,2696505_3,1
2677,nitroprusside,196,209,Nitroprusside infusion was associated with a significant (p less than 0.05) increase in heart rate and cardiac output; rebound hypertension was observed in three patients after discontinuation of nitroprusside.,2696505_3,0
2676,Nitroprusside,0,13,Nitroprusside infusion was associated with a significant (p less than 0.05) increase in heart rate and cardiac output; rebound hypertension was observed in three patients after discontinuation of nitroprusside.,2696505_3,0
6287,cardiac output,103,117,Nitroprusside infusion was associated with a significant (p less than 0.05) increase in heart rate and cardiac output; rebound hypertension was observed in three patients after discontinuation of nitroprusside.,2696505_3,1
10977,rebound hypertension,119,139,Nitroprusside infusion was associated with a significant (p less than 0.05) increase in heart rate and cardiac output; rebound hypertension was observed in three patients after discontinuation of nitroprusside.,2696505_3,1
10980,PO2,9,12,Arterial PO2 decreased in both groups.,2696505_5,0
2678,nitroprusside,55,68,It was concluded that labetalol offers advantages over nitroprusside.,2696505_6,0
10982,nephrotoxicity,57,71,Phlorizin-induced glycosuria does not prevent gentamicin nephrotoxicity in rats.,2709684_0,1
10983,ARF,243,246,"Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).",2709684_1,0
6288,diabetes mellitus,41,58,"Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).",2709684_1,1
6289,acute renal failure,222,241,"Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF).",2709684_1,1
10985,non-diabetic,61,73,The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).,2709684_2,1
10987,tubular glucose reabsorption,131,159,The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).,2709684_2,1
2679,phlorizin,165,174,The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).,2709684_2,0
10986,chronic solute diuresis,84,107,The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).,2709684_2,1
10984,nephrotoxicity,31,45,The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin (P).,2709684_2,1
10988,mild glycosuria,13,28,DM rats with mild glycosuria (similar in degree to that of the P treated animals) were also studied.,2709684_3,0
10992,Group III,82,91,"Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild DM + gentamicin).",2709684_5,0
10991,Group II,55,63,"Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild DM + gentamicin).",2709684_5,0
2680,Group 1,0,7,"Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild DM + gentamicin).",2709684_5,0
2681,Group IV,115,123,"Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild DM + gentamicin).",2709684_5,0
10998,renal dysfunction,125,142,"In Group I, P induced a moderate and stable glycosuria (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of renal dysfunction (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (tubular necrosis score [maximum 4], zero).",2709684_7,1
10994,Group I,3,10,"In Group I, P induced a moderate and stable glycosuria (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of renal dysfunction (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (tubular necrosis score [maximum 4], zero).",2709684_7,0
2682,CCr,153,156,"In Group I, P induced a moderate and stable glycosuria (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of renal dysfunction (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage (tubular necrosis score [maximum 4], zero).",2709684_7,0
11002,Group II,3,11,"In Group II, P did not prevent gentamicin-ARF (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/- 321 micrograms/day; and tubular necrosis score, 3.9 +/- 0.1).",2709684_8,0
11003,gentamicin-ARF,31,45,"In Group II, P did not prevent gentamicin-ARF (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/- 321 micrograms/day; and tubular necrosis score, 3.9 +/- 0.1).",2709684_8,0
11006,tubular necrosis score,155,177,"In Group II, P did not prevent gentamicin-ARF (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/- 321 micrograms/day; and tubular necrosis score, 3.9 +/- 0.1).",2709684_8,1
2683,CCr,67,70,"In Group II, P did not prevent gentamicin-ARF (maximal decrease in CCr at day 9.89%, P less than 0.001; peak lysozymuria, 1863 +/- 321 micrograms/day; and tubular necrosis score, 3.9 +/- 0.1).",2709684_8,0
11008,Group III,46,55,"These values were not different from those of Group III: maximal decrease in CCr 73% (P less than 0.001); lysozymuria, 2147 +/- 701 micrograms/day; tubular necrosis score, 3.8 +/- 0.1.(ABSTRACT TRUNCATED AT 250 WORDS)",2709684_9,0
2684,CCr,77,80,"These values were not different from those of Group III: maximal decrease in CCr 73% (P less than 0.001); lysozymuria, 2147 +/- 701 micrograms/day; tubular necrosis score, 3.8 +/- 0.1.(ABSTRACT TRUNCATED AT 250 WORDS)",2709684_9,0
11013,cross-tolerance,100,115,"Catalepsy induced by combinations of ketamine and morphine: potentiation, antagonism, tolerance and cross-tolerance in the rat.",2716967_0,1
11015,cross-tolerance,37,52,"Pre-treatment with ketamine produced cross-tolerance to morphine, whereas pretreatment with morphine did not induce cross-tolerance to ketamine but rather augmented the cataleptic response; this augmentation was attributed to residual morphine in the brain.",2716967_2,1
11017,cross-tolerance,116,131,"Pre-treatment with ketamine produced cross-tolerance to morphine, whereas pretreatment with morphine did not induce cross-tolerance to ketamine but rather augmented the cataleptic response; this augmentation was attributed to residual morphine in the brain.",2716967_2,1
6290,loss of,49,56,"The present studies explored the duration of the loss of righting reflex induced by sub-effective doses of ketamine and morphine, administered simultaneously.",2716967_3,1
6291,loss of,15,22,"Latency to the loss of righting reflex, rigidity and behavior on recovery, reflected the relative predominance of ketamine or morphine in each combination.",2716967_5,1
11025,cataleptic effects,31,49,Naloxone inhibited the induced cataleptic effects.,2716967_6,0
11032,cross-tolerance,193,208,"Rats, tolerant to ketamine-dominant combinations, were cross-tolerant to both drugs, while those tolerant to morphine-dominant combinations were cross-tolerant to morphine but showed either no cross-tolerance or an augmented response to ketamine.",2716967_8,1
11035,ID50,208,212,"While the mutual potentiation, antagonism and tolerance suggest common mechanisms for the induced catalepsy, differences in latency, rigidity and behavior, asymmetry of cross-tolerance and a widely-different ID50 for naloxone would argue against an action at a single opioid site.",2716967_9,0
11036,opioid,268,274,"While the mutual potentiation, antagonism and tolerance suggest common mechanisms for the induced catalepsy, differences in latency, rigidity and behavior, asymmetry of cross-tolerance and a widely-different ID50 for naloxone would argue against an action at a single opioid site.",2716967_9,0
11034,cross-tolerance,169,184,"While the mutual potentiation, antagonism and tolerance suggest common mechanisms for the induced catalepsy, differences in latency, rigidity and behavior, asymmetry of cross-tolerance and a widely-different ID50 for naloxone would argue against an action at a single opioid site.",2716967_9,1
11038,sympathetic function,74,94,Hydrocortisone-induced hypertension in humans: pressor responsiveness and sympathetic function.,2722224_0,1
11037,Hydrocortisone-induced hypertension,0,35,Hydrocortisone-induced hypertension in humans: pressor responsiveness and sympathetic function.,2722224_0,1
11039,Oral hydrocortisone,0,19,Oral hydrocortisone increases blood pressure and enhances pressor responsiveness in normal human subjects.,2722224_1,0
6292,blood pressure,30,44,Oral hydrocortisone increases blood pressure and enhances pressor responsiveness in normal human subjects.,2722224_1,1
6293,blood pressure,72,86,"We studied the effects of 1 week of oral hydrocortisone (200 mg/day) on blood pressure, cardiac output, total peripheral resistance, forearm vascular resistance, and norepinephrine spillover to plasma in eight healthy male volunteers.",2722224_2,1
11040,oral hydrocortisone,36,55,"We studied the effects of 1 week of oral hydrocortisone (200 mg/day) on blood pressure, cardiac output, total peripheral resistance, forearm vascular resistance, and norepinephrine spillover to plasma in eight healthy male volunteers.",2722224_2,0
11041,peripheral resistance,110,131,"We studied the effects of 1 week of oral hydrocortisone (200 mg/day) on blood pressure, cardiac output, total peripheral resistance, forearm vascular resistance, and norepinephrine spillover to plasma in eight healthy male volunteers.",2722224_2,1
11042,vascular resistance,141,160,"We studied the effects of 1 week of oral hydrocortisone (200 mg/day) on blood pressure, cardiac output, total peripheral resistance, forearm vascular resistance, and norepinephrine spillover to plasma in eight healthy male volunteers.",2722224_2,1
6294,cardiac output,88,102,"We studied the effects of 1 week of oral hydrocortisone (200 mg/day) on blood pressure, cardiac output, total peripheral resistance, forearm vascular resistance, and norepinephrine spillover to plasma in eight healthy male volunteers.",2722224_2,1
6295,blood pressure,19,33,"Although diastolic blood pressure remained unchanged, systolic blood pressure increased from 119 to 135 mm Hg (SED +/- 3.4, p less than 0.01), associated with an increased cardiac output (5.85-7.73 l/min, SED +/- 0.46, p less than 0.01).",2722224_3,1
6296,blood pressure,63,77,"Although diastolic blood pressure remained unchanged, systolic blood pressure increased from 119 to 135 mm Hg (SED +/- 3.4, p less than 0.01), associated with an increased cardiac output (5.85-7.73 l/min, SED +/- 0.46, p less than 0.01).",2722224_3,1
6297,SED,111,114,"Although diastolic blood pressure remained unchanged, systolic blood pressure increased from 119 to 135 mm Hg (SED +/- 3.4, p less than 0.01), associated with an increased cardiac output (5.85-7.73 l/min, SED +/- 0.46, p less than 0.01).",2722224_3,1
6298,cardiac output,172,186,"Although diastolic blood pressure remained unchanged, systolic blood pressure increased from 119 to 135 mm Hg (SED +/- 3.4, p less than 0.01), associated with an increased cardiac output (5.85-7.73 l/min, SED +/- 0.46, p less than 0.01).",2722224_3,1
6299,SED,205,208,"Although diastolic blood pressure remained unchanged, systolic blood pressure increased from 119 to 135 mm Hg (SED +/- 3.4, p less than 0.01), associated with an increased cardiac output (5.85-7.73 l/min, SED +/- 0.46, p less than 0.01).",2722224_3,1
11047,peripheral vascular resistance,6,36,"Total peripheral vascular resistance fell from 15.1 to 12.2 mm Hg/l/min (SED +/- 1.03, p less than 0.05).",2722224_4,1
6300,SED,73,76,"Total peripheral vascular resistance fell from 15.1 to 12.2 mm Hg/l/min (SED +/- 1.03, p less than 0.05).",2722224_4,1
6301,SED,246,249,"Resting forearm vascular resistance remained unchanged, but the reflex response to the cold pressor test was accentuated, the rise in resistance increasing from 10.5 mm Hg/ml/100 ml/min (R units) before treatment to 32.6 R units after treatment (SED +/- 6.4, p less than 0.025).",2722224_5,1
6302,SED,275,278,"The rise in forearm vascular resistance accompanying intra-arterial norepinephrine (25, 50, and 100 ng/min) was also significantly greater after hydrocortisone, increasing from an average of 14.9 +/- 2.4 R units before treatment to 35.1 +/- 5.5 R units after hydrocortisone (SED +/- 6.0, p less than 0.05).",2722224_6,1
11056,vascular resistance,20,39,"The rise in forearm vascular resistance accompanying intra-arterial norepinephrine (25, 50, and 100 ng/min) was also significantly greater after hydrocortisone, increasing from an average of 14.9 +/- 2.4 R units before treatment to 35.1 +/- 5.5 R units after hydrocortisone (SED +/- 6.0, p less than 0.05).",2722224_6,1
6303,nervous system,132,146,Measurement of resting norepinephrine spillover rate to plasma and norepinephrine uptake indicated that overall resting sympathetic nervous system activity was not increased.,2722224_8,1
6304,blood pressure,20,34,The rise in resting blood pressure with hydrocortisone is associated with an increased cardiac output (presumably due to increased blood volume).(ABSTRACT TRUNCATED AT 250 WORDS),2722224_9,1
6305,cardiac output,87,101,The rise in resting blood pressure with hydrocortisone is associated with an increased cardiac output (presumably due to increased blood volume).(ABSTRACT TRUNCATED AT 250 WORDS),2722224_9,1
6306,Neuromuscular blockade,0,22,Neuromuscular blockade with magnesium sulfate and nifedipine.,2750819_0,1
2685,magnesium sulfate,28,45,Neuromuscular blockade with magnesium sulfate and nifedipine.,2750819_0,0
6307,neuromuscular blockade,59,81,A patient who received tocolysis with nifedipine developed neuromuscular blockade after 500 mg of magnesium sulfate was administered.,2750819_1,1
2686,magnesium sulfate,98,115,A patient who received tocolysis with nifedipine developed neuromuscular blockade after 500 mg of magnesium sulfate was administered.,2750819_1,0
11063,tocolysis,23,32,A patient who received tocolysis with nifedipine developed neuromuscular blockade after 500 mg of magnesium sulfate was administered.,2750819_1,0
2687,tocolytics,43,53,Caution should be exercised when these two tocolytics are combined.,2750819_3,0
2688,local anesthetic,50,66,Chronic carbamazepine inhibits the development of local anesthetic seizures kindled by cocaine and lidocaine.,2790457_0,0
11064,Chronic carbamazepine,0,21,Chronic carbamazepine inhibits the development of local anesthetic seizures kindled by cocaine and lidocaine.,2790457_0,0
11065,carbamazepine,15,28,The effects of carbamazepine (CBZ) treatment on local anesthetic-kindled seizures and lethality were evaluated in different stages of the kindling process and under different methods of CBZ administration.,2790457_1,0
11069,CBZ,186,189,The effects of carbamazepine (CBZ) treatment on local anesthetic-kindled seizures and lethality were evaluated in different stages of the kindling process and under different methods of CBZ administration.,2790457_1,0
11066,CBZ,30,33,The effects of carbamazepine (CBZ) treatment on local anesthetic-kindled seizures and lethality were evaluated in different stages of the kindling process and under different methods of CBZ administration.,2790457_1,0
11070,Chronic oral CBZ,0,16,"Chronic oral CBZ inhibited the development of both lidocaine- and cocaine-induced seizures, but had little effect on the fully developed local anesthetic seizures.",2790457_2,0
2690,local anesthetic,137,153,"Chronic oral CBZ inhibited the development of both lidocaine- and cocaine-induced seizures, but had little effect on the fully developed local anesthetic seizures.",2790457_2,0
11071,cocaine-induced seizures,66,90,"Chronic oral CBZ inhibited the development of both lidocaine- and cocaine-induced seizures, but had little effect on the fully developed local anesthetic seizures.",2790457_2,1
2689,lidocaine-,51,61,"Chronic oral CBZ inhibited the development of both lidocaine- and cocaine-induced seizures, but had little effect on the fully developed local anesthetic seizures.",2790457_2,0
11072,Chronic CBZ,0,11,Chronic CBZ also decreased the incidence of seizure-related mortality in the cocaine-injected rats.,2790457_3,0
11073,seizure-related mortality,44,69,Chronic CBZ also decreased the incidence of seizure-related mortality in the cocaine-injected rats.,2790457_3,1
11075,CBZ,6,9,Acute CBZ over a range of doses (15-50 mg/kg) had no effect on completed lidocaine-kindled or acute cocaine-induced seizures.,2790457_4,0
11077,cocaine-kindled seizures,88,112,injection of CBZ (15 mg/kg) also was without effect on the development of lidocaine- or cocaine-kindled seizures.,2790457_6,1
2691,lidocaine-,74,84,injection of CBZ (15 mg/kg) also was without effect on the development of lidocaine- or cocaine-kindled seizures.,2790457_6,0
11076,CBZ,13,16,injection of CBZ (15 mg/kg) also was without effect on the development of lidocaine- or cocaine-kindled seizures.,2790457_6,0
11079,CBZ,28,31,The differential effects of CBZ depending upon stage of seizure development suggest that distinct mechanisms underlie the development versus maintenance of local anesthetic-kindled seizures.,2790457_7,0
11081,CBZ,74,77,"The effectiveness of chronic but not repeated, intermittent injections of CBZ suggests that different biochemical consequences result from the different treatment regimens.",2790457_8,0
11083,chronic CBZ,24,35,"The possible utility of chronic CBZ in preventing the development of toxic side effects in human cocaine users is suggested by these data, but remains to be directly evaluated.",2790457_9,0
6308,side effects,75,87,"The possible utility of chronic CBZ in preventing the development of toxic side effects in human cocaine users is suggested by these data, but remains to be directly evaluated.",2790457_9,1
11086,chronic amphotericin B nephrotoxicity,25,62,Sodium status influences chronic amphotericin B nephrotoxicity in rats.,2802551_0,1
11087,amphotericin B,29,43,"The nephrotoxic potential of amphotericin B (5 mg/kg per day intraperitoneally for 3 weeks) has been investigated in salt-depleted, normal-salt, and salt-loaded rats.",2802551_1,0
2692,creatinine,48,58,"In salt-depleted rats, amphotericin B decreased creatinine clearance linearly with time, with an 85% reduction by week 3.",2802551_2,0
11093,amphotericin B,23,37,"In salt-depleted rats, amphotericin B decreased creatinine clearance linearly with time, with an 85% reduction by week 3.",2802551_2,0
11094,normal-salt,16,27,"In contrast, in normal-salt rats creatinine clearance was decreased but to a lesser extent at week 2 and 3, and in salt-loaded rats creatinine clearance did not change for 2 weeks and was decreased by 43% at week 3.",2802551_3,0
2694,creatinine,132,142,"In contrast, in normal-salt rats creatinine clearance was decreased but to a lesser extent at week 2 and 3, and in salt-loaded rats creatinine clearance did not change for 2 weeks and was decreased by 43% at week 3.",2802551_3,0
2693,creatinine,33,43,"In contrast, in normal-salt rats creatinine clearance was decreased but to a lesser extent at week 2 and 3, and in salt-loaded rats creatinine clearance did not change for 2 weeks and was decreased by 43% at week 3.",2802551_3,0
11098,normal-salt,152,163,All rats in the sodium-depleted group had histopathological evidence of patchy tubular cytoplasmic degeneration in tubules that was not observed in any normal-salt or salt-loaded rat.,2802551_4,0
11100,amphotericin B,18,32,Concentrations of amphotericin B in plasma were not significantly different among the three groups at any time during the study.,2802551_5,0
11101,amphotericin B,32,46,"However, at the end of 3 weeks, amphotericin B levels in the kidneys and liver were significantly higher in salt-depleted and normal-salt rats than those in salt-loaded rats, with plasma/kidney ratios of 21, 14, and 8 in salt-depleted, normal-salt, and salt-loaded rats, respectively.",2802551_6,0
2695,creatinine,29,39,"In conclusion, reductions in creatinine clearance and renal amphotericin B accumulation after chronic amphotericin B administration were enhanced by salt depletion and attenuated by sodium loading in rats.",2802551_7,0
11111,cerebral venous thrombosis,30,56,"Magnetic resonance imaging of cerebral venous thrombosis secondary to ""low-dose"" birth control pills.",2819587_0,1
11112,birth control pills,81,100,"Magnetic resonance imaging of cerebral venous thrombosis secondary to ""low-dose"" birth control pills.",2819587_0,0
2696,low-dose,71,79,"Magnetic resonance imaging of cerebral venous thrombosis secondary to ""low-dose"" birth control pills.",2819587_0,0
6309,deep venous thrombosis,51,73,The clinical and radiographic features of cerebral deep venous thrombosis in a 21-year-old white woman are presented.,2819587_1,1
11114,nulliparous,5,16,This nulliparous patient presented with relatively mild clinical symptoms and progressing mental status changes.,2819587_2,1
11115,clinical symptoms,56,73,This nulliparous patient presented with relatively mild clinical symptoms and progressing mental status changes.,2819587_2,1
11116,mental status,90,103,This nulliparous patient presented with relatively mild clinical symptoms and progressing mental status changes.,2819587_2,1
2697,low-dose,32,40,"The only known risk factor was ""low-dose"" oral contraceptive pills.",2819587_3,0
11117,oral contraceptive pills,42,66,"The only known risk factor was ""low-dose"" oral contraceptive pills.",2819587_3,0
11120,internal cerebral veins,78,101,"The magnetic resonance image (MRI) showed increased signal intensity from the internal cerebral veins, vein of Galen, and straight sinus.",2819587_4,1
11121,straight sinus,122,136,"The magnetic resonance image (MRI) showed increased signal intensity from the internal cerebral veins, vein of Galen, and straight sinus.",2819587_4,1
2698,oxprenolol,64,74,Beta-2-adrenoceptor-mediated hypokalemia and its abolishment by oxprenolol.,2826064_0,0
2699,oxprenolol,45,55,"Subsequently we investigated the efficacy of oxprenolol in antagonizing such hypokalemia, together with the pharmacokinetic interaction between both drugs.",2826064_2,0
11127,terbutaline,62,73,Six healthy subjects were given a 0.5 mg subcutaneous dose of terbutaline on two occasions: 1 hour after oral administration of a placebo and 1 hour after 80 mg oxprenolol orally.,2826064_3,0
2700,oxprenolol,161,171,Six healthy subjects were given a 0.5 mg subcutaneous dose of terbutaline on two occasions: 1 hour after oral administration of a placebo and 1 hour after 80 mg oxprenolol orally.,2826064_3,0
11129,terbutaline,27,38,"In the 7-hour period after terbutaline administration, plasma samples were taken for determination of plasma potassium levels and drug concentrations.",2826064_4,0
2701,Oxprenolol,0,10,"Oxprenolol caused decreases of 65% and 56% of terbutaline volume of distribution and clearance, respectively, and an increase of 130% of its AUC.",2826064_6,0
2702,oxprenolol,52,62,"In spite of higher terbutaline concentrations after oxprenolol pretreatment, the hypokalemia was almost completely antagonized by the beta 2-blocking action.",2826064_7,0
11136,beta 2-blocking action,134,156,"In spite of higher terbutaline concentrations after oxprenolol pretreatment, the hypokalemia was almost completely antagonized by the beta 2-blocking action.",2826064_7,0
11138,MSH/ACTH,45,53,A dystonia-like syndrome after neuropeptide (MSH/ACTH) stimulation of the rat locus ceruleus.,2840807_0,0
11137,dystonia-like syndrome,2,24,A dystonia-like syndrome after neuropeptide (MSH/ACTH) stimulation of the rat locus ceruleus.,2840807_0,1
2703,neuropeptide,31,43,A dystonia-like syndrome after neuropeptide (MSH/ACTH) stimulation of the rat locus ceruleus.,2840807_0,0
11139,locus ceruleus,78,92,A dystonia-like syndrome after neuropeptide (MSH/ACTH) stimulation of the rat locus ceruleus.,2840807_0,1
11140,movement disorder,4,21,"The movement disorder investigated in these studies has some features in common with human idiopathic dystonia, and information obtained in these studies may be of potential clinical benefit.",2840807_1,1
6310,dystonia,102,110,"The movement disorder investigated in these studies has some features in common with human idiopathic dystonia, and information obtained in these studies may be of potential clinical benefit.",2840807_1,1
11141,LC,79,81,The present experimental results indicated that peptidergic stimulation of the LC resulted in a NE-mediated inhibition of cerebellar Purkinje cells located at terminals of the ceruleo-cerebellar pathway.,2840807_2,0
11150,movement disorder,410,427,"However, it is not certain as to the following: (a) what receptors were stimulated by the ACTH N-terminal fragments at the LC that resulted in this disorder; (b) whether NE, released onto Purkinje cell synapses located at terminals of the ceruleo-cerebellar pathway, did indeed cause the long-term depression at Purkinje cell synapses (previously described by others) that resulted in the long duration of the movement disorder; (c) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei, the output targets of the Purkinje cell axons, that may have been an important contributing factor to this disorder.",2840807_3,1
11146,LC,123,125,"However, it is not certain as to the following: (a) what receptors were stimulated by the ACTH N-terminal fragments at the LC that resulted in this disorder; (b) whether NE, released onto Purkinje cell synapses located at terminals of the ceruleo-cerebellar pathway, did indeed cause the long-term depression at Purkinje cell synapses (previously described by others) that resulted in the long duration of the movement disorder; (c) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei, the output targets of the Purkinje cell axons, that may have been an important contributing factor to this disorder.",2840807_3,0
11147,ceruleo-cerebellar pathway,239,265,"However, it is not certain as to the following: (a) what receptors were stimulated by the ACTH N-terminal fragments at the LC that resulted in this disorder; (b) whether NE, released onto Purkinje cell synapses located at terminals of the ceruleo-cerebellar pathway, did indeed cause the long-term depression at Purkinje cell synapses (previously described by others) that resulted in the long duration of the movement disorder; (c) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei, the output targets of the Purkinje cell axons, that may have been an important contributing factor to this disorder.",2840807_3,1
11149,long duration,389,402,"However, it is not certain as to the following: (a) what receptors were stimulated by the ACTH N-terminal fragments at the LC that resulted in this disorder; (b) whether NE, released onto Purkinje cell synapses located at terminals of the ceruleo-cerebellar pathway, did indeed cause the long-term depression at Purkinje cell synapses (previously described by others) that resulted in the long duration of the movement disorder; (c) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei, the output targets of the Purkinje cell axons, that may have been an important contributing factor to this disorder.",2840807_3,1
11154,Purkinje cell,626,639,"However, it is not certain as to the following: (a) what receptors were stimulated by the ACTH N-terminal fragments at the LC that resulted in this disorder; (b) whether NE, released onto Purkinje cell synapses located at terminals of the ceruleo-cerebellar pathway, did indeed cause the long-term depression at Purkinje cell synapses (previously described by others) that resulted in the long duration of the movement disorder; (c) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei, the output targets of the Purkinje cell axons, that may have been an important contributing factor to this disorder.",2840807_3,1
11145,ACTH N-terminal,90,105,"However, it is not certain as to the following: (a) what receptors were stimulated by the ACTH N-terminal fragments at the LC that resulted in this disorder; (b) whether NE, released onto Purkinje cell synapses located at terminals of the ceruleo-cerebellar pathway, did indeed cause the long-term depression at Purkinje cell synapses (previously described by others) that resulted in the long duration of the movement disorder; (c) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei, the output targets of the Purkinje cell axons, that may have been an important contributing factor to this disorder.",2840807_3,0
11153,interpositus nuclei,579,598,"However, it is not certain as to the following: (a) what receptors were stimulated by the ACTH N-terminal fragments at the LC that resulted in this disorder; (b) whether NE, released onto Purkinje cell synapses located at terminals of the ceruleo-cerebellar pathway, did indeed cause the long-term depression at Purkinje cell synapses (previously described by others) that resulted in the long duration of the movement disorder; (c) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei, the output targets of the Purkinje cell axons, that may have been an important contributing factor to this disorder.",2840807_3,1
2704,beta-adrenergic blocking agent,33,63,Flestolol: an ultra-short-acting beta-adrenergic blocking agent.,2870085_0,0
11155,Flestolol,0,9,Flestolol: an ultra-short-acting beta-adrenergic blocking agent.,2870085_0,0
11156,Flestolol,0,9,"Flestolol (ACC-9089) is a nonselective, competitive, ultra-short-acting beta-adrenergic blocking agent, without any intrinsic sympathomimetic activity.",2870085_1,0
2705,beta-adrenergic blocking agent,72,102,"Flestolol (ACC-9089) is a nonselective, competitive, ultra-short-acting beta-adrenergic blocking agent, without any intrinsic sympathomimetic activity.",2870085_1,0
6312,chest pain,103,113,"In patients with unstable angina, flestolol infusion was found to be safe and effective in controlling chest pain.",2870085_10,1
11174,flestolol,34,43,"In patients with unstable angina, flestolol infusion was found to be safe and effective in controlling chest pain.",2870085_10,0
6311,unstable angina,17,32,"In patients with unstable angina, flestolol infusion was found to be safe and effective in controlling chest pain.",2870085_10,1
2710,beta-adrenergic blocking agent,79,109,"It is concluded that flestolol is a potent, well-tolerated, ultra-short-acting beta-adrenergic blocking agent.",2870085_11,0
11175,flestolol,21,30,"It is concluded that flestolol is a potent, well-tolerated, ultra-short-acting beta-adrenergic blocking agent.",2870085_11,0
11177,flestolol,7,16,Use of flestolol in the critical care setting is currently undergoing investigation.,2870085_12,0
2706,esterases,35,44,Flestolol is metabolized by plasma esterases and has an elimination half-life of approximately 6.5 minutes.,2870085_2,0
11158,Flestolol,0,9,Flestolol is metabolized by plasma esterases and has an elimination half-life of approximately 6.5 minutes.,2870085_2,0
11160,flestolol,31,40,"In long-term infusion studies, flestolol was well tolerated at the effective beta-blocking dose (5 micrograms/kg/min) for up to seven days.",2870085_4,0
11161,beta-blocking dose,77,95,"In long-term infusion studies, flestolol was well tolerated at the effective beta-blocking dose (5 micrograms/kg/min) for up to seven days.",2870085_4,0
11162,Flestolol,0,9,Flestolol blood concentrations increased linearly with increasing dose and good correlation exists between blood concentrations of flestolol and beta-adrenergic blockade.,2870085_5,0
11165,flestolol,131,140,Flestolol blood concentrations increased linearly with increasing dose and good correlation exists between blood concentrations of flestolol and beta-adrenergic blockade.,2870085_5,0
2707,beta-adrenergic,145,160,Flestolol blood concentrations increased linearly with increasing dose and good correlation exists between blood concentrations of flestolol and beta-adrenergic blockade.,2870085_5,0
11166,Flestolol,0,9,Flestolol produced a dose-dependent attenuation of isoproterenol-induced tachycardia.,2870085_6,0
2708,beta blockers,86,99,Electrophysiologic and hemodynamic effects of flestolol are similar to those of other beta blockers.,2870085_7,0
11170,flestolol,46,55,Electrophysiologic and hemodynamic effects of flestolol are similar to those of other beta blockers.,2870085_7,0
2709,beta blockers,23,36,"In contrast with other beta blockers, flestolol-induced effects reverse rapidly (within 30 minutes) following discontinuation because of its short half-life.",2870085_8,0
11171,Flestolol,0,9,Flestolol effectively reduced heart rate in patients with supraventricular tachyarrhythmia.,2870085_9,0
11173,supraventricular tachyarrhythmia,58,90,Flestolol effectively reduced heart rate in patients with supraventricular tachyarrhythmia.,2870085_9,1
11172,heart rate,30,40,Flestolol effectively reduced heart rate in patients with supraventricular tachyarrhythmia.,2870085_9,1
11181,prejunctional beta-adrenoceptor,112,143,Enhanced stimulus-induced neurotransmitter overflow in epinephrine-induced hypertensive rats is not mediated by prejunctional beta-adrenoceptor activation.,2886572_0,0
2711,(1,121,123,"The present study examines the effect of 6-day epinephrine treatment (100 micrograms/kg per h, s.c.) on stimulus-induced (1 Hz) endogenous neurotransmitter overflow from the isolated perfused kidney of vehicle- and epinephrine-treated rats.",2886572_1,0
11188,extraneuronal,87,100,This difference in fractional overflow between groups was not affected by neuronal and extraneuronal uptake blockade.,2886572_6,1
2712,Propranolol,0,11,Propranolol had no effect on stimulus-induced overflow in either group.,2886572_7,0
2713,bromocriptine,111,124,"Immunohistochemical, electron microscopic and morphometric studies of estrogen-induced rat prolactinomas after bromocriptine treatment.",2887062_0,0
6313,prolactinomas,91,104,"Immunohistochemical, electron microscopic and morphometric studies of estrogen-induced rat prolactinomas after bromocriptine treatment.",2887062_0,1
11204,bromocriptine (3,223,239,"To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).",2887062_1,0
6315,prolactinoma,173,185,"To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).",2887062_1,1
2714,bromocriptine,26,39,"To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).",2887062_1,0
6314,prolactinoma,43,55,"To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).",2887062_1,1
6316,body weight,249,260,"To clarify the effects of bromocriptine on prolactinoma cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight).",2887062_1,1
11225,rough endoplasmic reticulum,98,125,"An increase in the volume density of secretory granules and a decrease in the volume densities of rough endoplasmic reticulum and microtubules was determined by morphometric analysis, suggesting that bromocriptine inhibits protein synthesis as well as bringing about a disturbance of the prolactin secretion.",2887062_10,0
6320,prolactin secretion,288,307,"An increase in the volume density of secretory granules and a decrease in the volume densities of rough endoplasmic reticulum and microtubules was determined by morphometric analysis, suggesting that bromocriptine inhibits protein synthesis as well as bringing about a disturbance of the prolactin secretion.",2887062_10,1
2719,bromocriptine,200,213,"An increase in the volume density of secretory granules and a decrease in the volume densities of rough endoplasmic reticulum and microtubules was determined by morphometric analysis, suggesting that bromocriptine inhibits protein synthesis as well as bringing about a disturbance of the prolactin secretion.",2887062_10,0
2720,protein synthesis,223,240,"An increase in the volume density of secretory granules and a decrease in the volume densities of rough endoplasmic reticulum and microtubules was determined by morphometric analysis, suggesting that bromocriptine inhibits protein synthesis as well as bringing about a disturbance of the prolactin secretion.",2887062_10,0
6317,prolactinoma,148,160,"Electron microscopy disclosed many secretory granules, slightly distorted rough endoplasmic reticulum, and partially dilated Golgi cisternae in the prolactinoma cells.",2887062_3,1
11207,secretory granules,35,53,"Electron microscopy disclosed many secretory granules, slightly distorted rough endoplasmic reticulum, and partially dilated Golgi cisternae in the prolactinoma cells.",2887062_3,0
11208,rough endoplasmic reticulum,74,101,"Electron microscopy disclosed many secretory granules, slightly distorted rough endoplasmic reticulum, and partially dilated Golgi cisternae in the prolactinoma cells.",2887062_3,0
2715,bromocriptine,81,94,These findings suggest that lowered serum prolactin levels in the early phase of bromocriptine treatment may result from an impaired secretion of prolactin due to decreasing numbers of cytoplasmic microtubules.,2887062_5,0
11214,early phase,66,77,These findings suggest that lowered serum prolactin levels in the early phase of bromocriptine treatment may result from an impaired secretion of prolactin due to decreasing numbers of cytoplasmic microtubules.,2887062_5,1
11215,impaired secretion,124,142,These findings suggest that lowered serum prolactin levels in the early phase of bromocriptine treatment may result from an impaired secretion of prolactin due to decreasing numbers of cytoplasmic microtubules.,2887062_5,1
6318,prolactinoma,4,16,"The prolactinoma cells at this time were well granulated, with vesiculated rough endoplasmic reticulum and markedly dilated Golgi cisternae.",2887062_7,1
11218,rough endoplasmic reticulum,75,102,"The prolactinoma cells at this time were well granulated, with vesiculated rough endoplasmic reticulum and markedly dilated Golgi cisternae.",2887062_7,0
11221,endoplasmic reticulum,134,155,"Electron microscopical immunohistochemistry revealed positive reaction products noted on the secretory granules, Golgi cisternae, and endoplasmic reticulum of the untreated rat prolactinoma cells.",2887062_8,0
6319,prolactinoma,177,189,"Electron microscopical immunohistochemistry revealed positive reaction products noted on the secretory granules, Golgi cisternae, and endoplasmic reticulum of the untreated rat prolactinoma cells.",2887062_8,1
2716,reaction products,62,79,"Electron microscopical immunohistochemistry revealed positive reaction products noted on the secretory granules, Golgi cisternae, and endoplasmic reticulum of the untreated rat prolactinoma cells.",2887062_8,0
11223,adenoma cells,126,139,"However, only secretory granules showed the positive reaction products for prolactin 6 h after bromocriptine treatment of the adenoma cells.",2887062_9,1
2717,reaction products,53,70,"However, only secretory granules showed the positive reaction products for prolactin 6 h after bromocriptine treatment of the adenoma cells.",2887062_9,0
2718,bromocriptine,95,108,"However, only secretory granules showed the positive reaction products for prolactin 6 h after bromocriptine treatment of the adenoma cells.",2887062_9,0
6321,respiratory paralysis,49,70,GABA involvement in naloxone induced reversal of respiratory paralysis produced by thiopental.,2893236_0,1
2722,general anesthetics,96,115,"No agent is yet available to reverse respiratory paralysis produced by CNS depressants, such as general anesthetics.",2893236_1,0
6322,respiratory paralysis,37,58,"No agent is yet available to reverse respiratory paralysis produced by CNS depressants, such as general anesthetics.",2893236_1,1
2721,CNS depressants,71,86,"No agent is yet available to reverse respiratory paralysis produced by CNS depressants, such as general anesthetics.",2893236_1,0
6323,respiratory paralysis,32,53,In this study naloxone reversed respiratory paralysis induced by thiopental in rats.,2893236_2,1
2723,aspartate,139,148,"25 mg/kg, i.v. thiopental produced anesthesia without altering respiratory rate, increased GABA, decreased glutamate, and had no effect on aspartate or glycine levels compared to controls in rat cortex and brain stem.",2893236_3,0
6324,brain stem,206,216,"25 mg/kg, i.v. thiopental produced anesthesia without altering respiratory rate, increased GABA, decreased glutamate, and had no effect on aspartate or glycine levels compared to controls in rat cortex and brain stem.",2893236_3,1
11232,respiratory depressant action,106,135,Pretreatment of rats with thiosemicarbazide for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental.,2893236_4,0
11231,anesthetic action,73,90,Pretreatment of rats with thiosemicarbazide for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental.,2893236_4,0
11230,thiosemicarbazide,26,43,Pretreatment of rats with thiosemicarbazide for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental.,2893236_4,0
11233,respiratory arrest,35,53,"50 mg/kg, i.v. thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain.",2893236_5,1
6325,brain stem,130,140,"50 mg/kg, i.v. thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain.",2893236_5,1
2724,amino acids,170,181,"50 mg/kg, i.v. thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain.",2893236_5,0
6326,respiratory paralysis,36,57,"Naloxone (2.5 mg/kg, i.v.) reversed respiratory paralysis, glutamate and GABA levels to control values in brain stem and cortex with no changes in caudate or cerebellum.",2893236_6,1
6327,brain stem,106,116,"Naloxone (2.5 mg/kg, i.v.) reversed respiratory paralysis, glutamate and GABA levels to control values in brain stem and cortex with no changes in caudate or cerebellum.",2893236_6,1
6328,respiratory paralysis,37,58,These data suggest naloxone reverses respiratory paralysis produced by thiopental and involves GABA in its action.,2893236_7,1
11234,reflex bradycardia,21,39,Diazepam facilitates reflex bradycardia in conscious rats.,2894433_0,1
11237,diazepam (1,30,41,Intravenous administration of diazepam (1-30 mg kg-1) produced a dose-dependent decrease in both the mean arterial pressure and the heart rate.,2894433_2,0
11241,heart rate,132,142,Intravenous administration of diazepam (1-30 mg kg-1) produced a dose-dependent decrease in both the mean arterial pressure and the heart rate.,2894433_2,1
11240,mean arterial pressure,101,123,Intravenous administration of diazepam (1-30 mg kg-1) produced a dose-dependent decrease in both the mean arterial pressure and the heart rate.,2894433_2,1
11238,kg-1,48,52,Intravenous administration of diazepam (1-30 mg kg-1) produced a dose-dependent decrease in both the mean arterial pressure and the heart rate.,2894433_2,0
11242,reflex bradycardia,6,24,"Also, reflex bradycardia was produced in rats by intravenous infusion of adrenaline (1.25-2.5 micrograms kg-1).",2894433_3,1
11243,kg-1,105,109,"Also, reflex bradycardia was produced in rats by intravenous infusion of adrenaline (1.25-2.5 micrograms kg-1).",2894433_3,0
11246,adrenaline-induced reflex bradycardia,137,174,"Intravenous pretreatment of the rats with diazepam, although causing no change in the adrenaline-induced pressor effect, did enhance the adrenaline-induced reflex bradycardia.",2894433_4,1
11250,benzodiazepine-GABA-chloride channel macromolecular complex,229,288,"However, the diazepam enhancement of adrenaline-induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).",2894433_5,0
2725,picrotoxin,143,153,"However, the diazepam enhancement of adrenaline-induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).",2894433_5,0
11247,adrenaline-induced reflex bradycardia,37,74,"However, the diazepam enhancement of adrenaline-induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).",2894433_5,1
11249,agent blocks chloride channels,158,188,"However, the diazepam enhancement of adrenaline-induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex).",2894433_5,0
11251,benzodiazepine-GABA-chloride channel macromolecular complex,49,108,The data indicate that diazepam acts through the benzodiazepine-GABA-chloride channel macromolecular complex within the central nervous system to facilitate reflex bradycardia mediated through baroreceptor reflexes in response to an acute increase in arterial pressure.,2894433_6,0
11252,reflex bradycardia,157,175,The data indicate that diazepam acts through the benzodiazepine-GABA-chloride channel macromolecular complex within the central nervous system to facilitate reflex bradycardia mediated through baroreceptor reflexes in response to an acute increase in arterial pressure.,2894433_6,1
11254,acute increase,233,247,The data indicate that diazepam acts through the benzodiazepine-GABA-chloride channel macromolecular complex within the central nervous system to facilitate reflex bradycardia mediated through baroreceptor reflexes in response to an acute increase in arterial pressure.,2894433_6,1
6329,central nervous system,120,142,The data indicate that diazepam acts through the benzodiazepine-GABA-chloride channel macromolecular complex within the central nervous system to facilitate reflex bradycardia mediated through baroreceptor reflexes in response to an acute increase in arterial pressure.,2894433_6,1
11255,arterial pressure,251,268,The data indicate that diazepam acts through the benzodiazepine-GABA-chloride channel macromolecular complex within the central nervous system to facilitate reflex bradycardia mediated through baroreceptor reflexes in response to an acute increase in arterial pressure.,2894433_6,1
6330,lupus erythematosus,22,41,Sulfasalazine-induced lupus erythematosus.,2894766_0,1
6331,pleural effusions,23,40,"Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis.",2894766_1,1
6332,cardiac tamponade,72,89,"Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis.",2894766_1,1
2726,sulfasalazine,179,192,"Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis.",2894766_1,0
6333,ulcerative colitis,213,231,"Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis.",2894766_1,1
2727,sulfasalazine,23,36,"After cessation of the sulfasalazine and completion of a six-week course of corticosteroids, these problems resolved over a period of four to six months.",2894766_2,0
11260,joint symptoms,154,168,"It is suggested that the patient had sulfasalazine-induced lupus, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms.",2894766_3,1
11259,pulmonary parenchymal,102,123,"It is suggested that the patient had sulfasalazine-induced lupus, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms.",2894766_3,1
6334,serositis,88,97,"It is suggested that the patient had sulfasalazine-induced lupus, which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms.",2894766_3,1
6335,inflammatory bowel disease,56,82,Physicians who use sulfasalazine to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine-induced lupus syndrome.,2894766_4,1
2728,sulfasalazine,19,32,Physicians who use sulfasalazine to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine-induced lupus syndrome.,2894766_4,0
2729,dietary sodium,135,149,Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction.,28952_0,0
11263,hypokalaemia,27,39,Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction.,28952_0,1
6336,essential hypertension,94,116,Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction.,28952_0,1
11262,potassium loss,8,22,Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction.,28952_0,1
11265,hypokalaemia,61,73,"To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment.",28952_1,1
11268,hypokalaemia,220,232,"To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment.",28952_1,1
6337,essential hypertension,183,205,"To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment.",28952_1,1
11266,oral diuretic,106,119,"To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment.",28952_1,0
11269,low-sodium,54,64,Six patients received a normal-sodium diet and four a low-sodium (17 mmol/day) diet.,28952_3,0
11274,low-sodium group,133,149,"In the normal-sodium group the highest mean potassium deficit was 176 mmol on day 9, after which some potassium was regained; in the low-sodium group the highest deficit was 276 mmol on day 13.",28952_7,0
11275,normal-sodium group,4,23,The normal-sodium group showed an immediate but temporary rise of the renin and aldosterone levels; in the low-sodium group renin and aldosterone increased more slowly but remained elevated.,28952_8,0
11276,low-sodium group,107,123,The normal-sodium group showed an immediate but temporary rise of the renin and aldosterone levels; in the low-sodium group renin and aldosterone increased more slowly but remained elevated.,28952_8,0
11277,potassium loss,75,89,"It is concluded that dietary sodium restriction increases diuretic-induced potassium loss, presumably by an increased activity of the renin-angiotensin-aldosterone system, while sodium delivery to the distal renal tubules remains sufficiently high to allow increased potassium secretion.",28952_9,1
2730,dietary sodium,21,35,"It is concluded that dietary sodium restriction increases diuretic-induced potassium loss, presumably by an increased activity of the renin-angiotensin-aldosterone system, while sodium delivery to the distal renal tubules remains sufficiently high to allow increased potassium secretion.",28952_9,0
11282,anxiolytic drugs,67,83,Reversal of neuroleptic-induced catalepsy by novel aryl-piperazine anxiolytic drugs.,2907585_0,0
11281,neuroleptic-induced catalepsy,12,41,Reversal of neuroleptic-induced catalepsy by novel aryl-piperazine anxiolytic drugs.,2907585_0,1
11283,anxiolytic drug,10,25,"The novel anxiolytic drug, buspirone, reverses catalepsy induced by haloperidol.",2907585_1,0
11284,aryl-piperazine analogues,12,37,A series of aryl-piperazine analogues of buspirone and other 5-hydroxytryptaminergic agonists were tested for their ability to reverse haloperidol induced catalepsy.,2907585_2,0
11286,reverse haloperidol,127,146,A series of aryl-piperazine analogues of buspirone and other 5-hydroxytryptaminergic agonists were tested for their ability to reverse haloperidol induced catalepsy.,2907585_2,0
11285,5-hydroxytryptaminergic,61,84,A series of aryl-piperazine analogues of buspirone and other 5-hydroxytryptaminergic agonists were tested for their ability to reverse haloperidol induced catalepsy.,2907585_2,0
11288,reverse catalepsy,82,99,Those drugs with strong affinity for 5-hydroxytryptamine1a receptors were able to reverse catalepsy.,2907585_3,1
11287,5-hydroxytryptamine1a receptors,37,68,Those drugs with strong affinity for 5-hydroxytryptamine1a receptors were able to reverse catalepsy.,2907585_3,0
11289,5-HT receptors,30,44,Drugs with affinity for other 5-HT receptors or weak affinity were ineffective.,2907585_4,0
11290,postsynaptic 5-HT receptors,23,50,"However, inhibition of postsynaptic 5-HT receptors neither inhibited nor potentiated reversal of catalepsy and leaves open the question as to the site or mechanism for this effect.",2907585_5,0
2732,edrophonium,77,88,Glycopyrronium requirements for antagonism of the muscarinic side effects of edrophonium.,2917114_0,0
2731,Glycopyrronium,0,14,Glycopyrronium requirements for antagonism of the muscarinic side effects of edrophonium.,2917114_0,0
11295,kg-1,187,191,"We have compared, in 60 adult patients, the cardiovascular effects of glycopyrronium 5 micrograms kg-1 and 10 micrograms kg-1 given either simultaneously or 1 min before edrophonium 1 mg kg-1.",2917114_1,0
11293,kg-1,98,102,"We have compared, in 60 adult patients, the cardiovascular effects of glycopyrronium 5 micrograms kg-1 and 10 micrograms kg-1 given either simultaneously or 1 min before edrophonium 1 mg kg-1.",2917114_1,0
2733,glycopyrronium,70,84,"We have compared, in 60 adult patients, the cardiovascular effects of glycopyrronium 5 micrograms kg-1 and 10 micrograms kg-1 given either simultaneously or 1 min before edrophonium 1 mg kg-1.",2917114_1,0
2734,edrophonium,170,181,"We have compared, in 60 adult patients, the cardiovascular effects of glycopyrronium 5 micrograms kg-1 and 10 micrograms kg-1 given either simultaneously or 1 min before edrophonium 1 mg kg-1.",2917114_1,0
11294,kg-1,121,125,"We have compared, in 60 adult patients, the cardiovascular effects of glycopyrronium 5 micrograms kg-1 and 10 micrograms kg-1 given either simultaneously or 1 min before edrophonium 1 mg kg-1.",2917114_1,0
11300,min-1,129,134,Both groups receiving 10 micrograms kg-1 showed increases in heart rate of up to 30 beat min-1 (95% confidence limits 28-32 beat min-1).,2917114_3,0
11298,min-1,89,94,Both groups receiving 10 micrograms kg-1 showed increases in heart rate of up to 30 beat min-1 (95% confidence limits 28-32 beat min-1).,2917114_3,0
11296,kg-1,36,40,Both groups receiving 10 micrograms kg-1 showed increases in heart rate of up to 30 beat min-1 (95% confidence limits 28-32 beat min-1).,2917114_3,0
11301,kg-1,35,39,"Use of glycopyrronium 5 micrograms kg-1 provided greater cardiovascular stability and, given 1 min before the edrophonium, was sufficient to minimize early, edrophonium-induced bradycardias.",2917114_4,0
2735,glycopyrronium,7,21,"Use of glycopyrronium 5 micrograms kg-1 provided greater cardiovascular stability and, given 1 min before the edrophonium, was sufficient to minimize early, edrophonium-induced bradycardias.",2917114_4,0
2736,edrophonium,110,121,"Use of glycopyrronium 5 micrograms kg-1 provided greater cardiovascular stability and, given 1 min before the edrophonium, was sufficient to minimize early, edrophonium-induced bradycardias.",2917114_4,0
2737,low dose,5,13,This low dose of glycopyrronium provided good control of oropharyngeal secretions.,2917114_5,0
2738,glycopyrronium,17,31,This low dose of glycopyrronium provided good control of oropharyngeal secretions.,2917114_5,0
11304,Chronic carbamazepine,0,21,"Chronic carbamazepine treatment in the rat: efficacy, toxicity, and effect on plasma and tissue folate concentrations.",2924746_0,0
2739,antiepileptic drug,53,71,Folate depletion has often been a problem in chronic antiepileptic drug (AED) therapy.,2924746_1,0
11306,CBZ,15,18,"Carbamazepine (CBZ), a commonly used AED, has been implicated in some clinical studies.",2924746_2,0
11307,AED,37,40,"Carbamazepine (CBZ), a commonly used AED, has been implicated in some clinical studies.",2924746_2,0
11305,Carbamazepine,0,13,"Carbamazepine (CBZ), a commonly used AED, has been implicated in some clinical studies.",2924746_2,0
11309,chronic CBZ,52,63,A rat model was developed to examine the effects of chronic CBZ treatment on folate concentrations in the rat.,2924746_3,0
11310,high doses,89,99,"In the course of developing this model, a common vehicle, propylene glycol, by itself in high doses, was found to exhibit protective properties against induced seizures and inhibited weight gain.",2924746_4,0
11311,protective properties,122,143,"In the course of developing this model, a common vehicle, propylene glycol, by itself in high doses, was found to exhibit protective properties against induced seizures and inhibited weight gain.",2924746_4,0
2740,propylene glycol,58,74,"In the course of developing this model, a common vehicle, propylene glycol, by itself in high doses, was found to exhibit protective properties against induced seizures and inhibited weight gain.",2924746_4,0
6338,weight gain,183,194,"In the course of developing this model, a common vehicle, propylene glycol, by itself in high doses, was found to exhibit protective properties against induced seizures and inhibited weight gain.",2924746_4,1
11314,CBZ,115,118,Seizures induced by hexafluorodiethyl ether (HFDE) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock (MES).,2924746_5,0
11313,HFDE,45,49,Seizures induced by hexafluorodiethyl ether (HFDE) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock (MES).,2924746_5,0
11312,hexafluorodiethyl ether,20,43,Seizures induced by hexafluorodiethyl ether (HFDE) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock (MES).,2924746_5,0
6339,weight gain,182,193,Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against HFDE-induced seizures and was minimally toxic as measured by weight gain over 8 weeks of treatment.,2924746_6,1
11317,aqueous suspension,33,51,Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against HFDE-induced seizures and was minimally toxic as measured by weight gain over 8 weeks of treatment.,2924746_6,0
11316,CBZ,23,26,Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against HFDE-induced seizures and was minimally toxic as measured by weight gain over 8 weeks of treatment.,2924746_6,0
11320,CBZ,4,7,"The CBZ levels measured in plasma and brain of these animals, however, were below those normally considered protective.",2924746_7,0
11322,adverse effect,40,54,"This treatment with CBZ had no apparent adverse effect on folate concentrations in the rat, and, indeed, the folate concentration increased in liver after 6 weeks of treatment and in plasma at 8 weeks of treatment.",2924746_8,1
11321,CBZ,20,23,"This treatment with CBZ had no apparent adverse effect on folate concentrations in the rat, and, indeed, the folate concentration increased in liver after 6 weeks of treatment and in plasma at 8 weeks of treatment.",2924746_8,0
6340,myocardial ischemia,21,40,Dipyridamole-induced myocardial ischemia.,2950248_0,1
2741,dipyridamole,87,99,Angina and ischemic electrocardiographic changes occurred after administration of oral dipyridamole in four patients awaiting urgent myocardial revascularization procedures.,2950248_1,0
6341,side effect,61,72,"To our knowledge, this has not previously been reported as a side effect of preoperative dipyridamole therapy, although dipyridamole-induced myocardial ischemia has been demonstrated to occur in animals and humans with coronary artery disease.",2950248_2,1
6342,myocardial ischemia,141,160,"To our knowledge, this has not previously been reported as a side effect of preoperative dipyridamole therapy, although dipyridamole-induced myocardial ischemia has been demonstrated to occur in animals and humans with coronary artery disease.",2950248_2,1
6343,coronary artery disease,219,242,"To our knowledge, this has not previously been reported as a side effect of preoperative dipyridamole therapy, although dipyridamole-induced myocardial ischemia has been demonstrated to occur in animals and humans with coronary artery disease.",2950248_2,1
2742,dipyridamole,89,101,"To our knowledge, this has not previously been reported as a side effect of preoperative dipyridamole therapy, although dipyridamole-induced myocardial ischemia has been demonstrated to occur in animals and humans with coronary artery disease.",2950248_2,0
11325,Epicardial,0,10,"Epicardial coronary collateral vessels were demonstrated in all four patients; a coronary ""steal"" phenomenon may be the mechanism of the dipyridamole-induced ischemia observed.",2950248_3,1
2743,atrial natriuretic factor,42,67,Inhibition of sympathoadrenal activity by atrial natriuretic factor in dogs.,2951327_0,0
2744,natriuretic factor,32,50,infusions of human alpha-atrial natriuretic factor.,2951327_2,0
2746,/- 1,149,153,"Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.",2951327_3,0
2747,/- 1,178,182,"Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.",2951327_3,0
11330,Mean arterial pressure,0,22,"Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.",2951327_3,1
2745,/- 1,139,143,"Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin.",2951327_3,0
11338,/- 5,228,232,"The release rate of epinephrine (control, 6.7 +/- 0.6 ng/kg/min) declined immediately during infusions of atrial natriuretic factor to a minimum of 49 +/- 5% of control (p less than 0.001) during 0.1 microgram/kg/min and to 63 +/- 5% (0.1 greater than p greater than 0.05) or 95 +/- 13% (not significant) during 0.3 or 1.0 microgram/kg/min.",2951327_4,0
11336,/- 5,152,156,"The release rate of epinephrine (control, 6.7 +/- 0.6 ng/kg/min) declined immediately during infusions of atrial natriuretic factor to a minimum of 49 +/- 5% of control (p less than 0.001) during 0.1 microgram/kg/min and to 63 +/- 5% (0.1 greater than p greater than 0.05) or 95 +/- 13% (not significant) during 0.3 or 1.0 microgram/kg/min.",2951327_4,0
11335,/-,47,49,"The release rate of epinephrine (control, 6.7 +/- 0.6 ng/kg/min) declined immediately during infusions of atrial natriuretic factor to a minimum of 49 +/- 5% of control (p less than 0.001) during 0.1 microgram/kg/min and to 63 +/- 5% (0.1 greater than p greater than 0.05) or 95 +/- 13% (not significant) during 0.3 or 1.0 microgram/kg/min.",2951327_4,0
2748,atrial natriuretic factor,106,131,"The release rate of epinephrine (control, 6.7 +/- 0.6 ng/kg/min) declined immediately during infusions of atrial natriuretic factor to a minimum of 49 +/- 5% of control (p less than 0.001) during 0.1 microgram/kg/min and to 63 +/- 5% (0.1 greater than p greater than 0.05) or 95 +/- 13% (not significant) during 0.3 or 1.0 microgram/kg/min.",2951327_4,0
2749,atrial natriuretic factor,47,72,Steady state arterial plasma concentrations of atrial natriuretic factor were 39 +/- 10 pg/ml (n = 6) during infusions of saline and 284 +/- 24 pg/ml (n = 6) and 1520 +/- 300 pg/ml (n = 9) during 0.03 and 0.1 microgram/kg/min infusions of the factor.(ABSTRACT TRUNCATED AT 250 WORDS),2951327_5,0
11341,/-,82,84,Steady state arterial plasma concentrations of atrial natriuretic factor were 39 +/- 10 pg/ml (n = 6) during infusions of saline and 284 +/- 24 pg/ml (n = 6) and 1520 +/- 300 pg/ml (n = 9) during 0.03 and 0.1 microgram/kg/min infusions of the factor.(ABSTRACT TRUNCATED AT 250 WORDS),2951327_5,0
2750,iohexol,33,40,"Selective injection of iopentol, iohexol and metrizoate into the left coronary artery of the dog.",2980315_0,0
11346,iopentol,23,31,"Selective injection of iopentol, iohexol and metrizoate into the left coronary artery of the dog.",2980315_0,0
11347,metrizoate,45,55,"Selective injection of iopentol, iohexol and metrizoate into the left coronary artery of the dog.",2980315_0,0
6344,coronary artery,70,85,"Selective injection of iopentol, iohexol and metrizoate into the left coronary artery of the dog.",2980315_0,1
6345,ventricular fibrillation,13,37,Induction of ventricular fibrillation and decrease of aortic pressure.,2980315_1,1
11348,aortic pressure,54,69,Induction of ventricular fibrillation and decrease of aortic pressure.,2980315_1,1
2751,iohexol,98,105,"In twenty beagle dogs selective injections were made into the left coronary artery with iopentol, iohexol and metrizoate in doses of 4 ml, 8 ml and 16 ml.",2980315_2,0
6346,coronary artery,67,82,"In twenty beagle dogs selective injections were made into the left coronary artery with iopentol, iohexol and metrizoate in doses of 4 ml, 8 ml and 16 ml.",2980315_2,1
11351,metrizoate,110,120,"In twenty beagle dogs selective injections were made into the left coronary artery with iopentol, iohexol and metrizoate in doses of 4 ml, 8 ml and 16 ml.",2980315_2,0
11350,iopentol,88,96,"In twenty beagle dogs selective injections were made into the left coronary artery with iopentol, iohexol and metrizoate in doses of 4 ml, 8 ml and 16 ml.",2980315_2,0
2752,iohexol,35,42,"Thirty-six iopentol injections, 35 iohexol injections and 37 metrizoate injections were made.",2980315_3,0
11353,metrizoate,61,71,"Thirty-six iopentol injections, 35 iohexol injections and 37 metrizoate injections were made.",2980315_3,0
11352,iopentol,11,19,"Thirty-six iopentol injections, 35 iohexol injections and 37 metrizoate injections were made.",2980315_3,0
11354,iopentol,90,98,Frequencies of ventricular fibrillation were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after metrizoate (22%).,2980315_4,0
11356,metrizoate,132,142,Frequencies of ventricular fibrillation were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after metrizoate (22%).,2980315_4,0
6347,ventricular fibrillation,15,39,Frequencies of ventricular fibrillation were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after metrizoate (22%).,2980315_4,1
11355,iohexol (3,108,118,Frequencies of ventricular fibrillation were significantly lower (p less than 0.05) after iopentol (0%) and iohexol (3%) than after metrizoate (22%).,2980315_4,0
2753,iohexol,13,20,Iopentol and iohexol also produced significantly less decrease in aortic blood pressure than metrizoate at the different doses.,2980315_5,0
6348,blood pressure,73,87,Iopentol and iohexol also produced significantly less decrease in aortic blood pressure than metrizoate at the different doses.,2980315_5,1
11357,Iopentol,0,8,Iopentol and iohexol also produced significantly less decrease in aortic blood pressure than metrizoate at the different doses.,2980315_5,0
11358,metrizoate,93,103,Iopentol and iohexol also produced significantly less decrease in aortic blood pressure than metrizoate at the different doses.,2980315_5,0
11359,Thyroid function,0,16,Thyroid function and urine-concentrating ability during lithium treatment.,3001299_0,1
6349,nephrogenic diabetes insipidus,100,130,It has been suggested that adenylate cyclase inhibition may be important in the development of both nephrogenic diabetes insipidus and hypothyroidism during lithium treatment.,3001299_1,1
2754,adenylate cyclase,27,44,It has been suggested that adenylate cyclase inhibition may be important in the development of both nephrogenic diabetes insipidus and hypothyroidism during lithium treatment.,3001299_1,0
2756,DDAVP,96,101,We measured serum thyroxine and urine-concentrating ability (Umax) in response to desmopressin (DDAVP) in 85 patients receiving lithium.,3001299_2,0
2755,desmopressin,82,94,We measured serum thyroxine and urine-concentrating ability (Umax) in response to desmopressin (DDAVP) in 85 patients receiving lithium.,3001299_2,0
11363,taking lithium,59,73,Hypothyroidism developed in eight patients while they were taking lithium.,3001299_3,0
11366,hypothyroid,46,57,Impaired Umax was found in both euthyroid and hypothyroid patients while some hypothyroid patients concentrated their urine well.,3001299_4,1
11364,Umax,9,13,Impaired Umax was found in both euthyroid and hypothyroid patients while some hypothyroid patients concentrated their urine well.,3001299_4,0
11365,euthyroid,32,41,Impaired Umax was found in both euthyroid and hypothyroid patients while some hypothyroid patients concentrated their urine well.,3001299_4,1
11367,hypothyroid,78,89,Impaired Umax was found in both euthyroid and hypothyroid patients while some hypothyroid patients concentrated their urine well.,3001299_4,1
6350,Remodelling,0,11,Remodelling of nerve structure in experimental isoniazid neuropathy in the rat.,3015327_0,1
11373,axon shrinkage,96,110,"There was also evidence of a subtle direct toxic effect on the entire fibre population, causing axon shrinkage masked by readjustment of the myelin sheath.",3015327_3,1
11374,myelin sheath,141,154,"There was also evidence of a subtle direct toxic effect on the entire fibre population, causing axon shrinkage masked by readjustment of the myelin sheath.",3015327_3,1
11375,immunoreactive corticotropin-releasing factor,14,59,Inhibition of immunoreactive corticotropin-releasing factor secretion into the hypophysial-portal circulation by delayed glucocorticoid feedback.,3015567_0,0
11376,hypophysial-portal,79,97,Inhibition of immunoreactive corticotropin-releasing factor secretion into the hypophysial-portal circulation by delayed glucocorticoid feedback.,3015567_0,1
2757,corticotropin-releasing factor,124,154,Nitroprusside-induced hypotension evokes ACTH secretion which is primarily mediated by enhanced secretion of immunoreactive corticotropin-releasing factor (irCRF) into the hypophysial-portal circulation.,3015567_1,0
11378,irCRF,156,161,Nitroprusside-induced hypotension evokes ACTH secretion which is primarily mediated by enhanced secretion of immunoreactive corticotropin-releasing factor (irCRF) into the hypophysial-portal circulation.,3015567_1,0
2758,arginine vasopressin,40,60,Portal plasma concentrations of neither arginine vasopressin nor oxytocin are significantly altered in this paradigm.,3015567_2,0
2760,arginine vasopressin,231,251,"Application of a delayed feedback signal, in the form of a 2-h systemic corticosterone infusion in urethane-anesthetized rats with pharmacological blockade of glucocorticoid synthesis, is without effect on the resting secretion of arginine vasopressin and oxytocin at any corticosterone feedback dose tested.",3015567_3,0
2759,glucocorticoid synthesis,159,183,"Application of a delayed feedback signal, in the form of a 2-h systemic corticosterone infusion in urethane-anesthetized rats with pharmacological blockade of glucocorticoid synthesis, is without effect on the resting secretion of arginine vasopressin and oxytocin at any corticosterone feedback dose tested.",3015567_3,0
11383,irCRF,8,13,"Resting irCRF levels are suppressed only at the highest corticosterone infusion rate, which resulted in systemic corticosterone levels of 40 micrograms/dl.",3015567_4,0
11384,irCRF,15,20,Suppression of irCRF secretion in response to nitroprusside-induced hypotension is observed and occurs at a plasma corticosterone level between 8-12 micrograms/dl.,3015567_5,0
11388,irCRF,137,142,These studies provide further evidence for a strong central component of the delayed feedback process which is mediated by modulation of irCRF release.,3015567_6,0
2761,delta 9-tetrahydrocannabinol,50,78,Noradrenergic involvement in catalepsy induced by delta 9-tetrahydrocannabinol.,3031535_0,0
11389,Noradrenergic,0,13,Noradrenergic involvement in catalepsy induced by delta 9-tetrahydrocannabinol.,3031535_0,0
2762,delta 9-tetrahydrocannabinol,95,123,"In order to elucidate the role of the catecholaminergic system in the cataleptogenic effect of delta 9-tetrahydrocannabinol (THC), the effect of pretreatment with 6-hydroxydopamine (6-OHDA) or with desipramine and 6-OHDA and lesions of the locus coeruleus were investigated in rats.",3031535_1,0
11390,cataleptogenic,70,84,"In order to elucidate the role of the catecholaminergic system in the cataleptogenic effect of delta 9-tetrahydrocannabinol (THC), the effect of pretreatment with 6-hydroxydopamine (6-OHDA) or with desipramine and 6-OHDA and lesions of the locus coeruleus were investigated in rats.",3031535_1,0
11391,6-hydroxydopamine,163,180,"In order to elucidate the role of the catecholaminergic system in the cataleptogenic effect of delta 9-tetrahydrocannabinol (THC), the effect of pretreatment with 6-hydroxydopamine (6-OHDA) or with desipramine and 6-OHDA and lesions of the locus coeruleus were investigated in rats.",3031535_1,0
11392,6-OHDA,182,188,"In order to elucidate the role of the catecholaminergic system in the cataleptogenic effect of delta 9-tetrahydrocannabinol (THC), the effect of pretreatment with 6-hydroxydopamine (6-OHDA) or with desipramine and 6-OHDA and lesions of the locus coeruleus were investigated in rats.",3031535_1,0
11393,6-OHDA,214,220,"In order to elucidate the role of the catecholaminergic system in the cataleptogenic effect of delta 9-tetrahydrocannabinol (THC), the effect of pretreatment with 6-hydroxydopamine (6-OHDA) or with desipramine and 6-OHDA and lesions of the locus coeruleus were investigated in rats.",3031535_1,0
11395,cataleptogenic effect,4,25,"The cataleptogenic effect of THC was significantly reduced in rats treated with 6-OHDA and in rats with lesions of the locus coeruleus but not in rats treated with desipramine and 6-OHDA, as compared with control rats.",3031535_2,0
11398,6-OHDA,180,186,"The cataleptogenic effect of THC was significantly reduced in rats treated with 6-OHDA and in rats with lesions of the locus coeruleus but not in rats treated with desipramine and 6-OHDA, as compared with control rats.",3031535_2,0
11396,6-OHDA,80,86,"The cataleptogenic effect of THC was significantly reduced in rats treated with 6-OHDA and in rats with lesions of the locus coeruleus but not in rats treated with desipramine and 6-OHDA, as compared with control rats.",3031535_2,0
11399,cataleptogenic,21,35,"On the contrary, the cataleptogenic effect of haloperidol was significantly reduced in rats treated with desipramine and 6-OHDA but not in rats treated with 6-OHDA or in rats with lesions of the locus coeruleus.",3031535_3,0
11400,6-OHDA,121,127,"On the contrary, the cataleptogenic effect of haloperidol was significantly reduced in rats treated with desipramine and 6-OHDA but not in rats treated with 6-OHDA or in rats with lesions of the locus coeruleus.",3031535_3,0
11402,6-OHDA,157,163,"On the contrary, the cataleptogenic effect of haloperidol was significantly reduced in rats treated with desipramine and 6-OHDA but not in rats treated with 6-OHDA or in rats with lesions of the locus coeruleus.",3031535_3,0
11403,locus coeruleus,195,210,"On the contrary, the cataleptogenic effect of haloperidol was significantly reduced in rats treated with desipramine and 6-OHDA but not in rats treated with 6-OHDA or in rats with lesions of the locus coeruleus.",3031535_3,1
11404,noradrenergic,28,41,"These results indicate that noradrenergic neurons have an important role in the manifestation of catalepsy induced by THC, whereas dopaminergic neurons are important in catalepsy induced by haloperidol.",3031535_4,0
2763,dopaminergic,131,143,"These results indicate that noradrenergic neurons have an important role in the manifestation of catalepsy induced by THC, whereas dopaminergic neurons are important in catalepsy induced by haloperidol.",3031535_4,0
6351,allergic rhinitis,156,173,"Multicenter, double-blind, multiple-dose, parallel-groups efficacy and safety trial of azelastine, chlorpheniramine, and placebo in the treatment of spring allergic rhinitis.",3057041_0,1
2764,chlorpheniramine,99,115,"Multicenter, double-blind, multiple-dose, parallel-groups efficacy and safety trial of azelastine, chlorpheniramine, and placebo in the treatment of spring allergic rhinitis.",3057041_0,0
11408,azelastine,87,97,"Multicenter, double-blind, multiple-dose, parallel-groups efficacy and safety trial of azelastine, chlorpheniramine, and placebo in the treatment of spring allergic rhinitis.",3057041_0,0
2765,antiallergic,20,32,"Azelastine, a novel antiallergic medication, was compared with chlorpheniramine maleate and placebo for efficacy and safety in the treatment of spring allergic rhinitis in a multicenter, double-blind, multiple-dose, parallel-groups study.",3057041_1,0
2766,chlorpheniramine maleate,63,87,"Azelastine, a novel antiallergic medication, was compared with chlorpheniramine maleate and placebo for efficacy and safety in the treatment of spring allergic rhinitis in a multicenter, double-blind, multiple-dose, parallel-groups study.",3057041_1,0
6352,allergic rhinitis,151,168,"Azelastine, a novel antiallergic medication, was compared with chlorpheniramine maleate and placebo for efficacy and safety in the treatment of spring allergic rhinitis in a multicenter, double-blind, multiple-dose, parallel-groups study.",3057041_1,1
11409,Azelastine,0,10,"Azelastine, a novel antiallergic medication, was compared with chlorpheniramine maleate and placebo for efficacy and safety in the treatment of spring allergic rhinitis in a multicenter, double-blind, multiple-dose, parallel-groups study.",3057041_1,0
11426,Lower doses,0,11,Lower doses of azelastine were statistically more effective than placebo only during portions of the first 3 weeks of the study.,3057041_10,0
11427,azelastine,15,25,Lower doses of azelastine were statistically more effective than placebo only during portions of the first 3 weeks of the study.,3057041_10,0
2768,chlorpheniramine,26,42,"In contrast, although the chlorpheniramine group did have fewer symptoms than the placebo group during the study, the difference never reached statistical significance during any week of the study.",3057041_11,0
6355,side effects,22,34,There were no serious side effects in any of the treatment groups.,3057041_12,1
6356,altered taste,15,28,Drowsiness and altered taste perception were increased significantly over placebo only in the high-dose azelastine group.,3057041_13,1
11428,high-dose azelastine,94,114,Drowsiness and altered taste perception were increased significantly over placebo only in the high-dose azelastine group.,3057041_13,0
6357,seasonal allergic rhinitis,60,86,"Azelastine appears to be a safe, efficacious medication for seasonal allergic rhinitis.",3057041_14,1
11429,Azelastine,0,10,"Azelastine appears to be a safe, efficacious medication for seasonal allergic rhinitis.",3057041_14,0
11413,aeroallergens,155,168,"Subjects ranged in age from 18 to 60 years of age and had at least a 2-year history of spring allergic rhinitis, confirmed by positive skin test to spring aeroallergens.",3057041_3,0
6353,allergic rhinitis,94,111,"Subjects ranged in age from 18 to 60 years of age and had at least a 2-year history of spring allergic rhinitis, confirmed by positive skin test to spring aeroallergens.",3057041_3,1
2767,chlorpheniramine,169,185,"Medications were given four times daily; the azelastine groups received 0.5, 1.0, or 2.0 mg in the morning and evening with placebo in the early and late afternoon; the chlorpheniramine group received 4.0 mg four times daily.",3057041_4,0
11414,azelastine,45,55,"Medications were given four times daily; the azelastine groups received 0.5, 1.0, or 2.0 mg in the morning and evening with placebo in the early and late afternoon; the chlorpheniramine group received 4.0 mg four times daily.",3057041_4,0
11419,total symptoms,21,35,"Individual symptoms, total symptoms, and major symptoms were compared to determine efficacy of medication.",3057041_6,1
11420,adverse experiences,36,55,"Elicited, volunteered, and observed adverse experiences were recorded for each subject and compared among groups.",3057041_7,1
11421,Vital signs,0,11,"Vital signs, body weights, serum chemistry values, complete blood cell counts, urine studies, and electrocardiograms were obtained for each subject and compared among groups.",3057041_8,1
6354,body weights,13,25,"Vital signs, body weights, serum chemistry values, complete blood cell counts, urine studies, and electrocardiograms were obtained for each subject and compared among groups.",3057041_8,1
11423,blood cell,60,70,"Vital signs, body weights, serum chemistry values, complete blood cell counts, urine studies, and electrocardiograms were obtained for each subject and compared among groups.",3057041_8,0
11425,azelastine,68,78,Symptoms relief in the group receiving the highest concentration of azelastine (2.0 mg twice daily) was statistically greater than in the placebo group during all weeks of the study.,3057041_9,0
6358,renal insufficiency,35,54,Reversibility of captopril-induced renal insufficiency after prolonged use in an unusual case of renovascular hypertension.,3070035_0,1
6359,renovascular hypertension,97,122,Reversibility of captopril-induced renal insufficiency after prolonged use in an unusual case of renovascular hypertension.,3070035_0,1
6360,renal artery,57,69,"We report a case of severe hypertension with an occluded renal artery to a solitary kidney, who developed sudden deterioration of renal function following treatment with captopril.",3070035_1,1
6361,solitary kidney,75,90,"We report a case of severe hypertension with an occluded renal artery to a solitary kidney, who developed sudden deterioration of renal function following treatment with captopril.",3070035_1,1
11430,sudden deterioration,106,126,"We report a case of severe hypertension with an occluded renal artery to a solitary kidney, who developed sudden deterioration of renal function following treatment with captopril.",3070035_1,1
11431,renal function,130,144,"We report a case of severe hypertension with an occluded renal artery to a solitary kidney, who developed sudden deterioration of renal function following treatment with captopril.",3070035_1,1
11432,His renal function,0,18,His renal function remained impaired but stable during 2 years' treatment with captopril but returned to pre-treatment levels soon after cessation of the drug.,3070035_2,1
6362,renal failure,50,63,This indicates reversibility in captopril-induced renal failure even after its prolonged use and suggests that no organic damage occurs to glomerular arterioles following chronic ACE inhibition.,3070035_3,1
11434,glomerular arterioles,139,160,This indicates reversibility in captopril-induced renal failure even after its prolonged use and suggests that no organic damage occurs to glomerular arterioles following chronic ACE inhibition.,3070035_3,1
2769,HMG CoA reductase inhibitors,0,28,HMG CoA reductase inhibitors.,3076126_0,0
2772,creatine kinase,20,35,Minor elevations of creatine kinase levels are reported in about 5% of patients.,3076126_11,0
2773,cyclosporin,192,203,"Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.",3076126_12,0
6363,renal failure,85,98,"Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin.",3076126_12,1
11447,well-tolerated agents,50,71,Lovastatin and simvastatin are both effective and well-tolerated agents for lowering elevated levels of serum cholesterol.,3076126_13,0
11449,hypercholesterolaemia,112,133,"As wider use confirms their safety profile, they will gain increasing importance in the therapeutic approach to hypercholesterolaemia and its consequences.",3076126_14,1
11448,therapeutic approach,88,108,"As wider use confirms their safety profile, they will gain increasing importance in the therapeutic approach to hypercholesterolaemia and its consequences.",3076126_14,0
2770,HMG CoA reductase inhibitors,103,131,Lovastatin and simvastatin are the 2 best-known members of the class of hypolipidaemic agents known as HMG CoA reductase inhibitors.,3076126_2,0
2771,LDL-cholesterol,104,119,"Both agents show substantial clinical efficacy, with reductions in total cholesterol of over 30% and in LDL-cholesterol of 40% in clinical studies.",3076126_5,0
11439,HDL-cholesterol,20,35,Modest increases in HDL-cholesterol levels of about 10% are also reported.,3076126_6,0
11441,adverse experiences,128,147,"Clinical tolerability of both agents has been good, with fewer than 3% of patients withdrawn from treatment because of clinical adverse experiences.",3076126_7,1
11443,short term,129,139,Ophthalmological examinations in over 1100 patients treated with one or the other agent have revealed no evidence of significant short term (up to 2 years) cataractogenic potential.,3076126_8,1
11444,cataractogenic,156,170,Ophthalmological examinations in over 1100 patients treated with one or the other agent have revealed no evidence of significant short term (up to 2 years) cataractogenic potential.,3076126_8,1
6364,rheumatoid arthritis,44,64,Toxicity due to remission inducing drugs in rheumatoid arthritis.,3084782_0,1
11451,Cw4,29,32,Association with HLA-B35 and Cw4 antigens.,3084782_1,0
2774,HLA-B35,17,24,Association with HLA-B35 and Cw4 antigens.,3084782_1,0
6365,rheumatoid arthritis,26,46,Twenty-five patients with rheumatoid arthritis (RA) who developed toxicity while taking remission inducing drugs and 30 without toxicity were studied for possible associations with class I and II HLA antigens.,3084782_2,1
2775,HLA antigens,196,208,Twenty-five patients with rheumatoid arthritis (RA) who developed toxicity while taking remission inducing drugs and 30 without toxicity were studied for possible associations with class I and II HLA antigens.,3084782_2,0
11453,class I antigens B35-Cw4,124,148,"A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.",3084782_3,0
11454,thiosulphate,185,197,"A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.",3084782_3,0
11455,B35,202,205,"A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.",3084782_3,0
2777,D-Penicillamine,89,104,"A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.",3084782_3,0
2776,Tiopronin,76,85,"A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35.",3084782_3,0
2778,DR5,37,40,Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the Tiopronin related nephritis group.,3084782_4,0
2779,Tiopronin,99,108,Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the Tiopronin related nephritis group.,3084782_4,0
11459,nigrostriatal,109,122,Transient contralateral rotation following unilateral substantia nigra lesion reflects susceptibility of the nigrostriatal system to exhaustion by amphetamine.,3088349_0,1
11458,substantia nigra,54,70,Transient contralateral rotation following unilateral substantia nigra lesion reflects susceptibility of the nigrostriatal system to exhaustion by amphetamine.,3088349_0,1
11461,contralateral rotation,69,91,"Following unilateral 6-OHDA induced SN lesion, a transient period of contralateral rotation has been reported to precede the predominant ipsilateral circling.",3088349_1,1
11460,6-OHDA,21,27,"Following unilateral 6-OHDA induced SN lesion, a transient period of contralateral rotation has been reported to precede the predominant ipsilateral circling.",3088349_1,0
11463,post lesion,11,22,"Three days post lesion, most rats circled predominantly contralaterally to the lesion.",3088349_3,1
11469,contralateral rotation,191,213,"A substantial degree of contralateral preference was still evident when amphetamine was administered for the first time 24 days after lesioning, indicating involvement of spared cells in the contralateral rotation.",3088349_5,1
11477,contralateral rotation,110,132,These findings suggest that amphetamine has an irreversible effect on the post-lesion DA pool contributing to contralateral rotation.,3088349_7,1
11479,ketoconazole,34,46,Hepatic reactions associated with ketoconazole in the United Kingdom.,3101906_0,0
11478,Hepatic reactions,0,17,Hepatic reactions associated with ketoconazole in the United Kingdom.,3101906_0,1
11481,Ketoconazole,0,12,Ketoconazole was introduced in the United Kingdom in 1981.,3101906_1,0
11489,Allergic manifestations,0,23,Allergic manifestations such as rash and eosinophilia were rare.,3101906_11,1
11490,liver function,81,95,"Hepatitis was usually reversible when treatment was stopped, with the results of liver function tests returning to normal after an average of 3.1 months.",3101906_12,1
11492,ketoconazole,52,64,In two of the three deaths probably associated with ketoconazole treatment the drug had been continued after the onset of jaundice and other symptoms of hepatitis.,3101906_13,0
11494,ketoconazole,126,138,Clinical and biochemical monitoring at regular intervals for evidence of hepatitis is advised during long term treatment with ketoconazole to prevent possible serious hepatic injury.,3101906_14,0
11495,hepatic injury,167,181,Clinical and biochemical monitoring at regular intervals for evidence of hepatitis is advised during long term treatment with ketoconazole to prevent possible serious hepatic injury.,3101906_14,1
6366,long term,101,110,Clinical and biochemical monitoring at regular intervals for evidence of hepatitis is advised during long term treatment with ketoconazole to prevent possible serious hepatic injury.,3101906_14,1
11482,hepatotoxicity,90,104,"By November 1984 the Committee on Safety of Medicines had received 82 reports of possible hepatotoxicity associated with the drug, including five deaths.",3101906_2,1
11484,hepatotoxicity,65,79,"The mean age of patients in the 16 probable cases was 57.9, with hepatotoxicity being more common in women.",3101906_5,1
11487,hepatocellular injury,52,73,The results of serum liver function tests suggested hepatocellular injury in 10 (63%); the rest showed a mixed pattern.,3101906_8,1
11486,liver function,21,35,The results of serum liver function tests suggested hepatocellular injury in 10 (63%); the rest showed a mixed pattern.,3101906_8,1
11497,Drug-induced hepatotoxicity,0,27,"Drug-induced hepatotoxicity, although common, has been reported only infrequently with sulfonylureas.",3107448_1,1
11498,hepatotoxicity,75,89,"For glyburide, a second-generation sulfonylurea, only two brief reports of hepatotoxicity exist.",3107448_2,1
2780,second-generation,17,34,"For glyburide, a second-generation sulfonylurea, only two brief reports of hepatotoxicity exist.",3107448_2,0
6367,type II diabetes mellitus,18,43,Two patients with type II diabetes mellitus developed an acute hepatitis-like syndrome soon after initiation of glyburide therapy.,3107448_3,1
11499,acute hepatitis-like syndrome,57,86,Two patients with type II diabetes mellitus developed an acute hepatitis-like syndrome soon after initiation of glyburide therapy.,3107448_3,1
6369,drug-induced hepatitis,122,144,"There was no serologic evidence of viral infection, and a liver biopsy sample showed a histologic pattern consistent with drug-induced hepatitis.",3107448_4,1
6368,viral infection,35,50,"There was no serologic evidence of viral infection, and a liver biopsy sample showed a histologic pattern consistent with drug-induced hepatitis.",3107448_4,1
11504,acute hepatitis-like illness,25,53,Glyburide can produce an acute hepatitis-like illness in some persons.,3107448_6,1
6370,hemolytic uremic syndrome,23,48,Mitomycin C associated hemolytic uremic syndrome.,3108839_0,1
2781,Mitomycin C,0,11,Mitomycin C associated hemolytic uremic syndrome.,3108839_0,0
6371,Hemolytic Uremic Syndrome,23,48,Mitomycin C associated Hemolytic Uremic Syndrome (HUS) is a potentially fatal but uncommon condition that is not yet widely recognised.,3108839_1,1
2782,Mitomycin C,0,11,Mitomycin C associated Hemolytic Uremic Syndrome (HUS) is a potentially fatal but uncommon condition that is not yet widely recognised.,3108839_1,0
6373,renal failure,83,96,"It consists of microangiopathic hemolytic anemia, thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10% of patients treated with this agent.",3108839_2,1
6372,microangiopathic hemolytic anemia,15,48,"It consists of microangiopathic hemolytic anemia, thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10% of patients treated with this agent.",3108839_2,1
2783,mitomycin C,113,124,"It consists of microangiopathic hemolytic anemia, thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10% of patients treated with this agent.",3108839_2,0
6374,renal failure,4,17,The renal failure usually develops about 8-10 mth after start of mitomycin C treatment and the mortality is approximately 60% from renal failure or pulmonary edema.,3108839_3,1
6375,renal failure,131,144,The renal failure usually develops about 8-10 mth after start of mitomycin C treatment and the mortality is approximately 60% from renal failure or pulmonary edema.,3108839_3,1
6376,pulmonary edema,148,163,The renal failure usually develops about 8-10 mth after start of mitomycin C treatment and the mortality is approximately 60% from renal failure or pulmonary edema.,3108839_3,1
2784,mitomycin C,65,76,The renal failure usually develops about 8-10 mth after start of mitomycin C treatment and the mortality is approximately 60% from renal failure or pulmonary edema.,3108839_3,0
11506,Renal lesions,0,13,"Renal lesions are similar to those seen in idiopathic HUS and include arteriolar fibrin thrombi, expanded subendothelial zones in glomerular capillary walls, ischemic wrinkling of glomerular basement membranes and mesangiolysis.",3108839_4,1
6377,subendothelial,106,120,"Renal lesions are similar to those seen in idiopathic HUS and include arteriolar fibrin thrombi, expanded subendothelial zones in glomerular capillary walls, ischemic wrinkling of glomerular basement membranes and mesangiolysis.",3108839_4,1
11508,arteriolar fibrin thrombi,70,95,"Renal lesions are similar to those seen in idiopathic HUS and include arteriolar fibrin thrombi, expanded subendothelial zones in glomerular capillary walls, ischemic wrinkling of glomerular basement membranes and mesangiolysis.",3108839_4,1
11510,mesangiolysis,214,227,"Renal lesions are similar to those seen in idiopathic HUS and include arteriolar fibrin thrombi, expanded subendothelial zones in glomerular capillary walls, ischemic wrinkling of glomerular basement membranes and mesangiolysis.",3108839_4,1
11511,endothelial cell,61,77,The mechanism of action is postulated as mitomycin C-induced endothelial cell damage.,3108839_5,1
2785,mitomycin C,178,189,We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema.,3108839_6,0
6380,pulmonary edema,202,217,We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema.,3108839_6,1
6379,renal failure,119,132,We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema.,3108839_6,1
11512,gastric adenocarcinoma,82,104,We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema.,3108839_6,1
6378,clinical course,16,31,We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema.,3108839_6,1
6381,muscle rigidity,52,67,Ketanserin pretreatment reverses alfentanil-induced muscle rigidity.,3115150_0,1
2786,Ketanserin,0,10,Ketanserin pretreatment reverses alfentanil-induced muscle rigidity.,3115150_0,0
6382,muscle rigidity,128,143,"Systemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the muscle rigidity produced in rats by the potent short-acting opiate agonist alfentanil.",3115150_1,1
2788,serotonin receptor antagonist,68,97,"Systemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the muscle rigidity produced in rats by the potent short-acting opiate agonist alfentanil.",3115150_1,0
2787,ketanserin,27,37,"Systemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the muscle rigidity produced in rats by the potent short-acting opiate agonist alfentanil.",3115150_1,0
2789,alfentanil,203,213,"Systemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the muscle rigidity produced in rats by the potent short-acting opiate agonist alfentanil.",3115150_1,0
11514,short-acting opiate,175,194,"Systemic pretreatment with ketanserin, a relatively specific type-2 serotonin receptor antagonist, significantly attenuated the muscle rigidity produced in rats by the potent short-acting opiate agonist alfentanil.",3115150_1,0
11516,left gastrocnemius muscle,64,89,"Following placement of subcutaneous electrodes in each animal's left gastrocnemius muscle, rigidity was assessed by analyzing root-mean-square electromyographic activity.",3115150_2,1
2790,ketanserin,16,26,Intraperitoneal ketanserin administration at doses of 0.63 and 2.5 mg/kg prevented the alfentanil-induced increase in electromyographic activity compared with animals pretreated with saline.,3115150_3,0
2791,alfentanil,100,110,Chlordiazepoxide at doses up to 10 mg/kg failed to significantly influence the rigidity produced by alfentanil.,3115150_4,0
2792,ketanserin,55,65,"Despite the absence of rigidity, animals that received ketanserin (greater than 0.31 mg/kg i.p.) followed by alfentanil were motionless, flaccid, and less responsive to external stimuli than were animals receiving alfentanil alone.",3115150_5,0
2794,alfentanil,214,224,"Despite the absence of rigidity, animals that received ketanserin (greater than 0.31 mg/kg i.p.) followed by alfentanil were motionless, flaccid, and less responsive to external stimuli than were animals receiving alfentanil alone.",3115150_5,0
2793,alfentanil,109,119,"Despite the absence of rigidity, animals that received ketanserin (greater than 0.31 mg/kg i.p.) followed by alfentanil were motionless, flaccid, and less responsive to external stimuli than were animals receiving alfentanil alone.",3115150_5,0
2795,ketanserin,19,29,Rats that received ketanserin and alfentanil exhibited less rearing and exploratory behavior at the end of the 60-min recording period than did animals that received ketanserin alone.,3115150_6,0
2796,alfentanil,34,44,Rats that received ketanserin and alfentanil exhibited less rearing and exploratory behavior at the end of the 60-min recording period than did animals that received ketanserin alone.,3115150_6,0
2797,ketanserin,166,176,Rats that received ketanserin and alfentanil exhibited less rearing and exploratory behavior at the end of the 60-min recording period than did animals that received ketanserin alone.,3115150_6,0
6383,muscle rigidity,63,78,"These results, in combination with previous work, suggest that muscle rigidity, a clinically relevant side-effect of parenteral narcotic administration, may be partly mediated via serotonergic pathways.",3115150_7,1
2798,serotonergic,180,192,"These results, in combination with previous work, suggest that muscle rigidity, a clinically relevant side-effect of parenteral narcotic administration, may be partly mediated via serotonergic pathways.",3115150_7,0
6384,side-effect,102,113,"These results, in combination with previous work, suggest that muscle rigidity, a clinically relevant side-effect of parenteral narcotic administration, may be partly mediated via serotonergic pathways.",3115150_7,1
2799,serotonin antagonists,25,46,"Pretreatment with type-2 serotonin antagonists may be clinically useful in attenuating opiate-induced rigidity, although further studies will be necessary to assess the interaction of possibly enhanced CNS, cardiovascular, and respiratory depression.",3115150_8,0
6385,opiate-induced,87,101,"Pretreatment with type-2 serotonin antagonists may be clinically useful in attenuating opiate-induced rigidity, although further studies will be necessary to assess the interaction of possibly enhanced CNS, cardiovascular, and respiratory depression.",3115150_8,1
6386,respiratory depression,227,249,"Pretreatment with type-2 serotonin antagonists may be clinically useful in attenuating opiate-induced rigidity, although further studies will be necessary to assess the interaction of possibly enhanced CNS, cardiovascular, and respiratory depression.",3115150_8,1
11523,lumbar epidural block,93,114,Antagonism of diazepam-induced sedative effects by Ro15-1788 in patients after surgery under lumbar epidural block.,3120485_0,1
2800,Ro15-1788,51,60,Antagonism of diazepam-induced sedative effects by Ro15-1788 in patients after surgery under lumbar epidural block.,3120485_0,0
2802,Ro15-1788,208,217,"The aim of this study was to assess the efficacy of Ro15-1788 and a placebo in reversing diazepam-induced effects after surgery under epidural block, and to evaluate the local tolerance and general safety of Ro15-1788.",3120485_2,0
2801,Ro15-1788,52,61,"The aim of this study was to assess the efficacy of Ro15-1788 and a placebo in reversing diazepam-induced effects after surgery under epidural block, and to evaluate the local tolerance and general safety of Ro15-1788.",3120485_2,0
11525,epidural block,134,148,"The aim of this study was to assess the efficacy of Ro15-1788 and a placebo in reversing diazepam-induced effects after surgery under epidural block, and to evaluate the local tolerance and general safety of Ro15-1788.",3120485_2,1
11526,local tolerance,170,185,"The aim of this study was to assess the efficacy of Ro15-1788 and a placebo in reversing diazepam-induced effects after surgery under epidural block, and to evaluate the local tolerance and general safety of Ro15-1788.",3120485_2,1
11527,epidural anaesthesia,66,86,Fifty-seven patients were sedated with diazepam for surgery under epidural anaesthesia.,3120485_3,1
2803,Ro15-1788,42,51,Antagonism of diazepam-induced effects by Ro15-1788 was investigated postoperatively in a double-blind placebo-controlled trial.,3120485_4,0
11528,diazepam-induced effects,14,38,Antagonism of diazepam-induced effects by Ro15-1788 was investigated postoperatively in a double-blind placebo-controlled trial.,3120485_4,0
11532,vital signs,110,121,"The patient's subjective assessment of mood rating, an objective test of performance, a test for amnesia, and vital signs were recorded for up to 300 min after administration of the trial drug.",3120485_5,1
11535,vital signs,93,104,"No significant differences between the two groups were observed for mood rating, amnesia, or vital signs.",3120485_6,1
2804,Ro15-1788,4,13,The Ro15-1788 group showed a significant improvement in the performance test up to 120 min after administration of the drug.,3120485_7,0
11537,injection site,41,55,There was no evidence of reaction at the injection site.,3120485_8,0
11538,oral contraception,23,41,Chorea associated with oral contraception.,3123611_0,0
2805,oral contraceptives,48,67,Three patients developed chorea while receiving oral contraceptives.,3123611_1,0
11540,oral contraception,71,89,The third patient had acute amphetamine-induced chorea after prolonged oral contraception.,3123611_3,0
2806,sex hormones,35,47,Prolonged administration of female sex hormones is a possible cause of chorea in women who have not previously had chorea or rheumatic fever.,3123611_4,0
11541,cause of,62,70,Prolonged administration of female sex hormones is a possible cause of chorea in women who have not previously had chorea or rheumatic fever.,3123611_4,1
6387,rheumatic fever,125,140,Prolonged administration of female sex hormones is a possible cause of chorea in women who have not previously had chorea or rheumatic fever.,3123611_4,1
6388,Intracranial pressure,0,21,Intracranial pressure increases during alfentanil-induced rigidity.,3125768_0,1
6389,Intracranial pressure,0,21,Intracranial pressure (ICP) was measured during alfentanil-induced rigidity in rats.,3125768_1,1
6390,ICP,23,26,Intracranial pressure (ICP) was measured during alfentanil-induced rigidity in rats.,3125768_1,1
11544,central venous,23,37,"Ten rats had arterial, central venous (CVP), and subdural cannulae inserted under halothane anesthesia.",3125768_2,1
2807,/- 1,76,80,"The animals were mechanically ventilated to achieve normocarbia (PCO2 = 42 +/- 1 mmHg, mean +/- SE).",3125768_3,0
11548,PCO2,65,69,"The animals were mechanically ventilated to achieve normocarbia (PCO2 = 42 +/- 1 mmHg, mean +/- SE).",3125768_3,0
11547,normocarbia,52,63,"The animals were mechanically ventilated to achieve normocarbia (PCO2 = 42 +/- 1 mmHg, mean +/- SE).",3125768_3,1
2808,alfentanil,58,68,"Following instrumentation, halothane was discontinued and alfentanil (125 mu/kg) administered iv during emergence from halothane anesthesia.",3125768_4,0
11550,somatic rigidity,32,48,"In the five rats that developed somatic rigidity, ICP and CVP increased significantly above baseline (delta ICP 7.5 +/- 1.0 mmHg, delta CVP 5.9 +/- 1.3 mmHg).",3125768_5,1
6391,ICP,50,53,"In the five rats that developed somatic rigidity, ICP and CVP increased significantly above baseline (delta ICP 7.5 +/- 1.0 mmHg, delta CVP 5.9 +/- 1.3 mmHg).",3125768_5,1
6392,ICP,108,111,"In the five rats that developed somatic rigidity, ICP and CVP increased significantly above baseline (delta ICP 7.5 +/- 1.0 mmHg, delta CVP 5.9 +/- 1.3 mmHg).",3125768_5,1
11555,metocurine,70,80,These variables returned to baseline when rigidity was abolished with metocurine.,3125768_6,0
2809,alfentanil,77,87,"In five rats that did not become rigid, ICP and CVP did not change following alfentanil.",3125768_7,0
6393,ICP,40,43,"In five rats that did not become rigid, ICP and CVP did not change following alfentanil.",3125768_7,1
2810,alfentanil,66,76,"These observations suggest that rigidity should be prevented when alfentanil, and, presumably, other opiates, are used in the anesthetic management of patients with ICP problems.",3125768_8,0
6394,ICP,165,168,"These observations suggest that rigidity should be prevented when alfentanil, and, presumably, other opiates, are used in the anesthetic management of patients with ICP problems.",3125768_8,1
11561,F344,80,84,Co-carcinogenic effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole.,3131282_0,0
11560,forestomach carcinogenesis,45,71,Co-carcinogenic effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole.,3131282_0,1
11558,Co-carcinogenic,0,15,Co-carcinogenic effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole.,3131282_0,0
11559,retinyl acetate,26,41,Co-carcinogenic effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole.,3131282_0,0
2811,butylated hydroxyanisole,103,127,Co-carcinogenic effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole.,3131282_0,0
11563,forestomach tumorigenesis,101,126,The potential modifying effect of retinyl acetate (RA) on butylated hydroxyanisole (BHA)-induced rat forestomach tumorigenesis was examined.,3131282_1,1
11562,retinyl acetate,34,49,The potential modifying effect of retinyl acetate (RA) on butylated hydroxyanisole (BHA)-induced rat forestomach tumorigenesis was examined.,3131282_1,0
2812,butylated hydroxyanisole,58,82,The potential modifying effect of retinyl acetate (RA) on butylated hydroxyanisole (BHA)-induced rat forestomach tumorigenesis was examined.,3131282_1,0
11564,F344,5,9,"Male F344 rats, 5 weeks of age, were maintained on diet containing 1% or 2% BHA by weight and simultaneously on drinking water supplemented with RA at various concentrations (w/v) for 52 weeks.",3131282_2,0
2814,drinking water,112,126,"Male F344 rats, 5 weeks of age, were maintained on diet containing 1% or 2% BHA by weight and simultaneously on drinking water supplemented with RA at various concentrations (w/v) for 52 weeks.",3131282_2,0
2813,BHA,76,79,"Male F344 rats, 5 weeks of age, were maintained on diet containing 1% or 2% BHA by weight and simultaneously on drinking water supplemented with RA at various concentrations (w/v) for 52 weeks.",3131282_2,0
6395,squamous cell papilloma,231,254,"In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.",3131282_3,1
11567,forestomach,211,222,"In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.",3131282_3,1
2815,BHA,19,22,"In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.",3131282_3,0
11565,hyperplastic changes,40,60,"In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.",3131282_3,1
11568,RA-free water,366,379,"In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.",3131282_3,0
11566,forestomach epithelium,68,90,"In groups given 2% BHA, although marked hyperplastic changes of the forestomach epithelium were observed in all animals, co-administration of 0.25% RA significantly (P less than 0.05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with carcinoma) in the group given RA-free water.",3131282_3,1
6396,epithelial hyperplasia,157,179,"In rats given 1% BHA, RA co-administered at a dose of 0.05, 0.1, 0.2 or 0.25% showed a dose-dependent enhancing effect on the development of the BHA-induced epithelial hyperplasia.",3131282_4,1
2816,BHA,17,20,"In rats given 1% BHA, RA co-administered at a dose of 0.05, 0.1, 0.2 or 0.25% showed a dose-dependent enhancing effect on the development of the BHA-induced epithelial hyperplasia.",3131282_4,0
11573,forestomach,52,63,RA alone did not induce hyperplastic changes in the forestomach.,3131282_6,1
11572,hyperplastic changes,24,44,RA alone did not induce hyperplastic changes in the forestomach.,3131282_6,1
11575,BHA forestomach carcinogenesis,64,94,These findings indicate that RA acted as a co-carcinogen in the BHA forestomach carcinogenesis of the rat.,3131282_7,1
11574,co-carcinogen,43,56,These findings indicate that RA acted as a co-carcinogen in the BHA forestomach carcinogenesis of the rat.,3131282_7,0
6397,cardiotoxicity,46,60,"A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C.Since 1975 mitomycin C (MMC) has been suggested to be cardiotoxic, especially when combined with or given following doxorubicin.",3137399_0,1
2817,mitomycin C,95,106,"A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C.Since 1975 mitomycin C (MMC) has been suggested to be cardiotoxic, especially when combined with or given following doxorubicin.",3137399_0,0
2818,cardiotoxic,138,149,"A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C.Since 1975 mitomycin C (MMC) has been suggested to be cardiotoxic, especially when combined with or given following doxorubicin.",3137399_0,0
6398,side effect,53,64,Data on dose dependency or incidence concerning this side effect were not known.,3137399_1,1
6402,cardiotoxicity,98,112,"Based on the combined data from the present study and the literature, we suggest that MMC-related cardiotoxicity is dose dependent, occurring at cumulative dose levels of 30 mg m-2 or more, mainly in patients also (previously or simultaneously) treated with doxorubicin.",3137399_10,1
11592,m-2,177,180,"Based on the combined data from the present study and the literature, we suggest that MMC-related cardiotoxicity is dose dependent, occurring at cumulative dose levels of 30 mg m-2 or more, mainly in patients also (previously or simultaneously) treated with doxorubicin.",3137399_10,0
11593,risk group,58,68,The incidence is likely to be less than 10% even for this risk group.,3137399_11,0
11583,EF,158,160,"All patients were studied by repeated physical examinations, chest X-rays, electro- and echocardiography and radionuclide left ventricular ejection fraction (EF) determinations.",3137399_4,0
11584,m-2,58,61,One of the patients developed cardiac failure after 30 mg m-2 MMC and only 150 mg m-2 doxorubicin.,3137399_6,0
11586,m-2,82,85,One of the patients developed cardiac failure after 30 mg m-2 MMC and only 150 mg m-2 doxorubicin.,3137399_6,0
6399,cardiac failure,30,45,One of the patients developed cardiac failure after 30 mg m-2 MMC and only 150 mg m-2 doxorubicin.,3137399_6,1
11587,EF,47,49,The cardiac failure was predicted by a drop in EF determined during a cold pressor test.,3137399_7,0
6400,cardiac failure,4,19,The cardiac failure was predicted by a drop in EF determined during a cold pressor test.,3137399_7,1
6401,cardiotoxicity,46,60,"None of the other patients developed clinical cardiotoxicity, nor did the studied parameters change.",3137399_8,1
11594,cause of myocardial infarction,35,65,Verapamil withdrawal as a possible cause of myocardial infarction in a hypertensive woman with a normal coronary angiogram.,3173179_0,1
2819,antihypertensive drug,46,67,Verapamil is an effective and relatively-safe antihypertensive drug.,3173179_1,0
11596,cardiac contractility,87,108,"Serious adverse effects are uncommon and mainly have been related to the depression of cardiac contractility and conduction, especially when the drug is combined with beta-blocking agents.",3173179_2,1
11597,beta-blocking agents,167,187,"Serious adverse effects are uncommon and mainly have been related to the depression of cardiac contractility and conduction, especially when the drug is combined with beta-blocking agents.",3173179_2,0
6403,adverse effects,8,23,"Serious adverse effects are uncommon and mainly have been related to the depression of cardiac contractility and conduction, especially when the drug is combined with beta-blocking agents.",3173179_2,1
6404,myocardial infarction,26,47,We report a case in which myocardial infarction coincided with the introduction of captopril and the withdrawal of verapamil in a previously asymptomatic woman with severe hypertension.,3173179_3,1
11599,vascular alpha 2-adrenoreceptor,81,112,Possible mechanisms that involve a verapamil-related increase in platelet and/or vascular alpha 2-adrenoreceptor affinity for catecholamines are discussed.,3173179_4,0
11600,Haemolytic-uraemic syndrome,0,27,Haemolytic-uraemic syndrome after treatment with metronidazole.,3173180_0,1
11602,haemolytic-uraemic syndrome,77,104,This paper describes the clinical features of six children who developed the haemolytic-uraemic syndrome after treatment with metronidazole.,3173180_1,1
11601,clinical features,25,42,This paper describes the clinical features of six children who developed the haemolytic-uraemic syndrome after treatment with metronidazole.,3173180_1,1
11603,bowel surgery,72,85,These children were older and were more likely to have undergone recent bowel surgery than are other children with this condition.,3173180_2,1
11607,haemolytic-uraemic syndrome,345,372,"While the involvement of metronidazole in the aetiology of the haemolytic-uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic-uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic-uraemic syndrome.",3173180_3,1
11606,haemolytic-uraemic syndrome,239,266,"While the involvement of metronidazole in the aetiology of the haemolytic-uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic-uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic-uraemic syndrome.",3173180_3,1
11604,haemolytic-uraemic syndrome,63,90,"While the involvement of metronidazole in the aetiology of the haemolytic-uraemic syndrome is not established firmly, the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic-uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic-uraemic syndrome.",3173180_3,1
11610,tiazofurin,44,54,Reversible cerebral lesions associated with tiazofurin usage: MR demonstration.,3183120_0,0
11608,cerebral lesions,11,27,Reversible cerebral lesions associated with tiazofurin usage: MR demonstration.,3183120_0,1
11612,chemotherapeutic agent,30,52,Tiazofurin is an experimental chemotherapeutic agent currently undergoing clinical evaluation.,3183120_1,0
11611,Tiazofurin,0,10,Tiazofurin is an experimental chemotherapeutic agent currently undergoing clinical evaluation.,3183120_1,0
11613,cerebral abnormalities,79,101,We report our results with magnetic resonance (MR) in demonstrating reversible cerebral abnormalities concurrent with the use of this drug.,3183120_2,1
11617,5-fluorouracil,84,98,Adverse cardiac effects during induction chemotherapy treatment with cis-platin and 5-fluorouracil.,3187073_0,0
2820,cis-platin,69,79,Adverse cardiac effects during induction chemotherapy treatment with cis-platin and 5-fluorouracil.,3187073_0,0
11616,induction chemotherapy,31,53,Adverse cardiac effects during induction chemotherapy treatment with cis-platin and 5-fluorouracil.,3187073_0,1
11615,Adverse cardiac effects,0,23,Adverse cardiac effects during induction chemotherapy treatment with cis-platin and 5-fluorouracil.,3187073_0,1
11619,esophageal carcinoma,64,84,Survival for patients with advanced head and neck carcinoma and esophageal carcinoma is poor with radiotherapy and/or surgery.,3187073_1,1
11618,head and neck carcinoma,36,59,Survival for patients with advanced head and neck carcinoma and esophageal carcinoma is poor with radiotherapy and/or surgery.,3187073_1,1
6409,chest pain,45,55,"The most common signs of cardiotoxicity were chest pain, ST-T wave changes and atrial fibrillation.",3187073_10,1
6410,atrial fibrillation,79,98,"The most common signs of cardiotoxicity were chest pain, ST-T wave changes and atrial fibrillation.",3187073_10,1
6408,cardiotoxicity,25,39,"The most common signs of cardiotoxicity were chest pain, ST-T wave changes and atrial fibrillation.",3187073_10,1
11628,ST-T wave,57,66,"The most common signs of cardiotoxicity were chest pain, ST-T wave changes and atrial fibrillation.",3187073_10,1
6411,ventricular fibrillation,21,45,This was followed by ventricular fibrillation in one patient and sudden death in another.,3187073_11,1
6412,sudden death,65,77,This was followed by ventricular fibrillation in one patient and sudden death in another.,3187073_11,1
6413,chest pain,131,141,It is concluded that patients on 5-FU treatment should be under close supervision and that the treatment should be discontinued if chest pain or tachyarrhythmia is observed.,3187073_12,1
6414,tachyarrhythmia,145,160,It is concluded that patients on 5-FU treatment should be under close supervision and that the treatment should be discontinued if chest pain or tachyarrhythmia is observed.,3187073_12,1
11629,5-FU,33,37,It is concluded that patients on 5-FU treatment should be under close supervision and that the treatment should be discontinued if chest pain or tachyarrhythmia is observed.,3187073_12,0
2821,cis-platin,22,32,"In the present study, cis-platin (80-120 mg/m2BSA) and 5-FU (1000 mg/m2BSA daily as a continuous infusion during 5 days) were given to 76 patients before radiotherapy and surgery.",3187073_3,0
11621,5-FU,55,59,"In the present study, cis-platin (80-120 mg/m2BSA) and 5-FU (1000 mg/m2BSA daily as a continuous infusion during 5 days) were given to 76 patients before radiotherapy and surgery.",3187073_3,0
11620,mg/m2BSA,41,49,"In the present study, cis-platin (80-120 mg/m2BSA) and 5-FU (1000 mg/m2BSA daily as a continuous infusion during 5 days) were given to 76 patients before radiotherapy and surgery.",3187073_3,0
11622,mg/m2BSA,66,74,"In the present study, cis-platin (80-120 mg/m2BSA) and 5-FU (1000 mg/m2BSA daily as a continuous infusion during 5 days) were given to 76 patients before radiotherapy and surgery.",3187073_3,0
11623,adverse cardiac effects,66,89,The aim of the study was to clarify the incidence and severity of adverse cardiac effects to this treatment.,3187073_4,1
6405,cardiovascular disease,42,64,"In the pre-treatment evaluation, signs of cardiovascular disease were found in 33 patients (43%).",3187073_6,1
11626,adverse cardiac effects,18,41,"During treatment, adverse cardiac effects were observed in 14 patients (18%).",3187073_7,1
6406,cardiotoxicity,17,31,The incidence of cardiotoxicity was not higher in patients with signs of cardiovascular disease than in those without in the pre-treatment evaluation.,3187073_9,1
6407,cardiovascular disease,73,95,The incidence of cardiotoxicity was not higher in patients with signs of cardiovascular disease than in those without in the pre-treatment evaluation.,3187073_9,1
6415,gestational trophoblastic disease,27,60,Death from chemotherapy in gestational trophoblastic disease.,3192036_0,1
6416,choriocarcinoma,113,128,Multiple cytotoxic drug administration is the generally accepted treatment of patients with a high-risk stage of choriocarcinoma.,3192036_1,1
11630,high-risk stage,94,109,Multiple cytotoxic drug administration is the generally accepted treatment of patients with a high-risk stage of choriocarcinoma.,3192036_1,1
11634,Actomycin-D,89,100,"The multiple drug schema consisted of: Etoposide 16.213, Methotrexate, Cyclophosphamide, Actomycin-D, and Cisplatin.",3192036_3,0
11633,Cyclophosphamide,71,87,"The multiple drug schema consisted of: Etoposide 16.213, Methotrexate, Cyclophosphamide, Actomycin-D, and Cisplatin.",3192036_3,0
2822,Etoposide,39,48,"The multiple drug schema consisted of: Etoposide 16.213, Methotrexate, Cyclophosphamide, Actomycin-D, and Cisplatin.",3192036_3,0
2823,Cisplatin,106,115,"The multiple drug schema consisted of: Etoposide 16.213, Methotrexate, Cyclophosphamide, Actomycin-D, and Cisplatin.",3192036_3,0
2824,Etoposide,71,80,"On the first day of the schedule, moderate high doses of Methotrexate, Etoposide and Cyclophosphamide were administered.",3192036_4,0
11636,Cyclophosphamide,85,101,"On the first day of the schedule, moderate high doses of Methotrexate, Etoposide and Cyclophosphamide were administered.",3192036_4,0
11635,high doses,43,53,"On the first day of the schedule, moderate high doses of Methotrexate, Etoposide and Cyclophosphamide were administered.",3192036_4,0
11637,clinical picture resembling,67,94,"Within 8 hours after initiation of therapy the patient died with a clinical picture resembling massive pulmonary obstruction due to choriocarcinomic tissue plugs, probably originating from the uterus.",3192036_5,1
11638,pulmonary obstruction,103,124,"Within 8 hours after initiation of therapy the patient died with a clinical picture resembling massive pulmonary obstruction due to choriocarcinomic tissue plugs, probably originating from the uterus.",3192036_5,1
11639,choriocarcinomic,132,148,"Within 8 hours after initiation of therapy the patient died with a clinical picture resembling massive pulmonary obstruction due to choriocarcinomic tissue plugs, probably originating from the uterus.",3192036_5,1
11641,uterine veins,109,122,"Formation of these plugs was probably due to extensive tumor necrosis at the level of the walls of the major uterine veins, which resulted in an open exchange of tumor plugs to the vascular spaces; decrease in tumor tissue coherence secondary to chemotherapy may have further contributed to the formation of tumor emboli.",3192036_6,1
11640,tumor necrosis,55,69,"Formation of these plugs was probably due to extensive tumor necrosis at the level of the walls of the major uterine veins, which resulted in an open exchange of tumor plugs to the vascular spaces; decrease in tumor tissue coherence secondary to chemotherapy may have further contributed to the formation of tumor emboli.",3192036_6,1
11646,acute onset of,80,94,"In view of the close time association between the start of chemotherapy and the acute onset of massive embolism other explanations, such as spontaneous necrosis, must be considered less likely.",3192036_7,1
11647,massive embolism,95,111,"In view of the close time association between the start of chemotherapy and the acute onset of massive embolism other explanations, such as spontaneous necrosis, must be considered less likely.",3192036_7,1
11648,spontaneous necrosis,140,160,"In view of the close time association between the start of chemotherapy and the acute onset of massive embolism other explanations, such as spontaneous necrosis, must be considered less likely.",3192036_7,1
11651,drug resistance,118,133,"Patients with large pelvic tumor loads are, according to existing classifications, at high risk to die and to develop drug resistance.",3192036_8,1
11650,high risk,86,95,"Patients with large pelvic tumor loads are, according to existing classifications, at high risk to die and to develop drug resistance.",3192036_8,1
11649,pelvic tumor loads,20,38,"Patients with large pelvic tumor loads are, according to existing classifications, at high risk to die and to develop drug resistance.",3192036_8,1
11655,nicotine-induced locomotor hyperactivity,23,63,Receptor mechanisms of nicotine-induced locomotor hyperactivity in chronic nicotine-treated rats.,3220106_0,1
11659,L-[3H]nicotine,184,198,"At the end of each pretreatment period, animals were used for (i) determining their locomotor response to acutely injected nicotine (0.2 mg/kg, s.c.) and (ii) measuring the density of L-[3H]nicotine and [3H]spiperone binding sites in the striatum.",3220106_2,0
11660,[3H]spiperone binding sites,203,230,"At the end of each pretreatment period, animals were used for (i) determining their locomotor response to acutely injected nicotine (0.2 mg/kg, s.c.) and (ii) measuring the density of L-[3H]nicotine and [3H]spiperone binding sites in the striatum.",3220106_2,0
11663,[3H]spiperone,91,104,"We observed no changes in nicotine-induced locomotor response, striatal L-[3H]nicotine and [3H]spiperone binding in the animals pretreated with nicotine for 1 day.",3220106_3,0
11662,striatal,63,71,"We observed no changes in nicotine-induced locomotor response, striatal L-[3H]nicotine and [3H]spiperone binding in the animals pretreated with nicotine for 1 day.",3220106_3,1
2825,binding sites,205,218,"In rats which were pretreated with nicotine for 5 days, there was a significant increase in the nicotine-stimulated locomotor response which was associated with an increase in the number of L-[3H]nicotine binding sites and also with an elevated dopamine (DA) level in the striatum.",3220106_4,0
11664,striatal [3H]spiperone binding sites,14,50,The number of striatal [3H]spiperone binding sites was not affected.,3220106_5,0
2826,binding sites,149,162,"However, this response was correlated with an elevated number of striatal [3H]spiperone binding sites, whereas the number of striatal L-[3H]nicotine binding sites and the striatal DA level were normal.",3220106_7,0
11667,striatal,125,133,"However, this response was correlated with an elevated number of striatal [3H]spiperone binding sites, whereas the number of striatal L-[3H]nicotine binding sites and the striatal DA level were normal.",3220106_7,1
11668,striatal,171,179,"However, this response was correlated with an elevated number of striatal [3H]spiperone binding sites, whereas the number of striatal L-[3H]nicotine binding sites and the striatal DA level were normal.",3220106_7,1
11666,striatal [3H]spiperone binding sites,65,101,"However, this response was correlated with an elevated number of striatal [3H]spiperone binding sites, whereas the number of striatal L-[3H]nicotine binding sites and the striatal DA level were normal.",3220106_7,0
2827,nicotinic receptors,163,182,"These results suggest that chronic nicotine-treated rats develop locomotor hyperactivity in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration, followed by inducing DA receptor supersensitivity in the striatum.",3220106_8,0
11669,locomotor hyperactivity,65,88,"These results suggest that chronic nicotine-treated rats develop locomotor hyperactivity in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration, followed by inducing DA receptor supersensitivity in the striatum.",3220106_8,1
11672,Pulmonary shunt,0,15,Pulmonary shunt and cardiovascular responses to CPAP during nitroprusside-induced hypotension.,322550_0,1
11674,CPAP,48,52,Pulmonary shunt and cardiovascular responses to CPAP during nitroprusside-induced hypotension.,322550_0,0
2828,sodium nitroprusside,160,180,The effects of continuous positive airway pressure (CPAP) on cardiovascular dynamics and pulmonary shunt (QS/QT) were investigated in 12 dogs before and during sodium nitroprusside infusion that decreased mean arterial blood pressure 40-50 per cent.,322550_1,0
11677,pulmonary shunt,89,104,The effects of continuous positive airway pressure (CPAP) on cardiovascular dynamics and pulmonary shunt (QS/QT) were investigated in 12 dogs before and during sodium nitroprusside infusion that decreased mean arterial blood pressure 40-50 per cent.,322550_1,1
11676,CPAP,52,56,The effects of continuous positive airway pressure (CPAP) on cardiovascular dynamics and pulmonary shunt (QS/QT) were investigated in 12 dogs before and during sodium nitroprusside infusion that decreased mean arterial blood pressure 40-50 per cent.,322550_1,0
6417,blood pressure,219,233,The effects of continuous positive airway pressure (CPAP) on cardiovascular dynamics and pulmonary shunt (QS/QT) were investigated in 12 dogs before and during sodium nitroprusside infusion that decreased mean arterial blood pressure 40-50 per cent.,322550_1,1
11681,systemic vascular resistance,172,200,"Before nitroprusside infusion, 5 cm H2O CPAP significantly, P less than .05, decreased arterial blood pressure, but did not significantly alter heart rate, cardiac output, systemic vascular resistance, or QS/QT.",322550_2,1
11679,CPAP,40,44,"Before nitroprusside infusion, 5 cm H2O CPAP significantly, P less than .05, decreased arterial blood pressure, but did not significantly alter heart rate, cardiac output, systemic vascular resistance, or QS/QT.",322550_2,0
2829,nitroprusside,7,20,"Before nitroprusside infusion, 5 cm H2O CPAP significantly, P less than .05, decreased arterial blood pressure, but did not significantly alter heart rate, cardiac output, systemic vascular resistance, or QS/QT.",322550_2,0
6419,cardiac output,156,170,"Before nitroprusside infusion, 5 cm H2O CPAP significantly, P less than .05, decreased arterial blood pressure, but did not significantly alter heart rate, cardiac output, systemic vascular resistance, or QS/QT.",322550_2,1
6418,blood pressure,96,110,"Before nitroprusside infusion, 5 cm H2O CPAP significantly, P less than .05, decreased arterial blood pressure, but did not significantly alter heart rate, cardiac output, systemic vascular resistance, or QS/QT.",322550_2,1
11683,CPAP,11,15,Ten cm H2O CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and decreased cardiac output and QS/QT.,322550_3,0
6420,blood pressure,86,100,Ten cm H2O CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and decreased cardiac output and QS/QT.,322550_3,1
2830,nitroprusside,23,36,Ten cm H2O CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and decreased cardiac output and QS/QT.,322550_3,0
11684,heart rate,129,139,Ten cm H2O CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and decreased cardiac output and QS/QT.,322550_3,1
6421,cardiac output,154,168,Ten cm H2O CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and decreased cardiac output and QS/QT.,322550_3,1
2831,Nitroprusside,0,13,"Nitroprusside caused significant decreases in arterial blood pressure and systemic vascular resistance and increases in heart rate, but did not change cardiac output or QS/QT.",322550_4,0
11687,heart rate,120,130,"Nitroprusside caused significant decreases in arterial blood pressure and systemic vascular resistance and increases in heart rate, but did not change cardiac output or QS/QT.",322550_4,1
6423,cardiac output,151,165,"Nitroprusside caused significant decreases in arterial blood pressure and systemic vascular resistance and increases in heart rate, but did not change cardiac output or QS/QT.",322550_4,1
11686,systemic vascular resistance,74,102,"Nitroprusside caused significant decreases in arterial blood pressure and systemic vascular resistance and increases in heart rate, but did not change cardiac output or QS/QT.",322550_4,1
6422,blood pressure,55,69,"Nitroprusside caused significant decreases in arterial blood pressure and systemic vascular resistance and increases in heart rate, but did not change cardiac output or QS/QT.",322550_4,1
11689,CPAP,12,16,Five cm H2O CPAP during nitroprusside did not further alter any of the above-mentioned variables.,322550_5,0
2832,nitroprusside,24,37,Five cm H2O CPAP during nitroprusside did not further alter any of the above-mentioned variables.,322550_5,0
6425,cardiac output,59,73,"However, 10 cm H2O CPAP decreased arterial blood pressure, cardiac output, and QS/QT.",322550_6,1
6424,blood pressure,43,57,"However, 10 cm H2O CPAP decreased arterial blood pressure, cardiac output, and QS/QT.",322550_6,1
11690,CPAP,19,23,"However, 10 cm H2O CPAP decreased arterial blood pressure, cardiac output, and QS/QT.",322550_6,0
2833,nitroprusside,25,38,These data indicate that nitroprusside infusion rates that decrease mean arterial blood pressure by 40-50 per cent do not change cardiac output or QS/QT.,322550_7,0
6426,blood pressure,82,96,These data indicate that nitroprusside infusion rates that decrease mean arterial blood pressure by 40-50 per cent do not change cardiac output or QS/QT.,322550_7,1
6427,cardiac output,129,143,These data indicate that nitroprusside infusion rates that decrease mean arterial blood pressure by 40-50 per cent do not change cardiac output or QS/QT.,322550_7,1
2834,nitroprusside,7,20,"During nitroprusside infusion low levels of CPAP do not markedly alter cardiovascular dynamics, but high levels of CPAP (10 cm H2O), while decreasing QS/QT, produce marked decreases in arterial blood pressure and cardiac output.",322550_8,0
11693,CPAP,44,48,"During nitroprusside infusion low levels of CPAP do not markedly alter cardiovascular dynamics, but high levels of CPAP (10 cm H2O), while decreasing QS/QT, produce marked decreases in arterial blood pressure and cardiac output.",322550_8,0
11694,CPAP,115,119,"During nitroprusside infusion low levels of CPAP do not markedly alter cardiovascular dynamics, but high levels of CPAP (10 cm H2O), while decreasing QS/QT, produce marked decreases in arterial blood pressure and cardiac output.",322550_8,0
11695,QS/QT,150,155,"During nitroprusside infusion low levels of CPAP do not markedly alter cardiovascular dynamics, but high levels of CPAP (10 cm H2O), while decreasing QS/QT, produce marked decreases in arterial blood pressure and cardiac output.",322550_8,0
6428,blood pressure,194,208,"During nitroprusside infusion low levels of CPAP do not markedly alter cardiovascular dynamics, but high levels of CPAP (10 cm H2O), while decreasing QS/QT, produce marked decreases in arterial blood pressure and cardiac output.",322550_8,1
6429,cardiac output,213,227,"During nitroprusside infusion low levels of CPAP do not markedly alter cardiovascular dynamics, but high levels of CPAP (10 cm H2O), while decreasing QS/QT, produce marked decreases in arterial blood pressure and cardiac output.",322550_8,1
2836,bendrofluazide,92,106,"The beta adrenergic blocking drug, timolol, tended to correct the hypokalemia of short-term bendrofluazide treatment in 6 healthy male subjects and although the effect was small it was significant.",326460_1,0
2835,beta adrenergic,4,19,"The beta adrenergic blocking drug, timolol, tended to correct the hypokalemia of short-term bendrofluazide treatment in 6 healthy male subjects and although the effect was small it was significant.",326460_1,0
2837,bendrofluazide,92,106,Timolol also reduced the rise in plasma aldosterone and urine potassium excretion following bendrofluazide and increased the urine sodium/potassium ratio.,326460_2,0
11696,plasma aldosterone,33,51,Timolol also reduced the rise in plasma aldosterone and urine potassium excretion following bendrofluazide and increased the urine sodium/potassium ratio.,326460_2,0
6430,St. Anthony's fire,0,18,"St. Anthony's fire, then and now: a case report and historical review.",3300918_0,1
2838,methysergide,122,134,"A rare case of morbid vasospasm, together with striking angiographic findings, is described secondary to the ingestion of methysergide by a 48-year-old woman.",3300918_1,0
6431,vasospasm,22,31,"A rare case of morbid vasospasm, together with striking angiographic findings, is described secondary to the ingestion of methysergide by a 48-year-old woman.",3300918_1,1
6432,migraine headache,183,200,"A discussion of the history of ergot includes its original discovery, the epidemics of gangrene that it has caused through the ages and its past and present role in the management of migraine headache.",3300918_3,1
2839,calcium channel blockers,22,46,"Despite the advent of calcium channel blockers and beta-adrenergic antagonists, ergot preparations continue to play a major role in migraine therapy, so that the danger of St. Anthony's fire persists.",3300918_4,0
11701,ergot preparations,80,98,"Despite the advent of calcium channel blockers and beta-adrenergic antagonists, ergot preparations continue to play a major role in migraine therapy, so that the danger of St. Anthony's fire persists.",3300918_4,0
2840,beta-adrenergic antagonists,51,78,"Despite the advent of calcium channel blockers and beta-adrenergic antagonists, ergot preparations continue to play a major role in migraine therapy, so that the danger of St. Anthony's fire persists.",3300918_4,0
6433,St. Anthony's fire,172,190,"Despite the advent of calcium channel blockers and beta-adrenergic antagonists, ergot preparations continue to play a major role in migraine therapy, so that the danger of St. Anthony's fire persists.",3300918_4,1
11703,Cardiac transplantation,0,23,Cardiac transplantation: improved quality of survival with a modified immunosuppressive protocol.,3311455_0,1
11705,renal function,15,29,The effects on renal function on two different immunosuppressive protocols were evaluated retrospectively in two subsequent groups of heart transplant recipients.,3311455_1,1
11707,heart transplant,134,150,The effects on renal function on two different immunosuppressive protocols were evaluated retrospectively in two subsequent groups of heart transplant recipients.,3311455_1,1
11708,group I,3,10,"In group I, cyclosporine was given before the procedure at a loading dose of 17.5 mg/kg and then continued after the procedure to keep a whole blood level about 1000 ng/ml.",3311455_2,0
11709,loading dose,61,73,"In group I, cyclosporine was given before the procedure at a loading dose of 17.5 mg/kg and then continued after the procedure to keep a whole blood level about 1000 ng/ml.",3311455_2,0
2841,cyclosporine,12,24,"In group I, cyclosporine was given before the procedure at a loading dose of 17.5 mg/kg and then continued after the procedure to keep a whole blood level about 1000 ng/ml.",3311455_2,0
11711,group II,3,11,"In group II, cyclosporine was started only after the procedure at a lower dosage and was complemented by azathioprine, which was used for the first postoperative week.",3311455_3,0
2842,cyclosporine,13,25,"In group II, cyclosporine was started only after the procedure at a lower dosage and was complemented by azathioprine, which was used for the first postoperative week.",3311455_3,0
11713,perioperative renal function,25,53,Group II showed a better perioperative renal function as determined by serum blood urea nitrogen and serum creatinine levels.,3311455_4,1
11712,Group II,0,8,Group II showed a better perioperative renal function as determined by serum blood urea nitrogen and serum creatinine levels.,3311455_4,0
2843,creatinine,107,117,Group II showed a better perioperative renal function as determined by serum blood urea nitrogen and serum creatinine levels.,3311455_4,0
11715,Group II,0,8,Group II also showed a significant decrease of chronic nephrotoxicity secondary to long-term therapy with cyclosporine.,3311455_5,0
11716,chronic nephrotoxicity,47,69,Group II also showed a significant decrease of chronic nephrotoxicity secondary to long-term therapy with cyclosporine.,3311455_5,1
2844,cyclosporine,106,118,Group II also showed a significant decrease of chronic nephrotoxicity secondary to long-term therapy with cyclosporine.,3311455_5,0
11717,late renal function,28,47,"Despite this improvement in late renal function, group II still shows a slow rise in serum creatinine.",3311455_6,1
11718,group II,49,57,"Despite this improvement in late renal function, group II still shows a slow rise in serum creatinine.",3311455_6,0
2845,creatinine,91,101,"Despite this improvement in late renal function, group II still shows a slow rise in serum creatinine.",3311455_6,0
6434,side effect,196,207,We think that even these lower dosages of cyclosporine can cause chronic nephrotoxicity and that further modification of the immunosuppressive regimen is required to completely abolish this toxic side effect.,3311455_7,1
11719,chronic nephrotoxicity,65,87,We think that even these lower dosages of cyclosporine can cause chronic nephrotoxicity and that further modification of the immunosuppressive regimen is required to completely abolish this toxic side effect.,3311455_7,1
2846,cyclosporine,42,54,We think that even these lower dosages of cyclosporine can cause chronic nephrotoxicity and that further modification of the immunosuppressive regimen is required to completely abolish this toxic side effect.,3311455_7,0
11721,Systolic pressure variation,0,27,Systolic pressure variation is greater during hemorrhage than during sodium nitroprusside-induced hypotension in ventilated dogs.,3341566_0,1
6435,blood pressure,118,132,"The systolic pressure variation (SPV), which is the difference between the maximal and minimal values of the systolic blood pressure (SBP) after one positive-pressure breath, was studied in ventilated dogs subjected to hypotension.",3341566_1,1
11724,positive-pressure breath,149,173,"The systolic pressure variation (SPV), which is the difference between the maximal and minimal values of the systolic blood pressure (SBP) after one positive-pressure breath, was studied in ventilated dogs subjected to hypotension.",3341566_1,1
11725,Mean arterial pressure,0,22,"Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage (HEM, n = 7) or by continuous infusion of sodium nitroprusside (SNP, n = 7).",3341566_2,1
2847,sodium nitroprusside,127,147,"Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage (HEM, n = 7) or by continuous infusion of sodium nitroprusside (SNP, n = 7).",3341566_2,0
6436,cardiac output,35,49,During HEM-induced hypotension the cardiac output was significantly lower and systemic vascular resistance higher compared with that in the SNP group.,3341566_3,1
11728,systemic vascular resistance,78,106,During HEM-induced hypotension the cardiac output was significantly lower and systemic vascular resistance higher compared with that in the SNP group.,3341566_3,1
11729,central venous,14,28,"The systemic, central venous, pulmonary capillary wedge pressures, and heart rates, were similar in the two groups.",3341566_4,1
11730,pulmonary capillary wedge pressures,30,65,"The systemic, central venous, pulmonary capillary wedge pressures, and heart rates, were similar in the two groups.",3341566_4,1
11733,arterial pressure,43,60,Analysis of the respiratory changes in the arterial pressure waveform enabled differentiation between the two groups.,3341566_5,1
11734,SPV,4,7,"The SPV during hypotension was 15.7 +/- 6.7 mm Hg in the HEM group, compared with 9.1 +/- 2.0 mm Hg in the SNP group (P less than 0.02).",3341566_6,0
11738,mm Hg,94,99,"The SPV during hypotension was 15.7 +/- 6.7 mm Hg in the HEM group, compared with 9.1 +/- 2.0 mm Hg in the SNP group (P less than 0.02).",3341566_6,0
11741,mechanical breath,64,81,"The delta down, which is the measure of decrease of SBP after a mechanical breath, was 20.3 +/- 8.4 and 10.1 +/- 3.8 mm Hg in the HEM and SNP groups, respectively, during hypotension (P less than 0.02).",3341566_7,1
11748,cesarean section,36,52,Ventricular tachyarrhythmias during cesarean section after ritodrine therapy: interaction with anesthetics.,3358181_0,1
6437,Ventricular tachyarrhythmias,0,28,Ventricular tachyarrhythmias during cesarean section after ritodrine therapy: interaction with anesthetics.,3358181_0,1
2848,ritodrine,59,68,Ventricular tachyarrhythmias during cesarean section after ritodrine therapy: interaction with anesthetics.,3358181_0,0
2850,ritodrine,140,149,This case illustrates that patients receiving ritodrine for preterm labor may risk interactions between the residual betamimetic effects of ritodrine and the effects of anesthetics during cesarean section.,3358181_1,0
11751,cesarean section,188,204,This case illustrates that patients receiving ritodrine for preterm labor may risk interactions between the residual betamimetic effects of ritodrine and the effects of anesthetics during cesarean section.,3358181_1,1
2849,ritodrine,46,55,This case illustrates that patients receiving ritodrine for preterm labor may risk interactions between the residual betamimetic effects of ritodrine and the effects of anesthetics during cesarean section.,3358181_1,0
6438,preterm labor,60,73,This case illustrates that patients receiving ritodrine for preterm labor may risk interactions between the residual betamimetic effects of ritodrine and the effects of anesthetics during cesarean section.,3358181_1,1
2851,ritodrine,108,117,Such interactions may result in serious cardiovascular complications even after cessation of an infusion of ritodrine.,3358181_2,0
6439,cardiovascular complications,40,68,Such interactions may result in serious cardiovascular complications even after cessation of an infusion of ritodrine.,3358181_2,1
2852,alpha-adrenergic,83,99,"After delivery of the infant, there should be no contraindication to the use of an alpha-adrenergic vasopressor such as phenylephrine to treat hypotensive patients with tachycardia.",3358181_6,0
11754,calcium entry blocker,149,170,Two patients with signs of carbamazepine neurotoxicity after combined treatment with verapamil showed complete recovery after discontinuation of the calcium entry blocker.,3371379_2,0
11755,carbamazepine,37,50,Use of verapamil in combination with carbamazepine should either be avoided or prescribed only with appropriate adjustment of the carbamazepine dose (usually reduction of the carbamazepine dose by one half).,3371379_3,0
2853,benztropine,18,29,Ethopropazine and benztropine in neuroleptic-induced parkinsonism.,33969_0,0
11758,Ethopropazine,0,13,Ethopropazine and benztropine in neuroleptic-induced parkinsonism.,33969_0,0
11759,neuroleptic-induced parkinsonism,33,65,Ethopropazine and benztropine in neuroleptic-induced parkinsonism.,33969_0,1
11761,fluphenazine enanthate,116,138,In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients.,33969_1,0
2854,benztropine,60,71,In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients.,33969_1,0
11760,ethopropazine,30,43,In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients.,33969_1,0
2855,benztropine,18,29,"Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug.",33969_2,0
11764,antiparkinsonian drug,158,179,"Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug.",33969_2,0
11763,parkinsonian,80,92,"Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug.",33969_2,0
11762,Ethopropazine,0,13,"Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug.",33969_2,0
6440,tardive dyskinesia,68,86,"However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.",33969_3,1
11765,ethopropazine,198,211,"However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.",33969_3,0
2856,benztropine,9,20,"However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients.",33969_3,0
11766,anticholinergic drug,42,62,"This suggests that benztropine is not the anticholinergic drug of choice in the treatment of neuroleptic-induced parkinsonian symptoms, because of its more toxic central and peripheral atropinic effect.",33969_4,0
2857,benztropine,19,30,"This suggests that benztropine is not the anticholinergic drug of choice in the treatment of neuroleptic-induced parkinsonian symptoms, because of its more toxic central and peripheral atropinic effect.",33969_4,0
11767,peripheral atropinic,174,194,"This suggests that benztropine is not the anticholinergic drug of choice in the treatment of neuroleptic-induced parkinsonian symptoms, because of its more toxic central and peripheral atropinic effect.",33969_4,0
6442,hepatic failure,59,74,"Paracetamol-associated coma, metabolic acidosis, renal and hepatic failure.",3403780_0,1
6441,metabolic acidosis,29,47,"Paracetamol-associated coma, metabolic acidosis, renal and hepatic failure.",3403780_0,1
6443,metabolic acidosis,10,28,"A case of metabolic acidosis, acute renal failure and hepatic failure following paracetamol ingestion is presented.",3403780_1,1
6444,acute renal failure,30,49,"A case of metabolic acidosis, acute renal failure and hepatic failure following paracetamol ingestion is presented.",3403780_1,1
6445,hepatic failure,54,69,"A case of metabolic acidosis, acute renal failure and hepatic failure following paracetamol ingestion is presented.",3403780_1,1
2858,paracetamol,80,91,"A case of metabolic acidosis, acute renal failure and hepatic failure following paracetamol ingestion is presented.",3403780_1,0
11768,diagnostic difficulty,4,25,The diagnostic difficulty at presentation is highlighted.,3403780_2,1
6446,Sexual dysfunction,0,18,Sexual dysfunction among patients with arthritis.,3409645_0,1
6448,rheumatoid arthritis,94,114,"The relationship of arthritis and sexual dysfunction was investigated among 169 patients with rheumatoid arthritis, osteoarthritis and spondyloarthropathy, 130 of whom were pair-matched to controls.",3409645_1,1
6447,sexual dysfunction,34,52,"The relationship of arthritis and sexual dysfunction was investigated among 169 patients with rheumatoid arthritis, osteoarthritis and spondyloarthropathy, 130 of whom were pair-matched to controls.",3409645_1,1
6449,spondyloarthropathy,135,154,"The relationship of arthritis and sexual dysfunction was investigated among 169 patients with rheumatoid arthritis, osteoarthritis and spondyloarthropathy, 130 of whom were pair-matched to controls.",3409645_1,1
11771,depressed mood,37,51,Assessments of marital happiness and depressed mood were also made using the CES-D and the Azrin Marital Happiness Scale (AMHS).,3409645_2,1
6450,Sexual dysfunctions,0,19,"Sexual dysfunctions were found to be common among patients and controls, the majority in both groups reporting one or more dysfunctions.",3409645_3,1
6451,co-morbidity,96,108,Impotence was more common among male patients than controls and was found to be associated with co-morbidity and the taking of methotrexate.,3409645_4,1
11777,sexual difficulties,78,97,"Depressed mood was more common among patients and was associated with certain sexual difficulties, but not with impotence.",3409645_5,1
11775,Depressed mood,0,14,"Depressed mood was more common among patients and was associated with certain sexual difficulties, but not with impotence.",3409645_5,1
11778,Marital unhappiness,0,19,"Marital unhappiness, as indicated by AMHS scores, was not associated with arthritis but was associated with sexual dysfunction, sexual dissatisfaction and being female.",3409645_6,1
6452,sexual dysfunction,108,126,"Marital unhappiness, as indicated by AMHS scores, was not associated with arthritis but was associated with sexual dysfunction, sexual dissatisfaction and being female.",3409645_6,1
11781,sexual dissatisfaction,128,150,"Marital unhappiness, as indicated by AMHS scores, was not associated with arthritis but was associated with sexual dysfunction, sexual dissatisfaction and being female.",3409645_6,1
6453,fulminant hepatitis,41,60,Quinidine phenylethylbarbiturate-induced fulminant hepatitis in a pregnant woman.,3411101_0,1
6454,fulminant hepatitis,64,83,We report the case of a 19-year-old Laotian patient affected by fulminant hepatitis during the third trimester of her pregnancy after a 1-month administration of quinidine phenylethylbarbiturate.,3411101_2,1
11783,quinidine phenylethylbarbiturate,162,194,We report the case of a 19-year-old Laotian patient affected by fulminant hepatitis during the third trimester of her pregnancy after a 1-month administration of quinidine phenylethylbarbiturate.,3411101_2,0
11784,orthotopic liver transplantation,38,70,"After delivery, the patient underwent orthotopic liver transplantation.",3411101_3,1
11785,liver transplantation,50,71,The patient was in good condition 16 months after liver transplantation.,3411101_4,1
6455,fulminant hepatitis,66,85,Quinidine itself or phenylethylbarbiturate may be responsible for fulminant hepatitis in this patient.,3411101_5,1
11786,phenylethylbarbiturate,20,42,Quinidine itself or phenylethylbarbiturate may be responsible for fulminant hepatitis in this patient.,3411101_5,0
11789,renal pelvis,134,146,"Does paracetamol cause urothelial cancer or renal papillary necrosis?The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.",3412544_0,1
6457,cancer of,120,129,"Does paracetamol cause urothelial cancer or renal papillary necrosis?The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.",3412544_0,1
2859,paracetamol,5,16,"Does paracetamol cause urothelial cancer or renal papillary necrosis?The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.",3412544_0,0
2860,paracetamol,218,229,"Does paracetamol cause urothelial cancer or renal papillary necrosis?The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.",3412544_0,0
11788,renal papillary necrosis?The,44,72,"Does paracetamol cause urothelial cancer or renal papillary necrosis?The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.",3412544_0,1
11787,urothelial,23,33,"Does paracetamol cause urothelial cancer or renal papillary necrosis?The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.",3412544_0,1
6456,papillary necrosis,98,116,"Does paracetamol cause urothelial cancer or renal papillary necrosis?The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls.",3412544_0,1
11791,renal pelvis,144,156,"The risk of renal papillary necrosis was increased nearly 20-fold by consumption of phenacetin, which also increased the risk for cancer of the renal pelvis and bladder but not for ureteric cancer.",3412544_1,1
6459,cancer of,130,139,"The risk of renal papillary necrosis was increased nearly 20-fold by consumption of phenacetin, which also increased the risk for cancer of the renal pelvis and bladder but not for ureteric cancer.",3412544_1,1
6458,papillary necrosis,18,36,"The risk of renal papillary necrosis was increased nearly 20-fold by consumption of phenacetin, which also increased the risk for cancer of the renal pelvis and bladder but not for ureteric cancer.",3412544_1,1
11792,ureteric cancer,181,196,"The risk of renal papillary necrosis was increased nearly 20-fold by consumption of phenacetin, which also increased the risk for cancer of the renal pelvis and bladder but not for ureteric cancer.",3412544_1,1
2861,paracetamol,67,78,"By contrast, we were unable to substantiate an increased risk from paracetamol consumption for renal papillary necrosis or any of these cancers although there was a suggestion of an association with cancer of the ureter.",3412544_2,0
6461,cancer of the ureter,199,219,"By contrast, we were unable to substantiate an increased risk from paracetamol consumption for renal papillary necrosis or any of these cancers although there was a suggestion of an association with cancer of the ureter.",3412544_2,1
6460,papillary necrosis,101,119,"By contrast, we were unable to substantiate an increased risk from paracetamol consumption for renal papillary necrosis or any of these cancers although there was a suggestion of an association with cancer of the ureter.",3412544_2,1
11793,exercise-induced ischemia,74,99,Mechanisms of myocardial ischemia induced by epinephrine: comparison with exercise-induced ischemia.,3413271_0,1
6462,myocardial ischemia,14,33,Mechanisms of myocardial ischemia induced by epinephrine: comparison with exercise-induced ischemia.,3413271_0,1
6464,coronary artery disease,87,110,The role of epinephrine in eliciting myocardial ischemia was examined in patients with coronary artery disease.,3413271_1,1
6463,myocardial ischemia,37,56,The role of epinephrine in eliciting myocardial ischemia was examined in patients with coronary artery disease.,3413271_1,1
11796,ST segment depression,75,96,Both epinephrine and exercise produced myocardial ischemia as evidenced by ST segment depression and angina.,3413271_3,1
6465,myocardial ischemia,39,58,Both epinephrine and exercise produced myocardial ischemia as evidenced by ST segment depression and angina.,3413271_3,1
6466,myocardial ischemia,27,46,"However, the mechanisms of myocardial ischemia induced by epinephrine were significantly different from those of exercise.",3413271_4,1
11797,Exercise-induced myocardial ischemia,0,36,"Exercise-induced myocardial ischemia was marked predominantly by increased heart rate and rate-pressure product with a minor contribution of end-diastolic volume, while epinephrine-induced ischemia was characterized by a marked increase in contractility and a less pronounced increase in heart rate and rate-pressure product.",3413271_5,1
11803,emotional distress,93,111,"These findings indicate that ischemia produced by epinephrine, as may occur during states of emotional distress, has a mechanism distinct from that due to physical exertion.",3413271_6,1
6467,hemolytic anemia,30,46,Dapsone-associated Heinz body hemolytic anemia in a Cambodian woman with hemoglobin E trait.,3425586_0,1
11805,hemoglobin E trait,73,91,Dapsone-associated Heinz body hemolytic anemia in a Cambodian woman with hemoglobin E trait.,3425586_0,1
11806,hemoglobin E trait,23,41,A Cambodian woman with hemoglobin E trait (AE) and leprosy developed a Heinz body hemolytic anemia while taking a dose of dapsone (50 mg/day) not usually associated with clinical hemolysis.,3425586_1,1
2862,AE,43,45,A Cambodian woman with hemoglobin E trait (AE) and leprosy developed a Heinz body hemolytic anemia while taking a dose of dapsone (50 mg/day) not usually associated with clinical hemolysis.,3425586_1,0
6468,hemolytic anemia,82,98,A Cambodian woman with hemoglobin E trait (AE) and leprosy developed a Heinz body hemolytic anemia while taking a dose of dapsone (50 mg/day) not usually associated with clinical hemolysis.,3425586_1,1
11809,clinical hemolysis,170,188,A Cambodian woman with hemoglobin E trait (AE) and leprosy developed a Heinz body hemolytic anemia while taking a dose of dapsone (50 mg/day) not usually associated with clinical hemolysis.,3425586_1,1
11811,GSH,124,127,"Her red blood cells (RBCs) had increased incubated Heinz body formation, decreased reduced glutathione (GSH), and decreased GSH stability.",3425586_2,0
11810,GSH,104,107,"Her red blood cells (RBCs) had increased incubated Heinz body formation, decreased reduced glutathione (GSH), and decreased GSH stability.",3425586_2,0
2863,reduced glutathione,83,102,"Her red blood cells (RBCs) had increased incubated Heinz body formation, decreased reduced glutathione (GSH), and decreased GSH stability.",3425586_2,0
11812,pentose phosphate,4,21,The pentose phosphate shunt activity of the dapsone-exposed AE RBCs was increased compared to normal RBCs.,3425586_3,0
2864,AE,60,62,The pentose phosphate shunt activity of the dapsone-exposed AE RBCs was increased compared to normal RBCs.,3425586_3,0
11813,GSH,109,112,"Although the AE RBCs from an individual not taking dapsone had increased incubated Heinz body formation, the GSH content and GSH stability were normal.",3425586_4,0
11814,GSH,125,128,"Although the AE RBCs from an individual not taking dapsone had increased incubated Heinz body formation, the GSH content and GSH stability were normal.",3425586_4,0
2865,AE,13,15,"Although the AE RBCs from an individual not taking dapsone had increased incubated Heinz body formation, the GSH content and GSH stability were normal.",3425586_4,0
2866,AE,64,66,The pentose phosphate shunt activity of the non-dapsone-exposed AE RBCs was decreased compared to normal RBCs.,3425586_5,0
11815,pentose phosphate,4,21,The pentose phosphate shunt activity of the non-dapsone-exposed AE RBCs was decreased compared to normal RBCs.,3425586_5,0
6469,hemolytic anemia,128,144,"Thus, AE RBCs appear to have an increased sensitivity to oxidant stress both in vitro and in vivo, since dapsone does not cause hemolytic anemia at this dose in hematologically normal individuals.",3425586_6,1
2867,AE,6,8,"Thus, AE RBCs appear to have an increased sensitivity to oxidant stress both in vitro and in vivo, since dapsone does not cause hemolytic anemia at this dose in hematologically normal individuals.",3425586_6,0
11822,tight-binding inhibitor,177,200,"Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.",3431591_0,0
11821,"N10-propargyl-5,8-dideazafolic acid",135,170,"Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.",3431591_0,0
11820,CB,117,119,"Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.",3431591_0,0
11819,"N10-propargyl-5,8-dideazafolic acid",80,115,"Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.",3431591_0,0
2868,thymidylate synthase,204,224,"Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.",3431591_0,0
11818,thymidylate synthase inhibitor,49,79,"Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB 3717).CB 3717, N10-propargyl-5,8-dideazafolic acid, is a tight-binding inhibitor of thymidylate synthase (TS) whose cytotoxicity is mediated solely through the inhibition of this enzyme.",3431591_0,0
2869,polyglutamates,82,96,Recent preclinical studies have focused on the intracellular formation of CB 3717 polyglutamates.,3431591_1,0
11824,CB,74,76,Recent preclinical studies have focused on the intracellular formation of CB 3717 polyglutamates.,3431591_1,0
11851,CB,80,82,Pharmacokinetic investigations have shown that alkaline diuresis does not alter CB 3717 plasma levels or urinary excretion and that satisfactory urinary alkalinization can be readily achieved.,3431591_11,0
11827,CB,133,135,"Following a 12-hour exposure of L1210 cells to 50 microM [3H]CB 3717, 30% of the extractable radioactivity could be accounted for as CB 3717 tetra- and pentaglutamate, as determined by high-pressure liquid chromatography (HPLC) analyses.",3431591_2,0
11828,pentaglutamate,152,166,"Following a 12-hour exposure of L1210 cells to 50 microM [3H]CB 3717, 30% of the extractable radioactivity could be accounted for as CB 3717 tetra- and pentaglutamate, as determined by high-pressure liquid chromatography (HPLC) analyses.",3431591_2,0
6470,L1210,32,37,"Following a 12-hour exposure of L1210 cells to 50 microM [3H]CB 3717, 30% of the extractable radioactivity could be accounted for as CB 3717 tetra- and pentaglutamate, as determined by high-pressure liquid chromatography (HPLC) analyses.",3431591_2,1
6471,L1210,26,31,"As inhibitors of isolated L1210 TS, CB 3717 di-, tri-, tetra- and pentaglutamate are 26-, 87-, 119- and 114-fold more potent than CB 3717, respectively, and their formation may, therefore, be an important determinant of CB 3717 cytotoxicity.",3431591_3,1
11831,CB,36,38,"As inhibitors of isolated L1210 TS, CB 3717 di-, tri-, tetra- and pentaglutamate are 26-, 87-, 119- and 114-fold more potent than CB 3717, respectively, and their formation may, therefore, be an important determinant of CB 3717 cytotoxicity.",3431591_3,0
11832,tri-,49,53,"As inhibitors of isolated L1210 TS, CB 3717 di-, tri-, tetra- and pentaglutamate are 26-, 87-, 119- and 114-fold more potent than CB 3717, respectively, and their formation may, therefore, be an important determinant of CB 3717 cytotoxicity.",3431591_3,0
11833,pentaglutamate,66,80,"As inhibitors of isolated L1210 TS, CB 3717 di-, tri-, tetra- and pentaglutamate are 26-, 87-, 119- and 114-fold more potent than CB 3717, respectively, and their formation may, therefore, be an important determinant of CB 3717 cytotoxicity.",3431591_3,0
11834,CB,130,132,"As inhibitors of isolated L1210 TS, CB 3717 di-, tri-, tetra- and pentaglutamate are 26-, 87-, 119- and 114-fold more potent than CB 3717, respectively, and their formation may, therefore, be an important determinant of CB 3717 cytotoxicity.",3431591_3,0
6472,breast cancer,66,79,"In early clinical studies with CB 3717, activity has been seen in breast cancer, ovarian cancer, hepatoma, and mesothelioma.",3431591_4,1
11837,CB,31,33,"In early clinical studies with CB 3717, activity has been seen in breast cancer, ovarian cancer, hepatoma, and mesothelioma.",3431591_4,0
6473,ovarian cancer,81,95,"In early clinical studies with CB 3717, activity has been seen in breast cancer, ovarian cancer, hepatoma, and mesothelioma.",3431591_4,1
11838,hepatotoxicity,20,34,"Toxicities included hepatotoxicity, malaise, and dose-limiting nephrotoxicity.",3431591_5,1
11839,nephrotoxicity,63,77,"Toxicities included hepatotoxicity, malaise, and dose-limiting nephrotoxicity.",3431591_5,1
11841,CB,124,126,This latter effect is thought to be due to drug precipitation within the renal tubule as a result of the poor solubility of CB 3717 under acidic conditions.,3431591_6,0
6474,renal tubule,73,85,This latter effect is thought to be due to drug precipitation within the renal tubule as a result of the poor solubility of CB 3717 under acidic conditions.,3431591_6,1
11840,drug precipitation,43,61,This latter effect is thought to be due to drug precipitation within the renal tubule as a result of the poor solubility of CB 3717 under acidic conditions.,3431591_6,1
11844,CB,60,62,"In an attempt to overcome this problem, a clinical trial of CB 3717 administered with alkaline diuresis is under way.",3431591_7,0
11845,mg/m2,35,40,Preliminary results at 400 and 500 mg/m2 suggest that a reduction in nephrotoxicity may have been achieved with only 1 instance of renal toxicity in 10 patients.,3431591_8,0
11846,nephrotoxicity,69,83,Preliminary results at 400 and 500 mg/m2 suggest that a reduction in nephrotoxicity may have been achieved with only 1 instance of renal toxicity in 10 patients.,3431591_8,1
11847,renal toxicity,131,145,Preliminary results at 400 and 500 mg/m2 suggest that a reduction in nephrotoxicity may have been achieved with only 1 instance of renal toxicity in 10 patients.,3431591_8,1
11848,Hepatotoxicity,0,14,Hepatotoxicity and malaise are again the most frequent side effects.,3431591_9,1
6475,side effects,55,67,Hepatotoxicity and malaise are again the most frequent side effects.,3431591_9,1
6476,needle-stick,23,35,Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin.,343678_0,1
11854,Type B hepatitis,0,16,Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin.,343678_0,1
11860,type B hepatitis,167,183,"Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.",343678_2,1
11858,ISG,62,65,"Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.",343678_2,0
2871,hepatitis B surface antigen,215,242,"Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.",343678_2,0
2870,serum globulin,46,60,"Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.",343678_2,0
11856,Hepatitis B immune globulin,0,27,"Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.",343678_2,0
11857,HBIG,29,33,"Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.",343678_2,0
6477,needle-stick,190,202,"Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen (HBsAG)-positive donors.",343678_2,1
6478,seroconversion,92,106,"Clinical hepatitis developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001).",343678_3,1
11862,Clinical hepatitis,0,18,"Clinical hepatitis developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001).",343678_3,1
11863,HBIG,40,44,"Clinical hepatitis developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001).",343678_3,0
11864,ISG,60,63,"Clinical hepatitis developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001).",343678_3,0
11865,anti-HBs,108,116,"Clinical hepatitis developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001).",343678_3,0
11867,HBIG,73,77,Mild and transient side-effects were noted in 3.0% of ISG and in 3.2% of HBIG recipients.,343678_4,0
6479,side-effects,19,31,Mild and transient side-effects were noted in 3.0% of ISG and in 3.2% of HBIG recipients.,343678_4,1
11866,ISG,54,57,Mild and transient side-effects were noted in 3.0% of ISG and in 3.2% of HBIG recipients.,343678_4,0
11868,DNAP,55,59,Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBE).,343678_5,0
2872,DNA polymerase,39,53,Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBE).,343678_5,0
2873,e antigen,65,74,Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBE).,343678_5,0
2874,HBeAg,89,94,Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody (HBeAg; anti-HBE).,343678_5,0
2875,HBeAg,14,19,Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors.,343678_6,0
11869,DNAP,5,9,Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors.,343678_6,0
11870,infectivity,83,94,Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors.,343678_6,0
11874,type B hepatitis,81,97,Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups.,343678_7,1
11872,Hepatitis B immune globulin,0,27,Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups.,343678_7,0
11873,ISG,63,66,Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups.,343678_7,0
11877,type B hepatitis,34,50,The efficacy of ISG in preventing type B hepatitis cannot be ascertained because a true placebo group was not included.,343678_8,1
11876,ISG,16,19,The efficacy of ISG in preventing type B hepatitis cannot be ascertained because a true placebo group was not included.,343678_8,0
11878,poor metabolizer,78,94,"Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, propafenone, diltiazem, and sparteine.",3437726_0,0
2877,sparteine,138,147,"Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, propafenone, diltiazem, and sparteine.",3437726_0,0
2876,propafenone,110,121,"Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, propafenone, diltiazem, and sparteine.",3437726_0,0
6480,coronary artery disease,37,60,A 47-year-old patient suffering from coronary artery disease was admitted to the CCU in shock with III.,3437726_1,1
11879,CCU,81,84,A 47-year-old patient suffering from coronary artery disease was admitted to the CCU in shock with III.,3437726_1,0
6481,AV block,0,8,"AV block, severe hypotension, and impairment of ventricular function.",3437726_2,1
11880,ventricular function,48,68,"AV block, severe hypotension, and impairment of ventricular function.",3437726_2,1
11882,admission diltiazem,16,35,Two days before admission diltiazem (60 mg b.i.d.) was prescribed in addition.,3437726_4,0
2878,propafenone,86,97,"Three months later the patient was exposed to a single dose of metoprolol, diltiazem, propafenone (since he had received this drug in the past), and sparteine (as a probe for the debrisoquine/sparteine type polymorphism of oxidative drug metabolism).",3437726_7,0
2879,sparteine,149,158,"Three months later the patient was exposed to a single dose of metoprolol, diltiazem, propafenone (since he had received this drug in the past), and sparteine (as a probe for the debrisoquine/sparteine type polymorphism of oxidative drug metabolism).",3437726_7,0
11887,metabolizer,32,43,"It was found that he was a poor metabolizer of all four drugs, indicating that their metabolism is under the same genetic control.",3437726_8,0
11889,sparteine/debrisoquine,67,89,"Therefore, patients belonging to the poor-metabolizer phenotype of sparteine/debrisoquine polymorphism in drug metabolism, which constitutes 6.4% of the German population, may experience adverse drug reactions when treated with standard doses of one of these drugs alone.",3437726_9,0
6482,adverse drug reactions,187,209,"Therefore, patients belonging to the poor-metabolizer phenotype of sparteine/debrisoquine polymorphism in drug metabolism, which constitutes 6.4% of the German population, may experience adverse drug reactions when treated with standard doses of one of these drugs alone.",3437726_9,1
6483,prostate cancer,28,43,Production of autochthonous prostate cancer in Lobund-Wistar rats by treatments with N-nitroso-N-methylurea and testosterone.,3461217_0,1
11893,N-nitroso-N-methylurea,85,107,Production of autochthonous prostate cancer in Lobund-Wistar rats by treatments with N-nitroso-N-methylurea and testosterone.,3461217_0,0
11898,tumor-bearing,236,249,"More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.",3461217_1,1
11895,prostate adenocarcinomas,75,99,"More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.",3461217_1,1
11899,metastatic lesions,266,284,"More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.",3461217_1,1
11896,N-nitroso-N-methylurea,132,154,"More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.",3461217_1,0
2880,TP,201,203,"More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.",3461217_1,0
11897,testosterone propionate,175,198,"More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions.",3461217_1,0
2881,TP,93,95,"Within the same timeframe, no L-W rat developed a similar palpable PA when treated only with TP.",3461217_3,0
2882,TP,13,15,"In L-W rats, TP acted as a tumor enhancement agent, with primary emphasis on the development of prostate cancer.",3461217_4,0
11903,tumor enhancement agent,27,50,"In L-W rats, TP acted as a tumor enhancement agent, with primary emphasis on the development of prostate cancer.",3461217_4,0
6484,prostate cancer,96,111,"In L-W rats, TP acted as a tumor enhancement agent, with primary emphasis on the development of prostate cancer.",3461217_4,1
11905,bromperidol,43,54,"A total of sixty patients were trated with bromperidol first in open conditions (20 patients), then on a double blind basis (40 patients) with haloperidol as the reference substance.",347884_1,0
6487,side effects,45,57,No differences were observed with respect to side effects and general tolerability.,347884_10,1
11919,general tolerability,62,82,No differences were observed with respect to side effects and general tolerability.,347884_10,1
11909,daily dose,4,14,The daily dose (initial dose: 1 mg; mean dose at the end of the trial: 4.47 mg) was always administered in one single dose.,347884_3,0
11911,single dose,111,122,The daily dose (initial dose: 1 mg; mean dose at the end of the trial: 4.47 mg) was always administered in one single dose.,347884_3,0
6486,side effects,87,99,Nine patients exhibited mild to moderate extrapyramidal concomitant symptoms; no other side effects were observed.,347884_6,1
6485,extrapyramidal,41,55,Nine patients exhibited mild to moderate extrapyramidal concomitant symptoms; no other side effects were observed.,347884_6,1
11916,psychotic syndromes,114,133,"In the double blind study with haloperidol, both substances were found to be highly effective in the treatment of psychotic syndromes belonging predominantly to the schizophrenia group.",347884_8,1
11918,bromperidol,90,101,"Certain clues, including the onset of action, seem to be indicative of the superiority of bromperidol.",347884_9,0
11920,acute hepatitis,51,66,Prolonged cholestasis after troleandomycin-induced acute hepatitis.,3496378_0,1
11922,anicteric cholestasis,99,120,We report the case of a patient in whom troleandomycin-induced hepatitis was followed by prolonged anicteric cholestasis.,3496378_1,1
6488,hypereosinophilia,92,109,Jaundice occurred after administration of troleandomycin for 7 days and was associated with hypereosinophilia.,3496378_2,1
2883,troleandomycin,42,56,Jaundice occurred after administration of troleandomycin for 7 days and was associated with hypereosinophilia.,3496378_2,0
11925,alkaline phosphatase,127,147,Jaundice disappeared within 3 months but was followed by prolonged anicteric cholestasis marked by pruritus and high levels of alkaline phosphatase and gammaglutamyltransferase activities.,3496378_3,0
2884,gammaglutamyltransferase,152,176,Jaundice disappeared within 3 months but was followed by prolonged anicteric cholestasis marked by pruritus and high levels of alkaline phosphatase and gammaglutamyltransferase activities.,3496378_3,0
11924,anicteric cholestasis,67,88,Jaundice disappeared within 3 months but was followed by prolonged anicteric cholestasis marked by pruritus and high levels of alkaline phosphatase and gammaglutamyltransferase activities.,3496378_3,1
11927,onset of,103,111,"Finally, pruritus disappeared within 19 months, and liver tests returned to normal 27 months after the onset of hepatitis.",3496378_4,1
6489,neurotoxicity,27,40,Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy.,3503576_0,1
2885,deferoxamine,63,75,Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy.,3503576_0,0
11928,transfusion-dependent anemia,86,114,Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion-dependent anemia who were receiving iron chelation therapy with daily subcutaneous deferoxamine.,3503576_1,1
2886,deferoxamine,181,193,Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion-dependent anemia who were receiving iron chelation therapy with daily subcutaneous deferoxamine.,3503576_1,0
6490,neurotoxicity,20,33,Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion-dependent anemia who were receiving iron chelation therapy with daily subcutaneous deferoxamine.,3503576_1,1
2892,deferoxamine,46,58,Moderate abnormalities require a reduction of deferoxamine to 25 mg/kg per dose with careful monitoring.,3503576_10,0
11935,Moderate abnormalities,0,22,Moderate abnormalities require a reduction of deferoxamine to 25 mg/kg per dose with careful monitoring.,3503576_10,1
2893,at 10,157,162,"In those with symptoms of hearing loss, the drug should be stopped for four weeks, and when the audiogram is stable or improved, therapy should be restarted at 10 to 25 mg/kg per dose.",3503576_11,0
6493,hearing loss,26,38,"In those with symptoms of hearing loss, the drug should be stopped for four weeks, and when the audiogram is stable or improved, therapy should be restarted at 10 to 25 mg/kg per dose.",3503576_11,1
6494,serum ferritin,131,145,Serial audiograms should be performed every six months in those without problems and more frequently in young patients with normal serum ferritin values and in those with auditory dysfunction.,3503576_12,1
6495,auditory dysfunction,171,191,Serial audiograms should be performed every six months in those without problems and more frequently in young patients with normal serum ferritin values and in those with auditory dysfunction.,3503576_12,1
6491,high frequency,94,108,"Twenty-two patients in the affected group had abnormal audiograms with deficits mostly in the high frequency range of 4,000 to 8,000 Hz and in the hearing threshold levels of 30 to 100 decibels.",3503576_2,1
2887,deferoxamine,5,17,"When deferoxamine therapy was discontinued and serial studies were performed, audiograms in seven cases reverted to normal or near normal within two to three weeks, and nine of 13 patients with symptoms became asymptomatic.",3503576_3,0
11930,permanent disability,97,117,Audiograms from 15 patients remained abnormal and four patients required hearing aids because of permanent disability.,3503576_4,1
11931,lower doses,156,167,"Since 18 of the 22 patients were initially receiving deferoxamine doses in excess of the commonly recommended 50 mg/kg per dose, therapy was restarted with lower doses, usually 50 mg/kg per dose or less depending on the degree of auditory abnormality, and with the exception of two cases no further toxicity was demonstrated.",3503576_5,0
11932,auditory abnormality,230,250,"Since 18 of the 22 patients were initially receiving deferoxamine doses in excess of the commonly recommended 50 mg/kg per dose, therapy was restarted with lower doses, usually 50 mg/kg per dose or less depending on the degree of auditory abnormality, and with the exception of two cases no further toxicity was demonstrated.",3503576_5,1
2888,deferoxamine,53,65,"Since 18 of the 22 patients were initially receiving deferoxamine doses in excess of the commonly recommended 50 mg/kg per dose, therapy was restarted with lower doses, usually 50 mg/kg per dose or less depending on the degree of auditory abnormality, and with the exception of two cases no further toxicity was demonstrated.",3503576_5,0
6492,ototoxicity,242,253,"Auditory deterioration and improvement, demonstrated serially in individual patients receiving and not receiving deferoxamine, respectively, provided convincing evidence for a cause-and-effect relation between deferoxamine administration and ototoxicity.",3503576_6,1
11933,Auditory deterioration,0,22,"Auditory deterioration and improvement, demonstrated serially in individual patients receiving and not receiving deferoxamine, respectively, provided convincing evidence for a cause-and-effect relation between deferoxamine administration and ototoxicity.",3503576_6,1
2890,deferoxamine,210,222,"Auditory deterioration and improvement, demonstrated serially in individual patients receiving and not receiving deferoxamine, respectively, provided convincing evidence for a cause-and-effect relation between deferoxamine administration and ototoxicity.",3503576_6,0
2889,deferoxamine,113,125,"Auditory deterioration and improvement, demonstrated serially in individual patients receiving and not receiving deferoxamine, respectively, provided convincing evidence for a cause-and-effect relation between deferoxamine administration and ototoxicity.",3503576_6,0
2891,deferoxamine,105,117,"Based on these data, a plan of management was developed that allows effective yet safe administration of deferoxamine.",3503576_7,0
11934,audiogram abnormalities,51,74,A dose of 50 mg/kg is recommended in those without audiogram abnormalities.,3503576_8,1
11937,netilmicin,34,44,Relative efficacy and toxicity of netilmicin and tobramycin in oncology patients.,3535719_0,0
2895,piperacillin sodium,114,133,We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe infections.,3535719_1,0
2894,tobramycin sulfate,75,93,We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe infections.,3535719_1,0
11938,netilmicin,53,63,We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe infections.,3535719_1,0
11940,Nephrotoxicity,0,14,Nephrotoxicity occurred in a similar proportion in patients treated with netilmicin and tobramycin (17% vs 11%).,3535719_3,1
11941,netilmicin,73,83,Nephrotoxicity occurred in a similar proportion in patients treated with netilmicin and tobramycin (17% vs 11%).,3535719_3,0
11942,netilmicin,42,52,Ototoxicity occurred in four (9.5%) of 42 netilmicin and piperacillin and in 12 (22%) of 54 tobramycin and piperacillin-treated patients.,3535719_4,0
6496,Ototoxicity,0,11,Ototoxicity occurred in four (9.5%) of 42 netilmicin and piperacillin and in 12 (22%) of 54 tobramycin and piperacillin-treated patients.,3535719_4,1
11944,netilmicin,62,72,"Of those evaluated with posttherapy audiograms, three of four netilmicin and piperacillin-treated patients had auditory thresholds return to baseline compared with one of nine tobramycin and piperacillin-treated patients.",3535719_5,0
11946,netilmicin,194,204,The number of greater than or equal to 15-dB increases in auditory threshold as a proportion of total greater than or equal to 15-dB changes (increases and decreases) was significantly lower in netilmicin and piperacillin- vs tobramycin and piperacillin-treated patients (18 of 78 vs 67 of 115).,3535719_6,0
11947,netilmicin,102,112,We conclude that aminoglycoside-associated ototoxicity was less severe and more often reversible with netilmicin than with tobramycin.,3535719_7,0
6497,ototoxicity,43,54,We conclude that aminoglycoside-associated ototoxicity was less severe and more often reversible with netilmicin than with tobramycin.,3535719_7,1
11948,Lidocaine-induced cardiac asystole,0,34,Lidocaine-induced cardiac asystole.,354896_0,0
2896,nodal,172,177,Intravenous administration of a single 50-mg bolus of lidocaine in a 67-year-old man resulted in profound depression of the activity of the sinoatrial and atrioventricular nodal pacemakers.,354896_1,0
6498,sinoatrial,140,150,Intravenous administration of a single 50-mg bolus of lidocaine in a 67-year-old man resulted in profound depression of the activity of the sinoatrial and atrioventricular nodal pacemakers.,354896_1,1
11949,profound depression,97,116,Intravenous administration of a single 50-mg bolus of lidocaine in a 67-year-old man resulted in profound depression of the activity of the sinoatrial and atrioventricular nodal pacemakers.,354896_1,1
11950,associated conditions,28,49,"The patient had no apparent associated conditions which might have predisposed him to the development of bradyarrhythmias; and, thus, this probably represented a true idiosyncrasy to lidocaine.",354896_2,1
11951,true idiosyncrasy,162,179,"The patient had no apparent associated conditions which might have predisposed him to the development of bradyarrhythmias; and, thus, this probably represented a true idiosyncrasy to lidocaine.",354896_2,1
6499,bradyarrhythmias,105,121,"The patient had no apparent associated conditions which might have predisposed him to the development of bradyarrhythmias; and, thus, this probably represented a true idiosyncrasy to lidocaine.",354896_2,1
6500,juvenile rheumatoid arthritis,33,62,Flurbiprofen in the treatment of juvenile rheumatoid arthritis.,3560095_0,1
6501,juvenile rheumatoid arthritis,26,55,"Thirty-four patients with juvenile rheumatoid arthritis, who were treated with flurbiprofen at a maximum dose of 4 mg/kg/day, had statistically significant decreases from baseline in 6 arthritis indices after 12 weeks of treatment.",3560095_1,1
11954,tender joints,40,53,"Improvements were seen in the number of tender joints, the severity of swelling and tenderness, the time of walk 50 feet, the duration of morning stiffness and the circumference of the left knee.",3560095_2,1
11955,morning stiffness,138,155,"Improvements were seen in the number of tender joints, the severity of swelling and tenderness, the time of walk 50 feet, the duration of morning stiffness and the circumference of the left knee.",3560095_2,1
6502,side effect,29,40,"The most frequently observed side effect was fecal occult blood (25% of patients); however, there was no other evidence of gastrointestinal (GI) bleeding in these patients.",3560095_3,1
11958,gastrointestinal (GI) bleeding,123,153,"The most frequently observed side effect was fecal occult blood (25% of patients); however, there was no other evidence of gastrointestinal (GI) bleeding in these patients.",3560095_3,1
6503,abdominal pain,80,94,One patient was prematurely discontinued from the study for severe headache and abdominal pain.,3560095_4,1
6504,side effects,5,17,Most side effects were mild and related to the GI tract.,3560095_5,1
11959,GI tract,47,55,Most side effects were mild and related to the GI tract.,3560095_5,1
2897,nonsteroidal antiinflammatory agents,63,99,Hyperkalemia has recently been recognized as a complication of nonsteroidal antiinflammatory agents (NSAID) such as indomethacin.,3560096_1,0
2898,prostacyclin,122,134,"Several recent studies have stressed the renal sparing features of sulindac, owing to its lack of interference with renal prostacyclin synthesis.",3560096_2,0
11966,adverse renal effects,92,113,These observations indicate that initial hopes that sulindac may not be associated with the adverse renal effects of other NSAID are probably not justified.,3560096_6,1
6505,Drug-induced,0,12,Drug-induced arterial spasm relieved by lidocaine.,3564823_0,1
11967,arterial spasm,13,27,Drug-induced arterial spasm relieved by lidocaine.,3564823_0,1
11971,cerebral ischaemia,114,132,"Following major intracranial surgery in a 35-year-old man, sodium pentothal was intravenously infused to minimize cerebral ischaemia.",3564823_2,1
11969,intracranial surgery,16,36,"Following major intracranial surgery in a 35-year-old man, sodium pentothal was intravenously infused to minimize cerebral ischaemia.",3564823_2,1
11970,sodium pentothal,59,75,"Following major intracranial surgery in a 35-year-old man, sodium pentothal was intravenously infused to minimize cerebral ischaemia.",3564823_2,0
6506,vasospasm,8,17,Intense vasospasm with threatened gangrene arose in the arm used for the infusion.,3564823_3,1
6507,vasospasm,161,170,"Since the cranial condition precluded use of more usual methods, lidocaine was given intra-arterially, with careful cardiovascular monitoring, to counteract the vasospasm.",3564823_4,1
2899,Calcitonin receptors,0,20,"Calcitonin receptors are found in the brain, and intracerebral infusions of calcitonin can produce behavioral effects.",3615541_1,0
11977,food intake,51,62,In previous experiments we found that decreases in food intake were induced by local administration of calcitonin into several hypothalamic sites and into the nucleus accumbens.,3615541_3,1
11978,nucleus accumbens,159,176,In previous experiments we found that decreases in food intake were induced by local administration of calcitonin into several hypothalamic sites and into the nucleus accumbens.,3615541_3,1
11984,cefazedone,41,51,The hematologic effects of cefonicid and cefazedone in the dog: a potential model of cephalosporin hematotoxicity in man.,3629586_0,0
11985,hematotoxicity,99,113,The hematologic effects of cefonicid and cefazedone in the dog: a potential model of cephalosporin hematotoxicity in man.,3629586_0,1
2900,cefonicid,27,36,The hematologic effects of cefonicid and cefazedone in the dog: a potential model of cephalosporin hematotoxicity in man.,3629586_0,0
2901,Cephalosporin antibiotics,0,25,"Cephalosporin antibiotics cause a variety of hematologic disturbances in man, the pathogeneses and hematopathology of which remain poorly characterized.",3629586_1,0
11986,hematologic disturbances,45,69,"Cephalosporin antibiotics cause a variety of hematologic disturbances in man, the pathogeneses and hematopathology of which remain poorly characterized.",3629586_1,1
11987,pathogeneses,82,94,"Cephalosporin antibiotics cause a variety of hematologic disturbances in man, the pathogeneses and hematopathology of which remain poorly characterized.",3629586_1,0
11988,hematopathology,99,114,"Cephalosporin antibiotics cause a variety of hematologic disturbances in man, the pathogeneses and hematopathology of which remain poorly characterized.",3629586_1,1
11989,blood dyscrasias,63,79,There is a need for a well-defined animal model in which these blood dyscrasias can be studied.,3629586_2,1
11992,cefazedone,82,92,"In four subacute toxicity studies, the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose-dependent incidence of anemia, neutropenia, and thrombocytopenia after 1-3 months of treatment.",3629586_3,0
2902,cefonicid,69,78,"In four subacute toxicity studies, the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose-dependent incidence of anemia, neutropenia, and thrombocytopenia after 1-3 months of treatment.",3629586_3,0
2903,cefonicid,135,144,A nonregenerative anemia was the most compromising of the cytopenias and occurred in approximately 50% of dogs receiving 400-500 mg/kg cefonicid or 540-840 mg/kg cefazedone.,3629586_4,0
11996,cefazedone,162,172,A nonregenerative anemia was the most compromising of the cytopenias and occurred in approximately 50% of dogs receiving 400-500 mg/kg cefonicid or 540-840 mg/kg cefazedone.,3629586_4,0
11995,nonregenerative anemia,2,24,A nonregenerative anemia was the most compromising of the cytopenias and occurred in approximately 50% of dogs receiving 400-500 mg/kg cefonicid or 540-840 mg/kg cefazedone.,3629586_4,1
11997,erythron,120,128,All three cytopenias were completely reversible following cessation of treatment; the time required for recovery of the erythron (approximately 1 month) was considerably longer than that of the granulocytes and platelets (hours to a few days).,3629586_5,0
2904,cefonicid,105,114,"Upon rechallenge with either cephalosporin, the hematologic syndrome was reproduced in most dogs tested; cefonicid (but not cefazedone)-treated dogs showed a substantially reduced induction period (15 +/- 5 days) compared to that of the first exposure to the drug (61 +/- 24 days).",3629586_6,0
11998,rechallenge,5,16,"Upon rechallenge with either cephalosporin, the hematologic syndrome was reproduced in most dogs tested; cefonicid (but not cefazedone)-treated dogs showed a substantially reduced induction period (15 +/- 5 days) compared to that of the first exposure to the drug (61 +/- 24 days).",3629586_6,0
12000,/- 5,202,206,"Upon rechallenge with either cephalosporin, the hematologic syndrome was reproduced in most dogs tested; cefonicid (but not cefazedone)-treated dogs showed a substantially reduced induction period (15 +/- 5 days) compared to that of the first exposure to the drug (61 +/- 24 days).",3629586_6,0
11999,hematologic syndrome,48,68,"Upon rechallenge with either cephalosporin, the hematologic syndrome was reproduced in most dogs tested; cefonicid (but not cefazedone)-treated dogs showed a substantially reduced induction period (15 +/- 5 days) compared to that of the first exposure to the drug (61 +/- 24 days).",3629586_6,1
2905,red cell,58,66,"This observation, along with the rapid rate of decline in red cell mass parameters of affected dogs, suggests that a hemolytic component complicated the red cell production problem and that multiple toxicologic mechanisms contributed to the cytopenia.",3629586_7,0
12008,blood dyscrasias,148,164,We conclude that the administration of high doses of cefonicid or cefazedone to dogs can induce hematotoxicity similar to the cephalosporin-induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders.,3629586_8,1
12007,hematotoxicity,96,110,We conclude that the administration of high doses of cefonicid or cefazedone to dogs can induce hematotoxicity similar to the cephalosporin-induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders.,3629586_8,1
12006,cefazedone,66,76,We conclude that the administration of high doses of cefonicid or cefazedone to dogs can induce hematotoxicity similar to the cephalosporin-induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders.,3629586_8,0
2906,cefonicid,53,62,We conclude that the administration of high doses of cefonicid or cefazedone to dogs can induce hematotoxicity similar to the cephalosporin-induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders.,3629586_8,0
12005,high doses,39,49,We conclude that the administration of high doses of cefonicid or cefazedone to dogs can induce hematotoxicity similar to the cephalosporin-induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders.,3629586_8,0
12016,2-bromoethylamine,217,234,"Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.",3653576_1,0
12015,HCBD,173,177,"Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.",3653576_1,0
12012,proximal tubular,49,65,"Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.",3653576_1,1
12011,renal damage,29,41,"Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.",3653576_1,1
2907,puromycin aminonucleoside,180,205,"Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.",3653576_1,0
12017,BEA,236,239,"Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.",3653576_1,1
12014,hexachloro-1:3-butadiene,147,171,"Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively.",3653576_1,0
12020,alkaline phosphatase,58,78,"Several routine indicators of nephrotoxicity, the enzymes alkaline phosphatase and N-acetyl-beta-glucosaminidase, and the molecular weight of protein excretion were determined on urine samples.",3653576_2,0
12022,molecular weight,122,138,"Several routine indicators of nephrotoxicity, the enzymes alkaline phosphatase and N-acetyl-beta-glucosaminidase, and the molecular weight of protein excretion were determined on urine samples.",3653576_2,0
12021,N-acetyl-beta-glucosaminidase,83,112,"Several routine indicators of nephrotoxicity, the enzymes alkaline phosphatase and N-acetyl-beta-glucosaminidase, and the molecular weight of protein excretion were determined on urine samples.",3653576_2,0
12019,nephrotoxicity,30,44,"Several routine indicators of nephrotoxicity, the enzymes alkaline phosphatase and N-acetyl-beta-glucosaminidase, and the molecular weight of protein excretion were determined on urine samples.",3653576_2,1
12023,Tubular damage,0,14,Tubular damage produced by HCBD or BEA was discriminated both quantitatively and qualitatively from glomerular damage produced by PAN.,3653576_3,1
12026,glomerular damage,100,117,Tubular damage produced by HCBD or BEA was discriminated both quantitatively and qualitatively from glomerular damage produced by PAN.,3653576_3,1
12025,BEA,35,38,Tubular damage produced by HCBD or BEA was discriminated both quantitatively and qualitatively from glomerular damage produced by PAN.,3653576_3,1
12027,molecular weight,101,117,"The latter was characterized by a pronounced increase in protein excretion, especially proteins with molecular weight greater than 40,000 Da.",3653576_4,0
12029,molecular weights,136,153,"In contrast, protein excretion in tubular damage was raised only slightly and characterized by excretion of proteins of a wide range of molecular weights.",3653576_5,0
12028,tubular damage,34,48,"In contrast, protein excretion in tubular damage was raised only slightly and characterized by excretion of proteins of a wide range of molecular weights.",3653576_5,1
12032,papillary damage,43,59,Proximal tubular damage caused by HCBD and papillary damage caused by BEA were distinguished both by conventional urinalysis (volume and specific gravity) and by measurement of the two urinary enzymes.,3653576_6,1
12030,Proximal tubular damage,0,23,Proximal tubular damage caused by HCBD and papillary damage caused by BEA were distinguished both by conventional urinalysis (volume and specific gravity) and by measurement of the two urinary enzymes.,3653576_6,1
12033,BEA,70,73,Proximal tubular damage caused by HCBD and papillary damage caused by BEA were distinguished both by conventional urinalysis (volume and specific gravity) and by measurement of the two urinary enzymes.,3653576_6,1
12035,Alkaline phosphatase,0,20,Alkaline phosphatase and glucose were markedly and transiently elevated in proximal tubular damage and N-acetyl-beta-glucosaminidase showed a sustained elevation in papillary damage.,3653576_7,0
12036,proximal tubular damage,75,98,Alkaline phosphatase and glucose were markedly and transiently elevated in proximal tubular damage and N-acetyl-beta-glucosaminidase showed a sustained elevation in papillary damage.,3653576_7,1
12037,N-acetyl-beta-glucosaminidase,103,132,Alkaline phosphatase and glucose were markedly and transiently elevated in proximal tubular damage and N-acetyl-beta-glucosaminidase showed a sustained elevation in papillary damage.,3653576_7,0
12038,papillary damage,165,181,Alkaline phosphatase and glucose were markedly and transiently elevated in proximal tubular damage and N-acetyl-beta-glucosaminidase showed a sustained elevation in papillary damage.,3653576_7,1
12041,renal damage,178,190,It is concluded that both selective urinary enzymes and the molecular weight pattern of urinary proteins can be used to provide diagnostic information about the possible site of renal damage.,3653576_8,1
6508,Reye syndrome,20,33,"Twenty-six cases of Reye syndrome from The Children's Hospital, Camperdown, Australia, occurring between 1973 and 1982 were reviewed.",3670965_1,1
6509,Reye syndrome,110,123,"Of these, 20 cases met the US Public Health Service Centers for Disease Control criteria for the diagnosis of Reye syndrome.",3670965_2,1
2908,paracetamol,83,94,"Aspirin or salicylate ingestion had occurred in only one of the 20 cases (5%), and paracetamol (acetaminophen) had been administered in only six of the cases (30%).",3670965_3,0
6510,Reye syndrome,44,57,Pathologic confirmation of the diagnosis of Reye syndrome was accomplished in 90% of the cases.,3670965_4,1
6511,Reye syndrome,17,30,"The incidence of Reye syndrome in New South Wales, Australia, is estimated from this study to be approximately nine cases per 1 million children compared with recent US data of ten to 20 cases per 1 million children and three to seven cases per 1 million children in Great Britain.",3670965_5,1
6512,Reye syndrome,24,37,The mortality for these Reye syndrome cases in Australia was 45% as compared with a 32% case-fatality rate in the United States.,3670965_6,1
2909,paracetamol,138,149,"In Australia, the pediatric usage of aspirin has been extremely low for the past 25 years (less than 1% of total dosage units sold), with paracetamol (acetaminophen) dominating the pediatric analgesic and antipyretic market.",3670965_7,0
6513,Reye syndrome,0,13,"Reye syndrome may be disappearing from Australia despite a total lack of association with salicylates or aspirin ingestion, since there were no cases found at The Children's Hospital in 1983, 1984, or 1985.",3670965_8,1
12049,Cerebral blood flow,0,19,Cerebral blood flow and metabolism during isoflurane-induced hypotension in patients subjected to surgery for cerebral aneurysms.,3676049_0,1
6514,cerebral aneurysms,110,128,Cerebral blood flow and metabolism during isoflurane-induced hypotension in patients subjected to surgery for cerebral aneurysms.,3676049_0,1
6515,cerebral aneurysm,168,185,Cerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane-induced hypotension in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm.,3676049_1,1
6516,subarachnoid,54,66,Flow and metabolism were measured 5-13 days after the subarachnoid haemorrhage by a modification of the classical Kety-Schmidt technique using xenon-133 i.v.,3676049_2,1
2910,nitrous oxide,88,101,"Anaesthesia was maintained with an inspired isoflurane concentration of 0.75% (plus 67% nitrous oxide in oxygen), during which CBF and CMRO2 were 34.3 +/- 2.1 ml/100 g min-1 and 2.32 +/- 0.16 ml/100 g min-1 at PaCO2 4.1 +/- 0.1 kPa (mean +/- SEM).",3676049_3,0
12056,CMRO2,135,140,"Anaesthesia was maintained with an inspired isoflurane concentration of 0.75% (plus 67% nitrous oxide in oxygen), during which CBF and CMRO2 were 34.3 +/- 2.1 ml/100 g min-1 and 2.32 +/- 0.16 ml/100 g min-1 at PaCO2 4.1 +/- 0.1 kPa (mean +/- SEM).",3676049_3,0
12061,PaCO2,210,215,"Anaesthesia was maintained with an inspired isoflurane concentration of 0.75% (plus 67% nitrous oxide in oxygen), during which CBF and CMRO2 were 34.3 +/- 2.1 ml/100 g min-1 and 2.32 +/- 0.16 ml/100 g min-1 at PaCO2 4.1 +/- 0.1 kPa (mean +/- SEM).",3676049_3,0
12055,CBF,127,130,"Anaesthesia was maintained with an inspired isoflurane concentration of 0.75% (plus 67% nitrous oxide in oxygen), during which CBF and CMRO2 were 34.3 +/- 2.1 ml/100 g min-1 and 2.32 +/- 0.16 ml/100 g min-1 at PaCO2 4.1 +/- 0.1 kPa (mean +/- SEM).",3676049_3,0
12063,Controlled hypotension,0,22,"Controlled hypotension to an average MAP of 50-55 mm Hg was induced by increasing the dose of isoflurane, and maintained at an inspired concentration of 2.2 +/- 0.2%.",3676049_4,1
12069,CBF,90,93,"This resulted in a significant decrease in CMRO2 (to 1.73 +/- 0.16 ml/100 g min-1), while CBF was unchanged.",3676049_5,0
12068,ml/100 g min-1,67,81,"This resulted in a significant decrease in CMRO2 (to 1.73 +/- 0.16 ml/100 g min-1), while CBF was unchanged.",3676049_5,0
12067,/-,59,61,"This resulted in a significant decrease in CMRO2 (to 1.73 +/- 0.16 ml/100 g min-1), while CBF was unchanged.",3676049_5,0
12066,CMRO2,43,48,"This resulted in a significant decrease in CMRO2 (to 1.73 +/- 0.16 ml/100 g min-1), while CBF was unchanged.",3676049_5,0
12070,CBF,36,39,"There was a significant increase in CBF, although CMRO2 was unchanged, compared with pre-hypotensive values.",3676049_7,0
12071,CMRO2,50,55,"There was a significant increase in CBF, although CMRO2 was unchanged, compared with pre-hypotensive values.",3676049_7,0
2911,bromocriptine,32,45,Postpartum psychosis induced by bromocriptine.,3686155_0,0
12074,Postpartum psychosis,0,20,Postpartum psychosis induced by bromocriptine.,3686155_0,1
2912,bromocriptine,113,126,"Two multigravida patients with no prior psychiatric history were seen with postpartum psychosis, having received bromocriptine for inhibition of lactation.",3686155_1,0
12077,postpartum psychosis,75,95,"Two multigravida patients with no prior psychiatric history were seen with postpartum psychosis, having received bromocriptine for inhibition of lactation.",3686155_1,1
12076,psychiatric history,40,59,"Two multigravida patients with no prior psychiatric history were seen with postpartum psychosis, having received bromocriptine for inhibition of lactation.",3686155_1,1
12075,multigravida,4,16,"Two multigravida patients with no prior psychiatric history were seen with postpartum psychosis, having received bromocriptine for inhibition of lactation.",3686155_1,1
6517,Parkinson's disease,104,123,Bromocriptine given in high doses has been associated with psychosis in patients receiving the drug for Parkinson's disease.,3686155_2,1
12078,high doses,23,33,Bromocriptine given in high doses has been associated with psychosis in patients receiving the drug for Parkinson's disease.,3686155_2,0
2913,Bromocriptine,0,13,Bromocriptine given in high doses has been associated with psychosis in patients receiving the drug for Parkinson's disease.,3686155_2,0
12080,low doses,82,91,These cases demonstrate that bromocriptine may cause psychosis even when given in low doses.,3686155_3,0
2914,bromocriptine,29,42,These cases demonstrate that bromocriptine may cause psychosis even when given in low doses.,3686155_3,0
12082,secondary mania,36,51,Triazolam-induced brief episodes of secondary mania in a depressed patient.,3693336_0,1
12084,brief episodes,44,58,Large doses of triazolam repeatedly induced brief episodes of mania in a depressed elderly woman.,3693336_1,1
12085,depressed elderly,73,90,Large doses of triazolam repeatedly induced brief episodes of mania in a depressed elderly woman.,3693336_1,1
12086,organic mental disorder,12,35,Features of organic mental disorder (delirium) were not present.,3693336_2,1
12087,Manic excitement,0,16,Manic excitement was coincident with the duration of action of triazolam.,3693336_3,1
12090,Hyperglycemic acidotic coma,0,27,Hyperglycemic acidotic coma and death in Kearns-Sayre syndrome.,3703509_0,1
6518,Kearns-Sayre syndrome,41,62,Hyperglycemic acidotic coma and death in Kearns-Sayre syndrome.,3703509_0,1
6519,Kearns-Sayre syndrome,93,114,This paper presents the clinical and metabolic findings in two young boys with long-standing Kearns-Sayre syndrome.,3703509_1,1
12092,oral prednisone,28,43,"Following short exposure to oral prednisone, both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria.",3703509_2,0
12091,short exposure,10,24,"Following short exposure to oral prednisone, both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria.",3703509_2,1
6520,polyphagia,110,120,"Following short exposure to oral prednisone, both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria.",3703509_2,1
12095,Nonketotic lactic acidosis,0,26,Nonketotic lactic acidosis was present in one and ketosis without a known serum lactate level was present in the other.,3703509_4,1
6521,Respiratory failure,0,19,Respiratory failure rapidly ensued and both patients expired in spite of efforts at resuscitation.,3703509_5,1
6522,Kearns-Sayre syndrome,107,128,We believe these two cases represent a newly described and catastrophic metabolic-endocrine failure in the Kearns-Sayre syndrome.,3703509_6,1
12097,metabolic-endocrine failure,72,99,We believe these two cases represent a newly described and catastrophic metabolic-endocrine failure in the Kearns-Sayre syndrome.,3703509_6,1
12098,cyclosporine nephrotoxicity,13,40,Experimental cyclosporine nephrotoxicity: risk of concomitant chemotherapy.,3708922_0,1
12100,chemotherapeutics,68,85,The role of cyclosporine (CSA) alone or in combination with various chemotherapeutics in the development of renal toxicity was evaluated in rats.,3708922_1,0
12101,renal toxicity,108,122,The role of cyclosporine (CSA) alone or in combination with various chemotherapeutics in the development of renal toxicity was evaluated in rats.,3708922_1,1
12099,CSA,26,29,The role of cyclosporine (CSA) alone or in combination with various chemotherapeutics in the development of renal toxicity was evaluated in rats.,3708922_1,0
2915,cyclosporine,12,24,The role of cyclosporine (CSA) alone or in combination with various chemotherapeutics in the development of renal toxicity was evaluated in rats.,3708922_1,0
12102,CSA,31,34,Administration of 20 mg/kg/day CSA for 4 weeks caused renal functional and structural changes similar to those reported in man.,3708922_2,1
12104,CSA,31,34,"The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.",3708922_3,1
12105,chemotherapeutic drugs,47,69,"The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.",3708922_3,0
12107,therapeutic doses,123,140,"The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.",3708922_3,0
12108,amphothericin B,143,158,"The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.",3708922_3,0
12110,CSA,255,258,"The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.",3708922_3,0
12109,ketoconazole,163,175,"The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model.",3708922_3,0
12111,toxic doses,14,25,"Gentamicin at toxic doses, however, increased CSA nephrotoxicity.",3708922_4,0
12112,CSA,46,49,"Gentamicin at toxic doses, however, increased CSA nephrotoxicity.",3708922_4,0
12113,nephrotoxicity,50,64,"Gentamicin at toxic doses, however, increased CSA nephrotoxicity.",3708922_4,1
12114,nephrotoxicity,10,24,"Thus, the nephrotoxicity induced by CSA has a different pathogenetic mechanism.",3708922_5,1
12115,CSA,36,39,"Thus, the nephrotoxicity induced by CSA has a different pathogenetic mechanism.",3708922_5,1
6523,neuropathic,75,86,The correlation between neurotoxic esterase inhibition and mipafox-induced neuropathic damage in rats.,3714122_0,1
2916,esterase,35,43,The correlation between neurotoxic esterase inhibition and mipafox-induced neuropathic damage in rats.,3714122_0,0
2917,esterase,72,80,"The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.",3714122_1,0
6524,neuropathic,24,35,"The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.",3714122_1,1
12118,Mipafox,155,162,"The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.",3714122_1,0
12117,NTE,110,113,"The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic organophosphate.",3714122_1,0
12121,Mipafox,116,123,"Brain and spinal cord NTE activities were measured in Long-Evans male rats 1 hr post-exposure to various dosages of Mipafox (ip, 1-15 mg/kg).",3714122_2,0
12124,post-exposure,138,151,These data were correlated with histologically scored cervical cord damage in a separate group of similarly dosed rats sampled 14-21 days post-exposure.,3714122_3,1
12123,cervical cord damage,54,74,These data were correlated with histologically scored cervical cord damage in a separate group of similarly dosed rats sampled 14-21 days post-exposure.,3714122_3,1
6525,spinal cord,90,101,Those dosages (greater than or equal to 10 mg/kg) that inhibited mean NTE activity in the spinal cord greater than or equal to 73% and brain greater than or equal to 67% of control values produced severe (greater than or equal to 3) cervical cord pathology in 85% of the rats.,3714122_4,1
12126,cervical cord,233,246,Those dosages (greater than or equal to 10 mg/kg) that inhibited mean NTE activity in the spinal cord greater than or equal to 73% and brain greater than or equal to 67% of control values produced severe (greater than or equal to 3) cervical cord pathology in 85% of the rats.,3714122_4,1
12125,NTE,70,73,Those dosages (greater than or equal to 10 mg/kg) that inhibited mean NTE activity in the spinal cord greater than or equal to 73% and brain greater than or equal to 67% of control values produced severe (greater than or equal to 3) cervical cord pathology in 85% of the rats.,3714122_4,0
12127,Mipafox,24,31,"In contrast, dosages of Mipafox (less than or equal to 5 mg/kg) which inhibited mean NTE activity in spinal cord less than or equal to 61% and brain less than or equal to 60% produced this degree of cord damage in only 9% of the animals.",3714122_5,0
12128,NTE,85,88,"In contrast, dosages of Mipafox (less than or equal to 5 mg/kg) which inhibited mean NTE activity in spinal cord less than or equal to 61% and brain less than or equal to 60% produced this degree of cord damage in only 9% of the animals.",3714122_5,0
12130,cord damage,199,210,"In contrast, dosages of Mipafox (less than or equal to 5 mg/kg) which inhibited mean NTE activity in spinal cord less than or equal to 61% and brain less than or equal to 60% produced this degree of cord damage in only 9% of the animals.",3714122_5,1
6526,spinal cord,101,112,"In contrast, dosages of Mipafox (less than or equal to 5 mg/kg) which inhibited mean NTE activity in spinal cord less than or equal to 61% and brain less than or equal to 60% produced this degree of cord damage in only 9% of the animals.",3714122_5,1
12132,Mipafox,112,119,These data indicate that a critical percentage of NTE inhibition in brain and spinal cord sampled shortly after Mipafox exposure can predict neuropathic damage in rats several weeks later.,3714122_6,0
6528,neuropathic,141,152,These data indicate that a critical percentage of NTE inhibition in brain and spinal cord sampled shortly after Mipafox exposure can predict neuropathic damage in rats several weeks later.,3714122_6,1
12131,NTE,50,53,These data indicate that a critical percentage of NTE inhibition in brain and spinal cord sampled shortly after Mipafox exposure can predict neuropathic damage in rats several weeks later.,3714122_6,0
6527,spinal cord,78,89,These data indicate that a critical percentage of NTE inhibition in brain and spinal cord sampled shortly after Mipafox exposure can predict neuropathic damage in rats several weeks later.,3714122_6,1
6529,Allergic reaction,0,17,Allergic reaction to 5-fluorouracil infusion.,3719553_0,1
12133,5-fluorouracil,21,35,Allergic reaction to 5-fluorouracil infusion.,3719553_0,0
12134,5-fluorouracil,88,102,"An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.",3719553_1,0
6530,allergic reaction,3,20,"An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.",3719553_1,1
6531,angioneurotic edema,35,54,"An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.",3719553_1,1
12136,oral cavity,157,168,"An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.",3719553_1,1
12138,renal function,212,226,"An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.",3719553_1,1
12135,recurrent carcinoma,130,149,"An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function.",3719553_1,1
6532,allergic reaction,89,106,Oral diphenhydramine and prednisone were ineffective in preventing the recurrence of the allergic reaction.,3719553_3,1
12139,Oral diphenhydramine,0,20,Oral diphenhydramine and prednisone were ineffective in preventing the recurrence of the allergic reaction.,3719553_3,0
6533,disease progression,100,119,Discontinuance of effective chemotherapy in this patient during partial remission resulted in fatal disease progression.,3719553_4,1
12140,partial remission,64,81,Discontinuance of effective chemotherapy in this patient during partial remission resulted in fatal disease progression.,3719553_4,1
6534,coronary disease,53,69,"Diuretics, potassium and arrhythmias in hypertensive coronary disease.",3732088_0,1
6535,cardiac arrhythmias,92,111,It has been proposed that modest changes in plasma potassium can alter the tendency towards cardiac arrhythmias.,3732088_1,1
6536,coronary artery disease,31,54,"If this were so, patients with coronary artery disease might be especially susceptible.",3732088_2,1
2918,amiloride,198,207,"Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.",3732088_3,0
6538,coronary artery disease,109,132,"Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.",3732088_3,1
6537,essential hypertension,76,98,"Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.",3732088_3,1
12142,myocardial electrical excitability,6,40,"Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.",3732088_3,1
12143,potassium-conserving diuretic,167,196,"Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study.",3732088_3,0
2919,amiloride,107,116,Plasma potassium concentrations were on average 1 mmol/L lower during the chlorthalidone phase compared to amiloride therapy.,3732088_4,0
6539,Blood pressure,0,14,"Blood pressure and volume states as assessed by bodyweight, plasma renin and noradrenaline (norepinephrine) concentrations were similar on the 2 regimens.",3732088_5,1
6540,bodyweight,48,58,"Blood pressure and volume states as assessed by bodyweight, plasma renin and noradrenaline (norepinephrine) concentrations were similar on the 2 regimens.",3732088_5,1
2920,amiloride,12,21,"Compared to amiloride treatment, the chlorthalidone phase was associated with an increased frequency of ventricular ectopic beats (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation.",3732088_6,0
6541,ventricular ectopic beats,104,129,"Compared to amiloride treatment, the chlorthalidone phase was associated with an increased frequency of ventricular ectopic beats (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation.",3732088_6,1
12149,monophasic,223,233,"Compared to amiloride treatment, the chlorthalidone phase was associated with an increased frequency of ventricular ectopic beats (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation.",3732088_6,0
12152,electrical instability,317,339,"Compared to amiloride treatment, the chlorthalidone phase was associated with an increased frequency of ventricular ectopic beats (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation.",3732088_6,1
12153,ventricular stimulation,358,381,"Compared to amiloride treatment, the chlorthalidone phase was associated with an increased frequency of ventricular ectopic beats (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation.",3732088_6,1
6542,heart disease,149,162,"The above results indicate that because potassium-losing diuretic therapy can increase myocardial electrical excitability in patients with ischaemic heart disease, even minor falls in plasma potassium concentrations are probably best avoided in such patients.",3732088_7,1
12154,myocardial electrical excitability,87,121,"The above results indicate that because potassium-losing diuretic therapy can increase myocardial electrical excitability in patients with ischaemic heart disease, even minor falls in plasma potassium concentrations are probably best avoided in such patients.",3732088_7,1
6544,rheumatoid arthritis,70,90,Myasthenia gravis caused by penicillamine and chloroquine therapy for rheumatoid arthritis.,3750012_0,1
6543,Myasthenia gravis,0,17,Myasthenia gravis caused by penicillamine and chloroquine therapy for rheumatoid arthritis.,3750012_0,1
6546,rheumatoid arthritis,137,157,We have described a unique patient who had reversible and dose-related myasthenia gravis after penicillamine and chloroquine therapy for rheumatoid arthritis.,3750012_1,1
6545,myasthenia gravis,71,88,We have described a unique patient who had reversible and dose-related myasthenia gravis after penicillamine and chloroquine therapy for rheumatoid arthritis.,3750012_1,1
2921,acetylcholine receptor,9,31,"Although acetylcholine receptor antibodies were not detectable, the time course was consistent with an autoimmune process.",3750012_2,0
12158,autoimmune process,103,121,"Although acetylcholine receptor antibodies were not detectable, the time course was consistent with an autoimmune process.",3750012_2,1
6547,Wernicke's encephalopathy,48,73,Transketolase abnormality in tolazamide-induced Wernicke's encephalopathy.,3762968_0,1
2922,Transketolase,0,13,Transketolase abnormality in tolazamide-induced Wernicke's encephalopathy.,3762968_0,0
2925,thiamine pyrophosphate,250,272,"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.",3762968_1,0
2924,transketolase,211,224,"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.",3762968_1,0
2923,transketolase,40,53,"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.",3762968_1,0
6548,Wernicke's encephalopathy,108,133,"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.",3762968_1,1
12159,thiamine-dependent enzyme,13,38,"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.",3762968_1,0
12160,TPP,274,277,"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.",3762968_1,0
12161,postalcoholic Wernicke-Korsakoff syndrome,307,348,"We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome.",3762968_1,1
6549,Wernicke's encephalopathy,109,134,"In addition to this patient, we also studied this enzyme from three diabetic kindreds without any history of Wernicke's encephalopathy and from four normal controls.",3762968_2,1
2926,transketolase,133,146,We found that the above-mentioned patient and one of the diabetic kindreds with no history of Wernicke's encephalopathy had abnormal transketolase as determined by its Km for TPP.,3762968_3,0
6550,Wernicke's encephalopathy,94,119,We found that the above-mentioned patient and one of the diabetic kindreds with no history of Wernicke's encephalopathy had abnormal transketolase as determined by its Km for TPP.,3762968_3,1
12164,TPP,175,178,We found that the above-mentioned patient and one of the diabetic kindreds with no history of Wernicke's encephalopathy had abnormal transketolase as determined by its Km for TPP.,3762968_3,0
6551,Wernicke's encephalopathy,122,147,These data suggest a similarity between postalcoholic Wernicke-Korsakoff syndrome and the patient with tolazamide-induced Wernicke's encephalopathy from the standpoint of transketolase abnormality.,3762968_4,1
2927,transketolase,171,184,These data suggest a similarity between postalcoholic Wernicke-Korsakoff syndrome and the patient with tolazamide-induced Wernicke's encephalopathy from the standpoint of transketolase abnormality.,3762968_4,0
12165,postalcoholic Wernicke-Korsakoff syndrome,40,81,These data suggest a similarity between postalcoholic Wernicke-Korsakoff syndrome and the patient with tolazamide-induced Wernicke's encephalopathy from the standpoint of transketolase abnormality.,3762968_4,1
2928,trihexyphenidyl,19,34,Bradycardia due to trihexyphenidyl hydrochloride.,3769769_0,0
12167,anticholinergic drug,52,72,"A chronic schizophrenic patient was treated with an anticholinergic drug, trihexyphenidyl hydrochloride.",3769769_1,0
12168,trihexyphenidyl hydrochloride,74,103,"A chronic schizophrenic patient was treated with an anticholinergic drug, trihexyphenidyl hydrochloride.",3769769_1,0
12169,sinus bradycardia,38,55,"The patient developed, paradoxically, sinus bradycardia.",3769769_2,1
2929,trihexyphenidyl,29,44,The reaction was specific to trihexyphenidyl and not to other anticholinergic drugs.,3769769_3,0
12170,anticholinergic drugs,62,83,The reaction was specific to trihexyphenidyl and not to other anticholinergic drugs.,3769769_3,0
12171,antidyskinetic drug,5,24,This antidyskinetic drug is widely used in clinical psychiatric practice and physicians should be aware of this side effect.,3769769_4,0
6552,side effect,112,123,This antidyskinetic drug is widely used in clinical psychiatric practice and physicians should be aware of this side effect.,3769769_4,1
6553,Post-operative,0,14,Post-operative rigidity after fentanyl administration.,3780697_0,1
12174,thoraco-abdominal rigidity,10,36,A case of thoraco-abdominal rigidity leading to respiratory failure is described in the post-operative period in an elderly patient who received a moderate dose of fentanyl.,3780697_1,1
6555,post-operative,88,102,A case of thoraco-abdominal rigidity leading to respiratory failure is described in the post-operative period in an elderly patient who received a moderate dose of fentanyl.,3780697_1,1
6554,respiratory failure,48,67,A case of thoraco-abdominal rigidity leading to respiratory failure is described in the post-operative period in an elderly patient who received a moderate dose of fentanyl.,3780697_1,1
2930,Anti-carcinogenic,0,17,Anti-carcinogenic action of phenobarbital given simultaneously with diethylnitrosamine in the rat.,3780814_0,0
2931,diethylnitrosamine,68,86,Anti-carcinogenic action of phenobarbital given simultaneously with diethylnitrosamine in the rat.,3780814_0,0
6556,carcinogenesis,124,138,The present work has been planned in order to elucidate the effect of phenobarbital (PB: 15 mg per rat of ingested dose) on carcinogenesis when it is administered simultaneously with diethylnitrosamine (DEN: 10 mg/kg/day).,3780814_1,1
2932,diethylnitrosamine,183,201,The present work has been planned in order to elucidate the effect of phenobarbital (PB: 15 mg per rat of ingested dose) on carcinogenesis when it is administered simultaneously with diethylnitrosamine (DEN: 10 mg/kg/day).,3780814_1,0
12176,hepatocarcinogenesis,115,135,"Wistar rats (180 g) were treated by DEN alone or by DEN + PB during 2, 4 and 6 weeks according to our schedule for hepatocarcinogenesis.",3780814_2,1
6557,preneoplastic,80,93,"After the end of the treatment, the number and the size of induced PAS positive preneoplastic foci was significantly reduced when PB was given simultaneously with DEN for 4 and 6 weeks.",3780814_3,1
6558,micronuclei,45,56,The mitotic inhibition and the production of micronuclei normally observed after partial hepatectomy in DEN treated rats were also significantly decreased in DEN + PB treated rats.,3780814_4,1
12178,hepatectomy,89,100,The mitotic inhibition and the production of micronuclei normally observed after partial hepatectomy in DEN treated rats were also significantly decreased in DEN + PB treated rats.,3780814_4,1
6559,carcinogenesis,40,54,"It is concluded that PB, which promotes carcinogenesis when administered after the DEN treatment, reduces the carcinogen effect when given simultaneously with DEN.",3780814_7,1
6560,muscular rigidity,57,74,On the mechanisms of the development of tolerance to the muscular rigidity produced by morphine in rats.,3780846_0,1
6561,muscular rigidity,36,53,The development of tolerance to the muscular rigidity produced by morphine was studied in rats.,3780846_1,1
12187,real tolerance,32,46,"Nevertheless, there occurs some real tolerance to this effect.",3780846_10,1
2937,dopaminergic,52,64,The rapid alternations of rigidity and the signs of dopaminergic activation observed in the animals of the AS/KS group might be due to rapid shifts in the predominance of various DA-innervated structures.,3780846_11,0
6562,akinetic,255,263,Rats treated for 11 days with morphine and withdrawn for 36-40 h showed differences in the development of tolerance: about half of the animals showed a rigidity after the test dose of morphine that was not significantly less than in the controls and were akinetic (A group).,3780846_3,1
6564,hyperkinetic,144,156,"The other rats showed a strong decrease in the rigidity and the occurrence of stereotyped (S) licking and/or gnawing in presence of akinetic or hyperkinetic (K) behaviour (AS/KS group), suggesting signs of dopaminergic activation.",3780846_4,1
6563,akinetic,132,140,"The other rats showed a strong decrease in the rigidity and the occurrence of stereotyped (S) licking and/or gnawing in presence of akinetic or hyperkinetic (K) behaviour (AS/KS group), suggesting signs of dopaminergic activation.",3780846_4,1
2933,dopaminergic,206,218,"The other rats showed a strong decrease in the rigidity and the occurrence of stereotyped (S) licking and/or gnawing in presence of akinetic or hyperkinetic (K) behaviour (AS/KS group), suggesting signs of dopaminergic activation.",3780846_4,0
2934,dopaminergic,96,108,"In a further series of experiments, haloperidol (0.2 mg/kg i.p.) was used in order to block the dopaminergic activation and to estimate the real degree of the tolerance to the rigidity without any dopaminergic interference.",3780846_6,0
2935,dopaminergic,197,209,"In a further series of experiments, haloperidol (0.2 mg/kg i.p.) was used in order to block the dopaminergic activation and to estimate the real degree of the tolerance to the rigidity without any dopaminergic interference.",3780846_6,0
2936,dopaminergic,153,165,"The results suggest that rigidity, which is assumed to be due to an action of morphine in the striatum, can be antagonized by another process leading to dopaminergic activation in the striatum.",3780846_9,0
6565,rhabdomyolysis,18,32,A case of massive rhabdomyolysis following molindone administration.,3782049_0,1
6566,Rhabdomyolysis,0,14,Rhabdomyolysis is a potentially lethal syndrome that psychiatric patients seem predisposed to develop.,3782049_1,1
12190,lethal syndrome,32,47,Rhabdomyolysis is a potentially lethal syndrome that psychiatric patients seem predisposed to develop.,3782049_1,1
6567,rhabdomyolysis,83,97,"The clinical signs and symptoms, typical laboratory features, and complications of rhabdomyolysis are presented.",3782049_2,1
12192,clinical signs and symptoms,4,31,"The clinical signs and symptoms, typical laboratory features, and complications of rhabdomyolysis are presented.",3782049_2,1
6569,acute renal failure,100,119,The case of a schizophrenic patient is reported to illustrate massive rhabdomyolysis and subsequent acute renal failure following molindone administration.,3782049_3,1
6568,rhabdomyolysis,70,84,The case of a schizophrenic patient is reported to illustrate massive rhabdomyolysis and subsequent acute renal failure following molindone administration.,3782049_3,1
6571,radial nerve,30,42,Compression neuropathy of the radial nerve due to pentazocine-induced fibrous myopathy.,3800626_0,1
6570,Compression neuropathy,0,22,Compression neuropathy of the radial nerve due to pentazocine-induced fibrous myopathy.,3800626_0,1
6572,side effect,41,52,"Fibrous myopathy is a common, well-known side effect of repeated pentazocine injection.",3800626_1,1
12197,Fibrous myopathy,0,16,"Fibrous myopathy is a common, well-known side effect of repeated pentazocine injection.",3800626_1,1
12198,fibrotic muscle,39,54,"However, compression neuropathy due to fibrotic muscle affected by pentazocine-induced myopathy has not previously been reported.",3800626_2,1
6573,compression neuropathy,9,31,"However, compression neuropathy due to fibrotic muscle affected by pentazocine-induced myopathy has not previously been reported.",3800626_2,1
12204,fibrous myopathy,314,330,"In a 37-year-old woman with documented pentazocine-induced fibrous myopathy of triceps and deltoid muscles bilaterally and a three-week history of right wrist drop, electrodiagnostic examination showed a severe but partial lesion of the right radial nerve distal to the branches to the triceps, in addition to the fibrous myopathy.",3800626_3,1
12201,deltoid muscles,91,106,"In a 37-year-old woman with documented pentazocine-induced fibrous myopathy of triceps and deltoid muscles bilaterally and a three-week history of right wrist drop, electrodiagnostic examination showed a severe but partial lesion of the right radial nerve distal to the branches to the triceps, in addition to the fibrous myopathy.",3800626_3,1
6574,wrist drop,153,163,"In a 37-year-old woman with documented pentazocine-induced fibrous myopathy of triceps and deltoid muscles bilaterally and a three-week history of right wrist drop, electrodiagnostic examination showed a severe but partial lesion of the right radial nerve distal to the branches to the triceps, in addition to the fibrous myopathy.",3800626_3,1
6575,radial nerve,243,255,"In a 37-year-old woman with documented pentazocine-induced fibrous myopathy of triceps and deltoid muscles bilaterally and a three-week history of right wrist drop, electrodiagnostic examination showed a severe but partial lesion of the right radial nerve distal to the branches to the triceps, in addition to the fibrous myopathy.",3800626_3,1
12205,fibrotic lateral head,81,102,Surgery revealed the right radial nerve to be severely compressed by the densely fibrotic lateral head of the triceps.,3800626_4,1
6576,radial nerve,27,39,Surgery revealed the right radial nerve to be severely compressed by the densely fibrotic lateral head of the triceps.,3800626_4,1
12206,neurolysis,18,28,Decompression and neurolysis were performed with good subsequent recovery of function.,3800626_5,1
6577,acute renal failure,21,40,Recurrent reversible acute renal failure from amphotericin.,3827439_0,1
6578,cryptogenic,15,26,A patient with cryptogenic cirrhosis and disseminated sporotrichosis developed acute renal failure immediately following the administration of amphotericin B on four separate occasions.,3827439_1,1
6579,acute renal failure,79,98,A patient with cryptogenic cirrhosis and disseminated sporotrichosis developed acute renal failure immediately following the administration of amphotericin B on four separate occasions.,3827439_1,1
12207,amphotericin B,143,157,A patient with cryptogenic cirrhosis and disseminated sporotrichosis developed acute renal failure immediately following the administration of amphotericin B on four separate occasions.,3827439_1,0
6580,renal failure,22,35,The abruptness of the renal failure and its reversibility within days suggests that there was a functional component to the renal dysfunction.,3827439_2,1
12208,renal dysfunction,124,141,The abruptness of the renal failure and its reversibility within days suggests that there was a functional component to the renal dysfunction.,3827439_2,1
6581,acute renal failure,147,166,"We propose that amphotericin, in the setting of reduced effective arterial volume, may activate tubuloglomerular feedback, thereby contributing to acute renal failure.",3827439_3,1
6582,Cerebral infarction,0,19,Cerebral infarction with a single oral dose of phenylpropanolamine.,3828020_0,1
12211,oral dose,34,43,Cerebral infarction with a single oral dose of phenylpropanolamine.,3828020_0,0
12213,cold preparations,168,185,"Phenylpropanolamine (PPA), a synthetic sympathomimetic that is structurally similar to amphetamine, is available over the counter in anorectics, nasal congestants, and cold preparations.",3828020_1,0
6583,PPA,21,24,"Phenylpropanolamine (PPA), a synthetic sympathomimetic that is structurally similar to amphetamine, is available over the counter in anorectics, nasal congestants, and cold preparations.",3828020_1,1
6585,cerebral infarction,136,155,"Its prolonged use or overuse has been associated with seizures, intracerebral hemorrhage, neuropsychiatric symptoms, and nonhemorrhagic cerebral infarction.",3828020_2,1
6584,intracerebral hemorrhage,64,88,"Its prolonged use or overuse has been associated with seizures, intracerebral hemorrhage, neuropsychiatric symptoms, and nonhemorrhagic cerebral infarction.",3828020_2,1
12215,neuropsychiatric symptoms,90,115,"Its prolonged use or overuse has been associated with seizures, intracerebral hemorrhage, neuropsychiatric symptoms, and nonhemorrhagic cerebral infarction.",3828020_2,1
12216,oral dose,93,102,We report the case of a young woman who suffered a cerebral infarction after taking a single oral dose of PPA.,3828020_3,0
6586,cerebral infarction,51,70,We report the case of a young woman who suffered a cerebral infarction after taking a single oral dose of PPA.,3828020_3,1
6587,PPA,106,109,We report the case of a young woman who suffered a cerebral infarction after taking a single oral dose of PPA.,3828020_3,1
2938,ethambutol,43,53,Bilateral optic neuropathy due to combined ethambutol and isoniazid treatment.,384871_0,0
6588,optic neuropathy,10,26,Bilateral optic neuropathy due to combined ethambutol and isoniazid treatment.,384871_0,1
12217,kidney transplantation,72,94,The case of a 40-year-old patient who underwent an unsuccessful cadaver kidney transplantation and was treated with ethambutol and isoniazid is reported.,384871_1,1
2939,ethambutol,116,126,The case of a 40-year-old patient who underwent an unsuccessful cadaver kidney transplantation and was treated with ethambutol and isoniazid is reported.,384871_1,0
6589,retrobulbar,12,23,A bilateral retrobulbar neuropathy with an unusual central bitemporal hemianopic scotoma was found.,384871_2,1
6590,bitemporal,59,69,A bilateral retrobulbar neuropathy with an unusual central bitemporal hemianopic scotoma was found.,384871_2,1
12218,small improvement,32,49,Ethambutol was stopped and only small improvement of the visual acuity followed.,384871_3,1
12219,visual acuity,57,70,Ethambutol was stopped and only small improvement of the visual acuity followed.,384871_3,1
2940,Ethambutol,0,10,Ethambutol was stopped and only small improvement of the visual acuity followed.,384871_3,0
12220,visual acuity,76,89,"Isoniazid was discontinued later, followed by a dramatic improvement in the visual acuity.",384871_4,1
6591,optic nerve,15,26,The hazards of optic nerve toxicity due to ethambutol are known.,384871_5,1
2941,ethambutol,43,53,The hazards of optic nerve toxicity due to ethambutol are known.,384871_5,0
2942,ethambutol,48,58,We emphasize the potential danger in the use of ethambutol and isoniazid.,384871_6,0
12221,meningeal leukemia,23,41,Remission induction of meningeal leukemia with high-dose intravenous methotrexate.,3856631_0,1
12222,high-dose,47,56,Remission induction of meningeal leukemia with high-dose intravenous methotrexate.,3856631_0,0
12223,intravenous methotrexate,57,81,Remission induction of meningeal leukemia with high-dose intravenous methotrexate.,3856631_0,0
12224,meningeal disease,64,81,Twenty children with acute lymphoblastic leukemia who developed meningeal disease were treated with a high-dose intravenous methotrexate regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10(-5) mol/L without the need for concomitant intrathecal dosing.,3856631_1,1
12225,high-dose,102,111,Twenty children with acute lymphoblastic leukemia who developed meningeal disease were treated with a high-dose intravenous methotrexate regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10(-5) mol/L without the need for concomitant intrathecal dosing.,3856631_1,0
6592,acute lymphoblastic leukemia,21,49,Twenty children with acute lymphoblastic leukemia who developed meningeal disease were treated with a high-dose intravenous methotrexate regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10(-5) mol/L without the need for concomitant intrathecal dosing.,3856631_1,1
12226,CSF methotrexate,187,203,Twenty children with acute lymphoblastic leukemia who developed meningeal disease were treated with a high-dose intravenous methotrexate regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10(-5) mol/L without the need for concomitant intrathecal dosing.,3856631_1,0
12228,loading dose,39,51,"The methotrexate was administered as a loading dose of 6,000 mg/m2 for a period of one hour followed by an infusion of 1,200 mg/m2/h for 23 hours.",3856631_2,0
12229,mg/m2,61,66,"The methotrexate was administered as a loading dose of 6,000 mg/m2 for a period of one hour followed by an infusion of 1,200 mg/m2/h for 23 hours.",3856631_2,0
12230,mg/m2/h,125,132,"The methotrexate was administered as a loading dose of 6,000 mg/m2 for a period of one hour followed by an infusion of 1,200 mg/m2/h for 23 hours.",3856631_2,0
12235,CSF methotrexate,292,308,"Leucovorin rescue was initiated 12 hours after the end of the infusion with a loading dose of 200 mg/m2 followed by 12 mg/m2 every three hours for six doses and then every six hours until the plasma methotrexate level decreased to less than 1 X 10(-7) mol/L. The mean steady-state plasma and CSF methotrexate concentrations achieved were 1.1 X 10(-3) mol/L and 3.6 X 10(-5) mol/L, respectively.",3856631_3,0
12233,mg/m2,119,124,"Leucovorin rescue was initiated 12 hours after the end of the infusion with a loading dose of 200 mg/m2 followed by 12 mg/m2 every three hours for six doses and then every six hours until the plasma methotrexate level decreased to less than 1 X 10(-7) mol/L. The mean steady-state plasma and CSF methotrexate concentrations achieved were 1.1 X 10(-3) mol/L and 3.6 X 10(-5) mol/L, respectively.",3856631_3,0
12232,mg/m2,98,103,"Leucovorin rescue was initiated 12 hours after the end of the infusion with a loading dose of 200 mg/m2 followed by 12 mg/m2 every three hours for six doses and then every six hours until the plasma methotrexate level decreased to less than 1 X 10(-7) mol/L. The mean steady-state plasma and CSF methotrexate concentrations achieved were 1.1 X 10(-3) mol/L and 3.6 X 10(-5) mol/L, respectively.",3856631_3,0
2943,Leucovorin,0,10,"Leucovorin rescue was initiated 12 hours after the end of the infusion with a loading dose of 200 mg/m2 followed by 12 mg/m2 every three hours for six doses and then every six hours until the plasma methotrexate level decreased to less than 1 X 10(-7) mol/L. The mean steady-state plasma and CSF methotrexate concentrations achieved were 1.1 X 10(-3) mol/L and 3.6 X 10(-5) mol/L, respectively.",3856631_3,0
12231,loading dose,78,90,"Leucovorin rescue was initiated 12 hours after the end of the infusion with a loading dose of 200 mg/m2 followed by 12 mg/m2 every three hours for six doses and then every six hours until the plasma methotrexate level decreased to less than 1 X 10(-7) mol/L. The mean steady-state plasma and CSF methotrexate concentrations achieved were 1.1 X 10(-3) mol/L and 3.6 X 10(-5) mol/L, respectively.",3856631_3,0
12237,partial remission,105,122,"All 20 patients responded to this regimen, 16/20 (80%) achieved a complete remission, and 20% obtained a partial remission.",3856631_4,1
12236,complete remission,66,84,"All 20 patients responded to this regimen, 16/20 (80%) achieved a complete remission, and 20% obtained a partial remission.",3856631_4,1
12239,bilirubin elevations,77,97,"The most common toxicities encountered were transient serum transaminase and bilirubin elevations, neutropenia, and mucositis.",3856631_5,1
6593,mucositis,116,125,"The most common toxicities encountered were transient serum transaminase and bilirubin elevations, neutropenia, and mucositis.",3856631_5,1
12238,serum transaminase,54,72,"The most common toxicities encountered were transient serum transaminase and bilirubin elevations, neutropenia, and mucositis.",3856631_5,0
6595,hemiparesis,45,56,One patient had focal seizures and transient hemiparesis but recovered completely.,3856631_6,1
6594,focal seizures,16,30,One patient had focal seizures and transient hemiparesis but recovered completely.,3856631_6,1
6596,acute lymphoblastic leukemia,119,147,High-dose intravenous methotrexate is an effective treatment for the induction of remission after meningeal relapse in acute lymphoblastic leukemia.,3856631_7,1
12241,meningeal relapse,98,115,High-dose intravenous methotrexate is an effective treatment for the induction of remission after meningeal relapse in acute lymphoblastic leukemia.,3856631_7,1
12240,High-dose,0,9,High-dose intravenous methotrexate is an effective treatment for the induction of remission after meningeal relapse in acute lymphoblastic leukemia.,3856631_7,0
2945,antineoplastic agents,34,55,Interaction of cyclosporin A with antineoplastic agents.,3865016_0,0
2944,cyclosporin A,15,28,Interaction of cyclosporin A with antineoplastic agents.,3865016_0,0
2946,etoposide,24,33,A synergistic effect of etoposide and cyclosporin A was observed in a patient with acute T-lymphocytic leukemia in relapse.,3865016_1,0
2947,cyclosporin A,38,51,A synergistic effect of etoposide and cyclosporin A was observed in a patient with acute T-lymphocytic leukemia in relapse.,3865016_1,0
6597,acute T-lymphocytic leukemia,83,111,A synergistic effect of etoposide and cyclosporin A was observed in a patient with acute T-lymphocytic leukemia in relapse.,3865016_1,1
2948,etoposide,34,43,The concomitant administration of etoposide and cyclosporin A resulted in eradication of hitherto refractory leukemic infiltration of bone marrow.,3865016_2,0
2949,cyclosporin A,48,61,The concomitant administration of etoposide and cyclosporin A resulted in eradication of hitherto refractory leukemic infiltration of bone marrow.,3865016_2,0
12242,leukemic infiltration of bone marrow,109,145,The concomitant administration of etoposide and cyclosporin A resulted in eradication of hitherto refractory leukemic infiltration of bone marrow.,3865016_2,1
6598,side effects,7,19,"Severe side effects in terms of mental confusion and progressive hyperbilirubinemia, however, point to an enhancement not only of antineoplastic effects but also of toxicity in normal tissues.",3865016_3,1
12243,mental confusion,32,48,"Severe side effects in terms of mental confusion and progressive hyperbilirubinemia, however, point to an enhancement not only of antineoplastic effects but also of toxicity in normal tissues.",3865016_3,1
2950,cyclosporin A,83,96,This report demonstrates for the first time that the pharmacodynamic properties of cyclosporin A may not be confined strictly to suppression of normal T-cell functions.,3865016_4,0
6599,adverse reactions,23,40,A prospective study of adverse reactions associated with vancomycin therapy.,3934126_0,1
12252,proven infection,51,67,Vancomycin was curative in 95% of 43 patients with proven infection.,3934126_2,1
6600,adverse reactions,45,62,Drugs were ceased in six patients because of adverse reactions; in three of these vancomycin was considered the likely cause.,3934126_3,1
12253,nephrotoxicity,73,87,"Reactions included thrombophlebitis (20 of 54 patients), rash (4 of 54), nephrotoxicity (4 of 50), proteinuria (1 of 50) and ototoxicity (1 of 11 patients tested by audiometry).",3934126_4,1
2951,(1,111,113,"Reactions included thrombophlebitis (20 of 54 patients), rash (4 of 54), nephrotoxicity (4 of 50), proteinuria (1 of 50) and ototoxicity (1 of 11 patients tested by audiometry).",3934126_4,0
12255,nephrotoxicity,74,88,Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.,3934126_5,1
6601,ototoxicity,93,104,Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.,3934126_5,1
2952,aminoglycoside,144,158,Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.,3934126_5,0
12254,peripheral cannulae,53,72,Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin.,3934126_5,1
12257,nephrotoxicity,24,38,Factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin.,3950060_0,1
12258,clinical outcome,43,59,Factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin.,3950060_0,1
2953,amikacin,82,90,Factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin.,3950060_0,0
2954,amikacin,35,43,Data from 60 patients treated with amikacin were analyzed for factors associated with nephrotoxicity.,3950060_1,0
12260,nephrotoxicity,86,100,Data from 60 patients treated with amikacin were analyzed for factors associated with nephrotoxicity.,3950060_1,1
12262,clinical outcome,72,88,"In 42 of these patients, data were examined for factors associated with clinical outcome.",3950060_2,1
2956,creatinine,79,89,"Variables evaluated included patient weight, age, sex, serum creatinine level, creatinine clearance, duration of therapy, total dose, mean daily dose, organism minimum inhibitory concentration (MIC), mean peak levels, mean trough levels, mean area under the serum concentration-time curve (AUC), total AUC, mean AUC greater than MIC, total AUC greater than MIC, mean Schumacher's intensity factor (IF), total IF, In (mean maximum concentration [Cmax]/MIC).",3950060_3,0
2955,creatinine,61,71,"Variables evaluated included patient weight, age, sex, serum creatinine level, creatinine clearance, duration of therapy, total dose, mean daily dose, organism minimum inhibitory concentration (MIC), mean peak levels, mean trough levels, mean area under the serum concentration-time curve (AUC), total AUC, mean AUC greater than MIC, total AUC greater than MIC, mean Schumacher's intensity factor (IF), total IF, In (mean maximum concentration [Cmax]/MIC).",3950060_3,0
12279,nephrotoxicity,130,144,"When the parameters were examined individually, duration of therapy and total AUC correlated significantly (P less than .05) with nephrotoxicity.",3950060_5,1
12287,MIC,66,69,"In contrast, a simultaneous multivariable analysis identified IF, MIC, and total dose according to one model and ln (mean Cmax/MIC) according to a second statistical model of parameters selected to have the greatest prospective value.",3950060_9,0
6602,Cardiac toxicity,0,16,Cardiac toxicity of 5-fluorouracil.,3952818_0,1
12291,5-fluorouracil,20,34,Cardiac toxicity of 5-fluorouracil.,3952818_0,0
12292,spontaneous angina,20,38,Report of a case of spontaneous angina.,3952818_1,1
12293,colon carcinoma,35,50,We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.,3952818_2,1
12295,5-fluorouracil,103,117,We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.,3952818_2,0
12296,5-FU,119,123,We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.,3952818_2,0
12294,liver metastasis,55,71,We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.,3952818_2,1
6603,chest pain,86,96,We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration.,3952818_2,1
6605,chest pain,97,107,"Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and chest pain promptly resolved with nifedipine.",3952818_3,1
6604,Prinzmetal's angina,72,91,"Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and chest pain promptly resolved with nifedipine.",3952818_3,1
12298,coronary spasm,24,38,"These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity.",3952818_4,1
12299,cause of cardiotoxicity,50,73,"These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity.",3952818_4,1
12300,5-FU,81,85,"These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity.",3952818_4,0
2957,calcium antagonists,96,115,"These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity.",3952818_4,0
12302,Dose-related,0,12,Dose-related beneficial and adverse effects of dietary corticosterone on organophosphorus-induced delayed neuropathy in chickens.,3961813_0,1
12303,dietary corticosterone,47,69,Dose-related beneficial and adverse effects of dietary corticosterone on organophosphorus-induced delayed neuropathy in chickens.,3961813_0,0
6606,adverse effects,28,43,Dose-related beneficial and adverse effects of dietary corticosterone on organophosphorus-induced delayed neuropathy in chickens.,3961813_0,1
12304,delayed neuropathy,98,116,Dose-related beneficial and adverse effects of dietary corticosterone on organophosphorus-induced delayed neuropathy in chickens.,3961813_0,1
12306,phosphorofluoridate,70,89,"Tri-ortho-tolyl phosphate (TOTP), 360 mg/kg, po, and 0,0'-diisopropyl phosphorofluoridate (DFP), 1 mg/kg sc, were administered to adult White Leghorn chickens 24 hr after they were placed on diets containing 0 to 300 ppm corticosterone.",3961813_1,0
12305,TOTP,27,31,"Tri-ortho-tolyl phosphate (TOTP), 360 mg/kg, po, and 0,0'-diisopropyl phosphorofluoridate (DFP), 1 mg/kg sc, were administered to adult White Leghorn chickens 24 hr after they were placed on diets containing 0 to 300 ppm corticosterone.",3961813_1,0
2958,DFP,91,94,"Tri-ortho-tolyl phosphate (TOTP), 360 mg/kg, po, and 0,0'-diisopropyl phosphorofluoridate (DFP), 1 mg/kg sc, were administered to adult White Leghorn chickens 24 hr after they were placed on diets containing 0 to 300 ppm corticosterone.",3961813_1,0
12309,clinical signs,40,54,Supplemented diets were continued until clinical signs and lesions of delayed neuropathy appeared.,3961813_2,1
12310,delayed neuropathy,70,88,Supplemented diets were continued until clinical signs and lesions of delayed neuropathy appeared.,3961813_2,1
12313,TOTP,213,217,"Although low concentrations (less than or equal to 50 ppm) of corticosterone had beneficial effects on TOTP-induced neuropathy, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP.",3961813_3,0
12312,clinical signs,173,187,"Although low concentrations (less than or equal to 50 ppm) of corticosterone had beneficial effects on TOTP-induced neuropathy, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP.",3961813_3,1
2959,DFP,221,224,"Although low concentrations (less than or equal to 50 ppm) of corticosterone had beneficial effects on TOTP-induced neuropathy, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP.",3961813_3,0
12314,TOTP,43,47,Neurotoxic esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given organophosphorous compounds.,3961813_4,0
12315,organophosphorous compounds,115,142,Neurotoxic esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given organophosphorous compounds.,3961813_4,0
2960,esterase,11,19,Neurotoxic esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given organophosphorous compounds.,3961813_4,0
2961,DFP,51,54,Neurotoxic esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given organophosphorous compounds.,3961813_4,0
2963,carboxylesterase,165,181,Chickens given 200 ppm corticosterone without TOTP or DFP had significantly elevated activity of plasma cholinesterase and significantly inhibited activity of liver carboxylesterase.,3961813_5,0
12316,TOTP,46,50,Chickens given 200 ppm corticosterone without TOTP or DFP had significantly elevated activity of plasma cholinesterase and significantly inhibited activity of liver carboxylesterase.,3961813_5,0
2962,DFP,54,57,Chickens given 200 ppm corticosterone without TOTP or DFP had significantly elevated activity of plasma cholinesterase and significantly inhibited activity of liver carboxylesterase.,3961813_5,0
12317,plasma cholinesterase,97,118,Chickens given 200 ppm corticosterone without TOTP or DFP had significantly elevated activity of plasma cholinesterase and significantly inhibited activity of liver carboxylesterase.,3961813_5,0
12319,peripheral nerves,73,90,Degenerating myelinated fibers were also evident in distal levels of the peripheral nerves of chickens given TOTP or DFP.,3961813_6,1
12320,TOTP,109,113,Degenerating myelinated fibers were also evident in distal levels of the peripheral nerves of chickens given TOTP or DFP.,3961813_6,0
2964,DFP,117,120,Degenerating myelinated fibers were also evident in distal levels of the peripheral nerves of chickens given TOTP or DFP.,3961813_6,0
12321,Hepatotoxicity,0,14,Hepatotoxicity of amiodarone.,3962737_0,1
6607,tachyarrhythmias,85,101,Amiodarone has proved very effective in the treatment of otherwise resistant cardiac tachyarrhythmias.,3962737_1,1
6608,side-effects,68,80,"The use of amiodarone has, however, been limited due to its serious side-effects.",3962737_2,1
12323,hepatotoxicity,104,118,A patient with cholestatic hepatitis due to amiodarone treatment is presented below and a review of the hepatotoxicity of amiodarone is given.,3962737_3,1
12322,cholestatic hepatitis,15,36,A patient with cholestatic hepatitis due to amiodarone treatment is presented below and a review of the hepatotoxicity of amiodarone is given.,3962737_3,1
12326,cholestatic hepatitis,155,176,"It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.",3962737_4,1
6610,alcoholic hepatitis,134,153,"It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.",3962737_4,1
6609,steatosis,100,109,"It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.",3962737_4,1
12327,micronodular cirrhosis,181,203,"It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.",3962737_4,1
12325,hepatic injury,46,60,"It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver.",3962737_4,1
12328,cholestatic injury,51,69,Therapy should be discontinued on the suspicion of cholestatic injury or hepatomegaly.,3962737_6,1
2965,dietary fat,40,51,Promotional effects of testosterone and dietary fat on prostate carcinogenesis in genetically susceptible rats.,3969369_0,0
6611,carcinogenesis,64,78,Promotional effects of testosterone and dietary fat on prostate carcinogenesis in genetically susceptible rats.,3969369_0,1
12333,prostate adenocarcinomas,87,111,"Germfree (GF) Lobund strain Wistar (LW) rats, fed vegetable diet L-485, have developed prostate adenocarcinomas spontaneously (10% incidence) at average age 34 months.",3969369_1,1
12336,gross tumors,173,185,"Conventional LW rats, implanted with testosterone at age 4 months, developed a higher incidence of prostate cancer after an average interval of 14 months: 24% had developed gross tumors, and 40% when it included microscopic tumors.",3969369_2,1
12337,microscopic tumors,212,230,"Conventional LW rats, implanted with testosterone at age 4 months, developed a higher incidence of prostate cancer after an average interval of 14 months: 24% had developed gross tumors, and 40% when it included microscopic tumors.",3969369_2,1
6612,prostate cancer,99,114,"Conventional LW rats, implanted with testosterone at age 4 months, developed a higher incidence of prostate cancer after an average interval of 14 months: 24% had developed gross tumors, and 40% when it included microscopic tumors.",3969369_2,1
2966,corn oil,120,128,"Preliminary results indicate that testosterone-treated LW rats that were fed the same diet, which was supplemented with corn oil up to 20% fat, developed prostate cancer after intervals of 6-12 months.",3969369_3,0
6613,prostate cancer,154,169,"Preliminary results indicate that testosterone-treated LW rats that were fed the same diet, which was supplemented with corn oil up to 20% fat, developed prostate cancer after intervals of 6-12 months.",3969369_3,1
6614,prostate cancer,52,67,Aged GF Sprague-Dawley (SD) rats have not developed prostate cancer spontaneously.,3969369_4,1
12338,diet L-485,25,35,Conventional SD rats fed diet L-485 and treated with testosterone developed only prostatitis.,3969369_5,0
6616,prostate cancer,112,127,Experimental designs should consider genetic susceptibility as a basic prerequisite for studies on experimental prostate cancer.,3969369_6,1
6615,genetic susceptibility,37,59,Experimental designs should consider genetic susceptibility as a basic prerequisite for studies on experimental prostate cancer.,3969369_6,1
6617,rheumatoid arthritis,40,60,Incidence of neoplasms in patients with rheumatoid arthritis exposed to different treatment regimens.,3970039_0,1
6618,rheumatoid arthritis,101,121,Immunosuppressive drugs have been used during the last 30 years in treatment of patients with severe rheumatoid arthritis.,3970039_1,1
12340,Immunosuppressive drugs,0,23,Immunosuppressive drugs have been used during the last 30 years in treatment of patients with severe rheumatoid arthritis.,3970039_1,0
12342,purine analogue,97,112,"The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and methotrexate (folic acid analogue).",3970039_2,0
12343,folic acid,133,143,"The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and methotrexate (folic acid analogue).",3970039_2,0
12341,cyclophosphamide,28,44,"The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and methotrexate (folic acid analogue).",3970039_2,0
2967,alkylating agents,63,80,"The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and methotrexate (folic acid analogue).",3970039_2,0
12344,immunosuppressive drugs,32,55,"There is evidence that all four immunosuppressive drugs can reduce synovitis, but disease activity almost always recurs after therapy is stopped.",3970039_3,0
12345,disease activity,82,98,"There is evidence that all four immunosuppressive drugs can reduce synovitis, but disease activity almost always recurs after therapy is stopped.",3970039_3,1
6619,adverse reactions,6,23,"Since adverse reactions are frequent, less than 50 percent of patients are able to continue a particular drug for more than one year.",3970039_4,1
2969,alkylating agents,121,138,"Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma.",3970039_6,0
2968,alkylating agents,22,39,"Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma.",3970039_6,0
6620,acute nonlymphocytic leukemia,81,110,"Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma.",3970039_6,1
6621,non-Hodgkin's lymphoma,195,217,"Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma.",3970039_6,1
12348,carcinoma of,47,59,Cyclophosphamide therapy increases the risk of carcinoma of the bladder.,3970039_7,1
12347,Cyclophosphamide,0,16,Cyclophosphamide therapy increases the risk of carcinoma of the bladder.,3970039_7,0
6622,rheumatoid arthritis,59,79,There have been several long-term studies of patients with rheumatoid arthritis treated with azathioprine and cyclophosphamide and the incidence of most of the common cancers is not increased.,3970039_8,1
12349,cyclophosphamide,110,126,There have been several long-term studies of patients with rheumatoid arthritis treated with azathioprine and cyclophosphamide and the incidence of most of the common cancers is not increased.,3970039_8,0
12350,immunosuppressive drugs,156,179,"Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected, and until further information is available, the use of immunosuppressive drugs, particularly alkylating agents, in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life-threatening complications.",3970039_9,0
12351,progressive disease,298,317,"Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected, and until further information is available, the use of immunosuppressive drugs, particularly alkylating agents, in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life-threatening complications.",3970039_9,1
2970,alkylating agents,194,211,"Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected, and until further information is available, the use of immunosuppressive drugs, particularly alkylating agents, in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life-threatening complications.",3970039_9,0
6623,rheumatoid arthritis,53,73,"Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected, and until further information is available, the use of immunosuppressive drugs, particularly alkylating agents, in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life-threatening complications.",3970039_9,1
6624,rheumatoid arthritis,233,253,"Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected, and until further information is available, the use of immunosuppressive drugs, particularly alkylating agents, in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life-threatening complications.",3970039_9,1
6625,left ventricular,103,119,"Time course alterations of QTC interval due to hypaque 76.Sequential measurement of QT interval during left ventricular angiography was made 30 seconds and one, three, five and ten minutes after injection of hypaque 76.",3973521_0,1
12354,hypaque,47,54,"Time course alterations of QTC interval due to hypaque 76.Sequential measurement of QT interval during left ventricular angiography was made 30 seconds and one, three, five and ten minutes after injection of hypaque 76.",3973521_0,0
12356,hypaque,208,215,"Time course alterations of QTC interval due to hypaque 76.Sequential measurement of QT interval during left ventricular angiography was made 30 seconds and one, three, five and ten minutes after injection of hypaque 76.",3973521_0,0
12357,left ventricles,52,67,The subjects were ten patients found to have normal left ventricles and coronary arteries.,3973521_1,1
12358,coronary arteries,72,89,The subjects were ten patients found to have normal left ventricles and coronary arteries.,3973521_1,1
6626,cardiac output,122,136,Significant QTC prolongation occurred in 30 seconds to one minute in association with marked hypotension and elevation of cardiac output.,3973521_2,1
12359,QTC,12,15,Significant QTC prolongation occurred in 30 seconds to one minute in association with marked hypotension and elevation of cardiac output.,3973521_2,0
6627,nerve palsy,62,73,Warfarin-induced iliopsoas hemorrhage with subsequent femoral nerve palsy.,3985451_0,1
12360,iliopsoas hemorrhage,17,37,Warfarin-induced iliopsoas hemorrhage with subsequent femoral nerve palsy.,3985451_0,1
12363,right hip,166,175,We present the case of a 28-year-old man on chronic warfarin therapy who sustained a minor muscle tear and developed increasing pain and a flexure contracture of the right hip.,3985451_1,1
12362,flexure contracture,139,158,We present the case of a 28-year-old man on chronic warfarin therapy who sustained a minor muscle tear and developed increasing pain and a flexure contracture of the right hip.,3985451_1,1
12361,minor muscle tear,85,102,We present the case of a 28-year-old man on chronic warfarin therapy who sustained a minor muscle tear and developed increasing pain and a flexure contracture of the right hip.,3985451_1,1
12365,loss of quadriceps functions,129,157,"Surgical exploration revealed an iliopsoas hematoma and femoral nerve entrapment, resulting in a femoral nerve palsy and partial loss of quadriceps functions.",3985451_2,1
12364,iliopsoas hematoma,33,51,"Surgical exploration revealed an iliopsoas hematoma and femoral nerve entrapment, resulting in a femoral nerve palsy and partial loss of quadriceps functions.",3985451_2,1
6629,nerve palsy,105,116,"Surgical exploration revealed an iliopsoas hematoma and femoral nerve entrapment, resulting in a femoral nerve palsy and partial loss of quadriceps functions.",3985451_2,1
6628,nerve entrapment,64,80,"Surgical exploration revealed an iliopsoas hematoma and femoral nerve entrapment, resulting in a femoral nerve palsy and partial loss of quadriceps functions.",3985451_2,1
12368,flexure contracture,229,248,"Anticoagulant-induced femoral nerve palsy represents the most common form of warfarin-induced peripheral neuropathy; it is characterized by severe pain in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity.",3985451_3,1
12367,sensory impairment,205,223,"Anticoagulant-induced femoral nerve palsy represents the most common form of warfarin-induced peripheral neuropathy; it is characterized by severe pain in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity.",3985451_3,1
12366,inguinal region,159,174,"Anticoagulant-induced femoral nerve palsy represents the most common form of warfarin-induced peripheral neuropathy; it is characterized by severe pain in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity.",3985451_3,1
6631,peripheral neuropathy,94,115,"Anticoagulant-induced femoral nerve palsy represents the most common form of warfarin-induced peripheral neuropathy; it is characterized by severe pain in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity.",3985451_3,1
6630,nerve palsy,30,41,"Anticoagulant-induced femoral nerve palsy represents the most common form of warfarin-induced peripheral neuropathy; it is characterized by severe pain in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity.",3985451_3,1
6632,pericardial effusion,29,49,Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy.,3997294_0,1
12370,implanted pacemaker,38,57,"A patient with sinuatrial disease and implanted pacemaker was treated with amiodarone (maximum dose 1000 mg, maintenance dose 800 mg daily) for 10 months, for control of supraventricular tachyarrhythmias.",3997294_1,0
12372,supraventricular tachyarrhythmias,170,203,"A patient with sinuatrial disease and implanted pacemaker was treated with amiodarone (maximum dose 1000 mg, maintenance dose 800 mg daily) for 10 months, for control of supraventricular tachyarrhythmias.",3997294_1,1
12369,sinuatrial disease,15,33,"A patient with sinuatrial disease and implanted pacemaker was treated with amiodarone (maximum dose 1000 mg, maintenance dose 800 mg daily) for 10 months, for control of supraventricular tachyarrhythmias.",3997294_1,1
6633,pericardial effusions,38,59,"He developed pneumonitis, pleural and pericardial effusions, and a predominantly proximal motor neuropathy.",3997294_2,1
6634,motor neuropathy,90,106,"He developed pneumonitis, pleural and pericardial effusions, and a predominantly proximal motor neuropathy.",3997294_2,1
6635,sinoatrial block,19,35,Amiodarone-induced sinoatrial block.,4008111_0,1
6636,sinoatrial block,12,28,"We observed sinoatrial block due to chronic amiodarone administration in a 5-year-old boy with primary cardiomyopathy, Wolff-Parkinson-White syndrome and supraventricular tachycardia.",4008111_1,1
6637,primary cardiomyopathy,95,117,"We observed sinoatrial block due to chronic amiodarone administration in a 5-year-old boy with primary cardiomyopathy, Wolff-Parkinson-White syndrome and supraventricular tachycardia.",4008111_1,1
6638,Wolff-Parkinson-White syndrome,119,149,"We observed sinoatrial block due to chronic amiodarone administration in a 5-year-old boy with primary cardiomyopathy, Wolff-Parkinson-White syndrome and supraventricular tachycardia.",4008111_1,1
6639,supraventricular tachycardia,154,182,"We observed sinoatrial block due to chronic amiodarone administration in a 5-year-old boy with primary cardiomyopathy, Wolff-Parkinson-White syndrome and supraventricular tachycardia.",4008111_1,1
12375,chronic amiodarone,36,54,"We observed sinoatrial block due to chronic amiodarone administration in a 5-year-old boy with primary cardiomyopathy, Wolff-Parkinson-White syndrome and supraventricular tachycardia.",4008111_1,0
6640,sinoatrial block,75,91,Reduction in the dosage of amiodarone resulted in the disappearance of the sinoatrial block and the persistence of asymptomatic sinus bradycardia.,4008111_2,1
12378,low dose Desipramine,32,52,"An elderly patient treated with low dose Desipramine developed a delirium while her plasma level was in the ""subtherapeutic"" range.",4027862_1,0
2971,her,80,83,"An elderly patient treated with low dose Desipramine developed a delirium while her plasma level was in the ""subtherapeutic"" range.",4027862_1,0
12380,tricyclic drug,34,48,"Delirium, which may be induced by tricyclic drug therapy in the elderly, can be caused by tricyclics with low anticholinergic potency.",4027862_2,0
12381,Therapeutic ranges,0,18,Therapeutic ranges for antidepressants that have been derived from general adult population studies may not be appropriate for the elderly.,4027862_3,0
12384,Rat extraocular muscle regeneration,0,35,Rat extraocular muscle regeneration.,4038130_0,1
2974,mepivacaine hydrochloride,102,127,"Local anesthetics that are commonly used in ophthalmic surgery (0.75% bupivacaine hydrochloride, 2.0% mepivacaine hydrochloride, and 2.0% lidocaine hydrochloride plus 1:100,000 epinephrine) were injected into the retrobulbar area of rat eyes.",4038130_2,0
2973,bupivacaine hydrochloride,70,95,"Local anesthetics that are commonly used in ophthalmic surgery (0.75% bupivacaine hydrochloride, 2.0% mepivacaine hydrochloride, and 2.0% lidocaine hydrochloride plus 1:100,000 epinephrine) were injected into the retrobulbar area of rat eyes.",4038130_2,0
2975,lidocaine hydrochloride,138,161,"Local anesthetics that are commonly used in ophthalmic surgery (0.75% bupivacaine hydrochloride, 2.0% mepivacaine hydrochloride, and 2.0% lidocaine hydrochloride plus 1:100,000 epinephrine) were injected into the retrobulbar area of rat eyes.",4038130_2,0
2972,Local anesthetics,0,17,"Local anesthetics that are commonly used in ophthalmic surgery (0.75% bupivacaine hydrochloride, 2.0% mepivacaine hydrochloride, and 2.0% lidocaine hydrochloride plus 1:100,000 epinephrine) were injected into the retrobulbar area of rat eyes.",4038130_2,0
12387,"1:100,000 epinephrine",167,188,"Local anesthetics that are commonly used in ophthalmic surgery (0.75% bupivacaine hydrochloride, 2.0% mepivacaine hydrochloride, and 2.0% lidocaine hydrochloride plus 1:100,000 epinephrine) were injected into the retrobulbar area of rat eyes.",4038130_2,0
6641,retrobulbar,213,224,"Local anesthetics that are commonly used in ophthalmic surgery (0.75% bupivacaine hydrochloride, 2.0% mepivacaine hydrochloride, and 2.0% lidocaine hydrochloride plus 1:100,000 epinephrine) were injected into the retrobulbar area of rat eyes.",4038130_2,1
12388,physiological saline,28,48,Controls were injected with physiological saline.,4038130_3,0
12390,extraocular muscles,59,78,All three anesthetics produced massive degeneration of the extraocular muscles.,4038130_4,1
12389,massive degeneration,31,51,All three anesthetics produced massive degeneration of the extraocular muscles.,4038130_4,1
12392,muscle fibers,63,76,Muscle degeneration is followed by regeneration of the damaged muscle fibers.,4038130_5,1
12391,Muscle degeneration,0,19,Muscle degeneration is followed by regeneration of the damaged muscle fibers.,4038130_5,1
12393,muscle damage,15,28,"In addition to muscle damage, severe damage was also seen in harderian glands, especially after exposure to mepivacaine and lidocaine plus epinephrine.",4038130_6,1
12395,mepivacaine,108,119,"In addition to muscle damage, severe damage was also seen in harderian glands, especially after exposure to mepivacaine and lidocaine plus epinephrine.",4038130_6,0
12399,extraocular muscles,177,196,"With these findings in rats, it is hypothesized that the temporary diplopia sometimes seen in patients after ophthalmic surgery might be due to anesthetic-induced damage to the extraocular muscles.",4038130_7,1
12396,temporary diplopia sometimes,57,85,"With these findings in rats, it is hypothesized that the temporary diplopia sometimes seen in patients after ophthalmic surgery might be due to anesthetic-induced damage to the extraocular muscles.",4038130_7,1
12400,premature baby,39,53,The clinical and autopsy findings in a premature baby who died of acute renal failure after therapy with gentamicin (5 mg/kg/day) and penicillin are presented.,4069770_1,1
6642,acute renal failure,66,85,The clinical and autopsy findings in a premature baby who died of acute renal failure after therapy with gentamicin (5 mg/kg/day) and penicillin are presented.,4069770_1,1
12401,serum gentamicin,4,20,The serum gentamicin concentration had reached toxic levels when anuria developed.,4069770_2,0
2976,periodic acid,9,22,"Numerous periodic acid Schiff (PAS) positive, diastase resistant cytoplasmic inclusion bodies which appeared as myelin figures in cytosegresomes under the electron microscope were identified in the proximal convoluted tubules.",4069770_3,0
12403,inclusion bodies,77,93,"Numerous periodic acid Schiff (PAS) positive, diastase resistant cytoplasmic inclusion bodies which appeared as myelin figures in cytosegresomes under the electron microscope were identified in the proximal convoluted tubules.",4069770_3,0
2977,diastase,46,54,"Numerous periodic acid Schiff (PAS) positive, diastase resistant cytoplasmic inclusion bodies which appeared as myelin figures in cytosegresomes under the electron microscope were identified in the proximal convoluted tubules.",4069770_3,0
12406,rechallenge,56,67,Indomethacin-induced renal insufficiency: recurrence on rechallenge.,4071154_0,0
6643,renal insufficiency,21,40,Indomethacin-induced renal insufficiency: recurrence on rechallenge.,4071154_0,1
6645,cor pulmonale,116,129,"We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis, ascites, and cor pulmonale after indomethacin therapy.",4071154_1,1
6644,renal failure,42,55,"We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis, ascites, and cor pulmonale after indomethacin therapy.",4071154_1,1
12411,acute reversible oliguria,135,160,"Prompt restoration of renal function followed drug withdrawal, while re-exposure to a single dose of indomethacin caused recurrence of acute reversible oliguria.",4071154_2,1
6646,drug withdrawal,46,61,"Prompt restoration of renal function followed drug withdrawal, while re-exposure to a single dose of indomethacin caused recurrence of acute reversible oliguria.",4071154_2,1
12408,renal function,22,36,"Prompt restoration of renal function followed drug withdrawal, while re-exposure to a single dose of indomethacin caused recurrence of acute reversible oliguria.",4071154_2,1
12410,single dose,86,97,"Prompt restoration of renal function followed drug withdrawal, while re-exposure to a single dose of indomethacin caused recurrence of acute reversible oliguria.",4071154_2,0
2978,plasma volume,138,151,Our case supports the hypothesis that endogenous renal prostaglandins play a role in the maintenance of renal blood flow when circulating plasma volume is diminished.,4071154_3,0
12412,renal prostaglandins,49,69,Our case supports the hypothesis that endogenous renal prostaglandins play a role in the maintenance of renal blood flow when circulating plasma volume is diminished.,4071154_3,0
6647,compensatory,64,76,"Since nonsteroidal anti-inflammatory agents interfere with this compensatory mechanism and may cause acute renal failure, they should be used with caution in such patients.",4071154_4,1
6648,acute renal failure,101,120,"Since nonsteroidal anti-inflammatory agents interfere with this compensatory mechanism and may cause acute renal failure, they should be used with caution in such patients.",4071154_4,1
2979,nonsteroidal anti-inflammatory agents,6,43,"Since nonsteroidal anti-inflammatory agents interfere with this compensatory mechanism and may cause acute renal failure, they should be used with caution in such patients.",4071154_4,0
12414,liver tumours,40,53,Induction by paracetamol of bladder and liver tumours in the rat.,4090988_0,1
2980,paracetamol,13,24,Induction by paracetamol of bladder and liver tumours in the rat.,4090988_0,0
2981,hepatocyte,11,21,Effects on hepatocyte fine structure.,4090988_1,0
2982,paracetamol,97,108,Groups of male and female inbred Leeds strain rats were fed diets containing either 0.5% or 1.0% paracetamol by weight for up to 18 months.,4090988_2,0
12416,neoplastic nodules,62,80,"At the 1.0% dosage level, 20% of rats of both sexes developed neoplastic nodules of the liver, a statistically significant incidence.",4090988_3,1
12417,gross enlargement,23,40,"These rats also showed gross enlargement of their livers and an increase in foci of cellular alteration, the latter also being observed in the low dosage male rats.",4090988_4,1
12418,cellular alteration,84,103,"These rats also showed gross enlargement of their livers and an increase in foci of cellular alteration, the latter also being observed in the low dosage male rats.",4090988_4,1
12419,low dosage,143,153,"These rats also showed gross enlargement of their livers and an increase in foci of cellular alteration, the latter also being observed in the low dosage male rats.",4090988_4,0
12421,bladder carcinomas,122,140,"Papillomas of the transitional epithelium of the bladder developed in all paracetamol-treated groups, and three rats bore bladder carcinomas.",4090988_5,1
12422,bladder tumours,31,46,"However, significant yields of bladder tumours were only obtained from low dosage females and high dosage males.",4090988_6,1
12423,low dosage,71,81,"However, significant yields of bladder tumours were only obtained from low dosage females and high dosage males.",4090988_6,0
6649,bladder calculi,147,162,"Additionally, 20 to 25% of paracetamol-treated rats developed hyperplasia of the bladder epithelium, which was not coincident with the presence of bladder calculi.",4090988_7,1
2983,paracetamol,67,78,A low yield of tumours at various other sites also arose following paracetamol feeding.,4090988_8,0
12427,hepatic injury,12,26,Patterns of hepatic injury induced by methyldopa.,424937_0,1
6650,liver disease,21,34,Twelve patients with liver disease related to methyldopa were seen between 1967 and 1977.,424937_1,1
6651,nausea and vomiting,86,105,"Jaundice with tender hepatomegaly, usually preceded by symptoms of malaise, anorexia, nausea and vomiting, and associated with upper abdominal pain, was an invariable finding in all patients.",424937_3,1
6652,abdominal pain,133,147,"Jaundice with tender hepatomegaly, usually preceded by symptoms of malaise, anorexia, nausea and vomiting, and associated with upper abdominal pain, was an invariable finding in all patients.",424937_3,1
12428,tender hepatomegaly,14,33,"Jaundice with tender hepatomegaly, usually preceded by symptoms of malaise, anorexia, nausea and vomiting, and associated with upper abdominal pain, was an invariable finding in all patients.",424937_3,1
6653,massive hepatic necrosis,217,241,"Biochemical liver function tests indicated hepatocellular necrosis and correlated with histopathological evidence of hepatic injury, the spectrum of which ranged from fatty change and focal hepatocellular necrosis to massive hepatic necrosis.",424937_4,1
12432,hepatocellular necrosis,43,66,"Biochemical liver function tests indicated hepatocellular necrosis and correlated with histopathological evidence of hepatic injury, the spectrum of which ranged from fatty change and focal hepatocellular necrosis to massive hepatic necrosis.",424937_4,1
12431,liver function,12,26,"Biochemical liver function tests indicated hepatocellular necrosis and correlated with histopathological evidence of hepatic injury, the spectrum of which ranged from fatty change and focal hepatocellular necrosis to massive hepatic necrosis.",424937_4,1
12435,fatty change,167,179,"Biochemical liver function tests indicated hepatocellular necrosis and correlated with histopathological evidence of hepatic injury, the spectrum of which ranged from fatty change and focal hepatocellular necrosis to massive hepatic necrosis.",424937_4,1
12436,hepatocellular necrosis,190,213,"Biochemical liver function tests indicated hepatocellular necrosis and correlated with histopathological evidence of hepatic injury, the spectrum of which ranged from fatty change and focal hepatocellular necrosis to massive hepatic necrosis.",424937_4,1
12434,hepatic injury,117,131,"Biochemical liver function tests indicated hepatocellular necrosis and correlated with histopathological evidence of hepatic injury, the spectrum of which ranged from fatty change and focal hepatocellular necrosis to massive hepatic necrosis.",424937_4,1
12437,severe acute hepatitis,33,55,Most patients showed moderate to severe acute hepatitis or chronic active hepatitis with associated cholestasis.,424937_5,1
6654,chronic active hepatitis,59,83,Most patients showed moderate to severe acute hepatitis or chronic active hepatitis with associated cholestasis.,424937_5,1
6655,hepatic failure,38,53,"One patient died, having presented in hepatic failure, and another, who had been taking methyldopa for 7 years, showed slower clinical and biochemical resolution over a period of several months.",424937_7,1
6656,fulminant hepatitis,46,65,The remaining patient in the series developed fulminant hepatitis when the drug was accidentally recommenced 1 year after a prior episode of methyldopa-induced hepatitis.,424937_8,1
12439,episode of,130,140,The remaining patient in the series developed fulminant hepatitis when the drug was accidentally recommenced 1 year after a prior episode of methyldopa-induced hepatitis.,424937_8,1
12441,hepatic dysfunction,88,107,"In this latter patient, and in 2 others, the causal relationship between methyldopa and hepatic dysfunction was proved with the recurrence of hepatitis within 2 weeks of re-exposure to the drug.",424937_9,1
12442,re-exposure,170,181,"In this latter patient, and in 2 others, the causal relationship between methyldopa and hepatic dysfunction was proved with the recurrence of hepatitis within 2 weeks of re-exposure to the drug.",424937_9,1
6657,hemiparesis,10,21,Transient hemiparesis: a rare manifestation of diphenylhydantoin toxicity.,430165_0,1
6659,cerebellar dysfunction,131,153,"Among the common side effects of diphenylhydantoin (DPH) overdose, the most frequently encountered neurological signs are those of cerebellar dysfunction.",430165_2,1
6658,side effects,17,29,"Among the common side effects of diphenylhydantoin (DPH) overdose, the most frequently encountered neurological signs are those of cerebellar dysfunction.",430165_2,1
12443,neurological signs,99,117,"Among the common side effects of diphenylhydantoin (DPH) overdose, the most frequently encountered neurological signs are those of cerebellar dysfunction.",430165_2,1
6660,neurological manifestations,23,50,"Very rarely, the toxic neurological manifestations of this drug are of cerebral origin.",430165_3,1
12445,cerebral origin,71,86,"Very rarely, the toxic neurological manifestations of this drug are of cerebral origin.",430165_3,1
6661,hemiparesis,52,63,Two patients are presented who suffered progressive hemiparesis due to DPH overdose.,430165_4,1
12446,brain surgery,9,22,Both had brain surgery before DPH treatment.,430165_5,1
12448,focal neurological signs,93,117,It is assumed that patients with some cerebral damage are liable to manifest DPH toxicity as focal neurological signs.,430165_6,1
12447,cerebral damage,38,53,It is assumed that patients with some cerebral damage are liable to manifest DPH toxicity as focal neurological signs.,430165_6,1
2984,Suxamethonium,0,13,Suxamethonium infusion rate and observed fasciculations.,435349_0,0
2985,Suxamethonium chloride,0,22,Suxamethonium chloride (Sch) was administered i.v. to 36 adult males at six rates: 0.25 mg s-1 to 20 mg s-1.,435349_2,0
2986,Sch,24,27,Suxamethonium chloride (Sch) was administered i.v. to 36 adult males at six rates: 0.25 mg s-1 to 20 mg s-1.,435349_2,0
12450,s-1,91,94,Suxamethonium chloride (Sch) was administered i.v. to 36 adult males at six rates: 0.25 mg s-1 to 20 mg s-1.,435349_2,0
12451,s-1,104,107,Suxamethonium chloride (Sch) was administered i.v. to 36 adult males at six rates: 0.25 mg s-1 to 20 mg s-1.,435349_2,0
6662,ulnar nerve,103,114,The infusion was discontinued either when there was no muscular response to tetanic stimulation of the ulnar nerve or when Sch 120 mg was exceeded.,435349_3,1
2987,Sch,123,126,The infusion was discontinued either when there was no muscular response to tetanic stimulation of the ulnar nerve or when Sch 120 mg was exceeded.,435349_3,0
12453,tetanic stimulation,76,95,The infusion was discontinued either when there was no muscular response to tetanic stimulation of the ulnar nerve or when Sch 120 mg was exceeded.,435349_3,1
12458,s-1,79,82,Total fasciculation scores in the 30-mg bolus group and the 5-mg s-1 and 20-mg s-1 infusion groups were not significantly different.,435349_9,0
12457,s-1,65,68,Total fasciculation scores in the 30-mg bolus group and the 5-mg s-1 and 20-mg s-1 infusion groups were not significantly different.,435349_9,0
6663,involuntary movements,29,50,Tiapride in levodopa-induced involuntary movements.,458486_0,1
2988,Tiapride,0,8,Tiapride in levodopa-induced involuntary movements.,458486_0,0
6665,idiopathic Parkinson's disease,157,187,"Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.",458486_1,1
2990,metoclopramide,64,78,"Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.",458486_1,0
2989,Tiapride,0,8,"Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.",458486_1,0
12460,substituted benzamide,12,33,"Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.",458486_1,0
6664,involuntary movements,115,136,"Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease.",458486_1,1
12462,end-of-dose akinesia,86,106,"However, an unacceptable increase in disability from Parkinsonism with aggravation of end-of-dose akinesia led to its cessation in 14 patients.",458486_2,1
2991,Tiapride,0,8,"Tiapride had no effect on levodopa-induced early morning of ""off-period"" segmental dystonia.",458486_3,0
6666,dystonia,83,91,"Tiapride had no effect on levodopa-induced early morning of ""off-period"" segmental dystonia.",458486_3,1
2992,dopamine receptors,128,146,These results fail to support the notion that levodopa-induced dyskinesias are caused by overstimulation of a separate group of dopamine receptors.,458486_4,0
12465,liver function,77,91,Haematological complications were not troublesome and results of biochemical liver function tests remained normal.,4812392_2,1
6667,portal fibrosis,46,61,Minimal cholestasis was seen in two cases and portal fibrosis of a reversible degree in eight.,4812392_3,1
12469,reversible stage,158,174,Liver biopsies should be undertaken at regular intervals if azathioprine therapy is continued so that structural liver damage may be detected at an early and reversible stage.,4812392_4,1
12468,liver damage,113,125,Liver biopsies should be undertaken at regular intervals if azathioprine therapy is continued so that structural liver damage may be detected at an early and reversible stage.,4812392_4,1
12474,alkaline phosphatase,143,163,"Long-term administration of quinidine was associated with persistent elevation of serum concentrations of SGOT, lactic acid dehydrogenase, and alkaline phosphatase.",48362_1,0
2993,SGOT,106,110,"Long-term administration of quinidine was associated with persistent elevation of serum concentrations of SGOT, lactic acid dehydrogenase, and alkaline phosphatase.",48362_1,0
12473,lactic acid dehydrogenase,112,137,"Long-term administration of quinidine was associated with persistent elevation of serum concentrations of SGOT, lactic acid dehydrogenase, and alkaline phosphatase.",48362_1,0
12476,active hepatitis,20,36,Liver biopsy showed active hepatitis.,48362_2,1
12478,liver function,60,74,Discontinuance of quinidine therapy led to normalization of liver function tests.,48362_3,1
12480,abrupt elevation,59,75,"A challenge dose of quinidine caused clinical symptoms and abrupt elevation of SGOT, alkaline phosphatase, and lactic acid dehydrogenase values.",48362_4,1
12481,alkaline phosphatase,85,105,"A challenge dose of quinidine caused clinical symptoms and abrupt elevation of SGOT, alkaline phosphatase, and lactic acid dehydrogenase values.",48362_4,0
12482,lactic acid dehydrogenase,111,136,"A challenge dose of quinidine caused clinical symptoms and abrupt elevation of SGOT, alkaline phosphatase, and lactic acid dehydrogenase values.",48362_4,0
12479,clinical symptoms,37,54,"A challenge dose of quinidine caused clinical symptoms and abrupt elevation of SGOT, alkaline phosphatase, and lactic acid dehydrogenase values.",48362_4,1
2994,SGOT,79,83,"A challenge dose of quinidine caused clinical symptoms and abrupt elevation of SGOT, alkaline phosphatase, and lactic acid dehydrogenase values.",48362_4,0
12483,hepatotoxicity,45,59,We concluded that this patient had quinidine hepatotoxicity and believe that this is the first case reported with liver biopsy documentation.,48362_5,1
12485,renal arteries,51,65,Angiosarcoma was also present within pulmonary and renal arteries.,567256_2,1
6668,primary tumors,75,89,The possibility that the intraarterial lesions might represent independent primary tumors is considered.,567256_3,1
12486,intraarterial,25,38,The possibility that the intraarterial lesions might represent independent primary tumors is considered.,567256_3,1
12490,heparin-induced thrombocytopenia,104,136,Arterial thromboembolism in patients receiving systemic heparin therapy: a complication associated with heparin-induced thrombocytopenia.,591536_0,1
12487,Arterial thromboembolism,0,24,Arterial thromboembolism in patients receiving systemic heparin therapy: a complication associated with heparin-induced thrombocytopenia.,591536_0,1
12491,Arterial thromboembolism,0,24,Arterial thromboembolism is a recognized complication of systemic heparin therapy.,591536_1,1
12494,profound thrombocytopenia,182,207,"Characteristic of the entity is arterial occlusion by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.",591536_2,1
12492,distal ischemia,83,98,"Characteristic of the entity is arterial occlusion by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.",591536_2,1
6669,arterial occlusion,32,50,"Characteristic of the entity is arterial occlusion by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter.",591536_2,1
12496,clinically apparent,4,23,"The clinically apparent occlusion may be preceded by gastrointestinal and musculoskeletal symptoms that appear to be ischemic in origin, and might serve to warn the clinician of these complications.",591536_3,1
2995,platelet aggregation,83,103,The common factor relating thromboembolism and thrombocytopenia is heparin-induced platelet aggregation.,591536_5,0
12497,sodium warfarin,87,102,"Appropriate treatment consists of discontinuation of heparin, and anticoagulation with sodium warfarin if necessary.",591536_6,0
12500,(Hyoscine).Galanthamine hydrobromide,123,159,"Galanthamine hydrobromide, a longer acting anticholinesterase drug, in the treatment of the central effects of scopolamine (Hyoscine).Galanthamine hydrobromide, an anticholinesterase drug capable of penetrating the blood-brain barrier, was used in a patient demonstrating central effects of scopolamine (hyoscine) overdosage.",603022_0,0
12499,Galanthamine hydrobromide,0,25,"Galanthamine hydrobromide, a longer acting anticholinesterase drug, in the treatment of the central effects of scopolamine (Hyoscine).Galanthamine hydrobromide, an anticholinesterase drug capable of penetrating the blood-brain barrier, was used in a patient demonstrating central effects of scopolamine (hyoscine) overdosage.",603022_0,0
2996,anticholinesterase drug,43,66,"Galanthamine hydrobromide, a longer acting anticholinesterase drug, in the treatment of the central effects of scopolamine (Hyoscine).Galanthamine hydrobromide, an anticholinesterase drug capable of penetrating the blood-brain barrier, was used in a patient demonstrating central effects of scopolamine (hyoscine) overdosage.",603022_0,0
2997,anticholinesterase drug,164,187,"Galanthamine hydrobromide, a longer acting anticholinesterase drug, in the treatment of the central effects of scopolamine (Hyoscine).Galanthamine hydrobromide, an anticholinesterase drug capable of penetrating the blood-brain barrier, was used in a patient demonstrating central effects of scopolamine (hyoscine) overdosage.",603022_0,0
12504,non-depolarizing neuromuscular block,81,117,It is longer acting than physostigmine and is used in anaesthesia to reverse the non-depolarizing neuromuscular block.,603022_1,1
2998,flunitrazepam,18,31,administration of flunitrazepam in volunteers.,6103707_1,0
2999,Flunitrazepam,0,13,"Flunitrazepam 0.5, 1.0 or 2.0 mg was given by the oral or i.m.",6103707_2,0
12507,gas-liquid chromatography,52,77,"Plasma concentrations of the drug were estimated by gas-liquid chromatography, in a smaller number of the subjects.",6103707_4,0
12508,deep sleep,84,94,"The most striking effect was sedation which increased with the dose, 2 mg producing deep sleep although the subjects could still be aroused.",6103707_5,1
3000,i.m.,15,19,The effects of i.m. administration were apparent earlier and sometimes lasted longer than those following oral administration.,6103707_6,0
3001,flunitrazepam,13,26,injection of flunitrazepam significantly more often than with isotonic saline.,6103707_9,0
12510,isotonic saline,62,77,injection of flunitrazepam significantly more often than with isotonic saline.,6103707_9,0
12512,GYKI-41 099,16,27,"Pharmacology of GYKI-41 099 (chlorpropanol, Tobanum) a new potent beta-adrenergic antagonist.",6111982_0,0
12513,chlorpropanol,29,42,"Pharmacology of GYKI-41 099 (chlorpropanol, Tobanum) a new potent beta-adrenergic antagonist.",6111982_0,0
12514,Tobanum,44,51,"Pharmacology of GYKI-41 099 (chlorpropanol, Tobanum) a new potent beta-adrenergic antagonist.",6111982_0,0
3002,beta-adrenergic antagonist,66,92,"Pharmacology of GYKI-41 099 (chlorpropanol, Tobanum) a new potent beta-adrenergic antagonist.",6111982_0,0
3004,propranolol,89,100,"The compound GYKI-41 099, as a beta-adrenergic antagonist, is 3-8 times more potent than propranolol in vitro and in vivo.",6111982_1,0
3003,beta-adrenergic antagonist,31,57,"The compound GYKI-41 099, as a beta-adrenergic antagonist, is 3-8 times more potent than propranolol in vitro and in vivo.",6111982_1,0
12515,GYKI-41 099,13,24,"The compound GYKI-41 099, as a beta-adrenergic antagonist, is 3-8 times more potent than propranolol in vitro and in vivo.",6111982_1,0
3005,propranolol,51,62,Its antiarrhythmic effectiveness surpasses that of propranolol and pindolol inhibiting the ouabain arrhythmia in dogs and cats.,6111982_2,0
3006,ouabain,91,98,Its antiarrhythmic effectiveness surpasses that of propranolol and pindolol inhibiting the ouabain arrhythmia in dogs and cats.,6111982_2,0
12519,cardioselective,66,81,GYKI-41 900 has a negligible cardiodepressant activity; it is not cardioselective.,6111982_3,0
12521,unlabeled substance,21,40,The half life of the unlabeled substance in humans was more than 10 hours.,6111982_6,0
3007,bendrofluazide,21,35,Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension.,6115999_0,0
3008,propranolol,40,51,Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension.,6115999_0,0
12522,mild hypertension,73,90,Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension.,6115999_0,1
6670,Adverse reactions,0,17,Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension.,6115999_0,1
12523,mild hypertension,65,82,"Participants in the Medical Research Council treatment trial for mild hypertension are randomly allocated to one of four treatment groups: bendrofluazide, propranolol, or a placebo for either of these drugs.",6115999_2,1
3009,bendrofluazide,139,153,"Participants in the Medical Research Council treatment trial for mild hypertension are randomly allocated to one of four treatment groups: bendrofluazide, propranolol, or a placebo for either of these drugs.",6115999_2,0
3010,propranolol,155,166,"Participants in the Medical Research Council treatment trial for mild hypertension are randomly allocated to one of four treatment groups: bendrofluazide, propranolol, or a placebo for either of these drugs.",6115999_2,0
12525,active drugs,74,86,"23 582 patient-years of observation have been completed so far, 10 684 on active drugs and 12 898 on placebos.",6115999_4,0
12526,taking placebos,169,184,"The results show an association between bendrofluazide treatment and impotence, and impotence also occurred more frequently in patients taking propranolol than in those taking placebos.",6115999_5,0
3011,bendrofluazide,40,54,"The results show an association between bendrofluazide treatment and impotence, and impotence also occurred more frequently in patients taking propranolol than in those taking placebos.",6115999_5,0
3012,propranolol,143,154,"The results show an association between bendrofluazide treatment and impotence, and impotence also occurred more frequently in patients taking propranolol than in those taking placebos.",6115999_5,0
6673,Raynaud's phenomenon,178,198,"Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.",6115999_6,1
6672,impaired glucose tolerance,71,97,"Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.",6115999_6,1
6671,adverse reactions,6,23,"Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.",6115999_6,1
3014,propranolol,236,247,"Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.",6115999_6,0
12527,active drugs,50,62,"Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.",6115999_6,0
3013,bendrofluazide,148,162,"Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol.",6115999_6,0
3015,propranolol,52,63,No corneal disease is known to have occurred in the propranolol group.,6115999_7,0
6674,corneal disease,3,18,No corneal disease is known to have occurred in the propranolol group.,6115999_7,1
3016,uric acid,46,55,"Mean serum potassium level fell, and urea and uric acid levels rose, in men and women taking bendrofluazide.",6115999_8,0
3017,bendrofluazide,93,107,"Mean serum potassium level fell, and urea and uric acid levels rose, in men and women taking bendrofluazide.",6115999_8,0
3018,propranolol,7,18,"In the propranolol group, serum potassium and uric acid levels rose in both sexes, but the urea level rose significantly in women only.",6115999_9,0
3019,uric acid,46,55,"In the propranolol group, serum potassium and uric acid levels rose in both sexes, but the urea level rose significantly in women only.",6115999_9,0
3021,baclofen,40,48,"Serotonergic drugs, benzodiazepines and baclofen block muscimol-induced myoclonic jerks in a strain of mice.",6118280_0,0
6675,myoclonic jerks,72,87,"Serotonergic drugs, benzodiazepines and baclofen block muscimol-induced myoclonic jerks in a strain of mice.",6118280_0,1
3020,Serotonergic drugs,0,18,"Serotonergic drugs, benzodiazepines and baclofen block muscimol-induced myoclonic jerks in a strain of mice.",6118280_0,0
6676,myoclonic jerks,38,53,"In male Swiss mice, muscimol produced myoclonic jerks.",6118280_1,1
3022,muscimol,20,28,"In male Swiss mice, muscimol produced myoclonic jerks.",6118280_1,0
12531,i.p.,11,15,A 3 mg/kg (i.p.) dose induced this response in all of the mice tested and the peak response of 73 jerks per min was observed between 27 and 45 min.,6118280_2,0
3023,muscimol,188,196,Increasing the brain serotonin levels by the administration of 5-hydroxytryptophan (80-160 mg/kg) in combination with a peripheral decarboxylase inhibitor resulted in an inhibition of the muscimol effect.,6118280_3,0
12533,5-hydroxytryptophan,63,82,Increasing the brain serotonin levels by the administration of 5-hydroxytryptophan (80-160 mg/kg) in combination with a peripheral decarboxylase inhibitor resulted in an inhibition of the muscimol effect.,6118280_3,0
12534,peripheral decarboxylase inhibitor,120,154,Increasing the brain serotonin levels by the administration of 5-hydroxytryptophan (80-160 mg/kg) in combination with a peripheral decarboxylase inhibitor resulted in an inhibition of the muscimol effect.,6118280_3,0
3024,muscimol,114,122,"In doses of 3-10 mg/kg, the serotonin receptor agonist MK-212 caused a dose-dependent blockade of the response of muscimol.",6118280_5,0
12535,serotonin receptor agonist MK-212,28,61,"In doses of 3-10 mg/kg, the serotonin receptor agonist MK-212 caused a dose-dependent blockade of the response of muscimol.",6118280_5,0
3025,clonazepam,24,34,"Of the benzodiazepines, clonazepam (0.1-0.3 mg/kg) was found to be several fold more potent than diazepam (0.3-3 mg/kg) in blocking the myoclonic jerks.",6118280_6,0
6677,myoclonic jerks,136,151,"Of the benzodiazepines, clonazepam (0.1-0.3 mg/kg) was found to be several fold more potent than diazepam (0.3-3 mg/kg) in blocking the myoclonic jerks.",6118280_6,1
12537,(-)-baclofen (1,6,21,"While (-)-baclofen (1-3 mg/kg) proved to be an effective antagonist of muscimol, its (+)-isomer (5-20 mg/kg) lacked this property.",6118280_7,0
3027,(+)-isomer,85,95,"While (-)-baclofen (1-3 mg/kg) proved to be an effective antagonist of muscimol, its (+)-isomer (5-20 mg/kg) lacked this property.",6118280_7,0
3026,muscimol,71,79,"While (-)-baclofen (1-3 mg/kg) proved to be an effective antagonist of muscimol, its (+)-isomer (5-20 mg/kg) lacked this property.",6118280_7,0
3028,new drug,246,254,"Considering the fact that 5-HTP and the benzodiazepines have been found to be beneficial in the management of clinical myoclonus, the muscimol-induced myoclonus seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition.",6118280_8,0
12538,clinical myoclonus,110,128,"Considering the fact that 5-HTP and the benzodiazepines have been found to be beneficial in the management of clinical myoclonus, the muscimol-induced myoclonus seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition.",6118280_8,1
3029,(-)-baclofen,61,73,Our present study indicated the possible value of MK-212 and (-)-baclofen in the management of clinical myoclonus.,6118280_9,0
12540,MK-212,50,56,Our present study indicated the possible value of MK-212 and (-)-baclofen in the management of clinical myoclonus.,6118280_9,0
12541,clinical myoclonus,95,113,Our present study indicated the possible value of MK-212 and (-)-baclofen in the management of clinical myoclonus.,6118280_9,1
12543,beta-adrenergic blocking drugs,28,58,Adverse interaction between beta-adrenergic blocking drugs and verapamil--report of three cases.,6127992_0,0
12542,Adverse interaction,0,19,Adverse interaction between beta-adrenergic blocking drugs and verapamil--report of three cases.,6127992_0,1
12544,beta-adrenergic blocking drugs,151,181,"Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.",6127992_1,0
6679,cardiac failure,63,78,"Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.",6127992_1,1
6678,heart disease,30,43,"Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs.",6127992_1,1
12545,clinical picture,5,21,This clinical picture resolved completely with cessation of the combined therapy.,6127992_2,1
12547,left ventricular function,9,34,"Baseline left ventricular function, assessed by cardiac catheterisation or nuclear angiography, was normal in two patients and only mildly reduced in the other.",6127992_3,1
12551,profound adverse interactions,92,121,Simultaneously administration of beta-adrenergic blocking drugs and verapamil may result in profound adverse interactions and should only be administered with great caution.,6127992_4,1
12550,beta-adrenergic blocking drugs,33,63,Simultaneously administration of beta-adrenergic blocking drugs and verapamil may result in profound adverse interactions and should only be administered with great caution.,6127992_4,0
3030,sulphasalazine,27,41,Possible teratogenicity of sulphasalazine.,6133211_0,0
6680,inflammatory bowel disease,40,66,"Three infants, born of two mothers with inflammatory bowel disease who received treatment with sulphasalazine throughout pregnancy, were found to have major congenital anomalies.",6133211_1,1
3031,sulphasalazine,95,109,"Three infants, born of two mothers with inflammatory bowel disease who received treatment with sulphasalazine throughout pregnancy, were found to have major congenital anomalies.",6133211_1,0
6681,congenital anomalies,157,177,"Three infants, born of two mothers with inflammatory bowel disease who received treatment with sulphasalazine throughout pregnancy, were found to have major congenital anomalies.",6133211_1,1
6682,ulcerative colitis,43,61,"In the singleton pregnancy, the mother had ulcerative colitis, and the infant, a male, had coarctation of the aorta and a ventricular septal defect.",6133211_2,1
6683,coarctation of the aorta,91,115,"In the singleton pregnancy, the mother had ulcerative colitis, and the infant, a male, had coarctation of the aorta and a ventricular septal defect.",6133211_2,1
6684,ventricular septal defect,122,147,"In the singleton pregnancy, the mother had ulcerative colitis, and the infant, a male, had coarctation of the aorta and a ventricular septal defect.",6133211_2,1
12553,singleton pregnancy,7,26,"In the singleton pregnancy, the mother had ulcerative colitis, and the infant, a male, had coarctation of the aorta and a ventricular septal defect.",6133211_2,1
12554,twin pregnancy,7,21,"In the twin pregnancy, the mother had Crohn's disease.",6133211_3,1
6685,Crohn's disease,38,53,"In the twin pregnancy, the mother had Crohn's disease.",6133211_3,1
6686,polycystic kidney,53,70,"The first twin, a female, had a left Potter-type IIa polycystic kidney and a rudimentary left uterine cornu.",6133211_4,1
12556,Potter's facies,46,61,"The second twin, a male, had some features of Potter's facies, hypoplastic lungs, absent kidneys and ureters, and talipes equinovarus.",6133211_5,1
12557,absent kidneys,82,96,"The second twin, a male, had some features of Potter's facies, hypoplastic lungs, absent kidneys and ureters, and talipes equinovarus.",6133211_5,1
6687,hypoplastic,63,74,"The second twin, a male, had some features of Potter's facies, hypoplastic lungs, absent kidneys and ureters, and talipes equinovarus.",6133211_5,1
6688,talipes equinovarus,114,133,"The second twin, a male, had some features of Potter's facies, hypoplastic lungs, absent kidneys and ureters, and talipes equinovarus.",6133211_5,1
3032,sulphasalazine,54,68,"Despite reports to the contrary, it is suggested that sulphasalazine may be teratogenic.",6133211_6,0
12558,acid secretion,75,89,Comparison of the effectiveness of ranitidine and cimetidine in inhibiting acid secretion in patients with gastric hypersecretory states.,6150641_0,1
12560,receptor antagonists ranitidine,17,48,The H2-histamine receptor antagonists ranitidine and cimetidine were compared for their abilities to control gastric acid hypersecretion on a short- and long-term basis in 22 patients with gastric acid hypersecretory states.,6150641_1,0
6689,gastric acid,109,121,The H2-histamine receptor antagonists ranitidine and cimetidine were compared for their abilities to control gastric acid hypersecretion on a short- and long-term basis in 22 patients with gastric acid hypersecretory states.,6150641_1,1
6690,gastric acid,189,201,The H2-histamine receptor antagonists ranitidine and cimetidine were compared for their abilities to control gastric acid hypersecretion on a short- and long-term basis in 22 patients with gastric acid hypersecretory states.,6150641_1,1
12563,idiopathic hypersecretion,110,135,"Nineteen patients had Zollinger-Ellison syndrome, one patient had systemic mastocytosis, and two patients had idiopathic hypersecretion.",6150641_2,1
6691,Zollinger-Ellison syndrome,22,48,"Nineteen patients had Zollinger-Ellison syndrome, one patient had systemic mastocytosis, and two patients had idiopathic hypersecretion.",6150641_2,1
6692,systemic mastocytosis,66,87,"Nineteen patients had Zollinger-Ellison syndrome, one patient had systemic mastocytosis, and two patients had idiopathic hypersecretion.",6150641_2,1
3033,anticholinergic agents,44,66,"The actions of both drugs were increased by anticholinergic agents, and there was a close correlation between the daily maintenance dose of each drug needed to control acid secretion.",6150641_4,0
12565,control acid secretion,160,182,"The actions of both drugs were increased by anticholinergic agents, and there was a close correlation between the daily maintenance dose of each drug needed to control acid secretion.",6150641_4,1
12566,breast changes,37,51,Sixty percent of the males developed breast changes or impotence while taking cimetidine and in all cases these changes disappeared when cimetidine was replaced by ranitidine.,6150641_6,1
3034,creatinine,305,315,"Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.",6150641_7,0
12567,high doses,15,25,"Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy.",6150641_7,0
12570,acid secretion,56,70,The results show that both drugs can adequately inhibit acid secretion in patients with gastric hypersecretory states.,6150641_8,1
6693,side effects,105,117,"Both are safe at high doses, but ranitidine is threefold more potent and does not cause the antiandrogen side effects frequently seen with high doses of cimetidine.",6150641_9,1
12572,high doses,17,27,"Both are safe at high doses, but ranitidine is threefold more potent and does not cause the antiandrogen side effects frequently seen with high doses of cimetidine.",6150641_9,0
3035,antiandrogen,92,104,"Both are safe at high doses, but ranitidine is threefold more potent and does not cause the antiandrogen side effects frequently seen with high doses of cimetidine.",6150641_9,0
12573,high doses,139,149,"Both are safe at high doses, but ranitidine is threefold more potent and does not cause the antiandrogen side effects frequently seen with high doses of cimetidine.",6150641_9,0
12574,Epileptogenic,0,13,Epileptogenic properties of enflurane and their clinical interpretation.,6153967_0,1
6694,motor seizures,97,111,"In one patient, enflurane administered during a donor nephrectomy resulted in unexpected partial motor seizures.",6153967_2,1
12576,donor nephrectomy,48,65,"In one patient, enflurane administered during a donor nephrectomy resulted in unexpected partial motor seizures.",6153967_2,1
6695,generalized seizures,54,74,"Two other patients suffered from partial, complex and generalized seizures uncontrolled by medication.",6153967_4,1
12578,Epileptic foci,0,14,Epileptic foci delineated and activated by enflurane were surgically ablated and the patients are now seizure-free.,6153967_5,1
12581,epileptic foci,77,91,"On the other hand, enflurane may prove to be a safe fast acting activator of epileptic foci during corticography or depth electrode intraoperative recordings.",6153967_7,1
12585,antineoplastic chemotherapy,61,88,Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy.,6203452_0,0
6696,Thrombotic microangiopathy,0,26,Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy.,6203452_0,1
6697,renal failure,31,44,Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy.,6203452_0,1
12586,vinca alkaloid,219,233,"Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.",6203452_1,0
3037,bleomycin,202,211,"Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.",6203452_1,0
3036,cisplatin,191,200,"Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.",6203452_1,0
6700,microangiopathic hemolytic anemia,105,138,"Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.",6203452_1,1
6699,renal insufficiency,84,103,"Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.",6203452_1,1
6698,thrombotic microangiopathy,39,65,"Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a vinca alkaloid.",6203452_1,1
6701,thrombotic thrombocytopenic purpura,16,51,"One patient had thrombotic thrombocytopenic purpura, three the hemolytic-uremic syndrome, and one an apparent forme fruste of one of these disorders.",6203452_2,1
6703,forme fruste,110,122,"One patient had thrombotic thrombocytopenic purpura, three the hemolytic-uremic syndrome, and one an apparent forme fruste of one of these disorders.",6203452_2,1
6702,hemolytic-uremic syndrome,63,88,"One patient had thrombotic thrombocytopenic purpura, three the hemolytic-uremic syndrome, and one an apparent forme fruste of one of these disorders.",6203452_2,1
6704,intravascular coagulation,62,87,"Histologic examination of the renal tissue showed evidence of intravascular coagulation, primarily affecting the small arteries, arterioles, and glomeruli.",6203452_3,1
12589,small arteries,113,127,"Histologic examination of the renal tissue showed evidence of intravascular coagulation, primarily affecting the small arteries, arterioles, and glomeruli.",6203452_3,1
6705,tumor-free,25,35,"Because each patient was tumor-free or had only a small tumor at the onset of this syndrome, the thrombotic microangiopathy may have been induced by chemotherapy.",6203452_4,1
6706,thrombotic microangiopathy,97,123,"Because each patient was tumor-free or had only a small tumor at the onset of this syndrome, the thrombotic microangiopathy may have been induced by chemotherapy.",6203452_4,1
12590,small tumor,50,61,"Because each patient was tumor-free or had only a small tumor at the onset of this syndrome, the thrombotic microangiopathy may have been induced by chemotherapy.",6203452_4,1
6707,renal failure,145,158,"Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to cisplatin nephrotoxicity and the anemia and thrombocytopenia to drug-induced bone marrow suppression.",6203452_5,1
12594,cisplatin nephrotoxicity,178,202,"Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to cisplatin nephrotoxicity and the anemia and thrombocytopenia to drug-induced bone marrow suppression.",6203452_5,1
12595,drug-induced bone marrow,242,266,"Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to cisplatin nephrotoxicity and the anemia and thrombocytopenia to drug-induced bone marrow suppression.",6203452_5,1
12592,renal tissue,77,89,"Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to cisplatin nephrotoxicity and the anemia and thrombocytopenia to drug-induced bone marrow suppression.",6203452_5,1
6708,cardiac hypertrophy,37,56,Development of isoproterenol-induced cardiac hypertrophy.,6203632_0,1
12597,ISO,137,140,The development of cardiac hypertrophy was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol (ISO) (0.3 mg/kg body weight).,6203632_1,0
6709,cardiac hypertrophy,19,38,The development of cardiac hypertrophy was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol (ISO) (0.3 mg/kg body weight).,6203632_1,1
6710,body weight,153,164,The development of cardiac hypertrophy was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol (ISO) (0.3 mg/kg body weight).,6203632_1,1
3038,(1,88,90,These data indicate that the adaptive response to ISO shows an early hypertrophic phase (1-4 days) characterized by a substantial increase in RNA content and cardiac mass in the absence of changes in DNA.,6203632_10,0
12610,cardiac mass,158,170,These data indicate that the adaptive response to ISO shows an early hypertrophic phase (1-4 days) characterized by a substantial increase in RNA content and cardiac mass in the absence of changes in DNA.,6203632_10,1
6712,hypertrophic,69,81,These data indicate that the adaptive response to ISO shows an early hypertrophic phase (1-4 days) characterized by a substantial increase in RNA content and cardiac mass in the absence of changes in DNA.,6203632_10,1
12611,cellular hypertrophy,94,114,"However, prolonged stimulation (8-12 days) appears to represent a complex integration of both cellular hypertrophy and hyperplasia within the heart.",6203632_11,1
12600,Heart weight,0,12,Heart weight increased 44% after 8 days of treatment with a half time of 3.4 days.,6203632_3,1
12601,Ventricular RNA,0,15,Ventricular RNA content was elevated 26% after 24 h of a single injection and reached a maximal level following 8 days of therapy.,6203632_4,0
12602,Ventricular DNA,0,15,Ventricular DNA content was unchanged during the early stage (1-4 days) of hypertrophic growth but increased to a new steady-state level 19% above the controls after 8 days of treatment.,6203632_7,0
6711,hypertrophic,75,87,Ventricular DNA content was unchanged during the early stage (1-4 days) of hypertrophic growth but increased to a new steady-state level 19% above the controls after 8 days of treatment.,6203632_7,1
12612,International mexiletine,0,24,International mexiletine and placebo antiarrhythmic coronary trial: I. Report on arrhythmia and other findings.,6209318_0,0
3039,sustained release,34,51,The antiarrhythmic effects of the sustained release form of mexiletine (Mexitil-Perlongets) were evaluated in a double-blind placebo trial in 630 patients with recent documented myocardial infarction.,6209318_2,0
6713,myocardial infarction,178,199,The antiarrhythmic effects of the sustained release form of mexiletine (Mexitil-Perlongets) were evaluated in a double-blind placebo trial in 630 patients with recent documented myocardial infarction.,6209318_2,1
12614,antiarrhythmic effects,4,26,The antiarrhythmic effects of the sustained release form of mexiletine (Mexitil-Perlongets) were evaluated in a double-blind placebo trial in 630 patients with recent documented myocardial infarction.,6209318_2,0
12620,premature ventricular complexes,275,306,The primary response variable was based on central reading of 24 hour ambulatory electrocardiographic recordings and was defined as the occurrence of 30 or more single premature ventricular complexes in any two consecutive 30 minute blocks or one or more runs of two or more premature ventricular complexes in the entire 24 hour electrocardiographic recording.,6209318_3,1
12618,premature ventricular complexes,168,199,The primary response variable was based on central reading of 24 hour ambulatory electrocardiographic recordings and was defined as the occurrence of 30 or more single premature ventricular complexes in any two consecutive 30 minute blocks or one or more runs of two or more premature ventricular complexes in the entire 24 hour electrocardiographic recording.,6209318_3,1
3040,end point,119,128,"Large differences, regarded as statistically significant, between the mexiletine and placebo groups were noted in that end point at months 1 and 4, but only trends were observed at month 12.",6209318_4,0
12624,coronary events,17,32,The incidence of coronary events was similar in both groups.,6209318_7,1
6714,side effects,22,34,"Previously recognized side effects, particularly tremor and gastrointestinal problems, were more frequent in the mexiletine group than in the placebo group.",6209318_8,1
12625,gastrointestinal problems,60,85,"Previously recognized side effects, particularly tremor and gastrointestinal problems, were more frequent in the mexiletine group than in the placebo group.",6209318_8,1
6715,side effects,9,21,Multiple side effects of penicillamine therapy in one patient with rheumatoid arthritis.,6216862_0,1
6716,rheumatoid arthritis,67,87,Multiple side effects of penicillamine therapy in one patient with rheumatoid arthritis.,6216862_0,1
6717,systemic lupus erythematosus,26,54,"Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.",6216862_1,1
6718,myasthenia gravis,73,90,"Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.",6216862_1,1
6719,rheumatoid arthritis,173,193,"Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.",6216862_1,1
12627,Skin rashes,0,11,"Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis.",6216862_1,1
12629,skin lesion,4,15,"The skin lesion resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with penicillamine.",6216862_3,1
6720,side effect,93,104,"The skin lesion resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with penicillamine.",6216862_3,1
6722,rheumatoid arthritis,164,184,"The skin lesion resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with penicillamine.",6216862_3,1
6721,Wilson's disease,122,138,"The skin lesion resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with penicillamine.",6216862_3,1
6723,myocardial infarction,63,84,Changes in heart size during long-term timolol treatment after myocardial infarction.,6229975_0,1
6724,myocardial infarction,62,83,"The effect of long-term timolol treatment on heart size after myocardial infarction was evaluated by X-ray in a double-blind study including 241 patients (placebo 126, timolol 115).",6229975_1,1
12631,heart size,45,55,"The effect of long-term timolol treatment on heart size after myocardial infarction was evaluated by X-ray in a double-blind study including 241 patients (placebo 126, timolol 115).",6229975_1,1
6725,compensatory,69,81,These differences may be caused by timolol-induced bradycardia and a compensatory increase in end-diastolic volume.,6229975_4,1
12639,re-infarction,6,19,"After re-infarction, heart size increased in the placebo group and remained unchanged in the timolol group.",6229975_7,1
12642,antacid preparations,23,43,Obsolete but dangerous antacid preparations.,625456_0,0
12645,bicarbonate powders,165,184,One case of acute hypercalcaemia and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of calcium carbon-ate-sodium bicarbonate powders for more than 20 years.,625456_1,0
12643,acute hypercalcaemia,12,32,One case of acute hypercalcaemia and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of calcium carbon-ate-sodium bicarbonate powders for more than 20 years.,625456_1,1
12644,recurrent nephrolithiasis,44,69,One case of acute hypercalcaemia and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of calcium carbon-ate-sodium bicarbonate powders for more than 20 years.,625456_1,1
3041,Vitamin D3,0,10,Vitamin D3 toxicity in dairy cows.,6286738_0,0
3042,vitamin D3,26,36,"Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.",6286738_1,0
3043,vitamin D3,160,170,"Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.",6286738_1,0
12648,IU vitamin D3,57,70,"Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.",6286738_1,0
6726,hyperphosphatemia,118,135,"Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows.",6286738_1,1
3044,vitamin D3,73,83,Calcium concentrations 1 day postpartum were higher in cows treated with vitamin D3 about 32 days prepartum (8.8 mg/100 ml) than in control cows (5.5 mg/100 ml).,6286738_2,0
3045,vitamin D3,30,40,"None of the cows treated with vitamin D3 showed signs of milk fever during the peripartal period; however, 22% of the control cows developed clinical signs of milk fever during this period.",6286738_3,0
6727,milk fever,57,67,"None of the cows treated with vitamin D3 showed signs of milk fever during the peripartal period; however, 22% of the control cows developed clinical signs of milk fever during this period.",6286738_3,1
12654,peripartal,79,89,"None of the cows treated with vitamin D3 showed signs of milk fever during the peripartal period; however, 22% of the control cows developed clinical signs of milk fever during this period.",6286738_3,1
12656,clinical signs,141,155,"None of the cows treated with vitamin D3 showed signs of milk fever during the peripartal period; however, 22% of the control cows developed clinical signs of milk fever during this period.",6286738_3,1
6728,milk fever,159,169,"None of the cows treated with vitamin D3 showed signs of milk fever during the peripartal period; however, 22% of the control cows developed clinical signs of milk fever during this period.",6286738_3,1
3047,vitamin D3,139,149,"Signs of vitamin D3 toxicity were not observed in nonlactating nonpregnant cows; however, pregnant cows commonly developed severe signs of vitamin D3 toxicity and 10 of 17 cows died.",6286738_4,0
3046,vitamin D3,9,19,"Signs of vitamin D3 toxicity were not observed in nonlactating nonpregnant cows; however, pregnant cows commonly developed severe signs of vitamin D3 toxicity and 10 of 17 cows died.",6286738_4,0
12659,metastatic calcification,21,45,There was widespread metastatic calcification in the cows that died.,6286738_5,1
6730,milk fever,173,183,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,1
6731,milk fever,252,262,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,1
6729,milk fever,140,150,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,1
3049,vitamin D3,116,126,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,0
3050,vitamin D3,203,213,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,0
12661,prepartum,291,300,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,0
3048,vitamin D3,35,45,"Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum.",6286738_6,0
12662,peripheral nerves,12,29,Diseases of peripheral nerves as seen in the Nigerian African.,6287825_0,1
12665,primary benign,84,98,"The anatomical and aetiological diagnoses of peripheral nerve disease excluding its primary benign and malignant disorders, as seen in 358 Nigerians are presented.",6287825_1,1
6732,peripheral nerve disease,45,69,"The anatomical and aetiological diagnoses of peripheral nerve disease excluding its primary benign and malignant disorders, as seen in 358 Nigerians are presented.",6287825_1,1
12666,malignant disorders,103,122,"The anatomical and aetiological diagnoses of peripheral nerve disease excluding its primary benign and malignant disorders, as seen in 358 Nigerians are presented.",6287825_1,1
12673,Heredofamilial,0,14,Heredofamilial and connective tissue disorders were rare.,6287825_10,1
6738,connective tissue,19,36,Heredofamilial and connective tissue disorders were rare.,6287825_10,1
12674,clinical presentation,35,56,Some of the factors related to the clinical presentation and pathogenesis of the neuropathies are briefly discussed.,6287825_11,1
12668,Sensori-motor neuropathy,0,24,Sensori-motor neuropathy was the commonest presentation (50%).,6287825_3,1
6733,motor neuropathy,109,125,"Guillain-Barr   syndrome was the commonest identifiable cause (15.6%), accounting for half of the cases with motor neuropathy.",6287825_4,1
12669,sensori-motor neuropathy,134,158,Peripheral neuropathy due to nutritional deficiency of thiamine and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy.,6287825_5,1
6734,Peripheral neuropathy,0,21,Peripheral neuropathy due to nutritional deficiency of thiamine and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy.,6287825_5,1
12670,cause of autonomic neuropathy,32,61,Diabetes mellitus was the major cause of autonomic neuropathy.,6287825_6,1
6735,Diabetes mellitus,0,17,Diabetes mellitus was the major cause of autonomic neuropathy.,6287825_6,1
6736,drug-induced,41,53,Isoniazid was the most frequent agent in drug-induced neuropathy.,6287825_7,1
12672,reticuloendothelial system,102,128,Migraine (20%) was not an uncommon cause of cranial neuropathy although malignancies arising from the reticuloendothelial system or related structures of the head and neck were more frequent (26%).,6287825_8,1
12671,cause of cranial neuropathy,35,62,Migraine (20%) was not an uncommon cause of cranial neuropathy although malignancies arising from the reticuloendothelial system or related structures of the head and neck were more frequent (26%).,6287825_8,1
6737,head and neck,158,171,Migraine (20%) was not an uncommon cause of cranial neuropathy although malignancies arising from the reticuloendothelial system or related structures of the head and neck were more frequent (26%).,6287825_8,1
12676,left-sided Wilms tumor,44,66,Doxorubicin cardiomyopathy in children with left-sided Wilms tumor.,6292680_0,1
12675,Doxorubicin cardiomyopathy,0,26,Doxorubicin cardiomyopathy in children with left-sided Wilms tumor.,6292680_0,1
12678,tumor bed,122,131,Two children with Wilms tumor of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the tumor bed and conventional dosage of doxorubicin.,6292680_1,1
12677,left kidney,37,48,Two children with Wilms tumor of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the tumor bed and conventional dosage of doxorubicin.,6292680_1,1
3051,anthracycline,68,81,Two children with Wilms tumor of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the tumor bed and conventional dosage of doxorubicin.,6292680_1,0
6739,Wilms tumor,18,29,Two children with Wilms tumor of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the tumor bed and conventional dosage of doxorubicin.,6292680_1,1
6740,Wilms tumor,79,90,The cardiomyopathy is attributed 1) to the fact that radiation fields for left Wilms tumor include the lower portion of the heart and 2) to the interaction of doxorubicin and irradiation on cardiac muscle.,6292680_2,1
3052,cardiac muscle,190,204,The cardiomyopathy is attributed 1) to the fact that radiation fields for left Wilms tumor include the lower portion of the heart and 2) to the interaction of doxorubicin and irradiation on cardiac muscle.,6292680_2,0
6741,Wilms tumor,81,92,It is recommended that doxorubicin dosage be sharply restricted in children with Wilms tumor of the left kidney who receive postoperative irradiation.,6292680_3,1
12680,doxorubicin dosage,23,41,It is recommended that doxorubicin dosage be sharply restricted in children with Wilms tumor of the left kidney who receive postoperative irradiation.,6292680_3,0
12682,left kidney,100,111,It is recommended that doxorubicin dosage be sharply restricted in children with Wilms tumor of the left kidney who receive postoperative irradiation.,6292680_3,1
12684,extrapyramidal motor system,29,56,Effects of calcitonin on rat extrapyramidal motor system: behavioral and biochemical data.,6293644_0,1
12686,salmon calcitonin,23,40,"injection of human and salmon calcitonin on biochemical and behavioral parameters related to the extrapyramidal motor system, were investigated in male rats.",6293644_2,0
12689,partial prevention,87,105,Calcitonin injection resulted in a potentiation of haloperidol-induced catalepsy and a partial prevention of apomorphine-induced hyperactivity.,6293644_3,1
12693,striatal,91,99,Moreover calcitonin induced a significant decrease in nigral GAD activity but no change in striatal DA and DOPAC concentration or GAD activity.,6293644_4,1
3053,DOPAC,107,112,Moreover calcitonin induced a significant decrease in nigral GAD activity but no change in striatal DA and DOPAC concentration or GAD activity.,6293644_4,0
12691,nigral,54,60,Moreover calcitonin induced a significant decrease in nigral GAD activity but no change in striatal DA and DOPAC concentration or GAD activity.,6293644_4,1
6742,striatonigral,75,88,The results are discussed in view of a primary action of calcitonin on the striatonigral GABAergic pathway mediating the DA-related behavioral messages of striatal origin.,6293644_5,1
3054,GABAergic,89,98,The results are discussed in view of a primary action of calcitonin on the striatonigral GABAergic pathway mediating the DA-related behavioral messages of striatal origin.,6293644_5,0
12696,striatal,155,163,The results are discussed in view of a primary action of calcitonin on the striatonigral GABAergic pathway mediating the DA-related behavioral messages of striatal origin.,6293644_5,1
12697,acetylsalicylate,96,112,"A patient who allegedly consumed 100 tablets of an over-the-counter analgesic containing sodium acetylsalicylate, caffeine, and acetaminophen displayed no significant CNS stimulation despite the presence of 175 micrograms of caffeine per mL of serum.",6308277_1,0
3055,stimulatory,54,65,"Because salicylates have been reported to augment the stimulatory effects of caffeine on the CNS, attention was focused on the possibility that the presence of acetaminophen (52 micrograms/mL) reduced the CNS toxicity of caffeine.",6308277_2,0
12698,DBA/2J,11,17,Studies in DBA/2J mice showed that: 1) pretreatment with acetaminophen (100 mg/kg) increased the interval between the administration of caffeine (300 to 450 mg/kg IP) and the onset of fatal convulsions by a factor of about two; and 2) pretreatment with acetaminophen (75 mg/kg) reduced the incidence of audiogenic seizures produced in the presence of caffeine (12.5 to 75 mg/kg IP).,6308277_3,0
12702,audiogenic seizures,303,322,Studies in DBA/2J mice showed that: 1) pretreatment with acetaminophen (100 mg/kg) increased the interval between the administration of caffeine (300 to 450 mg/kg IP) and the onset of fatal convulsions by a factor of about two; and 2) pretreatment with acetaminophen (75 mg/kg) reduced the incidence of audiogenic seizures produced in the presence of caffeine (12.5 to 75 mg/kg IP).,6308277_3,1
12703,sound-induced seizures,17,39,The frequency of sound-induced seizures after 12.5 or 25 mg/kg caffeine was reduced from 50 to 5% by acetaminophen.,6308277_4,1
3056,convulsant,142,152,"In the absence of caffeine, acetaminophen (up to 300 mg/kg) did not modify the seizures induced by maximal electroshock and did not alter the convulsant dose of pentylenetetrezol in mice (tests performed by the Anticonvulsant Screening Project of NINCDS).",6308277_5,0
12707,radioactive adenosine,76,97,Acetaminophen (up to 150 micrograms/mL) did not retard the incorporation of radioactive adenosine into ATP in slices of rat cerebral cortex.,6308277_6,0
12708,cerebral cortex,124,139,Acetaminophen (up to 150 micrograms/mL) did not retard the incorporation of radioactive adenosine into ATP in slices of rat cerebral cortex.,6308277_6,1
12709,Naloxazone,0,10,"Naloxazone pretreatment modifies cardiorespiratory, temperature, and behavioral effects of morphine.",6308526_0,0
12713,lethal dose,48,59,"Behavioral and cardiorespiratory responses to a lethal dose of morphine were evaluated in rats pretreated with saline or naloxazone, an antagonist of high-affinity mu 1 opioid receptors.",6308526_1,0
12714,naloxazone,121,131,"Behavioral and cardiorespiratory responses to a lethal dose of morphine were evaluated in rats pretreated with saline or naloxazone, an antagonist of high-affinity mu 1 opioid receptors.",6308526_1,0
3057,high-affinity,150,163,"Behavioral and cardiorespiratory responses to a lethal dose of morphine were evaluated in rats pretreated with saline or naloxazone, an antagonist of high-affinity mu 1 opioid receptors.",6308526_1,0
3058,opioid receptors,169,185,"Behavioral and cardiorespiratory responses to a lethal dose of morphine were evaluated in rats pretreated with saline or naloxazone, an antagonist of high-affinity mu 1 opioid receptors.",6308526_1,0
12716,naloxazone,18,28,"Pretreatment with naloxazone significantly blocked morphine analgesia, catalepsy and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes.",6308526_2,0
3059,high-affinity,135,148,"Pretreatment with naloxazone significantly blocked morphine analgesia, catalepsy and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes.",6308526_2,0
12719,morphine-induced bradycardia,115,143,"Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced bradycardia was less affected.",6308526_3,1
6743,respiratory depression,83,105,"Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced bradycardia was less affected.",6308526_3,1
12717,naloxazone,10,20,"Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced bradycardia was less affected.",6308526_3,0
3060,mu receptors,40,52,Results indicate that subpopulations of mu receptors may mediate selective behavioral and cardiorespiratory responses to morphine.,6308526_4,0
12721,drug action,16,27,Modification of drug action by hyperammonemia.,6323692_0,0
6744,hyperammonemia,31,45,Modification of drug action by hyperammonemia.,6323692_0,1
12723,ammonium acetate,18,34,"Pretreatment with ammonium acetate (NH4Ac) (6 mmol/kg s.c.) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam, but NH4Ac treatment alone had no effect.",6323692_1,0
12724,NH4Ac,36,41,"Pretreatment with ammonium acetate (NH4Ac) (6 mmol/kg s.c.) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam, but NH4Ac treatment alone had no effect.",6323692_1,0
12726,NH4Ac,204,209,"Pretreatment with ammonium acetate (NH4Ac) (6 mmol/kg s.c.) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam, but NH4Ac treatment alone had no effect.",6323692_1,0
12725,muscular incoordination,163,186,"Pretreatment with ammonium acetate (NH4Ac) (6 mmol/kg s.c.) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam, but NH4Ac treatment alone had no effect.",6323692_1,0
6745,hyperammonemia,6,20,"Thus, hyperammonemia is capable of altering drug action and must be considered along with impaired drug metabolism in enhanced drug responses associated with liver disease.",6323692_2,1
6746,liver disease,158,171,"Thus, hyperammonemia is capable of altering drug action and must be considered along with impaired drug metabolism in enhanced drug responses associated with liver disease.",6323692_2,1
12734,NH4Ac,225,230,Experiments in vitro showed that acetylcholine-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.,6323692_3,0
12732,NH4Ac,143,148,Experiments in vitro showed that acetylcholine-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac.,6323692_3,0
12735,calcium-independent catecholamine,72,105,"Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.",6323692_4,0
12736,NH4Ac,149,154,"Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac.",6323692_4,0
12737,ammonia blocks calcium channels,29,60,These results suggested that ammonia blocks calcium channels.,6323692_5,0
12739,calcium channel blocker verapamil,42,75,Parallels in the actions of NH4Ac and the calcium channel blocker verapamil support this concept.,6323692_6,0
12738,NH4Ac,28,33,Parallels in the actions of NH4Ac and the calcium channel blocker verapamil support this concept.,6323692_6,0
12741,NH4Ac,35,40,"Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.",6323692_7,0
12742,muscular incoordination,104,127,"Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.",6323692_7,0
12744,NH4Ac,206,211,"Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.",6323692_7,0
3061,convulsant,225,235,"Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol.",6323692_7,0
6747,hyperammonemia,22,36,The data suggest that hyperammonemia exerts a calcium channel blocking action which enhances the effects of central nervous system depressants and certain opioid analgesics.,6323692_8,1
3063,central nervous system depressants,108,142,The data suggest that hyperammonemia exerts a calcium channel blocking action which enhances the effects of central nervous system depressants and certain opioid analgesics.,6323692_8,0
3064,opioid analgesics,155,172,The data suggest that hyperammonemia exerts a calcium channel blocking action which enhances the effects of central nervous system depressants and certain opioid analgesics.,6323692_8,0
3062,calcium channel,46,61,The data suggest that hyperammonemia exerts a calcium channel blocking action which enhances the effects of central nervous system depressants and certain opioid analgesics.,6323692_8,0
12747,thalamotomy,32,43,Levodopa-induced dyskinesia and thalamotomy.,6381653_0,1
6748,choreic,86,93,"Levodopa-induced dyskinesia of the limbs in thirteen cases of Parkinsonism, which was choreic, ballistic or dystonic in type, was alleviated almost completely by stereotaxic surgery using a microelectrode technique for the ventralis oralis anterior and posterior nuclei of the thalamus, but much less by the ventralis intermedius nucleus.",6381653_1,1
12749,dystonic,108,116,"Levodopa-induced dyskinesia of the limbs in thirteen cases of Parkinsonism, which was choreic, ballistic or dystonic in type, was alleviated almost completely by stereotaxic surgery using a microelectrode technique for the ventralis oralis anterior and posterior nuclei of the thalamus, but much less by the ventralis intermedius nucleus.",6381653_1,1
12752,ventralis oralis anterior,223,248,"Levodopa-induced dyskinesia of the limbs in thirteen cases of Parkinsonism, which was choreic, ballistic or dystonic in type, was alleviated almost completely by stereotaxic surgery using a microelectrode technique for the ventralis oralis anterior and posterior nuclei of the thalamus, but much less by the ventralis intermedius nucleus.",6381653_1,1
12753,ventralis intermedius nucleus,308,337,"Levodopa-induced dyskinesia of the limbs in thirteen cases of Parkinsonism, which was choreic, ballistic or dystonic in type, was alleviated almost completely by stereotaxic surgery using a microelectrode technique for the ventralis oralis anterior and posterior nuclei of the thalamus, but much less by the ventralis intermedius nucleus.",6381653_1,1
6749,thalamic,43,51,Control of levodopa-induced dyskinesias by thalamic lesions in the course of routine treatment of Parkinsonism is discussed.,6381653_2,1
12756,major depressive disorder,95,120,A double-blind study of the efficacy and safety of dothiepin hydrochloride in the treatment of major depressive disorder.,6386793_0,1
3065,dothiepin hydrochloride,51,74,A double-blind study of the efficacy and safety of dothiepin hydrochloride in the treatment of major depressive disorder.,6386793_0,0
3066,dothiepin,51,60,"In a 6-week double-blind parallel treatment study, dothiepin and amitriptyline were compared to placebo in the treatment of 33 depressed outpatients.",6386793_1,0
3067,Dothiepin,0,9,"Dothiepin and amitriptyline were equally effective in alleviating the symptoms of depressive illness, and both were significantly superior to placebo.",6386793_2,0
12760,depressive illness,82,100,"Dothiepin and amitriptyline were equally effective in alleviating the symptoms of depressive illness, and both were significantly superior to placebo.",6386793_2,1
6750,side effects,25,37,"The overall incidence of side effects and the frequency and severity of blurred vision, dry mouth, and drowsiness were significantly less with dothiepin than with amitriptyline.",6386793_3,1
3068,dothiepin,143,152,"The overall incidence of side effects and the frequency and severity of blurred vision, dry mouth, and drowsiness were significantly less with dothiepin than with amitriptyline.",6386793_3,0
12761,blurred vision,72,86,"The overall incidence of side effects and the frequency and severity of blurred vision, dry mouth, and drowsiness were significantly less with dothiepin than with amitriptyline.",6386793_3,1
12762,dry mouth,88,97,"The overall incidence of side effects and the frequency and severity of blurred vision, dry mouth, and drowsiness were significantly less with dothiepin than with amitriptyline.",6386793_3,1
3069,Dothiepin,0,9,Dothiepin also produced fewer CNS and cardiovascular effects.,6386793_4,0
3071,antidepressant drug,44,63,Dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients.,6386793_6,0
6751,side effects,86,98,Dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients.,6386793_6,1
3070,Dothiepin,0,9,Dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients.,6386793_6,0
12767,panic disorder,64,78,Behavioral effects of diazepam and propranolol in patients with panic disorder and agoraphobia.,6387529_0,1
3072,propranolol,35,46,Behavioral effects of diazepam and propranolol in patients with panic disorder and agoraphobia.,6387529_0,0
12768,oral doses,15,25,"The effects of oral doses of diazepam (single dose of 10 mg and a median dose of 30 mg/day for 2 weeks) and propranolol (single dose of 80 mg and a median dose of 240 mg/day for 2 weeks) on psychological performance of patients with panic disorders and agoraphobia were investigated in a double-blind, randomized and crossover design.",6387529_1,0
12769,single dose,39,50,"The effects of oral doses of diazepam (single dose of 10 mg and a median dose of 30 mg/day for 2 weeks) and propranolol (single dose of 80 mg and a median dose of 240 mg/day for 2 weeks) on psychological performance of patients with panic disorders and agoraphobia were investigated in a double-blind, randomized and crossover design.",6387529_1,0
3073,propranolol,108,119,"The effects of oral doses of diazepam (single dose of 10 mg and a median dose of 30 mg/day for 2 weeks) and propranolol (single dose of 80 mg and a median dose of 240 mg/day for 2 weeks) on psychological performance of patients with panic disorders and agoraphobia were investigated in a double-blind, randomized and crossover design.",6387529_1,0
12773,panic disorders,233,248,"The effects of oral doses of diazepam (single dose of 10 mg and a median dose of 30 mg/day for 2 weeks) and propranolol (single dose of 80 mg and a median dose of 240 mg/day for 2 weeks) on psychological performance of patients with panic disorders and agoraphobia were investigated in a double-blind, randomized and crossover design.",6387529_1,1
3074,propranolol,89,100,Both drugs impaired immediate free recall but the decrease was greater for diazepam than propranolol.,6387529_2,0
3075,propranolol,29,40,Patients tapped faster after propranolol than diazepam and they were more sedated after diazepam than propranolol.,6387529_4,0
3076,propranolol,102,113,Patients tapped faster after propranolol than diazepam and they were more sedated after diazepam than propranolol.,6387529_4,0
12778,behavioral impairment,53,74,Accumulation of drugs was not reflected in prolonged behavioral impairment.,6387529_7,1
6752,lung cancer,149,160,Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.,6402369_0,1
3077,sodium 2-mercaptoethane sulphonate,78,112,Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.,6402369_0,0
12779,urothelial,32,42,Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.,6402369_0,1
3078,MESNA,114,119,Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer.,6402369_0,0
12781,urothelial,118,128,The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.,6402369_1,1
12780,protective effect,4,21,The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.,6402369_1,0
3079,thiol,52,57,The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.,6402369_1,0
3080,sodium 2-mercaptoethane sulphonate,67,101,The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.,6402369_1,0
3081,MESNA,103,108,The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.,6402369_1,0
6753,lung cancer,218,229,The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.,6402369_1,1
3082,ifosfamide,149,159,The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle.,6402369_1,0
12788,mg/m2,74,79,"MESNA was given orally on the days of treatment with IF in 3 doses of 840 mg/m2, each administered at 0 hr (= injection of IF), 4 hr and 8 hr p.i.",6402369_2,0
3083,MESNA,0,5,"MESNA was given orally on the days of treatment with IF in 3 doses of 840 mg/m2, each administered at 0 hr (= injection of IF), 4 hr and 8 hr p.i.",6402369_2,0
12791,gross haematuria,129,145,Out of a total of 88 courses of this treatment we observed 10 episodes of asymptomatic microscopic haematuria and no episodes of gross haematuria.,6402369_3,1
12790,microscopic haematuria,87,109,Out of a total of 88 courses of this treatment we observed 10 episodes of asymptomatic microscopic haematuria and no episodes of gross haematuria.,6402369_3,1
3084,MESNA,51,56,In this group of 45 patients under protection with MESNA there were 5 complete remissions and 9 partial remissions (total 31%).,6402369_4,0
12792,partial remissions,96,114,In this group of 45 patients under protection with MESNA there were 5 complete remissions and 9 partial remissions (total 31%).,6402369_4,1
12794,prophylactic measures,91,112,A further group of 25 patients under polychemotherapy with IF were treated by conventional prophylactic measures (raised fluid intake and forced diuresis).,6402369_5,0
12800,pollakisuria,184,196,"In this group there were 1 complete and 5 partial remissions (total 24%), but nearly all patients developed either gross haematuria and/or symptoms of bladder irritation (cystitis and pollakisuria).",6402369_6,1
12798,gross haematuria,115,131,"In this group there were 1 complete and 5 partial remissions (total 24%), but nearly all patients developed either gross haematuria and/or symptoms of bladder irritation (cystitis and pollakisuria).",6402369_6,1
12799,bladder irritation,151,169,"In this group there were 1 complete and 5 partial remissions (total 24%), but nearly all patients developed either gross haematuria and/or symptoms of bladder irritation (cystitis and pollakisuria).",6402369_6,1
3085,MESNA,50,55,There were no appreciable differences between the MESNA series and the conventional prophylaxis series with respect to either haematological or systemic toxicity of the cytostatic treatment.,6402369_7,0
3086,cytostatic,169,179,There were no appreciable differences between the MESNA series and the conventional prophylaxis series with respect to either haematological or systemic toxicity of the cytostatic treatment.,6402369_7,0
12801,urinary epithelium,186,204,"Our results support the view that MESNA, given orally in conjunction with combined cytostatic regimens which include IF, simplifies the treatment and provides optimum protection for the urinary epithelium.",6402369_8,1
3087,MESNA,34,39,"Our results support the view that MESNA, given orally in conjunction with combined cytostatic regimens which include IF, simplifies the treatment and provides optimum protection for the urinary epithelium.",6402369_8,0
3088,cytostatic,83,93,"Our results support the view that MESNA, given orally in conjunction with combined cytostatic regimens which include IF, simplifies the treatment and provides optimum protection for the urinary epithelium.",6402369_8,0
3089,MESNA,21,26,Protection with oral MESNA is particularly suitable for outpatients.,6402369_9,0
6755,absence seizures,23,39,"Myoclonic, atonic, and absence seizures following institution of carbamazepine therapy in children.",6415512_0,1
12802,carbamazepine,65,78,"Myoclonic, atonic, and absence seizures following institution of carbamazepine therapy in children.",6415512_0,0
6754,Myoclonic,0,9,"Myoclonic, atonic, and absence seizures following institution of carbamazepine therapy in children.",6415512_0,1
12803,carbamazepine,48,61,"Five children, aged 3 to 11 years, treated with carbamazepine for epilepsy, had an acute aberrant reaction characterized by the onset of myoclonic, atypical absence and/or atonic (minor motor) seizures within a few days.",6415512_1,0
12805,onset of myoclonic,128,146,"Five children, aged 3 to 11 years, treated with carbamazepine for epilepsy, had an acute aberrant reaction characterized by the onset of myoclonic, atypical absence and/or atonic (minor motor) seizures within a few days.",6415512_1,1
12804,acute aberrant reaction,83,106,"Five children, aged 3 to 11 years, treated with carbamazepine for epilepsy, had an acute aberrant reaction characterized by the onset of myoclonic, atypical absence and/or atonic (minor motor) seizures within a few days.",6415512_1,1
12806,carbamazepine,9,22,"When the carbamazepine was discontinued, two of the children returned to their former state very quickly, two had the minor motor seizures resolve in 3 and 6 months, and one had the seizures persist.",6415512_2,0
6756,motor seizures,124,138,"When the carbamazepine was discontinued, two of the children returned to their former state very quickly, two had the minor motor seizures resolve in 3 and 6 months, and one had the seizures persist.",6415512_2,1
6757,ceroid lipofuscinosis,65,86,The child in whom the seizures persisted was later found to have ceroid lipofuscinosis.,6415512_3,1
3090,prostaglandin synthetase,10,34,Effect of prostaglandin synthetase inhibitors on experimentally induced convulsions in rats.,6433367_0,0
3092,picrotoxin,159,169,"To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.",6433367_1,0
12807,PGs,51,54,"To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.",6433367_1,0
12809,PG synthetase,97,110,"To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.",6433367_1,0
12811,PTZ,184,187,"To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.",6433367_1,0
3091,flurothyl,148,157,"To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.",6433367_1,0
3093,bicuculline,206,217,"To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.",6433367_1,0
12810,pentetrazol,171,182,"To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated.",6433367_1,0
12815,pretreatment agents,233,252,"Ibuprofen, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.",6433367_2,0
3098,bicuculline,168,179,"Ibuprofen, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.",6433367_2,0
3097,picrotoxin,153,163,"Ibuprofen, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.",6433367_2,0
12814,PTZ,123,126,"Ibuprofen, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.",6433367_2,0
3096,flurothyl,106,115,"Ibuprofen, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.",6433367_2,0
12812,meclofenamic acid,50,67,"Ibuprofen, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.",6433367_2,0
3095,low dose,41,49,"Ibuprofen, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.",6433367_2,0
3094,mefenamic acid,21,35,"Ibuprofen, sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents.",6433367_2,0
12816,PGs,27,30,"These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or bicuculline-induced convulsions.",6433367_3,0
12817,PTZ-induced convulsions,90,113,"These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or bicuculline-induced convulsions.",6433367_3,0
6758,adverse effects,54,69,Acute changes of blood ammonia may predict short-term adverse effects of valproic acid.,6436733_0,1
3099,valproic acid,73,86,Acute changes of blood ammonia may predict short-term adverse effects of valproic acid.,6436733_0,0
3101,antiepileptic drugs,97,116,Valproic acid (VPA) was given to 24 epileptic patients who were already being treated with other antiepileptic drugs.,6436733_1,0
12820,VPA,15,18,Valproic acid (VPA) was given to 24 epileptic patients who were already being treated with other antiepileptic drugs.,6436733_1,0
3100,Valproic acid,0,13,Valproic acid (VPA) was given to 24 epileptic patients who were already being treated with other antiepileptic drugs.,6436733_1,0
12823,VPA,31,34,"A standardized loading dose of VPA was administered, and venous blood was sampled at 0, 1, 2, 3, and 4 hours.",6436733_2,0
12822,loading dose,15,27,"A standardized loading dose of VPA was administered, and venous blood was sampled at 0, 1, 2, 3, and 4 hours.",6436733_2,0
12827,VPA,167,170,"Ammonia (NH3) was higher in patients who, during continuous therapy, complained of drowsiness (7 patients) than in those who were symptom-free (17 patients), although VPA plasma levels were similar in both groups.",6436733_3,0
12825,NH3,9,12,"Ammonia (NH3) was higher in patients who, during continuous therapy, complained of drowsiness (7 patients) than in those who were symptom-free (17 patients), although VPA plasma levels were similar in both groups.",6436733_3,0
12828,NH3,42,45,"By measuring VPA-induced changes of blood NH3 content, it may be possible to identify patients at higher risk of obtundation when VPA is given chronically.",6436733_4,0
12831,VPA,130,133,"By measuring VPA-induced changes of blood NH3 content, it may be possible to identify patients at higher risk of obtundation when VPA is given chronically.",6436733_4,0
6759,side effect,17,28,Proteinuria is a side effect of captopril treatment in hypertensive patients.,6454943_1,1
12833,renal abnormality,40,57,The possibility of reproducing the same renal abnormality with captopril was examined in SHR.,6454943_2,1
12834,aggravate proteinuria,68,89,Oral administration of captopril at 100 mg/kg for 14 days failed to aggravate proteinuria pre-existing in SHR.,6454943_3,1
12836,massive proteinuria,76,95,"Also, captopril treatment failed to potentiate or facilitate development of massive proteinuria invoked by puromycin aminonucleoside in SHR.",6454943_4,1
3102,puromycin aminonucleoside,107,132,"Also, captopril treatment failed to potentiate or facilitate development of massive proteinuria invoked by puromycin aminonucleoside in SHR.",6454943_4,0
6760,body weight,160,171,"Captopril had little or no demonstrable effects on serum electrolyte concentrations, excretion of urine, sodium and potassium, endogenous creatinine clearance, body weight, and food and water consumption.",6454943_5,1
3103,creatinine,138,148,"Captopril had little or no demonstrable effects on serum electrolyte concentrations, excretion of urine, sodium and potassium, endogenous creatinine clearance, body weight, and food and water consumption.",6454943_5,0
12838,water consumption,186,203,"Captopril had little or no demonstrable effects on serum electrolyte concentrations, excretion of urine, sodium and potassium, endogenous creatinine clearance, body weight, and food and water consumption.",6454943_5,1
3104,ketone bodies,9,22,"However, ketone bodies were consistently present in urine and several lethalities occurred during multiple dosing of captopril in SHR.",6454943_6,0
3106,suxamethonium,105,118,glycopyrrolate and atropine in the prevention of bradycardia and arrhythmias following repeated doses of suxamethonium in children.,6466532_1,0
3105,glycopyrrolate,0,14,glycopyrrolate and atropine in the prevention of bradycardia and arrhythmias following repeated doses of suxamethonium in children.,6466532_1,0
12840,kg-1,74,78,The effectiveness of administration of glycopyrrolate 5 and 10 micrograms kg-1 and atropine 10 and 20 micrograms kg-1 i.v.,6466532_2,0
12841,kg-1,113,117,The effectiveness of administration of glycopyrrolate 5 and 10 micrograms kg-1 and atropine 10 and 20 micrograms kg-1 i.v.,6466532_2,0
3107,glycopyrrolate,39,53,The effectiveness of administration of glycopyrrolate 5 and 10 micrograms kg-1 and atropine 10 and 20 micrograms kg-1 i.v.,6466532_2,0
3108,suxamethonium,115,128,"immediately before the induction of anaesthesia, to prevent arrhythmia and bradycardia following repeated doses of suxamethonium in children, was studied.",6466532_3,0
3109,glycopyrrolate,73,87,A control group was included for comparison with the lower dose range of glycopyrrolate and atropine.,6466532_4,0
12842,lower dose,53,63,A control group was included for comparison with the lower dose range of glycopyrrolate and atropine.,6466532_4,0
12843,active drugs,135,147,"A frequency of bradycardia of 50% was noted in the control group, but this was not significantly different from the frequency with the active drugs.",6466532_5,0
12845,min-1,70,75,Bradycardia (defined as a decrease in heart rate to less than 50 beat min-1) was prevented when the larger dose of either active drug was used.,6466532_6,0
12846,active drug,122,133,Bradycardia (defined as a decrease in heart rate to less than 50 beat min-1) was prevented when the larger dose of either active drug was used.,6466532_6,0
12847,kg-1,59,63,"It is recommended that either glycopyrrolate 10 micrograms kg-1 or atropine 20 micrograms kg-1 i.v. should immediately precede induction of anaesthesia, in children, if the repeated administration of suxamethonium is anticipated.",6466532_7,0
12848,kg-1,90,94,"It is recommended that either glycopyrrolate 10 micrograms kg-1 or atropine 20 micrograms kg-1 i.v. should immediately precede induction of anaesthesia, in children, if the repeated administration of suxamethonium is anticipated.",6466532_7,0
3110,glycopyrrolate,30,44,"It is recommended that either glycopyrrolate 10 micrograms kg-1 or atropine 20 micrograms kg-1 i.v. should immediately precede induction of anaesthesia, in children, if the repeated administration of suxamethonium is anticipated.",6466532_7,0
3111,suxamethonium,200,213,"It is recommended that either glycopyrrolate 10 micrograms kg-1 or atropine 20 micrograms kg-1 i.v. should immediately precede induction of anaesthesia, in children, if the repeated administration of suxamethonium is anticipated.",6466532_7,0
6761,heart block,9,20,Complete heart block following a single dose of trazodone.,6496797_0,1
6762,heart block,96,107,"Forty minutes after receiving a single starting dose of trazodone, a patient developed complete heart block.",6496797_1,1
6763,cardiac conduction,89,107,"The case illustrates that, despite the results of earlier studies, trazodone's effect on cardiac conduction may be severe in individuals at risk for conduction delay.",6496797_2,1
6764,conduction delay,149,165,"The case illustrates that, despite the results of earlier studies, trazodone's effect on cardiac conduction may be severe in individuals at risk for conduction delay.",6496797_2,1
3112,dacarbazine,35,46,Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma.,6503301_0,0
12851,Veno-occlusive liver disease,0,28,Veno-occlusive liver disease after dacarbazine therapy (DTIC) for melanoma.,6503301_0,1
6765,veno-occlusive disease,10,32,A case of veno-occlusive disease of the liver with fatal outcome after dacarbazine (DTIC) therapy for melanoma is reported.,6503301_1,1
12852,fatal outcome,51,64,A case of veno-occlusive disease of the liver with fatal outcome after dacarbazine (DTIC) therapy for melanoma is reported.,6503301_1,1
3113,dacarbazine,71,82,A case of veno-occlusive disease of the liver with fatal outcome after dacarbazine (DTIC) therapy for melanoma is reported.,6503301_1,0
6766,clinical course,22,37,There was a fulminant clinical course from start of symptoms until death.,6503301_2,1
6767,venous congestion,57,74,At autopsy the liver was enlarged and firm with signs of venous congestion.,6503301_3,1
12853,hepatic veins,24,37,Small- and medium-sized hepatic veins were blocked by thrombosis.,6503301_4,1
12857,neurologically-impaired child,38,67,Phenobarbital-induced dyskinesia in a neurologically-impaired child.,6504332_0,1
12858,neurologic impairment,30,51,A 2-year-old child with known neurologic impairment developed a dyskinesia soon after starting phenobarbital therapy for seizures.,6504332_1,1
6768,movement disorders,16,34,Known causes of movement disorders were eliminated after evaluation.,6504332_2,1
3114,anticonvulsant drugs,45,65,Phenobarbital should be added to the list of anticonvulsant drugs that can cause movement disorders.,6504332_4,0
6769,movement disorders,81,99,Phenobarbital should be added to the list of anticonvulsant drugs that can cause movement disorders.,6504332_4,1
6770,Ebstein's anomaly,30,47,Maternal lithium and neonatal Ebstein's anomaly: evaluation with cross-sectional echocardiography.,6518066_0,1
6771,Ebstein's anomaly,15,32,"In one infant, Ebstein's anomaly of the tricuspid valve was identified.",6518066_2,1
6772,tricuspid valve,40,55,"In one infant, Ebstein's anomaly of the tricuspid valve was identified.",6518066_2,1
6773,Ebstein's anomaly,103,120,In the other infant cross-sectional echocardiography provided reassurance that the infant did not have Ebstein's anomaly.,6518066_3,1
12865,cardiac malformations,190,211,"Cross-sectional echocardiographic screening of newborns exposed to lithium during gestation can provide highly accurate, noninvasive assessment of the presence or absence of lithium-induced cardiac malformations.",6518066_4,1
6774,myocardial infarction,50,71,Effects of training on the extent of experimental myocardial infarction in aging rats.,6534871_0,1
6775,myocardial infarction,65,86,"The effects of exercise on the severity of isoproterenol-induced myocardial infarction were studied in female albino rats of 20,40,60 and 80 weeks of age.",6534871_1,1
12866,GPT,32,35,Elevations in the serum GOT and GPT were maximum in the sedentary-isoproterenols and minimum in the exercise-controls.,6534871_4,0
12867,sedentary-isoproterenols,56,80,Elevations in the serum GOT and GPT were maximum in the sedentary-isoproterenols and minimum in the exercise-controls.,6534871_4,0
12870,GPT,110,113,These changes in the serum transaminases were associated with corresponding depletions in the cardiac GOT and GPT.,6534871_5,0
6776,myocardial infarction,21,42,Studies dealing with myocardial infarction are more informative when dealt with age.,6534871_7,1
3115,polyethylene glycol,10,29,Effect of polyethylene glycol 400 on adriamycin toxicity in mice.,6538499_0,0
12872,adriamycin,37,47,Effect of polyethylene glycol 400 on adriamycin toxicity in mice.,6538499_0,0
3116,organic solvent,28,43,"The effect of a widely used organic solvent, polyethylene glycol 400 (PEG 400), on the toxic action of an acute or chronic treatment with adriamycin (ADR) was evaluated in mice.",6538499_1,0
3117,polyethylene glycol,45,64,"The effect of a widely used organic solvent, polyethylene glycol 400 (PEG 400), on the toxic action of an acute or chronic treatment with adriamycin (ADR) was evaluated in mice.",6538499_1,0
3118,toxic action,87,99,"The effect of a widely used organic solvent, polyethylene glycol 400 (PEG 400), on the toxic action of an acute or chronic treatment with adriamycin (ADR) was evaluated in mice.",6538499_1,0
12875,ADR,150,153,"The effect of a widely used organic solvent, polyethylene glycol 400 (PEG 400), on the toxic action of an acute or chronic treatment with adriamycin (ADR) was evaluated in mice.",6538499_1,0
12874,adriamycin,138,148,"The effect of a widely used organic solvent, polyethylene glycol 400 (PEG 400), on the toxic action of an acute or chronic treatment with adriamycin (ADR) was evaluated in mice.",6538499_1,0
12877,chronic low-dose-ADR-associated lethality,56,97,PEG 400 impressively decreased both acute high-dose and chronic low-dose-ADR-associated lethality.,6538499_2,1
12876,high-dose,42,51,PEG 400 impressively decreased both acute high-dose and chronic low-dose-ADR-associated lethality.,6538499_2,0
12878,ADR,36,39,Such treatment did not diminish the ADR antitumor activity in L1210 leukemia and in Ehrlich ascites tumor.,6538499_4,0
12880,L1210 leukemia,62,76,Such treatment did not diminish the ADR antitumor activity in L1210 leukemia and in Ehrlich ascites tumor.,6538499_4,1
12883,ketamine catatonia,33,51,Effects of amine pretreatment on ketamine catatonia in pinealectomized or hypophysectomized animals.,6540303_0,1
12885,pineal idolamines,76,93,"The present studies were designed to clarify the role of catecholamines and pineal idolamines on ketamine-induced catatonia in the intact, pinealectomized or hypophysectomized chick and rat.",6540303_1,0
12886,ketamine-induced catatonia,97,123,"The present studies were designed to clarify the role of catecholamines and pineal idolamines on ketamine-induced catatonia in the intact, pinealectomized or hypophysectomized chick and rat.",6540303_1,1
12889,duration of catatonia,71,92,"In the pinealectomized chick, pretreatment with dopamine increased the duration of catatonia (DOC) after ketamine, but pretreatment with norepinephrine did not.",6540303_2,1
12891,pineal indolamines,4,22,The pineal indolamines exhibited mixed actions.,6540303_3,0
6777,pineal gland,99,111,"Serotonin and N-acetyl serotonin which augmented ketamine DOC, did not do so in the absence of the pineal gland, whereas melatonin potentiated the ketamine DOC in both the intact and pinealectomized chick.",6540303_4,1
12892,N-acetyl serotonin,14,32,"Serotonin and N-acetyl serotonin which augmented ketamine DOC, did not do so in the absence of the pineal gland, whereas melatonin potentiated the ketamine DOC in both the intact and pinealectomized chick.",6540303_4,0
6778,circadian rhythm,64,80,"Ketamine was more potent in the hypophysectomized chick and the circadian rhythm noted in the intact chick was absent; furthermore, melatonin did not augment the ketamine DOC whereas dopamine continued to do so.",6540303_5,1
12895,Heparin-induced thrombocytopenia,0,32,"Heparin-induced thrombocytopenia, thrombosis, and hemorrhage.",6615052_0,1
12896,heparin-induced thrombocytopenia,26,58,Sixty-two patients with a heparin-induced thrombocytopenia are reported.,6615052_1,1
12897,Clinical manifestations,0,23,"Clinical manifestations of this disorder include hemorrhage or, more frequently, thromboembolic events in patients receiving heparin.",6615052_2,1
12898,thromboembolic events,81,102,"Clinical manifestations of this disorder include hemorrhage or, more frequently, thromboembolic events in patients receiving heparin.",6615052_2,1
3119,platelet membrane,73,90,Immunologic testing has demonstrated the presence of a heparin-dependent platelet membrane antibody.,6615052_4,0
12902,thromboembolic,34,48,"The 20 deaths, 52 hemorrhagic and thromboembolic complications, and 21 surgical procedures to manage the complications confirm the seriousness of the disorder.",6615052_5,1
3120,platelet aggregation,94,114,"If the platelet count falls to less than 100,000/mm3, while the patient is receiving heparin, platelet aggregation testing, using the patient's plasma, is indicated.",6615052_7,0
12907,platelet anti-aggregating agents,45,77,"Management consists of cessation of heparin, platelet anti-aggregating agents, and alternate forms of anticoagulation when indicated.",6615052_8,0
3121,diatrizoate,30,41,Ventricular fibrillation from diatrizoate with and without chelating agents.,663266_0,0
3122,chelating agents,59,75,Ventricular fibrillation from diatrizoate with and without chelating agents.,663266_0,0
6779,Ventricular fibrillation,0,24,Ventricular fibrillation from diatrizoate with and without chelating agents.,663266_0,1
3123,Renografin,16,26,The toxicity of Renografin 76% was compared with that of Hypaque 76% by selective injection of each into the right coronary artery of dogs.,663266_1,0
12908,Hypaque,57,64,The toxicity of Renografin 76% was compared with that of Hypaque 76% by selective injection of each into the right coronary artery of dogs.,663266_1,0
6780,coronary artery,115,130,The toxicity of Renografin 76% was compared with that of Hypaque 76% by selective injection of each into the right coronary artery of dogs.,663266_1,1
3126,sodium citrate,133,147,"Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains calcium disodium edetate and no sodium citrate.",663266_2,0
3125,calcium disodium edetate,101,125,"Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains calcium disodium edetate and no sodium citrate.",663266_2,0
12910,disodium edetate,60,76,"Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains calcium disodium edetate and no sodium citrate.",663266_2,0
12911,Hypaque,84,91,"Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains calcium disodium edetate and no sodium citrate.",663266_2,0
3124,Renografin,0,10,"Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains calcium disodium edetate and no sodium citrate.",663266_2,0
12909,chelating agents sodium citrate,24,55,"Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains calcium disodium edetate and no sodium citrate.",663266_2,0
3128,chelating agents,92,108,"Ventricular fibrillation occurred significantly more often with Renografin, suggesting that chelating agents contribute to toxicity in coronary angiography.",663266_3,0
3127,Renografin,64,74,"Ventricular fibrillation occurred significantly more often with Renografin, suggesting that chelating agents contribute to toxicity in coronary angiography.",663266_3,0
6781,Ventricular fibrillation,0,24,"Ventricular fibrillation occurred significantly more often with Renografin, suggesting that chelating agents contribute to toxicity in coronary angiography.",663266_3,1
12913,quaternary ammonium antiarrhythmic agent,29,69,"Sublingual absorption of the quaternary ammonium antiarrhythmic agent, UM-272.UM-272 (N,N-dimethylpropranolol), a quaternary antiarrhythmic agent, was administered sublingually to dogs with ouabain-induced ventricular tachycardias.",6634932_0,0
12914,UM-272.UM-272,71,84,"Sublingual absorption of the quaternary ammonium antiarrhythmic agent, UM-272.UM-272 (N,N-dimethylpropranolol), a quaternary antiarrhythmic agent, was administered sublingually to dogs with ouabain-induced ventricular tachycardias.",6634932_0,0
6782,ventricular tachycardias,206,230,"Sublingual absorption of the quaternary ammonium antiarrhythmic agent, UM-272.UM-272 (N,N-dimethylpropranolol), a quaternary antiarrhythmic agent, was administered sublingually to dogs with ouabain-induced ventricular tachycardias.",6634932_0,1
12915,N-dimethylpropranolol,88,109,"Sublingual absorption of the quaternary ammonium antiarrhythmic agent, UM-272.UM-272 (N,N-dimethylpropranolol), a quaternary antiarrhythmic agent, was administered sublingually to dogs with ouabain-induced ventricular tachycardias.",6634932_0,0
12916,quaternary antiarrhythmic agent,114,145,"Sublingual absorption of the quaternary ammonium antiarrhythmic agent, UM-272.UM-272 (N,N-dimethylpropranolol), a quaternary antiarrhythmic agent, was administered sublingually to dogs with ouabain-induced ventricular tachycardias.",6634932_0,0
12917,sublingually,164,176,"Sublingual absorption of the quaternary ammonium antiarrhythmic agent, UM-272.UM-272 (N,N-dimethylpropranolol), a quaternary antiarrhythmic agent, was administered sublingually to dogs with ouabain-induced ventricular tachycardias.",6634932_0,1
3129,anti-arrhythmic,5,20,Both anti-arrhythmic efficacy and bioavailability were compared to oral drug.,6634932_1,0
12918,oral drug,67,76,Both anti-arrhythmic efficacy and bioavailability were compared to oral drug.,6634932_1,0
12919,UM-272,11,17,Sublingual UM-272 converted ventricular tachycardia to sinus rhythm in all 5 dogs.,6634932_2,0
12920,sinus rhythm,55,67,Sublingual UM-272 converted ventricular tachycardia to sinus rhythm in all 5 dogs.,6634932_2,1
6783,ventricular tachycardia,28,51,Sublingual UM-272 converted ventricular tachycardia to sinus rhythm in all 5 dogs.,6634932_2,1
12921,oral drug,93,102,"The area under the plasma concentration time curve at 90 min was 4-12 times greater than for oral drug, suggesting the existence of an absorption-limiting process in the intestine, and providing an alternate form of administration for quaternary drugs.",6634932_3,0
12923,quaternary drugs,235,251,"The area under the plasma concentration time curve at 90 min was 4-12 times greater than for oral drug, suggesting the existence of an absorption-limiting process in the intestine, and providing an alternate form of administration for quaternary drugs.",6634932_3,0
12924,high-dose,35,44,Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation.,6637851_0,0
6784,ventricular tachycardia,68,91,Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation.,6637851_0,1
6785,ventricular fibrillation,95,119,Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation.,6637851_0,1
6786,ventricular tachycardia,75,98,"Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs.",6637851_1,1
3130,antiarrhythmic drugs,183,203,"Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs.",6637851_1,0
6787,cardiac arrest,119,133,"Amiodarone was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs.",6637851_1,1
12925,loading dose,4,16,The loading dose was 800 mg/day for 6 weeks and the maintenance dose was 600 mg/day.,6637851_2,0
12927,VF,136,138,Sixty-nine percent of patients continued treatment with amiodarone and had no recurrence of symptomatic VT or ventricular fibrillation (VF) over a follow-up of 6 to 52 months (mean +/- standard deviation 14.2 +/- 8.2).,6637851_3,0
12926,no recurrence,75,88,Sixty-nine percent of patients continued treatment with amiodarone and had no recurrence of symptomatic VT or ventricular fibrillation (VF) over a follow-up of 6 to 52 months (mean +/- standard deviation 14.2 +/- 8.2).,6637851_3,1
6788,ventricular fibrillation,110,134,Sixty-nine percent of patients continued treatment with amiodarone and had no recurrence of symptomatic VT or ventricular fibrillation (VF) over a follow-up of 6 to 52 months (mean +/- standard deviation 14.2 +/- 8.2).,6637851_3,1
3131,antiarrhythmic drug,169,188,Six percent of the patients had a nonfatal recurrence of VT and were successfully managed by continuing amiodarone at a higher dose or by the addition of a conventional antiarrhythmic drug.,6637851_4,0
12929,continuing amiodarone,93,114,Six percent of the patients had a nonfatal recurrence of VT and were successfully managed by continuing amiodarone at a higher dose or by the addition of a conventional antiarrhythmic drug.,6637851_4,0
6789,adverse drug reactions,12,34,One or more adverse drug reactions occurred in 51% of patients.,6637851_5,1
6790,Adverse effects,0,15,Adverse effects forced a reduction in the dose of amiodarone in 41% and discontinuation of amiodarone in 10% of patients.,6637851_6,1
6791,adverse reactions,28,45,"The most common symptomatic adverse reactions were tremor or ataxia (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).",6637851_7,1
12931,thyroid function abnormalities,132,162,"The most common symptomatic adverse reactions were tremor or ataxia (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).",6637851_7,1
12930,visual halos,101,113,"The most common symptomatic adverse reactions were tremor or ataxia (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).",6637851_7,1
12932,pulmonary interstitial infiltrates,172,206,"The most common symptomatic adverse reactions were tremor or ataxia (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%).",6637851_7,1
3132,antiarrhythmic drugs,117,137,"Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients.",6637851_8,0
12933,large-dose amiodarone,9,30,"Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients.",6637851_8,0
12934,VF,87,89,"Although large-dose amiodarone is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients.",6637851_8,0
12936,VF,128,130,"However, when the dose is adjusted based on clinical response or the development of adverse effects, 75% of patients with VT or VF can be successfully managed with amiodarone.",6637851_9,0
12935,clinical response,44,61,"However, when the dose is adjusted based on clinical response or the development of adverse effects, 75% of patients with VT or VF can be successfully managed with amiodarone.",6637851_9,1
6792,adverse effects,84,99,"However, when the dose is adjusted based on clinical response or the development of adverse effects, 75% of patients with VT or VF can be successfully managed with amiodarone.",6637851_9,1
12937,adriamycin,15,25,Early adjuvant adriamycin in superficial bladder carcinoma.,6640832_0,0
12938,superficial bladder carcinoma,29,58,Early adjuvant adriamycin in superficial bladder carcinoma.,6640832_0,1
6793,transitional cell carcinoma,67,94,A multicenter study was performed in 110 patients with superficial transitional cell carcinoma of the bladder.,6640832_1,1
6796,tumor-free,77,87,"In patients that were free of recurrence during the first year, 80% remained tumor-free during the 2- to 3-year follow-up period.",6640832_11,1
12948,free of,22,29,"In patients that were free of recurrence during the first year, 80% remained tumor-free during the 2- to 3-year follow-up period.",6640832_11,1
12950,drug itself,80,91,"The beneficial effect of Adriamycin appears obvious and might be related to the drug itself, the early and repeated instillations after TUR, or both.",6640832_13,0
12949,Adriamycin,25,35,"The beneficial effect of Adriamycin appears obvious and might be related to the drug itself, the early and repeated instillations after TUR, or both.",6640832_13,0
12942,transurethral resection,75,98,Adriamycin (50 mg/50 ml) was administered intravesically within 24 h after transurethral resection of TA-T1 (O-A) bladder tumors.,6640832_2,1
12943,TA-T1,102,107,Adriamycin (50 mg/50 ml) was administered intravesically within 24 h after transurethral resection of TA-T1 (O-A) bladder tumors.,6640832_2,0
6794,bladder tumors,114,128,Adriamycin (50 mg/50 ml) was administered intravesically within 24 h after transurethral resection of TA-T1 (O-A) bladder tumors.,6640832_2,1
12940,Adriamycin,0,10,Adriamycin (50 mg/50 ml) was administered intravesically within 24 h after transurethral resection of TA-T1 (O-A) bladder tumors.,6640832_2,0
12944,local side-effects,82,100,"The tolerance was evaluated in these 110 patients, and 29 patients presented with local side-effects.",6640832_4,1
12945,chemical cystitis,24,41,In 24 of these patients chemical cystitis was severe enough for them to drop out of the study.,6640832_5,1
6795,side-effects,12,24,No systemic side-effects were observed.,6640832_6,1
12946,recurrent disease,63,80,"Of the 82 patients studied after 1 year, 23 had primary and 59 recurrent disease.",6640832_8,1
12953,high dose D-penicillamine,14,39,The effect of high dose D-penicillamine treatment on aortic permeability to albumin and on the ultrastructure of the vessel.,6666578_1,0
12954,aortic permeability,53,72,The effect of high dose D-penicillamine treatment on aortic permeability to albumin and on the ultrastructure of the vessel.,6666578_1,1
12979,high doses,62,72,"These observations support the hypothesis that treatment with high doses of D-pen may induce a fibroproliferative response in rat aorta, possibly by an inhibitory effect on the cross-linking of collagen and elastin.",6666578_10,0
12956,D-pen,60,65,Male Sprague-Dawley rats were treated with D-penicillamine (D-pen) 500 mg/kg/day for 10 or 42 days.,6666578_2,0
3133,D-penicillamine,43,58,Male Sprague-Dawley rats were treated with D-penicillamine (D-pen) 500 mg/kg/day for 10 or 42 days.,6666578_2,0
12957,TEM,91,94,Changes in aortic morphology were examined by light- and transmission-electron microscopy (TEM).,6666578_4,0
12958,endothelial permeability,17,41,"In addition, the endothelial permeability and the penetration through the aortic wall of albumin were studied 10 minutes, 24 and 48 hours after i. v. injection of human serum 131I-albumin (131I-HSA).",6666578_5,1
12959,aortic wall,74,85,"In addition, the endothelial permeability and the penetration through the aortic wall of albumin were studied 10 minutes, 24 and 48 hours after i. v. injection of human serum 131I-albumin (131I-HSA).",6666578_5,1
12960,131I-HSA,189,197,"In addition, the endothelial permeability and the penetration through the aortic wall of albumin were studied 10 minutes, 24 and 48 hours after i. v. injection of human serum 131I-albumin (131I-HSA).",6666578_5,0
3134,human serum,163,174,"In addition, the endothelial permeability and the penetration through the aortic wall of albumin were studied 10 minutes, 24 and 48 hours after i. v. injection of human serum 131I-albumin (131I-HSA).",6666578_5,0
12962,elastolysis,23,34,"TEM revealed extensive elastolysis in the arterial wall of D-pen-treated rats, consistent with an inhibitory effect on crosslink formation.",6666578_6,1
12967,aortic wall,135,146,"In experimental animals excess deposition of collagen and glycoaminoglycans was observed in the subendothelial and medial layer of the aortic wall, together with prominent basal membrane substance around aortic smooth muscle cells.",6666578_7,1
6797,subendothelial,96,110,"In experimental animals excess deposition of collagen and glycoaminoglycans was observed in the subendothelial and medial layer of the aortic wall, together with prominent basal membrane substance around aortic smooth muscle cells.",6666578_7,1
12966,medial layer,115,127,"In experimental animals excess deposition of collagen and glycoaminoglycans was observed in the subendothelial and medial layer of the aortic wall, together with prominent basal membrane substance around aortic smooth muscle cells.",6666578_7,1
12965,glycoaminoglycans,58,75,"In experimental animals excess deposition of collagen and glycoaminoglycans was observed in the subendothelial and medial layer of the aortic wall, together with prominent basal membrane substance around aortic smooth muscle cells.",6666578_7,0
3135,hyaluronate,264,275,"The aorta/serum-ratio and the radioactive build-up 24 and 48 hours after injection of 131I-HSA was reduced in animals treated with D-pen for 42 days, indicating an impeded transmural transport of tracer which may be caused by a steric exclusion effect of abundant hyaluronate.",6666578_8,0
12970,131I-HSA,86,94,"The aorta/serum-ratio and the radioactive build-up 24 and 48 hours after injection of 131I-HSA was reduced in animals treated with D-pen for 42 days, indicating an impeded transmural transport of tracer which may be caused by a steric exclusion effect of abundant hyaluronate.",6666578_8,0
12975,131I-HSA,85,93,"The endothelial ultrastructure was unaffected by D-pen, and no differences in aortic 131I-HSA radioactivity or aorta/serum-ratio were recorded between experimental and control groups 10 minutes after tracer injection, indicating that the permeability of the endothelial barrier to albumin remained unaffected by D-pen treatment.",6666578_9,0
12982,EACA,35,39,Why may epsilon-aminocaproic acid (EACA) induce myopathy in man? Report of a case and literature review.,6674249_0,0
3136,epsilon-aminocaproic acid,8,33,Why may epsilon-aminocaproic acid (EACA) induce myopathy in man? Report of a case and literature review.,6674249_0,0
3137,epsilon-aminocaproic acid,46,71,A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.,6674249_1,0
12986,year-old,97,105,A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.,6674249_1,1
12985,EACA,73,77,A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.,6674249_1,0
12984,necrotizing myopathy,10,30,A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.,6674249_1,1
6798,subarachnoid,119,131,A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described.,6674249_1,1
12988,forestomach,127,138,Effect of aspirin on N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide-induced epithelial proliferation in the urinary bladder and forestomach of the rat.,6692345_0,1
12987,epithelial proliferation,75,99,Effect of aspirin on N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide-induced epithelial proliferation in the urinary bladder and forestomach of the rat.,6692345_0,1
6799,urinary bladder,107,122,Effect of aspirin on N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide-induced epithelial proliferation in the urinary bladder and forestomach of the rat.,6692345_0,1
3138,N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide,38,83,The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.,6692345_1,0
3139,N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide,38,83,The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.,6692345_1,0
12990,forestomach,199,210,The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.,6692345_1,1
3140,FANFT,85,90,The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of forestomach tumors.,6692345_1,0
3142,FANFT,219,224,An autoradiographic study was performed on male F-344 rats fed diet containing FANFT at a level of 0.2% and/or aspirin at a level of 0.5% to evaluate the effect of aspirin on the increased cell proliferation induced by FANFT in the forestomach and bladder.,6692345_2,0
3141,FANFT,79,84,An autoradiographic study was performed on male F-344 rats fed diet containing FANFT at a level of 0.2% and/or aspirin at a level of 0.5% to evaluate the effect of aspirin on the increased cell proliferation induced by FANFT in the forestomach and bladder.,6692345_2,0
12991,male F-344,43,53,An autoradiographic study was performed on male F-344 rats fed diet containing FANFT at a level of 0.2% and/or aspirin at a level of 0.5% to evaluate the effect of aspirin on the increased cell proliferation induced by FANFT in the forestomach and bladder.,6692345_2,0
12992,cell proliferation,189,207,An autoradiographic study was performed on male F-344 rats fed diet containing FANFT at a level of 0.2% and/or aspirin at a level of 0.5% to evaluate the effect of aspirin on the increased cell proliferation induced by FANFT in the forestomach and bladder.,6692345_2,1
12993,forestomach,232,243,An autoradiographic study was performed on male F-344 rats fed diet containing FANFT at a level of 0.2% and/or aspirin at a level of 0.5% to evaluate the effect of aspirin on the increased cell proliferation induced by FANFT in the forestomach and bladder.,6692345_2,1
12994,forestomach,7,18,"In the forestomach, and also in the liver, aspirin did not affect the FANFT-induced increase in labeling index.",6692345_4,1
12996,forestomach,164,175,"The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in FANFT carcinogenesis in the bladder and forestomach, and that aspirin's effect on FANFT in the forestomach is not due to an irritant effect associated with increased cell proliferation.",6692345_5,1
12999,cell proliferation,290,308,"The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in FANFT carcinogenesis in the bladder and forestomach, and that aspirin's effect on FANFT in the forestomach is not due to an irritant effect associated with increased cell proliferation.",6692345_5,1
12998,forestomach,219,230,"The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in FANFT carcinogenesis in the bladder and forestomach, and that aspirin's effect on FANFT in the forestomach is not due to an irritant effect associated with increased cell proliferation.",6692345_5,1
12997,aspirin's,186,195,"The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in FANFT carcinogenesis in the bladder and forestomach, and that aspirin's effect on FANFT in the forestomach is not due to an irritant effect associated with increased cell proliferation.",6692345_5,0
3143,FANFT,206,211,"The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in FANFT carcinogenesis in the bladder and forestomach, and that aspirin's effect on FANFT in the forestomach is not due to an irritant effect associated with increased cell proliferation.",6692345_5,0
12995,carcinogenicity,44,59,"The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in FANFT carcinogenesis in the bladder and forestomach, and that aspirin's effect on FANFT in the forestomach is not due to an irritant effect associated with increased cell proliferation.",6692345_5,0
13000,chronic ingestion,59,76,"Also, there appears to be an adaptation by the rats to the chronic ingestion of aspirin.",6692345_6,1
6800,Cerebral hemorrhage,0,19,Cerebral hemorrhage associated with phenylpropanolamine in combination with caffeine.,6695415_0,1
6802,side effects,74,86,Phenylpropanolamine (PPA) is a drug that has been associated with serious side effects including stroke.,6695415_1,1
6801,PPA,21,24,Phenylpropanolamine (PPA) is a drug that has been associated with serious side effects including stroke.,6695415_1,1
13002,diet preparations,38,55,"It is often combined with caffeine in diet preparations and ""look-alike"" pills.",6695415_2,0
13003,PPA/caffeine,25,37,"In order to determine if PPA/caffeine can lead to stroke in normotensive and/or hypertensive rats, we administered the combination in six times the allowed human dose calculated on a per weight basis for the rats two times per day for five days.",6695415_3,0
6804,cerebral hemorrhage,17,36,Subarachnoid and cerebral hemorrhage was noted in 18% of the hypertensive rats.,6695415_4,1
6803,Subarachnoid,0,12,Subarachnoid and cerebral hemorrhage was noted in 18% of the hypertensive rats.,6695415_4,1
13005,acute hypertension,57,75,A single PPA/caffeine administration (same dose) lead to acute hypertension in both the normotensive and hypertensive animals.,6695415_5,1
13004,PPA/caffeine,9,21,A single PPA/caffeine administration (same dose) lead to acute hypertension in both the normotensive and hypertensive animals.,6695415_5,0
6805,cerebral hemorrhage,52,71,These results suggest that PPA/caffeine can lead to cerebral hemorrhage in previously hypertensive animals when administered in greater than the allowed dosage.,6695415_6,1
13007,PPA/caffeine,27,39,These results suggest that PPA/caffeine can lead to cerebral hemorrhage in previously hypertensive animals when administered in greater than the allowed dosage.,6695415_6,0
6806,blood pressure,22,36,An acute elevation in blood pressure may be a contributing factor.,6695415_7,1
13009,acute elevation,3,18,An acute elevation in blood pressure may be a contributing factor.,6695415_7,1
6807,papillary necrosis,6,24,Renal papillary necrosis due to naproxen.,6699841_0,1
13011,high dose salicylates,112,133,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,0
13012,gold salts,138,148,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,0
13013,RPN,186,189,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,0
6809,papillary necrosis,166,184,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,1
6808,rheumatoid arthritis,23,43,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,1
13010,fenoprofen calcium,92,110,"A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy.",6699841_1,0
13014,factor predisposing,9,28,No other factor predisposing to RPN could be discovered.,6699841_2,0
13015,RPN,32,35,No other factor predisposing to RPN could be discovered.,6699841_2,0
13016,adverse renal effects,53,74,Sulindac was substituted for naproxen and no further adverse renal effects occurred over the next 12 months.,6699841_3,1
13017,RPN,35,38,We review previous reports linking RPN to antiinflammatory drug use and discuss possible advantages of sulindac in patients who have experienced renal toxicity from other antiinflammatory agents.,6699841_4,0
13018,renal toxicity,145,159,We review previous reports linking RPN to antiinflammatory drug use and discuss possible advantages of sulindac in patients who have experienced renal toxicity from other antiinflammatory agents.,6699841_4,1
3144,antiinflammatory agents,171,194,We review previous reports linking RPN to antiinflammatory drug use and discuss possible advantages of sulindac in patients who have experienced renal toxicity from other antiinflammatory agents.,6699841_4,0
3145,metoclopramide,39,53,A case of tardive dyskinesia caused by metoclopramide.,6727060_0,0
6810,tardive dyskinesia,10,28,A case of tardive dyskinesia caused by metoclopramide.,6727060_0,1
3146,metoclopramide,123,137,"Abnormal involuntary movements appeared in the mouth, tongue, neck and abdomen of a 64-year-old male patient after he took metoclopramide for gastrointestinal disorder in a regimen of 30 mg per day for a total of about 260 days.",6727060_1,0
6811,involuntary movements,9,30,"Abnormal involuntary movements appeared in the mouth, tongue, neck and abdomen of a 64-year-old male patient after he took metoclopramide for gastrointestinal disorder in a regimen of 30 mg per day for a total of about 260 days.",6727060_1,1
6812,gastrointestinal disorder,142,167,"Abnormal involuntary movements appeared in the mouth, tongue, neck and abdomen of a 64-year-old male patient after he took metoclopramide for gastrointestinal disorder in a regimen of 30 mg per day for a total of about 260 days.",6727060_1,1
3147,metoclopramide,9,23,"When the metoclopramide administration was discontinued, the abnormal movements gradually improved to a considerable extent.",6727060_3,0
6813,abnormal movements,61,79,"When the metoclopramide administration was discontinued, the abnormal movements gradually improved to a considerable extent.",6727060_3,1
6814,tardive dyskinesia,48,66,Attention to the possible induction of specific tardive dyskinesia is called for in the use of this drug.,6727060_4,1
13019,renal protein reabsorption,51,77,Nephrotoxic effects of aminoglycoside treatment on renal protein reabsorption and accumulation.,6728084_0,1
3148,aminoglycoside,23,37,Nephrotoxic effects of aminoglycoside treatment on renal protein reabsorption and accumulation.,6728084_0,0
13021,netilmicin,53,63,"To quantify the effects of gentamicin, kanamycin and netilmicin on renal protein reabsorption and accumulation, these drugs were administered to rats intraperitoneally (30 mg/kg/day) for 7, 14 or 21 days.",6728084_1,0
13037,renal reabsorption,107,125,"Thus, aminoglycosides may act as nephrotoxicants at glomerular and/or tubular level inducing impairment of renal reabsorption and accumulation of proteins.",6728084_10,1
3151,aminoglycosides,6,21,"Thus, aminoglycosides may act as nephrotoxicants at glomerular and/or tubular level inducing impairment of renal reabsorption and accumulation of proteins.",6728084_10,0
13036,inducing impairment,84,103,"Thus, aminoglycosides may act as nephrotoxicants at glomerular and/or tubular level inducing impairment of renal reabsorption and accumulation of proteins.",6728084_10,1
3149,N-acetyl-beta-D-glucosaminidase,123,154,"Scanning electron microscopy of the glomerular endothelia, urinary measurements of sodium, potassium, endogenous lysozyme, N-acetyl-beta-D-glucosaminidase (NAG) as well as clearance and accumulation experiments after i.v.",6728084_2,0
13026,GFR,75,78,administration of egg-white lysozyme and measurements of inulin clearance (GFR) were done in each treatment group.,6728084_3,0
13024,egg-white lysozyme,18,36,administration of egg-white lysozyme and measurements of inulin clearance (GFR) were done in each treatment group.,6728084_3,0
13027,endothelial fenestrae,67,88,"Gentamicin administration decreased diameter, density and shape of endothelial fenestrae.",6728084_4,0
13028,netilmicin,14,24,Kanamycin and netilmicin appeared to have no effect at the dose used.,6728084_5,0
3150,aminoglycosides,10,25,All three aminoglycosides decreased GFR and increased urinary excretion of sodium and potassium.,6728084_6,0
13029,GFR,36,39,All three aminoglycosides decreased GFR and increased urinary excretion of sodium and potassium.,6728084_6,0
13032,egg-white lysozyme,18,36,administration of egg-white lysozyme netilmicin had no effect.,6728084_8,0
13033,netilmicin,37,47,administration of egg-white lysozyme netilmicin had no effect.,6728084_8,0
6815,obstructive sleep apnea syndrome,17,49,Induction of the obstructive sleep apnea syndrome in a woman by exogenous androgen administration.,6732043_0,1
13040,physical changes,142,158,We documented airway occlusion during sleep and an abnormally high supraglottic resistance while awake in a 54-yr-old woman who had developed physical changes and the syndrome of obstructive sleep apnea while being administered exogenous androgens.,6732043_1,1
13039,supraglottic resistance,67,90,We documented airway occlusion during sleep and an abnormally high supraglottic resistance while awake in a 54-yr-old woman who had developed physical changes and the syndrome of obstructive sleep apnea while being administered exogenous androgens.,6732043_1,1
6816,obstructive sleep apnea,179,202,We documented airway occlusion during sleep and an abnormally high supraglottic resistance while awake in a 54-yr-old woman who had developed physical changes and the syndrome of obstructive sleep apnea while being administered exogenous androgens.,6732043_1,1
13043,supraglottic resistance,94,117,"When the androgens were withdrawn, the patient's physical changes, symptoms, sleep study, and supraglottic resistance all returned to normal.",6732043_2,1
6817,obstructive sleep apnea,49,72,A rechallenge with androgen produced symptoms of obstructive sleep apnea that abated upon withdrawal of the hormone.,6732043_3,1
13044,rechallenge,2,13,A rechallenge with androgen produced symptoms of obstructive sleep apnea that abated upon withdrawal of the hormone.,6732043_3,0
6818,sleep apnea,73,84,Previous reports have favored a role of androgens in the pathogenesis of sleep apnea.,6732043_4,1
6820,side effect,82,93,Development of the obstructive sleep apnea syndrome must be considered a possible side effect of androgen therapy.,6732043_7,1
6819,obstructive sleep apnea syndrome,19,51,Development of the obstructive sleep apnea syndrome must be considered a possible side effect of androgen therapy.,6732043_7,1
13045,Intra-arterial,0,14,Intra-arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system.,6747681_0,1
6822,central nervous system,75,97,Intra-arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system.,6747681_0,1
6821,malignant gliomas,50,67,Intra-arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system.,6747681_0,1
3152,BCNU,15,19,Intra-arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system.,6747681_0,0
6823,malignant gliomas,211,228,"Because of the rapid systemic clearance of BCNU (1,3-bis-(2-chloroethyl)-1-nitrosourea), intra-arterial administration should provide a substantial advantage over intravenous administration for the treatment of malignant gliomas.",6747681_1,1
3153,BCNU,43,47,"Because of the rapid systemic clearance of BCNU (1,3-bis-(2-chloroethyl)-1-nitrosourea), intra-arterial administration should provide a substantial advantage over intravenous administration for the treatment of malignant gliomas.",6747681_1,0
13058,loss of vision,60,74,A delayed complication in nine patients has been unilateral loss of vision secondary to a retinal vasculitis.,6747681_10,1
6830,retinal vasculitis,90,108,A delayed complication in nine patients has been unilateral loss of vision secondary to a retinal vasculitis.,6747681_10,1
6831,visual loss,17,28,The frequency of visual loss decreased after the concentration of the ethanol diluent was lowered.,6747681_11,1
3154,BCNU,38,42,"Thirty-six patients were treated with BCNU every 6 to 8 weeks, either by transfemoral catheterization of the internal carotid or vertebral artery or through a fully implantable intracarotid drug delivery system, beginning with a dose of 200 mg/sq m body surface area.",6747681_2,0
6825,vertebral artery,129,145,"Thirty-six patients were treated with BCNU every 6 to 8 weeks, either by transfemoral catheterization of the internal carotid or vertebral artery or through a fully implantable intracarotid drug delivery system, beginning with a dose of 200 mg/sq m body surface area.",6747681_2,1
6824,internal carotid,109,125,"Thirty-six patients were treated with BCNU every 6 to 8 weeks, either by transfemoral catheterization of the internal carotid or vertebral artery or through a fully implantable intracarotid drug delivery system, beginning with a dose of 200 mg/sq m body surface area.",6747681_2,1
6827,astrocytomas,37,49,Twelve patients with Grade III or IV astrocytomas were treated after partial resection of the tumor without prior radiation therapy.,6747681_3,1
6826,Grade III,21,30,Twelve patients with Grade III or IV astrocytomas were treated after partial resection of the tumor without prior radiation therapy.,6747681_3,1
13051,tumor size,78,88,"After two to seven cycles of chemotherapy, nine patients showed a decrease in tumor size and surrounding edema on contrast-enhanced computerized tomography scans.",6747681_4,1
6829,astrocytomas,50,62,"Twenty-four patients with recurrent Grade I to IV astrocytomas, whose resection and irradiation therapy had failed, received two to eight courses of intra-arterial BCNU therapy.",6747681_7,1
6828,Grade I,36,43,"Twenty-four patients with recurrent Grade I to IV astrocytomas, whose resection and irradiation therapy had failed, received two to eight courses of intra-arterial BCNU therapy.",6747681_7,1
13056,intra-arterial,149,163,"Twenty-four patients with recurrent Grade I to IV astrocytomas, whose resection and irradiation therapy had failed, received two to eight courses of intra-arterial BCNU therapy.",6747681_7,1
3155,BCNU,164,168,"Twenty-four patients with recurrent Grade I to IV astrocytomas, whose resection and irradiation therapy had failed, received two to eight courses of intra-arterial BCNU therapy.",6747681_7,0
3156,BCNU,90,94,"The catheterization procedure is safe, with no immediate complication in 111 infusions of BCNU.",6747681_9,0
3157,Cardiotoxic,0,11,Cardiotoxic and possible leukemogenic effects of adriamycin in nonhuman primates.10 monkeys (macaques) received adriamycin by monthly intravenous injections at 12 mg/m2 (1 mg/kg).,6769133_0,0
13063,mg/m2 (1,163,171,Cardiotoxic and possible leukemogenic effects of adriamycin in nonhuman primates.10 monkeys (macaques) received adriamycin by monthly intravenous injections at 12 mg/m2 (1 mg/kg).,6769133_0,0
13062,intravenous injections,134,156,Cardiotoxic and possible leukemogenic effects of adriamycin in nonhuman primates.10 monkeys (macaques) received adriamycin by monthly intravenous injections at 12 mg/m2 (1 mg/kg).,6769133_0,0
13061,adriamycin,112,122,Cardiotoxic and possible leukemogenic effects of adriamycin in nonhuman primates.10 monkeys (macaques) received adriamycin by monthly intravenous injections at 12 mg/m2 (1 mg/kg).,6769133_0,0
13059,adriamycin,49,59,Cardiotoxic and possible leukemogenic effects of adriamycin in nonhuman primates.10 monkeys (macaques) received adriamycin by monthly intravenous injections at 12 mg/m2 (1 mg/kg).,6769133_0,0
13066,mg/m2,161,166,8 of the 10 monkeys developed congestive heart failure at an average cumulative adriamycin dose (310 mg/m2) well below that considered the safe upper limit (550 mg/m2) in man.,6769133_1,0
13065,mg/m2,101,106,8 of the 10 monkeys developed congestive heart failure at an average cumulative adriamycin dose (310 mg/m2) well below that considered the safe upper limit (550 mg/m2) in man.,6769133_1,0
6832,congestive heart failure,30,54,8 of the 10 monkeys developed congestive heart failure at an average cumulative adriamycin dose (310 mg/m2) well below that considered the safe upper limit (550 mg/m2) in man.,6769133_1,1
13064,adriamycin,80,90,8 of the 10 monkeys developed congestive heart failure at an average cumulative adriamycin dose (310 mg/m2) well below that considered the safe upper limit (550 mg/m2) in man.,6769133_1,0
13067,myocardial lesions,20,38,"Histologically, the myocardial lesions resembled those found in human anthracycline-induced cardiomyopathy.",6769133_2,1
13070,adriamycin,87,97,1 of the 10 monkeys developed acute myeloblastic leukemia after receiving 324 mg/m2 of adriamycin; the 10th monkey is alive and well 26 months after the last dose of drug.,6769133_3,0
13069,mg/m2,78,83,1 of the 10 monkeys developed acute myeloblastic leukemia after receiving 324 mg/m2 of adriamycin; the 10th monkey is alive and well 26 months after the last dose of drug.,6769133_3,0
6833,acute myeloblastic leukemia,30,57,1 of the 10 monkeys developed acute myeloblastic leukemia after receiving 324 mg/m2 of adriamycin; the 10th monkey is alive and well 26 months after the last dose of drug.,6769133_3,1
3158,cardiotoxin,53,64,"Our results suggest that adriamycin is a more potent cardiotoxin in monkeys than in man, and that leukemia may be a consequence of prolonged treatment with this drug.",6769133_4,0
13072,adriamycin,25,35,"Our results suggest that adriamycin is a more potent cardiotoxin in monkeys than in man, and that leukemia may be a consequence of prolonged treatment with this drug.",6769133_4,0
13073,heart rate,117,127,"Provocation of postural hypotension by nitroglycerin in diabetic autonomic neuropathy?The effect of nitroglycerin on heart rate and systolic blood pressure was compared in 5 normal subjects, 12 diabetic subjects without autonomic neuropathy, and 5 diabetic subjects with autonomic neuropathy.",6773726_0,1
6834,postural hypotension,15,35,"Provocation of postural hypotension by nitroglycerin in diabetic autonomic neuropathy?The effect of nitroglycerin on heart rate and systolic blood pressure was compared in 5 normal subjects, 12 diabetic subjects without autonomic neuropathy, and 5 diabetic subjects with autonomic neuropathy.",6773726_0,1
6838,autonomic neuropathy,271,291,"Provocation of postural hypotension by nitroglycerin in diabetic autonomic neuropathy?The effect of nitroglycerin on heart rate and systolic blood pressure was compared in 5 normal subjects, 12 diabetic subjects without autonomic neuropathy, and 5 diabetic subjects with autonomic neuropathy.",6773726_0,1
6837,autonomic neuropathy,220,240,"Provocation of postural hypotension by nitroglycerin in diabetic autonomic neuropathy?The effect of nitroglycerin on heart rate and systolic blood pressure was compared in 5 normal subjects, 12 diabetic subjects without autonomic neuropathy, and 5 diabetic subjects with autonomic neuropathy.",6773726_0,1
6836,blood pressure,141,155,"Provocation of postural hypotension by nitroglycerin in diabetic autonomic neuropathy?The effect of nitroglycerin on heart rate and systolic blood pressure was compared in 5 normal subjects, 12 diabetic subjects without autonomic neuropathy, and 5 diabetic subjects with autonomic neuropathy.",6773726_0,1
6835,diabetic autonomic,56,74,"Provocation of postural hypotension by nitroglycerin in diabetic autonomic neuropathy?The effect of nitroglycerin on heart rate and systolic blood pressure was compared in 5 normal subjects, 12 diabetic subjects without autonomic neuropathy, and 5 diabetic subjects with autonomic neuropathy.",6773726_0,1
6841,blood pressure,278,292,"The magnitude and time course of the increase in heart rate and the decrease in systolic blood pressure after nitroglycerin were similar in the normal and diabetic subjects without autonomic neuropathy, whereas a lesser increase in heart rate and a greater decrease in systolic blood pressure occurred in the diabetic subjects with autonomic neuropathy.",6773726_1,1
6839,blood pressure,89,103,"The magnitude and time course of the increase in heart rate and the decrease in systolic blood pressure after nitroglycerin were similar in the normal and diabetic subjects without autonomic neuropathy, whereas a lesser increase in heart rate and a greater decrease in systolic blood pressure occurred in the diabetic subjects with autonomic neuropathy.",6773726_1,1
6840,autonomic neuropathy,181,201,"The magnitude and time course of the increase in heart rate and the decrease in systolic blood pressure after nitroglycerin were similar in the normal and diabetic subjects without autonomic neuropathy, whereas a lesser increase in heart rate and a greater decrease in systolic blood pressure occurred in the diabetic subjects with autonomic neuropathy.",6773726_1,1
6842,autonomic neuropathy,332,352,"The magnitude and time course of the increase in heart rate and the decrease in systolic blood pressure after nitroglycerin were similar in the normal and diabetic subjects without autonomic neuropathy, whereas a lesser increase in heart rate and a greater decrease in systolic blood pressure occurred in the diabetic subjects with autonomic neuropathy.",6773726_1,1
6843,autonomic neuropathy,140,160,"It is therefore suggested that caution should be exercised when prescribing vasodilator drugs in diabetic patients, particularly those with autonomic neuropathy.",6773726_2,1
3159,vasodilator drugs,76,93,"It is therefore suggested that caution should be exercised when prescribing vasodilator drugs in diabetic patients, particularly those with autonomic neuropathy.",6773726_2,0
6844,Tricuspid valve regurgitation,0,29,Tricuspid valve regurgitation and lithium carbonate toxicity in a newborn infant.,6794356_0,1
3160,lithium carbonate,34,51,Tricuspid valve regurgitation and lithium carbonate toxicity in a newborn infant.,6794356_0,0
13078,newborn infant,66,80,Tricuspid valve regurgitation and lithium carbonate toxicity in a newborn infant.,6794356_0,1
6847,congestive heart failure,64,88,"A newborn with massive tricuspid regurgitation, atrial flutter, congestive heart failure, and a high serum lithium level is described.",6794356_1,1
6845,tricuspid regurgitation,23,46,"A newborn with massive tricuspid regurgitation, atrial flutter, congestive heart failure, and a high serum lithium level is described.",6794356_1,1
6846,atrial flutter,48,62,"A newborn with massive tricuspid regurgitation, atrial flutter, congestive heart failure, and a high serum lithium level is described.",6794356_1,1
3161,lithium compounds,169,186,"This is the first patient to initially manifest tricuspid regurgitation and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.",6794356_2,0
6850,cardiac disease,128,143,"This is the first patient to initially manifest tricuspid regurgitation and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.",6794356_2,1
6848,tricuspid regurgitation,48,71,"This is the first patient to initially manifest tricuspid regurgitation and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.",6794356_2,1
6849,atrial flutter,76,90,"This is the first patient to initially manifest tricuspid regurgitation and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.",6794356_2,1
13079,first trimester of pregnancy,194,222,"This is the first patient to initially manifest tricuspid regurgitation and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy.",6794356_2,1
6851,tricuspid valve,41,56,Sixty-three percent of these infants had tricuspid valve involvement.,6794356_3,1
3162,Lithium carbonate,0,17,Lithium carbonate may be a factor in the increasing incidence of congenital heart disease when taken during early pregnancy.,6794356_4,0
6852,congenital heart disease,65,89,Lithium carbonate may be a factor in the increasing incidence of congenital heart disease when taken during early pregnancy.,6794356_4,1
6853,early pregnancy,108,123,Lithium carbonate may be a factor in the increasing incidence of congenital heart disease when taken during early pregnancy.,6794356_4,1
13080,neurologic depression,15,36,"It also causes neurologic depression, cyanosis, and cardiac arrhythmia when consumed prior to delivery.",6794356_5,1
6854,cardiac arrhythmia,52,70,"It also causes neurologic depression, cyanosis, and cardiac arrhythmia when consumed prior to delivery.",6794356_5,1
13083,impaired learning,59,76,Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents.,6817363_0,1
13082,compound aniracetam,21,40,Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents.,6817363_0,0
13084,aniracetam,14,24,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,0
3163,(1,210,212,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,0
13085,1-anisoyl-2-pyrrolidinone,38,63,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,0
3165,(3,505,507,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,0
3166,cycloheximide,800,813,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,0
3167,cycloheximide,1012,1025,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,0
3164,(2,380,382,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,0
13088,sublethal,314,323,"The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition).",6817363_1,1
13097,cognitive functions,49,68,These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10-100 mg/kg.,6817363_2,1
13098,oral aniracetam,82,97,These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10-100 mg/kg.,6817363_2,0
13099,aniracetam,42,52,The mechanisms underlying the activity of aniracetam and its 'therapeutic window' are unknown.,6817363_4,0
3168,Piracetam,0,9,"Piracetam, another pyrrolidinone derivative was used for comparison.",6817363_5,0
3169,pyrrolidinone,19,32,"Piracetam, another pyrrolidinone derivative was used for comparison.",6817363_5,0
13101,aniracetam,79,89,It was active only in six of nine tests and had about one-tenth the potency of aniracetam.,6817363_6,0
13102,aniracetam,26,36,The results indicate that aniracetam improves cognitive functions which are impaired by different procedure and in different phases of the learning and memory process.,6817363_7,0
6855,Blood pressure,0,14,Blood pressure response to chronic low-dose intrarenal noradrenaline infusion in conscious rats.,6861444_0,1
13105,h-1 kg-1,85,93,"Sodium chloride solution (0.9%) or noradrenaline in doses of 4, 12 and 36 micrograms h-1 kg-1 was infused for five consecutive days, either intrarenally (by a new technique) or intravenously into rats with one kidney removed.",6861444_1,0
3170,Sodium chloride solution,0,24,"Sodium chloride solution (0.9%) or noradrenaline in doses of 4, 12 and 36 micrograms h-1 kg-1 was infused for five consecutive days, either intrarenally (by a new technique) or intravenously into rats with one kidney removed.",6861444_1,0
13111,intrarenal,192,202,These results suggest that hypertension after chronic intrarenal noradrenaline infusion is produced by relatively higher levels of circulating noradrenaline and by triggering of an additional intrarenal pressor mechanism.,6861444_4,1
13112,adenohypophyseal tumors,37,60,Characterization of estrogen-induced adenohypophyseal tumors in the Fischer 344 rat.,6888657_0,1
13113,F344,33,37,"Pituitary tumors were induced in F344 female rats by chronic treatment with diethylstilbestrol (DES, 8-10 mg) implanted subcutaneously in silastic capsules.",6888657_1,0
6856,Pituitary tumors,0,16,"Pituitary tumors were induced in F344 female rats by chronic treatment with diethylstilbestrol (DES, 8-10 mg) implanted subcutaneously in silastic capsules.",6888657_1,1
3172,PRL,195,198,"The cell populations were examined regarding total cell recovery correlated with gland weight, intracellular prolactin (PRL) content and subsequent release in primary culture, immunocytochemical PRL staining, density and/or size alterations via separation on Ficoll-Hypaque and by unit gravity sedimentation, and cell cycle analysis, after acriflavine DNA staining, by laser flow cytometry.",6888657_3,0
3171,PRL,120,123,"The cell populations were examined regarding total cell recovery correlated with gland weight, intracellular prolactin (PRL) content and subsequent release in primary culture, immunocytochemical PRL staining, density and/or size alterations via separation on Ficoll-Hypaque and by unit gravity sedimentation, and cell cycle analysis, after acriflavine DNA staining, by laser flow cytometry.",6888657_3,0
13118,gland weight,81,93,"The cell populations were examined regarding total cell recovery correlated with gland weight, intracellular prolactin (PRL) content and subsequent release in primary culture, immunocytochemical PRL staining, density and/or size alterations via separation on Ficoll-Hypaque and by unit gravity sedimentation, and cell cycle analysis, after acriflavine DNA staining, by laser flow cytometry.",6888657_3,1
13120,acriflavine DNA,340,355,"The cell populations were examined regarding total cell recovery correlated with gland weight, intracellular prolactin (PRL) content and subsequent release in primary culture, immunocytochemical PRL staining, density and/or size alterations via separation on Ficoll-Hypaque and by unit gravity sedimentation, and cell cycle analysis, after acriflavine DNA staining, by laser flow cytometry.",6888657_3,0
3174,PRL,75,78,"Intracellular PRL content ranged from 1.9 to 9.4 times control levels, and PRL release in vitro was significantly and consistently higher than controls, after at least 8 days of DES exposure.",6888657_5,0
3173,PRL,14,17,"Intracellular PRL content ranged from 1.9 to 9.4 times control levels, and PRL release in vitro was significantly and consistently higher than controls, after at least 8 days of DES exposure.",6888657_5,0
3176,PRL,85,88,Increased density and/or size and PRL content were indicated for the majority of the PRL cell population in both types of separation protocols.,6888657_7,0
3175,PRL,34,37,Increased density and/or size and PRL content were indicated for the majority of the PRL cell population in both types of separation protocols.,6888657_7,0
3177,PRL,120,123,"The data extend the findings of other investigators, further establishing the DES-induced tumor as a model for study of PRL cellular control mechanisms.",6888657_9,0
13129,eserine,82,89,Effect of calcium chloride on gross behavioural changes produced by carbachol and eserine in cats.,6892185_0,0
3178,carbachol,68,77,Effect of calcium chloride on gross behavioural changes produced by carbachol and eserine in cats.,6892185_0,0
13128,gross behavioural,30,47,Effect of calcium chloride on gross behavioural changes produced by carbachol and eserine in cats.,6892185_0,1
13127,calcium chloride,10,26,Effect of calcium chloride on gross behavioural changes produced by carbachol and eserine in cats.,6892185_0,0
13133,clonic-tonic convulsions,255,279,"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.",6892185_1,0
13131,cerebral ventricles,49,68,"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.",6892185_1,1
13130,calcium chloride,14,30,"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.",6892185_1,0
3179,carbachol,292,301,"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.",6892185_1,0
13134,eserine,306,313,"The effect of calcium chloride injected into the cerebral ventricles of group-housed unanaesthetized cats upon vocalization (rage, hissing and snarling), fighting (attack with paws and claws, defense with paws and claws and biting), mydriasis, tremor and clonic-tonic convulsions produced by carbachol and eserine injected similarly was investigated.",6892185_1,0
13135,Calcium chloride,0,16,Calcium chloride depressed or almost completely abolished the vocalization and fighting due to carbachol and eserine.,6892185_2,0
3180,carbachol,95,104,Calcium chloride depressed or almost completely abolished the vocalization and fighting due to carbachol and eserine.,6892185_2,0
13136,eserine,109,116,Calcium chloride depressed or almost completely abolished the vocalization and fighting due to carbachol and eserine.,6892185_2,0
3181,carbachol,76,85,"On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.",6892185_3,0
13139,calcium chloride,132,148,"On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.",6892185_3,0
13137,clonic-tonic convulsions,41,65,"On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.",6892185_3,0
13138,eserine,90,97,"On the other hand, mydriasis, tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride.",6892185_3,0
3182,carbachol,180,189,"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.",6892185_4,0
13141,motor phenomena,99,114,"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.",6892185_4,1
13142,clonic-tonic convulsions,145,169,"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.",6892185_4,0
13143,eserine,194,201,"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.",6892185_4,0
13140,calcium chloride,20,36,"It is apparent that calcium chloride can ""dissociate"" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and clonic-tonic convulsions caused by carbachol and eserine.",6892185_4,0
13146,stabilizing action,122,140,Calcium chloride inhibited the vocalization and fighting produced by carbachol and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites.,6892185_5,0
3184,muscarinic,152,162,Calcium chloride inhibited the vocalization and fighting produced by carbachol and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites.,6892185_5,0
3183,carbachol,69,78,Calcium chloride inhibited the vocalization and fighting produced by carbachol and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites.,6892185_5,0
13144,Calcium chloride,0,16,Calcium chloride inhibited the vocalization and fighting produced by carbachol and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites.,6892185_5,0
13145,eserine,83,90,Calcium chloride inhibited the vocalization and fighting produced by carbachol and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites.,6892185_5,0
6857,central nervous system,108,130,These results further support the view that calcium ions in excess have an atropine-like action also in the central nervous system.,6892185_6,1
13147,calcium ions,44,56,These results further support the view that calcium ions in excess have an atropine-like action also in the central nervous system.,6892185_6,0
6858,cardiac arrhythmias,36,55,"Thiazide diuretics, hypokalemia and cardiac arrhythmias.",6942642_0,1
3185,Thiazide diuretics,0,18,"Thiazide diuretics, hypokalemia and cardiac arrhythmias.",6942642_0,0
3186,Thiazide diuretics,0,18,Thiazide diuretics are widely accepted as the cornerstone of antihypertensive treatment programs.,6942642_1,0
3190,K+,72,74,"The occurrence of PVC's correlated significantly with the fall in serum K+ observed r = 0.72, p less than 0.001.",6942642_10,0
3191,thiazide diuretics,28,46,In conclusion we found that thiazide diuretics cause hypokalemia and depletion of body potassium.,6942642_11,0
13150,metabolic consequence,38,59,Hypokalemia is a commonly encountered metabolic consequence of chronic thiazide therapy.,6942642_2,1
13152,diastolic hypertension,69,91,"We treated 38 patients (22 low renin, 16 normal renin) with moderate diastolic hypertension with hydrochlorothiazide (HCTC) administered on a twice daily schedule.",6942642_3,1
6859,blood pressure,112,126,"Initial dose was 50 mg and the dose was increased at monthly intervals to 100 mg, 150 mg and 200 mg daily until blood pressure normalized.",6942642_4,1
3187,HCTZ,90,94,"The serum K during the control period was 4.5 +/- 0.2 mEq/l an on 50, 100, 150 and 200 mg HCTZ daily 3.9 +/- 0.3, 3.4 +/- 0.2, 2.9 +/- 0.2, and 2.4 +/- 0.3 mEq/l, respectively.",6942642_5,0
3188,HCTZ,42,46,In 13 patients we observed the effects of HCTZ therapy (100 mg daily) on the occurrence of PVC's during rest as well as during static and dynamic exercise.,6942642_7,0
3189,HCTZ,29,33,"Corresponding figures during HCTZ therapy 100 mg daily were 1.4 +/- 0.1, 3.6 +/- 0.7 and 5.7 4/- 0.8, respectively.",6942642_9,0
13179,acute hepatic necrosis,34,56,Circulating lysosomal enzymes and acute hepatic necrosis.,7007443_0,1
13178,lysosomal enzymes,12,29,Circulating lysosomal enzymes and acute hepatic necrosis.,7007443_0,0
13181,N-acetylglucosaminidase,67,90,"The activities of the lysosomal enzymes acid and neutral protease, N-acetylglucosaminidase, and acid phosphatase were measured in the serum of patients with fulminant hepatic failure.",7007443_1,0
13180,lysosomal enzymes acid,22,44,"The activities of the lysosomal enzymes acid and neutral protease, N-acetylglucosaminidase, and acid phosphatase were measured in the serum of patients with fulminant hepatic failure.",7007443_1,0
6860,fulminant hepatic failure,157,182,"The activities of the lysosomal enzymes acid and neutral protease, N-acetylglucosaminidase, and acid phosphatase were measured in the serum of patients with fulminant hepatic failure.",7007443_1,1
3192,neutral protease,49,65,"The activities of the lysosomal enzymes acid and neutral protease, N-acetylglucosaminidase, and acid phosphatase were measured in the serum of patients with fulminant hepatic failure.",7007443_1,0
3193,acid phosphatase,96,112,"The activities of the lysosomal enzymes acid and neutral protease, N-acetylglucosaminidase, and acid phosphatase were measured in the serum of patients with fulminant hepatic failure.",7007443_1,0
6861,fulminant hepatic failure,128,153,"Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived.",7007443_2,1
3194,Acid protease,0,13,"Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived.",7007443_2,0
3195,cathepsin,15,24,"Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived.",7007443_2,0
6862,fulminant hepatic failure,241,266,"Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived.",7007443_2,1
3196,paracetamol,160,171,"Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived.",7007443_2,0
13182,viral hepatitis,274,289,"Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived.",7007443_2,1
3197,acid protease,38,51,"A correlation was found between serum acid protease activity and prothrombin time, and the increase in cathepsin D activity was sustained over several days compared with aspartate aminotransferase, which showed a sharp early peak and then a fall.",7007443_3,0
3199,aspartate aminotransferase,170,196,"A correlation was found between serum acid protease activity and prothrombin time, and the increase in cathepsin D activity was sustained over several days compared with aspartate aminotransferase, which showed a sharp early peak and then a fall.",7007443_3,0
3198,cathepsin,103,112,"A correlation was found between serum acid protease activity and prothrombin time, and the increase in cathepsin D activity was sustained over several days compared with aspartate aminotransferase, which showed a sharp early peak and then a fall.",7007443_3,0
13184,lysosomal proteases,12,31,"Circulating lysosomal proteases can damage other organs, and measurement of their activity may therefore be of added value in assessing prognosis in this condition.",7007443_4,0
3200,creatinine,214,224,In 35 patients (ages 20 to 86 yr) receiving cimetidine therapeutically two serum samples and all urine formed in the interim were collected for analysis of cimetidine by high-pressure liquid chromatography and for creatinine.,7053303_1,0
13187,intravenous cimetidine,77,99,"The extrapolated 6-hr serum concentration of cimetidine per unit dose, after intravenous cimetidine, increased with age of the patients.",7053303_3,0
3201,creatinine,37,47,"The ratio of cimetidine clearance to creatinine clearance (Rc) averaged 4.8 +/- 2.0, indicating net tubular secretion for cimetidine.",7053303_4,0
13188,Rc,59,61,"The ratio of cimetidine clearance to creatinine clearance (Rc) averaged 4.8 +/- 2.0, indicating net tubular secretion for cimetidine.",7053303_4,0
13191,Rc,0,2,"Rc seemed to be independent of age and decreased with increasing serum concentration of cimetidine, suggesting that secretion of cimetidine is a saturable process.",7053303_5,0
6863,kidney disease,164,178,There was only one case of dementia possibly due to cimetidine (with a drug level of 1.9 microgram/ml 6 hr after a dose) in a group of 13 patients without liver or kidney disease who had cimetidine levels above 1.25 microgram/ml.,7053303_6,1
13193,6-thioguanine,41,54,Hepatic veno-occlusive disease caused by 6-thioguanine.,7053705_0,0
6864,Hepatic veno-occlusive disease,0,30,Hepatic veno-occlusive disease caused by 6-thioguanine.,7053705_0,1
13196,6-thioguanine,165,178,Clinically reversible veno-occlusive disease of the liver developed in a 23-year-old man with acute lymphocytic leukemia after 10 months of maintenance therapy with 6-thioguanine.,7053705_1,0
13194,Clinically reversible veno-occlusive disease,0,44,Clinically reversible veno-occlusive disease of the liver developed in a 23-year-old man with acute lymphocytic leukemia after 10 months of maintenance therapy with 6-thioguanine.,7053705_1,1
6865,acute lymphocytic leukemia,94,120,Clinically reversible veno-occlusive disease of the liver developed in a 23-year-old man with acute lymphocytic leukemia after 10 months of maintenance therapy with 6-thioguanine.,7053705_1,1
13199,subintimal fibrosis,54,73,"Although this disease was clinically reversible, some subintimal fibrosis about the terminal hepatic veins persisted.",7053705_3,1
13200,hepatic veins,93,106,"Although this disease was clinically reversible, some subintimal fibrosis about the terminal hepatic veins persisted.",7053705_3,1
13201,clinically reversible hepatic veno-occlusive disease,79,131,"This case presented a unique opportunity to observe the histologic features of clinically reversible hepatic veno-occlusive disease over time, and may be the first case of veno-occlusive related solely to 6-thioguanine.",7053705_4,1
13202,veno-occlusive,172,186,"This case presented a unique opportunity to observe the histologic features of clinically reversible hepatic veno-occlusive disease over time, and may be the first case of veno-occlusive related solely to 6-thioguanine.",7053705_4,1
13203,6-thioguanine,205,218,"This case presented a unique opportunity to observe the histologic features of clinically reversible hepatic veno-occlusive disease over time, and may be the first case of veno-occlusive related solely to 6-thioguanine.",7053705_4,0
6866,optic neuropathy,23,39,Chlorpropamide-induced optic neuropathy.,7059267_0,1
3202,chlorpropamide,59,73,A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.,7059267_1,0
6868,toxic optic neuropathy,92,114,A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.,7059267_1,1
6867,adult-onset,25,36,A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.,7059267_1,1
3203,chlorpropamide,153,167,A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.,7059267_1,0
13204,Diabenese,75,84,A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy.,7059267_1,0
6869,Visual loss,0,11,"Visual loss occurs in diabetics for a variety of reasons, and accurate diagnosis is necessary to institute appropriate therapy.",7059267_2,1
6870,visual loss,105,116,The possibility of a drug-induced optic neuropathy should be considered in the differential diagnosis of visual loss in diabetics.,7059267_3,1
13205,drug-induced optic neuropathy,21,50,The possibility of a drug-induced optic neuropathy should be considered in the differential diagnosis of visual loss in diabetics.,7059267_3,1
6871,nephrotic syndrome,69,87,Plasma and urinary lipids and lipoproteins during the development of nephrotic syndrome induced in the rat by puromycin aminonucleoside.,7066357_0,1
3204,puromycin aminonucleoside,110,135,Plasma and urinary lipids and lipoproteins during the development of nephrotic syndrome induced in the rat by puromycin aminonucleoside.,7066357_0,0
6872,nephrotic syndrome,95,113,"This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the aminonucleoside.",7066357_1,1
6873,nephrotic syndrome,163,181,"This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the aminonucleoside.",7066357_1,1
3205,puromycin aminonucleoside,125,150,"This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the aminonucleoside.",7066357_1,0
3206,aminonucleoside,219,234,"This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the aminonucleoside.",7066357_1,0
13207,plasma lipoproteins,66,85,"This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se, or, at least in part, to the aminonucleoside.",7066357_1,0
13216,pre-nephrotic stage lipoproteinuria,7,42,"In the pre-nephrotic stage lipoproteinuria was negligible, while in the early nephrotic stage the urinary loss of plasma lipoproteins consisted mainly of HDL.",7066357_10,1
6877,nephrotic,78,87,"In the pre-nephrotic stage lipoproteinuria was negligible, while in the early nephrotic stage the urinary loss of plasma lipoproteins consisted mainly of HDL.",7066357_10,1
6878,loss of,106,113,"In the pre-nephrotic stage lipoproteinuria was negligible, while in the early nephrotic stage the urinary loss of plasma lipoproteins consisted mainly of HDL.",7066357_10,1
3215,puromycin aminonucleoside,33,58,These observations indicate that puromycin aminonucleoside alters plasma lipoproteins by lowering VLDL and increasing HDL.,7066357_11,0
13218,plasma lipoproteins,66,85,These observations indicate that puromycin aminonucleoside alters plasma lipoproteins by lowering VLDL and increasing HDL.,7066357_11,0
6879,nephrotic,73,82,It is likely that the early and striking increase of plasma HDL found in nephrotic rats is related to a direct effect of the drug on HDL metabolism.,7066357_12,1
6874,nephrotic syndrome,210,228,The purpose of the present study was to investigate the changes in plasma and urinary lipoproteins during the administration of puromycin aminonucleoside (20 mg/kg for 7 days) and the subsequent development of nephrotic syndrome.,7066357_2,1
3207,puromycin aminonucleoside,128,153,The purpose of the present study was to investigate the changes in plasma and urinary lipoproteins during the administration of puromycin aminonucleoside (20 mg/kg for 7 days) and the subsequent development of nephrotic syndrome.,7066357_2,0
6875,nephrotic,147,156,"Since massive albuminuria occurred after 6 days of treatment, the time-course study was divided into two stages: pre-nephrotic stage (day 1-5) and nephrotic stage (day 6-11).",7066357_3,1
13209,massive albuminuria,6,25,"Since massive albuminuria occurred after 6 days of treatment, the time-course study was divided into two stages: pre-nephrotic stage (day 1-5) and nephrotic stage (day 6-11).",7066357_3,1
13210,pre-nephrotic stage,113,132,"Since massive albuminuria occurred after 6 days of treatment, the time-course study was divided into two stages: pre-nephrotic stage (day 1-5) and nephrotic stage (day 6-11).",7066357_3,1
3209,triacylglycerol,56,71,"In pre-nephrotic stage the plasma level of fatty acids, triacylglycerol and VLDL decreased while that of phospholipid, cholesteryl esters and HDL remained constant.",7066357_4,0
3208,fatty acids,43,54,"In pre-nephrotic stage the plasma level of fatty acids, triacylglycerol and VLDL decreased while that of phospholipid, cholesteryl esters and HDL remained constant.",7066357_4,0
13212,pre-nephrotic stage,3,22,"In pre-nephrotic stage the plasma level of fatty acids, triacylglycerol and VLDL decreased while that of phospholipid, cholesteryl esters and HDL remained constant.",7066357_4,1
3210,cholesteryl esters,119,137,"In pre-nephrotic stage the plasma level of fatty acids, triacylglycerol and VLDL decreased while that of phospholipid, cholesteryl esters and HDL remained constant.",7066357_4,0
3211,apolipoprotein A-I,7,25,Plasma apolipoprotein A-I tended to increase (40% increase at day 5).,7066357_5,0
6876,nephrotic,20,29,"At the beginning of nephrotic stage (day 6) the concentration of plasma albumin dropped to a very low level, while that of apolipoprotein A-I increased abruptly (4-fold increase) and continued to rise, although less steeply, in the following days.",7066357_6,1
13213,plasma albumin,65,79,"At the beginning of nephrotic stage (day 6) the concentration of plasma albumin dropped to a very low level, while that of apolipoprotein A-I increased abruptly (4-fold increase) and continued to rise, although less steeply, in the following days.",7066357_6,0
3213,apolipoprotein A-I,123,141,"At the beginning of nephrotic stage (day 6) the concentration of plasma albumin dropped to a very low level, while that of apolipoprotein A-I increased abruptly (4-fold increase) and continued to rise, although less steeply, in the following days.",7066357_6,0
3212,low level,98,107,"At the beginning of nephrotic stage (day 6) the concentration of plasma albumin dropped to a very low level, while that of apolipoprotein A-I increased abruptly (4-fold increase) and continued to rise, although less steeply, in the following days.",7066357_6,0
13214,Plasma VLDL,0,11,Plasma VLDL and LDL increased at a later stage (day 9).,7066357_8,0
3214,apolipoprotein A-I,7,25,Plasma apolipoprotein A-I was found not only in HDL (1.063-1.210 g/ml) but also in the LDL density class (1.025-1.050 g/ml).,7066357_9,0
6880,aplastic anemia,6,21,Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol.,7072798_0,1
13219,ophthalmic chloramphenicol,58,84,Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol.,7072798_0,0
13220,woman died,14,24,A 73-year-old woman died of aplastic anemia less than two months after undergoing cataract extraction and beginning topical therapy with chloramphenicol.,7072798_1,1
13221,cataract extraction,82,101,A 73-year-old woman died of aplastic anemia less than two months after undergoing cataract extraction and beginning topical therapy with chloramphenicol.,7072798_1,1
6881,aplastic anemia,28,43,A 73-year-old woman died of aplastic anemia less than two months after undergoing cataract extraction and beginning topical therapy with chloramphenicol.,7072798_1,1
6882,aplastic anemia,19,34,The pattern of the aplastic anemia was associated with an idiosyncratic response to chloramphenicol.,7072798_3,1
6883,aplastic anemia,36,51,"This was the second report of fatal aplastic anemia after topical treatment with chloramphenicol for ocular conditions, although two cases of reversible bone marrow hypoplasia have also been reported.",7072798_4,1
6884,bone marrow,153,164,"This was the second report of fatal aplastic anemia after topical treatment with chloramphenicol for ocular conditions, although two cases of reversible bone marrow hypoplasia have also been reported.",7072798_4,1
13224,ocular conditions,101,118,"This was the second report of fatal aplastic anemia after topical treatment with chloramphenicol for ocular conditions, although two cases of reversible bone marrow hypoplasia have also been reported.",7072798_4,1
6887,Side Effects,162,174,"Any other suspected cases of ocular toxicity associated with topically applied chloramphenicol should be reported to the National Registry of Drug-Induced Ocular Side Effects, Oregon Health Sciences University, Portland, OR 97201.",7072798_5,1
6886,Drug-Induced,142,154,"Any other suspected cases of ocular toxicity associated with topically applied chloramphenicol should be reported to the National Registry of Drug-Induced Ocular Side Effects, Oregon Health Sciences University, Portland, OR 97201.",7072798_5,1
6885,ocular toxicity,29,44,"Any other suspected cases of ocular toxicity associated with topically applied chloramphenicol should be reported to the National Registry of Drug-Induced Ocular Side Effects, Oregon Health Sciences University, Portland, OR 97201.",7072798_5,1
6888,atrial tachycardia,96,114,A case is presented of a reversible intra-Hisian block occurring under amiodarone treatment for atrial tachycardia in a patient without clear intraventricular conduction abnormalities.,7083920_1,1
13227,intraventricular conduction abnormalities,142,183,A case is presented of a reversible intra-Hisian block occurring under amiodarone treatment for atrial tachycardia in a patient without clear intraventricular conduction abnormalities.,7083920_1,1
13226,intra-Hisian block,36,54,A case is presented of a reversible intra-Hisian block occurring under amiodarone treatment for atrial tachycardia in a patient without clear intraventricular conduction abnormalities.,7083920_1,1
3216,His,0,3,"His bundle recordings showed an atrial tachycardia with intermittent exit block and greatly prolonged BH and HV intervals (40 and 100 msec, respectively).",7083920_2,0
6890,exit block,69,79,"His bundle recordings showed an atrial tachycardia with intermittent exit block and greatly prolonged BH and HV intervals (40 and 100 msec, respectively).",7083920_2,1
6889,atrial tachycardia,32,50,"His bundle recordings showed an atrial tachycardia with intermittent exit block and greatly prolonged BH and HV intervals (40 and 100 msec, respectively).",7083920_2,1
3217,His,46,49,"Thirty days after amiodarone discontinuation, His bundle electrograms showed atrial flutter without intra-Hisian or infra-Hisian delay.",7083920_3,0
6891,atrial flutter,77,91,"Thirty days after amiodarone discontinuation, His bundle electrograms showed atrial flutter without intra-Hisian or infra-Hisian delay.",7083920_3,1
13232,intraventricular conduction,103,130,Amiodarone should be used with caution during long-term oral therapy in patients with or without clear intraventricular conduction defects.,7083920_4,1
13233,clear cell adenocarcinoma in,15,43,Development of clear cell adenocarcinoma in DES-exposed offspring under observation.,7088431_0,1
13234,clear cell adenocarcinoma of,13,41,Two cases of clear cell adenocarcinoma of the vagina detected at follow-up in young women exposed in utero to diethylstilbestrol are reported.,7088431_1,1
13236,small nodule,92,104,"In both instances, suspicion of the presence of carcinoma was aroused by the palpation of a small nodule in the vaginal fornix.",7088431_3,1
13240,uterine cavity,141,155,"Hysterosalpingography was performed on both patients and, in 1 instance, an abnormal x-ray film was reflected by the gross appearance of the uterine cavity found in the surgical specimen.",7088431_4,1
3218,thiopentone,24,35,Midazolam compared with thiopentone as an induction agent.,7102237_0,0
13242,induction agent,42,57,Midazolam compared with thiopentone as an induction agent.,7102237_0,0
3220,thiopentone,196,207,"In patients premedicated with scopolamine + morphine (+5 mg nitrazepam the evening before surgery), the sleep-inducing effect of midazolam 0.15 mg/kg i.v. was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v.",7102237_1,0
3219,morphine (+,44,55,"In patients premedicated with scopolamine + morphine (+5 mg nitrazepam the evening before surgery), the sleep-inducing effect of midazolam 0.15 mg/kg i.v. was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v.",7102237_1,0
13245,midazolam group,67,82,"Somewhat fewer cardiovascular and local sequelae were found in the midazolam group, but, although apnoea occurred less often in the midazolam group it lasted longer.",7102237_2,0
13246,apnoea,98,104,"Somewhat fewer cardiovascular and local sequelae were found in the midazolam group, but, although apnoea occurred less often in the midazolam group it lasted longer.",7102237_2,0
13244,local sequelae,34,48,"Somewhat fewer cardiovascular and local sequelae were found in the midazolam group, but, although apnoea occurred less often in the midazolam group it lasted longer.",7102237_2,1
3221,thiopentone,52,63,"On the whole, the differences between midazolam and thiopentone had no apparent clinical consequences.",7102237_3,0
13248,alternative agent,19,36,Midazolam is a new alternative agent for induction in combination anaesthesia.,7102237_4,0
13250,Extrapyramidal side effects,0,27,Extrapyramidal side effects and oral haloperidol: an analysis of explanatory patient and treatment characteristics.,7161250_0,1
13251,oral haloperidol,32,48,Extrapyramidal side effects and oral haloperidol: an analysis of explanatory patient and treatment characteristics.,7161250_0,0
13252,extrapyramidal side effects,17,44,The incidence of extrapyramidal side effects (EPS) was evaluated in 98 patients treated with haloperidol.,7161250_1,1
3222,antiparkinsonian,13,29,Prophylactic antiparkinsonian medication was effective in younger but not in older patients.,7161250_3,0
3223,antiparkinsonians,102,119,"Akathisia was controlled by the benzodiazepine lorazepam in 14 out of 16 patients, while prophylactic antiparkinsonians were ineffective.",7161250_5,0
6892,Akathisia,0,9,"Akathisia was controlled by the benzodiazepine lorazepam in 14 out of 16 patients, while prophylactic antiparkinsonians were ineffective.",7161250_5,1
3225,CD50,19,23,Median convulsant (CD50) and median lethal (LD50) doses of three representative local anesthetics were determined in adult mice to evaluate the threat to life of local anesthetic-induced convulsions.,7189975_1,0
3226,local anesthetics,80,97,Median convulsant (CD50) and median lethal (LD50) doses of three representative local anesthetics were determined in adult mice to evaluate the threat to life of local anesthetic-induced convulsions.,7189975_1,0
13257,LD50,44,48,Median convulsant (CD50) and median lethal (LD50) doses of three representative local anesthetics were determined in adult mice to evaluate the threat to life of local anesthetic-induced convulsions.,7189975_1,0
3224,convulsant,7,17,Median convulsant (CD50) and median lethal (LD50) doses of three representative local anesthetics were determined in adult mice to evaluate the threat to life of local anesthetic-induced convulsions.,7189975_1,0
13258,LD50,13,17,"The CD50 and LD50, respectively, were 57.7 and 58.7 mg/kg for bupivacaine, 111.0 and 133.1 mg/kg for lidocaine, and 243.4 and 266.5 mg/kg for chloroprocaine.",7189975_2,0
13259,chloroprocaine,142,156,"The CD50 and LD50, respectively, were 57.7 and 58.7 mg/kg for bupivacaine, 111.0 and 133.1 mg/kg for lidocaine, and 243.4 and 266.5 mg/kg for chloroprocaine.",7189975_2,0
3228,bupivacaine,62,73,"The CD50 and LD50, respectively, were 57.7 and 58.7 mg/kg for bupivacaine, 111.0 and 133.1 mg/kg for lidocaine, and 243.4 and 266.5 mg/kg for chloroprocaine.",7189975_2,0
3227,CD50,4,8,"The CD50 and LD50, respectively, were 57.7 and 58.7 mg/kg for bupivacaine, 111.0 and 133.1 mg/kg for lidocaine, and 243.4 and 266.5 mg/kg for chloroprocaine.",7189975_2,0
3229,bupivacaine,30,41,"When given intraperitoneally, bupivacaine thus was only about twice as toxic as lidocaine and four times as toxic as chloroprocaine.",7189975_3,0
13261,chloroprocaine,117,131,"When given intraperitoneally, bupivacaine thus was only about twice as toxic as lidocaine and four times as toxic as chloroprocaine.",7189975_3,0
6893,cardiopulmonary arrest,60,82,"Convulsions always preceded death, except after precipitous cardiopulmonary arrest from extreme doses.",7189975_4,1
3231,local anesthetic,15,31,"A CD50 dose of local anesthetic (causing convulsions in 50% of mice) was fatal in 90% of bupivacaine-induced seizures, in 57% of the chloroprocaine group, and in 6% of the lidocaine group.",7189975_5,0
3230,CD50,2,6,"A CD50 dose of local anesthetic (causing convulsions in 50% of mice) was fatal in 90% of bupivacaine-induced seizures, in 57% of the chloroprocaine group, and in 6% of the lidocaine group.",7189975_5,0
3233,local anesthetics,54,71,The narrow gap between convulsant and lethal doses of local anesthetics indicates that untreated convulsions present much more of a threat to life than heretofore appreciated.,7189975_6,0
3232,convulsant,23,33,The narrow gap between convulsant and lethal doses of local anesthetics indicates that untreated convulsions present much more of a threat to life than heretofore appreciated.,7189975_6,0
13266,lethal doses,38,50,The narrow gap between convulsant and lethal doses of local anesthetics indicates that untreated convulsions present much more of a threat to life than heretofore appreciated.,7189975_6,0
13267,untreated convulsions,87,108,The narrow gap between convulsant and lethal doses of local anesthetics indicates that untreated convulsions present much more of a threat to life than heretofore appreciated.,7189975_6,0
3234,serotonergic,75,87,REM sleep deprivation changes behavioral response to catecholaminergic and serotonergic receptor activation in rats.,7197363_0,0
13269,catecholaminergic,53,70,REM sleep deprivation changes behavioral response to catecholaminergic and serotonergic receptor activation in rats.,7197363_0,0
6894,REM sleep deprivation,0,21,REM sleep deprivation changes behavioral response to catecholaminergic and serotonergic receptor activation in rats.,7197363_0,1
6895,REM sleep deprivation,15,36,The effects of REM sleep deprivation (REMD) on apomorphine-induced aggressiveness and quipazine-induced head twitches in rats were determined.,7197363_1,1
3235,antidepressive,81,95,Results are discussed in terms of similarity to pharmacological effects of other antidepressive treatments.,7197363_3,0
13277,pharmacological effects,48,71,Results are discussed in terms of similarity to pharmacological effects of other antidepressive treatments.,7197363_3,0
6896,subarachnoid,22,34,"Neurologic effects of subarachnoid administration of 2-chloroprocaine-CE, bupivacaine, and low pH normal saline in dogs.",7199841_0,1
3236,bupivacaine,74,85,"Neurologic effects of subarachnoid administration of 2-chloroprocaine-CE, bupivacaine, and low pH normal saline in dogs.",7199841_0,0
3237,normal saline,98,111,"Neurologic effects of subarachnoid administration of 2-chloroprocaine-CE, bupivacaine, and low pH normal saline in dogs.",7199841_0,0
6897,subarachnoid,84,96,The purpose of this study was to evaluate the neurologic consequences of deliberate subarachnoid injection of large volumes of 2-chloroprocaine-CE in experimental animals.,7199841_1,1
6898,neurotoxicity,84,97,The possible role of low pH as well as total volume as potential factors in causing neurotoxicity was evaluated.,7199841_2,1
3240,normal saline,191,204,"The 65 dogs in the study received injections in the subarachnoid space as follows: 6 to 8 ml of bupivacaine (N = 15), 2-chloroprocaine-CE (N = 20), low pH normal saline (pH 3.0) (N = 20), or normal saline (N = 10).",7199841_3,0
3239,normal saline,155,168,"The 65 dogs in the study received injections in the subarachnoid space as follows: 6 to 8 ml of bupivacaine (N = 15), 2-chloroprocaine-CE (N = 20), low pH normal saline (pH 3.0) (N = 20), or normal saline (N = 10).",7199841_3,0
6899,subarachnoid,52,64,"The 65 dogs in the study received injections in the subarachnoid space as follows: 6 to 8 ml of bupivacaine (N = 15), 2-chloroprocaine-CE (N = 20), low pH normal saline (pH 3.0) (N = 20), or normal saline (N = 10).",7199841_3,1
3238,bupivacaine,96,107,"The 65 dogs in the study received injections in the subarachnoid space as follows: 6 to 8 ml of bupivacaine (N = 15), 2-chloroprocaine-CE (N = 20), low pH normal saline (pH 3.0) (N = 20), or normal saline (N = 10).",7199841_3,0
13280,hind-limb,100,109,Of the 20 animals that received subarachnoid injection of 2-chloroprocaine-CE seven (35%) developed hind-limb paralysis.,7199841_4,1
6900,subarachnoid,32,44,Of the 20 animals that received subarachnoid injection of 2-chloroprocaine-CE seven (35%) developed hind-limb paralysis.,7199841_4,1
3241,bupivacaine,34,45,"None of the animals that received bupivacaine, normal saline, or normal saline titrated to a pH 3.0 developed hind-limb paralysis.",7199841_5,0
3243,normal saline,65,78,"None of the animals that received bupivacaine, normal saline, or normal saline titrated to a pH 3.0 developed hind-limb paralysis.",7199841_5,0
13281,hind-limb,110,119,"None of the animals that received bupivacaine, normal saline, or normal saline titrated to a pH 3.0 developed hind-limb paralysis.",7199841_5,1
3242,normal saline,47,60,"None of the animals that received bupivacaine, normal saline, or normal saline titrated to a pH 3.0 developed hind-limb paralysis.",7199841_5,0
13283,subpial necrosis,83,99,"Of the 15 spinal cords of the animals that received 2-chloroprocaine-CE, 13 showed subpial necrosis; the nerve roots and subarachnoid vessels were normal.",7199841_6,1
13284,nerve roots,105,116,"Of the 15 spinal cords of the animals that received 2-chloroprocaine-CE, 13 showed subpial necrosis; the nerve roots and subarachnoid vessels were normal.",7199841_6,1
6901,subarachnoid,121,133,"Of the 15 spinal cords of the animals that received 2-chloroprocaine-CE, 13 showed subpial necrosis; the nerve roots and subarachnoid vessels were normal.",7199841_6,1
3246,normal saline,93,106,"The spinal cords of the animals that received bupivacaine, low pH normal saline (pH 3.0), or normal saline did not show abnormal findings.",7199841_7,0
3245,normal saline,66,79,"The spinal cords of the animals that received bupivacaine, low pH normal saline (pH 3.0), or normal saline did not show abnormal findings.",7199841_7,0
3244,bupivacaine,46,57,"The spinal cords of the animals that received bupivacaine, low pH normal saline (pH 3.0), or normal saline did not show abnormal findings.",7199841_7,0
6902,ventricular tachycardia,34,57,Procainamide-induced polymorphous ventricular tachycardia.,7234705_0,1
6903,ventricular tachycardia,49,72,Seven cases of procainamide-induced polymorphous ventricular tachycardia are presented.,7234705_1,1
6905,ventricular tachycardia,161,184,"In four patients, polymorphous ventricular tachycardia appeared after intravenous administration of 200 to 400 mg of procainamide for the treatment of sustained ventricular tachycardia.",7234705_2,1
3247,procainamide,117,129,"In four patients, polymorphous ventricular tachycardia appeared after intravenous administration of 200 to 400 mg of procainamide for the treatment of sustained ventricular tachycardia.",7234705_2,0
6904,ventricular tachycardia,31,54,"In four patients, polymorphous ventricular tachycardia appeared after intravenous administration of 200 to 400 mg of procainamide for the treatment of sustained ventricular tachycardia.",7234705_2,1
3248,procainamide,33,45,"In the remaining three patients, procainamide was administered orally for treatment of chronic premature ventricular contractions or atrial flutter.",7234705_3,0
6907,atrial flutter,133,147,"In the remaining three patients, procainamide was administered orally for treatment of chronic premature ventricular contractions or atrial flutter.",7234705_3,1
6906,premature ventricular contractions,95,129,"In the remaining three patients, procainamide was administered orally for treatment of chronic premature ventricular contractions or atrial flutter.",7234705_3,1
13286,recurrent syncope,40,57,These patients had Q-T prolongation and recurrent syncope due to polymorphous ventricular tachycardia.,7234705_4,1
6908,ventricular tachycardia,78,101,These patients had Q-T prolongation and recurrent syncope due to polymorphous ventricular tachycardia.,7234705_4,1
6909,ventricular fibrillation,62,86,"In two patients, the arrhythmia degenerated into irreversible ventricular fibrillation and both patients died.",7234705_6,1
6910,ventricular tachycardia,135,158,"In the seventh patient, a permanent ventricular pacemaker was inserted and, despite continuation of procainamide therapy, polymorphous ventricular tachycardia did not reoccur.",7234705_7,1
13288,ventricular pacemaker,36,57,"In the seventh patient, a permanent ventricular pacemaker was inserted and, despite continuation of procainamide therapy, polymorphous ventricular tachycardia did not reoccur.",7234705_7,0
3249,procainamide,100,112,"In the seventh patient, a permanent ventricular pacemaker was inserted and, despite continuation of procainamide therapy, polymorphous ventricular tachycardia did not reoccur.",7234705_7,0
6911,ventricular tachycardia,113,136,These seven cases demonstrate that procainamide can produce an acquired prolonged Q-T syndrome with polymorphous ventricular tachycardia.,7234705_8,1
3250,procainamide,35,47,These seven cases demonstrate that procainamide can produce an acquired prolonged Q-T syndrome with polymorphous ventricular tachycardia.,7234705_8,0
13289,acquired prolonged,63,81,These seven cases demonstrate that procainamide can produce an acquired prolonged Q-T syndrome with polymorphous ventricular tachycardia.,7234705_8,1
13296,carbon tetrachloride,285,305,"The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial ""calibrating"" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.",7248170_1,0
13292,micronodular,92,104,"The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial ""calibrating"" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.",7248170_1,0
13297,carbon tetrachloride,436,456,"The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial ""calibrating"" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.",7248170_1,0
13291,nodular liver,73,86,"The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial ""calibrating"" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.",7248170_1,1
13295,normal weight,252,265,"The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial ""calibrating"" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.",7248170_1,1
13294,testicular atrophy,214,232,"The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial ""calibrating"" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver.",7248170_1,1
6912,body weight,186,197,"The optimal rat size to begin phenobarbitone was determined as 100 g, and this size as a group had a mean maximum relative liver weight increase 47% greater than normal rats of the same body weight.",7248170_3,1
13299,carbon tetrachloride,41,61,The optimal time for the initial dose of carbon tetrachloride was after 14 days on phenobarbitone.,7248170_4,0
6913,aplastic anemia,6,21,Fatal aplastic anemia due to indomethacin--lymphocyte transformation tests in vitro.,7263204_0,1
13302,cause of aplastic anemia,56,80,"Although indomethacin has been implicated as a possible cause of aplastic anemia on the basis of a few clinical observations, its role has not been definitely established.",7263204_1,1
6914,aplastic anemia,16,31,A case of fatal aplastic anemia is described in which no drugs other than allopurinol and indomethacin were given.,7263204_2,1
6915,aplastic anemia,134,149,A positive lymphocyte transformation test with indomethacin in vitro further substantiates the potential role of this drug in causing aplastic anemia in a susceptible patient.,7263204_4,1
13306,Triamterene,0,11,Triamterene nephrolithiasis complicating dyazide therapy.,7265370_0,0
13307,triamterene,10,21,A case of triamterene nephrolithiasis is reported in a man after 4 years of hydrochlorothiazide-triamterene therapy for hypertension.,7265370_1,0
13309,triamterene,58,69,The stone passed spontaneously and was found to contain a triamterene metabolite admixed with uric acid salts.,7265370_2,0
13310,uric acid salts,94,109,The stone passed spontaneously and was found to contain a triamterene metabolite admixed with uric acid salts.,7265370_2,0
13311,triamterene,18,29,Factors affecting triamterene nephrolithiasis are discussed and 2 previously reported cases are reviewed.,7265370_3,0
13313,hemorrhage cystitis,29,48,A case of a busulfan-induced hemorrhage cystitis is reported.,7269015_1,1
3251,busulfan,53,61,The similarity between the histologic appearances of busulfan cystitis and both radiation and cyclophosphamide-induced cystitis is discussed and the world literature reviewed.,7269015_3,0
3252,busulfan,33,41,"In view of the known tendency of busulfan to induce cellular atypia and carcinoma in other sites, periodic urinary cytology is suggested in patients on long-term therapy.",7269015_4,0
13318,urinary cytology,107,123,"In view of the known tendency of busulfan to induce cellular atypia and carcinoma in other sites, periodic urinary cytology is suggested in patients on long-term therapy.",7269015_4,1
13317,cellular atypia,52,67,"In view of the known tendency of busulfan to induce cellular atypia and carcinoma in other sites, periodic urinary cytology is suggested in patients on long-term therapy.",7269015_4,1
13320,doxorubicin cardiomyopathy,52,78,Dose-effect and structure-function relationships in doxorubicin cardiomyopathy.,7282516_0,1
13323,Adriamycin,75,85,The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.,7282516_1,0
6916,myocardial disease,199,217,The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.,7282516_1,1
13321,anticancer drug doxorubicin,40,67,The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.,7282516_1,0
13322,DXR,69,72,The cardiomyopathy (CM) produced by the anticancer drug doxorubicin (DXR) (Adriamycin) provides a unique opportunity to analyze dose-effect and structure-function relationships during development of myocardial disease.,7282516_1,0
6917,endomyocardial,79,93,We measured the degree of morphologic damage by ultrastructural examination of endomyocardial biopsy and the degree of performance abnormally by right heart catheterization in patients receiving DXR.,7282516_2,1
13328,DXR,195,198,We measured the degree of morphologic damage by ultrastructural examination of endomyocardial biopsy and the degree of performance abnormally by right heart catheterization in patients receiving DXR.,7282516_2,0
13331,mg/m2,106,111,Morphologic damage was variable but was proportional to the total cumulative DXR dose between 100 and 600 mg/m2.,7282516_3,0
13330,DXR,77,80,Morphologic damage was variable but was proportional to the total cumulative DXR dose between 100 and 600 mg/m2.,7282516_3,0
13332,Performance abnormalities,0,25,"Performance abnormalities correlated weakly with dose, exhibited a curvilinear relationship, and had a ""threshold"" for expression.",7282516_4,1
3253,(r,70,72,"Catheterization abnormalities correlated well with morphologic damage (r = 0.57 to 0.78) in a subgroup of patients in whom exercise hemodynamics were measured, and this relationship also exhibited a curvilinear, threshold configuration.",7282516_5,0
13339,myocardial function,95,114,"In DXR-CM myocardial damage is proportional to the degree of cytotoxic insult (DXR dose) while myocardial function is preserved until a critical dose or degree of damage is reached, after which myocardial performance deteriorates rapidly.",7282516_6,1
13336,DXR-CM,3,9,"In DXR-CM myocardial damage is proportional to the degree of cytotoxic insult (DXR dose) while myocardial function is preserved until a critical dose or degree of damage is reached, after which myocardial performance deteriorates rapidly.",7282516_6,0
13337,myocardial damage,10,27,"In DXR-CM myocardial damage is proportional to the degree of cytotoxic insult (DXR dose) while myocardial function is preserved until a critical dose or degree of damage is reached, after which myocardial performance deteriorates rapidly.",7282516_6,1
13338,DXR,79,82,"In DXR-CM myocardial damage is proportional to the degree of cytotoxic insult (DXR dose) while myocardial function is preserved until a critical dose or degree of damage is reached, after which myocardial performance deteriorates rapidly.",7282516_6,0
6918,ventricular tachycardia,8,31,Variant ventricular tachycardia in desipramine toxicity.,7292072_0,1
6919,ventricular tachycardia,28,51,We report a case of variant ventricular tachycardia induced by desipramine toxicity.,7292072_1,1
13343,intraventricular conduction,174,201,"Unusual features of the arrhythmia are repetitive group beating, progressive shortening of the R-R interval, progressive widening of the QRS complex with eventual failure of intraventricular conduction, and changes in direction of the QRS axis.",7292072_2,1
6920,ventricular tachycardia,23,46,Recognition of variant ventricular tachycardia is important because therapy differs from that of classic ventricular tachycardia.,7292072_3,1
6921,ventricular tachycardia,105,128,Recognition of variant ventricular tachycardia is important because therapy differs from that of classic ventricular tachycardia.,7292072_3,1
6923,fulminant hepatic failure,39,64,Massive cerebral edema associated with fulminant hepatic failure in acetaminophen overdose: possible role of cranial decompression.,7337133_0,1
13346,cranial decompression,109,130,Massive cerebral edema associated with fulminant hepatic failure in acetaminophen overdose: possible role of cranial decompression.,7337133_0,1
6922,cerebral edema,8,22,Massive cerebral edema associated with fulminant hepatic failure in acetaminophen overdose: possible role of cranial decompression.,7337133_0,1
6925,fulminant hepatic failure,44,69,Cerebral edema may complicate the course of fulminant hepatic failure.,7337133_1,1
6924,Cerebral edema,0,14,Cerebral edema may complicate the course of fulminant hepatic failure.,7337133_1,1
6927,signs and symptoms,86,104,"We present a patient with fatal acetaminophen-induced fulminant hepatic failure, with signs and symptoms of cerebral edema, unresponsive to conventional medical therapy.",7337133_3,1
6928,cerebral edema,108,122,"We present a patient with fatal acetaminophen-induced fulminant hepatic failure, with signs and symptoms of cerebral edema, unresponsive to conventional medical therapy.",7337133_3,1
6926,fulminant hepatic failure,54,79,"We present a patient with fatal acetaminophen-induced fulminant hepatic failure, with signs and symptoms of cerebral edema, unresponsive to conventional medical therapy.",7337133_3,1
13348,Cranial decompression,0,21,Cranial decompression was carried out.,7337133_4,1
13349,cranial decompression,54,75,A justification of the need for further evaluation of cranial decompression in such patients is presented.,7337133_5,1
13350,Rebound hypertensive,0,20,Rebound hypertensive after sodium nitroprusside prevented by saralasin in rats.,7352670_0,1
3254,sodium nitroprusside,27,47,Rebound hypertensive after sodium nitroprusside prevented by saralasin in rats.,7352670_0,0
3255,saralasin,61,70,Rebound hypertensive after sodium nitroprusside prevented by saralasin in rats.,7352670_0,0
6929,blood pressure,64,78,The role of the renin--angiotensin system in the maintenance of blood pressure during halothane anesthesia and sodium nitroprusside (SNP)-induced hypotension was evaluated.,7352670_1,1
3257,sodium nitroprusside,111,131,The role of the renin--angiotensin system in the maintenance of blood pressure during halothane anesthesia and sodium nitroprusside (SNP)-induced hypotension was evaluated.,7352670_1,0
3256,renin--,16,23,The role of the renin--angiotensin system in the maintenance of blood pressure during halothane anesthesia and sodium nitroprusside (SNP)-induced hypotension was evaluated.,7352670_1,0
3258,(1,43,45,"Control rats received halothane anesthesia (1 MAC) for one hour, followed by SNP infusion, 40 microgram/kg/min, for 30 min, followed by a 30-min recovery period.",7352670_2,0
3260,angiotensin II,127,141,"A second group of rats was treated identically and, in addition, received an infusion of saralasin (a competitive inhibitor of angiotensin II) throughout the experimental period.",7352670_3,0
3259,saralasin,89,98,"A second group of rats was treated identically and, in addition, received an infusion of saralasin (a competitive inhibitor of angiotensin II) throughout the experimental period.",7352670_3,0
6930,blood pressure,63,77,"In each group, SNP infusion resulted in an initial decrease in blood pressure from 86 torr and 83 torr, respectively, to 48 torr.",7352670_4,1
6931,blood pressure,83,97,"During the SNP infusion the control animals demonstrated a progressive increase in blood pressure to 61 torr, whereas the saralasin-treated animals showed no change.",7352670_5,1
6932,blood pressure,34,48,"Following discontinuation of SNP, blood pressure in the control animals rebounded to 94 torr, as compared with 78 torr in the saralasin-treated rats.",7352670_6,1
6933,blood pressure,84,98,"This study indicates that with stable halothane anesthesia, the partial recovery of blood pressure during SNP infusion and the post-SNP rebound of blood pressure can be completely blocked by saralasin.",7352670_7,1
6934,blood pressure,147,161,"This study indicates that with stable halothane anesthesia, the partial recovery of blood pressure during SNP infusion and the post-SNP rebound of blood pressure can be completely blocked by saralasin.",7352670_7,1
3261,saralasin,191,200,"This study indicates that with stable halothane anesthesia, the partial recovery of blood pressure during SNP infusion and the post-SNP rebound of blood pressure can be completely blocked by saralasin.",7352670_7,0
3262,renin--,43,50,This demonstrates the participation of the renin--angiotensin system in antagonizing the combined hypotensive effects of halothane and SNP.,7352670_8,0
6935,sexual dysfunction,25,43,Subjective assessment of sexual dysfunction of patients on long-term administration of digoxin.,7416947_0,1
6936,longterm,71,79,Various data suggest that male patients who have received digoxin on a longterm basis have increased levels of serum estrogen and decreased levels of plasma testosterone and luteinizing hormone (LH).,7416947_1,1
13358,luteinizing hormone,174,193,Various data suggest that male patients who have received digoxin on a longterm basis have increased levels of serum estrogen and decreased levels of plasma testosterone and luteinizing hormone (LH).,7416947_1,0
6937,rheumatic heart disease,164,187,The patients of the study and control group (without digoxin) were of similar cardiac functional capacity and age (25-40 years) and were randomly selected from the rheumatic heart disease patients.,7416947_3,1
13362,sexual behavior,27,42,"A subjective assessment of sexual behavior in the study and control groups was carried out, using parameters such as sexual desire, sexual excitement, and frequency of sexual relations.",7416947_4,1
13364,sexual desire,117,130,"A subjective assessment of sexual behavior in the study and control groups was carried out, using parameters such as sexual desire, sexual excitement, and frequency of sexual relations.",7416947_4,1
13366,sexual relations,168,184,"A subjective assessment of sexual behavior in the study and control groups was carried out, using parameters such as sexual desire, sexual excitement, and frequency of sexual relations.",7416947_4,1
13367,sexual behavior,77,92,Personal interviews and a questionnaire were also used for the evaluation of sexual behavior.,7416947_5,1
13373,sexual relations,155,171,"Tests used to evaluate the changes in sexual behavior showed a significant decrease in sexual desire, sexual excitement phase (erection), and frequency of sexual relations in the study group.",7416947_8,1
13371,sexual desire,87,100,"Tests used to evaluate the changes in sexual behavior showed a significant decrease in sexual desire, sexual excitement phase (erection), and frequency of sexual relations in the study group.",7416947_8,1
13372,sexual excitement phase,102,125,"Tests used to evaluate the changes in sexual behavior showed a significant decrease in sexual desire, sexual excitement phase (erection), and frequency of sexual relations in the study group.",7416947_8,1
13375,nephrotoxicity,9,23,Clinical nephrotoxicity of tobramycin and gentamicin.,7420681_0,1
13377,aminoglycoside antibiotics,50,76,Nearly 3.2 million people in this country receive aminoglycoside antibiotics annually.,7420681_2,0
3263,Gentamicin sulfate,0,18,Gentamicin sulfate and tobramycin sulfate continue to demonstrate ototoxicity and nephrotoxicity in both animal and clinical studies.,7420681_3,0
13378,nephrotoxicity,82,96,Gentamicin sulfate and tobramycin sulfate continue to demonstrate ototoxicity and nephrotoxicity in both animal and clinical studies.,7420681_3,1
6938,ototoxicity,66,77,Gentamicin sulfate and tobramycin sulfate continue to demonstrate ototoxicity and nephrotoxicity in both animal and clinical studies.,7420681_3,1
3264,tobramycin sulfate,23,41,Gentamicin sulfate and tobramycin sulfate continue to demonstrate ototoxicity and nephrotoxicity in both animal and clinical studies.,7420681_3,0
3266,tobramycin sulfate,131,149,"In this study, 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg/kg/day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of aminoglycoside-related renal failure, defined as at least a one-third reduction in renal function.",7420681_4,0
3265,gentamicin sulfate,109,127,"In this study, 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg/kg/day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of aminoglycoside-related renal failure, defined as at least a one-third reduction in renal function.",7420681_4,0
13380,normal renal function,50,71,"In this study, 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg/kg/day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of aminoglycoside-related renal failure, defined as at least a one-third reduction in renal function.",7420681_4,1
6939,renal failure,255,268,"In this study, 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg/kg/day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of aminoglycoside-related renal failure, defined as at least a one-third reduction in renal function.",7420681_4,1
13381,renal function,315,329,"In this study, 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg/kg/day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of aminoglycoside-related renal failure, defined as at least a one-third reduction in renal function.",7420681_4,1
6940,renal failure,42,55,"In these 62 patients, no other causes for renal failure could be identified.",7420681_5,1
6941,renal failure,112,125,Five of 33 (15%) of the tobramycin-treated patients and 16 of 29 (55.2%) of the gentamicin-treated patients had renal failure.,7420681_6,1
6942,renal failure,37,50,"Thus, gentamicin was associated with renal failure more than three times as often as was tobramycin.",7420681_7,1
6944,Hodgkin disease,28,43,Endometrial carcinoma after Hodgkin disease in childhood.,7421734_0,1
6943,Endometrial carcinoma,0,21,Endometrial carcinoma after Hodgkin disease in childhood.,7421734_0,1
6946,Hodgkin disease,69,84,A 34-year-old patient developed metastic endometrial carcinoma after Hodgkin disease in childhood.,7421734_1,1
6945,endometrial carcinoma,41,62,A 34-year-old patient developed metastic endometrial carcinoma after Hodgkin disease in childhood.,7421734_1,1
13383,abdominal irradiation,30,51,"She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease, and received exogenous estrogens, a treatment implicated in the development of endometrial cancer in menopausal women.",7421734_2,1
6947,ovarian failure,8,23,"She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease, and received exogenous estrogens, a treatment implicated in the development of endometrial cancer in menopausal women.",7421734_2,1
6948,Hodgkin disease,73,88,"She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease, and received exogenous estrogens, a treatment implicated in the development of endometrial cancer in menopausal women.",7421734_2,1
6949,endometrial cancer,169,187,"She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease, and received exogenous estrogens, a treatment implicated in the development of endometrial cancer in menopausal women.",7421734_2,1
6951,endometrial carcinoma,110,131,Young women on replacement estrogens for ovarian failure after cancer therapy may also have increased risk of endometrial carcinoma and should be examined periodically.,7421734_3,1
13384,replacement estrogens,15,36,Young women on replacement estrogens for ovarian failure after cancer therapy may also have increased risk of endometrial carcinoma and should be examined periodically.,7421734_3,0
6950,ovarian failure,41,56,Young women on replacement estrogens for ovarian failure after cancer therapy may also have increased risk of endometrial carcinoma and should be examined periodically.,7421734_3,1
3267,cardiotoxic,4,15,The cardiotoxic effects of adriamycin were studied in mammalian myocardial cells in culture as a model system.,7423039_1,0
13387,adriamycin,27,37,The cardiotoxic effects of adriamycin were studied in mammalian myocardial cells in culture as a model system.,7423039_1,0
13389,Adriamycin,0,10,Adriamycin inhibited cell growth and the rhythmic contractions characteristic of myocardial cells in culture.,7423039_2,0
3268,cell growth,21,32,Adriamycin inhibited cell growth and the rhythmic contractions characteristic of myocardial cells in culture.,7423039_2,0
3269,adenylate,92,101,"A possible involvement of energy metabolism was suggested previously, and in this study the adenylate energy charge and phosphorylcreatine mole fraction were determined in the adriamycin-treated cells.",7423039_3,0
3270,adenylate,4,13,"The adenylate energy charge was found to be significantly decreased, while the phophorylcreatine mole fraction was unchanged.",7423039_4,0
3271,creatine phosphokinase,41,63,Such disparity suggests an inhibition of creatine phosphokinase.,7423039_5,0
13395,inrcease,117,125,"In the adriamycin-treated cells, the addition of adenosine increased the adenylate charge and, concomitant with this inrcease, the cells' functional integrity, in terms of percentage of beating cells and rate of contractions, was maintained.",7423039_7,0
3272,adenylate,73,82,"In the adriamycin-treated cells, the addition of adenosine increased the adenylate charge and, concomitant with this inrcease, the cells' functional integrity, in terms of percentage of beating cells and rate of contractions, was maintained.",7423039_7,0
3273,Creatinine,0,10,"Creatinine clearance, maximum urinary osmolality and 24 hour urine volume have been tested in 50 affectively ill patients who have been on long-term lithium for more than one year.",7437994_3,0
13399,glomerular filtration,43,64,No evidence was found for any reduction of glomerular filtration during lithium treatment.,7437994_5,1
13402,Age-dependent sensitivity,0,25,Age-dependent sensitivity of the rat to neurotoxic effects of streptomycin.,7444978_0,1
3274,Streptomycin sulfate,0,20,Streptomycin sulfate (300 mg/kg s.c.) was injected for various periods into preweanling rats and for 3 weeks into weanling rats.,7444978_1,0
13405,body movement,28,41,"Beginning at 8 days of age, body movement and hearing were examined for 6 and up to 17 weeks, respectively.",7444978_2,1
13406,Abnormal movements and deafness,0,31,"Abnormal movements and deafness occurred only in rats treated during the preweaning period; within this period the greatest sensitivities for these abnormalities occurred from 2 to 11-17 and 5 to 11 days of age, respectively, indicating that the cochlea is more sensitive to streptomycin than the site (vestibular or central) responsible for the dyskinesias.",7444978_3,1
6952,cardiotoxicity,23,37,"Late, late doxorubicin cardiotoxicity.",7449470_0,1
13409,chemotherapeutic agent,81,103,Cardiac toxicity is a major complication which limits the use of adriamycin as a chemotherapeutic agent.,7449470_1,0
6953,Cardiac toxicity,0,16,Cardiac toxicity is a major complication which limits the use of adriamycin as a chemotherapeutic agent.,7449470_1,1
13408,adriamycin,65,75,Cardiac toxicity is a major complication which limits the use of adriamycin as a chemotherapeutic agent.,7449470_1,0
13411,mg/m2,59,64,Cardiomyopathy is frequent when the total dose exceeds 600 mg/m2 and occurs within one to six months after cessation of therapy.,7449470_2,0
6954,cardiotoxicity,151,165,"A patient is reported who developed progressive cardiomyopathy two and one-half years after receiving 580 mg/m2 which apparently represents late, late cardiotoxicity.",7449470_3,1
13412,mg/m2,106,111,"A patient is reported who developed progressive cardiomyopathy two and one-half years after receiving 580 mg/m2 which apparently represents late, late cardiotoxicity.",7449470_3,0
3275,amiloride,71,80,Attenuation of the lithium-induced diabetes-insipidus-like syndrome by amiloride in rats.,7453952_0,0
3276,amiloride,14,23,"The effect of amiloride on lithium-induced polydipsia and polyuria and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl.",7453952_1,0
13416,LiCl,209,213,"The effect of amiloride on lithium-induced polydipsia and polyuria and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl.",7453952_1,0
3277,Amiloride,0,9,Amiloride reduced the drinking and urine volume of rats in an acute (6 or 12 h) and a subacute (3 days) experiment.,7453952_2,0
3278,(3,95,97,Amiloride reduced the drinking and urine volume of rats in an acute (6 or 12 h) and a subacute (3 days) experiment.,7453952_2,0
3279,amiloride,32,41,"6 h after the administration of amiloride, a reduction was observed in the lithium content of the renal medulla but not in the other organs studied.",7453952_3,0
3280,amiloride,99,108,"In all the experiments, the attenuation of the lithium-induced diabetes-insipidus-like syndrome by amiloride was accompanied by a reduction of the ratio between the lithium concentration in the renal medulla and its levels in the blood and an elevation in the plasma potassium level.",7453952_6,0
3282,amiloride,162,171,It is concluded that acute amiloride administration to lithium-treated patients suffering from polydipsia and polyuria might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous.,7453952_7,0
3281,amiloride,27,36,It is concluded that acute amiloride administration to lithium-treated patients suffering from polydipsia and polyuria might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous.,7453952_7,0
13425,terbutaline,45,56,Cardiovascular complications associated with terbutaline treatment for preterm labor.,7468724_0,0
6955,Cardiovascular complications,0,28,Cardiovascular complications associated with terbutaline treatment for preterm labor.,7468724_0,1
6956,preterm labor,71,84,Cardiovascular complications associated with terbutaline treatment for preterm labor.,7468724_0,1
13426,terbutaline,83,94,Severe cardiovascular complications occurred in eight of 160 patients treated with terbutaline for preterm labor.,7468724_1,0
6957,cardiovascular complications,7,35,Severe cardiovascular complications occurred in eight of 160 patients treated with terbutaline for preterm labor.,7468724_1,1
6958,preterm labor,99,112,Severe cardiovascular complications occurred in eight of 160 patients treated with terbutaline for preterm labor.,7468724_1,1
13428,twin gestations,38,53,Associated corticosteroid therapy and twin gestations appear to be predisposing factors.,7468724_2,1
6959,pathophysiology,28,43,Potential mechanisms of the pathophysiology are briefly discussed.,7468724_3,1
6960,Toxic hepatitis,0,15,Toxic hepatitis induced by antithyroid drugs: four cases including one with cross-reactivity between carbimazole and benzylthiouracil.,7504976_0,1
13431,benzylthiouracil,117,133,Toxic hepatitis induced by antithyroid drugs: four cases including one with cross-reactivity between carbimazole and benzylthiouracil.,7504976_0,0
13430,carbimazole,101,112,Toxic hepatitis induced by antithyroid drugs: four cases including one with cross-reactivity between carbimazole and benzylthiouracil.,7504976_0,0
3283,antithyroid drugs,27,44,Toxic hepatitis induced by antithyroid drugs: four cases including one with cross-reactivity between carbimazole and benzylthiouracil.,7504976_0,0
3284,antithyroid drugs,105,122,OBJECTIVE: This study was conducted to assess the occurrence of hepatic adverse effects encountered with antithyroid drugs.,7504976_1,0
6961,adverse effects,72,87,OBJECTIVE: This study was conducted to assess the occurrence of hepatic adverse effects encountered with antithyroid drugs.,7504976_1,1
13443,hepatotoxicity,10,24,"Moreover, hepatotoxicity may not be restricted to one class of antithyroid agents.",7504976_10,1
3288,antithyroid agents,63,81,"Moreover, hepatotoxicity may not be restricted to one class of antithyroid agents.",7504976_10,0
6962,toxic hepatitis,51,66,RESULTS: Four patients (1.7%) were identified with toxic hepatitis which could reasonably be attributed to the use of antithyroid agent.,7504976_3,1
3285,antithyroid agent,118,135,RESULTS: Four patients (1.7%) were identified with toxic hepatitis which could reasonably be attributed to the use of antithyroid agent.,7504976_3,0
13434,cholestatic hepatitis,19,40,Two patients had a cholestatic hepatitis induced by carbimazole (N  omercazole).,7504976_4,1
13435,carbimazole,52,63,Two patients had a cholestatic hepatitis induced by carbimazole (N  omercazole).,7504976_4,0
13436,carbimazole,71,82,Two others had a mixed (cholestatic and cytolytic) hepatitis following carbimazole.,7504976_5,0
6963,cholestatic,24,35,Two others had a mixed (cholestatic and cytolytic) hepatitis following carbimazole.,7504976_5,1
13438,Benzylthiouracil,94,110,One of the latter two patients further experienced a cytolytic hepatitis which appeared after Benzylthiouracil (Basd  ne) had replaced carbimazole.,7504976_6,0
13437,cytolytic hepatitis,53,72,One of the latter two patients further experienced a cytolytic hepatitis which appeared after Benzylthiouracil (Basd  ne) had replaced carbimazole.,7504976_6,1
13439,carbimazole,135,146,One of the latter two patients further experienced a cytolytic hepatitis which appeared after Benzylthiouracil (Basd  ne) had replaced carbimazole.,7504976_6,0
3286,antithyroid drugs,61,78,"CONCLUSION: Toxic hepatitis is a potential adverse effect of antithyroid drugs which warrants, as for haematological disturbances, a pre-therapeutic determination and a careful follow-up of relevant biological markers.",7504976_9,0
6964,Toxic hepatitis,12,27,"CONCLUSION: Toxic hepatitis is a potential adverse effect of antithyroid drugs which warrants, as for haematological disturbances, a pre-therapeutic determination and a careful follow-up of relevant biological markers.",7504976_9,1
3287,biological markers,199,217,"CONCLUSION: Toxic hepatitis is a potential adverse effect of antithyroid drugs which warrants, as for haematological disturbances, a pre-therapeutic determination and a careful follow-up of relevant biological markers.",7504976_9,0
13441,adverse effect,43,57,"CONCLUSION: Toxic hepatitis is a potential adverse effect of antithyroid drugs which warrants, as for haematological disturbances, a pre-therapeutic determination and a careful follow-up of relevant biological markers.",7504976_9,1
13446,spontaneous frequency,67,88,Interactive effects of variations in [Na]o and [Ca]o on rat atrial spontaneous frequency.,7516729_0,1
13445,[Ca]o,47,52,Interactive effects of variations in [Na]o and [Ca]o on rat atrial spontaneous frequency.,7516729_0,0
13444,[Na]o,37,42,Interactive effects of variations in [Na]o and [Ca]o on rat atrial spontaneous frequency.,7516729_0,0
13447,[Na]o,70,75,"The effects of varying the extracellular concentrations of Na and Ca ([Na]o and [Ca]o) on both, the spontaneous beating and the negative chronotropic action of verapamil, were studied in the isolated rat atria.",7516729_1,0
13448,[Ca]o,80,85,"The effects of varying the extracellular concentrations of Na and Ca ([Na]o and [Ca]o) on both, the spontaneous beating and the negative chronotropic action of verapamil, were studied in the isolated rat atria.",7516729_1,0
13493,LNa,83,86,Also the enhancement of verapamil effects on atrial beating was more pronounced at LNa than at LCa.(ABSTRACT TRUNCATED AT 250 WORDS),7516729_10,0
13492,atrial beating,45,59,Also the enhancement of verapamil effects on atrial beating was more pronounced at LNa than at LCa.(ABSTRACT TRUNCATED AT 250 WORDS),7516729_10,1
13452,BF,17,19,Basal frequency (BF) evaluated by surface electrogram was 223 +/- 4 beats/min.,7516729_2,0
13454,/- 4,63,67,Basal frequency (BF) evaluated by surface electrogram was 223 +/- 4 beats/min.,7516729_2,0
13457,[Na]o,38,43,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,0
13458,LNa,54,57,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,0
13459,[Na]o,97,102,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,0
13464,[Ca]o,201,206,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,0
13460,[Ca]o,116,121,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,0
13461,LNa+LCa,135,142,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,0
3289,/- 2,64,68,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,0
13462,/- 5,152,156,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,0
13463,[Na]o,170,175,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,0
13465,LNa+HCa,218,225,"It decreased by 16 +/- 3% by lowering [Na]o to 78 mM (LNa), 23 +/- 2% by lowering simultaneously [Na]o to 78 mM and [Ca]o to 0.675 mM (LNa+LCa) and 31 +/- 5% by lowering [Na]o to 78 mM plus increasing [Ca]o to 3.6 mM (LNa+HCa).",7516729_4,0
13468,BF,82,84,"At normal [Na]o, decrease (0.675 mM) or increase (3.6 mM) of [Ca]o did not modify BF; a reduction of ten times (0.135 mM of normal [Ca]o was effective to reduce BF by 40 +/- 13%.",7516729_5,0
13467,[Ca]o,61,66,"At normal [Na]o, decrease (0.675 mM) or increase (3.6 mM) of [Ca]o did not modify BF; a reduction of ten times (0.135 mM of normal [Ca]o was effective to reduce BF by 40 +/- 13%.",7516729_5,0
13466,[Na]o,10,15,"At normal [Na]o, decrease (0.675 mM) or increase (3.6 mM) of [Ca]o did not modify BF; a reduction of ten times (0.135 mM of normal [Ca]o was effective to reduce BF by 40 +/- 13%.",7516729_5,0
13470,BF,161,163,"At normal [Na]o, decrease (0.675 mM) or increase (3.6 mM) of [Ca]o did not modify BF; a reduction of ten times (0.135 mM of normal [Ca]o was effective to reduce BF by 40 +/- 13%.",7516729_5,0
3290,LCa,72,75,"Dose-dependent bradycardia induced by verapamil was potentiated by LNa, LCa, and HCa.",7516729_7,0
13475,HCa,81,84,"Dose-dependent bradycardia induced by verapamil was potentiated by LNa, LCa, and HCa.",7516729_7,0
13474,LNa,67,70,"Dose-dependent bradycardia induced by verapamil was potentiated by LNa, LCa, and HCa.",7516729_7,0
13481,LNa+HCa,216,223,"Independent but not additive effects of Na and Ca are shown by decreases in the values of [verapamil]o needed to reduce BF by 30% (IC30) with the following order of inhibitory potency: LNa > LCa > HCa > N, resulting LNa+HCa similar to LNa.",7516729_8,0
13480,HCa,197,200,"Independent but not additive effects of Na and Ca are shown by decreases in the values of [verapamil]o needed to reduce BF by 30% (IC30) with the following order of inhibitory potency: LNa > LCa > HCa > N, resulting LNa+HCa similar to LNa.",7516729_8,0
13479,LNa,185,188,"Independent but not additive effects of Na and Ca are shown by decreases in the values of [verapamil]o needed to reduce BF by 30% (IC30) with the following order of inhibitory potency: LNa > LCa > HCa > N, resulting LNa+HCa similar to LNa.",7516729_8,0
13477,BF,120,122,"Independent but not additive effects of Na and Ca are shown by decreases in the values of [verapamil]o needed to reduce BF by 30% (IC30) with the following order of inhibitory potency: LNa > LCa > HCa > N, resulting LNa+HCa similar to LNa.",7516729_8,0
13476,additive effects,20,36,"Independent but not additive effects of Na and Ca are shown by decreases in the values of [verapamil]o needed to reduce BF by 30% (IC30) with the following order of inhibitory potency: LNa > LCa > HCa > N, resulting LNa+HCa similar to LNa.",7516729_8,0
13482,LNa,235,238,"Independent but not additive effects of Na and Ca are shown by decreases in the values of [verapamil]o needed to reduce BF by 30% (IC30) with the following order of inhibitory potency: LNa > LCa > HCa > N, resulting LNa+HCa similar to LNa.",7516729_8,0
3291,LCa,191,194,"Independent but not additive effects of Na and Ca are shown by decreases in the values of [verapamil]o needed to reduce BF by 30% (IC30) with the following order of inhibitory potency: LNa > LCa > HCa > N, resulting LNa+HCa similar to LNa.",7516729_8,0
3292,LCa,113,116,The [verapamil]o that arrested atrial beating (AC) was also potentiated with the order LNa = LNa+LCa = LNa+HCa = LCa > HCa = N. The results indicate that rat atrial spontaneous beating is more dependent on [Na]o than on [Ca]o in a range of +/- 50% of their normal concentration.,7516729_9,0
13489,[Ca]o,220,225,The [verapamil]o that arrested atrial beating (AC) was also potentiated with the order LNa = LNa+LCa = LNa+HCa = LCa > HCa = N. The results indicate that rat atrial spontaneous beating is more dependent on [Na]o than on [Ca]o in a range of +/- 50% of their normal concentration.,7516729_9,0
13488,[Na]o,206,211,The [verapamil]o that arrested atrial beating (AC) was also potentiated with the order LNa = LNa+LCa = LNa+HCa = LCa > HCa = N. The results indicate that rat atrial spontaneous beating is more dependent on [Na]o than on [Ca]o in a range of +/- 50% of their normal concentration.,7516729_9,0
13487,HCa,119,122,The [verapamil]o that arrested atrial beating (AC) was also potentiated with the order LNa = LNa+LCa = LNa+HCa = LCa > HCa = N. The results indicate that rat atrial spontaneous beating is more dependent on [Na]o than on [Ca]o in a range of +/- 50% of their normal concentration.,7516729_9,0
13486,LNa+HCa,103,110,The [verapamil]o that arrested atrial beating (AC) was also potentiated with the order LNa = LNa+LCa = LNa+HCa = LCa > HCa = N. The results indicate that rat atrial spontaneous beating is more dependent on [Na]o than on [Ca]o in a range of +/- 50% of their normal concentration.,7516729_9,0
13485,LNa+LCa,93,100,The [verapamil]o that arrested atrial beating (AC) was also potentiated with the order LNa = LNa+LCa = LNa+HCa = LCa > HCa = N. The results indicate that rat atrial spontaneous beating is more dependent on [Na]o than on [Ca]o in a range of +/- 50% of their normal concentration.,7516729_9,0
13484,LNa,87,90,The [verapamil]o that arrested atrial beating (AC) was also potentiated with the order LNa = LNa+LCa = LNa+HCa = LCa > HCa = N. The results indicate that rat atrial spontaneous beating is more dependent on [Na]o than on [Ca]o in a range of +/- 50% of their normal concentration.,7516729_9,0
13495,Nephrotoxicity,0,14,Nephrotoxicity of cyclosporin A and FK506: inhibition of calcineurin phosphatase.,7542793_0,1
13496,calcineurin phosphatase,57,80,Nephrotoxicity of cyclosporin A and FK506: inhibition of calcineurin phosphatase.,7542793_0,0
3294,FK506,36,41,Nephrotoxicity of cyclosporin A and FK506: inhibition of calcineurin phosphatase.,7542793_0,0
3293,cyclosporin A,18,31,Nephrotoxicity of cyclosporin A and FK506: inhibition of calcineurin phosphatase.,7542793_0,0
13498,Fujimycine,34,44,"Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.",7542793_1,0
13497,CsA,15,18,"Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.",7542793_1,1
3295,Cyclosporin A,0,13,"Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.",7542793_1,0
3296,FK506,46,51,"Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.",7542793_1,0
13499,macrolide immunosuppressant rapamycin,83,120,"Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.",7542793_1,0
13501,proximal tubular,206,222,"Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days.",7542793_1,1
13505,CsA,28,31,The molecular mechanisms of CsA and FK506 toxicity were investigated.,7542793_2,0
13504,molecular mechanisms,4,24,The molecular mechanisms of CsA and FK506 toxicity were investigated.,7542793_2,0
3297,FK506,36,41,The molecular mechanisms of CsA and FK506 toxicity were investigated.,7542793_2,0
13506,intracytoplasmic receptors,50,76,"Cyclophilin A and FK506-binding protein, the main intracytoplasmic receptors for CsA and FK506, respectively, were each detected in renal tissue extract.",7542793_3,0
13507,CsA,81,84,"Cyclophilin A and FK506-binding protein, the main intracytoplasmic receptors for CsA and FK506, respectively, were each detected in renal tissue extract.",7542793_3,0
3298,Cyclophilin A,0,13,"Cyclophilin A and FK506-binding protein, the main intracytoplasmic receptors for CsA and FK506, respectively, were each detected in renal tissue extract.",7542793_3,0
3299,FK506-binding protein,18,39,"Cyclophilin A and FK506-binding protein, the main intracytoplasmic receptors for CsA and FK506, respectively, were each detected in renal tissue extract.",7542793_3,0
3301,tissue extract,138,152,"Cyclophilin A and FK506-binding protein, the main intracytoplasmic receptors for CsA and FK506, respectively, were each detected in renal tissue extract.",7542793_3,0
3300,FK506,89,94,"Cyclophilin A and FK506-binding protein, the main intracytoplasmic receptors for CsA and FK506, respectively, were each detected in renal tissue extract.",7542793_3,0
3304,rapamycin,166,175,"In the kidney, high levels of immunoreactive and enzymatically active calcineurin were found which were inhibited by the immunosuppressants CsA and FK506, but not by rapamycin.",7542793_4,0
13509,CsA,140,143,"In the kidney, high levels of immunoreactive and enzymatically active calcineurin were found which were inhibited by the immunosuppressants CsA and FK506, but not by rapamycin.",7542793_4,1
13508,immunoreactive,30,44,"In the kidney, high levels of immunoreactive and enzymatically active calcineurin were found which were inhibited by the immunosuppressants CsA and FK506, but not by rapamycin.",7542793_4,0
3302,calcineurin,70,81,"In the kidney, high levels of immunoreactive and enzymatically active calcineurin were found which were inhibited by the immunosuppressants CsA and FK506, but not by rapamycin.",7542793_4,0
3303,FK506,148,153,"In the kidney, high levels of immunoreactive and enzymatically active calcineurin were found which were inhibited by the immunosuppressants CsA and FK506, but not by rapamycin.",7542793_4,0
13510,immunophilin-drug-calcineurin complexes,18,57,"Finally, specific immunophilin-drug-calcineurin complexes formed only in the presence of CsA and FK506, but not rapamycin.",7542793_5,0
13511,CsA,89,92,"Finally, specific immunophilin-drug-calcineurin complexes formed only in the presence of CsA and FK506, but not rapamycin.",7542793_5,0
3306,rapamycin,112,121,"Finally, specific immunophilin-drug-calcineurin complexes formed only in the presence of CsA and FK506, but not rapamycin.",7542793_5,0
3305,FK506,97,102,"Finally, specific immunophilin-drug-calcineurin complexes formed only in the presence of CsA and FK506, but not rapamycin.",7542793_5,0
13513,calcineurin phosphatase,140,163,These results suggest that the nephrotoxic effects of CsA and FK506 is likely mediated through binding to renal immunophilin and inhibiting calcineurin phosphatase.,7542793_6,0
13512,CsA,54,57,These results suggest that the nephrotoxic effects of CsA and FK506 is likely mediated through binding to renal immunophilin and inhibiting calcineurin phosphatase.,7542793_6,0
3308,immunophilin,112,124,These results suggest that the nephrotoxic effects of CsA and FK506 is likely mediated through binding to renal immunophilin and inhibiting calcineurin phosphatase.,7542793_6,0
3307,FK506,62,67,These results suggest that the nephrotoxic effects of CsA and FK506 is likely mediated through binding to renal immunophilin and inhibiting calcineurin phosphatase.,7542793_6,0
6965,Acute renal failure,0,19,Acute renal failure in high dose carboplatin chemotherapy.,7565311_0,1
13514,high dose carboplatin,23,44,Acute renal failure in high dose carboplatin chemotherapy.,7565311_0,0
6966,acute renal failure,39,58,Carboplatin has been reported to cause acute renal failure when administered in high doses to adult patients.,7565311_1,1
13515,high doses,80,90,Carboplatin has been reported to cause acute renal failure when administered in high doses to adult patients.,7565311_1,0
3309,Carboplatin,0,11,Carboplatin has been reported to cause acute renal failure when administered in high doses to adult patients.,7565311_1,0
13516,high-dose carboplatin,53,74,We report a 4 1/2-year-old girl who was treated with high-dose carboplatin for metastatic parameningeal embryonal rhabdomyosarcoma.,7565311_2,0
13517,parameningeal embryonal rhabdomyosarcoma,90,130,We report a 4 1/2-year-old girl who was treated with high-dose carboplatin for metastatic parameningeal embryonal rhabdomyosarcoma.,7565311_2,1
13518,partial recovery,49,65,Acute renal failure developed followed by a slow partial recovery of renal function.,7565311_3,1
6967,Acute renal failure,0,19,Acute renal failure developed followed by a slow partial recovery of renal function.,7565311_3,1
13519,renal function,69,83,Acute renal failure developed followed by a slow partial recovery of renal function.,7565311_3,1
13520,Pseudo-allergic reactions,0,25,Pseudo-allergic reactions to corticosteroids: diagnosis and alternatives.,7582165_0,1
13521,paramethasone,37,50,Two patients treated with parenteral paramethasone (Triniol) and dexamethasone (Sedionbel) are described.,7582165_1,0
13522,Triniol,52,59,Two patients treated with parenteral paramethasone (Triniol) and dexamethasone (Sedionbel) are described.,7582165_1,0
13523,Sedionbel,80,89,Two patients treated with parenteral paramethasone (Triniol) and dexamethasone (Sedionbel) are described.,7582165_1,0
13540,pseudo-allergy,48,62,"To our knowledge, this is the first report of a pseudo-allergy caused by paramethasone.",7582165_11,1
13541,paramethasone,73,86,"To our knowledge, this is the first report of a pseudo-allergy caused by paramethasone.",7582165_11,0
3310,excipients,115,125,"In the two patients, skin and ELISA tests with paramethasone were negative, as was the prick test with each of its excipients.",7582165_5,0
13530,paramethasone,47,60,"In the two patients, skin and ELISA tests with paramethasone were negative, as was the prick test with each of its excipients.",7582165_5,0
3311,excipients,147,157,"A single-blind parenteral challenge with Triniol was positive in both patients after the administration of 1 ml of the drug, and negative with its excipients.",7582165_6,0
13534,Triniol,41,48,"A single-blind parenteral challenge with Triniol was positive in both patients after the administration of 1 ml of the drug, and negative with its excipients.",7582165_6,0
13537,pseudoallergic reactions,48,72,These results suggest that paramethasone caused pseudoallergic reactions in our patients.,7582165_8,1
13536,paramethasone,27,40,These results suggest that paramethasone caused pseudoallergic reactions in our patients.,7582165_8,0
13538,paramethasone,31,44,"Corticosteroids different from paramethasone also produced hypersensitivity reactions in these patients; however, a few of them were tolerated.",7582165_9,0
13539,hypersensitivity reactions,59,85,"Corticosteroids different from paramethasone also produced hypersensitivity reactions in these patients; however, a few of them were tolerated.",7582165_9,1
13543,beraprost,77,86,Clinical evaluation on combined administration of oral prostacyclin analogue beraprost and phosphodiesterase inhibitor cilostazol.,7596955_0,0
3312,prostacyclin,55,67,Clinical evaluation on combined administration of oral prostacyclin analogue beraprost and phosphodiesterase inhibitor cilostazol.,7596955_0,0
13544,phosphodiesterase inhibitor cilostazol,91,129,Clinical evaluation on combined administration of oral prostacyclin analogue beraprost and phosphodiesterase inhibitor cilostazol.,7596955_0,0
13548,CLZ,150,153,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,0
13547,phosphodiesterase inhibitor cilostazol,110,148,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,0
13546,BPT,92,95,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,0
13545,beraprost,81,90,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,0
3313,prostacyclin,59,71,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,0
13550,"cyclic adenosine 3',5'-monophosphate",256,292,"Among various oral antiplatelets, a combination of a novel prostacyclin analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate).",7596955_1,0
13571,BPT/CLZ,46,53,"In conclusion, the combined administration of BPT/CLZ is safe at doses used in the study, though the beneficial clinical effect of the combined administration has yet to be elucidated.",7596955_10,0
13554,BPT,83,86,"Twelve healthy volunteers were assigned to take BPT/CLZ in the following schedule; BPT: 40 micrograms at day 1 and 120 micrograms t.i.d. from day 7 to 14, CLZ: 200 mg t.i.d. from day 3 to 14.",7596955_3,0
13555,CLZ,155,158,"Twelve healthy volunteers were assigned to take BPT/CLZ in the following schedule; BPT: 40 micrograms at day 1 and 120 micrograms t.i.d. from day 7 to 14, CLZ: 200 mg t.i.d. from day 3 to 14.",7596955_3,0
13553,BPT/CLZ,48,55,"Twelve healthy volunteers were assigned to take BPT/CLZ in the following schedule; BPT: 40 micrograms at day 1 and 120 micrograms t.i.d. from day 7 to 14, CLZ: 200 mg t.i.d. from day 3 to 14.",7596955_3,0
13559,intraplatelet cAMP,123,141,"At various time intervals, physical examination and blood collection for ex vivo platelet aggregation and determination of intraplatelet cAMP were performed.",7596955_4,0
3314,platelet aggregation,81,101,"At various time intervals, physical examination and blood collection for ex vivo platelet aggregation and determination of intraplatelet cAMP were performed.",7596955_4,0
13560,vital signs,64,75,"Throughout the observation period, no significant alteration in vital signs was observed.",7596955_5,1
13561,short duration,51,65,"Seven out of 12 subjects experienced headache of a short duration accompanying facial flush in one and nausea in one, especially after ingestion of CLZ.",7596955_6,1
13562,facial flush,79,91,"Seven out of 12 subjects experienced headache of a short duration accompanying facial flush in one and nausea in one, especially after ingestion of CLZ.",7596955_6,1
13563,CLZ,148,151,"Seven out of 12 subjects experienced headache of a short duration accompanying facial flush in one and nausea in one, especially after ingestion of CLZ.",7596955_6,0
13564,vasodilating,46,58,"All of these symptoms, probably caused by the vasodilating effect of the two agents, were of mild degree and no special treatment was required.",7596955_7,0
13566,/-,78,80,Intraplatelet cAMP content was gradually but significantly increased to 9.84 +/- 4.59 pmol per 10(9) platelets at day 14 in comparison with the initial value (6.87 +/- 2.25 pmol).,7596955_8,0
13570,combined administration,138,161,The platelet aggregability was significantly suppressed at various time intervals but no additive or synergistic inhibitory effect by the combined administration was noted.,7596955_9,0
13577,coenzyme A reductase inhibitor,123,153,"A case of acute inflammatory myopathy associated with the use of pravastatin, a new hydrophilic 3-hydroxy-3 methylglutaril coenzyme A reductase inhibitor, is reported.",7604176_2,0
13574,acute inflammatory myopathy,10,37,"A case of acute inflammatory myopathy associated with the use of pravastatin, a new hydrophilic 3-hydroxy-3 methylglutaril coenzyme A reductase inhibitor, is reported.",7604176_2,1
13576,3-hydroxy-3,96,107,"A case of acute inflammatory myopathy associated with the use of pravastatin, a new hydrophilic 3-hydroxy-3 methylglutaril coenzyme A reductase inhibitor, is reported.",7604176_2,0
6968,non-insulin-dependent diabetes mellitus,47,86,"The patient, a 69-year-old man was affected by non-insulin-dependent diabetes mellitus and hypertension.",7604176_3,1
13579,acute myopathy,21,35,He was admitted with acute myopathy of the lower limbs which resolved in a few days after pravastatin discontinuation.,7604176_5,1
6969,lower limbs,43,54,He was admitted with acute myopathy of the lower limbs which resolved in a few days after pravastatin discontinuation.,7604176_5,1
13580,chronic autoimmune thyroiditis,53,83,"A previously unknown hypothyroidism, probably due to chronic autoimmune thyroiditis, was evidenced.",7604176_6,1
6970,CD4+,117,121,Muscle biopsy (left gastrocnemius) revealed a perimysial and endomysial inflammatory infiltrate with a prevalence of CD4+ lymphocytes.,7604176_7,1
13582,left gastrocnemius,15,33,Muscle biopsy (left gastrocnemius) revealed a perimysial and endomysial inflammatory infiltrate with a prevalence of CD4+ lymphocytes.,7604176_7,1
13583,perimysial,46,56,Muscle biopsy (left gastrocnemius) revealed a perimysial and endomysial inflammatory infiltrate with a prevalence of CD4+ lymphocytes.,7604176_7,1
6971,toxic myopathy,59,73,"While lovastatin and simvastatin have been associated with toxic myopathy, pravastatin-associated myopathy could represent a distinct, inflammatory entity.",7604176_8,1
13587,inflammatory entity,135,154,"While lovastatin and simvastatin have been associated with toxic myopathy, pravastatin-associated myopathy could represent a distinct, inflammatory entity.",7604176_8,1
13590,gastric intubation,55,73,This coma was prevented with 1.68 mmol L-dopa given by gastric intubation 15 minutes before the ammonium salt injection.,761833_2,1
3315,ammonium salt,96,109,This coma was prevented with 1.68 mmol L-dopa given by gastric intubation 15 minutes before the ammonium salt injection.,761833_2,0
13594,Bilateral nephrectomy,0,21,Bilateral nephrectomy eliminated the beneficial effect of L-dopa on blood and brain ammonia and the ammonia coma was not prevented.,761833_5,1
13597,renal function,157,171,"Thus, the reduction in blood and brain ammonia and the prevention of ammonia coma after L-dopa, can be accounted for by the peripheral effect of dopamine on renal function rather than its central action.",761833_6,1
6972,myocardial infarction,18,39,Etoposide-related myocardial infarction.,7619765_0,1
3316,etoposide,84,93,"The occurrence of a myocardial infarction is reported after chemotherapy containing etoposide, in a man with no risk factors for coronary heart disease.",7619765_1,0
6973,myocardial infarction,20,41,"The occurrence of a myocardial infarction is reported after chemotherapy containing etoposide, in a man with no risk factors for coronary heart disease.",7619765_1,1
6974,coronary heart disease,129,151,"The occurrence of a myocardial infarction is reported after chemotherapy containing etoposide, in a man with no risk factors for coronary heart disease.",7619765_1,1
3317,folinic acid,37,49,Study of the role of vitamin B12 and folinic acid supplementation in preventing hematologic toxicity of zidovudine.,7628595_0,0
13601,vitamin B12,21,32,Study of the role of vitamin B12 and folinic acid supplementation in preventing hematologic toxicity of zidovudine.,7628595_0,0
3318,folinic acid,86,98,"A prospective, randomized study was conducted to evaluate the role of vitamin B12 and folinic acid supplementation in preventing zidovudine (ZDV)-induced bone marrow suppression.",7628595_1,0
13603,vitamin B12,70,81,"A prospective, randomized study was conducted to evaluate the role of vitamin B12 and folinic acid supplementation in preventing zidovudine (ZDV)-induced bone marrow suppression.",7628595_1,0
6975,bone marrow,154,165,"A prospective, randomized study was conducted to evaluate the role of vitamin B12 and folinic acid supplementation in preventing zidovudine (ZDV)-induced bone marrow suppression.",7628595_1,1
13608,group II,282,290,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,0
13607,vitamin B12,243,254,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,0
13605,group I,158,165,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,0
3319,human immunodeficiency virus,13,41,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,0
3320,folinic acid,198,210,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,0
6976,CD4+,71,75,"Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37).",7628595_2,1
13610,group II,122,130,"Finally, 15 patients were excluded from the study (noncompliance 14, death 1); thus, 60 patients (31 in group I and 29 in group II) were eligible for analysis.",7628595_3,0
13609,group I,104,111,"Finally, 15 patients were excluded from the study (noncompliance 14, death 1); thus, 60 patients (31 in group I and 29 in group II) were eligible for analysis.",7628595_3,0
13612,group II,77,85,"During the study, vitamin B12 and folate levels were significantly higher in group II patients; however, no differences in hemoglobin, hematocrit, mean corpuscular volume, and white-cell, neutrophil and platelet counts were observed between groups at 3, 6, 9 and 12 months.",7628595_5,0
13611,vitamin B12,18,29,"During the study, vitamin B12 and folate levels were significantly higher in group II patients; however, no differences in hemoglobin, hematocrit, mean corpuscular volume, and white-cell, neutrophil and platelet counts were observed between groups at 3, 6, 9 and 12 months.",7628595_5,0
13615,group II,146,154,Severe hematologic toxicity (neutrophil count < 1000/mm3 and/or hemoglobin < 8 g/dl) occurred in 4 patients assigned to group I and 7 assigned to group II.,7628595_6,0
13614,group I,120,127,Severe hematologic toxicity (neutrophil count < 1000/mm3 and/or hemoglobin < 8 g/dl) occurred in 4 patients assigned to group I and 7 assigned to group II.,7628595_6,0
13616,vitamin B12,33,44,There was no correlation between vitamin B12 or folate levels and development of myelosuppression.,7628595_7,0
13617,myelosuppression,81,97,There was no correlation between vitamin B12 or folate levels and development of myelosuppression.,7628595_7,1
13620,myelotoxicity,119,132,"Vitamin B12 and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV-induced myelotoxicity in the overall treated population, although a beneficial effect in certain subgroups of patients cannot be excluded.",7628595_8,1
3321,folinic acid,16,28,"Vitamin B12 and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV-induced myelotoxicity in the overall treated population, although a beneficial effect in certain subgroups of patients cannot be excluded.",7628595_8,0
13618,Vitamin B12,0,11,"Vitamin B12 and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV-induced myelotoxicity in the overall treated population, although a beneficial effect in certain subgroups of patients cannot be excluded.",7628595_8,0
13624,halothane-induced antibodies,78,106,Halogenated anesthetics form liver adducts and antigens that cross-react with halothane-induced antibodies.,7647582_0,0
13621,Halogenated anesthetics,0,23,Halogenated anesthetics form liver adducts and antigens that cross-react with halothane-induced antibodies.,7647582_0,0
13628,hepatic injury,98,112,"Two halogenated anesthetics, enflurane and isoflurane, have been associated with an allergic-type hepatic injury both alone and following previous exposure to halothane.",7647582_1,1
13625,halogenated anesthetics,4,27,"Two halogenated anesthetics, enflurane and isoflurane, have been associated with an allergic-type hepatic injury both alone and following previous exposure to halothane.",7647582_1,0
13629,Halothane hepatitis,0,19,Halothane hepatitis appears to involve an aberrant immune response.,7647582_2,1
3322,immune response,51,66,Halothane hepatitis appears to involve an aberrant immune response.,7647582_2,0
13631,protein-bound biotransformation product,26,65,An antibody response to a protein-bound biotransformation product (trifluoroacetyl adduct) has been detected on halothane hepatitis patients.,7647582_3,0
13637,halothane-induced antibodies,76,104,"The subcellular and lobular production of hepatic neoantigens recognized by halothane-induced antibodies following enflurane and isoflurane, and the biochemical nature of these neoantigens was investigated in two animal models.",7647582_5,0
13636,hepatic neoantigens,42,61,"The subcellular and lobular production of hepatic neoantigens recognized by halothane-induced antibodies following enflurane and isoflurane, and the biochemical nature of these neoantigens was investigated in two animal models.",7647582_5,0
13638,neoantigens,177,188,"The subcellular and lobular production of hepatic neoantigens recognized by halothane-induced antibodies following enflurane and isoflurane, and the biochemical nature of these neoantigens was investigated in two animal models.",7647582_5,0
6977,centrilobular,136,149,Enflurane administration resulted in neoantigens detected in both the microsomal and cytosolic fraction of liver homogenates and in the centrilobular region of the liver.,7647582_6,1
3323,cytosolic,85,94,Enflurane administration resulted in neoantigens detected in both the microsomal and cytosolic fraction of liver homogenates and in the centrilobular region of the liver.,7647582_6,0
13640,neoantigens,37,48,Enflurane administration resulted in neoantigens detected in both the microsomal and cytosolic fraction of liver homogenates and in the centrilobular region of the liver.,7647582_6,0
13646,ocular instillation,36,55,Cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops.,7650771_0,0
6979,myasthenia gravis,186,203,"A patient developed a severe cholinergic syndrome from the use of echothiophate iodide ophthalmic drops, presented with profound muscle weakness and was initially given the diagnosis of myasthenia gravis.",7650771_1,1
6978,muscle weakness,129,144,"A patient developed a severe cholinergic syndrome from the use of echothiophate iodide ophthalmic drops, presented with profound muscle weakness and was initially given the diagnosis of myasthenia gravis.",7650771_1,1
13648,cholinergic syndrome,29,49,"A patient developed a severe cholinergic syndrome from the use of echothiophate iodide ophthalmic drops, presented with profound muscle weakness and was initially given the diagnosis of myasthenia gravis.",7650771_1,1
3324,eye drops,140,149,Red blood cell and serum cholinesterase levels were severely depressed and symptoms resolved spontaneously following discontinuation of the eye drops.,7650771_2,0
3325,flumazenil,14,24,Seizure after flumazenil administration in a pediatric patient.,7651879_0,0
3326,Flumazenil,0,10,Flumazenil is a benzodiazepine receptor antagonist used to reverse sedation and respiratory depression induced by benzodiazepines.,7651879_1,0
13652,reverse sedation,59,75,Flumazenil is a benzodiazepine receptor antagonist used to reverse sedation and respiratory depression induced by benzodiazepines.,7651879_1,1
13651,benzodiazepine receptor antagonist,16,50,Flumazenil is a benzodiazepine receptor antagonist used to reverse sedation and respiratory depression induced by benzodiazepines.,7651879_1,0
6980,respiratory depression,80,102,Flumazenil is a benzodiazepine receptor antagonist used to reverse sedation and respiratory depression induced by benzodiazepines.,7651879_1,1
6981,cardiac arrhythmias,13,32,Seizures and cardiac arrhythmias have complicated its use in adult patients.,7651879_2,1
3327,tricyclic antidepressants,38,63,Overdose patients who have coingested tricyclic antidepressants have a higher risk of these complications.,7651879_3,0
3328,flumazenil,56,66,Little information exists concerning adverse effects of flumazenil in children.,7651879_4,0
6982,adverse effects,37,52,Little information exists concerning adverse effects of flumazenil in children.,7651879_4,1
3329,flumazenil,118,128,We report the occurrence of a generalized tonic-clonic seizure in a pediatric patient following the administration of flumazenil.,7651879_5,0
6983,generalized tonic-clonic seizure,30,62,We report the occurrence of a generalized tonic-clonic seizure in a pediatric patient following the administration of flumazenil.,7651879_5,1
13654,13-cis-retinoic acid,17,37,Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation.,7707116_0,0
13655,bone marrow transplantation,79,106,Phase I trial of 13-cis-retinoic acid in children with neuroblastoma following bone marrow transplantation.,7707116_0,1
13658,cis-RA,74,80,PURPOSE: Treatment of neuroblastoma cell lines with 13-cis-retinoic acid (cis-RA) can cause sustained inhibition of proliferation.,7707116_1,0
13657,13-cis-retinoic acid,52,72,PURPOSE: Treatment of neuroblastoma cell lines with 13-cis-retinoic acid (cis-RA) can cause sustained inhibition of proliferation.,7707116_1,0
13677,marrow metastases,42,59,Three complete responses were observed in marrow metastases.,7707116_10,1
13684,cis-RA,79,85,The DLT correlated with serum levels > or = 10 mumol/L. CONCLUSION: The MTD of cis-RA given on this intermittent schedule was 160 mg/m2/d.,7707116_12,0
13688,DLT,4,7,"The DLT included hypercalcemia, and may be predicted by serum cis-RA levels.",7707116_14,0
13689,cis-RA,62,68,"The DLT included hypercalcemia, and may be predicted by serum cis-RA levels.",7707116_14,0
13691,cis-RA,32,38,Monitoring of serum calcium and cis-RA levels is indicated in future trials.,7707116_15,0
13659,cis-RA,6,12,"Since cis-RA has demonstrated clinical responses in neuroblastoma patients, it may be effective in preventing relapse after cytotoxic therapy.",7707116_2,0
13660,clinical responses,30,48,"Since cis-RA has demonstrated clinical responses in neuroblastoma patients, it may be effective in preventing relapse after cytotoxic therapy.",7707116_2,1
13665,bone marrow transplantation,206,233,"This phase I trial was designed to determine the maximal-tolerated dosage (MTD), toxicities, and pharmacokinetics of cis-RA administered on an intermittent schedule in children with neuroblastoma following bone marrow transplantation (BMT).",7707116_3,1
13664,cis-RA,117,123,"This phase I trial was designed to determine the maximal-tolerated dosage (MTD), toxicities, and pharmacokinetics of cis-RA administered on an intermittent schedule in children with neuroblastoma following bone marrow transplantation (BMT).",7707116_3,0
13667,cis-RA,98,104,"PATIENTS AND METHODS: Fifty-one assessable patients, 2 to 12 years of age, were treated with oral cis-RA administered in two equally divided doses daily for 2 weeks, followed by a 2-week rest period, for up to 12 courses.",7707116_4,0
13668,mg/m2/d,39,46,The dose was escalated from 100 to 200 mg/m2/d until dose-limiting toxicity (DLT) was observed.,7707116_5,0
13669,dose-limiting toxicity,53,75,The dose was escalated from 100 to 200 mg/m2/d until dose-limiting toxicity (DLT) was observed.,7707116_5,1
13670,DLT,77,80,The dose was escalated from 100 to 200 mg/m2/d until dose-limiting toxicity (DLT) was observed.,7707116_5,0
13672,cis-RA,20,26,RESULTS: The MTD of cis-RA was 160 mg/m2/d.,7707116_7,0
13673,Dose-limiting toxicities,0,24,"Dose-limiting toxicities in six of nine patients at 200 mg/m2/d included hypercalcemia (n = 3), rash (n = 2), and anemia/thrombocytopenia/emesis/rash (n = 1).",7707116_8,1
13675,anemia/thrombocytopenia/emesis/rash,114,149,"Dose-limiting toxicities in six of nine patients at 200 mg/m2/d included hypercalcemia (n = 3), rash (n = 2), and anemia/thrombocytopenia/emesis/rash (n = 1).",7707116_8,1
13676,cis-RA,30,36,All toxicities resolved after cis-RA was discontinued.,7707116_9,0
6984,cerebral ischemia,89,106,"Time dependence of plasma malondialdehyde, oxypurines, and nucleosides during incomplete cerebral ischemia in the rat.",7710775_0,1
3330,malondialdehyde,26,41,"Time dependence of plasma malondialdehyde, oxypurines, and nucleosides during incomplete cerebral ischemia in the rat.",7710775_0,0
13693,oxypurines,43,53,"Time dependence of plasma malondialdehyde, oxypurines, and nucleosides during incomplete cerebral ischemia in the rat.",7710775_0,0
6986,common carotid,89,103,Incomplete cerebral ischemia (30 min) was induced in the rat by bilaterally clamping the common carotid arteries.,7710775_1,1
6985,cerebral ischemia,11,28,Incomplete cerebral ischemia (30 min) was induced in the rat by bilaterally clamping the common carotid arteries.,7710775_1,1
3331,malondialdehyde,131,146,"Plasma extracts were analyzed by a highly sensitive high-performance liquid chromatographic method for the direct determination of malondialdehyde, oxypurines, and nucleosides.",7710775_3,0
13695,oxypurines,148,158,"Plasma extracts were analyzed by a highly sensitive high-performance liquid chromatographic method for the direct determination of malondialdehyde, oxypurines, and nucleosides.",7710775_3,0
13696,plasma oxypurines,46,63,"During ischemia, a time-dependent increase of plasma oxypurines and nucleosides was observed.",7710775_4,0
3332,malondialdehyde,7,22,"Plasma malondialdehyde, which was present in minimal amount at zero time (0.058 mumol/liter plasma; SD 0.015), increased after 5 min of ischemia, resulting in a fivefold increase after 30 min of carotid occlusion (0.298 mumol/liter plasma; SD 0.078).",7710775_5,0
13698,carotid occlusion,195,212,"Plasma malondialdehyde, which was present in minimal amount at zero time (0.058 mumol/liter plasma; SD 0.015), increased after 5 min of ischemia, resulting in a fivefold increase after 30 min of carotid occlusion (0.298 mumol/liter plasma; SD 0.078).",7710775_5,1
13701,cyclooxygenase inhibitor acetylsalicylate,159,200,"Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.",7710775_6,0
3334,malondialdehyde,424,439,"Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.",7710775_6,0
3333,malondialdehyde,17,32,"Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.",7710775_6,0
13702,drug nitroprusside,306,324,"Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model, one receiving 20 mg/kg b.w. of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher.",7710775_6,0
3335,malondialdehyde,52,67,"The present data indicate that the determination of malondialdehyde, oxypurines, and nucleosides in peripheral blood, may be used to monitor the metabolic alterations of tissues occurring during ischemic phenomena.(ABSTRACT TRUNCATED AT 250 WORDS)",7710775_7,0
13704,oxypurines,69,79,"The present data indicate that the determination of malondialdehyde, oxypurines, and nucleosides in peripheral blood, may be used to monitor the metabolic alterations of tissues occurring during ischemic phenomena.(ABSTRACT TRUNCATED AT 250 WORDS)",7710775_7,0
13706,Acute renal toxicity,0,20,Acute renal toxicity of doxorubicin (adriamycin)-loaded cyanoacrylate nanoparticles.,7724492_0,1
13707,cyanoacrylate nanoparticles,56,83,Acute renal toxicity of doxorubicin (adriamycin)-loaded cyanoacrylate nanoparticles.,7724492_0,0
13708,DXNP,39,43,Acute doxorubicin-loaded nanoparticle (DXNP) renal toxicity was explored in both normal rats and rats with experimental glomerulonephritis.,7724492_1,0
13709,renal toxicity,45,59,Acute doxorubicin-loaded nanoparticle (DXNP) renal toxicity was explored in both normal rats and rats with experimental glomerulonephritis.,7724492_1,1
13710,experimental glomerulonephritis,107,138,Acute doxorubicin-loaded nanoparticle (DXNP) renal toxicity was explored in both normal rats and rats with experimental glomerulonephritis.,7724492_1,1
3336,nanoparticle,25,37,Acute doxorubicin-loaded nanoparticle (DXNP) renal toxicity was explored in both normal rats and rats with experimental glomerulonephritis.,7724492_1,0
13728,mesangial cells,158,173,"Both effects (better survival and nephrosis) are most probably related to an enhanced capture of DXNP by cells of the mononuclear phagocyte system, including mesangial cells.",7724492_10,1
13727,DXNP,97,101,"Both effects (better survival and nephrosis) are most probably related to an enhanced capture of DXNP by cells of the mononuclear phagocyte system, including mesangial cells.",7724492_10,0
13712,DX,49,51,"In normal rats, 2/6 rats given free doxorubicin (DX) (5 mg/kg) died within one week, whereas all control animals and all rats having received free NP or DXNP survived.",7724492_2,0
13713,DXNP,153,157,"In normal rats, 2/6 rats given free doxorubicin (DX) (5 mg/kg) died within one week, whereas all control animals and all rats having received free NP or DXNP survived.",7724492_2,0
13711,free doxorubicin,31,47,"In normal rats, 2/6 rats given free doxorubicin (DX) (5 mg/kg) died within one week, whereas all control animals and all rats having received free NP or DXNP survived.",7724492_2,0
13715,DX,94,96,A 3 times higher proteinuria appeared in animals treated with DXNP than in those treated with DX.,7724492_3,0
13714,DXNP,62,66,A 3 times higher proteinuria appeared in animals treated with DXNP than in those treated with DX.,7724492_3,0
13718,free DX,76,83,"Two hr post-injection, DXNP was 2.7 times more concentrated in kidneys than free DX (p < 0.025).",7724492_5,0
13717,DXNP,23,27,"Two hr post-injection, DXNP was 2.7 times more concentrated in kidneys than free DX (p < 0.025).",7724492_5,0
13721,DXNP,125,129,"In rats with immune experimental glomerulonephritis, 5/6 rats given DX died within 7 days, in contrast to animals treated by DXNP, NP, or untreated, which all survived.",7724492_6,0
13720,DX,68,70,"In rats with immune experimental glomerulonephritis, 5/6 rats given DX died within 7 days, in contrast to animals treated by DXNP, NP, or untreated, which all survived.",7724492_6,0
13719,immune experimental glomerulonephritis,13,51,"In rats with immune experimental glomerulonephritis, 5/6 rats given DX died within 7 days, in contrast to animals treated by DXNP, NP, or untreated, which all survived.",7724492_6,1
13723,DX,187,189,"Proteinuria appeared in all series, but was 2-5 times more intense (p > 0.001) and prolonged after doxorubicin treatment (400-700 mg/day), without significant difference between DXNP and DX.",7724492_7,0
13722,DXNP,178,182,"Proteinuria appeared in all series, but was 2-5 times more intense (p > 0.001) and prolonged after doxorubicin treatment (400-700 mg/day), without significant difference between DXNP and DX.",7724492_7,0
13725,free DX,96,103,"These results demonstrate that, in these experimental conditions, DXNP killed less animals than free DX, despite of an enhanced renal toxicity of the former.",7724492_9,0
13724,DXNP,66,70,"These results demonstrate that, in these experimental conditions, DXNP killed less animals than free DX, despite of an enhanced renal toxicity of the former.",7724492_9,0
13726,renal toxicity,128,142,"These results demonstrate that, in these experimental conditions, DXNP killed less animals than free DX, despite of an enhanced renal toxicity of the former.",7724492_9,1
3338,E2,209,211,"Prostaglandin E2-induced bladder hyperactivity in normal, conscious rats: involvement of tachykinins?In normal conscious rats investigated by continuous cystometry, intravesically instilled prostaglandin (PG) E2 facilitated micturition and increased basal intravesical pressure.",7752389_0,0
3337,PG,205,207,"Prostaglandin E2-induced bladder hyperactivity in normal, conscious rats: involvement of tachykinins?In normal conscious rats investigated by continuous cystometry, intravesically instilled prostaglandin (PG) E2 facilitated micturition and increased basal intravesical pressure.",7752389_0,0
13731,basal intravesical pressure,250,277,"Prostaglandin E2-induced bladder hyperactivity in normal, conscious rats: involvement of tachykinins?In normal conscious rats investigated by continuous cystometry, intravesically instilled prostaglandin (PG) E2 facilitated micturition and increased basal intravesical pressure.",7752389_0,1
13733,NK2 receptor selective antagonist,90,123,"The effect was attenuated by both the NK1 receptor selective antagonist RP 67,580 and the NK2 receptor selective antagonist SR 48,968, given intra-arterially, suggesting that it was mediated by stimulation of both NK1 and NK2 receptors.",7752389_1,0
13732,NK1 receptor selective antagonist RP,38,74,"The effect was attenuated by both the NK1 receptor selective antagonist RP 67,580 and the NK2 receptor selective antagonist SR 48,968, given intra-arterially, suggesting that it was mediated by stimulation of both NK1 and NK2 receptors.",7752389_1,0
3340,NK2 receptors,222,235,"The effect was attenuated by both the NK1 receptor selective antagonist RP 67,580 and the NK2 receptor selective antagonist SR 48,968, given intra-arterially, suggesting that it was mediated by stimulation of both NK1 and NK2 receptors.",7752389_1,0
3339,NK1,214,217,"The effect was attenuated by both the NK1 receptor selective antagonist RP 67,580 and the NK2 receptor selective antagonist SR 48,968, given intra-arterially, suggesting that it was mediated by stimulation of both NK1 and NK2 receptors.",7752389_1,0
3341,PGE2,23,27,"Intra-arterially given PGE2 produced a distinct increase in bladder pressure before initiating a micturition reflex, indicating that the PG had a direct contractant effect on the detrusor smooth muscle.",7752389_2,0
13734,bladder pressure,60,76,"Intra-arterially given PGE2 produced a distinct increase in bladder pressure before initiating a micturition reflex, indicating that the PG had a direct contractant effect on the detrusor smooth muscle.",7752389_2,1
3342,PG,137,139,"Intra-arterially given PGE2 produced a distinct increase in bladder pressure before initiating a micturition reflex, indicating that the PG had a direct contractant effect on the detrusor smooth muscle.",7752389_2,0
3346,PG,251,253,"The effect of intra-arterial PGE2 could not be blocked by intra-arterial RP 67,580 or SR 48,968, which opens the possibility that the micturition reflex elicited by intra-arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically.",7752389_3,0
3345,PGE2,180,184,"The effect of intra-arterial PGE2 could not be blocked by intra-arterial RP 67,580 or SR 48,968, which opens the possibility that the micturition reflex elicited by intra-arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically.",7752389_3,0
3343,PGE2,29,33,"The effect of intra-arterial PGE2 could not be blocked by intra-arterial RP 67,580 or SR 48,968, which opens the possibility that the micturition reflex elicited by intra-arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically.",7752389_3,0
3344,RP,73,75,"The effect of intra-arterial PGE2 could not be blocked by intra-arterial RP 67,580 or SR 48,968, which opens the possibility that the micturition reflex elicited by intra-arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically.",7752389_3,0
6987,detrusor,183,191,"The present results thus suggest that intra-arterial PGE2, given near the bladder, may initiate micturition in the normal rat chiefly by directly contracting the smooth muscle of the detrusor.",7752389_4,1
3347,PGE2,53,57,"The present results thus suggest that intra-arterial PGE2, given near the bladder, may initiate micturition in the normal rat chiefly by directly contracting the smooth muscle of the detrusor.",7752389_4,0
13741,urothelium,136,146,"However, when given intravesically, PGE2 may stimulate micturition by releasing tachykinins from nerves in and/or immediately below the urothelium.",7752389_5,1
3348,PGE2,36,40,"However, when given intravesically, PGE2 may stimulate micturition by releasing tachykinins from nerves in and/or immediately below the urothelium.",7752389_5,0
3349,tachykinins,80,91,"However, when given intravesically, PGE2 may stimulate micturition by releasing tachykinins from nerves in and/or immediately below the urothelium.",7752389_5,0
3350,tachykinins,6,17,"These tachykinins, in turn, initiate a micturition reflex by stimulating NK1 and NK2 receptors.",7752389_6,0
3351,NK1,73,76,"These tachykinins, in turn, initiate a micturition reflex by stimulating NK1 and NK2 receptors.",7752389_6,0
3352,NK2 receptors,81,94,"These tachykinins, in turn, initiate a micturition reflex by stimulating NK1 and NK2 receptors.",7752389_6,0
13743,inflammatory conditions,103,126,"Prostanoids may, via release of tachykinins, contribute to both urge and bladder hyperactivity seen in inflammatory conditions of the lower urinary tract.",7752389_7,1
6988,urinary tract,140,153,"Prostanoids may, via release of tachykinins, contribute to both urge and bladder hyperactivity seen in inflammatory conditions of the lower urinary tract.",7752389_7,1
3353,Prostanoids,0,11,"Prostanoids may, via release of tachykinins, contribute to both urge and bladder hyperactivity seen in inflammatory conditions of the lower urinary tract.",7752389_7,0
3354,tachykinins,32,43,"Prostanoids may, via release of tachykinins, contribute to both urge and bladder hyperactivity seen in inflammatory conditions of the lower urinary tract.",7752389_7,0
6990,heart block,42,53,Refractory cardiogenic shock and complete heart block after verapamil SR and metoprolol treatment.,7785794_0,1
6989,cardiogenic shock,11,28,Refractory cardiogenic shock and complete heart block after verapamil SR and metoprolol treatment.,7785794_0,1
13744,verapamil SR,60,72,Refractory cardiogenic shock and complete heart block after verapamil SR and metoprolol treatment.,7785794_0,0
6991,heart block,55,66,A seventy-eight-year-old woman presented with complete heart block and refractory hypotension two days after a therapeutic dose of sustained-release verapamil with concomitant use of metoprolol.,7785794_2,1
13747,therapeutic dose,111,127,A seventy-eight-year-old woman presented with complete heart block and refractory hypotension two days after a therapeutic dose of sustained-release verapamil with concomitant use of metoprolol.,7785794_2,0
13748,sustained-release verapamil,131,158,A seventy-eight-year-old woman presented with complete heart block and refractory hypotension two days after a therapeutic dose of sustained-release verapamil with concomitant use of metoprolol.,7785794_2,0
3355,dobutamine,180,190,"The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine.",7785794_3,0
13749,intravenous atropine,98,118,"The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine.",7785794_3,0
13750,high doses,130,140,"The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine.",7785794_3,0
13751,pressor agents,144,158,"The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine.",7785794_3,0
6992,heart block,58,69,"The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine.",7785794_3,1
6993,heart block,104,115,"However, shortly after the use of intravenous calcium chloride, the refractory hypotension and complete heart block resolved.",7785794_4,1
13752,calcium chloride,46,62,"However, shortly after the use of intravenous calcium chloride, the refractory hypotension and complete heart block resolved.",7785794_4,0
13753,refractory hypotension,68,90,"However, shortly after the use of intravenous calcium chloride, the refractory hypotension and complete heart block resolved.",7785794_4,1
13754,Protective effect,0,17,Protective effect of misoprostol on indomethacin induced renal dysfunction in elderly patients.,7791169_0,0
13755,misoprostol,21,32,Protective effect of misoprostol on indomethacin induced renal dysfunction in elderly patients.,7791169_0,0
13756,renal dysfunction,57,74,Protective effect of misoprostol on indomethacin induced renal dysfunction in elderly patients.,7791169_0,1
13757,protective effects,36,54,OBJECTIVE: To evaluate the possible protective effects of misoprostol on renal function in hospitalized elderly patients treated with indomethacin.,7791169_1,0
13758,misoprostol,58,69,OBJECTIVE: To evaluate the possible protective effects of misoprostol on renal function in hospitalized elderly patients treated with indomethacin.,7791169_1,0
13759,renal function,73,87,OBJECTIVE: To evaluate the possible protective effects of misoprostol on renal function in hospitalized elderly patients treated with indomethacin.,7791169_1,1
13762,antiinflammatory drugs,106,128,"METHODS: Forty-five hospitalized elderly patients (> 65 years old) who required therapy with nonsteroidal antiinflammatory drugs (NSAID) were randomly assigned to receive either indomethacin, 150 mg/day (Group A), or indomethacin 150 mg/day plus misoprostol at 0.6 mg/day (Group B).",7791169_2,0
13764,Group A,204,211,"METHODS: Forty-five hospitalized elderly patients (> 65 years old) who required therapy with nonsteroidal antiinflammatory drugs (NSAID) were randomly assigned to receive either indomethacin, 150 mg/day (Group A), or indomethacin 150 mg/day plus misoprostol at 0.6 mg/day (Group B).",7791169_2,0
13766,misoprostol,246,257,"METHODS: Forty-five hospitalized elderly patients (> 65 years old) who required therapy with nonsteroidal antiinflammatory drugs (NSAID) were randomly assigned to receive either indomethacin, 150 mg/day (Group A), or indomethacin 150 mg/day plus misoprostol at 0.6 mg/day (Group B).",7791169_2,0
13768,Group B,273,280,"METHODS: Forty-five hospitalized elderly patients (> 65 years old) who required therapy with nonsteroidal antiinflammatory drugs (NSAID) were randomly assigned to receive either indomethacin, 150 mg/day (Group A), or indomethacin 150 mg/day plus misoprostol at 0.6 mg/day (Group B).",7791169_2,0
13770,blood urea nitrogen (,58,79,"Laboratory variables of renal function [serum creatinine, blood urea nitrogen (BUN) and electrolytes] were evaluated before initiation of therapy and every 2 days, until termination of the study (a period of at least 6 days).",7791169_3,0
3356,creatinine,46,56,"Laboratory variables of renal function [serum creatinine, blood urea nitrogen (BUN) and electrolytes] were evaluated before initiation of therapy and every 2 days, until termination of the study (a period of at least 6 days).",7791169_3,0
13769,renal function,24,38,"Laboratory variables of renal function [serum creatinine, blood urea nitrogen (BUN) and electrolytes] were evaluated before initiation of therapy and every 2 days, until termination of the study (a period of at least 6 days).",7791169_3,1
13772,Group A,55,62,"RESULTS: Forty-two patients completed the study, 22 in Group A and 20 in Group B. BUN and creatinine increased by > 50% of baseline levels in 54 and 45% of Group A patients, respectively, compared to only 20 and 10% of Group B patients (p < 0.05).",7791169_5,0
13773,B. BUN,79,85,"RESULTS: Forty-two patients completed the study, 22 in Group A and 20 in Group B. BUN and creatinine increased by > 50% of baseline levels in 54 and 45% of Group A patients, respectively, compared to only 20 and 10% of Group B patients (p < 0.05).",7791169_5,0
13774,Group A,156,163,"RESULTS: Forty-two patients completed the study, 22 in Group A and 20 in Group B. BUN and creatinine increased by > 50% of baseline levels in 54 and 45% of Group A patients, respectively, compared to only 20 and 10% of Group B patients (p < 0.05).",7791169_5,0
3357,creatinine,90,100,"RESULTS: Forty-two patients completed the study, 22 in Group A and 20 in Group B. BUN and creatinine increased by > 50% of baseline levels in 54 and 45% of Group A patients, respectively, compared to only 20 and 10% of Group B patients (p < 0.05).",7791169_5,0
13777,Group A,68,75,"Potassium (K) increment of 0.6 mEq/l or more was observed in 50% of Group A, but in only 15% of Group B patients (p < 0.05).",7791169_6,0
13778,Group B,96,103,"Potassium (K) increment of 0.6 mEq/l or more was observed in 50% of Group A, but in only 15% of Group B patients (p < 0.05).",7791169_6,0
3358,creatinine,28,38,"The mean increments in BUN, creatinine, and K were reduced by 63, 80, and 42%, respectively, in Group B patients compared to Group A. Response to treatment did not differ significantly between the 2 groups.",7791169_7,0
13781,renal dysfunction,90,107,CONCLUSION: Hospitalized elderly patients are at risk for developing indomethacin related renal dysfunction.,7791169_8,1
13782,misoprostol,12,23,Addition of misoprostol can minimize this renal impairment without affecting pain control.,7791169_9,0
13783,renal impairment,42,58,Addition of misoprostol can minimize this renal impairment without affecting pain control.,7791169_9,1
6994,side-effects,11,23,Safety and side-effects of alprazolam.,7802851_0,1
13786,panic disorder,37,51,Controlled study in agoraphobia with panic disorder.,7802851_1,1
7000,adverse effects,48,63,CONCLUSIONS: Alprazolam caused side-effects and adverse effects during treatment but many patients were willing to accept these.,7802851_11,1
6999,side-effects,31,43,CONCLUSIONS: Alprazolam caused side-effects and adverse effects during treatment but many patients were willing to accept these.,7802851_11,1
6995,side-effect,83,94,"The efficacy of alprazolam and placebo in panic disorder with agoraphobia, and the side-effect and adverse effect profiles of both drug groups were measured.",7802851_3,1
13787,panic disorder,42,56,"The efficacy of alprazolam and placebo in panic disorder with agoraphobia, and the side-effect and adverse effect profiles of both drug groups were measured.",7802851_3,1
13788,adverse effect,99,113,"The efficacy of alprazolam and placebo in panic disorder with agoraphobia, and the side-effect and adverse effect profiles of both drug groups were measured.",7802851_3,1
13790,panic disorder,72,86,METHOD: In London and Toronto 154 patients who met DSM-III criteria for panic disorder with agoraphobia were randomised to alprazolam or placebo.,7802851_4,1
13791,Mean alprazolam,9,24,RESULTS: Mean alprazolam dose was 5 mg daily.,7802851_7,0
13793,impaired memory,212,227,"Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.",7802851_8,1
6997,side-effects,161,173,"Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.",7802851_8,1
6996,adverse reactions,67,84,"Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.",7802851_8,1
13792,disinhibition,122,135,"Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.",7802851_8,1
13794,weight loss,229,240,"Compared with placebo subjects, alprazolam patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia.",7802851_8,1
6998,Side-effects,0,12,Side-effects tended to diminish during treatment but remained significant at week 8.,7802851_9,1
13796,Cognitive deterioration,0,23,Cognitive deterioration from long-term abuse of dextromethorphan: a case report.,7803371_0,1
3359,dextromethorphan,48,64,Cognitive deterioration from long-term abuse of dextromethorphan: a case report.,7803371_0,0
3360,Dextromethorphan,0,16,"Dextromethorphan (DM), the dextrorotatory isomer of 3-hydroxy-N-methylmorphinan, is the main ingredient in a number of widely available, over-the-counter antitussives.",7803371_1,0
13798,dextrorotatory isomer,27,48,"Dextromethorphan (DM), the dextrorotatory isomer of 3-hydroxy-N-methylmorphinan, is the main ingredient in a number of widely available, over-the-counter antitussives.",7803371_1,0
13799,3-hydroxy-N-methylmorphinan,52,79,"Dextromethorphan (DM), the dextrorotatory isomer of 3-hydroxy-N-methylmorphinan, is the main ingredient in a number of widely available, over-the-counter antitussives.",7803371_1,0
13801,respiratory suppressant,61,84,Initial studies (Bornstein 1968) showed that it possessed no respiratory suppressant effects and no addiction liability.,7803371_2,0
7001,Fraser,291,297,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,1
13802,toxic effects,46,59,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,1
13803,slurred speech,114,128,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,1
13809,McCarthy 1971,323,336,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,0
3363,et,386,388,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,0
3362,et,311,313,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,0
3361,et,244,246,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,0
13805,aggressive behavior,216,235,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,1
13804,mood changes,146,158,"The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989).",7803371_4,1
13810,DM overdoses,50,62,There have also been two reported fatalities from DM overdoses (Fleming 1986).,7803371_5,0
13812,chronic abuse,56,69,"However, there are no reports describing the effects of chronic abuse.",7803371_6,1
13813,cognitive deterioration,32,55,This report describes a case of cognitive deterioration resulting from prolonged use of DM.,7803371_7,1
7002,coronary artery disease,83,106,Effects of ouabain on myocardial oxygen supply and demand in patients with chronic coronary artery disease.,783197_0,1
3364,ouabain,11,18,Effects of ouabain on myocardial oxygen supply and demand in patients with chronic coronary artery disease.,783197_0,0
7003,heart failure,67,80,"A hemodynamic, volumetric, and metabolic study in patients without heart failure.",783197_1,1
7008,coronary artery disease,42,65,We conclude that in patients with chronic coronary artery disease who are not in clinical congestive heart failure left ventricular end-diastolic volume falls after ouabain administration even when it is initially normal.,783197_10,1
3372,ouabain,165,172,We conclude that in patients with chronic coronary artery disease who are not in clinical congestive heart failure left ventricular end-diastolic volume falls after ouabain administration even when it is initially normal.,783197_10,0
13830,congestive heart failure left ventricular end-diastolic,90,145,We conclude that in patients with chronic coronary artery disease who are not in clinical congestive heart failure left ventricular end-diastolic volume falls after ouabain administration even when it is initially normal.,783197_10,1
7009,compensatory,14,26,"Nevertheless, compensatory mechanisms prevent a deterioration of resting myocardial metabolism.",783197_12,1
13834,resting myocardial metabolism,65,94,"Nevertheless, compensatory mechanisms prevent a deterioration of resting myocardial metabolism.",783197_12,1
3365,digitalis glycosides,15,35,"The effects of digitalis glycosides on myocardial oxygen supply and demand are of particular interest in the presence of obstructive coronary artery disease, but have not been measured previously in man.",783197_2,0
7004,coronary artery disease,133,156,"The effects of digitalis glycosides on myocardial oxygen supply and demand are of particular interest in the presence of obstructive coronary artery disease, but have not been measured previously in man.",783197_2,1
3366,ouabain,27,34,"We assessed the effects of ouabain (0.015 mg/kg body weight) on hemodynamic, volumetric, and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical congestive heart failure.",783197_3,0
7005,body weight,48,59,"We assessed the effects of ouabain (0.015 mg/kg body weight) on hemodynamic, volumetric, and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical congestive heart failure.",783197_3,1
7007,congestive heart failure,190,214,"We assessed the effects of ouabain (0.015 mg/kg body weight) on hemodynamic, volumetric, and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical congestive heart failure.",783197_3,1
7006,coronary artery disease,149,172,"We assessed the effects of ouabain (0.015 mg/kg body weight) on hemodynamic, volumetric, and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical congestive heart failure.",783197_3,1
3367,ouabain,169,176,"Because the protocol was long and involved interventions which might affect the determinations, we also studied in nine patients using an identical protocol except that ouabain administration was omitted.",783197_4,0
3368,ouabain,109,116,"Left ventricular end-diastolic pressure and left ventricular end-diastolic volume fell in each patient given ouabain, even though they were initially elevated in only two patients.",783197_5,0
13824,mm Hg,86,91,Left ventricular end-diastolic pressure fell from 11.5+/-1.4 (mean+/-SE) to 5.6+/-0.9 mm Hg (P less than 0.001) and left ventricular end-diastolic volume fell from 100+/-17 to 82+/-12 ml/m2 (P less than 0.01) 1 h after ouabain infusion was completed.,783197_6,0
3369,ouabain,219,226,Left ventricular end-diastolic pressure fell from 11.5+/-1.4 (mean+/-SE) to 5.6+/-0.9 mm Hg (P less than 0.001) and left ventricular end-diastolic volume fell from 100+/-17 to 82+/-12 ml/m2 (P less than 0.01) 1 h after ouabain infusion was completed.,783197_6,0
3370,ouabain,70,77,No significant change in myocardial oxygen consumption occurred after ouabain administration but this may be related to a greater decrease in mean arterial pressure in the ouabain patients than in the control patients.,783197_9,0
3371,ouabain,172,179,No significant change in myocardial oxygen consumption occurred after ouabain administration but this may be related to a greater decrease in mean arterial pressure in the ouabain patients than in the control patients.,783197_9,0
13828,mean arterial pressure,142,164,No significant change in myocardial oxygen consumption occurred after ouabain administration but this may be related to a greater decrease in mean arterial pressure in the ouabain patients than in the control patients.,783197_9,1
7010,pulmonary tuberculosis,91,113,Crescentic fibrillary glomerulonephritis associated with intermittent rifampin therapy for pulmonary tuberculosis.,7834920_0,1
13835,fibrillary glomerulonephritis,11,40,Crescentic fibrillary glomerulonephritis associated with intermittent rifampin therapy for pulmonary tuberculosis.,7834920_0,1
13838,crescentic glomerulonephritis,68,97,This case study reveals an unusual finding of rapidly proliferative crescentic glomerulonephritis in a patient treated with rifampin who had no other identifiable causes for developing this disease.,7834920_1,1
7011,proliferative,54,67,This case study reveals an unusual finding of rapidly proliferative crescentic glomerulonephritis in a patient treated with rifampin who had no other identifiable causes for developing this disease.,7834920_1,1
7012,pulmonary tuberculosis,72,94,This patient underwent a 10-month regimen of rifampin and isoniazid for pulmonary tuberculosis and was discovered to have developed signs of severe renal failure five weeks after completion of therapy.,7834920_2,1
7013,renal failure,148,161,This patient underwent a 10-month regimen of rifampin and isoniazid for pulmonary tuberculosis and was discovered to have developed signs of severe renal failure five weeks after completion of therapy.,7834920_2,1
3373,fibrillar,79,88,"Renal biopsy revealed severe glomerulonephritis with crescents, electron dense fibrillar deposits and moderate lymphocytic interstitial infiltrate.",7834920_3,0
13842,fibrillar glomerulonephritis,106,134,This report documents the unusual occurrence of rapidly progressive glomerulonephritis with crescents and fibrillar glomerulonephritis in a patient treated with rifampin.,7834920_5,1
7014,ocular hypertension,22,41,Dexamethasone-induced ocular hypertension in perfusion-cultured human eyes.,7843916_0,1
13844,corticosteroid glaucoma,94,117,PURPOSE: Glucocorticoid administration can lead to the development of ocular hypertension and corticosteroid glaucoma in a subset of the population through a decrease in the aqueous humor outflow facility.,7843916_1,1
7015,ocular hypertension,70,89,PURPOSE: Glucocorticoid administration can lead to the development of ocular hypertension and corticosteroid glaucoma in a subset of the population through a decrease in the aqueous humor outflow facility.,7843916_1,1
13856,intertrabecular,99,114,"In contrast, the dexamethasone-treated hypertensive eyes had thickened trabecular beams, decreased intertrabecular spaces, thickened juxtacanalicular tissue, activated trabecular meshwork cells, and increased amounts of amorphogranular extracellular material, especially in the juxtacanalicular tissue and beneath the endothelial lining of the canal of Schlemm.",7843916_10,1
13859,juxtacanalicular,278,294,"In contrast, the dexamethasone-treated hypertensive eyes had thickened trabecular beams, decreased intertrabecular spaces, thickened juxtacanalicular tissue, activated trabecular meshwork cells, and increased amounts of amorphogranular extracellular material, especially in the juxtacanalicular tissue and beneath the endothelial lining of the canal of Schlemm.",7843916_10,1
7019,ocular hypertension,104,123,"CONCLUSION: Dexamethasone treatment of isolated, perfusion-cultured human eyes led to the generation of ocular hypertension in approximately 30% of the dexamethasone-treated eyes.",7843916_12,1
13863,corticosteroid glaucoma,107,130,Steroid treatment resulted in morphologic changes in the trabecular meshwork similar to those reported for corticosteroid glaucoma and open angle glaucoma.,7843916_13,1
7020,open angle glaucoma,135,154,Steroid treatment resulted in morphologic changes in the trabecular meshwork similar to those reported for corticosteroid glaucoma and open angle glaucoma.,7843916_13,1
7021,primary open angle glaucoma,116,143,This system may provide an acute model in which to study the pathogenic mechanisms involved in steroid glaucoma and primary open angle glaucoma.,7843916_14,1
13866,steroid glaucoma,95,111,This system may provide an acute model in which to study the pathogenic mechanisms involved in steroid glaucoma and primary open angle glaucoma.,7843916_14,1
3374,serum-free media,29,45,Paired eyes were perfused in serum-free media with or without 10(-7) M dexamethasone for 12 days.,7843916_4,0
7016,Intraocular,0,11,Intraocular pressure was monitored daily.,7843916_5,1
7017,intraocular,35,46,RESULTS: A significant increase in intraocular pressure developed in 13 of the 44 pairs of eyes perfused with dexamethasone with an average pressure rise of 17.5 +/- 3.8 mm Hg after 12 days of dexamethasone exposure.,7843916_7,1
7018,intraocular,89,100,"The contralateral control eyes, which did not receive dexamethasone, maintained a stable intraocular pressure during the same period.",7843916_8,1
3375,folinic acid,70,82,Acute confusion induced by a high-dose infusion of 5-fluorouracil and folinic acid.,7858459_0,0
13868,5-fluorouracil,51,65,Acute confusion induced by a high-dose infusion of 5-fluorouracil and folinic acid.,7858459_0,0
13867,high-dose,29,38,Acute confusion induced by a high-dose infusion of 5-fluorouracil and folinic acid.,7858459_0,0
3377,etoposide,87,96,"A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma.",7858459_1,0
3378,folinic acid,150,162,"A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma.",7858459_1,0
13870,high-dose 5-fluorouracil,98,122,"A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma.",7858459_1,0
3376,cisplatinum,74,85,"A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma.",7858459_1,0
13871,gastric adenocarcinoma,181,203,"A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma.",7858459_1,1
13876,5-fluorouracil,195,209,"He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion.",7858459_2,0
7022,neurologic symptoms,19,38,"He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion.",7858459_2,1
13872,mental confusion,42,58,"He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion.",7858459_2,1
3379,folinic acid,214,226,"He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion.",7858459_2,0
3380,folinic acid,84,96,"This complication reappeared on day 25 during the second dose of 5-fluorouracil and folinic acid, which were then the only drugs given.",7858459_3,0
13877,second dose,50,61,"This complication reappeared on day 25 during the second dose of 5-fluorouracil and folinic acid, which were then the only drugs given.",7858459_3,0
13878,5-fluorouracil,65,79,"This complication reappeared on day 25 during the second dose of 5-fluorouracil and folinic acid, which were then the only drugs given.",7858459_3,0
3381,folinic acid,8,20,"Because folinic acid was unlikely to be associated with this condition, neurotoxicity due to high-dose 5-fluorouracil was highly suspected.",7858459_4,0
13880,high-dose 5-fluorouracil,93,117,"Because folinic acid was unlikely to be associated with this condition, neurotoxicity due to high-dose 5-fluorouracil was highly suspected.",7858459_4,0
7023,neurotoxicity,72,85,"Because folinic acid was unlikely to be associated with this condition, neurotoxicity due to high-dose 5-fluorouracil was highly suspected.",7858459_4,1
13882,fluorocitrate,107,120,"The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.",7858459_5,0
13881,fluoroacetate,89,102,"The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.",7858459_5,0
7024,thiamine deficiency,122,141,"The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency.",7858459_5,1
13883,High-dose,0,9,High-dose 5-fluorouracil/folinic acid infusion therapy has recently become a popular regimen for various cancers.,7858459_6,0
3382,oxcarbazepine,37,50,Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics.,7862923_0,0
13884,switching carbamazepine,10,33,Effect of switching carbamazepine to oxcarbazepine on the plasma levels of neuroleptics.,7862923_0,0
13887,10-keto analogue oxcarbazepine,34,64,"Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.",7862923_2,0
13888,difficult-to-treat schizophrenic,75,107,"Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.",7862923_2,1
13886,Carbamazepine,0,13,"Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine.",7862923_2,0
7025,extrapyramidal,127,141,This change resulted within 2-4 weeks in the 50-200% increase in the plasma levels of these neuroleptics and the appearance of extrapyramidal symptoms.,7862923_3,1
3383,antipsychotic drugs,184,203,The results of this case report support the idea that in contrast with carbamazepine oxcarbazepine does not induce the hepatic microsomal enzyme systems regulating the inactivation of antipsychotic drugs.,7862923_5,0
13891,carbamazepine oxcarbazepine,71,98,The results of this case report support the idea that in contrast with carbamazepine oxcarbazepine does not induce the hepatic microsomal enzyme systems regulating the inactivation of antipsychotic drugs.,7862923_5,0
13892,Auditory disturbance,0,20,Auditory disturbance associated with interscalene brachial plexus block.,7880714_0,1
7026,brachial plexus,50,65,Auditory disturbance associated with interscalene brachial plexus block.,7880714_0,1
7027,brachial plexus,116,131,We performed an audiometric study in 20 patients who underwent surgery of the shoulder region under an interscalene brachial plexus block (IBPB).,7880714_1,1
13895,shoulder region,78,93,We performed an audiometric study in 20 patients who underwent surgery of the shoulder region under an interscalene brachial plexus block (IBPB).,7880714_1,1
13896,IBPB,139,143,We performed an audiometric study in 20 patients who underwent surgery of the shoulder region under an interscalene brachial plexus block (IBPB).,7880714_1,0
3384,Bupivacaine,0,11,Bupivacaine 0.75% with adrenaline was given followed by a 24-hr continuous infusion of 0.25% bupivacaine.,7880714_2,0
3385,bupivacaine,93,104,Bupivacaine 0.75% with adrenaline was given followed by a 24-hr continuous infusion of 0.25% bupivacaine.,7880714_2,0
13897,IBPB,83,87,"Three audiometric threshold measurements (0.25-18 kHz) were made: the first before IBPB, the second 2-6 h after surgery and the third on the first day after operation.",7880714_3,0
7028,hearing impairment,17,35,"In four patients hearing impairment on the side of the block was demonstrated after operation, in three measurements on the day of surgery and in one on the following day.",7880714_4,1
3386,bupivacaine,101,112,The maximum change in threshold was 35 dB at 6 kHz measured at the end of the continuous infusion of bupivacaine.,7880714_6,0
13899,sympathetic innervation,96,119,"IBPB may cause transient auditory dysfunction in the ipsilateral ear, possibly via an effect on sympathetic innervation.",7880714_8,1
7029,auditory dysfunction,25,45,"IBPB may cause transient auditory dysfunction in the ipsilateral ear, possibly via an effect on sympathetic innervation.",7880714_8,1
13898,IBPB,0,4,"IBPB may cause transient auditory dysfunction in the ipsilateral ear, possibly via an effect on sympathetic innervation.",7880714_8,0
13901,lipid peroxidation,15,33,Time course of lipid peroxidation in puromycin aminonucleoside-induced nephropathy.,7881871_0,0
3387,puromycin,37,46,Time course of lipid peroxidation in puromycin aminonucleoside-induced nephropathy.,7881871_0,0
3389,puromycin aminonucleoside,74,99,"Reactive oxygen species have been implicated in the pathogenesis of acute puromycin aminonucleoside (PAN)-induced nephropathy, with antioxidants significantly reducing the proteinuria.",7881871_1,0
3388,Reactive oxygen species,0,23,"Reactive oxygen species have been implicated in the pathogenesis of acute puromycin aminonucleoside (PAN)-induced nephropathy, with antioxidants significantly reducing the proteinuria.",7881871_1,0
13904,lipid peroxidation,34,52,The temporal relationship between lipid peroxidation in the kidney and proteinuria was examined in this study.,7881871_2,0
3390,puromycin aminonucleoside,48,73,"Rats were treated with a single IV injection of puromycin aminonucleoside, (PAN, 7.5 mg/kg) and 24 hour urine samples were obtained prior to sacrifice on days 3,5,7,10,17,27,41 (N = 5-10 per group).",7881871_3,0
13906,ice cold TRIS buffer,39,59,"The kidneys were removed, flushed with ice cold TRIS buffer.",7881871_4,0
3391,thiobarbituric acid reactive substances,109,148,Tissue lipid peroxidation was measured in whole homogenates as well as in lipid extracts from homogenates as thiobarbituric acid reactive substances.,7881871_6,0
13908,lipid peroxidation,7,25,Tissue lipid peroxidation was measured in whole homogenates as well as in lipid extracts from homogenates as thiobarbituric acid reactive substances.,7881871_6,0
13909,lipid extracts,74,88,Tissue lipid peroxidation was measured in whole homogenates as well as in lipid extracts from homogenates as thiobarbituric acid reactive substances.,7881871_6,0
13910,Lipid peroxidation,0,18,Lipid peroxidation in homogenates was maximal at day 3 and declined rapidly to control levels by day 17.,7881871_8,0
13911,lipid peroxidation,32,50,This study supports the role of lipid peroxidation in mediating the proteinuric injury in PAN nephropathy.,7881871_9,0
13912,proteinuric injury,68,86,This study supports the role of lipid peroxidation in mediating the proteinuric injury in PAN nephropathy.,7881871_9,1
13913,PAN nephropathy,90,105,This study supports the role of lipid peroxidation in mediating the proteinuric injury in PAN nephropathy.,7881871_9,1
3392,octreotide,51,61,Composition of gall bladder stones associated with octreotide: response to oral ursodeoxycholic acid.,7890216_0,0
13914,gall bladder stones,15,34,Composition of gall bladder stones associated with octreotide: response to oral ursodeoxycholic acid.,7890216_0,1
3393,ursodeoxycholic acid,80,100,Composition of gall bladder stones associated with octreotide: response to oral ursodeoxycholic acid.,7890216_0,0
13916,gall bladder stones,59,78,"Octreotide, an effective treatment for acromegaly, induces gall bladder stones in 13-60% of patients.",7890216_1,1
3394,Octreotide,0,10,"Octreotide, an effective treatment for acromegaly, induces gall bladder stones in 13-60% of patients.",7890216_1,0
7037,gall stones,34,45,"In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.",7890216_10,1
3398,octreotide,15,25,"In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.",7890216_10,0
7038,gall stone disease,135,153,"In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.",7890216_10,1
13930,cystic duct,205,216,"In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.",7890216_10,1
13929,cholesterol rich,81,97,"In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.",7890216_10,1
7039,gall stones,226,237,"In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium.",7890216_10,1
7030,gall stones,218,229,"Because knowledge of stone composition is essential for studies of their pathogenesis, treatment, and prevention, this was investigated by direct and indirect methods in 14 octreotide treated acromegalic patients with gall stones.",7890216_2,1
3395,octreotide,173,183,"Because knowledge of stone composition is essential for studies of their pathogenesis, treatment, and prevention, this was investigated by direct and indirect methods in 14 octreotide treated acromegalic patients with gall stones.",7890216_2,0
7031,gall stones,21,32,"Chemical analysis of gall stones retrieved at cholecystectomy from two patients, showed that they contained 71% and 87% cholesterol by weight.",7890216_3,1
7032,gall bladder,67,79,"In the remaining 12 patients, localised computed tomography of the gall bladder showed that eight had stones with maximum attenuation scores of < 100 Hounsfield units (values of < 100 HU predict cholesterol rich, dissolvable stones).",7890216_4,1
3396,HU,184,186,"In the remaining 12 patients, localised computed tomography of the gall bladder showed that eight had stones with maximum attenuation scores of < 100 Hounsfield units (values of < 100 HU predict cholesterol rich, dissolvable stones).",7890216_4,0
13918,cholesterol rich,195,211,"In the remaining 12 patients, localised computed tomography of the gall bladder showed that eight had stones with maximum attenuation scores of < 100 Hounsfield units (values of < 100 HU predict cholesterol rich, dissolvable stones).",7890216_4,1
7033,Gall bladder,0,12,"Gall bladder bile was obtained by ultrasound guided, fine needle puncture from six patients.",7890216_5,1
13919,ultrasound guided,34,51,"Gall bladder bile was obtained by ultrasound guided, fine needle puncture from six patients.",7890216_5,1
13920,needle puncture,58,73,"Gall bladder bile was obtained by ultrasound guided, fine needle puncture from six patients.",7890216_5,1
7034,microcrystal,157,169,"All six patients had supersaturated bile (mean (SEM) cholesterol saturation index of 1.19 (0.08) (range 1.01-1.53)) and all had abnormally rapid cholesterol microcrystal nucleation times (< 4 days (range 1-4)), whilst in four, the bile contained cholesterol microcrystals immediately after sampling.",7890216_6,1
13923,cholesterol microcrystals,246,271,"All six patients had supersaturated bile (mean (SEM) cholesterol saturation index of 1.19 (0.08) (range 1.01-1.53)) and all had abnormally rapid cholesterol microcrystal nucleation times (< 4 days (range 1-4)), whilst in four, the bile contained cholesterol microcrystals immediately after sampling.",7890216_6,1
13921,supersaturated bile,21,40,"All six patients had supersaturated bile (mean (SEM) cholesterol saturation index of 1.19 (0.08) (range 1.01-1.53)) and all had abnormally rapid cholesterol microcrystal nucleation times (< 4 days (range 1-4)), whilst in four, the bile contained cholesterol microcrystals immediately after sampling.",7890216_6,0
13926,UDCA,132,136,"Of the 12 patients considered for oral ursodeoxycholic acid (UDCA) treatment, two had a blocked cystic duct and were not started on UDCA while one was lost to follow up.",7890216_7,0
13924,UDCA,61,65,"Of the 12 patients considered for oral ursodeoxycholic acid (UDCA) treatment, two had a blocked cystic duct and were not started on UDCA while one was lost to follow up.",7890216_7,0
3397,ursodeoxycholic acid,39,59,"Of the 12 patients considered for oral ursodeoxycholic acid (UDCA) treatment, two had a blocked cystic duct and were not started on UDCA while one was lost to follow up.",7890216_7,0
13925,cystic duct,96,107,"Of the 12 patients considered for oral ursodeoxycholic acid (UDCA) treatment, two had a blocked cystic duct and were not started on UDCA while one was lost to follow up.",7890216_7,1
7035,gall stone,115,125,"After one year of treatment, five of the remaining nine patients showed either partial (n = 3) or complete (n = 2) gall stone dissolution, suggesting that their stones were cholesterol rich.",7890216_8,1
13928,cholesterol rich,173,189,"After one year of treatment, five of the remaining nine patients showed either partial (n = 3) or complete (n = 2) gall stone dissolution, suggesting that their stones were cholesterol rich.",7890216_8,1
7036,gall stone,68,78,"This corresponds, by actuarial (life table) analysis, to a combined gall stone dissolution rate of 58.3 (15.9%).",7890216_9,1
13931,combination N-butyl-deoxynojirimycin,27,63,"The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.We conducted a double-blind, randomized phase II study to evaluate the safety and activity of combination therapy with N-butyl-deoxynojirimycin (SC-48334) (an alpha-glucosidase I inhibitor) and zidovudine versus zidovudine alone.",7905523_0,0
13932,SC-48334,65,73,"The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.We conducted a double-blind, randomized phase II study to evaluate the safety and activity of combination therapy with N-butyl-deoxynojirimycin (SC-48334) (an alpha-glucosidase I inhibitor) and zidovudine versus zidovudine alone.",7905523_0,0
13935,N-butyl-deoxynojirimycin,268,292,"The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.We conducted a double-blind, randomized phase II study to evaluate the safety and activity of combination therapy with N-butyl-deoxynojirimycin (SC-48334) (an alpha-glucosidase I inhibitor) and zidovudine versus zidovudine alone.",7905523_0,0
13936,SC-48334,294,302,"The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.We conducted a double-blind, randomized phase II study to evaluate the safety and activity of combination therapy with N-butyl-deoxynojirimycin (SC-48334) (an alpha-glucosidase I inhibitor) and zidovudine versus zidovudine alone.",7905523_0,0
13937,alpha-glucosidase I inhibitor,308,337,"The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.We conducted a double-blind, randomized phase II study to evaluate the safety and activity of combination therapy with N-butyl-deoxynojirimycin (SC-48334) (an alpha-glucosidase I inhibitor) and zidovudine versus zidovudine alone.",7905523_0,0
13938,SC-48334,106,114,Patients with 200 to 500 CD4 cells/mm3 who tolerated < or = 12 weeks of prior zidovudine therapy received SC-48334 (1000 mg every 8 h) and zidovudine (100 mg every 8 h) or zidovudine and placebo.,7905523_1,0
3399,human immunodeficiency virus,126,154,The mean SC-48334 steady-state trough level (4.04 +/- 0.99 micrograms/ml) was below the in vitro inhibitory concentration for human immunodeficiency virus (HIV).,7905523_4,0
13941,SC-48334,9,17,The mean SC-48334 steady-state trough level (4.04 +/- 0.99 micrograms/ml) was below the in vitro inhibitory concentration for human immunodeficiency virus (HIV).,7905523_4,0
13948,antigenemia,51,62,"The number of patients with suppression of HIV p24 antigenemia in the combination and zidovudine groups was six (40%) and two (11%) at week 4 (p = 0.10) and five (45%) and two (14%) at week 24 (p = 0.08), respectively.",7905523_7,1
3400,p24,47,50,"The number of patients with suppression of HIV p24 antigenemia in the combination and zidovudine groups was six (40%) and two (11%) at week 4 (p = 0.10) and five (45%) and two (14%) at week 24 (p = 0.08), respectively.",7905523_7,0
13949,weight loss,42,53,"Diarrhea, flatulence, abdominal pain, and weight loss were common for combination recipients.(ABSTRACT TRUNCATED AT 250 WORDS)",7905523_8,1
7040,abdominal pain,22,36,"Diarrhea, flatulence, abdominal pain, and weight loss were common for combination recipients.(ABSTRACT TRUNCATED AT 250 WORDS)",7905523_8,1
13950,nondepolarizing neuromuscular blocking agents,27,72,Prolonged paralysis due to nondepolarizing neuromuscular blocking agents and corticosteroids.,7910951_0,0
13951,nondepolarizing neuromuscular blocking agents,21,66,"The long-term use of nondepolarizing neuromuscular blocking agents (ND-NMBA) has recently been implicated as a cause of prolonged muscle weakness, although the site of the lesion and the predisposing factors have been unclear.",7910951_1,0
13952,ND-NMBA,68,75,"The long-term use of nondepolarizing neuromuscular blocking agents (ND-NMBA) has recently been implicated as a cause of prolonged muscle weakness, although the site of the lesion and the predisposing factors have been unclear.",7910951_1,0
7041,muscle weakness,130,145,"The long-term use of nondepolarizing neuromuscular blocking agents (ND-NMBA) has recently been implicated as a cause of prolonged muscle weakness, although the site of the lesion and the predisposing factors have been unclear.",7910951_1,1
13955,respiratory insufficiency,50,75,We report 3 patients (age 37-52 years) with acute respiratory insufficiency who developed prolonged weakness following the discontinuation of ND-NMBAs.,7910951_2,1
13956,ND-NMBAs,142,150,We report 3 patients (age 37-52 years) with acute respiratory insufficiency who developed prolonged weakness following the discontinuation of ND-NMBAs.,7910951_2,0
13957,intravenous corticosteroids,27,54,Two patients also received intravenous corticosteroids.,7910951_3,0
13958,Renal function,0,14,"Renal function was normal but hepatic function was impaired in all patients, and all had acidosis.",7910951_4,1
13959,hepatic function,30,46,"Renal function was normal but hepatic function was impaired in all patients, and all had acidosis.",7910951_4,1
13961,low amplitude compound,36,58,"Electrophysiologic studies revealed low amplitude compound motor action potentials, normal sensory studies, and fibrillations.",7910951_5,1
3401,vecuronium,10,20,"The serum vecuronium level measured in 1 patient 14 days after the drug had been discontinued was 172 ng/mL. A muscle biopsy in this patient showed loss of thick, myosin filaments.",7910951_7,0
7042,loss of,148,155,"The serum vecuronium level measured in 1 patient 14 days after the drug had been discontinued was 172 ng/mL. A muscle biopsy in this patient showed loss of thick, myosin filaments.",7910951_7,1
13968,ND-NMBA,106,113,The weakness in these patients is due to pathology at both the neuromuscular junction (most likely due to ND-NMBA) and muscle (most likely due to corticosteroids).,7910951_8,0
7043,neuromuscular junction,63,85,The weakness in these patients is due to pathology at both the neuromuscular junction (most likely due to ND-NMBA) and muscle (most likely due to corticosteroids).,7910951_8,1
13969,Hepatic dysfunction,0,19,Hepatic dysfunction and acidosis are contributing risk factors.,7910951_9,1
13971,multiforme,9,19,Erythema multiforme and hypersensitivity myocarditis caused by ampicillin.,7919560_0,0
13972,hypersensitivity myocarditis,24,52,Erythema multiforme and hypersensitivity myocarditis caused by ampicillin.,7919560_0,1
13973,multiforme,40,50,OBJECTIVE: To report a case of erythema multiforme and hypersensitivity myocarditis caused by ampicillin.,7919560_1,1
13974,hypersensitivity myocarditis,55,83,OBJECTIVE: To report a case of erythema multiforme and hypersensitivity myocarditis caused by ampicillin.,7919560_1,1
13976,multiforme,44,54,Medications were discontinued when erythema multiforme and congestive heart failure caused by myocarditis occurred.,7919560_3,0
7044,congestive heart failure,59,83,Medications were discontinued when erythema multiforme and congestive heart failure caused by myocarditis occurred.,7919560_3,1
3402,methylprednisolone,29,47,The patient was treated with methylprednisolone and gradually improved.,7919560_4,0
13978,multiforme,51,61,"DISCUSSION: After most infections causing erythema multiforme and myocarditis were ruled out, a drug-induced allergic reaction was suspected.",7919560_6,1
13979,drug-induced allergic reaction,96,126,"DISCUSSION: After most infections causing erythema multiforme and myocarditis were ruled out, a drug-induced allergic reaction was suspected.",7919560_6,1
13982,Hypersensitivity myocarditis,13,41,CONCLUSIONS: Hypersensitivity myocarditis is a rare and dangerous manifestation of allergy to penicillins.,7919560_8,1
13983,manifestation of allergy,66,90,CONCLUSIONS: Hypersensitivity myocarditis is a rare and dangerous manifestation of allergy to penicillins.,7919560_8,1
13984,sleep disturbance,21,38,Clomipramine-induced sleep disturbance does not impair its prolactin-releasing action.,7930386_0,1
13985,prolactin-releasing action,59,85,Clomipramine-induced sleep disturbance does not impair its prolactin-releasing action.,7930386_0,0
13986,sleep disturbance,56,73,"The present study was undertaken to examine the role of sleep disturbance, induced by clomipramine administration, on the secretory rate of prolactin (PRL) in addition to the direct drug effect.",7930386_1,1
3403,PRL,151,154,"The present study was undertaken to examine the role of sleep disturbance, induced by clomipramine administration, on the secretory rate of prolactin (PRL) in addition to the direct drug effect.",7930386_1,0
3405,at 10,40,45,Plasma PRL concentrations were analysed at 10 min intervals and underlying secretory rates calculated by a deconvolution procedure.,7930386_4,0
3404,PRL,7,10,Plasma PRL concentrations were analysed at 10 min intervals and underlying secretory rates calculated by a deconvolution procedure.,7930386_4,0
3406,PRL,69,72,"For both experiments the drug intake led to significant increases in PRL secretion, acting preferentially on tonic secretion as pulse amplitude and frequency did not differ significantly from corresponding control values.",7930386_5,0
13993,tonic secretion,109,124,"For both experiments the drug intake led to significant increases in PRL secretion, acting preferentially on tonic secretion as pulse amplitude and frequency did not differ significantly from corresponding control values.",7930386_5,1
13996,sleep cycles,120,132,During the night clomipramine ingestion altered the complete sleep architecture in that it suppressed REM sleep and the sleep cycles and induced increased wakefulness.,7930386_6,1
7045,REM sleep,102,111,During the night clomipramine ingestion altered the complete sleep architecture in that it suppressed REM sleep and the sleep cycles and induced increased wakefulness.,7930386_6,1
3407,PRL,28,31,"As the relative increase in PRL secretion expressed as a percentage of the mean did not significantly differ between the night and day time studies (46 +/- 19% vs 34 +/- 10%), it can be concluded that the observed sleep disturbance did not interfere with the drug action per se.",7930386_7,0
13999,sleep disturbance,214,231,"As the relative increase in PRL secretion expressed as a percentage of the mean did not significantly differ between the night and day time studies (46 +/- 19% vs 34 +/- 10%), it can be concluded that the observed sleep disturbance did not interfere with the drug action per se.",7930386_7,1
14000,drug action,259,270,"As the relative increase in PRL secretion expressed as a percentage of the mean did not significantly differ between the night and day time studies (46 +/- 19% vs 34 +/- 10%), it can be concluded that the observed sleep disturbance did not interfere with the drug action per se.",7930386_7,0
7046,REM sleep,16,25,"The presence of REM sleep was shown not to be a determining factor either for secretory pulse amplitude and frequency, as, for both, mean nocturnal values were similar with and without prior clomipramine ingestion.",7930386_8,1
3408,indocyanine green,27,44,Survey of complications of indocyanine green angiography in Japan.,7977601_0,0
3409,indocyanine green,36,53,PURPOSE: We evaluated the safety of indocyanine green for use in fundus angiography.,7977601_1,0
3417,indocyanine green,175,192,CONCLUSIONS: A comparison of frequency of adverse reactions to indocyanine green with the previously reported frequency of such reactions to fluorescein sodium indicated that indocyanine green is a safe as fluorescein for use in angiography.,7977601_10,0
3416,fluorescein sodium,141,159,CONCLUSIONS: A comparison of frequency of adverse reactions to indocyanine green with the previously reported frequency of such reactions to fluorescein sodium indicated that indocyanine green is a safe as fluorescein for use in angiography.,7977601_10,0
3415,indocyanine green,63,80,CONCLUSIONS: A comparison of frequency of adverse reactions to indocyanine green with the previously reported frequency of such reactions to fluorescein sodium indicated that indocyanine green is a safe as fluorescein for use in angiography.,7977601_10,0
7048,adverse reactions,42,59,CONCLUSIONS: A comparison of frequency of adverse reactions to indocyanine green with the previously reported frequency of such reactions to fluorescein sodium indicated that indocyanine green is a safe as fluorescein for use in angiography.,7977601_10,1
3410,indocyanine green,61,78,"METHODS: We sent a questionnaire concerning complications of indocyanine green to 32 institutions in Japan, which were selected on the basis of the client list from the Topcon Company, which manufactures the indocyanine green fundus camera.",7977601_2,0
3411,indocyanine green,208,225,"METHODS: We sent a questionnaire concerning complications of indocyanine green to 32 institutions in Japan, which were selected on the basis of the client list from the Topcon Company, which manufactures the indocyanine green fundus camera.",7977601_2,0
3412,indocyanine green,83,100,"RESULTS: Ophthalmologists at 15 institutions responded, reporting a total of 3,774 indocyanine green angiograms performed on 2,820 patients between June 1984 and September 1992.",7977601_3,0
3413,indocyanine green,47,64,"Before angiography, intradermal or intravenous indocyanine green testing, or both was performed at 13 of 15 institutions.",7977601_4,0
3414,indocyanine green,14,31,"The dosage of indocyanine green used for angiography varied from 25 to 75 mg, depending upon the institution.",7977601_6,0
14005,mild reactions,68,82,"There were 13 cases of adverse reactions (0.34%), ten of which were mild reactions such as nausea, exanthema, urtication, itchiness, and urgency to defecate, and did not require treatment.",7977601_7,1
7047,adverse reactions,23,40,"There were 13 cases of adverse reactions (0.34%), ten of which were mild reactions such as nausea, exanthema, urtication, itchiness, and urgency to defecate, and did not require treatment.",7977601_7,1
7049,pulmonary edema,62,77,"A 72-year-old woman was admitted to the hospital with ""flash"" pulmonary edema, preceded by chest pain, requiring intubation.",7988234_1,1
7050,chest pain,91,101,"A 72-year-old woman was admitted to the hospital with ""flash"" pulmonary edema, preceded by chest pain, requiring intubation.",7988234_1,1
7053,diabetes mellitus,109,126,"Her medical history included coronary artery disease with previous myocardial infarctions, hypertension, and diabetes mellitus.",7988234_2,1
3418,Her,0,3,"Her medical history included coronary artery disease with previous myocardial infarctions, hypertension, and diabetes mellitus.",7988234_2,0
7051,coronary artery disease,29,52,"Her medical history included coronary artery disease with previous myocardial infarctions, hypertension, and diabetes mellitus.",7988234_2,1
7052,myocardial infarctions,67,89,"Her medical history included coronary artery disease with previous myocardial infarctions, hypertension, and diabetes mellitus.",7988234_2,1
3419,angiotensin-converting enzyme inhibitors,36,76,Current medications did not include angiotensin-converting enzyme inhibitors or beta-blockers.,7988234_4,0
3420,beta-blockers,80,93,Current medications did not include angiotensin-converting enzyme inhibitors or beta-blockers.,7988234_4,0
14008,intravenous metoprolol,59,81,"During the first day of hospitalization (while intubated), intravenous metoprolol was given, resulting in severe angioedema.",7988234_6,0
3421,diphenhydramine hydrochloride,68,97,The angioedema resolved after therapy with intravenous steroids and diphenhydramine hydrochloride.,7988234_7,0
14009,intravenous steroids,43,63,The angioedema resolved after therapy with intravenous steroids and diphenhydramine hydrochloride.,7988234_7,0
3422,ancrod,11,17,Failure of ancrod in the treatment of heparin-induced arterial thrombosis.,8012887_0,0
14010,heparin-induced arterial thrombosis,38,73,Failure of ancrod in the treatment of heparin-induced arterial thrombosis.,8012887_0,1
14012,heparin-induced thrombosis,44,70,The morbidity and mortality associated with heparin-induced thrombosis remain high despite numerous empirical therapies.,8012887_1,1
14014,reexposure,156,166,"Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with heparin induced platelet aggregation who require brief reexposure to heparin, but its success in patients who have developed the thrombosis syndrome is not well defined.",8012887_2,0
3423,Ancrod,0,6,"Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with heparin induced platelet aggregation who require brief reexposure to heparin, but its success in patients who have developed the thrombosis syndrome is not well defined.",8012887_2,0
3424,platelet aggregation,117,137,"Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with heparin induced platelet aggregation who require brief reexposure to heparin, but its success in patients who have developed the thrombosis syndrome is not well defined.",8012887_2,0
14015,thrombosis syndrome,230,249,"Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with heparin induced platelet aggregation who require brief reexposure to heparin, but its success in patients who have developed the thrombosis syndrome is not well defined.",8012887_2,1
3425,ancrod,41,47,The authors present a case of failure of ancrod treatment in a patient with heparin-induced thrombosis.,8012887_3,0
14016,heparin-induced thrombosis,76,102,The authors present a case of failure of ancrod treatment in a patient with heparin-induced thrombosis.,8012887_3,1
7054,Water intoxication,0,18,Water intoxication associated with oxytocin administration during saline-induced abortion.,803783_0,1
7055,water intoxication,14,32,Four cases of water intoxication in connection with oxytocin administration during saline-induced abortions are described.,803783_1,1
7056,water intoxication,17,35,The mechanism of water intoxication is discussed in regard to these cases.,803783_2,1
14020,muscular irritability,297,318,"Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.",803783_3,1
7057,water intoxication,184,202,"Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches.",803783_3,1
3427,Ringers lactate,73,88,"The oxytocin should be given only in Ringers lactate or, alternately, in Ringers lactate and a 5 per cent dextrose and water solutions.",803783_4,0
3426,Ringers lactate,37,52,"The oxytocin should be given only in Ringers lactate or, alternately, in Ringers lactate and a 5 per cent dextrose and water solutions.",803783_4,0
14021,water solutions,119,134,"The oxytocin should be given only in Ringers lactate or, alternately, in Ringers lactate and a 5 per cent dextrose and water solutions.",803783_4,0
14025,cellular mediated immunity,28,54,Light chain proteinuria and cellular mediated immunity in rifampin treated patients with tuberculosis.,804391_0,0
14024,Light chain proteinuria,0,23,Light chain proteinuria and cellular mediated immunity in rifampin treated patients with tuberculosis.,804391_0,1
14026,Light chain proteinuria,0,23,Light chain proteinuria was found in 9 of 17 tuberculosis patients treated with rifampin.,804391_1,1
14027,cellular mediated immunity,21,47,Concomitant assay of cellular mediated immunity in these patients using skin test antigen and a lymphokine in vitro test provided results that were different.,804391_2,0
14030,PHA-P,198,203,"Response to Varidase skin test antigen was negative for all eight tuberculosis patients tested, but there occurred a hyper-responsiveness of the lymphocytes of these eight patients to phytomitogen (PHA-P).",804391_3,0
7058,hyper-responsiveness,117,137,"Response to Varidase skin test antigen was negative for all eight tuberculosis patients tested, but there occurred a hyper-responsiveness of the lymphocytes of these eight patients to phytomitogen (PHA-P).",804391_3,1
14029,Varidase skin test antigen,12,38,"Response to Varidase skin test antigen was negative for all eight tuberculosis patients tested, but there occurred a hyper-responsiveness of the lymphocytes of these eight patients to phytomitogen (PHA-P).",804391_3,0
3428,phytomitogen,184,196,"Response to Varidase skin test antigen was negative for all eight tuberculosis patients tested, but there occurred a hyper-responsiveness of the lymphocytes of these eight patients to phytomitogen (PHA-P).",804391_3,0
14032,serum binding,70,83,This last finding may be related to time of testing and/or endogenous serum binding of rifampin which could have inhibited mitogen activity for the lymphocyte.,804391_5,0
14034,KF17837,0,7,KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity.,8045270_0,0
14035,adenosine A2A receptor antagonist,27,60,KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity.,8045270_0,0
14037,KF17837,0,7,KF17837 is a novel selective adenosine A2A receptor antagonist.,8045270_1,0
14038,adenosine A2A receptor antagonist,29,62,KF17837 is a novel selective adenosine A2A receptor antagonist.,8045270_1,0
14039,KF17837,23,30,"Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner.",8045270_2,0
14042,adenosine A2A receptor agonist,165,195,"Oral administration of KF17837 (2.5, 10.0 and 30.0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner.",8045270_2,0
3429,(1,58,60,KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.).,8045270_3,0
14044,KF17837,0,7,KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.).,8045270_3,0
14047,anticataleptic effects,6,28,"These anticataleptic effects were exhibited dose dependently at doses from 0.625 and 2.5 mg/kg p.o., respectively.",8045270_4,0
3430,"L-3,4-dihydroxyphenylalanine",102,130,"Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.).",8045270_5,0
3431,benserazide,160,171,"Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.).",8045270_5,0
14049,anticataleptic effects,53,75,"Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.).",8045270_5,0
14048,KF17837,10,17,"Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.).",8045270_5,0
14053,KF17837,29,36,These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists.,8045270_6,0
14055,adenosine A2A receptor antagonists,175,209,These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists.,8045270_6,0
3432,dopaminergic,106,118,These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists.,8045270_6,0
14054,adenosine A2A receptor antagonist,59,92,These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists.,8045270_6,0
14056,KF17837,13,20,"Furthermore, KF17837 may be a useful drug in the treatment of parkinsonism.",8045270_7,0
14057,coniine,10,17,Effect of coniine on the developing chick embryo.,8073369_0,0
14059,Conium maculatum,26,42,"Coniine, an alkaloid from Conium maculatum (poison hemlock), has been shown to be teratogenic in livestock.",8073369_1,0
14058,Coniine,0,7,"Coniine, an alkaloid from Conium maculatum (poison hemlock), has been shown to be teratogenic in livestock.",8073369_1,0
14073,coniine,78,85,There was a statistically significant (P < or = 0.01) decrease in movement in coniine and nicotine sulfate treated chicks as determined by ultrasound.,8073369_10,0
7061,arthrogryposis,105,119,"In summary, the chick embryo provides a reliable and simple experimental animal model of coniine-induced arthrogryposis.",8073369_12,1
3434,nicotinic receptor,51,69,Data from this model support a mechanism involving nicotinic receptor blockade with subsequent decreased fetal movement.,8073369_13,0
7059,arthrogryposis,33,47,"The major teratogenic outcome is arthrogryposis, presumably due to nicotinic receptor blockade.",8073369_2,1
14060,teratogenic outcome,10,29,"The major teratogenic outcome is arthrogryposis, presumably due to nicotinic receptor blockade.",8073369_2,1
3433,nicotinic receptor,67,85,"The major teratogenic outcome is arthrogryposis, presumably due to nicotinic receptor blockade.",8073369_2,0
14061,coniine,9,16,"However, coniine has failed to produce arthrogryposis in rats or mice and is only weakly teratogenic in rabbits.",8073369_3,0
7060,arthrogryposis,39,53,"However, coniine has failed to produce arthrogryposis in rats or mice and is only weakly teratogenic in rabbits.",8073369_3,1
14063,coniine,69,76,The purpose of this study was to evaluate and compare the effects of coniine and nicotine in the developing chick.,8073369_4,0
14064,coniine,18,25,"Concentrations of coniine and nicotine sulfate were 0.015%, 0.03%, 0.075%, 0.15%, 0.75%, 1.5%, 3%, and 6% and 1%, 5%, and 10%, respectively.",8073369_5,0
14067,coniine,87,94,All concentrations of nicotine sulfate caused some lethality but a no effect level for coniine lethality was 0.75%.,8073369_7,0
14066,nicotine sulfate,22,38,All concentrations of nicotine sulfate caused some lethality but a no effect level for coniine lethality was 0.75%.,8073369_7,0
14068,coniine,32,39,The deformations caused by both coniine and nicotine sulfate were excessive flexion or extension of one or more toes.,8073369_8,0
14069,nicotine sulfate,44,60,The deformations caused by both coniine and nicotine sulfate were excessive flexion or extension of one or more toes.,8073369_8,0
14072,cranial hemorrhage,146,164,"No histopathological alterations or differences in bone formation were seen in the limbs or toes of any chicks from any group; however, extensive cranial hemorrhage occurred in all nicotine sulfate-treated chicks.",8073369_9,1
14071,bone formation,51,65,"No histopathological alterations or differences in bone formation were seen in the limbs or toes of any chicks from any group; however, extensive cranial hemorrhage occurred in all nicotine sulfate-treated chicks.",8073369_9,1
7062,allergic reactions,10,28,Immediate allergic reactions to amoxicillin.,8092427_0,1
14074,beta-lactam antibiotics,63,86,A large group of patients with suspected allergic reactions to beta-lactam antibiotics was evaluated.,8092427_1,0
7063,allergic reactions,41,59,A large group of patients with suspected allergic reactions to beta-lactam antibiotics was evaluated.,8092427_1,1
14101,RAST,0,4,RAST was positive for AX in 22 patients (41%) and to BPO in just 5 (9%).,8092427_11,0
14102,BPO,53,56,RAST was positive for AX in 22 patients (41%) and to BPO in just 5 (9%).,8092427_11,0
14104,BPO,60,63,None of the sera with negative RAST for AX were positive to BPO.,8092427_12,0
14103,RAST,31,35,None of the sera with negative RAST for AX were positive to BPO.,8092427_12,0
7064,allergic reaction,100,117,"Challenge tests with AX were performed in 23 subjects (43%) to establish the diagnosis of immediate allergic reaction to AX, and in 15 cases (28%) both skin test and RAST for AX were negative.",8092427_13,1
14107,RAST,166,170,"Challenge tests with AX were performed in 23 subjects (43%) to establish the diagnosis of immediate allergic reaction to AX, and in 15 cases (28%) both skin test and RAST for AX were negative.",8092427_13,0
3439,PG,0,2,PG was well tolerated by all 54 patients.,8092427_14,0
3440,PG,73,75,We describe the largest group of AX-allergic patients who have tolerated PG reported so far.,8092427_15,0
14077,RAST,55,59,"A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives.",8092427_2,0
14079,beta-lactam antibiotics,171,194,"A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives.",8092427_2,0
14082,penicillin derivatives,292,314,"A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate allergic responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives.",8092427_2,0
3435,PG,112,114,"Skin tests were performed with benzylpenicilloyl-poly-L-lysine (BPO-PLL), benzylpenicilloate, benzylpenicillin (PG), ampicillin (AMP), and AX.",8092427_3,0
14084,benzylpenicilloyl-poly-L-lysine (BPO-PLL),31,72,"Skin tests were performed with benzylpenicilloyl-poly-L-lysine (BPO-PLL), benzylpenicilloate, benzylpenicillin (PG), ampicillin (AMP), and AX.",8092427_3,0
14085,benzylpenicilloate,74,92,"Skin tests were performed with benzylpenicilloyl-poly-L-lysine (BPO-PLL), benzylpenicilloate, benzylpenicillin (PG), ampicillin (AMP), and AX.",8092427_3,0
14087,BPO-PLL,9,16,RAST for BPO-PLL and AX-PLL was done.,8092427_4,0
14088,AX-PLL,21,27,RAST for BPO-PLL and AX-PLL was done.,8092427_4,0
3436,PG,134,136,"When both skin test and RAST for BPO were negative, single-blind, placebo-controlled challenge tests were done to ensure tolerance of PG or sensitivity to AX.",8092427_5,0
14091,BPO,33,36,"When both skin test and RAST for BPO were negative, single-blind, placebo-controlled challenge tests were done to ensure tolerance of PG or sensitivity to AX.",8092427_5,0
14090,RAST,24,28,"When both skin test and RAST for BPO were negative, single-blind, placebo-controlled challenge tests were done to ensure tolerance of PG or sensitivity to AX.",8092427_5,0
14094,beta-lactam antibiotics,54,77,A total of 177 patients were diagnosed as allergic to beta-lactam antibiotics.,8092427_6,0
14095,AX allergy,46,56,We selected the 54 (30.5%) cases of immediate AX allergy with good tolerance of PG.,8092427_7,1
14096,good tolerance,62,76,We selected the 54 (30.5%) cases of immediate AX allergy with good tolerance of PG.,8092427_7,1
3437,PG,80,82,We selected the 54 (30.5%) cases of immediate AX allergy with good tolerance of PG.,8092427_7,0
14098,BPO,44,47,"All the patients were skin test negative to BPO; 49 of 51 (96%) were also negative to MDM, and 44 of 46 (96%) to PG.",8092427_9,0
14099,MDM,86,89,"All the patients were skin test negative to BPO; 49 of 51 (96%) were also negative to MDM, and 44 of 46 (96%) to PG.",8092427_9,0
3438,PG,113,115,"All the patients were skin test negative to BPO; 49 of 51 (96%) were also negative to MDM, and 44 of 46 (96%) to PG.",8092427_9,0
14110,intravenous nitroglycerin,55,80,Reversal by phenylephrine of the beneficial effects of intravenous nitroglycerin in patients with acute myocardial infarction.,809711_0,0
7065,myocardial infarction,104,125,Reversal by phenylephrine of the beneficial effects of intravenous nitroglycerin in patients with acute myocardial infarction.,809711_0,1
7066,myocardial infarction,73,94,"Nitroglycerin has been shown to reduce ST-segment elevation during acute myocardial infarction, an effect potentiated in the dog by agents that reverse nitroglycerin-induced hypotension.",809711_1,1
14112,reverse nitroglycerin-induced hypotension,144,185,"Nitroglycerin has been shown to reduce ST-segment elevation during acute myocardial infarction, an effect potentiated in the dog by agents that reverse nitroglycerin-induced hypotension.",809711_1,1
14111,ST-segment,39,49,"Nitroglycerin has been shown to reduce ST-segment elevation during acute myocardial infarction, an effect potentiated in the dog by agents that reverse nitroglycerin-induced hypotension.",809711_1,1
14113,combined nitroglycerin,51,73,Our study was designed to determine the effects of combined nitroglycerin and phenylephrine therapy.,809711_2,0
14114,intravenous nitroglycerin,67,92,"Ten patients with acute transmural myocardial infarctions received intravenous nitroglycerin, sufficient to reduce mean arterial pressure from 107 +/- 6 to 85 +/- 6 mm Hg (P less than 0.001), for 60 minutes.",809711_3,0
14115,mean arterial pressure,115,137,"Ten patients with acute transmural myocardial infarctions received intravenous nitroglycerin, sufficient to reduce mean arterial pressure from 107 +/- 6 to 85 +/- 6 mm Hg (P less than 0.001), for 60 minutes.",809711_3,1
7067,myocardial infarctions,35,57,"Ten patients with acute transmural myocardial infarctions received intravenous nitroglycerin, sufficient to reduce mean arterial pressure from 107 +/- 6 to 85 +/- 6 mm Hg (P less than 0.001), for 60 minutes.",809711_3,1
3441,/- 2,53,57,Left ventricular filling pressure decreased from 19 +/- 2 to 11 +/- 2 mm Hg (P less than 0.001).,809711_4,0
14119,/- 2 mm Hg,65,75,Left ventricular filling pressure decreased from 19 +/- 2 to 11 +/- 2 mm Hg (P less than 0.001).,809711_4,0
7068,Left ventricular,0,16,Left ventricular filling pressure decreased from 19 +/- 2 to 11 +/- 2 mm Hg (P less than 0.001).,809711_4,1
14120,SigmaST,0,7,"SigmaST, the sum of ST-segment elevations in 16 precordial leads, decreased (P less than 0.02) with intravenous nitroglycerin.",809711_5,0
14123,intravenous nitroglycerin,100,125,"SigmaST, the sum of ST-segment elevations in 16 precordial leads, decreased (P less than 0.02) with intravenous nitroglycerin.",809711_5,0
7069,left ventricular,160,176,"Subsequent addition of phenylephrine infusion, sufficient to re-elevate mean arterial pressure to 106 +/- 4 mm Hg (P less than 0.001) for 30 minutes, increased left ventricular filling pressure to 17 +/- 2 mm Hg (P less than 0.05) and also significantly increased sigmaST (P less than 0.05).",809711_6,1
14124,mean arterial pressure,72,94,"Subsequent addition of phenylephrine infusion, sufficient to re-elevate mean arterial pressure to 106 +/- 4 mm Hg (P less than 0.001) for 30 minutes, increased left ventricular filling pressure to 17 +/- 2 mm Hg (P less than 0.05) and also significantly increased sigmaST (P less than 0.05).",809711_6,1
7070,myocardial infarction,126,147,Our results suggest that addition of phenylephrine to nitroglycerin is not beneficial in the treatment of patients with acute myocardial infarction.,809711_7,1
14127,nondopaminergic drugs,10,31,Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys.,8106150_0,0
14129,MPTP,65,69,A group of four monkeys was rendered parkinsonian with the toxin MPTP.,8106150_1,0
14128,parkinsonian,37,49,A group of four monkeys was rendered parkinsonian with the toxin MPTP.,8106150_1,0
14130,L-DOPA/benserazide 50/12.5,40,66,They were then treated chronically with L-DOPA/benserazide 50/12.5 mg/kg given orally daily for 2 months.,8106150_2,0
3442,antiparkinsonian,30,46,"This dose produced a striking antiparkinsonian effect, but all animals manifested dyskinesia.",8106150_3,0
7071,dyskinetic,135,145,A series of agents acting primarily on neurotransmitters other than dopamine were then tested in combination with L-DOPA to see if the dyskinetic movements would be modified.,8106150_4,1
7072,dyskinetic,119,129,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,1
14132,parkinsonian symptomatology,171,198,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,1
3445,MK-801,90,96,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,0
3444,propranolol,73,84,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,0
14131,5-MDOT,65,71,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,0
3443,methysergide,51,63,"Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology.",8106150_5,0
7073,dyskinetic,60,70,"However, yohimbine and meperidine reduced predominantly the dyskinetic movements.",8106150_6,1
3446,yohimbine,9,18,"However, yohimbine and meperidine reduced predominantly the dyskinetic movements.",8106150_6,0
14133,dystonic,54,62,Baclofen was also useful in one monkey against a more dystonic form of dyskinesia.,8106150_7,1
3447,Baclofen,0,8,Baclofen was also useful in one monkey against a more dystonic form of dyskinesia.,8106150_7,0
14134,dystonic movements,23,41,Atropine converted the dystonic movements into chorea.,8106150_8,1
7074,neurotoxicity,38,51,Hallucinations and ifosfamide-induced neurotoxicity.,8111719_0,1
7075,neurotoxicity,51,64,BACKGROUND: Hallucinations as a symptom of central neurotoxicity are a known but poorly described side effect of ifosfamide.,8111719_1,1
3448,ifosfamide,113,123,BACKGROUND: Hallucinations as a symptom of central neurotoxicity are a known but poorly described side effect of ifosfamide.,8111719_1,0
7076,side effect,98,109,BACKGROUND: Hallucinations as a symptom of central neurotoxicity are a known but poorly described side effect of ifosfamide.,8111719_1,1
14136,mental status,78,91,Most cases of ifosfamide-induced hallucinations have been reported with other mental status changes.,8111719_2,1
14138,high-dose ifosfamide,28,48,All patients were receiving high-dose ifosfamide as part of their bone marrow transplant procedure.,8111719_4,0
7077,bone marrow,66,77,All patients were receiving high-dose ifosfamide as part of their bone marrow transplant procedure.,8111719_4,1
7078,neurotoxicity,70,83,CONCLUSIONS: Hallucinations may be the sole or first manifestation of neurotoxicity.,8111719_7,1
14140,ifosfamide-induced hallucinations,45,78,"The clinician should be alerted for possible ifosfamide-induced hallucinations, which may occur without other signs of neurotoxicity. ""Eyes-closed"" hallucinatory experiences appear to be an unusual feature of this presentation.",8111719_9,1
7079,neurotoxicity,119,132,"The clinician should be alerted for possible ifosfamide-induced hallucinations, which may occur without other signs of neurotoxicity. ""Eyes-closed"" hallucinatory experiences appear to be an unusual feature of this presentation.",8111719_9,1
14143,neuromuscular disorders,69,92,Acetazolamide-induced nephrolithiasis: implications for treatment of neuromuscular disorders.,8170551_0,1
3449,Carbonic anhydrase inhibitors,0,29,Carbonic anhydrase inhibitors can cause nephrolithiasis.,8170551_1,0
3450,carbonic anhydrase inhibitor,43,71,We studied 20 patients receiving long-term carbonic anhydrase inhibitor treatment for periodic paralysis and myotonia.,8170551_2,0
7080,periodic paralysis,86,104,We studied 20 patients receiving long-term carbonic anhydrase inhibitor treatment for periodic paralysis and myotonia.,8170551_2,1
7081,renal calculi,48,61,Three patients on acetazolamide (15%) developed renal calculi.,8170551_3,1
14144,acetazolamide,18,31,Three patients on acetazolamide (15%) developed renal calculi.,8170551_3,0
7082,renal calculus,50,64,"Extracorporeal lithotripsy successfully removed a renal calculus in one patient and surgery removed a staghorn calculus in another, permitting continued treatment.",8170551_4,1
7083,staghorn calculus,102,119,"Extracorporeal lithotripsy successfully removed a renal calculus in one patient and surgery removed a staghorn calculus in another, permitting continued treatment.",8170551_4,1
14145,Extracorporeal lithotripsy,0,26,"Extracorporeal lithotripsy successfully removed a renal calculus in one patient and surgery removed a staghorn calculus in another, permitting continued treatment.",8170551_4,1
14146,Renal function,0,14,Renal function remained normal in all patients.,8170551_5,1
14147,acetazolamide,37,50,Nephrolithiasis is a complication of acetazolamide but does not preclude its use.,8170551_6,0
3451,calcium channel blockers,11,35,Effects of calcium channel blockers on bupivacaine-induced toxicity.,8231633_0,0
3452,calcium channel blockers,62,86,The purpose of this study was to investigate the influence of calcium channel blockers on bupivacaine-induced acute toxicity.,8231633_1,0
3453,calcium channel blockers,29,53,"For each of the three tested calcium channel blockers (diltiazem, verapamil and bepridil) 6 groups of mice were treated by two different doses, i.e. 2 and 10 mg/kg/i.p., or an equal volume of saline for the control group (n = 20); 15 minutes later, all the animals were injected with a single 50 mg/kg/i.p.",8231633_2,0
3454,bepridil,80,88,"For each of the three tested calcium channel blockers (diltiazem, verapamil and bepridil) 6 groups of mice were treated by two different doses, i.e. 2 and 10 mg/kg/i.p., or an equal volume of saline for the control group (n = 20); 15 minutes later, all the animals were injected with a single 50 mg/kg/i.p.",8231633_2,0
3455,bupivacaine,8,19,dose of bupivacaine.,8231633_3,0
3456,convulsant,4,14,"The convulsant activity, the time of latency to convulse and the mortality rate were assessed in each group.",8231633_4,0
3457,calcium channel blockers,90,114,The local anesthetic-induced mortality was significantly increased by the three different calcium channel blockers.,8231633_5,0
3461,bepridil,209,217,The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine-induced convulsions; this effect was less pronounced with bepridil.,8231633_6,0
3460,calcium channel blockers,74,98,The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine-induced convulsions; this effect was less pronounced with bepridil.,8231633_6,0
3459,bupivacaine,27,38,The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine-induced convulsions; this effect was less pronounced with bepridil.,8231633_6,0
3458,convulsant,4,14,The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine-induced convulsions; this effect was less pronounced with bepridil.,8231633_6,0
14154,bupivacaine-induced convulsions,139,170,The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine-induced convulsions; this effect was less pronounced with bepridil.,8231633_6,0
7084,telangiectasia,43,57,Photodistributed nifedipine-induced facial telangiectasia.,8251368_0,1
14155,Adalat,39,45,"Five months after starting nifedipine (Adalat), two patients developed photodistributed facial telangiectasia, which became more noticeable with time.",8251368_1,0
7085,telangiectasia,95,109,"Five months after starting nifedipine (Adalat), two patients developed photodistributed facial telangiectasia, which became more noticeable with time.",8251368_1,1
14157,drug amlodipine,34,49,"One commenced the closely related drug amlodipine 3 years later, with recurrence of telangiectasia.",8251368_4,0
7086,telangiectasia,84,98,"One commenced the closely related drug amlodipine 3 years later, with recurrence of telangiectasia.",8251368_4,1
7087,telangiectasia,29,43,The photodistribution of the telangiectasia suggests a significant drug/light interaction.,8251368_5,1
7088,rheumatoid arthritis,79,99,Penicillamine-induced rapidly progressive glomerulonephritis in a patient with rheumatoid arthritis.,8267029_0,1
3462,D-penicillamine,120,135,A 67-year-old woman with rheumatoid arthritis presented rapidly progressive glomerulonephritis (RPGN) after 5 months of D-penicillamine (250 mg/day) treatment.,8267029_1,0
14159,RPGN,96,100,A 67-year-old woman with rheumatoid arthritis presented rapidly progressive glomerulonephritis (RPGN) after 5 months of D-penicillamine (250 mg/day) treatment.,8267029_1,0
7089,rheumatoid arthritis,25,45,A 67-year-old woman with rheumatoid arthritis presented rapidly progressive glomerulonephritis (RPGN) after 5 months of D-penicillamine (250 mg/day) treatment.,8267029_1,1
14161,inflammatory cells,124,142,Light microscopy study showed severe glomerulonephritis with crescent formation in 60% of the glomeruli and infiltration of inflammatory cells in the wall of an arteriole.,8267029_2,1
3463,C3,57,59,"Immunofluorescence revealed scanty granular IgG, IgA and C3 deposits along the capillary walls and mesangium.",8267029_3,0
14162,granular IgG,35,47,"Immunofluorescence revealed scanty granular IgG, IgA and C3 deposits along the capillary walls and mesangium.",8267029_3,0
14164,mesangium,99,108,"Immunofluorescence revealed scanty granular IgG, IgA and C3 deposits along the capillary walls and mesangium.",8267029_3,1
14166,cyclophosphamide,60,76,"The patient was treated with steroid pulse, plasmapheresis, cyclophosphamide and antiplatelet agents.",8267029_4,0
3464,antiplatelet agents,81,100,"The patient was treated with steroid pulse, plasmapheresis, cyclophosphamide and antiplatelet agents.",8267029_4,0
14165,steroid pulse,29,42,"The patient was treated with steroid pulse, plasmapheresis, cyclophosphamide and antiplatelet agents.",8267029_4,1
14167,renal function,23,37,A complete recovery of renal function was achieved in a few weeks.,8267029_5,1
14169,renal function,112,126,This new case of RPGN in the course of D-penicillamine treatment emphasizes the need for frequent monitoring of renal function and evaluation of urinary sediment and proteinuria in these patients.,8267029_6,1
14168,RPGN,17,21,This new case of RPGN in the course of D-penicillamine treatment emphasizes the need for frequent monitoring of renal function and evaluation of urinary sediment and proteinuria in these patients.,8267029_6,0
14170,urinary sediment,145,161,This new case of RPGN in the course of D-penicillamine treatment emphasizes the need for frequent monitoring of renal function and evaluation of urinary sediment and proteinuria in these patients.,8267029_6,1
3465,D-penicillamine,39,54,This new case of RPGN in the course of D-penicillamine treatment emphasizes the need for frequent monitoring of renal function and evaluation of urinary sediment and proteinuria in these patients.,8267029_6,0
3466,D-penicillamine,30,45,The prompt discontinuation of D-penicillamine and vigorous treatment measures could allow for a good prognosis as in this case.,8267029_7,0
3467,D-penicillamine,80,95,A case of polymyositis in a patient with primary biliary cirrhosis treated with D-penicillamine.,8268147_0,0
7090,primary biliary cirrhosis,41,66,A case of polymyositis in a patient with primary biliary cirrhosis treated with D-penicillamine.,8268147_0,1
14171,rheumatologic diseases,48,70,"Although D-penicillamine has been used for many rheumatologic diseases, toxicity limits its usefulness in many patients.",8268147_1,1
3468,D-penicillamine,9,24,"Although D-penicillamine has been used for many rheumatologic diseases, toxicity limits its usefulness in many patients.",8268147_1,0
14172,autoimmune complications,55,79,"Polymyositis/dermatomyositis can develop as one of the autoimmune complications of D-penicillamine treatment, but its exact pathogenesis remains unclear.",8268147_2,1
3469,D-penicillamine,83,98,"Polymyositis/dermatomyositis can develop as one of the autoimmune complications of D-penicillamine treatment, but its exact pathogenesis remains unclear.",8268147_2,0
7091,Polymyositis/dermatomyositis,0,28,"Polymyositis/dermatomyositis can develop as one of the autoimmune complications of D-penicillamine treatment, but its exact pathogenesis remains unclear.",8268147_2,1
7092,primary biliary cirrhosis,25,50,"We report a patient with primary biliary cirrhosis, who developed polymyositis while receiving D-penicillamine therapy.",8268147_3,1
3470,D-penicillamine,95,110,"We report a patient with primary biliary cirrhosis, who developed polymyositis while receiving D-penicillamine therapy.",8268147_3,0
7093,clinical course,25,40,We described the special clinical course of the patient.,8268147_4,1
3471,D-penicillamine,19,34,Patients receiving D-penicillamine therapy should be followed carefully for the development of autoimmune complications like polymyositis/dermatomyositis.,8268147_5,0
14173,autoimmune complications,95,119,Patients receiving D-penicillamine therapy should be followed carefully for the development of autoimmune complications like polymyositis/dermatomyositis.,8268147_5,1
7094,polymyositis/dermatomyositis,125,153,Patients receiving D-penicillamine therapy should be followed carefully for the development of autoimmune complications like polymyositis/dermatomyositis.,8268147_5,1
7095,Hyperalgesia,0,12,Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine.,8278214_0,1
14174,terminal cancer,30,45,Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine.,8278214_0,1
14176,high doses,73,83,Eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia.,8278214_1,0
14177,intravenous morphine,87,107,Eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia.,8278214_1,0
7096,hyperalgesia,118,130,Eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia.,8278214_1,1
14175,terminal stages,29,44,Eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia.,8278214_1,1
7098,hyperesthesia,51,64,Five patients developed universal hyperalgesia and hyperesthesia which in 2 cases were accompanied by myoclonus.,8278214_3,1
7097,hyperalgesia,34,46,Five patients developed universal hyperalgesia and hyperesthesia which in 2 cases were accompanied by myoclonus.,8278214_3,1
14178,pre-existing neuralgia,16,38,In 3 patients a pre-existing neuralgia increased to excruciating intensity and in 2 of these cases myoclonus occurred simultaneously.,8278214_4,1
14179,hyperalgesia/myoclonus,68,90,"Although only few clinical descriptions of the relationship between hyperalgesia/myoclonus and high doses of morphine are available, experimental support from animal studies indicates that morphine, or its metabolites, plays a causative role for the observed behavioural syndrome.",8278214_5,1
14181,behavioural syndrome,259,279,"Although only few clinical descriptions of the relationship between hyperalgesia/myoclonus and high doses of morphine are available, experimental support from animal studies indicates that morphine, or its metabolites, plays a causative role for the observed behavioural syndrome.",8278214_5,1
3472,opioids,107,114,The possible mechanisms are discussed and treatment proposals given suggesting the use of more efficacious opioids with less excitatory potency in these situations.,8278214_6,0
3473,prostaglandin E1,27,43,Epidural blood flow during prostaglandin E1 or trimethaphan induced hypotension.,8302922_0,0
3474,trimethaphan,47,59,Epidural blood flow during prostaglandin E1 or trimethaphan induced hypotension.,8302922_0,0
3478,TMP,67,70,"To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.",8302922_1,0
3477,trimethaphan,53,65,"To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.",8302922_1,0
14185,spinal surgery,128,142,"To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.",8302922_1,1
14187,postero-lateral interbody fusion,222,254,"To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.",8302922_1,1
14186,EBF,144,147,"To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.",8302922_1,0
14184,EBF,116,119,"To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.",8302922_1,0
3476,PGE1,44,48,"To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.",8302922_1,0
3475,prostaglandin E1,26,42,"To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced hypotension on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under isoflurane anaesthesia.",8302922_1,0
14189,micrograms.kg-1.min-1,73,94,"An initial dose of 0.1 microgram.kg-1.min-1 of PGE1 (15 patients), or 10 micrograms.kg-1.min-1 of TMP (15 patients) was administered intravenously after the dural opening and the dose was adjusted to maintain the mean arterial blood pressure (MAP) at about 60 mmHg.",8302922_2,0
7099,blood pressure,227,241,"An initial dose of 0.1 microgram.kg-1.min-1 of PGE1 (15 patients), or 10 micrograms.kg-1.min-1 of TMP (15 patients) was administered intravenously after the dural opening and the dose was adjusted to maintain the mean arterial blood pressure (MAP) at about 60 mmHg.",8302922_2,1
3480,TMP,98,101,"An initial dose of 0.1 microgram.kg-1.min-1 of PGE1 (15 patients), or 10 micrograms.kg-1.min-1 of TMP (15 patients) was administered intravenously after the dural opening and the dose was adjusted to maintain the mean arterial blood pressure (MAP) at about 60 mmHg.",8302922_2,0
3479,PGE1,47,51,"An initial dose of 0.1 microgram.kg-1.min-1 of PGE1 (15 patients), or 10 micrograms.kg-1.min-1 of TMP (15 patients) was administered intravenously after the dural opening and the dose was adjusted to maintain the mean arterial blood pressure (MAP) at about 60 mmHg.",8302922_2,0
14188,microgram.kg-1.min-1,23,43,"An initial dose of 0.1 microgram.kg-1.min-1 of PGE1 (15 patients), or 10 micrograms.kg-1.min-1 of TMP (15 patients) was administered intravenously after the dural opening and the dose was adjusted to maintain the mean arterial blood pressure (MAP) at about 60 mmHg.",8302922_2,0
14190,hypotensive drug,4,20,The hypotensive drug was discontinued at the completion of the operative procedure.,8302922_3,0
14192,RPP,59,62,"After starting PGE1 or TMP, MAP and rate pressure product (RPP) decreased significantly compared with preinfusion values (P < 0.01), and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation.",8302922_4,0
3483,PGE1,170,174,"After starting PGE1 or TMP, MAP and rate pressure product (RPP) decreased significantly compared with preinfusion values (P < 0.01), and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation.",8302922_4,0
3482,TMP,23,26,"After starting PGE1 or TMP, MAP and rate pressure product (RPP) decreased significantly compared with preinfusion values (P < 0.01), and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation.",8302922_4,0
3481,PGE1,15,19,"After starting PGE1 or TMP, MAP and rate pressure product (RPP) decreased significantly compared with preinfusion values (P < 0.01), and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation.",8302922_4,0
14196,EBF,67,70,"EBFF did not change during PGE1 infusion whereas in the TMP group, EBF decreased significantly at 30 and 60 min after the start of TMP (preinfusion: 45.9 +/- 13.9 ml/100g/min.",8302922_6,0
3486,TMP,131,134,"EBFF did not change during PGE1 infusion whereas in the TMP group, EBF decreased significantly at 30 and 60 min after the start of TMP (preinfusion: 45.9 +/- 13.9 ml/100g/min.",8302922_6,0
14195,EBFF,0,4,"EBFF did not change during PGE1 infusion whereas in the TMP group, EBF decreased significantly at 30 and 60 min after the start of TMP (preinfusion: 45.9 +/- 13.9 ml/100g/min.",8302922_6,0
3485,TMP,56,59,"EBFF did not change during PGE1 infusion whereas in the TMP group, EBF decreased significantly at 30 and 60 min after the start of TMP (preinfusion: 45.9 +/- 13.9 ml/100g/min.",8302922_6,0
3484,PGE1,27,31,"EBFF did not change during PGE1 infusion whereas in the TMP group, EBF decreased significantly at 30 and 60 min after the start of TMP (preinfusion: 45.9 +/- 13.9 ml/100g/min.",8302922_6,0
3487,PGE1,27,31,These results suggest that PGE1 may be preferable to TMP for hypotensive anaesthesia in spinal surgery because TMP decreased EBF.,8302922_9,0
3488,TMP,53,56,These results suggest that PGE1 may be preferable to TMP for hypotensive anaesthesia in spinal surgery because TMP decreased EBF.,8302922_9,0
3489,TMP,111,114,These results suggest that PGE1 may be preferable to TMP for hypotensive anaesthesia in spinal surgery because TMP decreased EBF.,8302922_9,0
14203,EBF,125,128,These results suggest that PGE1 may be preferable to TMP for hypotensive anaesthesia in spinal surgery because TMP decreased EBF.,8302922_9,0
14202,spinal surgery,88,102,These results suggest that PGE1 may be preferable to TMP for hypotensive anaesthesia in spinal surgery because TMP decreased EBF.,8302922_9,1
3490,daunorubicin,10,22,Liposomal daunorubicin in advanced Kaposi's sarcoma: a phase II study.,8305357_0,0
7100,Kaposi's sarcoma,35,51,Liposomal daunorubicin in advanced Kaposi's sarcoma: a phase II study.,8305357_0,1
14207,AIDS related Kaposi's sarcoma,143,172,We report a non-randomized Phase II clinical trial to assess the efficacy and safety of liposomal daunorubicin (DaunoXome) in the treatment of AIDS related Kaposi's sarcoma.,8305357_1,1
3491,daunorubicin,98,110,We report a non-randomized Phase II clinical trial to assess the efficacy and safety of liposomal daunorubicin (DaunoXome) in the treatment of AIDS related Kaposi's sarcoma.,8305357_1,0
14206,DaunoXome,112,121,We report a non-randomized Phase II clinical trial to assess the efficacy and safety of liposomal daunorubicin (DaunoXome) in the treatment of AIDS related Kaposi's sarcoma.,8305357_1,0
7103,cardiotoxicity,25,39,There was no evidence of cardiotoxicity.,8305357_10,1
14210,tolerated agent,79,94,"In this small patient sample, liposomal daunorubicin was an effective and well tolerated agent in the treatment of Kaposi's sarcoma.",8305357_11,0
3492,daunorubicin,40,52,"In this small patient sample, liposomal daunorubicin was an effective and well tolerated agent in the treatment of Kaposi's sarcoma.",8305357_11,0
7104,Kaposi's sarcoma,115,131,"In this small patient sample, liposomal daunorubicin was an effective and well tolerated agent in the treatment of Kaposi's sarcoma.",8305357_11,1
7101,Kaposi's sarcoma,36,52,Eleven homosexual men with advanced Kaposi's sarcoma were entered in the trial.,8305357_2,1
7102,Kaposi's sarcoma,17,33,"Stabilization of Kaposi's sarcoma occurred in the remaining six, maintained until the end of the trial period in four.",8305357_7,1
3493,puromycin,36,45,Dup 753 prevents the development of puromycin aminonucleoside-induced nephrosis.,8319760_0,0
3496,losartan,250,258,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,0
3495,Dup 753,241,248,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,0
14212,hypoalbuminemia,59,74,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,1
3494,puromycin aminonucleoside,166,191,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,0
7105,nephrotic syndromes,18,37,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,1
3497,angiotensin II receptor antagonist,269,303,"The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day.",8319760_1,0
3498,puromycin,97,106,The results suggest a possible involvement of the renin-angiotensin system in the development of puromycin aminonucleoside-induced nephrosis.,8319760_2,0
14217,auditory cortex,37,52,Neuroplasticity of the adult primate auditory cortex following cochlear hearing loss.,8372922_0,1
7106,cochlear hearing loss,63,84,Neuroplasticity of the adult primate auditory cortex following cochlear hearing loss.,8372922_0,1
14216,Neuroplasticity,0,15,Neuroplasticity of the adult primate auditory cortex following cochlear hearing loss.,8372922_0,1
14219,primary auditory area,54,75,Tonotopic organization is an essential feature of the primary auditory area (A1) of primate cortex.,8372922_1,1
7108,cochlear hearing loss,91,112,The region of cortex that represents the low frequencies was not obviously affected by the cochlear hearing loss.,8372922_10,1
7107,cochlear hearing loss,101,122,The purpose of this study was to determine if changes occur in this tonotopic organization following cochlear hearing loss.,8372922_3,1
14225,temporal gyrus,31,45,"Under anesthesia, the superior temporal gyrus of adult macaque monkeys was exposed, and the tonotopic organization of A1 was mapped using conventional microelectrode recording techniques.",8372922_4,1
14229,loss of tone-burst,55,73,The actual frequencies deafened were determined by the loss of tone-burst elicited auditory brainstem responses.,8372922_6,1
7109,nervous system,51,65,Long-term effects of vincristine on the peripheral nervous system.,8384253_0,1
7110,Non-Hodgkin's Lymphoma,20,42,Forty patients with Non-Hodgkin's Lymphoma treated with vincristine between 1984 and 1990 (cumulative dose 12 mg in 18-24 weeks) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system.,8384253_1,1
7111,long term,172,181,Forty patients with Non-Hodgkin's Lymphoma treated with vincristine between 1984 and 1990 (cumulative dose 12 mg in 18-24 weeks) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system.,8384253_1,1
7112,nervous system,223,237,Forty patients with Non-Hodgkin's Lymphoma treated with vincristine between 1984 and 1990 (cumulative dose 12 mg in 18-24 weeks) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system.,8384253_1,1
7116,Neuropathic,0,11,Neuropathic complaints were not very troublesome on the long term.,8384253_11,1
7117,long term,56,65,Neuropathic complaints were not very troublesome on the long term.,8384253_11,1
7118,signs and symptoms,72,90,It is concluded that with the above mentioned vincristine dose schedule signs and symptoms of vincristine neuropathy are reversible for a great deal and prognosis is fairly good.,8384253_12,1
7113,neuropathic,47,58,The patients were interviewed with emphasis on neuropathic symptoms.,8384253_2,1
14235,vibratory perception,68,88,"Physical and quantitative sensory examination with determination of vibratory perception and thermal discrimination thresholds were performed, four to 77 months (median 34 months) after vincristine treatment.",8384253_3,1
14236,thermal discrimination,93,115,"Physical and quantitative sensory examination with determination of vibratory perception and thermal discrimination thresholds were performed, four to 77 months (median 34 months) after vincristine treatment.",8384253_3,1
7114,neuropathic,31,42,Twenty-seven patients reported neuropathic symptoms.,8384253_4,1
7115,signs and symptoms,26,44,In these patients sensory signs and symptoms predominated.,8384253_6,1
14239,penile pain,30,41,Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction.,8386779_0,1
3499,Sodium bicarbonate,0,18,Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction.,8386779_0,0
7119,erectile dysfunction,83,103,Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction.,8386779_0,1
14245,penile pain,195,206,"In an attempt to determine whether penile pain associated with intracorporeal injections could be due to the acidity of the medication, we performed a randomized study comparing the incidence of penile pain following intracorporeal injections with or without the addition of sodium bicarbonate to the intracorporeal medications.",8386779_1,1
14241,penile pain,35,46,"In an attempt to determine whether penile pain associated with intracorporeal injections could be due to the acidity of the medication, we performed a randomized study comparing the incidence of penile pain following intracorporeal injections with or without the addition of sodium bicarbonate to the intracorporeal medications.",8386779_1,1
3500,sodium bicarbonate,275,293,"In an attempt to determine whether penile pain associated with intracorporeal injections could be due to the acidity of the medication, we performed a randomized study comparing the incidence of penile pain following intracorporeal injections with or without the addition of sodium bicarbonate to the intracorporeal medications.",8386779_1,0
3502,sodium bicarbonate,69,87,prostaglandin E1 with (pH 7.05) or without (pH 4.17) the addition of sodium bicarbonate (0.03 mEq.).,8386779_6,0
3501,prostaglandin E1,0,16,prostaglandin E1 with (pH 7.05) or without (pH 4.17) the addition of sodium bicarbonate (0.03 mEq.).,8386779_6,0
14248,penile pain,206,217,"Of the 19 patients without sodium bicarbonate added to the medication 11 (58%) complained of penile pain due to the medication, while only 1 of the 19 men (5%) who received sodium bicarbonate complained of penile pain.",8386779_7,1
14247,penile pain,93,104,"Of the 19 patients without sodium bicarbonate added to the medication 11 (58%) complained of penile pain due to the medication, while only 1 of the 19 men (5%) who received sodium bicarbonate complained of penile pain.",8386779_7,1
3504,sodium bicarbonate,173,191,"Of the 19 patients without sodium bicarbonate added to the medication 11 (58%) complained of penile pain due to the medication, while only 1 of the 19 men (5%) who received sodium bicarbonate complained of penile pain.",8386779_7,0
3503,sodium bicarbonate,27,45,"Of the 19 patients without sodium bicarbonate added to the medication 11 (58%) complained of penile pain due to the medication, while only 1 of the 19 men (5%) who received sodium bicarbonate complained of penile pain.",8386779_7,0
14249,penile pain,37,48,"From these data we conclude that the penile pain following intracorporeal injections is most likely due to the acidity of the medication, which can be overcome by elevating the pH to a neutral level.",8386779_8,1
7120,CD4+,47,51,"Patient response was assessed using changes in CD4+ lymphocyte subset count, HIV p24 antigen, weight, and quality of life.",8387218_1,1
3505,p24 antigen,81,92,"Patient response was assessed using changes in CD4+ lymphocyte subset count, HIV p24 antigen, weight, and quality of life.",8387218_1,0
14254,quality of life,106,121,"Patient response was assessed using changes in CD4+ lymphocyte subset count, HIV p24 antigen, weight, and quality of life.",8387218_1,1
14260,serum amylase,37,50,Thirteen patients developed a raised serum amylase without abdominal pain.,8387218_10,0
7127,abdominal pain,59,73,Thirteen patients developed a raised serum amylase without abdominal pain.,8387218_10,1
7128,glucose tolerance,25,42,"Seven patients developed glucose tolerance curves characteristic of diabetes but these were mild, did not require treatment and returned to normal on ceasing didanosine.",8387218_11,1
7121,opportunistic infections,33,57,Seventy patients developed major opportunistic infections whilst on therapy; this was the first AIDS diagnosis in 17.,8387218_2,1
7122,CD4+,22,26,"Only minor changes in CD4+ lymphocyte subset count were observed in AIDS patients, although a more significant rise occurred in those with earlier stages of disease.",8387218_3,1
7123,CD4+,138,142,"Of those positive for p24 antigen at the commencement of the study 67% showed a positive response, and this was most likely in those with CD4+ lymphocyte subset counts above 100 mm3.",8387218_4,1
3506,p24 antigen,22,33,"Of those positive for p24 antigen at the commencement of the study 67% showed a positive response, and this was most likely in those with CD4+ lymphocyte subset counts above 100 mm3.",8387218_4,0
14259,quality of life,78,93,Most patients showed improvement in individual parameters and global score of quality of life.,8387218_6,1
7124,Adverse reactions,0,17,Adverse reactions possibly attributable to didanosine were common.,8387218_7,1
7125,side-effect,16,27,"The most common side-effect was diarrhoea, which resulted in cessation of therapy in 19 individuals.",8387218_8,1
7126,Peripheral neuropathy,0,21,Peripheral neuropathy occurred in 12 patients and pancreatitis in six.,8387218_9,1
3507,oral contraceptives,78,97,Hepatic adenomas and focal nodular hyperplasia of the liver in young women on oral contraceptives: case reports.,839274_0,0
14261,Hepatic adenomas,0,16,Hepatic adenomas and focal nodular hyperplasia of the liver in young women on oral contraceptives: case reports.,839274_0,1
7129,focal nodular hyperplasia,21,46,Hepatic adenomas and focal nodular hyperplasia of the liver in young women on oral contraceptives: case reports.,839274_0,1
7130,focal nodular hyperplasia,40,65,"Two cases of hepatic adenoma and one of focal nodular hyperplasia presumably associated with the use of oral contraceptives, are reported.",839274_1,1
14263,hepatic adenoma,13,28,"Two cases of hepatic adenoma and one of focal nodular hyperplasia presumably associated with the use of oral contraceptives, are reported.",839274_1,1
3508,oral contraceptives,104,123,"Two cases of hepatic adenoma and one of focal nodular hyperplasia presumably associated with the use of oral contraceptives, are reported.",839274_1,0
14265,clinical presentation,35,56,"Special reference is made to their clinical presentation, which may be totally asymptomatic.",839274_2,1
14271,hepatic adenoma,57,72,Histologic differences and clinical similarities between hepatic adenoma and focal nodular hyperplasia of the liver are discussed.,839274_4,1
7131,focal nodular hyperplasia,77,102,Histologic differences and clinical similarities between hepatic adenoma and focal nodular hyperplasia of the liver are discussed.,839274_4,1
14274,focal lesions,103,116,Immunohistochemical studies with antibodies to neurofilament proteins on axonal damage in experimental focal lesions in rat.,8410052_0,1
14273,axonal damage,73,86,Immunohistochemical studies with antibodies to neurofilament proteins on axonal damage in experimental focal lesions in rat.,8410052_0,1
3509,neurofilament proteins,47,69,Immunohistochemical studies with antibodies to neurofilament proteins on axonal damage in experimental focal lesions in rat.,8410052_0,0
7132,axonal injury,160,173,"Immunohistochemistry with monoclonal antibodies against neurofilament (NF) proteins of middle and high molecular weight class, NF-M and NF-H, was used to study axonal injury in the borderzone of focal lesions in rats.",8410052_1,1
14277,NF-H,136,140,"Immunohistochemistry with monoclonal antibodies against neurofilament (NF) proteins of middle and high molecular weight class, NF-M and NF-H, was used to study axonal injury in the borderzone of focal lesions in rats.",8410052_1,0
14278,focal lesions,195,208,"Immunohistochemistry with monoclonal antibodies against neurofilament (NF) proteins of middle and high molecular weight class, NF-M and NF-H, was used to study axonal injury in the borderzone of focal lesions in rats.",8410052_1,1
3511,neurofilament,56,69,"Immunohistochemistry with monoclonal antibodies against neurofilament (NF) proteins of middle and high molecular weight class, NF-M and NF-H, was used to study axonal injury in the borderzone of focal lesions in rats.",8410052_1,0
3510,monoclonal antibodies,26,47,"Immunohistochemistry with monoclonal antibodies against neurofilament (NF) proteins of middle and high molecular weight class, NF-M and NF-H, was used to study axonal injury in the borderzone of focal lesions in rats.",8410052_1,0
14276,NF-M,127,131,"Immunohistochemistry with monoclonal antibodies against neurofilament (NF) proteins of middle and high molecular weight class, NF-M and NF-H, was used to study axonal injury in the borderzone of focal lesions in rats.",8410052_1,0
14275,NF,71,73,"Immunohistochemistry with monoclonal antibodies against neurofilament (NF) proteins of middle and high molecular weight class, NF-M and NF-H, was used to study axonal injury in the borderzone of focal lesions in rats.",8410052_1,0
3512,high molecular weight,98,119,"Immunohistochemistry with monoclonal antibodies against neurofilament (NF) proteins of middle and high molecular weight class, NF-M and NF-H, was used to study axonal injury in the borderzone of focal lesions in rats.",8410052_1,0
14279,Focal injury,0,12,Focal injury in the cortex was produced by infusion of lactate at acid pH or by stab caused by needle insertion.,8410052_2,1
14280,lactate at acid,55,70,Focal injury in the cortex was produced by infusion of lactate at acid pH or by stab caused by needle insertion.,8410052_2,0
7133,status epilepticus,90,108,Infarcts in substantia nigra pars reticulata were evoked by prolonged pilocarpine-induced status epilepticus.,8410052_3,1
14283,NFs,33,36,Immunohistochemical staining for NFs showed characteristic terminal clubs of axons in the borderzone of lesions.,8410052_4,0
14285,molecular weight,101,117,Differences in the labelling pattern occurred with different antibodies which apparently depended on molecular weight class of NFs and phosphorylation state.,8410052_5,0
14286,NFs,127,130,Differences in the labelling pattern occurred with different antibodies which apparently depended on molecular weight class of NFs and phosphorylation state.,8410052_5,0
3513,phosphorylation,135,150,Differences in the labelling pattern occurred with different antibodies which apparently depended on molecular weight class of NFs and phosphorylation state.,8410052_5,0
14288,NFs,37,40,These immunohistochemical changes of NFs can serve as a marker for axonal damage in various experimental traumatic or ischemic lesions.,8410052_6,0
14289,axonal damage,67,80,These immunohistochemical changes of NFs can serve as a marker for axonal damage in various experimental traumatic or ischemic lesions.,8410052_6,1
14290,ischemic lesions,118,134,These immunohistochemical changes of NFs can serve as a marker for axonal damage in various experimental traumatic or ischemic lesions.,8410052_6,1
14291,dentate gyrus,67,80,Loss of glutamate decarboxylase mRNA-containing neurons in the rat dentate gyrus following pilocarpine-induced seizures.,8410199_0,1
14294,dentate gyrus,138,151,In situ hybridization methods were used to determine if glutamic acid decarboxylase (GAD) mRNA-containing neurons within the hilus of the dentate gyrus are vulnerable to seizure-induced damage in a model of chronic seizures.,8410199_1,1
14296,chronic seizures,207,223,In situ hybridization methods were used to determine if glutamic acid decarboxylase (GAD) mRNA-containing neurons within the hilus of the dentate gyrus are vulnerable to seizure-induced damage in a model of chronic seizures.,8410199_1,1
14295,seizure-induced damage,170,192,In situ hybridization methods were used to determine if glutamic acid decarboxylase (GAD) mRNA-containing neurons within the hilus of the dentate gyrus are vulnerable to seizure-induced damage in a model of chronic seizures.,8410199_1,1
3514,glutamic acid decarboxylase,56,83,In situ hybridization methods were used to determine if glutamic acid decarboxylase (GAD) mRNA-containing neurons within the hilus of the dentate gyrus are vulnerable to seizure-induced damage in a model of chronic seizures.,8410199_1,0
7134,hippocampal,78,89,"Sprague-Dawley rats were injected intraperitoneally with pilocarpine, and the hippocampal formation was studied histologically at 1, 2, 4, and 8 week intervals after pilocarpine-induced seizures.",8410199_2,1
3515,cRNA,70,74,"In situ hybridization histochemistry, using a digoxigenin-labeled GAD cRNA probe, demonstrated a substantial decrease in the number of GAD mRNA-containing neurons in the hilus of the dentate gyrus in the pilocarpine-treated rats as compared to controls at all time intervals.",8410199_3,0
14302,dentate gyrus,183,196,"In situ hybridization histochemistry, using a digoxigenin-labeled GAD cRNA probe, demonstrated a substantial decrease in the number of GAD mRNA-containing neurons in the hilus of the dentate gyrus in the pilocarpine-treated rats as compared to controls at all time intervals.",8410199_3,1
14307,neuronal loss,257,270,"Additional neuronanatomical studies, including cresyl violet staining, neuronal degeneration methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels.",8410199_4,1
14305,cresyl,47,53,"Additional neuronanatomical studies, including cresyl violet staining, neuronal degeneration methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels.",8410199_4,0
3516,glial fibrillary acidic protein,136,167,"Additional neuronanatomical studies, including cresyl violet staining, neuronal degeneration methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels.",8410199_4,0
7135,loss of,4,11,The loss of GAD mRNA-containing neurons in the hilus contrasted with the relative preservation of labeled putative basket cells along the inner margin of the granule cell layer.,8410199_5,1
14311,dentate gyrus,65,78,Quantitative analyses of labeled neurons in three regions of the dentate gyrus in the 1 and 2 week groups showed statistically significant decreases in the mean number of GAD mRNA-containing neurons in the hilus of both groups of experimental animals.,8410199_6,1
14316,seizure-induced damage,143,165,"The results indicate that, in this model, a subpopulation of GAD mRNA-containing neurons within the dentate gyrus is selectively vulnerable to seizure-induced damage.",8410199_8,1
14315,dentate gyrus,100,113,"The results indicate that, in this model, a subpopulation of GAD mRNA-containing neurons within the dentate gyrus is selectively vulnerable to seizure-induced damage.",8410199_8,1
14317,differential vulnerability,5,31,Such differential vulnerability appears to be another indication of the heterogeneity of GABA neurons.,8410199_9,1
14319,mental confusion,127,143,Pharmacokinetic and clinical studies in patients with cimetidine-associated mental confusion.15 cases of cimetidine-associated mental confusion have been reported.,84204_0,1
14322,hepatic function,138,154,"In order that this syndrome might be investigated changes in mental status (M.S.) were correlated with serum concentrations and renal and hepatic function in 36 patients, 30 patients had no M.S. change on cimetidine and 6 had moderate to severe changes.",84204_1,1
7136,liver dysfunction,36,53,"These 6 patients had both renal and liver dysfunction (P less than 0.05), as well as cimetidine trough-concentrations of more than 1.25 microgram/ml (P less than 0.05).",84204_2,1
14326,lumbar puncture,85,100,"The severity of M.S. changes increased as trough-concentrations rose, 5 patients had lumbar puncture.",84204_3,1
7137,central nervous system,241,263,The cerebrospinal fluid: serum ratio of cimetidine concentrations was 0.24:1 and indicates that cimetidine passes the blood-brain barrier; it also raises the possibility that M.S. changes are due to blockade of histamine H2-receptors in the central nervous system.,84204_4,1
3517,histamine H2-receptors,211,233,The cerebrospinal fluid: serum ratio of cimetidine concentrations was 0.24:1 and indicates that cimetidine passes the blood-brain barrier; it also raises the possibility that M.S. changes are due to blockade of histamine H2-receptors in the central nervous system.,84204_4,0
14331,mental confusion,62,78,Patients likely to have both raised trough-concentrations and mental confusion are those with both severe renal and hepatic dysfunction.,84204_5,1
14332,hepatic dysfunction,116,135,Patients likely to have both raised trough-concentrations and mental confusion are those with both severe renal and hepatic dysfunction.,84204_5,1
3518,somatostatin analog,46,65,Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients.,8421099_0,0
3519,octreotide,67,77,Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients.,8421099_0,0
14334,gallbladder function,82,102,Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients.,8421099_0,1
14335,gallstone formation,107,126,Prospective study of the long-term effects of somatostatin analog (octreotide) on gallbladder function and gallstone formation in Chinese acromegalic patients.,8421099_0,1
14336,gallbladder function,36,56,This article reports the changes in gallbladder function examined by ultrasonography in 20 Chinese patients with active acromegaly treated with sc injection of the somatostatin analog octreotide in dosages of 300-1500 micrograms/day for a mean of 24.2 +/- 13.9 months.,8421099_1,1
14338,somatostatin analog octreotide,164,194,This article reports the changes in gallbladder function examined by ultrasonography in 20 Chinese patients with active acromegaly treated with sc injection of the somatostatin analog octreotide in dosages of 300-1500 micrograms/day for a mean of 24.2 +/- 13.9 months.,8421099_1,0
14337,active acromegaly,113,130,This article reports the changes in gallbladder function examined by ultrasonography in 20 Chinese patients with active acromegaly treated with sc injection of the somatostatin analog octreotide in dosages of 300-1500 micrograms/day for a mean of 24.2 +/- 13.9 months.,8421099_1,1
7138,acute cholecystitis,99,118,"During treatment with octreotide, 17 patients developed sludge, 10 had gallstones, and 1 developed acute cholecystitis requiring surgery.",8421099_2,1
3520,octreotide,22,32,"During treatment with octreotide, 17 patients developed sludge, 10 had gallstones, and 1 developed acute cholecystitis requiring surgery.",8421099_2,0
3521,octreotide,20,30,"After withdrawal of octreotide in 10 patients without gallstones, 8 patients assessed had return of normal gallbladder contractility within 1 month.",8421099_5,0
14340,return of normal gallbladder,90,118,"After withdrawal of octreotide in 10 patients without gallstones, 8 patients assessed had return of normal gallbladder contractility within 1 month.",8421099_5,1
3522,(3,128,130,"In 8 of the remaining 10 patients who developed gallstones during treatment, gallbladder contractility normalized in 5 patients (3 of whom has disappearance of their stones within 3 weeks), and remained depressed in 3 (2 of whom had stones present at 6 months).",8421099_6,0
3523,(2,218,220,"In 8 of the remaining 10 patients who developed gallstones during treatment, gallbladder contractility normalized in 5 patients (3 of whom has disappearance of their stones within 3 weeks), and remained depressed in 3 (2 of whom had stones present at 6 months).",8421099_6,0
14342,bile sludge,114,125,"Our results suggest that the suppression of gallbladder contractility is the cause of the successive formation of bile sludge, gallstones, and cholecystitis during octreotide therapy in Chinese acromegalic patients.",8421099_7,1
3524,octreotide,164,174,"Our results suggest that the suppression of gallbladder contractility is the cause of the successive formation of bile sludge, gallstones, and cholecystitis during octreotide therapy in Chinese acromegalic patients.",8421099_7,0
3525,octreotide,94,104,It is therefore very important to follow the changes of gallbladder function during long-term octreotide therapy of acromegalic patients.,8421099_8,0
14343,gallbladder function,56,76,It is therefore very important to follow the changes of gallbladder function during long-term octreotide therapy of acromegalic patients.,8421099_8,1
14344,Parkinson disability,12,32,Increase of Parkinson disability after fluoxetine medication.,8423889_0,1
7139,Parkinson's disease,42,61,Depression is a major clinical feature of Parkinson's disease.,8423889_1,1
14346,clinical feature,22,38,Depression is a major clinical feature of Parkinson's disease.,8423889_1,1
14347,motor disability,34,50,We report the increased amount of motor disability in four patients with idiopathic Parkinson's disease after exposure to the antidepressant fluoxetine.,8423889_2,1
14348,antidepressant fluoxetine,126,151,We report the increased amount of motor disability in four patients with idiopathic Parkinson's disease after exposure to the antidepressant fluoxetine.,8423889_2,0
7140,idiopathic Parkinson's disease,73,103,We report the increased amount of motor disability in four patients with idiopathic Parkinson's disease after exposure to the antidepressant fluoxetine.,8423889_2,1
7141,Parkinson's disease,89,108,The possibility of a clinically relevant dopamine-antagonistic capacity of fluoxetine in Parkinson's disease patients must be considered.,8423889_3,1
14350,neuropsychological function,74,101,Effects of deliberate hypotension induced by labetalol with isoflurane on neuropsychological function.,8424298_0,1
14351,brain function,40,54,The effect of deliberate hypotension on brain function measured by neuropsychological tests was studied in 41 adult patients.,8424298_1,1
14353,middle-ear surgery,44,62,Twenty-four patients were anaesthetized for middle-ear surgery with deliberate hypotension induced by labetalol with isoflurane (hypotensive group).,8424298_2,1
14361,/- 0.3 kPa,189,199,"The mean arterial pressure was 77 +/- 2 mmHg (10.3 +/- 0.3 kPa) before hypotension and 50 +/- 0 mmHg (6.7 +/- 0.0 kPa) during hypotension in the hypotensive group, and 86 +/- 2 mmHg (11.5 +/- 0.3 kPa) during anaesthesia in the control group.",8424298_4,0
14356,/- 0.3 kPa,52,62,"The mean arterial pressure was 77 +/- 2 mmHg (10.3 +/- 0.3 kPa) before hypotension and 50 +/- 0 mmHg (6.7 +/- 0.0 kPa) during hypotension in the hypotensive group, and 86 +/- 2 mmHg (11.5 +/- 0.3 kPa) during anaesthesia in the control group.",8424298_4,0
14355,/- 2 mmHg,35,44,"The mean arterial pressure was 77 +/- 2 mmHg (10.3 +/- 0.3 kPa) before hypotension and 50 +/- 0 mmHg (6.7 +/- 0.0 kPa) during hypotension in the hypotensive group, and 86 +/- 2 mmHg (11.5 +/- 0.3 kPa) during anaesthesia in the control group.",8424298_4,0
14354,mean arterial pressure,4,26,"The mean arterial pressure was 77 +/- 2 mmHg (10.3 +/- 0.3 kPa) before hypotension and 50 +/- 0 mmHg (6.7 +/- 0.0 kPa) during hypotension in the hypotensive group, and 86 +/- 2 mmHg (11.5 +/- 0.3 kPa) during anaesthesia in the control group.",8424298_4,1
7142,Sinus arrest,0,12,Sinus arrest associated with continuous-infusion cimetidine.,8437969_0,1
7143,bradyarrhythmias,122,138,The administration of intermittent intravenous infusions of cimetidine is infrequently associated with the development of bradyarrhythmias.,8437969_1,1
7145,sinus arrest,114,126,"A 40-year-old man with leukemia and no history of cardiac disease developed recurrent, brief episodes of apparent sinus arrest while receiving continuous-infusion cimetidine 50 mg/hour.",8437969_2,1
7144,cardiac disease,50,65,"A 40-year-old man with leukemia and no history of cardiac disease developed recurrent, brief episodes of apparent sinus arrest while receiving continuous-infusion cimetidine 50 mg/hour.",8437969_2,1
14377,dechallenge,88,99,"The arrhythmias were temporally related to cimetidine administration, disappeared after dechallenge, and did not recur during ranitidine treatment.",8437969_3,0
7146,sinus arrest,35,47,This is the first reported case of sinus arrest associated with continuous-infusion cimetidine.,8437969_4,1
7147,rheumatoid arthritis,17,37,Apparent cure of rheumatoid arthritis by bone marrow transplantation.,8441146_0,1
14380,bone marrow transplantation,41,68,Apparent cure of rheumatoid arthritis by bone marrow transplantation.,8441146_0,1
14381,bone marrow transplantation,115,142,We describe the induction of sustained remissions and possible cure of severe erosive rheumatoid arthritis (RA) by bone marrow transplantation (BMT) in 2 patients.,8441146_1,1
7148,rheumatoid arthritis,86,106,We describe the induction of sustained remissions and possible cure of severe erosive rheumatoid arthritis (RA) by bone marrow transplantation (BMT) in 2 patients.,8441146_1,1
3526,D-penicillamine,86,101,BMT was used to treat severe aplastic anemia which was caused by gold in one case and D-penicillamine in the other.,8441146_2,0
7149,aplastic anemia,29,44,BMT was used to treat severe aplastic anemia which was caused by gold in one case and D-penicillamine in the other.,8441146_2,1
14383,BMT,0,3,BMT was used to treat severe aplastic anemia which was caused by gold in one case and D-penicillamine in the other.,8441146_2,0
14386,BMT,53,56,"Although short term remission of severe RA following BMT has been reported, these are the first cases for which prolonged followup has been available.",8441146_4,0
14385,short term,9,19,"Although short term remission of severe RA following BMT has been reported, these are the first cases for which prolonged followup has been available.",8441146_4,1
14388,therapeutic option,67,85,This experience raises the question of the role of BMT itself as a therapeutic option for patients with uncontrolled destructive synovitis.,8441146_5,0
14389,destructive synovitis,117,138,This experience raises the question of the role of BMT itself as a therapeutic option for patients with uncontrolled destructive synovitis.,8441146_5,1
14387,BMT,51,54,This experience raises the question of the role of BMT itself as a therapeutic option for patients with uncontrolled destructive synovitis.,8441146_5,0
14390,levomepromazine-fluvoxamine,29,56,Seizures induced by combined levomepromazine-fluvoxamine treatment.,8473723_0,0
14391,levomepromazine-fluvoxamine,29,56,We report a case of combined levomepromazine-fluvoxamine treatment-induced seizures.,8473723_1,0
14392,fluvoxamine,36,47,It seems that combined treatment of fluvoxamine with phenothiazines may possess proconvulsive activity.,8473723_2,0
7150,ventricular tachycardia,41,64,Case report: pentamidine and polymorphic ventricular tachycardia revisited.,8475949_0,1
3527,pentamidine,13,24,Case report: pentamidine and polymorphic ventricular tachycardia revisited.,8475949_0,0
7152,torsade de pointes,89,107,"Pentamidine isethionate has been associated with ventricular tachyarrhythmias, including torsade de pointes.",8475949_1,1
14395,Pentamidine isethionate,0,23,"Pentamidine isethionate has been associated with ventricular tachyarrhythmias, including torsade de pointes.",8475949_1,0
7151,ventricular tachyarrhythmias,49,77,"Pentamidine isethionate has been associated with ventricular tachyarrhythmias, including torsade de pointes.",8475949_1,1
7154,torsade,126,133,Pentamidine-induced torsade de pointes may be related to serum magnesium levels and hypomagnesemia may synergistically induce torsade.,8475949_3,1
7153,torsade de pointes,20,38,Pentamidine-induced torsade de pointes may be related to serum magnesium levels and hypomagnesemia may synergistically induce torsade.,8475949_3,1
14398,hypomagnesemia,84,98,Pentamidine-induced torsade de pointes may be related to serum magnesium levels and hypomagnesemia may synergistically induce torsade.,8475949_3,1
7155,Torsade de pointes,0,18,Torsade de pointes occurred after an average of 10 days of treatment with pentamidine.,8475949_4,1
3528,pentamidine,74,85,Torsade de pointes occurred after an average of 10 days of treatment with pentamidine.,8475949_4,0
3529,pentamidine,50,61,"In these patients, no other acute side effects of pentamidine were observed.",8475949_5,0
7156,side effects,34,46,"In these patients, no other acute side effects of pentamidine were observed.",8475949_5,1
3530,pentamidine,93,104,"Torsade de pointes can be treated when recognized early, possibly without discontinuation of pentamidine.",8475949_6,0
7157,Torsade de pointes,0,18,"Torsade de pointes can be treated when recognized early, possibly without discontinuation of pentamidine.",8475949_6,1
14406,adverse events,166,180,"MEASUREMENTS: Plasma total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol, and triglycerides; and laboratory and clinical evidence of adverse events monitored periodically throughout the study.",8480959_5,1
3531,low-density lipoprotein,28,51,"MEASUREMENTS: Plasma total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol, and triglycerides; and laboratory and clinical evidence of adverse events monitored periodically throughout the study.",8480959_5,0
3532,high-density lipoprotein,63,87,"MEASUREMENTS: Plasma total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol, and triglycerides; and laboratory and clinical evidence of adverse events monitored periodically throughout the study.",8480959_5,0
3533,LDL cholesterol,133,148,"RESULTS: Among women, lovastatin (20 to 80 mg/d) produced sustained (12- to 48-week), dose-related changes (P < 0.001): decreases in LDL cholesterol (24% to 40%) and triglycerides (9% to 18%), and increases in HDL cholesterol (6.7% to 8.6%).",8480959_6,0
14407,HDL cholesterol,210,225,"RESULTS: Among women, lovastatin (20 to 80 mg/d) produced sustained (12- to 48-week), dose-related changes (P < 0.001): decreases in LDL cholesterol (24% to 40%) and triglycerides (9% to 18%), and increases in HDL cholesterol (6.7% to 8.6%).",8480959_6,0
14409,muscle symptoms,21,36,"Myopathy, defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal, was rare and associated with the highest recommended daily dose of lovastatin (80 mg).",8480959_9,1
3534,creatine kinase,42,57,"Myopathy, defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal, was rare and associated with the highest recommended daily dose of lovastatin (80 mg).",8480959_9,0
7158,rhabdomyolysis,11,25,Tetany and rhabdomyolysis due to surreptitious furosemide--importance of magnesium supplementation.,8492347_0,1
14414,hypomagnesemia,51,65,"Diuretics may induce hypokalemia, hypocalcemia and hypomagnesemia.",8492347_1,1
7159,muscle weakness,35,50,"While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).",8492347_2,1
14415,hypomagnesemia,59,73,"While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).",8492347_2,1
7160,muscle spasms,93,106,"While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2).",8492347_2,1
14418,magnesium depletion,131,150,"Symptomatic hypokalemia has been reported in such patients (3-7) and in one case hypocalcemia was observed (8), but the effects of magnesium depletion were not noted in these patients.",8492347_4,1
3535,(3,59,61,"Symptomatic hypokalemia has been reported in such patients (3-7) and in one case hypocalcemia was observed (8), but the effects of magnesium depletion were not noted in these patients.",8492347_4,0
14419,nephrotoxicity,22,36,Ciprofloxacin-induced nephrotoxicity in patients with cancer.,8494478_0,1
14420,Nephrotoxicity,0,14,Nephrotoxicity associated with ciprofloxacin is uncommon.,8494478_1,1
7161,acute renal failure,40,59,Five patients with cancer who developed acute renal failure that followed treatment with ciprofloxacin are described and an additional 15 cases reported in the literature are reviewed.,8494478_2,1
3536,creatinine,30,40,"Other than elevation of serum creatinine levels, characteristic clinical manifestations and abnormal laboratory findings are not frequently present.",8494478_3,0
14421,clinical manifestations,64,87,"Other than elevation of serum creatinine levels, characteristic clinical manifestations and abnormal laboratory findings are not frequently present.",8494478_3,1
14422,laboratory findings,101,120,"Other than elevation of serum creatinine levels, characteristic clinical manifestations and abnormal laboratory findings are not frequently present.",8494478_3,1
7162,interstitial nephritis,9,31,Allergic interstitial nephritis is believed to be the underlying pathological-process.,8494478_4,1
14423,pathological-process,65,85,Allergic interstitial nephritis is believed to be the underlying pathological-process.,8494478_4,1
7163,acute renal failure,155,174,An improvement in renal function that followed the discontinuation of the offending antibiotic supports the presumptive diagnosis of ciprofloxacin-induced acute renal failure.,8494478_6,1
14426,renal function,18,32,An improvement in renal function that followed the discontinuation of the offending antibiotic supports the presumptive diagnosis of ciprofloxacin-induced acute renal failure.,8494478_6,1
14428,Venous complications,0,20,Venous complications of midazolam versus diazepam.,8514073_0,1
14429,venous complications,43,63,"Although some studies have suggested fewer venous complications are associated with midazolam than with diazepam for endoscopic procedures, this variable has not been well documented.",8514073_1,1
14432,venous complications,44,64,We prospectively evaluated the incidence of venous complications after intravenous injection of diazepam or midazolam in 122 consecutive patients undergoing colonoscopy and esophagogastroduodenoscopy.,8514073_2,1
14434,esophagogastroduodenoscopy,173,199,We prospectively evaluated the incidence of venous complications after intravenous injection of diazepam or midazolam in 122 consecutive patients undergoing colonoscopy and esophagogastroduodenoscopy.,8514073_2,1
14435,venous complications,9,29,"Overall, venous complications were more frequent with diazepam (22 of 62 patients) than with midazolam (4 of 60 patients) (p < 0.001).",8514073_3,1
3537,(1,105,107,"A palpable venous cord was present in 23% (14 of 62) of patients in the diazepam group, compared with 2% (1 of 60 patients) in the midazolam group (p < 0.002).",8514073_4,0
14436,venous cord,11,22,"A palpable venous cord was present in 23% (14 of 62) of patients in the diazepam group, compared with 2% (1 of 60 patients) in the midazolam group (p < 0.002).",8514073_4,1
14443,venous complications,180,200,"Smoking, nonsteroidal anti-inflammatory drug use, intravenous catheter site, dwell time of the needle, alcohol use, and pain during the injection had no effect on the incidence of venous complications.",8514073_7,1
7164,visual hallucinations,26,47,Clarithromycin-associated visual hallucinations in a patient with chronic renal failure on continuous ambulatory peritoneal dialysis.,8546130_0,1
7165,chronic renal failure,66,87,Clarithromycin-associated visual hallucinations in a patient with chronic renal failure on continuous ambulatory peritoneal dialysis.,8546130_0,1
7167,chronic renal failure,42,63,Visual hallucinations are a rare event in chronic renal failure and not related to uremia per se.,8546130_1,1
7166,Visual hallucinations,0,21,Visual hallucinations are a rare event in chronic renal failure and not related to uremia per se.,8546130_1,1
3538,clarithromycin,114,128,"Unreported in the literature is visual hallucinations occurring in association with the new macrolide antibiotic, clarithromycin.",8546130_2,0
14444,macrolide antibiotic,92,112,"Unreported in the literature is visual hallucinations occurring in association with the new macrolide antibiotic, clarithromycin.",8546130_2,0
7168,visual hallucinations,32,53,"Unreported in the literature is visual hallucinations occurring in association with the new macrolide antibiotic, clarithromycin.",8546130_2,1
7169,end-stage renal disease,42,65,We describe such a case in a patient with end-stage renal disease (ESRD) maintained on continuous ambulatory peritoneal dialysis (CAPD).,8546130_3,1
7170,ESRD,67,71,We describe such a case in a patient with end-stage renal disease (ESRD) maintained on continuous ambulatory peritoneal dialysis (CAPD).,8546130_3,1
14447,aluminum intoxication,145,166,"The combination of a relatively high dose of clarithromycin in face of chronic renal failure in a functionally anephric patient, with underlying aluminum intoxication, may have facilitated the appearance of this neurotoxic side effect.",8546130_4,1
14445,high dose,32,41,"The combination of a relatively high dose of clarithromycin in face of chronic renal failure in a functionally anephric patient, with underlying aluminum intoxication, may have facilitated the appearance of this neurotoxic side effect.",8546130_4,0
3539,clarithromycin,45,59,"The combination of a relatively high dose of clarithromycin in face of chronic renal failure in a functionally anephric patient, with underlying aluminum intoxication, may have facilitated the appearance of this neurotoxic side effect.",8546130_4,0
7172,side effect,223,234,"The combination of a relatively high dose of clarithromycin in face of chronic renal failure in a functionally anephric patient, with underlying aluminum intoxication, may have facilitated the appearance of this neurotoxic side effect.",8546130_4,1
7171,chronic renal failure,71,92,"The combination of a relatively high dose of clarithromycin in face of chronic renal failure in a functionally anephric patient, with underlying aluminum intoxication, may have facilitated the appearance of this neurotoxic side effect.",8546130_4,1
7174,ESRD,204,208,"It is important to understand the pharmacokinetics of medications in face of chronic renal failure, the possibility of drug interactions, and how these factors should help guide medication therapy in the ESRD patient.",8546130_5,1
7173,chronic renal failure,77,98,"It is important to understand the pharmacokinetics of medications in face of chronic renal failure, the possibility of drug interactions, and how these factors should help guide medication therapy in the ESRD patient.",8546130_5,1
14449,peroxisomes,11,22,Changes in peroxisomes in preneoplastic liver and hepatoma of mice induced by alpha-benzene hexachloride.,85485_0,0
3540,hexachloride,92,104,Changes in peroxisomes in preneoplastic liver and hepatoma of mice induced by alpha-benzene hexachloride.,85485_0,0
7175,preneoplastic,26,39,Changes in peroxisomes in preneoplastic liver and hepatoma of mice induced by alpha-benzene hexachloride.,85485_0,1
3541,hexachloride,111,123,Peroxisomes in hepatomas and hyperplastic preneoplastic liver lesions induced in mice by 500 ppm alpha-benzene hexachloride were examined histochemically and electron microscopically.,85485_1,0
14450,Peroxisomes,0,11,Peroxisomes in hepatomas and hyperplastic preneoplastic liver lesions induced in mice by 500 ppm alpha-benzene hexachloride were examined histochemically and electron microscopically.,85485_1,0
14451,preneoplastic liver lesions,42,69,Peroxisomes in hepatomas and hyperplastic preneoplastic liver lesions induced in mice by 500 ppm alpha-benzene hexachloride were examined histochemically and electron microscopically.,85485_1,1
7176,tumor cells,119,130,"Although most of the hepatomas were well-differentiated tumors and contained a considerable number of peroxisomes, the tumor cells did not respond to ethyl-alpha-p-chlorophenoxyisobutyrate with proliferation of peroxisomes.",85485_2,1
14454,ethyl-alpha-p-chlorophenoxyisobutyrate,150,188,"Although most of the hepatomas were well-differentiated tumors and contained a considerable number of peroxisomes, the tumor cells did not respond to ethyl-alpha-p-chlorophenoxyisobutyrate with proliferation of peroxisomes.",85485_2,0
14457,hyperplastic nodules,40,60,"At the 16th week of carcinogen feeding, hyperplastic nodules appeared and advanced to further stages.",85485_3,1
14464,ethyl-alpha-p-chlorophenoxyisobutyrate,99,137,No abnormal matrical inclusions of peroxisomes were formed in the cells of hyperplastic nodules by ethyl-alpha-p-chlorophenoxyisobutyrate unlike in the case of rats.,85485_7,0
14463,hyperplastic nodules,75,95,No abnormal matrical inclusions of peroxisomes were formed in the cells of hyperplastic nodules by ethyl-alpha-p-chlorophenoxyisobutyrate unlike in the case of rats.,85485_7,1
3542,vinorelbine,18,29,Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma.,8558192_0,0
7177,squamous cell,44,57,Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma.,8558192_0,1
14469,VNB,180,183,European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group.PURPOSE: To evaluate the response rate and toxic effects of vinorelbine (VNB) administered as a single agent in metastatic squamous cell esophageal carcinoma. PATIENTS AND METHODS: Forty-six eligible patients with measurable lesions were included and were stratified according to previous chemotherapy.,8558192_1,0
14468,toxic effects,150,163,European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group.PURPOSE: To evaluate the response rate and toxic effects of vinorelbine (VNB) administered as a single agent in metastatic squamous cell esophageal carcinoma. PATIENTS AND METHODS: Forty-six eligible patients with measurable lesions were included and were stratified according to previous chemotherapy.,8558192_1,0
3543,vinorelbine,167,178,European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group.PURPOSE: To evaluate the response rate and toxic effects of vinorelbine (VNB) administered as a single agent in metastatic squamous cell esophageal carcinoma. PATIENTS AND METHODS: Forty-six eligible patients with measurable lesions were included and were stratified according to previous chemotherapy.,8558192_1,0
14466,Cancer Gastrointestinal Treat Cancer,52,88,European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group.PURPOSE: To evaluate the response rate and toxic effects of vinorelbine (VNB) administered as a single agent in metastatic squamous cell esophageal carcinoma. PATIENTS AND METHODS: Forty-six eligible patients with measurable lesions were included and were stratified according to previous chemotherapy.,8558192_1,1
7178,squamous cell,230,243,European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group.PURPOSE: To evaluate the response rate and toxic effects of vinorelbine (VNB) administered as a single agent in metastatic squamous cell esophageal carcinoma. PATIENTS AND METHODS: Forty-six eligible patients with measurable lesions were included and were stratified according to previous chemotherapy.,8558192_1,1
14470,single agent,203,215,European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group.PURPOSE: To evaluate the response rate and toxic effects of vinorelbine (VNB) administered as a single agent in metastatic squamous cell esophageal carcinoma. PATIENTS AND METHODS: Forty-six eligible patients with measurable lesions were included and were stratified according to previous chemotherapy.,8558192_1,0
7179,grade 3,24,31,At least one episode of grade 3 or 4 granulocytopenia was seen in 59% of patients.,8558192_10,1
7180,grade 2,2,9,"A grade 2 or 3 infection occurred in 16% of patients, but no toxic deaths occurred.",8558192_11,1
14481,toxic deaths,61,73,"A grade 2 or 3 infection occurred in 16% of patients, but no toxic deaths occurred.",8558192_11,1
7181,side effects,6,18,"Other side effects were rare, and peripheral neurotoxicity has been minor (26% grade 1).",8558192_12,1
7183,grade 1,79,86,"Other side effects were rare, and peripheral neurotoxicity has been minor (26% grade 1).",8558192_12,1
7182,neurotoxicity,45,58,"Other side effects were rare, and peripheral neurotoxicity has been minor (26% grade 1).",8558192_12,1
14482,VNB,37,40,CONCLUSION: These data indicate that VNB is an active agent in metastatic esophageal squamous cell carcinoma.,8558192_13,0
3544,active agent,47,59,CONCLUSION: These data indicate that VNB is an active agent in metastatic esophageal squamous cell carcinoma.,8558192_13,0
7184,squamous cell carcinoma,85,108,CONCLUSION: These data indicate that VNB is an active agent in metastatic esophageal squamous cell carcinoma.,8558192_13,1
14484,VNB,78,81,"Given its excellent tolerance profile and low toxicity, further evaluation of VNB in combination therapy is warranted.",8558192_14,0
14474,25-mg/m2,33,41,VNB was administered weekly as a 25-mg/m2 short intravenous (i.v.) infusion.,8558192_3,0
14473,VNB,0,3,VNB was administered weekly as a 25-mg/m2 short intravenous (i.v.) infusion.,8558192_3,0
14475,partial response,72,88,"RESULTS: Six of 30 patients (20%) without prior chemotherapy achieved a partial response (PR) (95% confidence interval [CI], 8% to 39%).",8558192_4,1
14477,DI,27,29,The median dose-intensity (DI) was 20 mg/m2/wk.,8558192_8,0
14479,grade 4,49,56,VNB was well tolerated and zero instances of WHO grade 4 nonhematologic toxicity occurred.,8558192_9,1
14478,VNB,0,3,VNB was well tolerated and zero instances of WHO grade 4 nonhematologic toxicity occurred.,8558192_9,0
14480,nonhematologic,57,71,VNB was well tolerated and zero instances of WHO grade 4 nonhematologic toxicity occurred.,8558192_9,1
7185,nervous system,32,46,Contribution of the sympathetic nervous system to salt-sensitivity in lifetime captopril-treated spontaneously hypertensive rats.,8586822_0,1
14486,salt-sensitivity,50,66,Contribution of the sympathetic nervous system to salt-sensitivity in lifetime captopril-treated spontaneously hypertensive rats.,8586822_0,1
7186,nervous system,125,139,"OBJECTIVE: To test the hypothesis that, in lifetime captopril-treated spontaneously hypertensive rats (SHR), the sympathetic nervous system contributes importantly to the hypertensive effect of dietary sodium chloride supplementation.",8586822_1,1
3545,dietary sodium chloride,194,217,"OBJECTIVE: To test the hypothesis that, in lifetime captopril-treated spontaneously hypertensive rats (SHR), the sympathetic nervous system contributes importantly to the hypertensive effect of dietary sodium chloride supplementation.",8586822_1,0
3546,sodium chloride,131,146,METHODS: Male SHR (aged 6 weeks) that had been treated from conception onward with either captopril or vehicle remained on a basal sodium chloride diet or were fed a high sodium chloride diet.,8586822_2,0
3547,sodium chloride,171,186,METHODS: Male SHR (aged 6 weeks) that had been treated from conception onward with either captopril or vehicle remained on a basal sodium chloride diet or were fed a high sodium chloride diet.,8586822_2,0
14489,ganglionic,42,52,"After 2 weeks, the rats were subjected to ganglionic blockade and 2 days later, an infusion of clonidine.",8586822_3,1
14490,mean arterial pressure,60,82,RESULTS: Lifetime captopril treatment significantly lowered mean arterial pressure in both groups.,8586822_4,1
3548,hexamethonium,47,60,Intravenous infusion of the ganglionic blocker hexamethonium resulted in a rapid decline in MAP that eliminated the dietary sodium chloride-induced increase in MAP in both groups.,8586822_5,0
3549,dietary sodium,116,130,Intravenous infusion of the ganglionic blocker hexamethonium resulted in a rapid decline in MAP that eliminated the dietary sodium chloride-induced increase in MAP in both groups.,8586822_5,0
14492,ganglionic,28,38,Intravenous infusion of the ganglionic blocker hexamethonium resulted in a rapid decline in MAP that eliminated the dietary sodium chloride-induced increase in MAP in both groups.,8586822_5,0
3550,sodium chloride,199,214,Infusion of the central nervous system alpha2-adrenergic receptor agonist clonidine also resulted in a greater reduction in MAP in both groups of SHR that were fed the high (compared with the basal) sodium chloride diet.,8586822_6,0
7187,nervous system,81,95,"CONCLUSIONS: In both lifetime captopril-treated and control SHR, the sympathetic nervous system contributes to the pressor effects of a high sodium chloride diet.",8586822_7,1
3551,sodium chloride,141,156,"CONCLUSIONS: In both lifetime captopril-treated and control SHR, the sympathetic nervous system contributes to the pressor effects of a high sodium chloride diet.",8586822_7,0
14495,aponidine hydrochloride ophthalmic solution,35,78,Evaluation of adverse reactions of aponidine hydrochloride ophthalmic solution.,8590259_0,0
7188,adverse reactions,14,31,Evaluation of adverse reactions of aponidine hydrochloride ophthalmic solution.,8590259_0,1
14498,apraclonidine,124,137,We prospectively evaluated the adverse reactions of apraclonidine in 20 normal volunteers by instilling a single drop of 1% apraclonidine in their right eyes.,8590259_1,0
7189,adverse reactions,31,48,We prospectively evaluated the adverse reactions of apraclonidine in 20 normal volunteers by instilling a single drop of 1% apraclonidine in their right eyes.,8590259_1,1
14496,apraclonidine,52,65,We prospectively evaluated the adverse reactions of apraclonidine in 20 normal volunteers by instilling a single drop of 1% apraclonidine in their right eyes.,8590259_1,0
14501,pupil diameter,104,118,"Examinations, including blood pressure, pulse rate, conjunctiva and cornea, intraocular pressure (IOP), pupil diameter, basal tear secretion and margin reflex distance of both upper and lower eyelids, were performed prior to entry and at 1, 3, 5 and 7 hours after instillation.",8590259_2,1
7191,intraocular,76,87,"Examinations, including blood pressure, pulse rate, conjunctiva and cornea, intraocular pressure (IOP), pupil diameter, basal tear secretion and margin reflex distance of both upper and lower eyelids, were performed prior to entry and at 1, 3, 5 and 7 hours after instillation.",8590259_2,1
7190,blood pressure,24,38,"Examinations, including blood pressure, pulse rate, conjunctiva and cornea, intraocular pressure (IOP), pupil diameter, basal tear secretion and margin reflex distance of both upper and lower eyelids, were performed prior to entry and at 1, 3, 5 and 7 hours after instillation.",8590259_2,1
14502,basal tear secretion,120,140,"Examinations, including blood pressure, pulse rate, conjunctiva and cornea, intraocular pressure (IOP), pupil diameter, basal tear secretion and margin reflex distance of both upper and lower eyelids, were performed prior to entry and at 1, 3, 5 and 7 hours after instillation.",8590259_2,1
14503,apraclonidine,224,237,The ocular hypotensive effects were statistically significant for apraclonidine-treated eyes throughout the study and also statistically significant for contralateral eyes from three hours after topical administration of 1% apraclonidine.,8590259_3,0
7192,blood pressure,22,36,"Decreases in systolic blood pressure were statistically, but not clinically, significant.",8590259_4,1
7193,blood pressure,36,50,"No significant changes in diastolic blood pressure, pulse rate and basal tear secretion were noted.",8590259_5,1
14505,basal tear secretion,67,87,"No significant changes in diastolic blood pressure, pulse rate and basal tear secretion were noted.",8590259_5,1
14506,Upper lid retraction,0,20,Upper lid retraction was frequently noted.,8590259_7,1
7195,corneal abrasion,195,211,"While the elevations of the upper lid margin in most subjects were not more than 2 mm and did not cause noticeable change in appearance, one subject suffered from mechanical entropion and marked corneal abrasion 3 hours after instillation of the medication.",8590259_8,1
7194,entropion,174,183,"While the elevations of the upper lid margin in most subjects were not more than 2 mm and did not cause noticeable change in appearance, one subject suffered from mechanical entropion and marked corneal abrasion 3 hours after instillation of the medication.",8590259_8,1
3552,Thiopentone,0,11,Thiopentone pretreatment for propofol injection pain in ambulatory patients.,8595686_0,0
3559,thiopentone,120,131,We conclude that lidocaine reduces the incidence and severity of propofol injection pain in ambulatory patients whereas thiopentone only reduces its severity.,8595686_10,0
3553,propofol,135,143,"In a randomized, double-blind trial, 90 women were allocated to receive one of three treatments prior to induction of anaesthesia with propofol.",8595686_2,0
14512,Group T,89,96,"Patients in Group C received 2 ml normal saline, Group L, 2 ml, lidocaine 2% (40 mg) and Group T, 2 ml thiopentone 2.5% (50 mg).",8595686_3,0
3554,normal saline,34,47,"Patients in Group C received 2 ml normal saline, Group L, 2 ml, lidocaine 2% (40 mg) and Group T, 2 ml thiopentone 2.5% (50 mg).",8595686_3,0
3555,thiopentone,103,114,"Patients in Group C received 2 ml normal saline, Group L, 2 ml, lidocaine 2% (40 mg) and Group T, 2 ml thiopentone 2.5% (50 mg).",8595686_3,0
14513,Venous discomfort,0,17,Venous discomfort was assessed with a visual analogue scale (VAS) 5-15 sec after commencing propofol administration using an infusion pump (rate 1000 micrograms.kg-1.min-1).,8595686_4,1
14515,infusion pump,125,138,Venous discomfort was assessed with a visual analogue scale (VAS) 5-15 sec after commencing propofol administration using an infusion pump (rate 1000 micrograms.kg-1.min-1).,8595686_4,0
14516,micrograms.kg-1.min-1,150,171,Venous discomfort was assessed with a visual analogue scale (VAS) 5-15 sec after commencing propofol administration using an infusion pump (rate 1000 micrograms.kg-1.min-1).,8595686_4,0
3556,propofol,92,100,Venous discomfort was assessed with a visual analogue scale (VAS) 5-15 sec after commencing propofol administration using an infusion pump (rate 1000 micrograms.kg-1.min-1).,8595686_4,0
14521,Group C,164,171,Loss of consciousness occurred in 60-90 sec. Visual analogue scores (mean +/- SD) during induction were lower in Groups L (3.3 +/- 2.5) and T (4.1 +/- 2.7) than in Group C (5.6 +/- 2.3); P = 0.0031.,8595686_5,0
7196,Loss of consciousness,0,21,Loss of consciousness occurred in 60-90 sec. Visual analogue scores (mean +/- SD) during induction were lower in Groups L (3.3 +/- 2.5) and T (4.1 +/- 2.7) than in Group C (5.6 +/- 2.3); P = 0.0031.,8595686_5,1
14523,venous discomfort,17,34,The incidence of venous discomfort was lower in Group L (76.6%; P < 0.05) than in Group C (100%) but not different from Group T (90%).,8595686_6,1
14524,Group C,82,89,The incidence of venous discomfort was lower in Group L (76.6%; P < 0.05) than in Group C (100%) but not different from Group T (90%).,8595686_6,0
14525,Group T,120,127,The incidence of venous discomfort was lower in Group L (76.6%; P < 0.05) than in Group C (100%) but not different from Group T (90%).,8595686_6,0
3557,(r,108,110,The VAS scores for recall of pain in the recovery room were correlated with the VAS scores during induction (r = 0.7045; P < 0.0001).,8595686_7,0
3558,propofol,57,65,"Assessing their overall satisfaction, 89.7% would choose propofol anaesthesia again.",8595686_9,0
14534,droperidol,27,37,Angioedema associated with droperidol administration.,8599504_0,0
14536,localized edema,90,105,"Angioedema, also known as angioneurotic edema or Quincke's disease, is a well-demarcated, localized edema involving the subcutaneous tissues that may cause upper-airway obstruction.",8599504_1,1
14535,Quincke's disease,49,66,"Angioedema, also known as angioneurotic edema or Quincke's disease, is a well-demarcated, localized edema involving the subcutaneous tissues that may cause upper-airway obstruction.",8599504_1,1
14537,subcutaneous tissues,120,140,"Angioedema, also known as angioneurotic edema or Quincke's disease, is a well-demarcated, localized edema involving the subcutaneous tissues that may cause upper-airway obstruction.",8599504_1,1
14538,upper-airway obstruction,156,180,"Angioedema, also known as angioneurotic edema or Quincke's disease, is a well-demarcated, localized edema involving the subcutaneous tissues that may cause upper-airway obstruction.",8599504_1,1
7197,angioneurotic edema,26,45,"Angioedema, also known as angioneurotic edema or Quincke's disease, is a well-demarcated, localized edema involving the subcutaneous tissues that may cause upper-airway obstruction.",8599504_1,1
14539,tongue swelling,124,139,We report the case of a previously healthy 19-year-old man with no known drug allergies in whom angioedema with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of droperidol.,8599504_2,1
14541,droperidol,228,238,We report the case of a previously healthy 19-year-old man with no known drug allergies in whom angioedema with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of droperidol.,8599504_2,0
7198,drug allergies,73,87,We report the case of a previously healthy 19-year-old man with no known drug allergies in whom angioedema with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of droperidol.,8599504_2,1
14542,malignant bone tumor,42,62,Late cardiotoxicity after treatment for a malignant bone tumor.,8600333_0,1
7199,cardiotoxicity,5,19,Late cardiotoxicity after treatment for a malignant bone tumor.,8600333_0,1
14544,malignant bone tumors,56,77,"Cardiac function was assessed in long-term survivors of malignant bone tumors who were treated according to Rosen's T5 or T10 protocol, both including doxorubicin.",8600333_1,1
14543,Cardiac function,0,16,"Cardiac function was assessed in long-term survivors of malignant bone tumors who were treated according to Rosen's T5 or T10 protocol, both including doxorubicin.",8600333_1,1
3560,T10,122,125,"Cardiac function was assessed in long-term survivors of malignant bone tumors who were treated according to Rosen's T5 or T10 protocol, both including doxorubicin.",8600333_1,0
14545,Rosen's T5,108,118,"Cardiac function was assessed in long-term survivors of malignant bone tumors who were treated according to Rosen's T5 or T10 protocol, both including doxorubicin.",8600333_1,0
14562,Life-long cardiac follow-up,0,27,Life-long cardiac follow-up in these patients is warranted.,8600333_10,1
14563,heart rate,38,48,The results of our study suggest that heart rate variability and LVPW index could be sensitive indicators for cardiotoxicity.,8600333_11,1
7203,cardiotoxicity,110,124,The results of our study suggest that heart rate variability and LVPW index could be sensitive indicators for cardiotoxicity.,8600333_11,1
14546,mg/m2,45,50,Cumulative doses of doxorubicin were 225-550 mg/m2 (median dose 360).,8600333_3,0
3561,radionuclide,152,164,"The evaluation consisted of a history, physical examination, electrocardiogram (ECG), signal averaged ECG, 24-hour ambulatory ECG, echocardiography and radionuclide angiography.",8600333_4,0
7201,left ventricular,167,183,"Eighteen of 31 (58%) patients showed cardiac toxicity, defined as having one or more of the following abnormalities: late potentials, complex ventricular arrhythmias, left ventricular dilation, decreased shortening fraction, or decreased ejection fraction.",8600333_5,1
14551,complex ventricular arrhythmias,134,165,"Eighteen of 31 (58%) patients showed cardiac toxicity, defined as having one or more of the following abnormalities: late potentials, complex ventricular arrhythmias, left ventricular dilation, decreased shortening fraction, or decreased ejection fraction.",8600333_5,1
14553,ejection fraction,238,255,"Eighteen of 31 (58%) patients showed cardiac toxicity, defined as having one or more of the following abnormalities: late potentials, complex ventricular arrhythmias, left ventricular dilation, decreased shortening fraction, or decreased ejection fraction.",8600333_5,1
7200,cardiac toxicity,37,53,"Eighteen of 31 (58%) patients showed cardiac toxicity, defined as having one or more of the following abnormalities: late potentials, complex ventricular arrhythmias, left ventricular dilation, decreased shortening fraction, or decreased ejection fraction.",8600333_5,1
14554,cardiac abnormalities,17,38,The incidence of cardiac abnormalities increased with length of follow-up (P< or = .05).,8600333_6,1
14555,length of follow-up,54,73,The incidence of cardiac abnormalities increased with length of follow-up (P< or = .05).,8600333_6,1
14557,heart rate,107,117,"No correlation could be demonstrated between cumulative dose of doxorubicin and cardiac status, except for heart rate variability.",8600333_7,1
14559,left ventricular posterior wall thickness,40,81,"When adjusted to body surface area, the left ventricular posterior wall thickness (LVPW index) was decreased in all patients.",8600333_8,1
7202,cardiotoxicity,37,51,"The incidence of doxorubicin-induced cardiotoxicity is high and increases with follow-up, irrespective of cumulative dose.",8600333_9,1
7204,blood pressure,6,20,Acute blood pressure elevations with caffeine in men with borderline systemic hypertension.,8607407_0,1
14565,borderline systemic hypertension,58,90,Acute blood pressure elevations with caffeine in men with borderline systemic hypertension.,8607407_0,1
14588,BP,102,104,"Thus, in borderline hypertensive men, exaggerated responses to caffeine were: selective for diastolic BP, consistent with greater vasoconstriction, replicated in 2 protocols, and representative of nearly all borderline hypertensives.",8607407_10,0
7206,disease progression,145,164,"We suspect that the potential for caffeine to stabilize high resistance states in susceptible persons suggests that its use may facilitate their disease progression, as well as hinder accurate diagnosis and treatment.",8607407_11,1
7205,blood pressure,75,89,Borderline hypertensive men (n = 24) were selected with screening systolic blood pressure (BP) of 140 to 160 mm Hg and/or diastolic BP 90 to 99 mm Hg.,8607407_3,1
14572,parental history,39,55,Low-risk controls (n = 24) reported no parental history of hypertension and had screening BP < 130/85 mm Hg.,8607407_4,1
14581,systemic vascular resistance (+,213,244,"Caffeine-induced changes in diastolic BP were 2 to 3 times larger in borderline subjects than in controls (+8.4 vs +3.8 mm Hg, p < 0.0001), and were attributable to larger changes in impedance-derived measures of systemic vascular resistance (+135 vs +45 dynes.s.cm-5, p < 0.004).",8607407_6,1
14579,(+,106,108,"Caffeine-induced changes in diastolic BP were 2 to 3 times larger in borderline subjects than in controls (+8.4 vs +3.8 mm Hg, p < 0.0001), and were attributable to larger changes in impedance-derived measures of systemic vascular resistance (+135 vs +45 dynes.s.cm-5, p < 0.004).",8607407_6,0
14584,resting predrug,80,95,"Consequently, whereas all participants exhibited normotensive levels during the resting predrug baseline, 33% of borderline subjects achieved hypertensive BP levels after caffeine ingestion.",8607407_9,0
7207,cognitive impairment,63,83,Absence of effect of sertraline on time-based sensitization of cognitive impairment with haloperidol.,8617710_0,1
14594,psychomotor function,148,168,"This double-blind, randomized, placebo-controlled study evaluated the effects of haloperidol alone and haloperidol plus sertraline on cognitive and psychomotor function in 24 healthy male subjects.",8617710_1,1
7210,side effect,4,15,The side effect profiles of sertraline and of placebo were similar.,8617710_10,1
7211,cognitive impairment,52,72,CONCLUSION: Haloperidol produced a clear profile of cognitive impairment that was not worsened by concomitant sertraline administration.,8617710_11,1
14597,sertraline dose,116,131,"From Days 9 to 25, subjects were randomly assigned to either sertraline (12 subjects) or placebo (12 subjects); the sertraline dose was titrated from 50 to 200 mg/day from Days 9 to 16, and remained at 200 mg/day for the final 10 days of the drug administration period.",8617710_3,0
14599,Cognitive function,0,18,"Cognitive function testing was performed before dosing and over a 24-hour period after dosing on Days 1, 2, and 25.",8617710_4,1
14602,cognitive function,23,41,RESULTS: Impairment of cognitive function was observed 6 to 8 hours after administration of haloperidol on Day 2 but was not evident 23 hours after dosing.,8617710_5,1
14603,single-dose,5,16,"When single-dose haloperidol was given again 25 days later, greater impairment with earlier onset was noted in several tests in both treatment groups, suggesting enhancement of this effect.",8617710_6,0
3562,(2,15,17,Three subjects (2 on sertraline and 1 on placebo) withdrew from the study because of side effects.,8617710_8,0
7208,side effects,85,97,Three subjects (2 on sertraline and 1 on placebo) withdrew from the study because of side effects.,8617710_8,1
7209,side effects,36,48,Ten subjects in each group reported side effects related to treatment.,8617710_9,1
14605,Persistent paralysis,0,20,Persistent paralysis after prolonged use of atracurium in the absence of corticosteroids.,8638206_0,1
3563,atracurium,44,54,Persistent paralysis after prolonged use of atracurium in the absence of corticosteroids.,8638206_0,0
3564,Neuromuscular blocking agents,0,29,Neuromuscular blocking agents (NMBAs) are often used for patients requiring prolonged mechanical ventilation.,8638206_1,0
14606,NMBAs,31,36,Neuromuscular blocking agents (NMBAs) are often used for patients requiring prolonged mechanical ventilation.,8638206_1,0
14608,NMBAs,116,121,"Reports of persistent paralysis after the discontinuance of these drugs have most often involved aminosteroid-based NMBAs such as vecuronium bromide, especially when used in conjunction with corticosteroids.",8638206_2,0
3565,vecuronium bromide,130,148,"Reports of persistent paralysis after the discontinuance of these drugs have most often involved aminosteroid-based NMBAs such as vecuronium bromide, especially when used in conjunction with corticosteroids.",8638206_2,0
3566,Atracurium besylate,0,19,"Atracurium besylate, a short-acting benzylisoquinolinium NMBA that is eliminated independently of renal or hepatic function, has also been associated with persistent paralysis, but only when used with corticosteroids.",8638206_3,0
14609,short-acting benzylisoquinolinium NMBA,23,61,"Atracurium besylate, a short-acting benzylisoquinolinium NMBA that is eliminated independently of renal or hepatic function, has also been associated with persistent paralysis, but only when used with corticosteroids.",8638206_3,0
14610,hepatic function,107,123,"Atracurium besylate, a short-acting benzylisoquinolinium NMBA that is eliminated independently of renal or hepatic function, has also been associated with persistent paralysis, but only when used with corticosteroids.",8638206_3,1
3567,sex hormones,102,114,Coexistence of cerebral venous sinus and internal carotid artery thrombosis associated with exogenous sex hormones.,8638876_0,0
7212,internal carotid artery thrombosis,41,75,Coexistence of cerebral venous sinus and internal carotid artery thrombosis associated with exogenous sex hormones.,8638876_0,1
14613,cerebral venous sinus,15,36,Coexistence of cerebral venous sinus and internal carotid artery thrombosis associated with exogenous sex hormones.,8638876_0,1
7213,nausea and vomiting,61,80,"A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.",8638876_2,1
7214,hemiparesis,87,98,"A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and estradiol.",8638876_2,1
7215,Diabetes mellitus,0,17,Diabetes mellitus (DM) was found during admission.,8638876_3,1
14618,hemorrhagic infarct,29,48,Computed tomography showed a hemorrhagic infarct in the right frontal lobe and increased density in the superior sagittal sinus (SSS).,8638876_4,1
7217,sagittal sinus,113,127,Computed tomography showed a hemorrhagic infarct in the right frontal lobe and increased density in the superior sagittal sinus (SSS).,8638876_4,1
7216,frontal lobe,62,74,Computed tomography showed a hemorrhagic infarct in the right frontal lobe and increased density in the superior sagittal sinus (SSS).,8638876_4,1
14620,ICA,78,81,Left carotid angiography found occlusion of the left internal carotid artery (ICA).,8638876_5,1
14619,Left carotid,0,12,Left carotid angiography found occlusion of the left internal carotid artery (ICA).,8638876_5,1
7218,internal carotid artery,53,76,Left carotid angiography found occlusion of the left internal carotid artery (ICA).,8638876_5,1
7219,sagittal sinus,61,75,"Right carotid angiograms failed to show the SSS and inferior sagittal sinus, suggestive of venous sinus thrombosis.",8638876_6,1
7220,venous sinus thrombosis,91,114,"Right carotid angiograms failed to show the SSS and inferior sagittal sinus, suggestive of venous sinus thrombosis.",8638876_6,1
14622,venous sinus occlusion,43,65,Coexistence of the cerebral artery and the venous sinus occlusion has been described infrequently.,8638876_7,1
7221,cerebral artery,19,34,Coexistence of the cerebral artery and the venous sinus occlusion has been described infrequently.,8638876_7,1
14625,venous sinus,212,224,"In this case, the authors postulate that the use of estradiol and progesterone and the underlying DM increased vascular thrombogenicity, which provided a common denominator for thrombosis of both the ICA and the venous sinus.",8638876_8,1
14623,vascular thrombogenicity,111,135,"In this case, the authors postulate that the use of estradiol and progesterone and the underlying DM increased vascular thrombogenicity, which provided a common denominator for thrombosis of both the ICA and the venous sinus.",8638876_8,1
14624,ICA,200,203,"In this case, the authors postulate that the use of estradiol and progesterone and the underlying DM increased vascular thrombogenicity, which provided a common denominator for thrombosis of both the ICA and the venous sinus.",8638876_8,1
7222,non-small cell lung cancer,36,62,Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial.,8643966_0,1
3568,paclitaxel,68,78,Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial.,8643966_0,0
3570,Taxol,12,17,"Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antineoplastic activity against different tumor types, notably ovarian and breast carcinoma.",8643966_1,0
3569,Paclitaxel,0,10,"Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antineoplastic activity against different tumor types, notably ovarian and breast carcinoma.",8643966_1,0
14629,tumor types,135,146,"Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antineoplastic activity against different tumor types, notably ovarian and breast carcinoma.",8643966_1,1
7223,breast carcinoma,168,184,"Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antineoplastic activity against different tumor types, notably ovarian and breast carcinoma.",8643966_1,1
7228,Grade 1,0,7,Grade 1 or 2 polyneuropathy affected 56% of patients while only one (2%) experienced severe polyneuropathy.,8643966_10,1
7229,polyneuropathy,13,27,Grade 1 or 2 polyneuropathy affected 56% of patients while only one (2%) experienced severe polyneuropathy.,8643966_10,1
7230,polyneuropathy,92,106,Grade 1 or 2 polyneuropathy affected 56% of patients while only one (2%) experienced severe polyneuropathy.,8643966_10,1
3575,(2,68,70,Grade 1 or 2 polyneuropathy affected 56% of patients while only one (2%) experienced severe polyneuropathy.,8643966_10,0
14641,myalgia/arthralgia,24,42,"Similarly, grade 1 or 2 myalgia/arthralgia was observed in 63.2% of patients, but only 14.3% experienced grade 3 or 4.",8643966_11,1
7231,grade 1,11,18,"Similarly, grade 1 or 2 myalgia/arthralgia was observed in 63.2% of patients, but only 14.3% experienced grade 3 or 4.",8643966_11,1
7232,grade 3,105,112,"Similarly, grade 1 or 2 myalgia/arthralgia was observed in 63.2% of patients, but only 14.3% experienced grade 3 or 4.",8643966_11,1
7235,grade 3,109,116,"Nausea and vomiting were infrequent, with 14% of patients experiencing grade 1 or 2 and only 2% experiencing grade 3 or 4.",8643966_12,1
7234,grade 1,71,78,"Nausea and vomiting were infrequent, with 14% of patients experiencing grade 1 or 2 and only 2% experiencing grade 3 or 4.",8643966_12,1
7233,Nausea and vomiting,0,19,"Nausea and vomiting were infrequent, with 14% of patients experiencing grade 1 or 2 and only 2% experiencing grade 3 or 4.",8643966_12,1
14644,nonhematologic,202,216,"Paclitaxel is thus an active single agent in this patient population, with a 3-hour infusion proving comparably effective to a 24-hour infusion and superior in terms of the incidence of hematologic and nonhematologic toxicity.",8643966_13,1
14642,active single agent,22,41,"Paclitaxel is thus an active single agent in this patient population, with a 3-hour infusion proving comparably effective to a 24-hour infusion and superior in terms of the incidence of hematologic and nonhematologic toxicity.",8643966_13,0
3576,Paclitaxel,0,10,"Paclitaxel is thus an active single agent in this patient population, with a 3-hour infusion proving comparably effective to a 24-hour infusion and superior in terms of the incidence of hematologic and nonhematologic toxicity.",8643966_13,0
14645,NSCLC,82,87,"Further phase II studies with paclitaxel combined with other drugs active against NSCLC are indicated, and phase III studies comparing paclitaxel with standard chemotherapy remain to be completed.",8643966_14,0
3577,paclitaxel,30,40,"Further phase II studies with paclitaxel combined with other drugs active against NSCLC are indicated, and phase III studies comparing paclitaxel with standard chemotherapy remain to be completed.",8643966_14,0
3578,paclitaxel,135,145,"Further phase II studies with paclitaxel combined with other drugs active against NSCLC are indicated, and phase III studies comparing paclitaxel with standard chemotherapy remain to be completed.",8643966_14,0
7224,non-small cell lung cancer,105,131,Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.,8643966_2,1
3571,paclitaxel,31,41,Two phase II trials of 24-hour paclitaxel infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%.,8643966_2,0
14633,grade 4,71,78,Leukopenia was dose limiting: as many as 62.5% of patients experienced grade 4 leukopenia.,8643966_3,1
3572,paclitaxel,54,64,We investigated the efficacy and toxicity of a 3-hour paclitaxel infusion in a phase II trial in patients with inoperable stage IIIB or IV NSCLC.,8643966_4,0
14637,mg/m2,15,20,Paclitaxel 225 mg/m2 was infused over 3 hours every 3 weeks with standard prophylactic premedication.,8643966_7,0
14638,prophylactic premedication,74,100,Paclitaxel 225 mg/m2 was infused over 3 hours every 3 weeks with standard prophylactic premedication.,8643966_7,0
3573,Paclitaxel,0,10,Paclitaxel 225 mg/m2 was infused over 3 hours every 3 weeks with standard prophylactic premedication.,8643966_7,0
14639,partial remission,52,69,"Of 50 patients evaluable for response, 12 (24%) had partial remission, 26 (52%) had no change, and 12 had disease progression (24%).",8643966_8,1
14640,no change,84,93,"Of 50 patients evaluable for response, 12 (24%) had partial remission, 26 (52%) had no change, and 12 had disease progression (24%).",8643966_8,1
7225,disease progression,106,125,"Of 50 patients evaluable for response, 12 (24%) had partial remission, 26 (52%) had no change, and 12 had disease progression (24%).",8643966_8,1
7227,grade 1,106,113,"Hematologic toxicities were mild: only one patient (2%) developed grade 3 or 4 neutropenia, while 29% had grade 1 or 2.",8643966_9,1
7226,grade 3,66,73,"Hematologic toxicities were mild: only one patient (2%) developed grade 3 or 4 neutropenia, while 29% had grade 1 or 2.",8643966_9,1
3574,(2,51,53,"Hematologic toxicities were mild: only one patient (2%) developed grade 3 or 4 neutropenia, while 29% had grade 1 or 2.",8643966_9,0
14650,head and neck cancers,74,95,A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.,8643971_0,1
3580,cisplatin,38,47,A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.,8643971_0,0
3579,paclitaxel,22,32,A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.,8643971_0,0
14651,head and neck carcinomas,38,62,Improved outcomes among patients with head and neck carcinomas require investigations of new drugs for induction therapy.,8643971_1,1
3581,new drugs,89,98,Improved outcomes among patients with head and neck carcinomas require investigations of new drugs for induction therapy.,8643971_1,0
3590,paclitaxel,5,15,"With paclitaxel doses of 200 mg/m2 and higher, granulocyte colony-stimulating factor 5 micrograms/kg/d is given (days 4 through 12).",8643971_10,0
14669,mg/m2,29,34,"With paclitaxel doses of 200 mg/m2 and higher, granulocyte colony-stimulating factor 5 micrograms/kg/d is given (days 4 through 12).",8643971_10,0
14670,granulocyte colony-stimulating factor 5,47,86,"With paclitaxel doses of 200 mg/m2 and higher, granulocyte colony-stimulating factor 5 micrograms/kg/d is given (days 4 through 12).",8643971_10,0
14671,partial response,105,121,"Of 18 patients evaluable for response, seven (39%) achieved a complete response and six (33%) achieved a partial response.",8643971_11,1
14672,no change,19,28,Three patients had no change and disease progressed in two.,8643971_12,1
14673,surgery/radiotherapy,42,62,Eleven responding patients had subsequent surgery/radiotherapy or radical radiotherapy.,8643971_14,1
14674,radical radiotherapy,66,86,Eleven responding patients had subsequent surgery/radiotherapy or radical radiotherapy.,8643971_14,1
14676,clinical complete,77,94,Two pathologic complete responses were observed in patients who had achieved clinical complete responses.,8643971_15,1
14675,pathologic complete responses,4,33,Two pathologic complete responses were observed in patients who had achieved clinical complete responses.,8643971_15,1
14678,grade 3 myalgia,101,116,"Alopecia, paresthesias, and arthralgias/myalgias have occurred frequently, but with one exception (a grade 3 myalgia) they have been grade 1 or 2.",8643971_16,1
7239,grade 1,133,140,"Alopecia, paresthesias, and arthralgias/myalgias have occurred frequently, but with one exception (a grade 3 myalgia) they have been grade 1 or 2.",8643971_16,1
14677,arthralgias/myalgias,28,48,"Alopecia, paresthesias, and arthralgias/myalgias have occurred frequently, but with one exception (a grade 3 myalgia) they have been grade 1 or 2.",8643971_16,1
7240,head and neck cancer,84,104,Paclitaxel/cisplatin is an effective first-line regimen for locoregionally advanced head and neck cancer and continued study is warranted.,8643971_18,1
14679,Paclitaxel/cisplatin,0,20,Paclitaxel/cisplatin is an effective first-line regimen for locoregionally advanced head and neck cancer and continued study is warranted.,8643971_18,0
3591,paclitaxel,53,63,Results thus far suggest no dose-response effect for paclitaxel doses above 200 mg/m2.,8643971_19,0
14682,mg/m2,80,85,Results thus far suggest no dose-response effect for paclitaxel doses above 200 mg/m2.,8643971_19,0
14654,paclitaxel/cisplatin,223,243,"Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients.",8643971_2,0
7236,head and neck cancer,193,213,"Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients.",8643971_2,1
3583,Taxol,95,100,"Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients.",8643971_2,0
3582,paclitaxel,83,93,"Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients.",8643971_2,0
7237,ovarian cancer,342,356,"Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients.",8643971_2,1
3586,granulocyte colony-stimulating factor,142,179,We initiated a phase I/II trial to determine the response and toxicity of escalating paclitaxel doses combined with fixed-dose cisplatin with granulocyte colony-stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma.,8643971_3,0
3585,cisplatin,127,136,We initiated a phase I/II trial to determine the response and toxicity of escalating paclitaxel doses combined with fixed-dose cisplatin with granulocyte colony-stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma.,8643971_3,0
3584,paclitaxel,85,95,We initiated a phase I/II trial to determine the response and toxicity of escalating paclitaxel doses combined with fixed-dose cisplatin with granulocyte colony-stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma.,8643971_3,0
14656,head and neck carcinoma,243,266,We initiated a phase I/II trial to determine the response and toxicity of escalating paclitaxel doses combined with fixed-dose cisplatin with granulocyte colony-stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma.,8643971_3,1
7238,Primary tumor,0,13,"Primary tumor sites were oropharynx, 10 patients; hypopharynx, four; larynx, two; oral cavity, three; unknown primary, two; and nasal cavity and parotid gland, one each.",8643971_5,1
14661,parotid gland,145,158,"Primary tumor sites were oropharynx, 10 patients; hypopharynx, four; larynx, two; oral cavity, three; unknown primary, two; and nasal cavity and parotid gland, one each.",8643971_5,1
14660,nasal cavity,128,140,"Primary tumor sites were oropharynx, 10 patients; hypopharynx, four; larynx, two; oral cavity, three; unknown primary, two; and nasal cavity and parotid gland, one each.",8643971_5,1
14658,hypopharynx,50,61,"Primary tumor sites were oropharynx, 10 patients; hypopharynx, four; larynx, two; oral cavity, three; unknown primary, two; and nasal cavity and parotid gland, one each.",8643971_5,1
14659,oral cavity,82,93,"Primary tumor sites were oropharynx, 10 patients; hypopharynx, four; larynx, two; oral cavity, three; unknown primary, two; and nasal cavity and parotid gland, one each.",8643971_5,1
14662,stage III,48,57,"Of 20 patients evaluable for toxicity, four had stage III and 16 had stage IV disease.",8643971_6,1
14663,stage IV disease,69,85,"Of 20 patients evaluable for toxicity, four had stage III and 16 had stage IV disease.",8643971_6,1
3587,paclitaxel,75,85,"Treatment, given every 21 days for a maximum of three cycles, consisted of paclitaxel by 3-hour infusion followed the next day by a fixed dose of cisplatin (75 mg/m2).",8643971_7,0
14665,mg/m2,160,165,"Treatment, given every 21 days for a maximum of three cycles, consisted of paclitaxel by 3-hour infusion followed the next day by a fixed dose of cisplatin (75 mg/m2).",8643971_7,0
3588,cisplatin,146,155,"Treatment, given every 21 days for a maximum of three cycles, consisted of paclitaxel by 3-hour infusion followed the next day by a fixed dose of cisplatin (75 mg/m2).",8643971_7,0
14666,intrapatient,61,73,"The dose levels incorporate escalating paclitaxel doses, and intrapatient escalations within a given dose level are permitted if toxicity permits.",8643971_8,0
3589,paclitaxel,39,49,"The dose levels incorporate escalating paclitaxel doses, and intrapatient escalations within a given dose level are permitted if toxicity permits.",8643971_8,0
14668,mg/m2,61,66,"At the time of this writing, dose level 4 (260, 270, and 280 mg/m2) is being evaluated; three patients from this level are evaluable.",8643971_9,0
3593,carboplatin,25,36,Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer.,8643973_0,0
3592,Paclitaxel,0,10,Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer.,8643973_0,0
7241,ovarian cancer,77,91,Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer.,8643973_0,1
3596,carboplatin,173,184,"In a phase I study to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.",8643973_1,0
3595,Taxol,74,79,"In a phase I study to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.",8643973_1,0
3594,paclitaxel,62,72,"In a phase I study to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.",8643973_1,0
7242,ovarian cancer,235,249,"In a phase I study to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.",8643973_1,1
3597,paclitaxel,251,261,"In a phase I study to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer, paclitaxel doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2.",8643973_1,0
3603,paclitaxel,46,56,The recommended dose for phase III studies is paclitaxel 185 mg/m2 and carboplatin AUC 6.,8643973_10,0
14700,mg/m2,61,66,The recommended dose for phase III studies is paclitaxel 185 mg/m2 and carboplatin AUC 6.,8643973_10,0
3604,carboplatin,71,82,The recommended dose for phase III studies is paclitaxel 185 mg/m2 and carboplatin AUC 6.,8643973_10,0
3598,carboplatin,18,29,The fixed dose of carboplatin at levels 1 through 4 was given to achieve an area under the concentration-time curve (AUC) of 5 using the Calvert formula.,8643973_2,0
3599,carboplatin,22,33,"In levels 5 and 6 the carboplatin dose was targeted at AUCs of 6 and 7.5, respectively, combined with a fixed paclitaxel dose of 185 mg/m2.",8643973_3,0
3600,paclitaxel,110,120,"In levels 5 and 6 the carboplatin dose was targeted at AUCs of 6 and 7.5, respectively, combined with a fixed paclitaxel dose of 185 mg/m2.",8643973_3,0
14693,mg/m2,133,138,"In levels 5 and 6 the carboplatin dose was targeted at AUCs of 6 and 7.5, respectively, combined with a fixed paclitaxel dose of 185 mg/m2.",8643973_3,0
14696,myelosuppression,50,66,"The dose-limiting toxicity of the combination was myelosuppression (leukopenia, granulocytopenia, and thrombocytopenia).",8643973_5,1
7243,Neurotoxicity,0,13,Neurotoxicity was largely moderate.,8643973_6,1
7244,complete or partial,88,107,"So far, 14 patients are evaluable for response; of these, eight (57%) showed objective (complete or partial) response and disease stabilized in six patients.",8643973_7,1
7245,disease progression,15,34,No patient had disease progression.,8643973_8,1
3601,paclitaxel,36,46,We conclude that the combination of paclitaxel 185 mg/m2 administered as a 3-hour infusion followed immediately by a 1-hour infusion of carboplatin at an AUC of 6 can be administered safely in a 21-day schedule in the outpatient setting.,8643973_9,0
3602,carboplatin,136,147,We conclude that the combination of paclitaxel 185 mg/m2 administered as a 3-hour infusion followed immediately by a 1-hour infusion of carboplatin at an AUC of 6 can be administered safely in a 21-day schedule in the outpatient setting.,8643973_9,0
14697,mg/m2,51,56,We conclude that the combination of paclitaxel 185 mg/m2 administered as a 3-hour infusion followed immediately by a 1-hour infusion of carboplatin at an AUC of 6 can be administered safely in a 21-day schedule in the outpatient setting.,8643973_9,0
3605,propranolol,46,57,Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease.,8649546_0,0
7246,Parkinson's disease,61,80,Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease.,8649546_0,1
14703,low-dose propranolol,99,119,Seven patients suffering from Parkinson's disease (PD) with severely disabling dyskinesia received low-dose propranolol as an adjunct to the currently used medical treatment.,8649546_1,0
14702,severely disabling dyskinesia,60,89,Seven patients suffering from Parkinson's disease (PD) with severely disabling dyskinesia received low-dose propranolol as an adjunct to the currently used medical treatment.,8649546_1,1
7247,Parkinson's disease,30,49,Seven patients suffering from Parkinson's disease (PD) with severely disabling dyskinesia received low-dose propranolol as an adjunct to the currently used medical treatment.,8649546_1,1
14704,parkinsonian motor disability,84,113,There was a significant 40% improvement in the dyskinesia score without increase of parkinsonian motor disability.,8649546_2,1
7248,dystonia,68,76,"Ballistic and choreic dyskinesia were markedly ameliorated, whereas dystonia was not.",8649546_3,1
14705,choreic dyskinesia,14,32,"Ballistic and choreic dyskinesia were markedly ameliorated, whereas dystonia was not.",8649546_3,1
14706,low doses,43,52,This study suggests that administration of low doses of beta-blockers may improve levodopa-induced ballistic and choreic dyskinesia in PD.,8649546_4,0
14708,choreic dyskinesia,113,131,This study suggests that administration of low doses of beta-blockers may improve levodopa-induced ballistic and choreic dyskinesia in PD.,8649546_4,1
3606,beta-blockers,56,69,This study suggests that administration of low doses of beta-blockers may improve levodopa-induced ballistic and choreic dyskinesia in PD.,8649546_4,0
14711,acute myopathy,40,54,Occasional case reports have shown that acute myopathy may occur in patients treated with massive doses of corticosteroids.,8665051_1,1
3608,ATPase,0,6,"ATPase staining of the diaphragm, scalenus medius, and gastrocnemius showed type IIb fiber atrophy in the steroid groups and also diaphragmatic type IIa atrophy with T, whereas histologic examinations revealed a normal muscular pattern with absence of necrosis.",8665051_10,0
14729,scalenus medius,34,49,"ATPase staining of the diaphragm, scalenus medius, and gastrocnemius showed type IIb fiber atrophy in the steroid groups and also diaphragmatic type IIa atrophy with T, whereas histologic examinations revealed a normal muscular pattern with absence of necrosis.",8665051_10,1
14731,type IIa,144,152,"ATPase staining of the diaphragm, scalenus medius, and gastrocnemius showed type IIb fiber atrophy in the steroid groups and also diaphragmatic type IIa atrophy with T, whereas histologic examinations revealed a normal muscular pattern with absence of necrosis.",8665051_10,1
14733,normal muscular pattern,212,235,"ATPase staining of the diaphragm, scalenus medius, and gastrocnemius showed type IIb fiber atrophy in the steroid groups and also diaphragmatic type IIa atrophy with T, whereas histologic examinations revealed a normal muscular pattern with absence of necrosis.",8665051_10,1
7250,diaphragmatic,130,143,"ATPase staining of the diaphragm, scalenus medius, and gastrocnemius showed type IIb fiber atrophy in the steroid groups and also diaphragmatic type IIa atrophy with T, whereas histologic examinations revealed a normal muscular pattern with absence of necrosis.",8665051_10,1
7251,muscle atrophy,81,95,"Finally, a pair-fed (PF) study, performed in 18 rats (C, T, and PF), showed that muscle atrophy was considerably less pronounced in PF animals than in T-treated animals.",8665051_11,1
14734,PF,21,23,"Finally, a pair-fed (PF) study, performed in 18 rats (C, T, and PF), showed that muscle atrophy was considerably less pronounced in PF animals than in T-treated animals.",8665051_11,0
14735,PF,64,66,"Finally, a pair-fed (PF) study, performed in 18 rats (C, T, and PF), showed that muscle atrophy was considerably less pronounced in PF animals than in T-treated animals.",8665051_11,0
14736,PF,132,134,"Finally, a pair-fed (PF) study, performed in 18 rats (C, T, and PF), showed that muscle atrophy was considerably less pronounced in PF animals than in T-treated animals.",8665051_11,0
3610,(2,125,127,"We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.",8665051_12,0
14738,diaphragm contractile,233,254,"We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.",8665051_12,1
14740,acute nutritional deprivation,350,379,"We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.",8665051_12,1
3611,(3,267,269,"We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.",8665051_12,0
7252,muscle wasting,109,123,"We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.",8665051_12,1
3609,(1,17,19,"We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.",8665051_12,0
7253,muscle necrosis,294,309,"We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone.",8665051_12,1
3607,methylprednisolone,89,107,"Therefore, 60 male rats were randomly assigned to receive daily injection of saline (C), methylprednisolone (M), or triamcinolone (T) 80 mg/kg/d for 5 d. Nutritional intake, measured daily in 15 animals, showed a significant reduction of food intake in the steroid-treated groups (-50 and -79% in M and T, respectively).",8665051_3,0
7249,body weight,43,54,This was associated with a similar loss in body weight.,8665051_4,1
14715,diaphragm contractility,29,52,"In the 45 remaining animals, diaphragm contractility and histopathologic features of several muscles were studied.",8665051_5,1
14722,T group,142,149,"Maximal twitches of the diaphragm were lower in the C group (653 +/- 174 g/cm(2)) than in the M group (837 +/- 171 g/cm(2); p < 0.05) and the T group (765 +/- 145 g/cm(2), NS).",8665051_7,0
7254,chronic renal failure,51,72,Habitual use of acetaminophen as a risk factor for chronic renal failure: a comparison with phenacetin.,8669433_0,1
7255,chronic renal failure,137,158,"Six epidemiologic studies in the United States and Europe indicate that habitual use of phenacetin is associated with the development of chronic renal failure and end-stage renal disease (ESRD), with a relative risk in the range of 4 to 19.",8669433_1,1
7257,ESRD,188,192,"Six epidemiologic studies in the United States and Europe indicate that habitual use of phenacetin is associated with the development of chronic renal failure and end-stage renal disease (ESRD), with a relative risk in the range of 4 to 19.",8669433_1,1
7256,end-stage renal disease,163,186,"Six epidemiologic studies in the United States and Europe indicate that habitual use of phenacetin is associated with the development of chronic renal failure and end-stage renal disease (ESRD), with a relative risk in the range of 4 to 19.",8669433_1,1
7259,ESRD,202,206,"However, three case control studies, one each in North Carolina, northern Maryland, and West Berlin, Germany, showed that habitual use of acetaminophen is also associated with chronic renal failure and ESRD, with a relative risk in the range of 2 to 4.",8669433_3,1
7258,chronic renal failure,176,197,"However, three case control studies, one each in North Carolina, northern Maryland, and West Berlin, Germany, showed that habitual use of acetaminophen is also associated with chronic renal failure and ESRD, with a relative risk in the range of 2 to 4.",8669433_3,1
7260,ESRD,93,97,"These studies suggest that both phenacetin and acetaminophen may contribute to the burden of ESRD, with the risk of the latter being somewhat less than that of the former.",8669433_4,1
14752,single agent,44,56,"Thus, acetaminophen has been used both as a single agent and in combination with other analgesics, whereas phenacetin was available only in combinations.",8669433_7,0
7261,ESRD,79,83,"The possibility that habitual use of acetaminophen alone increases the risk of ESRD has not been clearly demonstrated, but cannot be dismissed.",8669433_8,1
3612,mesna,42,47,Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis.,8677458_0,0
14754,Hemorrhagic cystitis,0,20,Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent.,8677458_1,1
3613,ifosfamide,54,64,Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent.,8677458_1,0
3614,mesna,104,109,Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent.,8677458_1,0
3615,cytotoxic agent,125,140,Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent.,8677458_1,0
3616,Mesna,0,5,"Mesna is generally administered by the intravenous route, although experience with oral delivery of the drug has increased.",8677458_2,0
14756,intravenous access,87,105,The continuous subcutaneous administration of mesna has the advantage of not requiring intravenous access.,8677458_3,0
3617,mesna,46,51,The continuous subcutaneous administration of mesna has the advantage of not requiring intravenous access.,8677458_3,0
3618,mesna,120,125,"In addition, subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary mesna concentrations, such as in a patient taking oral mesna who experiences severe ifosfamide-induced emesis and is unable to absorb the drug.",8677458_4,0
14758,neutralizing agent,42,60,"In addition, subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary mesna concentrations, such as in a patient taking oral mesna who experiences severe ifosfamide-induced emesis and is unable to absorb the drug.",8677458_4,0
3619,mesna,175,180,"In addition, subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary mesna concentrations, such as in a patient taking oral mesna who experiences severe ifosfamide-induced emesis and is unable to absorb the drug.",8677458_4,0
3621,ifosfamide,162,172,"Limited clinical experience with continuous subcutaneous mesna administration suggests it is a safe, practical, and economic method of drug delivery that permits ifosfamide to be administered successfully in the outpatient setting.",8677458_5,0
3620,mesna,57,62,"Limited clinical experience with continuous subcutaneous mesna administration suggests it is a safe, practical, and economic method of drug delivery that permits ifosfamide to be administered successfully in the outpatient setting.",8677458_5,0
7262,critically ill,27,41,This article describes two critically ill patients in whom transient episodes of hypotension reproducibly developed after administration of acetaminophen.,8682684_4,1
14765,transient episodes,59,77,This article describes two critically ill patients in whom transient episodes of hypotension reproducibly developed after administration of acetaminophen.,8682684_4,1
7263,allergic reactions,18,36,Other symptoms of allergic reactions were not clinically detectable.,8682684_5,1
14766,hypotensive episodes,4,24,The hypotensive episodes were severe enough to require vasopressor administration.,8682684_6,1
14768,unknown origin,105,119,The reports illustrate the need for clinicians to consider acetaminophen in patients with hypotension of unknown origin.,8682684_7,1
3622,lignocaine,67,77,Leg and back pain after spinal anaesthesia involving hyperbaric 5% lignocaine.,8686832_0,0
14770,hyperbaric,53,63,Leg and back pain after spinal anaesthesia involving hyperbaric 5% lignocaine.,8686832_0,1
7264,back pain,8,17,Leg and back pain after spinal anaesthesia involving hyperbaric 5% lignocaine.,8686832_0,1
14769,spinal anaesthesia,24,42,Leg and back pain after spinal anaesthesia involving hyperbaric 5% lignocaine.,8686832_0,1
3623,lignocaine,54,64,"Fifty-four patients, aged 27-90 years, who were given lignocaine 5% in 6.8% glucose solution for spinal anaesthesia were studied.",8686832_1,0
3624,glucose solution,76,92,"Fifty-four patients, aged 27-90 years, who were given lignocaine 5% in 6.8% glucose solution for spinal anaesthesia were studied.",8686832_1,0
14771,spinal anaesthesia,97,115,"Fifty-four patients, aged 27-90 years, who were given lignocaine 5% in 6.8% glucose solution for spinal anaesthesia were studied.",8686832_1,1
14772,dural puncture,66,80,The patients affected were younger (p < 0.05) and the site of the dural puncture was higher (p < 0.01) than those individuals without pain.,8686832_3,1
14773,alcohol intake,107,121,"Five of the 13 patients (38%) with pain and seven of the 41 patients (17%) without pain admitted to a high alcohol intake, which might be a contributing factor.",8686832_4,1
14776,hyperbaric,63,73,Leg and/or back pain is associated with the intrathecal use of hyperbaric 5% lignocaine.,8686832_5,1
14775,intrathecal,44,55,Leg and/or back pain is associated with the intrathecal use of hyperbaric 5% lignocaine.,8686832_5,1
7265,back pain,11,20,Leg and/or back pain is associated with the intrathecal use of hyperbaric 5% lignocaine.,8686832_5,1
3625,lignocaine,77,87,Leg and/or back pain is associated with the intrathecal use of hyperbaric 5% lignocaine.,8686832_5,0
7266,diabetic nephropathy,127,147,Reduction of heparan sulphate-associated anionic sites in the glomerular basement membrane of rats with streptozotocin-induced diabetic nephropathy.,8690168_0,1
14782,cuprolinic blue,223,238,"Heparan sulphate-associated anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of diabetes by streptozotocin and in age- adn sex-matched control rats, employing the cationic dye cuprolinic blue.",8690168_1,0
14781,cationic dye,210,222,"Heparan sulphate-associated anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of diabetes by streptozotocin and in age- adn sex-matched control rats, employing the cationic dye cuprolinic blue.",8690168_1,0
14780,adn,166,169,"Heparan sulphate-associated anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of diabetes by streptozotocin and in age- adn sex-matched control rats, employing the cationic dye cuprolinic blue.",8690168_1,0
14779,streptozotocin,139,153,"Heparan sulphate-associated anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of diabetes by streptozotocin and in age- adn sex-matched control rats, employing the cationic dye cuprolinic blue.",8690168_1,0
3627,chondroitinase ABC,214,232,"The heparan sulphate specificity of the cuprolinic blue staining was demonstrated by glycosaminoglycan-degrading enzymes, showing that pretreatment of the sections with heparitinase abolished all staining, whereas chondroitinase ABC had no effect.",8690168_3,0
3626,heparan,4,11,"The heparan sulphate specificity of the cuprolinic blue staining was demonstrated by glycosaminoglycan-degrading enzymes, showing that pretreatment of the sections with heparitinase abolished all staining, whereas chondroitinase ABC had no effect.",8690168_3,0
14789,heparitinase,169,181,"The heparan sulphate specificity of the cuprolinic blue staining was demonstrated by glycosaminoglycan-degrading enzymes, showing that pretreatment of the sections with heparitinase abolished all staining, whereas chondroitinase ABC had no effect.",8690168_3,0
14787,glycosaminoglycan-degrading enzymes,85,120,"The heparan sulphate specificity of the cuprolinic blue staining was demonstrated by glycosaminoglycan-degrading enzymes, showing that pretreatment of the sections with heparitinase abolished all staining, whereas chondroitinase ABC had no effect.",8690168_3,0
7267,externa,106,113,The majority of anionic sites (74% in diabetic and 81% in control rats) were found within the lamina rara externa of the glomerular basement membrane.,8690168_4,1
14790,anionic sites,16,29,The majority of anionic sites (74% in diabetic and 81% in control rats) were found within the lamina rara externa of the glomerular basement membrane.,8690168_4,0
7268,externa,157,164,"A minority of anionic sites were scattered throughout the lamina densa and lamina rara interna, and were significantly smaller than those in the lamina rara externa of the glomerular basement membrane (p<0.001 and p<0.01 for diabetic and control rats, respectively).",8690168_5,1
14792,lamina densa,58,70,"A minority of anionic sites were scattered throughout the lamina densa and lamina rara interna, and were significantly smaller than those in the lamina rara externa of the glomerular basement membrane (p<0.001 and p<0.01 for diabetic and control rats, respectively).",8690168_5,1
14793,lamina rara interna,75,94,"A minority of anionic sites were scattered throughout the lamina densa and lamina rara interna, and were significantly smaller than those in the lamina rara externa of the glomerular basement membrane (p<0.001 and p<0.01 for diabetic and control rats, respectively).",8690168_5,1
14795,heparan sulphate anionic sites,32,62,"At the same time, the number of heparan sulphate anionic sites and the total anionic site surface (number of anionic sites x mean anionic site surface) in the lamina rara externa of the glomerular basement membrane was reduced by 19% (p<0.021) and by 26% (p<0.02), respectively.",8690168_7,0
7269,externa,171,178,"At the same time, the number of heparan sulphate anionic sites and the total anionic site surface (number of anionic sites x mean anionic site surface) in the lamina rara externa of the glomerular basement membrane was reduced by 19% (p<0.021) and by 26% (p<0.02), respectively.",8690168_7,1
14799,anionic site,17,29,Number and total anionic site surface in the remaining part of the glomerular basement membrane (lamina densa and lamina rara interna) were not significantly changed.,8690168_8,0
14801,lamina densa,97,109,Number and total anionic site surface in the remaining part of the glomerular basement membrane (lamina densa and lamina rara interna) were not significantly changed.,8690168_8,1
14802,lamina rara interna,114,133,Number and total anionic site surface in the remaining part of the glomerular basement membrane (lamina densa and lamina rara interna) were not significantly changed.,8690168_8,1
7270,externa,172,179,"We conclude that in streptozotocin-diabetic rats with an increased urinary albumin excretion, a reduced heparan sulphate charge barrier/density is found at the lamina rara externa of the glomerular basement membrane.",8690168_9,1
3628,heparan,104,111,"We conclude that in streptozotocin-diabetic rats with an increased urinary albumin excretion, a reduced heparan sulphate charge barrier/density is found at the lamina rara externa of the glomerular basement membrane.",8690168_9,0
14805,vagal bradycardia,29,46,Mediation of enhanced reflex vagal bradycardia by L-dopa via central dopamine formation in dogs.,869641_0,1
14806,heart rate,51,61,L-Dopa (5 mg/kg i.v.) decreased blood pressure and heart rate after extracerebral decarboxylase inhibition with MK-486 (25 mg/kg i.v.) in anesthetize MAO-inhibited dogs.,869641_1,1
3629,MK-486,112,118,L-Dopa (5 mg/kg i.v.) decreased blood pressure and heart rate after extracerebral decarboxylase inhibition with MK-486 (25 mg/kg i.v.) in anesthetize MAO-inhibited dogs.,869641_1,0
7271,blood pressure,32,46,L-Dopa (5 mg/kg i.v.) decreased blood pressure and heart rate after extracerebral decarboxylase inhibition with MK-486 (25 mg/kg i.v.) in anesthetize MAO-inhibited dogs.,869641_1,1
14810,DL-Threo-dihydroxyphenylserine,104,134,"In addition, reflex bradycardia caused by injected norepinephrine was significantly enhanced by L-dopa, DL-Threo-dihydroxyphenylserine had no effect on blood pressure, heart rate or reflex responses to norepinephrine.",869641_2,0
14811,heart rate,168,178,"In addition, reflex bradycardia caused by injected norepinephrine was significantly enhanced by L-dopa, DL-Threo-dihydroxyphenylserine had no effect on blood pressure, heart rate or reflex responses to norepinephrine.",869641_2,1
14809,reflex bradycardia,13,31,"In addition, reflex bradycardia caused by injected norepinephrine was significantly enhanced by L-dopa, DL-Threo-dihydroxyphenylserine had no effect on blood pressure, heart rate or reflex responses to norepinephrine.",869641_2,1
7272,blood pressure,152,166,"In addition, reflex bradycardia caused by injected norepinephrine was significantly enhanced by L-dopa, DL-Threo-dihydroxyphenylserine had no effect on blood pressure, heart rate or reflex responses to norepinephrine.",869641_2,1
14813,FLA-63,0,6,"FLA-63, a dopamine-beta-oxidase inhibitor, did not have any effect on the hypotension, bradycardia or reflex-enhancing effect of L-dopa.",869641_3,0
14814,dopamine-beta-oxidase inhibitor,10,41,"FLA-63, a dopamine-beta-oxidase inhibitor, did not have any effect on the hypotension, bradycardia or reflex-enhancing effect of L-dopa.",869641_3,0
14815,heart rate,68,78,Pimozide did not affect the actions of L-dopa on blood pressure and heart rate but completely blocked the enhancement of reflexes.,869641_4,1
7273,blood pressure,49,63,Pimozide did not affect the actions of L-dopa on blood pressure and heart rate but completely blocked the enhancement of reflexes.,869641_4,1
7274,blood pressure,51,65,Removal of the carotid sinuses caused an elevation blood pressure and heart rate and abolished the negative chronotropic effect of norepinephrine.,869641_5,1
14816,carotid sinuses,15,30,Removal of the carotid sinuses caused an elevation blood pressure and heart rate and abolished the negative chronotropic effect of norepinephrine.,869641_5,1
14817,heart rate,70,80,Removal of the carotid sinuses caused an elevation blood pressure and heart rate and abolished the negative chronotropic effect of norepinephrine.,869641_5,1
7275,blood pressure,92,106,"However, L-dopa restored the bradycardia caused by norepinephrine in addition to decreasing blood pressure and heart rate.",869641_6,1
14819,heart rate,111,121,"However, L-dopa restored the bradycardia caused by norepinephrine in addition to decreasing blood pressure and heart rate.",869641_6,1
7276,blood pressure,31,45,5-HTP (5 mg/kg i.v.) decreased blood pressure and heart rate and decreased the reflex bradycardia to norepinephrine.,869641_7,1
14820,heart rate,50,60,5-HTP (5 mg/kg i.v.) decreased blood pressure and heart rate and decreased the reflex bradycardia to norepinephrine.,869641_7,1
3630,alpha-receptor,72,86,It is concluded that L-dopa enhances reflex bradycardia through central alpha-receptor stimulation.,869641_8,0
14821,reflex bradycardia,37,55,It is concluded that L-dopa enhances reflex bradycardia through central alpha-receptor stimulation.,869641_8,1
7277,carotid sinus,105,118,"Furthermore, the effects are mediated through dopamine rather than norepinephrine and do not require the carotid sinus baroreceptors.",869641_9,1
3632,tacrolimus,54,64,Microangiopathic hemolytic anemia complicating FK506 (tacrolimus) therapy.,8701950_0,0
7278,Microangiopathic hemolytic anemia,0,33,Microangiopathic hemolytic anemia complicating FK506 (tacrolimus) therapy.,8701950_0,1
3631,FK506,47,52,Microangiopathic hemolytic anemia complicating FK506 (tacrolimus) therapy.,8701950_0,0
3633,FK506,101,106,We describe 3 episodes of microangiopathic hemolytic anemia (MAHA) in 2 solid organ recipients under FK506 (tacrolimus) therapy.,8701950_1,0
3634,tacrolimus,108,118,We describe 3 episodes of microangiopathic hemolytic anemia (MAHA) in 2 solid organ recipients under FK506 (tacrolimus) therapy.,8701950_1,0
7279,microangiopathic hemolytic anemia,26,59,We describe 3 episodes of microangiopathic hemolytic anemia (MAHA) in 2 solid organ recipients under FK506 (tacrolimus) therapy.,8701950_1,1
3635,FK506,34,39,"In both cases, discontinuation of FK506 and treatment with plasma exchange, fresh frozen plasma replacement, corticosteroids, aspirin, and dipyridamole led to resolution of MAHA.",8701950_2,0
3636,dipyridamole,139,151,"In both cases, discontinuation of FK506 and treatment with plasma exchange, fresh frozen plasma replacement, corticosteroids, aspirin, and dipyridamole led to resolution of MAHA.",8701950_2,0
3637,FK506,34,39,"In one patient, reintroduction of FK506 led to rapid recurrence of MAHA.",8701950_3,0
3639,cyclosporin A,91,104,"In our experience and according to the literature, FK506 does not seem to cross-react with cyclosporin A (CyA), an immuno-suppressive drug already known to induce MAHA.",8701950_5,0
14827,immuno-suppressive drug,115,138,"In our experience and according to the literature, FK506 does not seem to cross-react with cyclosporin A (CyA), an immuno-suppressive drug already known to induce MAHA.",8701950_5,0
14826,CyA,106,109,"In our experience and according to the literature, FK506 does not seem to cross-react with cyclosporin A (CyA), an immuno-suppressive drug already known to induce MAHA.",8701950_5,0
14825,cross-react,74,85,"In our experience and according to the literature, FK506 does not seem to cross-react with cyclosporin A (CyA), an immuno-suppressive drug already known to induce MAHA.",8701950_5,0
3638,FK506,51,56,"In our experience and according to the literature, FK506 does not seem to cross-react with cyclosporin A (CyA), an immuno-suppressive drug already known to induce MAHA.",8701950_5,0
14829,apnoea,51,57,The use of serum cholinesterase in succinylcholine apnoea.,871943_0,0
14828,serum cholinesterase,11,31,The use of serum cholinesterase in succinylcholine apnoea.,871943_0,0
14831,human serum cholinesterase,145,171,Fifteen patients demonstrating unexpected prolonged apnoea lasting several hours after succinylcholine have been treated by a new preparation of human serum cholinesterase.,871943_1,0
14833,serum cholinesterase,86,106,In 12 patients biochemical genetic examinations confirmed the presence of an atypical serum cholinesterase.,871943_3,0
14834,serum cholinesterase,56,76,It is therefore supposed that other unknown variants of serum cholinesterase exist which cannot hydrolyze succinylcholine.,871943_5,0
14836,apnoea,51,57,The use of serum cholinesterase in succinylcholine apnoea provided considerable relief to both patient and anaesthetist.,871943_6,0
14835,serum cholinesterase,11,31,The use of serum cholinesterase in succinylcholine apnoea provided considerable relief to both patient and anaesthetist.,871943_6,0
3640,sulfation,10,19,Increased sulfation and decreased 7alpha-hydroxylation of deoxycholic acid in ethinyl estradiol-induced cholestasis in rats.,873132_0,0
3642,ethinyl,78,85,Increased sulfation and decreased 7alpha-hydroxylation of deoxycholic acid in ethinyl estradiol-induced cholestasis in rats.,873132_0,0
14837,7alpha-hydroxylation,34,54,Increased sulfation and decreased 7alpha-hydroxylation of deoxycholic acid in ethinyl estradiol-induced cholestasis in rats.,873132_0,0
14838,estradiol-induced cholestasis,86,115,Increased sulfation and decreased 7alpha-hydroxylation of deoxycholic acid in ethinyl estradiol-induced cholestasis in rats.,873132_0,1
3641,deoxycholic acid,58,74,Increased sulfation and decreased 7alpha-hydroxylation of deoxycholic acid in ethinyl estradiol-induced cholestasis in rats.,873132_0,0
3644,ethinyl,94,101,"Deoxycholic acid conjugation, transport capacity, and metabolism were compared in control and ethinyl estradiol-treated rats.",873132_1,0
3643,Deoxycholic acid,0,16,"Deoxycholic acid conjugation, transport capacity, and metabolism were compared in control and ethinyl estradiol-treated rats.",873132_1,0
3645,deoxycholic acid,62,78,"Control rats were found to have a lower capacity to transport deoxycholic acid than taurodeoxycholic acid, and both were decreased by ethinyl estradiol treatment.",873132_2,0
3646,taurodeoxycholic acid,84,105,"Control rats were found to have a lower capacity to transport deoxycholic acid than taurodeoxycholic acid, and both were decreased by ethinyl estradiol treatment.",873132_2,0
3647,ethinyl estradiol,134,151,"Control rats were found to have a lower capacity to transport deoxycholic acid than taurodeoxycholic acid, and both were decreased by ethinyl estradiol treatment.",873132_2,0
3648,deoxycholate,22,34,"During [24-14C]sodium deoxycholate infusion, [14C]biliary bile acid secretion increased, but bile flow did not change significantly in either control or ethinyl estradiol-treated rats.",873132_3,0
3649,bile acid,58,67,"During [24-14C]sodium deoxycholate infusion, [14C]biliary bile acid secretion increased, but bile flow did not change significantly in either control or ethinyl estradiol-treated rats.",873132_3,0
3650,ethinyl,153,160,"During [24-14C]sodium deoxycholate infusion, [14C]biliary bile acid secretion increased, but bile flow did not change significantly in either control or ethinyl estradiol-treated rats.",873132_3,0
14844,7alpha-hydroxylation,145,165,"Ethinyl estradiol-treated animals excreted significantly less 14C as taurocholic acid than did control animals, consistent with an impairment of 7alpha-hydroxylation of taurodeoxycholic acid.",873132_4,0
3651,Ethinyl,0,7,"Ethinyl estradiol-treated animals excreted significantly less 14C as taurocholic acid than did control animals, consistent with an impairment of 7alpha-hydroxylation of taurodeoxycholic acid.",873132_4,0
3652,taurocholic acid,69,85,"Ethinyl estradiol-treated animals excreted significantly less 14C as taurocholic acid than did control animals, consistent with an impairment of 7alpha-hydroxylation of taurodeoxycholic acid.",873132_4,0
3653,taurodeoxycholic acid,169,190,"Ethinyl estradiol-treated animals excreted significantly less 14C as taurocholic acid than did control animals, consistent with an impairment of 7alpha-hydroxylation of taurodeoxycholic acid.",873132_4,0
14843,14C,62,65,"Ethinyl estradiol-treated animals excreted significantly less 14C as taurocholic acid than did control animals, consistent with an impairment of 7alpha-hydroxylation of taurodeoxycholic acid.",873132_4,0
3656,sulfation,109,118,"Ethinyl estradiol treatment did not impair conjugation of deoxycholic acid, but did result in an increase in sulfation of taurodeoxycholic acid from 1.5% in controls to nearly 4.0% (P less than 0.01).",873132_5,0
3655,deoxycholic acid,58,74,"Ethinyl estradiol treatment did not impair conjugation of deoxycholic acid, but did result in an increase in sulfation of taurodeoxycholic acid from 1.5% in controls to nearly 4.0% (P less than 0.01).",873132_5,0
3657,taurodeoxycholic acid,122,143,"Ethinyl estradiol treatment did not impair conjugation of deoxycholic acid, but did result in an increase in sulfation of taurodeoxycholic acid from 1.5% in controls to nearly 4.0% (P less than 0.01).",873132_5,0
3654,Ethinyl estradiol,0,17,"Ethinyl estradiol treatment did not impair conjugation of deoxycholic acid, but did result in an increase in sulfation of taurodeoxycholic acid from 1.5% in controls to nearly 4.0% (P less than 0.01).",873132_5,0
3658,deoxycholic acid,89,105,These results are consistent with the hypothesis that the rat has a poorer tolerance for deoxycholic acid than do certain other species.,873132_6,0
14847,choleretic,95,105,"Furthermore, the rat converts deoxycholic acid, a poor choleretic, to taurocholic acid, a good choleretic.",873132_7,0
14846,poor choleretic,50,65,"Furthermore, the rat converts deoxycholic acid, a poor choleretic, to taurocholic acid, a good choleretic.",873132_7,0
3659,deoxycholic acid,30,46,"Furthermore, the rat converts deoxycholic acid, a poor choleretic, to taurocholic acid, a good choleretic.",873132_7,0
3660,taurocholic acid,70,86,"Furthermore, the rat converts deoxycholic acid, a poor choleretic, to taurocholic acid, a good choleretic.",873132_7,0
3662,sulfation,67,76,"When this conversion is impaired with ethinyl estradiol treatment, sulfation may be an important alternate pathway for excretion of this potentially harmful bile acid.",873132_8,0
3663,bile acid,157,166,"When this conversion is impaired with ethinyl estradiol treatment, sulfation may be an important alternate pathway for excretion of this potentially harmful bile acid.",873132_8,0
3661,ethinyl estradiol,38,55,"When this conversion is impaired with ethinyl estradiol treatment, sulfation may be an important alternate pathway for excretion of this potentially harmful bile acid.",873132_8,0
14848,anticancer drugs,15,31,Effect of some anticancer drugs and combined chemotherapy on renal toxicity.,8739323_0,0
14849,renal toxicity,61,75,Effect of some anticancer drugs and combined chemotherapy on renal toxicity.,8739323_0,1
14859,CY,192,194,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,0
14858,5-FU,185,189,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,0
14855,cyclophosphamide,119,135,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,0
14854,5-FU,109,113,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,0
14853,5-fluorouracil,93,107,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,0
14852,MTX,87,90,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,0
14851,nitrogranulogen,51,66,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,0
14856,CY,137,139,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,0
14850,anticancer drugs,26,42,"The nephrotoxic action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats.",8739323_1,0
3664,creatinine,27,37,"After drug administration, creatinine concentrations in the plasma and in the urine of the rats were determined, as well as creatinine clearance.",8739323_2,0
3665,creatinine,124,134,"After drug administration, creatinine concentrations in the plasma and in the urine of the rats were determined, as well as creatinine clearance.",8739323_2,0
14862,drug administration,6,25,"After drug administration, creatinine concentrations in the plasma and in the urine of the rats were determined, as well as creatinine clearance.",8739323_2,0
3667,creatinine,143,153,After MTX administration a significant increase (p = 0.0228) in the plasma creatinine concentration and a significant (p = 0.0001) decrease in creatinine clearance was noted compared to controls.,8739323_4,0
3666,creatinine,75,85,After MTX administration a significant increase (p = 0.0228) in the plasma creatinine concentration and a significant (p = 0.0001) decrease in creatinine clearance was noted compared to controls.,8739323_4,0
14864,MTX,6,9,After MTX administration a significant increase (p = 0.0228) in the plasma creatinine concentration and a significant (p = 0.0001) decrease in creatinine clearance was noted compared to controls.,8739323_4,0
3670,cytostatics,205,216,"After the administration of NG, 5-FU and CY neither a statistically significant increase in creatinine concentration nor an increase in creatinine clearance was observed compared to the group receiving no cytostatics.",8739323_5,0
3669,creatinine,136,146,"After the administration of NG, 5-FU and CY neither a statistically significant increase in creatinine concentration nor an increase in creatinine clearance was observed compared to the group receiving no cytostatics.",8739323_5,0
3668,creatinine,92,102,"After the administration of NG, 5-FU and CY neither a statistically significant increase in creatinine concentration nor an increase in creatinine clearance was observed compared to the group receiving no cytostatics.",8739323_5,0
14865,5-FU,32,36,"After the administration of NG, 5-FU and CY neither a statistically significant increase in creatinine concentration nor an increase in creatinine clearance was observed compared to the group receiving no cytostatics.",8739323_5,0
14866,CY,41,43,"After the administration of NG, 5-FU and CY neither a statistically significant increase in creatinine concentration nor an increase in creatinine clearance was observed compared to the group receiving no cytostatics.",8739323_5,0
3672,creatinine,141,151,"Following polytherapy according to the CMF regimen, a statistically significant decrease (p = 0.0343) in creatinine clearance was found, but creatinine concentration did not increase significantly compared to controls.",8739323_6,0
14868,CMF,39,42,"Following polytherapy according to the CMF regimen, a statistically significant decrease (p = 0.0343) in creatinine clearance was found, but creatinine concentration did not increase significantly compared to controls.",8739323_6,0
3671,creatinine,105,115,"Following polytherapy according to the CMF regimen, a statistically significant decrease (p = 0.0343) in creatinine clearance was found, but creatinine concentration did not increase significantly compared to controls.",8739323_6,0
14867,polytherapy,10,21,"Following polytherapy according to the CMF regimen, a statistically significant decrease (p = 0.0343) in creatinine clearance was found, but creatinine concentration did not increase significantly compared to controls.",8739323_6,0
14869,CY,0,2,"CY caused hemorrhagic cystitis in 40% of rats, but it did not cause this complication when combined with 5-FU and MTX.",8739323_7,0
14870,hemorrhagic cystitis,10,30,"CY caused hemorrhagic cystitis in 40% of rats, but it did not cause this complication when combined with 5-FU and MTX.",8739323_7,1
14871,5-FU,105,109,"CY caused hemorrhagic cystitis in 40% of rats, but it did not cause this complication when combined with 5-FU and MTX.",8739323_7,0
14872,MTX,114,117,"CY caused hemorrhagic cystitis in 40% of rats, but it did not cause this complication when combined with 5-FU and MTX.",8739323_7,0
14874,MTX,69,72,"Histologic changes were found in rat kidneys after administration of MTX, CY and NG, while no such change was observed after 5-FU and joint administration of MTX + 5-FU + CY compared to controls.",8739323_8,0
14879,CY,171,173,"Histologic changes were found in rat kidneys after administration of MTX, CY and NG, while no such change was observed after 5-FU and joint administration of MTX + 5-FU + CY compared to controls.",8739323_8,0
14878,5-FU,164,168,"Histologic changes were found in rat kidneys after administration of MTX, CY and NG, while no such change was observed after 5-FU and joint administration of MTX + 5-FU + CY compared to controls.",8739323_8,0
14877,MTX,158,161,"Histologic changes were found in rat kidneys after administration of MTX, CY and NG, while no such change was observed after 5-FU and joint administration of MTX + 5-FU + CY compared to controls.",8739323_8,0
14876,5-FU,125,129,"Histologic changes were found in rat kidneys after administration of MTX, CY and NG, while no such change was observed after 5-FU and joint administration of MTX + 5-FU + CY compared to controls.",8739323_8,0
14875,CY,74,76,"Histologic changes were found in rat kidneys after administration of MTX, CY and NG, while no such change was observed after 5-FU and joint administration of MTX + 5-FU + CY compared to controls.",8739323_8,0
14873,Histologic changes,0,18,"Histologic changes were found in rat kidneys after administration of MTX, CY and NG, while no such change was observed after 5-FU and joint administration of MTX + 5-FU + CY compared to controls.",8739323_8,1
14882,5-FU,50,54,Our studies indicate that nephrotoxicity of MTX + 5-FU + CY administered jointly is lower than in monotherapy.,8739323_9,0
14881,MTX,44,47,Our studies indicate that nephrotoxicity of MTX + 5-FU + CY administered jointly is lower than in monotherapy.,8739323_9,0
14883,CY,57,59,Our studies indicate that nephrotoxicity of MTX + 5-FU + CY administered jointly is lower than in monotherapy.,8739323_9,0
14880,nephrotoxicity,26,40,Our studies indicate that nephrotoxicity of MTX + 5-FU + CY administered jointly is lower than in monotherapy.,8739323_9,1
14885,nicotine's,38,48,The interpeduncular nucleus regulates nicotine's effects on free-field activity.,8741744_0,0
14884,interpeduncular nucleus,4,27,The interpeduncular nucleus regulates nicotine's effects on free-field activity.,8741744_0,1
14888,ventral midbrain,81,97,Partial lesions were made with kainic acid in the interpeduncular nucleus of the ventral midbrain of the rat.,8741744_1,1
3673,kainic acid,31,42,Partial lesions were made with kainic acid in the interpeduncular nucleus of the ventral midbrain of the rat.,8741744_1,0
14887,interpeduncular nucleus,50,73,Partial lesions were made with kainic acid in the interpeduncular nucleus of the ventral midbrain of the rat.,8741744_1,1
3674,i.m.,168,172,"Compared with sham-operated controls, lesions significantly (p < 0.25) blunted the early (<60 min) free-field locomotor hypoactivity caused by nicotine (0.5 mg kg(-1), i.m.), enhanced the later (60-120 min) nicotine-induced hyperactivity, and raised spontaneous nocturnal activity.",8741744_2,0
14892,interpeduncular nucleus,95,118,"Lesions reduced the extent of immunohistological staining for choline acetyltransferase in the interpeduncular nucleus (p <0.025), but not for tyrosine hydroxylase in the surrounding catecholaminergic A10 region.",8741744_3,1
14893,catecholaminergic A10,183,204,"Lesions reduced the extent of immunohistological staining for choline acetyltransferase in the interpeduncular nucleus (p <0.025), but not for tyrosine hydroxylase in the surrounding catecholaminergic A10 region.",8741744_3,0
3676,tyrosine hydroxylase,143,163,"Lesions reduced the extent of immunohistological staining for choline acetyltransferase in the interpeduncular nucleus (p <0.025), but not for tyrosine hydroxylase in the surrounding catecholaminergic A10 region.",8741744_3,0
3675,choline acetyltransferase,62,87,"Lesions reduced the extent of immunohistological staining for choline acetyltransferase in the interpeduncular nucleus (p <0.025), but not for tyrosine hydroxylase in the surrounding catecholaminergic A10 region.",8741744_3,0
14894,interpeduncular nucleus,21,44,We conclude that the interpeduncular nucleus mediates nicotinic depression of locomotor activity and dampens nicotinic arousal mechanisms located elsewhere in the brain.,8741744_4,1
3678,nicotinic,109,118,We conclude that the interpeduncular nucleus mediates nicotinic depression of locomotor activity and dampens nicotinic arousal mechanisms located elsewhere in the brain.,8741744_4,0
3677,nicotinic,54,63,We conclude that the interpeduncular nucleus mediates nicotinic depression of locomotor activity and dampens nicotinic arousal mechanisms located elsewhere in the brain.,8741744_4,0
14897,diet free of NAD-precursors,13,40,Influence of diet free of NAD-precursors on acetaminophen hepatotoxicity in mice.,8742498_0,0
14898,hepatotoxicity,58,72,Influence of diet free of NAD-precursors on acetaminophen hepatotoxicity in mice.,8742498_0,1
3680,PARP,134,138,"Recently, we demonstrated the hepatoprotective effects of nicotinic acid amide, a selective inhibitor of poly(ADP-ribose) polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-induced liver injury involves a step which depends on adenoribosylation.",8742498_1,0
14900,nicotinic acid amide,58,78,"Recently, we demonstrated the hepatoprotective effects of nicotinic acid amide, a selective inhibitor of poly(ADP-ribose) polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-induced liver injury involves a step which depends on adenoribosylation.",8742498_1,0
3679,poly(ADP-ribose) polymerase,105,132,"Recently, we demonstrated the hepatoprotective effects of nicotinic acid amide, a selective inhibitor of poly(ADP-ribose) polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-induced liver injury involves a step which depends on adenoribosylation.",8742498_1,0
14899,hepatoprotective,30,46,"Recently, we demonstrated the hepatoprotective effects of nicotinic acid amide, a selective inhibitor of poly(ADP-ribose) polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-induced liver injury involves a step which depends on adenoribosylation.",8742498_1,0
7280,liver injury,239,251,"Recently, we demonstrated the hepatoprotective effects of nicotinic acid amide, a selective inhibitor of poly(ADP-ribose) polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)-hepatitis, suggesting that the AAP-induced liver injury involves a step which depends on adenoribosylation.",8742498_1,1
14903,AAP,139,142,"The present study investigates the effects of a diet free of precursors of NAD, the substrate on which PARP acts, in female NMRI mice with AAP hepatitis and evaluates the influence of simultaneous ethanol consumption in these animals.",8742498_2,0
3681,PARP,103,107,"The present study investigates the effects of a diet free of precursors of NAD, the substrate on which PARP acts, in female NMRI mice with AAP hepatitis and evaluates the influence of simultaneous ethanol consumption in these animals.",8742498_2,0
7281,Liver injuries,0,14,Liver injuries were quantified as serum activities of glutamate-oxaloacetate transaminase (GOT) and glutamate-pyruvate transaminase (GPT).,8742498_3,1
14906,GPT,133,136,Liver injuries were quantified as serum activities of glutamate-oxaloacetate transaminase (GOT) and glutamate-pyruvate transaminase (GPT).,8742498_3,0
14905,glutamate-pyruvate transaminase,100,131,Liver injuries were quantified as serum activities of glutamate-oxaloacetate transaminase (GOT) and glutamate-pyruvate transaminase (GPT).,8742498_3,0
3682,glutamate-oxaloacetate,54,76,Liver injuries were quantified as serum activities of glutamate-oxaloacetate transaminase (GOT) and glutamate-pyruvate transaminase (GPT).,8742498_3,0
14907,AAP,6,9,"While AAP caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD.",8742498_4,0
7282,adverse effects,207,222,"While AAP caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD.",8742498_4,1
14910,NAA,201,204,"While AAP caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD.",8742498_4,0
14909,nicotinic acid amide,179,199,"While AAP caused a 117-fold elevation of serum transaminase activities in mice kept on a standard laboratory diet, which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide (NAA), adverse effects were noted in animals fed a diet free of precursors of NAD.",8742498_4,0
14913,liver damage,188,200,"In these animals, only minor increases of serum transaminase activities were measured in the presence of AAP, and unlike the exacerbation caused by ethanol in mice on a standard diet, the liver damage was inhibited by 50% by ethanol.",8742498_5,1
14911,AAP,105,108,"In these animals, only minor increases of serum transaminase activities were measured in the presence of AAP, and unlike the exacerbation caused by ethanol in mice on a standard diet, the liver damage was inhibited by 50% by ethanol.",8742498_5,0
14914,NAA,56,59,"A further 64% reduction of hepatitis was observed, when NAA was given to ethanol/AAP-mice.",8742498_6,0
14917,NAA,151,154,Our results provide evidence that the AAP-induced hepatitis and its exacerbation by ethanol can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate NAD.,8742498_7,0
3684,enzyme's,186,194,Our results provide evidence that the AAP-induced hepatitis and its exacerbation by ethanol can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate NAD.,8742498_7,0
3683,PARP,143,147,Our results provide evidence that the AAP-induced hepatitis and its exacerbation by ethanol can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate NAD.,8742498_7,0
14916,end-product,117,128,Our results provide evidence that the AAP-induced hepatitis and its exacerbation by ethanol can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate NAD.,8742498_7,0
14919,substrate NAD,195,208,Our results provide evidence that the AAP-induced hepatitis and its exacerbation by ethanol can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate NAD.,8742498_7,0
14920,NAA,31,34,We see the main application of NAA as for the combinational use in pharmaceutical preparations of acetaminophen in order to avoid hepatic damage in patients treated with this widely used analgesic.,8742498_8,0
14921,hepatic damage,130,144,We see the main application of NAA as for the combinational use in pharmaceutical preparations of acetaminophen in order to avoid hepatic damage in patients treated with this widely used analgesic.,8742498_8,1
3685,pharmaceutical preparations,67,94,We see the main application of NAA as for the combinational use in pharmaceutical preparations of acetaminophen in order to avoid hepatic damage in patients treated with this widely used analgesic.,8742498_8,0
14923,functional deficits,33,52,Lithium-associated cognitive and functional deficits reduced by a switch to divalproex sodium: a case series.,8752018_0,1
3686,divalproex sodium,76,93,Lithium-associated cognitive and functional deficits reduced by a switch to divalproex sodium: a case series.,8752018_0,0
14925,bipolar disorder,94,110,BACKGROUND: Lithium remains a first-line treatment for the acute and maintenance treatment of bipolar disorder.,8752018_1,1
7285,loss of,189,196,"Although much has been written about the management of the more common adverse effects of lithium, such as polyuria and tremor, more subtle lithium side effects such as cognitive deficits, loss of creativity, and functional impairments remain understudied.",8752018_2,1
7283,adverse effects,71,86,"Although much has been written about the management of the more common adverse effects of lithium, such as polyuria and tremor, more subtle lithium side effects such as cognitive deficits, loss of creativity, and functional impairments remain understudied.",8752018_2,1
14927,functional impairments,213,235,"Although much has been written about the management of the more common adverse effects of lithium, such as polyuria and tremor, more subtle lithium side effects such as cognitive deficits, loss of creativity, and functional impairments remain understudied.",8752018_2,1
14926,cognitive deficits,169,187,"Although much has been written about the management of the more common adverse effects of lithium, such as polyuria and tremor, more subtle lithium side effects such as cognitive deficits, loss of creativity, and functional impairments remain understudied.",8752018_2,1
7284,side effects,148,160,"Although much has been written about the management of the more common adverse effects of lithium, such as polyuria and tremor, more subtle lithium side effects such as cognitive deficits, loss of creativity, and functional impairments remain understudied.",8752018_2,1
14928,functional impairments,134,156,This report summarizes our experience in switching bipolar patients from lithium to divalproex sodium to alleviate such cognitive and functional impairments.,8752018_3,1
3687,divalproex sodium,84,101,This report summarizes our experience in switching bipolar patients from lithium to divalproex sodium to alleviate such cognitive and functional impairments.,8752018_3,0
3688,divalproex sodium,94,111,"RESULTS: We report seven cases where substitution of lithium, either fully or partially, with divalproex sodium was extremely helpful in reducing the cognitive, motivational, or creative deficits attributed to lithium in our bipolar patients.",8752018_5,0
14933,cognitive deficits,129,147,"CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.",8752018_6,1
7286,loss of,149,156,"CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.",8752018_6,1
3689,divalproex sodium,40,57,"CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.",8752018_6,0
14934,functional impairments,173,195,"CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits, loss of creativity, and functional impairments.",8752018_6,1
14935,tramadol,56,64,Nightmares and hallucinations after long-term intake of tramadol combined with antidepressants.,8766220_0,0
14936,Tramadol,0,8,Tramadol is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat cancer pain and chronic non malignant pain.,8766220_1,0
14937,opioid,19,25,Tramadol is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat cancer pain and chronic non malignant pain.,8766220_1,0
14938,chronic non malignant pain,126,152,Tramadol is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat cancer pain and chronic non malignant pain.,8766220_1,1
7287,cancer pain,110,121,Tramadol is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat cancer pain and chronic non malignant pain.,8766220_1,1
3690,serotonergic,57,69,Tramadol is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat cancer pain and chronic non malignant pain.,8766220_1,0
14939,paroxetine,44,54,This drug was initiated in association with paroxetine and dosulepine hydrochloride in a tetraparetic patient with chronic pain.,8766220_2,0
14940,dosulepine hydrochloride,59,83,This drug was initiated in association with paroxetine and dosulepine hydrochloride in a tetraparetic patient with chronic pain.,8766220_2,0
7288,chronic pain,115,127,This drug was initiated in association with paroxetine and dosulepine hydrochloride in a tetraparetic patient with chronic pain.,8766220_2,1
14942,tramadol,152,160,Fifty-six days after initiation of the treatment the patient presented hallucinations that only stopped after the withdrawal of psycho-active drugs and tramadol.,8766220_3,0
3691,psycho-active drugs,128,147,Fifty-six days after initiation of the treatment the patient presented hallucinations that only stopped after the withdrawal of psycho-active drugs and tramadol.,8766220_3,0
14944,pain killers,47,59,"The case report questions the long term use of pain killers combined with psycho-active drugs in chronic non malignant pain, especially if pain is under control.",8766220_4,0
14945,chronic non malignant pain,97,123,"The case report questions the long term use of pain killers combined with psycho-active drugs in chronic non malignant pain, especially if pain is under control.",8766220_4,1
3692,psycho-active drugs,74,93,"The case report questions the long term use of pain killers combined with psycho-active drugs in chronic non malignant pain, especially if pain is under control.",8766220_4,0
7289,long term,30,39,"The case report questions the long term use of pain killers combined with psycho-active drugs in chronic non malignant pain, especially if pain is under control.",8766220_4,1
14947,4-aminopyridine,31,46,Effect of calcium chloride and 4-aminopyridine therapy on desipramine toxicity in rats.,8800187_0,0
14946,calcium chloride,10,26,Effect of calcium chloride and 4-aminopyridine therapy on desipramine toxicity in rats.,8800187_0,0
3693,tricyclic antidepressant,63,87,BACKGROUND: Hypotension is a major contributor to mortality in tricyclic antidepressant overdose.,8800187_1,0
7291,blood pressure,44,58,CaCl2 and 4-aminopyridine failed to improve blood pressure.,8800187_10,1
14958,CaCl2,0,5,CaCl2 and 4-aminopyridine failed to improve blood pressure.,8800187_10,0
14959,4-aminopyridine,10,25,CaCl2 and 4-aminopyridine failed to improve blood pressure.,8800187_10,0
14961,CaCl2,84,89,The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups.,8800187_11,0
14960,ventricular arrhythmias,17,40,The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups.,8800187_11,1
14962,CaCl2,34,39,CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced hypotension in rats.,8800187_12,0
14963,4-aminopyridine,43,58,CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced hypotension in rats.,8800187_12,0
14964,reverse tricyclic,67,84,CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced hypotension in rats.,8800187_12,0
14966,CaCl2,0,5,CaCl2 therapy may possibly worsen both cardiovascular and central nervous system toxicity.,8800187_13,0
14967,central nervous system toxicity,58,89,CaCl2 therapy may possibly worsen both cardiovascular and central nervous system toxicity.,8800187_13,1
3699,calcium channel,41,56,These findings do not support a role for calcium channel inhibition in the pathogenesis of tricyclic antidepressant-induced hypotension.,8800187_14,0
3694,tricyclic antidepressants,25,50,Recent data suggest that tricyclic antidepressants inhibit calcium influx in some tissues.,8800187_2,0
3695,calcium channel,43,58,This study addressed the potential role of calcium channel blockade in tricyclic antidepressant-induced hypotension.,8800187_3,0
7290,blood pressure,83,97,METHODS: Two interventions were studied that have been shown previously to improve blood pressure with calcium channel blocker overdose.,8800187_4,1
3696,calcium channel blocker,103,126,METHODS: Two interventions were studied that have been shown previously to improve blood pressure with calcium channel blocker overdose.,8800187_4,0
14951,4-aminopyridine,10,25,CaCl2 and 4-aminopyridine.,8800187_5,0
14950,CaCl2,0,5,CaCl2 and 4-aminopyridine.,8800187_5,0
14952,tricyclic antidepressant desipramine,31,67,"Anesthetized rats received the tricyclic antidepressant desipramine IP to produce hypotension, QRS prolongation, and bradycardia.",8800187_6,0
3697,NaHCO3,43,49,"Fifteen min later, animals received CaCl2, NaHCO3, or saline.",8800187_7,0
14953,CaCl2,36,41,"Fifteen min later, animals received CaCl2, NaHCO3, or saline.",8800187_7,0
14954,tricyclic antidepressant desipramine,38,74,"In a second experiment, rats received tricyclic antidepressant desipramine IP followed in 15 min by 4-aminopyridine or saline.",8800187_8,0
14955,4-aminopyridine,100,115,"In a second experiment, rats received tricyclic antidepressant desipramine IP followed in 15 min by 4-aminopyridine or saline.",8800187_8,0
14956,reversed hypotension,32,52,RESULTS: NaHCO3 briefly (5 min) reversed hypotension and QRS prolongation.,8800187_9,1
3698,NaHCO3,9,15,RESULTS: NaHCO3 briefly (5 min) reversed hypotension and QRS prolongation.,8800187_9,0
14969,renal function,24,38,Effect of nifedipine on renal function in liver transplant recipients receiving tacrolimus.,8829025_0,1
14970,liver transplant,42,58,Effect of nifedipine on renal function in liver transplant recipients receiving tacrolimus.,8829025_0,1
3700,tacrolimus,80,90,Effect of nifedipine on renal function in liver transplant recipients receiving tacrolimus.,8829025_0,0
3701,tacrolimus,93,103,The effect of nifedipine on renal function in liver transplant recipients who were receiving tacrolimus was evaluated between January 1992 and January 1996.,8829025_1,0
14972,liver transplant,46,62,The effect of nifedipine on renal function in liver transplant recipients who were receiving tacrolimus was evaluated between January 1992 and January 1996.,8829025_1,1
14971,renal function,28,42,The effect of nifedipine on renal function in liver transplant recipients who were receiving tacrolimus was evaluated between January 1992 and January 1996.,8829025_1,1
3702,tacrolimus,33,43,"Two groups of patients receiving tacrolimus were compared over a period of 1 year, one group comprising hypertensive patients who were receiving nifedipine, and the other comprising nonhypertensive patients not receiving nifedipine.",8829025_2,0
3703,creatinine,98,108,Nifedipine significantly improved kidney function as indicated by a significant lowering of serum creatinine levels at 6 and 12 months.,8829025_4,0
14974,kidney function,34,49,Nifedipine significantly improved kidney function as indicated by a significant lowering of serum creatinine levels at 6 and 12 months.,8829025_4,1
14975,nephrotoxicity,59,73,The observed positive impact of nifedipine on reducing the nephrotoxicity associated with tacrolimus in liver transplant recipients should be an important factor in selecting an agent to treat hypertension in this population.,8829025_5,1
3704,tacrolimus,90,100,The observed positive impact of nifedipine on reducing the nephrotoxicity associated with tacrolimus in liver transplant recipients should be an important factor in selecting an agent to treat hypertension in this population.,8829025_5,0
14977,liver transplant,104,120,The observed positive impact of nifedipine on reducing the nephrotoxicity associated with tacrolimus in liver transplant recipients should be an important factor in selecting an agent to treat hypertension in this population.,8829025_5,1
7292,cerebral hypoxia,58,74,Alpha and beta coma in drug intoxication uncomplicated by cerebral hypoxia.,88336_0,1
14978,drug intoxication,23,40,Alpha and beta coma in drug intoxication uncomplicated by cerebral hypoxia.,88336_0,1
7293,hypoxic,93,100,"Four patients who were rendered comatose or stuporous by drug intoxication, but who were not hypoxic, are described.",88336_1,1
14979,drug intoxication,57,74,"Four patients who were rendered comatose or stuporous by drug intoxication, but who were not hypoxic, are described.",88336_1,1
14981,alcohol withdrawal symptoms,58,85,"Three patients received high doses of chlormethiazole for alcohol withdrawal symptoms, and one took a suicidal overdose of nitrazepam.",88336_2,1
14980,high doses,24,34,"Three patients received high doses of chlormethiazole for alcohol withdrawal symptoms, and one took a suicidal overdose of nitrazepam.",88336_2,0
3705,chlormethiazole,38,53,"Three patients received high doses of chlormethiazole for alcohol withdrawal symptoms, and one took a suicidal overdose of nitrazepam.",88336_2,0
3706,chlormethiazole,59,74,"The patient with nitrazepam overdose and two of those with chlormethiazole intoxication conformed to the criteria of 'alpha coma', showing non-reactive generalized or frontally predominant alpha activity in the EEG.",88336_3,0
3707,chlormethiazole,45,60,The fourth patient who was unconscious after chlormethiazole administration exhibite generalized non-reactive activity in the slow beta range.,88336_4,0
14986,offending agents,92,108,All four recovered completely without neurological sequelae following the withdrawal of the offending agents.,88336_5,0
14985,neurological sequelae,38,59,All four recovered completely without neurological sequelae following the withdrawal of the offending agents.,88336_5,1
7294,brain stem,97,107,The similarities between the effects of structural lesions and pharmacological depression of the brain stem reticular formation are discussed.,88336_6,1
14988,behavioural picture,59,78,"It is concluded that when this electroencephalographic and behavioural picture is seen in drug intoxication, in the absence of significant hypoxaemia, a favourable outcome may be anticipated.",88336_8,1
14989,drug intoxication,90,107,"It is concluded that when this electroencephalographic and behavioural picture is seen in drug intoxication, in the absence of significant hypoxaemia, a favourable outcome may be anticipated.",88336_8,1
14990,hypoxaemia,139,149,"It is concluded that when this electroencephalographic and behavioural picture is seen in drug intoxication, in the absence of significant hypoxaemia, a favourable outcome may be anticipated.",88336_8,1
3709,amlodipine,143,153,"Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.",8841157_0,0
7295,essential hypertension,64,86,"Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.",8841157_0,1
3708,angiotensin II,17,31,"Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.",8841157_0,0
3710,angiotensin II,61,75,"OBJECTIVE: To compare the antihypertensive efficacy of a new angiotensin II antagonist, valsartan, with a reference therapy, amlodipine.",8841157_1,0
3711,amlodipine,125,135,"OBJECTIVE: To compare the antihypertensive efficacy of a new angiotensin II antagonist, valsartan, with a reference therapy, amlodipine.",8841157_1,0
3715,amlodipine,66,76,Responder rates at 8 weeks were 66.7% for valsartan and 60.2% for amlodipine (p = 0.39).,8841157_10,0
3718,amlodipine,211,221,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,0
3719,amlodipine,239,249,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,0
7300,drug-related,17,29,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,1
3716,amlodipine,73,83,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,0
3717,amlodipine,172,182,"The incidence of drug-related dependent edema was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine).",8841157_12,0
3720,amlodipine,70,80,CONCLUSIONS: The data show that valsartan is at least as effective as amlodipine in the treatment of mild to moderate hypertension.,8841157_13,0
15000,dihydropyridine calcium antagonists,150,185,"The results also show valsartan to be well tolerated and suggest that it is not associated with side effects characteristic of this comparator class, dihydropyridine calcium antagonists.",8841157_14,0
7301,side effects,96,108,"The results also show valsartan to be well tolerated and suggest that it is not associated with side effects characteristic of this comparator class, dihydropyridine calcium antagonists.",8841157_14,1
3712,amlodipine,186,196,METHODS: One hundred sixty-eight adult outpatients with mild to moderate hypertension were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks.,8841157_2,0
7296,blood pressure,44,58,"After 8 weeks of therapy, in patients whose blood pressure remained uncontrolled, 5 mg amlodipine was added to the initial therapy.",8841157_3,1
3713,amlodipine,87,97,"After 8 weeks of therapy, in patients whose blood pressure remained uncontrolled, 5 mg amlodipine was added to the initial therapy.",8841157_3,0
7297,blood pressure,81,95,The primary efficacy variable was change from baseline in mean sitting diastolic blood pressure at 8 weeks.,8841157_5,1
7298,blood pressure,56,70,Secondary variables included change in sitting systolic blood pressure and responder rates.,8841157_6,1
3714,amlodipine,28,38,"RESULTS: Both valsartan and amlodipine were effective at lowering blood pressure at 4, 8, and 12 weeks.",8841157_7,0
7299,blood pressure,66,80,"RESULTS: Both valsartan and amlodipine were effective at lowering blood pressure at 4, 8, and 12 weeks.",8841157_7,1
15002,cocaine-induced paranoia,50,74,A measure of pupillary oscillation as a marker of cocaine-induced paranoia.,8854309_0,1
15001,pupillary oscillation,13,34,A measure of pupillary oscillation as a marker of cocaine-induced paranoia.,8854309_0,1
15004,CIP,26,29,Cocaine-induced paranoia (CIP) remains an important drug-induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged.,8854309_1,0
7302,drug-induced,52,64,Cocaine-induced paranoia (CIP) remains an important drug-induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged.,8854309_1,1
15003,Cocaine-induced paranoia,0,24,Cocaine-induced paranoia (CIP) remains an important drug-induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged.,8854309_1,1
15005,idiopathic paranoia,74,93,Cocaine-induced paranoia (CIP) remains an important drug-induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged.,8854309_1,1
15008,CIP,131,134,Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).,8854309_2,0
3721,crack cocaine,94,107,Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).,8854309_2,0
15007,pupillary oscillation,12,33,Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29).,8854309_2,1
7303,cerebellar atrophy,88,106,The aim of this study was to evaluate the relationship between phenytoin medication and cerebellar atrophy in patients who had experienced clinical intoxication.,8864707_1,1
15014,clinical intoxication,139,160,The aim of this study was to evaluate the relationship between phenytoin medication and cerebellar atrophy in patients who had experienced clinical intoxication.,8864707_1,1
7304,cerebellar atrophy,69,87,We conclude that phenytoin overdosage does not necessarily result in cerebellar atrophy and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients.,8864707_10,1
15023,cause of cerebellar atrophy,146,173,We conclude that phenytoin overdosage does not necessarily result in cerebellar atrophy and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients.,8864707_10,1
7305,cerebellar disorders,103,123,Quantitative morphometric studies of the cerebellum provide valuable insights into the pathogenesis of cerebellar disorders.,8864707_11,1
7306,Serotonin syndrome,0,18,Serotonin syndrome from venlafaxine-tranylcypromine interaction.,8888541_0,1
7307,muscle rigidity,117,132,"Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, confusion, agitation and hyperthermia.",8888541_1,1
15025,serotonin 5HT1A receptors,25,50,"Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, confusion, agitation and hyperthermia.",8888541_1,0
7313,muscle rigidity,100,115,"He was intubated for airway protection and because of hypoventilation, and was paralyzed to control muscle rigidity.",8888541_10,1
7312,hypoventilation,54,69,"He was intubated for airway protection and because of hypoventilation, and was paralyzed to control muscle rigidity.",8888541_10,1
15034,non-immune thrombocytopenia,41,68,His subsequent course was remarkable for non-immune thrombocytopenia which resolved.,8888541_11,1
3728,His,0,3,His subsequent course was remarkable for non-immune thrombocytopenia which resolved.,8888541_11,0
15036,his CPK,50,57,The patient's maximal temperature was 101.2 F and his CPK remained < 500 units/L with no other evidence of rhabdomyolysis.,8888541_12,0
7314,rhabdomyolysis,107,121,The patient's maximal temperature was 101.2 F and his CPK remained < 500 units/L with no other evidence of rhabdomyolysis.,8888541_12,1
15038,aggressive sedation,50,69,This patient survived without sequelae due to the aggressive sedation and neuromuscular paralysis.,8888541_14,1
15039,neuromuscular paralysis,74,97,This patient survived without sequelae due to the aggressive sedation and neuromuscular paralysis.,8888541_14,1
3722,monoamine oxidase inhibitor,67,94,The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.,8888541_2,0
3723,serotonin reuptake inhibitor,117,145,The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.,8888541_2,0
15026,cause of,16,24,The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor.,8888541_2,1
15027,antidepressant agent,21,41,Venlafaxine is a new antidepressant agent that inhibits the reuptake of serotonin and norepinephrine.,8888541_3,0
3724,Venlafaxine,0,11,Venlafaxine is a new antidepressant agent that inhibits the reuptake of serotonin and norepinephrine.,8888541_3,0
15028,venlafaxine-MAOI,12,28,We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression.,8888541_4,0
7308,serotonin syndrome,62,80,We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression.,8888541_4,1
3725,venlafaxine,75,86,He had been well until the morning of presentation when he took 1/2 tab of venlafaxine.,8888541_5,0
3726,his,56,59,"Within 2 h he became confused with jerking movements of his extremities, tremors and rigidity.",8888541_6,0
7309,myoclonic jerks,101,116,"He was brought directly to a hospital where he was found to be agitated and confused with shivering, myoclonic jerks, rigidity, salivation and diaphoresis.",8888541_7,1
3727,His,0,3,His pupils were 7 mm and sluggishly reactive to light.,8888541_8,0
7310,blood pressure,18,32,"Vital signs were: blood pressure 120/67 mm Hg, heart rate 127/min, respiratory rate 28/min, and temperature 97 F. After 180 mg of diazepam i.v. he remained tremulous with muscle rigidity and clenched jaws.",8888541_9,1
15029,Vital signs,0,11,"Vital signs were: blood pressure 120/67 mm Hg, heart rate 127/min, respiratory rate 28/min, and temperature 97 F. After 180 mg of diazepam i.v. he remained tremulous with muscle rigidity and clenched jaws.",8888541_9,1
15032,heart rate,47,57,"Vital signs were: blood pressure 120/67 mm Hg, heart rate 127/min, respiratory rate 28/min, and temperature 97 F. After 180 mg of diazepam i.v. he remained tremulous with muscle rigidity and clenched jaws.",8888541_9,1
7311,muscle rigidity,171,186,"Vital signs were: blood pressure 120/67 mm Hg, heart rate 127/min, respiratory rate 28/min, and temperature 97 F. After 180 mg of diazepam i.v. he remained tremulous with muscle rigidity and clenched jaws.",8888541_9,1
15040,Late recovery,0,13,Late recovery of renal function in a woman with the hemolytic uremic syndrome.,891050_0,1
15041,renal function,17,31,Late recovery of renal function in a woman with the hemolytic uremic syndrome.,891050_0,1
7315,hemolytic uremic syndrome,52,77,Late recovery of renal function in a woman with the hemolytic uremic syndrome.,891050_0,1
15042,woman taking oral contraceptives,63,95,A case is reported of the hemolytic uremic syndrome (HUS) in a woman taking oral contraceptives.,891050_1,0
7316,hemolytic uremic syndrome,26,51,A case is reported of the hemolytic uremic syndrome (HUS) in a woman taking oral contraceptives.,891050_1,1
3729,dipyridamole,30,42,"She was treated with heparin, dipyridamole and hemodialysis; and after more than three months, her urinary output rose above 500 ml; and six months after the onset of anuria, dialysis treatment was stopped.",891050_2,0
3730,her,95,98,"She was treated with heparin, dipyridamole and hemodialysis; and after more than three months, her urinary output rose above 500 ml; and six months after the onset of anuria, dialysis treatment was stopped.",891050_2,0
15046,renal function,137,151,"This case emphasizes the possibility that HUS in adults is not invariably irreversible and that, despite prolonged oliguria, recovery of renal function can be obtained.",891050_3,1
15047,bilateral nephrectomy,105,126,"Therefore, in adult patients affected by HUS, dialysis should not be discontinued prematurely; moreover, bilateral nephrectomy, for treatment of severe hypertension and microangiopathic hemolytic anemia, should be performed with caution.",891050_4,1
7317,microangiopathic hemolytic anemia,169,202,"Therefore, in adult patients affected by HUS, dialysis should not be discontinued prematurely; moreover, bilateral nephrectomy, for treatment of severe hypertension and microangiopathic hemolytic anemia, should be performed with caution.",891050_4,1
15048,Cyclophosphamide,0,16,Cyclophosphamide associated bladder cancer--a highly aggressive disease: analysis of 12 cases.,8911359_0,0
7318,bladder cancer,28,42,Cyclophosphamide associated bladder cancer--a highly aggressive disease: analysis of 12 cases.,8911359_0,1
15049,aggressive disease,53,71,Cyclophosphamide associated bladder cancer--a highly aggressive disease: analysis of 12 cases.,8911359_0,1
15050,cyclophosphamide,74,90,"PURPOSE: We gained knowledge of the etiology, treatment and prevention of cyclophosphamide associated urothelial cancer.",8911359_1,0
15051,urothelial,102,112,"PURPOSE: We gained knowledge of the etiology, treatment and prevention of cyclophosphamide associated urothelial cancer.",8911359_1,1
7319,bladder cancer,117,131,MATERIALS AND METHODS: The medical records of 6 men and 6 women (mean age 55 years) with cyclophosphamide associated bladder cancer were reviewed.,8911359_2,1
15053,cyclophosphamide,89,105,MATERIALS AND METHODS: The medical records of 6 men and 6 women (mean age 55 years) with cyclophosphamide associated bladder cancer were reviewed.,8911359_2,0
7321,transitional cell carcinoma,38,65,RESULTS: All tumors were grade 3 or 4 transitional cell carcinoma.,8911359_3,1
7320,grade 3,25,32,RESULTS: All tumors were grade 3 or 4 transitional cell carcinoma.,8911359_3,1
15055,endoscopic resection,41,61,Of the 5 patients initially treated with endoscopic resection alone only 1 is alive without disease.,8911359_4,1
15056,early cystectomy,32,48,Of the 6 patients who underwent early cystectomy 4 were alive at 24 to 111 months.,8911359_5,1
15057,partial cystectomy,54,72,The remaining patient with extensive cancer underwent partial cystectomy for palliation and died 3 months later.,8911359_6,1
15059,aggressive disease,61,79,CONCLUSIONS: Cyclophosphamide associated bladder tumor is an aggressive disease.,8911359_7,1
15058,Cyclophosphamide,13,29,CONCLUSIONS: Cyclophosphamide associated bladder tumor is an aggressive disease.,8911359_7,0
7322,bladder tumor,41,54,CONCLUSIONS: Cyclophosphamide associated bladder tumor is an aggressive disease.,8911359_7,1
7323,bladder tumors,81,95,"However, long-term survival is possible when radical cystectomy is performed for bladder tumors with any sign of invasion and for recurrent high grade disease, even when noninvasive.",8911359_8,1
15061,high grade disease,140,158,"However, long-term survival is possible when radical cystectomy is performed for bladder tumors with any sign of invasion and for recurrent high grade disease, even when noninvasive.",8911359_8,1
15060,radical cystectomy,45,63,"However, long-term survival is possible when radical cystectomy is performed for bladder tumors with any sign of invasion and for recurrent high grade disease, even when noninvasive.",8911359_8,1
15063,antiepileptic drug valproate,77,105,Morphological features of encephalopathy after chronic administration of the antiepileptic drug valproate to rats.,8919272_0,0
15065,cerebellar cortex,64,81,A transmission electron microscopic study of capillaries in the cerebellar cortex.,8919272_1,1
15088,perivascular,88,100,"Damage to the capillary was accompanied by marked damage to neuroglial cells, mainly to perivascular processes of astrocytes.",8919272_11,1
15087,neuroglial cells,60,76,"Damage to the capillary was accompanied by marked damage to neuroglial cells, mainly to perivascular processes of astrocytes.",8919272_11,1
15091,Purkinje cells,110,124,Alterations in the structural elements of the BBB coexisted with marked lesions of neurons of the cerebellum (Purkinje cells are earliest).,8919272_13,1
15090,BBB,46,49,Alterations in the structural elements of the BBB coexisted with marked lesions of neurons of the cerebellum (Purkinje cells are earliest).,8919272_13,0
15094,cerebellar cortex,77,94,In electron micrographs both luminal and antiluminal sides of the BBB of the cerebellar cortex had similar lesions.,8919272_14,1
15093,BBB,66,69,In electron micrographs both luminal and antiluminal sides of the BBB of the cerebellar cortex had similar lesions.,8919272_14,0
7325,hyperammonemia,53,67,"The possible influence of the hepatic damage, mainly hyperammonemia, upon the development of valproate encephalopathy is discussed.",8919272_15,1
15096,valproate,93,102,"The possible influence of the hepatic damage, mainly hyperammonemia, upon the development of valproate encephalopathy is discussed.",8919272_15,0
15095,hepatic damage,30,44,"The possible influence of the hepatic damage, mainly hyperammonemia, upon the development of valproate encephalopathy is discussed.",8919272_15,1
7324,neurological disorders,193,215,"Long-term intragastric application of the antiepileptic drug sodium valproate (Vupral ""Polfa"") at the effective dose of 200 mg/kg b. w. once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating cerebellum damage (""valproate encephalopathy"").",8919272_2,1
15067,antiepileptic drug sodium valproate,42,77,"Long-term intragastric application of the antiepileptic drug sodium valproate (Vupral ""Polfa"") at the effective dose of 200 mg/kg b. w. once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating cerebellum damage (""valproate encephalopathy"").",8919272_2,0
15068,Polfa,87,92,"Long-term intragastric application of the antiepileptic drug sodium valproate (Vupral ""Polfa"") at the effective dose of 200 mg/kg b. w. once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating cerebellum damage (""valproate encephalopathy"").",8919272_2,0
15069,cerebellum damage,227,244,"Long-term intragastric application of the antiepileptic drug sodium valproate (Vupral ""Polfa"") at the effective dose of 200 mg/kg b. w. once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating cerebellum damage (""valproate encephalopathy"").",8919272_2,1
15070,valproate encephalopathy,247,271,"Long-term intragastric application of the antiepileptic drug sodium valproate (Vupral ""Polfa"") at the effective dose of 200 mg/kg b. w. once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating cerebellum damage (""valproate encephalopathy"").",8919272_2,1
15074,cerebellar cortex,97,114,The first ultrastructural changes in structural elements of the blood-brain-barrier (BBB) in the cerebellar cortex were detectable after 3 months of the experiment.,8919272_3,1
15073,BBB,85,88,The first ultrastructural changes in structural elements of the blood-brain-barrier (BBB) in the cerebellar cortex were detectable after 3 months of the experiment.,8919272_3,0
15076,cerebellar cortex,146,163,"They became more severe in the later months of the experiment, and were most severe after 12 months, located mainly in the molecular layer of the cerebellar cortex.",8919272_4,1
15079,capillary lumen,16,31,Reduced size of capillary lumen and occlusion were caused by swollen endothelial cells which had luminal protrusions and swollen microvilli.,8919272_7,1
15082,vessel wall,16,27,Pressure on the vessel wall was produced by enlarged perivascular astrocytic processes.,8919272_8,1
15083,perivascular,53,65,Pressure on the vessel wall was produced by enlarged perivascular astrocytic processes.,8919272_8,1
15085,tight cellular junctions,117,141,Fragments of necrotic endothelial cells were in the vascular lumens and in these there was loosening and breaking of tight cellular junctions.,8919272_9,0
15097,intracranial bleeding,6,27,Fatal intracranial bleeding associated with prehospital use of epinephrine.,8953972_0,1
15099,prehospital,44,55,Fatal intracranial bleeding associated with prehospital use of epinephrine.,8953972_0,1
7327,pulmonary edema,126,141,We present a case of paramedic misjudgment in the execution of a protocol for the treatment of allergic reaction in a case of pulmonary edema with wheezing.,8953972_1,1
7326,allergic reaction,95,112,We present a case of paramedic misjudgment in the execution of a protocol for the treatment of allergic reaction in a case of pulmonary edema with wheezing.,8953972_1,1
15101,sudden onset of respiratory distress,4,40,"The sudden onset of respiratory distress, rash, and a history of a new medicine led the two paramedics on the scene to administer subcutaneous epinephrine.",8953972_2,1
15102,subcutaneous epinephrine,130,154,"The sudden onset of respiratory distress, rash, and a history of a new medicine led the two paramedics on the scene to administer subcutaneous epinephrine.",8953972_2,0
7328,cardiac arrest,20,34,"Subsequently, acute cardiac arrest and fatal subarachnoid hemorrhage occurred.",8953972_3,1
7329,subarachnoid hemorrhage,45,68,"Subsequently, acute cardiac arrest and fatal subarachnoid hemorrhage occurred.",8953972_3,1
15103,prehospital care,51,67,"Epinephrine has a proven role in cardiac arrest in prehospital care; however, use by paramedics in patients with suspected allergic reaction and severe hypertension should be viewed with caution.",8953972_4,1
7330,cardiac arrest,33,47,"Epinephrine has a proven role in cardiac arrest in prehospital care; however, use by paramedics in patients with suspected allergic reaction and severe hypertension should be viewed with caution.",8953972_4,1
7331,allergic reaction,123,140,"Epinephrine has a proven role in cardiac arrest in prehospital care; however, use by paramedics in patients with suspected allergic reaction and severe hypertension should be viewed with caution.",8953972_4,1
3731,bradykinin B2 receptors,22,45,Role of activation of bradykinin B2 receptors in disruption of the blood-brain barrier during acute hypertension.,8955532_0,0
15105,acute hypertension,94,112,Role of activation of bradykinin B2 receptors in disruption of the blood-brain barrier during acute hypertension.,8955532_0,1
15104,blood-brain barrier,67,86,Role of activation of bradykinin B2 receptors in disruption of the blood-brain barrier during acute hypertension.,8955532_0,1
15108,acute hypertension,80,98,Cellular mechanisms which account for disruption the blood-brain barrier during acute hypertension are not clear.,8955532_1,1
15107,blood-brain barrier,53,72,Cellular mechanisms which account for disruption the blood-brain barrier during acute hypertension are not clear.,8955532_1,1
15111,acute hypertension,157,175,The goal of this study was to determine the role of synthesis/release of bradykinin to activate B2 receptors in disruption of the blood-brain barrier during acute hypertension.,8955532_2,1
3733,B2 receptors,96,108,The goal of this study was to determine the role of synthesis/release of bradykinin to activate B2 receptors in disruption of the blood-brain barrier during acute hypertension.,8955532_2,0
3732,bradykinin,73,83,The goal of this study was to determine the role of synthesis/release of bradykinin to activate B2 receptors in disruption of the blood-brain barrier during acute hypertension.,8955532_2,0
15109,synthesis/release,52,69,The goal of this study was to determine the role of synthesis/release of bradykinin to activate B2 receptors in disruption of the blood-brain barrier during acute hypertension.,8955532_2,0
15114,Hoe-140,192,199,Permeability of the blood-brain barrier was quantitated by clearance of fluorescent-labeled dextran before and during phenylephrine-induced acute hypertension in rats treated with vehicle and Hoe-140 (0.1 microM).,8955532_3,0
3734,dextran,92,99,Permeability of the blood-brain barrier was quantitated by clearance of fluorescent-labeled dextran before and during phenylephrine-induced acute hypertension in rats treated with vehicle and Hoe-140 (0.1 microM).,8955532_3,0
3735,dextran,101,108,"Phenylephrine infusion increased arterial pressure, arteriolar diameter and clearance of fluorescent dextran by a similar magnitude in both groups.",8955532_4,0
15115,arterial pressure,33,50,"Phenylephrine infusion increased arterial pressure, arteriolar diameter and clearance of fluorescent dextran by a similar magnitude in both groups.",8955532_4,1
15118,acute hypertension,73,91,These findings suggest that disruption of the blood-brain barrier during acute hypertension is not related to the synthesis/release of bradykinin to activate B2 receptors.,8955532_5,1
15119,synthesis/release,114,131,These findings suggest that disruption of the blood-brain barrier during acute hypertension is not related to the synthesis/release of bradykinin to activate B2 receptors.,8955532_5,0
3737,B2 receptors,158,170,These findings suggest that disruption of the blood-brain barrier during acute hypertension is not related to the synthesis/release of bradykinin to activate B2 receptors.,8955532_5,0
3736,bradykinin,135,145,These findings suggest that disruption of the blood-brain barrier during acute hypertension is not related to the synthesis/release of bradykinin to activate B2 receptors.,8955532_5,0
15122,DDATHF,66,72,A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.,8958188_0,0
15121,antipurine antifolate lometrexol,32,64,A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.,8958188_0,0
15123,folic acid,90,100,A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid.,8958188_0,0
15124,Lometrexol,0,10,"Lometrexol is an antifolate which inhibits glycinamide ribonucleotide formyltransferase (GARFT), an enzyme essential for de novo purine synthesis.",8958188_1,0
15125,glycinamide ribonucleotide formyltransferase,43,87,"Lometrexol is an antifolate which inhibits glycinamide ribonucleotide formyltransferase (GARFT), an enzyme essential for de novo purine synthesis.",8958188_1,0
15126,GARFT,89,94,"Lometrexol is an antifolate which inhibits glycinamide ribonucleotide formyltransferase (GARFT), an enzyme essential for de novo purine synthesis.",8958188_1,0
3738,antifolate,17,27,"Lometrexol is an antifolate which inhibits glycinamide ribonucleotide formyltransferase (GARFT), an enzyme essential for de novo purine synthesis.",8958188_1,0
15128,lometrexol,65,75,"Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs, notably methotrexate.",8958188_2,0
15130,lometrexol,45,55,"However, the initial clinical development of lometrexol was curtailed because of severe and cumulative antiproliferative toxicities.",8958188_3,0
15133,low dose folic acid,92,111,"Preclinical murine studies demonstrated that the toxicity of lometrexol can be prevented by low dose folic acid administration, i.e. for 7 days prior to and 7 days following a single bolus dose.",8958188_4,0
15132,lometrexol,61,71,"Preclinical murine studies demonstrated that the toxicity of lometrexol can be prevented by low dose folic acid administration, i.e. for 7 days prior to and 7 days following a single bolus dose.",8958188_4,0
15138,folic acid,182,192,This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation.,8958188_5,0
15135,lometrexol,54,64,This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation.,8958188_5,0
15136,folic acid,76,86,This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation.,8958188_5,0
15137,lometrexol,144,154,This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation.,8958188_5,0
7332,mucositis,21,30,Thrombocytopenia and mucositis were the major toxicities.,8958188_6,1
15139,lometrexol,37,47,Associated studies demonstrated that lometrexol plasma pharmacokinetics were not altered by folic acid administration indicating that supplementation is unlikely to reduce toxicity by enhancing lometrexol plasma clearance.,8958188_8,0
15141,lometrexol,194,204,Associated studies demonstrated that lometrexol plasma pharmacokinetics were not altered by folic acid administration indicating that supplementation is unlikely to reduce toxicity by enhancing lometrexol plasma clearance.,8958188_8,0
15140,folic acid,92,102,Associated studies demonstrated that lometrexol plasma pharmacokinetics were not altered by folic acid administration indicating that supplementation is unlikely to reduce toxicity by enhancing lometrexol plasma clearance.,8958188_8,0
15142,GARFT inhibitor,129,144,The work described in this report has identified for the first time a clinically acceptable schedule for the administration of a GARFT inhibitor.,8958188_9,0
15144,cocaine use,33,44,Fatal excited delirium following cocaine use: epidemiologic findings provide new evidence for mechanisms of cocaine toxicity.,8988571_0,1
15145,cocaine-induced excited delirium,39,71,"We describe an outbreak of deaths from cocaine-induced excited delirium (EDDs) in Dade County, Florida between 1979 and 1990.",8988571_1,1
7333,cocaine-related,23,38,"From a registry of all cocaine-related deaths in Dade County, Florida, from 1969-1990, 58 EDDs were compared with 125 victims of accidental cocaine overdose without excited delirium.",8988571_2,1
15146,body mass index,36,51,"They were less likely to have a low body mass index, and more likely to have died in police custody, to have received medical treatment immediately before death, to have survived for a longer period, to have developed hyperthermia, and to have died in summer months.",8988571_4,1
15147,benzoylecgonine,39,54,EDDs had concentrations of cocaine and benzoylecgonine in autopsy blood that were similar to those for controls.,8988571_5,0
3739,dopaminergic,101,113,"The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate agitation, delirium, aberrant thermoregulation, rhabdomyolysis, and sudden death.",8988571_6,0
7335,sudden death,250,262,"The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate agitation, delirium, aberrant thermoregulation, rhabdomyolysis, and sudden death.",8988571_6,1
7334,rhabdomyolysis,230,244,"The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate agitation, delirium, aberrant thermoregulation, rhabdomyolysis, and sudden death.",8988571_6,1
7337,preterm,46,53,Risk factors of sensorineural hearing loss in preterm infants.,8996652_0,1
7336,sensorineural hearing loss,16,42,Risk factors of sensorineural hearing loss in preterm infants.,8996652_0,1
7338,preterm,10,17,"Among 547 preterm infants of < or = 34 weeks gestation born between 1987 and 1991, 8 children (1.46%) developed severe progressive and bilateral sensorineural hearing loss.",8996652_1,1
7339,sensorineural hearing loss,145,171,"Among 547 preterm infants of < or = 34 weeks gestation born between 1987 and 1991, 8 children (1.46%) developed severe progressive and bilateral sensorineural hearing loss.",8996652_1,1
15153,perinatal complications,146,169,Perinatal risk factors of infants with hearing loss were compared with those of two control groups matched for gestation and birth weight and for perinatal complications.,8996652_2,1
7340,hearing loss,39,51,Perinatal risk factors of infants with hearing loss were compared with those of two control groups matched for gestation and birth weight and for perinatal complications.,8996652_2,1
7341,birth weight,125,137,Perinatal risk factors of infants with hearing loss were compared with those of two control groups matched for gestation and birth weight and for perinatal complications.,8996652_2,1
15154,perinatal complications,88,111,Our observations demonstrated an association of hearing loss with a higher incidence of perinatal complications.,8996652_3,1
7342,hearing loss,48,60,Our observations demonstrated an association of hearing loss with a higher incidence of perinatal complications.,8996652_3,1
7343,Ototoxicity,0,11,"Ototoxicity appeared closely related to a prolonged administration and higher total dose of ototoxic drugs, particularly aminoglycosides and furosemide.",8996652_4,1
3740,aminoglycosides,121,136,"Ototoxicity appeared closely related to a prolonged administration and higher total dose of ototoxic drugs, particularly aminoglycosides and furosemide.",8996652_4,0
7345,hearing loss,120,132,"Finally, we strongly recommend to prospectively and regularly perform audiologic assessment in sick preterm children as hearing loss is of delayed onset and in most cases bilateral and severe.",8996652_5,1
15158,delayed onset,139,152,"Finally, we strongly recommend to prospectively and regularly perform audiologic assessment in sick preterm children as hearing loss is of delayed onset and in most cases bilateral and severe.",8996652_5,1
7344,preterm,100,107,"Finally, we strongly recommend to prospectively and regularly perform audiologic assessment in sick preterm children as hearing loss is of delayed onset and in most cases bilateral and severe.",8996652_5,1
3741,Pemoline,0,8,Pemoline induced acute choreoathetosis: case report and review of the literature.,9022662_0,0
7346,choreoathetosis,23,38,Pemoline induced acute choreoathetosis: case report and review of the literature.,9022662_0,1
15161,attention deficit disorder,128,154,BACKGROUND: Pemoline is an oxazolidine derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder.,9022662_1,1
15160,oxazolidine derivative,27,49,BACKGROUND: Pemoline is an oxazolidine derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder.,9022662_1,0
3742,Pemoline,12,20,BACKGROUND: Pemoline is an oxazolidine derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder.,9022662_1,0
7351,choreoathetosis,50,65,"Despite treatment, the children continued to have choreoathetosis for approximately 24 hours.",9022662_10,1
3747,Pemoline,12,20,CONCLUSION: Pemoline associated movement disorder has been rarely reported in the acute toxicology literature.,9022662_12,0
15175,movement disorder,32,49,CONCLUSION: Pemoline associated movement disorder has been rarely reported in the acute toxicology literature.,9022662_12,1
3748,pemoline,94,102,The possibility of choreoathetoid movements should be considered in patients presenting after pemoline overdose.,9022662_13,0
15176,choreoathetoid,19,33,The possibility of choreoathetoid movements should be considered in patients presenting after pemoline overdose.,9022662_13,1
3743,Pemoline,0,8,Pemoline has not been commonly associated in the literature as a cause of acute movement disorders.,9022662_2,0
15163,cause of,65,73,Pemoline has not been commonly associated in the literature as a cause of acute movement disorders.,9022662_2,1
7347,movement disorders,80,98,Pemoline has not been commonly associated in the literature as a cause of acute movement disorders.,9022662_2,1
7348,choreoathetosis,98,113,The following case describes two children acutely poisoned with pemoline who experienced profound choreoathetosis.,9022662_3,1
3744,pemoline,64,72,The following case describes two children acutely poisoned with pemoline who experienced profound choreoathetosis.,9022662_3,0
15165,emergency department,76,96,"CASE REPORT: Two, 3-year-old male, identical twin siblings presented to the emergency department after found playing with a an empty bottle of pemoline originally containing 59 tablets.",9022662_4,1
15164,twin siblings,45,58,"CASE REPORT: Two, 3-year-old male, identical twin siblings presented to the emergency department after found playing with a an empty bottle of pemoline originally containing 59 tablets.",9022662_4,1
3745,pemoline,143,151,"CASE REPORT: Two, 3-year-old male, identical twin siblings presented to the emergency department after found playing with a an empty bottle of pemoline originally containing 59 tablets.",9022662_4,0
15167,attention deficit disorder,51,77,The children had a medical history significant for attention deficit disorder previously treated with methylphenidate without success.,9022662_5,1
3746,pemoline,28,36,This was their first day of pemoline therapy.,9022662_6,0
15168,choreoathetoid,4,18,The choreoathetoid movements began 45 min to 1 h after ingestion.,9022662_7,1
7349,movement disorders,38,56,The children gave no history of prior movement disorders and there was no family history of movement disorders.,9022662_8,1
7350,movement disorders,92,110,The children gave no history of prior movement disorders and there was no family history of movement disorders.,9022662_8,1
15170,family history,74,88,The children gave no history of prior movement disorders and there was no family history of movement disorders.,9022662_8,1
15174,choreoathetoid,130,144,The children received gastrointestinal decontamination and high doses of intravenous benzodiazepines in an attempt to control the choreoathetoid movements.,9022662_9,1
15173,intravenous benzodiazepines,73,100,The children received gastrointestinal decontamination and high doses of intravenous benzodiazepines in an attempt to control the choreoathetoid movements.,9022662_9,0
15172,high doses,59,69,The children received gastrointestinal decontamination and high doses of intravenous benzodiazepines in an attempt to control the choreoathetoid movements.,9022662_9,0
3749,venlafaxine,25,36,Seizure resulting from a venlafaxine overdose.,9034419_0,0
3750,venlafaxine,31,42,OBJECTIVE: To report a case of venlafaxine overdose.,9034419_1,0
3751,venlafaxine,76,87,CASE SUMMARY: A 40-year-old woman with major depression took an overdose of venlafaxine in an apparent suicide attempt.,9034419_2,0
15177,suicide attempt,103,118,CASE SUMMARY: A 40-year-old woman with major depression took an overdose of venlafaxine in an apparent suicide attempt.,9034419_2,1
3752,venlafaxine,26,37,"After the ingestion of 26 venlafaxine 50-mg tablets, the patient experienced a witnessed generalized seizure.",9034419_3,0
7352,generalized seizure,89,108,"After the ingestion of 26 venlafaxine 50-mg tablets, the patient experienced a witnessed generalized seizure.",9034419_3,1
3753,venlafaxine,53,64,"She was admitted to the medical intensive care unit, venlafaxine was discontinued, and no further sequelae were seen.",9034419_4,0
7353,generalized seizure,105,124,"DISCUSSION: To our knowledge, this is the first reported case of venlafaxine overdose that resulted in a generalized seizure.",9034419_5,1
3754,venlafaxine,65,76,"DISCUSSION: To our knowledge, this is the first reported case of venlafaxine overdose that resulted in a generalized seizure.",9034419_5,0
3755,venlafaxine,62,73,"Based on nonoverdose pharmacokinetics and pharmacodynamics of venlafaxine and the potential risks of available interventions, no emergent therapy was instituted.",9034419_6,0
15179,nonoverdose,9,20,"Based on nonoverdose pharmacokinetics and pharmacodynamics of venlafaxine and the potential risks of available interventions, no emergent therapy was instituted.",9034419_6,0
3756,venlafaxine,17,28,CONCLUSIONS: The venlafaxine overdose in our patient resulted in a single episode of generalized seizure but elicited no further sequelae.,9034419_7,0
7354,generalized seizure,85,104,CONCLUSIONS: The venlafaxine overdose in our patient resulted in a single episode of generalized seizure but elicited no further sequelae.,9034419_7,1
15182,keratectomy,47,58,Effect of myopic excimer laser photorefractive keratectomy on the electrophysiologic function of the retina and optic nerve.,9041081_0,1
15181,myopic excimer laser,10,30,Effect of myopic excimer laser photorefractive keratectomy on the electrophysiologic function of the retina and optic nerve.,9041081_0,1
7355,optic nerve,112,123,Effect of myopic excimer laser photorefractive keratectomy on the electrophysiologic function of the retina and optic nerve.,9041081_0,1
15185,photorefractive keratectomy,63,90,PURPOSE: To assess by electrophysiologic testing the effect of photorefractive keratectomy (PRK) on the retina and optic nerve.,9041081_1,1
7356,optic nerve,115,126,PURPOSE: To assess by electrophysiologic testing the effect of photorefractive keratectomy (PRK) on the retina and optic nerve.,9041081_1,1
3757,(D,224,226,METHODS: Standard pattern electroretinograms (P-ERGs) and standard pattern visual evoked potentials (P-VEPs) were done in 25 eyes of 25 patients who had myopic PRK for an attempted correction between 5.00 and 15.00 diopters (D) (mean 8.00 D).,9041081_3,0
7357,intraocular,74,85,"During the follow-up, 3 patients (12%) developed steroid-induced elevated intraocular pressure (IOP) that resolved after corticosteroid therapy was discontinued.",9041081_6,1
15193,posterior segment,64,81,CONCLUSION: Myopic excimer laser PRK did not seem to affect the posterior segment.,9041081_8,1
15194,functional impairment,61,82,The transient steroid-induced IOP rise did not seem to cause functional impairment.,9041081_9,1
3758,hydrogen peroxide,26,43,Neutrophil superoxide and hydrogen peroxide production in patients with acute liver failure.,9061311_0,0
7358,acute liver failure,72,91,Neutrophil superoxide and hydrogen peroxide production in patients with acute liver failure.,9061311_0,1
15195,Neutrophil superoxide,0,21,Neutrophil superoxide and hydrogen peroxide production in patients with acute liver failure.,9061311_0,0
7359,bacterial infections,98,118,Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure (ALF).,9061311_1,1
7360,acute liver failure,136,155,Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure (ALF).,9061311_1,1
15196,ALF,157,160,Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure (ALF).,9061311_1,0
3759,hydrogen peroxide,26,43,Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure (ALF).,9061311_1,0
15197,ALF,65,68,"In the present study, oxygen radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers.",9061311_2,0
3761,paracetamol,76,87,"In the present study, oxygen radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers.",9061311_2,0
3760,oxygen radical,22,36,"In the present study, oxygen radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers.",9061311_2,0
15201,ALF,107,110,Neutrophils from 14 ALF patients were stimulated via the complement receptors using zymosan opsonized with ALF or control serum.,9061311_3,0
15200,zymosan,84,91,Neutrophils from 14 ALF patients were stimulated via the complement receptors using zymosan opsonized with ALF or control serum.,9061311_3,0
15199,ALF,20,23,Neutrophils from 14 ALF patients were stimulated via the complement receptors using zymosan opsonized with ALF or control serum.,9061311_3,0
3762,complement receptors,57,77,Neutrophils from 14 ALF patients were stimulated via the complement receptors using zymosan opsonized with ALF or control serum.,9061311_3,0
15203,ALF,47,50,Superoxide and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects (P < 0.01).,9061311_4,0
3763,hydrogen peroxide,15,32,Superoxide and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects (P < 0.01).,9061311_4,0
15204,zymosan,79,86,Superoxide and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects (P < 0.01).,9061311_4,0
15205,ALF,102,105,Superoxide and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects (P < 0.01).,9061311_4,0
15207,zymosan,27,34,This defect persisted when zymosan opsonized by control serum was used (P < 0.05).,9061311_5,0
3766,fMLP,114,118,Superoxide and hydrogen peroxide production in neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine (fMLP) from a further 18 ALF patients was unaffected compared with control neutrophils.,9061311_6,0
3765,formyl-methionyl-leucyl-phenylalanine,75,112,Superoxide and hydrogen peroxide production in neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine (fMLP) from a further 18 ALF patients was unaffected compared with control neutrophils.,9061311_6,0
15209,ALF,138,141,Superoxide and hydrogen peroxide production in neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine (fMLP) from a further 18 ALF patients was unaffected compared with control neutrophils.,9061311_6,0
3764,hydrogen peroxide,15,32,Superoxide and hydrogen peroxide production in neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine (fMLP) from a further 18 ALF patients was unaffected compared with control neutrophils.,9061311_6,0
3767,C3 complement,6,19,Serum C3 complement levels were significantly reduced in ALF patients compared with control subjects (P < 0.0005).,9061311_7,0
15210,ALF,57,60,Serum C3 complement levels were significantly reduced in ALF patients compared with control subjects (P < 0.0005).,9061311_7,0
3769,serum complement,130,146,"These results demonstrate a neutrophil defect in ALF due to paracetamol overdose, that is complement dependent but independent of serum complement, possibly connected to the complement receptor.",9061311_8,0
3768,paracetamol,60,71,"These results demonstrate a neutrophil defect in ALF due to paracetamol overdose, that is complement dependent but independent of serum complement, possibly connected to the complement receptor.",9061311_8,0
3770,complement receptor,174,193,"These results demonstrate a neutrophil defect in ALF due to paracetamol overdose, that is complement dependent but independent of serum complement, possibly connected to the complement receptor.",9061311_8,0
15212,ALF,49,52,"These results demonstrate a neutrophil defect in ALF due to paracetamol overdose, that is complement dependent but independent of serum complement, possibly connected to the complement receptor.",9061311_8,0
15217,carbon tetrachloride,106,126,"Cholesteryl hemisuccinate treatment protects rodents from the toxic effects of acetaminophen, adriamycin, carbon tetrachloride, chloroform and galactosamine.",9067481_0,0
15216,adriamycin,94,104,"Cholesteryl hemisuccinate treatment protects rodents from the toxic effects of acetaminophen, adriamycin, carbon tetrachloride, chloroform and galactosamine.",9067481_0,0
15215,toxic effects,62,75,"Cholesteryl hemisuccinate treatment protects rodents from the toxic effects of acetaminophen, adriamycin, carbon tetrachloride, chloroform and galactosamine.",9067481_0,0
15214,Cholesteryl hemisuccinate,0,25,"Cholesteryl hemisuccinate treatment protects rodents from the toxic effects of acetaminophen, adriamycin, carbon tetrachloride, chloroform and galactosamine.",9067481_0,0
15218,galactosamine,143,156,"Cholesteryl hemisuccinate treatment protects rodents from the toxic effects of acetaminophen, adriamycin, carbon tetrachloride, chloroform and galactosamine.",9067481_0,0
15223,CCl4,211,215,"In addition to its use as a stabilizer/rigidifier of membranes, cholesteryl hemisuccinate, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).",9067481_1,0
15222,carbon tetrachloride,189,209,"In addition to its use as a stabilizer/rigidifier of membranes, cholesteryl hemisuccinate, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).",9067481_1,0
15220,cholesteryl hemisuccinate,64,89,"In addition to its use as a stabilizer/rigidifier of membranes, cholesteryl hemisuccinate, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).",9067481_1,0
15219,stabilizer/rigidifier,28,49,"In addition to its use as a stabilizer/rigidifier of membranes, cholesteryl hemisuccinate, tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4).",9067481_1,0
15227,gamma-cholesteryloxybutyric acid,171,203,"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.",9067481_2,0
15225,protective abilities,101,121,"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.",9067481_2,0
15226,non-hydrolyzable ether form,136,163,"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.",9067481_2,0
3771,chloroform-,281,292,"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.",9067481_2,0
15228,tris salt,205,214,"To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity.",9067481_2,0
15230,toxic chemical,129,143,"The results of these studies demonstrated that CS-mediated protection is not selective for a particular species, organ system or toxic chemical.",9067481_3,0
15236,adriamycin,262,272,"A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.",9067481_4,0
15235,galactosamine,186,199,"A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.",9067481_4,0
15232,single dose,49,60,"A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.",9067481_4,0
15234,CHCl3,161,166,"A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.",9067481_4,0
3772,cardiotoxic,239,250,"A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.",9067481_4,0
15233,CCl4,155,159,"A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration.",9067481_4,0
15239,toxic insult,97,109,Maximal CS-mediated protection was observed in experimental animals pretreated 24 h prior to the toxic insult.,9067481_5,0
7361,cell death,112,122,These data suggest that CS intervenes in a critical cellular event that is an important common pathway to toxic cell death.,9067481_6,1
15244,anionic CS molecule,93,112,"Our findings do suggest that CS-mediated protection is dependent on the action of the intact anionic CS molecule (non-hydrolyzable CSE was as protective as CS), whose mechanism has yet to be defined.",9067481_9,0
15247,hepatic function,94,110,Combined effects of prolonged prostaglandin E1-induced hypotension and haemodilution on human hepatic function.,9088814_0,1
15248,Combined effects,0,16,Combined effects of prolonged prostaglandin E1 (PGE1)-induced hypotension and haemodilution on hepatic function were studied in 30 patients undergoing hip surgery.,9088814_1,0
15250,hepatic function,95,111,Combined effects of prolonged prostaglandin E1 (PGE1)-induced hypotension and haemodilution on hepatic function were studied in 30 patients undergoing hip surgery.,9088814_1,1
15251,hip surgery,151,162,Combined effects of prolonged prostaglandin E1 (PGE1)-induced hypotension and haemodilution on hepatic function were studied in 30 patients undergoing hip surgery.,9088814_1,1
3773,prostaglandin E1,30,46,Combined effects of prolonged prostaglandin E1 (PGE1)-induced hypotension and haemodilution on hepatic function were studied in 30 patients undergoing hip surgery.,9088814_1,0
15254,group B,144,151,"The patients were randomly allocated to one of three groups; those in group A (n = 10) were subjected to controlled hypotension alone, those in group B (n = 10) to haemodilution alone and those in group C (n = 10) to both controlled hypotension and haemodilution.",9088814_2,0
15257,controlled hypotension,222,244,"The patients were randomly allocated to one of three groups; those in group A (n = 10) were subjected to controlled hypotension alone, those in group B (n = 10) to haemodilution alone and those in group C (n = 10) to both controlled hypotension and haemodilution.",9088814_2,1
15252,group A,70,77,"The patients were randomly allocated to one of three groups; those in group A (n = 10) were subjected to controlled hypotension alone, those in group B (n = 10) to haemodilution alone and those in group C (n = 10) to both controlled hypotension and haemodilution.",9088814_2,0
15256,group C,197,204,"The patients were randomly allocated to one of three groups; those in group A (n = 10) were subjected to controlled hypotension alone, those in group B (n = 10) to haemodilution alone and those in group C (n = 10) to both controlled hypotension and haemodilution.",9088814_2,0
15253,controlled hypotension,105,127,"The patients were randomly allocated to one of three groups; those in group A (n = 10) were subjected to controlled hypotension alone, those in group B (n = 10) to haemodilution alone and those in group C (n = 10) to both controlled hypotension and haemodilution.",9088814_2,1
15259,Haemodilution,0,13,"Haemodilution in groups B and C was produced by withdrawing approximately 1000 mL of blood and replacing it with the same amount of dextran solution, and final haematocrit values were 21 or 22%.",9088814_3,0
15261,dextran solution,132,148,"Haemodilution in groups B and C was produced by withdrawing approximately 1000 mL of blood and replacing it with the same amount of dextran solution, and final haematocrit values were 21 or 22%.",9088814_3,0
7362,blood pressure,89,103,Controlled hypotension in groups A and C was induced with PGE1 to maintain mean arterial blood pressure at 55 mmHg for 180 min.,9088814_4,1
3774,PGE1,58,62,Controlled hypotension in groups A and C was induced with PGE1 to maintain mean arterial blood pressure at 55 mmHg for 180 min.,9088814_4,0
15263,Controlled hypotension,0,22,Controlled hypotension in groups A and C was induced with PGE1 to maintain mean arterial blood pressure at 55 mmHg for 180 min.,9088814_4,1
15267,aceto-acetate/3-hydroxybutyrate,56,87,"Measurements included arterial ketone body ratio (AKBR, aceto-acetate/3-hydroxybutyrate) and clinical hepatic function parameters.",9088814_5,0
15268,clinical hepatic function,93,118,"Measurements included arterial ketone body ratio (AKBR, aceto-acetate/3-hydroxybutyrate) and clinical hepatic function parameters.",9088814_5,1
3776,LDH,293,296,"AKBR and biological hepatic function tests showed no change throughout the time course in groups A and B. In group C, AKBR showed a significant decrease at 120 min (-40%) and at 180 min (-49%) after the start of hypotension and at 60 min (-32%) after recovery of normotension, and SGOT, SGPT, LDH and total bilirubin showed significant increases after operation.",9088814_6,0
3775,SGOT,281,285,"AKBR and biological hepatic function tests showed no change throughout the time course in groups A and B. In group C, AKBR showed a significant decrease at 120 min (-40%) and at 180 min (-49%) after the start of hypotension and at 60 min (-32%) after recovery of normotension, and SGOT, SGPT, LDH and total bilirubin showed significant increases after operation.",9088814_6,0
15270,hepatic function,20,36,"AKBR and biological hepatic function tests showed no change throughout the time course in groups A and B. In group C, AKBR showed a significant decrease at 120 min (-40%) and at 180 min (-49%) after the start of hypotension and at 60 min (-32%) after recovery of normotension, and SGOT, SGPT, LDH and total bilirubin showed significant increases after operation.",9088814_6,1
15278,SGPT,287,291,"AKBR and biological hepatic function tests showed no change throughout the time course in groups A and B. In group C, AKBR showed a significant decrease at 120 min (-40%) and at 180 min (-49%) after the start of hypotension and at 60 min (-32%) after recovery of normotension, and SGOT, SGPT, LDH and total bilirubin showed significant increases after operation.",9088814_6,0
15279,haemodilution,111,124,The results suggest that a prolonged combination of more than 120 min of PGE1-induced hypotension and moderate haemodilution would cause impairment of hepatic function.,9088814_7,0
15280,hepatic function,151,167,The results suggest that a prolonged combination of more than 120 min of PGE1-induced hypotension and moderate haemodilution would cause impairment of hepatic function.,9088814_7,1
3777,selective serotonin reuptake inhibitor,104,142,"A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.",9098464_0,0
7363,hyperprolactinemia,46,64,"A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats.",9098464_0,1
7364,hyperprolactinemia,119,137,OBJECTIVE: The aim of this study was to investigate whether fluoxetine given to castrated and noncastrated rats caused hyperprolactinemia and its effects with respect to adenomyosis.,9098464_1,1
7365,hyperprolactinemia,107,125,"DESIGN: Fluoxetine, a serotonin reuptake inhibitor, was given to Wistar Albino rats for 98 days to produce hyperprolactinemia.",9098464_2,1
3778,serotonin reuptake inhibitor,22,50,"DESIGN: Fluoxetine, a serotonin reuptake inhibitor, was given to Wistar Albino rats for 98 days to produce hyperprolactinemia.",9098464_2,0
15285,Zeynep Kamil,88,100,"SETTING: Marmara University School of Medicine, Department of Histology and Embryology, Zeynep Kamil Women and Children's Hospital.",9098464_5,0
15287,Serum prolactin levels,23,45,"MAIN OUTCOME MEASURES: Serum prolactin levels, uterine histopathology.",9098464_6,1
15296,myometrial invasion,155,174,CONCLUSION: It was suggested that high serum prolactin levels cause degeneration of myometrial cells in the presence of ovarian steroids that results in a myometrial invasion by endometrial stroma.,9098464_9,1
15294,myometrial cells,84,100,CONCLUSION: It was suggested that high serum prolactin levels cause degeneration of myometrial cells in the presence of ovarian steroids that results in a myometrial invasion by endometrial stroma.,9098464_9,1
3779,calcium channel blockers,53,77,Cardiovascular alterations in rat fetuses exposed to calcium channel blockers.,9100294_0,0
15298,organogenesis,175,188,"Preclinical toxicologic investigation suggested that a new calcium channel blocker, Ro 40-5967, induced cardiovascular alterations in rat fetuses exposed to this agent during organogenesis.",9100294_1,1
3781,Ro 40-5967,84,94,"Preclinical toxicologic investigation suggested that a new calcium channel blocker, Ro 40-5967, induced cardiovascular alterations in rat fetuses exposed to this agent during organogenesis.",9100294_1,0
3780,calcium channel blocker,59,82,"Preclinical toxicologic investigation suggested that a new calcium channel blocker, Ro 40-5967, induced cardiovascular alterations in rat fetuses exposed to this agent during organogenesis.",9100294_1,0
3782,calcium channel blockers,66,90,The present study was designed to investigate the hypothesis that calcium channel blockers in general induce cardiovascular malformations indicating a pharmacologic class effect.,9100294_2,0
15300,cardiovascular malformations,109,137,The present study was designed to investigate the hypothesis that calcium channel blockers in general induce cardiovascular malformations indicating a pharmacologic class effect.,9100294_2,1
3783,calcium channel blockers,17,41,"We studied three calcium channel blockers of different structure, nifedipine, diltiazem, and verapamil, along with the new agent.",9100294_3,0
15303,cardiovascular malformations,167,195,Pregnant rats were administered one of these calcium channel blockers during the period of cardiac morphogenesis and the offspring examined on day 20 of gestation for cardiovascular malformations.,9100294_4,1
3784,calcium channel blockers,45,69,Pregnant rats were administered one of these calcium channel blockers during the period of cardiac morphogenesis and the offspring examined on day 20 of gestation for cardiovascular malformations.,9100294_4,0
15302,cardiac morphogenesis,91,112,Pregnant rats were administered one of these calcium channel blockers during the period of cardiac morphogenesis and the offspring examined on day 20 of gestation for cardiovascular malformations.,9100294_4,1
3785,calcium channel blockers,96,120,"A low incidence of cardiovascular malformations was observed after exposure to each of the four calcium channel blockers, but this incidence was statistically significant only for verapamil and nifedipine.",9100294_5,0
15304,cardiovascular malformations,19,47,"A low incidence of cardiovascular malformations was observed after exposure to each of the four calcium channel blockers, but this incidence was statistically significant only for verapamil and nifedipine.",9100294_5,1
15306,branching variants,49,67,"All four agents were associated with aortic arch branching variants, although significantly increased only for Ro 40-5967 and verapamil.",9100294_6,1
7366,aortic arch,37,48,"All four agents were associated with aortic arch branching variants, although significantly increased only for Ro 40-5967 and verapamil.",9100294_6,1
3786,Ro 40-5967,111,121,"All four agents were associated with aortic arch branching variants, although significantly increased only for Ro 40-5967 and verapamil.",9100294_6,0
7367,ventricular septal defect,15,40,Postinfarction ventricular septal defect associated with long-term steroid therapy.,9105126_0,1
7368,ventricular septal rupture,28,54,Two cases of postinfarction ventricular septal rupture in patients on long-term steroid therapy are presented and the favourable outcome in both cases described.,9105126_1,1
7369,septal rupture,77,91,A possible association between steroid therapy and subsequent postinfarction septal rupture is discussed.,9105126_2,1
15312,pilocarpine-,37,49,Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and status epilepticus in mice.,9121607_0,0
15313,acid-induced limbic,61,80,Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and status epilepticus in mice.,9121607_0,1
7370,status epilepticus,94,112,Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and status epilepticus in mice.,9121607_0,1
3788,kainic,54,60,Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and status epilepticus in mice.,9121607_0,0
3787,Neuroactive steroids,0,20,Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and status epilepticus in mice.,9121607_0,0
15314,progesterone (3 alpha-hydroxy,44,73,"Several structurally related metabolites of progesterone (3 alpha-hydroxy pregnane-20-ones) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice.",9121607_1,0
15315,deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones,96,157,"Several structurally related metabolites of progesterone (3 alpha-hydroxy pregnane-20-ones) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice.",9121607_1,0
15316,beta-epimers,171,183,"Several structurally related metabolites of progesterone (3 alpha-hydroxy pregnane-20-ones) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice.",9121607_1,0
15318,"pilocarpine-, kainic",231,251,"Several structurally related metabolites of progesterone (3 alpha-hydroxy pregnane-20-ones) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice.",9121607_1,0
3789,N-methyl-D-aspartate,262,282,"Several structurally related metabolites of progesterone (3 alpha-hydroxy pregnane-20-ones) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice.",9121607_1,0
15324,ED50,229,233,"Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).",9121607_2,0
7371,motor seizures,190,204,"Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).",9121607_2,1
7372,status epilepticus,209,227,"Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).",9121607_2,1
15319,3-hydroxy group,18,33,"Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).",9121607_2,0
15321,5-H,60,63,"Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.).",9121607_2,0
15328,ED50,109,113,"The corresponding epimers with the 3-hydroxy group in the beta-position were also effective but less potent (ED50 values, 33.8-63.5, i.p.).",9121607_3,0
15326,3-hydroxy group,35,50,"The corresponding epimers with the 3-hydroxy group in the beta-position were also effective but less potent (ED50 values, 33.8-63.5, i.p.).",9121607_3,0
15325,epimers,18,25,"The corresponding epimers with the 3-hydroxy group in the beta-position were also effective but less potent (ED50 values, 33.8-63.5, i.p.).",9121607_3,0
3793,clonazepam,312,322,"Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.",9121607_4,0
3791,clonazepam,88,98,"Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.",9121607_4,0
15332,motor impairment,250,266,"Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.",9121607_4,1
3792,"alpha,3",163,170,"Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.",9121607_4,0
3794,neuroactive steroids,345,365,"Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.",9121607_4,0
3790,neuroactive steroids,13,33,"Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity.",9121607_4,0
15336,onset of,112,120,"Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by kainic acid (32 mg/kg, s.c.), but did not completely protect against the seizures.",9121607_5,1
15337,limbic seizures,121,136,"Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by kainic acid (32 mg/kg, s.c.), but did not completely protect against the seizures.",9121607_5,1
3795,"alpha,3",20,27,"Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by kainic acid (32 mg/kg, s.c.), but did not completely protect against the seizures.",9121607_5,0
3796,kainic acid,148,159,"Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by kainic acid (32 mg/kg, s.c.), but did not completely protect against the seizures.",9121607_5,0
15338,second dose,16,27,"However, when a second dose of the steroid was administered 1 hr after the first dose, complete protection from the kainic acid-induced limbic seizures and status epilepticus was obtained.",9121607_6,0
3797,kainic,116,122,"However, when a second dose of the steroid was administered 1 hr after the first dose, complete protection from the kainic acid-induced limbic seizures and status epilepticus was obtained.",9121607_6,0
7373,status epilepticus,156,174,"However, when a second dose of the steroid was administered 1 hr after the first dose, complete protection from the kainic acid-induced limbic seizures and status epilepticus was obtained.",9121607_6,1
3798,NMDA,51,55,"The steroids also caused a dose-dependent delay in NMDA (257 mg/kg, s.c.)-induced lethality, but did not completely protect against NMDA seizures or lethality.",9121607_7,0
3799,NMDA,132,136,"The steroids also caused a dose-dependent delay in NMDA (257 mg/kg, s.c.)-induced lethality, but did not completely protect against NMDA seizures or lethality.",9121607_7,0
7375,status epilepticus,215,233,"We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.",9121607_8,1
3801,kainic,98,104,"We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.",9121607_8,0
15342,acid-induced seizures,105,126,"We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.",9121607_8,1
3800,neuroactive steroids,17,37,"We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.",9121607_8,0
15341,pilocarpine-,81,93,"We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.",9121607_8,0
7374,status epilepticus,131,149,"We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and kainic acid-induced seizures and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans.",9121607_8,1
7376,nephrotic syndrome,76,94,Hepatic and extrahepatic angiotensinogen gene expression in rats with acute nephrotic syndrome.,9154656_0,1
7377,nephrotic syndrome,107,125,Plasma concentration and urine excretion of the renin-angiotensin system proteins are altered in rats with nephrotic syndrome (NS).,9154656_1,1
15348,PF,259,261,"In this work the messenger ribonucleic acid (mRNA) levels of angiotensinogen (Ao) were analyzed with the slot-blot hybridization technique in liver and other extrahepatic tissues: kidney, heart, brain, and adrenal gland from control, nephrotic, and pair-fed (PF) rats.",9154656_2,0
7380,nephrotic,234,243,"In this work the messenger ribonucleic acid (mRNA) levels of angiotensinogen (Ao) were analyzed with the slot-blot hybridization technique in liver and other extrahepatic tissues: kidney, heart, brain, and adrenal gland from control, nephrotic, and pair-fed (PF) rats.",9154656_2,1
7378,extrahepatic,158,170,"In this work the messenger ribonucleic acid (mRNA) levels of angiotensinogen (Ao) were analyzed with the slot-blot hybridization technique in liver and other extrahepatic tissues: kidney, heart, brain, and adrenal gland from control, nephrotic, and pair-fed (PF) rats.",9154656_2,1
7379,adrenal gland,206,219,"In this work the messenger ribonucleic acid (mRNA) levels of angiotensinogen (Ao) were analyzed with the slot-blot hybridization technique in liver and other extrahepatic tissues: kidney, heart, brain, and adrenal gland from control, nephrotic, and pair-fed (PF) rats.",9154656_2,1
3802,ribonucleic acid,27,43,"In this work the messenger ribonucleic acid (mRNA) levels of angiotensinogen (Ao) were analyzed with the slot-blot hybridization technique in liver and other extrahepatic tissues: kidney, heart, brain, and adrenal gland from control, nephrotic, and pair-fed (PF) rats.",9154656_2,0
3803,angiotensinogen,61,76,"In this work the messenger ribonucleic acid (mRNA) levels of angiotensinogen (Ao) were analyzed with the slot-blot hybridization technique in liver and other extrahepatic tissues: kidney, heart, brain, and adrenal gland from control, nephrotic, and pair-fed (PF) rats.",9154656_2,0
15346,Ao,78,80,"In this work the messenger ribonucleic acid (mRNA) levels of angiotensinogen (Ao) were analyzed with the slot-blot hybridization technique in liver and other extrahepatic tissues: kidney, heart, brain, and adrenal gland from control, nephrotic, and pair-fed (PF) rats.",9154656_2,0
3804,puromycin,40,49,NS was induced by a single injection of puromycin amino-nucleoside (PAN).,9154656_3,0
15350,Ao,68,70,"Although a great urinary excretion and half-normal plasma levels of Ao were observed on day 6 after PAN injection, when NS was clearly established, hepatic Ao mRNA levels did not change.",9154656_4,0
7381,extrahepatic,61,73,"Furthermore, the Ao mRNA levels did not change in any of the extrahepatic tissues studied on day 6, nor did its hepatic levels at days 1, 3, 5, or 7 after PAN injection.",9154656_5,1
15354,extrahepatic Ao,40,55,These data suggest that the hepatic and extrahepatic Ao mRNA levels are unaltered during the development of the acute NS induced by PAN.,9154656_6,1
7382,Neuroleptic malignant syndrome,0,30,Neuroleptic malignant syndrome with risperidone.,9165568_0,1
15355,risperidone,36,47,Neuroleptic malignant syndrome with risperidone.,9165568_0,0
3805,dopamine D2 receptor,60,80,Neuroleptic malignant syndrome is thought to be a result of dopamine D2 receptor blockade in the striatum of the basal ganglia.,9165568_1,0
7384,basal ganglia,113,126,Neuroleptic malignant syndrome is thought to be a result of dopamine D2 receptor blockade in the striatum of the basal ganglia.,9165568_1,1
7383,Neuroleptic malignant syndrome,0,30,Neuroleptic malignant syndrome is thought to be a result of dopamine D2 receptor blockade in the striatum of the basal ganglia.,9165568_1,1
15357,benzisoxazole derivative,15,39,"Risperidone, a benzisoxazole derivative antipsychotic, has high serotonin 5-HT2 receptor blockade and dose-related D2 receptor blockade.",9165568_2,0
15356,Risperidone,0,11,"Risperidone, a benzisoxazole derivative antipsychotic, has high serotonin 5-HT2 receptor blockade and dose-related D2 receptor blockade.",9165568_2,0
3806,serotonin 5-HT2,64,79,"Risperidone, a benzisoxazole derivative antipsychotic, has high serotonin 5-HT2 receptor blockade and dose-related D2 receptor blockade.",9165568_2,0
3807,D2,115,117,"Risperidone, a benzisoxazole derivative antipsychotic, has high serotonin 5-HT2 receptor blockade and dose-related D2 receptor blockade.",9165568_2,0
15359,risperidone,87,98,The high ratio is believed to impart the low frequency of extrapyramidal symptoms with risperidone at low dosages.,9165568_3,0
7385,extrapyramidal,58,72,The high ratio is believed to impart the low frequency of extrapyramidal symptoms with risperidone at low dosages.,9165568_3,1
15358,low frequency,41,54,The high ratio is believed to impart the low frequency of extrapyramidal symptoms with risperidone at low dosages.,9165568_3,1
15360,low frequency,10,23,"With this low frequency of extrapyramidal symptoms, it was thought the frequency of neuroleptic malignant syndrome might also be lowered.",9165568_4,1
7386,extrapyramidal,27,41,"With this low frequency of extrapyramidal symptoms, it was thought the frequency of neuroleptic malignant syndrome might also be lowered.",9165568_4,1
7387,neuroleptic malignant syndrome,84,114,"With this low frequency of extrapyramidal symptoms, it was thought the frequency of neuroleptic malignant syndrome might also be lowered.",9165568_4,1
7388,neuroleptic malignant syndrome,30,60,A 73-year-old woman developed neuroleptic malignant syndrome after monotherapy with risperidone.,9165568_5,1
15362,risperidone,84,95,A 73-year-old woman developed neuroleptic malignant syndrome after monotherapy with risperidone.,9165568_5,0
3808,dantrolene,82,92,The syndrome reversed after discontinuing risperidone and starting treatment with dantrolene and bromocriptine.,9165568_6,0
3809,bromocriptine,97,110,The syndrome reversed after discontinuing risperidone and starting treatment with dantrolene and bromocriptine.,9165568_6,0
15363,risperidone,42,53,The syndrome reversed after discontinuing risperidone and starting treatment with dantrolene and bromocriptine.,9165568_6,0
15364,extrapyramidal side effects,36,63,It appears that the protection from extrapyramidal side effects observed with risperidone does not ensure protection from neuroleptic malignant syndrome.,9165568_7,1
7389,neuroleptic malignant syndrome,122,152,It appears that the protection from extrapyramidal side effects observed with risperidone does not ensure protection from neuroleptic malignant syndrome.,9165568_7,1
15365,risperidone,78,89,It appears that the protection from extrapyramidal side effects observed with risperidone does not ensure protection from neuroleptic malignant syndrome.,9165568_7,0
7390,side effects,19,31,The site of common side effects of sumatriptan.,9195768_0,1
3810,sumatriptan,35,46,The site of common side effects of sumatriptan.,9195768_0,0
15366,uncertain origin,85,101,"Atypical sensations following the use of subcutaneous sumatriptan are common, but of uncertain origin.",9195768_1,1
3811,sumatriptan,54,65,"Atypical sensations following the use of subcutaneous sumatriptan are common, but of uncertain origin.",9195768_1,0
15367,adverse event,65,78,"They are almost always benign, but can be mistaken for a serious adverse event by the patient.",9195768_2,1
15368,heat exposure,83,96,Two patients are presented with tingling or burning sensations limited to areas of heat exposure or sunburn.,9195768_3,1
7391,side effects,22,34,"In these individuals, side effects are most likely generated superficially in the skin.",9195768_4,1
3812,amikacin,35,43,Macula toxicity after intravitreal amikacin.,9199746_0,0
15369,visual prognosis,78,94,"BACKGROUND: Although intravitreal aminoglycosides have substantially improved visual prognosis in endophthalmitis, macular infarction may impair full visual recovery.",9199746_1,1
3813,aminoglycosides,34,49,"BACKGROUND: Although intravitreal aminoglycosides have substantially improved visual prognosis in endophthalmitis, macular infarction may impair full visual recovery.",9199746_1,0
7392,endophthalmitis,98,113,"BACKGROUND: Although intravitreal aminoglycosides have substantially improved visual prognosis in endophthalmitis, macular infarction may impair full visual recovery.",9199746_1,1
15370,macular infarction,115,133,"BACKGROUND: Although intravitreal aminoglycosides have substantially improved visual prognosis in endophthalmitis, macular infarction may impair full visual recovery.",9199746_1,1
7393,endophthalmitis,149,164,METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis.,9199746_2,1
3814,amikacin,90,98,METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis.,9199746_2,0
7394,Endophthalmitis,9,24,RESULTS: Endophthalmitis resolved with improvement in visual acuity to 6/24 at three months.,9199746_3,1
15371,visual acuity,54,67,RESULTS: Endophthalmitis resolved with improvement in visual acuity to 6/24 at three months.,9199746_3,1
7395,telangiectasis,71,85,Fundus fluorescein angiography confirmed macular capillary closure and telangiectasis.,9199746_4,1
15372,Fundus fluorescein angiography,0,30,Fundus fluorescein angiography confirmed macular capillary closure and telangiectasis.,9199746_4,1
15373,macular,41,48,Fundus fluorescein angiography confirmed macular capillary closure and telangiectasis.,9199746_4,1
15374,macular,96,103,CONCLUSIONS: Currently accepted intravitreal antibiotic regimens may cause retinal toxicity and macular ischaemia.,9199746_5,1
3815,carteolol hydrochloride,26,49,"The attenuating effect of carteolol hydrochloride, a beta-adrenoceptor antagonist, on neuroleptic-induced catalepsy in rats.",9201797_0,0
3816,beta-adrenoceptor antagonist,53,81,"The attenuating effect of carteolol hydrochloride, a beta-adrenoceptor antagonist, on neuroleptic-induced catalepsy in rats.",9201797_0,0
7396,akathisia,81,90,"It is known that beta-adrenoceptor antagonists are effective in the treatment of akathisia, one of the extrapyramidal side effects that occur during neuroleptic treatment.",9201797_1,1
3817,beta-adrenoceptor antagonists,17,46,"It is known that beta-adrenoceptor antagonists are effective in the treatment of akathisia, one of the extrapyramidal side effects that occur during neuroleptic treatment.",9201797_1,0
15375,extrapyramidal side effects,103,130,"It is known that beta-adrenoceptor antagonists are effective in the treatment of akathisia, one of the extrapyramidal side effects that occur during neuroleptic treatment.",9201797_1,1
15394,postsynaptic dopamine receptor,268,298,These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.,9201797_10,0
7400,akathisia,185,194,These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.,9201797_10,1
3832,carteolol,36,45,These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.,9201797_10,0
3833,antipsychotic effects,235,256,These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.,9201797_10,0
15392,haloperidol-induced catalepsy,55,84,These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity.,9201797_10,1
15378,neuroleptic-induced catalepsy,191,220,"Neuroleptic-induced catalepsy, a model of neuroleptic-induced extrapyramidal side effects, was considered suitable as a model for predicting neuroleptic-induced akathisia in humans, although neuroleptic-induced catalepsy was not considered a specific test for neuroleptic-induced akathisia.",9201797_2,1
15377,extrapyramidal side effects,62,89,"Neuroleptic-induced catalepsy, a model of neuroleptic-induced extrapyramidal side effects, was considered suitable as a model for predicting neuroleptic-induced akathisia in humans, although neuroleptic-induced catalepsy was not considered a specific test for neuroleptic-induced akathisia.",9201797_2,1
7397,akathisia,161,170,"Neuroleptic-induced catalepsy, a model of neuroleptic-induced extrapyramidal side effects, was considered suitable as a model for predicting neuroleptic-induced akathisia in humans, although neuroleptic-induced catalepsy was not considered a specific test for neuroleptic-induced akathisia.",9201797_2,1
7398,akathisia,280,289,"Neuroleptic-induced catalepsy, a model of neuroleptic-induced extrapyramidal side effects, was considered suitable as a model for predicting neuroleptic-induced akathisia in humans, although neuroleptic-induced catalepsy was not considered a specific test for neuroleptic-induced akathisia.",9201797_2,1
3820,propranolol,163,174,"Therefore, the effects of carteolol, a beta-adrenoceptor antagonist, on haloperidol-induced catalepsy in rats were behaviorally studied and compared with those of propranolol and biperiden, a muscarinic receptor antagonist.",9201797_3,0
3819,beta-adrenoceptor antagonist,39,67,"Therefore, the effects of carteolol, a beta-adrenoceptor antagonist, on haloperidol-induced catalepsy in rats were behaviorally studied and compared with those of propranolol and biperiden, a muscarinic receptor antagonist.",9201797_3,0
3818,carteolol,26,35,"Therefore, the effects of carteolol, a beta-adrenoceptor antagonist, on haloperidol-induced catalepsy in rats were behaviorally studied and compared with those of propranolol and biperiden, a muscarinic receptor antagonist.",9201797_3,0
15382,muscarinic receptor antagonist,192,222,"Therefore, the effects of carteolol, a beta-adrenoceptor antagonist, on haloperidol-induced catalepsy in rats were behaviorally studied and compared with those of propranolol and biperiden, a muscarinic receptor antagonist.",9201797_3,0
15380,haloperidol-induced catalepsy,72,101,"Therefore, the effects of carteolol, a beta-adrenoceptor antagonist, on haloperidol-induced catalepsy in rats were behaviorally studied and compared with those of propranolol and biperiden, a muscarinic receptor antagonist.",9201797_3,1
3821,biperiden,179,188,"Therefore, the effects of carteolol, a beta-adrenoceptor antagonist, on haloperidol-induced catalepsy in rats were behaviorally studied and compared with those of propranolol and biperiden, a muscarinic receptor antagonist.",9201797_3,0
3824,biperiden,38,47,"Carteolol, as well as propranolol and biperiden, inhibited the haloperidol-induced catalepsy.",9201797_4,0
3823,propranolol,22,33,"Carteolol, as well as propranolol and biperiden, inhibited the haloperidol-induced catalepsy.",9201797_4,0
3822,Carteolol,0,9,"Carteolol, as well as propranolol and biperiden, inhibited the haloperidol-induced catalepsy.",9201797_4,0
3827,biperiden,109,118,"The inhibitory effect of carteolol was almost comparable to that of propranolol, but was weaker than that of biperiden.",9201797_5,0
3826,propranolol,68,79,"The inhibitory effect of carteolol was almost comparable to that of propranolol, but was weaker than that of biperiden.",9201797_5,0
3825,carteolol,25,34,"The inhibitory effect of carteolol was almost comparable to that of propranolol, but was weaker than that of biperiden.",9201797_5,0
15384,stereotypy,92,102,Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and hyperlocomotion in rats.,9201797_6,1
3828,Carteolol,0,9,Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and hyperlocomotion in rats.,9201797_6,0
7399,postsynaptic,24,36,Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and hyperlocomotion in rats.,9201797_6,1
15385,hyperlocomotion,107,122,Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and hyperlocomotion in rats.,9201797_6,1
3829,Carteolol,0,9,Carteolol did not antagonize the inhibitory effects of haloperidol on apomorphine-induced stereotypy and locomotor activity in rats.,9201797_7,0
15388,5-HT1A,37,43,"In addition, carteolol did not evoke 5-HT1A receptor-stimulating behavioral signs such as flat body posture and forepaw treading and did not inhibit 5-hydroxytryptophan-induced head twitch in rats.",9201797_8,0
15389,flat body posture,90,107,"In addition, carteolol did not evoke 5-HT1A receptor-stimulating behavioral signs such as flat body posture and forepaw treading and did not inhibit 5-hydroxytryptophan-induced head twitch in rats.",9201797_8,1
3830,carteolol,13,22,"In addition, carteolol did not evoke 5-HT1A receptor-stimulating behavioral signs such as flat body posture and forepaw treading and did not inhibit 5-hydroxytryptophan-induced head twitch in rats.",9201797_8,0
3831,carteolol,9,18,"Finally, carteolol did not inhibit physostigmine-induced lethality in rats.",9201797_9,0
7401,Granulosa cell tumor,0,20,Granulosa cell tumor of the ovary associated with antecedent tamoxifen use.,9205462_0,1
3834,estrogenic effects,65,83,BACKGROUND: Increased attention has been focused recently on the estrogenic effects of tamoxifen.,9205462_1,0
15397,gynecologic tumors,74,92,Review of the literature reveals an association between tamoxifen use and gynecologic tumors.,9205462_2,1
7402,breast carcinoma,108,124,CASE: A 52-year-old postmenopausal woman was treated with tamoxifen for stage II estrogen receptor-positive breast carcinoma.,9205462_3,1
3835,alanine transaminase,31,51,Her aspartate transaminase and alanine transaminase levels increase markedly after 6 months of tamoxifen use.,9205462_4,0
15398,Her aspartate transaminase,0,26,Her aspartate transaminase and alanine transaminase levels increase markedly after 6 months of tamoxifen use.,9205462_4,0
7403,granulosa cell tumor,104,124,"After an additional 17 months of elevated serum transaminases, the patient was found to have a stage Ic granulosa cell tumor of the ovary.",9205462_5,1
7405,granulosa cell tumors,91,112,CONCLUSION: Patients with tamoxifen-induced liver dysfunction may be at increased risk for granulosa cell tumors because of alterations in tamoxifen metabolism.,9205462_6,1
7404,liver dysfunction,44,61,CONCLUSION: Patients with tamoxifen-induced liver dysfunction may be at increased risk for granulosa cell tumors because of alterations in tamoxifen metabolism.,9205462_6,1
3836,azidothymidine,32,46,Lifetime treatment of mice with azidothymidine (AZT) produces myelodysplasia.,9209318_0,0
7406,myelodysplasia,62,76,Lifetime treatment of mice with azidothymidine (AZT) produces myelodysplasia.,9209318_0,1
7408,long term,56,65,AZT has induced a macrocytic anemia in AIDS patients on long term AZT therapy.,9209318_1,1
7407,macrocytic anemia,18,35,AZT has induced a macrocytic anemia in AIDS patients on long term AZT therapy.,9209318_1,1
15399,phosphate hydroxyl linkages,136,163,It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of thymidine thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation.,9209318_2,0
15402,platelet counts,54,69,At 687 days mice that had been on 0.75 mg had average platelet counts of 2.5 x 10(6).,9209318_4,0
7409,myelodysplastic syndrome,99,123,Histological examination on 9 of 10 mice with such thrombocytopenia showed changes compatible with myelodysplastic syndrome (MDS).,9209318_5,1
15413,hypocellular marrow,390,409,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,1
15410,dysmyelopoiesis,272,287,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,1
15405,hypersegmented,66,80,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,1
15406,hypercellular marrow,126,146,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,1
15407,bizarre nuclei,181,195,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,1
15409,hyperplastic marrow,251,270,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,1
15411,hypocellular marrow,294,313,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,1
15412,dyserythropoiesis,351,368,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,1
7413,myelodysplasia,331,345,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,1
7411,myelodysplastic,81,96,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,1
7410,myelodysplasia,37,51,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,1
7412,myelosis,224,232,"There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow.",9209318_7,1
15414,ineffective hemopoiesis,54,77,"Above mentioned AZT incorporation may have induced an ineffective hemopoiesis in the primitive hemopoietic progenitor cells, which is known to be seen commonly in the myelodysplastic syndrome.",9209318_8,1
7414,myelodysplastic syndrome,167,191,"Above mentioned AZT incorporation may have induced an ineffective hemopoiesis in the primitive hemopoietic progenitor cells, which is known to be seen commonly in the myelodysplastic syndrome.",9209318_8,1
3837,Biphasic,0,8,Biphasic response of the SA node of the dog heart in vivo to selective administration of ketamine.,921394_0,0
15418,node artery,119,130,Effect of ketamine on the SA node of the dog heart was studied in vivo using a selective perfusion technique of the SA node artery.,921394_1,1
15419,direct action,127,140,Injections of ketamine in doses from 100 microgram to 3 mg into the artery produced a depression of the SA nodal activity by a direct action.,921394_2,0
3838,nodal,107,112,Injections of ketamine in doses from 100 microgram to 3 mg into the artery produced a depression of the SA nodal activity by a direct action.,921394_2,0
3839,stimulatory,59,70,This depression was followed by the sudden appearance of a stimulatory phase.,921394_3,0
15426,node artery,273,284,"Bilateral vagotomy and sympathectomy or prior administration of a ganglion blocker failed to inhibit the occurrence of the ketamine-induced tachycardia, while it was completely abolished in the reserpinized dogs or by a prior injection of a beta-blocking agent into the SA node artery.",921394_4,1
15425,beta-blocking agent,241,260,"Bilateral vagotomy and sympathectomy or prior administration of a ganglion blocker failed to inhibit the occurrence of the ketamine-induced tachycardia, while it was completely abolished in the reserpinized dogs or by a prior injection of a beta-blocking agent into the SA node artery.",921394_4,0
15422,ganglion blocker,66,82,"Bilateral vagotomy and sympathectomy or prior administration of a ganglion blocker failed to inhibit the occurrence of the ketamine-induced tachycardia, while it was completely abolished in the reserpinized dogs or by a prior injection of a beta-blocking agent into the SA node artery.",921394_4,0
15421,vagotomy,10,18,"Bilateral vagotomy and sympathectomy or prior administration of a ganglion blocker failed to inhibit the occurrence of the ketamine-induced tachycardia, while it was completely abolished in the reserpinized dogs or by a prior injection of a beta-blocking agent into the SA node artery.",921394_4,1
15427,node artery,173,184,This may indicate that an activation of the peripheral adrenergic mechanism plays an important role in the induction of the excitatory effect of ketamine injected in the SA node artery.,921394_5,1
7415,pituitary tumors,118,134,Over expression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat pituitary tumors may mediate estrogen-initiated tumor angiogenesis.,9214597_0,1
3840,vascular endothelial growth factor,19,53,Over expression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat pituitary tumors may mediate estrogen-initiated tumor angiogenesis.,9214597_0,0
15430,animal cancers,70,84,"Estrogens, which have been associated with several types of human and animal cancers, can induce tumor angiogenesis in the pituitary of Fischer 344 rats.",9214597_1,1
3850,E2,181,183,"Furthermore, immunohistochemical studies demonstrated that VEGFR-2 (flk-1/KDR), expression was elevated significantly in the endothelial cells of microblood vessels after 7 days of E2 exposure.",9214597_10,0
3849,VEGFR-2,59,66,"Furthermore, immunohistochemical studies demonstrated that VEGFR-2 (flk-1/KDR), expression was elevated significantly in the endothelial cells of microblood vessels after 7 days of E2 exposure.",9214597_10,0
3851,VEGF,47,51,These findings suggest that over expression of VEGF and its receptor (VEGFR-2) may play an important role in the initial step of the regulation of estrogen induced tumor angiogenesis in the rat pituitary.,9214597_11,0
3852,VEGFR-2,70,77,These findings suggest that over expression of VEGF and its receptor (VEGFR-2) may play an important role in the initial step of the regulation of estrogen induced tumor angiogenesis in the rat pituitary.,9214597_11,0
15433,tumor angiogenesis,27,45,"The mechanistic details of tumor angiogenesis induction, during estrogen carcinogenesis, are still unknown.",9214597_2,0
7416,carcinogenesis,73,87,"The mechanistic details of tumor angiogenesis induction, during estrogen carcinogenesis, are still unknown.",9214597_2,1
3841,factor VIII related antigen,155,182,"To elucidate the role of estrogen in the regulation of tumor angiogenesis in the pituitary of female rats, the density of blood vessels was analysed using factor VIII related antigen (FVIIIRAg) immunohistochemistry and the expression of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) was examined by Western blot and immunohistochemical analysis.",9214597_3,0
15438,VEGF/VPF,302,310,"To elucidate the role of estrogen in the regulation of tumor angiogenesis in the pituitary of female rats, the density of blood vessels was analysed using factor VIII related antigen (FVIIIRAg) immunohistochemistry and the expression of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) was examined by Western blot and immunohistochemical analysis.",9214597_3,0
15436,FVIIIRAg,184,192,"To elucidate the role of estrogen in the regulation of tumor angiogenesis in the pituitary of female rats, the density of blood vessels was analysed using factor VIII related antigen (FVIIIRAg) immunohistochemistry and the expression of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) was examined by Western blot and immunohistochemical analysis.",9214597_3,0
3842,permeability factor,281,300,"To elucidate the role of estrogen in the regulation of tumor angiogenesis in the pituitary of female rats, the density of blood vessels was analysed using factor VIII related antigen (FVIIIRAg) immunohistochemistry and the expression of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) was examined by Western blot and immunohistochemical analysis.",9214597_3,0
15437,vascular endothelial growth,237,264,"To elucidate the role of estrogen in the regulation of tumor angiogenesis in the pituitary of female rats, the density of blood vessels was analysed using factor VIII related antigen (FVIIIRAg) immunohistochemistry and the expression of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) was examined by Western blot and immunohistochemical analysis.",9214597_3,0
3843,VEGF receptor,18,31,The expression of VEGF receptor (VEGFR-2/Flk-1/KDR) was also examined by immunohistochemistry.,9214597_4,0
15441,VEGFR-2/Flk-1/KDR,33,50,The expression of VEGF receptor (VEGFR-2/Flk-1/KDR) was also examined by immunohistochemistry.,9214597_4,0
3844,E2,48,50,"The results demonstrated that 17beta-estradiol (E2) induces neovascularization, as well as the growth and enlargement of blood vessels after 7 days of exposure.",9214597_5,0
15443,neovascularization,60,78,"The results demonstrated that 17beta-estradiol (E2) induces neovascularization, as well as the growth and enlargement of blood vessels after 7 days of exposure.",9214597_5,1
15442,17beta-estradiol,30,46,"The results demonstrated that 17beta-estradiol (E2) induces neovascularization, as well as the growth and enlargement of blood vessels after 7 days of exposure.",9214597_5,0
3845,tumor angiogenic,9,25,The high tumor angiogenic potential was associated with an elevated VEGF/VPF protein expression in the E2 exposed pituitary of ovariectomized (OVEX) rats.,9214597_6,0
3846,E2,103,105,The high tumor angiogenic potential was associated with an elevated VEGF/VPF protein expression in the E2 exposed pituitary of ovariectomized (OVEX) rats.,9214597_6,0
15445,VEGF/VPF,68,76,The high tumor angiogenic potential was associated with an elevated VEGF/VPF protein expression in the E2 exposed pituitary of ovariectomized (OVEX) rats.,9214597_6,0
15448,endothelial specific lectin,47,74,"VEGF/VPF and FVIIIRAg immunohistochemistry and endothelial specific lectin (UEA1) binding studies, indicate that the elevation of VEGF protein expression initially occurred in both blood vessels and non-endothelial cells.",9214597_7,0
15447,FVIIIRAg,13,21,"VEGF/VPF and FVIIIRAg immunohistochemistry and endothelial specific lectin (UEA1) binding studies, indicate that the elevation of VEGF protein expression initially occurred in both blood vessels and non-endothelial cells.",9214597_7,0
15449,UEA1,76,80,"VEGF/VPF and FVIIIRAg immunohistochemistry and endothelial specific lectin (UEA1) binding studies, indicate that the elevation of VEGF protein expression initially occurred in both blood vessels and non-endothelial cells.",9214597_7,0
15451,VEGF protein,130,142,"VEGF/VPF and FVIIIRAg immunohistochemistry and endothelial specific lectin (UEA1) binding studies, indicate that the elevation of VEGF protein expression initially occurred in both blood vessels and non-endothelial cells.",9214597_7,0
15446,VEGF/VPF,0,8,"VEGF/VPF and FVIIIRAg immunohistochemistry and endothelial specific lectin (UEA1) binding studies, indicate that the elevation of VEGF protein expression initially occurred in both blood vessels and non-endothelial cells.",9214597_7,0
15454,VEGF/VPF,30,38,"After 15 days of E2 exposure, VEGF/VPF protein expression, in the non-endothelial cell population, sharply declined and was restricted to the blood vessels.",9214597_8,0
15455,blood vessels,142,155,"After 15 days of E2 exposure, VEGF/VPF protein expression, in the non-endothelial cell population, sharply declined and was restricted to the blood vessels.",9214597_8,1
3847,E2,17,19,"After 15 days of E2 exposure, VEGF/VPF protein expression, in the non-endothelial cell population, sharply declined and was restricted to the blood vessels.",9214597_8,0
15456,non-endothelial-derived,16,39,The function of non-endothelial-derived VEGF is not clear.,9214597_9,0
3848,VEGF,40,44,The function of non-endothelial-derived VEGF is not clear.,9214597_9,0
7417,nephrogenic diabetes insipidus,11,41,Persistent nephrogenic diabetes insipidus following lithium therapy.,9226773_0,1
15460,hypernatraemic dehydration,53,79,We report the case of a patient who developed severe hypernatraemic dehydration following a head injury.,9226773_1,1
7418,head injury,92,103,We report the case of a patient who developed severe hypernatraemic dehydration following a head injury.,9226773_1,1
7419,nephrogenic diabetes insipidus,67,97,"Ten years previously he had been diagnosed to have lithium-induced nephrogenic diabetes insipidus, and lithium therapy had been discontinued.",9226773_2,1
15462,polyuric,24,32,"He remained thirsty and polyuric despite cessation of lithium and investigations on admission showed him to have normal osmoregulated thirst and vasopressin secretion, with clear evidence of nephrogenic diabetes insipidus.",9226773_3,1
7420,nephrogenic diabetes insipidus,191,221,"He remained thirsty and polyuric despite cessation of lithium and investigations on admission showed him to have normal osmoregulated thirst and vasopressin secretion, with clear evidence of nephrogenic diabetes insipidus.",9226773_3,1
7421,nephrogenic diabetes insipidus,16,46,Lithium induced nephrogenic diabetes insipidus is considered to be reversible on cessation of therapy but polyuria persisted in this patient for ten years after lithium was stopped.,9226773_4,1
7422,nephrogenic diabetes insipidus,110,140,We discuss the possible renal mechanisms and the implications for management of patients with lithium-induced nephrogenic diabetes insipidus.,9226773_5,1
15465,NIK-247,11,18,Effects of NIK-247 on cholinesterase and scopolamine-induced amnesia.,9228650_0,0
3853,E-2020,189,195,"The effects of NIK-247 on cholinesterase, scopolamine-induced amnesia and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors tacrine and E-2020.",9228650_1,0
15469,cholinesterase inhibitors tacrine,151,184,"The effects of NIK-247 on cholinesterase, scopolamine-induced amnesia and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors tacrine and E-2020.",9228650_1,0
15467,NIK-247,15,22,"The effects of NIK-247 on cholinesterase, scopolamine-induced amnesia and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors tacrine and E-2020.",9228650_1,0
3856,acetylcholinesterase,51,71,"NIK-247, tacrine and E-2020 all strongly inhibited acetylcholinesterase (AChE) in human red blood cells (IC50s = 1.0 x 10(-6), 2.9 x 10(-7) and 3.7 x 10(-8) M, respectively).",9228650_2,0
3855,E-2020,21,27,"NIK-247, tacrine and E-2020 all strongly inhibited acetylcholinesterase (AChE) in human red blood cells (IC50s = 1.0 x 10(-6), 2.9 x 10(-7) and 3.7 x 10(-8) M, respectively).",9228650_2,0
3854,tacrine,9,16,"NIK-247, tacrine and E-2020 all strongly inhibited acetylcholinesterase (AChE) in human red blood cells (IC50s = 1.0 x 10(-6), 2.9 x 10(-7) and 3.7 x 10(-8) M, respectively).",9228650_2,0
15470,NIK-247,0,7,"NIK-247, tacrine and E-2020 all strongly inhibited acetylcholinesterase (AChE) in human red blood cells (IC50s = 1.0 x 10(-6), 2.9 x 10(-7) and 3.7 x 10(-8) M, respectively).",9228650_2,0
3858,E-2020,42,48,"In addition, NIK-247 and tacrine, but not E-2020, strongly inhibited butyrylcholinestrase (BuChE) in human serum.",9228650_3,0
3857,tacrine,25,32,"In addition, NIK-247 and tacrine, but not E-2020, strongly inhibited butyrylcholinestrase (BuChE) in human serum.",9228650_3,0
15475,BuChE,91,96,"In addition, NIK-247 and tacrine, but not E-2020, strongly inhibited butyrylcholinestrase (BuChE) in human serum.",9228650_3,0
15474,butyrylcholinestrase,69,89,"In addition, NIK-247 and tacrine, but not E-2020, strongly inhibited butyrylcholinestrase (BuChE) in human serum.",9228650_3,0
15473,NIK-247,13,20,"In addition, NIK-247 and tacrine, but not E-2020, strongly inhibited butyrylcholinestrase (BuChE) in human serum.",9228650_3,0
3859,human serum,101,112,"In addition, NIK-247 and tacrine, but not E-2020, strongly inhibited butyrylcholinestrase (BuChE) in human serum.",9228650_3,0
15477,NIK-247,35,42,"Moreover, the inhibitory effect of NIK-247 on AChE was reversible.",9228650_5,0
3860,low dose,41,49,These findings suggest that NIK-247 at a low dose (0.1-1 mg/kg p.o.) improves scopolamine-induced amnesia but does not affect spontaneous movement.,9228650_8,0
7423,Alzheimer's disease,76,95,The findings suggest that NIK-247 may be a useful drug for the treatment of Alzheimer's disease.,9228650_9,1
15480,NIK-247,26,33,The findings suggest that NIK-247 may be a useful drug for the treatment of Alzheimer's disease.,9228650_9,0
7424,cardiovascular disease,40,62,The role of nicotine in smoking-related cardiovascular disease.,9245658_0,1
7425,nervous system,35,49,Nicotine activates the sympathetic nervous system and in this way could contribute to cardiovascular disease.,9245658_1,1
7426,cardiovascular disease,86,108,Nicotine activates the sympathetic nervous system and in this way could contribute to cardiovascular disease.,9245658_1,1
15481,cardiovascular events,76,97,"Almost certainly, nicotine via its hemodynamic effects contributes to acute cardiovascular events, although current evidence suggests that the effects of nicotine are much less important than are the prothrombotic effects of cigarette smoking or the effects of carbon monoxide.",9245658_3,1
15483,prothrombotic,200,213,"Almost certainly, nicotine via its hemodynamic effects contributes to acute cardiovascular events, although current evidence suggests that the effects of nicotine are much less important than are the prothrombotic effects of cigarette smoking or the effects of carbon monoxide.",9245658_3,0
15486,carbon monoxide,261,276,"Almost certainly, nicotine via its hemodynamic effects contributes to acute cardiovascular events, although current evidence suggests that the effects of nicotine are much less important than are the prothrombotic effects of cigarette smoking or the effects of carbon monoxide.",9245658_3,0
15489,cardiovascular events,159,180,Clinical studies of pipe smokers and people using transdermal nicotine support the idea that toxins other than nicotine are the most important causes of acute cardiovascular events.,9245658_5,1
15488,transdermal nicotine,50,70,Clinical studies of pipe smokers and people using transdermal nicotine support the idea that toxins other than nicotine are the most important causes of acute cardiovascular events.,9245658_5,0
7427,adverse effects,126,141,"Finally, the dose response for cardiovascular events of nicotine appears to be flat, suggesting that if nicotine is involved, adverse effects might be seen with relatively low-level cigarette exposures.",9245658_6,1
15490,cardiovascular events,31,52,"Finally, the dose response for cardiovascular events of nicotine appears to be flat, suggesting that if nicotine is involved, adverse effects might be seen with relatively low-level cigarette exposures.",9245658_6,1
15492,Iatrogenically,0,14,Iatrogenically induced intractable atrioventricular reentrant tachycardia after verapamil and catheter ablation in a patient with Wolff-Parkinson-White syndrome and idiopathic dilated cardiomyopathy.,9249847_0,1
15493,catheter ablation,94,111,Iatrogenically induced intractable atrioventricular reentrant tachycardia after verapamil and catheter ablation in a patient with Wolff-Parkinson-White syndrome and idiopathic dilated cardiomyopathy.,9249847_0,1
7429,Wolff-Parkinson-White syndrome,130,160,Iatrogenically induced intractable atrioventricular reentrant tachycardia after verapamil and catheter ablation in a patient with Wolff-Parkinson-White syndrome and idiopathic dilated cardiomyopathy.,9249847_0,1
7428,atrioventricular reentrant tachycardia,35,73,Iatrogenically induced intractable atrioventricular reentrant tachycardia after verapamil and catheter ablation in a patient with Wolff-Parkinson-White syndrome and idiopathic dilated cardiomyopathy.,9249847_0,1
7430,idiopathic dilated cardiomyopathy,165,198,Iatrogenically induced intractable atrioventricular reentrant tachycardia after verapamil and catheter ablation in a patient with Wolff-Parkinson-White syndrome and idiopathic dilated cardiomyopathy.,9249847_0,1
15495,iatrogenically,132,146,"In a patient with WPW syndrome and idiopathic dilated cardiomyopathy, intractable atrioventricular reentrant tachycardia (AVRT) was iatrogenically induced.",9249847_1,1
7431,WPW syndrome,18,30,"In a patient with WPW syndrome and idiopathic dilated cardiomyopathy, intractable atrioventricular reentrant tachycardia (AVRT) was iatrogenically induced.",9249847_1,1
7432,idiopathic dilated cardiomyopathy,35,68,"In a patient with WPW syndrome and idiopathic dilated cardiomyopathy, intractable atrioventricular reentrant tachycardia (AVRT) was iatrogenically induced.",9249847_1,1
7433,atrioventricular reentrant tachycardia,82,120,"In a patient with WPW syndrome and idiopathic dilated cardiomyopathy, intractable atrioventricular reentrant tachycardia (AVRT) was iatrogenically induced.",9249847_1,1
7435,accessory pathway,114,131,"QRS without preexcitation, caused by junctional escape beats after verapamil or unidirectional antegrade block of accessory pathway after catheter ablation, established frequent AVRT attack.",9249847_2,1
15498,catheter ablation,138,155,"QRS without preexcitation, caused by junctional escape beats after verapamil or unidirectional antegrade block of accessory pathway after catheter ablation, established frequent AVRT attack.",9249847_2,1
15499,AVRT,178,182,"QRS without preexcitation, caused by junctional escape beats after verapamil or unidirectional antegrade block of accessory pathway after catheter ablation, established frequent AVRT attack.",9249847_2,1
7434,preexcitation,12,25,"QRS without preexcitation, caused by junctional escape beats after verapamil or unidirectional antegrade block of accessory pathway after catheter ablation, established frequent AVRT attack.",9249847_2,1
15497,junctional,37,47,"QRS without preexcitation, caused by junctional escape beats after verapamil or unidirectional antegrade block of accessory pathway after catheter ablation, established frequent AVRT attack.",9249847_2,1
15500,dopamine D1 receptor agonist,43,71,"Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.",9270571_0,0
3861,therapeutic use,10,25,"Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.",9270571_0,0
15503,parkinsonian,100,112,"Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.",9270571_0,0
15501,A-86929,73,80,"Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.",9270571_0,0
15505,D1 receptor agonists,38,58,The clinical utility of dopamine (DA) D1 receptor agonists in the treatment of Parkinson's disease (PD) is still unclear.,9270571_1,0
7436,Parkinson's disease,79,98,The clinical utility of dopamine (DA) D1 receptor agonists in the treatment of Parkinson's disease (PD) is still unclear.,9270571_1,1
15509,SKF-82958,351,360,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,0
15508,A-77636,171,178,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,0
15507,SKF-82958,65,74,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,0
15506,DA D1 receptor agonists,33,56,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,0
3862,therapeutic use,4,19,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,0
3863,hydrobromide,153,165,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,0
3864,pyran,256,261,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,0
15510,A-77636,387,394,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,0
15511,behavioral tolerance,416,436,"The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance).",9270571_2,1
15514,levodopa-induced dyskinesias,166,194,"We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.",9270571_3,1
15517,"[-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+",310,369,"We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.",9270571_3,0
3865,receptor agonist,450,466,"We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.",9270571_3,0
15516,"[-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+",310,369,"We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.",9270571_3,0
7437,dyskinetic,225,235,"We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.",9270571_3,1
15512,"1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",69,113,"We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of A-86929 ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action.",9270571_3,0
15520,4-quinoline hydrochloride,122,147,"Levodopa and the DA D2-like receptor agonist, LY-171555 ([4aR-trans]-4,4a,5,6,7,8,8a,9-o-dihydro-5n-propyl-2H-pyrazo lo-3-4-quinoline hydrochloride) were also used for comparison.",9270571_4,0
15518,LY-171555,46,55,"Levodopa and the DA D2-like receptor agonist, LY-171555 ([4aR-trans]-4,4a,5,6,7,8,8a,9-o-dihydro-5n-propyl-2H-pyrazo lo-3-4-quinoline hydrochloride) were also used for comparison.",9270571_4,0
3866,receptor agonist,28,44,"Levodopa and the DA D2-like receptor agonist, LY-171555 ([4aR-trans]-4,4a,5,6,7,8,8a,9-o-dihydro-5n-propyl-2H-pyrazo lo-3-4-quinoline hydrochloride) were also used for comparison.",9270571_4,0
15519,"[4aR-trans]-4,4a,5,6,7,8,8a,9-o-dihydro-5n-propyl-2H-pyrazo",57,116,"Levodopa and the DA D2-like receptor agonist, LY-171555 ([4aR-trans]-4,4a,5,6,7,8,8a,9-o-dihydro-5n-propyl-2H-pyrazo lo-3-4-quinoline hydrochloride) were also used for comparison.",9270571_4,0
7438,MPTP-induced parkinsonism,66,91,"Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.",9270571_5,1
15522,A-86929,24,31,"Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.",9270571_5,0
15523,LY-171555,108,117,"Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.",9270571_5,0
15525,LY-171555,219,228,"Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa.",9270571_5,0
7439,basal ganglia,171,184,Selective stimulation of the DA D1 receptor may provide better integration of neural inputs transmitted to the internal segment of the globus pallidus (referred to as the basal ganglia output) compared with levodopa and selective DA D2 receptor agonist.,9270571_6,1
15527,DA D1 receptor,29,43,Selective stimulation of the DA D1 receptor may provide better integration of neural inputs transmitted to the internal segment of the globus pallidus (referred to as the basal ganglia output) compared with levodopa and selective DA D2 receptor agonist.,9270571_6,0
15530,globus pallidus,135,150,Selective stimulation of the DA D1 receptor may provide better integration of neural inputs transmitted to the internal segment of the globus pallidus (referred to as the basal ganglia output) compared with levodopa and selective DA D2 receptor agonist.,9270571_6,1
15531,D2 receptor agonist,233,252,Selective stimulation of the DA D1 receptor may provide better integration of neural inputs transmitted to the internal segment of the globus pallidus (referred to as the basal ganglia output) compared with levodopa and selective DA D2 receptor agonist.,9270571_6,0
15535,therapeutic tools,145,162,Potent DA D1 receptor agents with an intermediate duration of efficacy such as A-86929 (approximately 4 hr at higher doses tested) are potential therapeutic tools in PD and merit further attention.,9270571_7,0
15532,DA D1 receptor agents,7,28,Potent DA D1 receptor agents with an intermediate duration of efficacy such as A-86929 (approximately 4 hr at higher doses tested) are potential therapeutic tools in PD and merit further attention.,9270571_7,0
15533,A-86929,79,86,Potent DA D1 receptor agents with an intermediate duration of efficacy such as A-86929 (approximately 4 hr at higher doses tested) are potential therapeutic tools in PD and merit further attention.,9270571_7,0
7440,liver disease,12,25,Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons.,9284778_0,1
15536,ozone-sparing substitutes,69,94,Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of chlorofluorocarbons.,9284778_0,0
15558,P450 2E1,23,31,"Autoantibodies against P450 2E1 or P58, previously associated with halothane hepatitis, were detected in the serum of five affected workers.",9284778_11,0
15559,P58,35,38,"Autoantibodies against P450 2E1 or P58, previously associated with halothane hepatitis, were detected in the serum of five affected workers.",9284778_11,0
7444,liver injury,93,105,INTERPRETATION: Repeated exposure of human beings to HCFCs 123 and 124 can result in serious liver injury in a large proportion of the exposed population.,9284778_12,1
15564,hepatotoxicity,32,46,"Although the exact mechanism of hepatotoxicity of these agents is not known, the results suggest that trifluoroacetyl-altered liver proteins are involved.",9284778_13,1
15537,hepatotoxicity,46,60,Limited studies in animals indicate potential hepatotoxicity of some of these compounds.,9284778_2,1
15540,"1-chloro-1,2,2,2-tetrafluoroethane",179,213,"We investigated an epidemic of liver disease in nine industrial workers who had had repeated accidental exposure to a mixture of 1,1-dichloro-2,2,2-trifluoroethane (HCFC 123) and 1-chloro-1,2,2,2-tetrafluoroethane (HCFC 124).",9284778_3,0
7441,liver disease,31,44,"We investigated an epidemic of liver disease in nine industrial workers who had had repeated accidental exposure to a mixture of 1,1-dichloro-2,2,2-trifluoroethane (HCFC 123) and 1-chloro-1,2,2,2-tetrafluoroethane (HCFC 124).",9284778_3,1
15539,"1,1-dichloro-2,2,2-trifluoroethane",129,163,"We investigated an epidemic of liver disease in nine industrial workers who had had repeated accidental exposure to a mixture of 1,1-dichloro-2,2,2-trifluoroethane (HCFC 123) and 1-chloro-1,2,2,2-tetrafluoroethane (HCFC 124).",9284778_3,0
15543,hepatotoxicity,190,204,"Both compounds are metabolised in the same way as 1-bromo-1-chloro-2,2,2-trifluoroethane (halothane) to form reactive trifluoroacetyl halide intermediates, which have been implicated in the hepatotoxicity of halothane.",9284778_5,1
15542,"1-bromo-1-chloro-2,2,2-trifluoroethane",50,88,"Both compounds are metabolised in the same way as 1-bromo-1-chloro-2,2,2-trifluoroethane (halothane) to form reactive trifluoroacetyl halide intermediates, which have been implicated in the hepatotoxicity of halothane.",9284778_5,0
7442,liver disease,65,78,We aimed to test whether HCFCs 123 and 124 can result in serious liver disease.,9284778_6,1
15545,trifluoroacetyl protein adducts,109,140,METHODS: For one severely affected worker liver biopsy and immunohistochemical stainings for the presence of trifluoroacetyl protein adducts were done.,9284778_7,0
15546,human liver cytochrome-P450 2E1,98,129,The serum of six affected workers and five controls was tested for autoantibodies that react with human liver cytochrome-P450 2E1 (P450 2E1) and P58 protein disulphide isomerase isoform (P58).,9284778_8,0
15547,P450 2E1,131,139,The serum of six affected workers and five controls was tested for autoantibodies that react with human liver cytochrome-P450 2E1 (P450 2E1) and P58 protein disulphide isomerase isoform (P58).,9284778_8,0
15548,P58,145,148,The serum of six affected workers and five controls was tested for autoantibodies that react with human liver cytochrome-P450 2E1 (P450 2E1) and P58 protein disulphide isomerase isoform (P58).,9284778_8,0
15549,isomerase isoform,168,185,The serum of six affected workers and five controls was tested for autoantibodies that react with human liver cytochrome-P450 2E1 (P450 2E1) and P58 protein disulphide isomerase isoform (P58).,9284778_8,0
15550,P58,187,190,The serum of six affected workers and five controls was tested for autoantibodies that react with human liver cytochrome-P450 2E1 (P450 2E1) and P58 protein disulphide isomerase isoform (P58).,9284778_8,0
7443,centrilobular,172,185,FINDINGS: The liver biopsy sample showed hepatocellular necrosis which was prominent in perivenular zone three and extended focally from portal tracts to portal tracts and centrilobular areas (bridging necrosis).,9284778_9,1
15551,hepatocellular necrosis,41,64,FINDINGS: The liver biopsy sample showed hepatocellular necrosis which was prominent in perivenular zone three and extended focally from portal tracts to portal tracts and centrilobular areas (bridging necrosis).,9284778_9,1
15553,portal tracts,137,150,FINDINGS: The liver biopsy sample showed hepatocellular necrosis which was prominent in perivenular zone three and extended focally from portal tracts to portal tracts and centrilobular areas (bridging necrosis).,9284778_9,1
15554,portal tracts,154,167,FINDINGS: The liver biopsy sample showed hepatocellular necrosis which was prominent in perivenular zone three and extended focally from portal tracts to portal tracts and centrilobular areas (bridging necrosis).,9284778_9,1
15567,Bile duct hamartoma,0,19,Bile duct hamartoma occurring in association with long-term treatment with danazol.,9293063_0,1
15568,danazol,75,82,Bile duct hamartoma occurring in association with long-term treatment with danazol.,9293063_0,0
15570,danazol,95,102,We report a case of bile duct hamartoma which developed in a patient who had been on long-term danazol treatment.,9293063_1,0
15569,bile duct hamartoma,20,39,We report a case of bile duct hamartoma which developed in a patient who had been on long-term danazol treatment.,9293063_1,1
15573,liver mass,26,36,"If the patient develops a liver mass, because of non-specific clinical features and imaging appearances, biopsy may be the only way to achieve a definitive diagnosis.",9293063_3,1
15574,immunoreactivity,15,31,Neuropeptide-Y immunoreactivity in the pilocarpine model of temporal lobe epilepsy.,9305828_0,0
7445,temporal lobe epilepsy,60,82,Neuropeptide-Y immunoreactivity in the pilocarpine model of temporal lobe epilepsy.,9305828_0,1
3867,Neuropeptide-Y,0,14,Neuropeptide-Y immunoreactivity in the pilocarpine model of temporal lobe epilepsy.,9305828_0,0
15577,granule cells,37,50,Neuropeptide-Y (NPY) is expressed by granule cells and mossy fibres of the hippocampal dentate gyrus during experimental temporal lobe epilepsy (TLE).,9305828_1,1
15576,NPY,16,19,Neuropeptide-Y (NPY) is expressed by granule cells and mossy fibres of the hippocampal dentate gyrus during experimental temporal lobe epilepsy (TLE).,9305828_1,0
15579,hippocampal dentate gyrus,75,100,Neuropeptide-Y (NPY) is expressed by granule cells and mossy fibres of the hippocampal dentate gyrus during experimental temporal lobe epilepsy (TLE).,9305828_1,1
7446,temporal lobe epilepsy,121,143,Neuropeptide-Y (NPY) is expressed by granule cells and mossy fibres of the hippocampal dentate gyrus during experimental temporal lobe epilepsy (TLE).,9305828_1,1
15580,TLE,145,148,Neuropeptide-Y (NPY) is expressed by granule cells and mossy fibres of the hippocampal dentate gyrus during experimental temporal lobe epilepsy (TLE).,9305828_1,0
15578,mossy fibres,55,67,Neuropeptide-Y (NPY) is expressed by granule cells and mossy fibres of the hippocampal dentate gyrus during experimental temporal lobe epilepsy (TLE).,9305828_1,1
3868,Neuropeptide-Y,0,14,Neuropeptide-Y (NPY) is expressed by granule cells and mossy fibres of the hippocampal dentate gyrus during experimental temporal lobe epilepsy (TLE).,9305828_1,0
7448,hippocampal,156,167,This expression may represent an endogenous damping mechanism since NPY has been shown to block seizure-like events following high-frequency stimulation in hippocampal slices.,9305828_2,1
7447,high-frequency,126,140,This expression may represent an endogenous damping mechanism since NPY has been shown to block seizure-like events following high-frequency stimulation in hippocampal slices.,9305828_2,1
15582,NPY,68,71,This expression may represent an endogenous damping mechanism since NPY has been shown to block seizure-like events following high-frequency stimulation in hippocampal slices.,9305828_2,0
15583,acute period,64,76,The pilocarpine (PILO) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage.,9305828_3,1
15584,spontaneous recurrent,111,132,The pilocarpine (PILO) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage.,9305828_3,1
7449,status epilepticus,80,98,The pilocarpine (PILO) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage.,9305828_3,1
7450,brain damage,154,166,The pilocarpine (PILO) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage.,9305828_3,1
15585,peroxidase-antiperoxidase,10,35,We report peroxidase-antiperoxidase immunostaining for NPY in several brain regions in this model.,9305828_4,0
15587,NPY,55,58,We report peroxidase-antiperoxidase immunostaining for NPY in several brain regions in this model.,9305828_4,0
15589,NPY,32,35,"PILO-injected animals exhibited NPY immunoreactivity in the region of the mossy fibre terminals, in the dentate gyrus inner molecular layer and, in a few cases, within presumed granule cells.",9305828_5,0
15592,dentate gyrus,104,117,"PILO-injected animals exhibited NPY immunoreactivity in the region of the mossy fibre terminals, in the dentate gyrus inner molecular layer and, in a few cases, within presumed granule cells.",9305828_5,1
15595,NPY,0,3,"NPY immunoreactivity was also dramatically changed in the entorhinal cortex, amygdala and sensorimotor areas.",9305828_6,0
15597,entorhinal cortex,58,75,"NPY immunoreactivity was also dramatically changed in the entorhinal cortex, amygdala and sensorimotor areas.",9305828_6,1
15602,interneurons,93,105,"In addition, PILO injected animals exhibited a reduction in the number of NPY-immunoreactive interneurons compared with controls.",9305828_7,0
15599,PILO,13,17,"In addition, PILO injected animals exhibited a reduction in the number of NPY-immunoreactive interneurons compared with controls.",9305828_7,0
15603,NPY,40,43,"The results demonstrate that changes in NPY expression, including expression in the granule cells and mossy fibres and the loss of vulnerable NPY neurons, are present in the PILO model of TLE.",9305828_8,0
15606,NPY,142,145,"The results demonstrate that changes in NPY expression, including expression in the granule cells and mossy fibres and the loss of vulnerable NPY neurons, are present in the PILO model of TLE.",9305828_8,0
15607,PILO,174,178,"The results demonstrate that changes in NPY expression, including expression in the granule cells and mossy fibres and the loss of vulnerable NPY neurons, are present in the PILO model of TLE.",9305828_8,0
15608,TLE,188,191,"The results demonstrate that changes in NPY expression, including expression in the granule cells and mossy fibres and the loss of vulnerable NPY neurons, are present in the PILO model of TLE.",9305828_8,0
7451,loss of,123,130,"The results demonstrate that changes in NPY expression, including expression in the granule cells and mossy fibres and the loss of vulnerable NPY neurons, are present in the PILO model of TLE.",9305828_8,1
15609,NPY,55,58,"However, the significance of this changed synthesis of NPY remains to be determined.",9305828_9,0
15610,Posteroventral medial pallidotomy,0,33,Posteroventral medial pallidotomy in advanced Parkinson's disease.,9321531_0,1
7452,Parkinson's disease,46,65,Posteroventral medial pallidotomy in advanced Parkinson's disease.,9321531_0,1
7453,Parkinson's disease,112,131,"BACKGROUND: Posteroventral medial pallidotomy sometimes produces striking improvement in patients with advanced Parkinson's disease, but the studies to date have involved small numbers of patients and short-term follow-up.",9321531_1,1
15631,axial symptoms,120,134,"Much of the benefit is sustained at two years, although some improvements, such as those on the ipsilateral side and in axial symptoms, wane within the first year.",9321531_10,1
3869,dopaminergic,45,57,The on-period symptoms that are resistant to dopaminergic therapy do not respond to pallidotomy.,9321531_11,0
15632,on-period symptoms,4,22,The on-period symptoms that are resistant to dopaminergic therapy do not respond to pallidotomy.,9321531_11,1
15633,pallidotomy,84,95,The on-period symptoms that are resistant to dopaminergic therapy do not respond to pallidotomy.,9321531_11,1
7455,drug withdrawal,99,114,"METHODS: Forty patients with Parkinson's disease underwent serial, detailed assessments both after drug withdrawal (""off"" period) and while taking their optimal medical regimens (""on"" period).",9321531_2,1
7454,Parkinson's disease,29,48,"METHODS: Forty patients with Parkinson's disease underwent serial, detailed assessments both after drug withdrawal (""off"" period) and while taking their optimal medical regimens (""on"" period).",9321531_2,1
15621,ipsilateral dyskinesias,476,499,"RESULTS: The percent improvements at six months were as follows: off-period score for overall motor function, 28 percent (95 percent confidence interval, 19 to 38 percent), with most of the improvement in the contralateral limbs; off-period score for activities of daily living, 29 percent (95 percent confidence interval, 19 to 39 percent); on-period score for contralateral dyskinesias, 82 percent (95 percent confidence interval, 72 to 91 percent); and on-period score for ipsilateral dyskinesias, 44 percent (95 percent confidence interval, 29 to 59 percent).",9321531_4,1
15619,contralateral dyskinesias,362,387,"RESULTS: The percent improvements at six months were as follows: off-period score for overall motor function, 28 percent (95 percent confidence interval, 19 to 38 percent), with most of the improvement in the contralateral limbs; off-period score for activities of daily living, 29 percent (95 percent confidence interval, 19 to 39 percent); on-period score for contralateral dyskinesias, 82 percent (95 percent confidence interval, 72 to 91 percent); and on-period score for ipsilateral dyskinesias, 44 percent (95 percent confidence interval, 29 to 59 percent).",9321531_4,1
15616,contralateral limbs,209,228,"RESULTS: The percent improvements at six months were as follows: off-period score for overall motor function, 28 percent (95 percent confidence interval, 19 to 38 percent), with most of the improvement in the contralateral limbs; off-period score for activities of daily living, 29 percent (95 percent confidence interval, 19 to 39 percent); on-period score for contralateral dyskinesias, 82 percent (95 percent confidence interval, 72 to 91 percent); and on-period score for ipsilateral dyskinesias, 44 percent (95 percent confidence interval, 29 to 59 percent).",9321531_4,1
15614,motor function,94,108,"RESULTS: The percent improvements at six months were as follows: off-period score for overall motor function, 28 percent (95 percent confidence interval, 19 to 38 percent), with most of the improvement in the contralateral limbs; off-period score for activities of daily living, 29 percent (95 percent confidence interval, 19 to 39 percent); on-period score for contralateral dyskinesias, 82 percent (95 percent confidence interval, 72 to 91 percent); and on-period score for ipsilateral dyskinesias, 44 percent (95 percent confidence interval, 29 to 59 percent).",9321531_4,1
15624,off-period parkinsonism,57,80,"The improvements in dyskinesias and the total scores for off-period parkinsonism, contralateral bradykinesia, and rigidity were sustained in the 11 patients examined at two years.",9321531_5,1
7456,bradykinesia,96,108,"The improvements in dyskinesias and the total scores for off-period parkinsonism, contralateral bradykinesia, and rigidity were sustained in the 11 patients examined at two years.",9321531_5,1
15626,postural stability,92,110,"The improvement in ipsilateral dyskinesias was lost after one year, and the improvements in postural stability and gait lasted only three to six months.",9321531_6,1
15625,ipsilateral dyskinesias,19,42,"The improvement in ipsilateral dyskinesias was lost after one year, and the improvements in postural stability and gait lasted only three to six months.",9321531_6,1
15630,off-period disability,115,136,"CONCLUSIONS: In late-stage Parkinson's disease, pallidotomy significantly reduces levodopa-induced dyskinesias and off-period disability.",9321531_9,1
15628,pallidotomy,48,59,"CONCLUSIONS: In late-stage Parkinson's disease, pallidotomy significantly reduces levodopa-induced dyskinesias and off-period disability.",9321531_9,1
15627,late-stage Parkinson's disease,16,46,"CONCLUSIONS: In late-stage Parkinson's disease, pallidotomy significantly reduces levodopa-induced dyskinesias and off-period disability.",9321531_9,1
7457,ventricular tachycardia,23,46,Clarithromycin-induced ventricular tachycardia.,9326871_0,1
3870,Clarithromycin,0,14,Clarithromycin is a relatively new macrolide antibiotic that offers twice-daily dosing.,9326871_1,0
15634,macrolide antibiotic,35,55,Clarithromycin is a relatively new macrolide antibiotic that offers twice-daily dosing.,9326871_1,0
15635,hydroxyl group,60,74,It differs from erythromycin only in the methylation of the hydroxyl group at position 6.,9326871_2,0
3871,macrolides,205,215,"Although the side-effect profile of erythromycin is established, including gastroenteritis and interactions with other drugs subject to hepatic mixed-function oxidase metabolism, experience with the newer macrolides is still being recorded.",9326871_3,0
3872,macrolides,143,153,Cardiotoxicity has been demonstrated after both intravenous and oral administration of erythromycin but has never been reported with the newer macrolides.,9326871_4,0
7458,Cardiotoxicity,0,14,Cardiotoxicity has been demonstrated after both intravenous and oral administration of erythromycin but has never been reported with the newer macrolides.,9326871_4,1
3873,clarithromycin,90,104,We report a case of ventricular dysrhythmias that occurred after six therapeutic doses of clarithromycin.,9326871_5,0
15638,ventricular dysrhythmias,20,44,We report a case of ventricular dysrhythmias that occurred after six therapeutic doses of clarithromycin.,9326871_5,1
15639,therapeutic doses,69,86,We report a case of ventricular dysrhythmias that occurred after six therapeutic doses of clarithromycin.,9326871_5,0
15640,dysrhythmias,4,16,The dysrhythmias resolved after discontinuation of the drug.,9326871_6,1
7459,erectile dysfunction,38,58,"Endocrine screening in 1,022 men with erectile dysfunction: clinical significance and cost-effective strategy.",9334596_0,1
15648,hormonal abnormalities,377,399,"PURPOSE: We reviewed the results of serum testosterone and prolactin determination in 1,022 patients referred because of erectile dysfunction and compared the data with history, results of physical examination, other etiological investigations and effects of endocrine therapy to refine the rules of cost-effective endocrine screening and to pinpoint actual responsibility for hormonal abnormalities.",9334596_1,1
7460,erectile dysfunction,121,141,"PURPOSE: We reviewed the results of serum testosterone and prolactin determination in 1,022 patients referred because of erectile dysfunction and compared the data with history, results of physical examination, other etiological investigations and effects of endocrine therapy to refine the rules of cost-effective endocrine screening and to pinpoint actual responsibility for hormonal abnormalities.",9334596_1,1
7463,pituitary tumors,4,20,Two pituitary tumors were discovered after testosterone determination.,9334596_11,1
7464,erectile dysfunction,191,211,"Most of the other low testosterone levels seemed to result from nonorganic hypothalamic dysfunction because of normal serum luteinizing hormone and prolactin and to have only a small role in erectile dysfunction (definite improvement in only 16 of 44 [36%] after androgen therapy, normal morning or nocturnal erections in 30% and definite vasculogenic contributions in 42%).",9334596_12,1
7465,vasculogenic,339,351,"Most of the other low testosterone levels seemed to result from nonorganic hypothalamic dysfunction because of normal serum luteinizing hormone and prolactin and to have only a small role in erectile dysfunction (definite improvement in only 16 of 44 [36%] after androgen therapy, normal morning or nocturnal erections in 30% and definite vasculogenic contributions in 42%).",9334596_12,1
15658,normal morning,281,295,"Most of the other low testosterone levels seemed to result from nonorganic hypothalamic dysfunction because of normal serum luteinizing hormone and prolactin and to have only a small role in erectile dysfunction (definite improvement in only 16 of 44 [36%] after androgen therapy, normal morning or nocturnal erections in 30% and definite vasculogenic contributions in 42%).",9334596_12,1
15657,luteinizing hormone,124,143,"Most of the other low testosterone levels seemed to result from nonorganic hypothalamic dysfunction because of normal serum luteinizing hormone and prolactin and to have only a small role in erectile dysfunction (definite improvement in only 16 of 44 [36%] after androgen therapy, normal morning or nocturnal erections in 30% and definite vasculogenic contributions in 42%).",9334596_12,0
15656,nonorganic hypothalamic dysfunction,64,99,"Most of the other low testosterone levels seemed to result from nonorganic hypothalamic dysfunction because of normal serum luteinizing hormone and prolactin and to have only a small role in erectile dysfunction (definite improvement in only 16 of 44 [36%] after androgen therapy, normal morning or nocturnal erections in 30% and definite vasculogenic contributions in 42%).",9334596_12,1
15659,sexual desire,46,59,"Determining testosterone only in cases of low sexual desire or abnormal physical examination would have missed 40% of the cases with low testosterone, including 37% of those subsequently improved by androgen therapy.",9334596_13,1
7466,prolactinoma,7,19,Only 1 prolactinoma was discovered.,9334596_16,1
7467,prolactinomas,28,41,"in 1.86% of 1,821 patients, prolactinomas in 7, 0.38%).",9334596_18,1
15662,prolactin greater,53,70,Bromocriptine was definitely effective in cases with prolactin greater than 35 ng./ml.,9334596_19,1
3876,Bromocriptine,0,13,Bromocriptine was definitely effective in cases with prolactin greater than 35 ng./ml.,9334596_19,0
15663,prolactin greater,52,69,Testosterone was low in less than 50% of cases with prolactin greater than 35 ng./ml.,9334596_21,1
7468,erectile dysfunction,83,103,CONCLUSIONS: Low prevalences and effects of low testosterone and high prolactin in erectile dysfunction cannot justify their routine determination.,9334596_22,1
7469,pituitary tumors,130,146,"However, cost-effective screening strategies recommended so far missed 40 to 50% of cases improved with endocrine therapy and the pituitary tumors.",9334596_23,1
15666,sexual desire,89,102,We now advocate that before age 50 years testosterone be determined only in cases of low sexual desire and abnormal physical examination but that it be measured in all men older than 50 years.,9334596_24,1
15668,sexual desire,52,65,"Prolactin should be determined only in cases of low sexual desire, gynecomastia and/or testosterone less than 4 ng./ml.",9334596_25,1
15649,sexual desire,100,113,"Every patient was screened for testosterone and 451 were screened for prolactin on the basis of low sexual desire, gynecomastia or testosterone less than 4 ng./ml.",9334596_3,1
15652,systematic prolactin,121,141,"Prolactin results were compared with those of a previous personal cohort of 1,340 patients with erectile dysfunction and systematic prolactin determination.",9334596_5,1
7461,erectile dysfunction,96,116,"Prolactin results were compared with those of a previous personal cohort of 1,340 patients with erectile dysfunction and systematic prolactin determination.",9334596_5,1
15654,sexual desire,85,98,"Main clinical criteria tested regarding efficiency in hormone determination were low sexual desire, small testes and gynecomastia.",9334596_6,1
3874,human chorionic gonadotropin,57,85,Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia.,9334596_7,0
15655,heptylate,44,53,Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia.,9334596_7,0
3875,bromocriptine,107,120,Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia.,9334596_7,0
7462,hyperprolactinemia,125,143,Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia.,9334596_7,1
3877,D2,75,77,Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels.,9351491_0,0
15669,Extrapyramidal side effects,0,27,Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels.,9351491_0,1
15670,risperidone,33,44,Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels.,9351491_0,0
3878,antipsychotic drug,18,36,Risperidone is an antipsychotic drug with high affinity at dopamine D2 and serotonin 5-HT2 receptors.,9351491_1,0
3879,dopamine D2,59,70,Risperidone is an antipsychotic drug with high affinity at dopamine D2 and serotonin 5-HT2 receptors.,9351491_1,0
3880,serotonin 5-HT2 receptors,75,100,Risperidone is an antipsychotic drug with high affinity at dopamine D2 and serotonin 5-HT2 receptors.,9351491_1,0
15671,Risperidone,0,11,Risperidone is an antipsychotic drug with high affinity at dopamine D2 and serotonin 5-HT2 receptors.,9351491_1,0
15673,risperidone,45,56,Previous clinical studies have proposed that risperidone's pharmacologic profile may produce improved efficacy for negative psychotic symptoms and decreased propensity for extrapyramidal side effects; features shared by so-called 'atypical' neuroleptics.,9351491_2,0
15676,extrapyramidal side effects,172,199,Previous clinical studies have proposed that risperidone's pharmacologic profile may produce improved efficacy for negative psychotic symptoms and decreased propensity for extrapyramidal side effects; features shared by so-called 'atypical' neuroleptics.,9351491_2,1
15675,psychotic symptoms,124,142,Previous clinical studies have proposed that risperidone's pharmacologic profile may produce improved efficacy for negative psychotic symptoms and decreased propensity for extrapyramidal side effects; features shared by so-called 'atypical' neuroleptics.,9351491_2,1
15677,risperidone,24,35,"To determine if routine risperidone treatment is associated with a unique degree of D2 receptor occupancy and pattern of clinical effects, we used [123I]IBZM SPECT to determine D2 occupancy in subjects treated with routine clinical doses of risperidone (n = 12) or haloperidol (n = 7).",9351491_3,0
15681,risperidone,241,252,"To determine if routine risperidone treatment is associated with a unique degree of D2 receptor occupancy and pattern of clinical effects, we used [123I]IBZM SPECT to determine D2 occupancy in subjects treated with routine clinical doses of risperidone (n = 12) or haloperidol (n = 7).",9351491_3,0
3882,D2,177,179,"To determine if routine risperidone treatment is associated with a unique degree of D2 receptor occupancy and pattern of clinical effects, we used [123I]IBZM SPECT to determine D2 occupancy in subjects treated with routine clinical doses of risperidone (n = 12) or haloperidol (n = 7).",9351491_3,0
3881,D2,84,86,"To determine if routine risperidone treatment is associated with a unique degree of D2 receptor occupancy and pattern of clinical effects, we used [123I]IBZM SPECT to determine D2 occupancy in subjects treated with routine clinical doses of risperidone (n = 12) or haloperidol (n = 7).",9351491_3,0
15679,SPECT,158,163,"To determine if routine risperidone treatment is associated with a unique degree of D2 receptor occupancy and pattern of clinical effects, we used [123I]IBZM SPECT to determine D2 occupancy in subjects treated with routine clinical doses of risperidone (n = 12) or haloperidol (n = 7).",9351491_3,0
3883,D2,42,44,Both risperidone and haloperidol produced D2 occupancy levels between approximately 60 and 90% at standard clinical doses.,9351491_4,0
15682,risperidone,5,16,Both risperidone and haloperidol produced D2 occupancy levels between approximately 60 and 90% at standard clinical doses.,9351491_4,0
15684,risperidone,90,101,There was no significant difference between occupancy levels obtained with haloperidol or risperidone.,9351491_5,0
15686,risperidone,64,75,Drug-induced parkinsonism was observed in subjects treated with risperidone (42%) and haloperidol (29%) and was observed at occupancy levels above 60%.,9351491_6,0
15685,Drug-induced parkinsonism,0,25,Drug-induced parkinsonism was observed in subjects treated with risperidone (42%) and haloperidol (29%) and was observed at occupancy levels above 60%.,9351491_6,1
15689,extrapyramidal side effects,178,205,"Based on these observations, it is concluded that 5-HT2 blockade obtained with risperidone at D2 occupancy rates of 60% and above does not appear to protect against the risk for extrapyramidal side effects.",9351491_7,1
3884,D2,94,96,"Based on these observations, it is concluded that 5-HT2 blockade obtained with risperidone at D2 occupancy rates of 60% and above does not appear to protect against the risk for extrapyramidal side effects.",9351491_7,0
15688,risperidone,79,90,"Based on these observations, it is concluded that 5-HT2 blockade obtained with risperidone at D2 occupancy rates of 60% and above does not appear to protect against the risk for extrapyramidal side effects.",9351491_7,0
15687,5-HT2,50,55,"Based on these observations, it is concluded that 5-HT2 blockade obtained with risperidone at D2 occupancy rates of 60% and above does not appear to protect against the risk for extrapyramidal side effects.",9351491_7,0
7470,breast cancer,43,56,Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.,9390208_0,1
15690,high-dose 5-FU,108,122,Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.,9390208_0,0
3886,leucovorin,127,137,Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.,9390208_0,0
3885,mitoxantrone,60,72,Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.,9390208_0,0
7471,treatment-related,177,194,Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.,9390208_0,1
15691,MFL,139,142,Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity.,9390208_0,0
7472,breast cancer,32,45,"For previously treated advanced breast cancer, there is no standard second-line therapy.",9390208_1,1
15708,Median survival,0,15,Median survival was 16 months.,9390208_12,1
15709,progression-free survival,7,32,Median progression-free survival was 5 months.,9390208_13,1
15710,relapse-free survival,25,46,A complete responder had relapse-free survival up to 17 months.,9390208_14,1
7474,cardiotoxicity,22,36,Major toxicities were cardiotoxicity and leukopenia.,9390208_15,1
7475,treatment-related,68,85,Eight patients were dead in the last follow-up; two of them died of treatment-related toxicity.,9390208_16,1
15711,MFL regimen,4,15,The MFL regimen achieves little palliative benefit and induces severe toxicity at a fairly high rate.,9390208_17,0
15713,heart function,119,133,Administration of this regimen to breast cancer patients who have been treated by chemotherapy and those with impaired heart function requires careful attention.,9390208_18,1
7476,breast cancer,34,47,Administration of this regimen to breast cancer patients who have been treated by chemotherapy and those with impaired heart function requires careful attention.,9390208_18,1
3887,mitoxantrone,30,42,"Combination chemotherapy with mitoxantrone, high-dose 5-fluorouracil (5-FU) and leucovorin (MFL regimen) had been reported as an effective and well tolerated regimen.",9390208_2,0
3888,leucovorin,80,90,"Combination chemotherapy with mitoxantrone, high-dose 5-fluorouracil (5-FU) and leucovorin (MFL regimen) had been reported as an effective and well tolerated regimen.",9390208_2,0
15695,5-FU,70,74,"Combination chemotherapy with mitoxantrone, high-dose 5-fluorouracil (5-FU) and leucovorin (MFL regimen) had been reported as an effective and well tolerated regimen.",9390208_2,0
15694,high-dose 5-fluorouracil,44,68,"Combination chemotherapy with mitoxantrone, high-dose 5-fluorouracil (5-FU) and leucovorin (MFL regimen) had been reported as an effective and well tolerated regimen.",9390208_2,0
15697,mg/m2,141,146,"From October 1993 to November 1995, we treated 13 patients with previously chemotherapy-treated metastatic breast cancer by mitoxantrone, 12 mg/m2, on day 1 and continuous infusion of 5-FU, 3000 mg/m2, together with leucovorin, 300 mg/m2, for 48 h from day 1 to 2.",9390208_3,0
15698,5-FU,184,188,"From October 1993 to November 1995, we treated 13 patients with previously chemotherapy-treated metastatic breast cancer by mitoxantrone, 12 mg/m2, on day 1 and continuous infusion of 5-FU, 3000 mg/m2, together with leucovorin, 300 mg/m2, for 48 h from day 1 to 2.",9390208_3,0
3890,leucovorin,216,226,"From October 1993 to November 1995, we treated 13 patients with previously chemotherapy-treated metastatic breast cancer by mitoxantrone, 12 mg/m2, on day 1 and continuous infusion of 5-FU, 3000 mg/m2, together with leucovorin, 300 mg/m2, for 48 h from day 1 to 2.",9390208_3,0
7473,breast cancer,107,120,"From October 1993 to November 1995, we treated 13 patients with previously chemotherapy-treated metastatic breast cancer by mitoxantrone, 12 mg/m2, on day 1 and continuous infusion of 5-FU, 3000 mg/m2, together with leucovorin, 300 mg/m2, for 48 h from day 1 to 2.",9390208_3,1
3889,mitoxantrone,124,136,"From October 1993 to November 1995, we treated 13 patients with previously chemotherapy-treated metastatic breast cancer by mitoxantrone, 12 mg/m2, on day 1 and continuous infusion of 5-FU, 3000 mg/m2, together with leucovorin, 300 mg/m2, for 48 h from day 1 to 2.",9390208_3,0
15701,metastatic sites,41,57,"Most of these patients had more than two metastatic sites, with lung metastasis predominant.",9390208_5,1
15702,lung metastasis,64,79,"Most of these patients had more than two metastatic sites, with lung metastasis predominant.",9390208_5,1
3891,anthracycline,37,50,Seven patients had been treated with anthracycline.,9390208_6,0
15704,mg/m2,111,116,Median number of courses of MFL regimen given was six and the median cumulative dose of mitoxantrone was 68.35 mg/m2.,9390208_8,0
3892,mitoxantrone,88,100,Median number of courses of MFL regimen given was six and the median cumulative dose of mitoxantrone was 68.35 mg/m2.,9390208_8,0
15705,stable disease,45,59,"One patient had complete response, seven had stable disease, none had partial response and five had progressive disease.",9390208_9,1
15706,partial response,70,86,"One patient had complete response, seven had stable disease, none had partial response and five had progressive disease.",9390208_9,1
7477,aplastic anemia,20,35,Ticlopidine-induced aplastic anemia: report of three Chinese patients and review of the literature.,9401499_0,1
7478,aplastic anemia,63,78,"In this study, three Chinese patients with ticlopidine-induced aplastic anemia were reported and another 13 patients in the English literature were reviewed.",9401499_1,1
3893,ticlopidine,56,67,"Agranulocytosis occurred 3-20 weeks after initiation of ticlopidine, so frequent examination of white cell count during treatment is recommended.",9401499_5,0
15717,of bone marrow,92,106,There seemed to be no direct correlation between the dose or duration used and the severity of bone marrow suppression.,9401499_6,1
3894,colony-stimulating factors,55,81,Treatment for ticlopidine-induced aplastic anemia with colony-stimulating factors seemed to have little effect.,9401499_7,0
7479,aplastic anemia,34,49,Treatment for ticlopidine-induced aplastic anemia with colony-stimulating factors seemed to have little effect.,9401499_7,1
3895,calcium channel blockers,58,82,"The fact that 5 of the 6 patients who received concurrent calcium channel blockers died, should alert clinicians to be more cautious when using these two drugs simultaneously.",9401499_8,0
15719,paraventricular,58,73,Upregulation of the expression of vasopressin gene in the paraventricular and supraoptic nuclei of the lithium-induced diabetes insipidus rat.,9406968_0,1
7481,diabetes insipidus,119,137,Upregulation of the expression of vasopressin gene in the paraventricular and supraoptic nuclei of the lithium-induced diabetes insipidus rat.,9406968_0,1
7480,supraoptic,78,88,Upregulation of the expression of vasopressin gene in the paraventricular and supraoptic nuclei of the lithium-induced diabetes insipidus rat.,9406968_0,1
15720,AVP,40,43,"The expression of arginine vasopressin (AVP) gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with lithium (Li)-induced polyuria, using in situ hybridization histochemistry and radioimmunoassay.",9406968_1,0
15721,paraventricular,57,72,"The expression of arginine vasopressin (AVP) gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with lithium (Li)-induced polyuria, using in situ hybridization histochemistry and radioimmunoassay.",9406968_1,1
15722,PVN,74,77,"The expression of arginine vasopressin (AVP) gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with lithium (Li)-induced polyuria, using in situ hybridization histochemistry and radioimmunoassay.",9406968_1,0
3896,arginine vasopressin,18,38,"The expression of arginine vasopressin (AVP) gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with lithium (Li)-induced polyuria, using in situ hybridization histochemistry and radioimmunoassay.",9406968_1,0
7482,supraoptic,83,93,"The expression of arginine vasopressin (AVP) gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with lithium (Li)-induced polyuria, using in situ hybridization histochemistry and radioimmunoassay.",9406968_1,1
15723,LiCl,53,57,The male Wistar rats consuming a diet that contained LiCl (60 mmol/kg) for 4 weeks developed marked polyuria.,9406968_2,0
15724,ionic concentrations,72,92,The Li-treated rats produced a large volume of hypotonic urine with low ionic concentrations.,9406968_3,0
15726,AVP,24,27,Plasma concentration of AVP and transcripts of AVP gene in the PVN and SON were significantly increased in the Li-treated rats compared with controls.,9406968_5,0
15728,PVN,63,66,Plasma concentration of AVP and transcripts of AVP gene in the PVN and SON were significantly increased in the Li-treated rats compared with controls.,9406968_5,0
7483,diabetes insipidus,220,238,These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat.,9406968_6,1
15731,PVN,186,189,These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat.,9406968_6,0
15729,AVP,131,134,These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat.,9406968_6,0
15733,Oddi spasm,50,60,Effect of glyceryl trinitrate on the sphincter of Oddi spasm evoked by prostigmine-morphine administration.,9431903_0,1
3897,glyceryl trinitrate,10,29,Effect of glyceryl trinitrate on the sphincter of Oddi spasm evoked by prostigmine-morphine administration.,9431903_0,0
15735,Oddi spasm,108,118,OBJECTIVE: In this study the effect of glyceryl trinitrate on the prostigmine-morphine-induced sphincter of Oddi spasm was evaluated in nine female patients with sphincter of Oddi dyskinesia.,9431903_1,1
3898,glyceryl trinitrate,39,58,OBJECTIVE: In this study the effect of glyceryl trinitrate on the prostigmine-morphine-induced sphincter of Oddi spasm was evaluated in nine female patients with sphincter of Oddi dyskinesia.,9431903_1,0
15736,Oddi dyskinesia,175,190,OBJECTIVE: In this study the effect of glyceryl trinitrate on the prostigmine-morphine-induced sphincter of Oddi spasm was evaluated in nine female patients with sphincter of Oddi dyskinesia.,9431903_1,1
15737,Oddi spasm,21,31,METHOD: Sphincter of Oddi spasm was induced by prostigmine-morphine administration (0.5 mg prostigmine intramuscularly and 10 mg morphine subcutaneously) and visualized by quantitative hepatobiliary scintigraphy.,9431903_2,1
3899,prostigmine,91,102,METHOD: Sphincter of Oddi spasm was induced by prostigmine-morphine administration (0.5 mg prostigmine intramuscularly and 10 mg morphine subcutaneously) and visualized by quantitative hepatobiliary scintigraphy.,9431903_2,0
3900,glyceryl trinitrate,41,60,The entire procedure was repeated during glyceryl trinitrate infusion (Nitrolingual 1 microg/kg/min for 120 min).,9431903_3,0
15756,CBD,390,393,"RESULTS: Prostigmine-morphine provocation caused significant increases in the time to peak activity (Tmax) over the hepatic hilum (HH: 34.33 +/- 5.05 vs. 22.77 +/- 3.26) and the common bile duct (CBD: 60.44 +/- 5.99 vs. 40.0 +/- 2.88) and in the half-time of excretion (T1/2) over the liver parenchyma (LP: 120.04 +/- 16.01 vs. 27.37 +/- 2.19), HH (117.61 +/- 14.71 vs. 31.85 +/- 3.99) and CBD (158.11 +/- 9.18 vs. 40.1 +/- 6.24), indicating a complete spasm at the level of the sphincter of Oddi.",9431903_4,0
15750,liver parenchyma,285,301,"RESULTS: Prostigmine-morphine provocation caused significant increases in the time to peak activity (Tmax) over the hepatic hilum (HH: 34.33 +/- 5.05 vs. 22.77 +/- 3.26) and the common bile duct (CBD: 60.44 +/- 5.99 vs. 40.0 +/- 2.88) and in the half-time of excretion (T1/2) over the liver parenchyma (LP: 120.04 +/- 16.01 vs. 27.37 +/- 2.19), HH (117.61 +/- 14.71 vs. 31.85 +/- 3.99) and CBD (158.11 +/- 9.18 vs. 40.1 +/- 6.24), indicating a complete spasm at the level of the sphincter of Oddi.",9431903_4,1
15743,HH,131,133,"RESULTS: Prostigmine-morphine provocation caused significant increases in the time to peak activity (Tmax) over the hepatic hilum (HH: 34.33 +/- 5.05 vs. 22.77 +/- 3.26) and the common bile duct (CBD: 60.44 +/- 5.99 vs. 40.0 +/- 2.88) and in the half-time of excretion (T1/2) over the liver parenchyma (LP: 120.04 +/- 16.01 vs. 27.37 +/- 2.19), HH (117.61 +/- 14.71 vs. 31.85 +/- 3.99) and CBD (158.11 +/- 9.18 vs. 40.1 +/- 6.24), indicating a complete spasm at the level of the sphincter of Oddi.",9431903_4,0
7484,common bile duct,178,194,"RESULTS: Prostigmine-morphine provocation caused significant increases in the time to peak activity (Tmax) over the hepatic hilum (HH: 34.33 +/- 5.05 vs. 22.77 +/- 3.26) and the common bile duct (CBD: 60.44 +/- 5.99 vs. 40.0 +/- 2.88) and in the half-time of excretion (T1/2) over the liver parenchyma (LP: 120.04 +/- 16.01 vs. 27.37 +/- 2.19), HH (117.61 +/- 14.71 vs. 31.85 +/- 3.99) and CBD (158.11 +/- 9.18 vs. 40.1 +/- 6.24), indicating a complete spasm at the level of the sphincter of Oddi.",9431903_4,1
15749,T1/2,270,274,"RESULTS: Prostigmine-morphine provocation caused significant increases in the time to peak activity (Tmax) over the hepatic hilum (HH: 34.33 +/- 5.05 vs. 22.77 +/- 3.26) and the common bile duct (CBD: 60.44 +/- 5.99 vs. 40.0 +/- 2.88) and in the half-time of excretion (T1/2) over the liver parenchyma (LP: 120.04 +/- 16.01 vs. 27.37 +/- 2.19), HH (117.61 +/- 14.71 vs. 31.85 +/- 3.99) and CBD (158.11 +/- 9.18 vs. 40.1 +/- 6.24), indicating a complete spasm at the level of the sphincter of Oddi.",9431903_4,0
15768,HH,274,276,"Glyceryl trinitrate infusion completely normalized the prostigmine-morphine-induced alterations in these quantitative parameters (TmaX over the LP: 11.33 +/- 1.13; over the HH: 18.88 +/- 1.48; and over the CBD: 36.22 +/- 1.92; and T1/2 over the LP: 28.21 +/- 1.83; over the HH: 33.42 +/- 3.10; and over the CBD: 41.66 +/- 6.33), suggesting an effective sphincter-relaxing effect of glyceryl trinitrate.",9431903_5,0
3902,glyceryl trinitrate,382,401,"Glyceryl trinitrate infusion completely normalized the prostigmine-morphine-induced alterations in these quantitative parameters (TmaX over the LP: 11.33 +/- 1.13; over the HH: 18.88 +/- 1.48; and over the CBD: 36.22 +/- 1.92; and T1/2 over the LP: 28.21 +/- 1.83; over the HH: 33.42 +/- 3.10; and over the CBD: 41.66 +/- 6.33), suggesting an effective sphincter-relaxing effect of glyceryl trinitrate.",9431903_5,0
15766,T1/2,231,235,"Glyceryl trinitrate infusion completely normalized the prostigmine-morphine-induced alterations in these quantitative parameters (TmaX over the LP: 11.33 +/- 1.13; over the HH: 18.88 +/- 1.48; and over the CBD: 36.22 +/- 1.92; and T1/2 over the LP: 28.21 +/- 1.83; over the HH: 33.42 +/- 3.10; and over the CBD: 41.66 +/- 6.33), suggesting an effective sphincter-relaxing effect of glyceryl trinitrate.",9431903_5,0
15760,TmaX,130,134,"Glyceryl trinitrate infusion completely normalized the prostigmine-morphine-induced alterations in these quantitative parameters (TmaX over the LP: 11.33 +/- 1.13; over the HH: 18.88 +/- 1.48; and over the CBD: 36.22 +/- 1.92; and T1/2 over the LP: 28.21 +/- 1.83; over the HH: 33.42 +/- 3.10; and over the CBD: 41.66 +/- 6.33), suggesting an effective sphincter-relaxing effect of glyceryl trinitrate.",9431903_5,0
3901,Glyceryl trinitrate,0,19,"Glyceryl trinitrate infusion completely normalized the prostigmine-morphine-induced alterations in these quantitative parameters (TmaX over the LP: 11.33 +/- 1.13; over the HH: 18.88 +/- 1.48; and over the CBD: 36.22 +/- 1.92; and T1/2 over the LP: 28.21 +/- 1.83; over the HH: 33.42 +/- 3.10; and over the CBD: 41.66 +/- 6.33), suggesting an effective sphincter-relaxing effect of glyceryl trinitrate.",9431903_5,0
3903,glyceryl trinitrate,77,96,CONCLUSION: These results provide the first evidence of the effectiveness of glyceryl trinitrate on the morphine-induced sphincter of Oddi spasm in humans.,9431903_6,0
15773,Oddi spasm,134,144,CONCLUSION: These results provide the first evidence of the effectiveness of glyceryl trinitrate on the morphine-induced sphincter of Oddi spasm in humans.,9431903_6,1
15775,Oddi dyskinesia,141,156,"Since glyceryl trinitrate is able to overcome even the drastic effect of morphine, it might be of relevance in the treatment of sphincter of Oddi dyskinesia.",9431903_7,1
3904,glyceryl trinitrate,6,25,"Since glyceryl trinitrate is able to overcome even the drastic effect of morphine, it might be of relevance in the treatment of sphincter of Oddi dyskinesia.",9431903_7,0
3905,Antinociceptive,0,15,"Antinociceptive and antiamnesic properties of the presynaptic cholinergic amplifier PG-9.The antinociceptive effect of 3 alpha-tropyl 2-(p-bromophenyl)propionate [(+/-)-PG-9] (10-40 mg kg-1 s.c.; 30-60 mg kg-1 p.o.; 10-30 mg kg-1 i.v.; 10-30 micrograms/mouse i.c.v.) was examined in mice, rats and guinea pigs by use of the hot-plate, abdominal-constriction, tail-flick and paw-pressure tests.",9495837_0,0
15783,kg-1,225,229,"Antinociceptive and antiamnesic properties of the presynaptic cholinergic amplifier PG-9.The antinociceptive effect of 3 alpha-tropyl 2-(p-bromophenyl)propionate [(+/-)-PG-9] (10-40 mg kg-1 s.c.; 30-60 mg kg-1 p.o.; 10-30 mg kg-1 i.v.; 10-30 micrograms/mouse i.c.v.) was examined in mice, rats and guinea pigs by use of the hot-plate, abdominal-constriction, tail-flick and paw-pressure tests.",9495837_0,0
15782,kg-1,205,209,"Antinociceptive and antiamnesic properties of the presynaptic cholinergic amplifier PG-9.The antinociceptive effect of 3 alpha-tropyl 2-(p-bromophenyl)propionate [(+/-)-PG-9] (10-40 mg kg-1 s.c.; 30-60 mg kg-1 p.o.; 10-30 mg kg-1 i.v.; 10-30 micrograms/mouse i.c.v.) was examined in mice, rats and guinea pigs by use of the hot-plate, abdominal-constriction, tail-flick and paw-pressure tests.",9495837_0,0
15776,antiamnesic,20,31,"Antinociceptive and antiamnesic properties of the presynaptic cholinergic amplifier PG-9.The antinociceptive effect of 3 alpha-tropyl 2-(p-bromophenyl)propionate [(+/-)-PG-9] (10-40 mg kg-1 s.c.; 30-60 mg kg-1 p.o.; 10-30 mg kg-1 i.v.; 10-30 micrograms/mouse i.c.v.) was examined in mice, rats and guinea pigs by use of the hot-plate, abdominal-constriction, tail-flick and paw-pressure tests.",9495837_0,0
15777,presynaptic,50,61,"Antinociceptive and antiamnesic properties of the presynaptic cholinergic amplifier PG-9.The antinociceptive effect of 3 alpha-tropyl 2-(p-bromophenyl)propionate [(+/-)-PG-9] (10-40 mg kg-1 s.c.; 30-60 mg kg-1 p.o.; 10-30 mg kg-1 i.v.; 10-30 micrograms/mouse i.c.v.) was examined in mice, rats and guinea pigs by use of the hot-plate, abdominal-constriction, tail-flick and paw-pressure tests.",9495837_0,0
15778,PG-9.The antinociceptive,84,108,"Antinociceptive and antiamnesic properties of the presynaptic cholinergic amplifier PG-9.The antinociceptive effect of 3 alpha-tropyl 2-(p-bromophenyl)propionate [(+/-)-PG-9] (10-40 mg kg-1 s.c.; 30-60 mg kg-1 p.o.; 10-30 mg kg-1 i.v.; 10-30 micrograms/mouse i.c.v.) was examined in mice, rats and guinea pigs by use of the hot-plate, abdominal-constriction, tail-flick and paw-pressure tests.",9495837_0,0
15780,(+/-)-PG-9,163,173,"Antinociceptive and antiamnesic properties of the presynaptic cholinergic amplifier PG-9.The antinociceptive effect of 3 alpha-tropyl 2-(p-bromophenyl)propionate [(+/-)-PG-9] (10-40 mg kg-1 s.c.; 30-60 mg kg-1 p.o.; 10-30 mg kg-1 i.v.; 10-30 micrograms/mouse i.c.v.) was examined in mice, rats and guinea pigs by use of the hot-plate, abdominal-constriction, tail-flick and paw-pressure tests.",9495837_0,0
15781,kg-1,185,189,"Antinociceptive and antiamnesic properties of the presynaptic cholinergic amplifier PG-9.The antinociceptive effect of 3 alpha-tropyl 2-(p-bromophenyl)propionate [(+/-)-PG-9] (10-40 mg kg-1 s.c.; 30-60 mg kg-1 p.o.; 10-30 mg kg-1 i.v.; 10-30 micrograms/mouse i.c.v.) was examined in mice, rats and guinea pigs by use of the hot-plate, abdominal-constriction, tail-flick and paw-pressure tests.",9495837_0,0
15779,alpha-tropyl 2-(p-bromophenyl)propionate,121,161,"Antinociceptive and antiamnesic properties of the presynaptic cholinergic amplifier PG-9.The antinociceptive effect of 3 alpha-tropyl 2-(p-bromophenyl)propionate [(+/-)-PG-9] (10-40 mg kg-1 s.c.; 30-60 mg kg-1 p.o.; 10-30 mg kg-1 i.v.; 10-30 micrograms/mouse i.c.v.) was examined in mice, rats and guinea pigs by use of the hot-plate, abdominal-constriction, tail-flick and paw-pressure tests.",9495837_0,0
15789,(+/-)-PG-9,0,10,(+/-)-PG-9 antinociception peaked 15 min after injection and then slowly diminished.,9495837_1,0
15794,H3 agonist R-(alpha)-methylhistamine,347,383,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,0
3907,dicyclomine,153,164,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,0
15793,gamma-aminobutyric acidB antagonist,260,295,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,0
15792,M1-selective antagonists pirenzepine,112,148,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,0
15791,(+/-)-PG-9,32,42,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,0
3911,polyamines,647,657,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,0
3910,hydrobromide,626,638,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,0
3909,opioid antagonist,228,245,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,0
3908,hemicholinium-3,196,211,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,0
15795,R-(alpha)-methylhistamine,358,383,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,0
3906,muscarinic antagonist,76,97,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,0
15800,2-(diethylamino)ethyl ester hydrochloride,490,531,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,0
15796,D2 antagonist quinpirole,389,413,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,0
15797,5-hydroxytryptamine4 antagonist,419,450,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,0
15799,2-(diethylamino)ethyl,490,511,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,0
15798,2-methoxy-4-amino-5-chlorobenzoic,451,484,"The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine.",9495837_2,0
3912,antinociceptive,69,84,"Based on these data, it can be postulated that (+/-)-PG-9 exerted an antinociceptive effect mediated by a central potentiation of cholinergic transmission.",9495837_3,0
15801,(+/-)-PG-9,47,57,"Based on these data, it can be postulated that (+/-)-PG-9 exerted an antinociceptive effect mediated by a central potentiation of cholinergic transmission.",9495837_3,0
15807,dicyclomine (2,104,118,(+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent amnesia induced by scopolamine (1 mg kg-1 i.p.) and dicyclomine (2 mg kg-1 i.p.) in the mouse passive-avoidance test.,9495837_4,0
15805,scopolamine (1,71,85,(+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent amnesia induced by scopolamine (1 mg kg-1 i.p.) and dicyclomine (2 mg kg-1 i.p.) in the mouse passive-avoidance test.,9495837_4,0
15803,(+/-)-PG-9,0,10,(+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent amnesia induced by scopolamine (1 mg kg-1 i.p.) and dicyclomine (2 mg kg-1 i.p.) in the mouse passive-avoidance test.,9495837_4,0
15817,M4,222,224,"Affinity profiles of (+/-)-PG-9 for muscarinic receptor subtypes, determined by functional studies (rabbit vas deferens for M1, guinea pig atrium for M2, guinea pig ileum for M3 and immature guinea pig uterus for putative M4), have shown an M4/M1 selectivity ratio of 10.2 that might be responsible for the antinociception and the anti-amnesic effect induced by (+/-)-PG-9 through an increase in acetylcholine extracellular levels.",9495837_5,0
15812,muscarinic receptor subtypes,36,64,"Affinity profiles of (+/-)-PG-9 for muscarinic receptor subtypes, determined by functional studies (rabbit vas deferens for M1, guinea pig atrium for M2, guinea pig ileum for M3 and immature guinea pig uterus for putative M4), have shown an M4/M1 selectivity ratio of 10.2 that might be responsible for the antinociception and the anti-amnesic effect induced by (+/-)-PG-9 through an increase in acetylcholine extracellular levels.",9495837_5,0
15811,(+/-)-PG-9,21,31,"Affinity profiles of (+/-)-PG-9 for muscarinic receptor subtypes, determined by functional studies (rabbit vas deferens for M1, guinea pig atrium for M2, guinea pig ileum for M3 and immature guinea pig uterus for putative M4), have shown an M4/M1 selectivity ratio of 10.2 that might be responsible for the antinociception and the anti-amnesic effect induced by (+/-)-PG-9 through an increase in acetylcholine extracellular levels.",9495837_5,0
15820,(+/-)-PG-9,362,372,"Affinity profiles of (+/-)-PG-9 for muscarinic receptor subtypes, determined by functional studies (rabbit vas deferens for M1, guinea pig atrium for M2, guinea pig ileum for M3 and immature guinea pig uterus for putative M4), have shown an M4/M1 selectivity ratio of 10.2 that might be responsible for the antinociception and the anti-amnesic effect induced by (+/-)-PG-9 through an increase in acetylcholine extracellular levels.",9495837_5,0
3913,antinociceptive,7,22,"In the antinociceptive and antiamnesic dose range, (+/-)-PG-9 did not impair mouse performance evaluated by the rota-rod test and Animex apparatus.",9495837_6,0
15823,(+/-)-PG-9,51,61,"In the antinociceptive and antiamnesic dose range, (+/-)-PG-9 did not impair mouse performance evaluated by the rota-rod test and Animex apparatus.",9495837_6,0
15822,antiamnesic,27,38,"In the antinociceptive and antiamnesic dose range, (+/-)-PG-9 did not impair mouse performance evaluated by the rota-rod test and Animex apparatus.",9495837_6,0
15827,heavy proteinuria,50,67,Four patients with rheumatoid arthritis developed heavy proteinuria after five to 12 months of treatment with D-penicillamine.,950631_1,1
7485,rheumatoid arthritis,19,39,Four patients with rheumatoid arthritis developed heavy proteinuria after five to 12 months of treatment with D-penicillamine.,950631_1,1
3914,D-penicillamine,110,125,Four patients with rheumatoid arthritis developed heavy proteinuria after five to 12 months of treatment with D-penicillamine.,950631_1,0
15829,glomerular capillary wall thickening,56,92,"Light microscopy of renal biopsy samples showed minimal glomerular capillary wall thickening and mesangial matrix increase, or no departure from normal.",950631_2,1
7486,epithelial cell,88,103,"Electron microscopy, however, revealed subepithelial electron-dense deposits, fusion of epithelial cell foot processes, and evidence of mesangial cell hyperactivity.",950631_3,1
15832,mesangial cell hyperactivity,136,164,"Electron microscopy, however, revealed subepithelial electron-dense deposits, fusion of epithelial cell foot processes, and evidence of mesangial cell hyperactivity.",950631_3,1
3915,C3,87,89,Immunofluorescence microscopy demonstrated granular capillary wall deposits of IgG and C3.,950631_4,0
15833,granular capillary wall,43,66,Immunofluorescence microscopy demonstrated granular capillary wall deposits of IgG and C3.,950631_4,1
3917,C4,188,190,"The findings were similar to those in early membranous glomerulonephritis, differences being observed however in the results of staining for the early-acting complement components C1q and C4.",950631_5,0
3916,C1q,180,183,"The findings were similar to those in early membranous glomerulonephritis, differences being observed however in the results of staining for the early-acting complement components C1q and C4.",950631_5,0
15834,early-acting complement components,145,179,"The findings were similar to those in early membranous glomerulonephritis, differences being observed however in the results of staining for the early-acting complement components C1q and C4.",950631_5,0
7487,membranous glomerulonephritis,44,73,"The findings were similar to those in early membranous glomerulonephritis, differences being observed however in the results of staining for the early-acting complement components C1q and C4.",950631_5,1
3918,classical pathway,65,82,It is tentatively concluded that complement was activated by the classical pathway.,950631_6,0
7488,cranial pain,13,25,Experimental cranial pain elicited by capsaicin: a PET study.,9514561_0,1
7489,migraine without aura,79,100,"Using a positron emission tomography (PET) study it was shown recently that in migraine without aura certain areas in the brain stem were activated during the headache state, but not in the headache free interval.",9514561_1,1
7490,brain stem,122,132,"Using a positron emission tomography (PET) study it was shown recently that in migraine without aura certain areas in the brain stem were activated during the headache state, but not in the headache free interval.",9514561_1,1
15838,migraine attack,68,83,It was suggested that this brain stem activation is inherent to the migraine attack itself and represents the so called 'migraine generator'.,9514561_2,1
7491,brain stem,27,37,It was suggested that this brain stem activation is inherent to the migraine attack itself and represents the so called 'migraine generator'.,9514561_2,1
7492,trigeminal nerve,148,164,A small amount of capsaicin was administered subcutaneously in the right forehead to evoke a burning painful sensation in the first division of the trigeminal nerve.,9514561_4,1
7494,cavernous sinus,125,140,"Increases of regional cerebral blood flow (rCBF) were found bilaterally in the insula, in the anterior cingulate cortex, the cavernous sinus and the cerebellum.",9514561_5,1
15843,rCBF,43,47,"Increases of regional cerebral blood flow (rCBF) were found bilaterally in the insula, in the anterior cingulate cortex, the cavernous sinus and the cerebellum.",9514561_5,0
15844,insula,79,85,"Increases of regional cerebral blood flow (rCBF) were found bilaterally in the insula, in the anterior cingulate cortex, the cavernous sinus and the cerebellum.",9514561_5,1
7493,cingulate,103,112,"Increases of regional cerebral blood flow (rCBF) were found bilaterally in the insula, in the anterior cingulate cortex, the cavernous sinus and the cerebellum.",9514561_5,1
7496,acute pain,124,134,Using the same stereotactic space limits as in the above mentioned migraine study no brain stem activation was found in the acute pain state compared to the pain free state.,9514561_6,1
7495,brain stem,85,95,Using the same stereotactic space limits as in the above mentioned migraine study no brain stem activation was found in the acute pain state compared to the pain free state.,9514561_6,1
15847,pain free,157,166,Using the same stereotactic space limits as in the above mentioned migraine study no brain stem activation was found in the acute pain state compared to the pain free state.,9514561_6,1
7498,cluster headache,236,252,"The increase of activation in the region of the cavernous sinus however, suggests that this structure is more likely to be involved in trigeminal transmitted pain as such, rather than in a specific type of headache as was suggested for cluster headache.",9514561_7,1
7497,cavernous sinus,48,63,"The increase of activation in the region of the cavernous sinus however, suggests that this structure is more likely to be involved in trigeminal transmitted pain as such, rather than in a specific type of headache as was suggested for cluster headache.",9514561_7,1
15848,trigeminal transmitted pain,135,162,"The increase of activation in the region of the cavernous sinus however, suggests that this structure is more likely to be involved in trigeminal transmitted pain as such, rather than in a specific type of headache as was suggested for cluster headache.",9514561_7,1
7499,hearing loss,46,58,The effect of different anaesthetic agents in hearing loss following spinal anaesthesia.,9522143_0,1
15850,spinal anaesthesia,69,87,The effect of different anaesthetic agents in hearing loss following spinal anaesthesia.,9522143_0,1
15849,anaesthetic agents,24,42,The effect of different anaesthetic agents in hearing loss following spinal anaesthesia.,9522143_0,0
15852,spinal anaesthesia,32,50,The cause of hearing loss after spinal anaesthesia is unknown.,9522143_1,1
15851,cause of hearing loss,4,25,The cause of hearing loss after spinal anaesthesia is unknown.,9522143_1,1
15854,post-operative sensorineural hearing loss,98,139,"Up until now, the only factor studied has been the effect of the diameter of the spinal needle on post-operative sensorineural hearing loss.",9522143_2,1
15853,spinal needle,81,94,"Up until now, the only factor studied has been the effect of the diameter of the spinal needle on post-operative sensorineural hearing loss.",9522143_2,1
7501,hearing loss,115,127,The aim of this study was to describe this hearing loss and to investigate other factors influencing the degree of hearing loss.,9522143_3,1
7500,hearing loss,43,55,The aim of this study was to describe this hearing loss and to investigate other factors influencing the degree of hearing loss.,9522143_3,1
3919,prilocaine,72,82,Two groups of 22 similar patients were studied: one group received 6 mL prilocaine 2%; and the other received 3 mL bupivacaine 0.5%.,9522143_4,0
3920,bupivacaine,115,126,Two groups of 22 similar patients were studied: one group received 6 mL prilocaine 2%; and the other received 3 mL bupivacaine 0.5%.,9522143_4,0
7502,hearing loss,54,66,Patients given prilocaine were more likely to develop hearing loss (10 out of 22) than those given bupivacaine (4 out of 22) (P < 0.05).,9522143_5,1
3921,prilocaine,15,25,Patients given prilocaine were more likely to develop hearing loss (10 out of 22) than those given bupivacaine (4 out of 22) (P < 0.05).,9522143_5,0
3922,bupivacaine,99,110,Patients given prilocaine were more likely to develop hearing loss (10 out of 22) than those given bupivacaine (4 out of 22) (P < 0.05).,9522143_5,0
15855,speech frequencies,29,47,The average hearing loss for speech frequencies was about 10 dB after prilocaine and 15 dB after bupivacaine.,9522143_6,1
3923,prilocaine,70,80,The average hearing loss for speech frequencies was about 10 dB after prilocaine and 15 dB after bupivacaine.,9522143_6,0
3924,bupivacaine,97,108,The average hearing loss for speech frequencies was about 10 dB after prilocaine and 15 dB after bupivacaine.,9522143_6,0
7503,hearing loss,12,24,The average hearing loss for speech frequencies was about 10 dB after prilocaine and 15 dB after bupivacaine.,9522143_6,1
15856,subjective hearing loss,35,58,None of the patients complained of subjective hearing loss.,9522143_7,1
15857,neurological deficit,12,32,A transient neurological deficit following intrathecal injection of 1% hyperbaric bupivacaine for unilateral spinal anaesthesia.,9522152_0,1
15859,hyperbaric bupivacaine,71,93,A transient neurological deficit following intrathecal injection of 1% hyperbaric bupivacaine for unilateral spinal anaesthesia.,9522152_0,0
15860,spinal anaesthesia,109,127,A transient neurological deficit following intrathecal injection of 1% hyperbaric bupivacaine for unilateral spinal anaesthesia.,9522152_0,1
15861,neurological deficit,32,52,We describe a case of transient neurological deficit that occurred after unilateral spinal anaesthesia with 8 mg of 1% hyperbaric bupivacaine slowly injected through a 25-gauge pencil-point spinal needle.,9522152_1,1
15862,spinal anaesthesia,84,102,We describe a case of transient neurological deficit that occurred after unilateral spinal anaesthesia with 8 mg of 1% hyperbaric bupivacaine slowly injected through a 25-gauge pencil-point spinal needle.,9522152_1,1
15863,hyperbaric bupivacaine,119,141,We describe a case of transient neurological deficit that occurred after unilateral spinal anaesthesia with 8 mg of 1% hyperbaric bupivacaine slowly injected through a 25-gauge pencil-point spinal needle.,9522152_1,0
7504,loss of,178,185,"The surgery and anaesthesia were uneventful, but 3 days after surgery, the patient reported an area of hypoaesthesia over L3-L4 dermatomes of the leg which had been operated on (loss of pinprick sensation) without reduction in muscular strength.",9522152_2,1
15866,muscular strength,227,244,"The surgery and anaesthesia were uneventful, but 3 days after surgery, the patient reported an area of hypoaesthesia over L3-L4 dermatomes of the leg which had been operated on (loss of pinprick sensation) without reduction in muscular strength.",9522152_2,1
15864,hypoaesthesia,103,116,"The surgery and anaesthesia were uneventful, but 3 days after surgery, the patient reported an area of hypoaesthesia over L3-L4 dermatomes of the leg which had been operated on (loss of pinprick sensation) without reduction in muscular strength.",9522152_2,1
7505,side effect,148,159,Prospective multicentre studies with a large population and a long follow-up should be performed in order to evaluate the incidence of this unusual side effect.,9522152_4,1
15868,long follow-up,62,76,Prospective multicentre studies with a large population and a long follow-up should be performed in order to evaluate the incidence of this unusual side effect.,9522152_4,1
15869,spinal anaesthesia,89,107,"However, we suggest that a low solution concentration should be preferred for unilateral spinal anaesthesia with a hyperbaric anaesthetic solution (if pencil-point needle and slow injection rate are employed), in order to minimize the risk of a localized high peak anaesthetic concentration, which might lead to a transient neurological deficit.",9522152_5,1
15873,neurological deficit,324,344,"However, we suggest that a low solution concentration should be preferred for unilateral spinal anaesthesia with a hyperbaric anaesthetic solution (if pencil-point needle and slow injection rate are employed), in order to minimize the risk of a localized high peak anaesthetic concentration, which might lead to a transient neurological deficit.",9522152_5,1
3925,prilocaine,78,88,Transient neurologic symptoms after spinal anesthesia: a lower incidence with prilocaine and bupivacaine than with lidocaine.,9523805_0,0
3926,bupivacaine,93,104,Transient neurologic symptoms after spinal anesthesia: a lower incidence with prilocaine and bupivacaine than with lidocaine.,9523805_0,0
15874,spinal anesthesia,36,53,Transient neurologic symptoms after spinal anesthesia: a lower incidence with prilocaine and bupivacaine than with lidocaine.,9523805_0,1
7506,neurologic symptoms,10,29,Transient neurologic symptoms after spinal anesthesia: a lower incidence with prilocaine and bupivacaine than with lidocaine.,9523805_0,1
15875,spinal anesthesia,107,124,BACKGROUND: Recent evidence suggests that transient neurologic symptoms (TNSs) frequently follow lidocaine spinal anesthesia but are infrequent with bupivacaine.,9523805_1,1
3927,bupivacaine,149,160,BACKGROUND: Recent evidence suggests that transient neurologic symptoms (TNSs) frequently follow lidocaine spinal anesthesia but are infrequent with bupivacaine.,9523805_1,0
7507,neurologic symptoms,52,71,BACKGROUND: Recent evidence suggests that transient neurologic symptoms (TNSs) frequently follow lidocaine spinal anesthesia but are infrequent with bupivacaine.,9523805_1,1
3935,prilocaine,63,73,"Times to ambulate and to void were similar after lidocaine and prilocaine (150 vs. 165 min and 238 vs. 253 min, respectively) but prolonged after bupivacaine (200 and 299 min, respectively; P < 0.05).",9523805_10,0
3936,bupivacaine,146,157,"Times to ambulate and to void were similar after lidocaine and prilocaine (150 vs. 165 min and 238 vs. 253 min, respectively) but prolonged after bupivacaine (200 and 299 min, respectively; P < 0.05).",9523805_10,0
3937,Prilocaine,13,23,CONCLUSIONS: Prilocaine may be preferable to lidocaine for short surgical procedures because it has a similar duration of action but a lower incidence of TNSs.,9523805_11,0
15876,short-acting local anesthetic,29,58,"However, identification of a short-acting local anesthetic to substitute for lidocaine for brief surgical procedures remains an important goal.",9523805_2,0
3928,Prilocaine,0,10,Prilocaine is an amide local anesthetic with a duration of action similar to that of lidocaine.,9523805_3,0
15878,amide local anesthetic,17,39,Prilocaine is an amide local anesthetic with a duration of action similar to that of lidocaine.,9523805_3,0
3930,bupivacaine,96,107,"Accordingly, the present, prospective double-blind study compares prilocaine with lidocaine and bupivacaine with respect to duration of action and relative risk of TNSs.",9523805_4,0
3929,prilocaine,66,76,"Accordingly, the present, prospective double-blind study compares prilocaine with lidocaine and bupivacaine with respect to duration of action and relative risk of TNSs.",9523805_4,0
3931,prilocaine,252,262,"METHODS: Ninety patients classified as American Society of Anesthesiologists physical status I or II who were scheduled for short gynecologic procedures under spinal anesthesia were randomly allocated to receive 2.5 ml 2% lidocaine in 7.5% glucose, 2% prilocaine in 7.5% glucose, or 0.5% bupivacaine in 7.5% glucose.",9523805_5,0
3932,bupivacaine,288,299,"METHODS: Ninety patients classified as American Society of Anesthesiologists physical status I or II who were scheduled for short gynecologic procedures under spinal anesthesia were randomly allocated to receive 2.5 ml 2% lidocaine in 7.5% glucose, 2% prilocaine in 7.5% glucose, or 0.5% bupivacaine in 7.5% glucose.",9523805_5,0
15883,spinal puncture,11,26,"Details of spinal puncture, extension and regression of spinal block, and the times to reach discharge criteria were noted.",9523805_7,1
15884,spinal block,56,68,"Details of spinal puncture, extension and regression of spinal block, and the times to reach discharge criteria were noted.",9523805_7,1
3934,bupivacaine,160,171,"RESULTS: Nine of 30 patients receiving lidocaine experienced TNSs, 1 of 30 patients receiving prilocaine (P = 0.03) had them, and none of 30 patients receiving bupivacaine had TNSs.",9523805_9,0
3933,prilocaine,94,104,"RESULTS: Nine of 30 patients receiving lidocaine experienced TNSs, 1 of 30 patients receiving prilocaine (P = 0.03) had them, and none of 30 patients receiving bupivacaine had TNSs.",9523805_9,0
3938,methylprednisolone,9,27,Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial.,9523850_0,0
15890,iron dextran,120,132,Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial.,9523850_0,0
15887,arthralgia-myalgia syndrome,49,76,Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial.,9523850_0,1
15892,TDI,48,51,The safety and efficacy of total dose infusion (TDI) of iron dextran has been well documented.,9523850_1,0
15893,iron dextran,56,68,The safety and efficacy of total dose infusion (TDI) of iron dextran has been well documented.,9523850_1,0
15905,arthralgia-myalgia syndrome,112,139,These data demonstrate that administration of MP before and after TDI reduces the frequency and severity of the arthralgia-myalgia syndrome.,9523850_11,1
15907,iron dextran,53,65,MP should be given routinely before and after TDI of iron dextran.,9523850_13,0
15894,arthralgia-myalgia syndrome develops,31,67,"In 40% of treated patients, an arthralgia-myalgia syndrome develops.",9523850_2,1
3939,methylprednisolone,128,146,"The purpose of this randomized, double-blind, prospective study was to investigate whether intravenous (i.v.) administration of methylprednisolone (MP) prevents this complication.",9523850_3,0
3940,normal saline,79,92,"Sixty-five patients, 34 women and 31 men, ages 36 to 80 years, received either normal saline before and after TDI (group 1), 125 mg i.v.",9523850_4,0
3941,group 1,115,122,"Sixty-five patients, 34 women and 31 men, ages 36 to 80 years, received either normal saline before and after TDI (group 1), 125 mg i.v.",9523850_4,0
15897,TDI,110,113,"Sixty-five patients, 34 women and 31 men, ages 36 to 80 years, received either normal saline before and after TDI (group 1), 125 mg i.v.",9523850_4,0
15898,TDI,27,30,"MP before and saline after TDI (group 2), or 125 mg i.v.",9523850_5,0
3942,group 2,32,39,"MP before and saline after TDI (group 2), or 125 mg i.v.",9523850_5,0
15899,TDI,20,23,MP before and after TDI (group 3).,9523850_6,0
15900,group 3,25,32,MP before and after TDI (group 3).,9523850_6,0
3943,group 1,23,30,"Fifty-eight percent of group 1 patients, 33% of group 2, and 26% of group 3 had reactions to TDI.",9523850_8,0
15901,group 3,68,75,"Fifty-eight percent of group 1 patients, 33% of group 2, and 26% of group 3 had reactions to TDI.",9523850_8,0
3944,group 2,48,55,"Fifty-eight percent of group 1 patients, 33% of group 2, and 26% of group 3 had reactions to TDI.",9523850_8,0
15903,group 3,130,137,"The severity of reactions (minimal, mild, and moderate, respectively) was as follows: group 1--6, 6, and 2; group 2--1, 5, and 0; group 3--5, 1, and 0.",9523850_9,0
3946,group 2,108,115,"The severity of reactions (minimal, mild, and moderate, respectively) was as follows: group 1--6, 6, and 2; group 2--1, 5, and 0; group 3--5, 1, and 0.",9523850_9,0
3945,group 1,86,93,"The severity of reactions (minimal, mild, and moderate, respectively) was as follows: group 1--6, 6, and 2; group 2--1, 5, and 0; group 3--5, 1, and 0.",9523850_9,0
15909,cisapride-diltiazem,43,62,Prolongation of the QT interval related to cisapride-diltiazem interaction.,9545159_0,0
3948,CYP3A4,34,40,"Cisapride, a cytochrome P450 3A4 (CYP3A4) substrate, is widely prescribed for the treatment of gastrointestinal motility disorders.",9545159_1,0
15911,gastrointestinal motility disorders,95,130,"Cisapride, a cytochrome P450 3A4 (CYP3A4) substrate, is widely prescribed for the treatment of gastrointestinal motility disorders.",9545159_1,1
3947,cytochrome P450 3A4,13,32,"Cisapride, a cytochrome P450 3A4 (CYP3A4) substrate, is widely prescribed for the treatment of gastrointestinal motility disorders.",9545159_1,0
15910,Cisapride,0,9,"Cisapride, a cytochrome P450 3A4 (CYP3A4) substrate, is widely prescribed for the treatment of gastrointestinal motility disorders.",9545159_1,0
7508,torsades de pointes,29,48,"Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.",9545159_2,1
7509,sudden cardiac death,54,74,"Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.",9545159_2,1
15913,azole antifungal agents,148,171,"Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.",9545159_2,0
3949,CYP3A4 inhibitors,192,209,"Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors.",9545159_2,0
15915,taking cisapride,68,84,"A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.",9545159_3,0
7510,gastroesophageal reflux,89,112,"A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.",9545159_3,1
3950,CYP3A4,176,182,"A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension.",9545159_3,0
15916,near syncope,19,31,The patient was in near syncope and had QT-interval prolongation.,9545159_4,1
15917,discontinuing cisapride,6,29,"After discontinuing cisapride, the QT interval returned to normal and symptoms did not recur.",9545159_5,0
3951,CYP3A4,91,97,"We suggest that caution be taken when cisapride is prescribed with any potent inhibitor of CYP3A4, including diltiazem.",9545159_6,0
15919,cisapride,38,47,"We suggest that caution be taken when cisapride is prescribed with any potent inhibitor of CYP3A4, including diltiazem.",9545159_6,0
15920,Cortical motor,0,14,Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia.,9549528_0,1
15922,parkinsonian,33,45,Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia.,9549528_0,1
15923,peak-dose dyskinesia,75,95,Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia.,9549528_0,1
15925,rCBF,50,54,"We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L-dopa medication, the first one without L-dopa induced dyskinesia (n = 23) and the other with moderate peak-dose dyskinesia (n = 15), and of a group of 14 normal subjects.",9549528_1,0
15927,primary motor cortex,157,177,"We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L-dopa medication, the first one without L-dopa induced dyskinesia (n = 23) and the other with moderate peak-dose dyskinesia (n = 15), and of a group of 14 normal subjects.",9549528_1,1
15930,peak-dose dyskinesia,324,344,"We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L-dopa medication, the first one without L-dopa induced dyskinesia (n = 23) and the other with moderate peak-dose dyskinesia (n = 15), and of a group of 14 normal subjects.",9549528_1,1
15933,rCBF,30,34,133Xe was used to measure the rCBF changes.,9549528_3,0
7512,supplementary motor,215,234,"The dyskinetic parkinsonian patients exhibited a pattern of response which was markedly different from those of the normal subjects and non-dyskinetic parkinsonian patients, with a significant overactivation in the supplementary motor area and the ipsi- and contralateral primary motor areas.",9549528_4,1
7511,dyskinetic,4,14,"The dyskinetic parkinsonian patients exhibited a pattern of response which was markedly different from those of the normal subjects and non-dyskinetic parkinsonian patients, with a significant overactivation in the supplementary motor area and the ipsi- and contralateral primary motor areas.",9549528_4,1
15938,primary motor areas,272,291,"The dyskinetic parkinsonian patients exhibited a pattern of response which was markedly different from those of the normal subjects and non-dyskinetic parkinsonian patients, with a significant overactivation in the supplementary motor area and the ipsi- and contralateral primary motor areas.",9549528_4,1
15939,peak dose dyskinesia,121,141,"These results are compatible with the hypothesis that an hyperkinetic abnormal involuntary movement, like L-dopa-induced peak dose dyskinesia, is due to a disinhibition of the primary and associated motor cortex secondary to an excessive outflow of the pallidothalamocortical motor loop.",9549528_5,1
15941,motor cortex,199,211,"These results are compatible with the hypothesis that an hyperkinetic abnormal involuntary movement, like L-dopa-induced peak dose dyskinesia, is due to a disinhibition of the primary and associated motor cortex secondary to an excessive outflow of the pallidothalamocortical motor loop.",9549528_5,1
15942,pallidothalamocortical motor loop,253,286,"These results are compatible with the hypothesis that an hyperkinetic abnormal involuntary movement, like L-dopa-induced peak dose dyskinesia, is due to a disinhibition of the primary and associated motor cortex secondary to an excessive outflow of the pallidothalamocortical motor loop.",9549528_5,1
7514,involuntary movement,79,99,"These results are compatible with the hypothesis that an hyperkinetic abnormal involuntary movement, like L-dopa-induced peak dose dyskinesia, is due to a disinhibition of the primary and associated motor cortex secondary to an excessive outflow of the pallidothalamocortical motor loop.",9549528_5,1
7513,hyperkinetic,57,69,"These results are compatible with the hypothesis that an hyperkinetic abnormal involuntary movement, like L-dopa-induced peak dose dyskinesia, is due to a disinhibition of the primary and associated motor cortex secondary to an excessive outflow of the pallidothalamocortical motor loop.",9549528_5,1
15944,acute bacterial sinusitis,59,84,Open-label assessment of levofloxacin for the treatment of acute bacterial sinusitis in adults.,9564988_0,1
3952,levofloxacin,25,37,Open-label assessment of levofloxacin for the treatment of acute bacterial sinusitis in adults.,9564988_0,0
15945,acute bacterial sinusitis,141,166,PURPOSE: To evaluate the efficacy and safety of levofloxacin (500 mg orally once daily for 10 to 14 days) in treating adult outpatients with acute bacterial sinusitis.,9564988_1,1
3953,levofloxacin,48,60,PURPOSE: To evaluate the efficacy and safety of levofloxacin (500 mg orally once daily for 10 to 14 days) in treating adult outpatients with acute bacterial sinusitis.,9564988_1,0
15962,M. catarrhalis,105,119,Microbiologic eradication rates (presumed plus documented) of the most common pathogens ranged from 93% (M. catarrhalis) to 100% (S. pneumoniae) at the post-therapy visit.,9564988_10,1
15963,S. pneumoniae,130,143,Microbiologic eradication rates (presumed plus documented) of the most common pathogens ranged from 93% (M. catarrhalis) to 100% (S. pneumoniae) at the post-therapy visit.,9564988_10,1
15967,Adverse events,0,14,Adverse events considered to be related to levofloxacin administration were reported by 29 patients (9%).,9564988_12,1
3954,levofloxacin,43,55,Adverse events considered to be related to levofloxacin administration were reported by 29 patients (9%).,9564988_12,0
15968,drug-related adverse events,16,43,"The most common drug-related adverse events were diarrhea, flatulence, and nausea; most adverse events were mild to moderate in severity.",9564988_13,1
15969,adverse events,88,102,"The most common drug-related adverse events were diarrhea, flatulence, and nausea; most adverse events were mild to moderate in severity.",9564988_13,1
15970,acute bacterial sinusitis,122,147,CONCLUSION: The results of this study indicate that levofloxacin 500 mg once daily is an effective and safe treatment for acute bacterial sinusitis.,9564988_14,1
3955,levofloxacin,52,64,CONCLUSION: The results of this study indicate that levofloxacin 500 mg once daily is an effective and safe treatment for acute bacterial sinusitis.,9564988_14,0
15949,nasal endoscopy,104,119,All patients had a pre-therapy Gram's stain and culture of sinus exudate obtained by antral puncture or nasal endoscopy.,9564988_3,1
7515,antral,85,91,All patients had a pre-therapy Gram's stain and culture of sinus exudate obtained by antral puncture or nasal endoscopy.,9564988_3,1
15950,Clinical response,0,17,Clinical response was assessed on the basis of signs and symptoms and sinus radiograph or computed tomography results.,9564988_4,1
7516,signs and symptoms,47,65,Clinical response was assessed on the basis of signs and symptoms and sinus radiograph or computed tomography results.,9564988_4,1
15955,pathogen(s),113,124,Microbiologic cure rates were determined on the basis of presumed plus documented eradication of the pre-therapy pathogen(s).,9564988_5,0
15956,Haemophilus influenzae,40,62,"RESULTS: The most common pathogens were Haemophilus influenzae, Streptococcus pneumoniae, Staphylococcus aureus, and Moraxella catarrhalis.",9564988_6,0
7518,Staphylococcus aureus,90,111,"RESULTS: The most common pathogens were Haemophilus influenzae, Streptococcus pneumoniae, Staphylococcus aureus, and Moraxella catarrhalis.",9564988_6,1
7517,Streptococcus pneumoniae,64,88,"RESULTS: The most common pathogens were Haemophilus influenzae, Streptococcus pneumoniae, Staphylococcus aureus, and Moraxella catarrhalis.",9564988_6,1
7519,Moraxella,117,126,"RESULTS: The most common pathogens were Haemophilus influenzae, Streptococcus pneumoniae, Staphylococcus aureus, and Moraxella catarrhalis.",9564988_6,1
7520,endometrial carcinoma,20,41,Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study.,9579567_0,1
7521,breast cancer,62,75,Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study.,9579567_0,1
7523,breast cancer,172,185,"F  d  ration Nationale des Centres de Lutte Contre le Cancer (FNCLCC).Since tamoxifen is widely used in breast cancer treatment and has been proposed for the prevention of breast cancer, its endometrial iatrogenic effects must be carefully examined.",9579567_1,1
7522,breast cancer,104,117,"F  d  ration Nationale des Centres de Lutte Contre le Cancer (FNCLCC).Since tamoxifen is widely used in breast cancer treatment and has been proposed for the prevention of breast cancer, its endometrial iatrogenic effects must be carefully examined.",9579567_1,1
7534,breast cancer,74,87,Pelvic radiotherapy may be an additional iatrogenic factor for women with breast cancer.,9579567_10,1
15987,Pelvic radiotherapy,0,19,Pelvic radiotherapy may be an additional iatrogenic factor for women with breast cancer.,9579567_10,1
15989,poorer prognosis,67,83,Endometrial cancers diagnosed in women treated with tamoxifen have poorer prognosis.,9579567_11,1
7535,Endometrial cancers,0,19,Endometrial cancers diagnosed in women treated with tamoxifen have poorer prognosis.,9579567_11,1
7536,breast cancer,32,45,Women who receive tamoxifen for breast cancer should be offered gynaecological surveillance during and after treatment.,9579567_12,1
7537,breast cancer,92,105,A long-term evaluation of the risk-benefit ratio of tamoxifen as a preventive treatment for breast cancer is clearly warranted.,9579567_13,1
7524,endometrial cancer,45,63,We have investigated the association between endometrial cancer and tamoxifen use or other treatments in women treated for breast cancer in a case-control study.,9579567_2,1
7525,breast cancer,123,136,We have investigated the association between endometrial cancer and tamoxifen use or other treatments in women treated for breast cancer in a case-control study.,9579567_2,1
7528,breast cancer,123,136,"Cases of endometrial cancer diagnosed after breast cancer (n = 135) and 467 controls matched for age, year of diagnosis of breast cancer and hospital and survival time with an intact uterus were included.",9579567_3,1
7527,breast cancer,44,57,"Cases of endometrial cancer diagnosed after breast cancer (n = 135) and 467 controls matched for age, year of diagnosis of breast cancer and hospital and survival time with an intact uterus were included.",9579567_3,1
15975,intact uterus,176,189,"Cases of endometrial cancer diagnosed after breast cancer (n = 135) and 467 controls matched for age, year of diagnosis of breast cancer and hospital and survival time with an intact uterus were included.",9579567_3,1
7526,endometrial cancer,9,27,"Cases of endometrial cancer diagnosed after breast cancer (n = 135) and 467 controls matched for age, year of diagnosis of breast cancer and hospital and survival time with an intact uterus were included.",9579567_3,1
7529,endometrial cancer,72,90,"Women who had received tamoxifen were significantly more likely to have endometrial cancer diagnosed than those who had not (crude relative risk = 4.9, p = 0.0001).",9579567_4,1
15980,pelvic radiotherapy,24,43,"Women who had undergone pelvic radiotherapy also had a higher risk (crude relative risk = 7.8, p = 0.0001).",9579567_6,1
7531,endometrial cancer,123,141,Women who had endometrial cancer and had received tamoxifen had more advanced disease and poorer prognosis than those with endometrial cancer who had not received this treatment.,9579567_8,1
7530,endometrial cancer,14,32,Women who had endometrial cancer and had received tamoxifen had more advanced disease and poorer prognosis than those with endometrial cancer who had not received this treatment.,9579567_8,1
15985,advanced disease,69,85,Women who had endometrial cancer and had received tamoxifen had more advanced disease and poorer prognosis than those with endometrial cancer who had not received this treatment.,9579567_8,1
15986,poorer prognosis,90,106,Women who had endometrial cancer and had received tamoxifen had more advanced disease and poorer prognosis than those with endometrial cancer who had not received this treatment.,9579567_8,1
7533,breast cancer,119,132,"Our results suggest a causal role of tamoxifen in endometrial cancer, particularly when used as currently proposed for breast cancer prevention.",9579567_9,1
7532,endometrial cancer,50,68,"Our results suggest a causal role of tamoxifen in endometrial cancer, particularly when used as currently proposed for breast cancer prevention.",9579567_9,1
7538,cardiac arrest,22,36,Suxamethonium-induced cardiac arrest and death following 5 days of immobilization.,9587734_0,1
3956,suxamethonium,125,138,The present report describes a case of cardiac arrest and subsequent death as a result of hyperkalaemia following the use of suxamethonium in a 23-year-old Malawian woman.,9587734_1,0
15991,hyperkalaemia,90,103,The present report describes a case of cardiac arrest and subsequent death as a result of hyperkalaemia following the use of suxamethonium in a 23-year-old Malawian woman.,9587734_1,1
7539,cardiac arrest,39,53,The present report describes a case of cardiac arrest and subsequent death as a result of hyperkalaemia following the use of suxamethonium in a 23-year-old Malawian woman.,9587734_1,1
7540,cardiac arrest,64,78,"Forty seconds after injection of suxamethonium, bradycardia and cardiac arrest occurred.",9587734_3,1
3957,suxamethonium,33,46,"Forty seconds after injection of suxamethonium, bradycardia and cardiac arrest occurred.",9587734_3,0
15994,L-1,59,62,The serum level of potassium was observed to be 8.4 mequiv L-1.,9587734_5,0
15996,predisposing conditions,139,162,"Apart from the reduction in the patient's level of consciousness, there were no signs of motor neurone damage or of any of the other known predisposing conditions for hyperkalaemia following the administration of suxamethonium.",9587734_6,1
15995,motor neurone,89,102,"Apart from the reduction in the patient's level of consciousness, there were no signs of motor neurone damage or of any of the other known predisposing conditions for hyperkalaemia following the administration of suxamethonium.",9587734_6,1
15997,hyperkalaemia,167,180,"Apart from the reduction in the patient's level of consciousness, there were no signs of motor neurone damage or of any of the other known predisposing conditions for hyperkalaemia following the administration of suxamethonium.",9587734_6,1
3958,suxamethonium,213,226,"Apart from the reduction in the patient's level of consciousness, there were no signs of motor neurone damage or of any of the other known predisposing conditions for hyperkalaemia following the administration of suxamethonium.",9587734_6,0
3959,her,22,25,"It is postulated that her death was caused by hypersensitivity to suxamethonium, associated with her 5-day immobilization.",9587734_7,0
3961,her,97,100,"It is postulated that her death was caused by hypersensitivity to suxamethonium, associated with her 5-day immobilization.",9587734_7,0
3960,suxamethonium,66,79,"It is postulated that her death was caused by hypersensitivity to suxamethonium, associated with her 5-day immobilization.",9587734_7,0
15999,Acute hepatitis,0,15,"Acute hepatitis, autoimmune hemolytic anemia, and erythroblastocytopenia induced by ceftriaxone.",9625142_0,1
7541,autoimmune hemolytic anemia,17,44,"Acute hepatitis, autoimmune hemolytic anemia, and erythroblastocytopenia induced by ceftriaxone.",9625142_0,1
16000,erythroblastocytopenia,50,72,"Acute hepatitis, autoimmune hemolytic anemia, and erythroblastocytopenia induced by ceftriaxone.",9625142_0,1
16002,oral ceftriaxone,67,83,An 80-yr-old man developed acute hepatitis shortly after ingesting oral ceftriaxone.,9625142_1,0
16001,acute hepatitis,27,42,An 80-yr-old man developed acute hepatitis shortly after ingesting oral ceftriaxone.,9625142_1,1
7542,autoimmune hemolytic anemia,208,235,"Although the transaminases gradually returned to baseline after withholding the beta lactam antibiotic, there was a gradual increase in serum bilirubin and a decrease in hemoglobin concentration caused by an autoimmune hemolytic anemia and erythroblastocytopenia.",9625142_2,1
16005,erythroblastocytopenia,240,262,"Although the transaminases gradually returned to baseline after withholding the beta lactam antibiotic, there was a gradual increase in serum bilirubin and a decrease in hemoglobin concentration caused by an autoimmune hemolytic anemia and erythroblastocytopenia.",9625142_2,1
16004,serum bilirubin,136,151,"Although the transaminases gradually returned to baseline after withholding the beta lactam antibiotic, there was a gradual increase in serum bilirubin and a decrease in hemoglobin concentration caused by an autoimmune hemolytic anemia and erythroblastocytopenia.",9625142_2,1
16003,beta lactam antibiotic,80,102,"Although the transaminases gradually returned to baseline after withholding the beta lactam antibiotic, there was a gradual increase in serum bilirubin and a decrease in hemoglobin concentration caused by an autoimmune hemolytic anemia and erythroblastocytopenia.",9625142_2,0
16006,systemic steroids,19,36,These responded to systemic steroids and immunoglobulins.,9625142_3,0
7543,side effects,57,69,Despite the widespread use of these agents this triad of side effects has not previously been reported in connection with beta lactam antibiotics.,9625142_4,1
16007,beta lactam antibiotics,122,145,Despite the widespread use of these agents this triad of side effects has not previously been reported in connection with beta lactam antibiotics.,9625142_4,0
16009,rostral,54,61,Contribution of the glycine site of NMDA receptors in rostral and intermediate-caudal parts of the striatum to the regulation of muscle tone in rats.,9630698_0,1
7544,muscle tone,129,140,Contribution of the glycine site of NMDA receptors in rostral and intermediate-caudal parts of the striatum to the regulation of muscle tone in rats.,9630698_0,1
3962,NMDA receptors,36,50,Contribution of the glycine site of NMDA receptors in rostral and intermediate-caudal parts of the striatum to the regulation of muscle tone in rats.,9630698_0,0
16008,glycine site,20,32,Contribution of the glycine site of NMDA receptors in rostral and intermediate-caudal parts of the striatum to the regulation of muscle tone in rats.,9630698_0,0
7545,muscle tone,135,146,The aim of the present study was to assess the contribution of the glycine site of NMDA receptors in the striatum to the regulation of muscle tone.,9630698_1,1
3963,NMDA receptors,83,97,The aim of the present study was to assess the contribution of the glycine site of NMDA receptors in the striatum to the regulation of muscle tone.,9630698_1,0
16011,glycine site,67,79,The aim of the present study was to assess the contribution of the glycine site of NMDA receptors in the striatum to the regulation of muscle tone.,9630698_1,0
7546,Muscle tone,0,11,"Muscle tone was examined using a combined mechanoand electromyographic method, which measured simultaneously the muscle resistance (MMG) of the rat's hind foot to passive extension and flexion in the ankle joint and the electromyographic activity (EMG) of the antagonistic muscles of that joint: gastrocnemius and tibialis anterior.",9630698_2,1
16019,tibialis anterior,314,331,"Muscle tone was examined using a combined mechanoand electromyographic method, which measured simultaneously the muscle resistance (MMG) of the rat's hind foot to passive extension and flexion in the ankle joint and the electromyographic activity (EMG) of the antagonistic muscles of that joint: gastrocnemius and tibialis anterior.",9630698_2,1
16016,ankle joint,200,211,"Muscle tone was examined using a combined mechanoand electromyographic method, which measured simultaneously the muscle resistance (MMG) of the rat's hind foot to passive extension and flexion in the ankle joint and the electromyographic activity (EMG) of the antagonistic muscles of that joint: gastrocnemius and tibialis anterior.",9630698_2,1
16013,muscle resistance,113,130,"Muscle tone was examined using a combined mechanoand electromyographic method, which measured simultaneously the muscle resistance (MMG) of the rat's hind foot to passive extension and flexion in the ankle joint and the electromyographic activity (EMG) of the antagonistic muscles of that joint: gastrocnemius and tibialis anterior.",9630698_2,1
7547,Muscle rigidity,0,15,Muscle rigidity was induced by haloperidol (2.5 mg/kg i.p.).,9630698_3,1
7548,muscle rigidity,220,235,"5,7-dichlorokynurenic acid (5,7-DCKA), a selective glycine site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-induced muscle rigidity (MMG) and the enhanced electromyographic activity (EMG).",9630698_4,1
16024,rostral region,149,163,"5,7-dichlorokynurenic acid (5,7-DCKA), a selective glycine site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-induced muscle rigidity (MMG) and the enhanced electromyographic activity (EMG).",9630698_4,1
16021,"5,7-DCKA",28,36,"5,7-dichlorokynurenic acid (5,7-DCKA), a selective glycine site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-induced muscle rigidity (MMG) and the enhanced electromyographic activity (EMG).",9630698_4,0
16022,glycine site,51,63,"5,7-dichlorokynurenic acid (5,7-DCKA), a selective glycine site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-induced muscle rigidity (MMG) and the enhanced electromyographic activity (EMG).",9630698_4,0
16020,"5,7-dichlorokynurenic acid",0,26,"5,7-dichlorokynurenic acid (5,7-DCKA), a selective glycine site antagonist, injected in doses of 2.5 and 4.5 microg/0.5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-induced muscle rigidity (MMG) and the enhanced electromyographic activity (EMG).",9630698_4,0
16027,"5,7-DCKA",0,8,"5,7-DCKA injected bilaterally in a dose of 4.5 microg/0.5 microl into the intermediate-caudal region of the striatum of rats not pretreated with haloperidol had no effect on the muscle tone.",9630698_5,0
7549,muscle tone,178,189,"5,7-DCKA injected bilaterally in a dose of 4.5 microg/0.5 microl into the intermediate-caudal region of the striatum of rats not pretreated with haloperidol had no effect on the muscle tone.",9630698_5,1
16030,glycine site,49,61,The present results suggest that blockade of the glycine site of NMDA receptors in the rostral part of the striatum may be mainly responsible for the antiparkinsonian action of this drug.,9630698_6,0
3965,antiparkinsonian,150,166,The present results suggest that blockade of the glycine site of NMDA receptors in the rostral part of the striatum may be mainly responsible for the antiparkinsonian action of this drug.,9630698_6,0
3964,NMDA receptors,65,79,The present results suggest that blockade of the glycine site of NMDA receptors in the rostral part of the striatum may be mainly responsible for the antiparkinsonian action of this drug.,9630698_6,0
7550,nervous system,44,58,Carboplatin toxic effects on the peripheral nervous system of the rat.,9636837_0,1
16033,CDDP,82,86,BACKGROUND: The most striking of carboplatin's advantages (CBDCA) over cisplatin (CDDP) is its markedly reduced rate of neurotoxic effects.,9636837_1,0
3968,cisplatin,71,80,BACKGROUND: The most striking of carboplatin's advantages (CBDCA) over cisplatin (CDDP) is its markedly reduced rate of neurotoxic effects.,9636837_1,0
3967,CBDCA,59,64,BACKGROUND: The most striking of carboplatin's advantages (CBDCA) over cisplatin (CDDP) is its markedly reduced rate of neurotoxic effects.,9636837_1,0
3966,carboplatin,33,44,BACKGROUND: The most striking of carboplatin's advantages (CBDCA) over cisplatin (CDDP) is its markedly reduced rate of neurotoxic effects.,9636837_1,0
3974,CBDCA,89,94,This model can be used alone or in combination with other drugs to explore the effect of CBDCA on the peripheral nervous system.,9636837_10,0
7555,nervous system,113,127,This model can be used alone or in combination with other drugs to explore the effect of CBDCA on the peripheral nervous system.,9636837_10,1
3969,CBDCA,20,25,"However, the use of CBDCA higher-intensity schedules and the association with other neurotoxic drugs in polychemotherapy may cause some concern about its safety with respect to peripheral nervous system damage.",9636837_2,0
7551,nervous system,188,202,"However, the use of CBDCA higher-intensity schedules and the association with other neurotoxic drugs in polychemotherapy may cause some concern about its safety with respect to peripheral nervous system damage.",9636837_2,1
3970,CBDCA,50,55,MATERIALS AND METHODS: Two different schedules of CBDCA administration (10 mg/kg and 15 mg/kg i.p. twice a week for nine times) were evaluated in Wistar rats.,9636837_3,0
16037,nerve conduction velocity,81,106,"Neurotoxicity was assessed for behavioral (tail-flick test), neurophysiological (nerve conduction velocity in the tail nerve), morphological, morphometrical and analytical effects.",9636837_4,1
16038,tail nerve,114,124,"Neurotoxicity was assessed for behavioral (tail-flick test), neurophysiological (nerve conduction velocity in the tail nerve), morphological, morphometrical and analytical effects.",9636837_4,1
7552,Neurotoxicity,0,13,"Neurotoxicity was assessed for behavioral (tail-flick test), neurophysiological (nerve conduction velocity in the tail nerve), morphological, morphometrical and analytical effects.",9636837_4,1
3971,CBDCA,9,14,RESULTS: CBDCA administration induced dose-dependent peripheral neurotoxicity.,9636837_5,0
7553,neurotoxicity,64,77,RESULTS: CBDCA administration induced dose-dependent peripheral neurotoxicity.,9636837_5,1
16042,Pain perception,0,15,"Pain perception and nerve conduction velocity in the tail were significantly impaired, particularly after the high-dose treatment.",9636837_6,1
16043,nerve conduction velocity,20,45,"Pain perception and nerve conduction velocity in the tail were significantly impaired, particularly after the high-dose treatment.",9636837_6,1
16045,high-dose,110,119,"Pain perception and nerve conduction velocity in the tail were significantly impaired, particularly after the high-dose treatment.",9636837_6,0
16048,CDDP,125,129,"The dorsal root ganglia sensory neurons and, to a lesser extent, satellite cells showed the same changes as those induced by CDDP, mainly affecting the nucleus and nucleolus of ganglionic sensory neurons.",9636837_7,0
16050,dorsal root ganglia,63,82,"Moreover, significant amounts of platinum were detected in the dorsal root ganglia and kidney after CBDCA treatment.",9636837_8,1
3972,CBDCA,100,105,"Moreover, significant amounts of platinum were detected in the dorsal root ganglia and kidney after CBDCA treatment.",9636837_8,0
3973,CBDCA,13,18,"CONCLUSIONS: CBDCA is neurotoxic in our model, and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that neurotoxicity is induced in the two drugs by the same mechanism.",9636837_9,0
16051,CDDP,137,141,"CONCLUSIONS: CBDCA is neurotoxic in our model, and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that neurotoxicity is induced in the two drugs by the same mechanism.",9636837_9,0
7554,neurotoxicity,167,180,"CONCLUSIONS: CBDCA is neurotoxic in our model, and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that neurotoxicity is induced in the two drugs by the same mechanism.",9636837_9,1
7556,drug abuse,61,71,Eating disorders and the associated behavioural problems and drug abuse are uncommon in pregnancy.,9653867_1,1
16052,Eating disorders,0,16,Eating disorders and the associated behavioural problems and drug abuse are uncommon in pregnancy.,9653867_1,1
16053,behavioural problems,36,56,Eating disorders and the associated behavioural problems and drug abuse are uncommon in pregnancy.,9653867_1,1
3975,her,125,128,When they do occur they are often unrecognized because of denial but when significant may pose a risk to both the mother and her fetus.,9653867_2,0
16055,metabolic disturbances,146,168,"This case illustrates a number of problems that may be encountered in women with eating disorders in pregnancy, including prolonged and recurrent metabolic disturbances and diuretic abuse.",9653867_3,1
16054,eating disorders,81,97,"This case illustrates a number of problems that may be encountered in women with eating disorders in pregnancy, including prolonged and recurrent metabolic disturbances and diuretic abuse.",9653867_3,1
16059,eating disorders,94,110,"In particular it illustrates the derangements of thyroid function seen in pregnant women with eating disorders and reminds us that when a cause for thyrotoxicosis remains obscure, thyroxine abuse should be considered and explored.",9653867_4,1
16057,thyroid function,49,65,"In particular it illustrates the derangements of thyroid function seen in pregnant women with eating disorders and reminds us that when a cause for thyrotoxicosis remains obscure, thyroxine abuse should be considered and explored.",9653867_4,1
3976,alpha1-adrenergic,49,66,Repeated trimipramine induces dopamine D2/D3 and alpha1-adrenergic up-regulation.,9660111_0,0
16062,dopamine D2/D3,30,44,Repeated trimipramine induces dopamine D2/D3 and alpha1-adrenergic up-regulation.,9660111_0,0
16061,Repeated trimipramine,0,21,Repeated trimipramine induces dopamine D2/D3 and alpha1-adrenergic up-regulation.,9660111_0,0
16063,TRI,14,17,"Trimipramine (TRI), which shows a clinical antidepressant activity, is chemically related to imipramine but does not inhibit the reuptake of noradrenaline and 5-hydroxytryptamine, nor does it induce beta-adrenergic down-regulation.",9660111_1,0
3977,beta-adrenergic,199,214,"Trimipramine (TRI), which shows a clinical antidepressant activity, is chemically related to imipramine but does not inhibit the reuptake of noradrenaline and 5-hydroxytryptamine, nor does it induce beta-adrenergic down-regulation.",9660111_1,0
3978,dopaminergic,117,129,"The aim of the present study was to find out whether TRI given repeatedly was able to induce adaptive changes in the dopaminergic and alpha1-adrenergic systems, demonstrated by us previously for various antidepressants.",9660111_3,0
3979,alpha1-adrenergic,134,151,"The aim of the present study was to find out whether TRI given repeatedly was able to induce adaptive changes in the dopaminergic and alpha1-adrenergic systems, demonstrated by us previously for various antidepressants.",9660111_3,0
16066,TRI,53,56,"The aim of the present study was to find out whether TRI given repeatedly was able to induce adaptive changes in the dopaminergic and alpha1-adrenergic systems, demonstrated by us previously for various antidepressants.",9660111_3,0
16068,TRI,0,3,TRI was given to male Wistar rats and male Albino Swiss mice perorally twice daily for 14 days.,9660111_4,0
16074,5-hydroxytryptophan,123,142,In the acute experiment TRI (given i.p.) does not antagonize the reserpine hypothermia in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats.,9660111_5,0
16072,TRI,24,27,In the acute experiment TRI (given i.p.) does not antagonize the reserpine hypothermia in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats.,9660111_5,0
16076,TRI,0,3,"TRI given repeatedly to rats increases the locomotor hyperactivity induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects).",9660111_6,0
16079,(+)-7-hydroxy-dipropyloaminotetralin,108,144,"TRI given repeatedly to rats increases the locomotor hyperactivity induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects).",9660111_6,0
16078,quinpirole,93,103,"TRI given repeatedly to rats increases the locomotor hyperactivity induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects).",9660111_6,0
16077,locomotor hyperactivity,43,66,"TRI given repeatedly to rats increases the locomotor hyperactivity induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects).",9660111_6,1
3981,dopamine D2,146,157,"TRI given repeatedly to rats increases the locomotor hyperactivity induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects).",9660111_6,0
3982,D3,162,164,"TRI given repeatedly to rats increases the locomotor hyperactivity induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects).",9660111_6,0
3980,d-amphetamine,78,91,"TRI given repeatedly to rats increases the locomotor hyperactivity induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects).",9660111_6,0
16081,TRI,80,83,The stereotypies induced by d-amphetamine or apomorphine are not potentiated by TRI.,9660111_7,0
3983,d-amphetamine,28,41,The stereotypies induced by d-amphetamine or apomorphine are not potentiated by TRI.,9660111_7,0
3984,alpha1-adrenergic,231,248,"It increases the behaviour stimulation evoked by phenylephrine (given intraventricularly) in rats, evaluated in the open field test as well as the aggressiveness evoked by clonidine in mice, both these effects being mediated by an alpha1-adrenergic receptor.",9660111_8,0
16084,TRI,83,86,"It may be concluded that, like other tricyclic antidepressants studied previously, TRI given repeatedly increases the responsiveness of brain dopamine D2 and D3 (locomotor activity but not stereotypy) as well as alpha1-adrenergic receptors to their agonists.",9660111_9,0
3986,dopamine D2,142,153,"It may be concluded that, like other tricyclic antidepressants studied previously, TRI given repeatedly increases the responsiveness of brain dopamine D2 and D3 (locomotor activity but not stereotypy) as well as alpha1-adrenergic receptors to their agonists.",9660111_9,0
3985,tricyclic antidepressants,37,62,"It may be concluded that, like other tricyclic antidepressants studied previously, TRI given repeatedly increases the responsiveness of brain dopamine D2 and D3 (locomotor activity but not stereotypy) as well as alpha1-adrenergic receptors to their agonists.",9660111_9,0
3987,D3,158,160,"It may be concluded that, like other tricyclic antidepressants studied previously, TRI given repeatedly increases the responsiveness of brain dopamine D2 and D3 (locomotor activity but not stereotypy) as well as alpha1-adrenergic receptors to their agonists.",9660111_9,0
3988,alpha1-adrenergic,212,229,"It may be concluded that, like other tricyclic antidepressants studied previously, TRI given repeatedly increases the responsiveness of brain dopamine D2 and D3 (locomotor activity but not stereotypy) as well as alpha1-adrenergic receptors to their agonists.",9660111_9,0
16090,postcibal small-bowel motor function,37,73,Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome.,9669632_0,1
16089,cisapride,11,20,Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome.,9669632_0,0
7557,irritable bowel syndrome,91,115,Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome.,9669632_0,1
16092,gastrointestinal motility,121,146,BACKGROUND: Irritable bowel syndrome is a common cause of abdominal pain and discomfort and may be related to disordered gastrointestinal motility.,9669632_1,1
16091,cause of abdominal pain,49,72,BACKGROUND: Irritable bowel syndrome is a common cause of abdominal pain and discomfort and may be related to disordered gastrointestinal motility.,9669632_1,1
7558,Irritable bowel syndrome,12,36,BACKGROUND: Irritable bowel syndrome is a common cause of abdominal pain and discomfort and may be related to disordered gastrointestinal motility.,9669632_1,1
16139,Cisapride,12,21,CONCLUSION: Cisapride affects jejunal contraction characteristics and some symptoms in IBS.,9669632_10,0
16140,IBS,87,90,CONCLUSION: Cisapride affects jejunal contraction characteristics and some symptoms in IBS.,9669632_10,0
7563,jejunal,30,37,CONCLUSION: Cisapride affects jejunal contraction characteristics and some symptoms in IBS.,9669632_10,1
16094,cisapride,82,91,"Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).",9669632_2,0
16093,prokinetic agent,64,80,"Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).",9669632_2,0
7560,irritable bowel syndrome,146,170,"Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).",9669632_2,1
7559,jejunal,109,116,"Our aim was to assess the effects of long-term treatment with a prokinetic agent, cisapride, on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS).",9669632_2,1
16096,IBS,36,39,"METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].",9669632_3,0
7561,jejunal,132,139,"METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].",9669632_3,1
16099,cisapride,188,197,"METHODS: Thirty-eight patients with IBS (constipation-predominant, n = 17; diarrhoea-predominant, n = 21) underwent 24-h ambulatory jejunal manometry before and after 12 week's treatment [cisapride, 5 mg three times daily (n = 19) or placebo (n = 19)].",9669632_3,0
16101,cisapride,124,133,RESULTS: In diarrhoea-predominant patients significant differences in contraction characteristics were observed between the cisapride and placebo groups.,9669632_4,0
16121,/-,493,495,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,0
16116,contraction frequency,365,386,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,1
16120,cisapride,436,445,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,0
16108,cisapride,135,144,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,0
16113,cisapride,282,291,"In cisapride-treated diarrhoea-predominant patients the mean contraction amplitude was higher (29.3 +/- 3.2 versus 24.9 +/- 2.6 mm Hg, cisapride versus placebo (P < 0.001); pretreatment, 25.7 +/- 6.0 mm Hg), the mean contraction duration longer (3.4 +/- 0.2 versus 3.0 +/- 0.2 sec, cisapride versus placebo (P < 0.001); pretreatment, 3.1 +/- 0.5 sec), and the mean contraction frequency lower (2.0 +/- 0.2 versus 2.5 +/- 0.4 cont./min, cisapride versus placebo (P < 0.001); pretreatment, 2.5 +/- 1.1 cont./min] than patients treated with placebo.",9669632_5,0
7562,jejunal,30,37,No significant differences in jejunal motility were found in the constipation-predominant IBS group.,9669632_6,1
16123,IBS,90,93,No significant differences in jejunal motility were found in the constipation-predominant IBS group.,9669632_6,0
16129,cisapride,164,173,"Symptom scores relating to the severity of constipation were lower in cisapride-treated constipation-predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P < 0.05); pretreatment, 62 +/- 19 mm].",9669632_8,0
16136,cisapride,122,131,"Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].",9669632_9,0
16133,cisapride,65,74,"Diarrhoea-predominant IBS patients had a higher pain score after cisapride therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0.05); pretreatment, 67 +/- 19 mm].",9669632_9,0
7564,breast cancer,14,27,Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women.,9672273_0,1
7570,breast cancer,74,87,41 cases of breast cancer occurred so far; there have been no deaths from breast cancer.,9672273_12,1
7569,breast cancer,12,25,41 cases of breast cancer occurred so far; there have been no deaths from breast cancer.,9672273_12,1
16150,breast-cancer frequency,26,49,There is no difference in breast-cancer frequency between the placebo (22 cases) and tamoxifen (19) arms.,9672273_13,1
7572,breast cancer,238,251,"There is a statistically significant reduction of breast cancer among women receiving tamoxifen who also used hormone-replacement therapy during the trial: among 390 women on such therapy and allocated to placebo, we found eight cases of breast cancer compared with one case among 362 women allocated to tamoxifen.",9672273_14,1
7571,breast cancer,50,63,"There is a statistically significant reduction of breast cancer among women receiving tamoxifen who also used hormone-replacement therapy during the trial: among 390 women on such therapy and allocated to placebo, we found eight cases of breast cancer compared with one case among 362 women allocated to tamoxifen.",9672273_14,1
16154,hypertriglyceridaemia,97,118,"Compared with the placebo group, there was a significantly increased risk of vascular events and hypertriglyceridaemia among women on tamoxifen.",9672273_15,1
16153,vascular events,77,92,"Compared with the placebo group, there was a significantly increased risk of vascular events and hypertriglyceridaemia among women on tamoxifen.",9672273_15,1
7573,breast cancer,115,128,"INTERPRETATION: Although this preliminary analysis has low power, in this cohort of women at low-to-normal risk of breast cancer, the postulated protective effects of tamoxifen are not yet apparent.",9672273_16,1
16156,protective effects,145,163,"INTERPRETATION: Although this preliminary analysis has low power, in this cohort of women at low-to-normal risk of breast cancer, the postulated protective effects of tamoxifen are not yet apparent.",9672273_16,0
7574,breast cancer,26,39,There were no deaths from breast cancer recorded in women in the study.,9672273_18,1
16142,chemopreventive agent,37,58,"BACKGROUND: Tamoxifen is a candidate chemopreventive agent in breast cancer, although the drug may be associated with the development of endometrial cancer.",9672273_2,0
7565,breast cancer,62,75,"BACKGROUND: Tamoxifen is a candidate chemopreventive agent in breast cancer, although the drug may be associated with the development of endometrial cancer.",9672273_2,1
7566,endometrial cancer,137,155,"BACKGROUND: Tamoxifen is a candidate chemopreventive agent in breast cancer, although the drug may be associated with the development of endometrial cancer.",9672273_2,1
16145,chemopreventive,68,83,Therefore we did a trial in hysterectomised women of tamoxifen as a chemopreventive.,9672273_3,0
7567,breast cancer,147,160,"METHODS: In October, 1992, we started a double-blind placebo-controlled, randomised trial of tamoxifen in women (mainly in Italy) who did not have breast cancer and who had had a hysterectomy.",9672273_4,1
7568,breast cancer,60,73,The primary endpoints are the occurrence of and deaths from breast cancer.,9672273_9,1
7575,postoperative pain,77,95,Pethidine-associated seizure in a healthy adolescent receiving pethidine for postoperative pain control.,9672936_0,1
3989,pethidine,63,72,Pethidine-associated seizure in a healthy adolescent receiving pethidine for postoperative pain control.,9672936_0,0
7576,PCA,113,116,A healthy 17-year-old male received standard intermittent doses of pethidine via a patient-controlled analgesia (PCA) pump for management of postoperative pain control.,9672936_1,1
7577,postoperative pain,141,159,A healthy 17-year-old male received standard intermittent doses of pethidine via a patient-controlled analgesia (PCA) pump for management of postoperative pain control.,9672936_1,1
3990,pethidine,67,76,A healthy 17-year-old male received standard intermittent doses of pethidine via a patient-controlled analgesia (PCA) pump for management of postoperative pain control.,9672936_1,0
16160,self-limited seizure,52,72,Twenty-three h postoperatively he developed a brief self-limited seizure.,9672936_2,1
16161,norpethidine,26,38,Both plasma pethidine and norpethidine were elevated in the range associated with clinical manifestations of central nervous system excitation.,9672936_3,0
16163,clinical manifestations,82,105,Both plasma pethidine and norpethidine were elevated in the range associated with clinical manifestations of central nervous system excitation.,9672936_3,1
7578,central nervous system,109,131,Both plasma pethidine and norpethidine were elevated in the range associated with clinical manifestations of central nervous system excitation.,9672936_3,1
3991,pethidine,12,21,Both plasma pethidine and norpethidine were elevated in the range associated with clinical manifestations of central nervous system excitation.,9672936_3,0
3992,pethidine,44,53,This method allowed frequent self-dosing of pethidine at short time intervals and rapid accumulation of pethidine and norpethidine.,9672936_5,0
3993,pethidine,104,113,This method allowed frequent self-dosing of pethidine at short time intervals and rapid accumulation of pethidine and norpethidine.,9672936_5,0
16167,norpethidine,118,130,This method allowed frequent self-dosing of pethidine at short time intervals and rapid accumulation of pethidine and norpethidine.,9672936_5,0
16168,postoperative analgesia,54,77,The routine use of pethidine via PCA even for a brief postoperative analgesia should be reconsidered.,9672936_6,1
7579,PCA,33,36,The routine use of pethidine via PCA even for a brief postoperative analgesia should be reconsidered.,9672936_6,1
3994,pethidine,19,28,The routine use of pethidine via PCA even for a brief postoperative analgesia should be reconsidered.,9672936_6,0
16169,toxic reaction,11,25,An unusual toxic reaction to axillary block by mepivacaine with adrenaline.,9698967_0,1
16170,axillary block,29,43,An unusual toxic reaction to axillary block by mepivacaine with adrenaline.,9698967_0,1
16171,mepivacaine,47,58,An unusual toxic reaction to axillary block by mepivacaine with adrenaline.,9698967_0,0
7581,atrial fibrillation,46,65,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,1
7582,loss of consciousness,106,127,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,1
7583,Dupuytren's contracture,336,359,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,1
7580,blood pressure,15,29,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,1
16172,axillary block,247,261,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,1
16173,mepivacaine,267,278,"An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture.",9698967_1,0
7584,atrial fibrillation,83,102,The block was successful and surgery was conducted as scheduled despite persisting atrial fibrillation.,9698967_3,1
16175,cardioversion,40,53,"Postoperatively, the patient refused DC cardioversion and was treated medically.",9698967_4,0
16177,mepivacaine,115,126,Both the temporal relationship of events and the response to treatment suggest that a rapid systemic absorption of mepivacaine with adrenaline and/or interaction of these drugs with the patient's cardiovascular medications were responsible for the perioperative complications.,9698967_5,0
16179,perioperative,248,261,Both the temporal relationship of events and the response to treatment suggest that a rapid systemic absorption of mepivacaine with adrenaline and/or interaction of these drugs with the patient's cardiovascular medications were responsible for the perioperative complications.,9698967_5,1
7585,bile duct,38,47,Drug-associated acute-onset vanishing bile duct and Stevens-Johnson syndromes in a child.,9721172_0,1
7586,Stevens-Johnson syndromes,52,77,Drug-associated acute-onset vanishing bile duct and Stevens-Johnson syndromes in a child.,9721172_0,1
16180,bile duct syndrome,16,34,"Acute vanishing bile duct syndrome is a rare but established cause of progressive cholestasis in adults, is most often drug or toxin related, and is of unknown pathogenesis.",9721172_1,1
16181,cause of,61,69,"Acute vanishing bile duct syndrome is a rare but established cause of progressive cholestasis in adults, is most often drug or toxin related, and is of unknown pathogenesis.",9721172_1,1
7588,hypersensitivity reaction,70,95,"Stevens-Johnson syndrome is a well-recognized immune complex-mediated hypersensitivity reaction that affects all age groups, is drug or infection induced, and has classic systemic, mucosal, and dermatologic manifestations.",9721172_3,1
7587,Stevens-Johnson syndrome,0,24,"Stevens-Johnson syndrome is a well-recognized immune complex-mediated hypersensitivity reaction that affects all age groups, is drug or infection induced, and has classic systemic, mucosal, and dermatologic manifestations.",9721172_3,1
16183,dermatologic manifestations,194,221,"Stevens-Johnson syndrome is a well-recognized immune complex-mediated hypersensitivity reaction that affects all age groups, is drug or infection induced, and has classic systemic, mucosal, and dermatologic manifestations.",9721172_3,1
7589,Stevens-Johnson syndrome,119,143,"A previously healthy child who developed acute, severe, rapidly progressive vanishing bile duct syndrome shortly after Stevens-Johnson syndrome is described; this was temporally associated with ibuprofen use.",9721172_4,1
16185,bile duct syndrome,86,104,"A previously healthy child who developed acute, severe, rapidly progressive vanishing bile duct syndrome shortly after Stevens-Johnson syndrome is described; this was temporally associated with ibuprofen use.",9721172_4,1
16184,healthy child,13,26,"A previously healthy child who developed acute, severe, rapidly progressive vanishing bile duct syndrome shortly after Stevens-Johnson syndrome is described; this was temporally associated with ibuprofen use.",9721172_4,1
3995,ursodeoxycholic acid,21,41,"Despite therapy with ursodeoxycholic acid, prednisone, and then tacrolimus, her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation.",9721172_5,0
3996,tacrolimus,64,74,"Despite therapy with ursodeoxycholic acid, prednisone, and then tacrolimus, her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation.",9721172_5,0
16187,her cholestatic,76,91,"Despite therapy with ursodeoxycholic acid, prednisone, and then tacrolimus, her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation.",9721172_5,1
16191,bile duct syndrome,200,218,This case documents acute drug-related vanishing bile duct syndrome in the pediatric age group and suggests shared immune mechanisms in the pathogenesis of both Stevens-Johnson syndrome and vanishing bile duct syndrome.,9721172_6,1
16189,bile duct syndrome,49,67,This case documents acute drug-related vanishing bile duct syndrome in the pediatric age group and suggests shared immune mechanisms in the pathogenesis of both Stevens-Johnson syndrome and vanishing bile duct syndrome.,9721172_6,1
7590,drug-related,26,38,This case documents acute drug-related vanishing bile duct syndrome in the pediatric age group and suggests shared immune mechanisms in the pathogenesis of both Stevens-Johnson syndrome and vanishing bile duct syndrome.,9721172_6,1
7591,Stevens-Johnson syndrome,161,185,This case documents acute drug-related vanishing bile duct syndrome in the pediatric age group and suggests shared immune mechanisms in the pathogenesis of both Stevens-Johnson syndrome and vanishing bile duct syndrome.,9721172_6,1
3997,appetite suppressants,65,86,High incidence of primary pulmonary hypertension associated with appetite suppressants in Belgium.,9727773_0,0
7592,primary pulmonary hypertension,18,48,High incidence of primary pulmonary hypertension associated with appetite suppressants in Belgium.,9727773_0,1
3998,appetite suppressant drugs,122,148,"Primary pulmonary hypertension is a rare, progressive and incurable disease, which has been associated with the intake of appetite suppressant drugs.",9727773_1,0
16192,incurable disease,58,75,"Primary pulmonary hypertension is a rare, progressive and incurable disease, which has been associated with the intake of appetite suppressant drugs.",9727773_1,1
7593,Primary pulmonary hypertension,0,30,"Primary pulmonary hypertension is a rare, progressive and incurable disease, which has been associated with the intake of appetite suppressant drugs.",9727773_1,1
4006,appetite suppressants,10,31,Intake of appetite suppressants may accelerate the progression of the disease.,9727773_10,0
3999,appetite suppressants,127,148,The importance of this association was evaluated in Belgium while this country still had no restriction on the prescription of appetite suppressants.,9727773_2,0
7594,primary pulmonary hypertension,26,56,Thirty-five patients with primary pulmonary hypertension and 85 matched controls were recruited over 32 months (1992-1994) in Belgium.,9727773_3,1
4000,appetite-suppressants,12,33,Exposure to appetite-suppressants was assessed on the basis of hospital records and standardized interview.,9727773_4,0
16195,fenfluramines,80,93,"Twenty-three of the patients had previously taken appetite suppressants, mainly fenfluramines, as compared with only 5 of the controls (66 versus 6%, p<0.0001).",9727773_5,0
4001,appetite suppressants,50,71,"Twenty-three of the patients had previously taken appetite suppressants, mainly fenfluramines, as compared with only 5 of the controls (66 versus 6%, p<0.0001).",9727773_5,0
4002,appetite suppressants,63,84,"Five patients died before the interview, all of them had taken appetite suppressants.",9727773_6,0
7595,primary pulmonary hypertension,31,61,"In 8 patients the diagnosis of primary pulmonary hypertension was uncertain, 5 of them had taken appetite suppressants.",9727773_7,1
4003,appetite suppressants,97,118,"In 8 patients the diagnosis of primary pulmonary hypertension was uncertain, 5 of them had taken appetite suppressants.",9727773_7,0
16196,severely ill,88,100,"The patients who had been exposed to appetite suppressants tended to be on average more severely ill, and to have a shorter median delay between onset of symptoms and diagnosis.",9727773_8,1
4004,appetite suppressants,37,58,"The patients who had been exposed to appetite suppressants tended to be on average more severely ill, and to have a shorter median delay between onset of symptoms and diagnosis.",9727773_8,0
7596,primary pulmonary hypertension,106,136,A policy of unrestricted prescription of appetite suppressants may lead to a high incidence of associated primary pulmonary hypertension.,9727773_9,1
4005,appetite suppressants,41,62,A policy of unrestricted prescription of appetite suppressants may lead to a high incidence of associated primary pulmonary hypertension.,9727773_9,0
16198,Inappropriate use,0,17,Inappropriate use of carbamazepine and vigabatrin in typical absence seizures.,9746003_0,1
16199,carbamazepine,21,34,Inappropriate use of carbamazepine and vigabatrin in typical absence seizures.,9746003_0,0
4007,vigabatrin,39,49,Inappropriate use of carbamazepine and vigabatrin in typical absence seizures.,9746003_0,0
7597,absence seizures,61,77,Inappropriate use of carbamazepine and vigabatrin in typical absence seizures.,9746003_0,1
4008,vigabatrin,18,28,Carbamazepine and vigabatrin are contraindicated in typical absence seizures.,9746003_1,0
7598,absence seizures,60,76,Carbamazepine and vigabatrin are contraindicated in typical absence seizures.,9746003_1,1
16200,Carbamazepine,0,13,Carbamazepine and vigabatrin are contraindicated in typical absence seizures.,9746003_1,0
7599,of children,28,39,"Of 18 consecutive referrals of children with resistant typical absences only, eight were erroneously treated with carbamazepine either as monotherapy or as an add-on.",9746003_2,1
16201,carbamazepine,114,127,"Of 18 consecutive referrals of children with resistant typical absences only, eight were erroneously treated with carbamazepine either as monotherapy or as an add-on.",9746003_2,0
4009,Vigabatrin,0,10,Vigabatrin was also used in the treatment of two children.,9746003_3,0
7600,myoclonic jerks,103,118,"Frequency of absences increased in four children treated with carbamazepine and two of these developed myoclonic jerks, which resolved on withdrawal of carbamazepine.",9746003_4,1
16204,carbamazepine,152,165,"Frequency of absences increased in four children treated with carbamazepine and two of these developed myoclonic jerks, which resolved on withdrawal of carbamazepine.",9746003_4,0
16203,carbamazepine,62,75,"Frequency of absences increased in four children treated with carbamazepine and two of these developed myoclonic jerks, which resolved on withdrawal of carbamazepine.",9746003_4,0
4010,vigabatrin,45,55,Absences were aggravated in both cases where vigabatrin was added on to concurrent treatment.,9746003_5,0
4011,sodium valproate,50,66,"Optimal control of the absences was achieved with sodium valproate, lamotrigine, or ethosuximide alone or in combination.",9746003_6,0
4012,lamotrigine,68,79,"Optimal control of the absences was achieved with sodium valproate, lamotrigine, or ethosuximide alone or in combination.",9746003_6,0
16205,Choreoathetoid,0,14,Choreoathetoid movements associated with rapid adjustment to methadone.,9754849_0,1
7601,hyperkinesias,13,26,Choreatiform hyperkinesias are known to be occasional movement abnormalities during intoxications with cocaine but not opiates.,9754849_1,1
16208,choreoathetoid,38,52,This is a case report of euphoria and choreoathetoid movements both transiently induced by rapid adjustment to the selective mu-opioid receptor agonist methadone in an inpatient previously abusing heroine and cocaine.,9754849_2,1
16209,mu-opioid receptor agonist,125,151,This is a case report of euphoria and choreoathetoid movements both transiently induced by rapid adjustment to the selective mu-opioid receptor agonist methadone in an inpatient previously abusing heroine and cocaine.,9754849_2,0
16210,neurobiological phenomena,20,45,Possible underlying neurobiological phenomena are discussed.,9754849_4,1
16212,folic acid,26,36,Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.,9758264_0,0
16215,folic acid-containing multivitamin,119,153,Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.,9758264_0,0
16211,Epileptogenic,0,13,Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.,9758264_0,1
7602,pregnancy in,207,219,Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.,9758264_0,1
7603,birth defects,262,275,Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.,9758264_0,1
7604,side effects,297,309,Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.,9758264_0,1
16213,folic acid,61,71,Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects.,9758264_0,0
7605,side effects,148,160,"RESULTS: Of 60 epileptic women with periconceptional folic acid (0.8 mg)-containing multivitamin supplementation, no one developed epilepsy-related side effects during the periconception period.",9758264_2,1
16221,periconception,172,186,"RESULTS: Of 60 epileptic women with periconceptional folic acid (0.8 mg)-containing multivitamin supplementation, no one developed epilepsy-related side effects during the periconception period.",9758264_2,1
16220,mg)-containing multivitamin,69,96,"RESULTS: Of 60 epileptic women with periconceptional folic acid (0.8 mg)-containing multivitamin supplementation, no one developed epilepsy-related side effects during the periconception period.",9758264_2,0
16219,folic acid,53,63,"RESULTS: Of 60 epileptic women with periconceptional folic acid (0.8 mg)-containing multivitamin supplementation, no one developed epilepsy-related side effects during the periconception period.",9758264_2,0
7606,cleft lip,45,54,One epileptic woman delivered a newborn with cleft lip and palate.,9758264_3,1
16222,periconception,63,77,Another patient exhibited with a cluster of seizures after the periconception period using another multivitamin.,9758264_4,1
16223,carbamazepine,61,74,This 22-year-old epileptic woman was treated continuously by carbamazepine and a folic acid (1 mg)-containing multivitamin from the 20th week of gestation.,9758264_5,0
16224,folic acid (1 mg)-containing multivitamin,81,122,This 22-year-old epileptic woman was treated continuously by carbamazepine and a folic acid (1 mg)-containing multivitamin from the 20th week of gestation.,9758264_5,0
7607,status epilepticus,14,32,She developed status epilepticus and later symptoms of systemic lupus erythematodes.,9758264_6,1
16225,systemic lupus erythematodes,55,83,She developed status epilepticus and later symptoms of systemic lupus erythematodes.,9758264_6,1
4013,Her,0,3,Her pregnancy ended with stillbirth.,9758264_7,0
16229,folic acid,180,190,"CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.",9758264_8,0
16227,blood-brain barrier,112,131,"CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.",9758264_8,1
16226,patient's autoimmune disease,36,64,"CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.",9758264_8,1
7608,drug-induced,75,87,"CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures.",9758264_8,1
7610,epileptic seizures,147,165,"Physiological dose (<1 mg) of folic acid both in healthy and 60 epileptic women, all without any autoimmune disease, did not increase the risk for epileptic seizures.",9758264_9,1
7609,autoimmune disease,97,115,"Physiological dose (<1 mg) of folic acid both in healthy and 60 epileptic women, all without any autoimmune disease, did not increase the risk for epileptic seizures.",9758264_9,1
16230,Physiological dose,0,18,"Physiological dose (<1 mg) of folic acid both in healthy and 60 epileptic women, all without any autoimmune disease, did not increase the risk for epileptic seizures.",9758264_9,0
16231,folic acid,30,40,"Physiological dose (<1 mg) of folic acid both in healthy and 60 epileptic women, all without any autoimmune disease, did not increase the risk for epileptic seizures.",9758264_9,0
7611,Adverse effects,0,15,Adverse effects of the atypical antipsychotics.,9766615_0,1
7612,Adverse effects,0,15,Adverse effects of antipsychotics often lead to noncompliance.,9766615_2,1
7613,adverse effects,57,72,"Thus, clinicians should address patients' concerns about adverse effects and attempt to choose medications that will improve their patients' quality of life as well as overall health.",9766615_3,1
7614,side effect,4,15,The side effect profiles of the atypical antipsychotics are more advantageous than those of the conventional neuroleptics.,9766615_4,1
7616,extrapyramidal,91,105,"Conventional agents are associated with unwanted central nervous system effects, including extrapyramidal symptoms (EPS), tardive dyskinesia, sedation, and possible impairment of some cognitive measures, as well as cardiac effects, orthostatic hypotension, hepatic changes, anticholinergic side effects, sexual dysfunction, and weight gain.",9766615_5,1
7621,weight gain,328,339,"Conventional agents are associated with unwanted central nervous system effects, including extrapyramidal symptoms (EPS), tardive dyskinesia, sedation, and possible impairment of some cognitive measures, as well as cardiac effects, orthostatic hypotension, hepatic changes, anticholinergic side effects, sexual dysfunction, and weight gain.",9766615_5,1
7620,sexual dysfunction,304,322,"Conventional agents are associated with unwanted central nervous system effects, including extrapyramidal symptoms (EPS), tardive dyskinesia, sedation, and possible impairment of some cognitive measures, as well as cardiac effects, orthostatic hypotension, hepatic changes, anticholinergic side effects, sexual dysfunction, and weight gain.",9766615_5,1
7617,tardive dyskinesia,122,140,"Conventional agents are associated with unwanted central nervous system effects, including extrapyramidal symptoms (EPS), tardive dyskinesia, sedation, and possible impairment of some cognitive measures, as well as cardiac effects, orthostatic hypotension, hepatic changes, anticholinergic side effects, sexual dysfunction, and weight gain.",9766615_5,1
16236,Conventional agents,0,19,"Conventional agents are associated with unwanted central nervous system effects, including extrapyramidal symptoms (EPS), tardive dyskinesia, sedation, and possible impairment of some cognitive measures, as well as cardiac effects, orthostatic hypotension, hepatic changes, anticholinergic side effects, sexual dysfunction, and weight gain.",9766615_5,0
16238,cardiac effects,215,230,"Conventional agents are associated with unwanted central nervous system effects, including extrapyramidal symptoms (EPS), tardive dyskinesia, sedation, and possible impairment of some cognitive measures, as well as cardiac effects, orthostatic hypotension, hepatic changes, anticholinergic side effects, sexual dysfunction, and weight gain.",9766615_5,1
7618,orthostatic hypotension,232,255,"Conventional agents are associated with unwanted central nervous system effects, including extrapyramidal symptoms (EPS), tardive dyskinesia, sedation, and possible impairment of some cognitive measures, as well as cardiac effects, orthostatic hypotension, hepatic changes, anticholinergic side effects, sexual dysfunction, and weight gain.",9766615_5,1
7619,side effects,290,302,"Conventional agents are associated with unwanted central nervous system effects, including extrapyramidal symptoms (EPS), tardive dyskinesia, sedation, and possible impairment of some cognitive measures, as well as cardiac effects, orthostatic hypotension, hepatic changes, anticholinergic side effects, sexual dysfunction, and weight gain.",9766615_5,1
16239,hepatic changes,257,272,"Conventional agents are associated with unwanted central nervous system effects, including extrapyramidal symptoms (EPS), tardive dyskinesia, sedation, and possible impairment of some cognitive measures, as well as cardiac effects, orthostatic hypotension, hepatic changes, anticholinergic side effects, sexual dysfunction, and weight gain.",9766615_5,1
7615,central nervous system,49,71,"Conventional agents are associated with unwanted central nervous system effects, including extrapyramidal symptoms (EPS), tardive dyskinesia, sedation, and possible impairment of some cognitive measures, as well as cardiac effects, orthostatic hypotension, hepatic changes, anticholinergic side effects, sexual dysfunction, and weight gain.",9766615_5,1
7622,weight gain,154,165,"The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).",9766615_6,1
7623,sexual dysfunction,167,185,"The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).",9766615_6,1
16240,atypical agents,10,25,"The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).",9766615_6,0
16245,lowered seizure,204,219,"The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only).",9766615_6,1
7624,adverse effects,45,60,"Since the incidence and severity of specific adverse effects differ among the various atypicals, the clinician should carefully consider which side effects are most likely to lead to the individual's dissatisfaction and noncompliance before choosing an antipsychotic for a particular patient.",9766615_7,1
7625,side effects,143,155,"Since the incidence and severity of specific adverse effects differ among the various atypicals, the clinician should carefully consider which side effects are most likely to lead to the individual's dissatisfaction and noncompliance before choosing an antipsychotic for a particular patient.",9766615_7,1
7626,ischemic stroke,68,83,The association of cocaine and amphetamine use with hemorrhagic and ischemic stroke is based almost solely on data from case series.,9799166_1,1
7627,Alzheimer's disease,112,131,"A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease.",9812111_0,1
7629,Alzheimer's disease,191,210,OBJECTIVE: The goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with Alzheimer's disease.,9812111_1,1
7628,side effects,66,78,OBJECTIVE: The goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with Alzheimer's disease.,9812111_1,1
7635,Alzheimer's disease,101,120,The narrow therapeutic window observed with haloperidol may also apply to other neuroleptics used in Alzheimer's disease patients with psychosis and disruptive behaviors.,9812111_10,1
4014,low dose,165,173,"METHOD: In a 6-week random-assignment, double-blind, placebo-controlled trial (phase A), haloperidol, 2-3 mg/day (standard dose), and haloperidol, 0.50-0.75 mg/day (low dose), were compared in 71 outpatients with Alzheimer's disease.",9812111_2,0
7630,Alzheimer's disease,213,232,"METHOD: In a 6-week random-assignment, double-blind, placebo-controlled trial (phase A), haloperidol, 2-3 mg/day (standard dose), and haloperidol, 0.50-0.75 mg/day (low dose), were compared in 71 outpatients with Alzheimer's disease.",9812111_2,1
4015,low-dose,95,103,"For the subsequent 6-week double-blind crossover phase (phase B), patients taking standard- or low-dose haloperidol were switched to placebo, and patients taking placebo were randomly assigned to standard- or low-dose haloperidol.",9812111_3,0
4016,low-dose,209,217,"For the subsequent 6-week double-blind crossover phase (phase B), patients taking standard- or low-dose haloperidol were switched to placebo, and patients taking placebo were randomly assigned to standard- or low-dose haloperidol.",9812111_3,0
4017,low-dose,115,123,"RESULTS: For the 60 patients who completed phase A, standard-dose haloperidol was efficacious and superior to both low-dose haloperidol and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on psychomotor agitation.",9812111_4,0
16269,standard-dose haloperidol,52,77,"RESULTS: For the 60 patients who completed phase A, standard-dose haloperidol was efficacious and superior to both low-dose haloperidol and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on psychomotor agitation.",9812111_4,0
7631,psychomotor agitation,221,242,"RESULTS: For the 60 patients who completed phase A, standard-dose haloperidol was efficacious and superior to both low-dose haloperidol and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on psychomotor agitation.",9812111_4,1
4018,low dose,106,114,Response rates according to three sets of criteria were greater with the standard dose (55%-60%) than the low dose (25%-35%) and placebo (25%-30%).,9812111_5,0
4019,low dose,36,44,"The advantage of standard dose over low dose was replicated in phase B. In phase A, extrapyramidal signs tended to be greater with the standard dose than in the other two conditions, primarily because of a subgroup (20%) who developed moderate to severe signs.",9812111_6,0
7632,extrapyramidal,84,98,"The advantage of standard dose over low dose was replicated in phase B. In phase A, extrapyramidal signs tended to be greater with the standard dose than in the other two conditions, primarily because of a subgroup (20%) who developed moderate to severe signs.",9812111_6,1
4020,Low-dose,0,8,Low-dose haloperidol did not differ from placebo on any measure of efficacy or side effects.,9812111_7,0
7633,side effects,79,91,Low-dose haloperidol did not differ from placebo on any measure of efficacy or side effects.,9812111_7,1
7634,extrapyramidal,156,170,"CONCLUSIONS: The results indicated a favorable therapeutic profile for haloperidol in doses of 2-3 mg/day, although a subgroup developed moderate to severe extrapyramidal signs.",9812111_8,1
7636,Acute renal failure,0,19,Acute renal failure subsequent to the administration of rifampicin.,982002_0,1
4021,rifampicin,56,66,Acute renal failure subsequent to the administration of rifampicin.,982002_0,0
16284,acute stage,16,27,"Although in the acute stage the renal lesions histologically appeared toxic, evidence suggestive of an immunological mechanism cannot be excluded.",982002_11,1
16285,renal lesions,32,45,"Although in the acute stage the renal lesions histologically appeared toxic, evidence suggestive of an immunological mechanism cannot be excluded.",982002_11,1
7637,acute renal failure,72,91,A clinical presentation is made of a 2-3 year follow-up of six cases of acute renal failure that have been reported earlier.,982002_2,1
7638,renal failure,37,50,The patients had developed transient renal failure after the intermittent administration of rifampicin.,982002_3,1
4022,rifampicin,92,102,The patients had developed transient renal failure after the intermittent administration of rifampicin.,982002_3,0
16280,olig-anuria,13,24,"The stage of olig-anuria lasted for 1-3 weeks, and five of the patients were treated by hemodialysis.",982002_4,1
16283,Renal function,0,14,Renal function was normal.,982002_9,1
4024,dipyridamole,33,45,"Effects of acetylsalicylic acid, dipyridamole, and hydrocortisone on epinephrine-induced myocardial injury in dogs.",983936_0,0
4023,acetylsalicylic acid,11,31,"Effects of acetylsalicylic acid, dipyridamole, and hydrocortisone on epinephrine-induced myocardial injury in dogs.",983936_0,0
16288,myocardial injury,89,106,"Effects of acetylsalicylic acid, dipyridamole, and hydrocortisone on epinephrine-induced myocardial injury in dogs.",983936_0,1
7639,myocardial infarction,205,226,A reproducible model for producing diffuse myocardial injury (epinephrine infusion) has been developed to study the cardioprotective effects of agents or maneuvers which might alter the evolution of acute myocardial infarction.,983936_1,1
16289,myocardial injury,43,60,A reproducible model for producing diffuse myocardial injury (epinephrine infusion) has been developed to study the cardioprotective effects of agents or maneuvers which might alter the evolution of acute myocardial infarction.,983936_1,1
4025,cardioprotective,116,132,A reproducible model for producing diffuse myocardial injury (epinephrine infusion) has been developed to study the cardioprotective effects of agents or maneuvers which might alter the evolution of acute myocardial infarction.,983936_1,0
16291,mitochondrial,171,184,"Infusions of epinephrine (4 mug per kilogram per minute for 6 hours) increased radiocalcium uptakes into intact myocardium and each of its subcellular components with the mitochondrial fraction showing the most consistent changes when compared to saline-infused control animals (4,957 vs. 827 counts per minute per gram of dried tissue or fraction).",983936_2,0
16294,calcium chloride,13,29,Infusions of calcium chloride sufficient to raise serum calcium concentrations 2 mEq.,983936_4,0
16298,myocardial cell,53,68,per liter failed to increase calcium influx into the myocardial cell.,983936_5,1
4026,acetylsalicylic acid,91,111,"Mitochondrial radiocalcium uptakes were significantly decreased in animals pretreated with acetylsalicylic acid or dipyridamole or when hydrocortisone was added to the epinephrine infusion (2,682,2,803, and 3,424 counts per minute per gram of dried fraction, respectively).",983936_6,0
4027,dipyridamole,115,127,"Mitochondrial radiocalcium uptakes were significantly decreased in animals pretreated with acetylsalicylic acid or dipyridamole or when hydrocortisone was added to the epinephrine infusion (2,682,2,803, and 3,424 counts per minute per gram of dried fraction, respectively).",983936_6,0
16299,Mitochondrial,0,13,"Mitochondrial radiocalcium uptakes were significantly decreased in animals pretreated with acetylsalicylic acid or dipyridamole or when hydrocortisone was added to the epinephrine infusion (2,682,2,803, and 3,424 counts per minute per gram of dried fraction, respectively).",983936_6,0
16304,microscopic damage,12,30,Evidence of microscopic damage was graded as less severe in the three treatment groups.,983936_8,1
4030,cardioprotective,74,90,"Acetylsalicylic acid, dipyridamole, and hydrocortisone all appear to have cardioprotective effects when tested in this model.",983936_9,0
4028,Acetylsalicylic acid,0,20,"Acetylsalicylic acid, dipyridamole, and hydrocortisone all appear to have cardioprotective effects when tested in this model.",983936_9,0
4029,dipyridamole,22,34,"Acetylsalicylic acid, dipyridamole, and hydrocortisone all appear to have cardioprotective effects when tested in this model.",983936_9,0
16305,SM-5887,63,70,Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs.,9848575_0,0
16306,normal heart,75,87,Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs.,9848575_0,1
4031,anthracycline,37,50,Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs.,9848575_0,0
16307,doxorubicin-induced cardiomyopathy,92,126,Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs.,9848575_0,1
16309,SM-5887,76,83,This study was designed to investigate the chronic cardiotoxic potential of SM-5887 and a possible deteriorating effect of SM-5887 on low-grade cardiotoxicity pre-induced by doxorubicin in beagle dogs.,9848575_1,0
7640,cardiotoxicity,144,158,This study was designed to investigate the chronic cardiotoxic potential of SM-5887 and a possible deteriorating effect of SM-5887 on low-grade cardiotoxicity pre-induced by doxorubicin in beagle dogs.,9848575_1,1
4032,cardiotoxic,51,62,This study was designed to investigate the chronic cardiotoxic potential of SM-5887 and a possible deteriorating effect of SM-5887 on low-grade cardiotoxicity pre-induced by doxorubicin in beagle dogs.,9848575_1,0
16310,SM-5887,123,130,This study was designed to investigate the chronic cardiotoxic potential of SM-5887 and a possible deteriorating effect of SM-5887 on low-grade cardiotoxicity pre-induced by doxorubicin in beagle dogs.,9848575_1,0
16316,SM-5887,149,156,"In the chronic treatment, beagle dogs of each sex were given intravenously once every 3 weeks, either a sublethal dose of doxorubicin (1.5 mg/kg) or SM-5887 (2.5 mg/kg).",9848575_2,0
7642,blood pressure,294,308,"Animals which received over six courses of doxorubicin demonstrated the electrocardiogram (ECG) changes, decrease of blood pressure and high-grade histopathological cardiomyopathy, while animals which were terminally sacrificed after the SM-5887 administration did not show any changes in ECG, blood pressure and histopathological examinations.",9848575_4,1
7641,blood pressure,117,131,"Animals which received over six courses of doxorubicin demonstrated the electrocardiogram (ECG) changes, decrease of blood pressure and high-grade histopathological cardiomyopathy, while animals which were terminally sacrificed after the SM-5887 administration did not show any changes in ECG, blood pressure and histopathological examinations.",9848575_4,1
16319,SM-5887,238,245,"Animals which received over six courses of doxorubicin demonstrated the electrocardiogram (ECG) changes, decrease of blood pressure and high-grade histopathological cardiomyopathy, while animals which were terminally sacrificed after the SM-5887 administration did not show any changes in ECG, blood pressure and histopathological examinations.",9848575_4,0
16317,histopathological cardiomyopathy,147,179,"Animals which received over six courses of doxorubicin demonstrated the electrocardiogram (ECG) changes, decrease of blood pressure and high-grade histopathological cardiomyopathy, while animals which were terminally sacrificed after the SM-5887 administration did not show any changes in ECG, blood pressure and histopathological examinations.",9848575_4,1
4033,cardiotoxic,36,47,"To examine a possibly deteriorating cardiotoxic effect of SM-5887, low-grade cardiomyopathy was induced in dogs by four courses of doxorubicin (1.5 mg/kg).",9848575_5,0
16322,low-grade cardiomyopathy,67,91,"To examine a possibly deteriorating cardiotoxic effect of SM-5887, low-grade cardiomyopathy was induced in dogs by four courses of doxorubicin (1.5 mg/kg).",9848575_5,1
16321,SM-5887,58,65,"To examine a possibly deteriorating cardiotoxic effect of SM-5887, low-grade cardiomyopathy was induced in dogs by four courses of doxorubicin (1.5 mg/kg).",9848575_5,0
16324,SM-5887,98,105,"Nine weeks after pre-treatment, dogs were given four courses of either doxorubicin (1.5 mg/kg) or SM-5887 (2.5 mg/kg) once every 3 weeks.",9848575_6,0
4034,cardiotoxic,14,25,The low-grade cardiotoxic changes were enhanced by the additional doxorubicin treatment.,9848575_7,0
16326,grade of cardiomyopathy,60,83,"On the contrary, the SM-5887 treatment did not progress the grade of cardiomyopathy.",9848575_8,1
16325,SM-5887,21,28,"On the contrary, the SM-5887 treatment did not progress the grade of cardiomyopathy.",9848575_8,0
7644,cardiotoxicity,125,139,"In conclusion, SM-5887 does not have any potential of chronic cardiotoxicity and deteriorating effect on doxorubicin-induced cardiotoxicity in dogs.",9848575_9,1
16327,SM-5887,15,22,"In conclusion, SM-5887 does not have any potential of chronic cardiotoxicity and deteriorating effect on doxorubicin-induced cardiotoxicity in dogs.",9848575_9,0
7643,cardiotoxicity,62,76,"In conclusion, SM-5887 does not have any potential of chronic cardiotoxicity and deteriorating effect on doxorubicin-induced cardiotoxicity in dogs.",9848575_9,1
16329,renal allografts,44,60,Clinical and histopathologic examination of renal allografts treated with tacrolimus (FK506) for at least one year.,9855119_0,1
4036,FK506,86,91,Clinical and histopathologic examination of renal allografts treated with tacrolimus (FK506) for at least one year.,9855119_0,0
4035,tacrolimus,74,84,Clinical and histopathologic examination of renal allografts treated with tacrolimus (FK506) for at least one year.,9855119_0,0
16331,renal transplant,80,96,BACKGROUND: We clinically and pathologically analyzed renal allografts from 1 9 renal transplant patients treated with tacrolimus (FK506) for more than 1 year.,9855119_1,1
4037,tacrolimus,119,129,BACKGROUND: We clinically and pathologically analyzed renal allografts from 1 9 renal transplant patients treated with tacrolimus (FK506) for more than 1 year.,9855119_1,0
4038,FK506,131,136,BACKGROUND: We clinically and pathologically analyzed renal allografts from 1 9 renal transplant patients treated with tacrolimus (FK506) for more than 1 year.,9855119_1,0
16330,renal allografts,54,70,BACKGROUND: We clinically and pathologically analyzed renal allografts from 1 9 renal transplant patients treated with tacrolimus (FK506) for more than 1 year.,9855119_1,1
16332,renal allograft,20,35,METHODS: Twenty-six renal allograft biopsy specimens from 1 9 renal transplant patients who underwent transplantations between 1991 and 1993 were evaluated.,9855119_2,1
16334,renal transplant,62,78,METHODS: Twenty-six renal allograft biopsy specimens from 1 9 renal transplant patients who underwent transplantations between 1991 and 1993 were evaluated.,9855119_2,1
16343,AR+CR,117,122,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,0
16341,acute rejection,59,74,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,1
4039,FK506,210,215,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,0
4040,FK506,251,256,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,0
7645,IgA nephropathy,141,156,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,1
16342,chronic rejection,88,105,"RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11).",9855119_4,1
4041,FK506,87,92,"Of the nonepisode biopsies, 7 and 4 biopsies showed minimal-type and mild-type chronic FK506 nephropathy, respectively.",9855119_5,0
16345,nonepisode,7,17,"Of the nonepisode biopsies, 7 and 4 biopsies showed minimal-type and mild-type chronic FK506 nephropathy, respectively.",9855119_5,0
7647,focal segmental glomerulosclerosis,163,197,"Chronic FK506 nephropathy consisted of rough and foamy tubular vacuolization (5 biopsies), arteriolopathy (angiodegeneration of the arteriolar wall; 20 biopsies), focal segmental glomerulosclerosis (4 biopsies) and the striped form of interstitial fibrosis (11 biopsies).",9855119_6,1
16350,interstitial fibrosis,235,256,"Chronic FK506 nephropathy consisted of rough and foamy tubular vacuolization (5 biopsies), arteriolopathy (angiodegeneration of the arteriolar wall; 20 biopsies), focal segmental glomerulosclerosis (4 biopsies) and the striped form of interstitial fibrosis (11 biopsies).",9855119_6,1
16349,arteriolar wall,132,147,"Chronic FK506 nephropathy consisted of rough and foamy tubular vacuolization (5 biopsies), arteriolopathy (angiodegeneration of the arteriolar wall; 20 biopsies), focal segmental glomerulosclerosis (4 biopsies) and the striped form of interstitial fibrosis (11 biopsies).",9855119_6,1
16348,angiodegeneration,107,124,"Chronic FK506 nephropathy consisted of rough and foamy tubular vacuolization (5 biopsies), arteriolopathy (angiodegeneration of the arteriolar wall; 20 biopsies), focal segmental glomerulosclerosis (4 biopsies) and the striped form of interstitial fibrosis (11 biopsies).",9855119_6,1
16347,tubular vacuolization,55,76,"Chronic FK506 nephropathy consisted of rough and foamy tubular vacuolization (5 biopsies), arteriolopathy (angiodegeneration of the arteriolar wall; 20 biopsies), focal segmental glomerulosclerosis (4 biopsies) and the striped form of interstitial fibrosis (11 biopsies).",9855119_6,1
4042,FK506,8,13,"Chronic FK506 nephropathy consisted of rough and foamy tubular vacuolization (5 biopsies), arteriolopathy (angiodegeneration of the arteriolar wall; 20 biopsies), focal segmental glomerulosclerosis (4 biopsies) and the striped form of interstitial fibrosis (11 biopsies).",9855119_6,0
7646,arteriolopathy,91,105,"Chronic FK506 nephropathy consisted of rough and foamy tubular vacuolization (5 biopsies), arteriolopathy (angiodegeneration of the arteriolar wall; 20 biopsies), focal segmental glomerulosclerosis (4 biopsies) and the striped form of interstitial fibrosis (11 biopsies).",9855119_6,1
4044,FK506,65,70,"The serum creatinine levels of patients in the mild-type chronic FK506 nephropathy group, which included 7 episode biopsies, were statistically higher than those in the minimum-type chronic FK506-nephropathy group (P< 0.001).",9855119_7,0
4043,creatinine,10,20,"The serum creatinine levels of patients in the mild-type chronic FK506 nephropathy group, which included 7 episode biopsies, were statistically higher than those in the minimum-type chronic FK506-nephropathy group (P< 0.001).",9855119_7,0
4046,FK506,202,207,"CONCLUSIONS: This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall, and suggests that mild-type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function.",9855119_8,0
4045,FK506,50,55,"CONCLUSIONS: This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall, and suggests that mild-type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function.",9855119_8,0
16354,renal allograft,270,285,"CONCLUSIONS: This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall, and suggests that mild-type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function.",9855119_8,1
16352,arteriolar wall,149,164,"CONCLUSIONS: This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall, and suggests that mild-type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function.",9855119_8,1
7648,arteriolopathy,90,104,"CONCLUSIONS: This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall, and suggests that mild-type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function.",9855119_8,1
7649,hyalinosis,131,141,"CONCLUSIONS: This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall, and suggests that mild-type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function.",9855119_8,1
16355,tight junctions,54,69,Different lobular distributions of altered hepatocyte tight junctions in rat models of intrahepatic and extrahepatic cholestasis.,9862868_0,0
7650,intrahepatic,87,99,Different lobular distributions of altered hepatocyte tight junctions in rat models of intrahepatic and extrahepatic cholestasis.,9862868_0,1
7651,extrahepatic cholestasis,104,128,Different lobular distributions of altered hepatocyte tight junctions in rat models of intrahepatic and extrahepatic cholestasis.,9862868_0,1
4047,hepatocyte,43,53,Different lobular distributions of altered hepatocyte tight junctions in rat models of intrahepatic and extrahepatic cholestasis.,9862868_0,0
4048,Hepatocyte,0,10,"Hepatocyte tight junctions (TJs), the only intercellular barrier between the sinusoidal and the canalicular spaces, play a key role in bile formation.",9862868_1,0
16356,TJs,28,31,"Hepatocyte tight junctions (TJs), the only intercellular barrier between the sinusoidal and the canalicular spaces, play a key role in bile formation.",9862868_1,0
16389,7H6,50,53,"After EE treatment, changes in immunostaining for 7H6 and ZO-1 were similar to those seen in periportal hepatocytes after BDL, but distributed more diffusely throughout the lobule.",9862868_10,0
16390,ZO-1,58,62,"After EE treatment, changes in immunostaining for 7H6 and ZO-1 were similar to those seen in periportal hepatocytes after BDL, but distributed more diffusely throughout the lobule.",9862868_10,0
16392,BDL,122,125,"After EE treatment, changes in immunostaining for 7H6 and ZO-1 were similar to those seen in periportal hepatocytes after BDL, but distributed more diffusely throughout the lobule.",9862868_10,0
16396,BDL,143,146,This study is the first to demonstrate that impairment of hepatocyte TJs occurs heterogenously in the liver lobule after BDL and suggests that BDL and EE treatments produce different lobular distributions of increased paracellular permeability.,9862868_11,0
16394,liver lobule,102,114,This study is the first to demonstrate that impairment of hepatocyte TJs occurs heterogenously in the liver lobule after BDL and suggests that BDL and EE treatments produce different lobular distributions of increased paracellular permeability.,9862868_11,1
16395,BDL,121,124,This study is the first to demonstrate that impairment of hepatocyte TJs occurs heterogenously in the liver lobule after BDL and suggests that BDL and EE treatments produce different lobular distributions of increased paracellular permeability.,9862868_11,0
16393,hepatocyte TJs,58,72,This study is the first to demonstrate that impairment of hepatocyte TJs occurs heterogenously in the liver lobule after BDL and suggests that BDL and EE treatments produce different lobular distributions of increased paracellular permeability.,9862868_11,0
16359,hepatocyte TJs,9,23,"Although hepatocyte TJs are impaired in cholestasis, attempts to localize the precise site of hepatocyte TJ damage by freeze-fracture electron microscopy have produced limited information.",9862868_2,0
16360,hepatocyte TJ,94,107,"Although hepatocyte TJs are impaired in cholestasis, attempts to localize the precise site of hepatocyte TJ damage by freeze-fracture electron microscopy have produced limited information.",9862868_2,0
16362,ZO-1,46,50,"Recently, several TJ-associated proteins like ZO-1 and 7H6 have been identified and characterized.",9862868_3,0
16363,7H6,55,58,"Recently, several TJ-associated proteins like ZO-1 and 7H6 have been identified and characterized.",9862868_3,0
16366,paracellular permeability,60,85,Immunolocalization of 7H6 appears to closely correlate with paracellular permeability.,9862868_4,1
16365,7H6,22,25,Immunolocalization of 7H6 appears to closely correlate with paracellular permeability.,9862868_4,0
16367,bile duct ligation,115,133,We used rat models of intrahepatic cholestasis by ethinyl estradiol (EE) treatment and extrahepatic cholestasis by bile duct ligation (BDL) to precisely determine the site of TJ damage.,9862868_5,1
4049,ethinyl estradiol,50,67,We used rat models of intrahepatic cholestasis by ethinyl estradiol (EE) treatment and extrahepatic cholestasis by bile duct ligation (BDL) to precisely determine the site of TJ damage.,9862868_5,0
16368,BDL,135,138,We used rat models of intrahepatic cholestasis by ethinyl estradiol (EE) treatment and extrahepatic cholestasis by bile duct ligation (BDL) to precisely determine the site of TJ damage.,9862868_5,0
16369,TJ,175,177,We used rat models of intrahepatic cholestasis by ethinyl estradiol (EE) treatment and extrahepatic cholestasis by bile duct ligation (BDL) to precisely determine the site of TJ damage.,9862868_5,0
7652,intrahepatic cholestasis,22,46,We used rat models of intrahepatic cholestasis by ethinyl estradiol (EE) treatment and extrahepatic cholestasis by bile duct ligation (BDL) to precisely determine the site of TJ damage.,9862868_5,1
7653,extrahepatic cholestasis,87,111,We used rat models of intrahepatic cholestasis by ethinyl estradiol (EE) treatment and extrahepatic cholestasis by bile duct ligation (BDL) to precisely determine the site of TJ damage.,9862868_5,1
16370,hepatocyte TJs,15,29,Alterations in hepatocyte TJs were assessed by double-immunolabeling for 7H6 and ZO-1 using a confocal laser scanning microscope.,9862868_6,0
16372,7H6,73,76,Alterations in hepatocyte TJs were assessed by double-immunolabeling for 7H6 and ZO-1 using a confocal laser scanning microscope.,9862868_6,0
16373,ZO-1,81,85,Alterations in hepatocyte TJs were assessed by double-immunolabeling for 7H6 and ZO-1 using a confocal laser scanning microscope.,9862868_6,0
16376,7H6,36,39,"In control rats, immunostaining for 7H6 and ZO-1 colocalized to outline bile canaliculi in a continuous fashion.",9862868_7,0
16377,ZO-1,44,48,"In control rats, immunostaining for 7H6 and ZO-1 colocalized to outline bile canaliculi in a continuous fashion.",9862868_7,0
16378,bile canaliculi,72,87,"In control rats, immunostaining for 7H6 and ZO-1 colocalized to outline bile canaliculi in a continuous fashion.",9862868_7,1
16380,7H6,13,16,"In contrast, 7H6 and ZO-1 immunostaining was more discontinuous, outlining the bile canaliculi after BDL.",9862868_8,0
16382,bile canaliculi,79,94,"In contrast, 7H6 and ZO-1 immunostaining was more discontinuous, outlining the bile canaliculi after BDL.",9862868_8,1
16381,ZO-1,21,25,"In contrast, 7H6 and ZO-1 immunostaining was more discontinuous, outlining the bile canaliculi after BDL.",9862868_8,0
16383,BDL,101,104,"In contrast, 7H6 and ZO-1 immunostaining was more discontinuous, outlining the bile canaliculi after BDL.",9862868_8,0
16387,BDL,154,157,"Immunostaining for 7H6, not ZO-1, decreased and predominantly appeared as discrete signals in the submembranous cytoplasm of periportal hepatocytes after BDL.",9862868_9,0
16384,7H6,19,22,"Immunostaining for 7H6, not ZO-1, decreased and predominantly appeared as discrete signals in the submembranous cytoplasm of periportal hepatocytes after BDL.",9862868_9,0
16386,periportal hepatocytes,125,147,"Immunostaining for 7H6, not ZO-1, decreased and predominantly appeared as discrete signals in the submembranous cytoplasm of periportal hepatocytes after BDL.",9862868_9,1
16385,ZO-1,28,32,"Immunostaining for 7H6, not ZO-1, decreased and predominantly appeared as discrete signals in the submembranous cytoplasm of periportal hepatocytes after BDL.",9862868_9,0
4050,fenfluramine,47,59,Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication.,9867728_0,0
7654,valvular heart disease,9,31,Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication.,9867728_0,1
4051,dexfenfluramine,64,79,Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication.,9867728_0,0
4053,dexfenfluramine,120,135,"BACKGROUND: Because uncontrolled echocardiographic surveys suggested that up to 30% to 38% of users of fenfluramine and dexfenfluramine had valvular disease, these drugs were withdrawn from the market.",9867728_1,0
4052,fenfluramine,103,115,"BACKGROUND: Because uncontrolled echocardiographic surveys suggested that up to 30% to 38% of users of fenfluramine and dexfenfluramine had valvular disease, these drugs were withdrawn from the market.",9867728_1,0
7655,valvular disease,140,156,"BACKGROUND: Because uncontrolled echocardiographic surveys suggested that up to 30% to 38% of users of fenfluramine and dexfenfluramine had valvular disease, these drugs were withdrawn from the market.",9867728_1,1
16406,aortic insufficiency,42,62,The second patient developed new moderate aortic insufficiency.,9867728_10,1
16407,diet medications,21,37,CONCLUSION: Users of diet medications are at risk for valvular heart disease.,9867728_11,0
7662,valvular heart disease,54,76,CONCLUSION: Users of diet medications are at risk for valvular heart disease.,9867728_11,1
16399,valvular abnormalities,54,76,OBJECTIVE: To determine the risk for new or worsening valvular abnormalities among users of fenfluramine or dexfenfluramine who underwent echocardiography before they began to take these medications.,9867728_2,1
4055,dexfenfluramine,108,123,OBJECTIVE: To determine the risk for new or worsening valvular abnormalities among users of fenfluramine or dexfenfluramine who underwent echocardiography before they began to take these medications.,9867728_2,0
4054,fenfluramine,92,104,OBJECTIVE: To determine the risk for new or worsening valvular abnormalities among users of fenfluramine or dexfenfluramine who underwent echocardiography before they began to take these medications.,9867728_2,0
4057,dexfenfluramine,47,62,PATIENTS: 46 patients who used fenfluramine or dexfenfluramine for 14 days or more and had echocardiograms obtained before therapy.,9867728_5,0
4056,fenfluramine,31,43,PATIENTS: 46 patients who used fenfluramine or dexfenfluramine for 14 days or more and had echocardiograms obtained before therapy.,9867728_5,0
7656,mitral regurgitation,98,118,"The primary outcome was new or worsening valvulopathy, defined as progression of either aortic or mitral regurgitation by at least one degree of severity and disease that met U.S. Food and Drug Administration criteria (at least mild aortic regurgitation or moderate mitral regurgitation).",9867728_7,1
7657,aortic regurgitation,233,253,"The primary outcome was new or worsening valvulopathy, defined as progression of either aortic or mitral regurgitation by at least one degree of severity and disease that met U.S. Food and Drug Administration criteria (at least mild aortic regurgitation or moderate mitral regurgitation).",9867728_7,1
7658,mitral regurgitation,266,286,"The primary outcome was new or worsening valvulopathy, defined as progression of either aortic or mitral regurgitation by at least one degree of severity and disease that met U.S. Food and Drug Administration criteria (at least mild aortic regurgitation or moderate mitral regurgitation).",9867728_7,1
16404,valvulopathy,41,53,"The primary outcome was new or worsening valvulopathy, defined as progression of either aortic or mitral regurgitation by at least one degree of severity and disease that met U.S. Food and Drug Administration criteria (at least mild aortic regurgitation or moderate mitral regurgitation).",9867728_7,1
16405,fenfluramine-phentermine,63,87,"RESULTS: Two patients (4.3% [95% CI, 0.6% to 14.8%]) receiving fenfluramine-phentermine developed valvular heart disease.",9867728_8,0
7659,valvular heart disease,98,120,"RESULTS: Two patients (4.3% [95% CI, 0.6% to 14.8%]) receiving fenfluramine-phentermine developed valvular heart disease.",9867728_8,1
7660,bicuspid aortic valve,17,38,One had baseline bicuspid aortic valve and mild aortic regurgitation that progressed to moderate regurgitation.,9867728_9,1
7661,aortic regurgitation,48,68,One had baseline bicuspid aortic valve and mild aortic regurgitation that progressed to moderate regurgitation.,9867728_9,1
4058,nerve growth factor,50,69,"Memory facilitation and stimulation of endogenous nerve growth factor synthesis by the acetylcholine releaser PG-9.The effects of PG-9 (3alpha-tropyl 2-(p-bromophenyl)propionate), the acetylcholine releaser, on memory processes and nerve growth factor (NGF) synthesis were evaluated.",9869257_0,0
16413,3alpha-tropyl 2-(p-bromophenyl)propionate,136,177,"Memory facilitation and stimulation of endogenous nerve growth factor synthesis by the acetylcholine releaser PG-9.The effects of PG-9 (3alpha-tropyl 2-(p-bromophenyl)propionate), the acetylcholine releaser, on memory processes and nerve growth factor (NGF) synthesis were evaluated.",9869257_0,0
16412,PG-9,130,134,"Memory facilitation and stimulation of endogenous nerve growth factor synthesis by the acetylcholine releaser PG-9.The effects of PG-9 (3alpha-tropyl 2-(p-bromophenyl)propionate), the acetylcholine releaser, on memory processes and nerve growth factor (NGF) synthesis were evaluated.",9869257_0,0
16410,PG-9.The,110,118,"Memory facilitation and stimulation of endogenous nerve growth factor synthesis by the acetylcholine releaser PG-9.The effects of PG-9 (3alpha-tropyl 2-(p-bromophenyl)propionate), the acetylcholine releaser, on memory processes and nerve growth factor (NGF) synthesis were evaluated.",9869257_0,0
16409,acetylcholine releaser,87,109,"Memory facilitation and stimulation of endogenous nerve growth factor synthesis by the acetylcholine releaser PG-9.The effects of PG-9 (3alpha-tropyl 2-(p-bromophenyl)propionate), the acetylcholine releaser, on memory processes and nerve growth factor (NGF) synthesis were evaluated.",9869257_0,0
4059,nerve growth factor,232,251,"Memory facilitation and stimulation of endogenous nerve growth factor synthesis by the acetylcholine releaser PG-9.The effects of PG-9 (3alpha-tropyl 2-(p-bromophenyl)propionate), the acetylcholine releaser, on memory processes and nerve growth factor (NGF) synthesis were evaluated.",9869257_0,0
16414,acetylcholine releaser,184,206,"Memory facilitation and stimulation of endogenous nerve growth factor synthesis by the acetylcholine releaser PG-9.The effects of PG-9 (3alpha-tropyl 2-(p-bromophenyl)propionate), the acetylcholine releaser, on memory processes and nerve growth factor (NGF) synthesis were evaluated.",9869257_0,0
16420,antimuscarinic drug scopolamine,164,195,"In the mouse passive-avoidance test, PG-9 (10-30 mg/kg, i.p.), administered 20 min before the training session, prevented amnesia induced by both the non selective antimuscarinic drug scopolamine and the M1-selective antagonist S-(-)-ET-126.",9869257_1,0
16417,PG-9,37,41,"In the mouse passive-avoidance test, PG-9 (10-30 mg/kg, i.p.), administered 20 min before the training session, prevented amnesia induced by both the non selective antimuscarinic drug scopolamine and the M1-selective antagonist S-(-)-ET-126.",9869257_1,0
16424,microg,48,54,"In the same experimental conditions, PG-9 (5-20 microg per mouse, i.c.v.) was also able to prevent antimuscarine-induced amnesia, demonstrating a central localization of the activity.",9869257_2,0
16423,PG-9,37,41,"In the same experimental conditions, PG-9 (5-20 microg per mouse, i.c.v.) was also able to prevent antimuscarine-induced amnesia, demonstrating a central localization of the activity.",9869257_2,0
16427,PG-9,32,36,"At the highest effective doses, PG-9 did not produce any collateral symptoms as revealed by the Irwin test, and it did not modify spontaneous motility and inspection activity, as revealed by the hole-board test.",9869257_3,0
16428,collateral symptoms,57,76,"At the highest effective doses, PG-9 did not produce any collateral symptoms as revealed by the Irwin test, and it did not modify spontaneous motility and inspection activity, as revealed by the hole-board test.",9869257_3,1
16431,PG-9,0,4,PG-9 was also able to increase the amount of NGF secreted in vitro by astrocytes in a dose-dependent manner.,9869257_4,0
16434,PG-9,37,41,The maximal NGF contents obtained by PG-9 were 17.6-fold of the control value.,9869257_5,0
16436,PG-9,83,87,"During culture, no morphological changes were found at effective concentrations of PG-9.",9869257_6,0
16437,PG-9,42,46,The current work indicates the ability of PG-9 to induce beneficial effects on cognitive processes and stimulate activity of NGF synthesis in astroglial cells.,9869257_7,0
16441,PG-9,11,15,"Therefore, PG-9 could represent a potential useful drug able to improve the function of impaired cognitive processes.",9869257_8,0
16443,dosage schedules,73,89,Therapeutic drug monitoring of tobramycin: once-daily versus twice-daily dosage schedules.,9875685_0,0
16445,tobramicyn,84,94,OBJECTIVE: To evaluate the effect of dosage regimen (once-daily vs. twice-daily) of tobramicyn on steady-state serum concentrations and toxicity.,9875685_1,0
4060,creatinine,16,26,"Increased serum creatinine was observed in 73% of patients in OD versus 57% of patients in TD, without evidence of nephrotoxicity.",9875685_12,0
16460,nephrotoxicity,115,129,"Increased serum creatinine was observed in 73% of patients in OD versus 57% of patients in TD, without evidence of nephrotoxicity.",9875685_12,1
16461,auditory function,48,65,"In TD group, three patients developed decreased auditory function, of which one presented with an auditory loss of -30 dB, whereas in the OD group only one patient presented decreased auditory function.",9875685_13,1
16462,auditory function,184,201,"In TD group, three patients developed decreased auditory function, of which one presented with an auditory loss of -30 dB, whereas in the OD group only one patient presented decreased auditory function.",9875685_13,1
7664,loss of,107,114,"In TD group, three patients developed decreased auditory function, of which one presented with an auditory loss of -30 dB, whereas in the OD group only one patient presented decreased auditory function.",9875685_13,1
16464,single-dose,8,19,"Using a single-dose therapy, peak concentration determination is not necessary, only trough samples should be monitored to ensure levels below 2 microg/ml.",9875685_15,0
16447,TD,69,71,Group OD (n = 22) received a once-daily dose of tobramycin and group TD (n = 21) received the same dose divided into two doses daily.,9875685_3,0
16450,renal function,82,96,"RESULTS: The two groups were comparable with respect to sex, age, body weight and renal function.",9875685_6,1
7663,body weight,66,77,"RESULTS: The two groups were comparable with respect to sex, age, body weight and renal function.",9875685_6,1
16451,cumulative dose,98,113,"No statistically significant differences were found in mean daily dose, duration of treatment, or cumulative dose.",9875685_7,0
16452,TD,81,83,Peak concentrations were > 6 microg/ml in 100% of the OD group and in 67% of the TD group (P< 0.01).,9875685_9,0
4061,beta-adrenoceptor antagonists,32,61,Enhanced bradycardia induced by beta-adrenoceptor antagonists in rats pretreated with isoniazid.,9915601_0,0
16467,reflex tachycardia,97,115,"High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).",9915601_1,1
16466,High doses,0,10,"High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).",9915601_1,0
4062,gamma-aminobutyric acid,190,213,"High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA).",9915601_1,0
4063,beta-adrenoceptor antagonists,86,115,"In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.",9915601_2,0
16468,chloralose-urethane,158,177,"In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane.",9915601_2,0
4064,propranolol,52,63,"Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.",9915601_3,0
4065,hexamethonium,141,154,"Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.",9915601_3,0
4066,carbachol,158,167,"Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol.",9915601_3,0
16469,methylatropine,53,67,Enhancement was not observed in rats pretreated with methylatropine or previously vagotomised.,9915601_4,0
4067,GABAergic,65,74,These results are compatible with interference by isoniazid with GABAergic inhibition of cardiac parasympathetic tone.,9915601_5,0
16470,parasympathetic tone,97,117,These results are compatible with interference by isoniazid with GABAergic inhibition of cardiac parasympathetic tone.,9915601_5,1
7665,ambiguus,70,78,"Such interference could be exerted centrally, possibly at the nucleus ambiguus, or peripherally at the sinus node.",9915601_6,1
7666,sinus node,103,113,"Such interference could be exerted centrally, possibly at the nucleus ambiguus, or peripherally at the sinus node.",9915601_6,1
4068,FK 506,66,72,"Mechanisms of FK 506-induced hypertension in the rat.-Tacrolimus (FK 506) is a powerful, widely used immunosuppressant.",9931093_0,0
16471,FK,14,16,"Mechanisms of FK 506-induced hypertension in the rat.-Tacrolimus (FK 506) is a powerful, widely used immunosuppressant.",9931093_0,0
4069,FK 506,24,30,The clinical utility of FK 506 is complicated by substantial hypertension and nephrotoxicity.,9931093_1,0
16473,substantial hypertension,49,73,The clinical utility of FK 506 is complicated by substantial hypertension and nephrotoxicity.,9931093_1,1
16474,nephrotoxicity,78,92,The clinical utility of FK 506 is complicated by substantial hypertension and nephrotoxicity.,9931093_1,1
16498,d-1,0,3,d-1) prevented FK 506-induced hypertension in rats.,9931093_10,0
16499,FK,15,17,d-1) prevented FK 506-induced hypertension in rats.,9931093_10,0
16500,ET-1,86,90,These results indicate that FK 506 may increase blood pressure not only by increasing ET-1 production but also by decreasing NO synthesis in the vasculature.,9931093_11,0
4077,FK 506,28,34,These results indicate that FK 506 may increase blood pressure not only by increasing ET-1 production but also by decreasing NO synthesis in the vasculature.,9931093_11,0
7668,blood pressure,48,62,These results indicate that FK 506 may increase blood pressure not only by increasing ET-1 production but also by decreasing NO synthesis in the vasculature.,9931093_11,1
4074,C-type natriuretic peptide,309,335,"To clarify the mechanisms of FK 506-induced hypertension, we studied the chronic effects of FK 506 on the synthesis of endothelin-1 (ET-1), the expression of mRNA of ET-1 and endothelin-converting enzyme-1 (ECE-1), the endothelial nitric oxide synthase (eNOS) activity, and the expression of mRNA of eNOS and C-type natriuretic peptide (CNP) in rat blood vessels.",9931093_2,0
4070,FK 506,92,98,"To clarify the mechanisms of FK 506-induced hypertension, we studied the chronic effects of FK 506 on the synthesis of endothelin-1 (ET-1), the expression of mRNA of ET-1 and endothelin-converting enzyme-1 (ECE-1), the endothelial nitric oxide synthase (eNOS) activity, and the expression of mRNA of eNOS and C-type natriuretic peptide (CNP) in rat blood vessels.",9931093_2,0
4071,endothelin-1,119,131,"To clarify the mechanisms of FK 506-induced hypertension, we studied the chronic effects of FK 506 on the synthesis of endothelin-1 (ET-1), the expression of mRNA of ET-1 and endothelin-converting enzyme-1 (ECE-1), the endothelial nitric oxide synthase (eNOS) activity, and the expression of mRNA of eNOS and C-type natriuretic peptide (CNP) in rat blood vessels.",9931093_2,0
4072,endothelin-converting enzyme-1,175,205,"To clarify the mechanisms of FK 506-induced hypertension, we studied the chronic effects of FK 506 on the synthesis of endothelin-1 (ET-1), the expression of mRNA of ET-1 and endothelin-converting enzyme-1 (ECE-1), the endothelial nitric oxide synthase (eNOS) activity, and the expression of mRNA of eNOS and C-type natriuretic peptide (CNP) in rat blood vessels.",9931093_2,0
4073,endothelial nitric oxide synthase,219,252,"To clarify the mechanisms of FK 506-induced hypertension, we studied the chronic effects of FK 506 on the synthesis of endothelin-1 (ET-1), the expression of mRNA of ET-1 and endothelin-converting enzyme-1 (ECE-1), the endothelial nitric oxide synthase (eNOS) activity, and the expression of mRNA of eNOS and C-type natriuretic peptide (CNP) in rat blood vessels.",9931093_2,0
16475,FK,29,31,"To clarify the mechanisms of FK 506-induced hypertension, we studied the chronic effects of FK 506 on the synthesis of endothelin-1 (ET-1), the expression of mRNA of ET-1 and endothelin-converting enzyme-1 (ECE-1), the endothelial nitric oxide synthase (eNOS) activity, and the expression of mRNA of eNOS and C-type natriuretic peptide (CNP) in rat blood vessels.",9931093_2,0
16477,ET-1,133,137,"To clarify the mechanisms of FK 506-induced hypertension, we studied the chronic effects of FK 506 on the synthesis of endothelin-1 (ET-1), the expression of mRNA of ET-1 and endothelin-converting enzyme-1 (ECE-1), the endothelial nitric oxide synthase (eNOS) activity, and the expression of mRNA of eNOS and C-type natriuretic peptide (CNP) in rat blood vessels.",9931093_2,0
16478,ET-1,166,170,"To clarify the mechanisms of FK 506-induced hypertension, we studied the chronic effects of FK 506 on the synthesis of endothelin-1 (ET-1), the expression of mRNA of ET-1 and endothelin-converting enzyme-1 (ECE-1), the endothelial nitric oxide synthase (eNOS) activity, and the expression of mRNA of eNOS and C-type natriuretic peptide (CNP) in rat blood vessels.",9931093_2,0
16479,ECE-1,207,212,"To clarify the mechanisms of FK 506-induced hypertension, we studied the chronic effects of FK 506 on the synthesis of endothelin-1 (ET-1), the expression of mRNA of ET-1 and endothelin-converting enzyme-1 (ECE-1), the endothelial nitric oxide synthase (eNOS) activity, and the expression of mRNA of eNOS and C-type natriuretic peptide (CNP) in rat blood vessels.",9931093_2,0
16480,eNOS,254,258,"To clarify the mechanisms of FK 506-induced hypertension, we studied the chronic effects of FK 506 on the synthesis of endothelin-1 (ET-1), the expression of mRNA of ET-1 and endothelin-converting enzyme-1 (ECE-1), the endothelial nitric oxide synthase (eNOS) activity, and the expression of mRNA of eNOS and C-type natriuretic peptide (CNP) in rat blood vessels.",9931093_2,0
16481,eNOS,300,304,"To clarify the mechanisms of FK 506-induced hypertension, we studied the chronic effects of FK 506 on the synthesis of endothelin-1 (ET-1), the expression of mRNA of ET-1 and endothelin-converting enzyme-1 (ECE-1), the endothelial nitric oxide synthase (eNOS) activity, and the expression of mRNA of eNOS and C-type natriuretic peptide (CNP) in rat blood vessels.",9931093_2,0
16482,CNP,337,340,"To clarify the mechanisms of FK 506-induced hypertension, we studied the chronic effects of FK 506 on the synthesis of endothelin-1 (ET-1), the expression of mRNA of ET-1 and endothelin-converting enzyme-1 (ECE-1), the endothelial nitric oxide synthase (eNOS) activity, and the expression of mRNA of eNOS and C-type natriuretic peptide (CNP) in rat blood vessels.",9931093_2,0
16484,endothelin type A receptor antagonist,40,77,"In addition, the effect of the specific endothelin type A receptor antagonist FR 139317 on FK 506-induced hypertension in rats was studied.",9931093_3,0
16485,FK,91,93,"In addition, the effect of the specific endothelin type A receptor antagonist FR 139317 on FK 506-induced hypertension in rats was studied.",9931093_3,0
4075,FK 506,0,6,"FK 506, 5 mg.",9931093_4,0
16486,kg-1,0,4,kg-1.,9931093_5,0
7667,blood pressure,32,46,"d-1 given for 4 weeks, elevated blood pressure from 102+/-13 to 152+/-15 mm Hg and increased the synthesis of ET-1 and the levels of ET-1 mRNA in the mesenteric artery (240% and 230%, respectively).",9931093_6,1
16487,d-1,0,3,"d-1 given for 4 weeks, elevated blood pressure from 102+/-13 to 152+/-15 mm Hg and increased the synthesis of ET-1 and the levels of ET-1 mRNA in the mesenteric artery (240% and 230%, respectively).",9931093_6,0
16490,ET-1,110,114,"d-1 given for 4 weeks, elevated blood pressure from 102+/-13 to 152+/-15 mm Hg and increased the synthesis of ET-1 and the levels of ET-1 mRNA in the mesenteric artery (240% and 230%, respectively).",9931093_6,0
16491,ET-1,133,137,"d-1 given for 4 weeks, elevated blood pressure from 102+/-13 to 152+/-15 mm Hg and increased the synthesis of ET-1 and the levels of ET-1 mRNA in the mesenteric artery (240% and 230%, respectively).",9931093_6,0
16492,mesenteric artery,150,167,"d-1 given for 4 weeks, elevated blood pressure from 102+/-13 to 152+/-15 mm Hg and increased the synthesis of ET-1 and the levels of ET-1 mRNA in the mesenteric artery (240% and 230%, respectively).",9931093_6,1
16493,ECE-1,48,53,Little change was observed in the expression of ECE-1 mRNA and CNP mRNA.,9931093_7,0
16494,CNP,63,66,Little change was observed in the expression of ECE-1 mRNA and CNP mRNA.,9931093_7,0
16495,eNOS,17,21,"FK 506 decreased eNOS activity and the levels of eNOS mRNA in the aorta (48% and 55%, respectively).",9931093_8,0
16496,eNOS,49,53,"FK 506 decreased eNOS activity and the levels of eNOS mRNA in the aorta (48% and 55%, respectively).",9931093_8,0
4076,FK 506,0,6,"FK 506 decreased eNOS activity and the levels of eNOS mRNA in the aorta (48% and 55%, respectively).",9931093_8,0
16497,kg-1,40,44,The administration of FR 139317 (10 mg. kg-1.,9931093_9,0
16502,functional impairment,15,36,Structural and functional impairment of mitochondria in adriamycin-induced cardiomyopathy in mice: suppression of cytochrome c oxidase II gene expression.,9952311_0,1
16504,cytochrome c oxidase,114,134,Structural and functional impairment of mitochondria in adriamycin-induced cardiomyopathy in mice: suppression of cytochrome c oxidase II gene expression.,9952311_0,0
16507,ADR,23,26,The use of adriamycin (ADR) in cancer chemotherapy has been limited due to its cumulative cardiovascular toxicity.,9952311_1,0
4078,cancer chemotherapy,31,50,The use of adriamycin (ADR) in cancer chemotherapy has been limited due to its cumulative cardiovascular toxicity.,9952311_1,0
16506,adriamycin,11,21,The use of adriamycin (ADR) in cancer chemotherapy has been limited due to its cumulative cardiovascular toxicity.,9952311_1,0
16508,ADR,26,29,Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase (COX) and suppresses its enzyme activity led us to investigate ADR's action on the cardiovascular functions and heart mitochondrial morphology in Balb-c mice i.p. treated with ADR for several weeks.,9952311_2,0
16509,mitochondrial cytochrome c oxidase,45,79,Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase (COX) and suppresses its enzyme activity led us to investigate ADR's action on the cardiovascular functions and heart mitochondrial morphology in Balb-c mice i.p. treated with ADR for several weeks.,9952311_2,0
16511,ADR's action,143,155,Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase (COX) and suppresses its enzyme activity led us to investigate ADR's action on the cardiovascular functions and heart mitochondrial morphology in Balb-c mice i.p. treated with ADR for several weeks.,9952311_2,0
16512,cardiovascular functions,163,187,Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase (COX) and suppresses its enzyme activity led us to investigate ADR's action on the cardiovascular functions and heart mitochondrial morphology in Balb-c mice i.p. treated with ADR for several weeks.,9952311_2,1
16513,mitochondrial,198,211,Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase (COX) and suppresses its enzyme activity led us to investigate ADR's action on the cardiovascular functions and heart mitochondrial morphology in Balb-c mice i.p. treated with ADR for several weeks.,9952311_2,0
16514,Balb-c,226,232,Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase (COX) and suppresses its enzyme activity led us to investigate ADR's action on the cardiovascular functions and heart mitochondrial morphology in Balb-c mice i.p. treated with ADR for several weeks.,9952311_2,0
16523,COXII,189,194,"In parallel, total RNA was extracted from samples of dissected heart and analyzed by Northern blot hybridization to determine the steady-state level of three RNA transcripts encoded by the COXII, COXIII, and COXIV genes.",9952311_4,0
16524,COXIII,196,202,"In parallel, total RNA was extracted from samples of dissected heart and analyzed by Northern blot hybridization to determine the steady-state level of three RNA transcripts encoded by the COXII, COXIII, and COXIV genes.",9952311_4,0
16525,COXIV,208,213,"In parallel, total RNA was extracted from samples of dissected heart and analyzed by Northern blot hybridization to determine the steady-state level of three RNA transcripts encoded by the COXII, COXIII, and COXIV genes.",9952311_4,0
16530,mitochondrial,347,360,"Our results indicated that 1) treatment of mice with ADR caused cardiovascular arrhythmias characterized by bradycardia, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent swelling, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment.",9952311_6,0
16531,Such abnormalities,0,18,"Such abnormalities were not observed in the mitochondria of liver tissue; and 3) among the three genes of COX enzyme examined, only COXII gene expression was suppressed by ADR treatment, mainly after 8 weeks in both heart and liver.",9952311_7,1
16534,ADR,172,175,"Such abnormalities were not observed in the mitochondria of liver tissue; and 3) among the three genes of COX enzyme examined, only COXII gene expression was suppressed by ADR treatment, mainly after 8 weeks in both heart and liver.",9952311_7,0
16538,mitochondrial,165,178,"Knowing that heart mitochondria represent almost 40% of heart muscle by weight, we conclude that the deteriorating effects of ADR on cardiovascular function involve mitochondrial structural and functional impairment.",9952311_8,0
16537,cardiovascular function,133,156,"Knowing that heart mitochondria represent almost 40% of heart muscle by weight, we conclude that the deteriorating effects of ADR on cardiovascular function involve mitochondrial structural and functional impairment.",9952311_8,1
16539,functional impairment,194,215,"Knowing that heart mitochondria represent almost 40% of heart muscle by weight, we conclude that the deteriorating effects of ADR on cardiovascular function involve mitochondrial structural and functional impairment.",9952311_8,1
